Generated by All in One SEO Pro v4.9.10, this is an llms-full.txt file, used by LLMs to index the site.
# Meridian Bioscience
## Posts
### [Blog](https://www.meridianbioscience.com/blog/)
**Published:** March 24, 2025
**Author:** hamza
**Content:**
# Page: Blog
It seems we can’t find what you’re looking for.
#### Latest From Lifescience
#### [Rise in Antibody Interference Post-COVID: Impacts on Diagnostic Assay Developers](https://www.meridianbioscience.com/lifescience-blog/rise-in-antibody-interference-post-covid-impacts-on-diagnostic-assay-developers/)
- [Blockers](https://www.meridianbioscience.com/category/lifescience-blog/blockers/), [Immunology](https://www.meridianbioscience.com/category/lifescience-blog/immunology/), [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/)
#### [Solving Enzyme Stability by Tackling Glycerol-Free Formulation Challenges](https://www.meridianbioscience.com/lifescience-blog/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/)
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/), [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/)
#### [The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS](https://www.meridianbioscience.com/lifescience-blog/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/)
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/), [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/)
#### Latest From Diagnostics
#### [Understanding Lead Poisoning: A Comprehensive Guide to Blood Lead Testing](https://www.meridianbioscience.com/diagnostics-blog/understanding-lead-poisoning-a-comprehensive-guide-to-blood-lead-testing/)
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [LeadCare](https://www.meridianbioscience.com/category/diagnostics-blog/leadcare/), [Pediatric & Neonatal](https://www.meridianbioscience.com/category/diagnostics-blog/pediatric-neonatal/)
#### [Unveiling H. pylori Trends: Updates on Diagnosis and Management](https://www.meridianbioscience.com/diagnostics-blog/unveiling-h-pylori-trends-updates-on-diagnosis-and-management/)
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/), [H. pylori](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/h-pylori/)
#### [Rethinking *Campylobacter*: Fast, Accurate Diagnostics for Better GI Outcomes](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
- [campylobacter](https://www.meridianbioscience.com/category/diagnostics-blog/campylobacter/), [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
---
### [Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-health-canada-license-for-alethia-cmv-assay/)
**Published:** July 8, 2026
**Author:** Holger
**Content:**
**CINCINNATI, OHIO, July 8, 2026 (PRNewswire)** – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its [Alethia® CMV assay](/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/). The addition of CMV expands Meridian’s existing Alethia menu, which includes *C. difficile*, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian’s molecular diagnostic offerings in the Canadian market.
The Alethia platform delivers accurate molecular results in less than an hour to support evidence-based clinical decisions. With a small footprint and simple workflow, Alethia helps labs run efficiently while delivering reliable molecular results. The platform uses LAMP technology (loop-mediated isothermal amplification) for a cost-effective molecular solution.
With the [Alethia CMV assay](/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/), Meridian delivers highly sensitive molecular detection with rapid turnaround time. Nearly 1 in 4 women carry cytomegalovirus (CMV), the most common congenital infection transmitted from mother to baby during pregnancy.1,2 Every year 1 in 200 babies are born with congenital CMV, and yet, the majority of pregnant women have never heard of it.3 Alethia CMV enables early detection of congenital CMV, which is vital in guiding appropriate clinical care for newborns. Congenital [CMV testing](/diagnostics/disease-areas/pediatric-neonatal/cmv/) empowers physicians and families with a full understanding of their newborn’s health prior to leaving the hospital.
“We are excited about the expanded menu offering of CMV on our Alethia platform in Canada. This allows Meridian to provide an important diagnostic solution for customers in the Canadian market. By utilizing saliva as the sample type, the assay delivers an easy-to-collect specimen for congenital CMV testing,” said Michelle Bosch, Vice President of Global Marketing. “The [Alethia CMV assay](/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/) provides clinicians with a valuable tool to aid in the diagnosis of congenital CMV.”
For more information on Alethia® CMV, including test and ordering details, visit the [Alethia CMV ](/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](https://www.meridianbioscience.com).
1. Silasi M, Cardenas I, Racicot K, Kwon J-Y, Aldo P, Mor G. VIRAL INFECTIONS DURING PREGNANCY. American Journal Of Reproductive Immunology (New York, NY : 1989). 2015;73(3):199-213. doi:10.1111/aji.12355.
2. Marchofdimes.org. (2018). Cytomegalovirus and pregnancy. \[online\] Available at:
3. Congenital CMV Facts. Centers for Disease Control and Prevention.
**Contact:**
Michelle Bosch, Vice President, Global Commercial Marketing and Business Management, DIAGNOSTICS
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: or
**Categories:** Press Release
---
### [Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows](https://www.meridianbioscience.com/press-release/meridian-bioscience-and-4bases-announce-collaboration-to-enable-rapid-globally-scalable-next-generation-sequencing-workflows/)
**Published:** June 10, 2026
**Author:** Hamza Shahzad
**Content:**
Ambient-stable NGS workflows, enabled by Meridian’s lyophilization expertise, expand global access to 4bases’ KaryoSolver™\*, a platform for rapid structural variant analysis
**Cincinnati, Ohio, June 10, 2026 (PRNewswire)** – The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA to support the global deployment of KaryoSolver, a next-generation cytogenetics assay, through advanced assay stabilization.
KaryoSolver represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deliver a complete picture. In contrast, KaryoSolver consolidates structural variant detection into a single assay with integrated data analysis, providing actionable genomic insights within hours.
However, bringing this innovation to a global market requires overcoming a critical barrier: reagent stability. Conventional liquid-based NGS library preparation solutions are inherently limited by short shelf life, creating significant challenges across the distribution chain, including the cost and complexity of refrigerated shipping and storage that have historically restricted scalable global expansion.
Meridian addressed this challenge through its advanced reagent stabilization platform, combining formulation science with optimized enzyme lyophilization technology. By stabilizing the NGS library preparation components, Meridian enabled KaryoSolver to be shipped and stored at ambient temperatures, eliminating cold-chain requirements, extending shelf life, and simplifying inventory management across the global distribution channels. In addition, lyophilization streamlines manufacturing, supporting more efficient and scalable production.
“Our platform technology enabled the transition of the assay into a room-temperature stable format while preserving the performance characteristics required for molecular diagnostics,” said Florent Chang-Pi-Hin, Vice President, Research and Development at Meridian Life Science. “By removing cold-chain constraints without sacrificing assay integrity, we’re helping expand access to reliable testing worldwide.”
In this collaboration, Meridian and 4bases R&D teams joined efforts to integrate Meridian’s stabilized NGS library preparation chemistries into 4bases’ Oxford Nanopore Technologies workflow.
“The idea behind KaryoSolver is to simplify access to comprehensive genetic diagnosis, and Meridian’s expertise in stabilization has been transformative,” said Fabio Grandi, COO & Co-Founder at 4bases. “Short shelf life and cold-chain requirements previously limited how far and how efficiently we could scale. With lyophilization, we can now reliably supply our global customers while simplifying logistics, reducing costs, and accelerating the adoption of KaryoSolver as a rapid, single-workflow solution for cytogenetics.”
Together, Meridian and 4bases are removing key barriers to advanced genomic testing, pairing breakthrough assay design with the stability, scalability, and operational efficiency required for effective global deployment.
4bases and Meridian Bioscience will both be exhibiting at the upcoming European Human Genetics Conference (ESHG) on June 13–16 in Gothenburg, Sweden, where attendees will have the opportunity to learn more about the companies’ collaboration and latest advances in ambient-stable next-generation sequencing workflows and cytogenetics solutions. Additional event details, including opportunities to schedule meetings with the Meridian Bioscience and 4bases’ teams during ESHG, can be found on [Meridian Life Science’s events page](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2026/) and on [4bases’](http://www.4bases.ch/) [website.](http://www.4bases.ch/)
Meridian Bioscience will also be exhibiting at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) 2026 meeting, taking place July 26-30 in Anaheim, California, where the company will showcase its broader molecular diagnostics and next-generation sequencing portfolio, including solutions designed to support ambient-stable assay development and workflow optimization.
For more information on Meridian’s ambient-stable solutions and services, please visit
#### About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that provide answers with speed, accuracy, and simplicity, redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com.](https://www.meridianbioscience.com/)
#### About 4bases SA
4bases SA is a Swiss biotechnology company specializing in the development and production of clinically validated, CE-IVD genetic diagnostic solutions for precision medicine. The company offers platform-independent next-generation sequencing (NGS) reagent kits, data analysis software, and diagnostic protocols designed to support healthcare professionals in delivering accurate and actionable genetic insights.
Through its integrated solutions, including proprietary analysis platforms and Oxford Nanopore-compatible workflows, 4bases enables comprehensive genomic analysis for applications such as hereditary disease, oncology, and cytogenetics. The company is committed to delivering high-quality, scalable technologies that improve diagnostic efficiency and patient outcomes worldwide. 4bases’ web address is [www.4bases.ch.](http://www.4bases.ch/)
#### Contact:
Ben Hahlen
Director of Product Management and Downstream Marketing Meridian Bioscience, Inc.
Phone: 513.991.1091
Email:
Sabrina Prada
Director of Communications 4bases SA
Phone: +41 91 610 04 20
Email:
\###
\*KaryoSolver™ is a trademark of 4bases and used with permission.
**Categories:** Press Release
---
### [Understanding Lead Poisoning: A Comprehensive Guide to Blood Lead Testing](https://www.meridianbioscience.com/diagnostics-blog/understanding-lead-poisoning-a-comprehensive-guide-to-blood-lead-testing/)
**Published:** September 3, 2024
**Author:** hamza
**Excerpt:** Lead poisoning remains a pressing public health issue, particularly harmful to young children with symptoms that often go unnoticed. From abdominal pain to developmental delays, understanding and recognizing the signs of lead exposure is crucial for early intervention. This article delves into the importance of rapid blood lead level testing, explores the subtle yet concerning symptoms, and outlines effective prevention and treatment strategies. With a focus on safeguarding our communities, especially vulnerable populations, we underscore the significance of timely detection and proactive measures to combat lead poisoning.
**Content:**
[Lead poisoning](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/?) remains a significant public health concern, particularly affecting young children. With symptoms ranging from abdominal pain and developmental delays to severe neurological changes, it’s crucial to have reliable and rapid testing methods. [LeadCare II](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/) stands out as an indispensable tool in detecting and managing lead exposure.
**The Critical Need for Blood Lead Level Testing**
Lead poisoning can be elusive, often presenting symptoms that mimic other conditions. Common lead poisoning symptoms include fatigue, irritability, and difficulty concentrating. These symptoms are particularly concerning in children as they can lead to lifelong cognitive and behavioral issues. Therefore, blood lead level testing is essential for early detection and intervention.
**How LeadCare II Works**
LeadCare II is a portable instrument that simplifies the process of testing blood lead levels, making it accessible across various health settings, from point-of-care clinics to large community health systems. The device incorporates an electrochemical detection method to measure the lead content from a small fingerstick sample. This process allows for rapid test results within minutes, enabling healthcare providers to take immediate action if elevated lead levels are detected.
**Importance of LeadCare II in Detecting Lead Poisoning in Children**
Children are particularly vulnerable to the effects of [lead poisoning due to their developing nervous systems](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/) and tendency to absorb more lead than adults. LeadCare II is instrumental in pediatric healthcare settings, allowing for routine testing during regular well-check health visits. Early detection with tools like LeadCare II is vital for initiating lead poisoning prevention, treatment, and intervention methods, which may involve environmental lead remediation or chelation therapy to bind and remove lead from the body.
**Lead Poisoning Treatments and Prevention**
When lead exposure is identified, treatment strategies are tailored based on the severity of the condition and the specific needs of the patient. Lead poisoning treatments involve a combination of removing the source of lead, dietary adjustments to improve iron and calcium intake, and in more severe cases, administering lead poisoning medications.
Preventive measures are equally crucial, including ensuring homes are free from lead-based paint or dust, checking for lead in water pipes, and providing public education on minimizing ongoing lead exposure. LeadCare II supports these preventive strategies by enabling widespread and accessible lead testing at the point-of-care.
**Broadening the Reach of Lead Testing**
The accessibility of [LeadCare II](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/) allows for broader implementation of lead testing, particularly in underserved or high-risk areas. By facilitating more accessible testing at the point-of-care, communities can better manage and prevent ongoing lead exposure risks. This proactive approach is not only crucial for individual health but also reduces the long-term public health burden of lead exposure.
**Conclusion**
LeadCare II has revolutionized the approach to managing lead poisoning, particularly in settings that require quick and reliable results. Its role in public health cannot be overstated, providing a critical tool in the fight against lead poisoning. As we continue to strive for better public health outcomes, the importance of accessible and effective blood lead level testing remains a cornerstone of preventative health measures.
By leveraging the capabilities of LeadCare II, healthcare providers can ensure safer environments for children and adults alike, underscoring the device’s invaluable contribution to public health.
**Categories:** Diagnostics Blog, LeadCare, Pediatric & Neonatal
---
### [Unveiling H. pylori Trends: Updates on Diagnosis and Management](https://www.meridianbioscience.com/diagnostics-blog/unveiling-h-pylori-trends-updates-on-diagnosis-and-management/)
**Published:** July 1, 2024
**Author:** hamza
**Excerpt:** As the battle against Helicobacter pylori continues to evolve, healthcare professionals are increasingly turning to advanced diagnostic tools and innovative treatment strategies to manage this pervasive infection. From the high precision of urea breath tests to the promising avenues of tailored antibiotic therapies, this article explores the cutting-edge developments that are setting new standards in gastrointestinal healthcare. With an emphasis on overcoming antibiotic resistance and enhancing treatment efficacy, these advances are not just reshaping clinical practices but are also offering new hope to millions affected by H. pylori-related diseases.
**Content:**
*Helicobacter pylor*i (*H. pylori)* infection is a prevalent condition worldwide, associated with various gastrointestinal diseases, including peptic ulcers, gastritis, and an increased risk of gastric cancer. The dynamic nature of *H. pylori* epidemiology, coupled with evolving resistance patterns, necessitates continuous updates in diagnostic and management strategies. This article highlights the latest trends in *H. pylori* diagnosis and management, providing insights into emerging diagnostic tools and therapeutic approaches.
## Advances in *H. pylori* Diagnosis
Early and accurate detection of *H. pylori* infection is crucial for effective management and treatment. The development and refinement of diagnostic tools have significantly improved the precision of [*H. pylori* detection](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/).
### Diagnostic Innovations
- [*H. pylori* Urea Breath Test](/diagnostics/platforms/urea-breath/): This remains a cornerstone for non-invasive diagnosis, favored for its high sensitivity and specificity. Recent advancements aim to streamline the process, making it more accessible and convenient for patients. This test is a reliable tool for both initial diagnosis and post-treatment verification of eradication.
- [*H. pylori* Stool Antigen Testing](/diagnostics/disease-areas/gastrointestinal/h-pylori/?country=US#:~:text=Learn%20More-,Stool%20Antigen%20Testing%20Solutions%20for%20H.%20pylori,-Noninvasive%20testing%20for): Advances in antigen testing have enhanced its accuracy, making it a reliable tool for both initial diagnosis and post-treatment verification of eradication.
- Serological Testing: While testing for *H. pylori* antibodies through blood or serum (such as *H*. *pylori* IgG detection) provides insights into exposure, its role in diagnosing active infection is limited due to the inability to distinguish between past and present infections.
- Molecular Testing: The use of *H. pylori* test kits that utilize polymerase chain reaction[ (PCR) for *H. pylori* DNA](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) or RNA detection is on the rise. These tests offer the promise of detecting antibiotic resistance genes directly from stool samples or biopsy specimens, guiding more targeted therapy.
## Emerging Trends in *H. pylori* Management
The treatment landscape for *H. pylori* infection is undergoing significant shifts, with an emphasis on overcoming antibiotic resistance and improving eradication rates.
### Tailored Antibiotic Therapy
Recognizing the global challenge of antibiotic resistance, there is a growing trend towards personalized treatment regimens. Tailored therapy, based on local resistance patterns or even individualized resistance testing, is becoming more common. This approach necessitates advanced *H. pylori* diagnostics, including molecular tests that can identify resistance mutations.
### Quadruple Therapies and Beyond
As resistance to standard triple therapy regimens increases, quadruple therapies, incorporating a proton pump inhibitor (PPI), two antibiotics, and a bismuth compound, are gaining traction. Research into even more innovative combinations, including the use of non-traditional antimicrobial agents, is ongoing.Non-Antibiotic Strategies
There is increasing interest in non-antibiotic management strategies for *H. pylori* infection:
Probiotics have shown potential in adjunctive therapy, aiming to restore gut microbiota balance and reduce side effects associated with antibiotic treatment. Vaccine development continues to be a critical area of research, offering the promise of a long-term solution to reduce *H. pylori* prevalence and its associated diseases.
### The Role of Diet and Natural Products
Dietary interventions and natural products are receiving attention for their potential role in managing *H. pylori* infection. Certain foods and supplements with antimicrobial properties against *H. pylori* are being studied, although more research is needed to establish their efficacy and role in treatment protocols.Conclusion
The landscape of [*H. pylori* diagnosis and management](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) is evolving rapidly, driven by technological advancements and a deeper understanding of the bacterium’s behavior and resistance mechanisms. The trend towards more precise diagnostics, tailored treatment regimens, and the exploration of non-antibiotic therapies reflects a comprehensive approach to tackling *H. pylori* infection. As research continues to unveil new insights, staying abreast of these developments is crucial for healthcare professionals aiming to optimize patient care and outcomes in the face of this persistent global health challenge.
**Categories:** Diagnostics Blog, Gastrointestinal, H. pylori
---
### [Rise in Antibody Interference Post-COVID: Impacts on Diagnostic Assay Developers](https://www.meridianbioscience.com/lifescience-blog/rise-in-antibody-interference-post-covid-impacts-on-diagnostic-assay-developers/)
**Published:** June 12, 2025
**Author:** hamza
**Content:**
**Since COVID-19, changes in the immune system, specifically increased levels of autoantibodies such as rheumatoid factor (RF), have begun to impact diagnostic testing by increasing the potential for interference in certain immunoassays.**
While the pandemic’s most visible clinical impact was respiratory disease, COVID-19 also left behind a complex immunological footprint. Even after full recovery, many individuals show signs of immune dysregulation, including elevated levels of autoantibodies – self-reactive antibodies commonly associated with autoimmune conditions.1 These changes are now being recognized as a potential source of interference in immunoassays, prompting assay developers to revisit performance considerations in the post-COVID landscape.
Among these, rheumatoid factor (RF) has been particularly notable. It is a common biomarker found in up to 80% of rheumatoid arthritis (RA) patients2 and is a known source of immunoassay interference. A 2021 study by Wang et al.3 demonstrated that RF levels increased after SARS-CoV-2 infection, even in individuals with no prior autoimmune disease. This has important implications for assay design and interpretation, particularly in maintaining reliability and clinical accuracy.
## The Evidence: COVID-19 and Rising RF Levels
Respiratory viral infections have been linked to an increased risk of autoimmune inflammatory arthritis.4 While RF has generally been considered functionally similar across diseases, new evidence suggests this may not be the case. A 2024 study published in the *Journal of Autoimmunity*5 identified polyreactive forms of RF in COVID-19 patients, uniquely capable of binding to a wide range of protein targets, including viral antigens.
There are five immunoglobulin isotypes of RF: IgM, IgG, IgA, IgD, and IgE, each with distinct immunological roles. Among these, IgM-RF is the most commonly measured and clinically relevant type, particularly in the context of RA diagnosis and assay interference. IgM-RF, which is typically the first to appear during immune activation, is also the most strongly associated with false-positive results in immunoassays due to its ability to bind animal-derived antibodies.6 Its high avidity and pentameric structure enable it to bind multiple IgG molecules simultaneously.
## Rheumatoid Factor and Fc-Mediated Assay Interference
Overall, RF is found in approximately 5–10% of the general population and in about 70% of rheumatoid arthritis patients.7 There is significant homology between the Fc domains of RF antibodies and those of several animal species, which may explain why RFs can bind to animal-derived antibodies.8,9
RF’s cross reactive properties, along with its tendency to bind nonspecifically to IgG, make it a well-recognized source of interference in immunoassays, particularly those that depend on high antibody-antigen specificity. In sandwich-based formats, RF can form false immune complexes by bridging detection and capture antibodies, mimicking a true signal even in the absence of the target antigen (refer to image 1). This mechanism can lead to false positives, misleading clinical interpretations, and reduced confidence in test results.10
### IgM Rheumatoid Factor (RF) Interference
Image 1: In sandwich immunoassays, IgM RF can bind non-specifically to the Fc regions of both capture and detection antibodies. This bridging mimics the presence of a true antigen-antibody complex, generating a false-positive signal—even when no target analyte is present.
In the context of SARS-CoV-2 antibody detection, this type of interference is well documented: RF can bind to the Fc portion of surface-bound antibodies, generating nonspecific signals that may result in misdiagnosis or inaccurate assessment of immune status.11
## Strategies for Mitigating Antibody-Mediated Interference in Immunoassays
As the diagnostic field adapts to the post-COVID era, it faces a range of emerging challenges—including the increasing relevance of assay interference due to post-infectious immune changes. To ensure that immunoassays remain accurate, reliable, and clinically actionable, several mitigation strategies should be considered:
- **Use recombinant antibodies or Fab fragments to eliminate Fc-based binding**
RF binds specifically to the Fc region of IgG. By replacing conventional antibodies with recombinant formats, such as truncated Fab fragments or Fc-free recombinant antibodies, developers can remove the primary binding site for RF and significantly reduce the risk of interference. These engineered antibodies are increasingly used in next-generation assays due to their improved consistency, reduced cross-reactivity, and better lot-to-lot reproducibility.
- **Incorporate interference-blocking reagents such as mouse IgG or active blockers such as human anti-mouse antibody (HAMA) and RF-blocking agents**
These reagents work by competitively binding interfering antibodies – such as RF or heterophilic antibodies – before they can interact with the capture or detection antibodies in the assay. The use of animal-free blocker formulations further improves assay robustness by eliminating cross-reactivity with animal-derived proteins, reducing the risk of heterophilic antibody interference and enhancing reproducibility across diverse patient samples.
- **Validate assays using post-COVID sample panels**
Validation protocols should now include testing with post-COVID clinical samples, especially those from individuals with long COVID or post-acute sequelae. These samples more accurately reflect the current immunological landscape and help developers identify and resolve potential sources of signal distortion that might not have been evident in pre-pandemic populations.
## Meridian’s Blocking Solutions: Designed for Today’s Diagnostic Challenges
To support assay developers navigating these post-COVID challenges, Meridian Bioscience offers a range of high-performance immunoassay blockers specifically engineered to reduce interference from rheumatoid factor, HAMA, and other heterophilic antibodies. Meridian’s portfolio includes both traditional blockers—such as highly purified mouse IgG and human anti-mouse antibody blockers—as well as animal-free formulations designed to minimize variability and cross-reactivity. Meridian’s leading proprietary blocker, TRU Block™, is available in three different strengths for HAMA interference reduction. It is widely used in commercial diagnostic kits across ELISA, lateral flow, and chemiluminescent platforms, and can be easily integrated into assay development workflows. Whether you are developing new diagnostics or troubleshooting interference in existing formats, Meridian’s blocker solutions provide a reliable, scalable approach to maintaining assay accuracy in the evolving immune landscape.
**Try Our Most Popular Blockers—Now in a Convenient Sample Pack**
Curious which blocker is right for your assay? Get started with our most trusted solutions in one easy kit. Ideal for side-by-side testing and fast comparison.
To learn more about Meridian’s blocking solutions, including the sample pack, visit:
.
[](https://www.meridianbioscience.com/lifescience/blockers-sample-pack-request/)
**References:**
1\. Mohan, A., *et al.* (2023). Navigating the post-COVID-19 immunological era: Understanding long COVID-19 and immune response. *Life (Basel)*, 13(11), 2121.
2\. Shapiro, S. C. (2021). Biomarkers in rheumatoid arthritis. *Cureus*, 13(5), e15063.
3\. Wang, E. Y., *et al.* (2021). Diverse functional autoantibodies in patients with COVID-19. *Nature*, 595(7866), 283–288.
4\. Joo, Y. B., *et al.* (2019). Respiratory viral infections and the risk of rheumatoid arthritis. *Arthritis Research & Therapy*, 21(1), 199.
5\. Shelef, M., *et al.* (2024). Polyreactive rheumatoid factors in COVID-19 patients. *Journal of Autoimmunity*, 112, 102110
6\. Nayeemuddin, S. N., *et al.* (2024). Heterophilic interference of rheumatoid factor in TSH immunometric assay: A cross-sectional observational study. Indian Journal of *Endocrinology and Metabolism*, 28(1), 29–34.
[https://doi.org/10.4103/ijem.ijem\_99\_23](https://doi.org/10.4103/ijem.ijem_99_23)
7\. Todd, D. J., *et al.* (2011). Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. *Arthritis & Rheumatism*, 63(4), 894–903.
8\. Nakamura, M., *et al.* (1988). Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu-1)+ B cells are polyreactive. *Journal of Immunology*, 140, 4180–4186.
9\. Burastero, S. E., *et al.* (1988). Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. *Journal of Experimental Medicine*, 168(6), 1979–1992.
10\. Gehin, J. E., *et al.* (2021). Rheumatoid factor and falsely elevated results in commercial immunoassays: Data from an early arthritis cohort. *Rheumatology International*, 41(9), 1657–1665.
11\. Kharlamova, N., *et al.* (2021). False positive results in SARS-CoV-2 serological tests for samples from patients with chronic inflammatory diseases. *Frontiers in Immunology*, 12, 666114.
**Categories:** Blockers, Immunology, Life Science Blog
---
### [Solving Enzyme Stability by Tackling Glycerol-Free Formulation Challenges](https://www.meridianbioscience.com/lifescience-blog/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/)
**Published:** March 4, 2025
**Author:** hamza
**Content:**
Imagine diagnostic assays that can be shipped and stored at room temperature, removing the need for freezing or refrigeration while maintaining stability and performance—even in remote areas.
Molecular diagnostics, known for their unparalleled sensitivity and specificity, are at the forefront of disease detection and play a critical role in timely healthcare decisions worldwide. However, the field still faces formidable logistical challenges: traditional liquid reagents require cold-chain management, a costly and complex necessity that limits accessibility, especially in low-resource settings.
#### The Role of Glycerol
Traditionally, enzyme buffers use glycerol as a cryoprotectant and stabilizer to prevent ice crystal formation that could damage enzymes when stored at -20°C1. A 50% glycerol buffer lowers the freezing point to -23°C2, allowing enzymes to be stored at -20°C without undergoing damaging freeze/thaw cycles3. However, glycerol’s ability to lower the freezing point also makes water removal during the freeze-drying process challenging, potentially leaving residual moisture4 that can compromise the quality of lyophilized products intended for ambient-temperature shipping and storage.
Glycerol can be removed from enzyme buffers using dialysis or filtration, but these methods are time-consuming and can change the salt concentration, leading to up to 20% enzyme loss5. Additionally, once glycerol is removed, extensive process optimization and quality control are needed to ensure the enzyme’s stability and functionality in the modified buffer. Therefore, the best approach for developing reagents suited for lyophilization, air-drying, and ambient-temperature stability is to formulate them without glycerol from the start. However, designing stable, glycerol-free formulations remain a significant challenge, requiring careful selection of stabilizers and other excipients that can protect the enzyme’s structure and activity. These stabilizers must not only preserve enzyme function during storage and use but also be compatible with downstream applications, ensuring consistent performance across different assay conditions. Deep expertise in enzymology and buffer optimization, combined with extensive screening, formulation optimization, and accelerated stability studies, is essential for successfully designing high-performing glycerol-free enzymes.
With over 40 years of innovation in reagent development, Meridian has engineered high-performing glycerol-free enzymes for PCR, LAMP, and NGS. These enzymes are designed to retain superior activity and stability after lyophilization, ensuring reliable performance across a range of molecular diagnostic applications.
Meridian also offers its expertise through custom formulation services, assisting in the conversion of existing enzyme formulations to glycerol-free versions. With a collaborative and flexible approach, Meridian provides assay developers with direct access to its deep knowledge of enzymology, enabling the rapid optimization of existing assay protocols or the development of new protocols incorporating lyophilized reagents.
#### Meridian’s Glycerol-Free Enzymes
A critical first step in creating a glycerol-free enzyme is using highly purified material, which is achieved through careful purification and strict quality control. Meridian’s extensive expertise in advanced buffer formulation allows for precise fine-tuning of the concentration of each component in the buffer, including magnesium, salts, PCR enhancers, and stabilizers. This optimization ensures that the buffer chemistry is tailored for each glycerol-free enzyme, resulting in optimal enzyme activity and full compatibility with lyophilization.
- **Glycerol-Free Enzyme Maintains Stability Even After Multiple Freeze-Thaw Cycles**
To test the resistance of Glycerol-Free Taq HS 50U/μL (MDX011) to freezing and thawing, a freeze thaw test was performed (10 and 15 cycles of freeze/thawing) and compared to fresh product (0 cycles of freeze/thawing). The results illustrate that Glycerol Free Taq Hot Start offers the same protection to freeze/thawing as a polymerase that contains glycerol.
[Visit product information for Glycerol-Free Taq HS 50U/μL (MDX011)](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/dna-polymerases/glycerol-free-taq-hs-50u-%c2%b5l/)
- **Glycerol-Free Enzyme Retains Full Functionality After Lyophilization with No Loss in Sensitivity or Speed**
A 10-fold serial dilution of human DNA (103 copies down to 10 copies) using Glycerol-Free Taq HS 50U/μL (MDX011) as a wet mix (black) or lyophilized mix (blue) to illustrate that lyophilization does not affect the quality of the Glycerol-Free Taq HS.
[Visit product information for Glycerol-Free Taq HS 50U/μL (MDX011)](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/dna-polymerases/glycerol-free-taq-hs-50u-%c2%b5l/)
- **Lyophilized Glycerol-Free Enzymes Deliver Superior Performance Over Traditional Liquid Formats**
Glycerol-Free HS Tth DNA Polymerase (MDX205) (red) was lyophilized and tested against HawkZ05 Fast Polymerase (Roche, containing glycerol) (green) in an RT-qPCR reaction to demonstrate that Meridian’s Glycerol-Free HS Tth DNA Polymerase has better performance and sensitivity than the other supplier enzyme.
[Visit product information for Glycerol-Free HS Tth DNA Polymerase (MDX205)](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/glycerol-free-hs-tth-dna-polymerase-hc/)
#### Conclusion
Developing glycerol-free enzymes requires a strategic approach that extends beyond simply removing glycerol. With over 40 years of expertise in enzyme purification and buffer optimization, Meridian has engineered high-performing glycerol-free enzymes for PCR, LAMP, and NGS, ensuring superior activity and stability after lyophilization. These enzymes offer assay developers seamless integration into lyophilization workflows, from R&D to large-scale production.
Beyond its ready-to-use glycerol-free enzyme portfolio, Meridian provides specialized formulation services to help convert existing enzyme formulations into glycerol-free versions optimized for stability and performance. Through a collaborative and adaptable approach, Meridian supports the development of lyophilized and air-dried assays tailored to specific application needs.
By enabling ambient-temperature stability, these advanced formulations eliminate cold chain dependencies, overcoming logistical barriers in remote and resource-limited settings where refrigeration is impractical. This innovation enhances global access to critical diagnostic tools, equipping healthcare providers with reliable, high-performance solutions that drive faster, more accurate disease detection and ultimately improve patient outcomes worldwide.
[Learn more here](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/) or contact us today.
[](https://meridianbiostg.wpengine.com/contact-us-life-science/)
**References:**
1\. Glycerol as an Enzyme-Stabilizing Agent: Effects on aldehyde dehydrogenase. (1972). In *Proc. Nat. Acad. Sci. USA* (Vol. 69, Issue 9, pp. 2373–2376) \[Journal-article\].
2\. Vagenende, V., et al. (2009). Mechanisms of protein stabilization and prevention of protein aggregation by glycerol. *Biochemistry*, 48(46), 11084–11096.
3\. Braham, S. A., et. al.(2021). Positive effect of glycerol on the stability of immobilized enzymes: Is it a universal fact? *Process Biochemistry*, 102, 108–121.
4\. Randolph, T. W. (1997). Phase Separation of Excipients during Lyophilization: Effects on Protein Stability. *Journal of Pharmaceutical Sciences, 86*(11), 1198–1203.
5\. Franks, F. (1993). Storage stabilization of proteins. In *Humana Press eBooks* (pp. 489–531). [https://doi.org/10.1007/978-1-59259-438-2\_14](https://doi.org/10.1007/978-1-59259-438-2_14)
**Categories:** Life Science Blog, Molecular, NGS
---
### [The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS](https://www.meridianbioscience.com/lifescience-blog/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/)
**Published:** January 2, 2025
**Author:** hamza
**Content:**
The world of diagnostics is evolving rapidly, driven by the growing need for personalized healthcare solutions. For decades, qPCR has been the backbone of diagnostic testing, offering unmatched speed, sensitivity, and efficiency for routine applications. However, as the complexity of diseases like cancer, genetic disorders, and emerging infectious diseases increases, so does the demand for technologies that can deliver deeper, broader insights.
In this blog, we explore how qPCR and NGS each play a vital role in molecular diagnostics, their unique strengths and limitations, and how combining these technologies can create a powerful, holistic approach to tackling complex diagnostic challenges. Whether identifying known disease markers quickly or uncovering novel variants for personalized treatment, knowing when to use each technology and how they complement each other is key to advancing diagnostics.
#### The Growing Demand for Personalized Diagnostics is Driving Innovation Beyond qPCR
Over the next four years, the personalized healthcare market is projected to grow at a CAGR of 10.8%, reaching nearly $590 billion by 2028.1,2
This growth is driven by the rising demand for personalized therapeutics and diagnostics as healthcare increasingly adopts tailored, patient-centered approaches. By integrating genetic, environmental, and lifestyle data, personalized medicine enables early detection and customized treatments tailored to a patient’s unique genetic profile. This approach is particularly vital for managing complex conditions such as cancer, autoimmune disorders, and genetic diseases, which can vary significantly between individuals.
While qPCR remains highly efficient and cost-effective for routine diagnostics, such as infectious disease testing, its role in personalized medicine is limited by its inability to capture the full genetic complexity of a patient’s genome. Designed to detect specific, pre-identified genetic markers using probes or primers, qPCR is limited in its ability to uncover the broad spectrum of mutations and genomic variations present in diseases like cancer. Identifying the unique genetic fingerprint of a disease is crucial for individualized treatment planning, as these mutations often play a key role in influencing therapeutic responses. To address these challenges, next-generation sequencing (NGS) is increasingly favored for its ability to analyze entire genomes or exomes, uncovering both known and novel variations that are essential for tailoring therapies to each patient’s unique genetic profile.
#### Next-Generation Sequencing
Next-generation sequencing (NGS) was first applied in diagnostics around the late 2000s3, providing transformative capabilities beyond what PCR-based and traditional sequencing methods could offer. Its ability to generate vast amounts of data from a single DNA sample provides exceptional analytical power, enabling high-throughput and comprehensive genomic analysis.
Unlike qPCR, which relies on probes or primers tailored to known variants, NGS reads large sections of genetic material, allowing for the detection of both known and novel variants in a single assay. It enables comprehensive analysis of entire genomes, exomes, or specific gene panels without needing prior knowledge of target sequences. This adaptability makes it suitable for a wide range of applications, including oncology, infectious disease monitoring, and hereditary disease testing.
A key factor driving the increased use of NGS is the reduced cost of sequencing, which has significantly enhanced its accessibility. Advances in sequencing technologies, combined with AI integration, have also improved its accuracy, efficiency, automation, and portability. These advancements have accelerated the pace of genomic analysis and enabled broader applications, such as precision medicine, where treatments are increasingly tailored to the genetic makeup of individual patients.4 Overall, the shift towards more accessible and rapid genomic testing has been essential in fueling the growth of precision medicine, especially in oncology, where timely genetic insights can dramatically influence treatment choices.
#### Choosing Between qPCR and NGS for Diagnostic Applications
When deciding between qPCR and NGS for diagnostic applications, it is essential to weigh the unique strengths of each technology. qPCR excels in scenarios where rapid, sensitive detection of specific, known genetic markers is required. Its speed and cost-effectiveness make it the preferred choice for routine testing, such as identifying pathogens in infectious diseases or confirming the presence of well-characterized mutations in hereditary conditions.
However, qPCR’s reliance on pre-designed probes or primers limits its ability to identify unknown or novel variants. This constraint is particularly limiting in complex scenarios such as oncology or emerging infectious diseases, where the dynamic and intricate genetic landscape demands a broader, more comprehensive approach.
NGS bridges this gap. NGS uncovers known and novel variants in a single assay by sequencing entire genomes, exomes, or targeted gene panels. This adaptability makes it invaluable for applications such as:
- **Infectious Disease Surveillance:** NGS sequences entire viral genomes, enabling the detection of emerging variants and aiding the public health response to evolving outbreaks.
- **Cancer Diagnostics:** Tumors often exhibit a complex array of mutations, including rare and novel variants. Comprehensive genomic profiling through NGS helps identify actionable mutations that guide precision therapies.
- **Genetic Disorder Diagnosis:** Hereditary conditions often involve rare or unique mutations. NGS provides the depth needed to uncover the full spectrum of variants associated with these disorders.
In summary, while qPCR delivers quicker results and can accelerate the initiation of targeted therapy, NGS, although slower, provides richer insights, making it the technology of choice for applications where genetic complexity demands a deeper understanding. Together, these technologies offer complementary strengths that can be leveraged to create more robust diagnostic workflows.
#### The Potential of a Holistic Technological Approach to Diagnostic Testing
The diagnostic landscape is moving toward a hybrid approach, where qPCR and NGS are integrated to maximize the strengths of each technology. Combining the speed and precision of qPCR with the comprehensive insights of NGS can significantly enhance diagnostic accuracy and efficiency.
For example:
- **Stepwise Testing:** Start with qPCR for rapid screening of known mutations or pathogens. When results are inconclusive or more information is needed, follow up with NGS to explore novel variants or broader genomic regions.
- **Layered Surveillance:** In infectious disease monitoring, qPCR is able to track specific variants of concern in real-time, while periodic NGS can provide a validation layer by sequencing the full pathogen genome. This approach was successfully used during the COVID-19 pandemic to track and monitor emerging variants5.
- **Comprehensive Oncology Workflows:** For cancer diagnostics, qPCR can serve as a first-pass tool to detect known mutations, while NGS identifies rare or complex mutations that drive personalized treatment strategies. This dual-technology model offers flexibility and scalability, allowing laboratories to tailor their workflows to the demands of individual cases. By leveraging qPCR for its speed and cost-effectiveness and NGS for its depth and adaptability, diagnostic providers can create a future-ready solution that addresses both routine and complex diagnostic needs.
Meridian is uniquely positioned to support this hybrid approach. With our range of enzymes and master mixes for qPCR and NGS, we provide solutions that enable seamless integration of these technologies. From lyo-ready master mixes for ambient-temperature stability to glycerol-free formulations for enhanced performance, our products are designed to support diagnostics at every level.
#### Conclusion: A Future of Complementary Diagnostics
As diagnostics evolve, the integration of qPCR and NGS is becoming essential to meet the growing demand for precision and personalized medicine. While qPCR remains the gold standard for rapid and targeted testing, NGS offers unparalleled depth and adaptability for uncovering novel and complex genetic information. Together, these technologies provide a pathway to more efficient, accurate, and comprehensive diagnostics, enabling better patient outcomes. This hybrid approach also enhances diagnostic workflows, supporting the growing demand for precision medicine and personalized healthcare solutions.
Meridian is at the forefront of this transformation, offering a portfolio of innovative solutions designed to empower diagnostic developers. From lyo-ready, ambient-temperature stable reagents to high-concentration, glycerol-free enzymes tailored for high-throughput workflows, our products are engineered to enhance performance, streamline operations, and support the most advanced diagnostic applications. Additionally, Meridian’s master mixes are optimized for multiplexing qPCR assays, enabling simultaneous detection of multiple targets with high sensitivity and specificity. Some of our leading products include:
- **dUTP master mixes** formulated with dUTP to prevent carryover contamination in high-throughput settings, when working with high-sensitivity applications, or reusing equipment between reactions
- **Lyo-Ready and Air-Dryable™ master mixes** designed for creating ambient-temperature stable assays
- **High-concentration and glycerol-free enzymes** for qPCR and NGS that are compatible with lyophilization
- **Glycerol-free NGS library preparation kit and enzymes** that aim to reduce the cost of NGS testing and improve NGS portability
[Learn more here](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes/) or contact us today to discuss how our tailored solutions can optimize your molecular diagnostics workflows.
[](https://meridianbiostg.wpengine.com/contact-us-life-science/)
**References:**
1\. Global Market Estimates. (2023). *Personalized healthcare market analysis: Size & forecasts by region, product, and end-user, 2023-2028.* Retrieved from
2\. Markets and Markets. (2024). *Personalized medicine market by product, application, end-user, & region – global forecast to 2028.* Retrieved from
3\. Drug Target Review. (2015, January 31). How next-generation sequencing came to be: A brief history. *Drug Target Review.* Retrieved from
4\. Clinical Lab Products. (2024). Next-generation sequencing: Driving innovation in precision medicine. *Clinical Lab Products.* Retrieved from
5\. Carattini, Y. L., *et al.* (2023). Combined use of RT-qPCR and NGS for identification and surveillance of SARS-CoV-2 variants of concern in residual clinical laboratory samples in Miami-Dade County, Florida. *Viruses, 15(3)*, 593.
**Categories:** Life Science Blog, Molecular, NGS
---
### [Next-Gen Synergies: Innovating POCT and NGS for Enhanced Molecular Diagnostics](https://www.meridianbioscience.com/lifescience-blog/next-gen-synergies-innovating-poct-and-ngs-for-enhanced-molecular-diagnostics/)
**Published:** August 12, 2024
**Author:** hamza
**Content:**
In recent years, point-of-care testing (POCT) and [next-generation sequencing](/lifescience/products/molecular-reagents/ngs-enzymes/) (NGS) have undergone remarkable advancements, establishing themselves as fundamental tools in modern healthcare. Their use has traditionally been viewed as somewhat opposing: POCT prioritizes speed and portability, whereas NGS is laboratory-based, labor-intensive and slow. However, building on the successful integration of PCR with POCT, it anticipates a similar synergy between POCT and NGS, driving the next wave of innovation in rapid and precise diagnostics. Technological advancements are blurring the lines between NGS and POCT, signaling a promising integration of speed and accuracy, which has become particularly evident in microfluidic devices for diagnostic testing.
#### Mini Marvels: POCT Microfluidic Devices
The traditional diagnostic method RT-qPCR is highly integral to the field of clinical diagnostics and research; however, it has limitations in scalability and ease of use. The COVID-19 pandemic not only highlighted its insufficiencies especially in resource-limited settings, but opened the door to newer, more adaptable platforms such as NGS and POCT.
## The Value of NGS Testing
The power of NGS lies in its ability to unlock previously inaccessible information for researchers and clinicians. The technology can deliver comprehensive genomic data enabling the analysis of hundreds of biomarkers in a single assay, providing detailed genetic insights that help guide critical health decisions. Traditionally, the bulk and complexity of NGS equipment confined it to laboratory settings. However, continuous improvements in NGS technology, including increased speed, portability, accuracy, and reduced costs, have made it more accessible and convenient.
Despite the relatively higher cost of NGS compared to other molecular diagnostic methods, NGS is expanding in the healthcare industry, especially in areas where detailed genetic insights can improve treatment and care, such as in non-invasive prenatal testing (NIPT), oncology, pharmacogenomics. Overall, the application of NGS into clinical testing and disease diagnostics is increasing at a staggering rate and its market value is projected to grow tenfold by 2032, increasing from $5.9 billion to $44 billion globally1.
#### Growth in NGS Market 2022 to 2032
As modern NGS platforms become more compact and user-friendly, their integration into clinical workflows with high-throughput sequencing will enable the simultaneous analysis of multiple samples increasing efficiency, particularly in large-scale studies and clinical trials. With the growing demand for advanced healthcare, NGS is poised to transform patient care, delivering critical insights that enhance outcomes and deepen our understanding of genetics.
### The Surge in POCT Innovation
POCT diagnostics have become invaluable for immediate diagnosis, significantly improving patient outcomes. Like NGS, the POCT market has surged due to technological advancements. Innovations utilizing cutting-edge molecular diagnostic techniques such as isothermal amplification methods, have made POCT more user-friendly and robust.
Microfluidic chips have notably advanced POCT by enabling precise control and manipulation of small fluid volumes on a microscale. These chips capture and analyze a wide range of biological samples, including blood, saliva, urine, and other bodily fluids. They are particularly effective at capturing:
- **Cells,** such as white blood cells, red blood cells, and circulating tumor cells (CTCs).
- **Biomolecules,** including proteins, nucleic acids (DNA, RNA), enzymes, and antibodies.
- **Pathogens,** such as bacteria, viruses, and other microorganisms.
- **Chemical Analytes,** including glucose, electrolytes, and other small molecules.
Microfluidic chips, designed to capture CTCs and analyze cell-free DNA (cfDNA), represent a major advancement in POCT especially in oncology. These chips are beneficial because they enable precise, real-time analysis of biological samples with minimal sample volumes, making them ideal for various applications, from RNA sequencing to mutation analysis, without the need for complex laboratory setups. This capability has propelled microfluidic chips as a powerful tool in expanding POC diagnostics, bringing critical testing directly to the patient.
However, while microfluidics excels in handling small sample volumes, certain applications, such as cancer biomarker detection, require larger volumes to process low-abundance analytes in complex biological samples. Balancing the benefits of miniaturization with the need for diagnostic sensitivity and accuracy remains a technological challenge that must be addressed to unlock the full potential of microfluidics in clinical diagnostics.
### Integrating NGS and POCT: Opportunities and Challenges
As both POCT and NGS continue to evolve technologically, their integration promises to combine complementary strengths: comprehensive genomic analysis with rapid response capabilities. The greatest benefit is that clinicians could achieve in-depth genetic analysis with quick turnaround times, leading to faster and more accurate disease detection and management2.
#### Unlocking the Potential of NGS for Point-of-Care Applications: What’s Needed to Bridge the Gap
[](#)
Such a powerful synergy has the potential to transform patient care, particularly in emergency settings where timely information is crucial, and in resource-limited environments, where conventional diagnostic methods may fall short. By providing detailed actionable data swiftly and efficiently, this integration opens avenues for more precise, personalized treatment plans. This could enhance overall healthcare outcomes through effective monitoring of individual responses to therapy and early detection of prognostic or diagnostic biomarkers at any stage of a disease.
However, integrating NGS with POCT is not without its challenges. NGS tests typically involve temperature-sensitive reagents that require cold chain shipping and storage, while POCT devices require robust operation at ambient temperature and in diverse environments to be effective. A major hurdle is ensuring NGS reagents can remain stable at ambient temperatures and are compatible with the miniaturized components of a microfluidic device. Additionally, miniaturization must balance the need for compactness with the requirement to maintain high performance and reliability, ensuring accurate operation despite the device’s small size and varying conditions.
Better data interpretation is also essential. Combining detailed genomic data with rapid test results requires robust bioinformatics tools to accurately interpret the data for effective clinical decision-making.
### The Road Ahead
Innovations in NGS testing and POCT devices continue to push the boundaries of diagnostics. The pandemic catalyzed rapid advancements in molecular diagnostics, potentially serving as a blueprint for tackling future infectious diseases. Moreover, the emergence of compact devices is making sequencing more convenient and portable, bringing the widespread integration of advanced NGS and POCT technologies closer to reality.
As AI is incorporated into NGS applications, diagnostics will become not only more precise but also faster. In the near future, real-time genomic data analysis could assist clinicians in making swift treatment decisions. AI’s ability to detect complex patterns significantly enhances NGS, increasing its potential as a ground-breaking tool for cancer detection and treatment.
The advent of portable sequencing devices marks a significant step towards the democratization and accessibility of sequencing. When combined with POCT, it enables immediate, in-depth diagnostics – such as accessing multiple biomarkers from a single test – along with comprehensive genomic information, even in remote locations. The synergy of NGS’s accuracy and POCT’s speed can redefine rapid diagnostic testing, expanding its menu and making it more personalized, precise, and timely.
### From Concept to Reality: Meridian Paving the Way for NGS/POCT Integration
Transforming new products from proof-of-concept design into tangible, scalable products is challenging, especially for innovative integrated NGS/POCT devices. Specifically, designing microfluidic devices requires advanced technical expertise and material compatibility.
Meridian’s new glycerol-free NGS library preparation enzymes aim to reduce the cost of NGS testing and improve NGS portability, enabling researchers to perform sequencing in various environments, such as resource-limited locations or point-of-care settings. The advantages of Meridian’s NGS solutions include:
- **Glycerol-Free:** Compatible with lyophilization, stable at room temperature for at least 12 months while maintaining complete enzyme activity, avoiding cold chain transport and reducing costs
- **High-Concentration Formula:** Ideal for miniaturized POCT devices, providing greater flexibility in reaction configuration and maximizing sample input volume, thereby enhancing detection sensitivity
- **Simplified Steps:** Features specially optimized reaction buffers that combine end repair and A-tailing in a single step, streamlining the operation process.
With the ongoing evolution of NGS and POCT, fueled by technological advancements and AI integration, the future promises rapid, portable, and highly accurate diagnostics. As these fields continue to converge, the potential for improved patient outcomes and more efficient healthcare solutions becomes increasingly tangible.
To learn more, visit our [website](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes)
[](https://meridianbiostg.wpengine.com/contact-us-life-science/)
**References:**
1\. Research, P. (2023, October 30).*Next Generation Sequencing Market Size, growth,Share, and Trends 2024 to 2034.*
2\. Sheffield, B. S., Beharry, A., Diep, J., Perdrizet, K., Iafolla, M. a. J., Raskin, W., Dudani, S., Brett, M. A., Starova, B., Olsen, B., & Cheema, P. K. (2022). Point of Care Molecular testing: Community-Based Rapid Next-Generation Sequencing to support cancer care. *Current Oncology*, 29(3), 1326–1334.
**Categories:** Life Science Blog, Molecular, NGS
---
### [Four Key Strategies to Enhance Sustainability in Diagnostic Testing](https://www.meridianbioscience.com/lifescience-blog/our-key-strategies-to-enhance-sustainability-in-diagnostic-testing/)
**Published:** June 4, 2024
**Author:** hamza
**Excerpt:** The article outlines four pivotal strategies for enhancing sustainability in diagnostic testing. It emphasizes the importance of reducing waste and environmental impact through innovative approaches such as optimizing test designs and utilizing eco-friendly materials. Additionally, it discusses the benefits of lyophilized reagents, which can decrease the carbon footprint associated with cold chain logistics. The piece is insightful, offering practical solutions for making diagnostic practices more sustainable while maintaining efficiency and effectiveness.
**Content:**
Diagnostic waste constitutes a tenth of all medical waste1, and most is infectious or hazardous, making reuse and recycling challenging. This includes waste generated from single-use diagnostic tests, laboratory reagents, and other related materials. The rising adoption of point-of-care diagnostic tests will only amplify this issue, underscoring the critical need for proper waste management and disposal to enhance sustainability in healthcare.2
Overall as consumer awareness and regulatory pressure to be more eco-conscious increases, adopting sustainability practices into healthcare becomes a necessary factor. A growing number of diagnostic developers have committed to the UN-backed “Race to Zero” initiative, pledging to achieve net-zero greenhouse gas emissions by 2050.3
Strategies that support sustainable practices focus on using resources efficiently to maximize productivity and eliminate waste. For diagnostic companies, this translates not only to helping the environment but also to reducing costs, building resilience, and providing a significant competitive advantage. There are several different approaches to enhance an assay’s sustainability and in this blog, we will delve into four key strategies that can make a significant impact.
## 1. Consider alternative sample types & patient self-collection
Diagnostic blood samples collected by phlebotomy are the most common type of biological specimens sent to laboratories. According to a study published in 2020 examining the carbon footprint of pathology testing for five common hospital pathology tests, most carbon dioxide equivalent (CO2e) emissions are associated with sample collection (range, 60% for full blood examination to 95% for coagulation profile)4. Replacing venous blood collected by a phlebotomist for patient self-collection of capillary blood using a fingerprick or other methods would immediately eliminate a significant portion of these carbon emissions. It would remove the need for PPE, a key contributor to CO2e emissions, and for patient travel to a collection site.
In addition, alternative sample types such as saliva and urine, where the analyte remains stable in the matrix and is not sensitive to temperature and other environmental factors, are ideal for reducing carbon emissions as they are easily transported by mail or post and do not require refrigeration. They also generally require less sophisticated sample collection devices, reducing the amount of hazardous waste produced in the collection process.
### 2. Lyophilize assay reagents to reduce CO2 emissions produced from cold chain transport and storage
Diagnostic manufacturers often produce reagents centrally and distribute them globally, resulting in the consequential impact of CO2 emissions. Some of this global distribution necessitates cold-chain shipping and storage to maintain product integrity.5 By lyophilizing reagents, – they remain stable at room temperature thereby removing the need for cold-chain transport, storage, monitoring, and the waste produced from cold-chain packaging6. This drastically reduces a test’s carbon footprint. In addition, lyophilized assays extend an assay’s shelf-life, reducing waste and associated costs on multiple levels.
### 3. Reduce the steps and materials used in an assay workflow
Plastics and consumables make up a large part of an assay’s environmental footprint, especially single‐use items. Currently, most molecular qPCR tests require RNA or DNA extraction prior to detection; however, extraction is expensive, time-consuming, and requires technical expertise. Eliminating this step in favor of direct detection can streamline the diagnostic workflow, reduce assay complexity, accelerate specimen processing, reduce time to results and decrease reagent usage.
Generally, improving an assay’s efficiency can reduce its carbon footprint. Strategies such as removing steps in a protocol, minimizing the volume of reagents used, and multiplex testing can be employed to reduce the hazardous waste produced in performing a test. However, to implement these strategies, the reagents used must meet certain criteria. High-concentration reagents are required to reduce assay volume, inhibitor-tolerant master mixes must be formulated to achieve a high sensitivity without nucleotide extraction and uniform multiplexing requires a mix to perform uniformly, with unbiased amplification of different targets.
### 4. Use animal-free reagents whenever possible
In recent years, there has been a growing movement towards developing animal-free reagents, with the European Medicines Agency (EMA) spearheading the implementation of the 3Rs principles (Replace, Reduce, Refine) to minimize the use of animals in diagnostics. These alternative reagents aim to improve assay performance and reproducibility, and reduce cost while also contributing to a more sustainable and humane future. Using animal-free reagents can improve assay carbon footprint, by reducing the environmental impact associated with sourcing and processing animal-derived materials. This approach eliminates the need for raising and maintaining animals, reducing land use, water consumption, and greenhouse gas emissions associated with animal agriculture. Additionally, it minimizes the use of chemicals and resources involved in processing animal-derived reagents.
Blockers, such as Mouse IgG, are used in immunoassays to reduce non-specific binding and other interference that can lead to false positive results. These reagents can be used in large amounts and require mice to be immunized in order to harvest the antibodies they produce.
The process has raised ethical concerns and prompted the exploration of alternative, animal-free methods for immunoassay blocker production.
In addition, antibodies, antigens, and enzymes from animal-free sources are increasingly available, whether as recombinant proteins/enzymes or derivatives from plants or bacteria. Animal-free reagents generally exhibit minimal variability and a lower risk of contamination compared to animal-origin counterparts. Their adoption represents a pivotal step towards ethical and sustainable practices in diagnostic manufacturing.
### Making tests more sustainable by design
Environmental sustainability is often described as a hierarchy of waste reduction: avoid, reduce, re‐use, and recycle7.
However, for pathology testing, the opportunities for re‐using or recycling items are limited due to infection control. The main opportunities for reducing waste and CO2 emissions involve utilizing sustainable materials, optimizing processes, reducing reagent volumes, and employing multiplex testing.
At Meridian, we believe sustainability starts with us. Across our entire operation, we strive to integrate the principles of sustainability and ethical practices into our business to deliver innovative, eco-conscious products to our customers and help empower them to achieve their sustainability goals. Some of our leading innovative and environmentally conscious products include:
- [Specimen-specific mixes](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/) formulated for sensitive detection from alternative sample types such as saliva, urine and stool
- [Lyo-Ready and Air-dryable™ master mixes](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/) as well as glycerol-free enzymes designed for creating ambient-temperature stable assays
- [High-concentration enzymes ](/lifescience/products/molecular-reagents/enzymes/) suited to assay miniaturization
- [Inhibitor-tolerant master mixes](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/) developed for direct amplification from crude lysates
- [Animal-free immunoassay blockers;](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/animal-free-blockers/) HAMA, HA and Rf
[](https://share.hsforms.com/1JZZ6N8s_Tqq3jCi-MFGg6Qc22yq)
**References:**
1\. Street, A., Vernooij, E. & Rogers, M.H. Diagnostic waste: whose responsibility?. *Global Health* **18**, 30 (2022).
2\. [Why the medical industry should tackle single-use diagnostic waste. Medical Plastics News](https://www.medicalplasticsnews.com/medical-plastics-industry-insights/latest-medical-plastics-insights/why-the-medical-industry-should-tackle-single-use-diagnostic/) (2022)
3\. [Study Finds Rapid Progress in Biotech & Pharma Companies Committing to UN Race to Zero through My Green Lab Certification Program. *My Green Lab*. (2023).](https://www.mygreenlab.org/2022-carbon-impact-of-biotech--pharma-report.html)
4\. McAlister, S., et al., The carbon footprint of pathology testing. *Med J Aust;* 212 (8): 377-382. (2020) doi: 10.5694/mja2.50583
5\. The cold chain innovates to meet post-COVID demands. *Nature* (2022)
6\. *Whyte*, S. Building a Greener Supply Chain: Key Considerations for Cold Chain. PharmTech 64 (5): 34-37. (2022)
7\. *Sustainable Materials Management: Non-Hazardous Materials and Waste Management Hierarchy.* United States Environmental Protection Agency.
**Categories:** Life Science Blog, Molecular, Sustainability
---
### [The Silent Threat of Cancer-Causing Viruses](https://www.meridianbioscience.com/lifescience-blog/the-silent-threat-of-cancer-causing-viruses/)
**Published:** May 6, 2024
**Author:** hamza
**Excerpt:** The article discusses the underappreciated risks posed by viruses that can lead to cancer. It highlights the significant influence of oncoviruses such as HPV, Hepatitis B, and Hepatitis C, which are linked to a range of cancers. The piece delves into the mechanisms through which these viruses operate and the global impact they have on cancer incidence, emphasizing the need for increased awareness and preventative measures in public health strategies.
**Content:**
When we think about cancer, we often associate it with genetic mutations, environmental factors, or lifestyle choices such as smoking. However, approximately 15-20% of cancers are caused by viruses, especially sexually transmitted viruses such as human papillomavirus (HPV), hepatitis B (HBV) and C (HCV)1. These viruses, termed oncoviruses, generally have several features in common: they are mostly DNA viruses, they mainly encode growth-stimulating proteins, and they establish persistent, long-term infection in the host, causing cancer 15-40 years after the initial infection2. Infection with oncoviruses may cause cancer directly by dysregulating tumor suppressor genes and other oncogenes in the host, or indirectly, by way of chronic inflammation or immune suppression. In this blog, we will provide a comprehensive overview of the seven known oncoviruses, HPV, HBV, HVC, Epstein-Barr virus (EBV), human T-lymphotropic virus 1 (HTLV-1), human herpesvirus 8 (HHV-8) and Merkel cell polyomavirus (MCPyV), as well as HIV, which is not technically an oncovirus but infection with HIV renders a patient vulnerable to developing malignancies, especially those transmitted by oncogenic viruses.
## Human papillomaviruses (HPVs)
Human papillomaviruses (HPVs) are a group of more than 150 related viruses that commonly cause warts. More than 40 types of HPV are sexually transmitted and according to the World Health Organization (WHO), HPV is the most common global sexually transmitted infection (STI) with up to 80% of sexually active people infected with one or more HPV virus type at some point in their lives. Approximately a dozen HPV types are known to cause cancer, and certain high-risk strains of HPV, particularly HPV types 16 and 18, are linked cervical cancer, which is the second most common cancer among women worldwide.
HPV infection can also lead to anal cancer (90% are caused by HPV), oropharyngeal cancer (70% are caused by HPV), penile cancer (63% are caused by HPV), vaginal cancer (75% are caused by HPV), and vulvar cancer (69% are caused by HPV)3.
However, cervical cancer is currently the only HPV-causing cancer with FDA-approved screening tests.
### Hepatitis B Virus (HBV) & hepatitis C Virus (HCV)
Viral hepatitis, a type of liver infection, is caused by hepatitis viruses, in particular hepatitis B (HBV) and hepatitis C (HCV). Globally, viral hepatitis is responsible for 80% of liver cancers and untreated chronic HBV or HCV infections represent the fastest-increasing cause of cancer death and the second fastest-increasing incidence of all cancers 4.
HBV and HCV are spread from person to person through sharing needles (such as during injection drug use), unprotected sex, or childbirth. The viruses can integrate their genetic material into the host cell’s DNA, disrupt cellular regulatory mechanisms, and promote uncontrolled cell growth, thereby contributing to the development of liver cancer. While not all cases of viral hepatitis lead to liver cancer, chronic infection with HBV or HCV significantly increases the risk of developing hepatocellular carcinoma over time.
### Epstein-Barr virus (EBV)
Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a type of herpes virus best known for causing infectious mononucleosis, often called “mono” or the “kissing disease.” In addition to kissing, EBV can be passed from person to person by coughing, sneezing, or by sharing drinking or eating utensils. More than 90% of the world’s population has been infected with EBV by their teen years5.
As with other herpes virus infections, EBV infection is life-long and stays latent in memory B cells. Infection with EBV increases the risk of several cancers, including Burkitt lymphoma, some types of Hodgkin’s and non-Hodgkin’s lymphoma, and stomach cancer. Overall, it’s estimated that EBV infection contributes to about 1.5% of cancers worldwide, with EBV-related cancers being more common in Africa and parts of Southeast Asia6.
### Human herpes virus 8 (HHV-8)
HHV-8, also known as Kaposi sarcoma–associated herpes virus (KSHV), belongs to the same family as EBV and causes Kaposi sarcoma (KS), a cancerous tumor of the connective tissue. KSHV is transmitted mainly through saliva, however, it can also be spread through sexual contact, blood transfusion, or transplants.
The seroprevalence of HHV-8 varies worldwide and is estimated to be 1% to 5% in the U.S. general population, 10% to 20% in certain Mediterranean countries and 30% to 80% in parts of sub-Saharan Africa. HIV-infection is an important risk factor for developing KS with almost 30% of AIDS patients infected with KS prior to the advent of effective antiretroviral therapy7.
### Human T-lymphotrophic virus-1 (HTLV-1)
HTLV-1 is a complex retrovirus that belongs to the primate T-lymphotropic virus (PTLV) family. It is a sexually transmitted disease endemic to Japan, Melanesia, Iran, Central and West Africa, the Caribbean, Australia, and the Middle East. Approximately 10 million people are infected with HTLV-1 around the world, but most of them remain asymptomatic. Only a small proportion (2%–5%) of HTLV-1-infected humans progress to adult T-cell leukemia/lymphoma (ATL), a very aggressive form of leukemia8.
### Merkel cell polyomavirus (MCPyV)
Merkel cell polyomavirus (MCPyV) is a virus associated with Merkel cell carcinoma (MCC), a rare but aggressive type of skin cancer that typically occurs in sun-exposed areas of the skin, such as the head and neck. The virus is found on the skin and mucosal surfaces and is thought to be a part of the normal human skin microbiome9.
MCPyV is transmitted through close contact with infected individuals and many people carry the virus without developing cancer. The development of MCC usually involves additional factors such as a weakened immune system or excessive exposure to ultraviolet (UV) radiation. Immunocompromised individuals, such as those with HIV/AIDS or undergoing organ transplantation and receiving immunosuppressive therapy, are at higher risk of developing MCC associated with MCPyV infection.
### Human immunodeficiency virus (HIV)
HIV, the virus that causes acquired immune deficiency syndrome (AIDS), is not an oncovirus that can cause cancer directly, but an infection that increases a person’s risk of getting several types of cancer, especially those caused by oncoviruses. HIV infects and destroys white blood cells known as helper T-cells, which weakens a body’s immune system causing it to be more susceptible to the development of cancer, including Hodgkin disease, Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer, and cancer of the skin, anus, lung, and liver10.
### The Vital Role of Testing in Detecting Asymptomatic Oncoviruses and Preventing Cancer
Understanding the role of viruses in cancer development is critical for developing preventive measures and targeted treatments. However, many oncoviruses are asymptotic, making them challenging to detect and diagnose, and individuals unaware that they are infected inadvertently transmit the infection to others. Routine screening and early detection can help identify viral infections before they progress to cancer or other serious complications.
### Meridian’s Molecular & Immunoassay STD Diagnostic Solutions
As a leader in infectious diseases, Meridian Bioscience has supported assay developers for over 45 years with innovative reagent solutions for STD diagnostic assays. With over 200 antigens and antibodies for STD immunoassay testing, and a large range of master mixes and enzymes for qPCR and isothermal amplification applications, Meridian is ready to provide solutions, big and small for the growth STD industry.
**References:**
1\. Bouza E., *et al.* (2021). Overview of virus and cancer relationships. Position Paper. *Rev Esp Quimioter*. 34(6):525-555. doi: 10.37201/req/058.2021.
2\. Kainat A. and Sudhakar J. (2023). Oncoviruses: How do they hijack their host and current treatment regimes, *Biochimica et Biophysica Acta* (BBA) – Reviews on Cancer. 1878(5). doi: org/10.1016/j.bbcan.2023.188960.
3\. [National Cancer Institute. *HPV and Cancer*. U.S. Department of Health and Human Services.](https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-andcancer#:~:text=HPV%20can%20cause%20six%20types,and%20cases%20of%20genital%20warts)
4\. [National Cancer Control Indicators. (2022) Hepatitis B and Hepatitis C Notification. Cancer Australia.](https://ncci.canceraustralia.gov.au/prevention/hepatitis/hepatitis-b-and-hepatitis-c-notification)
5\. Dunmire S.K., *et al.* (2015). Infectious Mononucleosis. *Curr Top Microbiol Immunol.* 390(Pt 1):211-40. doi: 10.1007/978-3-319-22822-8\_9.
6\. Shechter O., *et al.* (2022). Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. *Int J Mol Sci.* 23(22):14389. doi: 10.3390/ijms232214389.
7\. [Clinical Info HIV Gov. Federally Approved Clinical Practice Guidelines for HIV/AIDS](https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-herpesvirus#:~:text=Epidemiology,parts%20of%20sub%2DSaharan%20Africa)
8\. [Zhang L.l., *et al.* (2017). Human T-cell lymphotropic virus type 1 and its oncogenesis. *Acta Pharmacol Sin.* 38:1093–1103.](https://doi.org/10.1038/aps.2017.17)
9\. Yang J.F. and You J. (2022) Merkel cell polyomavirus and associated Merkel cell carcinoma. *Tumour Virus Res.* 200232. doi 10.1016/j.tvr.2021.200232.
10\. Omar A., *et al.* (2024) Cancer and HIV: The Molecular Mechanisms of the Deadly Duo. Cancers (Basel). 16(3):546. doi: 10.3390/cancers16030546.
**Categories:** Immunology, Life Science Blog
---
### [Bridging the Divide: Democratizing Genomic Testing by Lowering the Barriers to DNA Sequencing](https://www.meridianbioscience.com/lifescience-blog/bridging-the-divide-democratizing-genomic-testing-by-lowering-the-barriers-to-dna-sequencing/)
**Published:** April 8, 2024
**Author:** hamza
**Excerpt:** The article "Bridging the Divide: Democratizing Genomic Testing by Lowering the Barriers to DNA Sequencing" explores innovative ways to make DNA sequencing more accessible and affordable. It discusses how reducing technological and economic barriers can enhance global health outcomes by enabling broader use of genomic testing. The piece emphasizes the importance of collaboration and innovation in the field of genetics to democratize health diagnostics worldwide.
**Content:**
In recent years, genetic sequencing has emerged as a powerful tool in healthcare, offering insights into our genetic makeup and predispositions to various diseases. Traditionally, confined to specialized laboratories and research institutions, a genomic revolution is taking place with the democratization of genetic sequencing, where research labs worldwide have improved access to and reduced costs of next-generation sequencing (NGS) technology. Genomic-powered precision health driven by NGS technology is seen as the next major advancement in healthcare. It has the potential to substantially improve patient outcomes by identifying disease-causing variants, enabling the accurate and early detection of cancer, infectious diseases, rare genetic variants, prenatal abnormalities, and pharmacogenetic variations that can impact response to treatment.
## Addressing Disparities in Genetic Testing
According to a recent article in Nature Medicine, eighty-six percent of all genomics studies have been conducted in individuals of European descent1, highlighting a stark disparity in the availability and accessibility of genetic testing globally. As a result, the current genomic data available lacks representation from all populations and fails to capture the genetic diversity that exists across different ethnicities and geographical regions. Many diseases exhibit variations in prevalence, severity, and response to treatment based on genetic factors influenced by ethnicity and ancestry. Without adequate representation, the effectiveness of genomic research in addressing the genetic basis of disease in non-European populations is significantly limited.
### Overcoming Logistical Barriers to Next Generation Sequencing (NGS) Adoption
To achieve widespread adoption of NGS, several logistical barriers must be overcome to enhance its affordability and accessibility. Although the overall affordability has improved since 2007, when sequencing a single human genome cost more than US$10 million2, the cost of sequencing in low-income countries can still be five times higher than in high-income countries because of taxes, and the high cost of analysis, shipment, and infrastructure. Specifically, challenges in low-income countries include coordination of sample handling, reagent cost and procurement, quality-assured procedures, and data management. In addition to logistical complications, from an ethical standpoint, there is also a need to ensure that the benefits of genomic research are equitably distributed and that marginalized communities are not exploited. Efforts to democratize access to NGS technologies and genomic data should ideally be accompanied by initiatives to address disparities in healthcare access, promote inclusivity, and prioritize the needs and perspectives of vulnerable populations3.
### Advancements & Technological Growth in NGS
Advances in hardware and software have generally made sequencing faster and more affordable for labs of all sizes, catalyzing the expansion of the NGS market and its application in new environments. Sequencers that accommodate lower sample volumes are accessible at prices equivalent to those for high-volume users, allowing for less sequencing centralization and more democratization and control of samples and the resulting data.
In addition, new sequencing chemistry allows products to be shipped and used without the need for cold chain or temperature-controlled logistics. This innovation addresses a critical challenge faced by many countries, as cold chain logistics can be expensive, logistically complex, and sometimes inaccessible in resource-constrained settings. During the COVID pandemic, due to travel restrictions and disruptions in supply chains, cold chain logistics faced numerous challenges worldwide, highlighting the critical importance of developing alternative, resilient, temperature-stable solutions to support the efficient and reliable distribution of medical products. Enabling laboratories to conduct their own NGS research and analysis without sending samples to other countries overall minimizes costs, leads to faster lead times, and reduces sample handling logistics.
Overall, with the democratization of NGS technology and the continual decline in sequencing costs, its application will continue to expand to new areas, and the incorporation of new tools such as cloud-based NGS informatics platforms, machine learning, and artificial intelligence, will further fuel its role in transforming healthcare globally4.
Steps in an NGS Workflow
### Meridian’s Glycerol-Free Enzymes: Sustainable Solutions for NGS
Meridian has a comprehensive menu of glycerol-free NGS enzymes that are useful in all steps of an NGS workflow. The enzymes are specifically designed for lyophilization and offer a sustainable solution that effectively eliminates the need for cold-chain shipment and storage. They are formulated in a high-concentration format, meeting the demands for miniaturization which is often required for point-of-care devices, and maximizing the sample input quantity to improve assay sensitivity.
To learn more, visit our website:
[](/lifescience/products/molecular-reagents/ngs-enzymes/)
**References:**
1\. Fatumo, S., et al. A roadmap to increase diversity in genomic studies. *Nat Med*. 2022 Feb;28(2):243-250. doi: [10.1038/s41591-021-01672-4](https://www.nature.com/articles/s41591-021-01672-4)
2\. Stein, J. Expert urges widespread adoption of next-generation sequencing among physicians. *Urology Times*. 2002 Apr.
3\. de Araujo, L., *et al.* Implementation of targeted next-generation sequencing for the diagnosis of drug-resistant tuberculosis in low-resource settings: a programmatic model, challenges, and initial outcomes. Front. Public Health. 2023 Aug; Sec. Infectious Diseases: Epidemiology and Prevention (11)
4\. Frost & Sulivan. (2023) Next-generation Sequencing Informatics, Forecast to 2027.
**Categories:** Life Science Blog, Molecular, NGS
---
### [The 2023-2024 Respiratory Virus Season: Embracing the Evolving Landscape](https://www.meridianbioscience.com/lifescience-blog/the-2023-2024-respiratory-virus-season-embracing-the-evolving-landscape/)
**Published:** March 18, 2024
**Author:** hamza
**Excerpt:** The article provides an overview of the challenges and developments expected for the 2023-2024 respiratory virus season. It discusses the ongoing influence of COVID-19 alongside other respiratory viruses like influenza and RSV. The piece highlights advancements in diagnostic tests and public health strategies aimed at managing the evolving landscape of respiratory illnesses.
**Content:**
Four years ago, on March 11th, 2020, the World Health Organization declared COVID-19 a worldwide pandemic. With each respiratory season since then, the familiar specter of COVID-19 has persisted, but it is no longer the unprecedented emergency that dominates headlines. Instead, COVID has become part of the broader narrative of the respiratory virus season, sharing the stage with influenza and RSV.
## The Respiratory Virus Season in 2023 – 2024
So far, this year’s respiratory season in the U.S. appears to be in decline, with most indicators trending down after a late surge in December. Compared to the 2022-2023 season, flu and RSV infections started later in the season this year, and while COVID levels are still higher than they were last season, other COVID metrics such as emergency room visits, hospitalization rates and deaths, are lower now than previous seasons. Overall, the most commonly reported influenza viruses this year have been type A(H1N1) and type B viruses.
### Flu-related Pediatric Deaths
In early March, the CDC reported a further ten flu-related pediatric deaths, bringing the total for the season to 103. Over the past ten years, the number of pediatric flu deaths has ranged from 1 (2020-2021) to 199 (2019-2020) in a single season. This year, about half of the reported deaths (55) were associated with influenza A virus infection, and of the 31 influenza A specimens that were subtyped, 26 were influenza A(H1N1) and 5 were influenza A(H3N2) virus. Influenza B viruses were associated with 47 pediatric deaths this season. One death was associated with an influenza A(H1N1) virus and influenza B virus coinfection. Nearly 90% of the children who died were not vaccinated against flu .
In addition, for this respiratory season, China reported an increase in the incidence of mycoplasma pneumonia, predominantly affecting children. Although the circulating strain was mild, children were presenting with severe infections causing overcrowding in hospitals. The reasons attributed to this surge in M. pneumonia were (1) co-infections with other respiratory infections, (2) an immunity gap due to a lack of previous exposure during the COVID lockdown, and (3) resistance to macrolide antibiotics which are used to treat children infected with M. pneumonia. According to a study published in JAMA Network Open in 2022, nearly 80% of cases of M. pneumonia infections in China are resistant macrolide antibiotics, in contrast to less than 10% in Europe, America and Southeast Asia.
### Extinction of the Yamagata Lineage of Influenza B Viruses
Up until recently, most flu infections were caused by variants from two influenza A strains—H1N1 and H3N2—as well as from two influenza B strains—the Victoria and Yamagata lineages. However, since March 2020, the Yamagata lineage of influenza B viruses has not been isolated and it is now believed to be extinct. All of the precautions that helped people avoid COVID such as masks, staying at home and better ventilation, appear to have impacted the Yamagata viruses, which were already in decline before the pandemic.
As a result of this change, in September 2023 the World Health Organization said that “inclusion of the Yamagata-lineage antigens in influenza vaccines is no longer warranted.” Accordingly, the U.S. FDA is recommending a three-strain flu vaccine for the 2024-2025 season as opposed to the quadrivalent vaccine that has been recommended for the past 10 years.
### Major Shift in Respiratory Diagnostic Testing
As the flu season comes to a potential end in the northern hemisphere, the southern hemisphere is bracing itself for the start of its new season. Since November, monthly influenza cases in Australia have reached more than triple pre-pandemic levels, and the jump is largely thought to be due to increased travel to the northern hemisphere. However, predictions for the 2024 season are not available yet.
Since the pandemic, one major shift in respiratory diagnostic testing has been the adaptation of home testing for the flu and COVID-19. A range of home lateral flow tests are now available that can distinguish between flu and COVID with a single swab. In addition, syndromic molecular diagnostic assays that can simultaneously detect multiple pathogens or drug resistance markers, are replacing traditional panel-based ordering of infectious disease tests. Overall, rapid diagnostic solutions that expedite the identification and treatment of respiratory infections are gaining traction, modernizing the way healthcare providers diagnose and manage these conditions, ultimately leading to more efficient and effective patient care.
Meridian offers both highly sensitive and specific reagent solutions for rapid immunoassays and molecular (qPCR and LAMP) techniques to meet your needs. To learn more, visit our resource page:
[](https://info.meridianbioscience.com/multiplexing-respiratory-assay-reagent-solutions)
#### References:
Centers for Disease Control and Prevention. “More than 100 Flu-Related Deaths in Children Reported So Far This Season” [Centers for Disease Control and Prevention Wesbite](https://www.cdc.gov/flu/spotlights/2023-2024/pediatric-flu-deaths.htm). March 8, 2024.
Goodman, B. [“The Covid-19 pandemic killed off one strain of the flu, and that will change the next vaccines”](https://edition.cnn.com/2024/03/05/health/flu-vaccine-yamagata-strains/index.html) CNN Health. March 5, 2024.
Kim, K., *et al*. Global Trends in the Proportion of Macrolide-Resistant *Mycoplasma pneumoniae* Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220949. doi:10.1001/jamanetworkopen.2022.20949
**Categories:** Life Science Blog
---
### [Embracing Ethical Innovation: Breaking New Ground with Animal-Free Immunoassay Blockers](https://www.meridianbioscience.com/lifescience-blog/embracing-ethical-innovation-breaking-new-ground-with-animal-free-immunoassay-blockers/)
**Published:** March 11, 2024
**Author:** hamza
**Excerpt:** Embracing Ethical Innovation: Breaking New Ground with Animal-Free Immunoassay Blockers" discusses the shift towards more ethical laboratory practices by adopting animal-free immunoassay blockers. It explores how this innovation not only aligns with ethical standards but also enhances assay performance and reproducibility, supporting a sustainable and responsible scientific future.
**Content:**
In recent years, there has been a growing movement towards developing animal-free reagents that aim to improve assay performance and reproducibility while also contributing to a more sustainable and humane future. This shift reflects the broader commitment to ethical practices and innovation within the science community, with an aim to replace animal-derived reagents commonly used in laboratories with animal-free versions that are more scientifically robust.
Immunoassay blockers, such as Mouse IgG, are used in immunoassays to reduce non-specific binding and other interference that can lead to false positive results. These reagents can be used in large amounts and require mice to be immunized in order to harvest the antibodies they produce.
The process has raised ethical concerns and prompted the exploration of alternative, animal-free methods for immunoassay blocker production.
The COVID-19 pandemic highlighted the vulnerability of Mouse IgG supply chains to unforeseen events and the dependence on single-source suppliers, particularly those located in China. Recombinant reagents play a critical role in diversifying and de-risking supply chains by offering greater flexibility, reliability, and scalability compared to traditional manufacturing methods. Importantly, recombinant production processes can be tailored to meet specific demand requirements, enabling manufacturers to adjust production volumes more rapidly in response to market dynamics.
In addition to the ethical considerations, using animal-free blockers has several other benefits that make them ideal, sustainable alternatives over traditional animal-derived blockers.
## Top 5 Advantages of Animal-Free Blockers in Immunoassays
1. #### Enhanced Assay Specificity and Sensitivity
Animal-free blockers can improve assay specificity as they eliminate the potential for cross-reactivity or interference with animal-derived components within an assay. Moreover, animal-free blockers minimize the risk of nonspecific binding, enabling a higher signal-to-noise ratio, and better assay sensitivity. For assays detecting low-abundance analytes, this heightened sensitivity is particularly valuable.
2. #### Consistent Assay Performance
In addition to increasing assay specificity and sensitivity, animal-free blockers can improve assay reproducibility. Animal-derived reagents often suffer from batch-to-batch variability, whereas animal-free reagents are more chemically well-defined and contain a finite number of traceable ingredients that demonstrate greater consistency. This traceability and consistency also support regulatory advantages that can improve an assay’s speed to market.
3. #### Ethical Considerations & Improved Environmental Impact
There is growing societal awareness and expectations regarding cruelty-free and humane practices which are creating a shift towards ethical consumerism. Companies and individuals are increasingly seeking products and services aligned with their values. Animal-free blockers provide an opportunity for companies to actively participate in ethical innovation and showcase their dedication to advancing science and technology while contributing to a. more sustainable future.
4. #### Regulatory compliance
As the ethical landscape evolves, regulatory bodies are becoming more stringent about the use of animals in science. Embracing animal-free blockers aligns with more sustainable practices and also ensures compliance with changing regulations. Proactively addressing sustainability can help companies enhance their reputation in the eyes of consumers and regulatory authorities.
5. #### Reduced risk of contamination
Animal-derived components used in traditional blockers can carry contaminants, such as viruses, prions, and endotoxins, that can affect the accuracy of an assay. Animal-free reagents do not carry any of these risks.
The innovation and adoption of animal-free blockers represent a pivotal step towards ethical and sustainable practices in diagnostic manufacturing. Beyond the immediate benefits of improved assay performance and regulatory compliance, companies choosing this path position themselves as leaders in responsible business practices.
Meridian recently launched two new immunoassay interference blockers, K-Block™ and Mouse-Free IgG, which are 100% animal-free and have equivalent or superior performance compared to traditional animal-derived blockers. These products align with Meridian’s strategy to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers. Meridian hopes to encourage diagnostic manufacturers to adopt animal-free products, such as K-Block™ and Mouse-Free IgG, and actively contribute towards improving our community’s environmental footprint and supporting a more sustainable future. Meridian continues to lead the way in promoting environmental responsibility within the industry.
To learn more about K-Block™ and Mouse-Free IgG, join our webinar, **March 20th at 9 am PT**.
[](https://attendee.gotowebinar.com/register/1744617527550139739?source=blog)
All registrants will receive a copy of the webinar recording.
**Categories:** Immunology, Life Science Blog
---
### [Unlocking Success: Top Criteria to Consider when Choosing the Best Reagents for High-Throughput Assays](https://www.meridianbioscience.com/lifescience-blog/unlocking-success-top-criteria-to-consider-when-choosing-the-best-reagents-for-high-throughput-assays/)
**Published:** January 22, 2024
**Author:** hamza
**Excerpt:** The article provides a comprehensive guide on selecting reagents for high-throughput assays, emphasizing the importance of enzyme sensitivity and specificity, compatibility with automated systems, and the advantages of using glycerol-free reagents. It highlights how these factors contribute to the accuracy and efficiency of diagnostics.
**Content:**
High-throughput screening has become an indispensable tool in medical diagnostics, allowing pathologists to screen a large number of patient samples quickly and efficiently. First developed in the 1990s for drug discovery, high-throughput screening was quickly adapted for diagnostic purposes and evolved from traditional methods to sophisticated, technology-driven systems. The ongoing integration of new technologies such as assay miniaturization, automation, and robotics will shape the future of high-throughput diagnostic screening, offering faster, more accurate, and personalized diagnostic solutions for a wide range of medical conditions.
At the heart of high-throughput platforms are molecular enzymes that drive the assay reaction and influence an assay’s precision and performance. High-throughput platforms require specific enzyme solutions that are sensitive, specific, fast, stable, and enable a simplified workflow. Key features required to support high throughput diagnostic platforms include room-temperature stability, compatibility to fit several formats (e.g. glycerol-free), and suitability for multiplex assays. Carefully selected reagents contribute to a robust signal, minimizing false signals and enhancing the overall quality of the diagnostic screening data. In this blog, we will delve into the top criteria that diagnostic assay developers should consider when selecting reagents for their high-throughput assays.
## Enzyme Sensitivity and Specificity
Many high-throughput assays now incorporate multiplex screening panels that can detect over twenty targets simultaneously. To achieve precise target detection in multiplexing, high enzyme sensitivity and specificity are essential for differentiating between targets that may share similar structures and be present in varying concentrations. An assay with a wide dynamic range can detect a broad range of template concentrations without reaching saturation, providing better assay accuracy even at extremely low or high analyte concentrations. Overall, designing a high-throughput multiplex assay requires careful optimization of assay conditions, such as reaction kinetics, buffer composition, and temperature. Balancing these parameters for multiple targets simultaneously can be challenging, as changes that benefit one analyte may negatively impact others. Ready-made master mixes can help save time and effort during assay optimization and circumvent the tedious process of individually optimizing reaction conditions for each target. Alternatively, enzymes that are supplied with specialized buffers are also typically formulated to provide optimal conditions, requiring little optimization, they may also contain additives or stabilizers that enhance the sensitivity of an assay.
## High-Throughput Assay Development: Compatibility
In high-throughput assays, where speed and efficiency are paramount, addressing reagent compatibility in the planning stages reduces the likelihood of encountering errors during assay development and the need to perform extensive troubleshooting. For high-throughput platforms that use automated liquid handling systems or robotic platforms, ideal regent features include high concentration and low viscosity to ensure precise dispensing. Glycerol-free reagents are a popular solution as they eliminate potential interference with downstream applications, reduce background noise, and are compatible with automated systems requiring low viscosity.
## High-Concentration:
Enzymes and mixes provided at high concentrations (e.g. 50 U/µL or greater) offer several benefits for high-throughput applications, including accelerated reaction kinetics, enhanced enzymatic activity, smaller reaction volumes, and greater flexibility in assay design.
High-concentration enzymes often provide more consistent and reliable performance and contribute to better cost-effectiveness as less enzyme is needed to perform the reaction, which can be particularly important in large-scale applications where cost efficiency is a significant consideration.
*Glycerol-free Reagents:*
Glycerol, which is a common component in enzyme storage buffers, serves as a cryoprotectant and protein stabilizer, but it can increase the viscosity of a reagent and introduce pipetting challenges.
Glycerol-free enzymes are valuable in enhancing user precision during liquid handling and are particularly suitable for fast robot-aided automation processes. In addition, enzymes and master mixes that are glycerol-free can be lyophilized or air-dried to create room-temperature stable assays. Benefits to room-temperature stable assays include simplified, refrigeration-free shipping and storage logistics as well as increased shelf-life, as room-temperature stability can reduce the risk of reagent degradation during transportation or storage. Overall, room-temperature stable assays are more cost-effective to transport and contribute to more sustainable laboratory practices, reducing the environmental impact associated with assay production, storage, and transportation.
### Hot Start Enzymes:
Hot start enzymes enhance an assay’s precision, sensitivity, and reliability by inhibiting the activity of the DNA polymerase during the initial PCR setup. This is particularly important in high-throughput systems where reactions are prepared in bulk and multiple reactions are conducted simultaneously. Specifically, hot start enzymes maintain optimal reaction conditions during the entire setup process, reducing the risk of both unintended amplification and formation of primer-dimer artifacts.
There are different types of hot start [enzymes](/lifescience/products/molecular-reagents/enzymes/), and they can be classified based on the mechanisms used to inhibit the polymerase activity. The primary types include:
**Chemical-mediated:** Chemical modifications are added to the enzyme to inhibit polymerase activity at lower temperatures
**Antibody-mediated:** Antibodies specific to the polymerase physically block its active site at lower temperatures
**Aptamer-mediated:** Aptamers (short DNA sequences) specifically bind to the polymerase, reversibly inhibiting its activity at lower temperatures
Each type of hot start enzyme has advantages and characteristics that can impact the assay reaction and workflow, especially in the reaction set-up and activation time. When selecting a hot start enzyme for high-throughput applications, it is crucial to consider factors such as the sample volume, instrumentation, and sample type.
#### Conclusion
Selecting the best reagents for high-throughput assays is critical to developing a successful assay. Reagents that are easy to handle and require minimal preparation contribute to the efficiency of high-throughput assays, while enzyme performance directly impacts assay precision and accuracy. In addition to high quality and consistency, assay developers should also consider the cost-effectiveness of reagents. Evaluating the overall cost of reagents against the performance of the assay and its intended use is vital. Some high-quality reagents may come at a higher price, but the investment can be justified if they contribute to the overall success and reliability of the assay.
Meridian supports diagnostic manufacturers with enzymes suitable for all types of applications, including high-throughput systems. From high concentration and glycerol-free enzymes to lyophilization-ready master mixes and polymerases with different types of hot start, Meridian supplier reputation for quality control, customer support, and responsiveness to issues has solidified its position as a trusted partner for diagnostic manufacturers.
[To learn more about our high-throughput molecular assay solutions](https://www.meridianbioscience.com/lifescience/products/molecular-reagents)
**Categories:** Life Science Blog, Molecular
---
### [Revolutionizing STD Testing: Navigating the Advancements in Molecular and Immunoassay Techniques](https://www.meridianbioscience.com/lifescience-blog/revolutionizing-std-testing-navigating-the-advancements-in-molecular-and-immunoassay-techniques/)
**Published:** December 13, 2023
**Author:** hamza
**Excerpt:** The article highlights significant advancements in STD testing, focusing on the role of molecular and immunoassay techniques in enhancing diagnostic accuracy and speed. It discusses how these technologies address the need for rapid, reliable results in both point-of-care and laboratory settings, shaping future trends in sexual health diagnostics.
**Content:**
More than one million sexually transmitted diseases (STDs) are acquired every day worldwide and eight pathogens are responsible for most of them: human immunodeficiency virus (HIV), hepatitis B (HBV), herpes simplex virus (HSV), human papillomavirus (HPV), syphilis, gonorrhea, chlamydia and trichomoniasis. Early detection plays a pivotal role in reducing STD transmission – and an effective STD diagnostic assay ideally meets several important criteria such as accuracy, reliability, accessibility, user-friendliness, privacy considerations, and adaptability to the dynamic nature of STDs.
In recent years there have been several advancements in STD diagnostic testing and in this blog, we will delve into a comprehensive review of the main technologies for point-of-care (POC) and high-throughput laboratory assays, and [highlight the promising future that molecular](/lifescience/) and immunoassay techniques hold for STD diagnostics.
## Current Molecular and Immunoassay Tests
### Rapid Point-of-Care (POC) Tests: Speeding Up Intervention
Rapid tests utilizing molecular and immunoassay techniques have gained popularity for their speed in delivering quick results and are actively used for HIV, syphilis, and hepatitis diagnosis. In resource-limited settings, the World Health Organization (WHO) recommends RDTs (rapid diagnostic tests) for HIV, syphilis, and hepatitis B for all pregnant women at least once and as early as possible in certain high-prevalence regions (Figure 1). Dual HIV/syphilis RDTs, in particular, are recommended as a cost-saving alternative to standard testing and several dual HIV/syphilis RDTs have received WHO prequalification.1
However, RDT sensitivity can be low, especially in acute infections where the antibodies to the disease are still developing. New, emerging point-of-care nucleic acid tests (POC NATs) are positioned to improve the accuracy of current testing strategies when implemented in combination with RDTs.2
### High-Throughput Laboratory-based Tests: Precision in Bulk
In addition to POC tests, high-throughput tests play an important role, especially when large-scale testing is required, such as population screening or during a public health crisis. Often POC tests are used for rapid initial screening, and laboratory tests are used to confirm a diagnosis. Laboratory tests also often provide quantitative measurements, allowing healthcare professionals to assess the severity of a condition, monitor changes over time, and tailor treatment plans accordingly. POC tests, on the other hand, typically provide qualitative (yes or no) results.
Some laboratory tests such as western blots and culture are still used but are not suitable for large-scale screening due to various factors such as time, labor, and technical complexity. The most common types of high-throughput laboratory-based assays are:
### Enzyme-Linked Immunosorbent Assay (ELISA):
ELISA is a type of laboratory-based test that uses blood or saliva specimens to detect antibodies or antigens to a variety of diseases. It can process large volumes of samples quickly, making it an ideal and cost-effective approach for large-scale screening programs. It is widely used in blood banks to screen donors for HIV, syphilis, and hepatitis B and C.3
### PCR-based Nucleic Acid Amplification Tests:
PCR-based molecular detection of an organisms’s nucleic acids (DNA or RNA) in clinical samples represents the gold standard for the diagnosis of many STDs. PCR has several advantages such as high detection sensitivity, can be easily automated, and can detect organisms that cannot be grown in culture or are non-viable, allowing the utilization of more diverse and less invasive biological samples (such as urine or vaginal swabs).4 Their unparalleled sensitivity enables the detection of low pathogen concentrations which is critical for early diagnosis and detecting extragenital infections, such as rectal or pharyngeal gonorrhea in men.5
## Future Advancements in STD Testing
The future of STD testing will involve multiple advancements aimed at improving accessibility, accuracy, and efficiency. Current trends and developments in the future of STD testing include home testing, telemedicine and digital health platforms, technology innovations and multiplexing.
In order to circumvent the stigma associated with STD testing, point-of-care and home testing, along with telemedicine and digital health platforms are expanding, offering greater convenience and privacy. In addition, alternative sample types such as swabs, urine, and saliva are gaining popularity as they allow individuals to collect samples at home and send them to a laboratory for analysis.6
The increasing prevalence of STDs and the need for efficient, accurate, and comprehensive diagnostic methods have driven the adoption of multiplex detection. Given several STDs are closely connected, co-infection with more than one STD is not uncommon. Multiplex detection, where multiple pathogens are tested simultaneously within a single assay, enables healthcare professionals more comprehensive and efficient screening, also saving time and resources.7
In addition, technology innovations and integrations of advanced techniques such as molecular diagnostics and biosensors, lab-on-a-chip, and next-generation sequencing (NGS) will contribute to improved accuracy, accessibility, and efficiency of STD.
#### Next-Generation Sequencing (NGS): Unleashing Genetic Insight
Through the use of next-generation sequencing (NGS), the emerging field of clinical metagenomics could potentially revolutionize STD testing. NGS allows for rapid and comprehensive diagnosis by providing useful medical information in a single test. This includes universal pathogen detection, species determination, and identification of antimicrobial resistance. NGS, although more expensive than traditional culture or NAATs, could revolutionize our understanding of the genetic diversity of STD-causing agents and be more cost-effective in many situations by reducing the number of tests required.8
#### CRISPR-Based Diagnostics: Precision Redefined
Emerging as cutting-edge technology, CRISPR-based diagnostics offer highly specific and sensitive detection of nucleic acids. Molecular methods for detecting nucleic acids based on CRISPR-Cas systems appear to be highly sensitive, specific, and capable of one-step detection of both RNA and DNA. These tests have the potential to enhance the accuracy of STD diagnostics, becoming valuable tools for point-of-care testing.9
#### Microfluidic and Lab-on-a-Chip Technologies: Portability Redefined
Miniaturized technologies such microfluidic devices and lab-on-a-chip platforms hold promise for developing highly portable and efficient diagnostic tools. These technologies could bring sophisticated testing capabilities to even the most remote locations. Their miniaturized and integrated nature contributes to increased efficiency and reduced sample and volumes, when incorporated into microarrays, can be applied to high-throughput analysis of biomolecules, such as DNA, RNA, proteins, or cells.3
#### Conclusion
Molecular and immunoassay tests have revolutionized STD diagnostics, offering accuracy, efficiency, and accessibility. The current state of these tests forms a robust foundation for the future, where innovations such as NGS, CRISPR-based diagnostics, multiplex immunoassays, and microfluidic technologies are poised to elevate the precision and convenience of STD testing. As these advancements continue to unfold, the outlook for early detection, treatment, and prevention of STDs becomes increasingly optimistic.
### Meridian’s Molecular & Immunoassay STD Diagnostic Solutions
As a leader in infectious diseases, Meridian Bioscience has supported assay developers for over 45 years with innovative reagent solutions for [STD diagnostic assays](https://info.meridianbioscience.com/meridian-reagent-solutions-for-std-diagnostics). With over 200 antigens and antibodies for STD immunoassay testing, and a large range of master mixes and enzymes for qPCR and isothermal amplification applications, Meridian is ready to provide solutions, big and small to support STD diagnostics.
[To learn more, visit Meridian’s complete STD solutions ](https://info.meridianbioscience.com/meridian-reagent-solutions-for-std-diagnostics)
#### References:
1. Centers for Disease Control and Prevention. Impact of COVID-19 on STDs. [https://www.cdc.gov/std/statistics/2021/impact.htm](https://doi.org/10.1136/bmj.m4690). Accessed Nov 15, 2023.
1. World Health Organization. Global Sexually Transmitted Infections Programme: Dual HIV/syphilis rapid diagnostic tests. Available at: . Accessed 28 November 2023.
2. World Health Organization. WHO encourages countries to adapt HIV testing strategies in response to changing epidemic. 2019. Available at: . Accessed 28 November 2023.
3. American Red Cross. Infectious Disease, HLA and ABO Donor Qualification Testing. Available at: . Accessed 28 November 2023.
4. Caruso, G., Giammanco, A., Virruso, R., Fasciana, T. (2021) Current and Future Trends in the Laboratory Diagnosis of Sexually Transmitted Infections. Int J Environ Res Public Health.18(3):1038. doi: 10.3390/ijerph18031038.
5. Cornelisse, V.J., et al. (2017) Increased Detection of Pharyngeal and Rectal Gonorrhea in Men Who Have Sex With Men After Transition From Culture To Nucleic Acid Amplification Testing. Sex. Transm. Dis.;44:114–117. doi: 10.1097/OLQ.0000000000000553
6. Arnold, C. (2022) Home testing for syphilis gains support in wake of COVID. Nature. 605, 598-599. doi:
7. Naeem, F., Karellis, A., Nair, S., Routy, J.P., Yansouni, C.P., Kim, J., Pai, N. (2021) Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes. BMJ Glob Health. 6(7):e005670. doi: 10.1136/bmjgh-2021-005670.
8. Moretti, M. (2022) Latest Technological Advancements for STI Detection. Today’s Clinical Lab Trends. March 214, 2022. Available at:
9. Kostyusheva, A., Brezgin, S., Babin, Y., Vasilyeva, I., Glebe, D., Kostyushev, D., Chulanov, V. (2022) CRISPR-Cas systems for diagnosing infectious diseases. Methods. 203:431-446. doi: 10.1016/j.ymeth.2021.04.007.
**Categories:** Immunology, Life Science Blog
---
### [Could saliva become the go-to diagnostic specimen for infectious diseases, cancers, and other tests?](https://www.meridianbioscience.com/lifescience-blog/could-saliva-become-the-go-to-diagnostic-specimen-for-infectious-diseases-cancers-and-other-tests/)
**Published:** November 6, 2023
**Author:** hamza
**Excerpt:** This article explores the rise of saliva as a promising diagnostic specimen, detailing its advantages in point-of-care (POC) settings. Highlighting technological advances, it discusses how saliva can efficiently diagnose diseases traditionally reliant on more invasive methods, thus paving the way for broader application in healthcare diagnostics.
**Content:**
Point-of-care (POC) diagnostics are at the forefront of modern healthcare, offering rapid and convenient solutions for early disease detection and monitoring. A recent significant advancement in POC is the integration of saliva tests, which have the potential to make POC testing even more accessible and efficient. Saliva, often called the “mirror of the body,” contains a range of biomarkers, including DNA, RNA, proteins, and metabolites, making it a suitable specimen for a range of diseases including respiratory infections, STDs, tropical diseases, hormone disorders and cancer.
## The Point-of-Care (POC) Revolution
POC diagnostics are assays that can be conducted outside a traditional laboratory setting, often at or near the patient’s location. These tests are designed to be rapid, user-friendly, and capable of delivering results within 10 to 20 minutes. Sample collection plays a significant role in the accuracy and reliability of POC tests and many sample types such as blood, nasal or throat swabs, require a trained professional to collect and can cause patient discomfort and pain. Saliva, in contrast, is simple to obtain and can be self-sampled, offering better testing accessibility and lower testing costs. As a result, saliva is gaining attention in the field of remote POC and home-based testing across a wide range of disease targets.
## The Power of Saliva in POC Diagnostics
Until a few years ago, commercial saliva tests were only available for hormone testing, HIV, and drug/alcohol assays. One of the technological barriers faced with developing a salivary diagnostic has been assay sensitivity due to the low concentrations of analytes found in saliva compared to blood (100- to 1000-fold lower)1 and the high concentration of PCR and other assay inhibitors. However over the past decade, technological advances such as saliva-specific molecular master mixes, and innovative saliva collection devices that efficiently capture a specified volume of saliva and reduce the risk of insufficient samples or poor sample quality, have improved the usability of saliva specimens for diagnostic testing.
During the pandemic, there was a significant need for widespread population testing in order to control the spread of [SARS-CoV-2](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/). Consequently, saliva was highly sought after as an alternative specimen to nasopharyngeal swabs, and several studies proved its effectiveness when used in traditional SARS-CoV-2 PCR tests and in at-home rapid antigen tests2. In addition, research found that for repeat testing, saliva samples were more likely to be more acceptable to patients than nasopharyngeal swabs3.
Since the pandemic, using saliva has become more mainstream, and in vitro diagnostic companies are showing its utility in high-throughput instruments4 and in the detection of a range of diseases including tropical diseases5, heart disease, human papillomavirus (HPV)-related cancers, breast cancers, lung cancers, as well as monitoring treatment efficacy, detecting disease reoccurrence, and stratifying patient risk. Saliva testing is even being researched for the detection of new biomarkers such as tau protein for Alzheimer’s disease4.
## Saliva-Specific Mixes in Point-of-Care (POC) Diagnostics: A Game-Changer
POC diagnostics are at the forefront of a transformative shift towards faster and more accessible testing and saliva as a testing specimen is more user-friendly, more cost-effective, and can deliver faster collection-to-results than traditional matrixes such as blood. However, the challenges in using saliva as a sample type include ensuring sample quality, preventing contamination, and achieving efficient extraction methods despite the lower DNA and RNA concentrations. For molecular assays in particular, saliva has been a challenge due to the enzyme inhibitors inherently present, and several technologies have focused on improving DNA and RNA extraction techniques to minimize the carryover of inhibitors. Alternative technologies have focused on developing inhibitor-tolerant mixes that enable the direct detection from saliva to help minimize sample loss, increase assay testing-turn-around time, and minimize the potential for contamination.
Meridian’s [Specimen-Specific™ Direct Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/) are one the most advanced chemistries available designed for direct detection assays from saliva samples. These mixes are optimized for sensitive and robust performance using crude saliva and are ready to use, only requiring the addition of assay-specific primers and probes. In addition, they are formulated with excipients for downstream lyophilization or air-drying to create ambient temperature stable assays which are ideal for POC applications. In comparison studies, Meridian’s Saliva-Specific Master Mixes demonstrated their significant performance advantages in efficiently amplifying RNA and DNA from extracted samples and crude saliva samples, even after the mixes had been dried down and briefly stored at room temperature.
As saliva specimens for diagnostic testing expand into new disease areas, saliva-specific master mixes for molecular assays will be a game-changer, enabling assay developers quicker development times, simpler, extraction-free workflows, and greater assay performance in terms of sensitivity and inhibitor tolerance.
[To learn more about Meridian’s Specimen-Specific™ Direct Saliva mixes for PCR and LAMP applications](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
#### References:
1. Cui, Y. et al. (2022). Developments in diagnostic applications of saliva in human organ diseases. *Medicine in Novel Technology and Devices.* 13(100115)
2. Duncan, D.B. et al. (2023). Performance of saliva compared with nasopharyngeal swab for diagnosis of COVID-19 by NAAT in cross-sectional studies: Systematic review and meta-analysis. *Clin Biochem.* 117:84-93.
3. Covid-19: Concerns persist about purpose, ethics, and effect of rapid testing in Liverpool (2020) *BMJ*. 371:m4690
4. Michaud, S. (2022). Saliva in the Spotlight. Clinical Laboratory News. Retrieved Oct 19, 2023 from:
5. Diaz, J., et al. (2023). A mixed methods study assessing the adoption potential of a saliva-based malaria rapid test in the Democratic Republic of Congo. Malar J.;22(1):180.
**Categories:** Life Science Blog, Molecular
---
### [Diagnostic Technology Advancements Driven by the COVID-19 Pandemic](https://www.meridianbioscience.com/lifescience-blog/test-molecular-1/)
**Published:** September 4, 2023
**Author:** Moaaz Ahmad
**Content:**
Although [COVID-19 was the first global pandemic of the 21st century](/diagnostics/disease-areas/respiratory/coronavirus/), it follows a history of respiratory disease outbreaks, including previous pandemics such as the Spanish Flu of 1918, the Asian Flu (1957-1958), and the Hong Kong Flu (1968-1969). Unfortunately, it will not be the last pandemic, and news reports seem to continually alert us to the possibility of the next one, most recently revealing a new mutated bird flu from China that has scientists on high alert1.
For the diagnostic industry, COVID-19 brought about unprecedented changes, highlighting both the challenges and strengths of the industry and teaching us valuable insights for the next pandemic2. Furthermore, it led to advances in scientific technologies that allowed us to detect and characterize SARS-CoV-2 with unprecedented speed3.
## Significant Changes and Advancements in Diagnostic Technologies
### Multiplexing:
Several respiratory viruses including the flu and RSV share similar symptoms to COVID, and differentiating between these viruses became critical to the public health response and managing patient care. Demand for multiplexed PCR-based assays grew along with the adoption of automation and high-throughput platforms which were used to increase the capacity for multiplex testing4.
### Point-of-care (POC):
An accelerated shift was observed towards sharing control of disease diagnosis and management with patients, marking a transition from traditional provider-driven healthcare to a more patient-centered and collaborative model. Consequently, easy-to-use at-home, mobile and bedside devices gained significant popularity and the demand continues for at-home tests for a range of diseases including STDs5.
### Genomic Sequencing:
The early detection of [SARS-CoV-2](/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/) variants, along with a better knowledge of the mutational processes behind shifting patterns of virulence, transmissibility, and antigenicity, provided unprecedented support to make timely public health decisions during the pandemic. Advances in next-generation sequencing enabled rapid and efficient production of entire viral genomes at a low cost. Specifically, improvements to sequencing chemistry made sequencing reactions more accurate and reliable, reducing errors and the need for repeat sequencing6.
COVID-19-driven changes in the diagnostic industry will have a lasting impact on how healthcare systems approach diagnostics for various diseases and conditions in the years to come. They have highlighted the importance of innovation, scalability, and adaptability in the field of diagnostics.
To learn about Meridian’s innovative molecular reagents solutions for multiplexing [qPCR/RT-PCR solutions](/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/), point-of-care/ isothermal amplification and novel genotyping mixes, download a copy of our whitepaper, “Unmasking the Complexities: Overcoming Challenges in Multiplexing for COVID-19, Flu, and RSV Differential Diagnosis”.
[Download Now](https://collateral.meridianlifescience.com/view/511048128/)
### References
1. Pocock, A.C. “Alarming Discovery: Mutating Bird Flu in China Raises Pandemic Fears”. SciTechDaily. September 6, 2023. [https://scitechdaily.com/alarming-discovery-mutating-bird-flu-in-china-raises-pandemic-fears/#google\_vignette](https://scitechdaily.com/alarming-discovery-mutating-bird-flu-in-china-raises-pandemic-fears/#google_vignette) Accessed Sept 7, 2023
2. Das, S., Dunbar, S. (2022). The COVID-19 Pandemic – A Diagnostic Industry Perspective. Front Cell Infect Microbiol. 12:862440. [https://doi: 10.3389/fcimb.2022.862440.]()
3. Botti-Lodovico, Y. “Harnessing technology for pandemic preparedness demands system reform”. The Brookings Institution February 18, 2022. [https://www.brookings.edu/articles/harnessing-technology-for-pandemic-preparedness-demands-system-reform/ ](https://www.brookings.edu/articles/harnessing-technology-for-pandemic-preparedness-demands-system-reform/).Accessed Sept 7, 2023.
4. “Multiplex testing helps provide critical insights as respiratory viruses surge” Nature Portfolio. . Accessed Sept 7, 2023.
5. Spencer, S. E. W. “Interest in point-of-care technologies increases among health care professionals during pandemic” UMass Chan News. September 27, 2022. Accessed Sept 7, 2023.
6. Saravanan, K.A., *et al.* (2022) Role of genomics in combating COVID-19 pandemic. Gene. 823:146387. .
7. Safarchi, A., Fatima, S., Ayati, Z. *et al.* (2021) An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. Cell Biosci .11:164.
**Categories:** Life Science Blog, Molecular
---
### [Isothermal Amplification Techniques Gain Momentum](https://www.meridianbioscience.com/lifescience-blog/isothermal-amplification-techniques-gain-momentum/)
**Published:** July 3, 2023
**Author:** hamza
**Content:**
In the intricate realm of healthcare, where answers often hide in the tiniest of details, molecular diagnostics, especially point-of-care diagnostics, have emerged as a key to improving healthcare delivery. In particular, isothermal amplification techniques have gained popularity for their sensitivity and specificity which is on par with PCR.
### What is isothermal amplification?
DNA/RNA amplification is a fundamental technique used in molecular diagnostics for its ability to detect and amplify specific DNA sequences. One type of DNA amplification, called isothermal amplification enables rapid and consistent amplification of DNA or RNA under a single temperature condition, eliminating the need for thermal cycling which requires sophisticated equipment. [The concept of isothermal amplification](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/) started in the early 1990s with the self-sustained sequence replication (3SR)1 technique, and was quickly followed by nucleic acid sequence-based amplification (NASBA)3, strand displacement amplification (SDA)3, transcription-mediated amplification (TMA)4 and loop-mediated isothermal amplification (LAMP)5.
### Properties of Isothermal Amplification Methods
The versatility of isothermal amplification lends itself to a wide range of applications including point-of-care (POC) testing for diseases, environmental monitoring, and food safety. Several types of isothermal amplification methods exist, each with unique mechanisms and characteristics, and selecting the best method depends on a number of factors such as the final application.
### Types of Isothermal Amplification
#### LAMP
LAMP is a widely used isothermal amplification technique that employs a DNA polymerase and a set of four to six primers that specifically recognize multiple regions within the target DNA sequence to create stem-loop DNA structures. These structures serve as templates for continuous DNA synthesis, enabling rapid and exponential amplification. As amplification progresses, magnesium pyrophosphate starts to accumulate as a by-product and causes turbidity or the appearance of a white precipitate which can be observed by the naked eye. LAMP is highly regarded due to its high specificity, rapid amplification (within 30 minutes to an hour), and high resistance to common inhibitors found in complex samples including blood, saliva, and environmental samples.
#### NASBA
NASBA is a type of isothermal nucleic acid amplification technique that focuses on RNA amplification. This technique is particularly useful for applications such as viral load quantification, gene expression analysis, and the detection of RNA-based pathogens. NASBA utilizes two primers, known as the “sense” and “antisense” primers, which are designed to hybridize to the target RNA sequence, and through reverse transcriptase, generate a complementary strand of DNA (cDNA) which then serves as a template to synthesize multiple RNA copies. The new RNA strand and the cDNA template separate and re-join through denaturation and reannealing. This process is repeated in a cycle of reverse transcription (to create more cDNA), RNA synthesis, and exponential RNA amplification. NASBA offers benefits such as rapid amplification, high sensitivity and specificity and can provide quantitative data about the initial RNA concentration, making it valuable for applications such as viral load quantification in clinical virology.
#### Why is isothermal amplification so important in POC?
In point-of-care settings, healthcare providers must make decisions quickly, and the more sensitive, accurate and rapid the diagnostic assay, the swifter they can assess a patient’s condition, determine the most appropriate course of action, and initiate treatment. Traditionally molecular diagnostics based on PCR are performed within a laboratory setting as the assays require trained personnel, specialized equipment and controlled environments to reduce the potential for contamination. The development of isothermal amplification methods such as LAMP and NASBA have expanded the possibilities for performing molecular diagnostics outside the traditional lab setting to include clinics, field sites, and even homes, bringing molecular diagnostics closer to the point of patient care.
#### Meridian Isothermal Amplification Solutions
As [isothermal amplification grows in popularity](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/), Meridian is positioned to be a leader in reagent innovation for both LAMP and NASBA applications. For LAMP, Meridian offers Specimen-specific™ master mixes for blood, saliva, and stool that are lyophilization-ready, containing all the excipients necessary for freeze-drying. For NASBA, Meridian offers the complete enzyme cocktail including Glycerol-free T7 RNA Polymerase, RNase H and Avian Myeloblastosis Reverse Transcriptase (AMV-RT). To learn more about isothermal technologies, listen to our webinar “Is low-cost, sensitive, single-temperature amplification the future of molecular point-of-care testing?”
[Play Webinar](https://attendee.gotowebinar.com/register/2688444901593657432?source=MLS+Email)
#### References
1. Guatelli J.C., *et al.* 1990. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. PNAS. 87(5): 1874–1878.
2. Compton J. 1991. Nucleic acid sequence-based amplification. Nature. 350(6313): 91–92.
3. Walker G.T., *et al.* 1992. Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. PNAS. 89(1): 392–396.
4. Kacian D.L. & Fultz T.J. 1995. Nucleic acid sequence amplification methods. Biotechnol Adv. 3(13): 569.
5. Notomi T., *et al.* 2000. Loop-mediated isothermal amplification of DNA. NAR. 28(12): E63.
[Isothermal Amplification Mixes & Enzymes | Meridian Bioscience](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/?country=US)
6. Torres C., *et al.* 2011. LAVA: an open-source approach to designing LAMP (loop-mediated isothermal amplification) DNA signatures. BMC Bioinformatics. 12: 240. doi:10.1186/1471-2105-12-240. PMC 3213686. PMID 21679460.
**Categories:** Life Science Blog, Molecular
---
### [2025 Outlook: Emerging Viruses & Next-Gen Respiratory DX](https://www.meridianbioscience.com/lifescience-blog/emerging-viruses-next-generation-of-respiratory-diagnostics-2025-outlook/)
**Published:** May 2, 2025
**Author:** Salman Haider
**Content:**
The 2025 flu season has been more intense than recent years, with elevated infection rates and notable pressure on healthcare systems1. Alongside seasonal influenza, several emerging respiratory viruses are gaining attention from global health authorities, avian influenza (H5N1), and novel coronaviruses. As respiratory threats continue to evolve, so must our strategies for detection and response. With transmission patterns influenced by factors like global travel, urban density, and climate shifts, diagnostics play a central role—enabling faster identification, targeted treatment, and more effective outbreak management through tools such as POCT, syndromic panels, and genomic surveillance. ### National weekly hospital admission rates (per 100,000) for COVID-19, influenza, and RSV in the 2024/2025 respiratory season
## Key Trends from the 2025 Flu Season
A closer look at the 2024/2025 flu season reveals key trends in virus transmission, healthcare impact, and vaccine performance—reflected in rising test positivity rates, peak hospitalization data, and age-stratified vaccine effectiveness studies. - **High Positivity Rates:**Over 30% of flu tests were positive, indicating widespread community transmission—similar to 2009 pandemic levels2.
- **Hospitalization Surge:**Rates peaked at 14 per 100,000 in early February, signaling significant strain on healthcare systems³.
- **Variable Vaccine Effectiveness:**Adult vaccine effectiveness ranged from 36–55%, while rates in children and adolescents reached 59–78%⁴.
- **Geographic Differences in Virus Activity:**Flu peaked earlier in the southern U.S. and Australia, while northern regions and parts of Europe faced later but intense surges in flu and RSV. COVID-19 hospitalizations were more consistent across regions but spiked in major urban centers5.
- ***Mycoplasma pneumoniae* Activity Declines:**After gaining attention in 2024, global cases fell back to baseline by early 2025. North America saw only mild increases, while outbreaks in China and parts of EMEA subsided6.
- **Persistent Avian Influenza Activity:**Ongoing H5N1 outbreaks in poultry since 2022 continue to raise concern for zoonotic transmission7.
- **Surveillance of Novel Coronaviruses:**A newly identified bat coronavirus (HKU5-CoV-2) showed potential for human infection via the ACE2 receptor, prompting heightened monitoring8.
Overall, compared to recent years, the early and sustained rise in flu positivity rates, along with varied vaccine effectiveness across age groups, signals a shift in how seasonal influenza is affecting public health. For diagnostic assay developers, this highlights the need for sensitive and flexible solutions that can adapt to changing transmission patterns and the presence of multiple circulating pathogens. As a result, demand is increasing for rapid, scalable, and accessible assays—including point-of-care formats—that can accurately distinguish between flu, COVID-19, RSV, and emerging viruses. ### Preparing for the Unpredictable: The Role of Diagnostics in Emerging Respiratory Viruses
Vaccination remains the cornerstone of prevention for respiratory viruses like influenza, RSV, and COVID-19, but typically targets only known pathogens and dominant strains—providing only partial protection. As new respiratory viruses emerge, such as avian influenza (H5N1), and novel coronaviruses, a major challenge in global health is preparing for threats that are difficult to predict. Some viruses cause mild illness, while others may evolve with the potential to trigger widespread outbreaks. However, vaccine development is not feasible or necessary for every emerging virus, making other public health measures essential9,10. As a result, early detection, surveillance, and adaptable diagnostics play a vital role in managing new and unpredictable threats. Respiratory testing is a disease area at the center of diagnostic innovation, especially following the pandemic, which accelerated the shift toward at-home and point-of-care testing. This transition has enabled quicker detection and differentiation of flu, COVID-19, and other respiratory pathogens outside of centralized labs. In clinical settings, advanced syndromic molecular panels—leveraging qPCR and isothermal amplification technologies like LAMP—have become the standard for simultaneous detection of multiple viruses, including emerging coronaviruses12. New tools such as CRISPR-based diagnostics13 and next-generation sequencing (NGS)13 are further enhancing detection and surveillance, particularly for novel pathogens. Paired with AI-driven algorithms and digital platforms, these technologies are reshaping respiratory disease management—enabling faster diagnosis, more targeted treatment, and improved outbreak response14. ## How Meridian Supports Respiratory Assay Development
As respiratory threats continue to evolve, assay developers face increasing pressure to deliver accurate, rapid, and adaptable diagnostic solutions that work across both clinical and decentralized settings. Meridian provides the essential building blocks to help meet these demands. Our portfolio includes high-performance reagent solutions for molecular and immunoassay platforms, optimized for the sensitive and specific detection of respiratory pathogens. These solutions are designed for use in: - **Multiplex qPCR and LAMP assays**Meridian’s lyophilization-ready master mixes enable room-temperature stability and simplified storage
- **Point-of-care and at-home tests**Our specimen-specific mixes are designed for direct amplification workflows, minimizing sample prep and accelerating turnaround times
- **Next-generation sequencing (NGS)**We were the first to market with an ambient-temperature stable NGS sample prep kit that dramatically simplifies logistics while maintaining high sensitivity and reproducibility
- **Rapid immunoassays**Our portfolio includes high sensitivity paired antibodies and blocking reagents optimized for lateral flow and ELISA-based respiratory assays
Meridian’s reagents are tailored to help developers build assays that detect and differentiate between common and emerging respiratory viruses—including influenza, COVID-19, RSV and coronaviruses—with high sensitivity and minimal cross-reactivity. Whether you’re scaling up for syndromic panels or simplifying formats for decentralized use, our solutions support you from feasibility through commercialization. [To learn more, visit our resource page](https://www.meridianbioscience.com/multiplexing-respiratory-assay-reagent-solutions/?country=PK) or contact us today.
**References:**
1. History of Vaccines. (2025). 2025 *flu season most intense in over a decade.*
2. Centers for Disease Control and Prevention. (2025). *2024–2025 Season Outlook – February Update.*
3. Vergano, D. (2025). Why this year’s flu season is the worst in more than a decade. *Scientific American*.
4. Vax Before Travel. (2025, March 3). Flu shots about 50% effective this season.
5. Centers for Disease Control and Prevention. (2025). 2024–2025 Seasonal Activity Summary – April Update. Centers for Disease Control and Prevention.
6. World Health Organization. (2025). *Global surveillance update on Mycoplasma pneumoniae: January–March 2025*
7. Center for Infectious Disease Research and Policy. (2024). *Avian flu surge continues on US poultry farms as feds address contamination.*
8. Zhou, W., Xu, Y., Guo, H., Xu, Z., Shi, M., & Wang, L. (2024). Characterization of HKU5-CoV-2 reveals potential risk for human infection. *PubMed.*
9. Centers for Disease Control and Prevention. (2024). *The challenge of emerging respiratory viruses: Global preparedness report 2024.*
10. World Health Organization. (2023). *Pandemic preparedness: Lessons from COVID-19 and influenza.*[https://www.who.int/publications-detail/pandemic-preparedness-lessons-2023](https://pubs.acs.org/doi/10.1021/acssynbio.2c00496)*(for general preparedness, public health measures)*
11. ACS Publications. (2022). *CRISPR-based diagnostics: A new era for molecular testing.*
12. Pronyk, P. M., de Alwis, R., Rockett, R., Basile, K., Boucher, Y. F., Pang, V., & Sintchenko, V. (2023). Advancing pathogen genomics in resource-limited settings. *Cell Genomics*, 3(12), 100443.
13. Illumina. (2023). Next-generation sequencing for infectious disease surveillance. *(to support NGS tools in pathogen detection)*
14. Deloitte Insights. (2024). *How AI is reshaping infectious disease diagnostics.**(for AI-driven respiratory testing advances)*
**Categories:** Immunology, Life Science Blog, Molecular, NGS, POCT
---
### [What Would It Take to Bring NGS to the Point of Need](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
**Published:** February 24, 2026
**Author:** Holger
**Content:**
## NGS Workflows and Centralized Laboratory Challenges
[Next-generation sequencing](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes/) has become remarkably powerful but in many ways, it is still designed for a world of centralized laboratories and tightly controlled environments. Despite advances in instrumentation and chemistry, most NGS workflows remain tightly coupled to specialist infrastructure and unforgiving logistics.
There are early signs that this may be starting to change. Portable sequencing platforms, such as those introduced by Oxford Nanopore Technologies, are beginning to challenge the assumption that NGS must always live in a central lab \[1,2\]. That thought and process shift matters, but instrumentation is only part of the story. The broader workflow, especially how reagents are shipped, stored and handled, remains a major constraint.
### NGS in Decentralized and Low-Infrastructure Environments
For assay developers and their customers, those logistics will ultimately determine whether **decentralized NGS workflows** are viable in the real world.
Most NGS workflows in [molecular diagnostics](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/") were designed with well-equipped laboratories in mind. Cold-chain shipping, refrigerated storage, and careful reagent handling are still treated as standard requirements – even though they limit where NGS can realistically be deployed outside centralized lab settings.
In centralized labs, these constraints are manageable, but they come at a cost. Cold-chain logistics, freezer infrastructure and energy-intensive storage add operational overhead and are increasingly difficult to justify as organizations focus on cost control and sustainability.
Downstream, much of this burden is passed on to customers, who absorb shipping costs and must manage storage, inventory and day-to-day handling. Even as sequencing platforms become smaller and enable more portable NGS workflows, the chemistry around them often remains infrastructure dependent.
If the future includes field-deployable sequencing, point-of-care sequencing, and other low-infrastructure sequencing environments, then reagent stability becomes more than a convenience – it becomes foundational.
### Reagent handling: an underestimated constraint
Enzymatic fragmentation is now the most widely used approach for DNA shearing in NGS library preparation. It is reliable, well understood and embedded in most modern workflows. What is discussed less often is how operationally complex these workflows become once they leave the assay developer’s bench. A single NGS workflow may involve consumables that need to be kept deeply frozen (-80°C), frozen (-20°C), refrigerated (2-8°C) or at ambient temperatures (15-25°C) – sometimes all within the same assay.
Managing multiple storage conditions becomes part of the operational overhead, alongside the less visible challenges of freeze–thaw cycles, handling variability and long-term reagent consistency. None of this is unusual in NGS, but it means workflow complexity is often driven as much by logistics as by assay design.
For assay developers thinking about **workflow robustness, operational scalability** and **workflow standardization**, these constraints can slow adoption outside highly controlled laboratory environments.
### What Changes in NGS Workflows When Library Prep Doesn’t Need Refrigeration?
Now imagine starting from a different place.
- What if enzymatic fragmentation and library preparation reagents could be shipped and stored at ambient temperature?
- What if workflows were less sensitive to transport delays, storage constraints or variations in handling?
- What if **cold-chain-free reagents** were the default rather than the exception?
[Lyophilized reagents](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-enzymatic-dna-fragmentation-kit/) make this possible. By removing the need for refrigeration while maintaining enzymatic performance, lyophilized enzymatic fragmentation kits – especially when paired with lyophilizable library prep workflows – begin to ease the practical constraints that limit where NGS can operate.
This shift toward cold-chain-free reagents is not just a logistical improvement. It directly supports more resilient, decentralized NGS workflows and expands the feasibility of field-deployable sequencing and point-of-care sequencing models.
In practical terms, it enhances workflow robustness in environments where freezer infrastructure is limited or inconsistent – enabling low-infrastructure sequencing without sacrificing performance.
### Moving closer to point-of-need NGS
NGS isn’t field-friendly today. But the direction of opportunity is clear. As sequencing platforms evolve, workflow design needs to evolve alongside them. Reagent stability, often treated as secondary, may ultimately determine how far and how widely NGS can move beyond the central lab.
[Lyophilized enzymatic fragmentation](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-enzymatic-dna-fragmentation-kit/) and [library preparation reagents](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-library-preparation-kit/) represent one practical step toward closing the gap between what NGS can do and where it can realistically be used \[3,4\].
Perhaps the more useful question going forward is not just *how powerful NGS can become* –
but *how accessible do we want it to be* – and what needs to change to get there?
**At Meridian, we focus on the parts of the workflow that quietly determine whether NGS can travel, scale and perform reliably in the real world.**
[](https://share.hsforms.com/1cH8mviqdToGgvcVGKHm9Pgc22yq)
**References:**
1\. Oxford Nanopore Technologies. (2017). *One step closer to abolishing the cold chain: Lyophilized kits for field-based sequencing.* Oxford Nanopore Technologies.
2\. Chen, P., et al. (2023). Portable nanopore-sequencing technology: Trends in research and development from lab tools to commercially viable systems. *PMC.*
3\. Meridian Bioscience. (2026). *Meridian Life Science expands ambient-stable NGS portfolio with the launch of a lyophilized enzymatic DNA fragmentation kit.*
[Press release.](https://www.meridianbioscience.com/press-release/meridian-life-science-expands-ambient-stable-ngs-portfolio-with-the-launch-of-a-lyophilized-enzymatic-dna-fragmentation-kit/)
4\. Meridian Bioscience. (2024). *Meridian Bioscience unveils industry-first lyophilized library prep kit for next-generation sequencing, eliminating the need for cold-chain shipping and storage.*
[Press release.](https://www.meridianbioscience.com/press-release/meridian-bioscience-unveils-industry-first-lyophilized-library-prep-kit-for-next-generation-sequencing-eliminating-the-need-for-cold-chain-shipping-and-storage/)
**Categories:** Life Science Blog, Molecular, NGS
---
### [Liquid Biopsy: Entering a New Phase in Cancer Diagnostics](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
**Published:** March 26, 2026
**Author:** Holger
**Content:**
The term *liquid biopsy* has been part of the oncology research vocabulary for more than twenty years and is now moving into clinical cancer diagnostics. For much of that time, however, it remained largely within the academic research space, where scientists explored whether tumour-derived biomarkers could be detected in blood and other biofluids \[1,2\].
Over the past several years, that idea has started to move into real clinical practice \[1,3\] advances in [sequencing technologies](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/), molecular detection methods and analytical tools are now making it possible to detect genomic alterations that were simply too difficult to measure before \[2,4\]. As a result, liquid biopsy is beginning to influence how clinicians understand and manage cancer \[3\].
I was reminded of how quickly the field is evolving when I recently attended the [BloodPAC](https://www.bloodpac.org/) consortium meeting in San Diego. What struck me most was the level of collaboration in the room. Researchers, diagnostic developers, pharmaceutical companies, technology providers and regulators were all sitting together discussing how to move the field forward.
Many of these organizations compete in the marketplace. But during these discussions the focus wasn’t on competition – it was on solving the scientific and technical challenges that still stand between promising technology and reliable clinical tools.
One theme that came up repeatedly was the importance of analytical validation and reproducibility. A few years ago, the conversation centred on what liquid biopsy might make possible. Today the focus is on ensuring results are consistent across platforms, laboratories and clinical studies.
That shift says something important about where the field is today. Liquid biopsy is moving from discovery toward becoming a practical component of [precision oncology](https://www.meridianbioscience.com/lifescience/products/molecular/precision-oncology-solutions-driving-the-future-of-cancer-diagnostics/).
### Beyond Blood: Expanding Liquid Biopsy Sample Types
When people hear the term *liquid biopsy*, they often think of blood-based testing. Blood is still the most widely used sample type, but the concept is broader than that \[2,5\].
Researchers are also studying other biofluids – including urine, sputum and cerebrospinal fluid – to better understand tumour biology in different clinical settings \[5\].
What these approaches share is the same technical challenge: detecting extremely small signals within complex biological samples \[2,4\].
Tumour-derived DNA – often referred to as circulating tumour DNA (ctDNA) – can represent only a tiny fraction of the total cell-free DNA (cfDNA) present in a sample, sometimes well under one percent \[2,4\]. Detecting these rare variants requires highly sensitive molecular technologies as well as careful control of pre-analytical variables \[4\].
As liquid biopsy becomes more integrated into clinical care, achieving consistent performance across laboratories will be essential.
### A Field Shaped by Data
Another theme that surfaced during the BloodPAC discussions was the growing role of data analysis.
Liquid biopsy technologies generate enormous amounts of molecular information, and interpreting those data has become just as important as detecting the signals themselves \[6\].
Artificial intelligence (AI) and advanced computational tools are helping researchers identify patterns in complex genomic datasets and separate meaningful signals from background noise \[2,4\]. In many ways, liquid biopsy is becoming both a molecular biology challenge and a data science challenge.
The combination of sensitive molecular detection and advanced computational analysis is opening new possibilities for earlier detection and more precise monitoring of disease.
### Why Collaboration Matters
As the science grows more sophisticated, it has become clear that no single organization can address these challenges alone.
The Blood Profiling Atlas in Cancer (BloodPAC) Consortium brings together academic institutions, diagnostic companies, pharmaceutical organizations, technology providers and regulators to address many of the scientific and technical hurdles facing liquid biopsy \[7\].
Participants include groups such as Memorial Sloan Kettering Cancer Center, the National Cancer Institute, AstraZeneca, Illumina, Guardant Health, GRAIL, Exact Sciences, Natera and the U.S. Food and Drug Administration.
The early years of liquid biopsy were defined by discovery. Today the focus is on validation, standardization and building the frameworks needed for these technologies to be trusted in clinical practice \[3,7\].
### The Role of Enabling Technologies in Liquid Biopsy
Ultimately, the success of liquid biopsy depends on reliable molecular detection.
Whether a test analyses circulating tumour DNA in blood or biomarkers in another biofluid, identifying rare variants requires technologies capable of detecting extremely small signals with confidence.
At Meridian Life Science, much of our work focuses on supporting this molecular detection layer. Our genotyping technologies and [molecular reagents](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/) are designed to help researchers and diagnostic developers detect genetic variants with the sensitivity and reproducibility required for modern molecular diagnostics.
These tools may not always be visible to clinicians or patients, but they form part of the infrastructure that helps make liquid biopsy testing possible.
### Looking Ahead
Leaving the BloodPAC meeting, one impression stood out clearly: the liquid biopsy field has moved beyond its early discovery phase.
The focus now is on building the scientific and technical foundations that will allow these technologies to become part of routine clinical care. That includes improving analytical performance, establishing standards across laboratories, and developing frameworks that support regulatory confidence.
As advances in molecular technologies, computational analysis and collaborative science continue to converge, liquid biopsy is poised to play an even larger role in how cancer is detected, monitored and understood.
**Turning these advances into reliable clinical tools requires expertise in biomarker science, molecular assay development and diagnostic reagents.**
[](https://share.hsforms.com/1kilAJUigQrKVIzea0seqkQc22yq)
**References:**
1\. Wan, J.C.M. *et al.* (2017). *Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer.*
2\. Heitzer, E., Ulz, P., & Geigl, J. (2015). *Circulating tumor DNA as a liquid biopsy for cancer.* Clinical Chemistry.
3\. Merker, J.D. et al. (2022). *Circulating Tumor DNA Analysis in Patients with Cancer.* JAMA Oncology.
4\. Li, M. *et al.* (2005). *BEAMing up for detection and quantification of rare sequence variants.* Nature Methods.
5\. Crowley, E. *et al.* (2013). *Liquid biopsy: monitoring cancer genetics in the blood.* Nature Reviews Clinical Oncology.
6\. Liu, M.C. *et al.* (2020). *Sensitive and specific multi-cancer detection using circulating cell-free DNA.* Annals of Oncology.
7\. BloodPAC Consortium publications and resources.
**Categories:** Life Science Blog, Liquid Biopsy, Molecular
---
### [Rethinking Campylobacter: Fast, Accurate Diagnostics for Better GI Outcomes](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
**Published:** September 30, 2025
**Author:** hamza
**Content:**
### What Is *Campylobacter* and How Is It Transmitted?
*Campylobacter* is a genus of bacteria and one of the most common causes of bacterial gastroenteritis worldwide. The most prevalent species affecting humans is *Campylobacter jejuni*. Infection typically results from consuming undercooked poultry, unpasteurized milk, or contaminated water. Person-to-person transmission is rare but can occur through poor hygiene practices, especially in childcare or eldercare settings.
Campylobacteriosis is especially prevalent in the summer months and is a leading cause of foodborne illness in the United States.
### Symptoms and Complications of *Campylobacter* Infection
Symptoms usually appear 2 to 5 days after exposure and can include:
- Diarrhea (sometimes bloody)
- Abdominal cramping
- Fever
- Nausea and vomiting
- Malaise and fatigue
While most cases resolve without treatment in about a week, serious complications may arise, such as:
- **Guillain-Barré Syndrome (GBS)**: A rare but severe autoimmune response leading to paralysis
- **Reactive arthritis**
- **Sepsis** in immunocompromised individuals
- Prolonged diarrhea or post-infectious irritable bowel syndrome (IBS)
### Why Culture Is Not Enough to Diagnose *Campylobacter*
Traditional stool culture methods are time-consuming and often less sensitive. *Campylobacter* is fastidious and requires specific microaerophilic conditions to grow in culture. As a result, many cases go undiagnosed or misdiagnosed.
Limitations of culture-based detection:
- Takes 48–72 hours for preliminary results
- Requires skilled lab personnel
- Low sensitivity, especially if samples are delayed or mishandled
- Requires additional supplies such as gas jars and a special incubator
Modern immunoassays provide a faster, more accurate solution for identifying *Campylobacter* and differentiating it from other causes of infectious diarrhea. Meridian’s [*Campylobactor*](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/ "Campylobactor") are designed to streamline workflows and improve diagnostic confidence.
### Common Treatment for *Campylobacter*
Most *Campylobacter* infections are self-limiting and do not require antibiotics. However, antimicrobial therapy is recommended for:
- Patients with severe or prolonged symptoms
- High-risk populations (infants, elderly, immunocompromised)
- Cases involving bloodstream infection or extraintestinal manifestations
**Recommended treatment:**
- Antibiotics in high-risk populations
- Fluid and electrolyte replacement to prevent dehydration
### Support Smarter *Campylobacter* Testing with Meridian
Meridian Bioscience offers rapid, highly sensitive diagnostic tools that go beyond culture based methods. Our immunoassay platforms are optimized for detecting [*Campylobacter*](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/) directly from stool samples, supporting better clinical decisions and faster treatment.
**Take Action:** [Upgrade your approach to *Campylobacter* detection. Trust Meridian for fast, accurate GI diagnostics.](/diagnostics/disease-areas/gastrointestinal/campylobacter/)
**Categories:** campylobacter, Diagnostics Blog, Gastrointestinal
---
### [Double Trouble: Viral Co-Infections and Their Role in Cancer Progression](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
Cancer remains one of the world’s most complex diseases, arising from an interplay of genetic, environmental, and infectious factors. While inherited mutations and carcinogens are well-known drivers, viruses known as oncoviruses play a much larger role than many realize. Globally, an estimated one in six cancers is linked to viral infection, with pathogens such as HPV, HBV, HCV, EBV, and HTLV-1 responsible for millions of new cases each year.
Unlike genetic or environmental causes, viral oncogenesis can unfold through both direct and indirect mechanisms. Some viruses integrate into the host genome, silencing tumor suppressor genes or activating oncogenes. Others trigger chronic inflammation, immune evasion, or cellular stress that sets the stage for malignant transformation. While each of these viruses poses significant risks on their own, the danger can escalate when two or more infections occur together. In such cases, viral interactions can intensify inflammation and immune disruption, accelerating disease progression and complicating detection.
Yet despite this clear connection, virus-driven cancers often go undetected until late stages, especially in regions where access to advanced molecular testing is limited. Traditional diagnostics that focus on single pathogens may miss co-infections or early viral reactivation events. This gap highlights the growing need for comprehensive, multiplex diagnostic platforms capable of detecting multiple oncoviruses and related biomarkers in a single workflow.
Emerging technologies such as syndromic testing, multiplex lateral flow, and isothermal molecular assays are beginning to bridge that gap. These tools not only improve sensitivity and turnaround time but also make testing more accessible—bringing advanced detection closer to the point of care. When combined with preventive strategies such as vaccination, screening, and surveillance, they hold enormous potential to reduce the global burden of virus-driven cancers.
Meridian Life Science advances diagnostics across the spectrum — from high-throughput labs to point-of-care testing — with innovative [molecular](/lifescience/products/molecular-reagents/) and [immunoassay](/lifescience/products/antibodies-antigens/) solutions. By enabling developers to create reliable, scalable, and accessible assays, Meridian is helping drive the next generation of tools for early cancer detection and global health impact.
**Read the full article:**
[](https://share.hsforms.com/1FGymbutJQ-CZIjSL8w_llAc22yq)
**Categories:** Immunology, Life Science Blog, Molecular
---
### [Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio](https://www.meridianbioscience.com/press-release/meridian-bioscience-achieves-ivdr-certification-for-alethia-molecular-assay-portfolio/)
**Published:** February 23, 2026
**Author:** Holger
**Content:**
**CINCINNATI, OHIO, February 23, 2026 –** Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced that a broad portfolio of its Alethia molecular assays has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.
The certification, issued by GMED (Notified Body 0459), confirms that the following Alethia assays and associated external controls are compliant with IVDR requirements and are classified as Class C under the regulation:
- Alethia Pertussis and Alethia Pertussis External Controls
- Alethia GBS and Alethia GBS External Controls
- Alethia CMV and Alethia CMV External Controls
- Alethia Malaria and Alethia Malaria External Controls
- Alethia Chlamydia
- Alethia Gonorrhea
- Alethia HSV 1&2 and Alethia HSV 1&2 External Controls
IVDR represents a significant evolution in the European regulatory framework for in vitro diagnostics, introducing more rigorous requirements for clinical evidence, performance evaluation, quality systems, and post-market surveillance. Achieving IVDR certification underscores Meridian’s commitment to delivering high-quality, compliant diagnostic solutions to laboratories and healthcare providers across Europe.
“This milestone reflects the strength of our quality systems and the dedication of our regulatory, quality, and product teams,” said Susan Bogar, Vice President, Regulatory Affairs at Meridian Bioscience. “We are proud to continue supporting our European customers with IVDR-compliant molecular diagnostics that deliver reliable, actionable results.”
“This achievement reflects Merdian’s unwavering commitment to quality, regulatory excellence and customer continuity,” said Andy Kitzmiller, Chief Executive Office of Meridian Bioscience. “The transition to IVDR is one of the most demanding regulatory shifts our industry has faced. Successfully certifying our Alethia product demonstrates the strength of our teams and reinforces our long-term dedication to supporting healthcare providers across Europe with reliable, high-performance molecular diagnostics.”
The Alethia platform provides rapid, easy-to-use molecular testing designed to streamline workflows and deliver accurate detection of infectious diseases in clinical laboratory settings. With IVDR certification in place, Meridian reinforces its long-term commitment to the European market and to maintaining uninterrupted product availability during the industry-wide regulatory transition.
Meridian Bioscience will continue to advance its portfolio in alignment with evolving global regulatory standards while supporting customers through ongoing compliance and market access requirements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes diagnostic testing solutions and life science raw materials. Meridian’s diagnostic products provide accurate, simple, and cost-effective testing solutions to aid in the diagnosis and management of gastrointestinal, respiratory, parasitic, and other infectious diseases. The Company’s Life Science segment supplies critical raw materials used by researchers and other diagnostic manufacturers worldwide.
For more information, visit [www.meridianbioscience.com.](https://www.meridianbioscience.com/)
**Categories:** Press Release
---
### [Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit.](https://www.meridianbioscience.com/press-release/meridian-life-science-expands-ambient-stable-ngs-portfolio-with-the-launch-of-a-lyophilized-enzymatic-dna-fragmentation-kit/)
**Published:** February 18, 2026
**Author:** Moaaz Ahmad
**Content:**
The new product reinforces Meridian’s leadership in enzyme stabilization and enables simplified and decentralized Next-Generation-Sequencing sample preparation.
**CINCINNATI, OHIO, February 18, 2026 (PRNewswire) –** The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS Enzymatic DNA Fragmentation Kit. The kit is designed for ambient-temperature (15-25°C) shipping and storage, eliminating the need for cold-chain requirements and helping laboratories simplify their NGS sample preparation workflows.
The launch of this new kit extends Meridian’s enzyme stabilization strategy beyond PCR and isothermal amplification and into a critical step of NGS sample preparation, strengthening the company’s leading position as a technology partner for assay developers, platform providers and emerging sequencing applications.
**Removing Cold-Chain Constraints in NGS Sample Preparation**
Traditional NGS workflows rely on refrigerated reagents, which increases cost, handling complexity, and the risk of performance variability due to freeze-thaw cycles. This kit overcomes these limitations with a fully lyophilized formulation that remains stable at ambient temperatures and is rehydrated at the point of use, which reduces handling steps and supports consistent performance.
This kit is the only ambient-stable enzymatic DNA fragmentation solution commercially available and supports streamlined logistics, simplified laboratory operations, and a more robust workflow deployment across a wide range of sequencing environments.
**Supporting the Shift Towards Decentralized Sequencing**
As NGS expands beyond centralized laboratories, toward automated and point-of-need applications, reagent stability and logistics have become critical barriers to adoption. Meridian’s new enzymatic fragmentation kit addresses these challenges and is designed to integrate with Meridian’s lyophilized NGS library preparation chemistries, supporting emerging decentralized sequencing models where portability, automation, and ease of use are essential.
**Consistent, Controlled Fragmentation**
Fragmentation variability can impact library quality and downstream sequencing performance. Meridian’s enzymatic fragmentation kit enables precise time-controlled fragmentation, allowing users to produce consistent and adjustable fragment sizes without the need for mechanical shearing instruments.
**Simple Integration into NGS Workflows**
The ready-to-rehydrate format supports:
- Ambient-temperature storage and shipping
- Ready-to-use formulation – no freeze-thaw cycles
- Precise time-controlled enzymatic fragmentation
- Compatible with low-, medium-, and high-throughput workflows
- Suitable with automated workflows
Meridian’s Lyophilized NGS Enzymatic DNA Fragmentation Kit (MDX224) is compatible with established short-read library preparation workflows, including those used with Illumina® and Element Biosciences® sequencing platforms. Meridian can also support customers in adapting the kit to additional NGS platforms, with ongoing R&D efforts focused on compatibility with emerging sequencing technologies.
Assay and platform developers can integrate the kit into their own library preparation protocol enabling the creation of endto-end ambient-stable library preparation workflows tailored to specific instruments and uses.
“Our new Lyophilized NGS Enzymatic DNA Fragmentation Kit demonstrates how our enzyme stabilization technology can deliver practical value for next-generation sequencing users. By eliminating the cold-chain requirements, we improve consistency and usability today, while laying the foundation for broader access to sequencing technologies as the NGS landscape continues to evolve,” said Harald Ottenhof, Meridian’s Executive Vice President, Life Science.
For more information on Lyophilized NGS Enzymatic DNA Fragmentation Kit and Meridian’s NGS reagent portfolio, please
visit: [https://www.meridianbioscience.com/lyophilized-ngs-enzymatic-dna-fragmentation-kit/](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-enzymatic-dna-fragmentation-kit/)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that provide answers with speed, accuracy, and simplicity, redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com. ](https://www.meridianbioscience.com/)
**Contact:**
Lucy Pillai
Senior Director, Global Sales Operations and North American Sales
Meridian Bioscience, Inc.
Phone: 901.382.8716
Email:
\###
**Categories:** Press Release
---
### [Antigens Matter: How Native and Recombinant Formats Shape Immunoassay Success](https://www.meridianbioscience.com/lifescience-blog/antigens-native-vs-recombinant-immunoassays/)
**Published:** September 11, 2025
**Author:** Salman Haider
**Content:**
In antibody-based immunoassays, antigen selection is the key biological decision driving assay performance. The structure, epitope integrity, and expression format of the antigen determine how effectively antibodies are detected, and influence downstream considerations such as scalability, lot-to-lot consistency, and compatibility with formats such as ELISA, CLIA, and lateral flow.
Recombinant DNA technology, introduced in the 1980s, enabled in vitro antigen production, removing reliance on culturing live pathogens and opening the door to novel formats and otherwise inaccessible targets. One of the earliest examples was hepatitis C (HCV), where native antigen production was unfeasible due to the virus’s resistance to standard culturing. Recombinant expression of HCV core and NS3 antigens made serological testing possible and led to the first FDA-approved assays using recombinant antigens. Their value was further proven in second-generation HIV diagnostics, where recombinant gp41 and p24 replaced crude viral lysates, enhancing assay specificity and reducing false positives. Today, the decision between using native or recombinant antigens remains central to immunoassay design – shaping not only analytical performance, but also manufacturability, supply chain sustainability and clinical utility. MLS offers a wide selection of [recombinant antigens](/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-c?country=PK) for HCV.
## Native Antigens in Immunodiagnostics: Maximizing Sensitivity Through Epitope Diversity
Native antigens are proteins purified directly from whole pathogens, infected cell cultures, or human tissues, preserving the full spectrum of post-translational modifications (PTMs) and conformational epitopes found in vivo. Their structural fidelity makes them especially valuable in immunodiagnostics for pathogens like cytomegalovirus (CMV), which express distinct antigens at different stages of infection and trigger broad, polyclonal antibody responses. Because individuals generate antibodies to multiple viral proteins in varying amounts, native antigens more accurately reflect the true antigenic landscape – enhancing the likelihood of detecting clinically relevant antibodies that may be missed by linear or recombinant-only formats.
While native antigens offer important biological advantages, their use also presents practical challenges. Key advantages and limitations include:
### Advantages:
- Preserves native structure and PTMs, enabling recognition of conformational epitopes critical for detecting clinically relevant antibodies missed by linear or misfolded antigen
- Enables broad antibody detection by presenting full epitope diversity, increasing sensitivity and detection across diverse populations and immune backgrounds
- Broad epitope diversity enables detection of antibodies across all stages of infection – critical for pathogens like HSV, Rubella, and *Toxoplasma gondii*, where stage-specific immune responses require comprehensive antigen coverage
### Limitations:
- Subject to variable yield and quality due to dependence on biological source material, impacting consistency.
- Difficult to scale for manufacturing, especially when sourcing low-abundance or unculturable pathogens.
- Involves biosafety or ethical risks when derived from infectious agents or human tissues, limiting accessibility and use.
## Meeting Diagnostic Demands: The Strategic Role of Recombinant Antigens
Recombinant antigens are produced by expressing defined gene constructs in host systems such as *E. coli*, yeast, insect, or mammalian cells. This enables precise design control over antigen composition—allowing inclusion of key antibody-binding regions, exclusion of cross-reactive or homologous sequences, and fine-tuned incorporation or exclusion of structural features such as site-specific post-translational modifications (PTMs). Yields can be optimized, lot-to-lot consistency is easier to maintain, and reliance on native source material is eliminated, reducing risk and enabling scalable, controlled manufacturing. However, while these systems offer design flexibility, native-like PTMs which can be essential for accurate epitope presentation in some assays, are typically only replicated in mammalian or insect expression systems.
Beyond scalability, a key strategic advantage of recombinant antigens is their modularity. Developers can selectively express specific immunogenic domains or fragments to optimize assay performance. For example, in CMV (which elicits a broad, polyclonal immune response) recombinant antigens can enhance assay specificity by targeting low-abundance or stage-specific antigens that may trigger weak or variable antibody responses across individuals. This targeted approach can support earlier detection and improve overall clinical accuracy.
In many cases, recombinant antigens are not just advantageous but essential. Some pathogens cannot be sourced natively due to biological, safety, or ethical constraints. High-risk agents such as [HIV](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/human-immunodeficiency-virus-hiv?country=PK) and [Ebola](/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/ebola?country=PK) require high containment facilities, making native antigen production impractical or hazardous. Others, such as Treponema pallidum (syphilis), extremely difficult to culture, necessitate the use of recombinant antigens like TpN15, TpN17, and TpN47 to support serological assay development. For example, Meridian offers [more than a dozen TP antigens](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/treponema-pallidum-syphilis/?country=US) – all of them recombinant. In autoimmune diagnostics, antigens such as thyroglobulin are available in both native and recombinant formats, but the native form is typically derived from human tissue and is difficult to source—raising challenges around reproducibility, ethical considerations, and long-term supply stability. As demand for earlier and more precise detection grows, recombinant antigens offer a scalable solution when traditional sources are limiting.
While recombinant antigens address many sourcing and performance challenges, they also present specific strengths and limitations that must be considered in the diagnostic context:
### Advantages:
- Deliver high lot-to-lot consistency and purity, reducing variability in assay performance
- Scalable, animal-free production avoids biosafety and ethical sourcing constraints
- Allow targeted epitope selection to improve specificity and minimize cross-reactivity
- Support multiplexing and POC test design with custom antigen formats and stability profiles
### Limitations:
- May lack native PTMs unless expressed in mammalian or insect systems, potentially affecting antibody recognition
- Risk of misfolding in prokaryotic systems, which can compromise epitope integrity and reduce binding efficiency
- May show reduced sensitivity if key conformational epitopes are absent or improperly presented
## Hybrid Antigen Strategies: Enhancing Diagnostic Performance Through Complementary Formats
While recombinant antigens offer clear advantages in cross-reactivity control – enabling the selective expression of non-conserved or immunodominant regions to improve specificity – they may not fully represent the native antigenic landscape. Linear epitopes alone can miss conformational or post-translationally modified structures essential for antibody recognition, potentially limiting sensitivity. To overcome these challenges, many FDA-approved assays adopt a hybrid strategy that combines native and recombinant antigens to balance sensitivity and specificity.
This strategy is exemplified in fourth-generation HIV tests, which pair recombinant gp41 with native p24 (Meridian offers [both of these](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/human-immunodeficiency-virus-hiv?country=PK)) to enhance early detection while maintaining confirmatory accuracy. Lyme disease ([Borrelia](/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/borrelia-lyme-disease?country=PK)) assays often combine recombinant VlsE with native flagellar proteins to capture immune responses across different disease stages. [TORCH panels](/lifescience/products/antibodies-antigens/torch-childhood?country=PK), including Toxoplasma, Rubella, CMV, and HSV, frequently incorporate native antigens to preserve structural epitope integrity, while recombinant components help reduce cross-reactivity and improve consistency, particularly in HSV and CMV testing. Used together, native and recombinant antigens expand epitope coverage, reduce false negatives, and improve diagnostic sensitivity across diverse patient populations by capturing broader immune responses.
Native antigens present a diverse array of conformational and linear epitopes, enabling recognition by multiple antibodies or multiple binding sites on a single antibody. In contrast, recombinant antigens are typically designed to display a defined epitope or domain, offering high specificity for targeted antibody detection. Combining native and recombinant antigens allows assays to capture a broader range of antibody responses while maintaining specificity for clinically relevant targets.
### Your Reliable Source for Native and Recombinant Antigens at Scale
Whether you need the biological fidelity of native proteins or the design flexibility of recombinant formats, Meridian Bioscience offers validated antigens and expert support across every stage of assay development to meet your reagent needs. Both our native and recombinant antigens are manufactured under stringent quality controls to ensure lot-to-lot consistency, minimizing revalidation risk and supporting regulatory confidence. We maintain multiple lots in inventory to facilitate application testing, lot bridging, and long-term reservation, helping you move efficiently from feasibility to scale. With decades of experience in immunodiagnostics, Meridian is your trusted partner in building robust, commercially viable diagnostics.
**Explore our full portfolio of native and recombinant antigens to support your next diagnostic innovation.**
[](/contact-us-life-science/)
**Categories:** Life Science Blog
---
### [Smarter Library Prep for Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience-blog/blog-smarter-library-prep-for-whole-genome-sequencing/)
**Published:** October 11, 2025
**Author:** Moaaz Ahmad
**Content:**
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, powering discovery in oncology, infectious disease, inherited disorders, and even agriculture. By providing complete genomic coverage—including exonic and intronic regions—WGS enables the detection of a broad spectrum of genetic variation, from single nucleotide variants to large structural rearrangements. But while sequencing platforms continue to advance rapidly, one critical step remains a bottleneck: library preparation.
Traditional library prep workflows are labor-intensive, require cold-chain reagents, and depend on skilled personnel to achieve reproducible results. These hurdles limit scalability and create barriers to adoption in both high-throughput labs and decentralized testing environments. As sequencing moves closer to routine use in clinical and applied research settings, the need for smarter, more accessible library prep solutions has never been greater.
Recent innovations are tackling these challenges head-on. Lyophilized, ambient-temperature stable reagents eliminate the need for frozen shipping and storage, making logistics simpler and more sustainable. By reducing freeze-thaw variability, these reagents also improve consistency and reliability. At the same time, automation-ready and miniaturized protocols are streamlining workflows, lowering hands-on time, and cutting reagent costs—all while maintaining data quality. Together, these advances reduce the complexity that has traditionally slowed WGS adoption.
For assay developers, these workflow improvements translate into greater confidence in sequencing outcomes. Reliable, stable reagents mean cleaner libraries, better coverage uniformity, and fewer failed runs. Automation compatibility makes it easier to scale up studies without overburdening technicians or compromising data integrity. And because ambient-stable kits support deployment in resource-limited or decentralized settings, they expand the reach of WGS into new frontiers of research and clinical care.
*Curious about what’s next for WGS?* [Download our short report “From Sample to Sequence: Why Smarter Library Prep is Critical for Whole Genome Sequencing”](https://share.hsforms.com/1UD8K4ZKYT9yD-DgJ43Wqawc22yq) to uncover the hidden challenges of traditional library prep, explore breakthrough reagent stabilization technologies, and discover strategies to make sequencing faster, easier, and more scalable.
To learn more about our [Lyophilized Next-Generation Library Preparation Kit (MDX219)](/lifescience/products/molecular/lyophilized-ngs-library-preparation-kit/) or connect with a Meridian specialist. This ambient-stable, lyophilized format streamlines key steps while reducing complexity, ensuring efficient, reliable, and scalable WGS workflows.
[](https://share.hsforms.com/1UD8K4ZKYT9yD-DgJ43Wqawc22yq)
**Categories:** Life Science Blog, Molecular, NGS, POCT
---
### [Understanding Congenital Cytomegalovirus: Risks, Symptoms, and Management](https://www.meridianbioscience.com/diagnostics-blog/understanding-congenital-cytomegalovirus-risks-symptoms-and-management/)
**Published:** July 1, 2024
**Author:** hamza
**Excerpt:** Understanding the Risks and Management of Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus (CMV) poses significant risks to unborn children, marking it as a critical concern for expectant parents and healthcare professionals. As one of the predominant non-genetic causes of hearing loss and developmental disabilities in newborns, early recognition and intervention are vital. This article delves into the essentials of congenital CMV, including its transmission through the placenta, identifiable risks, and the subtleties of symptoms that may appear in infected newborns.
Transmission and Risks
CMV can be transmitted via bodily fluids and is more likely to be passed to the fetus during a primary infection in the mother during pregnancy than through reactivation of the virus. The potential severity of outcomes is influenced by the timing of the infection, with earlier infections posing a greater risk.
Early Detection and Management
Early diagnosis is key to managing and potentially mitigating the severe impacts of CMV on the infant. Newborns can be tested for CMV with simple saliva or urine tests, crucial steps in initiating timely treatment strategies that may include antiviral medications and ongoing monitoring for hearing or vision impairments.
Preventive Measures
The article also emphasizes preventive strategies that can dramatically reduce the risk of maternal infection, such as stringent hygiene practices and avoiding close contact with young children’s saliva and urine, which are common vectors for CMV transmission.
Understanding congenital CMV is the first step towards effective management and prevention, with informed actions and early treatment being instrumental in improving outcomes for affected infants.
**Content:**
[Congenital Cytomegalovirus (CMV)](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is a relatively common viral infection with significant implications for unborn children when the mother becomes infected during pregnancy. As one of the leading causes of non-genetic hearing loss and developmental disabilities in newborns, understanding the risks, recognizing the symptoms, and knowing the management options for congenital CMV is essential for expectant parents and healthcare providers alike. This article provides a comprehensive overview of congenital CMV, including its transmission, risks, symptoms, and the latest in management and prevention strategies.
## What is Congenital CMV?
Congenital CMV is an infection passed from a pregnant woman to her fetus through the placenta. CMV is a part of the herpesvirus family and is common worldwide. While the virus is generally harmless or causes mild illness in healthy children and adults, its transmission during pregnancy can lead to serious health complications for the unborn child.
## Transmission and Risks
CMV is transmitted through bodily fluids, such as saliva, urine, blood, and breast milk. Pregnant women can become infected with CMV for the first time or experience a reactivation of the virus if they have been infected previously. The primary risk factors for congenital CMV transmission include close contact with young children, who are often carriers of the virus, and working in childcare settings.
The risk of transmission to the fetus is higher if the mother has a primary CMV infection during pregnancy compared to reactivation of a previous infection. Additionally, the timing of the infection during pregnancy plays a critical role; infections in early pregnancy tend to have more severe outcomes than those occurring later.
## Symptoms of Congenital CMV
Many babies born with congenital CMV show no immediate symptoms, making early detection challenging. However, some infants may present with symptoms at birth, including:
- Low birth weight
- Prematurity
- Jaundice
- Purple skin splotches or a rash
- Microcephaly (small head)
- Enlarged liver and spleen
- Seizures
Long-term health problems can develop in some children, such as:
- Hearing loss
- Vision loss
- Intellectual disabilities
- Small head size
- Lack of coordination
- Seizures
## Diagnosis and Management
Early diagnosis of congenital [CMV is crucial for managing potential complications](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/). CMV testing in newborns usually involves a saliva or urine test within the first three weeks of life. For pregnant women, CMV testing might be recommended if there’s a high risk of infection or signs of the virus appear during pregnancy.
- Management of congenital CMV focuses on mitigating symptoms and preventing complications. Treatment options may include:
- Antiviral medications for symptomatic newborns, which can improve hearing and developmental outcomes in some cases.
- Regular hearing and vision screenings to monitor for delayed-onset hearing loss or vision problems.
- Developmental evaluations to assess for potential cognitive or motor delays and to initiate early intervention services if necessary.
## Prevention Strategies
Preventing CMV infection during pregnancy is key to reducing the risk of congenital CMV. Pregnant women can take several precautions to lower their risk of CMV infection, such as:
- Practicing good hygiene, including frequent handwashing with soap and water, especially after changing diapers or wiping noses.
- Avoiding sharing food, utensils, drinks, or straws with young children.
- Not kissing young children on the mouth or cheek.
## Conclusion
[Congenital CMV](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) remains a significant concern due to its potential to cause serious developmental issues in infants. However, with increased awareness, early detection, and appropriate management, many of the risks associated with congenital CMV can be mitigated. Pregnant women and those planning to become pregnant should be informed about CMV and take preventive measures to protect themselves and their unborn children from this common but potentially serious virus. As research continues, the hope for more effective treatments and a vaccine against CMV grows, offering a brighter future for those affected by congenital CMV.
**Categories:** CMV, Diagnostics Blog, Pediatric & Neonatal
---
### [New Frontiers in Congenital Cytomegalovirus Research: Current Developments and Future Prospects](https://www.meridianbioscience.com/diagnostics-blog/new-frontiers-in-congenital-cytomegalovirus-research-current-developments-and-future-prospects/)
**Published:** May 2, 2024
**Author:** hamza
**Excerpt:** Leading the Fight Against Congenital CMV: New Strategies and Hope
As one of the leading causes of sensory and neurological deficits in infants, congenital cytomegalovirus (CMV) presents a formidable public health challenge. Yet, recent advances in medical research and clinical practice offer new hope. This guide delves into the latest strategies revolutionizing the prevention and management of congenital CMV, providing crucial insights for healthcare providers, researchers, and families.
Advancements in Early Detection and Screening
Key to combating congenital CMV is early detection. The implementation of universal newborn screening and targeted maternal screening during pregnancy can drastically alter the course of the infection, facilitating timely interventions. These screenings are pivotal for identifying infections early, often before symptoms manifest, allowing for immediate and effective management strategies.
Innovative Treatments and Preventive Measures
Our guide explores the transformative impact of antiviral therapies, such as Valganciclovir, which have shown promising results in improving the health outcomes of infected infants. Additionally, the ongoing development of a CMV vaccine represents a major stride towards preemptive prevention, aiming to shield future generations from the virus.
With these emerging strategies, the landscape of congenital CMV management is shifting towards more proactive and preventive healthcare, offering a beacon of hope to those affected by this pervasive infection.
**Content:**
[Congenital cytomegalovirus (CMV) infection](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) remains a leading cause of birth defects and neurological disabilities in infants, presenting ongoing challenges to medical researchers and clinicians. Despite the significant impact of congenital CMV on public health, it has historically been under-recognized within the broader landscape of congenital infections. However, the tide is turning, with groundbreaking research efforts expanding our understanding and offering new avenues for prevention, diagnosis, and treatment. This article explores the current developments in congenital CMV research and looks ahead to the future prospects of this vital field.
## Advancements in Understanding CMV Transmission
A critical area of research is the understanding of how CMV is transmitted from mother to child and the factors that influence transmission risk. Recent studies have focused on the role of maternal immune response, genetic susceptibility, and the timing of infection during pregnancy. Insights from this research are crucial for developing strategies to prevent transmission, including potential therapeutic interventions to boost maternal immunity or block the virus’s path to the fetus.
## Diagnostic Innovations
Early detection of [congenital CMV infection](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is paramount for effective intervention, guiding current efforts to enhance diagnostic methods. Innovations in polymerase chain reaction (PCR) technology and non-invasive prenatal testing (NIPT) are promising areas of development. Researchers are also exploring the use of biomarkers to identify infections earlier in pregnancy, potentially allowing for timely interventions that could mitigate the impact of the virus on the developing fetus.
## Vaccine Development
Perhaps the most anticipated frontier in congenital CMV research is the development of a vaccine. Several vaccine candidates are in the pipeline, with strategies ranging from live attenuated vaccines to mRNA vaccines. Early clinical trials have shown promising results, indicating the potential for a CMV vaccine to significantly reduce the incidence of congenital infections. A successful vaccine would not only prevent many cases of congenital CMV but could also alleviate the considerable emotional and financial burden on affected families and the healthcare system.
## Antiviral Therapies
The treatment of congenital CMV infection has traditionally been limited to a few antiviral medications, with varying degrees of success. Current research efforts are focused on identifying new therapeutic targets and developing more effective and less toxic antiviral agents. Some of the most promising areas include drugs that inhibit the virus’s ability to replicate or that enhance the immune system’s response to the infection. Additionally, the potential for maternal antiviral therapy to prevent transmission is a subject of ongoing investigation.
## Stem Cell and Gene Therapy
Emerging technologies like stem cell therapy and gene editing present novel approaches to combating congenital CMV. These strategies aim to repair or replace damaged tissues in affected infants or to engineer resistance to CMV infection in utero. While still in the early stages of research, these approaches hold the promise of transformative treatments that could address the root causes of CMV-related disabilities.
## Public Health Strategies and Education
Beyond the laboratory, public health initiatives play a crucial role in combating congenital CMV. Efforts to increase awareness among healthcare professionals and expectant mothers are vital for preventing CMV transmission. Educational campaigns that promote hygiene practices capable of reducing CMV spread are also essential components of a comprehensive approach to managing this infection.
## Conclusion
The landscape of congenital [CMV](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) research is evolving rapidly, with new discoveries and technologies on the horizon that promise to improve the prevention, diagnosis, and treatment of this challenging infection. As researchers continue to push the boundaries of what is known about CMV, the future holds the potential for significant reductions in the incidence and impact of congenital CMV infections. Continued investment in research and public health initiatives will be critical to realizing these prospects, bringing hope to countless families worldwide.
**Categories:** CMV, Diagnostics Blog, Pediatric & Neonatal
---
### [Outdated and Ineffective: Why It’s Time to Say Goodbye to Serology for H. pylori Testing](https://www.meridianbioscience.com/diagnostics-blog/outdated-and-ineffective-why-its-time-to-say-goodbye-to-serology-for-h-pylori-testing/)
**Published:** July 25, 2025
**Author:** Moaaz Ahmad
**Content:**
*Helicobacter pylori* (*H. pylori*) is a widespread bacterial infection that affects the stomach lining and is a leading cause of peptic ulcers, chronic gastritis, and even gastric cancer. Accurate and timely *H. pylori* detection is essential to ensure appropriate treatment and reduce the risk of long-term gastrointestinal complications.
However, not all *H. pylori* testing methods are created equal. As clinical standards evolve, outdated methods like *H. pylori* serology tests no longer meet the demands of modern diagnostics, and continuing to use them could do more harm than good.
### Outdated Serology: An Unreliable Tool for *H. pylori* Detection
Historically, Helicobacter pylori testing included blood-based antibody tests (serology), which detect antibodies against the bacterium. But these antibodies can remain in the body even after the infection has cleared, making it impossible to differentiate between a current and past infection.
This limitation presents two significant clinical risks:
- False positives: Patients may receive unnecessary treatment, contributing to antibiotic resistance.
- False negatives: Active infections may go undetected, increasing the likelihood of serious complications such as gastric malignancies.
- Clinical Guidelines Recommend Against Serology
Major medical societies have issued clear guidance on *H. pylori* testing:
- The American College of Gastroenterology (ACG)
- The American Gastroenterological Association (AGA )
Both organizations recommend against using serology for *H. pylori* active infection diagnosis. Instead, they endorse non-invasive testing methods with higher accuracy:
- The *H. pylori* urea breath test (UBT)
- The *H. pylori* stool antigen test (SAT)
These tests are far superior in confirming active *H. pylori* infection, which is crucial for selecting the right treatment and ensuring clinical success.
### Why Labs Should Stop Using Serology for *H. pylori* Testing
Continuing to use serology for *H. pylori* testing can result in:
- Misdiagnosis and delayed treatment
- Unnecessary prescriptions
- Reduced laboratory credibility
- Denied reimbursement from health plans
- Most insurance providers now label *H. pylori* serology testing as not medically necessary, reflecting the shift in clinical best practices.
### A Better Way Forward: Accurate *H. pylori* Detection Tools
Modern, non-invasive tools like the BreathID® Urea Breath Test and the Curian® HpSA® stool antigen test provide accurate, efficient, and reimbursable solutions for diagnosing active *H. pylori* infections. The BreathID system delivers rapid, real-time breath test results, while Curian uses advanced fluorescent immunoassay technology to provide fast, objective, and reliable results—empowering labs to support clinicians with confidence.
### Conclusion: Make the Switch to Better *H. pylori* Testing
The science is clear: Helicobacter pylori testing must evolve. Serology is no longer a viable option for H. pylori detection and should be phased out in favor of proven, guideline-supported methods like the *H. pylori* urea breath test and *H. pylori* stool antigen testing.
### Ready to modernize your *H. pylori* testing approach?
[Explore Curian® HpSA and other innovative testing solutions](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
**Categories:** Diagnostics Blog
---
### [Why Modern Labs Are Moving Beyond Visual Interpretation in Diagnostic Testing](https://www.meridianbioscience.com/diagnostics-blog/why-modern-labs-are-moving-beyond-visual-interpretation-in-diagnostic-testing/)
**Published:** July 25, 2025
**Author:** Moaaz Ahmad
**Content:**
Colorimetric lateral flow assays (LFAs) have long been trusted in point-of-care and laboratory diagnostics due to their simplicity, low cost, and rapid results. However, traditional visual interpretation of these tests presents critical limitations in today’s increasingly data-driven and regulated healthcare environments. As diagnostic expectations grow more complex and precise, modern laboratories are turning to automated, objective technologies like Meridian Bioscience’s Curian® platform to deliver greater consistency, accuracy, and workflow efficiency.
### The Limitations of Visual Interpretation in Lateral Flow Assays
Visual interpretation relies on the human eye to detect and assess color changes or lines on lateral flow devices. While convenient, this approach can introduce variability that undermines diagnostic accuracy and reliability.
### Common limitations include:
- Subjective Variability: Lighting conditions, user experience, and technician fatigue can all affect interpretation. A faint test line might be read differently by different individuals, increasing the risk of inconsistent results.
- Borderline or Ambiguous Results: Results that fall in a “gray zone,” neither clearly positive nor negative, are especially vulnerable to misinterpretation, potentially leading to incorrect clinical decisions.
- High Training Burden: Maintaining reliable outcomes across staff requires extensive and ongoing training. Laboratories must commit substantial time and resources to ensure visual consistency, adding operational overhead.
### Why Laboratories Are Embracing Automated Digital Readers Like Curian
To address these challenges, more clinical laboratories are adopting automated digital reading platforms such as Curian by Meridian Bioscience. Built for enhanced immunoassay testing, Curian combines fluorescent technology with objective digital readouts, minimizing the risks of manual interpretation while delivering high-performance diagnostic results.
### Key Benefits of Curian’s Digital Immunoassay Technology:
- Objective, Reproducible Results: Curian’s digital reader ensures that every test is interpreted consistently, eliminating subjectivity and reader bias regardless of operator experience or environmental conditions.
- High Sensitivity and Specificity: Curian improves detection limits over traditional colorimetric LFAs, helping reduce both false positives and false negatives.
- Reduced Hands-On Time: With simple operation and rapid turnaround, Curian streamlines diagnostic workflows. The platform’s intuitive interface reduces manual steps, saving time and lowering the chance of user error.
- Seamless Integration with LIS/EMR Systems: Digital results from Curian can be directly integrated into Laboratory Information Systems (LIS) and Electronic Medical Records (EMR), improving documentation, data accessibility, and clinical decision-making.
### From Colorimetric to Fluorescent: Curian Leads the Shift
Meridian’s Curian platform represents a leap forward from traditional lateral flow testing. By combining fluorescent immunoassays with an automated reader, Curian is designed to provide a fully optimized diagnostic workflow with greater clarity, control, and confidence.
This digital transformation is not just about automation; it’s about elevating the quality of diagnostics. Fluorescent technology offers a wider dynamic range and superior analytical performance compared to colorimetric tests, making them ideal for environments that require high sensitivity and reproducibility.
### The Future of Diagnostic Testing: Curian at the Forefront
As healthcare systems demand faster, more accurate, and more traceable diagnostic solutions, the industry is rapidly moving beyond manual methods. Platforms like Curian are helping laboratories rise to the occasion, empowering them to meet increasing regulatory demands, improve patient outcomes, and operate more efficiently.
By investing in innovative diagnostic technology like Curian, labs are not only modernizing their operations but also preparing for a future where automation, accuracy, and integration are essential pillars of diagnostic excellence.
**Categories:** Diagnostics Blog
---
### [Shiga Toxin-Producing E. coli: The Urgent Need for Accurate, Antibiotic-Free Management](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
**Published:** September 29, 2025
**Author:** hamza
**Content:**
**What Is *E. coli*? Understanding STEC and How It Spreads**
*Escherichia coli* (*E. coli*) is a diverse group of bacteria that is commonly found in the intestines of humans and animals. While many strains are harmless, certain pathogenic types can cause serious illness. The most concerning among them is **Enterohemorrhagic *E. coli* (EHEC)**, also known as **Shiga toxin-producing *E. coli* (STEC)**.
While *E. coli* O157:H7 is the most well-known serotype, many non-O157 strains also produce Shiga toxin and are major contributors to foodborne illness outbreaks. It is typically transmitted through:
- Undercooked ground beef
- Contaminated produce or water
- Raw milk and unpasteurized dairy
- Contact with infected animals or their environments
### Symptoms of *E. coli* Infections and Shiga Toxin Complications
*E. coli* infections primarily affect the gastrointestinal system and can result in:
- Severe abdominal cramping
- Bloody diarrhea
- Nausea and vomiting
- Low-grade fever
However, the most dangerous aspect of these infections is the production of **Shiga toxin**, which can lead to serious complications, including:
- **Hemolytic Uremic Syndrome (HUS)**: A life-threatening condition causing hemolytic anemia, thrombocytopenia, and acute kidney failure
- Neurological complications
- Death, especially in children, the elderly, and immunocompromised patients
### Why Antibiotics Should Be Avoided in STEC Cases
Unlike many other bacterial infections, treating STEC with antibiotics is **strongly discouraged**. Studies show that antibiotic therapy may increase Shiga toxin release, worsening the patient’s condition and heightening the risk of HUS.
### Avoiding antibiotics is critical **for:**
- Reducing the risk of kidney failure
- Minimizing systemic complications
- Preventing potentially fatal outcomes
Supportive care, including hydration and monitoring, remains the standard of care.
### Why Culture Alone Falls Short in Detecting STEC
Traditional stool cultures are not equipped to detect Shiga toxins or differentiate between pathogenic and non-pathogenic *E. coli* strains. Cultures also:
- Require 48–72 hours for results
- Will miss non-O157 strains
- Fail to detect active Shiga toxin production
Modern immunoassay tests offer faster and more accurate detection of Shiga toxin-producing *E. coli* in stool samples.
Learn more about Meridian’s [Rapid E. Coli Diagnosis Solutions for Timely Intervention | Meridian Bioscience](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/?country=US) and how they support critical, timely intervention.
### Treatment for Shiga Toxin-Producing *E. coli*
The cornerstone of STEC treatment is supportive care only. Key recommendations include:
- **No antibiotics** or antimotility agents
- Intravenous fluids and electrolyte management
- Monitoring for signs of HUS, particularly in children and the elderly
Early identification and appropriate supportive therapy significantly improve outcomes.
### Meridian Bioscience: Diagnostic Confidence for STEC and Beyond
Meridian Bioscience offers cutting-edge GI diagnostic solutions that surpass conventional culture methods. Our tools enable rapid detection of Shiga toxins and other gastrointestinal pathogens, helping clinicians act fast and responsibly.
[Rapid E. Coli Diagnosis Solutions for Timely Intervention | Meridian Bioscience](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/?country=US)
**Take Action:** Elevate your diagnostic strategy with accurate, fast, culture-independent detection. Choose Meridian for a trusted, recommended STEC diagnosis.
**Categories:** Diagnostics Blog, E. coli, Gastrointestinal
---
### [Understanding H. pylori: Why Timely Testing and Retesting Matters](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
**Published:** September 29, 2025
**Author:** hamza
**Content:**
### What Is *H. pylori* and How Is It Transmitted?
*Helicobacter pylori* (*H. pylori*) is a spiral-shaped bacterium that infects the stomach lining and is a primary cause of peptic ulcers and chronic gastritis. It is also classified as a Group 1 carcinogen due to its association with gastric cancer. Transmission typically occurs in childhood through oral-oral or fecal-oral routes. Contaminated food, water, and close contact with infected individuals are common sources of infection.
### Symptoms and Health Risks of *H. pylori* Infection
While many individuals carry *H. pylori* asymptomatically, others may experience symptoms such as:
- Abdominal pain or discomfort
- Nausea
- Bloating
- Frequent burping
- Loss of appetite
- Unexplained weight loss
If left untreated, *H. pylori* can lead to serious complications, including:
- Peptic ulcers
- Chronic gastritis
- Iron deficiency anemia
- Vitamin B12 deficiency
- Gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Gastric cancer
### Who Should Be Tested for *H. pylori*?
Testing is critical for individuals presenting with persistent gastrointestinal symptoms. Certain populations who have an elevated risk and should be proactively screened are:
- Adult household members who live with someone with a confirmed *H. pylori* infection
- First-degree relatives (parents, siblings, children) with a family history of gastric cancer
- Individuals with unexplained iron deficiency anemia or B12 deficiency
- Patients under 60 with uninvestigated dyspepsia
For more on Meridian’s testing solutions, visit our [H. pylori disease area page](http://www.meridianbioscience.com/diagnostic-solutions/disease-areas/gastrointestinal/h-pylori/).
### How Is *H. pylori* Treated?
Standard treatment involves a combination of antibiotics and proton pump inhibitors (PPIs). Due to increasing antibiotic resistance, treatment should be guided by regional resistance patterns. Patient compliance and complete therapy adherence are essential to successful eradication.
### The Importance of Retesting After Treatment
A single round of treatment does not guarantee eradication. Clinical guidelines recommend retesting 4 weeks after therapy completion to confirm the bacteria has been eliminated. Failure to retest can result in:
- Continued gastric inflammation
- Risk of ulcer recurrence
- Increased gastric cancer risk
- Ongoing transmission to close contacts
Meridian’s [Curian HpSA](http://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa) test offers a reliable, non-invasive method for confirming eradication.
### Support Confident Diagnosis with Meridian Bioscience
Meridian Bioscience offers a comprehensive portfolio of **[non-invasive *H. pylori* diagnostic tools](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/)**, including urea breath testing as well as stool antigen testing platforms. With a focus on accuracy, efficiency, and ease of use, Meridian empowers laboratories and healthcare providers to deliver timely, reliable answers.
**Take Action:** Enhance your diagnostic solutions. Trust Meridian for definitive *H. pylori* detection and eradication testing.
**Categories:** Diagnostics Blog, Gastrointestinal, H. pylori
---
### [H. pylori Insights: Latest Trends in Symptoms, Treatments, and Prevention](https://www.meridianbioscience.com/diagnostics-blog/h-pylori-insights-latest-trends-in-symptoms-treatments-and-prevention/)
**Published:** April 10, 2024
**Author:** hamza
**Excerpt:** Here’s a compelling excerpt for the blog article "H. pylori Insights: Latest Trends in Symptoms, Treatments, and Prevention":
Exploring the Evolving Landscape of H. pylori Management
Helicobacter pylori, a key culprit behind peptic ulcers and chronic gastritis, continues to challenge medical science with its complex behavior and resistance patterns. This detailed exploration delves into the most recent advancements in detecting, treating, and preventing H. pylori infection. From cutting-edge diagnostic tests like the urea breath test and stool antigen testing, to innovative treatment strategies overcoming antibiotic resistance, the article provides crucial insights for healthcare professionals and those affected. Learn about the promising research towards effective vaccines and the best practices for minimizing the risk of infection.
**Content:**
[*Helicobacter pylori*](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/), commonly known as *H. pylori*, is a type of bacteria that infects the stomach lining and is a leading cause of peptic ulcers and chronic gastritis and can contribute to the development of gastric cancer. Understanding the latest trends in the symptoms, treatments, and prevention of *H. pylori* infections is crucial for both healthcare providers and the public. This article delves into the current state of *H. pylori* management, from diagnosis to treatment options and prevention strategies.
## Identifying *H. pylori* Infection Symptoms
*H. pylori* infection can be asymptomatic for many individuals, but when symptoms do occur, they may include:
- Burning or aching pain in the abdomen
- Abdominal pain that worsens when the stomach is empty
- Nausea
- Loss of appetite
- Frequent burping
- Bloating
- Unintentional weight loss
## *H. pylori* Testing and Diagnosis
Early detection and accurate diagnosis of [*H. pylori* infection](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) are vital for effective treatment. Various testing methods are available, each with its specific application and suitability.
*H. pylori* Urea Breath Test: This non-invasive test detects the presence of *H. pylori* by measuring the amount of carbon dioxide in the breath after drinking a urea solution. It’s highly sensitive and specific for active infections. It is useful for both initial diagnosis and confirming the eradication of the bacteria post-treatment.
*H. pylori* Stool Antigen Testing: This test looks for *H. pylori* antigens in a stool sample. It is also useful for both initial diagnosis and confirming the eradication of the bacteria post-treatment.
*H. pylori* Blood Test: Blood tests can detect antibodies to *H. pylori*, indicating past or present infection. However, they cannot distinguish between an active and a previous infection.
*H. pylori* Serum Test and IgG Detection: These tests measure the presence of specific antibodies to *H. pylori* in the blood and are often used for initial screening.
### Diagnostic Algorithm
A comprehensive [*H. pylori* Diagnostic](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) Algorithm often involves using non-invasive tests like the urea breath test and stool antigen testing as first-line diagnostics. Invasive methods, such as endoscopy with biopsy, may be employed in cases of complicated ulcers or when initial testing fails to confirm a diagnosis.
## Treatment Strategies
### *H. pylori* Treatment
The primary approach to treating *H. pylori* involves a combination of antibiotics to kill the bacteria and acid-reducing medications to reduce stomach acid, facilitating healing. The most common regimen is triple therapy, which includes two antibiotics (e.g., clarithromycin and amoxicillin) and a proton pump inhibitor (PPI) for 7–14 days. Quadruple therapy, which adds bismuth to the mix, may be used as a second-line treatment or in regions with high antibiotic resistance.
It’s important to follow the prescribed treatment plan and take all the medications as directed.
In some cases, more than one round of treatment (antibiotics) is required to take care of the infection.
### Resistance Considerations
Antibiotic resistance is a growing concern in [*H. pylori* treatment](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/). Tailoring antibiotic therapy based on local resistance patterns or following failed initial treatment is becoming increasingly important.
## Prevention Insights
Preventing *H. pylori* infection is challenging due to its widespread presence and unclear transmission routes. General recommendations include:
– Practicing good hand hygiene
– Ensuring food and water safety
– Avoiding direct contact with saliva or fecal matter from infected individuals
## *H. pylori* Vaccines
Research into vaccines for *H. pylori* is ongoing, with the hope of reducing the incidence of infection and its associated diseases in the future.
## Conclusion
The landscape of *H. pylori* management is evolving, with advancements in diagnostic methods, treatment regimens, and prevention strategies. Early and accurate detection through *H. pylori* testing is critical for effective management and reducing the risk of complications. As research continues to unfold, new insights promise to refine our approach to combating this common yet consequential bacterial infection, aiming for better patient outcomes and ultimately, the prevention of *H. pylori*-associated diseases.
**Categories:** Diagnostics Blog, Gastrointestinal, H. pylori
---
### [Breaking Down Congenital Cytomegalovirus: Insights into Diagnosis and Treatment](https://www.meridianbioscience.com/diagnostics-blog/breaking-down-congenital-cytomegalovirus-insights-into-diagnosis-and-treatment/)
**Published:** May 1, 2024
**Author:** hamza
**Content:**
[Congenital Cytomegalovirus (CMV) infection](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is a significant public health concern that affects infants and their families. It is the most common viral congenital infection in the United States and around the world and can lead to various long-term health problems such as hearing loss, vision loss, and developmental disabilities. It is crucial for healthcare providers, expectant mothers, and researchers to understand the nuances of CMV testing, diagnosis, and treatment. This article aims to provide information on current practices and advancements in managing congenital CMV.
## **Understanding CMV and Its Transmission**
[Cytomegalovirus (CMV)](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is a type of herpes virus that can infect people of all ages. In most cases, CMV causes mild or no symptoms in healthy children and adults. However, if a pregnant woman is infected with CMV, the virus can be transmitted to her unborn child, which can result in congenital CMV infection. This type of transmission can cause significant health problems for the newborn and can lead to long-term health issues.
## **CMV Testing and Diagnosis**
Early and accurate diagnosis of CMV infection is crucial, particularly in newborns and pregnant women. There are various testing methodologies used to detect the virus:
- CMV Blood Testing: This is a common approach for identifying CMV infections in mothers, including testing for the presence of CMV-specific antibodies (IgM and IgG) to determine recent or past infections.
- CMV Virus Testing: Utilizes polymerase chain reaction (PCR) and other molecular techniques to detect CMV DNA in blood, urine, saliva, or other bodily fluids, offering a direct measure of viral presence.
- CMV Infection Testing in Pregnancy: Special emphasis is placed on testing pregnant women who may be at risk of transmitting the virus to the fetus. Amniocentesis can be used to test for CMV in amniotic fluid, although this is generally reserved for cases where there is a high suspicion of infection.
- [Congenital CMV Testing](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/): Newborns suspected of having congenital CMV can undergo saliva, urine or blood tests within the first three weeks of life to accurately diagnose the infection. These tests look for active virus shedding, which indicates congenital infection.
### **CMV Testing Solutions**
Recent developments in CMV diagnostic tests aim to enhance their sensitivity, specificity, and accessibility. These include the creation of more efficient molecular-based assays, rapid point-of-care tests for instant results, and comprehensive screening programs for newborns and pregnant women. These solutions strive to enable early detection and intervention, which are crucial for improving outcomes in congenital CMV infection.
### **Treatment and Management of Congenital CMV**
Treatment options for congenital CMV infection are focused on reducing the long-term impacts of the disease. Antiviral medications, such as ganciclovir and valganciclovir, are used to treat symptomatic newborns. They have shown promising results in improving hearing outcomes and developmental milestones. It is crucial to provide early intervention services such as audiological, ophthalmological, and developmental assessments and therapies to support affected infants and their families.
The management of congenital CMV also involves preventive strategies to reduce the risk of maternal infection and subsequent vertical transmission. This includes educating pregnant women about CMV and promoting hygiene practices to avoid CMV exposure during pregnancy.
## **Conclusion**
The battle against [congenital CMV infection relies on effective diagnosis](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/), timely treatment, and comprehensive management strategies. Ongoing research and development in CMV testing solutions and therapeutic interventions offer hope for reducing the burden of this congenital infection. Diligent screening in newborns and pregnant women for early detection remains a cornerstone of managing congenital CMV, ensuring that affected infants receive the care and support they need to thrive.
**Categories:** CMV, Diagnostics Blog, Pediatric & Neonatal
---
### [Navigating H. pylori: Emerging Therapies and Treatment Innovations](https://www.meridianbioscience.com/diagnostics-blog/navigating-h-pylori-emerging-therapies-and-treatment-innovations/)
**Published:** June 1, 2024
**Author:** hamza
**Excerpt:** Helicobacter pylori, a pervasive but elusive bacterium, continues to challenge global health with its role in numerous gastrointestinal diseases, including peptic ulcers and gastric cancer. With traditional treatments becoming less effective due to escalating antibiotic resistance, the medical community is compelled to explore innovative therapeutic strategies. This article delves into the latest advancements in H. pylori management, from groundbreaking antibiotic combinations to promising non-antibiotic approaches like probiotics and phytomedicine. We also explore the frontier of vaccine development and tailored treatments tailored to combat resistance, offering new hope for millions affected worldwide.
**Content:**
[*Helicobacter pylori* (*H. pylor*i) infection](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) remains a global health challenge, with strong links to various gastrointestinal diseases such as peptic ulcers, gastritis, and gastric cancer. Despite the availability of effective treatment regimens, the increasing prevalence of antibiotic resistance has necessitated the exploration of new therapeutic avenues. This article delves into the emerging therapies and treatment innovations for *H. pylori*, highlighting the latest advancements and their implications for overcoming resistance and improving patient outcomes.
## Current State of *H. pylori* Management
Traditional management of *H. pylori* infection involves a combination of antibiotics and acid-suppressing drugs. However, the effectiveness of these treatments is diminishing due to the bacterium’s growing resistance to commonly used antibiotics. This has led to the development and exploration of new diagnostic and therapeutic strategies to combat *H. pylori* more effectively.
## Diagnostic Innovations
Accurate detection of *H. pylori* infection is the first step in effective management. Innovations in diagnostic approaches, including *H. pylori* testing and *H. pylori* detection methods such as the urea breath test and stool antigen testing, have enhanced the ability to identify infections accurately. These *H. pylori* identification test kits play a crucial role in tailoring treatment strategies to individual patients, improving the chances of successful eradication.
## Emerging Therapies and Innovations in Treatment
### Novel Antibiotic Combinations
To counteract antibiotic resistance, research has focused on novel antibiotic combinations and regimens. These include extending the duration of therapy, increasing doses, and incorporating newer antibiotics with different mechanisms of action. The aim is to optimize *H. pylori* treatment outcomes while minimizing the potential for resistance development.
### Non-Antibiotic Approaches
Emerging therapies for *H. pylori* infection also include non-antibiotic strategies, such as:
- Probiotics: Supplementing antibiotic therapy with probiotics has shown promise in enhancing treatment efficacy and reducing side effects.
- Vaccine Development: Although still in the experimental phase, vaccines against *H. pylori* offer a potential preventive strategy that could reduce the incidence of infection and associated diseases.
- Phytomedicine: Extracts from certain plants and natural products have demonstrated anti-*H. pylori* activity, presenting an alternative approach to treatment, especially in regions with high antibiotic resistance.
### Tailored Treatment Based on Resistance Patterns
The implementation of a tailored treatment approach based on local antibiotic resistance patterns represents a significant innovation in *H. pylori* management. By utilizing *H. pylor*i diagnostic algorithms and resistance testing, healthcare providers can select the most effective antibiotics for each patient, thereby increasing the likelihood of successful eradication.
### Advances in Delivery Systems
The development of novel drug delivery systems, including nanoparticle carriers and slow-release formulations, aims to improve the effectiveness of *H. pylor*i treatment. These innovations seek to enhance drug stability, reduce dosage frequency, and target the bacteria more precisely within the stomach lining.
## Prevention Strategies
In addition to therapeutic innovations, efforts to prevent *H. pylori* infection are crucial. This includes public health initiatives focused on improving hygiene practices and food safety, as well as the [development of *H. pylori* vaccines](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) which could offer long-term protection against infection.
## Conclusion
Navigating the landscape of *H. pylori* infection treatment is evolving, with emerging therapies and innovations offering new hope in the fight against this prevalent bacterium. By integrating advanced diagnostic methods, exploring non-antibiotic treatments, and tailoring therapies based on resistance patterns, the medical community is better positioned to manage *H. pylori* infection effectively. Continued research and innovation are essential to overcoming the challenges posed by antibiotic resistance, ultimately leading to improved outcomes for patients worldwide.
**Categories:** Diagnostics Blog, Gastrointestinal, H. pylori
---
### [Trends in H. pylori Infections: Insights and Strategies for Prevention](https://www.meridianbioscience.com/diagnostics-blog/trends-in-h-pylori-infections-insights-and-strategies-for-prevention/)
**Published:** April 1, 2024
**Author:** hamza
**Content:**
*Helicobacter pylori* (*H. pylori*) is a significant global health concern, with strong links to various gastrointestinal diseases and conditions such as gastritis, peptic ulcers, and gastric cancer. Understanding the trends in *H. pylor*i infections, including insights into its transmission and evolving strategies for prevention, is crucial in mitigating its public health impact. This article explores the latest trends and provides strategies for the prevention of *H. pylori* infections, emphasizing the importance of diagnosis, treatment innovations, and public health measures.
## Current Trends in *H. pylori* Infections
[*H. pylori* infections](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) remain prevalent worldwide, with variations in infection rates across different regions and populations. Factors contributing to these trends include socioeconomic status, living conditions, and the prevalence of antibiotic resistance. Increasing resistance to standard antibiotic treatments poses a significant challenge in managing *H. pylori* infections, necessitating innovative approaches to diagnosis, treatment, and prevention.
## Advances in Diagnosis
Early and accurate diagnosis of *H. pylori* infection is vital to effective management and prevention efforts. Recent advancements in diagnostic techniques, such as the *H. pylori* urea breath test, *H. pylori* stool antigen testing, and molecular methods for *H. pylor*i detection, have improved the accuracy and accessibility of *H. pylori* diagnostics. These advancements enable healthcare providers to identify infections more accurately and to monitor the effectiveness of treatment regimens, contributing to more targeted and effective management strategies.
## Innovative Treatment Strategies
As antibiotic resistance becomes more prevalent, there is a growing focus on developing new treatment strategies that can overcome resistance mechanisms. This includes the exploration of novel antibiotic regimens, the use of probiotics to support gastrointestinal health during and after treatment, and the investigation into vaccine development as a long-term preventive measure against *H. pylori* infection. Personalized treatment approaches, based on resistance patterns and individual patient factors, are also gaining attention as a way to enhance treatment efficacy and reduce the likelihood of treatment failure.
## Strategies for Prevention
Preventing *H. pylori* infections requires a multifaceted approach, combining public health initiatives, advances in medical research, and individual actions to reduce transmission risk.
### Public Health Measures
Improving sanitation, water quality, and living conditions are critical public health measures that can significantly reduce the transmission of *H. pylor*i. Additionally, education campaigns raising awareness about the routes of [*H. pylori*](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/) transmission and the importance of hygiene practices can also play a vital role in prevention efforts.
### Screening and Early Detection
Screening programs targeting populations at high risk for *H. pylori* infection can facilitate early detection and treatment, potentially preventing the progression to more serious gastrointestinal diseases. Utilizing non-invasive diagnostic tests, such as the *H. pylori* urea breath test and stool antigen tests, can make screening more accessible and less burdensome for individuals.
### Dietary and Lifestyle Factors
Emerging research suggests that certain dietary and lifestyle factors may influence the risk of *H. pylori* infection and its outcomes. Diets rich in fruits, vegetables, and fiber may offer some protective effects against *H. pylori*, while smoking and high salt consumption can increase the risk of complications from infection. Encouraging healthy dietary and lifestyle habits may thus contribute to the prevention and management of *H. pylori* infections.
## Conclusion
The trends in *H. pylori* infections highlight the ongoing challenges and the need for continued innovation in diagnosis, treatment, and prevention strategies. By leveraging advances in diagnostic methods, exploring new treatment avenues, and implementing effective public health measures, it is possible to reduce the burden of *H. pylori* infections. Ultimately, a comprehensive approach that combines medical research, public health initiatives, and individual actions will be essential in combating this pervasive health challenge and improving outcomes for those affected by *H. pylori* infections.
**Categories:** Diagnostics Blog, Gastrointestinal, H. pylori
---
### [Navigating Congenital Cytomegalovirus: Latest Trends in Prevention and Care](https://www.meridianbioscience.com/diagnostics-blog/navigating-congenital-cytomegalovirus-latest-trends-in-prevention-and-care/)
**Published:** August 1, 2024
**Author:** hamza
**Excerpt:** Congenital cytomegalovirus (CMV) is a critical public health issue with significant implications for unborn babies. As the leading non-genetic cause of hearing loss and developmental disabilities in infants, understanding and managing this infection is paramount. Recent advancements in CMV testing offer new hope, allowing for early detection and potentially reducing the impact on the child. This article delves into the latest trends in CMV prevention and care, highlighting the transformative role of innovative testing solutions in prenatal care.
The Importance of Early CMV Testing
With CMV testing during pregnancy becoming a cornerstone of prenatal care, new nucleic acid amplification tests (NAAT) and polymerase chain reaction (PCR) tests enhance the accuracy of detecting CMV DNA. Such innovations ensure that healthcare providers can intervene early, optimizing outcomes for both mother and child. This shift not only promises to minimize the transmission risks but also underscores the evolving landscape of maternal and infant health.
By embracing these advancements and integrating comprehensive prevention strategies, we can mitigate the impact of congenital CMV and support healthier futures for the next generation.
**Content:**
[Congenital cytomegalovirus (CMV) infection](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is a significant public health concern, posing serious risks to unborn babies when mothers become infected with CMV during pregnancy. As a leading cause of non-genetic hearing loss and developmental disabilities in infants, understanding and managing CMV infection is crucial. Recent advancements in CMV testing and care strategies have brought new hope to families and healthcare providers alike. This article explores the latest trends in the prevention and care of congenital CMV, emphasizing the pivotal role of innovative CMV testing solutions.
## The Importance of CMV Testing in Pregnancy
[CMV testing](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) during pregnancy is paramount for the early identification and management of potential infections. CMV virus testing, especially CMV blood testing and CMV pregnancy testing, allows healthcare providers to assess the risk of the virus being transmitted to the fetus. Early detection through cytomegalovirus testing can lead to interventions that may reduce the impact of the infection on the unborn child.
## Advancements in CMV Testing Solutions
The landscape of CMV infection testing has evolved significantly, with advancements in both the accuracy and accessibility of testing methods. Modern CMV testing solutions include nucleic acid amplification tests (NAAT) or polymerase chain reaction (PCR) tests, which can detect CMV DNA in blood, urine, saliva, and other bodily fluids. These tests offer high sensitivity and specificity, making them invaluable tools in diagnosing congenital CMV.
For pregnant women, CMV pregnancy testing has become an integral part of prenatal care. By identifying CMV infection early, healthcare providers can monitor the pregnancy more closely and consider interventions that might minimize the risk to the fetus.
## Universal Screening and Targeted Testing
Debate continues within the medical community regarding the best approach to CMV testing in pregnancy. Some experts advocate for universal screening, which would involve testing all pregnant women for CMV infection, while others recommend targeted testing for those at higher risk or showing symptoms of CMV infection. Regardless of the approach, the goal remains the same: to reduce the incidence of congenital CMV through early detection and intervention.
## Trends in the Prevention and Management of Congenital CMV
Prevention plays a critical role in the fight against congenital CMV. Public health initiatives focusing on educating pregnant women about CMV transmission have shown promise. Simple hygiene practices, such as hand washing, avoiding sharing food and utensils with young children, and refraining from kissing children on the lips, can significantly reduce the risk of CMV infection during pregnancy.
## Innovations in CMV Care and Treatment
For infants born with congenital CMV, early intervention is key to managing potential health complications. Antiviral medications, such as valganciclovir, have been used to treat symptomatic congenital CMV, showing improvements in hearing and developmental outcomes in some cases. Ongoing research into vaccine development and other therapeutic strategies offers hope for more effective prevention and treatment options in the future.
## The Role of Support and Education
Supporting families affected by congenital CMV is an essential aspect of care. Parental education on the implications of CMV and the importance of early intervention can empower families to seek the necessary support and resources. Additionally, raising awareness about CMV among healthcare providers and the public is crucial for improving outcomes for those affected by the virus.
## Conclusion
Navigating the complexities of congenital cytomegalovirus requires a multifaceted approach, combining advanced CMV testing, preventive measures, and comprehensive care strategies. The latest trends in CMV testing and management offer new pathways for reducing the impact of this infection on the most vulnerable. As research continues to advance, the prospects for preventing congenital CMV and supporting affected families grow increasingly promising, marking significant strides towards safeguarding the health of future generations.
**Categories:** CMV, Diagnostics Blog, Pediatric & Neonatal
---
### [Emerging Strategies in Congenital Cytomegalovirus Management: A Comprehensive Guide](https://www.meridianbioscience.com/diagnostics-blog/emerging-strategies-in-congenital-cytomegalovirus-management-a-comprehensive-guide/)
**Published:** June 1, 2024
**Author:** hamza
**Excerpt:** Exploring the Frontier of Congenital CMV Management
Congenital cytomegalovirus (CMV) infection, a significant challenge in public health, has far-reaching implications for infants born worldwide. Historically, effective management strategies for CMV have been limited, but the landscape is changing rapidly with new research and clinical practices offering a beacon of hope. This comprehensive guide delves into the latest emerging strategies in the fight against this pervasive infection, highlighting innovative approaches that promise to reshape outcomes for affected families and healthcare systems alike.
Advancements in Screening and Early Detection
Identifying congenital CMV early in life—or ideally during pregnancy—is crucial. The advent of universal newborn screening and targeted maternal testing during pregnancy represents a pivotal shift, enabling healthcare providers to intervene sooner and more effectively. These screening protocols not only enhance early detection but also set the stage for timely interventions that can mitigate long-term impacts.
Innovative Treatments and Preventive Measures
Recent strides in antiviral therapies, particularly with drugs like Valganciclovir, have shown improved outcomes in symptomatic infants, potentially altering the course of developmental challenges associated with the virus. Alongside treatment, the pursuit of a preventative vaccine and heightened public health initiatives underscores a holistic approach to managing and ultimately reducing the burden of congenital CMV.
Through these collective efforts, the path forward in congenital CMV management is becoming clearer, paving the way for significant advancements in both prevention and treatment.
**Content:**
Congenital cytomegalovirus (CMV) infection poses a significant challenge to public health, representing a leading cause of sensory and neurological deficits in infants worldwide. Despite its prevalence, congenital CMV has historically lacked highly effective management strategies. However, recent advancements in research and clinical practice are ushering in a new era of possibilities for preventing and managing this pervasive infection. This guide explores the latest emerging strategies in the battle against congenital CMV, offering hope and direction for healthcare providers, researchers, and affected families.
## Understanding Congenital CMV
Before diving into management strategies, it’s crucial to grasp the fundamentals of [congenital CMV](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/). This viral infection occurs when CMV is transmitted from a pregnant woman to her fetus, potentially leading to a spectrum of birth defects and developmental disabilities, including hearing loss, vision impairment, and intellectual disabilities. The risk of transmission and the severity of outcomes can vary significantly based on several factors, including the timing of infection during pregnancy and the mother’s immune status.
## Advances in CMV Screening and Early Detection
One of the most critical steps in managing congenital CMV is the early detection of the virus in newborns and, where possible, in pregnant women. Universal newborn screening has emerged as a potentially transformative strategy for identifying infants with congenital CMV, enabling early intervention and monitoring.
## Universal Newborn Screening
While not yet widely implemented, universal newborn CMV screening involves testing all newborns for [CMV infection](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) shortly after birth. This approach can identify asymptomatic infections that might otherwise go unnoticed until later in life when hearing loss or other developmental issues become apparent.
## Maternal Screening During Pregnancy
Screening pregnant women for CMV has also gained attention as a strategy for early intervention. By identifying pregnant women with primary CMV infections, healthcare providers can offer counseling on risk reduction and closely monitor the pregnancy for signs of fetal infection.
## Innovations in Antiviral Treatment
Antiviral therapy represents a cornerstone of congenital CMV management. Recent studies have focused on optimizing treatment regimens to improve outcomes while minimizing side effects.
### Valganciclovir for Symptomatic Infants
Valganciclovir, an oral antiviral medication, has shown promise in treating symptomatic congenital CMV. Recent research suggests that extending the duration of treatment may improve hearing outcomes and neurodevelopmental scores in affected infants.
## Vaccine Development
A vaccine against CMV is considered the holy grail in preventing congenital CMV infection. Several vaccine candidates are in various stages of development, with efforts focusing on preventing primary infection in women of childbearing age. While a fully effective CMV vaccine is not yet available, progress in this area offers hope for a future where congenital CMV can be prevented before it occurs.
## Public Health Initiatives and Awareness Campaigns
Raising awareness about CMV among healthcare providers, pregnant women, and the general public is critical for prevention. Public health initiatives that promote hygiene practices to prevent CMV transmission, such as handwashing and avoiding sharing food and utensils with young children, are simple yet effective strategies.
## Conclusion
The landscape of congenital [CMV management](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/) is evolving rapidly, with new strategies emerging for screening, treatment, and prevention. By embracing these advancements, healthcare providers can significantly impact the outcomes of affected infants, offering hope for families navigating the challenges of congenital CMV. Continued research and public health efforts are essential to further refine these strategies and move closer to the ultimate goal of eliminating congenital CMV as a major health concern.
**Categories:** CMV, Diagnostics Blog, Pediatric & Neonatal
---
### [Lab Equipment That Never Fails: Myth or Must-Have?](https://www.meridianbioscience.com/diagnostics-blog/lab-equipment-that-never-fails-myth-or-must-have/)
**Published:** July 22, 2025
**Author:** Moaaz Ahmad
**Content:**
In the realm of diagnostics, one universal truth prevails—no laboratory instrument is infallible. Yet, some decision-makers still pursue the ideal of a machine that operates flawlessly forever, without any breakdowns or errors. It’s a comforting notion, but let’s examine the reality.
At Meridian Bioscience, we recognize what truly matters: performance, support, and partnership—especially when challenges arise.
### The Reality of Lab Equipment: Failure is Inevitable
Even the most advanced diagnostic instruments, such as PCR analyzers and molecular platforms, are intricate machines. Like any sophisticated tool, they can and do experience failures. Whether it’s a software glitch, mechanical issue, or calibration problem, equipment downtime is an expected aspect of laboratory operations.
A study by Frost & Sullivan highlighted that lab managers ranked instrument maintenance and downtime as their top challenges, underscoring the inevitability of equipment issues in laboratory settings (Lab Manager, 2023).
### Deciding What to Buy: It’s About More Than Just Performance
When laboratories evaluate new instruments like the Revogene system, they consider more than just technical specifications:
- Ease of Use
- Cost of Ownership
- Test Menu
- Footprint and Scalability
- Reliability and Uptime
- Training and Technical Support Availability
- Regulatory and Quality Compliance
Once acquired, most platforms perform as expected—for a time. However, issues can arise, such as recurring problems, ambiguous error codes, or unexpected results.
### Error: Instrument, or Operator?
Determining the root cause of a malfunction is crucial. Is it the machine’s fault, or is human error to blame?
Research indicates that a significant portion of laboratory errors stem from human factors, including inadequate training and procedural lapses (Plebani, 2006).
This prompts important questions:
Are your technicians fully trained?
Are they using the equipment as specified in the Instructions for Use (IFU)?
Could a refresher course or re-certification reduce preventable errors?
Laboratory leadership might benefit from an internal review before considering a vendor switch—a proactive approach that can yield significant improvements.
### When the Instrument Is the Issue: What Now?
Even with a well-trained team, not all issues can be prevented. When equipment fails, your vendor’s response becomes your laboratory’s lifeline.
The Revogene system is supported by prompt, knowledgeable assistance and a customer success team dedicated to minimizing downtime. The objective? Rapid resolution with minimal disruption.
This is where vendors differentiate themselves—not just in the performance of their instruments, but in the speed and efficiency with which they help you recover from setbacks.
### Should You Switch Vendors?
Switching platforms is a substantial undertaking: new training, validation processes, potential downtime, and inherent risks.
How many errors are too many? That depends on your current vendor’s responsiveness.
A study by Lippi and Da Rin (2019) concluded that laboratories with strong vendor partnerships and effective internal processes experienced better long-term outcomes compared to those frequently switching vendors in response to equipment malfunctions.
Partnership fosters resilience, trust, and can lead to product improvements driven by your feedback.
### The Smarter Path: Backup and Partnership
Instead of switching vendors, consider adding redundancy to your laboratory. A backup Revogene system, for instance, can maintain throughput and alleviate concerns during maintenance or repairs.
Collaborating with your vendor—sharing insights, escalating concerns, and co-developing features—positions you as a partner in innovation, contributing to the advancement of diagnostic solutions.
### Final Thought: Play the Long Game
Laboratory equipment isn’t flawless—that’s a given. However, how we respond to challenges reveals our commitment to excellence and innovation.
Our recommendation? Stay. Collaborate. Solve. And let’s build the future of diagnostics—together.
### Explore the Revogene System
[Learn more about how Revogene delivers reliable results and responsive support for molecular diagnostics. ](/diagnostics/platforms/molecular/revogene/)
**References**
Lab Manager. (2023). Looking Beyond Routine Lab Equipment Maintenance. Retrieved from
Lippi, G., & Da Rin, G. (2019). Advantages and limitations of total laboratory automation: a personal overview. Clinical Chemistry and Laboratory Medicine (CCLM), 57(6), 802–811.
Plebani, M. (2006). Errors in clinical laboratories or errors in laboratory medicine? Clinical Chemistry and Laboratory Medicine (CCLM), 44(6), 750–759.
**Categories:** Diagnostics Blog
---
### [Home Testing a Key to Early Detection](https://www.meridianbioscience.com/lifescience-blog/the-shift-towards-home-testing-for-stds/)
**Published:** October 2, 2023
**Author:** Moaaz Ahmad
**Content:**
Early diagnosis for STDs is a key factor to better health outcomes, however, research shows that social stigma creates a major barrier to testing for sexually transmitted diseases. In recent years, at-home testing for STDs has become more common, increasing the accessibility and appeal to individuals who would otherwise be reluctant to test. As the rates of STDs continue to increase globally, home testing will hopefully help encourage earlier diagnoses which will in turn, reduce the spread of these diseases.1
## STDs are on the Rise
More than 35 bacterial, viral, and parasitic pathogens have been identified as sexually transmissible, and more than 1 million STDs are acquired every day worldwide, the majority of which are asymptomatic2. They are among the most common infectious diseases reported around the globe3 and the World Health Organization (WHO) estimated in 2016 that there are an estimated 374 million new infections every year of one of four curable STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. In the United States alone, the overall number of reported STDs has been on the rise since 2014 and shows no sign of slowing, with gonorrhea increasing by 74% since 20172. Although most STDs are not life-threatening, they result in a substantial burden of diseases4 and with STDs increasing globally, the WHO is calling for better access to testing and diagnostic services5.
### Global Prevalence of Chlamydia, Gonorrhea, Trichomoniasis and Syphilis
#### Image from:
Van Gerwen, O.T., Muzny, C.A. & Marrazzo, J.M. (2022). Sexually transmitted infections and female reproductive health. Nat Microbiol 7,1116–1126. https://doi.org/10.1038/s41564-022-01177-x
### COVID Spurred a Self-Testing Revolution
The COVID pandemic spurred a self-testing revolution6, with self-testing ranking as the most preferred form of testing for COVID-197. This newly developed comfort for specimen self-collection and analysis has created an overall desire for more home tests for various health conditions including sexually transmitted diseases (STDs). Given that self-collection provides privacy, convenience and better accessibility, making it easier for people to get tested, governments are now targeting point-of-care and at-home test for STDS in the hope that they will reduce the overall spread of these diseases8.
### How do At-Home STD Tests Work?
Home-based testing for STDs includes both self-collected mail-in specimens, and rapid assays that are sold over the counter (OTC) or ordered by mail8. Studies examining the popularity of STD home testing have shown that the testing rate is eleven times higher compared to clinic-based testing, demonstrating the dramatic preference for specimen self-collection9.
The type of specimen required for a test depends on the disease – chlamydia, gonorrhea and trichomoniasis typically require a vagina/urethral swab or urine sample, while HIV, syphilis, and hepatitis C generally require a finger prick (blood sample). Some tests for Chlamydia, gonorrhea and HIV only need an oral swab which is even more self-collection-friendly10.
### The Growing At-Home STD Market
According to Amesh Adalja, M.D., a senior scholar at the Johns Hopkins University Center for Health Security, the STD epidemic is “out of control. We know we are missing diagnoses. We know that contact tracing is happening late or not at all. If we’re really serious about tackling the STD crisis, we have to get more people diagnosed.” Encouragingly in the U.S., several state public health departments, including Alabama, Alaska and Maryland have started mailing free STD test kits to residents. Universities and nonprofits are also spearheading at-home testing efforts11. As dozens of commercial enterprises start jumping into or ramping up direct-to-consumer tests for STDs, newer tests that set a new bar in at-home STD testing11, are expected to improve consumer confidence and further encourage home testing.
As a whole, the recent July 2023 guidelines released by the WHO aimed at improving testing and diagnosis of STDs6 in combination with the strong growth anticipated in the home testing market (CAGR of 10.5% increase from 2022 to 2031)12, the STD at-home testing market is predicted to expand with next-generation tests that are easy to use and highly accurate.
### Meridian’s STD Home-Testing Reagent Solutions
Meridian is a leader in innovative molecular master mixes, and its Specimen-specific™ range of qPCR and LAMP mixes are ideal for extraction-free, sensitive amplification from saliva, urine or blood. These reagents, combined with Meridian’s extensive menu of highly sensitive antibody and antigen pairs to STDs provide companies looking to develop at-home STD assays, a single reliable vendor to support their assay development needs.
Interested to learn more about the applications and performance of Specimen-specific™ mixes for saliva samples? Download a copy of our whitepaper “ Saliva Specimen-specific™ Master Mixes for Multiplex.
[Download White Paper](https://collateral.meridianlifescience.com/view/1070676719/)
#### References:
1. Lee, A.S.D., Cody, S.L.. (2020). The Stigma of Sexually Transmitted Infections. Nurs. Clin. North Am. 55(3):295-305. https://doi.org/10.1016/j.cnur.2020.05.002
2. As STDs proliferate, companies rush to market at-home test kits. But are they reliable? [Liz Szabo, Kaiser Health News](https://www.fiercebiotech.com/person/liz-szabo-kaiser-health-news-0) Nov 21, 2022. [Fierce Biotech](https://www.fiercebiotech.com/medtech/stds-proliferate-companies-rush-market-home-test-kits-are-they-reliable)
3. WHO Sexually transmitted infections (STIs) Fact Sheet (2023). Retrieved from:
4. Fu. L., *et al.* (2022) Incidence Trends of Five Common Sexually Transmitted Infections Excluding HIV From 1990 to 2019 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2019. Front. Med. 9:851635.
5. Chesson, H.W., Mayaud, P., Aral, S.O. Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention. Major Infectious Diseases. 3rd edition. (Washington,DC, The International Bank for Reconstruction and Development, 2017) [https://doi.org/10.1596/978-1-4648-0524-0\_ch10](https://doi.org/10.1596/978-1-4648-0524-0_ch10)
6. WHO releases new guidance to improve testing and diagnosis of sexually transmitted infections (2023). Retrieved from:
7. Katy McLaughlin “[COVID-19: Implications for business](https://www.mckinsey.com/capabilities/risk-and-resilience/our-insights/covid-19-implications-for-business)” April 13, 2022. Accessed Sept 4 2023.
8. Mehta, Parang. “[What to Know About At-Home STD Tests.](https://www.webmd.com/sexual-conditions/what-to-know-about-at-home-std-tests.)” WebMed. January 14, 2023. Accessed Sept 4 2023.
9. Shih, S.L., Graseck, A.S., Secura, G.M., Peipert, J.F. (2011). Screening for sexually transmitted infections at home or in the clinic? Curr Opin Infect Dis.;24(1):78-84.
10. Mayo Clinic Staff. “[STD testing: What’s right for you?” Myo Clinic.](https://www.mayoclinic.org/diseases-conditions/sexually-transmitted-diseases-stds/in-depth/std-testing/art-20046019) Accessed Sept 4 2023.
11. Tucker, J.D., Bien, C.H., Peeling, R.W. (2013) Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis.;26(1):73-9. https://doi.org/10.1097/QCO.0b013e32835c21b0
12. Emily Hendersen. “[As STDS proliferate, companies rush to market at-home test kits. But are they reliable?](https://www.news-medical.net/news/20221120/As-STDS-proliferate-companies-rush-to-market-at-home-test-kits-But-are-they-reliable.aspx)” News-Medical.Net. Nov 20, 2022 Accessed Sept 4 2023.
13. “[At-Home Testing Market to Grow USD 45,582.24 Million by 2031 at a CAGR of 10.5%](https://www.prnewswire.com/news-releases/at-home-testing-market-to-grow-usd-45-582-24-million-by-2031-at-a-cagr-of-10-5--valuates-reports-301723386.html)” | Valuates Reports 17 Jan, 2023. Accessed Sept 4 2023.
**Categories:** Immunology, Life Science Blog
---
### [qPCR in Early Cancer Detection: Why It Still Leads the Pack](https://www.meridianbioscience.com/lifescience-blog/why-qpcr-still-leads-in-oncology/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
Cancer diagnostics have undergone a major transformation over the past two decades, shifting from late-stage diagnosis and generalized treatment toward earlier detection, molecular stratification, and personalized therapy. With this shift comes the need to detect clinically actionable biomarkers at increasingly low concentrations, while also supporting broader mutational profiling to expand access to molecularly matched therapies and guide more precise treatment decisions.
As the oncology diagnostics landscape continues to evolve — supporting earlier detection, real-time monitoring, companion diagnostics and decentralized testing – [quantitative PCR (qPCR)](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/) remains a foundational tool. Its combination of high analytical sensitivity, rapid turnaround time and cost-efficiency makes it uniquely suited for informing therapeutic decision-making at scale, especially in time-sensitive or resource-constrained settings.
## What Sets qPCR Apart in Oncology Diagnostics?
qPCR’s strong multiplexing capability allows multiple clinically relevant mutations to be detected in a single reaction, without compromising sensitivity or speed. This makes it particularly well-suited for oncology applications where actionable targets span several genes, and sample material is scarce. For example, in non-small cell lung cancer (NSCLC), multiplexed qPCR panels can simultaneously assess alterations in EGFR, KRAS, BRAF and ALK – delivering results faster and using less input material than sequential or panel-based next-generation sequencing (NGS) approaches. Solutions such as Biofidelity’s Aspyre Lung Reagents1 and the AmoyDx® Pan Lung Cancer PCR Panel2 showcase the strong clinical potential of multiplexed qPCR, with ongoing advancements expected to further expand regulatory clearance and clinical adoption. This makes qPCR an attractive option for labs aiming to expand molecular coverage without the complexity, cost or turnaround time associated with sequencing platforms. It is especially useful in tissue-limited cases such as fine needle aspirates or cell-free DNA (cfDNA) from liquid biopsies, where maximizing data from minimal input is critical.
## Fast Results with Minimal Infrastructure
Unlike sequencing platforms, which can take days to generate and analyze data, qPCR delivers clinically actionable results within hours. This rapid turnaround is especially valuable in time-sensitive scenarios such as selecting targeted therapies or enrolling patients into mutation-driven clinical trials where quick decision-making is critical.
qPCR is also highly scalable and automation-friendly, supporting high-throughput testing without the need for significant capital investment or complex infrastructure. Its compatibility with standardized 96- or 384-well formats makes it ideal for a wide range of settings, from centralized reference labs to hospital-based molecular laboratories and decentralized or resource-limited environments.
In addition, qPCR assays are generally easier to interpret, validate and implement within regulatory frameworks compared to more complex methods like next-generation sequencing (NGS).
## Cost-Effective for Scalable Cancer Screening
While sequencing technologies have deepened our understanding of the cancer genome, qPCR remains a significantly more cost-effective option for targeted mutation detection. Test costs typically range from $50 to $200 – substantially less than the $300 to $3,000 price range of NGS.
This affordability makes qPCR especially well-suited for large-scale screening initiatives and routine clinical diagnostics, particularly in resource-conscious healthcare systems. For example, in India, qPCR serves as a cornerstone of HPV-based cervical cancer screening3, while in China, it underpins EGFR mutation testing across both major cancer centers and regional hospitals4.
With its unique combination of speed, cost-efficiency and scalability, qPCR has become a practical and widely deployable tool for population-scale cancer screening – expanding access to precision diagnostics without compromising analytical accuracy.
### Key innovations in qPCR Chemistry include:
- **Inhibitor Resistance:** Next-generation polymerases and buffers are engineered to tolerate PCR inhibitors commonly found in clinical matrices, such as heparinized plasma, whole blood or FFPE-derived nucleic acids.
- **Thermal Stability:** Enzymes now withstand higher-temperature, faster-cycling protocols without loss of activity – enabling faster run times and greater assay reliability.
- **Lyophilization Compatibility:** Ambient-temperature stable formulations support cold chain–independent transport and storage – ideal for decentralized testing or OEM applications.
- **Multiplexing Efficiency:** Advanced master mixes and probe systems enable detection of multiple mutations in a single reaction – critical for cancers with complex mutational profiles.
Together, these advances have significantly broadened qPCR’s clinical utility—enhancing sensitivity, specificity and throughput — while enabling more reliable and efficient quantification of nucleic acids across a range of sample types and conditions.
## Meridian’s Reagent Solutions for Oncology Assay Developers
Meridian Bioscience offers a portfolio of qPCR and RT-qPCR reagents designed specifically for clinical and oncology applications. These include high-performance master mixes, custom-formulated master mixes and ambient-stable kits, for scalable diagnostic deployment.
### Product Highlights:
- **Robust Performance in Clinical Matrices:** Engineered for plasma, FFPE, cfDNA and low-input samples.
- **High Sensitivity:** Consistently detects low-frequency variants at <0.1% VAF.
- **Ambient-Stable Options:** Reduce cold chain costs and support global distribution.
- **Custom OEM Services:** Tailored formulations for regulatory alignment or diagnostic integration.
With a focus on workflow efficiency and clinical robustness, Meridian’s reagents empower oncology developers to build assays that meet the speed, sensitivity and scalability required in modern cancer diagnostics.
**Want to test your assay under real-world conditions?** Meridian’s oncology-focused qPCR reagents are available in a convenient sample pack, allowing side-by-side evaluation in your own workflow.
**Explore Our Oncology-Ready qPCR Solutions:**
[](https://share.hsforms.com/1kilAJUigQrKVIzea0seqkQc22yq?__hstc=92816578.86a0aa7980b8530cb2b819196ceb364a.1759408287245.1759408287245.1759408287245.1&__hssc=92816578.2.1759417246898&__hsfp=2111929243)
**References:**
1\. Amoy Diagnostics. (n.d.). *AmoyDx®* Pan Lung Cancer PCR Panel. Retrieved June 24, 2025, from Amoy Diagnostics website:
2\. Biofidelity. (n.d.). *Aspyre®* Lung Reagents. Biofidelity. Retrieved August 8, 2025, from
3\. Labani, S., *et al.*, (2014). CareHPV cervical cancer screening demonstration in a rural population of north India. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 176, 75–79.
4\. Li, W., *et al.*, (2021). Trends in molecular testing of lung cancer in the mainland People’s Republic of China over the decade 2010 to 2019. JTO Clinical and Research Reports, 2(4), 100163.
**Categories:** Life Science Blog, Liquid Biopsy, Molecular, Precision Oncology
---
### [AI is Revolutionizing Healthcare](https://www.meridianbioscience.com/lifescience-blog/ai-is-revolutionizing-healthcare/)
**Published:** August 7, 2023
**Author:** hamza
**Content:**
Artificial intelligence (AI) is everywhere these days, and healthcare is no exception. AI-powered tools and algorithms are revolutionizing the way diseases are detected and diagnosed which is improving patient outcomes while reducing healthcare costs. Most significantly, AI holds the promise of detecting diseases earlier, with more efficiency and greater accuracy.
### The Impact of AI in Diagnostics
One of the most remarkable attributes of AI is its ability to effectively handle and analyze large datasets. AI can identify patterns in data that are not immediately apparent, and in the same way that predictive mathematical models drive decision-making in the financial sector (which stocks to buy, how much to purchase, and when to sell), AI provides doctors with tools to guide their decision-making. This can help clinicians to make faster and more accurate diagnoses, develop personalized treatment plans, and monitor disease progression more effectively, thereby improving patient outcomes1.
Certain diseases such as heart disease and cancer directly change and alter tissue behavior. Heart disease can cause structural changes in cardiac tissues, such as hypertrophy fibrosis and atherosclerosis, whereas cancer causes cells to divide and grow uncontrollably, forming tumors that can metastasize and invade nearby tissues. Detecting the initial subtle changes in tissues caused by these diseases can be challenging and often are only apparent when they have progressed to more advanced stages and can be visualized with X-rays, CT scans, MRIs, and mammograms2.
AI algorithms hold the potential to detect subtle signs of diseases at an early stage, potentially leading to more successful treatments. For instance, AI can analyze medical images with high precision and identify small abnormalities or identify early-stage specific biomarkers and patterns in blood samples to determine whether someone is at risk of developing a disease. AI can integrate multiple data sources, assessing a patient’s medical history, lifestyle, and genetics, to provide a clear risk stratification to enable early intervention and mitigate disease progression.
### The Lagging Adoption of AI in Healthcare
Implementing AI within healthcare is slower than within other industries, partly because of the complementary innovations and regulatory changes that need to happen first1. Current privacy regulations make it difficult to collect and pool health care data, which poses challenges in using real health data to train AI models quickly as in other industries. Regulatory innovations will be needed for AI to be realized without compromising patient rights or quality of care and questions such as (1) who owns and can use health care data (2) how AI medical devices and software are approved, and (3) where the liability lies between medical providers and AI developers, will need to be addressed3. Experts argue that using AI effectively in healthcare will inevitably require retraining the workforce, retooling health services, and transforming workflows4.
However, even though healthcare may lag other industries in terms of AI adoption, it may be the ultimate testament to the value AI can bring across many dimensions — “introducing greater productivity and responsiveness into a sector burdened by financial squeezes, paperwork and regulations, while improving outcomes in life-or-death decisions”5. From a financial perspective, in the United States, wider adoption of AI could lead to savings of 5% to 10% in healthcare spending within the next five years, according to a paper recently published by the National Bureau of Economic Research6. So along with improved healthcare quality, earlier diagnosis, increased accessibility, better patient experience, and greater clinician satisfaction, AI is posed to deliver benefits in cost control to an industry that is experiencing significantly escalating costs.
### Diagnostic Technology Advancements Driven by the COVID-19 Pandemic
From every aspect, AI has the potential to deliver extraordinary improvements in healthcare, in particular, diagnostics. As noted in a recent publication on “The Potential Impact of Artificial Intelligence on Healthcare Spending” by The National Bureau of Economic Research6, “Medical knowledge is growing so rapidly that only six percent of what the average new physician is taught at medical school today will be relevant in ten years. Technology such as AI could provide valuable clinical data to the clinician at the time of diagnosis.”
Found this article interesting, and would like to read more? Learn about “Diagnostic Technology Advancements Driven by the COVID-19 Pandemic”.
[Read More](/ai-is-revolutionizing-healthcare/)
#### References
1. “How AI Can Enhance Diagnostics and Treatment Plans” Elevance Health. April 3, 2023. . Assessed Sept 5, 2023.
2. Al-Antari, M.A. (2023) Artificial Intelligence for Medical Diagnostics-Existing and Future AI Technology! Diagnostics (Basel). 12;13(4):688. .
3. Goldfarb, A., Teodoridis, F. “Why is AI adoption in health care lagging?”. March 2, 2022. . Assessed Sept 5, 2023.
4. Verspoo, K., Hensen, D, Coiera, E. “AI is already being used in healthcare. But not all of it is ‘medical grade’”. June 21 2023. . Assessed on Sept 5, 2023.
5. McKendrick, Joe. “Healthcare May Be The Ultimate Proving Ground For Artificial Intelligence”. Forbes. Feb 22, 2023. . Assessed Sept 5, 2023.
6. Sahni, Nikhil *et al.* “The Potential Impact of Artificial Intelligence on Healthcare Spending”. Jan 2023. . Assessed on Sept 5, 2023.
**Categories:** Immunology, Life Science Blog
---
### [The Rise of Sexually Transmitted Diseases and the Growing STD Diagnostics Market](https://www.meridianbioscience.com/lifescience-blog/the-rise-of-sexually-transmitted-diseases-and-the-growing-std-diagnostics-market/)
**Published:** December 4, 2023
**Author:** hamza
**Excerpt:** The article discusses the significant rise in sexually transmitted diseases and the corresponding growth of the STD diagnostics market. It highlights how technological advancements and increased awareness are driving the development of new testing methods that are more accessible and effective, facilitating early detection and prevention strategies.
**Content:**
More than one million sexually transmitted diseases and infections (STDs and STIs) are acquired every day worldwide and eight pathogens are responsible for the majority of them: human immunodeficiency virus (HIV), hepatitis B (HBV), herpes simplex virus (HSV), human papillomavirus (HPV), syphilis, gonorrhea, chlamydia and trichomoniasis.
## The Silent Surge in STDs
Preventing the spread of sexually transmitted diseases has been the cornerstone of public health efforts for decades. Still, many factors, such as asymptomatic infections, lack of accessible healthcare services, and the stigma around discussing sexual health, continue to pose significant challenges in effectively controlling disease transmission. Worryingly, since the COVID-19 pandemic, there has been a notable increase in the reported cases of several STDs worldwide. According to the CDC, in the U.S. alone, reported cases of gonorrhea and primary and secondary syphilis were up 10% and 7% in 2020, respectively, compared with 2019; and congenital syphilis increased by almost 15%1.
### STD Diagnostics Market Growth to 2032
In response to the rise of STDs, more products for STD testing, in particular HIV testing, are entering the market and new tools are being introduced that make testing easier and more accessible. Overall, the market is predicted to experience significant growth over the next decade, increasing at a GAGR of 7.23% from USD 9.25B (2022) to USD 18.29B (2032)2. While the laboratory testing segment currently dominates the market with a share of 79%, the future growth driver is expected to be point-of-care testing due to a growing demand for a more patient-centric testing model. In particular home testing and alternative sample types that allow for easy self-sampling (e.g. saliva and urine)3, are gaining traction in the market as individuals are increasingly open to the idea of self-testing post-COVID, creating new channels for STD health monitoring and STD diagnostics.
Another major shift is a move towards more molecular diagnostics for the diagnosis of STDs4. Immunoassay testing currently accounts for 45% of the STD market however, technological advancements focused on multiplex molecular analysis combined with an increasing need for automation to cope with the rising rates STDs, is driving more molecular-based testing on both point-of-care and high-throughput fully automated systems.
Overall, the STD diagnostics market will significantly evolve over the next decade in response to the complex challenges posed by the rising rates of sexually transmitted diseases. Advances in technology, coupled with increased awareness and innovative testing approaches, are pivotal in shaping a future where early detection and intervention can effectively mitigate the impact of STDs. Driven by targets set by the World Health Organization (WHO) to end the STD epidemic as a major public health concern5, more collaborative efforts will be needed between healthcare providers, policymakers, and the private sector in order to create a comprehensive and accessible sexual health ecosystem.
#### Meridian’s Molecular & Immunoassay STD Diagnostic Solutions
As a leader in infectious diseases, Meridian Bioscience has supported assay developers for over 45 years with innovative reagent solutions for STD diagnostic assays. With over 200 antigens and antibodies for STD immunoassay testing, and a large range of master mixes and enzymes for qPCR and isothermal amplification applications, Meridian is ready to provide solutions, big and small for the growth STD industry.
[To learn more, visit Meridian’s complete STD solutions ](https://info.meridianbioscience.com/meridian-reagent-solutions-for-std-diagnostics)
#### References:
1. Centers for Disease Control and Prevention. Impact of COVID-19 on STDs. [https://www.cdc.gov/std/statistics/2021/impact.htm](https://doi.org/10.1136/bmj.m4690). Accessed Nov 15, 2023.
2. Biospace. (2023, Aug 04) STD Diagnostics Market Size, Trends, Company Analysis and Forecast 2023-2032.
3. Melendez, J.H., et al. (2021). Home-Based Testing for Sexually Transmitted Infections: Leveraging Online Resources During the COVID-19 Pandemic. Sex Transm Dis;48(1):e8-e10. doi:10.1097/OLQ.0000000000001309
4. ReportLinker (2022, August 04). STD Diagnostics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027) \[Press Release\].
5. World Health Organization (2022, 2 September). New strategies to tackle and end STIs epidemics.
**Categories:** Immunology, Life Science Blog
---
### [Meridian Bioscience Appoints New CEO and Executive Team to Accelerate Global Growth](https://www.meridianbioscience.com/press-release/meridian-bioscience-appoints-new-ceo-and-executive-team-to-accelerate-global-growth/)
**Published:** October 16, 2025
**Author:** hamza
**Content:**
*New CEO, CFO, and EVP of Life Science named to drive strategic execution across Diagnostics and Life Science.*
**CINCINNATI, OHIO, October 14, 2025 (PRNewswire) –** Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced executive appointments aimed at strengthening global operations and accelerating strategic growth across Diagnostics and Life Science.
**Andy Kitzmiller Appointed President and Chief Executive Officer**
Andy Kitzmiller has been promoted to President and Chief Executive Officer, effective immediately. Since joining Meridian in 2022, Kitzmiller has served as Chief Financial Officer and, most recently, as Chief Financial Officer & Chief Operating Officer. During this time, he has played a central role in shaping and executing Meridian’s Vision for Value Creation. This multi-year strategy guides the company’s focus on customer experience, operational excellence, innovation, and long-term value growth.
“Andy’s leadership, financial discipline, and collaborative approach have been pivotal in driving Meridian’s performance and integration across our Diagnostics and Life Science businesses,” said Dr. Young-Shik Cho, Founder and Chairman of SD Biosensor, Meridian’s majority shareholder. “He is the right leader to guide Meridian into its next chapter, advancing our innovation vision, deepening our global partnerships, and delivering sustainable growth,” added Tom Kichler, Chairman of the Board.
Before joining Meridian, Kitzmiller held senior finance leadership roles at Hillenbrand, Inc. and Milacron. Additionally, he spent five years at GE Aviation (now GE Aerospace) and ten years at Deloitte & Touche LLP. Andy’s leadership has always focused on operational alignment, cross-functional collaboration, and value creation.
**Harald Ottenhoff Appointed Executive Vice President, Life Science**
Harald Ottenhoff, PhD, has been promoted to Executive Vice President, Life Science, succeeding Dr. Lourdes Weltzien, who retired in August 2025 after almost two decades of leadership at Meridian.
Dr. Ottenhoff brings more than 20 years of experience in the global life sciences industry, having held leadership positions at Thermo Fisher Scientific and Life Technologies, before joining Meridian in 2015. Over his tenure, he has led operations, commercial strategy, and global manufacturing within the Life Science division, with a strong focus on driving growth, innovation, and supply chain resilience.
“Harald’s deep scientific background and proven leadership make him uniquely positioned to lead our Life Science division into its next era of innovation and customer partnership,” said Kichler. “We also thank Dr. Weltzien for her many years of outstanding service and leadership, which laid the foundation for continued success.”
**Julie Smith Appointed Senior Vice President, Chief Financial Officer**
Julie Smith has been promoted to Senior Vice President, Chief Financial Officer, effective immediately. Smith, a nearly 22-year Meridian veteran, has played a pivotal role in the company’s financial stewardship and operational success. Most recently serving as Senior Vice President, Controller & Principal Accounting Officer, she has also held various other roles, providing financial leadership across both business units and corporate functions.
Since joining Meridian in 2004, Smith has been instrumental in advancing the company’s financial infrastructure, governance, and internal controls. She led Meridian’s global finance and accounting teams through key transformations and acquisitions, while strengthening financial reporting, compliance, and strategic planning processes.
“Julie has been a trusted leader and financial strategist for more than two decades,” said Kitzmiller. “Her deep institutional knowledge, operational insight, and commitment to Meridian’s mission will continue to strengthen our financial foundation and support our strategic goals.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that provide answers with speed, accuracy, and simplicity, redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](https://www.meridianbioscience.com/?country=US).
**Contact:**
Courtney Schulz
Director of Corporate and Digital Communications
Meridian Bioscience, Inc.
Phone: 513.991.1091
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage](https://www.meridianbioscience.com/press-release/meridian-bioscience-unveils-industry-first-lyophilized-library-prep-kit-for-next-generation-sequencing-eliminating-the-need-for-cold-chain-shipping-and-storage/)
**Published:** June 26, 2024
**Author:** hamza
**Excerpt:** Meridian Bioscience Introduces Groundbreaking Lyophilized NGS Library Preparation Kit
CINCINNATI, OHIO – Meridian Bioscience, Inc., a global leader in life science solutions, proudly unveils a groundbreaking innovation in Next-Generation Sequencing (NGS): the market's first lyophilized library preparation kit. This new kit is designed to significantly simplify and sustain the NGS process by stabilizing the library preparation at room temperature, eliminating the need for cold-chain logistics.
Dr. Florent Chang-Pi-Hin, Vice President of Life Science R&D at Meridian, emphasizes the kit’s alignment with both technological and environmental advancements. “Our lyophilized NGS library preparation kit is a leap forward in making NGS technologies accessible, sustainable, and cost-effective,” he stated. The kit not only addresses logistical and environmental challenges by reducing carbon emissions and operational costs but also offers unparalleled convenience and stability.
This announcement follows closely on the heels of Meridian's recent introduction of glycerol-free NGS enzymes, reinforcing its reputation as an innovator in eco-conscious and efficient diagnostic solutions. For more detailed information on this transformative new product and other innovative offerings from Meridian, visit their website or contact their Life Science division.
**Content:**
**CINCINNATI, OHIO, June 26, 2024 (PRNewswire)** – The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly introduces the market’s first innovative lyophilized Next-Generation Sequencing (NGS) library preparation kit. This pioneering kit underscores Meridian’s commitment to sustainable and cost-effective solutions within the life sciences industry. This announcement closely follows Meridian’s April 2024 launch of glycerol-free NGS enzymes, further establishing Meridian as a leader in developing innovative, eco-conscious, and cost-effective components for diagnostic assay developers.
This revolutionary lyophilized NGS library preparation kit, designed initially for sequencing by synthesis (SBS) protocols, marks a breakthrough in stabilizing the library preparation process at room temperature. By eliminating the requirement for cold-chain shipping and storage, Meridian’s innovative kit not only simplifies logistical and environmental challenges but also significantly reduces carbon emissions and operational costs, thereby streamlining the entire NGS workflow.
Dr. Florent Chang-Pi-Hin, Ph.D., Vice President of Life Science R&D at Meridian Bioscience, stated, “Our Lyophilized NGS library preparation kit exemplifies Meridian’s unwavering commitment to delivering innovative, eco-conscious, and cost-effective solutions for diagnostic assay manufacturers. As the pioneering product in its category, this kit signifies a substantial leap forward in enhancing the accessibility, sustainability, and affordability of NGS technologies.”
The kit can be transported and stored at ambient temperature and contains ready-to-use lyophilized reactions to simplify the end-repair, A-tailing, ligation, and library amplification steps of most sequencing protocols. By promoting sustainable practices and advancing the worldwide democratization of NGS, Meridian underscores its expertise in developing high-performing reagents with continuously improved stability properties.
“With this lyophilized NGS kit, we are addressing a critical need in the market,” Dr. Chang-Pi-Hin emphasized. “Our customers can now rely on a solution that meets their technical requirements and aligns with their sustainability and cost-saving objectives. This innovation strengthens our leadership in delivering cutting-edge, next-generation raw materials for assay manufacturers worldwide.”
While Meridian’s new Lyophilized NGS library preparation kit offers a comprehensive solution for those seeking the convenience of a ready-to-go option, developers who prefer a more customized approach can still access Meridian’s proprietary glycerol-free NGS enzymes and technologies. This unique flexibility supports Meridian’s goal to accelerate NGS accessibility through strategic partnerships, highlighting Meridian’s commitment to innovation and sustainability. By continuously empowering NGS assay developers with cutting-edge reagents, Meridian aims to push the boundaries of what is possible in assay development and diagnostics.
For more information about Meridian’s Lyophilized NGS library preparation kit and other innovative products, please visit [www.meridianbioscience.com/lyophilized-ngs-library-preparation-kit/](https://www.meridianbioscience.com/lyophilized-ngs-library-preparation-kit/) or contact .
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers](https://www.meridianbioscience.com/press-release/meridian-bioscience-leads-the-way-with-innovative-sustainable-solutions-for-in-vitro-diagnostic-manufacturers/)
**Published:** July 23, 2024
**Author:** hamza
**Content:**
**CINCINNATI, OHIO, July 23, 2024 (PRNewswire)** – The life science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announces its comprehensive suite of eco-conscious, cost-effective innovations tailored for diagnostic assay developers. Committed to advancing the sustainability goals of the *in vitro* Diagnostics (IVD) industry, Meridian has developed cutting-edge solutions that minimize waste, enhance efficiency, and broaden accessibility across molecular and immunoassays.
As diagnostic manufacturers face increasing pressure to integrate Environmental, Social, and Governance (ESG) sustainability into their operations, innovative solutions in raw materials and reagents are essential for reducing the carbon footprint of diagnostic assays.1 In response, Meridian has curated a comprehensive portfolio of eco-conscious and cost-efficient solutions designed to meet specific challenges like:
- **Overcoming Cold Chain Logistics Barriers:** Meridian’s glycerol-free, high-concentration molecular reagents and services enable the development of ambient-temperature stable assays, eliminating the need for cold chain logistics and ensuring robust and seamless supply chains. This reduces energy consumption in transit and storage as well as minimizes packaging requirements, particularly the use of refrigerant, dry ice, and expanded polystyrene foam (Styrofoam™).
- **Streamlining Workflows:** Meridian’s extraction-free, low-temperature molecular solutions streamline workflows by eliminating the need for multiple reagent-based extraction steps and reducing the overall energy consumption required for high-temperature processes. Streamlined workflows with fewer steps result in faster turnaround times and increased throughput, reducing operational energy and resource use.
- **Providing Animal-Free Alternatives:** Reagents generated using animal immunization present scientific and ethical concerns. Meridian’s animal-free recombinant alternatives for immunoassays (blockers, antibodies, and antigens) can offer greater versatility and reproducibility over animal immunization, ensuring continuity of supply while alleviating ethical concerns.
“As a premier supplier of essential raw materials for molecular and immunoassays, we believe that sustainability in the IVD industry begins with us,” said Lourdes Weltzien, Ph.D., President of Life Science at Meridian Bioscience. “Our innovative solutions are aligned with multiple United Nations (UN) Sustainable Development Goals. By leveraging these advancements, we enable our customers to achieve their sustainability goals, bolster their competitive edge, and realize significant improvements in operational efficiency and cost savings.”
Meridian’s product development strategy is centered on creating sustainable, cost-effective solutions. A robust lineup of product launches is planned for the latter half of 2024 and will continue well into 2025 and beyond. Meridian’s innovations enhance efficiency across supply chain and workflow processes, improve accessibility, and increase customers’ competitive advantage. Partnering with Meridian supports IVD manufacturers in further enhancing their diagnostics operations while continuing to contribute to a more ethical and sustainable future.
The Meridian Bioscience Life Science team will showcase its innovative sustainability solutions for IVD manufacturers at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, which will be held in Chicago from July 28 to August 1, 2024. Join us at the McCormick Place Convention Center in booth #3516.
For more information about Meridian’s sustainability solutions, please visit
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
**Reference:**
1. Ji, L., Wang, Y., Xie, Y., Xu, M., Cai, Y., Fu, S., Ma, L., & Su, X. (2022). Potential life-cycle environmental impacts of the COVID-19 nucleic acid test. *Environmental Science & Technology, 56*(18), 13398-13407.
**Contact:**
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability](https://www.meridianbioscience.com/press-release/meridian-bioscience-awarded-bronze-medal-by-ecovadis-for-the-second-consecutive-year-in-recognition-of-its-continued-dedication-to-sustainability/)
**Published:** November 5, 2024
**Author:** hamza
**Content:**
**CINCINNATI, Nov. 5, 2024 /PRNewswire/** — Meridian Bioscience, Inc., a leading provider of diagnostic solutions and life science raw materials, is proud to announce that it has been awarded a Bronze Medal in recognition of its continued commitment to sustainable business practices by EcoVadis, one of the world’s most trusted business sustainability rating platforms. This marks the second consecutive year that Meridian has earned the Bronze Medal, highlighting its consistent efforts to integrate corporate social responsibility (CSR) initiatives throughout its business processes.
EcoVadis assesses organizations across four key categories: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Meridian’s latest score of 66 places the company in the top 16% of all companies rated globally. This year’s score is a 9-point improvement over its 2023 score. The increase in Meridian’s EcoVadis score is the result of refining policies and implementing best practices that deliver more sustainable operations that contribute to a healthier planet. This enhanced score reflects the company’s dedication to continuous improvement in its ethical practices, environmental stewardship, and social responsibility.
“Our second consecutive Bronze Medal achievement is a clear indication of Meridian’s ongoing commitment to improving sustainability practices year over year,” said Andy Kitzmiller, Chief Operating Officer & Chief Financial Officer at Meridian Bioscience. “We are proud of our advancements and look forward to continuing this progress as we further align our operations with global sustainability standards to deliver long-term value for all Meridian stakeholders.”
To learn more about Meridian’s CSR initiatives, please visit: [https://www.meridianbioscience.com/about/corporate-social-responsibility/](https://c212.net/c/link/?t=0&l=en&o=4295266-1&h=3192091261&u=https%3A%2F%2Fwww.meridianbioscience.com%2Fabout%2Fcorporate-social-responsibility%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Fabout%2Fcorporate-social-responsibility%2F).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
**Contact:** Courtney Schulz
Director of Corporate and Digital Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
**Categories:** Press Release
---
### [Meridian Bioscience Wins the CDC's Lead Detect Prize Competition, Building on Decades of Leadership in Blood Lead Testing at the Point of Care](https://www.meridianbioscience.com/press-release/meridian-bioscience-wins-the-cdcs-lead-detect-prize-competition-building-on-decades-of-leadership-in-blood-lead-testing-at-the-point-of-care/)
**Published:** November 6, 2024
**Author:** hamza
**Content:**
**CINCINNATI, OHIO, November 6, 2024 (PRNewswire)** — Meridian Bioscience Inc., a leader in global diagnostics and life science materials and creator of the LeadCare® II Blood Lead Testing System, is pleased to announce its victory in the Centers for Disease Control and Prevention’s (CDC) Lead Detect Prize. This prestigious competition fostered the development of innovative, rapid lead detection technologies at the point of care, significantly enhancing public health efforts to prevent lead exposure and increase the accessibility of blood lead testing.
The Lead Detect Prize was established to accelerate the development of innovative point-of-care blood lead testing technologies. The challenge aimed to enhance testing solutions by providing funding and expertise and promoting partnerships. Five winners shared a $150,000 prize in the first phase and received exclusive access to a second phase that included a virtual accelerator. The second phase concluded with three winners dividing an $850,000 prize pool, with Meridian Bioscience taking home the first prize of $500,000. Meridian’s winning submission, detailing its vision for a next-generation blood lead testing system at the point of care, met or exceeded 100% of the challenge criteria.
Meridian’s entry capitalized on the company’s extensive experience and leadership in point-of-care lead testing, as demonstrated by the widespread use of the LeadCare II analyzer. This easy-to-use device has been crucial in enabling accessible and immediate assessments of lead exposure, particularly for at-risk pediatric populations.
“We are honored to receive this recognition, which reflects our dedication to our mission of enhancing global health through innovative diagnostics,” said Tony Serafini-Lamanna, President of the Meridian Bioscience Diagnostics Division. “Being acknowledged as the overall winner not only marks a significant achievement for our team but also reinforces our long-standing commitment to combating lead exposure through innovative point-of-care diagnostics. Our LeadCare II analyzer has set industry standards for point-of-care lead testing, and we are excited to build on this foundation with our next-generation lead detection technology.”
The Lead Detect Prize is a critical component of the CDC’s efforts to eliminate the health risks associated with lead exposure, such as irreversible neurological and cognitive impairments in children. Meridian Bioscience is dedicated to continuing its legacy of innovation in point-of-care lead testing and is committed to delivering advanced lead detection technology to the market, where it can significantly impact public health.
For additional information about Meridian Bioscience and its innovative diagnostic solutions, please visit www.meridianbioscience.com.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](http://www.meridianbioscience.com).
**About Lead Detect Prize**
The Lead Detect Prize seeks to accelerate the development of next-generation point-of-care blood lead testing technology. The challenge, on behalf of the Centers for Disease Control and Prevention, will advance blood lead test solutions by providing funding and expertise while fostering collaboration and partnership. Phase 1 awarded five winners an equal share of a $150,000 prize pool. Phase 1 winners were also exclusively invited to enter Phase 2 and participated in a virtual accelerator. Three Phase 2 winners were awarded a share of a $850,000 Phase 2 prize pool. Learn more by visiting [www.leaddetectprize.com](http://www.leaddetectprize.com).
**Contact:**
Courtney Schulz
Director of Corporate and Digital Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth’s 2025 “Force Of Nature” Award](https://www.meridianbioscience.com/press-release/meridian-bioscience-congratulates-catherine-lufkin-for-receiving-pure-earths-2025-force-of-nature-award/)
**Published:** March 6, 2025
**Author:** hamza
**Excerpt:** Meridian Bioscience’s Catherine Lufkin Honored with Pure Earth’s 2025 “Force of Nature” Award
Meridian Bioscience proudly celebrates Catherine Lufkin, Senior Director, Global Point of Care, for receiving Pure Earth’s prestigious 2025 “Force of Nature” Award. This honor recognizes her leadership in advancing environmental health and expanding access to blood lead testing in underserved communities. Lufkin’s efforts have been instrumental in Meridian’s partnership with Pure Earth, helping to combat lead poisoning worldwide.
Read more about this achievement and Meridian’s commitment to global health.
**Content:**
**CINCINNATI, OHIO, March 6, 2025 (PRNewswire)** – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly congratulates Catherine Lufkin, Senior Director, Global Point of Care, on being honored with Pure Earth’s 2025 “Force of Nature” Award. This prestigious recognition celebrates her leadership and dedication to advancing environmental health, particularly in the fight against lead poisoning.
Lufkin is being recognized at Pure Earth’s [International Women’s Day](https://www.pureearth.org/international-womens-day/) celebration for her unwavering commitment to ensuring access to fast, accurate blood lead testing in communities impacted by lead contamination. Her leadership has been instrumental in Meridian’s partnership with Pure Earth, which has provided [LeadCare® II](https://www.meridianbioscience.com/leadcare-ii-marketing/) blood lead testing technology to under-resourced communities worldwide since 2016. Her dedication to advancing lead testing was also a driving force behind Meridian winning the [CDC’s Lead Detect Prize](http://www.leaddetectprize.com/), a prestigious competition that fostered the development of innovative, rapid lead detection technologies to enhance public health efforts.
“We are immensely proud of Catherine’s achievements and this well-deserved recognition,” said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. “Her work exemplifies our mission to improve global health through innovation and collaboration. In our ongoing partnership with Pure Earth, we remain committed to reducing lead exposure and its harmful effects on vulnerable populations.”
The LeadCare II system, the only CLIA-waived point-of-care blood lead testing system, is a vital tool in Pure Earth’s global efforts to combat lead poisoning. It enables rapid, reliable testing, allowing for timely intervention and treatment. Through strategic collaboration, Meridian and Pure Earth continue working to expand access to testing in communities with high lead exposure risks, helping to safeguard children’s and families’ health worldwide.
“I am deeply honored to receive the “Force of Nature” Award from Pure Earth,” said Catherine Lufkin. “Lead exposure is a preventable public health crisis, and I am proud to contribute to efforts that bring vital testing solutions to those who need them most. This award underscores the power of partnership in driving meaningful change.”
Meridian Bioscience remains steadfast in supporting initiatives to reduce the global burden of lead poisoning. Through continued innovation and collaboration, the company is dedicated to protecting public health and improving lives, one person and one test at a time.
**About Pure Earth**
Founded in 1999, [Pure Earth](http://www.pureearth.org) is a global leader in developing evidence-based solutions to mercury and lead pollution. Committed to transparency, collaboration, measurable impact, and technical excellence, we work with partners worldwide to tackle the root causes of these toxic threats.
Our focus is protecting the most vulnerable—children and pregnant women living in toxic hotspots—by breaking the multigenerational cycle of poisoning that persists in many low- and middle-income countries. Through strategic partnerships with governments, communities, and industry, we identify and implement solutions that prevent toxic exposures, safeguard health, and restore contaminated environments.
Learn more about Pure Earth’s work to improve women’s health at [www.pureearth.org/womens-environmental-health/](https://www.pureearth.org/womens-environmental-health/)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](http://www.meridianbioscience.com/).
**Contact:**
Courtney Schulz
Director of Corporate and Digital Communications
Meridian Bioscience, Inc.
Phone: 513.991.1091
Email:
\###
**Categories:** Press Release
---
### [SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience](https://www.meridianbioscience.com/press-release/sd-biosensor-and-sjl-partners-complete-transaction-to-acquire-meridian-bioscience/)
**Published:** January 31, 2023
**Author:** hamza
**Content:**
CINCINNATI, OHIO & SEOUL, SOUTH KOREA, January 31, 2023 (PRNewswire) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”), announced today that they have completed the transaction to acquire Meridian.
Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will continue to operate as an independent entity, under new ownership, headquartered in Cincinnati, Ohio.
**About SD Biosensor, Inc.**
SD Biosensor, Inc., with its slogan ‘Beginning of all things that protect lives,’ is a global in-vitro diagnostics company that contributes to improving everyone’s quality of life by diagnosing diseases quickly and accurately. SD Biosensor is a Total Solution Provider in the IVD industry that develops and researches innovative diagnostic platforms. For further information, refer to the official website at [www.sdbiosensor.com/](https://www.sdbiosensor.com/).
**About SJL Partners**
SJL is a Korea-based private equity investment manager uniquely focused on cross-border partnership investments with market-leading strategic companies to support their inorganic growth in international markets. SJL’s portfolio includes investments into Momentive Performance Materials, a U.S.-based global leader in specialty silicones and silicone derivatives, Momentive Technologies, a leader in fused quartz and ceramic solutions, and Nexeon, a U.K.-based technology leader in anode materials for rechargeable batteries. Additional information is available at [www.sjlpartners.com](https://www.sjlpartners.com).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian’s website address is www.meridianbioscience.com.
Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com
\###
**Categories:** Press Release
---
### [Meridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-doj-announcement-regarding-former-executives-of-magellan-diagnostics/)
**Published:** April 5, 2023
**Author:** hamza
**Content:**
CINCINNATI, April 5, 2023 /PRNewswire/ — Meridian Bioscience, Inc. learned today that certain former employees of Magellan, a subsidiary of Meridian acquired in March 2016, were charged by the United States Attorney for the District of Massachusetts for alleged violations of certain federal laws. Meridian and its subsidiaries are not defendants in the action.
As previously disclosed, Meridian and Magellan have cooperated extensively with federal authorities in the investigation that led to these charges, and we have been and will continue to engage in resolution discussions with the Department of Justice. We have previously noted that we expect a loss to be probable in connection with the resolution, and we have reserved, as of calendar year-end 2022, an amount we believe to be a reasonable estimate of such loss.
All of the Company’s current products from the LeadCare line are FDA cleared and will remain available for clinical use. Meridian intends to continue to cooperate with the Department of Justice with respect to its investigation. Due to the pending litigation and ongoing discussions with the DOJ, we will not comment further at this time.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-fda-clearance-for-innovative-curian-shiga-toxin-assay/)
**Published:** April 19, 2023
**Author:** hamza
**Content:**
CINCINNATI, OHIO, April 19, 2023 (PRNewswire) – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) had granted clearance for the company’s new Curian® Shiga Toxin assay. This assay joins Curian HpSA® and Curian Campy as Meridian expands its Curian diagnostic platform to maintain leadership in the gastrointestinal disease testing market.
Foodborne illness is a severe global public health problem that causes 48 million people to get sick yearly and 128,000 hospitalizations from common bacterial agents like Campylobacter and E. coli.1 Meridian is expanding its foodborne immunofluorescent testing capabilities beyond Campylobacter by adding Shiga toxin to the Curian platform. Speedy diagnosis is essential with patients suspected of having a Shiga toxin-producing E. coli infection because the use of antibiotics for treatment can increase Shiga toxin release, leading to hemolytic uremic syndrome (HUS), a potentially life-threatening complication.
The Curian Shiga Toxin assay is designed for use with the Curian analyzer. The new assay is a rapid, qualitative, fluorescent immunoassay for the simultaneous detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test device. It is intended for use with cultures derived from human stool specimens to aid in diagnosing diseases caused by Shiga toxin-producing E. coli (STEC) infections, including non-O157 strains.
The immunofluorescent technology of the Curian platform provides an objective, rapid Shiga toxin result with an unmatched clinical sensitivity of 100% (Stx1), 100% (Stx2), and specificity of 99.4% (Stx1), 99.5% (Stx2) in prospective samples. Curian Shiga Toxin features a lower limit of detection than traditional rapid immunoassay testing. Combined with LIS connectivity, the Curian solution helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based lateral flow test results.
“We are excited to continue the expansion of the Curian platform with this highly sensitive and specific assay. Curian now features the broadest menu of GI tests on an immunoassay analyzer,” said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. “Curian Shiga Toxin has a market-leading three-step sample prep workflow and produces fast, objective results that can help laboratorians and clinicians provide an objective Shiga toxin diagnosis to get patients on the correct treatment and back on the road to wellness.”
Curian® and HpSA® are registered trademarks of Meridian Bioscience, Inc.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
1\. Centers for Disease Control and Prevention. December 2022. Foodborne Germs and Illnesses. Retrieved from https://www.cdc.gov/foodsafety/foodborne-germs.html.
Contact:
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
\###
**Categories:** Press Release
---
### [Meridian Bioscience Sets a New Sustainability Standard in Diagnostic Assay Development with the Launch of Two New Animal-Free Immunoassay Interference Blockers](https://www.meridianbioscience.com/press-release/meridian-bioscience-sets-a-new-sustainability-standard-in-diagnostic-assay-development-with-the-launch-of-two-new-animal-free-immunoassay-interference-blockers/)
**Published:** July 24, 2023
**Author:** hamza
**Content:**
**CINCINNATI, OHIO, July 24, 2023 (PRNewswire)** – The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new immunoassay interference blockers, K-Block™, and Mouse-Free IgG. These innovative blockers are 100% animal-free and have equivalent or superior performance compared to traditional animal-derived blockers. This product launch aligns with Meridian’s strategy to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers. By adopting these animal-free products, manufacturers can actively contribute to reducing their ecological impact by optimizing energy and resource consumption and staying compliant with evolving regulatory standards. Meridian continues to lead the way in promoting environmental responsibility within the industry.
Immunoassay interference can cause false positive and false negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA are the most prevalent and are identified in up to 25% of the patient population. Combined with HA, they represent the most significant factors leading to false positive immunoassay results. Avoiding immunoassay interference requires blockers to be included in every immunoassay. Historically, animal-based interference blockers have been used to improve assay accuracy; however, they are susceptible to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages – as seen during the COVID-19 pandemic. Meridian’s new animal-free immunoassay interference blockers mitigate those concerns.
Meridian’s new K-Block and Mouse-Free IgG overcome the challenges encountered with traditional animal-based blockers. These next-generation blockers improve assay specificity, decrease lot-to-lot variability, align with sustainability considerations, and alleviate contamination risks from animal-derived components. Initial experimental testing in ELISA-based assays demonstrated strong performance of K-Block and Mouse-FREE IgG versus other commercial animal-derived blockers.
“At Meridian, we are deeply committed to supporting our customers who are seeking non-animal-derived raw materials in diagnostic assays. Our novel 100% animal-free blockers deliver on this commitment while avoiding the need to consume millions of mice each year in the process. This innovative method not only allows us to scale up quickly but also delivers results that are equivalent or even superior in quality. With this new product line, we reaffirm our dedication to environmental sustainability and social responsibility, ensuring a more ethical and responsible approach in our operations as well as our customers.” commented Lourdes Weltzien, Ph.D., President – Life Science, Meridian Bioscience.
For more information on K-Block or Mouse Free-IgG, please visit [www.meridianbioscience.com/animal-free-blockers](https://www.meridianbioscience.com/animal-free-blockers).
You can learn more about animal-free blockers at the Meridian Bioscience exhibit booth (4039) during this year’s AACC conference held in July in Anaheim, California. Request a one-on-one meeting with a Meridian representative [www.meridianbioscience.com/2023-aacc-meeting](https://www.meridianbioscience.com/2023-aacc-meeting).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
Contact:
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
\###
**Categories:** Press Release
---
### [Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex](https://www.meridianbioscience.com/press-release/meridian-bioscience-continues-expansion-of-h-pylori-diagnostic-testing-solutions-with-fda-clearance-of-premier-hpsa-flex/)
**Published:** July 25, 2023
**Author:** hamza
**Excerpt:** United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools. Premier HpSA Flex joins the extensive Meridian H. pylori portfolio of products that includes BreathID® (urea breath test for H. pylori), Curian® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard® Stat! HpSA (rapid colorimetric antigen test)
**Content:**
**CINCINNATI, OHIO, July 25, 2023 (PRNewswire)** – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of *H. pylori* in both preserved and unpreserved stools. Premier HpSA Flex joins the extensive Meridian *H. pylori* portfolio of products that includes BreathID® (urea breath test for *H. pylori*), Curian® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard® Stat! HpSA (rapid colorimetric antigen test).
Meridian strives to continuously improve existing products. The Premier HpSA FLEX workflow improvement recently cleared by FDA allows clinicians to use preserved stools in Cary-Blair and C&S in addition to fresh or frozen unpreserved samples. Meridian’s Premier HpSA FLEX test is a non-invasive enzyme immunoassay used to qualitatively detect *Helicobacter pylori* (*H. pylori*) specific antigens in fresh, frozen, or preserved human fecal specimens. *Helicobacter pylori* infection is linked to several significant upper gastrointestinal (GI) conditions, including chronic gastritis, peptic ulcer disease, and gastric cancer.
“Meridian is committed to developing the industry’s broadest range of highly accurate Gastrointestinal diagnostic solutions enabling clinicians to use the sample types and testing platforms required in today’s ever-evolving healthcare landscape,” stated Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. “*H. pylori* is found in the stomach lining of 1 in 3 people1 and, if left untreated, can lead to gastric cancer. However, once diagnosed, an *H. pylori* infection can be easily treated with antibiotics. That is why we continue to develop highly accurate non-invasive, patient-friendly *H. pylori* testing methods to help clinicians get patients on the road to wellness as fast and safely as possible.”
You can learn more about Meridian’s diagnostic testing solutions by visiting their exhibit booth (4039) during this year’s AACC conference held in July in Anaheim, California. You can schedule a one-on-one meeting with a Meridian representative by emailing .
To learn more about *H. pylori* and Meridian’s testing solutions, please visit [www.meridianbioscience.com/hpylori](https://www.meridianbioscience.com/hpylori).
[1. Fennerty, M. B. *Helicobacter pylori*: why it still matters in 2005. Cleveland Clinic Journal of Medicine, 2005; 72(Suppl\_2), S1-7. https://doi.org/10.3949/ccjm.72.suppl\_2.s1.](https://doi.org/10.3949/ccjm.72.suppl_2.s1)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to Sustainability](https://www.meridianbioscience.com/press-release/meridian-bioscience-earns-ecovadis-bronze-medal-in-recognition-of-its-dedication-to-sustainability/)
**Published:** November 28, 2023
**Author:** hamza
**Content:**
**CINCINNATI, OHIO, November 28, 2023 (PRNewswire)** – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, has been awarded the distinguished EcoVadis Bronze Medal in recognition of the commitment to its sustainable business practices. In its inaugural assessment year, Meridian has laid the groundwork for annual evaluations to foster progressive enhancement of its sustainable business practices.
EcoVadis, a globally recognized provider of business sustainability ratings, applies a methodology encompassing 21 criteria across four themes: Environmental Impact, Fair Labor Practices, Ethics and Fair Business Practices, and Supply Chain Integrity. The EcoVadis assessment evaluates how well a company has integrated the principles of Sustainability/Corporate Social Responsibility (CSR) into its business and management system, and the Bronze Medal reflects a score among the top of all companies in Meridian’s industry.
“This accolade highlights our concerted efforts to operate responsibly and sustainably,” said Andy Kitzmiller, Chief Operating Officer and Chief Financial Officer of Meridian Bioscience. “Sustainability is a journey, not a destination, and Meridian has established a framework for continuous improvement that is not only good for the environment and society but also vital for the long-term success of our business.”
“We are proud of our initial score and equally as important, the assessment also highlights the path to not only meet but exceed the highest standards of corporate responsibility,” added Charles Wood, Vice President of Strategy and Corporate Development, who oversees CSR at Meridian Bioscience. ”We look forward to continued partnership within our global organization and externally with our customers, suppliers, and community to grow ethically and sustainably.”
For more information about Meridian’s sustainability efforts and EcoVadis rating, please visit [www.meridianbioscience.com/sustainability](https://www.meridianbioscience.com/sustainability/).
Contact:
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
\###
**Categories:** Press Release
---
### [Meridian Bioscience Senior Director of R&D, Dr. Dan (Dror) Siman-Tov, to Spotlight Lateral Flow Innovations at the Advanced Lateral Flow Conference 2024](https://www.meridianbioscience.com/press-release/meridian-bioscience-senior-director-of-rd-dr-dan-dror-siman-tov-to-spotlight-lateral-flow-innovations-at-the-advanced-lateral-flow-conference-2024/)
**Published:** February 12, 2024
**Author:** hamza
**Content:**
**CINCINNATI, OHIO, February 12, 2024 (PRNewswire)** – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, is proud to announce that Dr. Dan (Dror) Siman-Tov, Ph.D., MBA, Senior Director of R&D, Diagnostics, will be presenting at the Advanced Lateral Flow Conference 2024. The event is scheduled to take place at the Hard Rock Hotel in San Diego, California, on February 13-14, 2024.
Under the theme “Lateral Flow Diagnostics: Challenges, Advantages, and Technical Guidelines,” Dr. Siman-Tov’s presentation will delve into the intricate dynamics of lateral flow technology, highlighting its critical role in the rapid diagnostic sector. With his extensive experience and expertise in the development of diagnostic immunoassays in the last 20 years, Dr. Siman-Tov will provide invaluable insights into the complexity of the development and production of lateral flow devices, exploring the advantages they offer over other diagnostic techniques and will outline practical technical guidelines for lateral flow development and applications.
The Advanced Lateral Flow Conference 2024 aims to foster discussions on the latest innovations, trends, and solutions in lateral flow technology. Dr. Siman-Tov’s keynote will offer attendees a unique opportunity to gain perspectives from one of the leading figures in the diagnostics industry.
Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics Division, commented, “We are thrilled to have Dr. Siman-Tov represent Meridian Bioscience at the Advanced Lateral Flow Conference. His presentation is a testament to Meridian’s commitment to advancing diagnostic technologies and an opportunity to showcase our thought leadership in lateral flow diagnostics. We look forward to contributing to the global dialogue on improving healthcare outcomes through innovative diagnostic solutions.”
For more information about the conference and Dr. Siman-Tov’s presentation, please visit . To learn more about Meridian Bioscience diagnostic testing solutions, visit [www.meridianbioscience.com](https://www.meridianbioscience.com).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](http://www.meridianbioscience.com).
**About The Conference**
First launched in 2014, the Advanced Lateral Flow Conference (ALFC) has evolved to become the premier industry event for professionals involved in the development, manufacturing, and commercialization of lateral flow diagnostics. Over the course of several days, attendees dive into the industry’s latest trends, innovations, and best practices through an exciting lineup of presentations, discussions, and networking events. The ALFC is presented by DCN Dx, a global leader in IVD CDMO and CRO services, including contract end-to-end development, manufacturing, and commercialization of point-of-use tests. DCN Dx is based in Carlsbad, California. Learn more at www.alfc2024.com.
**Contact:**
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email:
\###
**Categories:** Press Release
---
### [Meridian Bioscience Drives Democratization of Next-Generation Sequencing (NGS) with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits](https://www.meridianbioscience.com/press-release/meridian-bioscience-drives-democratization-of-next-generation-sequencing-ngs-with-reagents-enabling-ambient-temperature-shipping-and-storage-of-sequencing-kits/)
**Published:** April 10, 2024
**Author:** hamza
**Excerpt:** Meridian Bioscience has launched a unique line of glycerol-free NGS enzymes, enabling ambient temperature storage and shipping, thereby making Next Generation Sequencing more globally accessible and sustainable by reducing the reliance on cold-chain logistics. This innovation aims to simplify NGS diagnostics development and logistics.
**Content:**
**CINCINNATI, OHIO, April 10, 2024 (PRNewswire)** – The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, has announced the launch of a comprehensive menu of glycerol-free NGS enzymes for use in all steps of a Next Generation Sequencing (“NGS”) workflow. With this latest release, Meridian establishes itself as the sole provider of the most extensive array of glycerol-free NGS enzymes to diagnostic developers, which is essential for enabling the preparation of sequencing kits that can be shipped and stored at ambient temperature. The ability to ship and store reagents without restrictions democratizes NGS, allowing global access.
Shipping sequencing kits in dry ice and storing them in freezers has always been inconvenient for NGS developers and researchers. Meridian’s glycerol-free enzyme formats enable lyophilization, providing a sustainable alternative by reducing carbon emissions associated with cold-chain logistics. This eradicates reliance on energy-intensive refrigeration and freezing methods. Additionally, eliminating cold-chain requirements simplifies transportation logistics, reducing packaging materials and transportation costs.
In addition to the shipping and storage stability enabled by being glycerol-free, the enzymes are available in a high-concentration format, meeting the demands for miniaturization, often required in point-of-care devices. This format not only allows for the utilization of smaller reagent volumes but also maximizes the sample input quantity while ensuring consistent performance. Meridian’s new glycerol-free high-concentration enzymes empower NGS assay developers to engineer the next generation of NGS diagnostic tests and workflows. This product launch stems from Meridian’s strategy to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers.
“At Meridian, the driving force behind product innovation is our unwavering commitment to understanding and alleviating our customers’ challenges. With the introduction of our new NGS glycerol-free enzymes product line, we are poised to eliminate the logistical hurdles our customers encounter in handling critical raw materials for NGS applications. In addition to offering these innovative enzymes, we can customize lyophilized reagents designed for specific NGS applications and provide them in bead formats if needed. Our objective with these innovations is to empower our clients to elevate and broaden their NGS capabilities globally,” commented Lourdes Weltzien, Ph.D., President of Life Science, Meridian Bioscience.
For more information on Meridian’s NGS enzymes, please visit [www.meridianbioscience.com/ngs-enzymes](http://www.meridianbioscience.com/ngs-enzymes)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Courtney Schulz
Director of Digital and Corporate Communications
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
\###
**Categories:** Press Release
---
### [Magellan Diagnostics Announces Voluntary Resolution of Federal Investigation Underlying Product Issues Were Remediated in 2018](https://www.meridianbioscience.com/press-release/magellan-diagnostics-announces-voluntary-resolution-of-federal-investigation-underlying-product-issues-were-remediated-in-2018/)
**Published:** May 21, 2024
**Author:** hamza
**Content:**
**BILLERICA, MA, –** Magellan Diagnostics, Inc. (Magellan), a Meridian Bioscience, Inc. (Meridian) company, today announced that it has finalized an agreement with the U.S. Department of Justice (DOJ) that resolves the DOJ’s investigation of Magellan. The investigation commenced in 2018 and primarily involved conduct by former Magellan employees that occurred between 2013 and 2017 concerning the use of venous blood samples with Magellan’s LeadCare® line of products. The use of venous blood samples was discontinued in 2018, and the product-related issues involved in the investigation were fully remediated at that time. As part of the resolution, Magellan will pay $42 million over time in accordance with the negotiated terms of the settlement.
“We are pleased to have reached an amicable resolution concerning issues that happened nearly a decade ago with Magellan,” said Tony Serafini-Lamanna, president of Magellan Diagnostics. “Magellan and Meridian engaged constructively with the DOJ to develop a mutually acceptable resolution, including fully cooperating with the DOJ and providing resources to support victims that were impacted. Magellan takes seriously our responsibility to provide reliable, FDA-cleared products to support some of our most vulnerable populations. The underlying issues that affected the results of some of Magellan’s products from 2013 to 2018 have been fully and effectively remediated. Today, the devices and tests sold by Magellan are safe, FDA-cleared and are performing as intended.”
This settlement does not affect the DOJ’s ongoing prosecution of three former Magellan employees who no longer work for the company.
The key terms of the settlement include:
- Magellan will continue to fully cooperate with the DOJ until all related investigations and prosecutions are concluded
- Payment of a fine of $21.8 million
- Forfeiture of $10.9 million of revenue from the sale of affected products
- Creation of a Victim Compensation Fund, initially funded with $9.3 million
- Engagement of a compliance monitor for the next two years
- Admission to two misdemeanor violations of the Federal Food, Drug, and Cosmetic Act
- Entering into a deferred prosecution agreement with the DOJ
Copies of the settlement documents and information regarding the victim compensation fund will soon be available on [Magellan’s website.](https://www.magellandx.com/)
Magellan is the leading provider of point of care pediatric lead testing solutions. All three of Magellan’s medical devices (LeadCare Ultra, LeadCare II and LeadCare Plus) and their testing kits have been fully remediated and cleared by the FDA.
**About Magellan Diagnostics, Inc.**
Magellan is a fully integrated diagnostics company that develops, manufactures, markets, and distributes innovative blood lead level testing solutions across the globe. Magellan has been a pioneer in the analysis of blood lead for over 50 years. Since the late 1960s, our company (then called ESA, Inc.) was founded by four PhD graduates from the Massachusetts Institute of Technology (MIT). Applying a novel technique called Anodic Stripping Voltammetry (ASV), they designed and built a bench top analyzer for the measurement of lead in blood. The company then adapted this technology to create smaller, portable instruments that can be used outside of traditional laboratory settings. This major achievement broadened the accessibility of lead testing by bringing it to the point of care.
In 2016, Magellan Diagnostics was acquired by Meridian Bioscience, Inc., an established diagnostics and life science industry leader. Magellan’s website address is .
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is [www.meridianbioscience.com](http://www.meridianbioscience.com).
\###
**Categories:** Press Release
---
### [Bioline Lancarkan Rangkaian Penuh Cerakin EPIK™ miRNA](https://www.meridianbioscience.com/press-release/bioline-lancarkan-rangkaian-penuh-cerakin-epik-mirna/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 11, 2017 (GLOBE NEWSWIRE) — Bioline, Syarikat PCR, anak syarikat milik penuh Meridian Bioscience Inc. (NASDAQ:VIVO) hari ini mengumumkan pengembangan Cerakin PIlih EPIK™ miRNA yang asalnya dibangunkan untuk kajian molekul mikroRNA (miRNA) individu. Dengan kerjasama MiRXES, Bioline mengeluarkan 800 Cerakin Pilih EPIK™ miRNA pada Mac 2016 dan ini telah bertambah untuk merangkumi semua organisma yang disenaraikan dalam miRBase keluaran 21, yang mewakili lebih 27,000 cerakin miRNA. Kajian baru-baru ini terus menunjukkan nilai klinikal molekul miRNA individu yang dibebaskan daripada tisu dan sel. Ekspresi sesetengah molekul miRNA individu berhubung kait dengan keadaan penyakit tertentu menjadikannya calon biopenanda yang kuat untuk pengesanan awal penyakit, ramalan penyakit dan pemantauan rawatan bagi manusia dan organisma lain.
Setiap cerakin direka oleh MiRXES secara *in silico* menggunakan algoritma berasaskan termodinamik proprietari dan termasuk primer transkriptase membalik tertentu miRNA dan primer PCR masa nyata bersarang hemi bersama transkriptase membalik Bioline, SensiSMART™ dengan SYBR®1 Green dan penampan beroptimum tinggi. Cerakin yang terhasil membolehkan pengesanan miRNA yang tahapnya sangat rendah dengan kekhususan yang sangat tinggi dan membenarkan pembezalayanan di antara jujukan miRNA yang berkaitan rapat.
Marco Calzavara, Presiden Bioline mengulas, “Saya berbesar hati untuk mengumumkan pengembangan Cerakin Pilih EPIK miRNA. Portfolio cerakin miRNA berkualiti tinggi yang bertambah ini akan lebih membantu penyelidik dengan pemprofilan ekspresi miRNA, pengkuantitian dan dalam penemuan biopenanda.”
Richard L. Eberly, Presiden, Ketua Pegawai Komersial berkata, “Pengeluaran rangkaian penuh Cerakin Pilih EPIK miRNA dan prestasinya yang dipertingkatkan merupakan penambahan yang penting pada portfolio kami. Ia meningkatkan fleksibiliti alat penyelidikan yang sangat berguna ini dengan membolehkan lebih ramai pelanggan sains hayat kami mencipta cerakin diagnostik molekul yang tepat dan tidak invasif pada manusia dan organisma lain.”
**Mengenai Meridian Bioscience Inc.**
Meridian ialah syarikat sains hayat berintegrasi penuh yang membangunkan, mengilang, memasarkan dan mengedar pelbagai jenis kit ujian diagnostik yang inovatif, reagen nadir, biologi dan komponen khusus. Dengan menggunakan pelbagai kaedah, ujian diagnostik kami memberikan ketepatan, keringkasan dan kepantasan pada diagnostik dan rawatan awal dan keadaan perubatan biasa seperti jangkitan dan keracunan plumbum. Produk diagnostik Meridian digunakan di luar tubuh manusia dan memerlukan sedikit atau tiada peralatan khas. Produk diagnostik Syarikat ini direka bagi meningkatkan kesejahteraan pesakit di samping mengurangkan jumlah kos penjagaan kesihatan. Meridian mempunyai kedudukan pasaran yang kukuh dalam bidang jangkitan gastrousus dan pernafasan bahagian atas serta ujian tahap plumbum dalam darah. Di samping itu, Meridian ialah pembekal reagen nadir serta biologi dan komponen khusus yang digunakan oleh organisasi dalam industri sains hayat dan agrobio yang terlibat dalam kajian serta oleh syarikat sebagai komponen dalam pembuatan diagnostik. Syarikat memasarkan produk dan teknologinya kepada hospital, makmal rujukan, pusat penyelidikan, pengilang diagnostik dan syarikat agribio di lebih daripada 70 buah negara di seluruh dunia. Saham Syarikat ini diniagakan dalam NASDAQ Global Select Market, simbol VIVO. Alamat tapak web Meridian ialah [www.meridianbioscience.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meridianbioscience.com&esheet=50874826&newsitemid=20140528006196&lan=en-US&anchor=www.meridianbioscience.com&index=1&md5=9d7530cd72c9cafcaeb68685906a1a9e "www.meridianbioscience.com").
**UNTUK MAKLUMAT TAMBAHAN:**
Untuk mendapatkan maklumat lanjut tentang Bioline, sila lawati [https://www.bioline.com](https://www.bioline.com/).
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR ialah tanda dagangan Thermo Fisher Scientific.
```
```
---
### Contact Data
```
MAKLUMAT HUBUNGAN:
Richard L. Eberly
Presiden, Ketua Pegawai Komersial
Meridian Bioscience Inc.
Telefon: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [바이오라인, EPIK™ miRNA Assays 제품군 확장](https://www.meridianbioscience.com/press-release/바이오라인-epik-mirna-assays-제품군-확장/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
미국 신시내티, Jan. 10, 2017 (GLOBE NEWSWIRE) — PCR 장비 전문 기업인 바이오라인(Bioline)이 개별 마이크로RNA(miRNA) 분자 연구용으로 개발되던 EPIK™ miRNA Select Assays 제품군을 확대한다고 발표했다. 바이오라인은 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(나스닥 거래명: VIVO)의 자회사이다. MiRXES와의 협업을 통해 2016년 3월 800 EPIK™ miRNA Select Assays를 출시한 바이오라인은 이번에 miRBase release 21에 등록된 모든 유기체를 포함시켰다. miRBase release 21은 2만 7,000종의 miRNA assay가 등록되어 있다. 세포 및 조직에서 검출되는 개별 miRNA 분자는 임상학적 가치가 높다는 사실이 최근 일련의 연구를 통해 밝혀진 바 있다. 특정한 질병 상태와 연관관계가 있는 개별 miRNA 분자가 발견될 경우 질병과 예후의 조기 진단, 인체와 기타 유기체 치료의 모니터링에 쓰일 수 있는 바이오마커 후보로서 잠재력이 있다.
MiRXES의 인실리코를 통해 개발된 각 assay는 자체 기술의 열역학 기반 알고리듬을 사용한다. 또한 miRNA 역전사효소 시발체와 부분 nested된 실시간 PCR 시발체, 그리고 SYBR® Green과 고도로 최적화된 버퍼를 갖춘 바이오라인의 역전사효소 SensiSMART™를 포함하고 있다. 이를 통해 극도로 적은 수준의 miRNA도 매우 정확하게 탐침하며 긴밀하게 연결된 miRNA 시퀀스간 구분이 가능해진다.
\* SYBR는 Thermo Fisher Scientific의 등록 상표임
마르코 칼사바라(Marco Calzavara) 바이오라인 사장은 “EPIK miRNA Select Assays 제품군을 확장하게 되어 기쁘다. 고품질의 miRNA assay 포트폴리오가 늘어나게 됨으로써 연구진들이 miRNA 프로파일링과 정량화, 바이오마커 발견을 진행할 수 있도록 더 많은 도움을 줄 수 있게 됐다”고 말했다.
리처드 에벌리(Richard L. Eberly) 메리디안 바이오사이언스 사장 겸 CCO(최고커머셜책임자)는 “각 분야를 아우르는 EPIK miRNA Select Assays 제품군을 구성하고 성능을 향상시킨 것은 포트폴리오 구성에 있어 중요한 일이다. 이를 통해 보다 많은 생명공학 분야 고객들이 정확하고 비침습적 분자 진단이 가능한 인체와 기타 유기체용 assay를 개발할 수 있게 되어 본 제품군의 유연성이 확장되었다”고 밝혔다.
**메리디안** **바이오사이언스(Meridian Bioscience, Inc.) 소개**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다. 당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. 자세한 정보는 홈페이지([www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mTLvwIfz537TpouVHK6Sc5n4kty3dZY11xgcOQ8zo0kCnYzCO3INAw89omhBqJW-9PNAsrrrEcs8B8I0Ehpvy8qN3UA9VpLCssC1Ajl_mGnxQbbHfH_XxSTzFwlN4O1qkV8obJnTFLGOnIwED4SqJ1V_ZmbySKpXJVBrpU4LUkWuQKD6j5V484EpG6xCuNB5Ecdh1egpxngFSoJsNyRaK2ZIOubHMHPUvHQuSatgwzuW8NRg8YIqahFbpTrirdjS_HLlSOFMBeG86vL_DIkT3T9p8qokkyrDpsmZNHuhXlfJ-xDFYvQHIfD71LT-zSU84oVN_3GWkxZFWHc-rN0SaQ9JedKu15DVolIiYXvZkR0= "www.meridianbioscience.com"))에서 확인할 수 있다.
**추가** **정보:**
바이오라인에 대한 정보는[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=4S_6LquMl4wiWn8VeBUu3Loao2VxKxtOi0MZnnokuGWY2coi79cerC104ovaK4Ylbj_MW9BsHvEkvQGrO51Lt33ebQ1Ta-H4inpTlPhNStk=)에서 확인 가능하다.
```
```
---
### Contact Data
```
연락처:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Launches the Full Range of EPIK™ miRNA Assays](https://www.meridianbioscience.com/press-release/bioline-launches-the-full-range-of-epik-mirna-assays/)
**Published:** January 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 09, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,000 miRNA assays. Recent studies continue to show the clinical value of individual miRNA molecules which are released from tissues and cells. The expression of certain individual miRNA molecules correlates with specific disease conditions making them promising biomarker candidates for the early detection of disease, prognosis and monitoring of treatment in both humans and other organisms.
Each assay is designed by MiRXES *in silico* using proprietary thermodynamics-based algorithms and include miRNA specific reverse transcriptase primers and hemi-nested real-time PCR primers along with Bioline reverse transcriptase, SensiSMART™ with SYBR®1 Green and highly optimized buffers. The resulting assays enable detection of extremely low levels of miRNA with very high specificity and allow the discrimination between closely related miRNA sequences.
Marco Calzavara, President of Bioline commented, “I am very pleased to announce the expansion of the EPIK miRNA Select Assays. The increased portfolio of high quality miRNA assays will help even more researchers with miRNA expression profiling, quantification and in biomarker discovery.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “The release of the full range of EPIK miRNA Select Assays and their enhanced performance are an important addition to our portfolio. They increase the flexibility of this highly useful research tool by allowing more of our life science customers to create accurate and non-invasive molecular diagnostic assays in humans and in other organisms.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meridianbioscience.com&esheet=50874826&newsitemid=20140528006196&lan=en-US&anchor=www.meridianbioscience.com&index=1&md5=9d7530cd72c9cafcaeb68685906a1a9e "www.meridianbioscience.com").
**FOR ADDITIONAL INFORMATION:**
For more information about Bioline, please visit .
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR is a registered trademark of Thermo Fisher Scientific.
```
```
---
## Tags
[LIFE SCIENCE](https://www.globenewswire.com/en/search/tag/life%2520science "LIFE SCIENCE")
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline lança conjunto completo de ensaios de miRNA EPIK™](https://www.meridianbioscience.com/press-release/bioline-lanca-conjunto-completo-de-ensaios-de-mirna-epik/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 10, 2017 (GLOBE NEWSWIRE) — A Bioline, empresa de RCP, subsidiária integral da Meridian Bioscience, Inc. (NASDAQ:VIVO), anunciou hoje a expansão dos ensaios de miRNA EPIK™ selecionados, originalmente desenvolvidos para o estudo de moléculas individuais de microRNA (miRNA). Em colaboração com a MiRXES, a Bioline liberou 800 ensaios selecionados de miRNA EPIK™ em março de 2016 e esse número agora aumentou para incluir todos os organismos listados no miRBase edição 21, o que representa 27.000 ensaios de miRNA. Estudos recentes continuam a mostrar o valor clínico das moléculas de miRNA individuais que são liberadas dos tecidos e células. A expressão de certas moléculas de miRNA individuais corresponde a condições de doenças específicas, fazendo delas candidatas de biomarcadores promissoras para a identificação precoce de doenças, prognósticos e acompanhamento de tratamento em humanos e outros organismos.
Cada ensaio é projetado pela MiRXES *in silico,* utilizando algoritmos próprios com base em termodinâmica, e inclui iniciadores de transcriptase reversa específicos de miRNA e iniciadores semiagrupados de RCP em tempo real junto com a transcriptase reversa da Bioline, a SensiSMART™ com SYBR®1 Green, e tampões altamente otimizados. O ensaio resultante possibilita a detecção de níveis de miRNA extremamente baixos com especificidade bem alta e permite a discriminação entre sequências de miRNA bastante próximas.
Marco Calzavara, Presidente da Bioline, comentou: “Estou muito satisfeito com a expansão dos Ensaios Selecionados de miRNA EPIK. A carteira crescente de ensaios de miRNA de alta qualidade ajudará cada vez mais pesquisadores na classificação e quantificação de miRNA, e na descoberta de biomarcadores”.
Richard L. Eberly, Presidente e Diretor Comercial, declarou: “O lançamento do conjunto completo de ensaios selecionados EPIK de miRNA e seu desempenho mais aprimorado são um acréscimo importante à nossa carteira. Eles aumentam a flexibilidade dessa ferramenta de pesquisa altamente útil ao permitirem que mais clientes de nossa ciência da vida criem ensaios de diagnóstico molecular precisos e não invasivos para humanos e outros organismos”.
**Sobre a Meridian Bioscience, Inc.**
A Meridian é uma empresa de ciências da vida completamente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de kits inovadores de diagnóstico, reagentes raros, biológicos e componentes especializados. Utilizando uma variedade de métodos, nossos testes de diagnósticos oferecem precisão, simplicidade e velocidade em diagnóstico e tratamento precoces de condições clínicas comuns, como infecções e envenenamento por chumbo. Os produtos de diagnóstico da Meridian são usados fora do corpo humano e requerem pouco ou nenhum equipamento especial. Os produtos de diagnóstico da empresa são projetados para aumentar o bem-estar do paciente ao mesmo tempo em que reduzem os custos com cuidados da saúde. A Meridian possui posições fortes no mercado nas áreas de infecções gastrointestinais e respiratórias superiores e análises do nível de chumbo no sangue. Além disso, a Meridian é fornecedora de reagentes raros, biológicos e componentes especializados utilizados por organizações de ciências da vida e indústrias bioagrícolas dedicadas à pesquisa e por empresas como componentes na produção de diagnósticos. A Empresa comercializa seus produtos e tecnologias com hospitais, laboratórios de referência, centros de pesquisa, fabricantes de diagnóstico e empresas bioagrícolas em mais de 70 países. As ações da Empresa são negociadas no Global Select Market da NASDAQ com o símbolo VIVO. O site da Meridian é [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
**PARA INFORMAÇÕES ADICIONAIS:**
Para obter mais informações sobre a Bioline, acesse [https://www.bioline.com](https://www.bioline.com/).
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR é uma marca registrada da Thermo Fisher Scientific.
```
```
---
### Contact Data
```
CONTATO:
Richard L. Eberly
Presidente e Diretor Comercial
Meridian Bioscience, Inc.
Telefone: 513 271 3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出全方位的EPIK™ miRNA檢測](https://www.meridianbioscience.com/press-release/bioline推出全方位的epik-mirna檢測/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
辛辛那提, Jan. 11, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. （NASDAQ代號：VIVO）旗下從事聚合酶鏈反應(PCR)產品業務的全資附屬公司Bioline今日宣佈擴增最初針對單個微型核糖核酸(miRNA)分子研究開發的EPIK™ miRNA篩選檢測。Bioline與MiRXES攜手合作，在2016年3月發佈800項EPIK™ miRNA篩選檢測，目前檢測已經增加至納入所有在miRBase Release 21版本列出的全部有機體，相當於超過27,000項miRNA檢測。最近的研究繼續顯現出組織及細胞釋放的單個微型核糖核酸分子的臨床價值。特定單個miRNA分子的表達與特定疾病狀況相關聯，令其成為早期檢測人類及其他有機體的疾病、診斷及監測治療中具有前景的生物標誌物選擇。
MiRXES透過計算生物學，利用基於熱力學的專有算法設計每項檢測，每項檢測包括miRNA特異逆轉錄引物及半巢式實時PCR引物連同Bioline的逆轉錄酶， SensiSMART™與SYBR®1 Green以及高度優化的緩衝液。上述試驗可檢測到濃度極低且特異性高的miRNA，並可以區分密切相關的miRNA序列。
Bioline總裁Marco Calzavara評論道：「我非常高興宣佈擴增EPIK miRNA篩選檢測。隨著優質miRNA檢測組合持續擴大，將會幫助到愈來愈多的研究員研究miRNA表達譜、定量及miRNA生物標誌物的發現。」
總裁兼首席貿易官Richard L. Eberly表示：「EPIK miRNA全方位篩選檢測的發佈及其增強的性能是我們產品組合的重要補充，令這一極為有用的研究工具更加靈活，方便我們在生命科學領域的更多客戶在人類及其他有機體中進行準確的非侵入性分子診斷檢測。」
**關於Meridian Bioscience, Inc.**
Meridian是一家綜合生命科學公司，涵蓋開發、生產、營銷、分銷範圍廣泛的新型診斷檢測試劑盒、稀有試劑以及特殊生物製劑及成份。利用多種方法，我們的診斷測試在早期診斷和常見疾病（如感染病及鉛中毒）治療過程具有高準確度、簡易及快速的特點。Meridian的診斷產品在人體外使用，只需極少或無需特殊設備。公司診斷產品旨在提升病人福祉，同時降低醫療保健總成本。Meridian在胃腸和上呼吸道感染、血鉛水平檢測領域佔據重要的市場地位。此外，Meridian亦為從事研究的生命科學及農業生物技術行業的機構及公司供應稀有試劑、特殊生物製劑及成份，作為生產診斷產品的成份。公司向全球70多個國家的醫院、參考實驗室、研究中心、診斷產品制造商及農業生物技術公司營銷其產品和技術。公司股份在NASDAQ全球精選市場（Global Select Market）交易，代號VIVO。Meridian網址為[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")。
**更多信息：**
欲了解關於Bioline的更多資料，請訪問網站[https://www.bioline.com](https://www.bioline.com/)。
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR是Thermo Fisher Scientific的註冊商標。
```
```
---
### Contact Data
```
聯繫方式：
Meridian Bioscience, Inc
總裁兼首席貿易官
Richard L. Eberly
電話：513.271.3700
電郵：rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience宣佈推出面向亞太地區的TruQuick™快速測試產品](https://www.meridianbioscience.com/press-release/meridian-bioscience宣佈推出面向亞太地區的truquick快速測試產品/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
辛辛那提, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO)今日宣佈推出綜合即時定點護理快速測試系列產品TruQuick™，可用於診斷熱帶疾病、傳染病、性傳播疾病、呼吸系統疾病、胃腸疾病、癌症和心臟病等各類疾病。該系列產品將迅速擴大Meridian高價值快速測試產品組合，促進該公司在亞太區以及環球其他新興市場的商業運營。
TruQuick™包括逾60種產品，採用側流免疫層析定性技術。TruQuick™快速測試可於10至20分鐘內，極為準確迅速地診斷傳染病致病菌及其他重大急性病。Meridian深知亞洲及其他新興市場對臨床實驗的要求注重迅速、靈敏、針對性以及產品豐富性。
Meridian亞太區總裁Lourdes Weltzien博士評價：「能為發展迅速的亞太區定點護理市場發佈快速測試新品牌TruQuick™，我們非常興奮。Meridian將根據地區需求和註冊的優先順序，迅速在全球其他地區推出TruQuick™品牌產品。」
總裁兼首席商務官Richard L. Eberly表示：「在世界各地的新興市場開展全球商業運營，為過去數年Meridian的關鍵策略之一。Meridian已於中國、新加坡、澳洲、非洲和南美拓展業務。我們為這些新興市場提供的產品類型正迅速增加。非常高興能夠在這些重要市場的商業渠道推出TruQuick™快速定點護理產品。」
**關於Meridian Bioscience, Inc.**
Meridian為一家綜合生命科學公司，負責開發、生產、營銷及分銷各類新型診斷檢測試劑盒、稀有試劑以及特殊生物製劑和成份。我們的診斷測試方式多樣，於早期診斷和傳染病、鉛中毒等常見疾病治療過程具有準確性高、簡易及快速的優點。Meridian的診斷產品於人體外使用，只需極少或無需特殊設備。本公司的診斷產品旨在改善病人健康的同時降低醫療保險的總成本。Meridian在胃腸及上呼吸道感染、血鉛水平檢測領域佔據重要的市場地位。此外，Meridian亦為從事研究的生命科學及農業生物技術行業的機構及製造診斷產品的公司供應稀有試劑、特殊生物製劑及成份。本公司向全球逾70個國家的醫院、參考實驗室、研究中心、診斷產品製造商及農業生物技術公司銷售其產品和技術。本公司股份於納斯達克Global Select Market交易，代號為VIVO。Meridian公司網址[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJLcTo8XHK5JqgEgM3yIQSVSRPxKeAXmRXk5KEw8IZHOezozgROFTonbay5CszADr678w2NIY9IatrjV31H_vDcRG2qNvuzB0sPCuux5NwuvMVC-98N1LNgwY5BvS9YbYPuyqIaho872YAO2nBvjoi-HGHMwvt9Yx4erbylwddgdWBLd-atlxigM040t9MakopG5yilMSp5jNPw_L9Wq1lgg7zewEcHgJtnei9inwHR6Q= "www.meridianbioscience.com")。
```
```
---
### Contact Data
```
聯絡方式：
Richard L. Eberly
總裁兼首席商務官
Meridian Bioscience, Inc.
電話：513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience宣布推出面向亚太地区的TruQuick™快速测试产品](https://www.meridianbioscience.com/press-release/meridian-bioscience宣布推出面向亚太地区的truquick快速测试产品/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
辛辛那提, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO)今天宣布推出综合即时检验的快速测试系列产品TruQuick™，可用于诊断热带疾病、传染病、性传播疾病、呼吸系统疾病、胃肠疾病、癌症和心脏病等各类疾病。该系列产品将迅速扩大Meridian高价值快速测试产品组合，促进该公司在亚太区以及全球其他新兴市场的商业运作。
TruQuick™是包括60多种产品，采用侧流免疫层析的定性技术。TruQuick™快速测试可以在10到20分钟内，相当准确、迅速地诊断传染病病原体及其他重大急性病。Meridian清楚，亚洲和其他新兴市场对临床测试的要求十分注重迅速、灵敏、针对性以及产品丰富程度。
Meridian亚太区总裁Lourdes Weltzien博士说道：“能够在发展迅速的亚太区即时检验市场推出快速测试新品牌TruQuick™，我们感到非常兴奋。Meridian将会根据地区需求和注册的优先顺序，迅速在全球其他地区推出TruQuick™品牌的产品。”
总裁兼首席商务官Richard L. Eberly表示：“过去数年间Meridian的一大关键策略就是在世界各地的新兴市场开展我们的全球商业经营。Meridian已经在中国、新加坡、澳大利亚、非洲和南美拓展业务。我们为这些新兴市场提供的产品类型正不断丰富，很高兴能够在这些重要市场的商业渠道中推出TruQuick™快速即时检验产品。”
**关于Meridian Bioscience, Inc.**
Meridian是一家综合性的生命科学公司，负责开发、生产、营销和经销广泛的新型诊断检测试剂盒、稀有试剂以及特殊生物制剂和成份。我们的诊断测试方式多种多样，在早期诊断和传染病、铅中毒等常见疾病的治疗过程具有准度高、简易及快速的特点。Meridian的诊断产品在人体外使用，只需要很少甚至不需要特殊设备。本公司诊断产品旨在改善病人的健康，同时降低医疗保健的总成本。Meridian在胃肠和上呼吸道感染、血铅水平检测领域占据重要的市场地位。此外，Meridian也为从事研究的生命科学及农业生物技术行业的机构和制造诊断产品的公司供应稀有试剂、特殊生物制剂及成份。本公司向全球70多个国家的医院、参考实验室、研究中心、诊断产品制造商及农业生物技术公司销售其产品和技术。本公司股份在纳斯达克Global Select Market交易，代号是VIVO。Meridian公司网址是[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJLcTo8XHK5JqgEgM3yIQSVSRPxKeAXmRXk5KEw8IZHOezozgROFTonbay5CszADr678w2NIY9IatrjV31H_vDcRG2qNvuzB0sPCuux5NwuvMVC-98N1LNgwY5BvS9YbYPuyqIaho872YAO2nBvjoi-HGHMwvt9Yx4erbylwddgdWBLd-atlxigM040t9MakopG5yilMSp5jNPw_L9Wq1lgg7zewEcHgJtnei9inwHR6Q= "www.meridianbioscience.com")。
```
```
---
### Contact Data
```
联系方式：
Richard L. Eberly
总裁兼首席商务官
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Announces the Launch of TruQuick™ Rapid Tests for Asia Pacific](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-the-launch-of-truquick-rapid-tests-for-asia-pacific/)
**Published:** February 3, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TruQuick™, a comprehensive point-of-care product menu of rapid tests for the diagnosis of tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases. This product menu will enable Meridian to rapidly expand its product portfolio of high value rapid tests for its commercial operations in Asia Pacific and other emerging markets around the world.
TruQuick™ is a qualitative lateral flow chromatographic immunoassay menu of over 60 products. TruQuick™ rapid tests can aid in the diagnosis of infectious pathogens and other important acute diseases in 10 to 20 minutes with high levels of accuracy and speed to results. Meridian understands the clinical testing requirements in Asia and other emerging markets for speed, sensitivity, specificity, and breadth of product line.
Lourdes Weltzien, Ph.D., President of Meridian Asia Pacific commented, “We are excited to launch the new TruQuick™ brand of rapid tests for the rapidly growing point-of-care market in the Asia Pacific region. As for other regions of the world, Meridian will quickly introduce the TruQuick™ brand of products based on regional demands and registration priorities.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “One of Meridian’s key strategies over the past few years has been to expand our global commercial operations in emerging markets around the world. Meridian has expanded operations in China, Singapore, Australia, Africa, and South America. The product portfolio for these emerging markets is rapidly expanding. We are delighted to add the TruQuick™ brand of rapid point-of-care products to our commercial channels in these important markets.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meridianbioscience.com&esheet=50874826&newsitemid=20140528006196&lan=en-US&anchor=www.meridianbioscience.com&index=1&md5=9d7530cd72c9cafcaeb68685906a1a9e "www.meridianbioscience.com").
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-first-quarter-2017-operating-results-reduces-regular-cash-dividend-and-revises-fiscal-2017-guidance-downward/)
**Published:** January 25, 2017
**Author:** hamza
**Content:**
GENERAL HIGHLIGHTS
CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
- reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year;
- reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year;
- reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases of 29% compared to the fiscal 2016 first quarter;
- revised the fiscal 2017 annual indicated cash dividend rate to $0.50 per share, and declared the regular quarterly cash dividend of $0.125 per share for the first quarter of fiscal 2017 (annual indicated rate of $0.50 per share);
- revised its fiscal 2017 guidance of per share diluted earnings to between $0.64 and $0.69 on net revenues of $193 million to $199 million.
FINANCIAL HIGHLIGHTS (UNAUDITED)
In Thousands, Except per Share Data
Three Months Ended December 31, 2016 2015 % ChangeNet Revenues$ 46,809 $ 47,160 -1 %Operating Income 10,085 13,586 -26 %Net Earnings 6,279 8,893 -29 %Diluted Earnings per Share$ 0.15 $ 0.21 -29 % December 31, 2016 2015 Cash and Equivalents$ 49,276 $ 53,422 Working Capital 105,004 107,499 Long-term Debt 57,620 – Shareholders’ Equity 165,732 168,574 Total Assets 250,055 186,435 COMPANY COMMENTS
John A. Kraeutler, Chief Executive Officer and Chairman of the Board said, “The first quarter of fiscal 2017 represents a contrast of strong performance from our Life Science and Magellan Diagnostics business units, with significant weakness coming from our core diagnostics business in the U.S. (part of the Americas region). Life Science revenues grew by 10% (12% in constant currency) over the comparable quarter last year. Magellan Diagnostics reported revenues that increased by 32% over the comparable period last year, which was prior to our acquisition in late March 2016. With regard to our EMEA diagnostics unit, we experienced continued improvement in performance, with constant currency growth of 5%, driven largely by positive traction of our ***illumi***gene Malaria test and related molecular products.
Our Americas diagnostics business experienced revenue declines in all major product categories, in part due to customer buying patterns and general weakness overall. While ***illumi****gene* experienced 3% growth in all testing categories, other than the hyper-competitive *C. difficile* arena, declines in sales of *C. difficile* and foodborne tests continued due to competitive market conditions. Globally, the *H. pylori* category revenues declined by 18% as a result of aggressive stock-and-block programs in the prior year period as a defense in anticipation of our May 2016 patent expiration. The competitive landscape for *H. pylori* testing is currently stable, and we expect to return to growth for the *H. pylori* product line for the year.
In late 2016, we implemented measures to stabilize our Americas core diagnostics business, anticipating a return to growth later this fiscal year. Key changes were made to our senior management team and further strengthening of leadership is expected to be completed in the second quarter. We have also completed additional distributor agreements with certain of our distribution partners, which we expect will improve our customer coverage and contribute to growth going forward. As the implementation actions in support of these relationships has just begun, the positive impact is not expected until later in the year. Additionally, we have hired experienced leadership to manage our distributor relationships in the Americas region. Our South American and Canadian businesses, which have been stagnant for years, are expected to provide positive growth in the second half of 2017.
In summary, we are very pleased with the trends in our Life Science, EMEA diagnostics and Magellan Diagnostics business units. The recovery in our core diagnostics unit is proceeding more slowly than planned. As a result, first quarter earnings were depressed as the core diagnostics unit generates the largest contribution to our profits. We are taking further action to align resources, reduce expenses and optimize investments in product development. The results of our first fiscal quarter have led to the downward revision in our revenue and earnings guidance, and the reduction in our annual indicated dividend rate is intended to enable us to fund our global expansion and new product development.”
CASH DIVIDEND MATTERS
Based on current business trends, the Board of Directors reduced the annual indicated dividend rate from $0.80 per share to $0.50, and declared the regular quarterly cash dividend of $0.125 per share for the first quarter ended December 31, 2016. The dividend is of record February 6, 2017 and payable February 16, 2017. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including any acquisitions.
FISCAL 2017 GUIDANCE REVISED DOWNWARD
Based on current business trends for the fiscal year ending September 30, 2017, management now expects net revenues to be in the range of $193 million to $199 million and per share diluted earnings to be between $0.64 and $0.69. Prior guidance was for revenues in the range of $205 million to $210 million and per share diluted earnings of $0.81 to $0.85. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.4 million at fiscal 2016 year end to approximately 42.6 million at fiscal 2017 year end. The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2017.
FINANCIAL CONDITION
The Company’s financial condition is sound. At December 31, 2016, current assets were $126.0 million compared to current liabilities of $21.0 million, resulting in working capital of $105.0 million and a current ratio of 6.0. Cash and equivalents were $49.3 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which relate to the acquisition of Magellan, totaled $57.6 million as of December 31, 2016.
FIRST QUARTER UNAUDITED OPERATING RESULTS
In Thousands, Except per Share Data
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the first quarters of fiscal 2017 and fiscal 2016.
Three Months Ended December 31, 2016 2015Net revenues$46,809 $47,160Cost of sales 17,359 15,577 Gross profit 29,450 31,583 Operating expenses Research and development 3,405 3,381 Selling and marketing 7,514 6,443 General and administrative 8,446 8,173 Total operating expenses 19,365 17,997 Operating income 10,085 13,586Other income (expense), net (426) 113 Earnings before income taxes 9,659 13,699 Income tax provision 3,380 4,806 Net earnings$6,279 $8,893 Net earnings per basic common share$0.15 $0.21Basic common shares outstanding 42,159 41,947 Net earnings per diluted common share$0.15 $0.21Diluted common shares outstanding 42,535 42,327The following table sets forth the unaudited segment data for the interim periods in fiscal 2017 and fiscal 2016 (in thousands).
Three Months Ended December 31, 2016 2015Net revenues Diagnostics$33,808 $35,301 Life Science 13,001 11,859 $46,809 $47,160Operating Income Diagnostics$6,643 $10,330 Life Science 3,267 3,236 Eliminations 175 20 $10,085 $13,586**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=baVXTtB4xq7tt0rS75W4yHgFjtOTTd1tZi1iYlEP0cvpvZO9tr9oOuf0Pvl7bYDWmPpxu0Fct_z5HsCUYwQDg7rmhBGn7ElyLdPy3Gobwr4m02vDYHQqSPcDCky0RqhK "www.meridianbioscience.com").
**Categories:** Press Release
---
### [Bioline lanza la gama completa de ensayos EPIK™ miRNA](https://www.meridianbioscience.com/press-release/bioline-lanza-la-gama-completa-de-ensayos-epik-mirna/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 10, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, una filial en propiedad absoluta de Meridian Bioscience, Inc. (NASDAQ:VIVO) ha anunciado hoy la ampliación de los ensayos de selección EPIK™ miRNA, desarrollados en su origen para el estudio de moléculas individuales de microRNA (miRNA, en inglés). En colaboración con MiRXES, en marzo de 2016, Bioline lanzó 800 ensayos de selección EPIK™ miRNA que ahora, han aumentado para incluir a todos los organismos enumerados en el lanzamiento 21 de miRBase, que representa más de 27.000 ensayos de miRNA. Estudios recientes siguen mostrando el valor médico de las moléculas miRNA individuales, que provienen de tejidos y células. La expresión de determinadas moléculas miRNA individuales se correlaciona con enfermedades concretas, lo que resulta prometedor para los candidatos de marcadores biológicos para la detección temprana de enfermedades, pronóstico y control del tratamiento, tanto en humanos como en otros organismos.
MiRXES diseña todos los ensayos *in silico* utilizando algoritmos propios basados en la termodinámica e incluye imprimaciones de transcriptasa inversos concretos de miRNA, así como imprimaciones de PRC semi incorporados a tiempo real, junto con la transcriptasa inversa de Bioline, SensiSMART™ con SYBR®1 Green y memorias intermedias totalmente optimizadas. Los resultados permiten la detección de niveles de miRNA extremadamente bajos con gran exactitud y permiten discernir entre secuencias de miRNA estrechamente relacionadas.
Marco Calzavara, presidente de Bioline, afirmó, “Me llena de orgullo anunciar la ampliación de los ensayos de selección EPIK miRNA. El aumento de la cartera de ensayos de miRNA de alta calidad ayudará a más investigadores a crear perfiles de expresión de miRNA, a cuantificarla y a descubrir marcadores biológicos”.
Richard L. Eberly el presidente y director comercial indicó, “El lanzamiento de la gama completa de ensayos de selección EPIK miRNA y su desempeño mejorado son una importante incorporación para nuestra cartera. Aumentan la flexibilidad de esta útil herramienta de investigación, para así permitir a más de nuestros clientes expertos en biología crear ensayos de diagnóstico molecular más precisos y no invasivos en humanos y otros organismos”.
**Acerca de Meridian Bioscience, Inc.**
Meridian es una compañía de ciencias biológicas totalmente integrada que desarrolla, fabrica, comercializa y distribuye una amplia gama de pruebas de diagnóstico innovadoras, reactivos poco frecuentes y productos biológicos y componentes especializados. Con el uso de una variedad de métodos, nuestras pruebas de diagnóstico brindan precisión, simplicidad y velocidad en el diagnóstico y el tratamiento temprano de afecciones médicas comunes, como infecciones e intoxicación por plomo. Los productos de diagnóstico de Meridian se usan fuera del cuerpo humano y prácticamente no requieren equipos especiales. Los productos de la compañía están diseñados para mejorar el bienestar del paciente y reducir al mismo tiempo los costos totales de la atención médica. Meridian tiene una sólida posición de mercado en áreas de diagnóstico de infecciones gastrointestinales y de las vías respiratorias superiores, y en pruebas de nivel de plomo en sangre. Además, Meridian provee reactivos poco frecuentes, productos biológicos especiales y componentes utilizados por las organizaciones de la industria de productos biológicos y agricultura biológica que realizan investigaciones, así como por compañías dedicadas a componentes para la fabricación de productos de diagnóstico. La Compañía comercializa sus productos y tecnología a hospitales, laboratorios de referencia, centros de investigación, fabricantes de productos de diagnóstico y compañías de agricultura biológica en más de 70 países de todo el mundo. Las acciones de la compañía cotizan en el NASDAQ Global Select Market, símbolo VIVO. La página web de Meridian es [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
**MÁS INFORMACIÓN:**
Para obtener más información acerca de Bioline, visite [https://www.bioline.com](https://www.bioline.com/).
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR es una marca registrada de Thermo Fisher Scientific.
```
```
---
### Contact Data
```
CONTACTO:
Richard L. Eberly
Presidente, director comercial
Meridian Bioscience, Inc.
Teléfono: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline เปิดตัวชุดตรวจ EPIK™ miRNA อย่างเต็มรูปแบบ](https://www.meridianbioscience.com/press-release/bioline-เปิดตัวชุดตรวจ-epik-mirna-อย่าง/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 11, 2017 (GLOBE NEWSWIRE) — Bioline ซึ่งเป็นบริษัท PCR อันเป็นหนึ่งในบริษัทในเครือที่ถือหุ้นทั้งหมด ของ Meridian Bioscience, Inc. (NASDAQ:VIVO) วันนี้ได้ประกาศการขยายตัวของชุดตรวจ EPIK™ miRNA Select ซึ่งแต่เดิมถูกพัฒนาขึ้นเพื่อการศึกษาโมเลกุล microRNA (miRNA) โดยเฉพาะ ในการทำงานร่วมกับ MiRXES บริษัท Bioline ได้ผลิตชุดตรวจ EPIK™ miRNA Select เป็นจำนวนทั้งหมด 800 ชุดด้วยกัน และขณะนี้ได้เพิ่มมากขึ้นโดยรวมสิ่งมีชีวิตทั้งหมดที่มี การลงชื่อไว้ในการแถลง miRBase 21 ซึ่งเป็นตัวแทนให้กับชุดตรวจกว่า 27,000 ชุด ผลการวิจัยล่าสุดยังคงชี้ให้เห็นคุณค่าทางการแพทย์ของโมเลกุล miRNA เดี่ยว ซึ่งถูก ปล่อยตัวออกมาจากเนื้อเยื่อและเซลล์ต่างๆ การแสดงออกของโมเลกุล miRNA เดี่ยวบางชนิดมีความสัมพันธ์กับเงื่อนไขเฉพาะของโรค ซึ่งทำให้โมเลกุลเหล่านี้ มีแนวโน้มที่กลายเป็นตัวชี้วัดทางชีวภาพสำหรับการตรวจสอบในช่วงต้นของโรค การทำนายโรค และ การควบคุมการรักษาโรคทั้งในมนุษย์และสิ่งมีชีวิตอื่นๆ
ชุดตรวจแต่ละชุดได้รับการออกแบบโดย MiRXES ด้วยการทำแบบจำลองโดยใช้ คอมพิวเตอร์ ซึ่งใช้อัลกอริทึมที่ยึดความเป็นพลวัตของความร้อนเป็นหลัก และรวมถึง ไพรเมอร์ miRNA reverse transcriptase และไพรเมอร์แบบ real-time PCR ครึ่ง-ซ้อน กันที่เฉพาะเจาะจง พร้อมกับเอนไซม์ Bioline reverse transcriptase SensiSMART ™ กับ SYBR®1 Green และบัฟเฟอร์เพิ่มประสิทธิภาพสูง ชุดตรวจส่งผลช่วยให้การตรวจสอบ ในระดับต่ำมากของ miRNA ด้วยความจำเพาะสูงมากและอนุญาตให้มีการเลือกปฏิบัติ ระหว่างลำดับ miRNA ต่างๆ ที่มีความเกี่ยวข้องอย่างใกล้ชิด
Marco Calzavara ซึ่งเป็นประธานของ Bioline ให้ความเห็นว่า “ผมมีความพึงพอใจเป็นอย่างยิ่งที่ได้ประกาศการขยายตัวของชุดตรวจ EPIK miRNA Select ผลงานชุดตรวจ miRNA ที่ได้รับการเพิ่มพูนคุณภาพให้สูงขึ้นนี้จะช่วยให้นักวิจัยมากขึ้นในการทำโปรไฟล์ การวัดปริมาณและการค้นพบตัวบ่งชี้ทางชีวภาพ”
Richard L. Eberly ซึ่งเป็นประธานและประธานเจ้าหน้าที่ฝ่ายพาณิชย์กล่าวว่า “การเปิดตัว อย่างเต็มรูปแบบของชุดตรวจ EPIK miRNA และประสิทธิภาพการทำงานที่เพิ่มขึ้นของมัน ถือเป็นการเพิ่มพูนที่สำคัญสำหรับผลงานของเรา ชุดตรวจนี้ได้เพิ่มความยืดหยุ่นของ เครื่องมือในการวิจัยอันมีประโยชน์อย่างมากโดยอนุญาตให้ลูกค้าด้านวิทยาศาสตร์เพื่อ ชีวิตของเราได้มีโอกาสมากขึ้นในการสร้างชุดตรวจวินิจฉัยที่มีความถูกต้องและไม่รุกราน โมเลกุลในมนุษย์และสิ่งมีชีวิตอื่นๆ”
**เกี่ยวกับ Meridian Bioscience, Inc.**
Meridian เป็นบริษัทด้านวิทยาศาสตร์เพื่อชีวิตแบบครบวงจรที่พัฒนา ผลิต ทำการตลาด และจัดจำหน่ายนวัตกรรมชุดตรวจวินิจฉัย สารเคมีที่หายาก ผลิตภัณฑ์ทางชีวภาพพิเศษ และส่วนประกอบต่างๆ ที่หลากหลาย ด้วยการใช้ประโยชน์จากวิธีการที่หลากหลาย การวินิจฉัยของเราให้ ความถูกต้อง เรียบง่ายและความรวดเร็วในการวินิจฉัยและการรักษา ของสภาพทางการแพทย์ทั่วไป เช่นการติดเชื้อและเป็นพิษตะกั่ว ผลิตภัณฑ์ด้านการวินิจฉัยของ Meridian ถูกใช้ภายนอกของร่างกายมนุษย์ และต้องใช้แค่อุปกรณ์พิเศษเล็กๆ น้อยๆ หรือ ไม่ต้องใช้เลย ผลิตภัณฑ์ด้านการวินิจฉัยของบริษัทฯ ได้รับการออกแบบ เพื่อเพิ่มพูนความเป็นอยู่ที่ดีของผู้ป่วยในขณะที่ลดละค่าใช้จ่ายรวมของการดูแลสุขภาพ Meridian มีสถานะทางการตลาดที่แข็งแกร่งในด้านการติดเชื้อระบบทางเดินหายใจ และระบบทางเดินอาหารส่วนบน และการทดสอบระดับสารตะกั่วในเลือด นอกจากนี้ Meridianยังเป็นผู้จัดจำหน่ายน้ำยาชีวภาพพิเศษและส่วนประกอบที่หายากซึ่งใช้โดยองค์กรในด้านวิทยาศาสตร์เพื่อชีวิตและอุตสาหกรรมเกษตรกรรมเชิงชีวภาพ ที่มีส่วนร่วมในการทำวิจัยและโดยบริษัทซึ่งใช้เป็นส่วนประกอบในการผลิตของผลิตภัณฑ์ ตรวจวินิจฉัยโรค บริษัทฯ ได้ทำการตลาดให้กับผลิตภัณฑ์และเทคโนโลยีสำหรับ โรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์การวิจัย ผู้ผลิตวินิจฉัยและบริษัทเกษตรกรรมเชิงชีวภาพในกว่า 70 ประเทศทั่วโลก หุ้นของบริษัทฯ มีการซื้อขายในตลาด NASDAQ Global Select ในสัญลักษณ์ VIVO เว็บไซต์ของ Meridian คือ [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")
**สำหรับข้อมูลเพิ่มเติม:**
สำหรับข้อมูลเพิ่มเติม เกี่ยวกับ Bioline กรุณาเยี่ยมชม [https://www.bioline.com](https://www.bioline.com/).
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR เป็นเครื่องหมายการค้าจดทะเบียนของ Thermo Fisher Scientific.
```
```
---
### Contact Data
```
ติดต่อ:
Richard L. Eberly
ประธานและประธานเจ้าหน้าที่ฝ่ายพาณิชย์
Meridian Bioscience, Inc. โทรศัพท์: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出全方位的EPIK™ miRNA检测](https://www.meridianbioscience.com/press-release/bioline推出全方位的epik-mirna检测/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
辛辛那提, Jan. 11, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. （NASDAQ代号：VIVO）旗下从事聚合酶链反应(PCR)产品业务的全资附属公司Bioline今日宣布扩增最初针对单个微型核糖核酸(miRNA)分子研究开发的EPIK™ miRNA筛选检测。Bioline与MiRXES携手合作，在2016年3月发布800项EPIK™ miRNA筛选检测，目前检测已经增加至纳入所有在miRBase Release 21版本列出的全部有机体，相当于超过27,000项miRNA检测。最近的研究继续显现出组织及细胞释放的单个微型核糖核酸分子的临床价值。特定单个miRNA分子的表达与特定疾病状况相关联，令其成为早期检测人类及其他有机体的疾病、诊断及监测治疗中具有前景的生物标志物选择。
MiRXES通过计算生物学，利用基于热力学的专有算法设计每项检测，每项检测包括miRNA特异逆转录引物及半巢式实时PCR引物连同Bioline的逆转录酶，SensiSMART™与SYBR®1 Green以及高度优化的缓冲液。上述试验可检测到浓度极低且特异性高的miRNA，并可以区分密切相关的miRNA序列。
Bioline总裁Marco Calzavara评论道：“我非常高兴宣布扩增EPIK miRNA筛选检测。随着优质miRNA检测组合持续扩大，将会帮助到越来越多的研究员研究miRNA表达谱、定量及miRNA生物标志物的发现。”
总裁兼首席贸易官Richard L. Eberly表示：“EPIK miRNA全方位筛选检测的发布及其增强的性能是我们产品组合的重要补充，令这一极为有用的研究工具更加灵活，方便我们在生命科学领域的更多客户在人类及其他有机体中进行准确的非侵入性分子诊断检测。”
**关于Meridian Bioscience, Inc.**
Meridian是一家综合生命科学公司，涵盖开发、生产、营销、分销范围广泛的新型诊断检测试剂盒、稀有试剂以及特殊生物制剂及成份。利用多种方法，我们的诊断测试在早期诊断和常见疾病（如感染病及铅中毒）治疗过程具有高准确度、简易及快速的特点。Meridian的诊断产品在人体外使用，只需极少或无需特殊设备。公司诊断产品旨在提升病人福祉，同时降低医疗保健总成本。Meridian在胃肠和上呼吸道感染、血铅水平检测领域占据重要的市场地位。此外，Meridian亦为从事研究的生命科学及农业生物技术行业的机构及公司供应稀有试剂、特殊生物制剂及成份，作为生产诊断产品的成份。公司向全球70多个国家的医院、参考实验室、研究中心、诊断产品制造商及农业生物技术公司营销其产品和技术。公司股份在NASDAQ全球精选市场（Global Select Market）交易，代号VIVO。Meridian网址为[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")。
**更多信息：**
欲了解关于Bioline的更多资料，请访问网站[https://www.bioline.com](https://www.bioline.com/)。
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR是Thermo Fisher Scientific的注册商标。
```
```
---
### Contact Data
```
联系方式：
Meridian Bioscience, Inc
总裁兼首席贸易官
Richard L. Eberly
电话：513.271.3700
电邮：rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Meluncurkan Sejumlah Penetapan Kadar miRNA EPIK™](https://www.meridianbioscience.com/press-release/bioline-meluncurkan-sejumlah-penetapan-kadar-mirna-epik/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Jan. 11, 2017 (GLOBE NEWSWIRE) — Bioline, Perusahaan PCR, anak perusahaan yang sepenuhnya dimiliki oleh Meridian Bioscience, Inc. (NASDAQ: VIVO) hari ini mengumumkan pengembangan Penetapan Kadar miRNA Terpilih EPIK™ yang pada awalnya dikembangkan untuk studi molekul microRNA (miRNA) individu. Dengan bekerja sama dengan MiRXES, Bioline merilis 800 Penetapan Kadar miRNA Terpilih EPIK™ pada bulan Maret 2016 dan saat ini telah ditingkatkan agar dapat mencakup semua organisme yang terdaftar pada rilis miRBase 21 yang mewakili lebih dari 27.000 penetapan kadar miRNA. Studi terbaru terus menunjukkan nilai klinis molekul miRNA individu yang dilepaskan dari jaringan dan sel. Ekspresi pada molekul miRNA individu tertentu memiliki keterkaitan dengan kondisi penyakit tertentu sehingga menjadikan mereka sebagai kandidat *biomarker* (penanda biologis) yang menjanjikan untuk deteksi dini penyakit, prognosis, dan pemantauan pengobatan pada manusia dan organisme lainnya.
Setiap penetapan kadar dirancang oleh MiRXES dengan metode *in silico* yang menggunakan algoritma berbasis termodinamika yang telah dipatenkan, serta mencakup primer transkriptase balik khusus miRNA dan primer PCR waktu nyata hemi-terkumpul bersama dengan transkriptase balik Bioline, SensiSMART ™ dengan SYBR®1 Green dan bufer yang sangat dioptimalkan. Hasil penetapan kadar memungkinkan untuk dilakukannya deteksi tingkat miRNA yang sangat rendah dengan spesifisitas yang sangat tinggi dan juga pembedaan antara urutan miRNA yang terkait erat.
Marco Calzavara selaku Presiden Bioline berkomentar, “Saya sangat senang dapat mengumumkan mengenai pengembangan Penetapan Kadar miRNA Terpilih EPIK. Portofolio penetapan kadar miRNA berkualitas tinggi yang ditingkatkan akan membantu lebih banyak lagi peneliti untuk melakukan pemrofilan ekspresi miRNA, kuantifikasi, dan menemukan *biomarker* (penanda biologis).”
Richard L. Eberly, Presiden, Direktur Perdagangan, menyatakan, “Rilis dari sejumlah Penetapan Kadar miRNA Terpilih EPIK dan juga peningkatan kinerjanya merupakan suatu penyertaan yang penting pada portofolio kami. Penetapan Kadar miRNA Terpilih EPIK tersebut akan dapat meningkatkan fleksibilitas alat penelitian yang sangat bermanfaat ini dengan memungkinkan lebih banyak pelanggan ilmu hayati kami untuk menciptakan penetapan kadar diagnostik molekul yang akurat dan non-invasif pada manusia dan organisme lain.”
**Tentang Meridian Bioscience, Inc**
Meridian merupakan perusahaan ilmu hayati yang mengembangkan, membuat, memasarkan, dan mendistribusikan berbagai kit uji diagnostik inovatif, reagan langka, komponen, dan biologis khusus. Dengan menggunakan berbagai metode, uji diagnostik kami memberikan akurasi, kemudahan, dan kecepatan dalam diagnosis awal dan pengobatan kondisi medis umum, seperti infeksi dan keracunan timbal. Produk diagnostik Meridian digunakan di luar tubuh manusia dan hanya memerlukan sedikit peralatan khusus atau tidak sama sekali. Produk diagnostik perusahaan dirancang untuk meningkatkan kesehatan pasien sambil mengurangi biaya perawatan kesehatan secara keseluruhan. Meridian memiliki posisi pasar yang kuat di bidang saluran pencernaan dan infeksi pernapasan atas dan pengujian kadar timbal dalam darah. Sebagai tambahan, Meridian adalah pemasok bahan reaksi langka, biologis khusus dan komponen yang digunakan oleh organisasi di ilmu hayati dan industri agribio yang terlibat dalam penelitian dan digunakan perusahaan sebagai komponen dalam pembuatan diagnostik. Perusahaan memasarkan produk dan teknologinya ke rumah sakit, laboratorium rujukan, pusat penelitian, produsen diagnostik, dan perusahaan agribio di lebih dari 70 negara di seluruh dunia. Saham perusahaan diperdagangkan di NASDAQ Global Select Market dengan simbol VIVO. Alamat situs web Meridian di [www.meridianbioscience.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meridianbioscience.com&esheet=50874826&newsitemid=20140528006196&lan=en-US&anchor=www.meridianbioscience.com&index=1&md5=9d7530cd72c9cafcaeb68685906a1a9e "www.meridianbioscience.com").
**UNTUK INFORMASI TAMBAHAN:**
Untuk informasi selengkapnya tentang Bioline, silakan kunjungi [https://www.bioline.com](https://www.bioline.com/).
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBR adalah merek dagang terdaftar di Thermo Fisher Scientific.
```
```
---
### Contact Data
```
KONTAK:
Richard L. Eberly
Presiden, Direktur Komersial
Meridian Bioscience, Inc.
Telepon: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [バイオライン、エピックmiRNAアッセイ各種を発表](https://www.meridianbioscience.com/press-release/バイオライン、エピックmirnaアッセイ各種を発表/)
**Published:** January 10, 2017
**Author:** hamza
**Content:**
シンシナティ, Jan. 11, 2017 (GLOBE NEWSWIRE) — メリディアン･バイオサイエンス社 (Meridian Bioscience, Inc.、NASDAQ:VIVO) の完全所有子会社であるPCR企業、バイオライン (Bioline) は本日、当初は個別のマイクロRNA (miRNA) の研究のために開発されたエピックmiRNAセレクト･アッセイ (EPIK™ miRNA Select Assay) の拡大を発表した。バイオラインは、MiRXESとの協力により800エピック™ miRNAセレクト･アッセイを2016年3月にリリースしたが、今回はmiRBaseのリリース21に記載されている全生物を網羅するよう拡大され、27,000のmiRNAアッセイが対象になった。最近の試験では、組織や細胞から放出される個別のmiRNA分子の臨床的価値が引き続き認められている。個別miRNA分子の発現は特定の疾患に関連しているため、ヒトおよびその他の生物における疾患の早期診断、予後判定、治療のモニタリングのために有望なバイオマーカー候補である。
各アッセイは、同社独自の熱力学ベースのアルゴリズムを駆使してMiRXESによってコンピュータで設計され、miRNA特有の逆転写酵素プライマーおよび半入れ子構造のリアルタイムPCRプライマーを含み、バイオラインの逆転写酵素センシスマート (SensiSMART™) (SYBR®1グリーン付属) および最適化の進んだ緩衝剤が使用されている。その結果のアッセイでは、極めて低量のmiRNAでも極めて高い特定性で検出することが可能であり、関係性の深いmiRNAシークエンスとも区別することができる。
バイオラインの社長マルコ･カルツァヴァーラ (Marco Calzavara) 氏は「エピックmiRNAセレクト･アッセイの拡大を発表できることを、たいへん嬉しく思っております。高品質miRNAアッセイのポートフォリオを拡大することで、miRNAの発現プロファイリング、定量化、バイオマーカー発見のために、より多くの研究者のお役に立つことができます」と述べている。
社長兼最高商務責任者 (President, Chief Commercial Officer) リチャード･L･エバリー (Richard L.Eberly) 氏は「エピックmiRNAセレクト･アッセイの全ラインのリリースおよびその性能強化は、当社のポートフォリオで重要な追加項目になっています。ライフサイエンス関係のより多くのお客様が、ヒトおよびその他の生物で、正確な非侵襲性分子診断アッセイを作り出すことができるようになり、この極めて有用なリサーチツールの柔軟性をより強化しています」と述べている。
**Meridian Bioscience, Inc. (メリディアン･バイオサイエンス社) について**
メリディアンは、多様な革新的診断テストキット、希少試薬、特殊バイオ製品およびコンポーネントの開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス会社である。同社の診断検査は、多様な方法を駆使して、感染症、鉛中毒などのよくある疾患の早期診断と治療のために、高精度、単純性、スピードを実現している。メリディアンの診断用製品は人体外で使用する製品であり、専門的装置はほとんど必要ないか、または全く不要である。同社の診断用製品は患者の心身の健康を強化し、同時に医療の合計結果コストを削減するよう設計されている。メリディアンは消化器系･呼吸器系上部の感染症および血中鉛濃度の診断分野で強力な市場地位を確保している。さらに、メリディアンは、ライフサイエンスおよび農業バイオ業界に携わる研究機関や、診断用製品の製造用コンポーネントとして企業などに、希少試薬や特殊バイオ製品、コンポーネントを供給している。同社は世界中70ヶ国以上の病院、基準検査機関、リサーチセンター、診断用製品メーカー、農業バイオ企業にもその製品、テクノロジーを販売している。同社の株式はナスダックのグローバル･セレクト･マーケットでシンボル「VIVO」で取引されている。メリディアンのウェブサイトは以下のとおりである。[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")
**追加情報：**
バイオラインについて詳しくは、[https://www.bioline.com](https://www.bioline.com/)を参照のこと。
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1 SYBRはThermo Fisher Scientificの登録商標である。
```
```
---
### Contact Data
```
問い合わせ先
リチャード･L･エバリー (Richard L. Eberly)
社長、最高商務責任者 (President, Chief Commercial Officer)
Meridian Bioscience, Inc.
電話： 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline เปิดตัวชุดเตรียมสารพันธุกรรมต้นแบบ JetSeq™ ใหม่](https://www.meridianbioscience.com/press-release/bioline-เปิดตัวชุดเตรียมสารพั/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 10, 2017 (GLOBE NEWSWIRE) — Bioline, บริษัท PCR ซึ่งเป็นบริษัทย่อยในเครือของ Meridian Bioscience, Inc. (NASDAQ: VIVO) วันนี้ประกาศการขยายตัวของผลงานชุดเตรียมสารพันธุกรรมต้นแบบสำหรับการเตรียมตัวอย่างด้วยเทคนิค Generation Sequencing (NGS)
JetSeq™ ได้รับการพัฒนาภายใต้ความร่วมมือกับ Oxford Gene Technology (OGT) ชุด JetSeq™ DNA Library Preparation Kits ใหม่ ใช้บัฟเฟอร์ที่เพิ่มประสิทธิภาพเพื่อให้ประสิทธิภาพของปฏิกิริยาสูงสุดและอัตราการแปลง (conversion rates) สูงสุด ที่ช่วยให้การเตรียมดีเอ็นเอด้วยเทคนิค Generation Sequencing (NGS) และการเชื่อมด้วยอะแด็บเตอร์สำหรับเครื่องมือรูปแบบ Illumina ให้มีคุณภาพสูงสุด การรวมกันของการซ่อมแซมปลาย end repair และ A-tailing ที่ตามด้วยการเชื่อมด้วยอะแด็บเตอร์โดยตรง ช่วยลดขั้นตอนการทำความสะอาดขึ้นและเวลาที่เกี่ยวข้อง ปรับปรุงผลผลิตและคุณภาพของการเตรียมดีเอ็นเอต้นแบบ พร้อมการลดปริมาณของดีเอ็นเอที่จำเป็น ชุดเตรียมสารพันธุกรรมต้นแบบใหม่สามารถใช้กับพอลิเมอเรส (polymerase) สำหรับเทคนิค PCR amplification ด้วยวัสดุเริ่มต้นที่ต่ำกว่าหรือชุด PCR-free ที่วัสดุที่เริ่มต้นไม่จำกัด
Marco Calzavara ประธาน Bioline แสดงความเห็นว่า “การเปิดตัวชุดเตรียมสารพันธุกรรมต้นแบบ JetSeq™ ใหม่ ต่อยอดชุด JetSeq ™ ที่เราได้เปิดตัวปีที่แล้ว ซึ่งนำพา Bioline ก้าวเข้าไปในพื้นที่ NGS ชุด JetSeq™ นี้ ถูกสร้างขึ้นบนความรู้ที่กว้างของเราในการสร้างเอนไซม์ที่มีประสิทธิภาพสูงและการกำหนดสารละลายบัฟเฟอร์ และให้ลูกค้าของเราทางเลือกที่มากยิ่งขึ้นในการเตรียมดีเอ็นเอ ซึ่งช่วยให้พวกเขาที่จะแก้ไขปัญหาแม้แต่ตัวอย่างที่ท้าทายมากที่สุดด้วยความเชื่อมั่นในด้านที่มีการเปลี่ยนแปลงรวดเร็วเช่นนี้”
Richard L. Eberly ประธาน หัวหน้าฝ่ายพาณิชย์กล่าวว่า “เรารู้สึกตื่นเต้นดีใจเกี่ยวกับการเปิดตัวของชุดเตรียมสารพันธุกรรมต้นแบบ JetSeq™ ใหม่ ซึ่งจะช่วยเพิ่มผลงานของเราและให้ทางเลือกมากขึ้นให้กับลูกค้าของวิทยาศาสตร์เพื่อชีวิตของเรา ช่วยให้การเตรียมการได้เร็วขึ้น ช่วยลดเวลาในการอ่านผลและเพิ่มปริมาณงาน การพัฒนาของครอบครัว JetSeq™ แสดงให้เห็นถึงความมุ่งมั่นของเราไม่เพียงแต่การพัฒนาอย่างต่อเนื่องและการขยายตัวของผลิตภัณฑ์จาก Bioline แต่ยังให้ลูกค้าของเราให้ทางเลือกมากขึ้นเกี่ยวกับสารที่ใช้เป็นตัวกระทำปฏิกิริยาที่มีคุณภาพสูง”
**เกี่ยวกับ Meridian Bioscience, Inc.**
Meridian เป็นบริษัทด้านวิทยาศาสตร์เพื่อชีวิตแบบครบวงจรที่พัฒนา ผลิต ทำการตลาด และจัดจำหน่ายนวัตกรรมชุดตรวจวินิจฉัย สารเคมีที่หายาก ผลิตภัณฑ์ทางชีวภาพพิเศษ และส่วนประกอบต่างๆ ด้วยการใช้ประโยชน์จากวิธีการที่หลากหลาย การวินิจฉัยของเราให้ความถูกต้อง เรียบง่ายและความรวดเร็วในการวินิจฉัยและการรักษาของสภาพทางการแพทย์ทั่วไป เช่นการติดเชื้อและเป็นพิษตะกั่ว ผลิตภัณฑ์ด้านการวินิจฉัยของ Meridian ถูกใช้ภายนอกของร่างกายมนุษย์ และต้องใช้แค่อุปกรณ์พิเศษเล็กๆ น้อยๆ หรือไม่ต้องใช้เลย ผลิตภัณฑ์ด้านการวินิจฉัยของบริษัทฯ ได้รับการออกแบบ เพื่อเพิ่มพูนความเป็นอยู่ที่ดีของผู้ป่วยในขณะที่ลดละค่าใช้จ่ายรวมของการดูแลสุขภาพ Meridian มีสถานะทางการตลาดที่แข็งแกร่งในด้านการติดเชื้อระบบทางเดินหายใจ และระบบทางเดินอาหารส่วนบน และการทดสอบระดับสารตะกั่วในเลือด นอกจากนี้ Meridian ยังเป็นผู้จัดจำหน่ายน้ำยาชีวภาพพิเศษและส่วนประกอบที่หายากซึ่งใช้โดยองค์กรในด้านวิทยาศาสตร์เพื่อชีวิตและอุตสาหกรรมเกษตรกรรมเชิงชีวภาพ ที่มีส่วนร่วมในการทำวิจัยและโดยบริษัทซึ่งใช้เป็นส่วนประกอบในการผลิตของผลิตภัณฑ์ตรวจวินิจฉัยโรค บริษัทฯ ได้ทำการตลาดให้กับผลิตภัณฑ์และเทคโนโลยีสำหรับโรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์การวิจัย ผู้ผลิตวินิจฉัยและบริษัทเกษตรกรรมเชิงชีวภาพในกว่า 70 ประเทศทั่วโลก หุ้นของบริษัทฯ มีการซื้อขายในตลาด NASDAQ Global Select ในสัญลักษณ์ VIVO เว็บไซต์ของ Meridian คือ [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbwnq3LgnLFDesny4Kk63KIT8oNpK02NHa7tp7yeLWKlyHIc2wY7gVPpx6rGxGnKz967YwJ_KhPBZnCXTI8NSv497NisFLsQu1KvSw0pSb01Jx0v-g-SFrq7F7EinJBHesYgW9eul2mUDVaBxRxxHsk8Q7K8graArmyQIxlcCngP2iW-j4reMuo34E3N3RlD9bOSM8zeCH6F9ckD7wDf03X67Pd_Ysay9ahaXqbv3HJ1oPv_N60PD7wIU8aivhLjhNkNrO_ys4QOfkbQ8GLDN7mvN99vjWcLY4l2A_ZIBf1Z-4XorP6RHal3_4wSxiIv9BM= "www.meridianbioscience.com")
**สำหรับข้อมูลเพิ่มเติม:**
สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Bioline กรุณาเยี่ยมชม [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsM6n5pL3lk_y8BNyNs7tRFKc6ZQRI5t79NWOxvxqkvO35TlKcLLCP8V4IgWr-partk=).
```
```
---
### Contact Data
```
ติดต่อ:
Richard L. Eberly
ประธานและหัวหน้าเจ้าหน้าที่ฝ่ายพาณิชย์
Meridian Bioscience, Inc.
โทรศัพท์: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Launches New JetSeq™ DNA Library Preparation Kits](https://www.meridianbioscience.com/press-release/bioline-launches-new-jetseq-dna-library-preparation-kits/)
**Published:** February 8, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 08, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the JetSeq™ DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation.
Developed in collaboration with Oxford Gene Technology (OGT), the new JetSeq™ DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the preparation of the highest quality NGS sequencing-ready, adapter-ligated DNA for Illumina’s Next Generation Sequencers. A combination of end repair and A-tailing followed by direct ligation of customer supplied adapters, reduces clean-up steps and hands-on time; significantly improving the yield and quality of sequence-ready libraries, reducing the amount of DNA required. The new kits are supplied either with polymerase, for PCR amplification with lower starting material, or PCR-free kit where starting material is not limited.
Marco Calzavara, President of Bioline commented, “The release of the new JetSeq™ DNA Library Preparation Kits compliments the JetSeq™ kit that we launched just over a year ago, moving Bioline further into the NGS space. The kits build on our extensive knowledge in the creation of highly efficient enzymes and buffer formulation and give our customers even more choice in library preparation, allowing them to tackle even the most challenging samples with confidence, in this very fast moving field.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are excited about the release of the new JetSeq™ DNA Library Preparation Kits. This enhances our portfolio and gives a greater choice to our life science customers; allowing faster preparation, reducing time to results, and increases throughput. The development of the JetSeq™ family shows our commitment, not just to the continued development and expansion of products from Bioline, but also to our customers, giving them a greater choice of these high quality reagents.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=jBA1HTjho_YRZKrE8EEJvoIU40NhvpjFHhiJpzv-HYeujZZZ2_WzrRlIP_xpava556e-cZEBkrJdq3SSdpdefADZbWW0da3rPh8HjBTfazSoOaM7T1auu_XThiqQ94YeD8wB61eoEN1aFrSs8CWo5yV8gwhCk_bjdlceR8h_X7uNSPsB4O8eMpbXKWwjAg1JiWH7DqXYAa5i4wlS_MIP1IFH7lkuTOQoCRcSE1EsLuU_yEiZpardH5vJzII_FkAxqtKn9IJ38K-0pmhV9KIkER9xMC2b4jj2cuNoYg7uo_Bculz-Bseb79-Fj6nqP60hv8eRHLt_4yXUZC1PcifmN4VwM18HdkLsQMqc9YGfAGk= "www.meridianbioscience.com").
**For Additional information:**
For more information about Bioline, please visit [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=do478LOp5DUw3uhWJzZrJi1ykl-RFkr4qMZ1yPTg0AHkw-V2zSWukZeItXpNj3hDSZBBmZIdJtDIiibSPfut8y0wn1eQT7n5daAEIBAAo5g=).
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Mengumumkan Peluncuran Uji Cepat TruQuick™ untuk Asia Pasifik](https://www.meridianbioscience.com/press-release/meridian-bioscience-mengumumkan-peluncuran-uji-cepat-truquick-untuk-asia-pasifik/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan peluncuran TruQuick™, sebuah menu produk *point-of-care* komprehensif uji cepat untuk diagnosis penyakit tropis, menular, ditularkan secara seksual, saluran pernafasan, gastrointestinal, kanker, dan kardiak. Menu produk ini akan memudahkan Meridian untuk secara cepat mengembangkan portofolio produk uji cepat bernilai tinggi untuk pengoperasian komersialnya di Asia Pasifik dan pasar negara berkembang lain di seluruh dunia.
TruQuick™ adalah menu immunoassay kromatografi aliran samping kualitatif lebih dari 60 produk. Uji cepat TruQuick™ bisa membantu dalam diagnosis patogen menular dan penyakit akut utama lain dalam 10 sampai 20 menit dengan tingkat akurasi tinggi dan kecepatan hasil. Meridian memahami kebutuhan pengujian klinis di Asia dan pasar negara berkembang lain akan kecepatan, sensitivitas, kekhususan, dan keluasan lini produk.
Lourdes Weltzien, Ph.D., Presiden Meridian Asia Pacific berkomentar, “Kami bersemangat meluncurkan merek uji cepat TruQuick™ baru untuk pasar *point-of-care* yang bertumbuh pesat di region Asia Pasifik. Untuk region lain di dunia, Meridian akan segera memperkenalkan merek produk TruQuick™ berdasarkan permintaan regional dan prioritas pendaftaran.”
Richard L. Eberly, Presiden, Direktur Komersial, menerangkan, “Salah satu strategi kunci Meridian selama beberapa tahun belakangan adalah mengembangkan pengoperasian komersial global kami dalam pasar negara berkembang di seluruh dunia. Meridian telah mengembangkan pengoperasian di Tiongkok, Singapura, Australia, Afrika, dan Amerika Selatan. Portofolio produk untuk pasar-pasar negara berkembang ini berkembang pesat. Kami senang menambahkan merek produk *point-of-care* cepat TruQuick™ pada saluran komersial kami dalam pasar-pasar penting ini.”
**Tentang Meridian Bioscience, Inc.**
Meridian merupakan perusahaan ilmu hayati berintegrasi penuh yang mengembangkan, membuat, memasarkan, dan mendistribusikan berbagai kit uji diagnostik inovatif, reagen langka, produk biologis dan komponen spesial. Dengan menggunakan berbagai metode, uji diagnostik kami memberikan akurasi, kemudahan, dan kecepatan dalam diagnosis awal dan pengobatan kondisi medis umum, seperti infeksi dan keracunan timbal. Produk diagnostik Meridian digunakan di luar tubuh manusia dan hanya memerlukan sedikit peralatan khusus atau tidak sama sekali. Produk diagnostik Perusahaan dirancang untuk meningkatkan kesehatan pasien sambil mengurangi biaya perawatan kesehatan secara keseluruhan. Meridian memiliki posisi pasar yang kuat di bidang infeksi gastrointestinal dan saluran pernapasan atas dan pengujian kadar timbal dalam darah. Sebagai tambahan, Meridian adalah pemasok reagen langka, produk biologis dan komponen khusus yang digunakan oleh organisasi dalam industri ilmu hayati dan agribio yang terlibat dalam penelitian dan digunakan oleh perusahaan sebagai komponen dalam pembuatan diagnostik. Perusahaan memasarkan produk dan teknologinya ke rumah sakit, laboratorium rujukan, pusat penelitian, produsen diagnostik, dan perusahaan agribio di lebih dari 70 negara di seluruh dunia. Saham perusahaan diperdagangkan di NASDAQ Global Select Market dengan simbol VIVO. Alamat situs web Meridian adalah [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJLcTo8XHK5JqgEgM3yIQSVSRPxKeAXmRXk5KEw8IZHOezozgROFTonbay5CszADr678w2NIY9IatrjV31H_vDcRG2qNvuzB0sPCuux5NwuvMVC-98N1LNgwY5BvS9YbYPuyqIaho872YAO2nBvjoi-HGHMwvt9Yx4erbylwddgdWBLd-atlxigM040t9MakopG5yilMSp5jNPw_L9Wq1lgg7zewEcHgJtnei9inwHR6Q= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
KONTAK:
Richard L. Eberly
Presiden, Direktur Komersial
Meridian Bioscience, Inc.
Telepon: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience anuncia o lançamento dos testes rápidos TruQuick™ para a região Ásia-Pacífico](https://www.meridianbioscience.com/press-release/meridian-bioscience-anuncia-o-lancamento-dos-testes-rapidos-truquick-para-a-regiao-asia-pacifico/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 06, 2017 (GLOBE NEWSWIRE) — A Meridian Bioscience, Inc. (NASDAQ:VIVO) anunciou hoje o lançamento do TruQuick™, um menu compreensivo de produtos de testes rápidos para atendimento local capaz de diagnosticar doenças tropicais, infecciosas, sexualmente transmissíveis, respiratórias, gastrointestinais, cancerígenas e cardíacas. Esse menu de produtos possibilitará que a Meridian expanda rapidamente sua preciosa carteira de produtos de testes rápidos para suas operações comerciais na região Ásia-Pacífico e outros mercados emergentes em todo o mundo.
O TruQuick™ é um menu de imunoensaio cromatográfico do fluxo lateral qualitativo de mais de 60 produtos. Os testes rápidos TruQuick™ podem auxiliar no diagnóstico de patógenos infecciosos e outras doenças agudas em 10 ou 20 minutos com altos níveis de precisão e rapidez nos resultados. A Meridian conhece os requisitos de teste clínico na Ásia e em outros mercados emergentes para obter rapidez, sensibilidade, especificidade e amplitude da linha de produtos.
Lourdes Weltzien, Ph.D. e Presidente da Meridian Asia-Pacific, comentou: “Estamos entusiasmados em lançar a nova marca TruQuick™ de teste rápidos para os mercados de atendimento local em intenso crescimento na região Ásia-Pacífico. Já para as outras regiões do mundo, a Meridian logo irá apresentar a marca de produtos TruQuick™ com base em demandas regionais e prioridades de registros.”
Richard L. Eberly, Presidente e Diretor Comercial, declarou: “Uma das principais estratégias da Meridian nos últimos anos tem sido expandir nossas operações comerciais globais para os mercados emergentes no mundo todo. A Meridian expandiu operações na China, em Singapura, na Austrália, na África e na América do Sul. A carteira de produtos para esses mercados emergentes está se expandindo com rapidez. Estamos satisfeitos por somar a marca de produtos para rápido atendimento local TruQuick™ aos nossos canais comerciais nesses mercados.”
**Sobre a Meridian Bioscience, Inc.**
A Meridian é uma empresa de ciências da vida completamente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de kits inovadores de diagnóstico, reagentes raros, biológicos especializados e componentes. Utilizando uma variedade de métodos, nossos testes de diagnósticos oferecem precisão, simplicidade e velocidade em diagnóstico e tratamento precoces de condições clínicas comuns, como infecções e envenenamento por chumbo. Os produtos de diagnóstico da Meridian são usados fora do corpo humano e requerem pouco ou nenhum equipamento especial. Os produtos de diagnóstico da Empresa são projetados para aumentar o bem-estar do paciente ao mesmo tempo em que reduzem os custos com cuidados da saúde. A Meridian possui posições fortes no mercado nas áreas de infecções gastrointestinais e respiratórias superiores e análises do nível de chumbo no sangue. Além disso, a Meridian é fornecedora de reagentes raros, biológicos especializados e componentes utilizados por organizações de ciências da vida e indústrias bioagrícolas dedicadas à pesquisa e por empresas como componentes na produção de diagnósticos. A Empresa comercializa seus produtos e tecnologias com hospitais, laboratórios de referência, centros de pesquisa, fabricantes de diagnóstico e empresas bioagrícolas em mais de 70 países. As ações da Empresa são negociadas no Global Select Market da NASDAQ com o símbolo VIVO. O site da Meridian é [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJrIxbrEeo9e61shwlIPz13RrYPIndciF8iQZnYwN0dzmi-MFmPGha8HEOhkYGE1f3kPeAjemy5Ubd2Nh5q-XFC6wiSW9zzdo_Ez5v1lMNeAvBWDybPeCDTM9SuTiIm7wIctBZoTHXfVWcxzFnmmC0L6ze0L6yIBJS4S4BPMRT6mEnp7PUOwVIqcPjkS4bQvI5ZLzE4IoW2djkHwB01EwUcrJKhNzV9F3UYouWHQ7YUuE= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
CONTATO:
Richard L. Eberly
Presidente e Diretor Comercial
Meridian Bioscience, Inc.
Telefone: 513 271 3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Mengumumkan Pelancaran Ujian Pantas TruQuick™ bagi Asia Pasifik](https://www.meridianbioscience.com/press-release/meridian-bioscience-mengumumkan-pelancaran-ujian-pantas-truquick-bagi-asia-pasifik/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan pelancaran TruQuick™, iaitu menu produk titik penjagaan yang menyeluruh bagi ujian pantas untuk diagnosis penyakit tropika, berjangkit, kelamin, pernafasan, gastrousus, kanser dan penyakit jantung. Menu produk ini akan membolehkan Meridian meluaskan portfolio produk ujian pesat nilai tingginya untuk operasi komersial di Asia Pasifik dan pasaran baru lain di seluruh dunia.
TruQuick™ adalah menu immunoassay kualitatif aliran sisi kromatografi yang melebihi 60 produk. Ujian pantas TruQuick™ boleh membantu dalam keputusan diagnosis patogen berjangkit dan penyakit akut penting dalam masa 10 hingga 20 minit dengan tahap ketepatan dan kelajuan yang tinggi. Meridian memahami keperluan ujian klinikal di Asia dan pasaran lain yang baru untuk kelajuan, kepekaan, kekhususan dan keluasan barisan produk.
Lourdes Weltzien, Ph.D., Presiden Meridian Asia Pasifik berkata, “Kami teruja untuk melancarkan jenama ujian pantas baru TruQuick™ untuk pasaran titik penjagaan yang pesat berkembang di rantau Asia Pasifik. Bagi kawasan-kawasan lain di dunia, Meridian akan memperkenalkan jenama produk TruQuick™ dengan pantas berdasarkan permintaan serantau dan keutamaan pendaftaran. “
Richard L. Eberly, Presiden, Ketua Pegawai Komersial, menyatakan, “Salah satu strategi utama Meridian sejak beberapa tahun kebelakangan ini adalah untuk meluaskan operasi komersial global kami dalam pasaran baru di seluruh dunia. Meridian telah meluaskan operasinya ke China, Singapura, Australia, Afrika dan Amerika Selatan. Portfolio produk untuk pasaran-pasaran baru sedang berkembang pesat. Kami gembira untuk menambah jenama produk titik penjagaan TruQuick™ yang pesat kepada saluran perdagangan kita di pasaran yang penting.”
**Mengenai Meridian Bioscience, Inc.**
Meridian ialah syarikat sains hayat berintegrasi penuh yang membangunkan, mengilangkan, memasarkan dan mengedar pelbagai jenis kit ujian diagnostik yang inovatif, reagen nadir, teknologi dan komponen biologi khusus. Dengan menggunakan pelbagai kaedah, produk dan ujian diagnostik kami ini dapat menyediakan ketepatan, keringkasan dan kepantasan apabila mendiagnosis secara awal dan merawat keadaan perubatan biasa seperti jangkitan dan peracunan plumbum. Produk diagnostik Meridian digunakan di luar tubuh manusia dan memerlukan sedikit atau tiada peralatan khas. Produk diagnostik Syarikat ini direka bentuk bagi meningkatkan kesejahteraan pesakit di samping mengurangkan jumlah kos penjagaan kesihatan. Meridian mempunyai kedudukan pasaran yang kukuh dalam bidang jangkitan gastrousus dan pernafasan bahagian atas serta ujian tahap plumbum dalam darah. Di samping itu, Meridian ialah pembekal reagen nadir, teknologi dan komponen biologi khusus yang digunakan dalam industri sains hayat dan agrobiologi yang melibatkan kajian dan oleh syarikat sebagai komponen dalam pembuatan diagnosis. Syarikat memasarkan produk dan teknologinya kepada hospital, makmal rujukan, pusat penyelidikan, pengilang diagnostik dan syarikat agribio di lebih daripada 70 buah negara di seluruh dunia. Saham Syarikat ini diniagakan dalam NASDAQ Global Select Market, simbol VIVO. Alamat laman web Meridian ialah [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJLcTo8XHK5JqgEgM3yIQSVSRPxKeAXmRXk5KEw8IZHOezozgROFTonbay5CszADr678w2NIY9IatrjV31H_vDcRG2qNvuzB0sPCuux5NwuvMVC-98N1LNgwY5BvS9YbYPuyqIaho872YAO2nBvjoi-HGHMwvt9Yx4erbylwddgdWBLd-atlxigM040t9MakopG5yilMSp5jNPw_L9Wq1lgg7zewEcHgJtnei9inwHR6Q= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
MAKLUMAT HUBUNGAN:
Richard L. Eberly
Presiden, Ketua Pegawai Komersial
Meridian Bioscience, Inc.
Telefon: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience anuncia el lanzamiento de las pruebas rápidas TruQuick™ para la región Asía-Pacífico](https://www.meridianbioscience.com/press-release/meridian-bioscience-anuncia-el-lanzamiento-de-las-pruebas-rapidas-truquick-para-la-region-asia-pacifico/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) ha anunciado hoy el lanzamiento de TruQuick™, una completa gama de productos de diagnóstico en puntos de atención de pruebas rápidas para el diagnóstico de enfermedades tropicales, infecciosas, de transmisión sexual, respiratorias, gastrointestinales, cardíacas y cáncer. Esta gama de productos permitirá a Meridian ampliar rápidamente su cartera de productos de pruebas rápidas de alto valor para sus operaciones comerciales en la región Asia-Pacífico y otros mercados emergentes de todo el mundo.
TruQuick™ es una gama de inmuno-ensayo cromatográfico de flujo lateral de detección cualitativa de más de 60 productos. Las pruebas rápidas TruQuick™ pueden ayudar en el diagnóstico de patógenos infecciosos y otras enfermedades agudas importantes en 10 a 20 minutos con altos niveles de exactitud y velocidad en los resultados. Meridian entiende las necesidades de las pruebas clínicas en Asia y otros mercados emergentes por la velocidad, sensibilidad, especificidad y amplitud de la línea de productos.
“Estamos muy contentos de lanzar la nueva marca TruQuick™ de pruebas rápidas destinada al mercado de diagnóstico en los puntos de atención de la región de Asia-Pacífico que está experimentando un rápido crecimiento”, comentó la Doctora Lourdes Weltzien, Presidenta de Meridian Asia Pacific. “Al igual que en otras regiones del mundo, Meridian introducirá rápidamente la marca de productos TruQuick™ sobre la base de las demandas regionales y las prioridades de registro”.
“Una de las estrategias clave de Meridian en los últimos años ha sido expandir nuestras operaciones comerciales globales en los mercados emergentes de todo el mundo”, ha declarado Richard L. Eberly, Presidente y Director Comercial. “Meridian ha extendido sus operaciones a China, Singapur, Australia, África y Sudamérica. La cartera de productos para estos mercados emergentes se está ampliando rápidamente. Estamos encantados de agregar la marca TruQuick ™ de productos de diagnóstico urgente en el punto de atención a nuestros canales comerciales en estos importantes mercados”.
**Acerca de Meridian Bioscience, Inc.**
Meridian es una compañía de ciencias biológicas totalmente integrada que desarrolla, fabrica, comercializa y distribuye una amplia gama de pruebas de diagnóstico innovadoras, reactivos poco frecuentes y productos biológicos y componentes especializados. Con el uso de una variedad de métodos, nuestras pruebas de diagnóstico brindan precisión, simplicidad y velocidad en el diagnóstico y el tratamiento temprano de afecciones médicas comunes, como infecciones e intoxicación por plomo. Los productos de diagnóstico de Meridian se usan fuera del cuerpo humano y prácticamente no requieren de equipos especiales. Los productos de diagnóstico de la Compañía están diseñados para mejorar el bienestar del paciente y reducir al mismo tiempo los costos totales de la atención médica. Meridian tiene una sólida posición de mercado en áreas de diagnóstico de infecciones de las vías respiratorias superiores y gastrointestinales, y en pruebas de nivel de plomo en sangre. Además, Meridian provee reactivos poco frecuentes, productos biológicos especiales y componentes utilizados por las organizaciones de la industria de productos biológicos y agricultura biológica que realizan investigaciones, así como por compañías dedicadas a componentes para la fabricación de productos de diagnóstico. La Compañía comercializa sus productos y tecnología a hospitales, laboratorios de referencia, centros de investigación, fabricantes de productos de diagnóstico y compañías de agricultura biológica en más de 70 países de todo el mundo. Las acciones de la Compañía cotizan en el NASDAQ Global Select Market, símbolo VIVO. La página web de Meridian es [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJLcTo8XHK5JqgEgM3yIQSVSRPxKeAXmRXk5KEw8IZHOezozgROFTonbay5CszADr678w2NIY9IatrjV31H_vDcRG2qNvuzB0sPCuux5NwuvMVC-98N1LNgwY5BvS9YbYPuyqIaho872YAO2nBvjoi-HGHMwvt9Yx4erbylwddgdWBLd-atlxigM040t9MakopG5yilMSp5jNPw_L9Wq1lgg7zewEcHgJtnei9inwHR6Q= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
CONTACTO:
Richard L. Eberly
Presidente, Director Comercial
Meridian Bioscience, Inc.
Teléfono: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [メリディアン･バイオサイエンス、アジア太平洋地域向けに「トゥルークイック (TruQuick™) 」高速検査の発売を発表](https://www.meridianbioscience.com/press-release/メリディアン･バイオサイエンス、アジア太平洋/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
シンシナティ発, Feb. 07, 2017 (GLOBE NEWSWIRE) — メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ:VIVO) は本日、熱帯病、感染症、性病、呼吸器系疾患、消化器系疾患、癌、心臓病の診断用の臨床現場向け包括的高速検査ライン、「トゥルークイック (TruQuick™) 」の発売を発表した。この製品ラインの導入により、アジア太平洋地域および世界中の新興市場において、重要な高速検査用製品ポートフォリオを急速に拡張することができる。
トゥルークイックは、60種以上の製品で構成される、定量的ラテラルフロー･クロマトグラフィー･イムノアッセイ製品ラインである。トゥルークイック高速検査は、感染性の病原体およびその他の重要な急性疾患を、10～20分以内に高精度で診断できる。メリディアンでは、アジアおよびその他の新興市場における、臨床検査のスピード、感応度、特定性、製品ラインの網羅性に対する需要について理解している。
メリディアン･アジア･パシフィック担当プレジデント、ローデス･ウェルツィエン博士 (Dr. Lourdes Weltzien) は次のように述べている。「アジア太平洋地域で急速に成長中の臨床現場向けに、新しいトゥルークイック･ブランドの高速検査をローンチできることを大変嬉しく思っています。世界の他地域でも、地域の需要や登録の優先度に合わせてトゥルークイック･ブランドの製品を速やかに導入していきます。」
社長兼最高商務責任者、リチャード･L･エバリー (Richard L. Eberly) は次のように述べている。「過去数年間にわたり、メリディアンの戦略では、世界中の新興市場においてグローバルな商業活動を繰り広げていくことを重視してきました。中国、シンガポール、オーストラリア、アフリカ、南米で事業を拡張しています。これらの新興市場向け製品ポートフォリオは急速に拡張中です。トゥルークイック･ブランドの臨床現場向け高速検査製品を、これらの重要な市場における事業チャネルに追加できたことをたいへん嬉しく思っています。」
**メリディアン･バイオサイエンス** **(Meridian Bioscience, Inc.) について**
メリディアンは、多様な革新的診断テストキット、希少試薬、特殊バイオ製品、コンポーネントの開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス企業である。同社の診断検査は、多様な方法を駆使して、感染症、鉛中毒などのよくある疾患の早期診断と治療のために、高精度、単純性、スピードを実現している。メリディアンの診断用製品は人体外で使用する製品であり、専門的装置はほとんど必要ないか、全く不要である。同社の診断用製品は患者の心身の健康を強化し、同時に医療の合計結果コストを削減するよう設計されている。同社では消化器系･呼吸器系上部の感染症および血中鉛濃度の診断分野で強力な市場地位を確保している。さらに、ライフサイエンスおよび農業バイオ業界の研究機関や、診断用製品の製造用コンポーネントとして、企業などに希少試薬や特殊バイオ製品、コンポーネントを供給している。同社は世界中70ヶ国以上の病院、基準検査機関、リサーチセンター、診断用製品メーカー、農業バイオ企業にもその製品とテクノロジーを販売している。同社の株式はナスダックのグローバル･セレクト･マーケットでシンボル「VIVO」で取引されている。メリディアンのウェブサイトは以下のとおりである。[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_eIxzh-BymfZruxWlcqMRn1kU-V8xctLzAlJ0WKKNKSApfTb4kghiA0NZmdlyHTRnJrIxbrEeo9e61shwlIPz13RrYPIndciF8iQZnYwN0dzmi-MFmPGha8HEOhkYGE1f3kPeAjemy5Ubd2Nh5q-XFC6wiSW9zzdo_Ez5v1lMNeAvBWDybPeCDTM9SuTiIm7wIctBZoTHXfVWcxzFnmmC0L6ze0L6yIBJS4S4BPMRT6mEnp7PUOwVIqcPjkS4bQvI5ZLzE4IoW2djkHwB01EwUcrJKhNzV9F3UYouWHQ7YUuE= "www.meridianbioscience.com")
```
```
---
### Contact Data
```
問い合わせ先：
リチャード･L･エバリー (Richard L. Eberly)
社長、最高商務責任者 (President, Chief Commercial Officer)
Meridian Bioscience, Inc.
電話：513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience เปิดตัวชุดทดสอบ TruQuick™ สำหรับเอเชียแปซิฟิก](https://www.meridianbioscience.com/press-release/meridian-bioscience-เปิดตัวชุดทดสอบ-truquick-สำ/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) วันนี้ได้ประกาศการเปิดตัว TruQuick™ ซึ่งเป็นชุดทดสอบ ณ จุดดูแลผู้ป่วยที่ครอบคลุมสำหรับการตรวจวิเคราะห์โรคเขตร้อน โรคติดเชื้อ โรคติดต่อทางเพศสัมพันธ์ โรคระบบทางเดินหายใจ โรคระบบทางเดินอาหาร โรคมะเร็งและโรคหัวใจ เมนูสินค้านี้จะช่วยให้ Meridian สามารถขยายรายการผลิตภัณฑ์ชุดทดสอบที่มีมูลค่าสูงสำหรับการดำเนินงานในเชิงพาณิชย์อย่างรวดเร็วในภูมิภาคเอเชียแปซิฟิกและตลาดเกิดใหม่อื่นๆ ทั่วโลก
TruQuick™ เป็นรายการชุดทดสอบรวดเร็ววิธีอิมมูโนแอสเสย์โครมาโทกราฟีแบบการไหลแลเทอรอลเชิงคุณภาพ ชุดทดสอบรวดเร็ว TruQuick™ สามารถช่วยในการวินิจฉัยโรคของเชื้อโรคและโรคติดเชื้อเฉียบพลันอื่นๆ ที่สำคัญภายใน 10 ถึง 20 นาทีด้วยความแม่นยำสูงและรวดเร็วในการอ่านผล Meridian เข้าใจความต้องการสำหรับการทดสอบทางคลินิกในเอเชียและตลาดเกิดใหม่อื่นๆ สำหรับความรวดเร็ว ความไว ความจำเพาะและความกว้างของสายผลิตภัณฑ์
Lourdes Weltzien, Ph.D. ประธานของ Meridian Asia Pacific กล่าวว่า “เรารู้สึกตื่นเต้นที่จะเปิดตัวชุดทดสอบอย่างรวดเร็วแบรนด์ใหม่ TruQuick™ สำหรับตลาด ณ จุดดูแลผู้ป่วย (point-of-care) ในภูมิภาคเอเชียแปซิฟิกที่มีการเติบโตอย่างรวดเร็ว ส่วนภูมิภาคอื่นๆ ของโลก Meridian จะแนะนำผลิตภัณฑ์แบรนด์ TruQuick™ โดยดูจากความต้องการในระดับภูมิภาคและลำดับความสำคัญของการลงทะเบียน”
Richard L. Eberly ประธาน หัวหน้าฝ่ายการค้ากล่าวว่า “หนึ่งในกลยุทธ์ที่สำคัญของ Meridian ในช่วงปีที่ผ่านมาคือการขยายการดำเนินงานในเชิงพาณิชย์ทั่วโลกของเราในตลาดเกิดใหม่รอบโลก Meridian ได้ขยายการดำเนินงานในประเทศจีน สิงคโปร์ ออสเตรเลีย แอฟริกาและอเมริกาใต้ กลุ่มผลิตภัณฑ์สำหรับตลาดเกิดใหม่เหล่านี้กำลังขยายตัวอย่างรวดเร็ว เรามีความยินดีที่จะเพิ่มผลิตภัณฑ์ชุดทดสอบอย่างรวดเร็ว ณ จุดดูแลผู้ป่วยแบรนด์ TruQuick™ มายังช่องทางการค้าของเราในตลาดที่สำคัญเหล่านี้”
**เกี่ยวกับ** **Meridian Bioscience, Inc.**
**Meridian เป็นบริษัทด้านชีววิทยาศาสตร์แบบครบวงจรที่พัฒนา ผลิต ทำการตลาดและจัดจำหน่ายนวัตกรรมชุดตรวจวินิจฉัย การทดสอบสารเคมีที่หายาก ชีวภาพพิเศษและผลิตภัณฑ์ที่เกี่ยวข้อง ผลิตภัณฑ์และชุดทดสอบวินิจฉัยเหล่านี้จึงให้ความแม่นยำ ความง่ายและความรวดเร็วในการวินิจฉัยแต่เนิ่นๆ และการรักษาภาวะทางการแพทย์ทั่วไป เช่น การติดเชื้อ และเป็นพิษตะกั่ว ผลิตภัณฑ์ด้านการวินิจฉัยของ Meridian ถูกใช้ภายนอกของร่างกายมนุษย์ และต้องใช้แค่อุปกรณ์พิเศษเล็กๆ น้อยๆ หรือ ไม่ต้องใช้เลย ผลิตภัณฑ์ด้านการวินิจฉัยของบริษัทฯ ได้รับการออกแบบ เพื่อเพิ่มพูนความเป็นอยู่ที่ดีของผู้ป่วยในขณะที่ลดละค่าใช้จ่ายรวมของการดูแลสุขภาพ Meridian มีสถานะทางการตลาดที่แข็งแกร่งในด้านการติดเชื้อระบบทางเดินหายใจ และระบบทางเดินอาหารส่วนบน และการทดสอบระดับสารตะกั่วในเลือด นอกจากนี้ Meridian ยังเป็นผู้จัดจำหน่ายน้ำยาชีวภาพพิเศษและส่วนประกอบที่หายากซึ่งใช้โดยองค์กรในด้านวิทยาศาสตร์เพื่อชีวิตและอุตสาหกรรมเกษตรกรรมเชิงชีวภาพ ที่มีส่วนร่วมในการทำวิจัยและโดยบริษัทซึ่งใช้เป็นส่วนประกอบในการผลิตของผลิตภัณฑ์ตรวจวินิจฉัยโรค บริษัทฯ ได้ทำการตลาดให้กับผลิตภัณฑ์และเทคโนโลยีสำหรับโรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์การวิจัย ผู้ผลิตวินิจฉัยและบริษัทเกษตรกรรมเชิงชีวภาพในกว่า 70 ประเทศทั่วโลก หุ้นของบริษัทฯ มีการซื้อขายในตลาด Global Select ของ NASDAQ** **ในสัญลักษณ์ VIVO เว็บไซต์ของ Meridian คือ www.meridianbioscience.com**
```
```
---
### Contact Data
```
ติดต่อ:
Richard L. Eberly
ประธาน หัวหน้าฝ่ายการค้า
Meridian Bioscience, Inc.
โทรศัพท์: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [메리디안 바이오사이언스, 아태지역 겨냥한 신속진단 제품 브랜드 TruQuick™ 출시](https://www.meridianbioscience.com/press-release/메리디안-바이오사이언스-아태지역-겨냥한-신속진/)
**Published:** February 6, 2017
**Author:** hamza
**Content:**
미국 신시내티, Feb. 07, 2017 (GLOBE NEWSWIRE) — 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(나스닥 거래명: VIVO)가 복합 현장진단 제품인 TruQuick™을 출시했다. 본 솔루션은 열대성, 전염성, 성매개감염, 호흡기, 소화기, 암 및 심장 질환의 신속 진단을 목적으로 한다. 메르디안은 본 솔루션을 통해 아태지역을 비롯한 신흥 시장 내 판매를 위한 고부가가치 신속진단 테스트 포트폴리오를 확대할 것이다.
TruQuick™은 정성분석 방식으로 60개 이상의 측방유동 면역 크로마토그래피 검사로 구성되어 있다. TruQuick™의 신속 진단은 전염성 병원균을 비롯해 주요 급성질환에 대한 진단을 10~20분 내에 끝낼 수 있으며 정확도가 높고 빠른 결과 도출이 가능하다. 메리디안은 아시아와 기타 신흥시장 내에서 속도, 민감성, 특수성, 풍부한 제품군을 갖춘 임상시험에 대한 수요에 대응해 본 솔루션을 내놓게 되었다.
루즈 웰친(Lourdes Weltzien) 메리디안 아태지사장은 “급성장세에 있는 아태지역 현장진단 시장에 새로운 신속진단 브랜드인 TruQuick™를 출시하게 되어 기쁘다. 메리디안은 앞으로 다른 지역에서도 현지 수요와 당국의 허가 빈도를 고려해 TruQuick™ 제품군을 신속히 내놓을 계획에 있다”고 말했다.
리처드 E. 에벌리(Richard L. Eberly) 메리디안 사장 겸 최고영업책임자는 “최근 몇 년간 메리디안의 핵심 경영 전략 중 하나는 신흥시장에 대한 영업 역량 확대였으며 이에 중국, 싱가포르, 호주, 아프리카, 남미 지역으로 영업 범위를 넓혀 왔다. 또한 이들 신흥 시장을 겨냥한 제품 포트폴리오 역시 빠르게 늘리고 있다. 신속, 현장진단 제품 브랜드인 TruQuick™ 출시를 통해 신흥 시장에 공급할 제품 범위를 확대하게 되어 기쁘다”고 밝혔다.
**메리디안** **바이오사이언스(Meridian Bioscience, Inc.) 소개**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다. 당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SGDRglI43HRZiCBo0aGD1F-mhbZlFEs_7SBtf0ltl2LB6lK4VhDIpr8VtE3yCd_ehWf7SPab2K9Q9qLJS7t002N5tlD7QHUgMsQ91PUnyRCBlIUU02U2EOMh6PUrscODGUZdCKAh-8sasOts53tUb-jg0Og59Cwi8uT6KIwnvn1w8w22xKvK49pUDqOR0IaRZYtHwrvUXzkwesuIFmWWbhG-3gb6VeGYVSjl0DScD4fa-yvI75e-2v0Xn-LqpES7Vgk0MXJyB9iSOqY7pVbCwldaL3bIS_tBg4_JqBMEDBVa_GQ9txJAwjKKC8Oqic-e4zCbCN-auDoOGy_uGl3pO02F2ZMiukaIx1iLGBY3wiV6wL21DBSBBA1HkgmzMSchiphhJrj-_-7Iy21ZZDOvggHmzXcH5NMAPxgPX-4WFWNHougELzVc2MxT4LY9NH96tiSWRLr7cMfcdDXUI19UCu-xM1cDcEFUcgPy6tToNIouSjW99NEhAB86FxsJcpnXMhF2qmCp3_pGo8eRLpT5oCT-74KWCyGxaJ2x9SEHTGiS_r8nh5vzOXUXy820zvxxL7Hb2GTyO78QgHkSbAFrY0_EBMcMYK8S4WtOhA9H8lo= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
연락처:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出新型JetSeq™ DNA建庫試劑盒](https://www.meridianbioscience.com/press-release/bioline推出新型jetseq-dna建庫試劑盒/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
辛辛那提, Feb. 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc.（納斯達克代號：VIVO）的全資中國附屬公司Bioline今日宣佈，擴充用於下一代測序(NGS)樣本製備的JetSeq™ DNA建庫試劑盒的產品組合。
透過與牛津基因技術公司(OGT)的合作研發，新型JetSeq™DNA建庫試劑盒使用預先優化的緩衝系統，提供最大的反應效率及最高的轉化率，從而能夠製備最高質量的NGS序列準備、適配器連接的DNA文庫，用於Illumina的下一代測序。終端修復結合進行A尾端添加，隨後直接與客戶提供的適配器連接，減少清理步驟及操作時間，大大提高序列準備文庫的產量及質量，降低所需DNA的數量。新型試劑盒與聚合酶（用於對原始材料數量要求低的PCR擴增）或PCR-free試劑盒（對原始材料並無限制）一同提供。
Bioline總裁Marco Calzavara表示：「新型JetSeq™ DNA建庫試劑盒的推出擴充了我們一年前剛剛推出的JetSeq™試劑盒，推動Bioline在NGS領域的發展更進一步。新型試劑盒建基於我們對創造高效聚合酶及緩衝液配方知識的深入了解，為我們的客戶在文庫製備過程中提供更多選擇，使他們在這個快速變化的領域，即使面對最具挑戰性的樣本，也有信心對其進行處理。」
總裁兼首席商務官Richard L. Eberly表示：「我們很高興推出新型JetSeq™ DNA 建庫試劑盒。這增強了我們的產品組合，亦為我們的生命科學客戶提供更多的選擇，製備速度更快、結果呈現所需時間更短，並提高了產量。JetSeq™系列的擴充，表明我們不僅堅守持續開發及擴充Bioline提供的產品的承諾，亦體現我們對客戶的承諾，為他們提供更多高質量試劑的選擇。」
**關於Meridian Bioscience, Inc.**
Meridian為一家綜合生命科學公司，負責開發、生產、營銷及分銷各類新型診斷檢測試劑盒、稀有試劑以及特殊生物製劑和成份。我們的診斷測試方式多樣，於早期診斷和傳染病、鉛中毒等常見疾病治療過程具有準確性高、簡易及快速的優點。Meridian的診斷產品於人體外使用，只需極少或無需特殊設備。本公司的診斷產品旨在於改善病人健康的同時降低醫療保健的總成本。Meridian在胃腸及上呼吸道感染、血鉛水平檢測領域佔據重要的市場地位。此外，Meridian亦向從事研究的生命科學及農業生物技術行業的機構及製造診斷產品的公司，供應稀有試劑、特殊生物製劑及成份。本公司向全球逾70個國家的醫院、參考實驗室、研究中心、診斷產品製造商及農業生物技術公司銷售其產品和技術。本公司股份於納斯達克Global Select Market交易，代號為VIVO。Meridian公司網址為[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbwnq3LgnLFDesny4Kk63KIT8oNpK02NHa7tp7yeLWKlyHIc2wY7gVPpx6rGxGnKz967YwJ_KhPBZnCXTI8NSv497NisFLsQu1KvSw0pSb01Jx0v-g-SFrq7F7EinJBHesYgW9eul2mUDVaBxRxxHsk8Q7K8graArmyQIxlcCngP2iW-j4reMuo34E3N3RlD9bOSM8zeCH6F9ckD7wDf03X67Pd_Ysay9ahaXqbv3HJ1oPv_N60PD7wIU8aivhLjhNkNrO_ys4QOfkbQ8GLDN7mvN99vjWcLY4l2A_ZIBf1Z-4XorP6RHal3_4wSxiIv9BM= "www.meridianbioscience.com")。
**更多資訊：**
欲了解關於Bioline的更多資訊，請訪問[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsPAiGczYD7UCdsRHU8WNtlLGW-1Tk1DqOKOXEn0CkKV6CGoRB80WjPa-d_GEDgierE=)。
```
```
---
### Contact Data
```
聯絡方式：
Richard L. Eberly
總裁兼首席商務官
Meridian Bioscience, Inc.
電話：513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline lança novos kits de preparação de biblioteca de DNA JetSeq™](https://www.meridianbioscience.com/press-release/bioline-lanca-novos-kits-de-preparacao-de-biblioteca-de-dna-jetseq/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 09, 2017 (GLOBE NEWSWIRE) — A Bioline, empresa de RCT, subsidiária integral da Meridian Bioscience, Inc. (NASDAQ:VIVO), anunciou hoje a expansão da carteira de preparação de biblioteca de DNA JetSeq™ para preparação de amostras de sequenciação de última geração (NGS, em inglês).
Desenvolvidos em colaboração com a Oxford Gene Technology (OGT), os novos kits de preparação de biblioteca de DNA JetSeq™ utilizam tampões pré-otimizados para proporcionar uma máxima eficiência de reação e as mais altas taxas de conversão, possibilitando a preparação de DNAs ligados a adaptadores e prontos para sequenciação NGS para os sequenciadores de última geração da Illumina. Uma combinação de reparo de terminal e resíduo-A, seguida da ligação direta dos adaptadores fornecidos do cliente, reduz o número de etapas de limpeza e o tempo de manipulação, melhorando significativamente a rentabilidade e qualidade das bibliotecas prontas para sequenciar, o que reduz a quantidade de DNA necessária. Os novos kits são fornecidos com polimerase, para amplificação de RCT com matérias-primas mais reduzidas, ou kits livres de RCT, nos quais as matérias-primas não têm limitações.
Marco Calzavara, Presidente da Bioline, comentou: “O lançamento dos novos kits de preparação de biblioteca de DNA JetSeq™ enaltece o conjunto JetSeq™ que lançamos há apenas um ano, fazendo com que a Bioline avance mais no espaço NGS. Os kits baseiam-se em nosso amplo conhecimento em criação de enzimas altamente eficientes e formulação de tampões e dá aos nossos clientes ainda mais escolhas em preparação de bibliotecas, permitindo que eles tratem com confiança até mesmo as amostras mais desafiadoras nesse campo tão dinâmico.”
Richard L. Eberly, Presidente e Diretor Comercial, declarou: “Estamos entusiasmados com o lançamento dos novos kits de preparação de biblioteca de DNA JetSeq™. Isso reforça nossa carteira e dá aos nossos clientes de ciências da vida uma melhor opção, permitindo preparações mais rápidas e reduzindo o tempo para obter resultados, além de aumentar a produtividade. O desenvolvimento da família JetSeq™ mostra nosso compromisso não apenas com o desenvolvimento contínuo e a expansão dos produtos da Bioline, mas também com nossos clientes, oferecendo-lhes uma melhor alternativa para esses reagentes de alta qualidade.”
**Sobre a Meridian Bioscience, Inc.**
A Meridian é uma empresa de ciências da vida completamente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de kits inovadores de diagnóstico, reagentes raros, biológicos especializados e componentes. Utilizando uma variedade de métodos, nossos testes de diagnósticos oferecem precisão, simplicidade e velocidade em diagnóstico e tratamento precoces de condições clínicas comuns, como infecções e envenenamento por chumbo. Os produtos de diagnóstico da Meridian são usados fora do corpo humano e requerem pouco ou nenhum equipamento especial. Os produtos de diagnóstico da Empresa são projetados para aumentar o bem-estar do paciente ao mesmo tempo em que reduzem os custos com cuidados da saúde. A Meridian possui posições fortes no mercado nas áreas de infecções gastrointestinais e respiratórias superiores e análises do nível de chumbo no sangue. Além disso, a Meridian é fornecedora de reagentes raros, biológicos especializados e componentes utilizados por organizações de ciências da vida e indústrias bioagrícolas dedicadas à pesquisa e por empresas como componentes na produção de diagnósticos. A Empresa comercializa seus produtos e tecnologias com hospitais, laboratórios de referência, centros de pesquisa, fabricantes de diagnóstico e empresas bioagrícolas em mais de 70 países. As ações da Empresa são negociadas no Global Select Market da NASDAQ com o símbolo VIVO. O site da Meridian é [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbw1dOL7XGGkMRFAXf6PBmxpR4TGv8xQqwHip6PvsjBtnj4oaHvx7XJ9PjuGpALVs-qEkMl9AQ5RR3Jz3xu6paYJkAUL7oLZXTEtJroUfM-vsqSRbgIug8GN4GGNUGNqvZegdxxsmNF0ZyyYAt0vWFMl-xaaFza3MWcVGXWWXlNhLX8O9Fi_M0WRtG6q3cRKrMsVjP992zPfsV--_j0wLU1B8lxO-z7pndT_X2yo95rwzhMrbRDxOsADOB5w8xDK3HMIxXbdvBnN49scuNLIrnHf8sVmJs0dTKC6JiW2NL_oicyO7gok6BsTWx5zydMT2Ao= "www.meridianbioscience.com").
**Para informações adicionais:**
Para obter mais informações sobre a Bioline, acesse [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsN4YntoAqNQjH03PBH97rKlAcAYm_uq2xCYt-EMfF_hq6v43_rJCBJcZTRkCNXhL-0=).
```
```
---
### Contact Data
```
CONTATO:
Richard L. Eberly
Presidente e Diretor Comercial
Meridian Bioscience, Inc.
Telefone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Merilis Kit Preparasi Pustaka DNA JetSeq™ Baru](https://www.meridianbioscience.com/press-release/bioline-merilis-kit-preparasi-pustaka-dna-jetseq-baru/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 10, 2017 (GLOBE NEWSWIRE) — Bioline, Perusahaan PCR, anak perusahaan yang dimiliki sepenuhnya oleh Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan perluasan portofolio Preparasi Pustaka DNA JetSeq™ untuk preparasi sampel Pengurutan Generasi Berikutnya (*Next Generation Sequencing*/NGS).
Dikembangkan dalam kolaborasi dengan Oxford Gene Technology (OGT), Kit Preparasi Pustaka DNA JetSeq™ yang baru menggunakan bufer yang dioptimalkan sebelumnya untuk memberikan efisiensi reaksi maksimal dan laju konversi yang paling tinggi, memungkinkan preparasi pengurutan NGS cepat dengan kualitas paling tinggi, DNA terligasi adaptor untuk Pengurut Generasi Berikutnya milik Illumina. Kombinasi perbaikan ujung dan *A-tailing* diikuti dengan ligasi langsung adaptor yang disediakan oleh konsumen, mengurangi tahap pembersihan dan penanganan tepat waktu; secara signifikan meningkatkan hasil dan kualitas pustaka pengurutan cepat, mengurangi jumlah DNA yang diperlukan. Kit baru disediakan baik dengan polimerase, untuk amplifikasi PCR dengan bahan awal yang lebih sedikit, maupun kit bebas PCR dengan bahan awal yang tidak terbatas.
Marco Calzavara, President Bioline berkomentar, “Rilis Kit Preparasi Pustaka DNA JetSeq™ yang baru melengkapi kit JetSeq™ yang baru saja kita rilis setahun yang lalu, membuat Bioline bergerak lebih lanjut ke bidang NGS. Kit dibentuk atas pengetahuan luas kami dalam penciptaan formulasi bufer dan enzim yang sangat efisien dan memberikan konsumen kami lebih banyak pilihan dalam preparasi pustaka, memungkinkan mereka untuk menyelesaikan sampel yang paling menantang dengan percaya diri, dalam bidang yang bergerak sangat cepat ini.”
Richard L. Eberly, President, Kepala Staf Komersial, menyatakan, “Kami sangat antusias dengan rilis Kit Preparasi Pustaka DNA JetSeq™ yang baru. Hal ini memperkuat portofolio kami dan memberikan pilihan yang lebih besar bagi konsumen ilmu hayati kami; memungkinkan preparasi yang lebih cepat, mengurangi waktu untuk hasil, dan meningkatkan *throughput*. Perkembangan famili JetSeq™ menunjukkan komitmen kami, tidak hanya bagi perkembangan dan perluasan terus menerus untuk produk dari Bioline, namun juga bagi konsumen kami, memberikan mereka pilihan yang lebih besar untuk reagen dengan kualitas tinggi tersebut.”
**Tentang Meridian Bioscience, Inc.**
Meridian merupakan perusahaan ilmu hayati yang mengembangkan, membuat, memasarkan, dan mendistribusikan berbagai kit uji diagnostik inovatif, reagan langka, komponen, dan biologis khusus. Dengan menggunakan berbagai metode, uji diagnostik kami memberikan akurasi, kemudahan, dan kecepatan dalam diagnosis awal dan pengobatan kondisi medis umum, seperti infeksi dan keracunan timbal. Produk diagnostik Meridian digunakan di luar tubuh manusia dan hanya memerlukan sedikit peralatan khusus atau tidak sama sekali. Produk diagnostik perusahaan dirancang untuk meningkatkan kesehatan pasien sambil mengurangi biaya perawatan kesehatan secara keseluruhan. Meridian memiliki posisi pasar yang kuat di bidang saluran pencernaan dan infeksi pernapasan atas dan pengujian kadar timbal dalam darah. Sebagai tambahan, Meridian adalah pemasok bahan reaksi langka, biologis khusus dan komponen yang digunakan oleh organisasi di ilmu hayati dan industri agribio yang terlibat dalam penelitian dan digunakan perusahaan sebagai komponen dalam pembuatan diagnostik. Perusahaan memasarkan produk dan teknologinya ke rumah sakit, laboratorium rujukan, pusat penelitian, produsen diagnostik, dan perusahaan agribio di lebih dari 70 negara di seluruh dunia. Saham perusahaan diperdagangkan di NASDAQ Global Select Market dengan simbol VIVO. Alamat situs web Meridian di [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbw1dOL7XGGkMRFAXf6PBmxpR4TGv8xQqwHip6PvsjBtnj4oaHvx7XJ9PjuGpALVs-qEkMl9AQ5RR3Jz3xu6paYJ4dpEj1QqXaYnxQ7nxlZz5fo8nUE9gq0gitrWfLMOKXG-06YuIytDpmUhOdDsOZYMZ3SsLhfHYmMTe_nv_gf3RQ0D0AfAT1MVeACccHY9U6foytsYwwnXEW1ta26b-NZfYmIGfYFQY5mLfDEUiOp_4RVeBD_wxw5VUp9aCAD8j8dg5eiaTwY-HjE_qQ3JWNtb1nIxBPoZ_tyGQWm8S0hqQW1u8exBMTqC7YrSMSBhonQ= "www.meridianbioscience.com").
**Untuk informasi Tambahan:**
Untuk informasi selengkapnya tentang Bioline, silakan kunjungi [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsN4YntoAqNQjH03PBH97rKlAcAYm_uq2xCYt-EMfF_hq6v43_rJCBJcZTRkCNXhL-0=).
```
```
---
### Contact Data
```
KONTAK:
Richard L. Eberly
Presiden, Direktur Komersial
Meridian Bioscience, Inc.
Telepon: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Melancarkan Kit Penyediaan Pustaka DNA JetSeq™ Baru](https://www.meridianbioscience.com/press-release/bioline-melancarkan-kit-penyediaan-pustaka-dna-jetseq-baru/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 10, 2017 (GLOBE NEWSWIRE) — Bioline, Syarikat PCR, iaitu anak syarikat milik penuh Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan pengembangan portfolio Penyediaan Pustaka DNA JetSeq™ untuk penyediaan sampel Penjujukan Generasi Mendatang (NGS).
Dibangunkan bersama dengan Oxford Gene Technology (OGT), Kit Penyediaan Pustaka DNA JetSeq™ menggunakan penimbal yang dipraoptimumkan untuk memberikan keberkesanan tindak balas maksimum dan kadar penukaran yang tertinggi, lalu membolehkan penyediaan DNA yang sedia penjujukan NGS kualiti tertinggi dan meligat penyesuai untuk Penjujuk Generasi Mendatang Ilumina. Gabungan pembaikan hujung dan pengekoran A yang diikuti oleh ligasi langsung penyesuai bekalan pelanggan, mengurangkan langkah pembersihan dan tempoh amali; lalu menambah baik hasil dan kualiti pustaka sedia penjujukan serta mengurangkan jumlah DNA yang diperlukan dengan ketara. Kit baru dibekalkan sama ada dengan polimerase, untuk amplifikasi PCR dengan bahan pemula yang lebih rendah, atau kit bebas PCR di mana bahan pemulanya tidak terhad.
Marco Calzavara, Presiden Bioline mengulas, “Keluaran Kit Penyediaan Pustaka DNA JetSeq™ baru ini melengkapi kit JetSeq™ yang kami lancarkan setahun lalu, yang memacu Bioline ke dalam bidang NGS dengan lebih lanjut. Kit ini dibina berdasarkan pengetahuan luas kami dalam penciptaan enzim dan pembentukan penimbal yang amat berkesan serta memberi pelanggan kami lebih banyak pilihan dalam penyediaan pustaka, membolehkan mereka menangani walaupun sampel yang paling mencabar dengan penuh yakin, dalam bidang yang berkembang pesat ini.”
Richard L. Eberly, Presiden, Ketua Pegawai Komersial, berkata, “Kami amat gembira tentang keluaran Kit Penyediaan Pustaka DNA JetSeq™ baru. Ini meningkatkan portfolio kami dan memberikan pilihan yang lebih baik kepada pelanggan sains hayat kami; membolehkan penyediaan yang lebih cepat, mengurangkan masa mendapat hasil dan meningkatkan daya pemprosesan. Pembangunan rangkaian JetSeq™ ini menunjukkan komitmen kami, bukan hanya untuk pembangunan dan pengembangan produk daripada Bioline yang berterusan, tetapi juga kepada pelanggan kami, dengan memberi mereka pilihan reagen kualiti tinggi yang lebih baik.”
**Mengenai Meridian Bioscience, Inc.**
Meridian ialah syarikat sains hayat berintegrasi penuh yang membangunkan, mengilangkan, memasarkan dan mengedar pelbagai jenis kit ujian diagnostik yang inovatif, reagen nadir, teknologi dan komponen biologi khusus. Dengan menggunakan pelbagai kaedah, produk dan ujian diagnostik kami ini dapat menyediakan ketepatan, keringkasan dan kepantasan apabila mendiagnosis secara awal dan merawat keadaan perubatan biasa seperti jangkitan dan keracunan plumbum. Produk diagnostik Meridian digunakan di luar tubuh manusia dan memerlukan sedikit atau tiada peralatan khas. Produk diagnostik Syarikat ini direka bentuk bagi meningkatkan kesejahteraan pesakit di samping mengurangkan jumlah kos penjagaan kesihatan. Meridian mempunyai kedudukan pasaran yang kukuh dalam bidang jangkitan gastrousus dan pernafasan bahagian atas serta ujian tahap plumbum dalam darah. Di samping itu, Meridian ialah pembekal reagen nadir, teknologi dan komponen biologi khusus yang digunakan dalam industri sains hayat dan agrobiologi yang melibatkan kajian dan digunakan oleh syarikat sebagai komponen dalam pembuatan diagnosis. Syarikat memasarkan produk dan teknologinya kepada hospital, makmal rujukan, pusat penyelidikan, pengilang diagnostik dan syarikat agribio di lebih daripada 70 buah negara di seluruh dunia. Saham Syarikat ini diniagakan dalam NASDAQ Global Select Market, simbol VIVO. Alamat laman web Meridian ialah [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbw1dOL7XGGkMRFAXf6PBmxpR4TGv8xQqwHip6PvsjBtnj4oaHvx7XJ9PjuGpALVs-qEkMl9AQ5RR3Jz3xu6paYJ4dpEj1QqXaYnxQ7nxlZz5fo8nUE9gq0gitrWfLMOKXG-06YuIytDpmUhOdDsOZYMZ3SsLhfHYmMTe_nv_gf3RQ0D0AfAT1MVeACccHY9U6foytsYwwnXEW1ta26b-NZfYmIGfYFQY5mLfDEUiOp_4RVeBD_wxw5VUp9aCAD8j8dg5eiaTwY-HjE_qQ3JWNtb1nIxBPoZ_tyGQWm8S0hqQW1u8exBMTqC7YrSMSBhonQ= "www.meridianbioscience.com").
**Untuk Maklumat tambahan:**
Untuk mendapatkan maklumat lanjut tentang Bioline, sila lawati [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsN4YntoAqNQjH03PBH97rKlAcAYm_uq2xCYt-EMfF_hq6v43_rJCBJcZTRkCNXhL-0=).
```
```
---
### Contact Data
```
MAKLUMAT HUBUNGAN:
Richard L. Eberly
Presiden, Ketua Pegawai Komersial
Meridian Bioscience, Inc.
Telefon: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline lanza nuevos JetSeq™ DNA Library Preparation Kits](https://www.meridianbioscience.com/press-release/bioline-lanza-nuevos-jetseq-dna-library-preparation-kits/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Feb. 09, 2017 (GLOBE NEWSWIRE) — Bioline, la compañía de la PCR, una filial propiedad total de Meridian Bioscience, Inc. (NASDAQ:VIVO), ha anunciado hoy la ampliación de la cartera de JetSeq™ DNA Library Preparation para la preparación de muestras de secuenciación de nueva generación (NGS).
Desarrollados en conjunto con Oxford Gene Technology (OGT), los nuevos JetSeq™ DNA Library Preparation Kits utilizan buffers optimizados previamente para brindar eficiencia de reacción máxima y valores más altos de conversión, lo que permite preparar ADN de la máxima calidad, ligado por adaptador y listo para la secuenciación NGS para los secuenciadores de la nueva generación de Illumina. La combinación de la reparación del terminal y A-tailing seguido de la unión directa de los adaptadores proporcionados por los clientes reduce los pasos de purificación y el tiempo, lo que mejora perceptiblemente la calidad y el rendimiento de las genotecas listas para la secuenciación y reduce la cantidad de ADN requerido. Los nuevos kits se suministran con polimerasa, para la amplificación de la PCR con menos material de partida, o un kit libre de PCR en el que el material de partida no es limitado.
Marco Calzavara, Presidente de Bioline, declaró “El lanzamiento de los nuevos JetSeq™ DNA Library Preparation Kits complementa al kit JetSeq™ que lanzamos hace un año, lo que ubica a Bioline en el campo de la NGS. Los kits parten de nuestro vasto conocimiento en la creación de enzimas altamente eficientes y la formulación de buffers y brindan a nuestros clientes aún más opciones para la preparación de genotecas, lo que les permite abordar las muestras más exigentes con confianza, en este ámbito en constante evolución.”
Richard L. Eberly, Presidente, Director Comercial, afirmó “Estamos encantados con el lanzamiento de los nuevos JetSeq™ DNA Library Preparation Kits. Esto amplia nuestra cartera y brinda más opciones a nuestros clientes en el área de las ciencias naturales, lo que les permite mayor velocidad de preparación, menor tiempo para los resultados y mayor producción. El desarrollo de la familia JetSeq™ muestra nuestro compromiso, no sólo con el continuo desarrollo y expansión de los productos de Bioline, sino también con nuestros clientes, lo que les brinda una amplia gama de reactivos de alta calidad”.
**Acerca de Meridian Bioscience, Inc.**
Meridian es una compañía de ciencias biológicas totalmente integrada que desarrolla, fabrica, comercializa y distribuye una amplia gama de kits de pruebas de diagnóstico innovadoras, reactivos infrecuentes, agentes biológicos especiales y componentes. Con el uso de una variedad de métodos, nuestras pruebas de diagnóstico brindan precisión, simplicidad y rapidez en el diagnóstico temprano y tratamiento de afecciones médicas comunes, como infecciones e intoxicaciones por plomo. Los productos de diagnóstico de Meridian se usan fuera del cuerpo humano y casi no requieren equipos especiales. Los productos de diagnóstico de la Compañía están diseñados para mejorar el bienestar del paciente y reducir al mismo tiempo los costos totales de atención médica. Meridian tiene una sólida posición de mercado en áreas de infecciones gastrointestinales y de las vías respiratorias superiores y en las pruebas de nivel de plomo en la sangre. Además, Meridian provee reactivos infrecuentes, productos biológicos especiales y componentes que utilizan organizaciones de ciencias biológicas e industrias agro-bio que se dedican a la investigación y que utilizan las compañías como componentes en la fabricación de diagnósticos. La Compañía comercializa sus productos y tecnologías en hospitales, laboratorios de referencia, centros de investigación, fabricantes de productos de diagnóstico y compañías agrobiológicas en más de 70 países de todo el mundo. Las acciones de la Compañía se negocian en el NASDAQ Global Select Market con el símbolo VIVO. El sitio web de Meridian es [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbw1dOL7XGGkMRFAXf6PBmxpR4TGv8xQqwHip6PvsjBtnj4oaHvx7XJ9PjuGpALVs-qEkMl9AQ5RR3Jz3xu6paYJ4dpEj1QqXaYnxQ7nxlZz5fo8nUE9gq0gitrWfLMOKXG-06YuIytDpmUhOdDsOZYMZ3SsLhfHYmMTe_nv_gf3RQ0D0AfAT1MVeACccHY9U6foytsYwwnXEW1ta26b-NZfYmIGfYFQY5mLfDEUiOp_4RVeBD_wxw5VUp9aCAD8j8dg5eiaTwY-HjE_qQ3JWNtb1nIxBPoZ_tyGQWm8S0hqQW1u8exBMTqC7YrSMSBhonQ= "www.meridianbioscience.com").
**Para más información:**
Para obtener más información acerca de Bioline, visite [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsN4YntoAqNQjH03PBH97rKlAcAYm_uq2xCYt-EMfF_hq6v43_rJCBJcZTRkCNXhL-0=).
```
```
---
### Contact Data
```
CONTACTO:
Richard L. Eberly
Presidente, Director Comercial
Meridian Bioscience, Inc.
Teléfono: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Meluncurkan JetSeq DNA Quantification Kit Baru](https://www.meridianbioscience.com/press-release/bioline-meluncurkan-jetseq-dna-quantification-kit-baru/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 28, 2017 (GLOBE NEWSWIRE) — Bioline, Perusahaan PCR, anak perusahaan yang dimiliki sepenuhnya oleh Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan perluasan portofolio JetSeq™ untuk preparasi sampel Pengurutan Generasi Berikutnya (Next Generation Sequencing/NGS).
JetSeq™ Library Quantification Kit terbaru merupakan pengujian berbasis qPCR-yang memberikan kuantifikasi pada fragmen DNA yang terikat pada adapter dengan cepat akurat, dan sensitif untuk preparasi of Illumina yang kompatibel dengan pustaka NGS. JetSeq™ Library Quantification Kit memanfaatkan SYBR®1 Green I untuk mendeteksi dan menyimpan semua komponen yang diperlukan kuantifikasi pustaka, termasuk dilution buffer, primer adapter P5 dan P7 serta 6 standar DNA pre-diluted untuk meminimalkan pipetting, mengurangi variabilitas dan meningkatkan reproduksibilitas. Kit ini telah memenuhi standar untuk melakukan kuantifikasi pada delapan belas pustaka pelat individual atau hingga tujuh puluh enam pustaka saat beberapa pustaka dikuantifikasi pada pelat yang sama.
Marco Calzavara, President Bioline berkomentar, “Rilis JetSeq™ Library Quantification Kit yang baru melengkapi kit preparasi pustaka JetSeq™ yang diluncurkan bulan lalu, menjadikan Bioline selangkah lebih maju dalam bidang NGS. Kit ini disusun berdasarkan pengalaman mendalam kami dalam qPCR sehingga dapat memberikan solusi yang cepat, sensitif, dan dapat diandalkan untuk menetapkan konsentrasi pustaka, memberikan pelanggan kepercayaan dalam densitas kluster yang dimuat pada platform pengurutan Illumina.”
Richard L. Eberly, President, Chief Commercial Officer, menyatakan, “Dengan senan hati, kami mengumumkan rilis JetSeq™ Library Quantification Kit terbaru; yang menjadi tambahan penting dalam portofolio produk NGS yang tidak pernah berhenti bertambah dan memberikan konsumen kepercayaan dalam melakukan kuantifikasi pustaka pengurutan. Perkembangan lebih lanjut famili JetSeq™ menunjukkan komitmen kami, tidak hanya bagi perkembangan dan perluasan terus menerus untuk produk dari Bioline, namun juga bagi konsumen kami, memberikan mereka dukungan yang lebih mapan dalam pasar yang terus berkembang ini.”
**Tentang Meridian Bioscience, Inc.**
Meridian merupakan perusahaan ilmu hayati yang mengembangkan, membuat, memasarkan, dan mendistribusikan berbagai kit uji diagnostik inovatif, reagan langka, komponen, dan biologis khusus. Dengan menggunakan berbagai metode, uji diagnostik kami memberikan akurasi, kemudahan, dan kecepatan dalam diagnosis awal dan pengobatan kondisi medis umum, seperti infeksi dan keracunan timbal. Produk diagnostik Meridian digunakan di luar tubuh manusia dan hanya memerlukan sedikit peralatan khusus atau tidak sama sekali. Produk diagnostik perusahaan dirancang untuk meningkatkan kesehatan pasien sambil mengurangi biaya perawatan kesehatan secara keseluruhan. Meridian memiliki posisi pasar yang kuat di bidang saluran pencernaan dan infeksi pernapasan atas dan pengujian kadar timbal dalam darah. Sebagai tambahan, Meridian adalah pemasok bahan reaksi langka, biologis khusus dan komponen yang digunakan oleh organisasi di ilmu hayati dan industri agribio yang terlibat dalam penelitian dan digunakan perusahaan sebagai komponen dalam pembuatan diagnostik. Perusahaan memasarkan produk dan teknologinya ke rumah sakit, laboratorium rujukan, pusat penelitian, produsen diagnostik, dan perusahaan agribio di lebih dari 70 negara di seluruh dunia. Saham perusahaan diperdagangkan di NASDAQ Global Select Market dengan simbol VIVO. Alamat situs web Meridian di [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com").
**UNTUK INFORMASI TAMBAHAN:**
Untuk informasi selengkapnya tentang Bioline, silakan kunjungi [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwprLQeHoUrx_x0Sr45DtYeJUbd2vOEqZ2P2mQSFL2maMPXLoi33I4JhKOr4tA75-o=).
1 SYBR adalah merek dagang terdaftar di Thermo Fisher Scientific.
```
```
---
### Contact Data
```
KONTAK:
Richard L. Eberly
Presiden, Direktur Komersial
Meridian Bioscience, Inc.
Telepon: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出新型JetSeq DNA定量试剂盒](https://www.meridianbioscience.com/press-release/bioline推出新型jetseq-dna定量试剂盒/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
辛辛那提, March 28, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc.（NASDAQ:VIVO）旗下的全资子公司Bioline（PCR Company）今天宣布，扩充用于新一代测序（NGS）样本制备的JetSeq™试剂盒的产品组合。
新型JetSeq™建库定量试剂盒是一种基于qPCR的检测方法，可以在Illumina兼容的NGS文库制备过程中提供快速、准确和灵敏的接头连接DNA片段。JetSeq™建库定量试剂盒依靠SYBR®1 Green I进行检测，并且含有文库定量检测所需要的全部成分，包括稀释缓冲液、P5和P7接头引物、以及六种预稀释DNA标准，以最大程度减少移液，减轻变异程度，从而提高再现性。试剂盒拥有足够的标准，可以对不同板上的共18个文库进行定量，或者对同一块板上的76个文库进行定量。
Bioline总裁Marco Calzavara评论说：“新型JetSeq™建库定量试剂盒的推出扩充了对Bioline上个月推出的JetSeq™建库试剂盒，推动我们在NGS领域向前迈进。此试剂盒是以我们丰富的qPCR知识为基础，可为判定文库浓度提供一种快速、灵敏和可靠的解决方案，令客户对在加载到Illumina测序平台上的簇密度更有信心。”
总裁兼首席执行官Richard L. Eberly表示：“我们很高兴宣布推出新型JetSeq™建库定量试剂盒；这是我们不断扩大的NGS产品组合的一个重要补充，并且可以增强生命科学客户在测序文库定量方面的信心。JetSeq™系列的扩充，表明我们不仅持续开发和扩充Bioline提供的产品，还致力于在这个快速增长的市场为我们的客户提供更多的支持。”
**关于Meridian Bioscience, Inc.**
Meridian为一家全面综合生命科学公司，负责开发、生产、营销及分销各类新型诊断检测试剂盒、稀有试剂以及特殊生物制剂和成份。我们的诊断测试方式多样，在早期诊断和传染病、铅中毒等常见疾病治疗过程具有准确性高、简易及快速的优点。Meridian的诊断产品于人体外使用，只需极少或无需特殊设备。本公司的诊断产品旨在改善病人健康的同时降低医疗保健的总成本。Meridian在胃肠及上呼吸道感染、血铅水平检测领域拥有强大的市场地位。此外，Meridian也向从事研究的生命科学及农业生物技术行业的机构及制造诊断产品的公司供应稀有试剂、特殊生物制剂及成份。本公司向全球逾70个国家的医院、参考实验室、研究中心、诊断产品制造商及农业生物技术公司销售其产品和技术。本公司股份于纳斯达克Global Select Market交易，代码为VIVO。Meridian公司网址为[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com")。
**获取更多信息：**
了解关于Bioline的更多信息，请访问[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwq4VTQAMknpI2xK0-scmLEHETalINorhoy-YcM772e1KSqym930ID3pXMHsUAODcs=)
1 SYBR是Thermo Fisher Scientific的注册商标。
```
```
---
### Contact Data
```
联系人：
Richard L. Eberly
总裁兼首席商务官
Meridian Bioscience, Inc.
电话： 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline เปิดตัวชุดตรวจสอบปริมาณดีเอ็นเอ JetSeq รุ่นใหม่](https://www.meridianbioscience.com/press-release/bioline-เปิดตัวชุดตรวจสอบปริม/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 28, 2017 (GLOBE NEWSWIRE) — Bioline ซึ่งเป็นบริษัท PCR รายหนึ่งที่เป็นบริษัทย่อยอยู่ในเครือ Meridian Bioscience, Inc. (NASDAQ:VIVO) วันนี้ได้ประกาศการขยายตัวของผลงาน JetSeq™ สำหรับการเตรียมตัวอย่าง Next Generation Sequencing (NGS)
ชุดการวัดปริมาณข้อมูลห้องสมุด JetSeq ™ รุ่นใหม่เป็นแบบทดสอบที่ใช้ qPCR เพื่อให้การวิเคราะห์ปริมาณดีเอ็นเอที่เชื่อมต่อกับอะแดปเตอร์ได้อย่างรวดเร็ว ถูกต้องแม่นยำ และมีความละเอียดอ่อนในระหว่างการจัดทำห้องสมุด NGS ที่สามารถรองรับ Illumina ได้ ชุดการวัดปริมาณข้อมูลห้องสมุด JetSeq ™ อาศัย SYBR®1 Green I สำหรับการตรวจจับและมีองค์ประกอบที่จำเป็นทั้งหมดสำหรับการจัดปริมาณห้องสมุด ซึ่งประกอบด้วยบัฟเฟอร์เจือจาง ไพรเมอร์อะแดปเตอร์ P5 และ P7 และหกมาตรฐานดีเอ็นเอก่อนเจือจับเพื่อลดการปิเปต ลดความแปรปรวน และด้วยเหตุนี้เพิ่มความสามารถในการทำซ้ำ ชุดนี้มีมาตรฐานเพียงพอสำหรับการหาจำนวนห้องสมุด18 แห่งในแต่ละแผ่น หรือห้องสมุดถึง 76 แห่งเมื่อห้องสมุดหลายแห่งมีการวัดปริมาณบนแผ่นเดียวกัน
นาย Marco Calzavara ซึ่งเป็นประธานของ Bioline ให้ความเห็นว่า “การเปิดตัวชุดการวัดปริมาณข้อมูลห้องสมุดJetSeq ™ รุ่นใหม่สนับสนุนชุดเครื่องมือเตรียมห้องสมุด JetSeq ™ที่ Bioline ได้ประกาศเปิดตัวเมื่อเดือนที่แล้ว ซึ่งทำให้เราเคลื่อนเข้าไปในพื้นที่ NGS ได้ดียิ่งขึ้น ชุดนี้ถูกสร้างขึ้นจากความรู้ที่กว้างขวางของเราเกี่ยวกับ qPCR ซึ่งทำให้เกิดเป็นโซลูชันที่รวดเร็ว ละเอียด และเชื่อถือได้ เพื่อกำหนดความเข้มข้นของห้องสมุด ซึ่งทำให้ลูกค้ามีความมั่นใจในความหนาแน่นของคลัสเตอร์ที่โหลดอยู่บนแพลตฟอร์มการจัดลำดับ Illumina”
นาย Richard L. Eberly ซึ่งเป็นประธานและหัวหน้าเจ้าหน้าที่ฝ่ายการพาณิชย์ กล่าวว่า “เรามีความยินดีอย่างยิ่งที่ได้เปิดตัวชุดการวัดปริมาณข้อมูลห้องสมุด JetSeq ™ รุ่นใหม่ นี่ถือเป็นส่วนสำคัญยิ่งสำหรับการเพิ่มผลงานผลิตภัณฑ์ NGS ที่กำลังเพิ่มมากขึ้น และทำให้ลูกค้าด้านวิทยาศาสตร์ของเรามีความเชื่อมั่นในการจัดลำดับห้องสมุดของพวกเขามากขึ้น การพัฒนาต่อไปของตระกูล JetSeq ™แสดงให้เห็นถึงความมุ่งมั่นของเรา ไม่ใช่แค่การพัฒนาและการขยายตัวผลิตภัณฑ์อย่างต่อเนื่องจาก Bioline แต่ยังให้กับลูกค้าของเราเพื่อให้พวกเขาได้รับการสนับสนุนที่ดีขึ้นในตลาดที่กำลังเติบโตอย่างรวดเร็วนี้”
**เกี่ยวกับ Meridian Bioscience, Inc.**
Meridian เป็นบริษัทด้านวิทยาศาสตร์เพื่อชีวิตแบบครบวงจรที่พัฒนา ผลิต ทำการตลาด และจัดจำหน่ายนวัตกรรมชุดตรวจวินิจฉัย สารเคมีที่หายาก ผลิตภัณฑ์ทางชีวภาพพิเศษ และส่วนประกอบต่างๆ ด้วยการใช้ประโยชน์จากวิธีการที่หลากหลาย การวินิจฉัยของเราให้ความถูกต้อง เรียบง่ายและความรวดเร็วในการวินิจฉัยและการรักษา ของสภาพทางการแพทย์ทั่วไป เช่นการติดเชื้อและเป็นพิษตะกั่ว ผลิตภัณฑ์ด้านการวินิจฉัยของ Meridian ถูกใช้ภายนอกของร่างกายมนุษย์ และต้องใช้แค่อุปกรณ์พิเศษเล็กๆ น้อยๆ หรือ ไม่ต้องใช้เลย ผลิตภัณฑ์ด้านการวินิจฉัยของบริษัทฯ ได้รับการออกแบบ เพื่อเพิ่มพูนความเป็นอยู่ที่ดีของผู้ป่วยในขณะที่ลดละค่าใช้จ่ายรวมของการดูแลสุขภาพ Meridian มีสถานะทางการตลาดที่แข็งแกร่งในด้านการติดเชื้อระบบทางเดินหายใจ และระบบทางเดินอาหารส่วนบน และการทดสอบระดับสารตะกั่วในเลือด นอกจากนี้ Meridian ยังเป็นผู้จัดจำหน่ายน้ำยาชีวภาพพิเศษและส่วนประกอบที่หายากซึ่งใช้โดยองค์กรในด้านวิทยาศาสตร์เพื่อชีวิตและอุตสาหกรรมเกษตรกรรมเชิงชีวภาพ ที่มีส่วนร่วมในการทำวิจัยและโดยบริษัทซึ่งใช้เป็นส่วนประกอบในการผลิตของผลิตภัณฑ์ตรวจวินิจฉัยโรค บริษัทฯ ได้ทำการตลาดให้กับผลิตภัณฑ์และเทคโนโลยีสำหรับโรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์การวิจัย ผู้ผลิตวินิจฉัยและบริษัทเกษตรกรรมเชิงชีวภาพในกว่า 70 ประเทศทั่วโลก หุ้นของบริษัทฯ มีการซื้อขายในตลาด NASDAQ Global Select ในสัญลักษณ์ VIVO เว็บไซต์ของ Meridian คือ [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vCOklMKOMXbegLEVYGCVR1q9rredcULzz6DmtR8OFaUWP-OkGY3pTpRJ2q6A4LEkJ5cWAIzRTUibOOdUJ3TQ3yp "www.meridianbioscience.com")
**สำหรับข้อมูลเพิ่มเติม**
สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Bioline กรุณาเยี่ยมชม [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwq4VTQAMknpI2xK0-scmLEHETalINorhoy-YcM772e1KSqym930ID3pXMHsUAODcs=).
1 SYBR เป็นเครื่องหมายการค้าจดทะเบียนของ Thermo Fisher Scientific
```
```
---
### Contact Data
```
ติดต่อ
Richard L. Eberly
ประธาน, หัวหน้าเจ้าหน้าที่ฝ่ายการพาณิชย์
Meridian Bioscience, Inc.
โทรศัพท์: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [바이오라인, JetSeq DNA 정량화 키트 신제품 출시](https://www.meridianbioscience.com/press-release/바이오라인-jetseq-dna-정량화-키트-신제품-출시/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
신시내티, March 28, 2017 (GLOBE NEWSWIRE) — PCR 장비 전문 기업으로 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ: VIVO)의 자회사인 바이오라인(Bioline)이 차세대 염기서열분석(NGS) 시료 조제용 JetSeq™ 포트폴리오를 확대한다.
새로 출시되는 JetSeq™ Library Quantification Kit는 qPCR 기반의 분석법으로 일루미나(Illumina)와 호환되는 NGS 라이브러리의 조제 과정에서 어댑터가 결찰된 DNA 조각을 빠르고 정확하며 세밀하게 정량화할 수 있다. 본 제품은 SYBR®\* 그린 I를 이용해 DNA를 탐지하며 희석 버퍼, P5와 P7 어댑터 프라이머, 희석 전 DNA 표준 6종 등 라이브러리 정량화에 필요한 모든 요소들을 갖추고 있다. 이를 통해 피펫팅을 최소화하고 가변성을 줄여 재현성을 높이게 된다. 또한 다양한 표준을 가지고 있기 때문에 18개의 라이브러리를 개별 플레이트에서 정량화할 수 있으며 여러 개의 라이브러리가 동일 플레이트에서 정량화될 시 76개의 라이브러리를 정량화할 수 있다.
\* SYBR는 Thermo Fisher Scientific의 등록 상표다.
마르코 칼사바라(Marco Calzavara) 바이오라인 사장은 “JetSeq™ Library Quantification Kit 신제품은 지난 2월 바이오라인이 출시한 JetSeq™ Library 조제키트를 보완하는 제품으로 NGS 분야 사업 범위를 한층 확대할 것이다. 당사의 광범위한 qPCR 분야 전문성에 기반한 본 제품은 신속하고 세밀하며 신뢰성 있는 솔루션으로 라이브러리 집중도를 판단, 고객들에게 일루미나 시퀀싱 플랫폼에 장착된 클러스터 밀도에 대한 신뢰를 부여한다”고 밝혔다.
리처드 에벌리(Richard L. Eberly) 메리디안 바이오사이언스 사장 겸 최고커머셜책임자는 “JetSeq™ Library Quantification Kit 신제품을 출시하게 되어 기쁘게 생각한다. 본 제품은 증가세에 있는 당사의 NGS 제품 포트폴리오의 중요한 부분을 차지하며, 생명공학 분야 고객사 입장에선 시퀀싱 라이브러리 정량화에 대해 더 큰 신뢰감을 갖게 된다. JetSeq™ 제품군 확대는 바이오라인 제품 개발 및 제품군 확대는 물론 급성장세에 있는 시장 내 고객들에 대한 지원을 강화할 수 있게 한다”고 말했다.
**메리디안** **바이오사이언스(Meridian Bioscience, Inc.) 소개**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다. 당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. 자세한 정보는 [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com")에서 확인할 수 있다.
**추가** **정보** **안내:**
바이오라인에 대한 정보는 [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPyP7PYpqZTRoLpb7G-hcfWjNfDUDT_nPrgg1Tc2TYpUErHz1UR5bu4GgBBIhXX70-3T_0-7NyUgOSmVpro4hysTHQ9TT_nJtiZTAvm0J8M_V18ztKJXznFoW8znUC6HdBywFoEgoAxiKDRA7fa1iE8hvx-lmPigGmHyj1vKKvJf3IbAmv5wAMm1BBlj0fA0zUtlYwZy3R7r4wWtE7W8ZYrWllRVMfx9lgSNCGA200w70A==)에서 확인할 수 있다.
```
```
---
### Contact Data
```
연락처:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Launches New JetSeq DNA Quantification Kits](https://www.meridianbioscience.com/press-release/bioline-launches-new-jetseq-dna-quantification-kits/)
**Published:** March 27, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation.
The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Library Quantification Kit relies on SYBR®1 Green I for detection and contains all of the components required for library quantification, including dilution buffer, P5 and P7 adapter primers and six pre-diluted DNA standards to minimize pipetting, reduce variability and thereby increase reproducibility. The kit has sufficient standards to quantify eighteen libraries on individual plates or up to seventy-six libraries when multiple libraries are quantified on the same plate.
Marco Calzavara, President of Bioline commented, “The release of the new JetSeq™ Library Quantification Kit compliments the JetSeq™ Library preparation kits that Bioline launched last month, moving us even further into the NGS space. The kit builds on our extensive knowledge in qPCR, providing a fast, sensitive and reliable solution to determine library concentrations, giving customers confidence in the cluster density loaded on Illumina sequencing platforms.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are pleased to announce the release of the new JetSeq™ Library Quantification Kit; this is an important addition to our ever-increasing portfolio of NGS products and gives our life science customers greater confidence in the quantification of their sequencing libraries. The further development of the JetSeq™ family shows our commitment, not just to the continued development and expansion of products from Bioline, but also to our customers, giving them a greater support around this fast-growing market.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meridianbioscience.com&esheet=50874826&newsitemid=20140528006196&lan=en-US&anchor=www.meridianbioscience.com&index=1&md5=9d7530cd72c9cafcaeb68685906a1a9e "www.meridianbioscience.com").
**FOR ADDITIONAL INFORMATION:**
For more information about Bioline, please visit .
1 SYBR is a registered trademark of Thermo Fisher Scientific.
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa](https://www.meridianbioscience.com/press-release/magellan-diagnostics-meridian-bioscience-inc-nasdaq-vivo-continues-global-development-signs-exclusive-partnership-to-provide-portable-blood-lead-testing-in-africa/)
**Published:** March 7, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 07, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian since March 2016, has signed an exclusive distribution agreement with Biofirm Technologies, one of the leading providers of laboratory equipment, consumables, reagents, and medical equipment in East and Central Africa. Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes. LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily, from just two drops of blood.
Lead exposure is a global health threat because, even at low levels, it can cause behavioral and learning disabilities, hyperactivity and lower IQ, as well as hypertension and kidney dysfunction. A [2015 report](https://www.globenewswire.com/Tracker?data=dTqOFzbtRECjhBG6rfYsUqbONVgU1_v8GHcy2ijq7T7OZESZzq00zQq7jRNnTPl4y2aiRCN6tCA2zLbqgSFiek--RDzccPXI1ZupB_8H529RL9xIxvsm8xKpFqdRdAQZ2XMs4RQfE5_COozW0et6eA== "2015 report") by the World Health Organization on lead poisoning explains that African countries have a “range of ongoing, lead-related public health concerns” driven by numerous “sources of lead to which African children may be exposed, often simultaneously.” These sources include: lead paint in homes, on toys and on playground equipment; occupational sources from mining, smelting, battery manufacture/recycling, and e-waste processing; as well traditional medicines, cosmetics, and artisanal cookware. The report goes on to describe a health economic study that “conservatively estimated that, annually, around 98.2 million IQ points are lost in Africa due to lead exposure, translating into economic losses of US $134.7 billion.”
Describing the need for LeadCare II in Africa, Amy Winslow, president and CEO of Magellan Diagnostics explained, “We have seen devastating news of entire communities destroyed by lead poisoning, whether by artisanal gold mining in Zamfara, Nigeria, or from industrial exposures in Mombasa, Kenya. Sadly, behind these headlines is the quieter reality that lead exposure sources are myriad, resulting in blood lead levels for children and pregnant women that are far above what we see in the U.S. To understand the challenges of lead poisoning, and to find solutions, you must have a simple way to identify who is most at risk. We look forward to helping Biofirm Technologies provide LeadCare II to address this need.”
Lourdes Weltzien, president of Meridian Asia Pacific, who is in charge of leveraging Meridian’s global footprint to expand distribution of LeadCare II commented, “We have seen incredible interest in LeadCare II from regions across the globe, especially in areas like Africa, China, India and Australia where battery manufacturing/recycling, e-waste, or mining and smelting industries are common. Lead poisoning is a devastating and preventable disease. We are looking forward to having a positive impact with a device that can be used anywhere and provide answers in 3 minutes, ultimately helping to preserve the potential of millions of children.”
Distribution activities with Biofirm Technologies will begin immediately, focusing on developing awareness, at clinical and governmental levels, about the problem of lead poisoning. Education will address sources of lead exposure, consequences – including deficits in fertility, fetal growth, intellectual development, learning and behavior – as well as how portable testing can rapidly identify at-risk populations.
**About Magellan Diagnostics, Inc.**
Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of Meridian Bioscience, Inc., Magellan is headquartered outside Boston in Billerica, Massachusetts, and is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure. We are committed to educating clinicians, policy makers, payers, families and communities about the permanent health damage caused by lead and how to detect and address lead exposure. For more information, visit [www.magellandx.com](https://www.globenewswire.com/Tracker?data=FH_ENctcpmm-uN472EuRvxzMVS9oaCvk7w5BbDK3lGIhWSrW1IaeyneYYfmmZVI9ufDgOyYT1cvZSmV7OcJXeYD0tEiq8rWkTofSpU9NHI8= "www.magellandx.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=6_wXqmTAJT-usd7DmB4Kn9E_AYm1Xa5eLtkyWIFzil3j-maG7unimj7s_i9htjdxIw6k_qG5D-RAgtGHthqcUE974zm2L3SfF6rH_R7NEfNCqkLLkTCa2EP3y1_vD16U "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
Amy Winslow
President, Chief Executive Officer
Magellan Diagnostics
Phone: 978-856-2345
Email: info@magellandx.com
Lourdes Weltzien
President of Meridian Asia Pacific
Telephone: 901-382-8716 or
Email: info@meridianlifescience.com
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [바이오라인, JetSeq™ DNA 라이브러리 조제 키트 신제품 출시](https://www.meridianbioscience.com/press-release/바이오라인-jetseq-dna-라이브러리-조제-키트-신제품-출시/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
미국 신시내티, Feb. 10, 2017 (GLOBE NEWSWIRE) — PCR 장비 전문 기업으로 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(나스닥 거래명: VIVO)의 자회사인 바이오라인(Bioline)이 차세대 염기서열분석(NGS) 시료 조제용 JetSeq™ DNA Library Preparation 포트폴리오를 확대한다고 발표했다.
Oxford Gene Technology (OGT)와의 협업을 통해 개발한 JetSeq™ DNA Library Preparation 키트는 선최적화된 버퍼로 반응 효율성과 형질 전환율을 극대화해 일루미나(Illumina) 차세대 염기서열분석기에 쓰이는 최고 품질의 DNA를 조제할 수 있다. 이 DNA는 NGS 시퀀싱이 가능하며 어댑터가 결찰된 DNA다. 또한 DNA의 끝부분 복구와 A-tailing, 그리고 고객이 공급한 어댑터의 직접 결찰을 통해 clean-up 절차와 hands-on 시간을 줄일 수 있다. 즉, 시퀀싱이 가능한 라이브러리의 수율과 품질을 크게 향상시켜 DNA 필요량을 감소시키는 것이다. 신제품 키트는 적은 시재료로 PCR 증폭을 하기 위한 폴리메라아제, 그리고 시재료에 제한이 없는 PCR-free 키트로 나뉘어 출시된다.
마르코 칼사바라(Marco Calzavara) 바이오라인 사장은 “JetSeq™ DNA Library Preparation 키트 신제품은 1년 전 처음 출시한 키트를 보완한 제품으로 바이오라인의 NGS 분야 사업 범위를 한층 확대할 것이다. 본 제품은 고도로 효율적인 효소와 버퍼 제형에 대한 우리 회사의 깊이 있는 기술력에 기반하고 있으며 고객들의 라이브러리 조제 선택의 폭을 넓혀 나날이 까다로워지고 있는 시료를 보다 손쉽게 취급할 수 있게 한다”고 말했다.
리처드 에벌리(Richard L. Eberly) 메리디안 바이오사이언스 사장 겸 최고커머셜책임자는 “JetSeq™ DNA Library Preparation 키트를 출시하게 되어 기쁘다. 우리 회사의 포트폴리오를 한층 확대하게 될 본 제품은 고객들의 선택의 폭도 넓힘으로써 조제와 결과 도출 시간을 단축하고 처리량을 늘릴 것이다. JetSeq™ 제품군은 바이오라인 제품 개발 및 제품군 확대 뿐만 아니라 고객들에게 보다 많은 고품질 시약을 제공할 수 있게 한다”고 밝혔다.
**메리디안** **바이오사이언스(Meridian Bioscience, Inc. ) 소개**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다. 당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=jBA1HTjho_YRZKrE8EEJvoIU40NhvpjFHhiJpzv-HYeujZZZ2_WzrRlIP_xpava556e-cZEBkrJdq3SSdpdefADZbWW0da3rPh8HjBTfazSoOaM7T1auu_XThiqQ94YeD8wB61eoEN1aFrSs8CWo5yV8gwhCk_bjdlceR8h_X7uNSPsB4O8eMpbXKWwjAg1JiWH7DqXYAa5i4wlS_MIP1IFH7lkuTOQoCRcSE1EsLuU_yEiZpardH5vJzII_FkAxqtKn9IJ38K-0pmhV9KIkER9xMC2b4jj2cuNoYg7uo_Bculz-Bseb79-Fj6nqP60hv8eRHLt_4yXUZC1PcifmN4VwM18HdkLsQMqc9YGfAGk= "www.meridianbioscience.com")
**추가** **정보:**
바이오라인에 대한 자세한 정보는 [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=do478LOp5DUw3uhWJzZrJi1ykl-RFkr4qMZ1yPTg0AHkw-V2zSWukZeItXpNj3hDSZBBmZIdJtDIiibSPfut8y0wn1eQT7n5daAEIBAAo5g=)에서 확인할 수 있다.
```
```
---
### Contact Data
```
연락처:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出新型JetSeq™ DNA建库试剂盒](https://www.meridianbioscience.com/press-release/bioline推出新型jetseq-dna建库试剂盒/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
辛辛那提, Feb. 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc.（纳斯达克代号：VIVO）的全资中国附属公司Bioline今日宣布，扩充用于下一代测序(NGS)样本制备的JetSeq™ DNA建库试剂盒的产品组合。
透过与牛津基因技术公司(OGT)的合作研发，新型JetSeq™ DNA建库试剂盒使用预先优化的缓冲系统，提供最大的反应效率及最高的转化率，从而能够制备最高质量的NGS序列准备、适配器连接的DNA文库，用于Illumina的下一代测序。终端修复结合进行A尾端添加，随后直接与客户提供的适配器连接，减少清理步骤及操作时间，大大提高序列准备文库的产量及质量，降低所需DNA的数量。新型试剂盒与聚合酶（用于对原始材料数量要求低的PCR扩增）或PCR-free试剂盒（对原始材料并无限制）一同提供。
Bioline总裁Marco Calzavara表示：“新型JetSeq™ DNA建库试剂盒的推出扩充了我们一年前刚刚推出的JetSeq™试剂盒，推动Bioline在NGS领域的发展更进一步。新型试剂盒建基于我们对创造高效聚合酶及缓冲液配方知识的深入了解，为我们的客户在文库制备过程中提供更多选择，使他们在这个快速变化的领域，即使面对最具挑战性的样本，也有信心对其进行处理。”
总裁兼首席商务官Richard L. Eberly表示：“我们很高兴推出新型JetSeq™ DNA 建库试剂盒。这增强了我们的产品组合，亦为我们的生命科学客户提供更多的选择，制备速度更快、结果呈现所需时间更短，并提高了产量。JetSeq™系列的扩充，表明我们不仅坚守持续开发及扩充Bioline提供的产品的承诺，亦体现我们对客户的承诺，为他们提供更多高质量试剂的选择。”
关于Meridian Bioscience, Inc.
Meridian为一家综合生命科学公司，负责开发、生产、营销及分销各类新型诊断检测试剂盒、稀有试剂以及特殊生物制剂和成份。我们的诊断测试方式多样，于早期诊断和传染病、铅中毒等常见疾病治疗过程具有准确性高、简易及快速的优点。Meridian的诊断产品于人体外使用，只需极少或无需特殊设备。本公司的诊断产品旨在于改善病人健康的同时降低医疗保健的总成本。Meridian在胃肠及上呼吸道感染、血铅水平检测领域占据重要的市场地位。此外，Meridian亦向从事研究的生命科学及农业生物技术行业的机构及制造诊断产品的公司，供应稀有试剂、特殊生物制剂及成份。本公司向全球逾70个国家的医院、参考实验室、研究中心、诊断产品制造商及农业生物技术公司销售其产品和技术。本公司股份于纳斯达克Global Select Market交易，代号为VIVO。Meridian公司网址为[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbwnq3LgnLFDesny4Kk63KIT8oNpK02NHa7tp7yeLWKlyHIc2wY7gVPpx6rGxGnKz967YwJ_KhPBZnCXTI8NSv497NisFLsQu1KvSw0pSb01Jx0v-g-SFrq7F7EinJBHesYgW9eul2mUDVaBxRxxHsk8Q7K8graArmyQIxlcCngP2iW-j4reMuo34E3N3RlD9bOSM8zeCH6F9ckD7wDf03X67Pd_Ysay9ahaXqbv3HJ1oPv_N60PD7wIU8aivhLjhNkNrO_ys4QOfkbQ8GLDN7mvN99vjWcLY4l2A_ZIBf1Z-4XorP6RHal3_4wSxiIv9BM= "www.meridianbioscience.com")。
**更多资讯：**
欲了解关于Bioline的更多资讯，请访问[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsPAiGczYD7UCdsRHU8WNtlLGW-1Tk1DqOKOXEn0CkKV6CGoRB80WjPa-d_GEDgierE=)。
```
```
---
### Contact Data
```
联络方式：
Richard L. Eberly
总裁兼首席商务官
Meridian Bioscience, Inc.
电话：513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [バイオライン、新しいJetSeq™ DNAライブラリー調製キットを発売](https://www.meridianbioscience.com/press-release/バイオライン、新しいjetseq-dnaライブラリー調製キッ/)
**Published:** February 9, 2017
**Author:** hamza
**Content:**
シンシナティ発, Feb. 10, 2017 (GLOBE NEWSWIRE) — メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ: VIVO) の完全所有子会社であるPCR企業、バイオライン (Bioline) は本日、次世代シーケンシング (NGS) サンプル調製用のJetSeq™ DNAライブラリー調製ポートフォリオの拡張を発表した。
オックスフォード･ジーン･テクノロジー (Oxford Gene Technology、OGT) との協力によって開発された新しいJetSeq™ DNAライブラリー調製キットは、最適化済みのバッファを使用して最大限の反応効率と最高の変換率を実現し、イルミナ (Illumina) の次世代シーケンサー用にNGSシーケンシングに対応し、アダプターライゲーションを行った最高品質のDNAの調製が可能になる。エンドリペアとAテーリングを組み合わせ、顧客が提供するアダプターの直接ライゲーションを行うことにより、クリーンアップ手順とハンズオンタイムが短縮され、イールドおよびシーケンシング用ライブラリーの品質が大幅に改善し、DNAの必要量が削減される。新しいキットは少量の出発原料でPCR増幅用ポリメラーゼ付き、または出発原料に制限がない場合のためのPCR無しのキットが選択できる。
バイオラインの社長マルコ･カルザヴァラ (Marco Calzavara) は次のように述べている。「新しいJetSeq™ DNAライブラリー調製キットは、一年程前に発売したJetSeq™キットを補足するもので、バイオラインによるNGS分野への進出をさらに進めることになります。このキットは、この急速に展開中の分野において、極めて効率の良い酵素とバッファフォーミュラ生成についての当社の広範囲にわたる知識に基づいており、ライブラリー調製に対してより多くの選択肢をお客様にお届けし、お客様が極めて難しいサンプルでも自信を持って取り組めるようにしています」
社長兼最高商務責任者、リチャード･L･エバリー (Richard L. Eberly) は次のように述べている。「新しいJetSeq™ DNAライブラリー調製キットの発売について、大変嬉しく思っています。これにより、ポートフォリオが強化され、ライフサイエンス分野のお客様により多様な選択肢を提供できるようになります。さらにより迅速に調製が可能になり、結果が出るまでの時間を短縮し、処理能力を拡大できます。JetSeq™ファミリーの開発は、バイオラインによる継続した製品開発･拡大に対するコミットメントだけでなく、より多くの高品質試薬をお客様にお届けするというコミットメントも実証しています」
**メリディアン･バイオサイエンス (Meridian Bioscience, Inc.) について**
メリディアンは、多様な革新的診断テスト･キット、希少試薬、特殊バイオ製品、コンポーネントの開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス企業である。同社の診断検査は、多様な方法を駆使して感染症、鉛中毒などのよくある疾患の早期診断と治療のために、高精度、単純性、スピードを実現している。メリディアンの診断用製品は人体外で使用する製品であり、専門的装置はほとんど必要ないか、または全く不要である。同社の診断用製品は患者の心身の健康を強化し、同時に医療の合計結果コストを削減するよう設計されている。同社では消化器系･呼吸器系上部の感染症および血中鉛濃度の診断分野で強力な市場地位を確保している。さらに、研究に携わるライフサイエンスおよび農業バイオ業界の機関や、診断用製品の製造用コンポーネントとして、企業などに希少試薬や特殊バイオ製品、コンポーネントを供給している。同社は世界中70ヶ国以上の病院、基準検査機関、リサーチセンター、診断用製品メーカー、農業バイオ企業にもその製品とテクノロジーを販売している。同社の株式はナスダックのグローバル･セレクト･マーケットでシンボル「VIVO」で取引されている。メリディアンのウェブサイトは以下のとおりである。[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hffh0j71_0Wc45-4rP18xm-21XlxHUdRJlqxyUFFJbw1dOL7XGGkMRFAXf6PBmxpR4TGv8xQqwHip6PvsjBtnj4oaHvx7XJ9PjuGpALVs-qEkMl9AQ5RR3Jz3xu6paYJkAUL7oLZXTEtJroUfM-vsqSRbgIug8GN4GGNUGNqvZegdxxsmNF0ZyyYAt0vWFMl-xaaFza3MWcVGXWWXlNhLX8O9Fi_M0WRtG6q3cRKrMsVjP992zPfsV--_j0wLU1B8lxO-z7pndT_X2yo95rwzhMrbRDxOsADOB5w8xDK3HMIxXbdvBnN49scuNLIrnHf8sVmJs0dTKC6JiW2NL_oicyO7gok6BsTWx5zydMT2Ao= "www.meridianbioscience.com")
**追加情報：**
バイオライン (Bioline) について詳しくは、[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=30c3jkMvMIUlXpE7Yiun5ZYR-lwvTa8YRReI-VYiNsN4YntoAqNQjH03PBH97rKlAcAYm_uq2xCYt-EMfF_hq6v43_rJCBJcZTRkCNXhL-0=)を参照のこと。
```
```
---
### Contact Data
```
問い合わせ先：
リチャード･L･エバリー (Richard L. Eberly)
社長、最高商務責任者 (President, Chief Commercial Officer)
Meridian Bioscience, Inc.
電話：513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-second-quarter-fiscal-2017-operating-results-on-thursday-april-27-2017/)
**Published:** March 29, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 29, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, April 27, 2017. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=HJ8VFYOHi0pU_eWZapPWr3qJJyfbRLaIsE96xs2IAThS-ka1B7ptq3uzwoP0wf4e6iFpDQymR_UOAANFyZL2aTjFbafV6fcCjk0Kwqq6butgQ7dCY3AUT3Atmk14yhIA "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. For more information, please visit [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=HJ8VFYOHi0pU_eWZapPWr3qJJyfbRLaIsE96xs2IATjJGLBgVFqkrQIozLea1Ow7eBq9i2nsJgJvkKm8m7DOlYYWpTYSGeRzfApx5b4SmHiPCNBMfM_3CXGnIJAsfvAaaHgO4RiGOKFRUfu3egz49EWWc65-Pi_Rjr8AZqckvkxrPpp9Y0QGOZS1eLq00O9SleOQd7JDRvZ3QeEDr9YnDfRoH0g5Nw2zfTHGHrpYlS26-PExF9BNvNu0NblLUvvlXIl3bxnIx0K6se1I1HrRcVFDLFBNPqGV4vsNfDwiZlRxL4kNx-M64HCgETCeWcgI8WjIAZOS1pRMIwTDy6S3c5eElZ3Vcn-RfU_EVcCvDfo= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline lança novos kits de quantificação de DNA JetSeq](https://www.meridianbioscience.com/press-release/bioline-lanca-novos-kits-de-quantificacao-de-dna-jetseq/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 28, 2017 (GLOBE NEWSWIRE) — A Bioline, empresa de PCR, subsidiária integral da Meridian Bioscience, Inc. (NASDAQ:VIVO), anunciou hoje mais uma expansão para sua carteira JetSeq™ para preparação de amostras de Sequenciamento de última geração (NGS, na sigla em inglês).
O novo Kit de Quantificação de Biblioteca JetSeq™ é um ensaio baseado em qPCR que fornece quantificação rápida, precisa e sensível de fragmentos de DNA ligados ao adaptador durante a preparação de bibliotecas de NGS compatíveis com Illumina. O Kit de Quantificação de Biblioteca JetSeq™ conta com o SYBR®1 Green I para detecções e contém todos os componentes necessários para quantificação da biblioteca, incluindo tampões de diluição, adaptadores primários P5 e P7 e seis padrões de DNA pré-diluídos para minimizar a pipetagem, reduzir a variabilidade e dessa forma aumentar a reprodutibilidade. O kit possui padrões suficientes para quantificar dezoito bibliotecas em placas individuais ou até setenta e seis bibliotecas quando várias bibliotecas são quantificadas na mesma placa.
Marco Calzavara, Presidente da Bioline, comentou: “O lançamento do novo Kit de Quantificação de Bibliotecas JetSeq™ complementa os kits de preparação de Bibliotecas JetSeq™ lançados pela Bioline no mês passado, levando-nos ainda mais longe no espaço de NGS. O kit tem por base nosso extenso conhecimento em qPCR, que oferece uma solução rápida, sensível e confiável para determinar concentrações da biblioteca, dando aos clientes a confiança na densidade do agrupamento carregado nas plataformas de sequenciamento Illumina.”
Richard L. Eberly, Presidente e Diretor Comercial, declarou: “Estamos satisfeitos em anunciar o lançamento do novo Kit de Quantificação de Biblioteca JetSeq™; esse é um complemento importante para nossa sempre crescente carteira de produtos de NGS e dá aos nossos clientes de ciências da vida uma maior confiança na quantificação de suas bibliotecas de sequenciamento. O desenvolvimento contínuo da família JetSeq™ mostra nosso compromisso não somente com o desenvolvimento continuado e a expansão dos produtos da Bioline, mas também com nossos clientes, dando a eles um maior suporte acerca desse mercado em franco crescimento.”
**Sobre a Meridian Bioscience, Inc.**
A Meridian é uma empresa de ciências da vida completamente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de kits inovadores de diagnóstico, reagentes raros, biológicos especializados e componentes. Utilizando uma variedade de métodos, nossos testes de diagnósticos oferecem precisão, simplicidade e velocidade em diagnóstico e tratamento precoces de condições clínicas comuns, como infecções e envenenamento por chumbo. Os produtos de diagnóstico da Meridian são usados fora do corpo humano e requerem pouco ou nenhum equipamento especial. Os produtos de diagnóstico da Empresa são projetados para aumentar o bem-estar do paciente ao mesmo tempo em que reduzem os custos com cuidados da saúde. A Meridian possui posições fortes no mercado nas áreas de infecções gastrointestinais e respiratórias superiores e análises do nível de chumbo no sangue. Além disso, a Meridian é fornecedora de reagentes raros, biológicos especializados e componentes utilizados por organizações de ciências da vida e indústrias bioagrícolas dedicadas à pesquisa e por empresas como componentes na produção de diagnósticos. A Empresa comercializa seus produtos e tecnologias com hospitais, laboratórios de referência, centros de pesquisa, fabricantes de diagnóstico e empresas bioagrícolas em mais de 70 países. As ações da Empresa são negociadas no Global Select Market da NASDAQ com o símbolo VIVO. O site da Meridian é [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com").
**PARA INFORMAÇÕES ADICIONAIS:**
Para obter mais informações sobre a Bioline, acesse [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwprLQeHoUrx_x0Sr45DtYeJUbd2vOEqZ2P2mQSFL2maMPXLoi33I4JhKOr4tA75-o=).
1 SYBR é uma marca registrada da Thermo Fisher Scientific.
```
```
---
### Contact Data
```
CONTATO:
Richard L. Eberly
Presidente e Diretor Comercial
Meridian Bioscience, Inc.
Telefone: 513.271.3700
rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [バイオライン、新しいジェットシーク (JetSeq) DNA定量化キットを発売](https://www.meridianbioscience.com/press-release/バイオライン、新しいジェットシーク-jetseq-dna定量化/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
シンシナティ発, March 28, 2017 (GLOBE NEWSWIRE) — メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ:VIVO) の完全所有子会社であるPCR企業、バイオライン (Bioline) は、本日、次世代シークエンシング (NGS) 試料準備用のジェットシーク (JetSeq™) ポートフォリオの更なる拡張を発表した。
新しいジェットシーク･ライブラリー定量化キット (JetSeq™ Library Quantification Kit) は、イルミナ (Illumina) 対応のNGSライブラリーの準備中に、アダプターライゲーション済みDNA切片の高速、正確かつ敏感な定量化を実現するqPCR方式アッセイである。ジェットシーク･ライブラリー定量化キットは、検出用にSYBR®1 グリーンI (SYBR®1 Green I) を使用し、希釈バッファ、P5およびP7アダプタープライマー、ピペット採取作業を最小限に抑え可変度を削減して再現性を向上させるための6個のDNA標準を含む、ライブラリー定量化に必要なすべてのコンポーネントを含んでいる。キットには、個別プレートで18件のライブラリーを定量化するか、または複数のライブラリーを同一のプレートで定量化する場合には76件のライブラリーを定量化するために十分な量の標準が含まれている。
バイオラインの社長マルコ・カルザヴァラ (Marco Calzavara) は「新しいジェットシーク･ライブラリー定量化キットは、先月発売したジェットシーク･ライブラリー準備キットを補足するもので、NGS分野にさらに進出することになります。このキットはqPCRにおける当社の豊かな知識を活用してライブラリーの濃度を判定する、迅速で、感度および信頼性の高いソリューションを提供し、イルミナ･シークエンシングプラットフォームにロードされたクラスター密度に確信を持っていただけます」と述べている。
社長兼最高商務責任者 (President, Chief Commercial Officer)、リチャード L. エバリー (Richard L. Eberly) は「新しいジェットシーク･ライブラリー定量化キットのリリースを発表できることを嬉しく思っています。当社のNGS製品ポートフォリオをさらに拡張する重要な追加であり、ライフサイエンスのお客様にとっては、シークエンシングライブラリーの定量化に対する確信を一層強化します。ジェットシーク･ファミリーの更なる発展は、バイオラインによる継続した製品開発･拡大に対するコミットメントだけでなく、この急成長中の市場でお客様により多くのサポートを提供するというコミットメントも実証しています」と語った。
**メリディアン･バイオサイエンス (Meridian Bioscience, Inc.) について**
メリディアンは、多様な革新的診断テスト･キット、希少試薬、特殊バイオ製品およびコンポーネントの開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス企業である。同社の診断検査は、多様な方法を駆使して感染症、鉛中毒などのよくある疾患の早期診断と治療のために、高精度、単純性、スピードを実現している。メリディアンの診断用製品は人体外で使用する製品であり、専門的装置はほとんど必要ないか、または全く不要である。同社の診断用製品は患者の心身の健康を強化し、同時に医療の合計結果コストを削減するよう設計されている。同社では消化器系･呼吸器系上部の感染症および血中鉛濃度の診断分野で強力な市場地位を確保している。さらに、ライフサイエンスおよび農業バイオ業界に携わる研究機関や、診断用製品の製造用コンポーネントとして、企業などに希少試薬、特殊バイオ製品およびコンポーネントを供給している。同社は世界中70ヶ国以上の病院、基準検査機関、リサーチセンター、診断用製品メーカー、農業バイオ企業にもその製品、テクノロジーを販売している。同社の株式はナスダックのグローバル・セレクト・マーケットでシンボル「VIVO」で取引されている。メリディアンのウェブサイトは以下のとおりである。[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com")
**追加情報：**
バイオラインについて詳しくは、[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwprLQeHoUrx_x0Sr45DtYeJUbd2vOEqZ2P2mQSFL2maMPXLoi33I4JhKOr4tA75-o=)を参照のこと。
1 SYBRはサーモ･フィッシャー･サイエンティフィック (Thermo Fisher Scientific) の登録商標である。
```
```
---
### Contact Data
```
問い合わせ先：
リチャード L. エバリー (Richard L. Eberly)
社長、最高商務責任者 (President, Chief Commercial Officer)
Meridian Bioscience, Inc.
電話：513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Melancarkan Kit Pengkuantitian DNA JetSeq Baharu](https://www.meridianbioscience.com/press-release/bioline-melancarkan-kit-pengkuantitian-dna-jetseq-baharu/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 28, 2017 (GLOBE NEWSWIRE) — Bioline, Syarikat PCR, iaitu anak syarikat milik penuh Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan pengembangan lanjutan portfolio JetSeq™ untuk penyediaan sampel Penjujukan Generasi Mendatang (NGS).
Kit Pengkuantitian Pustaka JetSeq™ baharu merupakan asai berasaskan qPCR yang memberikan pengkuantitian serpihan DNA berligat penyesuai yang pantas, tepat dan sensitif apabila penyediaan pustaka NGS yang serasi dengan Illumina. Kit Pengkuantitian Pustaka JetSeq™ bergantung pada SYBR®1 Green I untuk pengesanan dan mengandungi semua komponen yang diperlukan bagi pengkuantitian pustaka, termasuk penimbal pencairan, primer penyesuai P5 dan P7 serta enam piawai DNA pracair untuk meminimumkan penggunaan pipet, mengurangkan kebolehubahan dan dengan itu, meningkatkan kebolehulangan. Kit ini mempunyai piawai yang cukup untuk mengkuantitikan lapan belas pustaka pada plat individu atau sehingga tujuh puluh enam pustaka apabila berbilang pustaka dikuantitikan pada plat yang sama.
Marco Calzavara, Presiden Bioline mengulas, “Pengeluaran Kit Pengkuantitian Pustaka JetSeq™ baharu ini melengkapi kit penyediaan Pustaka JetSeq™ yang dilancarkan oleh Bioline pada bulan yang lalu, yang memacu kami ke dalam bidang NGS dengan lebih lanjut. Kit ini terbina atas pengetahuan mendalam kami dalam qPCR, dan memberikan penyelesaian yang pantas, sensitif dan boleh dipercayai untuk menentukan kepekatan pustaka dan memberikan keyakinan kepada pelanggan dalam ketumpatan gugusan yang dimuatkan pada platform penjujukan Illumina.”
Richard L. Eberly, Presiden, Ketua Pegawai Komersial, berkata, “Kami berbesar hati untuk mengumumkan pengeluaran Kit Pengkuantitian Pustaka JetSeq™; ini merupakan tambahan penting kepada portfolio produk NGS kami yang makin bertambah serta memberi pelanggan sains hayat kami keyakinan yang lebih tinggi dalam pengkuantitian pustaka penjujukan mereka. Pembangunan lanjutan rangkaian JetSeq™ ini menunjukkan komitmen kami, bukan hanya untuk pembangunan dan pengembangan produk daripada Bioline yang berterusan, tetapi juga kepada pelanggan kami, dengan memberi mereka sokongan yang lebih tinggi dalam pasaran yang berkembang pesat ini.”
**Mengenai Meridian Bioscience, Inc.**
Meridian ialah syarikat sains hayat berintegrasi penuh yang membangunkan, mengilangkan, memasarkan dan mengedar pelbagai jenis kit ujian diagnostik yang inovatif, reagen nadir, teknologi dan komponen biologi khusus. Dengan menggunakan pelbagai kaedah, produk dan ujian diagnostik kami ini dapat menyediakan ketepatan, keringkasan dan kepantasan apabila mendiagnosis secara awal dan merawat keadaan perubatan biasa seperti jangkitan dan peracunan plumbum. Produk diagnostik Meridian digunakan di luar tubuh manusia dan memerlukan sedikit atau tiada peralatan khas. Produk diagnostik Syarikat ini direka bentuk bagi meningkatkan kesejahteraan pesakit di samping mengurangkan jumlah kos penjagaan kesihatan. Meridian mempunyai kedudukan pasaran yang kukuh dalam bidang jangkitan gastrousus dan pernafasan bahagian atas serta ujian tahap plumbum dalam darah. Di samping itu, Meridian ialah pembekal reagen nadir, teknologi dan komponen biologi khusus yang digunakan dalam industri sains hayat dan agrobiologi yang melibatkan kajian serta digunakan oleh syarikat sebagai komponen dalam pembuatan diagnosis. Syarikat memasarkan produk dan teknologinya kepada hospital, makmal rujukan, pusat penyelidikan, pengilang diagnostik dan syarikat agribio di lebih daripada 70 buah negara di seluruh dunia. Saham Syarikat ini diniagakan dalam NASDAQ Global Select Market, simbol VIVO. Alamat tapak web Meridian ialah [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com").
**UNTUK MAKLUMAT TAMBAHAN:**
Untuk mendapatkan maklumat lanjut tentang Bioline, sila lawati [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwprLQeHoUrx_x0Sr45DtYeJUbd2vOEqZ2P2mQSFL2maMPXLoi33I4JhKOr4tA75-o=).
1 SYBR ialah tanda dagangan Thermo Fisher Scientific.
```
```
---
### Contact Data
```
MAKLUMAT HUBUNGAN:
Richard L. Eberly
Presiden, Ketua Pegawai Komersial
Meridian Bioscience, Inc.
Telefon: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline推出新型JetSeq DNA定量試劑盒](https://www.meridianbioscience.com/press-release/bioline推出新型jetseq-dna定量試劑盒/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
辛辛那提, March 28, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc.（NASDAQ:VIVO）旗下全資子公司Bioline（PCR Company）今日宣佈，將進一步擴充用於新一代測序（NGS）樣本製備的JetSeq™試劑盒的產品組合。
新型JetSeq™建庫定量試劑盒為基於qPCR的檢測方法，可於Illumina相容的NGS文庫製備過程中提供快速、準確和靈敏的接頭連接DNA片段。JetSeq™建庫定量試劑盒依賴SYBR®1 Green I進行檢測，含有文庫定量檢測所需要全部成分，包括稀釋緩衝液、P5和P7接頭引物、以及六種預稀釋DNA標準，以最大程度減少移液，減輕變異程度，從而提高再現性。試劑盒擁有足夠標準，可對各板共18個文庫進行定量，或對同一塊板的76個文庫進行定量。
Bioline總裁Marco Calzavara評價稱：「新型JetSeq™建庫定量試劑盒的推出擴充了Bioline上個月推出的JetSeq™建庫試劑盒，推動我們在NGS領域向前邁進。此試劑盒是以我們豐富的qPCR知識為基礎，可為判定文庫濃度提供一種快速、靈敏和可靠的解決方案，令客戶對在載入到Illumina測序平臺上的簇密度更有信心。」
總裁兼首席執行官Richard L. Eberly表示：「我們很高興宣佈推出新型JetSeq™建庫定量試劑盒；這是我們不斷擴大的NGS產品組合的一個重要補充，可以增強生命科學客戶在測序文庫定量方面的信心。JetSeq™系列的擴充，表明我們不僅持續開發和擴充Bioline提供的產品，亦致力於在此快速增長的市場為我們的客戶提供更多支持。」
**關於Meridian Bioscience, Inc.**
Meridian為一家全面綜合生命科學公司，負責開發、生產、營銷及分銷各類新型診斷檢測試劑盒、稀有試劑以及特殊生物製劑和成份。我們的診斷測試方式多樣，在早期診斷和傳染病、鉛中毒等常見疾病治療過程具有準確性高、簡易及快速的優點。Meridian的診斷產品於人體外使用，只需極少或無需特殊設備。本公司的診斷產品旨在改善病人健康的同時降低醫療保健的總成本。Meridian在胃腸及上呼吸道感染、血鉛水平檢測領域的市場地位穩固。此外，Meridian亦向從事研究的生命科學及農業生物技術行業的機構及製造診斷產品的公司供應稀有試劑、特殊生物製劑及成份。本公司向全球逾70個國家的醫院、參考實驗室、研究中心、診斷產品製造商及農業生物技術公司銷售其產品和技術。公司股份於納斯達克Global Select Market交易，代號為VIVO。Meridian公司網址為[www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com")。
**獲取更多資訊：**
獲取關於Bioline的更多資訊，請瀏覽[https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwq4VTQAMknpI2xK0-scmLEHETalINorhoy-YcM772e1KSqym930ID3pXMHsUAODcs=)
1 SYBR為Thermo Fisher Scientific的註冊商標。
```
```
---
### Contact Data
```
聯絡人：
Richard L. Eberly
總裁兼首席商務官
Meridian Bioscience, Inc.
電話： 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline lanza los nuevos kits JetSeq para la cuantificación de ADN](https://www.meridianbioscience.com/press-release/bioline-lanza-los-nuevos-kits-jetseq-para-la-cuantificacion-de-adn/)
**Published:** March 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, March 28, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, una subsidiaria de propiedad absoluta de Meridian Bioscience, Inc. (NASDAQ:VIVO) anunció hoy la ampliación adicional de la cartera JetSeq™ para la preparación de muestras de secuenciación de nueva generación (Next Generation Sequencing, NGS).
El nuevo kit de cuantificación de genotecas JetSeq™ es un ensayo basado en la reacción en cadena de la polimerasa cuantitativa (quantitative polymerase chain reaction, qPCR) que permite la cuantificación rápida, precisa y sensible de fragmentos de ADN ligados por adaptador durante la preparación de genotecas de NGS compatibles con Illumina. El kit de cuantificación de genotecas JetSeq™ se basa en SYBR®1 Green I para la detección y contiene todos los componentes necesarios para la cuantificación de genotecas, incluido el tampón de dilución, cebadores de los adaptadores P5 y P7, y seis estándares de ADN prediluidos para minimizar el pipeteado, reducir la variabilidad y, de ese modo, aumentar la reproducibilidad. El kit cuenta con una cantidad suficiente de estándares como para cuantificar dieciocho genotecas en placas individuales o hasta setenta y seis cuando se cuantifican múltiples genotecas en la misma placa.
Marco Calzavara, presidente de Bioline, declaró “El lanzamiento del nuevo kit de cuantificación de genotecas JetSeq™ complementa los kits de preparación de genotecas JetSeq™ que Bioline lanzó el mes pasado, lo que permite adentrarnos aún más en el campo de la NGS. El kit parte de nuestro amplio conocimiento de la qPCR, y proporciona una solución rápida, sensible y fiable para determinar las concentraciones de genotecas, a fin de brindar a los clientes la confianza en la densidad de clúster cargado en las plataformas de secuenciación de Illumina”.
Por otro lado, el presidente y director comercial, Richard L. Eberly, afirmó: “Estamos encantados de anunciar el lanzamiento del kit de cuantificación de genotecas JetSeq™. Esta es una importante adición a nuestra creciente cartera de productos de NGS y brinda a nuestros clientes del área de las ciencias biológicas más confianza en la cuantificación de sus genotecas de secuenciación. El mayor desarrollo del conjunto de productos JetSeq™ muestra nuestro compromiso, no solo con el desarrollo y la expansión continuos de los productos de Bioline, sino también con nuestros clientes, para brindarles más apoyo en este mercado de rápido crecimiento”.
**Acerca de Meridian Bioscience, Inc.**
Meridian es una compañía de ciencias biológicas totalmente integrada que desarrolla, fabrica, comercializa y distribuye una amplia gama de kits de pruebas de diagnóstico innovadoras, reactivos infrecuentes, componentes y productos biológicos especiales. Con el uso de una variedad de métodos, nuestras pruebas de diagnóstico brindan precisión, simplicidad y velocidad en el diagnóstico temprano y el tratamiento de afecciones médicas comunes, como infecciones e intoxicación por plomo. Los productos de diagnóstico de Meridian se usan fuera del cuerpo humano y casi no requieren de equipos especiales. Los productos de diagnóstico de la compañía están diseñados para mejorar el bienestar del paciente y reducir al mismo tiempo los costos totales de atención médica. Meridian tiene una sólida posición de mercado en áreas de diagnóstico de infecciones de las vías respiratorias superiores y gastrointestinales, y pruebas de nivel de plomo en sangre. Además, Meridian es un proveedor de reactivos infrecuentes, componentes y productos biológicos especiales utilizados por organizaciones de ciencias biológicas e industrias agrobiológicas dedicadas a la investigación y por otras compañías como componentes en la fabricación de pruebas de diagnóstico. La compañía comercializa sus productos y tecnologías en hospitales, laboratorios de referencia, centros de investigación, fabricantes de productos de diagnóstico y compañías agrobiológicas en más de 70 países de todo el mundo. Las acciones de la Compañía cotizan en el NASDAQ Global Select Market, con el símbolo VIVO. El sitio web de Meridian es [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mYnyP1Q_a3gFTytScqgerpunw2Wb7wRtiPFYl3-0-vC_yga6KLaK_Tv8C639PNOvDeTOJDmL7QbqLrJFADDggIrLvoJTsdQawig0oVU0JBlGb8oNUQNiiKhgoV8pEQl0 "www.meridianbioscience.com").
**PARA OBTENER MÁS INFORMACIÓN:**
Para obtener más información acerca de Bioline, visite [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=3b6z9VX3xqWuvVruIiIEMpOmo2owYnD3TZARDN5KLPwprLQeHoUrx_x0Sr45DtYeJUbd2vOEqZ2P2mQSFL2maMPXLoi33I4JhKOr4tA75-o=).
1 SYBR es una marca comercial registrada de Thermo Fisher Scientific.
```
```
---
### Contact Data
```
CONTACTO:
Richard L. Eberly
Presidente y director comercial
Meridian Bioscience, Inc.
Teléfono: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria](https://www.meridianbioscience.com/press-release/new-testing-procedure-holds-promise-as-a-critical-tool-in-the-global-effort-to-eliminate-malaria/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.
Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed ***illumi****gene®* Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal.
“***illumi****gene* Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria,” said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. “Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions. ***illumi****gene* Malaria shows this capacity.”
***illumi****gene* Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.
Despite a 60% decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world’s population is at risk of malaria (2). In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths (3). Also that year, Sub-Saharan Africa was home to 90% of malaria cases and 92% of malaria deaths (4). More than two-thirds (70%) of all malaria deaths occur in children under the age of five (5).
While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as “loads.” Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.
“People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging,” said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. “If testing doesn’t identify them, eliminating malaria is impossible because these individuals can spread the disease to others.”
That scenario is playing out in the fact that malaria is no longer only a disease of sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14% to 86% in more recent studies. On pooling the reports, nearly 43% of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70% of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries.
While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of ***illumi****gene* Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat. ***illumi****gene* Malaria is user-friendly, doesn’t require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.
“This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread,” said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.
The availability of the field laboratory-deployable and user-friendly, ***illumi****gene* Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.
“Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it,” said Kraeutler.
***illumi****gene* Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network. It is the tenth assay now available on our ***illumi****gene* platform that is in use in nearly 1,500 institutions around the world.
1 – Meridian news release, “New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis”, 1.26.16
2 – World Health Organization: 10 facts on malaria ([https://www.who.int/features/factfiles/malaria/en/](https://www.globenewswire.com/Tracker?data=IGJYyyhd0kcR8L3ZoXNXEo1iFiwbt_sgCmS-QU8FXe0QYSN_SXhbeLG4WD0ACxzhakdYsA6ygACCvsrD8PqvEF51eMfXl1MShh1QmDl3SlkGwxrhgRKQak3rDtUSJJOpL2YW6KP8XL93NvRumb8NCPP4PTATIMByaAlEwoN3rEQ=)) Updated December 2016
3 – ibid
4 – ibid
5 – ibid
6 – The World Health Organization, *Global Technical Strategy for Malaria: 2016-2030*
**About [Meridian Bioscience](https://www.globenewswire.com/Tracker?data=LfQE7Go94tpj_mL3u_hBxYJbd1nMTmL2vZQTzPf6Y92d4XkNR0PhXqGde4rXhTvizeqKi09AmIp7QHSuPm88tWXMTiLiGE8BCaA-DBaODD3ydwu2KMhKAj8vcDkwVzCLsqI65B5dF-gWFivZL4ZWbH3f7KsRecwZwdsYy72B3mo= "Meridian Bioscience"), *illumigene* Malaria & LAMP Technology**
- ***illumi****gene* Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite.
- LAMP (Loop Mediated Isothermal Amplification) is Molecular detection technology which targets DNA and uses premeasured and self-contained reagents. Unlike current PCR testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results. ***illumi****gene* testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
- ***illumi****gene* technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to perform the test. Results are available in under an hour.
- LAMP-based ***illumi****gene* tests are already used to diagnose infectious diseases including *C. difficile*, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
- ***illumi****gene* tests have been approved and used in other diseases for over 5 years.
- The benefits of ***illumi****gene* Malaria are highlighted on the microsite: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**About Meridian Bioscience, Inc**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=fYFQGdpIpbXo8UFcjsy3JrYhfvdNKIAs_4PY-Xq5L0GsHbM6SBU4NueS0uLTcITL8yci4B8_4ocLJPvtIuE-_ag2c0rutSS21KYet4gLXmG1U850kg1Z7741KC9OW0KcGKA6zjx22-hdaFyAe_Xy0Dt73Xhp6urvj0YGHpnWmBoJilGx3uJySU4xSMUznF-1-Rc6lNuNCSiLYYYLmIknlOpyAeQuLtffy-mTuUWeCelxTnWGpZTQe2dzfdis1dPVFg9sUe8nZ6FASS0BMXyCDbI1cY4kO2crNAd3puW8AcI5AMLo6d9KJv87kvkIQwAYnKav3HuLbtd7-ychlL4u5vXcDbe93tgKxtOfgAsJisQ= "www.meridianbioscience.com").
```
```
---
## Tags
[World Malaria Day](https://www.globenewswire.com/en/search/tag/world%2520malaria%2520day "World Malaria Day") [Malaria](https://www.globenewswire.com/en/search/tag/malaria "Malaria") [illumigene](https://www.globenewswire.com/en/search/tag/illumigene "illumigene") [Meridian Bioscience](https://www.globenewswire.com/en/search/tag/meridian%2520bioscience "Meridian Bioscience") [Daouda Ndiaye](https://www.globenewswire.com/en/search/tag/daouda%2520ndiaye "Daouda Ndiaye") [Slava Elagin](https://www.globenewswire.com/en/search/tag/slava%2520elagin "Slava Elagin") [John A. Kraeutler](https://www.globenewswire.com/en/search/tag/john%2520a%C2%A7%2520kraeutler "John A. Kraeutler") [LAMP technology](https://www.globenewswire.com/en/search/tag/lamp%2520technology "LAMP technology")
### Related Links
- [Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options.](https://www.molecularendsmalaria.com/)
---
### Contact Data
```
For Investor Relations, contact:
513-271-3700
John A. Kraeutler, Chief Executive Officer
For all other inquiries, contact:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection](https://www.meridianbioscience.com/press-release/eccmid-presentation-to-demonstrate-revolutionary-breakthrough-in-malaria-detection/)
**Published:** April 17, 2017
**Author:** hamza
**Content:**
## New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) — Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) will feature impressive results regarding a revolutionary breakthrough in the world of malaria detection. His presentation at ECCMID is scheduled for April 25, 2017, which is also World Malaria Day.
Dr. van Gool’s research focused on the efficacy of ***illumi****gene* Malaria, a molecular-based, field laboratory-deployed test for malaria developed by Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO). The test, which is up to 80,000 times more sensitive at detecting the malaria parasite than current diagnostic testing options, was developed by Meridian Bioscience with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal.
Dr. van Gool, MD, PhD, is with the Department of Clinical Parasitology, Academic Medical Center at the University of Amsterdam. His presentation of a pivotal, multi-centre study in a non-endemic West European setting will show that among returning travellers and immigrants, 100 percent accurate detection of malaria was observed utilizing the ***illumi****gene* Malaria molecular test, including detection of all five malaria species and double infections. In the same population, an estimated 10 percent of cases were misjudged as being negative for malaria utilizing RDT testing. The finding of 100 percent accurate detection in patients negative for malaria with ***illumi****gene* Malaria was impressive, as many patients examined for malaria in non-endemic countries prove to be negative for the infection and harbour other diseases. “These findings support burgeoning evidence that ***illumi****gene* Malaria and ***illumi****gene* Malaria PLUS assays are among the first molecular diagnostic tests for malaria in which high sensitivity and specificity, ease of handling and short time to result are combined – all being essential elements in the emergency setting of malaria diagnosis in clinical laboratories,” said Dr. van Gool.
“***illumi****gene* Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria,” said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. “Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions. ***illumi****gene* Malaria shows this capacity.”
***illumi****gene* Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.
Despite a 60 percent decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world’s population is at risk of malaria. (2) In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths. (3) Also that year, Sub-Saharan Africa was home to 90 percent of malaria cases and 92 percent of malaria deaths. (4) More than two-thirds (70 percent) of all malaria deaths occur in children under the age of five. (5)
While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as “loads.” Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.
“People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging,” said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. “If testing doesn’t identify them, eliminating malaria is impossible because these individuals can spread the disease to others.”
That scenario is playing out in the fact that malaria is no longer only a disease of Sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14 percent to 86 percent in more recent studies. On pooling the reports, nearly 43 percent of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70 percent of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries.
While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of ***illumi****gene* Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat. ***illumi****gene* Malaria is user-friendly, does not require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.
“This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread,” said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.
The availability of the field laboratory-deployable and user-friendly, ***illumi****gene* Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.
“Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it,” said Kraeutler.
***illumi****gene* Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network. It is the tenth assay now available on our ***illumi****gene* platform that is used in nearly 1,500 institutions around the world.
1 – Meridian news release, “New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis”, 1.26.16
2 – World Health Organization: 10 facts on malaria ([https://www.who.int/features/factfiles/malaria/en/](https://www.globenewswire.com/Tracker?data=d1zzaLiBksDbB8MoPR2vZ1U0ThHLqLSnlZKbTQjy9RbF9ZfDqmIvtP-mHxeLhjC1tfHdWx0r3EiYa8dLdW84bIT_A8XIQco-a-9tdi1A2Yt9xTMITQzmZfD9x-SLLTXMove_yxNjdSGUDEO77H4BW3myjqe4pQdsU-EiSPm4zWg=)) Updated December 2016
3 – ibid
4 – ibid
5 – ibid
6 – The World Health Organization, *Global Technical Strategy for Malaria: 2016-2030*
**About Meridian Bioscience, *illumigene* Malaria & LAMP Technology**
- ***illumi****gene* Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the malaria parasite.
- LAMP (Loop Mediated Isothermal Amplification) is molecular detection technology which targets DNA and uses premeasured and self-contained reagents. Unlike current polymerase chain reaction (PCR) testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results. ***illumi****gene* testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
- ***illumi****gene* technology is simple, accurate and easy to use, which means that no special technical expertise is needed to perform the test. Results are available in under an hour.
- LAMP-based ***illumi****gene* tests are already used to diagnose infectious diseases including *C. difficile*, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
- ***illumi****gene* tests have been approved and used in other diseases for over five years.
**About Meridian Bioscience, Inc**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.eu](https://www.globenewswire.com/Tracker?data=k9B5NFA1z8xbHnk-aJ7BbvkfHUZ2HJHOCYJjE26nLx65eoMnIiUq7tHotd0yuBCkotJBuW97kt1BleTe1WB5fd639O_e9ocz_9gdB-vGP5A= "www.meridianbioscience.eu").
```
```
---
## Tags
[Malaria](https://www.globenewswire.com/en/search/tag/malaria "Malaria") [Infectious Diseases](https://www.globenewswire.com/en/search/tag/infectious%2520diseases "Infectious Diseases") [New Molecular Test](https://www.globenewswire.com/en/search/tag/new%2520molecular%2520test "New Molecular Test") [ECCMID](https://www.globenewswire.com/en/search/tag/eccmid "ECCMID") [Molecular Diagnostics](https://www.globenewswire.com/en/search/tag/molecular%2520diagnostics "Molecular Diagnostics") [World Malaria Day](https://www.globenewswire.com/en/search/tag/world%2520malaria%2520day "World Malaria Day") [van Gool](https://www.globenewswire.com/en/search/tag/van%2520gool "van Gool") [Meridian Bioscience](https://www.globenewswire.com/en/search/tag/meridian%2520bioscience "Meridian Bioscience")
### Related Links
- [Leading malaria researcher Tom van Gool’s presentation at ECCMID on April 25, 2017, World Malaria Day, will feature impressive results regarding the efficacy of illumigene Malaria, a molecular-based, field laboratory-deployed test for malaria.](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html)
---
### Contact Data
```
For Investor Relations, contact:
513-271-3700
John A. Kraeutler, Chief Executive Officer
For all other inquiries, contact:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [Prosedur Pengujian Baru Berpotensi Besar Menjadi Alat Penting dalam Upaya Global untuk Memberantas Malaria](https://www.meridianbioscience.com/press-release/prosedur-pengujian-baru-berpotensi-besar-menjadi-alat-penting-dalam-upaya-global-untuk-memberantas-malaria/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## Uji molekuler yang dapat diterapkan di laboratorium lapangan hingga 80.000 kali lebih sensitif daripada pilihan-pilihan yang ada saat ini
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — Saat komunitas global berkumpul pada Hari Malaria Sedunia untuk merayakan keberhasilan dan merencanakan strategi memberantas penyakit ini dari muka bumi, secercah sinar harapan baru muncul dari tempat yang mengejutkan: sisi pengujian dari persamaan tersebut.
Meridian Bioscience, Inc., yang berlokasi di Cincinnati, Ohio (NASDAQ:VIVO) telah mengembangkan ***illumi****gene®* Malaria, yaitu suatu uji molekuler yang dapat diterapkan di laboratorium lapangan untuk malaria yang 80.000 kali lebih sensitif dalam mendeteksi parasit malaria daripada pilihan-pilihan pengujian yang ada saat ini. Uji ini dikembangkan oleh Meridian dengan bantuan teknis dari Pusat Pengendalian dan Pencegahan Penyakit (CDC) dan Cheikh Anta Diop University of Dakar, Senegal.
“***illumi****gene* Malaria berpotensi untuk mengubah praktik-praktik saat ini. Diagnosis yang lebih cepat dan lebih akurat merupakan hal sangat penting dalam memerangi malaria,” kata Profesor Daouda Ndiaye, Departemen Parasitologi dan Mikologi, Cheikh Anta Diop University. “Diagnosis sebelumnya memungkinkan memberikan perawatan yang tepat, yang mengarah pada hasil-hasil klinis yang lebih baik bagi orang yang terjangkit malaria dan tetap memberikan perawatan malaria bagi orang yang tepat. Mendeteksi keberadaan parasit malaria dengan jumlah parasit yang sedikit dalam tubuh manusia bukanlah hal yang mudah dan terbukti sulit untuk dilakukan, oleh karena itu diperlukan alat diagnostik laboratorium yang kuat dan sensitif untuk melacak sumber malaria di daerah-daerah praeliminasi. ***illumi****gene* Malaria dapat menunjukkan kapasitas ini.”
***illumi****gene* Malaria mendapatkan peringkat pertama dalam bidang inovasi perawatan darurat dan pengujian *point-of-care* pada Konferensi Journées Internationales de Biologie / Association des Colloques Nationaux des Biologistes di Paris dan ditandai dengan CE agar dapat dijual di Eropa.
Meskipun sejak tahun 2000 terjadi penurunan sebesar 60% pada angka kematian karena malaria berkat upaya pencegahan lebih baik dan peningkatan tindakan pengendalian, malaria masih merupakan satu dari tiga pembunuh teratas anak-anak di seluruh dunia, yang merenggut satu nyawa setiap menit setiap hari. (1) Menurut data terakhir dari Organisasi Kesehatan Dunia, hampir setengah dari populasi dunia berisiko terkena malaria (2). Pada tahun 2015, ada sekitar 212 juta kasus malaria dan diperkirakan sebanyak 429.000 kematian karena malaria (3). Pada tahun yang sama, Afrika Sub-Sahara merupakan wilayah dengan jumlah kasus malaria terbanyak sebesar 90% dan 92% untuk kematian karena malaria (4). Lebih dari dua pertiga (70%) dari semua kasus kematian karena malaria terjadi pada anak berusia di bawah lima tahun (5).
Meski malaria dapat dicegah dan diobati (6), diagnosis yang tepat sangatlah penting. Pengujian molekuler dalam mendeteksi parasit malaria pada tingkat yang sangat rendah, dikenal sebagai “jumlah parasit malaria dalam darah (*load*)”, terbukti lebih efektif dibandingkan dengan pilihan-pilihan yang ada saat ini. Mengidentifikasi orang dengan jumlah parasit malaria dalam darah yang rendah memiliki dua manfaat, yaitu untuk memastikan mereka menerima pengobatan dan mencegah penyebaran penyakit ini kepada orang lain.
“Orang dapat menjadi pembawa penyakit malaria tanpa menunjukkan gejala apa pun, dan mendeteksi individu tanpa gejala ini dapat menjadi tantangan yang berat,” kata Slava Elagin, *Executive Vice President*, Penelitian & Pengembangan di Meridian Bioscience. “Jika pengujian tidak mengidentifikasi mereka, maka tindakan untuk pemberantasan penyakit malaria menjadi mustahil untuk dilakukan karena individu-individu ini dapat menyebarkan penyakit ini kepada orang lain.”
Skenario tersebut dijalankan karena malaria bukan lagi merupakan suatu penyakit yang diderita oleh orang-orang di wilayah Afrika Sub-Sahara dan Asia Selatan saja. Peningkatan jumlah orang yang beremigrasi dari negara-negara tempat malaria bersifat endemis telah menyebabkan angka kejadian yang lebih tinggi di Eropa dan Timur Tengah. Pada studi yang lebih baru, perbandingan kasus malaria yang masuk telah meningkat selama beberapa tahun terakhir dari semula hanya 14% menjadi 86%. Dalam mengumpulkan laporan tersebut, hampir 43% kasus malaria yang tercatat di pusat-pusat utama Eropa terjadi pada orang-orang yang bukan asli penduduk negara tersebut. Tingkat penyakit malaria ditemukan jauh lebih tinggi pada imigran menetap yang melakukan perjalanan untuk mengunjungi teman dan keluarga di negara asal mereka. Mereka dapat menjelaskan hingga 70% kasus dalam beberapa laporan dan peningkatan ini menekankan kebutuhan akan alat diagnostik yang lebih baik di negara-negara nonendemis dan endemis.
Meskipun bukan merupakan suatu konsep yang baru, pengujian molekuler secara tradisional merupakan sebuah proses kompleks yang membutuhkan laboratorium yang lengkap dan juga personel pengujian yang sangat terlatih. Terobosan ***illumi****gene* Malaria yang dilakukan oleh Meridian Bioscience ialah bahwa ***illumi****gene* Malaria dapat digunakan di laboratorium lapangan, tempat infeksi malaria merupakan deteksi muatan tertinggi dan rendah yang paling menantang untuk didiagnosis dan diobati. ***illumi****gene* Malaria sangat mudah digunakan dan tidak memerlukan pelatihan khusus atau investasi modal, hasilnya dapat diperoleh dalam waktu satu jam dan bahan uji dapat disimpan pada suhu kamar.
“Ini adalah suatu kemajuan besar untuk memberikan perawatan yang lebih baik kepada mereka yang terinfeksi malaria dan untuk menghentikan penyebarannya,” kata John A. Kraeutler, *Chief Executive Officer* sekaligus *Chairman of the Board* Meridian Bioscience.
Ketersediaan ***illumi****gene* Malaria yang mudah digunakan dan dapat diterapkan di laboratorium lapangan akan menyempurnakan protokol pengujian yang ada, bukan menggantikannya. ***illumi****gene* Malaria akan bergabung dengan uji diagnostik cepat (RDT) dan mikroskopi untuk menciptakan jaringan protokol deteksi yang akan membantu penanganan langsung di lokasi yang paling dibutuhkan.
“Malaria adalah penyakit mematikan dan kami bangga bekerja sama dengan semua individu berbakat dan berdedikasi di seluruh dunia dalam upaya untuk memberantasnya,” kata Kraeutler.
***illumi****gene* Malaria akan didistribusikan di wilayah Eropa, Timur Tengah, dan Afrika oleh Meridian Bioscience Europe dan di pasar-pasar internasional tambahan oleh jaringan distribusi global yang dimiliki oleh perusahaan. Ini adalah uji kesepuluh yang sekarang tersedia di platform ***illumi****gene* kami yang sedang digunakan oleh hampir 1.500 institusi di seluruh dunia.
1 – Siaran pers terbaru Meridian, “New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis”, 1.26.16
2 – Organisasi Kesehatan Dunia: 10 fakta mengenai malaria () Diperbarui Desember 2016
3 – ibid
4 – ibid
5 – ibid
6 – Organisasi Kesehatan Dunia, *Global Technical Strategy for Malaria: 2016-2030*
**Tentang [Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience"), *illumigene* Malaria & Teknologi LAMP**
·***illumi****gene* Malaria merupakan suatu uji diagnostik untuk malaria yang dikembangkan oleh Meridian Bioscience. Ini adalah uji molekuler yang menggunakan teknologi *Loop-Mediated Isothermal Amplification* (LAMP) untuk memperkuat DNA dan mendeteksi keberadaan parasit Malaria.
·LAMP (*Loop Mediated Isothermal Amplification*) merupakan teknologi pendeteksi molekuler yang menargetkan DNA dan menggunakan reagen sudah terukur dan utuh. Tidak seperti pengujian PCR yang ada saat ini, LAMP tidak memerlukan siklus suhu. LAMP menginkubasi, mendeteksi, dan melaporkan di satu suhu yang memungkinkan hasil lebih cepat. Kit pengujian ***illumi****gene* dapat disimpan pada suhu ruangan, sementara metode-metode molekuler saat ini memerlukan penyimpanan di tempat dingin.
·Teknologi ***illumi****gene* bersifat sederhana, akurat, dan mudah digunakan yang berarti tidak diperlukan keahlian teknis khusus untuk melakukan uji. Hasil tersedia dalam waktu kurang dari satu jam.
·Uji ***illumi****gene* berbasis LAMP telah digunakan untuk mendiagnosis penyakit menular, termasuk *C. difficile*, batuk rejan, dan Herpes Simplex Virus, serta terbukti sangat akurat.
·Uji ***illumi****gene* telah disetujui dan digunakan dalam pengobatan penyakit lain selama lebih dari 5 tahun.
·Manfaat dari ***illumi****gene* Malaria disorot pada situs mikro: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**Tentang Meridian Bioscience, Inc**
Meridian merupakan perusahaan ilmu hayati yang mengembangkan, membuat, memasarkan, dan mendistribusikan berbagai kit uji diagnostik inovatif, reagen langka, komponen, dan biologis khusus. Dengan menggunakan berbagai metode, uji diagnostik kami memberikan akurasi, kemudahan, dan kecepatan dalam diagnosis awal dan pengobatan kondisi medis umum, seperti infeksi dan keracunan timbal. Produk diagnostik Meridian digunakan di luar tubuh manusia dan hanya memerlukan sedikit peralatan khusus atau tidak sama sekali. Produk diagnostik perusahaan dirancang untuk meningkatkan kesehatan pasien sekaligus mengurangi biaya perawatan kesehatan secara keseluruhan. Meridian memiliki posisi pasar yang kuat di bidang saluran pencernaan dan infeksi pernapasan atas dan pengujian kadar timbal dalam darah. Sebagai tambahan, Meridian adalah pemasok bahan reaksi langka, biologis khusus dan komponen yang digunakan oleh organisasi di ilmu hayati dan industri agribio yang terlibat dalam penelitian dan digunakan perusahaan sebagai komponen dalam pembuatan diagnostik. Perusahaan memasarkan produk dan teknologinya ke rumah sakit, laboratorium rujukan, pusat penelitian, produsen diagnostik, dan perusahaan agribio di lebih dari 70 negara di seluruh dunia. Saham perusahaan diperdagangkan di NASDAQ Global Select Market dengan simbol VIVO. Alamat situs web Meridian di [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Untuk Hubungan Investor, hubungi:
513-271-3700
John A. Kraeutler, Chief Executive Officer
Untuk semua pertanyaan lainnya, hubungi:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [Nuevo procedimiento de prueba promete ser una herramienta crucial en el esfuerzo global para eliminar el paludismo](https://www.meridianbioscience.com/press-release/nuevo-procedimiento-de-prueba-promete-ser-una-herramienta-crucial-en-el-esfuerzo-global-para-eliminar-el-paludismo/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## Una prueba molecular de laboratorio de campo que es hasta 80.000 veces más sensible que las opciones actuales
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — Mientras la comunidad global se reúne en el Día Mundial del Paludismo para celebrar los éxitos y el plan estratégico para eliminar la enfermedad de la faz de la tierra, un nuevo rayo de esperanza surge de un sorprendente lugar: del lado de la prueba de diagnóstico en la ecuación.
Meridian Bioscience, Inc. de Cincinnati, Ohio (NASDAQ:VIVO) ha desarrollado ***illumi****gene®* Malaria, una prueba molecular de laboratorio de campo para el paludismo que es hasta 80.000 veces más sensible a la hora de detectar el parásito del paludismo en comparación con las pruebas actuales. La prueba ha sido desarrollada por Meridian con la asistencia técnica de los Centros para el Control y Prevención de Enfermedades (CDC) y la Universidad Cheikh Anta Diop de Dakar, en Senegal.
“***illumi****gene* Malaria tiene el potencial de cambiar las prácticas actuales. Es vital que los diagnósticos sean más rápidos y precisos en la lucha contra el paludismo”, explica el profesor Daouda Ndiaye, del Departamento de Parasitología-Micología de la Universidad Cheikh Anta Diop. “Los diagnósticos tempranos permiten prescribir el tratamiento correcto, y esto nos lleva a mejores resultados clínicos para la persona que padece paludismo y mantiene los tratamientos contra el paludismo para las personas indicadas. Además, debido a la dificultad de la detección del parásito del paludismo en personas con un recuento bajo de parásitos, se necesita una herramienta de diagnóstico sólida, sensible y de laboratorio de campo para rastrear el reservorio del paludismo en regiones donde se encuentra pre-erradicada. ***llumi****gene* Malaria tiene esta capacidad”.
***illumi****gene* Malaria fue galardonada, en primer lugar, en el prestigioso congreso Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes en París y posee el marcado CE para su venta en Europa.
A pesar de un descenso del 60% en las muertes por paludismo desde el año 2000 gracias a una mejor prevención y un aumento de las medidas de control, el paludismo sigue estando entre las tres enfermedades que causan más muertes infantiles alrededor del mundo, llevándose una vida cada minuto. (1) Según los últimos datos de la Organización Mundial de la Salud, casi la mitad de la población mundial está en riesgo de padecer paludismo (2). En 2015, existían aproximadamente 212 millones de casos de paludismo y una estimación de 429.000 muertes por paludismo (3). Además, durante ese año el África subsahariana fue el lugar del 90% de los casos de paludismo y del 92% de las muertes (4). Más de dos tercios (70%) de todas las muertes por paludismo ocurren en niños menores de cinco años (5).
Aunque el paludismo puede prevenirse y tratarse (6), es crucial un diagnóstico adecuado. La prueba molecular ha demostrado ser más efectiva que las opciones actuales en la detección del parásito del paludismo en niveles muy bajos, conocidos como “carga”. Identificar personas con carga baja tiene el doble beneficio de asegurarse de que reciben el tratamiento y de prevenir la propagación de la enfermedad.
“Las personas pueden ser portadoras de paludismo sin mostrar síntomas, y detectar a estas personas asintomáticas es complicado”, explica Slava Elagin, vicepresidenta ejecutiva, Investigación y Desarrollo de Meridian Bioscience. “Si la prueba no los identifica, es imposible eliminar el paludismo, porque estas personas pueden propagar la enfermedad a otras”.
Este escenario se está haciendo realidad debido al hecho de que el paludismo ya no es solo una enfermedad en el África subsahariana y el sur de Asia. El aumento del número de personas que emigran desde estos países donde el paludismo es endémica ha tenido como resultado una incidencia en Europa y Oriente Medio. La proporción de los casos de paludismo importados durante los últimos años ha aumentado del 14% al 86% según muchos estudios recientes. Poniendo en común los informes, aproximadamente un 43% de los casos de paludismo registrados en centros de referencia europeos ocurrían en personas que no eran del país. Las tasas de paludismo son mucho más elevadas en inmigrantes establecidos que visitan amigos y familiares en sus países de origen. Estas personas pueden suponer hasta el 70% de los casos en muchos informes, y este aumento subraya la necesidad de un mejor diagnóstico tanto en los países donde el paludismo es endémico como en los que no lo es.
Aunque no se trate de un concepto nuevo, la prueba molecular ha sido tradicionalmente un proceso complejo que requería laboratorios completamente equipados y un personal altamente formado. La innovación de ***illumi****gene* Malaria de Meridian Bioscience es que puede desarrollarse en un laboratorio de campo, donde la infección de paludismo es más elevada y la detección de la carga baja más complicada de diagnosticar y tratar. ***illumi****gene* Malaria es apta para los usuarios, no requiere de una formación especial o una inversión de capital, los resultados aparecen en menos de una hora y los materiales para la prueba pueden almacenarse a temperatura ambiente.
“Es un gran paso en la lucha para ofrecer una mejor atención a aquellos que están infectados de paludismo y para frenar su propagación”, cuenta John A. Kraeutler, director general y presidente del consejo de Meridian Bioscience.
La disponibilidad de ***llumi****gene* Malaria, en un laboratorio de campo y apto para usuarios, mejorará los protocolos de pruebas existentes, en lugar de sustituirlos. Incorporará pruebas de detección rápida (RDT, por sus siglas en inglés) y un microscopio para crear una red de protocolos de detección que ayudará al tratamiento directo donde más se necesita.
“El paludismo es una enfermedad devastadora y estamos orgullosos de trabajar con todas estas personas dedicadas y con talento alrededor del mundo en la lucha para eliminarlo”, añade Kaeutler.
***illumi****gene* Malaria se distribuirá en Europa, Oriente Medio y regiones de África de la mano de Meridian Bioscience Europe y en mercados internacionales adicionales de mano de la red de distribución global de la empresa. Esta es la décima prueba disponible en nuestra plataforma ***illumi****gene* que está en uso en aproximadamente 1.500 instituciones alrededor del mundo.
1 – Meridian news release, “New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis”, 26/01/2016
2 – World Health Organization: 10 facts on malaria () Actualizado en diciembre de 2016
3 – *ibid.*
4 – *ibid.*
5 – *ibid.*
6 – The World Health Organization, *Global Technical Strategy for Malaria: 2016-2030*
**Acerca de [Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience"), *illumigene* Malaria y LAMP Technology**
- ***illumi****gene* Malaria es una prueba de diagnóstico para el paludismo desarrollada por Meridian Bioscience. Es una prueba molecular que utiliza una tecnología de amplificación isotérmica mediada por asas (LAMP) para ampliar el ADN y detectar la presencia del parásito del paludismo.
- La LAMP (ampliación isotérmica mediada por asas) es una tecnología de detección molecular que se dirige al ADN y utiliza reactivos premedidos y autocontenidos. A diferencia de la prueba de reacción en cadena de polimerasa (RCP), no requiere un ciclo de temperatura. La LAMP incuba, detecta e informa a una misma temperatura y permite así unos resultados más rápidos. Los kits de las pruebas ***illumi****gene* pueden almacenarse a temperatura ambiente, mientras que los métodos moleculares actuales necesitan refrigeración.
- La tecnología de ***illumi****gene* es simple, precisa y fácil de utilizar, por lo tanto, no se necesita un conocimiento especializado y técnico para realizar la prueba. Los resultados están disponibles en menos de una hora.
- Las pruebas de ***illumi****gene* basadas en la LAMP ya se utilizan para diagnosticar enfermedades infecciosas, incluyendo la tos ferina, el virus del herpes simple y la *C.* *difficile*, en las que se han obtenido resultados muy precisos.
- Las pruebas de ***llumi****gene* han sido aprobadas y utilizadas en otras enfermedades durante más de 5 años.
- Los beneficios de ***llumi****gene* Malaria están señalados en el micrositio: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**Acerca de Meridian Bioscience, Inc**
Meridian es una compañía de ciencias biológicas totalmente integrada que desarrolla, fabrica, comercializa y distribuye una amplia gama de pruebas de diagnóstico innovadoras, reactivos poco frecuentes y productos biológicos y componentes especializados. Con el uso de una variedad de métodos, nuestras pruebas de diagnóstico brindan precisión, simplicidad y velocidad en el diagnóstico y el tratamiento temprano de afecciones médicas comunes, como infecciones e intoxicación por plomo Los productos de diagnóstico de Meridian se usan fuera del cuerpo humano y prácticamente no requieren de equipos especiales. Los productos de diagnóstico de la Compañía están diseñados para mejorar el bienestar del paciente y reducir al mismo tiempo los costos totales de la atención médica. Meridian tiene una sólida posición de mercado en áreas de diagnóstico de infecciones de las vías respiratorias superiores y gastrointestinales, y en pruebas de nivel de plomo en sangre. Además, Meridian provee reactivos poco frecuentes, productos biológicos especiales y componentes utilizados por las organizaciones de la industria de productos biológicos y agricultura biológica que realizan investigaciones, así como por compañías dedicadas a componentes para la fabricación de productos de diagnóstico. La Compañía comercializa sus productos y tecnología a hospitales, laboratorios de referencia, centros de investigación, fabricantes de productos de diagnóstico y compañías de agricultura biológica en más de 70 países de todo el mundo. Las acciones de la Compañía cotizan en el NASDAQ Global Select Market, símbolo VIVO. La página web de Meridian [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contacto con Relaciones con inversionistas en el:
513-271-3700
John A. Kraeutler, Director general
Para otras consultas, póngase en contacto en el:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [Prosedur Ujian Baru Memegang Janji Sebagai Alat Kritikal dalam Usaha Global untuk Menghapuskan Malaria](https://www.meridianbioscience.com/press-release/prosedur-ujian-baru-memegang-janji-sebagai-alat-kritikal-dalam-usaha-global-untuk-menghapuskan-malaria/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## Makmal lapangan letak atur molekul menguji sehingga 80,000 kali lebih sensitif daripada pilihan semasa
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — Ketika masyarakat global berkumpul untuk Hari Malaria Sedunia bagi meraikan kejayaan dan strategi plot untuk menghapuskan penyakit ini dari muka bumi, satu sinar harapan baru muncul dari tempat yang mengejutkan: sisi pengujian persamaan.
Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) telah membangunkan ***illumi****gene®* Malaria, suatu ujian makmal lapangan letak atur berasaskan molekul untuk malaria yang sehingga 80,000 kali lebih sensitif mengesan parasit malaria berbanding pilihan pengujian semasa. Ujian ini telah dibangunkan oleh Meridian dengan bantuan teknikal daripada Pusat Kawalan dan Pencegahan Penyakit (CDC) dan Universiti Cheikh Anta Diop Dakar, Senegal.
“***illumi****gene* Malaria mempunyai potensi untuk mengubah amalan semasa. Diagnosis yang cepat dan lebih tepat adalah penting dalam memerangi malaria,” kata Profesor Daouda Ndiaye, Jabatan Parasitologi-Mikologi, Universiti Cheikh Anta Diop. “Diagnosis awal membolehkan rawatan yang betul ditentukan, yang membawa kepada hasil klinikal yang lebih baik bagi pesakit malaria dan membolehkan rawatan malaria diberikan kepada individu yang sepatutnya. Dan oleh kerana mengesan parasit malaria dalam manusia dengan kiraan parasit yang rendah telah terbukti sukar, alat diagnostik makmal lapangan letak atur yang sensitif dan teguh diperlukan untuk mengesan takungan malaria di kawasan-kawasan pra-penyingkiran. ***illumi****gene* Malaria menunjukkan kapasiti ini.”
***illumi****gene* Malaria telah mendapat tempat pertama bagi inovasi dalam rawatan kecemasan dan ujian di tempat penjagaan di Persidangan Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes berprestij di Paris, dan bertanda CE untuk dijual di Eropah.
Walaupun penurunan 60% dalam kematian malaria sejak tahun 2000 disebabkan oleh pencegahan yang lebih baik dan langkah-langkah kawalan meningkat, malaria masih merupakan salah satu daripada tiga pembunuh utama kanak-kanak di seluruh dunia, mengorbankan satu nyawa bagi setiap minit setiap hari. (1) Menurut data terkini dari Pertubuhan Kesihatan Sedunia, hampir separuh daripada penduduk dunia adalah berisiko mendapat malaria (2). Pada tahun 2015, terdapat kira-kira 212 juta kes malaria dan dianggarkan 429,000 kematian disebabkan oleh malaria (3). Juga pada tahun yang sama, Sub-Sahara Afrika adalah pusat kepada 90% kes malaria dan 92% daripada kematian malaria (4). Lebih daripada dua pertiga (70%) daripada semua kematian malaria berlaku pada kanak-kanak di bawah umur lima tahun (5).
Walaupun malaria boleh dicegah dan dirawat (6), diagnosis yang betul adalah kritikal. Ujian molekul telah terbukti lebih berkesan daripada pilihan semasa dalam mengesan parasit malaria pada tahap yang sangat rendah, yang dikenali sebagai “muatan.” Mengenal pasti individu muatan rendah mempunyai dua manfaat iaitu untuk memastikan mereka menerima rawatan dan mencegah penyebaran penyakit ini kepada orang lain.
“Orang boleh menjadi pembawa malaria tanpa menunjukkan sebarang gejala, dan mengesan individu-individu asimptomatik ini adalah mencabar,” kata Slava Elagin, Naib Presiden Eksekutif, Penyelidikan & Pembangunan di Meridian Bioscience. “Jika ujian tidak dapat mengenal pasti mereka, menghapuskan malaria adalah mustahil kerana individu-individu ini boleh menyebarkan penyakit ini kepada orang lain.”
Senario ini terjadi atas fakta bahawa malaria tidak lagi hanya penyakit sub-Sahara Afrika dan Asia Selatan. Semakin banyak orang berhijrah dari negara-negara di mana malaria adalah endemik telah menyebabkan insiden yang lebih tinggi di Eropah dan Timur Tengah. Dalam kajian yang lebih terkini menunjukkan peratusan kes malaria yang diimport telah meningkat dalam tempoh beberapa tahun lepas daripada 14% kepada 86%. Pada pengumpulan laporan, hampir 43% daripada kes-kes malaria yang berdaftar di pusat-pusat utama Eropah berlaku di pusat bukan warganegara. Kadar malaria adalah lebih tinggi pada pendatang yang menetap yang pergi melawat rakan-rakan dan saudara-mara di negara asal mereka. Mereka boleh menyumbang sehingga 70% daripada kes-kes berdasarkan beberapa laporan dan peningkatan ini menekankan keperluan untuk alat diagnostik yang lebih baik dalam kedua-dua negara bukan endemik dan endemik.
Walaupun bukan konsep baru, ujian molekul secara tradisinya merupakan satu proses yang kompleks yang memerlukan makmal serba lengkap dan kakitangan ujian yang terlatih. Kejayaan ***illumi****gene* Malaria oleh Meridian Bioscience adalah kerana ia boleh digunakan dalam makmal lapangan, di mana tempat jangkitan malaria yang paling tinggi dan pengesanan muatan rendah paling mencabar untuk didiagnosis dan dirawat. ***illumi****gene* Malaria adalah mesra pengguna, tidak memerlukan latihan khas atau pelaburan modal, hasil keputusan boleh didapati dalam masa kurang satu jam dan bahan-bahan ujian boleh disimpan pada suhu bilik.
“Ini adalah satu langkah besar dalam usaha bagi memberi penjagaan yang lebih baik untuk mereka yang dijangkiti malaria dan untuk menghentikan penyebarannya,” kata John A. Kraeutler, Ketua Pegawai Eksekutif dan Pengerusi Lembaga Meridian Bioscience.
Adanya makmal lapangan letak atur dan mesra pengguna, ***illumi****gene* Malaria akan meningkatkan dan bukannya menggantikan protokol ujian yang sedia ada. Ia akan menyertai ujian diagnostik (RDT) dan mikroskopi yang pesat untuk mewujudkan kumpulan protokol pengesanan yang akan membantu rawatan terus di mana ia diperlukan.
“Malaria adalah penyakit yang amat dahsyat dan kami bangga untuk bekerjasama dengan semua individu yang berbakat dan berdedikasi di seluruh dunia dalam usaha untuk menghapuskannya,” kata Kraeutler.
***illumi****gene* Malaria akan diedarkan di Eropah, Timur Tengah dan rantau Afrika oleh Meridian Bioscience Eropah dan tambahan di pasaran antarabangsa oleh rangkaian pengedaran global Syarikat. Cerakinan kesepuluh kini boleh didapati di platform ***illumi****gene* kami yangsedang digunakan di lebih 1,500 institusi di seluruh dunia.
1 – Kenyataan akhbar Meridian, “Ujian Malaria Baru, *illumigene* Malaria, Menetapkan Piawaian Diagnosis Tertinggi Baru”, 1.26.16
2 – Pertubuhan Kesihatan Sedunia: 10 fakta mengenai malaria () Kemaskini Disember 2016
3 – ibid
4 – ibid
5 – ibid
6 – Pertubuhan Kesihatan Sedunia, *Strategi Teknikal Global untuk Malaria: 2016-2030*
**Mengenai [Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience"), *illumigene* Malaria & Teknologi LAMP**
- ***illumi****gene* Malaria adalah ujian diagnostik untuk malaria yang dibangunkan oleh Meridian Bioscience. Ia adalah ujian molekul yang menggunakan teknologi Loop-Mediated Isothermal Amplification (LAMP) untuk menguatkan DNA dan mengesan kehadiran parasit Malaria tersebut.
- LAMP (Loop Mediated Isothermal Amplification) adalah teknologi pengesanan molekul yang mensasarkan DNA dan menggunakan bahan uji pra ukur dan serba lengkap. Tidak seperti ujian PCR semasa, ia tidak memerlukan suhu berkitaran. LAMP mengeram, mengesan dan melaporkan pada suhu tunggal, membolehkan keputusan yang lebih cepat. Kit ujian ***illumi****gene* boleh disimpan di bawah keadaan sekeliling, manakala kaedah molekul semasa memerlukan penyimpanan sejuk.
- Teknologi ***illumi****gene* adalah mudah, tepat dan mudah untuk digunakan yang bermaksud tiada kepakaran teknikal khusus diperlukan untuk melakukan ujian. Keputusan boleh didapati kurang daripada satu jam.
- Ujian ***illumi****gene* berdasarkan LAMP telah digunakan untuk mendiagnosis penyakit berjangkit termasuk *C. difficile*, batuk kokol dan Virus Herpes Simpleks, yang telah membuktikan ketepatannya.
- Ujian ***illumi****gene* telah diluluskan dan digunakan dalam penyakit lain selama lebih 5 tahun.
- Manfaat ***illumi****gene* Malaria diketengahkan di laman mikro: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**Mengenai Meridian Bioscience, Inc**
Meridian ialah syarikat sains hayat bersepadu sepenuhnya yang membangunkan, mengeluarkan, memasarkan dan mengedarkan pelbagai kit ujian diagnostik inovatif, reagen nadir, biologikal dan komponen khusus. Menggunakan pelbagai kaedah, ujian diagnostik kami memberikan ketepatan, kesederhanaan dan kelajuan dalam diagnosis dan rawatan awal bagi keadaan perubatan biasa, seperti jangkitan dan keracunan plumbum. Produk diagnostik Meridian digunakan di luar tubuh manusia dan memerlukan sedikit atau tanpa peralatan khas. Produk diagnostik Syarikat direka untuk meningkatkan kesejahteraan pesakit di samping mengurangkan jumlah kos penjagaan kesihatan. Meridian mempunyai kedudukan pasaran yang kukuh dalam bidang jangkitan gastrousus dan pernafasan atas dan ujian tahap plumbum dalam darah. Di samping itu, Meridian adalah pembekal reagen nadir, biologikal dan komponen khusus yang digunakan oleh organisasi dalam bidang sains hayat dan industri agribio yang terlibat dalam penyelidikan dan oleh syarikat sebagai komponen dalam pembuatan diagnostik. Syarikat ini memasarkan produk dan teknologi kepada hospital, makmal rujukan, pusat penyelidikan, diagnostik pengeluar dan syarikat agribio di lebih daripada 70 buah negara di seluruh dunia. Saham Syarikat didagangkan di Pasaran Pilihan Global NASDAQ, simbol VIVO. Alamat laman web Meridian ialah [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Untuk Perhubungan Pelabur, sila hubungi:
513-271-3700
John A. Kraeutler, Ketua Pegawai Eksekutif
Untuk semua pertanyaan lain, sila hubungi:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [Novo procedimento de testes é ferramenta fundamental promissora no esforço global para eliminar malária](https://www.meridianbioscience.com/press-release/novo-procedimento-de-testes-e-ferramenta-fundamental-promissora-no-esforco-global-para-eliminar-malaria/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## Teste molecular implantável em laboratório de campo é até 80.000 vezes mais sensível que opções atuais
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — À medida em que a comunidade global se reúne para o Dia Mundial de Luta contra a Malária no intuito de celebrar conquistas e traçar estratégias para eliminar a doença da face da Terra, um novo raio de esperança está surgindo de um lugar surpreendente: o lado experimental da equação.
A Meridian Bioscience, Inc. de Cincinnati, Ohio (NASDAQ:VIVO), desenvolveu o ***illumi****gene®* Malaria, um teste implementável em laboratório e baseado em moléculas para malária que é até 80.000 vezes mais sensível na detecção do parasita da malária que as opções de testagem atuais. O teste foi desenvolvido pela Meridian com a assistência técnica dos Centros para Controle e Prevenção de Doenças (CDC, em inglês) e a Universidade Cheikh Anta Diop de Dacar, Senegal.
“O ***illumi****gene* Malaria possui o potencial para mudar as práticas atuais. O diagnóstico mais rápido e preciso é essencial na luta contra a malária”, disse o Professor Daouda Ndiaye, do Departamento de Parasitologia-Micologia da Universidade de Cheikh Anta Diop. “O diagnóstico precoce possibilita que se prescreva o tratamento correto, o que leva a melhores resultados clínicos para a pessoa com malária e conserva os tratamentos de malária para as pessoas certas. E como a detecção do parasita da malária em pessoas com baixa contagem de parasitas tem se provado difícil, uma ferramenta de diagnóstico robusta, sensível e implementável em laboratório de campo é necessária para rastrear o reservatório de malária em regiões de pré-eliminação. O ***illumi****gene* Malaria apresenta essa capacidade.”
O ***illumi****gene* Malaria foi premiado em primeiro lugar por inovação em tratamento de emergência e teste no local de prestação de cuidados pela prestigiada Conferência Journées Internationales de Biologie/Association des Colloques Nationaux des Biologistes em Paris e tem a marca do Comitê Europeu para venda na Europa.
Apesar de uma redução de 60% no número de mortes por malária desde 2000, devido à adoção de melhores medidas de prevenção e aumento do controle, a malária ainda é um dos três principais causadores de mortes de crianças em todo o mundo, com uma média de uma criança por minuto. (1) De acordo com os dados mais recentes da Organização Mundial de Saúde, quase metade da população mundial está sob risco de malária (2). Em 2015, houve aproximadamente 212 milhões de casos de malária e estimaram-se 429.000 mortes por malária (3). Também naquele ano, a África Subsaariana foi palco de 90% dos casos de malária e 92% das mortes por malária (4). Mais de dois terços (70%) de todas as mortes por malária ocorreram em crianças menores de cinco anos de idade (5).
Embora a malária seja evitável e tratável (6), o diagnóstico adequado é essencial. A testagem molecular provou ser mais eficiente que as atuais opções na detecção do parasita da malária em níveis muito baixos, conhecidos como “cargas”. Identificar indivíduos com cargas baixas traz o duplo benefício de garantir que eles recebam tratamento e prevenir que a doença se espalhe a outras pessoas.
“As pessoas podem ser portadoras de malária sem apresentar qualquer sintoma, e identificar esses indivíduos assintomáticos pode ser desafiador”, disse Slava Elagin, Vice-Presidente Executivo de Pesquisa e Desenvolvimento da Meridian Bioscience. “Se os testes não os identificam, é impossível eliminar a malária, pois esses indivíduos podem disseminar a doença para outros.”
Esse cenário se desenrola no momento em que a malária já não é mais apenas uma doença da África Subsaariana e do Sul Asiático. Um número crescente de pessoas que emigram de países onde a malária é endêmica resultou na maior incidência de casos na Europa e no Oriente Médio. A proporção de casos de malária importados aumentou durante os últimos anos de 14% para 86% nos estudos mais recentes. Compilando os relatórios, quase 43% dos casos de malária registrados nos principais centros europeus ocorreram em estrangeiros. As taxas de malária são muito maiores em imigrantes estabelecidos que viajam para visitar amigos e parentes em seus países de origem. Eles são responsáveis por até 70% dos casos de acordo com vários relatórios, e esse aumento destaca a necessidade de melhores ferramentas de diagnóstico tanto nos países não endêmicos quanto nos endêmicos.
Embora não seja um conceito novo, a testagem molecular tem sido tradicionalmente um processo complexo que requer laboratórios totalmente equipados e equipe de testagem altamente treinada. A reviravolta do ***illumi****gene* Malaria da Meridian Bioscience é que ele pode ser implementado no laboratório de campo, onde a infecção por malária é mais alta e a detecção de carga baixa é mais problemática de diagnosticar e tratar. O ***illumi****gene* Malaria é fácil de usar, não requer treinamento ou investimento de capital especial, produz resultados em menos de uma hora e os materiais de teste podem ser armazenados à temperatura ambiente.
“Esse é um grande avanço na luta para trazer melhores cuidados àqueles que foram infectados pela malária e para interromper a disseminação da doença”, disse John A. Kraeutler, Diretor-Executivo e Presidente do Conselho da Meridian Bioscience.
A disponibilidade do ***illumi****gene* Malaria, que é implementável em laboratório de campo e fácil de usar, irá melhorar os protocolos de teste ao invés de substituí-los. Ele se unirá aos testes de diagnóstico rápido (RDTs, em inglês) e de microscópio para criar uma rede de protocolos de detecção que irá ajudar a direcionar o tratamento onde ele for mais necessário.
“A malária é uma doença devastadora e nós estamos orgulhosos por trabalhar com todos os talentosos e dedicados indivíduos de todo o mundo na luta para eliminá-la”, disse Kraeutler.
O ***illumi****gene* Malaria será distribuído nas regiões da Europa, Oriente Médio e África pela Meridian Bioscience Europe, e nos mercados internacionais restantes pela rede de distribuição global da empresa. Agora ele é o décimo ensaio disponível em nossa plataforma ***illumi****gene* que está em uso por aproximadamente 1.500 instituições ao redor do mundo.
1 – Comunicado de imprensa da Meridian, “New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis”, de 26 de janeiro de 2016.
2 – Organização Mundial de Saúde: 10 fatos sobre a malária () Atualizado em dezembro de 2016
3 – ibid
4 – ibid
5 – ibid
6 – Organização Mundial de Saúde, *Estratégia Técnica Mundial para a Malária: 2016-2030*
**Sobre a [Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience"), *illumigene* Malaria e a Tecnologia LAMP**
- O ***illumi****gene* Malaria é um teste de diagnóstico para malária desenvolvido pela Meridian Bioscience. É um teste molecular que usa a tecnologia Loop-Mediated Isothermal Amplification (LAMP) para ampliar o DNA e detectar a presença do parasita da malária.
- A LAMP (Loop Mediated Isothermal Amplification) é uma tecnologia de detecção molecular que marca o DNA e utiliza regentes pré-concebidos e autônomos. Ao contrário dos atuais testes de PCR, ele não necessita de um ciclo de temperatura. A LAMP incuba, detecta e reporta a uma única temperatura, permitindo resultados mais rápidos. Os kits de teste do ***illumi****gene* podem ser armazenados nas condições ambientais, enquanto os métodos moleculares atuais precisam de armazenagem refrigerada.
- O ***illumi****gene* possui uma tecnologia simples, precisa e fácil de usar, o que significa que nenhum conhecimento técnico específico é necessário para realizar o teste. Os resultados ficam disponíveis em menos de uma hora.
- Os testes do ***illumi****gene* baseados em LAMP já são utilizados para o diagnóstico de doenças contagiosas incluindo *C. difficile*, coqueluche e Herpes Simplex Virus, nos quais eles demonstraram alta precisão.
- Os testes com ***illumi****gene* foram aprovados e utilizados em outras doenças por mais de 5 anos.
- Os benefícios do ***illumi****gene* Malaria estão em destaque no microsite: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**Sobre a Meridian Bioscience, Inc**
A Meridian é uma empresa de ciências da vida completamente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de kits inovadores de diagnóstico, reagentes raros, biológicos especializados e componentes. Utilizando uma variedade de métodos, nossos testes de diagnósticos oferecem precisão, simplicidade e velocidade em diagnóstico e tratamento precoces de condições clínicas comuns, como infecções e envenenamento por chumbo. Os produtos de diagnóstico da Meridian são usados fora do corpo humano e requerem pouco ou nenhum equipamento especial. Os produtos de diagnóstico da Empresa são projetados para aumentar o bem-estar do paciente ao mesmo tempo em que reduzem os custos com cuidados da saúde. A Meridian possui posições fortes no mercado nas áreas de infecções gastrointestinais e respiratórias superiores e análises do nível de chumbo no sangue. Além disso, a Meridian é fornecedora de reagentes raros, biológicos especializados e componentes utilizados por organizações de ciências da vida e indústrias bioagrícolas dedicadas à pesquisa e por empresas como componentes na produção de diagnósticos. A Empresa comercializa seus produtos e tecnologias com hospitais, laboratórios de referência, centros de pesquisa, fabricantes de diagnóstico e empresas bioagrícolas em mais de 70 países. As ações da Empresa são negociadas no Global Select Market da NASDAQ com o símbolo VIVO. O site da Meridian é [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Para Relações com Investidores, entre em contato com:
513-271-3700
John A. Kraeutler, Diretor-Executivo
Para todas as outras questões, entre em contato com:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [新たな検査手法が全世界的なマラリア撲滅への重要なツールとなる期待](https://www.meridianbioscience.com/press-release/新たな検査手法が全世界的なマラリア撲滅への重/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## 従来検査の最大8万倍もの高感度を備える分子検査、現地でも使用可能
シンシナティ発, April 24, 2017 (GLOBE NEWSWIRE) — 全地球におけるマラリア根絶の成功を祝し、それに向けた取り組みを画策する「世界マラリア･デー （World Malaria Day） 」に、世界中のコミュニティが集結する中、驚くべきことにマラリア検査の分野から新たな希望が報告された。
米国オハイオ州シンシナティのメリディアン･バイオサイエンス （Meridian Bioscience, Inc.） （NASDAQ:VIVO） は、イルミジーン･マラリア （***illumi****gene®* Malaria） を開発した。これは、マラリア原虫検出能力において従来検査の最大8万倍もの高感度を備える、分子ベースで、野外で使用可能なマラリア検査で、米国疾病管理予防センター （Centers for Disease Control and Prevention、CDC） およびセネガル共和国ダカール市のシェイク･アンタ･ジョップ大学 （Cheikh Anta Diop University） の技術協力を得てメリディアンが開発したものである。
シェイク･アンタ･ジョップ大学、寄生虫･菌類学部のダオウダ･ニディアイ教授 （Professor Daouda NDIAYE） は「イルミジーン･マラリアは、現在の慣行を変化させる可能性を持っています。マラリアと戦うためには、より迅速で正確な診断が不可欠です。早期に診断できれば正しい治療を処方でき、マラリア患者の臨床転帰を改善し、適切な人だけに対してマラリアの治療を行えるようになります。極微小の原虫血症のキャリアが住民のなかに存在するため、マラリアがまだ撲滅されていない地域で原虫保有を追跡するためには、地域社会の現地で使用可能な高感度で信頼性の高いスクリーニング･ツールが必要になります。**イルミ**ジーン･マラリアはそのような能力を示しています」と述べている。
イルミジーン･マラリアは、2016年にパリで開催された権威あるJIB/ACNBH （Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes） 会議の救急治療、医療現場検査における革新賞で1位を受賞しており、欧州における販売には基準適合マーク （CEマーク） が表示されている。
予防策･管理策の改善によってマラリアによる死亡は2000年以降、60%削減されたが、マラリアは現在でも世界中で子供の死因上位3位に入り、毎日1分あたりに1人の死亡につながっている （1）。世界保健機関の最新データによると、全世界人口のほぼ半数がマラリアのリスクを抱えている （2）。2015年にはおよそ2億1,200万件のマラリア感染があり、マラリア感染による死者は429,000人であった （3）。同年、マラリア感染件数の90%およびマラリア感染による死者の92%がサハラ砂漠以南のアフリカ地域であった （4）。マラリア感染による死者の3分の2以上 （70%） が、5歳未満の子供である （5）。
マラリアは予防および治療が可能である一方 （6）、的確な診断が極めて重要である。マラリア原虫検出は、「ロード （loads） 」と呼ばれる非常に低いレベルで行う分子検査がより効果的であることが証明されている。低いロードの患者の識別は、確実に治療を受けることや他者への感染を防ぐことが可能になるという２重の利点がある。
メリディアン･バイオサイエンスの研究開発担当専務副社長 （Executive Vice President Research & Development）、スラヴァ･エラギン （Slava Elagin） は次のように述べている。「マラリアの症状がなくてもキャリアとなっていることがあり、こうした無症候性の患者を検出することは困難です。検査によってこうした無症候性の患者を識別できない場合には、マラリア撲滅は不可能になります。こうした個人によって他者に感染することがあるからです。」
実際、マラリアは、もはやサハラ砂漠以南のアフリカと南アジアの地域に限定されていないため、このシナリオは現実となっている。マラリアが蔓延する国々からの移住者数が増加したために、欧州および中近東諸国における感染率が増加した。最新の研究では、輸入マラリアの関連件数は過去数年間に14%から86%へと増加したとされる。各種報告の集計によると、主要欧州都市で記録されたマラリア感染者のほぼ43%が、欧州圏外の国籍保持者であった。出身地における友人や家族を訪問する欧州諸国定住の移民間でのマラリア感染率は、かなり高い。数件の報告によると、こうしたケースでの感染件数が70%に上るとされており、こうした増加は、マラリアが風土病であるなしにかかわらず、すべての国で信頼性の高い診断ツールが必要とされる現状を裏付けている。
分子検査は新しい概念ではないものの、従来は、完全装備の研究室および高度な技術を持つ専門家を要する複雑なプロセスであった。メリディアン･バイオサイエンスが開発した画期的なイルミジーン･マラリアは、マラリア感染が最も蔓延し、診断と治療のための極微小の検出が最も困難な現地において導入可能なことである。イルミジーン･マラリアは容易に使用でき、専門技能や資本投資を必要とせず、1時間未満で結果が得られる。検査試料を室温で保管できる。
メリディアン･バイオサイエンスの最高業務責任者兼取締役会議長のジョン･A･クレウトラー （John A. Kraeutler） 氏は、「これは、マラリア感染患者のケアおよび感染予防に向ける大きな前進を意味します」と述べた。
野外で容易に使用できるイルミジーン･マラリアが使用可能になることで、既存の検査プロトコルに取って代わるというより、むしろそれを強化することになる。迅速診断検査 （RDT） および顕微鏡検査に加えて、精密な検出プロトコルの創出を実現し、最も必要な箇所に対して治療を行うことができるようになる。
「マラリアは悲惨な感染病です。当社は、世界中からの才能ある献身的な人々と共にマラリア撲滅を目指して戦うことができて光栄に思います」と、クレウトラー氏は述べた。
イルミジーン･マラリアは、メリディアン･バイオサイエンス･ヨーロッパによって欧州、中近東、アフリカ地域に販売され、その他の海外市場は同社の海外販売ネットワークによって販売される。世界中1,500近くの機関が利用する同社のイルミジーン･プラットフォームで利用可能になった10種目のアッセイ製品である。
1 – メリディアンのニュースリリース「New Malaria Test, *illumi*gene Malaria, Sets a New Gold Standard for Diagnosis」、1.26.16
2 – 世界保健機構: 「10 facts on malaria」 （） 2016年12月更新
3 – ibid
4 – ibid
5 – ibid
6 – 世界保健機構、「*Global Technical Strategy for Malaria: 2016-2030*」
**[メリディアン･バイオサイエンス](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "メリディアン･バイオサイエンス")**の**イルミジーン･マラリアとLAMPテクノロジーについて**
- イルミジーン･マラリア （illumigene® Malaria） は、メリディアン･バイオサイエンスが開発したマラリア診断テストである。ループ媒介等温増幅 （Loop-Mediated Isothermal Amplification、LAMP） テクノロジーを駆使してDNAを増幅し、マラリア原虫の存在を検出する分子検査である。
- LAMP （Loop Mediated Isothermal Amplification） は、DNAを標的として前処理済み培地含有型の試薬を使用する分子検出技術である。LAMPテクノロジーは、ポリメラーゼ連鎖反応 （PCR） テクノロジーとは異なり、温度サイクルテストを要さず、単一温度で培養･検出･報告を行うため、より迅速に結果を得ることができる。イルミジーン試験キットは、冷蔵保管が必要な従来の分子手法と異なり、室温で保管可能である。
- イルミジーン･テクノロジーは単純かつ精度が高く、使用も容易なため、専門技能･知識がなくてもテストを使用できる。結果は1時間未満で得られる。
- LAMPを使用しているイルミジーン･テストは、既に、クロストリジウム･ディフィシル、百日咳、単純ヘルペス･ウィルスを含めた感染症の診断に使用されており、高い精度が実証されている。
- イルミジーン･テストは、他の疾患で5年以上にわたり承認取得･使用されている。
- イルミジーン･マラリアの特徴は以下のマイクロサイトに掲載される: [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com")
**メリディアン･バイオサイエンスについて**
メリディアン･バイオサイエンス （Meridian Bioscience, Inc.） は、多様な革新的診断テスト･キット、希少試薬、特殊バイオ医薬品および製剤の開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス企業である。多様な方法を駆使する当社の診断テストは、感染症や鉛中毒などのよくある疾患の早期診断と治療において、高精度、単純性、スピードを実現している。メリディアンの診断用製品は体外使用製品であり、専門的装置はほとんど必要としないか、まったく不要である。同社の製品は患者の心身の健康を強化し、同時に医療の費用対効果を高めるよう設計されている。メリディアンは消化器系･呼吸器系上部の感染症および血中鉛レベル試験の診断分野で強力な市場地位を持つ。さらに、メリディアンは生命科学およびアグリバイオ産業界において研究に携わるバイオ製薬会社や診断製品の製造企業が成分に使用する希少試薬、特殊生物物質、関連製剤のサプライヤーでもある。同社は世界中70ヶ国以上の病院、基準検査機関、リサーチセンター、診断用製品メーカー、アグリバイオ企業にその製品、テクノロジーを販売している。同社の株式はナスダックのグローバル･セレクト･マーケットでシンボル「VIVO」で取引されている。メリディアンのウェブサイトは以下のとおりである。[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
問い合わせ先
513-271-3700
最高業務責任者 （Chief Executive Officer）
ジョン･A･クレウトラー （John A. Kraeutler）
その他に関する問い合わせ先
513-403-7222
ジョー･シールズ （Joe Shields）
```
**Categories:** Press Release
---
### [새로운 말라리아 테스트 절차, 질병 퇴치를 위한 전세계적 노력에 핵심적 도구로 사용될 수 있어](https://www.meridianbioscience.com/press-release/새로운-말라리아-테스트-절차-질병-퇴치를-위한-전세/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## 현장 실험실에서 도입 가능한 분자 테스트, 기존 방식보다 검출감도 최대 8만배 향상
신시내티, April 24, 2017 (GLOBE NEWSWIRE) — ‘세계 말라리아의 날’을 맞아 전세계가 그 동안의 말라리아 퇴치 관련 성과를 자축하고 새로운 전략 구상에 나서고 있다. 이런 가운데 진단검사 분야에서 중요한 도구가 개발되어 말라리아 퇴치의 새로운 희망으로 떠오르고 있다.
메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ:VIVO)는 기존의 말라리아 원충 검사법보다 검출감도를 최대 8만배 향상시킨 분자 기반의 실험실 현장 개발 테스트 ***illumi****gene®* Malaria를 개발한 바 있다. 본 테스트는 미국 질병통제예방센터(CDC)와 세네갈 다카르대학의 기술지원을 통해 개발되었다.
다우다 은자이(Daouda Ndiaye) 다카르대 기생충-의진균학과 교수는 “***illumi****gene* Malaria는 기존의 테스트 실무 작업을 뒤바꿔 놓을 잠재력을 가지고 있다. 말라리아와의 싸움은 신속, 정확한 진단이 핵심이기 때문이다. 말라리아의 조기 진단은 곧 정확한 치료제의 처방, 그리고 임상결과 향상으로 이어지며, 실제 환자에게 올바른 치료를 실시할 수 있다. 특히 기생체 수가 적은 환자의 경우 말라리아 원충 검사가 어렵다. 따라서 말라리아가 퇴치 전 단계에 있는 지역 내에서 원충 서식지를 추적하기 위해서는 강력하고 검출감도가 높으며 실험실 현장에서 도입 가능한 진단 도구가 필요한 것이다”고 밝혔다.
***illumi****gene* Malaria는 지난해 파리에서 열린 JIB/ACNBH(Journees Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference) 컨퍼런스에서 응급치료 및 현장진단 혁신부문 1위를 차지했으며, 유럽 내 판매를 위한 CE마크를 획득했다.
과거에 비해 개선된 사전 예방과 통제 대책으로 인해 말라리아로 인한 사망자는 2000년 이후 60% 감소했지만, 말라리아는 여전히 전 세계 어린이 사망요인 가운데 상위 3위 안에 포함되며 매일 1분에 1명꼴로 생명을 앗아가고 있다. (1) 세계보건기구(WHO) 최근 자료에 따르면 전세계 인구의 절반 가까이가 말라리아 감염 위험에 노출되어 있는 것으로 나타났다 (2). 2015년에만 약 2억 1,200만건의 말라리아 감염 사례가 보고되었으며 42만 9,000여명이 말라리아로 인해 사망했다 (3). 이 가운데 사하라 이남 아프리카 지역은 감염 사례의 90%. 사망자수의 92%를 차지했다 (4). 전체 말라리아 사망자 가운데 70%는 5세 이하 아동이었다.
말라리아는 예방과 치료가 가능한 질병이지만 (6) 이를 위해서는 올바른 진단이 필수적이다. 분자 검사는 기생체 수가 매우 적은 상황에서 기존의 말라리아 원충 검사법보다 더 효과적이라는 사실이 검증되었다. 이렇게 기생체 수가 적은 환자를 식별해낼 경우 질병의 치료와 확산 방지라는 이중의 효과를 거둘 수 있다.
슬라바 엘라진(Slava Elagin) 메리디안 바이오사이언스 R&D부문장은 “말라리아는 증상이 전혀 없이도 사람을 매개체로 만들 수 있으며 이러한 무증상 매개체를 탐지해 내는 건 쉬운 일이 아니다. 만약 검사 단계에서 (매개체를) 식별해내지 못할 경우 이들이 질병을 확산시키기 때문에 말라리아 퇴치는 불가능해진다”고 말했다.
말라리아는 더 이상 사하라 이남 아프리카와 남부 아시아 지역에 국한된 질병이 아니다. 말라리아가 풍토병에 속하는 지역에서 이민을 떠나는 사람들이 증가함에 따라, 지난 수년간 유럽과 중동 지역에서의 발병률은 14%에서 86%로 증가했다는 사실이 최근 발표된 다수의 연구 결과를 통해 드러나고 있다. 이를 종합하면 전체 말라리아 발병 사례의 약 43%는 유럽지역 주요 센터 내에서 외국인에 의해 발생되었으며, 친구나 친척 방문을 위해 모국으로 여행을 다녀온 현지 정착 이민자들의 발병률이 훨씬 높은 것으로 나타났다. 다수의 연구 결과를 종합한 결과 이들이 차지하는 비중은 전체 발병 사례의 최대 70%였다. 이는 말라리아가 풍토병으로 토착화된 국가와 그렇지 않은 국가 모두 향상된 진단 도구가 필요하다는 사실을 보여준다.
분자 검사는 새로운 형태의 검사법은 아니지만 각종 장비를 완벽하게 갖춘 실험실과 고도로 숙련된 전문가가 있어야 하기 때문에 전통적으로 복잡한 절차를 요구했다. 메리디안 바이오사이언스가 일궈낸 혁신 제품인 ***illumi****gene* Malaria는 현장 실험실에서 도입이 가능하다. 현장 실험실의 경우 말라리아 감염 환자의 기생체 수가 가장 높거나 낮은 경우가 많아 진단과 치료에 어려움을 겪고 있다. 사용자 친화적 제품으로 별도의 훈련이나 자본 투자를 필요로 하지 않는 ***illumi****gene* Malaria는 1시간 내에 결과를 도출해낼 수 있으며 검사 재료는 실온에서 보관 가능하다.
존 크라우틀러(John A. Kraeutler) 메리디안 바이오사이언스 CEO 겸 회장은 “본 제품은 말라리아 감염 환자들에게 더 나은 치료를 제공하고 감염 확산을 방지하는 데 있어 큰 발전을 일궈냈다고 볼 수 있다”고 밝혔다.
현장 실험실에서 도입 가능하며 사용자 친화적인 ***illumi****gene* Malaria는 기존의 검사 프로토콜을 대체하기보다는 더욱 확대할 것이다. 또한 본 제품은 신속진단검사(RDT), 현미경 검사법과 더불어 필요한 환자를 직접 치료할 수 있는 다양한 검출 프로토콜을 생성할 것이다.
크라우틀러 회장은 “말라리아와 같은 치명적 질병을 퇴치하기 위해 능력 있고 헌신적인 전세계 전문가들과 협업을 진행해온 것을 자랑스럽게 생각한다”고 덧붙였다.
***illumi****gene* Malaria는 메리디안 바이오사이언스 유럽지사를 통해 유럽, 중동, 아프리카 지역에 유통될 예정이며 이외에도 글로벌 유통망을 통해 다른 지역으로도 판매를 계획하고 있다. 본 제품은 전세계 1,500여곳의 기관에서 사용하는 ***illumi****gene* 플랫폼에 포함되는 10번째 검사법이다.
1 –메리디안 보도자료 “새로운 말라리아 테스트인 *illumi*gene Malaria, 진단분야의 새로운 표준 확립하다, 2016년 1월 26일
2 – 세계보건기구: 말라리아에 대한 10가지 팩트([https://www.who.int/features/factfiles/malaria/en/](https://www.globenewswire.com/Tracker?data=IGJYyyhd0kcR8L3ZoXNXEo1iFiwbt_sgCmS-QU8FXe0QYSN_SXhbeLG4WD0ACxzhakdYsA6ygACCvsrD8PqvEF51eMfXl1MShh1QmDl3SlkGwxrhgRKQak3rDtUSJJOpL2YW6KP8XL93NvRumb8NCPP4PTATIMByaAlEwoN3rEQ=)), 2016년 12월 기준
3 – ibid
4 – ibid
5 – ibid
6 –세계보건기구 “말라리아 퇴치를 위한 글로벌 단위의 기술적 전략: 2016~2030”
**[Meridian Bioscience](https://www.globenewswire.com/Tracker?data=LfQE7Go94tpj_mL3u_hBxYJbd1nMTmL2vZQTzPf6Y92d4XkNR0PhXqGde4rXhTvizeqKi09AmIp7QHSuPm88tWXMTiLiGE8BCaA-DBaODD3ydwu2KMhKAj8vcDkwVzCLsqI65B5dF-gWFivZL4ZWbH3f7KsRecwZwdsYy72B3mo= "Meridian Bioscience"), *illumigene* Malaria & LAMP 기술** **소개**
- ***illumi****gene* Malaria는 메리디안 바이오사이언스가 개발한 진단 테스트로 고리매개등온증폭(LAMP) 기술을 이용한 분자 테스트를 통해 DNA 증폭과 말라리아 원충 존재 여부를 감지한다.
- LAMP 기술은 분자 진단 기술로 DNA를 타깃으로 하며 사전 측정된 독립적인 시약을 사용한다. LAMP 기술은 기존의 중합효소 연쇄반응(PCR) 검사와는 달리 온도 사이클링을 요구하지 않으며 단일 온도에서 배양, 검출, 보고하기 때문에 신속한 결과를 얻을 수 있다. 기존의 분자 기법이 냉장 보관을 필요로 하는 데 비해 ***illumi****gene* 검사키트는 실온 보관이 가능하다.
- ***illumi****gene* 기술은 단순하면서도 정확하며 사용이 간편해 테스트 과정에서 기술적 전문성이 필요 없으며 테스트 결과는 1시간 내에 확인할 수 있다.
- LAMP에 기반한 ***illumi****gene* 테스트는 이미 클로스트리듐 디피실(C. difficile), 백일해, 단순포진바이러스 등의 감염병 진단에 사용되고 있으며 고도의 정확성을 갖추었음이 입증되었다.
- ***illumi****gene* 테스트는 승인된 제품으로 5년 동안 다른 질병 테스트에 이용되었다.
- ***illumi****gene* Malaria의 주요 장점은 [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com")에서 확인할 수 있다.
**메리디안** **바이오사이언스(Meridian Bioscience, Inc) 소개**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다. 당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=fYFQGdpIpbXo8UFcjsy3JrYhfvdNKIAs_4PY-Xq5L0GsHbM6SBU4NueS0uLTcITL8yci4B8_4ocLJPvtIuE-_ag2c0rutSS21KYet4gLXmG1U850kg1Z7741KC9OW0KcGKA6zjx22-hdaFyAe_Xy0Dt73Xhp6urvj0YGHpnWmBoJilGx3uJySU4xSMUznF-1-Rc6lNuNCSiLYYYLmIknlOpyAeQuLtffy-mTuUWeCelxTnWGpZTQe2dzfdis1dPVFg9sUe8nZ6FASS0BMXyCDbI1cY4kO2crNAd3puW8AcI5AMLo6d9KJv87kvkIQwAYnKav3HuLbtd7-ychlL4u5vXcDbe93tgKxtOfgAsJisQ= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
투자자 연락처:
513-271-3700
John A. Kraeutler, Chief Executive Officer
언론 연락처:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [新檢測程序有望成為全球消除瘧疾的關鍵工具](https://www.meridianbioscience.com/press-release/新檢測程序有望成為全球消除瘧疾的關鍵工具/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## 可在現場實驗室部署的分子檢測比目前的檢測方案敏感80,000倍
辛辛那提, April 24, 2017 (GLOBE NEWSWIRE) — 正當全球社群為了世界瘧疾日共聚一堂，慶祝在地球上消除瘧疾所取得的成就和試點策略，一個讓人意外的領域也出現了希望的曙光：檢測領域。
位於俄亥俄州辛辛那提的Meridian Bioscience, Inc.（納斯達克代碼：VIVO）為瘧疾開發了一種以分子為基礎、可在現場實驗室部署的檢測產品***illumi****gene®* Malaria，其偵測瘧疾寄生蟲的敏感度比目前的檢測方案高80,000倍。該檢測由Meridian開發，並由疾病控制和預防中心（CDC）和塞內加爾的Cheikh Anta Diop University of Dakar提供技術協助。
Cheikh Anta Diop University寄生蟲學 – 真菌學部門教授Daouda Ndiaye表示：「***illumi****gene* Malaria或能改變現行的做法，而，更快且更準確的診斷正是消除瘧疾的關鍵。提早診斷有助於制定正確的治療方案，改善瘧疾患者的臨床結果，並能確保為患者持續提供正確的瘧疾治療。另外，事實證明，在寄生蟲數量較低的患者身上難以檢測出瘧疾寄生蟲，因此需要一種強大、高敏感及可在現場實驗室部署的診斷工具，在之前已經消除瘧疾的地區追蹤瘧疾傳染源。***illumi****gene* Malaria便具備這種能力。」
***illumi****gene* Malaria獲知名的《國際生物雜誌》/巴黎的Association des Colloques Nationaux des Biologistes Conference評選為緊急治療和醫護點檢測排名第一的創新產品，在歐洲銷售時並可加貼CE標誌。
由於預防措施的改善以控制措施的強化，瘧疾死亡率自2000年以來已經下跌了60%，儘管如此，瘧疾仍然是全球三大兒童致命疾病之一，每天每分鐘就有一人死於瘧疾(1)。世界衛生組織的最新數據顯示，全球接近一半的人口面臨瘧疾的風險 (2)。在2015年，約有2.12億宗瘧疾病例，估計約429,000人死於瘧疾(3)。另外，在當年度，90%的瘧疾病例和92%的瘧疾死亡人數均來自撒哈拉以南非洲地區(4)。超過三分之二（70%）的瘧疾死亡人數均為未滿五歲的兒童 (5)。
雖然瘧疾可以防治(6)，但正確的診斷至關重要。事實證明，在偵測數量極低的瘧疾寄生蟲時（稱為「負荷量」），分子檢測比目前的檢測方案更加有效。辨識出寄生蟲低負荷量的個人可帶來雙重效益，一方面可確保他們得到治療，另一方面也能防止把疾病傳染給其他人。
Meridian Bioscience研發部執行副總裁Slava Elagin指出：「人們在沒有任何徵狀時也會成為瘧疾的傳播媒介，但檢測無臨床徵狀的人士非常困難。倘若無法檢測出他們患有瘧疾，則根本不可能消除瘧疾，因為這些人會將瘧疾傳染給其他人。」
由於瘧疾不再只是撒哈拉以南非洲及非洲南部地區的獨有疾病，前述狀況正在發酵。從瘧疾傳染源國家遷出的人口數量不斷增加，導致歐洲和中東的病例增多。最近的研究顯示，輸入性瘧疾病例的比例已於過去數年內從14%增加至86%。綜合這些報告，在主要歐洲中心登記的瘧疾病例中接近43%是由非國民感染。前往祖國探訪親友的已定居移民瘧疾發病率偏高，數份報告指出，他們在總病例中的佔比高達70%，這突顯出有必要同時在瘧疾的非流行國家和流行國家部署更精準的診斷工具。
雖然分子檢測並非新概念，但過去的流程很複雜，需要配置完備的實驗室以及訓練有素的檢測人員。Meridian Bioscience的***illumi****gene* Malaria，最大突破在於可部署在現場實驗室，這裡正是瘧疾感染率最高且低負荷量檢測導致難以診斷及治療之地。***illumi****gene* Malaria易於使用、無須特別培訓或資本投資，在一個小時內即能獲得結果，並且可在室溫下存儲檢測材料。
Meridian Bioscience執行長兼董事長John A. Kraeutler表示：「這是努力為瘧疾感染者提供更好醫護服務以及阻止其擴散所邁出的重要一步。」
提供可在現場實驗室部署及易於使用的***illumi****gene* Malaria將會整合現有檢測方案，而不是取而代之。它將加入快速診斷檢測（RDT）和顯微鏡檢查，以打造一個檢測方案網絡，有助於在最需要的地區進行直接治療。
Kraeutler續稱：「瘧疾是一種致命性的疾病；就此，能夠與世界各地所有才華橫溢、兢兢業業的人員攜手努力消除瘧疾，我們倍感自豪。」
***illumi****gene* Malaria將由Meridian Bioscience Europe於歐洲、中東和非洲地區經銷，在其它國家市場則由該公司的全球經銷網經銷。它是我們的***illumi****gene* 平台所提供的第十種化驗產品，獲全球各地接近1,500家機構廣泛使用。
1 – Meridian新聞稿，「全新瘧疾檢測產品*illumi*gene Malaria為診斷設立了新的黃金標準」，2016年1月26日
2 – 世界衛生組織：有關瘧疾的10個事實() ，於2016年12月更新
3 – 出處同上
4 – 出處同上
5 – 出處同上
6 – 世界衛生組織，*全球應對瘧疾的技術策略：2016年至2030年*
**[Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience")、*illumigene* Malaria和 LAMP 技術簡介**
- ***illumi****gene* Malaria是由Meridian Bioscience開發的瘧疾診斷檢測產品，是一種分子檢測產品，使用環介導等溫擴增（LAMP）技術以擴增DNA及檢測瘧疾寄生蟲的存在。
- LAMP（環介導等溫擴增）是一種分子檢測技術，它靶定DNA及使用預先調製及內含培養基的試劑。 與目前的PCR檢測不同的是，它並不需要溫度循環。LAMP在單一溫度孵化、檢測及報告，從而更快得出結果。***illumi****gene*檢測套件可在常溫條件下儲存，而目前的分子檢測方法則需要冷藏。
- ***illumi****gene*技術簡單、準確及易於使用，這代表從此之後檢測並不需要專家的專業技術知識，而且在一個小時內即可取得結果。
- 基於LAMP的***illumi****gene*檢測已經用於診斷傳染性疾病，包括*艱難梭狀桿菌*、百日咳和單純皰疹病毒，而且事實證明其檢測結果非常準確。
- ***illumi****gene*檢測已獲核准，並已在其他疾病上使用超過5年。
- ***illumi****gene* Malaria的好處載於微型網站：[www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com")。
**Meridian Bioscience, Inc簡介**
Meridian是一家全方位整合的生命科學公司，開發、製造、銷售及經銷廣泛的創新診斷檢測套件、稀有試劑、特種生物製品和組件。我們的診斷檢測使用各種方法，在常見疾病的早期診斷和治療中提供準確、簡潔和快速的檢測，例如傳染病和鉛中毒。Meridian的診斷產品用於人體外部，並且需要甚少或根本不需要特殊設備。公司的診斷產品旨在改善患者的健康，同時降低醫療保健的總體成本。Meridian在胃腸道和上呼吸道感染和血鉛濃度檢測領域擁有強大的市場地位。此外，Meridian為生物科學和農業生物產業的研究組織以及製造診斷組件的公司提供稀有試劑，特種生物製品和組件。公司向的產品與技術銷售給全球70多國的醫院、參考實驗室、研究中心、診斷製造商和農業生物公司。公司的股票在納斯達克全球精選市場交易，股票代碼為VIVO。Meridian的網址為[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")。
```
```
---
### Contact Data
```
投資者關係事宜請聯絡：
513-271-3700
John A. Kraeutler，執行長
對於所有其他查詢，請聯絡：
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [新检测手段有望成为全球消除疟疾的关键工具](https://www.meridianbioscience.com/press-release/新检测手段有望成为全球消除疟疾的关键工具/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## 可在现场实验室部署的分子检测比目前的检测方法敏感80,000倍
辛辛那提, April 24, 2017 (GLOBE NEWSWIRE) — 在全球社区为了世界疟疾日共聚一堂，庆祝在地球上消除疟疾所取得的成功和试点策略之时，一个令人意想不到的领域出现了希望的曙光：检测领域。
位于俄亥俄州辛辛那提的Meridian Bioscience, Inc.（纳斯达克：VIVO）针对疟疾开发出一个基于分子、可在现场实验室部署的检测产品***illumi****gene®* Malaria，这种检测产品在发现疟疾寄生虫方面比目前的检测方法敏感80,000倍。该检测由Meridian开发，并由疾病控制和预防中心（CDC）和塞内加尔的Cheikh Anta Diop University of Dakar提供技术协助。
Cheikh Anta Diop University寄生虫学 – 真菌学系教授Daouda Ndiaye表示：「***illumi****gene* Malaria有望改变当前的做法，更快更准确的诊断是消除疟疾的关键。尽早确诊有助于制定正确的治疗方案，为疟疾患者带来更好的临床结果并确保为合适的患者持续提供疟疾治疗。另外，事实证明，在寄生虫数量较低的患者身上难以检测出疟疾寄生虫，因此需要一种强大、敏感及可在现场实验室部署的诊断工具，在尚未消除疟疾的地区追踪疟疾储存宿主。而***illumi****gene* Malaria具备这种能力。」
***illumi****gene* Malaria被知名的《国际生物杂志》/巴黎的Association des Colloques Nationaux des Biologistes Conference评选为急诊治疗和医护点检测排名第一的创新产品，并且在欧洲销售时加贴CE标志。
尽管由于改进预防工作及加强控制措施，疟疾死亡率自2000年以来已经下降了60%，但疟疾仍然是全球儿童的三大致命疾病之一，每天每分钟就有一人死于疟疾(1)。世界卫生组织的最新数据显示，全球接近一半的人口存在疟疾风险 (2)。2015年，约有2.12亿個疟疾病例，约429,000人死于疟疾(3)。另外，同年90%的疟疾病例和92%的疟疾死亡人数均发生在撒哈拉以南的非洲地区(4)。死于疟疾者超过三分之二（70%）为五岁以下的儿童 (5)。
虽然疟疾可防可治(6)，但正确的诊断至关重要。事实证明，在检测数量极低的疟疾寄生虫方面（称为“负荷量”），分子检测比目前的检测方法更加有效。发现低负荷量的个人可带来双重效益，一方面可确保他们得到治疗，另一方面也可防止将该疾病传染给其他人。
Meridian Bioscience研发部执行副总裁Slava Elagin表示：「一个人即使没有任何症状也可能是疟疾携带者，发现这些没有临床症状的个体非常困难。如果无法通过检测手段发现这些个体，就根本不可能根除疟疾，因为这些人会将疟疾传染给其他人。」
由于疟疾不再是撒哈拉以南非洲及非洲南部地区的独有疾病，这种情况正在恶化。越来越多的人从疟疾流行的国家迁出，已经导致欧洲和中东疟疾病例增多。最近的研究显示，输入性疟疾病例的比例已在过去数年里从14%增加至86%。综合这些报告，在主要欧洲中心登记的疟疾病例，近43%是由非国民感染。前往祖籍国探访亲友的已定居移民，疟疾发病率高得多。在数份报告中，他们在总病例中的占比最高达70%，这更说明有必要在疟疾的非流行国家和流行国家部署更好的诊断工具。
虽然分子检测并非一个新概念，但一直以来是一个复杂的流程，需要有完备的实验室及高素质的检测人员。Meridian Bioscience开发的***illumi****gene* Malaria的突破性进展在于，它可在疟疾感染率最高且低负荷量检测导致难以诊断及治疗之地区的现场实验室部署。***illumi****gene* Malaria易于使用、无需专门培训或资本投资，一个小时即可生成结果，并且可在室温下存储检测材料。
Meridian Bioscience首席执行官兼董事会主席John A. Kraeutler表示：「这是努力向疟疾感染者提供更好医护服务并阻止疟疾扩散而迈出的重要一步。」
提供可在现场实验室部署及易于使用的***illumi****gene* Malaria将会强化而不是替代现有检测手段。它将与快速诊断检测（RDT）和显微镜检查一起，组成一个检测手段网络，有助于在最有需要的地区提供直接治疗。
Kraeutler表示：「疟疾是一种危害很大的疾病，我们很自豪能够与世界各地所有才华横溢、兢兢业业的人士共同致力于消除疟疾。」
***illumi****gene* Malaria将由Meridian Bioscience Europe在欧洲、中东和非洲地区分销，其它国际市场由该公司的全球分销网络分销。它是我们的***illumi****gene*平台提供的第十种化验产品，被全球各地约1,500家机构广泛使用。
1 – Meridian新闻稿，“全新疟疾检测产品*illumi*gene Malaria为诊断确立了新的黄金标准”，2016年1月26日
2 – 世界卫生组织：有关疟疾的10个事实() ，于2016年12月更新
3 – 出处同上
4 – 出处同上
5 – 出处同上
6 – 世界卫生组织，*全球应对疟疾的技术策略：2016年至2030年*
**[Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience")、*illumigene* Malaria和 LAMP 技术简介**
- ***illumi****gene* Malaria是由Meridian Bioscience开发的疟疾诊断检测产品。它是一种分子检测产品，使用环介导等温扩增（LAMP）技术以扩增DNA并检测疟疾寄生虫的存在。
- LAMP（环介导等温扩增）是一种分子检测技术，它靶定DNA并使用预先调制及内含培养基的试剂。与目前的PCR检测不同的是，它并不需要温度循环。LAMP在单一温度孵化、检测及报告，从而更快得出结果。***illumi****gene* 检测试剂盒可在常温条件下储存，而目前的分子检测方法要求冷藏。
- ***illumi****gene*技术简单、准确、易用，这意味着开展此检测并不需要专家的专业技术知识。在一个小时内即可取得结果。
- 基于LAMP的***illumi****gene*检测已经用于诊断传染性疾病，包括*艰难梭菌*、百日咳和单纯疱疹病毒，而且事实证明其检测结果非常准确。
- ***illumi****gene*检测已获批准，并已在其他疾病上使用超过5年。
- ***illumi****gene* Malaria的优势载于微型网站：[www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com")。
**Meridian Bioscience, Inc简介**
Meridian为一家全面综合生命科学公司，负责开发、生产、营销及分销各类新型诊断检测试剂盒、稀有试剂以及特殊生物制剂和成份。我们的诊断测试方式多样，在早期诊断和传染病、铅中毒等常见疾病的治疗过程具有准确性高、简易及快速的优点。Meridian的诊断产品于人体外使用，只需极少或无需特殊设备。本公司的诊断产品旨在改善病人健康，同时降低医疗保健的总成本。Meridian在胃肠及上呼吸道感染、血铅水平检测领域拥有强大的市场地位。此外，Meridian也向从事研究的生命科学及农业生物技术行业的机构及制造诊断产品的公司供应稀有试剂、特殊生物制剂及成份。本公司向全球逾70个国家的医院、参考实验室、研究中心、诊断产品制造商及农业生物技术公司销售产品和技术。本公司股份于纳斯达克Global Select Market交易，代码为VIVO。Meridian公司网址为[www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com")。
```
```
---
### Contact Data
```
投资者关系事宜请联系：
513-271-3700
John A. Kraeutler，首席执行官
所有其他查询请联系：
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [ขั้นตอนการทดสอบใหม่คาดว่าจะเป็นเครื่องมือสำคัญในความพยายามของโลกเพื่อขจัดโรคมาลาเรีย](https://www.meridianbioscience.com/press-release/ขั้นตอนการทดสอบใหม่คาด/)
**Published:** April 24, 2017
**Author:** hamza
**Content:**
## การทดสอบโมเลกุลในห้องปฏิบัติการภาคสนาม มีความไวกว่าตัวเลือกในปัจจุบันถึง 80,000 ครั้ง
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — ในขณะที่ชุมชนโลกมารวมตัวกันในวันโรคมาลาเรียโลกเพื่อเฉลิมฉลองความสำเร็จและวางแผนกลยุทธ์ในการกำจัดโรคนี้ออกจากพื้นโลก แสงสว่างแห่งความหวังใหม่ก็ได้ส่องเข้ามาจากสถานที่ที่คาดไม่ถึง นั่นคือด้านการทดสอบของสมการ
บริษัท Meridian Bioscience, Inc. ใน Cincinnati, Ohio (NASDAQ:VIVO) ได้พัฒนา ***illumi****gene®* Malaria ขึ้นซึ่งเป็นการทดสอบที่ใช้โมเลกุลเพื่อตรวจหาโรคมาลาเรียในห้องปฏิบัติการภาคสนาม ซึ่งมีความไวสูงถึง 80,000 ครั้งในการตรวจพบปรสิตมาลาเรียเมื่อเทียบกับตัวเลือกการทดสอบในปัจจุบัน การทดสอบนี้ได้พัฒนาขึ้นโดยบริษัท Meridian โดยได้รับความช่วยเหลือด้านเทคนิคจากศูนย์ควบคุมและป้องกันโรค (CDC) และมหาวิทยาลัย Cheikh Anta Diop ของ Dakar เซเนกัล
“***illumi****gene* Malaria มีศักยภาพในการเปลี่ยนแปลงการปฏิบัติในปัจจุบัน การวินิจฉัยโรคได้อย่างรวดเร็วและแม่นยำยิ่งขึ้นเป็นสิ่งสำคัญในการต่อสู้กับโรคมาลาเรีย” ศาสตราจารย์ Daouda Ndiaye ภาควิชาปรสิตวิทยา – วิทยา มหาวิทยาลัย Cheikh Anta Diop กล่าวไว้ “การวินิจฉัยในระยะแรกช่วยให้สามารถทำการรักษาได้อย่างถูกต้อง ซึ่งจะนำไปสู่ผลลัพธ์ทางคลินิกที่ดีขึ้นสำหรับผู้ที่เป็นโรคมาลาเรียและทำการรักษาโรคมาลาเรียให้กับคนที่เหมาะสม และเนื่องจากการตรวจจับปรสิตมาลาเรียในคนที่มีจำนวนปรสิตต่ำเป็นเรื่องที่พิสูจน์แล้วว่ายาก จึงจำเป็นต้องมีเครื่องมือวินิจฉัยที่มีประสิทธิภาพ มีความไว และใช้ได้ในห้องปฏิบัติการ เพื่อตรวจติดตามแหล่งที่มาของเชื้อมาลาเรียในบริเวณก่อนการกำจัด ***illumi****gene* Malaria แสดงให้เห็นว่ามีความสามารถเหล่านี้”
***illumi****gene* Malaria ได้รับรางวัลที่หนึ่งสำหรับนวัตกรรมในการรักษาฉุกเฉินและการทดสอบนอกห้องปฏิบัติการในการประชุมอันทรงเกียรติ Journées Internationales de Biologie / Association des Colloques Nationaux des Biologistes ในกรุงปารีสและได้รับเครื่องหมาย CE สำหรับการจำหน่ายในยุโรป
แม้ว่าจะมีผู้เสียชีวิตจากโรคมาลาเรียลดลงร้อยละ 60 ตั้งแต่ปี พ. ศ. 2543 เนื่องจากมีการป้องกันและมาตรการควบคุมโรคที่ดีขึ้น แต่มาลาเรียก็ยังคงเป็นหนึ่งในสามโรคร้ายที่เป็นสาเหตุการเสียชีวิตของเด็กทั่วโลก โดยมีเด็กที่เสียชีวิตจากโรคนี้หนึ่งรายในทุกๆ นาทีของทุกวัน (1) ตามข้อมูลล่าสุดจากองค์การอนามัยโลก เกือบครึ่งหนึ่งของประชากรโลกมีความเสี่ยงต่อโรคมาลาเรีย (2) ในปี พ.ศ. 2558 มีผู้ป่วยเป็นมาลาเรียประมาณ 212 ล้านรายและประมาณ 429,000 รายเสียชีวิตจากการเป็นโรคมาลาเรีย (3) นอกจากนี้ ในปีเดียวกันนั้น บริเวณทางใต้ของทะเลทรายซาฮาราในแอฟริกายังเป็นสถานที่ที่มีผู้ป่วยมาลาเรียถึงร้อยละ 90 และเสียชีวิตจากโรคนี้ถึงร้อยละ 92 (4) มากกว่าสองในสาม (ร้อยละ 70) ของการเสียชีวิตจากโรคมาลาเรียทั้งหมดเกิดขึ้นในเด็กที่มีอายุต่ำกว่าห้าขวบ (5)
ในขณะที่โรคมาลาเรียสามารถป้องกันได้และสามารถรักษาได้ (6) การวินิจฉัยที่ถูกต้องเป็นสิ่งสำคัญ การทดสอบโมเลกุลได้พิสูจน์มาแล้วว่ามีประสิทธิภาพมากกว่าตัวเลือกปัจจุบันในการตรวจจับปรสิตมาลาเรียในระดับที่ต่ำมากหรือที่เรียกว่า “โหลด” การระบุบุคคลที่มีโหลดต่ำมีประโยชน์สองประการในการทำให้มั่นใจได้ว่าพวกเขาได้รับการรักษาและป้องกันการแพร่กระจายของโรคไปยังผู้อื่น
“มนุษย์สามารถเป็นพาหะของโรคมาลาเรียได้โดยไม่แสดงอาการใดๆ และการตรวจหาบุคคลที่ไม่แสดงอาการเหล่านี้อาจเป็นเรื่องที่ท้าทาย” นาย Slava Elagin ซึ่งเป็นรองประธานบริหารฝ่ายวิจัยและพัฒนาของ Meridian Bioscience กล่าวไว้ “ถ้าการทดสอบไม่สามารถระบุพวกเขาได้ ก็จะไม่สามารถกำจัดโรคมาลาเรียออกได้ เพราะบุคคลเหล่านี้สามารถทำให้โรคแพร่กระจายไปยังผู้อื่นได้”
สถานการณ์เช่นนี้กำลังเกิดขึ้นด้วยข้อเท็จจริงที่ว่าโรคมาลาเรียไม่ได้เป็นเพียงแค่โรคของบริเวณทางใต้ของทะเลทรายซาฮาราในแอฟริกาและเอเชียใต้เท่านั้น จำนวนผู้อพยพจากประเทศที่มีเชื้อมาลาเรียเพิ่มขึ้นส่งผลให้เกิดอุบัติการณ์ที่สูงขึ้นในยุโรปและตะวันออกกลาง สัดส่วนของกรณีเป็นโรคมาลาเรียที่นำเข้าเพิ่มขึ้นในช่วง 2-3 ปีที่ผ่านมาตั้งแต่ร้อยละ 14 ถึงร้อยละ 86 ในการศึกษาวิจัยล่าสุด
เมื่อรวบรวมรายงานแล้ว เกือบร้อยละ 43 ของกรณีโรคมาลาเรียที่จดทะเบียนที่ศูนย์ในยุโรปที่สำคัญเกิดขึ้นในผู้เป็นชาวต่างชาติ อัตราการเกิดโรคมาลาเรียสูงขึ้นมากในผู้อพยพที่เดินทางไปเยี่ยมเยียนเพื่อนและญาติในประเทศต้นกำเนิด ซึ่งมีสัดส่วนถึงร้อยละ 70 ของจำนวนกรณีในรายงานหลายฉบับและการเพิ่มขึ้นนี้ได้เน้นย้ำถึงความจำเป็นต้องมีเครื่องมือการวินิจฉัยที่ดีขึ้นทั้งในประเทศที่ไม่ใช่ถิ่นและเป็นถิ่นของโรค
แม้ว่าจะไม่ใช่แนวความคิดใหม่ แต่การทดสอบโมเลกุลก็เป็นกระบวนการที่ซับซ้อนซึ่งต้องใช้ห้องทดลองที่มีอุปกรณ์ครบครันและบุคลากรที่ได้รับการฝึกอบรมมาเป็นอย่างดี ความก้าวหน้าของ ***illumi****gene* Malaria โดยบริษัท Meridian Bioscience คือการที่สามารถใช้งานได้ในห้องปฏิบัติการภาคสนาม ซึ่งการติดเชื้อมาเลเรียมีสูงสุดและการตรวจหาในโหลดต่ำเป็นเรื่องท้าทายมากที่สุดสำหรับการวินิจฉัยและรักษา ***illumi****gene* Malaria สามารถใช้งานได้ง่าย ไม่จำเป็นต้องได้รับการฝึกอบรมหรือการลงทุนเป็นพิเศษ ให้ผลลัพธ์ได้ภายในหนึ่งชั่วโมงและสามารถเก็บวัสดุทดสอบได้ที่อุณหภูมิห้อง
“นี่เป็นก้าวสำคัญในการต่อสู้เพื่อให้การดูแลผู้ติดเชื้อมาเลเรียได้ดีขึ้นและหยุดยั้งการแพร่ระบาดของโรค” นาย John A. Kraeutler ซึ่งเป็นประธานเจ้าหน้าที่บริหารและประธานคณะกรรมการของบริษัท Meridian Bioscience กล่าวไว้
ความพร้อมใช้งานของ ***illumi****gene* Malaria ซึ่งเป็นการทดสอบที่ใช้ได้ในห้องปฏิบัติการภาคสนามและใช้งานได้ง่าย จะช่วยเพิ่มประสิทธิภาพมากกว่าที่จะแทนที่เกณฑ์วิธีการทดสอบที่มีอยู่ โดยจะรวมตัวกับการทดสอบวินิจฉัยอย่างรวดเร็ว (RDTs) และกล้องจุลทรรศน์เพื่อสร้างเว็บของเกณฑ์วิธีการตรวจหาที่จะช่วยเหลือการรักษาโดยตรงในที่ที่ต้องการมากที่สุด
“มาลาเรียเป็นโรคที่ร้ายแรงและเรามีความภาคภูมิใจที่ได้ร่วมงานกับทุกคนที่มีพรสวรรค์และความทุ่มเททั่วโลกในการสู้รบเพื่อกำจัดมันโรคร้ายนี้” นาย Kraeutler กล่าวไว้
***illumi****gene* Malaria จะมีจัดจำหน่ายในยุโรป ตะวันออกกลาง และแอฟริกาโดยบริษัท Meridian Bioscience Europe และในตลาดต่างประเทศเพิ่มเติมโดยเครือข่ายการจัดจำหน่ายทั่วโลกของ บริษัทฯ ปัจจุบันการทดสอบครั้งที่ 10 ที่มีอยู่ในแพลตฟอร์ม ***illumi****gene* ของเราที่มีการใช้งานอยู่ในเกือบ 1,500 สถาบันทั่วโลก
1 – ข่าวประชาสัมพันธ์ของ Meridian “การทดสอบมาเลเรียใหม่ *illumi*gene Malaria ได้กำหนดมาตรฐานใหม่ในการวินิจฉัยโรค”, 1.26.16
2 – องค์การอนามัยโลก: 10 ข้อเท็จจริงเกี่ยวกับโรคมาลาเรีย () อัพเดทในเดือนธันวาคม 2559
3 – เช่นเดียวกับข้อ 2
4 – เช่นเดียวกับข้อ 2
5 – เช่นเดียวกับข้อ 2
6 – องค์การอนามัยโลก, *กลยุทธ์ทางเทคนิคระดับโลกสำหรับโรคมาลาเรีย: 2016-2030*
**เกี่ยวกับบริษัท [Meridian Bioscience](https://www.meridianbioscience.eu/em-strong-illumi-strong-gene-em-reg-malaria.html "Meridian Bioscience"), *illumigene* Malaria และเทคโนโลยี LAMP**
- ***illumi****gene* Malaria เป็นการตรวจวินิจฉัยโรคมาลาเรียที่ได้รับการพัฒนาโดยบริษัท Meridian Bioscience โดยเป็นการทดสอบระดับโมเลกุลที่ใช้เทคโนโลยี Isothermal Loop-Mediate Amplification (LAMP) เพื่อขยาย DNA และตรวจจับการปรากฏตัวของปรสิตมาลาเรีย
- LAMP (Loop Mediated Isothermal Amplification) คือเทคโนโลยีการตรวจจับระดับโมเลกุลที่กำหนดเป้าหมาย DNA และใช้สารรีเอเจนต์ที่ตรวจวัดได้และมีอยู่ในตัว แตกต่างจากการทดสอบ PCR ในปัจจุบัน LAMP ไม่จำเป็นต้องมีรอบอุณหภูมิ แต่สามารถทำการอบ ตรวจจับ และรายงานที่อุณหภูมิเดียวเพื่อให้ได้ผลลัพธ์ที่รวดเร็วขึ้น ชุดทดสอบ ***illumi****gene* สามารถเก็บไว้ภายใต้สภาพแวดล้อมที่มีอยู่ ในขณะที่วิธีการโมเลกุลในปัจจุบันจำเป็นต้องเก็บในความเย็น
- เทคโนโลยี ***illumi****gene* ไม่ยุ่งยาก ถูกต้อง และใช้งานได้ง่าย ซึ่งหมายความว่าไม่จำเป็นต้องมีผู้เชี่ยวชาญด้านเทคนิคเพื่อทำการทดสอบ จะได้ผลลัพธ์ภายในเวลาไม่ถึงหนึ่งชั่วโมง
- การทดสอบ ***illumi****gene* ซึ่งใช้เทคโนโลยี LAMP เป็นพื้นฐานพร้อมสำหรับวินิจฉัยโรคติดเชื้อ ได้แก่ C. difficile โรคไอกรน และ ไวรัสเริม ซึ่งพิสูจน์แล้วว่ามีความแม่นยำสูง
- การทดสอบ ***illumi****gene* ได้รับการอนุมัติและสามารถใช้ในโรคอื่นๆ มานานกว่า 5 ปีแล้ว
- ข้อดีของ ***illumi****gene* Malaria ได้รวบรวมไว้ที่ [www.molecularendsmalaria.com](https://www.molecularendsmalaria.com/ "www.molecularendsmalaria.com").
**เกี่ยวกับบริษัท Meridian Bioscience, Inc**
Meridian เป็นบริษัทด้านวิทยาศาสตร์เพื่อชีวิตแบบครบวงจรที่พัฒนา ผลิต ทำการตลาด และจัดจำหน่ายหลากหลายสินค้าที่เป็นนวัตกรรมเช่น ชุดทดสอบวินิจฉัย น้ำยาบริสุทธิ์ และผลิตภัณฑ์ที่เกี่ยวข้อง พร้อมกับมีการบริการเทคโนโลยีชีวเวชภัณฑ์ ด้วยการใช้วิธีที่หลากหลาย ผลิตภัณฑ์และการทดสอบวินิจฉัยเหล่านี้ให้มาซึ่งความถูกต้อง เรียบง่าย และความรวดเร็วในการวินิจฉัยและการรักษาในระยะแรกสำหรับอาการทางการแพทย์ทั่วไป เช่น ระบบทางเดินอาหาร และการติดเชื้อไวรัสทางเดินหายใจ และระดับตะกั่วในเลือด ผลิตภัณฑ์ด้านการวินิจฉัยของ Meridian เอาไว้สำหรับการใช้นอกร่างกายมนุษย์และต้องการแค่อุปกรณ์พิเศษเล็กๆ น้อยๆ หรือไม่ต้องมีอุปกรณ์พิเศษใดๆ ทั้งสิ้น ผลิตภัณฑ์ของบริษัทได้รับการออกแบบเพื่อทำให้ผู้ป่วยมีความเป็นอยู่ที่ดี ในขณะที่ลดค่าใช้จ่ายของการดูแลสุขภาพ Meridian มีสถานะทางการตลาดที่แข็งแกร่งในด้านการติดเชื้อระบบทางเดินหายใจและระบบทางเดินอาหารส่วนบน เซรุ่มวิทยา ปรสิตวิทยาและการวินิจฉัยโรคเชื้อรา และการทดสอบระดับตะกั่วในเลือด นอกจากนี้เ Meridian ยังเป็นผู้จัดจำหน่ายน้ำยาที่หายาก สินค้าทางชีวภาพพิเศษ และเทคโนโลยีที่เกี่ยวข้องซึ่งใช้โดยบริษัทชีวเวชภัณฑ์ที่ทำการวิจัยยาและวัคซีนใหม่ๆ บริษัทได้ทำการตลาดผลิตภัณฑ์และเทคโนโลยีของเขาสำหรับโรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์การวิจัย ผู้ผลิตวินิจฉัย และ บริษัทเทคโนโลยีชีวภาพในกว่า 70 ประเทศทั่วโลก หุ้นของบริษัทมีการซื้อขายในตลาด NASDAQ Global Select ในสัญลักษณ์ VIVO ที่อยู่เว็บไซต์ของ Meridian คือ [www.meridianbioscience.com](https://www.meridianbioscience.com/ "www.meridianbioscience.com").
```
```
---
### Contact Data
```
สำหรับฝ่ายความสัมพันธ์กับนักลงทุน กรุณาติดต่อ:
513-271-3700
John A. Kraeutler ประธานเจ้าหน้าที่บริหาร
สำหรับข้อซักถามอื่นๆ กรุณาติดต่อ:
513-403-7222
Joe Shields
```
**Categories:** Press Release
---
### [Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-recent-fda-matters-related-to-magellan-diagnostics/)
**Published:** June 30, 2017
**Author:** hamza
**Content:**
CINCINNATI, June 30, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The letter requested information on an FDA Safety Notification released in May 2017 pertaining to venous blood lead testing performed on the systems produced by Magellan Diagnostics, a subsidiary of Meridian Bioscience.
On May 17, 2017 and June 6, 2017, Meridian Bioscience commented on interactions between the FDA and Magellan Diagnostics, noting that the company was cooperating fully, and working closely, with the FDA. The matters connected with the FDA Safety Notification pertaining to venous blood lead testing occurred at Magellan Diagnostics prior to Meridian Bioscience’s acquisition of Magellan Diagnostics in March 2016.
The FDA concluded an inspection of Magellan’s quality system on June 29, 2017. Magellan is committed to addressing the FDA investigators’ observations. “Magellan’s access to extensive dialogue with the FDA during its inspection provided valuable insight that, coupled with the help of Meridian’s regulatory team, will assist us in our response to the observations,” commented Amy Winslow, Magellan’s President and CEO.
Matters surrounding the performance of diagnostic tests can be complex and certainly the current situation involving the Magellan Diagnostics test is no exception. Magellan understands the desire of the Senators to understand this issue more thoroughly and reiterates the following points:
- The testing under review pertains only to samples collected in venous blood collection tubes and is a small portion (approximately 10%) of the testing performed on Magellan systems.
- The FDA has stated that all LeadCare® Blood Lead Testing Systems can be used with capillary blood samples. Capillary blood samples are the predominant sample type used by physicians testing at the point of care, which facilitates patient education and intervention.
Meridian and Magellan continue to take these matters very seriously and will continue to work closely and fully with the FDA and CDC to address the concerns identified as quickly as possible.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=sswZonwEUH3WO84H70tPabs7IfZmX2XrzaQhP3DYFQpTBmRrJRcJYv0e5eSHhQhCQqhxvYlrXNeySjw6ppPnaL2jojHdEBj-rjqphQt2s6SU1fCKonkKZkD2ucK7Ri6f "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday, July 27, 2017](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-third-quarter-fiscal-2017-operating-results-on-thursday-july-27-2017/)
**Published:** June 28, 2017
**Author:** hamza
**Content:**
CINCINNATI, June 28, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its third quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, July 27, 2017. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1TpeUFEf-tsdhpqIb7JCQvUOLVycwrbOzRNBy-Uj4d_p-y9yYjG_Z0q7P3x5wqA07QK17NMSOPxIw2X0O71ahz_TJGxH1Xm0AXG94gu3e2ZG_CuW865jaxLNpni0o7Xn "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. For more information, please visit [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1TpeUFEf-tsdhpqIb7JCQvUOLVycwrbOzRNBy-Uj4d8JlMC-yuGxs4MEiqL6yHoDuVrvrvmsMwIEDaxcut3oTPPFo22x8Izd80rsrDAZu95EDPhZBtQ8RoprMf751Zv1LSRKxm2LMpSFsNBQoT1higKR7rOsOLZtVj7h2q70psUgPFalkbHJcSYd9-mL7gXD7zDoSFij_ZIcJB1csDi4L6vkZV23MJAGB0Q6lCahcG0Nhi_8azNJJnGweQYS0rmqcVcAhjB_vjYLqgwk9PmmH9ZwFSvucHwQvystVlRT8fqQgAcpQ0NyiEJUoIOaWtUTXlqa5svy8Jasdf2wspMrrLog0ulWcTgQ8b_Fee84sfk= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-recent-fda-posting-related-to-magellan-diagnostics/)
**Published:** June 6, 2017
**Author:** hamza
**Content:**
CINCINNATI, June 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments on the FDA’s recent recall notice posting.
On May 17, 2017 Meridian Bioscience, Inc. commented that its subsidiary, Magellan Diagnostics, was working closely with the U.S. Food and Drug Administration (FDA) regarding the use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems (LeadCare, LeadCare II, Ultra and Plus). These comments were made in connection with the FDA’s May 17, 2017 Field Safety Notice advising customers to “discontinue using Magellan’s LeadCare System Testing Systems with venous blood samples.” This notice also advised that all LeadCare systems can be used with capillary blood samples. The notice indicated the systems affected by this warning were all four of the systems noted above.
On May 25, 2017 the FDA published the associated recall notice for LeadCare Ultra and LeadCare Plus after customers using these systems were notified. On June 5, 2017 it published the associated recall notice for LeadCare and LeadCare II after these customers were notified. Both notices restated the direction to discontinue venous blood samples and indicated that the systems can be used with capillary blood testing.
Consistent with our comments in our May 17, 2017 release, the LeadCare II testing system, which is point-of-care (CLIA-waived), predominantly utilizes capillary blood samples (finger or heel stick). Approximately 10% of Magellan’s revenue and approximately 1% of Meridian’s overall revenue is derived from venous blood draws. We continue to work with the FDA and do not expect this occurrence to cause any material adverse effect to Meridian’s financial results. Meridian and Magellan continue to take these matters very seriously and continue to work closely and fully with the FDA and CDC to address the concerns identified with venous samples as quickly as possible.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=vnusFjRqvONV8dxlfBBKPsBR3JwKs5BvkPjKG7U3LZPpk7gOzqCMtS6BjaLG_IkGN53l0PzW08slPAbwbzHWNOI60RjZypj_Lg9lpqyAo_l9wE_jcOd9_kXrz-0mU7cPmou5DqYflshGC9idQw9NfMCUplt0-lutMDoktPH6z_nbfVo8VC2nsMcBzzvl6LYNd-09m94DmT4T799p17AaFBGP8w4kc3iM0ynv5JNy-Va92AHnqfzO_YfsUUmyY597Gjr8RHgLKLaxkg47UJmLCL-PuXBnLxO8Oxmv4-RSBNLpcxu9sf-LubgfQL4ukBqvZw1bqYwyf_f_u6kHZ0-ryaRunnkF_UEpyjru_1cWmBU= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-fda-matter-involving-its-subsidiary-magellan-diagnostics/)
**Published:** May 17, 2017
**Author:** hamza
**Content:**
CINCINNATI, May 17, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc.’s subsidiary, Magellan Diagnostics, Inc., is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems. Magellan’s primary product is the LeadCare II, a point-of-care (CLIA-waived) blood lead testing system, on which the vast majority of tests are performed with capillary blood samples. Capillary samples are not affected by this notification. In addition to LeadCare II, Magellan Diagnostics has three moderately complex systems in use – LeadCare Ultra and LeadCare Plus, which were cleared by FDA in 2013 and 2015, respectively, and the original LeadCare, launched in 1997 and which the company has been phasing out. In contrast to the LeadCare II, these systems are used in laboratory settings where both venous and capillary samples are analyzed.
Today, FDA issued a warning that the results from venous samples may be underestimated and provide inaccurate results. Magellan is currently undertaking efforts to move customers to capillary blood testing (fingerstick) with the LeadCare II testing system as a corrective action in response to the FDA warning. The LeadCare II System was designed to help ensure broad-based blood lead screening is available by providing a quick, easy and accurate way to identify children, pregnant women and adults at risk for lead exposure. Magellan remains committed to the importance of providing accurate results at the point of care, as this creates the best opportunity to facilitate patient education and intervention.
Venous blood sample testing on Magellan’s systems consists of approximately 10% of Magellan’s revenue and approximately 1% of Meridian’s overall revenue. Meridian and Magellan do not expect this occurrence to cause any material adverse effect to Meridian’s financial results. Meridian and Magellan take these matters very seriously and will continue to work closely and fully with the FDA and CDC to address the concerns identified with venous samples as quickly as possible.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=p-aMthyzGqP_8UuUGtpp3TbS1SK2bo0QB2824Nhmu045wU90BFOQncIWEMF8EI4l6K8PBr55BIm83xA7obiLYSss7EAkYPja0CDEG3Z4lvTubasNlvsPPfFyJqb2qnuN6fWUHwDo0pp7zJtwol02BBG5-aBMcFT8KPEggXquRy6BNaIsBP2vOE3TQCegtp9w8MOei8lRpUL7GBRKKsbd9q0vkTGqDSNeTyLWurBFMqLZH42IT6HWQ8KOKnKU3dntpX1bix075l3MbtPBAUpeQUapuCUyk0KnkFG9pTJw1Jdoc1S9EAraZyJZHlI7Tr51F9AeTsRmytj5DSED6f-Ee_C_SsGHj6puBkS9Ix4bBNY= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire](https://www.meridianbioscience.com/press-release/meridian-bioscience-engages-korn-ferry-to-conduct-ceo-search-as-john-a-kraeutler-announces-plans-to-retire/)
**Published:** May 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, May 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced it will commence a global search for a new Chief Executive Officer in conjunction with the planned retirement of John A. Kraeutler in accordance with the terms of his employment agreement. Mr. Kraeutler plans to continue to serve in the capacity of CEO until his successor is found. Going forward he will be available to assist the new CEO during the transition and onboarding phases, and will remain as Executive Chairman of Meridian’s Board of Directors. A committee of the Board will begin the search immediately with the assistance of Korn Ferry, a global talent advisory firm
“The Board thanks Mr. Kraeutler for his entrepreneurial vision and many achievements that led to Meridian’s growth and status as a leading and well regarded diagnostics and life sciences company,” said David Phillips, Lead Director. “The Board and Mr. Kraeutler have planned for the transition of his leadership, and they will work together to bring on a CEO who can take Meridian to the next level, utilizing its considerable assets.”
“The Board would like to recognize, with deep appreciation, the contributions and dedication of its management team and employees that define Meridian. Under Mr. Kraeutler’s leadership, they have achieved many significant milestones.”
Mr. Kraeutler commented, “Since having joined the Company in January 1992, numerous opportunities and challenges have been managed successfully that have enabled Meridian Bioscience to become a global leader in diagnostics and life science tools. It has been my pleasure to have led such a dedicated and capable team that has built this diversified, efficient business that supplies vital products and tools for improving healthcare worldwide. This succession process is an essential part of helping to ensure the future growth of Meridian Bioscience and I look forward to welcoming a CEO with a clear vision and the skills to drive the Company forward.”
**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Korn Ferry** Korn Ferry is the preeminent global people and organizational advisory firm. Korn Ferry helps leaders, organizations, and societies succeed by releasing the full power and potential of people. Korn Ferry’s nearly 7,000 colleagues deliver services through its Executive Search, Hay Group and Futurestep divisions.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=8fP-iuK40WzedG5kFdN3AIbwC3i-6M2AQw4SSpfYfgil4_4Qp1P_l-NyrQgbgN5gRwkK-cJJI8KOcymryzup0-jncMp26Pz23NJI9MLRQBxEeV46tsa55aYwr34voftt "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women](https://www.meridianbioscience.com/press-release/magellan-diagnostics-meridian-bioscience-inc-nasdaq-vivo-launches-national-education-initiative-on-risks-of-lead-exposure-for-pregnant-women/)
**Published:** May 9, 2017
**Author:** hamza
**Content:**
## Kickoff panel highlights common risks and what obstetricians can do to help protect their patients.
CINCINNATI, May 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian, has embarked on a major new initiative to increase awareness among obstetricians and pregnant women about the risks of lead poisoning. The effort is being kicked off today with an expert-led discussion of lead poisoning in pregnancy at a national gathering of obstetricians in San Diego, California.
Lead exposure is a pervasive health threat which, even at low levels, can cause behavioral and learning disabilities, hyperactivity and lower IQ in children. In adults, it can result in difficulty becoming pregnant and maintaining a healthy pregnancy, reduced fertility, as well as hypertension and kidney dysfunction. It is estimated that in the US, 1 in every 100 women of childbearing age has a blood lead level above the current reference value of 5 µg/dL.
Mary Jean Brown, ScD, RN, Adjunct Assistant Professor of Social and Behavioral Sciences at the Harvard TH Chan School of Public Health; and the Former Chief of the Lead Poisoning Prevention Branch at the Centers for Disease Control and Prevention (CDC) who spoke at the Magellan-sponsored event is an author of the seminal 2010 CDC report on lead exposure in pregnancy. She explained, “Because lead crosses the placental barrier, maternal blood lead passes to baby. There is clear evidence that across a broad range of maternal exposure levels, lead can negatively impact both maternal and child health.”
“Since news of the lead in water crisis in Flint, Michigan and in other communities across the nation has become widespread, the public is more aware that lead poisoning is still a problem,” said Amy Winslow, president and CEO of Magellan Diagnostics, “but few realize that pregnant women should also be concerned about lead exposure. We want obstetricians and expectant moms to be aware of the risks, and of the importance that a simple screening test can have in avoiding the consequences of undiagnosed lead exposure.”
Magellan’s program also featured recommendations from Jeanne Hewitt PhD, RN Director, Community Engagement at the University of Wisconsin-Milwaukee Children’s Environmental Health Sciences Center, an environmental public health nurse and researcher who has studied lead exposure for years. Dr. Hewitt described the women who are at risk, “Do-it-yourself renovations are very popular, but many women don’t realize they may be creating lead dust that can be inhaled or ingested. If a woman lives or works in an area where the water may be tainted with lead this is a concern. We also find that many immigrant families have higher levels of lead exposure from their country of origin. In addition, my research has focused on how lead in second hand smoke is also an underappreciated source of exposure.”
Discussing how obstetricians can respond if they identify lead poisoning, Dr. Brown commented, “The first and most important step is to find the source of the lead and eliminate it. It is also critical to focus on the mother’s nutritional status – anemia and other deficiencies can worsen the effects of lead exposure. Finally, it’s important to educate Mom on the sources of lead, so that they can bring their newborns home to a lead-free environment.”
Magellan’s Lead in Pregnancy initiative is scheduled to run throughout the spring and summer, culminating during Women’s Health Quarter at the end of the year. The company will be hosting webinars and local educational events across the country, including mobile blood lead testing, in addition to offering introductory programs designed to help obstetricians start to perform lead screening as part of the services they offer to their patients. For more information, visit: [www2.magellandx.com/ob](https://www.globenewswire.com/Tracker?data=2NvUuJIBIAfmMzIxGpRxDBmfo5lc_Hnm2DnT0uAMOTRE9Jsp_PruBxm_q1IDYYL0HGS22PFxrLBHftUc94a_LI1LDPo-h9ZKIiUA79UpuOo= "www2.magellandx.com/ob").
**About Magellan Diagnostics, Inc**.
Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of Meridian Bioscience, Inc., Magellan is headquartered outside Boston in Billerica, Massachusetts, and is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure, including [LeadCare II](https://www.globenewswire.com/Tracker?data=GcAxWi3uhMYy5H2BpcM3nyp4fHYPyEWqPyeseh9gSrYm8GYbLTtEqZHlF7lDvwBRJ9NRdvObiUT-D-21IHoskg== "LeadCare II"), the only point-of-care system used to diagnose lead poisoning in physician offices and clinics. We are committed to educating clinicians, policy makers, payers, families and communities about the permanent health damage caused by lead and how to detect and address lead exposure. For more information, visit [www.magellandx.com](https://www.globenewswire.com/Tracker?data=OHbIw5ZnayiRM_pp9-kmWTodbwR0GnM2y8VMw4lk7L0M4OydJx-jGS05pU_PP9wyS26uUgMwiTQxXoXuGae6tanMPmg88FI9BfihlmLD3Dw= "www.magellandx.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=pENZVPUPtl19jThO4vnQQVebZY6tE5IebeXhUjuEygQut4xDafd9HOQh-xOwcJkRDBR_9ymhHBU06qcjodr2YnArgzzENN1ODrg6OiuxxmbvY2lXILxLOippmRO5d7_RzYE-BUv6pvLZaJeLtn-X2sLSNjAcJauh16p0eXqHCj6-LMzodcMV5rV7Lxrp_lf9DmaxgTh9ys68IxAMH7AyThfEFYGgQ2cH36p9GZkUYRFWsl-Yyj9VB_wVXBIWvxpnzCIehv_Nb6rhVAU8stqofWcIpckU9hMAVpZbTrIBgt6vk8ve-Ob-6qGmdiSQW3S9xO2p_YzbWAhBl07f2rW5-vtQ_KYyEOjDENqdtS0j9hE= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of Antigens and Antibodies for Diagnostic Applications](https://www.meridianbioscience.com/press-release/meridian-continues-its-fight-against-tropical-diseases-by-introducing-the-most-comprehensive-menu-of-antigens-and-antibodies-for-diagnostic-applications/)
**Published:** May 4, 2017
**Author:** hamza
**Content:**
CINCINNATI, May 04, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the most comprehensive product offering of tropical disease biologicals intended for the development and manufacture of point-of-care (POC) diagnostic tests. This product menu from Meridian Life Science, Inc., a wholly-owned subsidiary of Meridian Bioscience, Inc., of over 150 highest quality biologicals consisting of native, recombinant antigens and antibodies is the most comprehensive offering available for commercial applications. In addition, many of these biologicals that we have supplied are currently in diagnostic assays for zika, dengue, chikungunya, malaria, lyme, leptospirosis, leishmaniasis, and chagas; which have obtained FDA, ANVISA, and CE approvals.
Tropical and vector-borne diseases account for more than 17% of all infectious diseases, causing more than 1 million deaths annually. Recognizing infected patients early in their clinical course is critical to preventing outbreaks. Tropical and vector-borne diseases are among the most complex of all infectious diseases to prevent and control. Many of these pathogens are also vector-borne diseases, transmitted between humans by a vector which is typically a blood-sucking anthropoid (e.g., mosquitoes, ticks, fleas, lice, and mites). Serological POC diagnostics are the most rapid and convenient methods available for tropical and vector-borne diseases. Tests either detect antigens from the infectious agent or virus specific IgG/IgM antibodies and include formats such as solid-phase dip-sticks (ELISA), particle agglutination, and lateral flow. Ideally, screening assays should have minimal cross-reactivity with other infectious diseases and have a high sensitivity, especially during the early stages of the infection.
Meridian Life Science, Inc. has dedicated great efforts to offer a complete range of antigens and antibodies ideal for the development of sensitive and specific immunoassays that detect tropical and vector-borne diseases. Lourdes Weltzien, Ph.D., Vice President of Meridian Life Science and President of Meridian Asia Pacific commented, “As soon as the WHO officially declared on February 1, 2016, that the Zika virus was a public health emergency of international concern; we immediately launched our recombinant antigens for Zika tests development, which have already been approved in high volume tests by various regulatory agencies around the world. The Zika virus is a pathogen spread by the bite of an infected *Aedes aegypti* mosquito; which is the same mosquito that transmits dengue, chikungunya, and yellow fever. In addition to Zika, we have also enhanced our antigen and antibody offer for chikungunya, dengue, and yellow fever.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are pleased to announce the release of the expanded range of antigens and antibodies for emerging Tropical diseases. This is an important addition of products to our ever-increasing portfolio of biologicals that are incorporated into diagnostic products and provides all of our global life science customers the ability to quickly develop diagnostic tests for these important pathogens. The further development of the Tropical disease family of biologicals demonstrates our commitment, not just to the continued development and expansion of products from Meridian Life Science, but also to our diagnostic manufacturing customers who desire to quickly address this emerging global market of Tropical diseases.”
To learn more, please visit our Tropical Diseases section at [www.meridianlifescience.com](https://www.globenewswire.com/Tracker?data=_OJIDQ0hpqSCavnLmRD1TGs4pX0ZddkEd_KS_X4wHT1ffOEoNfR3XC7i9nroOq2sMqITmLl6UgQ8TFmjjQpLYO0MTJtKD4kVzK0tqaJV-8Sj_a79ypjcjvLp_Q6kxXdT "www.meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=_OJIDQ0hpqSCavnLmRD1TIcQkU-RajHDNqe47hHTbWHM0knjMUAo_upZzywrMasEqnkcewocPFK1ExTewSdHGEi7Iy4k9WvWG7uO6-98_RN05Ayxy5D8ZuvWOo28iFi3Tu51jbP3h0Jvydd-YaJ_RhLLR-L3AQ-r22jmQS24VvKD4FhB2WolJtqLjzL-VNIwiF9XT-mLuy7m-h6IafKU_hFT0cekywqJP4R3mqGp6OQYnxLKNn0_0KpJkEJDMZ0WysXCd27speSuhd1zKufyVxQb4Sd6daTKXFS8pfJSa7MDrlCDcUQL-CEPzwpxQcbILnMVOW1CA4-jRM5Xg2cYSPqL061yPgJcb7fgCeqP_5A= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Reports Second Quarter 2017 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-second-quarter-2017-operating-results-declares-regular-cash-dividend-and-reaffirms-fiscal-2017-guidance/)
**Published:** April 27, 2017
**Author:** hamza
**Content:**
GENERAL HIGHLIGHTS
CINCINNATI, April 27, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
- reported fiscal 2017 second quarter and first six months net revenues of $54.1 and $100.9 million, respectively, increases of 6% and 3%, respectively, from the same period of the prior fiscal year;
- reported second quarter operating income of $14.2 million, a decrease of 6% from the same period of the prior fiscal year;
- reported six months operating income of $24.3 million, a decrease of 16% from the same period of the prior fiscal year;
- reported second quarter net earnings of $9.3 million, or $0.22 per diluted share, increases of 2% and 5%, respectively, compared to the fiscal 2016 second quarter. When compared to the fiscal 2016 second quarter net earnings on a non-GAAP basis, the fiscal 2017 net earnings and net earnings per diluted share each decreased 8%. This non-GAAP financial measure excluded the effect of fiscal 2016 second quarter costs associated with acquisition activity (see non-GAAP financial measure reconciliation below);
- reported first six months net earnings of $15.6 million, or $0.37 per diluted share, decreases of 13% and 12%, respectively, compared to the same period of fiscal 2016. When compared to the first six months of fiscal 2016 on a non-GAAP basis, the year-to-date fiscal 2016 net earnings and net earnings per diluted share decreased 19% and 18%, respectively. This non-GAAP financial measure excluded the effect of fiscal 2016 first six months costs associated with acquisition activity (see non-GAAP financial measure reconciliation below);
- declared the regular quarterly cash dividend of $0.125 per share for the second quarter of fiscal 2017 (annual indicated rate of $0.50 per share);
- reaffirmed fiscal 2017 guidance of per share diluted earnings between $0.64 and $0.69 on net revenues of $193 million to $199 million.
FINANCIAL HIGHLIGHTS (UNAUDITED)
In Thousands, Except per Share Data
Three Months Ended Six Months Ended March 31, March 31, 2017 2016 % Change 2017 2016 % ChangeNet Revenues$ 54,125 $ 51,259 6 % $ 100,934 $ 98,419 3 %Operating Income 14,186 15,156 -6 % 24,271 28,742 -16 %Net Earnings 9,312 9,091 2 % 15,591 17,984 -13 %Diluted Earnings per Share$ 0.22 $ 0.21 5 % $ 0.37 $ 0.42 -12 %Diluted Earnings per Share excluding effect of acquisition-related costs (Q2-16)$ 0.22 $ 0.24 -8 % $ 0.37 $ 0.45 -18 % March 31, 2017 2016 Cash and Equivalents$ 54,745 $ 48,946 Working Capital 108,896 106,930 Long-term Debt 56,879 59,842 Shareholders’ Equity 170,828 169,846 Total Assets 251,902 258,361
COMPANY COMMENTS
John A. Kraeutler, Chief Executive Officer and Chairman of the Board said, “The second quarter of fiscal 2017 rebounded from the first quarter both in terms of revenues and net earnings performance. The overall portfolio performed well; however, our Life Science segment was especially strong posting record revenues of $16.4 million and 20% growth over the prior year on a constant currency basis. Our Diagnostics segment, which has been relatively weak due to increased competition, increased by 2% on a constant currency basis compared to the second quarter of fiscal 2016. However, when considering sequential quarter-over-quarter improvement, the Diagnostics segment showed a renewing strength. On a consolidated basis, revenues grew 6% on a constant currency basis over the prior year quarter.
Both business units within our Life Science segment achieved double-digit revenue growth on a constant currency basis over the prior year quarter. Our immunoassay reagents business had a record quarter, with revenues growing by 25%. This growth was fueled by sales of Zika biologicals and selected viral proteins and reagents. Our molecular tools and components business grew nearly 10% on a constant currency basis, driven by qPCR reagents and augmented by revenues from new products serving the next generation sequencing and miRNA research markets.
Within the Diagnostics segment, quarterly revenues for the core diagnostics unit declined 8% on a constant currency basis compared to the prior year; however, as compared to the first quarter of fiscal 2017, both molecular and non-molecular categories improved materially, increasing by nearly 20% sequentially. We believe that the recent leadership changes and our renewed distribution relationships are having the positive effects we anticipated. Revenue growth in our respiratory product category of 14%, on a constant currency basis compared to the prior year second quarter, offset declines in other categories. Overall, Meridian’s ***illumi****gene* test revenue declined 2% on a constant currency basis compared to the prior year second quarter; however, excluding the *C. difficile* test revenue, ***illumi****gene* revenues increased 6%, driven by growth in tests for Group A Strep, Mycoplasma, HSV, and malaria. When compared with the first quarter of fiscal 2017, the ***illumi****gene* category increased by approximately $1.8 million with improvements in most test categories including *C. difficile*. Our *H.pylori* revenues declined 6% on a constant currency basis compared to the prior year quarter as a result of stock-and-block activities in advance of our May 2016 patent expiration in the U.S. However, revenues for this product category improved over the first quarter of fiscal 2017. The competitive landscape presently remains stable for this product category, and we expect flat to low single-digit growth for the year. Our *C.difficile* business held up better this quarter but still declined 13% over the prior year quarter (vs. 34% in the first quarter compared to the same quarter in 2016.) Foodborne revenues declined 30% compared to the prior year quarter, due in part to the timing of distributor orders, but increased by 14% sequentially.
Magellan Diagnostics revenues were $3.6 million for the quarter and were flat compared to last year (pre-acquisition). For the six months, revenues increased 17% and reflect some lumpiness in distributor and international orders quarter-to-quarter.
Our focus on stabilizing our core diagnostics business in the Americas continues, and we believe we are seeing progress in this area. We are strengthening many areas of the business, including the leadership in our sales and marketing organizations, our distribution relationships around the globe, our investments in new product development, and our promotion of Meridian’s game-changing ***illumi****gene* malaria product.
We are encouraged by this quarter’s revenues and net earnings, keeping in mind that the second fiscal quarter is historically our strongest quarter of the year given our broad portfolio of respiratory products. We look forward to reporting more progress on our growth initiatives in our third quarter earnings release.
Finally, some comments are appropriate regarding our opportunities relating to Meridian’s ***illum****igene* menu expansion for insect vector diseases, including malaria. As much of this week is dedicated to the elimination of malaria around the world, with key events held in New York City and Vienna, Austria, we are very encouraged that the Meridian ***illum****igene* malaria test is being recognized as the first significant innovation in the last fifteen years in detecting these parasites. We have seen rapid clinical lab acceptance of the test in Europe as “travelers” require highly sensitive testing and we are working diligently to have ***illum****igene* malaria adopted in the endemic regions of the world as a highly accurate enhancement of current control and treatment procedures.”
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the second quarter ended March 31, 2017. The dividend is of record May 8, 2017 and payable May 18, 2017. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including any acquisitions.
FISCAL 2017 GUIDANCE REAFFIRMED
For the fiscal year ending September 30, 2017, management expects net revenues to be in the range of $193 million to $199 million and per share diluted earnings to be between $0.64 and $0.69. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.4 million at fiscal 2016 year end to approximately 42.6 million at fiscal 2017 year end. The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2017.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At March 31, 2017, current assets were $128.8 million compared to current liabilities of $19.9 million, resulting in working capital of $108.9 million and a current ratio of 6.5 Cash and equivalents were $54.7 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which relate to the 2016 acquisition of Magellan, totaled $56.9 million as of March 31, 2017.
INTERIM UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2017 and fiscal 2016.
Three Months Ended Six Months Ended March 31, March 31, 2017 2016 2017 2016 Net revenues$ 54,125 $ 51,259 $ 100,934 $ 98,419 Cost of sales 20,594 17,687 37,953 33,264 Gross profit 33,531 33,572 62,981 65,155 Operating expenses Research and development 3,907 3,129 7,312 6,510 Selling and marketing 8,012 7,210 15,526 13,653 General and administrative 7,426 6,875 15,872 14,769 Acquisition-related costs – 1,202 – 1,481 Total operating expenses 19,345 18,416 38,710 36,413 Operating income 14,186 15,156 24,271 28,742 Other income (expense), net 4 (364) (422) (251) Earnings before income taxes 14,190 14,792 23,849 28,491 Income tax provision 4,878 5,701 8,258 10,507 Net earnings$ 9,312 $ 9,091 $ 15,591 $ 17,984 Net earnings per basic common share$ 0.22 $ 0.22 $ 0.37 $ 0.43 Basic common shares outstanding 42,202 42,053 42,177 41,984 Net earnings per diluted common share$ 0.22 $ 0.21 $ 0.37 $ 0.42 Diluted common shares outstanding 42,568 42,425 42,539 42,360 The following table sets forth the unaudited segment data for the interim periods in fiscal 2017 and fiscal 2016 (in thousands).
Three Months Ended Six Months Ended March 31, March 31, 2017 2016 2017 2016 Net revenues Diagnostics$ 37,772 $ 37,354 $ 71,580 $ 72,655 Life Science 16,353 13,905 29,354 25,764 $ 54,125 $ 51,259 $ 100,934 $ 98,419 Operating Income Diagnostics$ 9,595 $ 11,196 $ 16,238 $ 21,526 Life Science 4,571 4,154 7,838 7,390 Eliminations 20 (194) 195 (174) $ 14,186 $ 15,156 $ 24,271 $ 28,742 NON-GAAP FINANCIAL MEASURES
In this press release, we have provided information on net earnings, basic earnings per share and diluted earnings per share excluding the effect on the fiscal 2016 periods of costs associated with acquisition activity. We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to acquisition activity; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the acquisition activity noted above, in the tables below for the three and six month periods ended March 31, 2017 and 2016.
Three Months Six Months Ended March 31, Ended March 31, 2017 2016 2017 2016 Net Earnings – U.S. GAAP basis$ 9,312 $ 9,091 $15,591 $17,984 Acquisition-related costs – 1,000 – 1,233 Adjusted Earnings$ 9,312 $10,091 $15,591 $19,217 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.22 $ 0.22 $ 0.37 $ 0.43 Acquisition-related costs – 0.02 – 0.03 Adjusted Basic EPS$ 0.22 $ 0.24 $ 0.37 $ 0.46 Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.22 $ 0.21 $ 0.37 $ 0.42 Acquisition-related costs – 0.02 – 0.03 Adjusted Diluted EPS$ 0.22 $ 0.24 \*$ 0.37 $ 0.45 \*Does not sum to total due to rounding. **FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=nBVUrE-o4uNEfTmwi41rW07DDfgOeQPEiUFIr-xnC9D_uu-WtRSsZZQ0DSxPmgA-WNT7ViZIdnOMAY6QxNac4SYiudeTKxKcMtomGmzlMk3ek7zs9HtJFEhMdFy-KUydRRHvAmLKXHmhY5jokweLFuSyR0ZpCFwsMTrl5cVM27_SMBb-LnuwJK9CGECh4twanTVj9s3cB2kR_gD6Ljg1A1gSxh65O5hMVXd8lUaC6NJTzmFWTjf_hmqIw94AMOzbZqgXZzVrm6ZONBUw7Cqb8DYrsPuFvssD775qVQs3DYH_mUNwcUxFsWoAuep6pldrzd3RX5wZwbO-_gpq1gbh1ETofDSbmg9gg6gQRMlT2zQ= "www.meridianbioscience.com").
**Categories:** Press Release
---
### [Meridian Bioscience Comments on Recent FDA Press Statement](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-recent-fda-press-statement/)
**Published:** July 13, 2017
**Author:** hamza
**Content:**
CINCINNATI, July 13, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following comments regarding the FDA press statement and website announcement concerning the posting of the Form FDA-483 issued following the inspection of Magellan Diagnostics, which closed on June 29, 2017. As FDA noted, this Form represents the investigators’ observations and is not a final Agency determination. Consistent with FDA policy, Magellan will promptly submit responses to the Form FDA-483 for the Agency’s consideration.
Meridian Bioscience, Inc. and Magellan reiterate their mutual commitment to strengthening Magellan’s quality system and ensuring all aspects of the system are in full compliance. Both organizations take this very seriously and Magellan is addressing the observations noted in the Form FDA-483 with the highest sense of urgency.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dqSwpI1-iwWcUC6YR9vsa4JmQhBAPhzB4TnWfxhKbyxodFtEgKrtlBIazXiN_POHCmmG6Ltq4L5PANmVtx45DU_lA4pfg_rI7hziHtcE1xKZ2RnCParQkQ_SzO1HfGffdjbYjXM9E-EcpjmX4e6iYly6Ty6ka01MpxUjdXTP9kZha8ceEgRzSu-T43Ed9toWG1fRV7TnRWYA7jCIt2kHpqxgw7OHvrzYYzBuVJRDIYUS-EMKHVefO60czMLBEgEEkD9mEYgo4drDZ7ejMVMz7kd2H6e4pG9qkR_U8RriJnQ0zWnSDueuRtDf3Mz8Y2sROkveKl8PXyorF2xwlYHdJSU56N3EjlvE9b3pMjz0alc= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker](https://www.meridianbioscience.com/press-release/meridian-launches-tru-block-ultra-a-powerful-immunoassay-interference-blocker/)
**Published:** September 5, 2017
**Author:** hamza
**Content:**
CINCINNATI, Sept. 05, 2017 (GLOBE NEWSWIRE) — Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TRU Block® ULTRA. This product is the result of years of R&D aimed at creating the most powerful immunoassay interference blocker in the market. The advantage of TRU Block ULTRA over others in the market is its active blocking technology across various assay types and its powerful assay interference blocking against human anti-mouse antibodies (HAMA), rheumatoid factor (RH), and heterophilic antibodies (HA). The blocking effectiveness of TRU Block ULTRA has been proven in ELISA and lateral flow assay formats. The enhanced performance of TRU Block ULTRA allows IVD manufacturers to use this active blocker at reduced concentrations to achieve HAMA blocker cost reductions as well as broad coverage against HA/RF.
Blockers are used in ELISA and lateral flow assays to improve their sensitivity and specificity by reducing interference from proteins in patient samples that could produce false results and lead to incorrect diagnosis. Double mouse monoclonal assays and competitive assays are specifically prone to HA interference and require a specialized blocker to remove HAMA and RF which can cause false results. A blocker such as TRU Block ULTRA, contains a specific binder directed against all types of heterophilic interference including HAMA and RF. Once bound to the interfering antibodies, this blocker prevents further binding of HA to other assay components through steric hindrance.
Richard L. Eberly, President, Chief Commercial Officer, stated, “Over the past 40 years, Meridian has established strategic relationships with the top *in vitro* diagnostic companies by providing high quality and competitive antigens, antibodies, blockers, and PCR amplification enzymes for IVD commercial assays. TRU Block ULTRA is the next generation interference blocker that can deliver superior blocking performance and improve the accuracy of a diagnostic assay. To learn more about Meridian’s extensive range of blocking reagents, please visit us at [www.meridianlifescience.com](https://www.globenewswire.com/Tracker?data=q5uBASzeprkygrC4CJj8aY3b8wFMQY23U83yEe9YQL2YPe5hwHV3_O-vXtAQPXGTkNTod7q2GRrbGGbSI-cACXRG82Wm6C5StwO_WdtDTXX8jVAPaoiFruMT6onTk8Cx "www.meridianlifescience.com").”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=q5uBASzeprkygrC4CJj8aWLNBsDDjsVPiAb9AnahqasZTpBHsDskM_-aD5icg5MH8h5t224rwtZlIpkoFS8K35xepeCq5seqgwvbQT8mkS9haOooQFrhm9vkou6m8JeuU1X8dhXFJZ3Vbkwr5urx9Mbv_cItOMzXLOpCwj_i2e9iSuIYylKiZME02tf8Grw9SFceAQRU_YV-ds595tMA3YKPl-ARrKpAD2ca_54a-HdcdzeYM4swuGVZaJwcZ4ihbV5REw0Id0yM7-b0iqcGqweYFen4PLnWuOSefBspgzI4KHvvrz4ihoyitueTK_-yPEJDqt1y5Ty7-tEM46aoHdPnN1yaZ4dd37WxJ_JiSEc= "www.meridianbioscience.com").
**FOR ADDITIONAL INFORMATION:** For more information about Meridian Life Science, Inc., please visit [https://www.meridianlifescience.com/](https://www.globenewswire.com/Tracker?data=ixiYynfYfywKk1o0KMLMT8eALIhzNp4d0vCLypMZEbggIEtqa_HGG-CdAvBi6o_cHAE7IA40pBg2X9k5sDxGTcsOFLsPOJzLtEtbFcutS2YJzGU0Y9L31Rh2h3VORmwt).
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test](https://www.meridianbioscience.com/press-release/meridian-initiates-clinical-trials-for-new-neonatal-saliva-cmv-illumigene-test/)
**Published:** August 9, 2017
**Author:** hamza
**Content:**
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new ***illumi****gene* CMV molecular amplification test*.* This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns. Meridian has enrolled an international team of world experts in neonatal CMV infections in order to support the clinical studies.
According to the CDC, congenital CMV infection occurs when a baby is born with a Cytomegalovirus infection. About one out of every 200 babies are born with congenital CMV infection. Women can pass CMV to their baby during pregnancy if the virus in the woman’s blood crosses through the placenta and infects the baby. Congenital CMV infection can cause developmental disabilities such as hearing and vision loss, cerebral palsy, mental disability, and in rare cases, death. Early detection is integral in establishing appropriate treatment. Congenital CMV can be diagnosed if the virus is detected in a baby’s urine or saliva, within 2 to 3 weeks from birth. CMV is a public health issue and legislation has been passed or is under consideration in numerous states regarding CMV education and testing in neonates.
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are excited to initiate clinical trials for this important new test as part of our commitment to expand the menu of ***illumi****gene* to include new and novel ways of improving healthcare and impacting human lives.”
John A. Kraeutler, Chief Executive Officer and Chairman of the Board said, “We support testing for neonates and are excited to progress to the clinical trial phase with ***illumi****gene* CMV. We believe the CMV market is in critical need of a procedurally simple, rapid, and sensitive test that is saliva based. We look forward to a positive outcome of our ***illumi****gene* CMV clinical trial and subsequent submission to the FDA.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mr4hDG2Whzlmdhc_3CQw5hGiuF-dsalWlCoIHc1Icbvi4OOwlmV7INyaj6zzSXaAK2GfCpA8OzKFqkY8BrRYX1L2nkf_DS2v_ts5iiaB4teen1_qzl9V1LOxkw_xTqb0zjMO0srZ9mjCXTpFaoQjEdhNZJa3WOe5m1PzFewI4Zdj3DtYfQogJNR0x3S65JUQFT-InLqx07FlBxs3vWYFkFzS4eWhIbatT-fPJQnmHW_1v1Fq4CeU1pV-PA6WzLRV6p5bYpsSn0paw6Tom9AJ-d85HEsor5KGgOwMaBVFKNbZg2cjLdCj73cU3TULAyk9dGLxSywXNyXfpzu8NRbza1SdeslUXEH9TmGAAXCm4pQ= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line](https://www.meridianbioscience.com/press-release/meridian-bioscience-introduces-the-expansion-of-its-immunocard-stat-product-line/)
**Published:** August 8, 2017
**Author:** hamza
**Content:**
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of its Immuno*Card* STAT!® product line with the addition of Immuno*Card* STAT! FLU A&B. The Immuno*Card* STAT! FLU A&B product is CLIA waived and meets the new FDA reclassification requirements. Immuno*Card* STAT! FLU A&B detects the presence of influenza A & B in nasal and nasopharyngeal swabs. The product can also be used to test aspirates and nasal washes. The Immuno*Card* STAT! FLU A&B test has a simple procedure with minimal hands on time that provides qualitative results in 10 to 15 minutes.
Immuno*Card* STAT! FLU A&B meets the testing needs of all point-of-care environments like CLIA-waived physician offices, Emergency Rooms, moderately complex physician offices, and the core hospital laboratory. Immuno*Card* STAT! FLU A&B compliments Immuno*Card* STAT! EHEC, Immuno*Card* STAT! *Crypto/Giardia*, Immuno*Card* STAT! CAMPY, Immuno*Card* STAT! HpSA, Immuno*Card* STAT! *Strep* A, Immuno*Card* STAT! Rotavirus, and Immuno*Card* STAT! Mono.
The influenza testing landscape has changed since the FDA issued a reclassification of the rapid influenza virus antigen tests on January 12, 2017. In addition to reclassifying such devices from Class I to Class II, the FDA has put special controls in place that redefine sensitivity and specificity performance criteria that must be met by the manufacturers of rapid influenza devices after January 12, 2018. The Immuno*Card* STAT! FLU A&B CLIA-waived test meets the criteria set by the FDA.
Charles Caso, Vice President Sales & Marketing, Global Diagnostics, commented, “Immuno*Card* STAT! FLU A&B allows us to meet our current customer requirements and, with CLIA waiver, opens up a whole new market for Meridian Bioscience. We will begin taking orders immediately with ship dates in early September.”
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=zyHQZJxeWe7v0ooUQJesnp9QhIjWQ-n_q88tRzKsx9ijQ48QSihkBDzyjDbXuzOcoiwQyZFMRQpzSXGHi0XQv1ldko7a8WvNGkp4Yoh6IsPL889MbH-T_Zn-8CHqh2sDl2SrNWL-JQX3bWnDJwnx6nOHLE4N_RSRNVcogHqvRzZRGSCK5moepX5S66WFZvNeTmdxmRRAW790b8X4ZkBfkBJxA4Qbi3flOf93te0ye1f2ewYi_SKO_vbE9K8O6jK9CtuY9wQl3GMQbgZfR2UJ_uie8guOP42Ih7r7lsGUrh_LBYzkyHSTXW9NbutMWgvLqBMCF4wx6TyXA_liRP_xCx92g3C94IYlHT0lgTaVflg= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Elects John Rice to the Board of Directors](https://www.meridianbioscience.com/press-release/meridian-bioscience-elects-john-rice-to-the-board-of-directors/)
**Published:** August 8, 2017
**Author:** hamza
**Content:**
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017.
Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Mr. Rice has served as the Director of Life Sciences at CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. He has served on the board of directors of several privately held healthcare companies.
John A. Kraeutler, Chairman and Chief Executive Officer, commented, “With the election of John to the Board of Directors of Meridian Bioscience we have added key strategic and scientific strengths to help guide our future growth. Our Nominating Committee has been working diligently for the last year to add specific skills to the Board. We are very pleased that John has agreed to join our team. I look forward to working with John and our existing directors as we build a strong future for Meridian Bioscience.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=krqv2eKa6f4Q1l9PagWeWJIreCAolO7QA-_NdDfGxfLDM32jD9xaKMX9H7w-rviSRSEknXyrSK7jfEyUDfDoLNuuQWd6Z87fAvUAtZfszc-hm0JPWZymDkL0mi5qKr2HF2xIfWJnA51yZWnINW_0kaeVDloEdaTuSWB2wFQFLwgES63CHaOxzBGDhkH7LFmLOcRXCev3wXcKnPTIWBDtsY-wHzsXKFymeUyRLJ1GEpPnRSTS-UiwFr9LgQHro_41QvJRG8n6Hr25-A7IFOvGqAS-ISOLwYulsihwZ1qRY1ivAUZiU3DJDq-xdIY4p-SR_dAUB1zVnYNZWJsvH0WBTSKQvCL56IRerrLttqADJz8= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
Contact:
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
```
**Categories:** Press Release
---
### [Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing](https://www.meridianbioscience.com/press-release/bioline-launches-new-jetseq-clean-kit-for-next-generation-sequencing/)
**Published:** August 2, 2017
**Author:** hamza
**Content:**
CINCINNATI, Aug. 02, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio today for Next-Generation Sequencing (NGS) library preparation.
The new JetSeq Clean Kit is a clean-up system based on paramagnetic bead technology, designed for efficient purification of nucleic acid fragments in the next-generation sequencing workflow. JetSeq Clean removes salts, primers, primer-dimers, and dNTPs; while library fragments are selectively bound to the magnetic particles based on their size, allowing one-sided and two-sided “solid phase reversible immobilization” (SPRI) size selection. Purified library fragments are eluted from the magnetic particles using water or a low salt buffer and can be used directly for all downstream NGS applications.
Marco Calzavara, President of Bioline commented, “We are pleased to announce the release of the new JetSeq Clean Kit. The release of the new JetSeq Clean Kit complements the JetSeq Library preparation and JetSeq Quantification kits, extending our portfolio of high quality products to help researchers with NGS library preparation.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “This is another important addition to our innovative portfolio of NGS products and gives our life science customers greater confidence in the production their sequencing libraries. The continued development of the JetSeq family shows our commitment to the expansion of products from Bioline in this field and continued commitment to our customers, giving them a greater support around this fast-growing field.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=i9rY6jcClotEdbxGwwHi7PsaqjKnoM1-XTc-9PWrqyL9VqhPQK2rQlvdKSUwWSOGIAuv1OoEDn1I7Gqol8UT1xXrf9l68BlHI5xfE4JWZEmLKX1OwKvS1bS8JrlXMNkzKyPftGQF8KA8CjOq4Z7gFE-KbA3FkLgTiuF_EIU-WHOEqfzOD6sy0zLU3qRcFbHvQIkvNtsgsfJLrHo9zlnkqH6zOBt5fNTmrzAhZ31nBa2MfZyFHnh1V35RBsUlEGcpaqIeWU62tU1VgOaCfcMrbaJjOWsa7UVA7y2zZx9xwxVl3suq2rkQL-GIJOlyQwkJ_JvvS9bOHzqOdJG71H7o8MHkxq4nYRj-TOO91sMtLa8= "www.meridianbioscience.com").
**FOR ADDITIONAL INFORMATION:** For more information about Bioline, please visit [https://www.bioline.com](https://www.globenewswire.com/Tracker?data=2UGsOXvDEzstTeUO9E9dLbENPVUvTstIySj500CRxWztG3GKIgPEZgax6ubPUrQVcW8ivbQ4nO7FrO7oBSBqZsttqmYcjiOFoyNqXMYb9cQ=).
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-third-fiscal-quarter-2017-operating-results-including-non-cash-goodwill-impairment-chargedeclares-regular-cash-dividend-and-reaffirms-fiscal-2017-guidance-excluding-the/)
**Published:** July 27, 2017
**Author:** hamza
**Content:**
GENERAL HIGHLIGHTS
CINCINNATI, July 27, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
- reported fiscal 2017 third quarter and first nine months net revenues of $50.1 and $151.1 million, respectively, a decrease of 1% and an increase of 1%, respectively, from the same periods of the prior fiscal year;
- reported third quarter operating income of $4.3 million (including a $6.6 million non-cash goodwill impairment charge), a decrease of 69% from the same period of the prior fiscal year;
- reported nine months operating income of $28.6 million (including a $6.6 million non-cash goodwill impairment charge), a decrease of 33% from the same period of the prior fiscal year, which included $1.5 million of costs associated with acquisition activity;
- reported third quarter net earnings of $0.2 million, or $0.01 per diluted share, on a GAAP basis, decreases of 97% and 95%, respectively, compared to the fiscal 2016 third quarter. On a non-GAAP basis, earnings were $6.9 million, or $0.16 per diluted share, decreases of 22% and 24%, respectively, compared to the fiscal 2016 third quarter. Non-GAAP basis excludes the effect of a goodwill impairment charge (see non-GAAP financial measure reconciliation below);
- reported first nine months net earnings of $15.8 million, or $0.37 per diluted share, on a GAAP basis, a 41% decrease compared to the same period of fiscal 2016. On a non-GAAP basis, earnings were $22.5 million, or $0.53 per diluted share, a 20% decrease compared to the non-GAAP earnings of the first nine months of fiscal 2016. Non-GAAP basis excludes the effect of goodwill impairment in the fiscal 2017 period and the effect of costs associated with acquisition activity during the fiscal 2016 period (see non-GAAP financial measure reconciliation below);
- announced the recording of a non-cash goodwill impairment charge of $6.6 million, on both a pre-tax and after-tax basis, in the third quarter of fiscal 2017. Relating to the carrying value of the Company’s Magellan Diagnostics subsidiary (“Magellan”), acquired in March 2016, the impairment reflects management’s assessment of recent FDA activities associated with Magellan’s blood lead tests using venous blood samples and the potential impacts on the timing and level of Magellan’s operating results (see further detail below);
- declared the regular quarterly cash dividend of $0.125 per share for the third quarter of fiscal 2017 (annual indicated rate of $0.50 per share);
- reaffirmed fiscal 2017 guidance of per share diluted earnings between $0.64 and $0.69, excluding the effect of the goodwill impairment charge, on net revenues of $193 million to $199 million.
FINANCIAL HIGHLIGHTS (UNAUDITED)
In Thousands, Except per Share Data
Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 % Change 2017 2016 % ChangeNet Revenues$ 50,140 $ 50,665 -1 % $ 151,074 $ 149,084 1 %Operating Income 4,304 13,741 -69 % 28,575 42,483 -33 %Net Earnings 240 8,754 -97 % 15,831 26,738 -41 %Diluted Earnings per Share$ 0.01 $ 0.21 -95 % $ 0.37 $ 0.63 -41 %Diluted Earnings per Share excluding effect of goodwill impairment charge (Q3-17) and acquisition-related costs (Q2-16) (see non-GAAP financial measure reconciliation below)$ 0.16 $ 0.21 -24 % $ 0.53 $ 0.66 -20 % June 30, 2017 2016 Cash and Equivalents$ 55,253 $ 45,803 Working Capital 109,188 106,672 Long-term Debt 55,763 59,101 Shareholders’ Equity 167,549 168,853 Total Assets 245,143 254,946 NON-CASH GOODWILL IMPAIRMENT CHARGE
During the quarter, the Company recorded a non-cash impairment charge of $6.6 million related to the carrying value of its Magellan subsidiary, acquired in March 2016. On June 29, 2017, the FDA, in connection with its recent Safety Notification and quality system inspection, issued its Form FDA 483 to Magellan. Because one of the Form FDA 483 observations involves a Medical Device Report, we expect that the FDA will issue a Warning Letter requiring periodic reporting on our remediation progress. Upon evaluation of the Form FDA 483 and potential Warning Letter, we believe we may experience further delays in reinstating venous blood sample testing on our LeadCare products, and in obtaining 510(k) clearance for new Magellan products. We may also have delays in obtaining export certifications for Magellan products during the remediation period. It is the quantitative assessment of the impacts of these expected further delays that has resulted in the goodwill write-down during the quarter. Given all of the factors considered, we do not anticipate, at this time, any further goodwill impairment charge from the Magellan acquisition.
This impairment charge does not impact our cash flow, our dividend or our bank covenants. Our outlook for Magellan’s LeadCare® II testing volume, utilizing capillary blood sample testing, continues to be healthy. In the 60+ days since the FDA released its Safety Notification (which pertained to venous blood lead testing performed on the systems produced by Magellan), 176 new LeadCare II systems have been placed in physician offices and clinics. For the nine months ended June 30, 2017, LeadCare II placements have increased 11% over the prior year comparable period. These placements and ongoing placements of LeadCare II point-of-care systems and related capillary blood testing are expected to drive revenue growth in 2018 and beyond.
The matters connected with the FDA Safety Notification occurred at Magellan prior to Meridian’s acquisition of the company. Meridian is committed to working diligently to strengthen Magellan’s quality system and to address the observations noted in the Form FDA 483 with the highest sense of urgency. We believe point-of-care lead testing is critical to addressing elevated lead levels among children and adults across the globe, as testing at the point-of-care improves compliance and facilitates patient education and intervention.
Beyond the impact of the impairment charge previously noted, we believe the impact on revenue related to the FDA’s Safety Notification was $0.2 million during the quarter. This represents the impact of reduced venous blood sample testing sales from the time of the May 17th Safety Notice through June 30, 2017. The costs associated with the matter were less than $0.1 million, resulting in a total impact of less than $0.01 on diluted earnings per share for the quarter.
COMPANY COMMENTS
John A. Kraeutler, Chief Executive Officer and Chairman of the Board said, “Our overall business continued to stabilize, with third quarter fiscal 2017 consolidated revenues declining 1% (flat on a constant currency basis), reflecting continued strong performance from both of our Life Science units, largely offset by modest declines in our Diagnostics segment. Our Life Science segment revenues grew 8% (10% in constant currency), while the Diagnostics segment declined 4% (also 4% in constant currency).
Within the Life Science segment, our molecular components unit grew 10% (15% in constant currency) and our immunoassay components unit grew 7% (also 7% in constant currency). New molecular components launched in the last year and growth in antigen and antibody sales in the Asia Pacific region continued to drive increases in revenue for these units.
With respect to the Diagnostics segment, our core diagnostics unit posted a revenue decline of 3.5% (3% in constant currency). Importantly, we saw improvement in several key product categories, including foodborne testing (11% growth), *H. pylori* (5% growth), and molecular products excluding *C. difficile* (9% growth). We are seeing some degree of stabilization in our *C. difficile* business, with revenues averaging $5 million per quarter over the last three quarters. Customers are exploring a variety of different testing algorithms (molecular, toxin, antigen testing), presenting an opportunity as we offer tests in each of these formats and can provide a total solution. Many of our competitors do not offer this range of product formats. Revenues for our Magellan diagnostics unit declined 9% (also 9% in constant currency) as a result of the combined effects of lower revenue from venous blood testing in the quarter and favorable acquisition-related matters in the previous year.
Our consolidated revenues for the nine months ended June 30, 2017 increased 1% (2% in constant currency). Our Life Science segment revenues grew 12% (14% in constant currency), while the Diagnostics segment declined 2% (also 2% in constant currency). Within the Life Science segment, our molecular components unit grew 7% (13% in constant currency) and our immunoassay components unit grew 15% (also 15% in constant currency). Again, new molecular components and growth in antigen and antibody sales in the Asia Pacific region continue to drive increases in revenue for these units. Within the Diagnostics segment, the core diagnostic unit posted a revenue decline of 10.5% (10% in constant currency). While the rebuilding continues, the core diagnostic unit is showing signs of stabilization as we improved performance in many key product categories in the third quarter, as noted above. Revenues for our Magellan unit increased $8.4 million for the year representing the inclusion of nine months of revenue in fiscal 2017 versus three months of revenue in fiscal 2016. On a pro forma basis including the pre-acquisition period, Magellan revenues increased 6% for the nine month period.
With regard to the recent FDA issues within Magellan Diagnostics which occurred prior to our acquisition in March 2016, we are committed to remediating both specifically noted quality weaknesses, as well as undertaking a complete upgrade of their quality system. Our global reputation for quality and compliance is world class, and our intention is to elevate Magellan to that same standard.
As we enter the fourth quarter and prepare for the start of Fiscal 2018, we expect that our investments in research and development will increase, as new tests and new diagnostic platforms move towards commercialization. These strategic investments are expected to have no impact on our previously-stated fiscal 2017 guidance. Finally, as we celebrate our 40th year, we are proud that we have been an innovator in biomedical tests and technologies, while consistently remaining profitable and financially efficient throughout our history. Our balance sheet is solid and we continue to evaluate opportunities for collaboration and for potential acquisitions.”
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the third quarter ended June 30, 2017. The dividend is payable on August 17, 2017 to shareholders of record as of the close of business on August 7, 2017. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings on both a GAAP and non-GAAP basis, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
FISCAL 2017 GUIDANCE REAFFIRMED,
EXCLUDING THE EFFECT OF GOODWILL IMPAIRMENT CHARGE
For the fiscal year ending September 30, 2017, management expects net revenues to be in the range of $193 million to $199 million and per share diluted earnings to be between $0.64 and $0.69, excluding the effect of the goodwill impairment charge. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.4 million at fiscal 2016 year end to approximately 42.6 million at fiscal 2017 year end. The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2017.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At June 30, 2017, current assets were $129.2 million compared to current liabilities of $20.0 million, resulting in working capital of $109.2 million and a current ratio of 6.5. Cash and equivalents were $55.3 million, and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which relate to the 2016 acquisition of Magellan, totaled $55.8 million as of June 30, 2017.
INTERIM UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2017 and fiscal 2016.
Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Net revenues$ 50,140 $ 50,665 $ 151,074 $ 149,084 Cost of sales 18,943 17,756 56,896 51,020 Gross profit 31,197 32,909 94,178 98,064 Operating expenses Research and development 3,906 3,546 11,218 10,056 Selling and marketing 7,885 8,085 23,411 21,738 General and administrative 8,474 7,537 24,346 22,306 Goodwill impairment charge 6,628 – 6,628 – Acquisition-related costs – – – 1,481 Total operating expenses 26,893 19,168 65,603 55,581 Operating income 4,304 13,741 28,575 42,483 Other expense, net (358) (340) (780) (591) Earnings before income taxes 3,946 13,401 27,795 41,892 Income tax provision 3,706 4,647 11,964 15,154 Net earnings$ 240 $ 8,754 $ 15,831 $ 26,738 Net earnings per basic common share$ 0.01 $ 0.21 $ 0.38 $ 0.64 Basic common shares outstanding 42,203 42,076 42,184 42,000 Net earnings per diluted common share$ 0.01 $ 0.21 $ 0.37 $ 0.63 Diluted common shares outstanding 42,593 42,463 42,556 42,379 The following table sets forth the unaudited segment data for the interim periods in fiscal 2017 and fiscal 2016 (in thousands).
Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Net revenues Diagnostics$ 35,949 $ 37,523 $ 107,529 $ 110,178 Life Science 14,191 13,142 43,545 38,906 $ 50,140 $ 50,665 $ 151,074 $ 149,084 Operating Income Diagnostics$ 914 $ 9,886 $ 17,152 $ 31,412 Life Science 3,388 3,696 11,226 11,086 Eliminations 2 159 197 (15) $ 4,304 $ 13,741 $ 28,575 $ 42,483 NON-GAAP FINANCIAL MEASURES
In this press release, we have supplemented our reported GAAP financial information with information on net earnings, basic earnings per share and diluted earnings per share, excluding the effect of a goodwill impairment charge on the fiscal 2017 periods and the effect of costs associated with acquisition activity on the fiscal 2016 periods, as applicable, each of which is a non-GAAP financial measure. We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of goodwill impairment and non-routine costs related to acquisition activity; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the goodwill impairment charge and costs of acquisition activity noted above, in the tables below for the three and nine month periods ended June 30, 2017 and 2016.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
Three Months Nine Months Ended June 30, Ended June 30, 2017 2016 2017 2016 Net Earnings – U.S. GAAP basis$ 240 $ 8,754 $ 15,831 $ 26,738 Goodwill impairment charge 6,628 – 6,628 – Acquisition-related costs, net of tax – – – 1,233 Adjusted Earnings$ 6,868 $ 8,754 $ 22,459 $ 27,971 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.01 $ 0.21 $ 0.38 $ 0.64 Goodwill impairment charge 0.16 – 0.16 – Acquisition-related costs, net of tax – – – 0.03 Adjusted Basic EPS$ 0.16 \*$ 0.21 $ 0.53 \*$ 0.67 Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.01 $ 0.21 $ 0.37 $ 0.63 Goodwill impairment charge 0.16 – 0.16 – Acquisition-related costs, net of tax – – – 0.03 Adjusted Diluted EPS$ 0.16 \*$ 0.21 $ 0.53 $ 0.66 \*Does not sum to total due to rounding.**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=HyN3vawVVVgChcZ42WeTuFeimWW530Bm_mgnizsAI82whMk-OgeVL6MUhl2ay7NP282Laguiz4k1bUitIHhzLuXRmHJvdZMOcJKvRgCkzYUHjyyXt7lcwxegKSy7nSbGiUt7YuJqYvAw8ttOpvF1Lm9FCzVf9FWufvuSCz_daDvaJYJlAs0X-TWYAmywwUrqHZ76bgUrG7-eC3DOmbc26ar3ck-A7eZhhwDMByUWvXfomC6pWX2Z0wME37jf3nRSjewPSeyfDnk3tBCJYlTQHl0cS1btDUhCzlHidnV59YyoMkw0r2MuVmkNKKrru-pWzMGSi2S0oUl3MiN_0AY7WdG5InmzHDtN8tDmtl03C8U= "www.meridianbioscience.com").
**Categories:** Press Release
---
### [Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China](https://www.meridianbioscience.com/press-release/meridian-announces-wholly-foreign-owned-enterprise-wfoe-office-in-beijing-china/)
**Published:** July 20, 2017
**Author:** hamza
**Content:**
CINCINNATI, July 20, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the opening of Meridian Bioscience Beijing, LLC, its wholly foreign owned enterprise (WFOE) in Beijing, China. Meridian opened a representative office (RO) in Beijing in 2015, and now this office has been transitioned to a WFOE to better serve its Chinese customers. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) in the New China Life Insurance (NCI) Tower Center, in the heart of the central business district (CBD) of Beijing.
Over the years, Meridian has established strategic relationships with the top *in vitro* diagnostic companies in China by providing high quality antigens, antibodies, blockers, and PCR amplification enzymes to the Chinese IVD market. Many of Meridian’s biologicals are used in the manufacturing of high volume Chinese FDA approved assays in China. Meridian’s commitment to and support of IVD customers in China will be greatly enhanced with this improved local representation. Through the WFOE; Meridian now has a local sales, marketing and distribution function for research and IVD customers in China. This will enable our employees in China to further increase opportunities with existing customers and help to attract new customers in the expanding Chinese market. The ability to maintain inventory in China, will expedite the selling process by making the sampling of our products faster and more convenient.
Lourdes Weltzien, Ph.D., Vice President and General Manager of Meridian Life Science, Inc. and President of Asia Pacific Markets, stated, “We are excited to transition our representative office to a WFOE in Beijing and bring enhanced local support to our customers in China. We continue to demonstrate Meridian’s increased commitment to our Chinese customers by expanding local resources to better service their needs for high quality life science products. Our business in China continues to grow rapidly and we are committed to continued investments in such an important market.”
Richard L. Eberly, President, Chief Commercial Officer, commented, “China represents one of our higher growth geographies within the Asia-Pacific region for our life science products. Over the last three (3) years our revenues in China have grown cumulatively by over 400%. The establishment of the WFOE reflects our continued investment in and commitment to Chinese research and IVD customers.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=QCtwdMO8Y7go6ym9EY1nNt7srpHk4sRzEABWYJ_f9bcpjfpc8n_H4uT-tWxQcbkpH_Wrttkx7BlI810L--gPDoPGpQbeXAx20qWxq2gnX1iqcwxQR1ZJ9Pez7lFQnANDPlJ0AeudtSLoO7GNRQY7mb8LAuO5eKccQ5Zz32hrDK54Z29RwcWPuLA2nlKOAbQ3Gy_zsVEEiFwTNvI86zaWNkaauBcYKNSpIPRYE6RvOOF56MigzmBCwEHDiXXVYk1Xlw4hvYJiIUEjVAqP0BRMruGatmG65XO8iiPfl9jl3cDgBMIhdznCk-J0G8Pvv1XtcOcighuPQ6EGN30aGXik7n7pnl0eAGUY-O_fOYNpFSg= "www.meridianbioscience.com").
```
```
---
### Contact Data
```
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
```
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal Year 2018 Operating Results on Thursday, April 26, 2018](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-second-quarter-fiscal-year-2018-operating-results-on-thursday-april-26-2018/)
**Published:** April 4, 2018
**Author:** hamza
**Content:**
CINCINNATI, April 04, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2018 operating results before the NASDAQ market opens on Thursday, April 26, 2018. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=rbQyb86rKLCvi1l6JH7fcRoYx_ATBaOcDxs13C6N-DofAtDyOZLtv5vTsmFGl9B1yCQxGSNyrvS6x8wW6WQez4g9X-6BFr1IHnls8xdpM_XjtXfkUdRYnoV6-rb-LwEu "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=rbQyb86rKLCvi1l6JH7fcRoYx_ATBaOcDxs13C6N-DpFKN_MAJyhzsZnGByog3ZzZbQQv1K_jXenR9oHz0TvwXHhHBEcoBHDnjt5UrSzjqBqV6Ki4IEWWVC66m7IENXZU-UOuQNx93joJIxCkrF0dKsjmi-wQ5Py5ZYkjKOW_SWhF9wqKn7_eZkuUsFznPaY_alCs7hIJfkqtcJQgiFjJeAX0Z0V77s195oimnFGyTg-k2rgTiNQgH9x8LmdD6Whi8DNm7p2NIz3hMIBjUIitxco6xqiERyjBgPSiqyZJxV48HAorGgmVGoXnGMwjKlhOx2GFm59lJKlLmiAJsT1pnEI67lX1duY9P_4god8-mY= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Nw-5VEzkMX_3mQCa4bkh6DIeAHdZuUuisC7r7aGLo6VTzhx892SBdA2EyjDM0ZecAUWeSOuMnlUmi4mKbV1cDh25HiDxJk9im2XLMt0cpnspLqV3mutcrgls75tdMhC0 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Realigns Organizational Structure](https://www.meridianbioscience.com/press-release/meridian-bioscience-realigns-organizational-structure/)
**Published:** March 21, 2018
**Author:** hamza
**Content:**
- New Structure Consists of two Business Units, Diagnostics and Life Science, Supported by a Global Corporate Team
- Realignment Aimed at Building a Stronger, More Sustainable Organization; Paving the Way for Future Growth
- Resulting Cost Savings to be Reinvested Back into the Business
CINCINNATI, March 21, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the realignment of its business structure aimed at building a stronger, more sustainable organization and paving the way for future growth. Effective immediately, the Company will conduct operations through two Business Units, Diagnostics and Life Science, both of which will be supported by a global corporate team.
Jack Kenny, Chief Executive Officer, commented, “This structural realignment represents the culmination of an in-depth review of Meridian’s business since my arrival. Since joining the Company in October 2017, I have been impressed with the many strengths across Meridian’s businesses. I have also become aware of untapped potential resulting from the inefficient and often costly structure embedded within each of the businesses. This new model will cultivate Meridian’s existing strengths while leveraging relationships across each of the business units; drive increased efficiency and cost savings; and, ultimately, increase shareholder value.
Each of the two business units will now have a consolidated sales and marketing team supporting the entire product portfolio. This consolidation will enable strong commercial relationships to be expanded across product lines and markets.
Corporate functions have been redefined under the new organizational structure. This will allow the corporate team to provide more cohesive support across the Diagnostics and Life Science Business Units while reducing duplicative efforts.
Savings from this realignment will be fully reinvested back into the business, with an emphasis on bolstering R&D spending, business development, and customer-facing roles. As a result of this reinvestment, the realignment will have no impact on fiscal 2018 non-GAAP guidance. It should be noted this guidance published on October 19, 2017 does not include the positive impact of Tax Reform which will be addressed in our second quarter of fiscal 2018 earnings release.
The potential that this realignment provides is exciting, and represents the first step in our path towards sustainable growth. Our next step will be to define our growth strategy for the next three-to-five years. In that regard, we are in the late stages of a search for an executive to lead our business development and strategy initiatives. We look forward to reporting on developments as the year progresses.”
**Diagnostics Business Unit**
The Diagnostics Business Unit consists of three business areas: Molecular (***illumi***gene brand); Core (Premier®, MERIFLUOR® and Para-Pak® brands); and Point of Care (Immuno*Card*®, TRU, Magellan LeadCare®, and Curian™ brands, with Curian representing a new diagnostic platform which is currently under development). All commercial activities, including sales and marketing, have been consolidated to serve the entire business unit.
For the time being, Jack Kenny will act as the Executive Vice President of the Diagnostics Business Unit, in addition to his role as CEO. Jack will lead the effort to integrate the diagnostics businesses into one high-performing organization, accelerating growth and delivering new products to market.
**Life Science Business Unit**
The Life Science Business Unit consists of Immunological reagents (MLS) and Molecular reagents (Bioline). All commercial activities, including sales and marketing, have been consolidated to serve the entire business unit.
Lourdes G. Weltzien, Ph.D., has been promoted to Executive Vice President, Life Science, and will lead the Life Science Business Unit, driving increased scale and efficiency from the consolidated businesses while pursuing new growth opportunities. Dr. Weltzien has been instrumental in driving growth and profitability in the life science business over the past nine years, while also heading up Meridian’s move into the Asia Pacific marketplace by opening Meridian’s office in China.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. We have identified a material weakness in our internal control over financial reporting that, if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Zd5mD1TiNDFwbMe651ZuIcjxJK-vvscoN_0DPXpebTcLAAsZfDuAWMUJBOpmYmnyinDUN1zydrhR543HuX4i3ZrkXpUE2pYs9kRfgTdI4V79NCERT3cNe9u3Ff6HvJFFU92NtimhBTpN5u1_WoyN7mgytY7Dn74Masf09oAeyh7z0ZaBGn4Pw-DvCCsdDZUS99xzL0ULvzWAk8NIh0kCK383U89Ux2Zb0dTGt4WwXjnvYNl92Yj790BieCG5lCc1aKZVRiYSqiJYt7MWuxG8ptUpVfTB4jHRBs7ng-zKVFhQSWPHlAdc_JOUNzq4Fg0AnN74ZuDhW3-UeXSL9nXvZfLPn2nK3Sw7CQx_H5-ccks= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=vx7SVwu_tJQkNiTzZUR5-Rt2cRkbgQNeDO62NR3mrJS41lGKALzirju9odaAmbtjuJKZSR92jgNLEZEezOgJPAlSa3Kqe94No2XjwKXowL5FmthQ6PkbPECf5HY9Gh8B "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-first-quarter-2018-operating-results-declares-regular-first-quarter-cash-dividend-and-reaffirms-fiscal-2018-guidance/)
**Published:** January 25, 2018
**Author:** hamza
**Content:**
CINCINNATI, Jan. 25, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
GENERAL HIGHLIGHTS
- reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the prior fiscal year;
- reported first quarter operating income of $8.1 million (including $1.5 million of costs associated with transition to a new CEO and litigation costs), a decrease of 20% from the same period of the prior fiscal year;
- reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, on a GAAP basis, flat compared to the fiscal 2017 first quarter. On a non-GAAP basis, earnings were $6.5 million, or $0.15 per diluted share, an increase of 4% and flat, respectively. Non-GAAP basis excludes the effect of CEO transition costs, litigation costs and certain one-time tax effects of the recently-enacted U.S. Tax Cuts and Jobs Act (the “tax reform act”) (see non-GAAP financial measure reconciliation below);
- declared the regular quarterly cash dividend of $0.125 per share for the first quarter of fiscal 2018 (annual indicated rate of $0.50 per share); and
- reaffirmed its fiscal 2018 guidance of per share diluted earnings between $0.59 and $0.62 on a GAAP basis (between $0.65 and $0.68 on a non-GAAP basis) on net revenues of $207 million to $212 million, before the impact of the tax reform act.
FINANCIAL HIGHLIGHTS (UNAUDITED)
In Thousands, Except per Share Data
Three Months Ended December 31, 2017 2016 % ChangeNet Revenues$ 52,283 $ 46,809 12 %Operating Income 8,061 10,085 -20 %Net Earnings 6,302 6,279 – %Diluted Earnings per Share$ 0.15 $ 0.15 – % December 31, 2017 2016 Cash and Equivalents$ 54,711 $ 49,276 Working Capital 113,143 105,004 Long-term Debt 53,530 57,620 Shareholders’ Equity 172,878 165,732 Total Assets 251,951 250,055
TAX REFORM IMPACT
Our GAAP net earnings for the quarter include the effects of the U.S. Tax Cuts and Jobs Act (the “tax reform act”), signed into law by the President during December. Included therein are (i) a benefit of $1.7 million ($0.04 per diluted share) primarily related to the re-measurement of our U.S. net deferred tax liabilities; and (ii) a provisional charge of $850,000 ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax, based upon reasonable estimates of the income tax effects. Excluding discrete items, we preliminarily estimate our effective tax rate to range from 26% to 27% on a normalized basis during fiscal 2018. We are in the early stages of assessing the opportunities tax reform creates for us to invest in and further strengthen our business, and at this time, we have not made any decisions in this regard. Approximately 25% of our cash is held outside of the U.S. At this time, we do not expect a large influx of cash from overseas.
COMPANY COMMENTS
Jack Kenny, Chief Executive Officer, commented, “We are pleased with Meridian’s overall performance during the first quarter of fiscal 2018. Both our Diagnostics and Life Science segments contributed to the solid performance. Diagnostic revenues increased 11% over the fiscal 2017 first quarter (10% on a constant currency basis), while Life Science revenues grew 14% (12% on a constant currency basis). The healthy start to fiscal 2018 provides continued confidence that investment initiatives aimed at strengthening our business and developing new products remain on track.
Our core diagnostics business got off to a great start in fiscal 2018, with revenues increasing 17% over the first quarter of fiscal 2017 (15% on a constant currency basis), benefitting from a lower comparable in the same period last year, as well as a strong respiratory season this year. Additionally, both our foodborne and *H. pylori* product families posted strong double-digit growth compared to the year-ago period. *C. difficile* revenues continue to be stable at approximately $5 million per quarter. The overall performance of this segment reflects the early success of initiatives aimed at improving our commercial effectiveness while we invest for future growth.
Our Magellan lead testing business unit revenues declined by 20% in the quarter year-over-year. Magellan was impacted by reduced test volumes on LeadCare systems using venous blood and by a difficult comparable due to a large, non-repeating international order in the year-ago period. We continued to drive placements of LeadCare® II in the quarter, which will facilitate ongoing growth of this business. We anticipate a rebound in the Magellan business in the second quarter and a return to growth for the quarter. We are continuing to work with the FDA regarding the use of venous blood with Magellan’s LeadCare Testing Systems. We remain committed to strengthening Magellan’s quality system and ensuring that all aspects of the system are in full compliance. We take this issue very seriously and are continuing to progress with the highest sense of urgency.
Our Life Science segment posted another strong quarter with revenues increasing 14% year-over-year (12% on a constant currency basis), with both our immunoassay components and reagents unit, and our molecular components unit, posting double-digit growth. Investments in the Asia-Pacific markets continue to perform well, with revenues in China growing approximately 115% over last year’s comparable quarter. We continue to be very pleased with the performance of this segment.
During the quarter we made progress on a number of research and development initiatives. The development of our Curian platform, leveraging both optical and fluorescent technologies, is progressing nicely. We expect this platform and initial assays to launch in early calendar 2019 and contribute to revenues in the second half of fiscal 2019. Our ***illumi****gene* CMV, the first molecular test for cytomegalovirus, is targeted to launch late in calendar year 2018. This test is designed to detect the presence of cytomegalovirus in newborns, which can cause hearing loss as well as intellectual disability. We are making continued progress in our development of our *H. pylori*/Clarithromycin resistance assay and expect to enter clinical trials near the end of calendar 2018. We remain confident that we are deploying our investments towards products and platforms that will not only grow Meridian’s top- and bottom-line as we move beyond fiscal 2018, but importantly, serve to improve patient outcomes.
Our financial position remains solid, and cash flows from operating activities remain strong. We continue to evaluate opportunities for collaboration and potential acquisitions.
As we evaluate our businesses, we will continue to search for areas where we can further improve operational efficiency and position the Company for higher growth. The Meridian team is motivated towards these efforts. We look forward to providing more detail on these initiatives in subsequent quarters as we move through this process.
Our business outlook for fiscal 2018 remains unchanged. Overall, we believe the Diagnostics segment is on track, with strong respiratory revenues offsetting recent weakness in our lead testing revenues. Our Life Science segment is also on track, with good growth coming from both the immunoassay and molecular component businesses. We recognize we will have a difficult comparison for the second quarter; however, our solid start to the year is encouraging. We are currently evaluating the impact of the tax reform act and will publish updated guidance to reflect these tax revisions once our evaluation is complete.”
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the first quarter ended December 31, 2017. The dividend is payable on February 15, 2018 to shareholders of record as of the close of business on February 5, 2018. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings on both a GAAP and non-GAAP basis, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
FISCAL 2018 GUIDANCE REAFFIRMED
Excluding the impact of the tax reform act, for the fiscal year ending September 30, 2018, management expects net revenues to be in the range of $207 million to $212 million and per share diluted earnings to be between $0.59 and $0.62 on a GAAP basis. On a non-GAAP basis, fiscal 2018 earnings are expected to be between $0.65 and $0.68 per diluted share The per share estimates assume an increase in average diluted shares outstanding from approximately 42.6 million at fiscal 2017 year end to approximately 42.8 million at fiscal 2018 year end.
The Company is evaluating the overall impact of the tax reform act. We will adjust guidance at a later date after management’s further assessment and upon the issuance of additional interpretations and guidance on the tax reform act. The impact of the tax reform act during the first quarter is described above in “TAX REFORM IMPACT”. Overall, we expect the impact of the tax reform act to be favorable for the year, given the expectation that a lower effective tax rate and the one-time favorable impact of re-measuring deferred tax balances will more than offset the repatriation transition tax.
The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2018.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At December 31, 2017, current assets were $136.6 million compared to current liabilities of $23.5 million, resulting in working capital of $113.1 million and a current ratio of 5.8. Cash and equivalents were $54.7 million, and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which were incurred in connection with the 2016 acquisition of Magellan, totaled $53.5 million as of December 31, 2017.
FIRST QUARTER UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the first quarters of fiscal 2018 and fiscal 2017.
Three Months Ended December 31, 2017 2016Net revenues$ 52,283 $ 46,809 Cost of sales 20,497 17,770 Gross profit 31,786 29,039 Operating expenses Research and development 4,496 3,597 Selling and marketing 8,842 7,618 General and administrative 8,904 7,739 CEO transition and litigation costs 1,483 – Total operating expenses 23,725 18,954 Operating income 8,061 10,085 Other income (expense), net (403) (426) Earnings before income taxes 7,658 9,659 Income tax provision 1,356 3,380 Net earnings$ 6,302 $ 6,279 Net earnings per basic common share$ 0.15 $ 0.15 Basic common shares outstanding 42,263 42,159 Net earnings per diluted common share$ 0.15 $ 0.15 Diluted common shares outstanding 42,662 42,535
The following table sets forth the unaudited segment data for the interim periods in fiscal 2018 and fiscal 2017 (in thousands).
Three Months Ended December 31, 2017 2016Net Revenues Diagnostics$ 37,490 $ 33,808 Life Science 14,793 13,001 $ 52,283 $ 46,809 Operating Income Diagnostics$ 5,291 $ 6,643 Life Science 2,784 3,267 Eliminations (14) 175 $ 8,061 $ 10,085
NON-GAAP FINANCIAL MEASURES
In this press release, we have supplemented our reported GAAP financial information with information on net earnings, basic earnings per share and diluted earnings per share excluding the effects of CEO transition costs, litigation costs and certain one-time tax effects of the tax reform act. We have provided in the tables below reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of these non-routine items, for the first quarters ended December 31, 2017 and December 31, 2016.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
FIRST QUARTER
GAAP TO NON-GAAP RECONCILATION TABLES
(In Thousands, Except per Share Data)
Three Months Ended December 31, 2017 2016Net Earnings – U.S. GAAP basis$ 6,302 $ 6,279 CEO transition and litigation costs\* 1,080 – One-time benefit from tax law change (1,695) – Repatriation transition tax 854 – Adjusted Earnings$ 6,541 $ 6,279 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.15 $ 0.15 CEO transition and litigation costs 0.03 – One-time benefit from tax law change (0.04) – Repatriation transition tax 0.02 – Adjusted Basic EPS$ 0.15 \*\*$ 0.15 Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.15 $ 0.15 CEO transition and litigation costs 0.03 – One-time benefit from tax law change (0.04) – Repatriation transition tax 0.02 – Adjusted Diluted EPS$ 0.15 \*\*$ 0.15
\* Net of tax
\*\* Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. We have identified a material weakness in our internal control over financial reporting that, if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers, and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1z559UPLAEr296xthUUGFOHcl2znWCQ7eL4ZclPILvLIvCwICcDJJbvg2qd2uzqnYwR7iFY-t45DQmM9MrABDJYZr_m64-lxJaJfhGhq79d4agEkGFlbCeRGduL70WaweZdaQtKWqdomdO-UYmiEzV14nIkKeXBH_wfExFRsj5rbeGwyG5-HMiMjhKfiREeUGiEY23pfRNmafM8CNWuGzF5y7XbZ3FZfHMjmRzKxXO3HqYMW8mCiYUOiZM-9786dlSQG-lXx_SuwmSTOPuA2hxUq9wXYCxDjylKFPKXW5M52vgfnH4khQSXa1fUasFI8D1FqYItC_2UenPTuPPh94M4awkq-iDJLKk10eCuPqIA= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=CWnHGYNetUjz1HfEa-Fb1WLsUDRgoqb8KripM_jE1B-LVv4xctLqGbuScfZvNgKFI37c7m6OQlRsdYD9BElScQVLuH7pW4a_ebvSZ3hlMCZ5Ygq591k-WwFVkroLFsx-)
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-first-quarter-fiscal-year-2018-operating-results-on-thursday-january-25-2018/)
**Published:** January 19, 2018
**Author:** hamza
**Content:**
CINCINNATI, Jan. 19, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its first quarter fiscal 2018 operating results before the NASDAQ market opens on Thursday, January 25, 2018. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=qVfM7E6Tfx1RWr06wA-3HLDDkRTTMF9JFPmzkh31AJDhuxjRTvoCCDm82sOBEqoBZhYpKrZDNK8_ijiOiRGRgQY91h1e8mI8N4DWAJyGzolcAj6B9Kb74yHys7D6aTpw "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=qVfM7E6Tfx1RWr06wA-3HLDDkRTTMF9JFPmzkh31AJATTejjpmt1k-auhANXK7J_9R5hr9nxkg015Dt8YE9tTjOw_i5s7dtDoihcUEod60FfrcEE2LMD4pLKY2wCWotEFPwrxUBnOfWZTgkH6SbVk2I7GoUS29ZVTzaMLhvpyPv_nTEHvIn7FLZ53UUgqI7Uh4_lnHBdIbX_jwJ4hCW7iDwzoZV9sPYt2vJHRnmgsrsmHDa6I41aoWRs5TVXRSiZHEp6E4M67KGo1tfan37v2pQJi0WF_43wO6Yk7UID9130iELCuCdkbQ4vHIDPONevVACV05Wpve7Jc9kiv4ChKIxgx1aPFukTWgZMukY8Kfo= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=8G2ulGvESpBA7NoLK8ie0jFljFY6MzPDzgm8kKkbok8tVeIQo7_h64KHEyxte58WLBGpIkK2jRXBhgZOlBBQ9qPJ7zq_79fcpzxOdDWs6rUdMAEuMBpR5sUplA1xqz8C "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-fourth-quarter-and-full-year-operating-results-declares-regular-fourth-quarter-cash-dividend-sets-fiscal-2018-cash-dividend-rate-and-reaffirms-fiscal-2018-guidance/)
**Published:** November 9, 2017
**Author:** hamza
**Content:**
GENERAL HIGHLIGHTS
CINCINNATI, Nov. 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
- reported fourth quarter and full-year fiscal 2017 net revenues of $49.7 million and $200.8 million, respectively, increases of 6% and 2%, respectively, from the same periods of the prior fiscal year;
- reported fourth quarter operating income of $8.8 million (including $0.8 million of costs associated with transition to a new CEO and defense of certain intellectual property; collectively, “CEO transition and IP defense costs”), a decrease of 1% from the same period of the prior fiscal year, which included $0.7 million of costs associated with reorganizing the sales and marketing leadership;
- reported full-year fiscal 2017 operating income of $37.4 million (including $0.8 million of CEO transition and IP defense costs and a $6.6 million non-cash goodwill impairment charge), a decrease of 27% from the same period of the prior fiscal year, which included $2.2 million of costs associated with acquisition activity and reorganizing the sales and marketing leadership;
- reported fourth quarter fiscal 2017 net earnings of $5.7 million, or $0.13 per diluted share, on a GAAP basis, an increase of 4% and flat, respectively, compared to the fiscal 2016 fourth quarter. On a non-GAAP basis, earnings were $6.2 million, or $0.15 per diluted share, increases of 5% and 7%, respectively. Non-GAAP basis excludes the effect of CEO transition and IP defense costs in the fiscal 2017 fourth quarter and the effect of costs associated with reorganizing sales and marketing leadership during the fiscal 2016 fourth quarter (see non-GAAP financial measure reconciliation below);
- reported full-year fiscal 2017 net earnings of $21.6 million, or $0.51 per diluted share, on a GAAP basis, decreases of 33% compared to fiscal 2016. On a non-GAAP basis, earnings were $28.7 million, or $0.67 per diluted share, decreases of 15% and 16%, respectively, compared to fiscal 2016. Non-GAAP basis excludes the effect of CEO transition and IP defense costs and goodwill impairment in fiscal 2017 and the effect of costs associated with acquisition activity and reorganizing the sales and marketing leadership during fiscal 2016 (see non-GAAP financial measure reconciliation below);
- declared the regular quarterly cash dividend of $0.125 per share for the fourth quarter of fiscal 2017 (annual indicated rate of $0.50 per share);
- announced the fiscal 2018 annual indicated cash dividend rate of $0.50 per share; and
- reaffirmed its fiscal 2018 guidance of per share diluted earnings between $0.59 and $0.62 on a GAAP basis (between $0.65 and $0.68 on a non-GAAP basis) on net revenues of $207 million to $212 million.
FINANCIAL HIGHLIGHTS (UNAUDITED)In Thousands, Except per Share Data Three Months Ended Twelve Months Ended September 30, September 30, 2017 2016 % Change 2017 2016 % Change Net Revenues$49,697 $46,998 6% $200,771 $196,082 2%Operating Income 8,807 8,895 -1% 37,382 51,378 -27%Net Earnings 5,726 5,491 4% 21,557 32,229 -33%Diluted Earnings per Share$0.13 $0.13 –% $0.51 $0.76 -33%Diluted Earnings per Share excluding effect of CEO transition and IP defense costs (Q4-17), goodwill impairment charge (Q3-17), sales and marketing leadership reorganization costs (Q4-16), and acquisition-related costs (Q2-16) (see non-GAAP financial measure reconciliation)$0.15 $0.14 7% $0.67 $0.80 -16% September 30, 2017 2016 Cash and Equivalents$57,072 $47,226 Working Capital 110,988 104,220 Long-term Debt 54,647 58,360 Shareholders’ Equity 169,585 166,472 Total Assets 249,777 252,028
COMPANY COMMENTS
Jack Kenny, Chief Executive Officer, commented, “Meridian’s results for fiscal 2017 were in-line with preliminary results that were published on October 19, 2017. Our Americas core diagnostic business continues to show encouraging signs of stabilization as demonstrated by its 4% growth in the fourth quarter. Magellan revenues exceeded $18 million for fiscal 2017, representing 2% growth. Our Life Science segment continued to perform extremely well, with top-line growth of 12% during fiscal 2017, exceeding internal expectations. Both units contributed to this growth, with non-molecular reagents revenues growing 15% year-over-year during fiscal 2017, and molecular reagents revenues growing 8% (12% in constant currency). Our investments in the Asia-Pacific markets, including our recently launched Meridian Bioscience Beijing, LLC subsidiary, continue to perform very well and contributed to this strong growth. Revenues in China grew over 40% to almost $6 million. New products, such as our Zika biologicals and JetSeq™, positively impacted Life Science growth as well.
We are confident that fiscal 2018 will be another year of revenue growth for Meridian. While in many respects fiscal 2017 represented a year of rebuilding, the entire organization is now energized towards our planned investment initiatives aimed at achieving revenue growth across all business units. Our financial position is solid; and cash flows from operating activities remain strong.
On the research and development front we are excited about the opportunities in front of us. We are confident that we are deploying our investments towards products and platforms that will not only grow Meridian’s top- and bottom-line, but importantly serve to improve patient outcomes. Our new Curian diagnostic platform is poised to broaden our diagnostic portfolio with important new capabilities in fluorescent technology. In addition to planned investments aimed at driving top-line growth, we will pursue opportunities to improve operational efficiencies across the business.
With regard to the FDA matters within Magellan Diagnostics, which occurred prior to our acquisition in March 2016, we remain committed to strengthening Magellan’s quality system and ensuring that all aspects of the system are in full compliance. We take this issue very seriously and are continuing to progress with the highest sense of urgency.”
John A. Kraeutler, Executive Chairman of the Board, commented, “As we enter the early days of fiscal 2018, I remain confident that the Meridian team is well-poised to deliver on its stated revenue and earnings guidance for the year, as well as new product and market initiatives setting the stage for a period of accelerated revenue and earnings growth beginning in fiscal 2019. In addition to our pursuit of internal investments, we continue to explore additional growth opportunities through carefully selected acquisitions. Our objective is to build shareholder value through higher revenues, earnings, cash flow, and cash dividends.”
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the fourth quarter ended September 30, 2017. The dividend is payable on November 30, 2017 to shareholders of record as of the close of business on November 20, 2017. The Board of Directors has approved the indicated regular quarterly cash dividend rate of $0.125 per share for fiscal 2018, an annual indicated dividend rate of $0.50 per share. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings on both a GAAP and non-GAAP basis, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
FISCAL 2018 GUIDANCE REAFFIRMED
For the fiscal year ending September 30, 2018, management expects net revenues to be in the range of $207 million to $212 million and per share diluted earnings to be between $0.59 and $0.62 on a GAAP basis. On a non-GAAP basis, fiscal 2018 earnings are expected to be between $0.65 and $0.68 per diluted share. This guidance assumes the medical device tax moratorium continues in calendar 2018. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.6 million at fiscal 2017 year end to approximately 42.8 million at fiscal 2018 year end. The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2018.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At September 30, 2017, current assets were $133.9 million compared to current liabilities of $22.9 million, resulting in working capital of $111.0 million and a current ratio of 5.8. Cash and equivalents were $57.1 million, and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which were incurred in connection with the 2016 acquisition of Magellan, totaled $54.6 million as of September 30, 2017.
FOURTH QUARTER AND FISCAL 2017 UNAUDITED OPERATING RESULTS(In Thousands, Except per Share Data) The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim and annual periods of fiscal 2017 and fiscal 2016. Three Months Ended Twelve Months Ended September 30, September 30, 2017 2016 2017 2016 Net revenues$49,697 $46,998 $200,771 $196,082 Cost of sales 19,042 17,275 75,938 68,295 Gross profit 30,655 29,723 124,833 127,787 Operating expenses Research and development 4,462 3,759 15,680 13,815 Selling and marketing 8,690 8,133 32,101 29,871 General and administrative 7,934 8,259 32,280 30,565 CEO transition and IP defense costs 762 – 762 – Goodwill impairment charge – – 6,628 – Sales and marketing leadership reorganization costs – 677 – 677 Acquisition-related costs – – – 1,481 Total operating expenses 21,848 20,828 87,451 76,409 Operating income 8,807 8,895 37,382 51,378 Other income (expense), net (173) (143) (953) (734)Earnings before income taxes 8,634 8,752 36,429 50,644 Income tax provision 2,908 3,261 14,872 18,415 Net earnings$5,726 $5,491 $21,557 $32,229 Net earnings per basic common share$0.14 $0.13 $0.51 $0.77 Basic common shares outstanding 42,205 42,086 42,188 42,010 Net earnings per diluted common share$0.13 $0.13 $0.51 $0.76 Diluted common shares outstanding 42,616 42,480 42,571 42,393
The following table sets forth the unaudited segment data for the interim and annual periods in fiscal 2017 and fiscal 2016 (in thousands). Three Months Ended Twelve Months Ended September 30, September 30, 2017 2016 2017 2016 Net revenues Diagnostics$35,992 $34,936 $143,521 $145,114 Life Science 13,705 12,062 57,250 50,968 $49,697 $46,998 $200,771 $196,082 Operating Income Diagnostics$5,934 $6,790 $23,086 $38,202 Life Science 2,860 1,911 14,086 12,997 Eliminations 13 194 210 179 $8,807 $8,895 $37,382 $51,378
NON-GAAP FINANCIAL MEASURES
In this press release, we have supplemented our reported GAAP financial information with information on net earnings, basic earnings per share and diluted earnings per share excluding the effects of the following non-routine items, each of which is a non-GAAP measure (presented with periods impacted):
1. CEO transition and IP defense costs (Fiscal 2017 Fourth Quarter & Full Year)
2. Goodwill impairment (Fiscal 2017 Full Year)
3. Sales and marketing leadership reorganization costs (Fiscal 2016 Fourth Quarter & Full Year)
4. Acquisition-related costs (Fiscal 2016 Full Year)
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the non-routine items noted above, in the tables below for the fourth quarters and full-year fiscal years ended September 30, 2017 and September 30, 2016.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
FOURTH QUARTER AND FISCAL YEARGAAP TO NON-GAAP RECONCILATION TABLES(In Thousands, Except per Share Data) Three Months Twelve Months Ended September 30, Ended September 30, 2017 2016 2017 2016 Net Earnings – U.S. GAAP basis$5,726 $5,491 $21,557 $32,229 CEO transition and IP defense costs\* 495 – 495 – Goodwill impairment charge – – 6,628 – Sales & marketing leadership reorganization\* – 431 – 431 Acquisition-related costs\* – – – 1,233 Adjusted Earnings$6,221 $5,922 $28,680 $33,893 Net Earnings per Basic Common Share – U.S. GAAP basis$0.14 $0.13 $0.51 $0.77 CEO transition and IP defense costs 0.01 – 0.01 – Goodwill impairment charge – – 0.16 – Sales & marketing leadership reorganization – 0.01 – 0.01 Acquisition-related costs – – – 0.03 Adjusted Basic EPS$0.15 $0.14 $0.68 $0.81 Net Earnings per Diluted Common Share – U.S. GAAP basis$0.13 $0.13 $0.51 $0.76 CEO transition and IP defense costs 0.01 – 0.01 – Goodwill impairment charge – – 0.16 – Sales & marketing leadership reorganization – 0.01 – 0.01 Acquisition-related costs – – – 0.03 Adjusted Diluted EPS$0.15\*\* $0.14 $0.67\*\* $0.80 \*Net of tax. \*\*Does not sum to total due to rounding.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=9najIATh7FNJ3NX7BoSKExApfT7Z44nd9Vp_hQoAz82V_NNIxtP2Q2dJk9Crha1LTu0HnstkOWAodwgCbYwDmtd8QqTudwkCB4k3RNlLZsFN_QhU0HLEZLkPW04X3RI1VsVLEqnkewlGpwf4ZEpNy3hv3sg4edsB8SaeAM3-CK6clg81o9WLEAWQZL9jmEExWnTUT4d50rfFvYDRUD3JFt1abYsDiMdDAK3Xa9ks54PlR7Sb4Eo4wxolH8L6ID1oYeHSfIvTOeioWI5gc4jtmLSoyk2vsAcGLaeL1xd4zEJWgknc2LCrvIBvi63GX5jmWcJrcpK7Z9hdqjQd55bQi8DQTLYIBhn8QAy9_3PdaFA= "www.meridianbioscience.com").
**Contact:**
John A. KraeutlerJack KennyExecutive Chairman of the BoardChief Executive OfficerMeridian Bioscience, Inc.Meridian Bioscience, Inc.Phone: 513.271.3700Phone: 513.271.3700Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com "mbi@meridianbioscience.com")Email: mbi@meridianbioscience.com
**Categories:** Press Release
---
### [Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-comments-on-fda-press-statement-regarding-its-warning-letter-issued-to-magellan-diagnostics/)
**Published:** October 23, 2017
**Author:** hamza
**Content:**
CINCINNATI, Oct. 23, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the FDA has issued a Warning Letter related to matters at its Magellan Diagnostics subsidiary. In our July 27, 2017 press release, Meridian indicated that it expected Magellan would receive a Warning Letter based on the observations from the FDA’s inspection, which was completed on June 29, 2017. Since the issuance of the FDA 483 Inspectional Observations at the conclusion of the inspection, Magellan has initiated prompt and comprehensive quality system remediation activities. Magellan will promptly submit a response to the Warning Letter for the Agency’s consideration.
Meridian Bioscience, Inc. and Magellan reiterate their mutual commitment to strengthening Magellan’s quality system and ensuring all aspects of the system are in full compliance. Both organizations take this very seriously. Magellan is addressing the observations noted in the Form FDA 483 and the Warning Letter with the highest sense of urgency.
**Forward Looking Statements**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=QZsDzCbtcFByjHx3KSI387lO1dbrmelVMewORssN2_GU42t4nyXS1I0k-1uJY60xgcfXsNTEA6zemjTQwtl0QeECSFnYj63lhZXlAR8DYWwm_k0RWkXQThg36f-cu67Cr7r8XDpQbTz4bhyO3xucGSkbBpFqEMu_jUZxP7gQ9gY_HsPYBMz67BhXB6HaQXCAMcj7EPnVcaDKytxn2hf6PmcHCOJ4TNsnnwY5FO2vZXwKp4ShtMfitIDAjouhY9fNIJIz8iVlExJJNNX-nkcOMqGsqZM3Gvqd7pLz7JQRrmdCrXG4P--tLMufPR7pnVxFI1L_nnw9aWFBzy9DHhGkB1QLUFMyiGTE7yvzx9_hM2M= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Lcy840Qd3Hs_F0FXhCck66aK7xffaPYx92JwxGNgcTG5FoqDkV2KINe_DLK9F8_VycmY1HaK3OHQ2Tv6DucwJeDyMudcY2GYky-Dkx475xbFgb7tZlRE_WmfaUgyShn_ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-comments-on-preliminary-fiscal-2017-operating-results-and-provides-fiscal-2018-revenue-and-earnings-guidance/)
**Published:** October 19, 2017
**Author:** hamza
**Content:**
CINCINNATI, Oct. 19, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal 2017, ended on September 30, 2017, to be approximately $200.5 million, an increase of 2% compared to the prior year. Diluted earnings per share on a GAAP basis are expected to be $0.50 to $0.51. On a non-GAAP basis, excluding the third fiscal quarter goodwill impairment charge of $6.6 million, and fourth fiscal quarter CEO transition costs and litigation costs associated with protecting intellectual property of $.5 million after tax, earnings per share are expected to be $0.66 to $0.67.
The preliminary results reflect fourth quarter revenue of approximately $49.5 million, representing 5% growth compared to the prior year. The Diagnostic and the Life Science Segments reported revenue growth of 3% and 14%, respectively. The Americas diagnostics business, which consists predominately of the U.S. market, reported revenue growth of 4%, indicating the efforts over the last 15 months to strengthen this unit are showing results. Major core diagnostic product families including Food and *H. pylori* posted growth, while other product families are stabilizing. Our *C.difficile* business achieved $5 million in revenues for the quarter, representing the third consecutive quarter of revenues at or above the $5 million level. Our ***illumi****gene* product family experienced its third consecutive quarter of revenues at $8 million or above. Magellan revenues were down 7%, primarily as a result of a large international order that occurred in the prior year. We continued to see a steady stream of Magellan LeadCare II analyzer placements during the quarter. Both Life Science Units performed very well. The Bioline molecular component unit grew 9%, while the immunoassay component and reagent unit grew 18% in the quarter.
FISCAL 2018 REVENUE AND EARNINGS GUIDANCE
Based on planning and budgeting activities for fiscal 2018, net revenues for fiscal 2018 are expected to be between $207 and $212 million, representing growth of 3% to 6%. On a GAAP basis, per share diluted earnings for fiscal 2018 are expected to be between $0.59 and $0.62. On a non-GAAP basis, fiscal 2018 earnings are expected to be between $0.65 and $0.68, resulting in relatively flat earnings compared to fiscal 2017 on a non-GAAP basis. Non-GAAP adjustments include CEO transition costs and litigation costs associated with protecting intellectual property. This guidance also assumes the medical device tax moratorium continues in calendar 2018.
Our fiscal 2018 guidance reflects a concerted effort to invest for the future. We are increasing our focus on investments in research and development; and sales and marketing. We also expect the resumption of making provisions for incentive compensation in conjunction with the achievement of operating objectives. We expect the increased investments in these areas to drive higher revenue levels in fiscal 2018. Looking ahead to fiscal 2019, we expect that these investments will result in higher levels of both revenue and earnings growth as new products across all business units are introduced to the market in late fiscal 2018 and in 2019.
Per share estimates assume an increase in the average diluted shares outstanding from approximately 42.6 million to 42.8 million at fiscal 2018 year end. Revenue and earnings guidance provided in this press release does not include the impact of any acquisitions the Company may complete during fiscal 2018.
COMPANY COMMENTS
John A. Kraeutler, Executive Chairman of the Board, said, “We are pleased with our fourth quarter results and the positive momentum going into fiscal 2018. Each of our business units is expected to deliver growth in fiscal 2018, yielding overall revenue growth of 3% to 6% during fiscal 2018. Within the Diagnostics segment, the core diagnostic business is expected to generate low single-digit growth as we stabilize and modestly grow the *C.difficile*, foodborne and *H.pylori* product families. We expect mid-to-high single-digit growth in our malaria and respiratory product categories. Our ***illumi****gene* Group A Strep and Mycoplasma tests, as well as a new rapid influenza test, are key growth drivers for the respiratory family.
The Magellan business unit is expected to deliver high single-digit to low double-digit growth with continued LeadCare II penetration in pediatric and Ob-Gyn offices, along with international growth.
Our Meridian Life Science component business is expected to deliver mid-single-digit growth fueled by its tropical disease reagent menu and growth in China. Our Bioline molecular component business is expected to again have mid-to-high single-digit growth coming from new products such as its lyo (lyophilized) ready mixes and other real time PCR components.
We have several important new product development efforts underway that will progress during fiscal 2018, and which are driving higher levels of research and development spending. This includes our new Curian diagnostic platform and a novel combined *C.difficile* Toxins A/B and GDH test. We expect this test to launch in late fiscal 2018. We also expect to launch ***illumi****gene* CMV, the first molecular test for cytomegalovirus, late in fiscal 2018. This test will detect the presence of cytomegalovirus in newborns. This virus can cause hearing and vision loss and intellectual disability. We expect to complete development on our *H.pylori*/Clarithromycin resistance assay during fiscal 2018 and enter clinical trials in early 2019. These analyte specific reagents are currently available in our product catalogue.
Our Magellan business unit is diligently working to strengthen its quality system and working closely with the FDA. In parallel, it expects to complete development of a new assay platform that provides improved lead testing and additional assay menu for the pediatric and Ob-Gyn physician office market. On the life science front, our Bioline business has a robust pipeline of products geared toward components used in next generation sequencing and real time PCR applications.
These important product development activities will expand our base of revenue growth drivers well into the future. By building this broad base of revenue growth drivers in each of the business units, we believe each unit has the tools to generate higher levels of revenue growth as we move into the second half of 2018 and into 2019.
Our financial condition remains strong. Our cash position and cash flows from operating activities also remain strong. We plan to recommend to the Board maintaining our dividend at its current annual indicated rate of $0.50 per share. We continue to seek acquisition and collaboration opportunities to expand and diversify our revenue base. We expect that with an expanded base of revenues from new products, and our proven financial efficiency, fiscal 2018 will set the stage for a period of accelerated revenue and earnings growth beginning in fiscal 2019. I am pleased to have Jack Kenny on board as CEO, and I look forward to his leadership in maximizing the many assets in the Meridian portfolio and providing leadership in building an even more robust portfolio in the future.”
Jack Kenny, Chief Executive Officer, said, “Meridian is entering fiscal 2018 with a sound Plan aimed at investing for the future. The Company has a 40 year history of innovation and profitable operations. I look forward to managing toward Plan during fiscal 2018 and continuing the strategy of building a broad base of revenue growth drivers as Meridian marches toward its 50th anniversary.”
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=F9xJ2HDXhfjeDEigzkpVVKYR5V_jVT5R1-ZWnZA5BGzUhVysM3dCums-Pubb7IAGGJQhqKej7KBTsl5L8-cXMK6nObCNk8mL-mm9nXkEeVSdmeQh--LtZrj0o28Vl3T8b9kdQZd1qd7s1pi3ziTOyCSRlqfbisCPV9SgoCVjik_LP072Y8zJu1oGbwyxX_WJBW95YAYr9dBc8jt5qmBaYpLsxpIFxzFkw-up51Tf6MB07zu07lEdubJ68kv1O1Z4Zj7oVCGUtq-jCH1zBFjDfPwj2v5_4_R3UOrJQt5kh9X6wdzC3R8GFRM28E2Rg2x-DmXu_iX8du9zrC2qFfuyfTo6arfrBdmwRMNMO_Hvn2I= "www.meridianbioscience.com").
**Contact:** John A. Kraeutler
Executive Chairman of the Board
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SsiGte2qU9wTr5aRWo4jswpDdBuqM6zqJhxGEsllzIO73z7Pk4GwZeeiQf6kpWS702OJ1MWvAhNHnzCqZBeCdXOgzThiid7Nm3MkC0e6yIxs-NMWpiBqfW5aQlJdm3V9 "mbi@meridianbioscience.com")
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SsiGte2qU9wTr5aRWo4jswpDdBuqM6zqJhxGEsllzIMybLjfaSTgmG2t1piRNuR4bQ927kBsi33GXMbLfIhANQcmgkTsxbKZfjKcZbzr_ULKZVOIAophgTQiKMzXDazV "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-fiscal-2018-revenue-and-earnings-guidance-on-thursday-october-19-2017/)
**Published:** October 16, 2017
**Author:** hamza
**Content:**
CINCINNATI, Oct. 16, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its fiscal 2018 Revenue and Earnings Guidance before the NASDAQ market opens on Thursday, October 19. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=GVZ4T1p-mIBxwK4M3t9IehrtzsAQKV_GxfyVgghaB5p52_Sb-NlhJN7pKcn7hYm7AXMMNGYPK475QaaKePpw5GOnQQId_uhWXe6QqGsz3ZD5qJGvindBNEs8x1GRPf2_ "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. For more information, please visit [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=GVZ4T1p-mIBxwK4M3t9IehrtzsAQKV_GxfyVgghaB5r-MbNMy0_BOSJMSdjrQJsFQBOLpQ_xEC20z6AzB_Wp7KAaRJ3BopWvRYa5n8ytLD-UKkKRRZPCoxTPRCjLyGW-lv_EOOuXf4xELm1iXF55UgDy4ymV4p5OJvPvquFmAm6x4xnN2A7cgDRXeQTTM5Fzr04Xcw5AKIp0Ckw-ebb8dfUJ18nyHfWpbiQWdV3ti4rLqBENxRviRFJ4PN4uA3BJqSkEzTJimym9rQo_2amLTlGiSdiEDMw9h6yLOfSlZJ_xjv2HN0NR0ylKvwRG7i7NHVQsaZzMqwVLZmbMJlclYOzXERYicBcR1vOb8BPkNsc= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=ybc5julUF_LkrYthRWoYR7hbjj2xDTH9dMjZNELJjJqG4fyqxyEOtuwWliMnABmZLVFDATSq1tcYS8ATtPoO3Y-13JpT8ipKNDoyZNUC0cEq9A1YsGiDgiJF8fSC0gQ8 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Appoints Jack Kenny as Chief Executive Officer](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-appoints-jack-kenny-as-chief-executive-officer/)
**Published:** October 10, 2017
**Author:** hamza
**Content:**
CINCINNATI, Oct. 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has appointed John (Jack) P. Kenny as Chief Executive Officer, effective October 9, 2017. This addition to Meridian’s management team is consistent with the succession planning described in our May 10, 2017 press release. Mr. Kenny joins Meridian after a search of several months by a Special Committee of the Board of Directors, working closely with management. Mr. Kenny has also been appointed to Meridian’s Board of Directors effective October 9, 2017.
Concurrent with the hiring of Mr. Kenny, John (Jack) A. Kraeutler, Chief Executive Officer and Chairman of the Board, steps down as CEO and takes the title of Executive Chairman.
Mr. Kenny most recently served as Senior Vice President/General Manager, North America, at Siemens Healthcare. Mr. Kenny led a turnaround of the business to restore sales growth while driving increased profits and revamped the culture to build a sustainable, high-performing commercial organization. He has held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics. Mr. Kenny holds a BS, Management Systems, from Kettering University in Flint, Michigan.
Jack Kraeutler commented, “Mr. Kenny has an excellent background and a strong track record in adding value to commercially-oriented businesses. He is a high-energy leader who has the ability to motivate employees and is well-suited to leading Meridian. I believe that Mr. Kenny will fit into the organization seamlessly and will drive Meridian’s next phase of growth. I look forward to working with Mr. Kenny during fiscal 2018 to ensure a smooth transition.”
Mr. Kenny commented, “I am excited to join Meridian Bioscience. I have watched the Company’s progress for many years. The Company’s reputation in the marketplace is strong. Meridian has a strong product portfolio, a solid infrastructure, a sound financial position, and an exceptional team of employees. I see opportunities to develop the business based upon both current and new products. I am looking forward to contributing my knowledge and leadership skills to grow the business and enhance shareholder value.”
David Phillips, Lead Director, stated, “On behalf of the Board of Directors, I want to thank Jack Kraeutler for his leadership in guiding Meridian Bioscience over the past 25 years. We are very pleased with the appointment of Jack Kenny to the position of CEO at Meridian. The entire Board believes he will continue Meridian’s history of dynamic leadership and company growth and is fully committed to his success.”
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s actual results, financial condition, or continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, and other periodic filings with the Securities and Exchange Commission contain a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dsVDq87M-_o_XBT3_WOqQfzG4y8TY-WajDIay4xDr0rVTJQGd2hbpCRbCVaDF8VW1BuHbqMnzHFDpqlmKQ5OcQ5FoplWJijd_9Ux8pJjCLuk0lDpChDCBzDiCmVeknA9VwuTzoP98LMINMXpq4nXti2DuB8L3h-uenL1g0sCCeci6Y7EseeKHtQGpbgit_2CCZmSM2kC3Uo7EkZcgMMzEhWW4jR2j3zj25iDhODM-klghGLiEndnBAnizECkbddZSiCcvyfwjBlI6Ainc0Yo51MZ241l-Hh3Kgqb8j_6aq4LcvitgtaS1Ci_u7Td0nAKOf-eX1Yn5P-ov8R19FV-fNbbKN6DzGEi4zmSr2g-0ho= "www.meridianbioscience.com").
**Contact:**
John A. Kraeutler
Executive Chairman
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=aTgHX54c0GAXU3P0zBA7lPoXdxBfOybtdK3iUhTbcVNPBvRCo8KfgQEePUohC-wrQHtYJFnWR9LpyHPt6l3vLZkNf2htbtIG1pyT86MAHJEl1o5MoI6sDHm4rr9SDSNr "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conference on the Prevention of Lead and Heavy Metal Toxicity in Hyderabad, India](https://www.meridianbioscience.com/press-release/meridian-contributes-to-upcoming-leadcon-2017-third-annual-international-conference-on-the-prevention-of-lead-and-heavy-metal-toxicity-in-hyderabad-india/)
**Published:** September 19, 2017
**Author:** hamza
**Content:**
## Company to share perspectives on the role that point-of-care screening for lead exposure can play in improving human health
CINCINNATI, Sept. 19, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that Magellan Diagnostics, Inc., a business unit of Meridian, will support and participate in an international conference on the impacts of lead and heavy metal exposure on health. The meeting, “LEADCON 2017” takes place from 21-23 September and is organized by ICMR – National Institute of Nutrition in Hyderabad, India. Meridian’s participation is part of the company’s ongoing, strategic effort to leverage the company’s global footprint to expand Magellan’s blood lead testing platform internationally, where lead poisoning is a significant threat to the health of young children and pregnant women.
With average childhood blood lead levels nearly ten times higher than in the U.S., many of India’s children will suffer the lifelong neurotoxic effects of lead poisoning. In a country with over 26 million children under age 5, the impact of this environmental poison has been quantified as a loss of 121 million IQ points, with economic costs of $236 billion. Because lead poisoning often occurs without overt symptoms, it is frequently underdiagnosed, particularly in developing countries where both awareness of the threat and access to diagnostic tools are lacking. “Magellan’s continued sponsorship of and participation in this conference is part of our commitment to helping protect children from the effects of lead poisoning by creating awareness around the world. We are honored to be a part of this important meeting,” commented Amy Winslow, CEO of Magellan Diagnostics, Inc.
Dr. Lourdes Weltzien, president of Meridian Asia Pacific, will represent Magellan and present a seminar titled: “The Global Threat of Lead Poisoning and the Role of On-Site Rapid Blood Lead Testing.” Her talk will share US experiences in lead poisoning education and prevention gained along with a review of the role that point-of-care (POC) testing can play in making broad-based, community level screening feasible – even in low resource-based settings.
In the near-term, Meridian and Magellan plan to work with experts and advocates in other regions threatened by lead poisoning, following models similar to LEADCON, to help expand education and action on lead poisoning prevention across the globe.
**About Magellan Diagnostics, Inc.** Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of Meridian Bioscience, Inc., Magellan is headquartered outside Boston in Billerica, Massachusetts, and is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure. We are committed to educating clinicians, policy makers, payers, families and communities about the permanent health damage caused by lead and how to detect and address lead exposure. For more information, visit [www.magellandx.com](https://www.globenewswire.com/Tracker?data=h-p5UENhvl-OxheMkFFv9XSlWm3VhmmKszH34epoTtsCjkqGfmRWIJjDEUJn8wOh2z_XTkHMu4yAU3UpgLV-f4M17RpD7ZH8telK5lOE6z9Mi4o-iwuquWoLH_52k2sL1wnEO4abmctsIjx2-fwdVFJL-PaG_FmWf3HR874MsZfOK5HuVUGvtckFK7a6-tHr_-dCkFMGgpnqqaf1s5L6dIhPoiNg7YrMypMY9llYDL5i1QqxAZXMvKOQXiM80QH- "www.magellandx.com").
**About Meridian Bioscience, Inc**.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=3RGDdp9i9TuoGC6TaD7Fo5e9x6-2yeUvMF9hPE47lbumaXa2rMid4NmZGp5Kjc2RrquNJNBZS68JDKo4Sm677CZ_XQt7CdFQNAtBYpX8LrOsa7USRx9zCBwZfdnC9XfEQbvp-4d9tEU3IdPGdzsGo4QZZ7eeF2l4A7z7N8Y8AdVvwYuekmhQ_m5J_s-uu0uEkmbUCCo_klaGUCwI7lht-ypUKtUxy4tkApDWqJltAHKk8FXAOxkfrmGl6D7xvrIs1lUb7cQhJSQtp4osUSdA76n1N8L29UV1CwnEMErR8NOTnOuhvfAPBV3qKug_qYHIVdd_E7H-ablRc_9lmWioi6aXhW0K3hUObGxM0cPkaIs= "www.meridianbioscience.com").
Contact:
Amy Winslow
President, Chief Executive Officer
Magellan Diagnostics
Phone: 978-856-2345
Email: [info@magellandx.com](https://www.globenewswire.com/Tracker?data=wnmIXco4WjuyVzlOLRM56eeJM4lUC3xVXdWX0HOU9RWLmQ6bPo8VRFWV1nKf9gKLxnt7ucuxJR_p6jo0TaAQyy_iy9cyat6168cBmkAMF74= "info@magellandx.com")
John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=b1WX1lw5eE-C0uHCrGl3ZwrevODcJWp4Dx6IaNUK6f0q_yB2fbJCJF5iClHl8FUEpOUwXReJ70194X27Pp4kHr6yKOL5DZokeFRExlhyYI3VdZ5lFrYrGTATbg6G_g66 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal Year 2018 Operating Results on Tuesday, July 31, 2018](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-expects-to-report-third-quarter-fiscal-year-2018-operating-results-on-tuesday-july-31-2018/)
**Published:** June 28, 2018
**Author:** hamza
**Content:**
CINCINNATI, June 28, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading life science company, expects to release its third quarter fiscal 2018 operating results before the NASDAQ market opens on Tuesday, July 31, 2018. The release will be available shortly thereafter on Meridian’s website at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=CjPOBkDzKg7d0Yt7OBLNJ_mqnN9QLN7fYkJrGINhq3PyUOkuv3UC4kBqF7aSnMb17U8T9K-IfuaEixyPqvLFsSIL5-SLI33VTdqgVWwS7DZloplg3K1h37Cab3qKtc7c "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=CjPOBkDzKg7d0Yt7OBLNJ_mqnN9QLN7fYkJrGINhq3MP03wQzsH0E9IYqnxeSbeuWSEzPMykId2tbgxTC6PuNRzvwn_D5_ZAcJk0Mpo7SIXNkp8TWZfHoNqh4mrfxInR).
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Q5Sd4USa1MDRizswkSYKiYxDdFB_TgGcxVZmeho2i8BjhUYTCLb8meIt8FeqoRHPNY5pJ-VOOnwCfm0GmbnRqBlBFcb1-Su0GtrKeC0kWs_MUb-xAUTO4potO6E1trUN "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key Emerging Disease on the WHO’s Priority List](https://www.meridianbioscience.com/press-release/meridian-introduces-critical-raw-materials-for-nipah-virus-diagnosis-a-key-emerging-disease-on-the-whos-priority-list/)
**Published:** May 30, 2018
**Author:** hamza
**Content:**
CINCINNATI, May 30, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the availability of critical antigens and antibodies for Nipah virus immunological assay development in response to the World Health Organization’s (WHO) list of eight priority diseases that could cause severe outbreaks or have epidemic potential. Last week, at least 13 people died as a result of a Nipah virus outbreak in Kerala, India. The Nipah virus outbreak in India’s southern state of Kerala is suspected to have spread to the neighboring state of Karnataka.
The Nipah virus can be transmitted to humans from animals (bats, pigs, cattle, goats), and also directly through human-to-human contact. Nipah virus infection in humans causes a range of clinical presentations, from asymptomatic infection (subclinical) to acute respiratory infection and fatal encephalitis. Fruit bats of the Pteropodidae family are the natural host of the Nipah virus. The Nipah virus is an RNA virus that is part of the Paramyxovidae family that was first identified as a zoonotic pathogen after an outbreak involving severe respiratory illness in pigs and encephalitic disease in humans in Malaysia and Singapore in 1998 and 1999. There is no treatment or vaccine available for either people or animals and the mortality rate is 70%. The primary treatment for humans is supportive care. The Nipah virus has killed more than 260 people in Malaysia, Bangladesh and India since 1998.
Dr. Lourdes Weltzien, Executive Vice President for Meridian’s Life Science division, commented, “We have paid careful attention to the WHO’s list of priority diseases in an effort to produce critical raw materials for assay development prior to disease outbreaks. We launched our Zika antigens and antibody raw materials prior to the 2016 outbreak when no diagnostic tests were yet developed, and we are pleased to have done the same for Nipah. No commercial diagnostic tests have been developed for the Nipah virus yet, and the availability of high quality antibodies and antigens is critical to the development of such tests. It is the mission of Meridian Life Science to develop innovative raw materials that can quickly address diseases that have epidemic potential.”
**About Meridian Life Science, a Division of Meridian Bioscience, Inc.**
Meridian Life Science provides innovative solutions and large-scale manufacturing of antibodies, viral antigens, recombinant proteins, PCR Enzymes and Master mixes, Lyo-Ready formulations, nucleotides and critical assay reagents to diagnostic and biotechnology companies. For more than 40 years Meridian has focused on offering products and services that advance the development of diagnostic assays. In addition to a full line of immunoassay and molecular reagents supplied to the top diagnostic companies, Meridian offers process development and manufacturing services under a stringent quality system. For more information please see: www.meridianbioscience.com/lifescience
**About Meridian Bioscience, Inc.** Meridian Bioscience believes that healthcare is human. It is about saving lives, curing disease and improving outcomes. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis.
Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in the areas such as gastrointestinal and upper respiratory infections and blood lead level testing.
We work harder every day to build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience shares are traded through NASDAQ’s Global Select Market, symbol VIVO. You can find us online at [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=APT5LguB4MadHr8Pt7Vl4u6TetYshaAxDh2J0HaNl1IHAOTjTtTgyii0bTW8GxSVYXy-bLbXRItpq_9AqVEqfRoPwok7MVNnc-gdzrJJwiOLwQpotBvKTH9PRPL7wG-x "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: +1.513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=_54-nq47erc5dHy3m4XAHPlmlT9QpwS5R2mHDAPxa9zEKp2jeQ68g07sdsk4Prww5IDGS2gy4K3PdajjB9Wujz_NkIZbNzcyp1UI5UWH-45YQJ1LIWL7jf9pv84NPUeB)
Dr. Lourdes Weltzien
Executive Vice President, Life Science
Meridian Life Science, Inc.
Phone: +1.901.382.8716
Email: [info@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=a8svNFz5gsVHtQk438hAZccMFSKVmtzzO7Gw9dCQFkoTOB7BglTTzMSqwJmuOQgX4nS76bNGtQcuBC34JeMP2s51qg4Kzdov0Mhv2Kw_ln4juE_KF888xoxRZZYsuJv3 "info@meridianlifescience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-second-quarter-2018-operating-results-declares-regular-second-quarter-cash-dividend-and-updates-fiscal-2018-guidance/)
**Published:** April 26, 2018
**Author:** hamza
**Content:**
CINCINNATI, April 26, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
GENERAL HIGHLIGHTS
- Reported record fiscal 2018 second quarter and first six months net revenues of $56.5 million and $108.7 million, respectively, increases of 4% and 8%, respectively, from the same periods of the prior fiscal year;
- reported second quarter operating income of $7.7 million (including $4.9 million of costs associated with executive transition and realignment, and litigation costs), a decrease of 46% from the same period of the prior fiscal year;
- reported six months operating income of $15.7 million (including $6.4 million of costs associated with executive transition and realignment, and litigation costs), a decrease of 35% from the same period of the prior fiscal year;
- reported second quarter net earnings of $5.3 million, or $0.12 per diluted share, on a GAAP basis, decreases of 43% and 45%, respectively, compared to the fiscal 2017 second quarter. On a non-GAAP basis, earnings were $8.9 million, or $0.21 per diluted share, decreases of 5% each compared to the fiscal 2017 second quarter. Non-GAAP basis excludes the effect of executive transition and realignment costs, and litigation costs (see non-GAAP financial measure reconciliation below);
- reported first six months net earnings of $11.6 million, or $0.27 per diluted share, on a GAAP basis, decreases of 26% and 27%, respectively, compared to the same period of fiscal 2017. On a non-GAAP basis, earnings were $15.4 million, or $0.36 per diluted share, decreases of 1% and 3%, respectively, compared to the same period of fiscal 2017. Non-GAAP basis excludes the effect of executive transition and realignment costs, litigation costs and certain one-time tax effects of the recently-enacted U.S. Tax Cuts and Jobs Act (the “tax reform act”) (see non-GAAP financial measure reconciliation below);
- declared the regular quarterly cash dividend of $0.125 per share for the second quarter of fiscal 2018 (annual indicated rate of $0.50 per share); and
- updated its fiscal 2018 guidance of per share diluted earnings to between $0.69 and $0.72 on a non-GAAP basis on net revenues of $209 million to $214 million.
FINANCIAL HIGHLIGHTS (UNAUDITED)In Thousands, Except per Share Data Three Months Ended Six Months Ended March 31, March 31, 2018 2017 % Change 2018 2017 % ChangeNet Revenues$56,451 $54,125 4% $108,734 $100,934 8%Operating Income 7,678 14,186 -46% 15,739 24,271 -35%Net Earnings 5,288 9,312 -43% 11,590 15,591 -26%Diluted Earnings per Share$0.12 $0.22 -45% $0.27 $0.37 -27%Diluted Earnings per Share excluding effect of executive transition and realignment costs, litigation costs and certain effects of tax reform legislation (see non-GAAP financial measure reconciliation)$0.21 $0.22 -5% $0.36 $0.37 -3% March 31, 2018 2017 Cash and Equivalents$56,400 $54,745 Working Capital 113,691 108,896 Long-term Debt 52,414 56,879 Shareholders’ Equity 174,336 170,828 Total Assets 254,547 251,902
COMPANY COMMENTS
Jack Kenny, Chief Executive Officer, commented, “We delivered record top-line performance (versus a strong comparable) during the quarter, reflecting solid contributions from both the Diagnostics and Life Science segments. This strong top-line performance contributed to non-GAAP diluted earnings per share of $0.21. Diagnostics revenues grew 5% in the quarter year-over-year (3% on a constant currency basis), while Life Science revenues advanced 2% (1% on a constant currency basis). Year-to-date Diagnostics revenues are up 8% year-over-year (6% on a constant currency basis), while Life Science revenues have advanced 7% (5% on a constant currency basis).
Our Diagnostics Segment benefitted from a strong respiratory season. Additionally, we are seeing continued stabilization across product lines including *H*. *pylori* and *C*. *difficile* and believe that efforts to improve our commercial effectiveness are materializing. Our foodborne product line, though down for the quarter, is stable for the six month period compared to last year. As expected, our Magellan LeadCare® testing product line delivered double-digit growth for the quarter against an easier comparison and placements of LeadCare II in the quarter increased compared to the prior quarter due to multi-analyzer placements at two health care systems. We continue to work closely with the FDA regarding the use of venous blood with Magellan’s LeadCare Testing Systems. We remain committed to enhancing Magellan’s quality system, and are progressing with the appropriate focus and resources. During fiscal 2018, we have invested approximately $1 million dollars to enhance the quality system and to work with the FDA in efforts to regain our claim for use of venous blood on the testing systems sometime in the future.
Our Life Science Segment turned in respectable performance during the quarter, with our molecular reagents product line posting another quarter of robust growth. While overall growth in the quarter was subdued due to a tough comparison for our immunological reagents, this segment is performing very well. Additionally, we are continuing to reap benefits from our investments in Asia-Pacific markets, with revenues in China growing approximately $0.8 million for the second quarter and $1.6 million year-to-date over fiscal 2017.
We continue to drive increased investment in research and development initiatives. Our Curian platform, which leverages both optical and fluorescent technologies, is expected to launch with its initial assays in calendar 2019. We expect this platform to contribute to revenues in the second half of fiscal 2019. Our ***illumi***gene CMV, the first molecular test for cytomegalovirus, is targeted to launch late in calendar year 2018. This test is designed to detect the presence of cytomegalovirus in newborns, which can cause hearing loss as well as intellectual disability. Progress on our *H*. *pylori*/Clarithromycin resistance assay continues and we expect to enter clinical trials near the end of calendar 2018.
As we look ahead to the second half of fiscal 2018, both our Diagnostics and Life Science segments remain on track to perform in-line with original expectations. Our previously announced organizational realignment is in place, integration efforts are underway, and we continue to be excited about the potential to increase efficiencies and decrease costs across the business. We remain committed to reinvesting potential savings resulting from this realignment back into the business, with an emphasis on bolstering R&D spending, business development, and customer-facing roles.
Based upon the strength of our first half results, particularly in our respiratory business, we are increasing our fiscal 2018 revenue guidance. Non-GAAP diluted earnings per share guidance has been adjusted to reflect the positive benefit of tax revisions resulting from the tax reform act, balanced by higher expected costs related to FDA remediation and R&D spending.”
TAX REFORM IMPACT
Our GAAP net earnings for the year include the effects of the U.S. Tax Cuts and Jobs Acts (the “tax reform act”) signed into law during December 2017. Included therein are (i) a benefit of $1.7 million ($0.04 per diluted share) in the first quarter primarily related to the re-measurement of our U.S. net deferred tax liabilities; and (ii) a provisional charge of $850,000 ($0.02 per diluted share) in the first quarter for the mandatory U.S. repatriation transition tax. Excluding these discrete items, we are estimating our effective tax rate to be in the range of 26% to 27% on a normalized basis during fiscal 2018. Approximately 25% of our cash is held outside of the U.S. At this time, we do not expect to repatriate large amounts of cash from overseas subsidiaries.
Looking to fiscal 2019 and beyond, upon completing strategic planning activities this summer, we will determine the extent to which future savings resulting from tax reform will be utilized to increase R&D spending and for other initiatives, such as to fund increases in entry level wages and our community benefit programs.
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the second quarter ended March 31, 2018. The dividend is payable on May 17, 2018 to shareholders of record as of the close of business on May 7, 2018. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings on both a GAAP and non-GAAP basis, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
FISCAL 2018 GUIDANCE UPDATED
The Company now expects revenues for the fiscal year ending September 30, 2018 of between $209 million to $214 million, compared to the previous guidance range of $207 million to $212 million.
Management expects non-GAAP net earnings for fiscal 2018 to be between $0.69 and $0.72 per share, an increase from the previously published range of $0.65 to $0.68. Non-GAAP earnings per share for fiscal year 2018 excludes the impacts of litigation costs, executive transition and realignment costs, potential future costs associated with the realignment of our organizational structure and the one-time benefit of tax reform, namely the re-measurement of deferred tax liabilities and the repatriation transition tax*.* Several of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided.
These per share estimates assume an increase in average shares outstanding from approximately 42.6 million at fiscal 2017 year-end to approximately 42.8 million at fiscal 2018 year-end.
The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2018.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At March 31, 2018, current assets were $139.5 million compared to current liabilities of $25.8 million, resulting in working capital of $113.7 million and a current ratio of 5.4. Cash and equivalents were $56.4 million, and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which were incurred in connection with the 2016 acquisition of Magellan, totaled $52.4 million as of March 31, 2018.
INTERIM UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2018 and fiscal 2017.
Three Months Ended Six Months Ended March 31, March 31, 2018 2017 2018 2017 Net revenues$56,451 $54,125 $108,734 $100,934 Cost of sales 21,882 20,648 42,379 38,418 Gross profit 34,569 33,477 66,355 62,516 Operating expenses Research and development 4,222 3,951 8,702 7,548 Selling and marketing 8,648 8,066 17,458 15,684 General and administrative 9,110 7,274 18,062 15,013 Executive transition and realignment costs 3,458 – 4,192 – Litigation costs 1,453 – 2,202 – Total operating expenses 26,891 19,291 50,616 38,245 Operating income 7,678 14,186 15,739 24,271 Other income (expense), net (454) 4 (857) (422) Earnings before income taxes 7,224 14,190 14,882 23,849 Income tax provision 1,936 4,878 3,292 8,258 Net earnings$5,288 $9,312 $11,590 $15,591 Net earnings per basic common share$0.12 $0.22 $0.27 $0.37 Basic common shares outstanding 42,323 42,202 42,289 42,177 Net earnings per diluted common share$0.12 $0.22 $0.27 $0.37 Diluted common shares outstanding 42,732 42,568 42,693 42,539
The following table sets forth the unaudited segment data for the interim periods in fiscal 2018 and fiscal 2017 (in thousands).
Three Months Ended Six Months Ended March 31, March 31, 2018 2017 2018 2017Net revenues Diagnostics$39,782 $37,772 $77,272 $71,580 Life Science 16,669 16,353 31,462 29,354 $56,451 $54,125 $108,734 $100,934Operating Income Diagnostics$8,986 $9,595 $15,760 $16,238 Life Science 3,576 4,571 6,360 7,838 Executive Transition and Realignment Costs, and Litigation Costs (4,911) – (6,394) – Eliminations 27 20 13 195 $7,678 $14,186 $15,739 $24,271
NON-GAAP FINANCIAL MEASURES
In this press release, we have supplemented our reported GAAP financial information with information on net earnings, basic earnings per share and diluted earnings per share excluding the effects of executive transition and realignment costs, litigation costs and certain one-time tax effects of the tax reform act. We have provided in the tables below reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of these non-routine items, for the second quarters and six month periods ended March 31, 2018 and March 31, 2017.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
SECOND QUARTER AND SIX MONTH YEAR-TO-DATEGAAP TO NON-GAAP RECONCILATION TABLES(In Thousands, Except per Share Data) Three Months Six Months Ended March 31, Ended March 31, 2018 2017 2018 2017Net Earnings – U.S. GAAP basis$5,288 $9,312 $11,590 $15,591 Executive transition and realignment costs\* 2,517 – 3,052 – Litigation costs\* 1,058 – 1,603 – One-time benefit from tax law change – – (1,695) – Repatriation transition tax – – 854 – Adjusted Earnings$8,863 $9,312 $15,404 $15,591 Net Earnings per Basic Common Share – U.S. GAAP basis$0.12 $0.22 $0.27 $0.37 Executive transition and realignment costs 0.06 – 0.07 – Litigation costs 0.02 – 0.04 – One-time benefit from tax law change – – (0.04) – Repatriation transition tax – – 0.02 – Adjusted Basic EPS$0.21\*\*$0.22 $0.36 $0.37 Net Earnings per Diluted Common Share – U.S. GAAP basis$0.12 $0.22 $0.27 $0.37 Executive transition and realignment costs 0.06 – 0.07 – Litigation costs 0.02 – 0.04 – One-time benefit from tax law change – – (0.04) – Repatriation transition tax – – 0.02 – Adjusted Diluted EPS$0.21\*\*$0.22 $0.36 $0.37 \*Net of tax. \*\*Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers, and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=xMD2EaUgRj65QpzTkwzN3FdAuZQYT63_jURIfiYsKwrluJ3FymZxA9o4RrCBBRFBdQp8Z3Ri73_l7AQr-SmyXUPw3nnAJzm2b8ec-Hupnc48xhasuabQ_aEfPAJIlGJVhCBtXPaRVyJUgY30L55BnVyYeTdo4EKvYb4c4d490I-1bfFXKeA8aVbQsiEOZZlx8TBmThhWTzuuh7LiZl6InMiAJwakETYkJtw7dylZ_x36ILuomgaU3nt8eME_A0J_IzbrCfoEWUDhEv2NKRFD49NXAhSavuoHAWs_DmLMEcORx-X_9uTskAjGpPMM_1OBPhZYzvupAtSESUTV-nTZwkoSaimMbMAFJC2TEif_PNU= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=b4tg6BzgA6yYxp07nEGw4rvl_02rLDaqa5rFQ3WeB1isiddbujTYDkjIiWo0XlxHg_fc8gDwgj19iN_rD4gr87lv2Kkr0HO5NYt2sV36_6GcLG6CkDRsOYoaZ_AnC6Er)
**Categories:** Press Release
---
### [Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-first-quarter-2019-operating-results-declares-regular-first-quarter-cash-dividend-and-provides-updated-fiscal-2019-guidance/)
**Published:** January 24, 2019
**Author:** hamza
**Content:**
CINCINNATI, Jan. 24, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018.
**First Quarter 2019 Highlights:**
- Total revenue decreased 1.5% to $51.5 million, as compared to $52.3 million in the first quarter of fiscal 2018 (1% decrease in constant-currency)
- Reported operating income of $10.6 million (including $0.6 million of costs associated with litigation), an increase of 31% from the first quarter of fiscal 2018, which included $1.5 million of costs associated with restructuring activities and litigation
- Reported GAAP EPS of $0.19 per diluted share and non-GAAP EPS of $0.20 per diluted share, increases of 27% and 33%, respectively, from the first quarter of fiscal 2018 (see non-GAAP financial measure reconciliation below)
- Declared regular quarterly cash dividend of $0.125 per share
- Received FDA clearance for our new Alethia™ CMV Molecular Amplification Test (formerly, the ***illumi****gene* brand)
- Submitted regulatory documents to FDA in connection with efforts to reinstate our blood chemistry products’ venous blood claims
**First Quarter 2019 Results**
Total revenue for the first quarter of fiscal 2019 decreased 1.5% to $51.5 million, compared to $52.3 million in the first quarter of 2018. This decrease was primarily driven by our Diagnostics business unit revenues decreasing 2% from $37.5 million to $36.7 million, as volume pressures in a number of our molecular products, and pricing in certain gastrointestinal lines more than offset growth in blood-lead chemistry products. Sales in our Life Science business unit were relatively flat at $14.8 million, reflecting the effects of inconsistent order patterns with a number of our multi-national IVD manufacturing customers and broadly in China.
Operating income for the fiscal 2019 first quarter increased $2.5 million to $10.6 million from the first quarter of fiscal 2018. This increase primarily results from the combined effects of a $0.9 million decrease in restructuring and litigation costs, and a $2.0 million decrease in other operating expenses. Excluding the effects of the restructuring and litigation costs in each period, operating income increased 17% over the fiscal 2018 first quarter to $11.1 million. R&D spending was down in the quarter compared to first quarter of fiscal 2018, which included clinical trial expenses for the recently-cleared congenital CMV assay. Sales and marketing expenses in the quarter were down due to fiscal 2018 organization streamlining initiatives, particularly in our Life Science business, as well as lower sales commissions as a result of lower revenues. General and administrative expenses were down in the quarter, also due in large part to the effects of organizational streamlining initiatives in fiscal 2018. Fiscal first quarter operating income in Diagnostics increased 3% despite the decrease in revenues because of lower operating expenses. Operating income for the fiscal first quarter was up 74% in Life Science, driven by the continued benefit of fiscal 2018 restructuring activities, including a lower-cost commercial organization, as well as overall productivity improvements.
Net earnings for the first quarter of fiscal 2019 totaled $8.1 million, or $0.19 per diluted share, as compared to $6.3 million, or $0.15 per diluted share, for the first quarter of fiscal 2018. On a non-GAAP basis, earnings were $8.6 million, or $0.20 per diluted share, increases of 31% and 33%, respectively. Non-GAAP basis excludes the effect of litigation costs in both the fiscal 2019 and 2018 periods, and in fiscal 2018, also excludes restructuring costs and certain one-time tax effects of the U.S. Tax Cuts and Jobs Act (the “tax reform act”) enacted in December 2017 (see non-GAAP financial measure reconciliation below).
Jack Kenny, Chief Executive Officer, commented, “While revenue growth in the first quarter was below our expectations, the realignment and efficiency actions taken in fiscal 2018, combined with continued expense management discipline, allowed us to deliver strong earnings growth and profit margins. We are committed to re-invest in the business and intend to increasingly re-deploy such savings into future growth initiatives, including strengthening our molecular product portfolio. We are in the early stages of executing our strategy, including re-positioning our Diagnostics business for sustainable topline growth. Our molecular diagnostics products are experiencing more competitive pressure than we anticipated, and a very high volume of flu and other respiratory illness testing in the second quarter of fiscal 2018 will make for difficult comparisons for our Diagnostics business unit in the second quarter. We believe new commercial and product initiatives already in place in our Diagnostics business will yield positive results and increasingly contribute to financial results through fiscal 2019. These factors, combined with our continued expectation for strong, but periodically inconsistent, growth in our Life Science business, are reflected in our updated guidance for fiscal 2019.”
**Tax Reform Impact** Our GAAP net earnings for both fiscal year periods include the effects of the tax reform act signed into law during December 2017. The fiscal 2019 first quarter reflects the lower U.S. federal tax rate of 21% being fully phased-in and the fiscal 2018 first quarter includes: (i) a benefit of $1.7 million ($0.04 per diluted share) primarily related to the re-measurement of our U.S. net deferred tax liabilities based on the new federal rate; and (ii) a charge of $0.9 million ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax. Our effective tax rate for the first quarter of fiscal 2019 is 23%.
**Cash Dividend Matters** The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the first quarter ended December 31, 2018. The dividend is payable on February 14, 2019 to shareholders of record as of the close of business on February 4, 2019. The Company regularly evaluates its capital allocation priorities and remains committed to distributing excess capital to shareholders through dividends and other available means absent imminent reinvestment opportunities in the business. The actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
**Fiscal 2019 Guidance**
The following is a summary of the Company’s revised financial guidance for the fiscal year ending September 30, 2019:
Consolidated Net revenues
Operating margin
Tax rate
Earnings per Share Flat-2% growth
~19% (GAAP), ~20% (Non-GAAP)
24.5%-25.0%
$0.72-$0.74 (GAAP)
$0.74-$0.76 (Non-GAAP) Diagnostics Life ScienceNet revenues
Operating margin Low single-digit decline
Down from F2018 and Q1-F2019 High single-digit to low double-digit growth
Significant improvement vs. F2018 The revenue, earnings and operating margin guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2019.
**FDA Remediation**
We continue to make progress with our remediation plan for our blood-chemistry manufacturing facility, and submitted in late December 2018, the regulatory documents to reinstate our venous blood claims for all three blood-lead assays.
**Financial Condition** The Company’s financial condition remains sound. At December 31, 2018, cash and equivalents were $61.5 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations totaled $49.1 million as of December 31, 2018.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Eric Rasmussen, Chief Financial Officer, will host a conference call on Thursday, January 24, 2019 beginning at 9:00 a.m. Eastern Time to discuss the first quarter financial results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5086695. A replay will be available for 14 days beginning at 2:00 p.m. Eastern Time on January 24, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5086695.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the first quarters of fiscal 2019 and fiscal 2018.
Three Months Ended December 31, 2018 2017 Net revenues$51,480 $52,283 Cost of sales 19,908 20,273 Gross profit 31,572 32,010 Operating expenses Research and development 3,967 4,420 Selling and marketing 7,563 8,844 General and administrative 8,902 9,202 Restructuring costs – 734 Litigation costs 589 749 Total operating expenses 21,021 23,949 Operating income 10,551 8,061 Other expense net (75) (403)Earnings before income taxes 10,476 7,658 Income tax provision 2,370 1,356 Net earnings$8,106 $6,302 Net earnings per basic common share$0.19 $0.15 Basic common shares outstanding 42,446 42,263 Net earnings per diluted common share$0.19 $0.15 Diluted common shares outstanding 42,905 42,662 **Non-GAAP Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$11,140 $9,544 Net earnings 8,558 6,541 Net earnings per diluted common share$0.20 $0.15
**Condensed Balance Sheet Data**
December 31, 2018 2017 Cash and equivalents$ 61,523 $ 54,711 Working capital 118,924 113,143 Long-term debt 49,063 53,530 Shareholders’ equity 178,642 172,878 Total assets 249,857 251,951
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2019 and fiscal 2018 (in thousands).
Three Months Ended December 31, 2018 2017Net Revenues – By Product Platform/Type Diagnostics Molecular assays$7,298 $8,717Immunoassays & blood chemistry assays 29,367 28,773Total Diagnostics 36,665 37,490Life Science Molecular reagents 6,589 5,688Immunological reagents 8,226 9,105Total Life Science 14,815 14,793Total Net Revenues$51,480 $52,283 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$18,633 $20,270Respiratory illness assays 7,977 7,486Blood chemistry assays 4,466 4,266Other 5,589 5,468Total Diagnostics 36,665 37,490Life Science Americas 4,534 5,250EMEA 7,455 5,185ROW 2,826 4,358Total Life Science 14,815 14,793Total Net Revenues$51,480 $52,283 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
OPERATING INCOME Diagnostics$ 8,786 $ 8,569 Life Science 5,129 2,943 Corporate (2,802) (2,072)Restructuring and Litigation Costs (589) (1,483)Eliminations 27 104 Total Operating Income$ 10,551 $ 8,061
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of restructuring costs, litigation costs, and certain one-time tax effects of the tax reform act. We have provided in the tables below reconciliations of operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share, with and without the effects of these non-routine items, for the first quarters ended December 31, 2018 and December 31, 2017.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of the results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FIRST QUARTER**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Ended December 31, 2018 2017Operating Expenses – U.S. GAAP basis$21,021 $23,949 Restructuring costs – (734)Litigation costs (589) (749)Adjusted Operating Expenses$20,432 $22,466 Operating Income – U.S. GAAP basis$10,551 $8,061 Restructuring costs – 734 Litigation costs 589 749 Adjusted Operating Income$11,140 $9,544 Net Earnings – U.S. GAAP basis$8,106 $6,302 Restructuring costs\* – 535 Litigation costs\* 452 545 One-time benefit from tax law change – (1,695)Repatriation transition tax – 854 Adjusted Earnings$8,558 $6,541 Net Earnings per Basic Common Share – U.S. GAAP basis$0.19 $0.15 Restructuring costs – 0.01 Litigation costs 0.01 0.01 One-time benefit from tax law change – (0.04)Repatriation transition tax – 0.02 Adjusted Basic EPS$0.20 $0.15
Net Earnings per Diluted Common Share – U.S. GAAP basis$0.19 $0.15 Restructuring costs – 0.01 Litigation costs 0.01 0.01 One-time benefit from tax law change – (0.04)Repatriation transition tax – 0.02 Adjusted Diluted EPS$0.20 $0.15 \* Net of tax.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=gzzqjtmONPqKfDd2cPD9MIgF8w0taae2pEdAtC-IUhcOBgsFCWBvr6ZCiCi72FHrV-W0Oeb0AMwwqzy22GOt-NoiFk0Ih1h3jLDwU1Z6PN-61Fb9CB3o5WgBZBBTNs1d)
**Categories:** Press Release
---
### [Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-preliminary-first-quarter-2019-revenue-first-quarter-2019-financial-results-conference-call-to-be-held-on-january-24-2019/)
**Published:** January 7, 2019
**Author:** hamza
**Content:**
CINCINNATI, Jan. 07, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018. The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment. The Life Science segment is expected to post revenue about in line with first quarter 2018.
Jack Kenny, Chief Executive Officer, commented, “Demand in the first quarter was softer than expected in both of our business segments. In Diagnostics, we experienced weakness in major molecular product lines. In Life Science, bulk order shipments, which are historically prone to quarterly swings, were also weaker than planned, particularly for immunoassay products and in China. While we remain positive about the prospects in our business, we intend to take both short- and long-term actions to address areas of sustained weakness and mitigate the impact on the Company’s profitability. We also remain committed to executing our strategic plan and making the necessary investments to position the Company for sustainable, long-term growth.”
The Company will present at the J.P. Morgan 2019 Healthcare Conference on Thursday, January 10, 2019 at 10:30 a.m. PT in San Francisco, CA. and will report first quarter 2019 financial results on Thursday, January 24, 2019.
**First Quarter 2019 Financial Results Conference Call**
The Company will hold a conference call on January 24, 2019 beginning at 9:00 a.m. Eastern Time to discuss the first quarter financial results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5086695.
A replay will be available for 14 days beginning at 2:00 p.m. Eastern Time on January 24, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5086695.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Eric Rasmussen
Chief Financial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=2G5bTQA7znmAykadQGnKFHDQElgUG99mCHuAlkgN4dTRfJBYlW9CHBGjkx2PBkPPUfxEdhLL_tIStN3Asydax2qo9HSnNg83eH-QxClOUNn9herdBI6KL1hS5qICfNBS "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Gets FDA Clearance for New Neonatal Saliva CMV Test](https://www.meridianbioscience.com/press-release/meridian-gets-fda-clearance-for-new-neonatal-saliva-cmv-test/)
**Published:** December 6, 2018
**Author:** hamza
**Content:**
CINCINNATI, Dec. 06, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance for its new Alethia™ CMV Molecular Amplification Test (formerly, the ***illumi***gene brand)*.* This assay is designed to specifically detect congenital Cytomegalovirus (cCMV) infection in newborns from an easy-to-collect saliva sample. Alethia CMV is the first qualitative test in a molecular amplification format, FDA-cleared for cCMV testing in newborns.
Congenital CMV is the most common congenital infection and a leading cause of childhood hearing loss, cognitive deficits, and visual impairment. According to the CDC about 1 out of every 200 babies are born with cCMV infection; and approximately 10% to 25% of all childhood sensorial hearing loss (SNHL) can be attributed to cCMV. Babies are at risk of infection during pregnancy if the virus in the mother’s blood crosses through the placenta. Early detection is critical in establishing appropriate treatment. Diagnosis can be attained by detecting the virus in a baby’s saliva or urine within 2 to 3 weeks from birth. CMV is a public health issue and legislation has been passed or is under consideration in numerous states regarding CMV education and testing recommendations in neonates.
Lawrence Mertz, Senior Vice-President of Research and Development, stated, “We are excited to be the first to develop and bring to market a very important test for newborns. It is an advancement in testing for a viral infection that can lead to such complicated and long-lasting conditions in children.”
Jack Kenny, Chief Executive Officer, said, “Unfortunately cCMV infection is more common than other newborn related illnesses, like Group B *Strep* for example, yet the level of awareness is considerably lower. With Alethia CMV, we not only look to increase awareness, but also provide laboratories with an FDA-cleared test that they can use with confidence when diagnosing newborns with cCMV. Alethia CMV helps meet a critical need with a simple-to-collect saliva sample in combination with a procedurally simple, rapid, and sensitive test. Alethia CMV marks the launch of the new branding for our current molecular platform.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SUZSt9s4YeHKCVm8027at0qwpPNRV34mBSVKJ9lz3NlaBNZGry7Xc3NBiQESNzgKee6CcqyMhQqxteUQssKxTIohsdne-KvWJ4TGiSpdWDBFEZa0ARy6IDvjR61_5iheDKMEamxyPFRezl9Dk8I8tPurR3-F_qSr4ezlluujMzAEbhQT_G1xSWirF6iVcsIJ8v01S53dUqyYCnJbOSFLYOuygBn4pbJf5kJ2IJuW2YVO6fBT78t8OM6WqIYZEq-wW2YdZvbtfRbMu_QZXsEi54pusfxmyJbM9cc69Xa-NQw= "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=2xsbzZL2tTCz6D-YH5XCYaWJ75sUvV0HaQzT1M-8jYzcZk9-Yg6Pr2Me2j_-8oLwf1G4NiNZlAedKIqIDcWRcZeCME6_SkIdrQSZg0B88CgS4FT6uu83MqvV0ia3tItJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate, and Provides Fiscal 2019 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-fourth-quarter-and-full-year-operating-results-sets-fiscal-2019-cash-dividend-rate-and-provides-fiscal-2019-guidance/)
**Published:** November 8, 2018
**Author:** hamza
**Content:**
CINCINNATI, Nov. 08, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2018.
**Business Highlights:**
- Completed consolidation of separately-run businesses into two integrated global business units
- Streamlined organization to build a stronger, more efficient and sustainable management structure
- Entered into a strategic collaboration with DiaSorin to sell Helicobacter Pylori tests
- Launched new branding strategy
- Released fiscal 2019 guidance of per share diluted earnings between $0.74 and $0.76 on net revenue growth of 2%-4% and operating margin of approximately 20%
**Fourth Quarter 2018 Financial Highlights:**
- Total revenue increased 7% to $53.1 million, as compared to $49.7 million in the fourth quarter of fiscal 2017
- Diagnostics segment revenues grew 2% to $36.8 million (also 2% growth in constant-currency)
- Life Science segment revenues grew 19% to $16.3 million (20% growth in constant-currency)
- Reported operating income of $7.1 million (including $4.6 million of costs associated with restructuring activities and litigation costs), a decrease of 19% from the fourth quarter of fiscal 2017, which included $0.8 million of similar costs
- Reported GAAP EPS of $0.13 per diluted share and non-GAAP EPS of $0.20 per diluted share (see non-GAAP financial measure reconciliation below)
- Declared regular quarterly cash dividend of $0.125 per share
**Full Fiscal Year 2018 Financial Highlights:**
- Total revenue increased 6% to $213.6 million, as compared to $200.8 million in fiscal 2017
- Diagnostics segment revenues grew 5% to $150.5 million (4% growth in constant-currency)
- Life Science segment revenues grew 10% to $63.1 million (9% growth in constant-currency)
- Reported operating income of $31.6 million (including $13.1 million of costs associated with restructuring activities and litigation costs), a decrease of 16% from fiscal 2017, which included $0.8 million of similar costs and a $6.6 million non-cash goodwill impairment charge
- Reported GAAP EPS of $0.56 per diluted share and non-GAAP EPS of $0.74 per diluted share (see non-GAAP financial measure reconciliation below)
- Returned $21.2 million to shareholders through dividend distributions
**Fourth Quarter 2018 Results**
Total revenue for the fourth quarter of fiscal 2018 increased 7% to $53.1 million, compared to $49.7 million in the fourth quarter of 2017. This increase was primarily driven by growth in our Life Science business unit, which increased revenue by 19% from $13.7 million to $16.3 million, driven largely by volume increases for our multi-national IVD manufacturing customers, and IVD manufacturing customers in China. Sales in our Diagnostics business increased 2% in the quarter to $36.8 million as volume growth in blood/lead chemistry and respiratory illness assays more than offset pricing and volume pressures in our gastrointestinal assays, including molecular products.
Operating income for the fiscal 2018 fourth quarter decreased $1.7 million to $7.1 million. This decrease primarily results from a $3.8 million increase in restructuring and litigation costs, partially offset by a net $0.6 million decrease in other operating expenses. Excluding the effects of the restructuring and litigation costs in each period, operating income increased 22% over the fiscal 2017 fourth quarter to $11.7 million. R&D spending was down in the quarter due to timing of product development projects. Sales and marketing expenses in the quarter were down due to organization streamlining initiatives, particularly in our Life Science business. General and administrative expenses were up in the quarter due in large part to a new company-wide incentive compensation program. Fiscal fourth quarter operating income in Diagnostics increased slightly driven by sales volume increases offset largely by pricing pressures in certain gastrointestinal products and the impact of increased sales and marketing staff and infrastructure investments. Operating income for the fiscal fourth quarter in Life Science was up 72% driven by revenue growth and the benefit of a lower-cost commercial organization, post restructuring.
Net earnings for the fourth quarter of fiscal 2018 totaled $5.4 million, or $0.13 per diluted share, as compared to $5.7 million, or $0.13 per diluted share, for the fourth quarter of fiscal 2017. On a non-GAAP basis, earnings were $8.6 million, or $0.20 per diluted share, increases of 38% and 33%, respectively. Non-GAAP basis excludes the effect of restructuring and litigation costs in both the fiscal 2018 and 2017 periods, and in fiscal 2018, also excludes certain one-time tax effects of the U.S. Tax Cuts and Jobs Act (the “tax reform act”) enacted in December 2017 (see non-GAAP financial measure reconciliation below).
Jack Kenny, Chief Executive Officer, commented, “We are pleased to report these very positive fourth quarter and full-year results, and believe that they are starting to demonstrate the effectiveness of the realignment and streamlining activities we initiated earlier this year. In addition to very solid finishes to the year in both of our segments, the fourth quarter also included a number of noteworthy corporate governance events including the addition of a new Board member, the appointment of a new Chairman of the Board and the retirement of long time Meridian CEO and Chairman, Jack Kraeutler. On the operational front, the fourth quarter also saw us negotiate a strategic collaboration agreement with DiaSorin to sell Helicobacter Pylori tests, resulting in a signed agreement in early October – an agreement we are confident will be mutually beneficial for both our organizations for years to come. We are eager and excited to build upon these successes and continue the momentum as we progress through fiscal 2019.”
**Full Fiscal Year 2018 Results**
Total revenue for the fiscal year ended September 30, 2018 totaled $213.6 million, a 6% increase over the $200.8 million achieved in fiscal 2017. This increase reflects growth of 5% (4% on a constant-currency basis) to $150.5 million in Diagnostics, driven largely by volume growth for our respiratory illness assays, and growth of 10% in Life Science (9% on a constant-currency basis) supported by volume increases in all three geographic markets. Life Science revenues in China increased by over 40% on a full year basis.
During fiscal 2018, operating income totaled $31.6 million, a decrease of $5.8 million. This decrease primarily results from a $12.3 million increase in restructuring and litigation costs and a $6.3 million increase in other operating expenses. The effects of these increased expenses were partially offset by a $6.2 million increase in gross profit, reflecting primarily the increase in revenue noted above, and fiscal 2017 including a $6.6 million goodwill impairment charge. Excluding the effects of the restructuring and litigation costs in each period, and fiscal 2017’s goodwill impairment charge, operating income remained relatively flat compared to fiscal 2017 at $44.6 million.
Net earnings totaled $23.8 million, or $0.56 per diluted share, for fiscal 2018, as compared to $21.6 million, or $0.51 per diluted share, in fiscal 2017. On a non-GAAP basis, earnings were $31.7 million, or $0.74 per diluted share, increases of 11% and 10%, respectively, over fiscal 2017’s non-GAAP earnings of $28.7 million, or $0.67 per diluted share. Non-GAAP basis excludes the effect of restructuring costs, litigation costs and certain one-time tax effects of the tax reform act in fiscal 2018; and in fiscal 2017, excludes the effect of restructuring costs, litigation costs and goodwill impairment (see non-GAAP financial measure reconciliation below).
**Tax Reform Impact**
Our GAAP net earnings for the year include the effects of the tax reform act signed into law during December 2017. Included therein are (i) a benefit of $2.7 million ($0.06 per diluted share) primarily related to the re-measurement of our U.S. net deferred tax liabilities, recorded throughout the fiscal year as follows: $1.7 million, or $0.04 per diluted share, in the first quarter; $0.7 million, or $0.02 per diluted share, in the third quarter; and $0.3 million, or $0.01 per diluted share, in the fourth quarter; and (ii) a charge of $0.9 million ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax, substantially all of which was recorded in the first quarter. Excluding these discrete items, our effective tax rates for the fourth quarter and full-year fiscal 2018 are 25% and 27%, respectively. Approximately 25% of our cash is held outside of the U.S. At this time, we do not expect to repatriate large amounts of cash from overseas subsidiaries.
**Cash Dividend Matters**
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the fourth quarter ended September 30, 2018. The dividend is payable on November 30, 2018 to shareholders of record as of the close of business on November 19, 2018. The Board of Directors has approved the indicated regular quarterly cash dividend rate of $0.125 per share for fiscal 2019, an annual indicated rate of $0.50 per share. The Company regularly evaluates its capital allocation priorities and remains committed to distributing excess capital to shareholders through dividends and other available means absent imminent reinvestment opportunities in the business. The actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
**Fiscal 2019 Guidance**
The following is a summary of the company’s financial guidance for the fiscal year ending September 30, 2019:
Consolidated Net revenues 2%-4% growth Operating margin ~20% Tax rate 25.5% Earnings per Share $0.74-$0.76 Diagnostics Life Science Net revenues Low single-digit growth Low double-digit growth Operating margin Down 0-50 bps year-over-year Continued improvement over run rate The revenue, earnings and operating margin guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2019.
**FDA Remediation**
We continue to make progress with our remediation plan for our blood-chemistry manufacturing facility. We currently expect to submit regulatory documents to reinstate our venous blood claims in early calendar year 2019.
**Financial Condition**
The Company’s financial condition remains sound. At September 30, 2018, cash and equivalents were $59.8 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations totaled $50.2 million as of September 30, 2018.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, Melissa Lueke, Chief Financial Officer, and Eric Rasmussen, Executive Vice President, Corporate Development, will host a conference call on Thursday, November 8, 2018 beginning at 9:00 a.m. Eastern Time to discuss the results and answer questions. During the conference call, the company will also introduce key elements of its business strategy and discuss other business and financial developments.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 2238529. A replay will be available for 14 days beginning at 12:00 p.m. Eastern Time on November 8, 2018 by dialing (855) 859-2056 and entering pass code 2238529.
**FOURTH QUARTER AND FISCAL 2018 UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim and annual periods of fiscal 2018 and fiscal 2017.
Three Months Ended Twelve Months Ended September 30, September 30, 2018 2017 2018 2017 Net revenues$53,100 $49,697 $213,571 $200,771 Cost of sales 20,950 19,067 83,110 76,479 Gross profit 32,150 30,630 130,461 124,292 Operating expenses Research and development 3,625 4,524 16,870 16,036 Selling and marketing 8,506 8,743 34,468 32,388 General and administrative 8,333 7,794 34,488 31,096 Restructuring costs 3,601 134 8,706 134 Litigation costs 975 628 4,345 628 Goodwill impairment charge – – – 6,628 Total operating expenses 25,040 21,823 98,877 86,910 Operating income 7,110 8,807 31,584 37,382 Other expense, net (232) (173) (1,204) (953) Earnings before income taxes 6,878 8,634 30,380 36,429 Income tax provision 1,444 2,908 6,531 14,872 Net earnings$5,434 $5,726 $23,849 $21,557 Net earnings per basic common share$0.13 $0.14 $0.56 $0.51 Basic common shares outstanding 42,391 42,205 42,325 42,188 Net earnings per diluted common share$0.13 $0.13 $0.56 $0.51 Diluted common shares outstanding 42,821 42,616 42,754 42,571 **Non-GAAP Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$11,686 $9,569 $44,635 $44,772 Net earnings 8,579 6,221 31,705 28,680 Net earnings per diluted common share$0.20 $0.15 $0.74 $0.67
**Condensed Balance Sheet Data**
September 30, 2018 2017Cash and equivalents$59,763 $57,072Working capital 114,880 110,988Long-term debt 50,180 54,647Shareholders’ equity 175,418 169,585Total assets 251,377 249,777
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim and annual periods in fiscal 2018 and fiscal 2017 (in thousands).
Three Months Ended Twelve Months Ended September 30, September 30, 2018 2017 2018 2017 Net Revenues – By Product Platform/Type Diagnostics Molecular assays$7,784 $8,269 $34,011 $33,901 Immunoassays & blood chemistry assays 29,030 27,723 116,443 109,620 Total Diagnostics 36,814 35,992 150,454 143,521 Life Science Molecular reagents 6,648 6,105 24,613 21,998 Immunological reagents 9,638 7,600 38,504 35,252 Total Life Science 16,286 13,705 63,117 57,250 Total Net Revenues$53,100 $49,697 $213,571 $200,771 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$19,172 $20,194 $78,803 $78,068 Respiratory illness assays 6,134 4,752 28,908 23,662 Blood chemistry assays 5,581 4,994 19,109 18,212 Other 5,927 6,052 23,634 23,579 Total Diagnostics 36,814 35,992 150,454 143,521 Life Science Americas 5,118 4,296 20,792 19,978 EMEA 6,187 5,402 24,530 21,968 ROW 4,981 4,007 17,795 15,304 Total Life Science 16,286 13,705 63,117 57,250 Total Net Revenues$53,100 $49,697 $213,571 $200,771 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World OPERATING INCOME Diagnostics(1)$6,775 $6,696 $29,701 $23,848 Life Science 4,905 2,860 14,912 14,086 Restructuring and Litigation Costs (4,576) (762) (13,051) (762) Eliminations 6 13 22 210 Total Operating Income$7,110 $8,807 $31,584 $37,382 (1) Twelve Months Ended September 30, 2017 includes a goodwill impairment charge of $6.6 million.
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of restructuring costs, litigation costs, goodwill impairment charge, and certain one-time tax effects of the tax reform act. We have provided in the tables below reconciliations of operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share, with and without the effects of these non-routine items, for the fourth quarters and fiscal years ended September 30, 2018 and September 30, 2017.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of the results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FOURTH QUARTER AND FISCAL YEAR**
**GAAP TO NON-GAAP RECONCILATION TABLES**
(In Thousands, Except per Share Data)
Three Months Twelve Months Ended September 30, Ended September 30, 2018 2017 2018 2017 Operating Expenses – U.S. GAAP basis$25,040 $21,823 $98,877 $86,910 Restructuring costs (3,601) (134) (8,706) (134) Litigation costs (975) (628) (4,345) (628) Goodwill impairment charge – – – (6,628) Adjusted Operating Expenses$20,464 $21,061 $85,826 $79,520 Operating Income – U.S. GAAP basis$7,110 $8,807 $31,584 $37,382 Restructuring costs 3,601 134 8,706 134 Litigation costs 975 628 4,345 628 Goodwill impairment charge – – – 6,628 Adjusted Operating Income$11,686 $9,569 $44,635 $44,772 Net Earnings – U.S. GAAP basis$5,434 $5,726 $23,849 $21,557 Restructuring costs\* 2,693 87 6,430 87 Litigation costs\* 738 408 3,205 408 Goodwill impairment charge – – – 6,628 One-time benefit from tax law change (308) – (2,655) – Repatriation transition tax 22 – 876 – Adjusted Earnings$8,579 $6,221 $31,705 $28,680 Net Earnings per Basic Common Share – U.S. GAAP basis$0.13 $0.14 $0.56 $0.51 Restructuring costs 0.06 – 0.15 – Litigation costs 0.02 0.01 0.08 0.01 Goodwill impairment charge – – – 0.16 One-time benefit from tax law change (0.01) – (0.06) – Repatriation transition tax – – 0.02 – Adjusted Basic EPS$0.20 $0.15 $0.75 $0.68 Net Earnings per Diluted Common Share – U.S. GAAP basis$0.13 $0.13 $0.56 $0.51 Restructuring costs 0.06 – 0.15 – Litigation costs 0.02 0.01 0.07 0.01 Goodwill impairment charge – – – 0.16 One-time benefit from tax law change (0.01) – (0.06) – Repatriation transition tax – – 0.02 – Adjusted Diluted EPS$0.20 $0.15 \*\*$ 0.74 $ 0.67 \*\* \*Net of tax. \*\*Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=AmzV7aniBVDN5pz8IL-72HLrvN15F95b8POBz8zbCMimZtDOXBVslgrjZSVRbcccGfdYt-lbvLf5aOITO8-bzgoEVtCH0_RAnl6PqnirA6D0sY7n9OU5FhriRydMCy_t).
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=qd5KepnMkfGg8lRhPx5UQk-zQNfMZuGG-ZIw1gDw8a1CL4Qz4ZZ8Ay1b-v5uBZCmWicXbioLJBKES7BCcuT7xyOfX-TGb9TD13cxOVc9gl_KtEzvbGASvvvKMZVb5ZWC)
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-fourth-quarter-and-full-year-2018-financial-results-conference-call-on-november-8-2018/)
**Published:** October 17, 2018
**Author:** hamza
**Content:**
CINCINNATI, Oct. 17, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2018 financial results Thursday, November 8, 2018.
Jack Kenny, Chief Executive Officer, Melissa Lueke, Chief Financial Officer, and Eric Rasmussen, Corporate Development, will host a conference call beginning at 9:00 a.m. Eastern Time to discuss the results and answer questions. During the conference call, the company will also introduce key elements of its business strategy, as well as discuss other business and financial developments.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 2238529.
A replay will be available for 14 days beginning at 12:00 p.m. Eastern Time on November 8, 2018 by dialing (855) 859-2056 and entering pass code 2238529.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dYuSEdMJ7oarimEuj8kYrsBgcfyYc3KLdB455gdOLWR4EmnzEHeRXf1zG--1q9orJWkb_80lvO0vHLnxIOpmW3CeLvvRtG8PC6I7QIw8s8PSztF9Upyb8ZS2NFuNxtpj "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [DiaSorin and Meridian Enter Into a Strategic Collaboration to Sell Helicobacter Pylori Stool Antigen Test in the United States and in the United Kingdom](https://www.meridianbioscience.com/press-release/diasorin-and-meridian-enter-into-a-strategic-collaboration-to-sell-helicobacter-pylori-stool-antigen-test-in-the-united-states-and-in-the-united-kingdom/)
**Published:** October 9, 2018
**Author:** hamza
**Content:**
SALUGGIA, Italy and CINCINNATI, Oct. 09, 2018 (GLOBE NEWSWIRE) — **DiaSorin** **S.p.A.** (FTSE Italy Mid Cap: DIA) and **Meridian Bioscience, Inc**. (NASDAQ:VIVO) today announced that DiaSorin Inc., a subsidiary of DiaSorin S.p.A. and Meridian Bioscience, Inc. have entered into a strategic collaboration to sell DiaSorin’s FDA-cleared *Helicobacter pylori* stool antigen test to detect *H. pylori* for use on its automated LIAISON platform under the Meridian brand name worldwide.
As part of this agreement, Meridian and DiaSorin will begin collaborating on sales and marketing efforts to hospitals and reference laboratories in the U.S. Moreover, Meridian will receive royalties on sales of the LIAISON *H. pylori* stool antigen test in the U.S. and now also in the UK, in addition to the royalties received under the previous agreement.
This new collaboration will result in the termination of all pending legal disputes and will expand the scope of the previous agreement between DiaSorin and Meridian, which focused on the sale, by DiaSorin, of co-developed products in major countries in continental Europe.
*Helicobacter pylori* is one of the most common bacterial infections in humans, affecting nearly 50% of the world’s population and it has been associated with the development of serious upper gastrointestinal (GI) conditions including chronic gastritis, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT).
Additionally, Meridian and DiaSorin have outlined a framework where they may partner to develop other stool-based tests for use on the LIAISON platform.
**Carlo Rosa**, **Chief Executive Officer at DiaSorin**, commented *“We are pleased to enter into this collaboration with Meridian Bioscience. Our stool testing products have been very successful and we are confident that, through this alliance with Meridian, we can continue to expand the adoption of our automated LIAISON platform and its large menu of tests in key markets, like the U.S. and UK. This collaboration creates synergies between state-of-the-art products and technology, which will result in expanded access to a fully automated test for the detection of H. pylori antigen in stool. Moreover, I’m confident that DiaSorin and Meridian will be able to develop additional stool-based tests, leveraging a reliable technology, a broad menu offer for the clients and a large chemiluminescent platform installed base worldwide.”*
**Jack Kenny, Chief Executive Officer at Meridian Bioscience**, continued, *“We are excited to team up with DiaSorin to facilitate the advancement of automated HpSA testing. Working together with DiaSorin, we believe we can accelerate the growth in testing to detect helicobacter pylori, a cause of stomach ulcers. Importantly, today many patients suffering from stomach ulcers are not tested, or are tested with less effective serology methods. Non-invasive stool testing platforms are highly accurate and cost effective. Furthermore, these tests can be used in the monitoring and testing of eradication of the H. pylori infection. DiaSorin and Meridian have enjoyed a collaborative relationship for almost ten years. I look forward to further strengthening this relationship as we embark upon this new partnership.”*
***About DiaSorin Group***
*Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “Diagnostic Specialist.”*
*More info at www.diasorin.com*
**About Meridian Bioscience, Inc.**
*Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.*
*Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com*
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**For additional information, please contact:**
**Riccardo Fava****Ines Di Terlizzi**Investor Relations & Corporate Communication Senior DirectorInvestor RelatorDiaSorin S.p.A. DiaSorin S.p.A.Tel: +39.0161.487988Tel: +39.0161.487567 [riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it "riccardo.fava@diasorin.it")[ines.diterlizzi@diasorin.it](mailto:ines.diterlizzi@diasorin.it "ines.diterlizzi@diasorin.it") **Jack Kenny** Chief Executive Officer Meridian Bioscience, Inc. Phone: 513.271.3700 Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Retirement of John A. Kraeutler, Executive Chairman of the Board; Appoints David C. Phillips as Chairman of the Board; and Elects Felicia Williams to the Board of Directors](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-retirement-of-john-a-kraeutler-executive-chairman-of-the-board-appoints-david-c-phillips-as-chairman-of-the-board-and-elects-felicia-williams-to-the-board-of-directo/)
**Published:** September 24, 2018
**Author:** hamza
**Content:**
CINCINNATI, Sept. 24, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that John (Jack) A. Kraeutler, Executive Chairman of the Board, will retire effective September 30, 2018. In connection with Mr. Kraeutler’s retirement the Board has appointed David C. Phillips to the position of Chairman, effective September 30, 2018. Additionally, the Board has elected Felicia Williams to the Board of Directors effective September 20, 2018. Ms. Williams has also been appointed to serve on the Audit Committee.
Felicia Williams has served as Executive Vice President, Controller and Enterprise Risk Officer at Macy’s Inc. since June 2016. Previously she had served as Senior Vice President, Finance and Risk Management at Macy’s from February 2011 through June 2016; and in other finance, treasury, risk management and internal audit capacities since joining the Company in June 2004. Prior to her time at Macy’s, Ms. Williams served in various financial positions at the Coca-Cola Hellenic Bottling Company and The Coca-Cola Company from June 1994 through June 2004.
Jack Kraeutler commented, “Reflecting on my service to Meridian Bioscience, I was guided by four passions: a passion for science; our customers; our team members; and our shareholders. As I look forward to retirement I am confident that Meridian has a strong leadership team and talented group of employees in place to build upon each of these four elements; and to move the Company forward towards a new phase of growth and prosperity.”
David C. Phillips, Chairman of the Board, commented, “I would like to express my deep appreciation for Jack’s many contributions to Meridian Bioscience since joining the Company in January 1992. Meridian has enjoyed numerous successes during his tenure. I wish Jack a happy and healthy retirement.”
Mr. Phillips continued, “It is my pleasure to welcome Felicia Williams to the Board of Directors. Felicia has amassed an impressive breadth of management experience during her career. Her strong financial background well-positions Felicia to provide meaningful insight as a member of the Audit Committee. I look forward to working with Felicia as we build a strong future for Meridian Bioscience.”
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=gBjlQF8hUZ5dXBHsx5brWxgDXeGoB_Pk6q7IcjmafG8B-Mfxr9RY9Abl3vQBSqbGTB4gPzr_BjlQ8ZgjWBN_HizOnCIwNOGHc3tsXiAvDhq0Q_lLmao7C1dcxiRYDt1x "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Third Quarter 2018 Operating Results, Declares Regular Third Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-third-quarter-2018-operating-results-declares-regular-third-quarter-cash-dividend-and-reaffirms-fiscal-2018-guidance/)
**Published:** July 31, 2018
**Author:** hamza
**Content:**
CINCINNATI, July 31, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
GENERAL HIGHLIGHTS
- Reported record fiscal 2018 third quarter and first nine months net revenues of $51.7 million and $160.5 million, respectively, increases of 3% and 6%, respectively, from the same periods of the prior fiscal year;
- reported third quarter operating income of $8.7 million (including $2.1 million of costs associated with executive transition and realignment, and litigation), an increase of 103% from the same period of the prior fiscal year, which included a $6.6 million non-cash goodwill impairment charge;
- reported nine months operating income of $24.5 million (including $8.5 million of costs associated with executive transition and realignment, and litigation), a decrease of 14% from the same period of the prior fiscal year, which included a $6.6 million non-cash goodwill impairment charge;
- reported third quarter net earnings of $6.8 million, or $0.16 per diluted share, on a GAAP basis, compared to $0.2 million, or $0.01 per diluted share, in the fiscal 2017 third quarter, which included the effect of a goodwill impairment charge. On a non-GAAP basis, earnings were $7.7 million, or $0.18 per diluted share, increases of 12% and 13%, respectively, compared to the fiscal 2017 third quarter. Non-GAAP basis earnings exclude the effect of executive transition and realignment costs, litigation costs and certain one-time tax effects of the recently-enacted U.S. Tax Cuts and Jobs Act (the “tax reform act”) in fiscal 2018, and the effect a goodwill impairment charge in fiscal 2017 (see non-GAAP financial measures reconciliation below);
- reported first nine months net earnings of $18.4 million, or $0.43 per diluted share, on a GAAP basis, increases of 16% compared to the same period of fiscal 2017. On a non-GAAP basis, earnings were $23.1 million, or $0.54 per diluted share, increases of 3% and 2%, respectively, compared to the same period of fiscal 2017. Non-GAAP basis earnings exclude the effect of executive transition and realignment costs, litigation costs and certain one-time tax effects of the tax reform act in fiscal 2018, and the effect a goodwill impairment charge in fiscal 2017 (see non-GAAP financial measures reconciliation below);
- declared the regular quarterly cash dividend of $0.125 per share for the third quarter of fiscal 2018 (annual indicated rate of $0.50 per share); and
- reaffirmed its fiscal 2018 guidance of per share diluted earnings of between $0.69 and $0.72 on a non-GAAP basis on net revenues of $209 million to $214 million.
FINANCIAL HIGHLIGHTS (UNAUDITED) In Thousands, Except per Share Data Three Months Ended Nine Months Ended June 30, June 30, 2018 2017 % Change 2018 2017 % ChangeNet Revenues$ 51,737 $ 50,140 3% $ 160,471 $ 151,074 6%Operating Income 8,735 4,304 103% 24,474 28,575 -14%Net Earning 6,825 240 NMF(1) 18,415 15,831 16%Diluted Earnings per Share$ 0.16 $ 0.01 NMF(1) $ 0.43 $ 0.37 16%Diluted Earnings per Share excluding effect of executive transition and realignment costs, litigation costs and certain effects of tax reform legislation (fiscal 2018) and goodwill impairment charge (fiscal 2017) (see non-GAAP financial measures reconciliation)$ 0.18 $ 0.16 13% $ 0.54 $ 0.53 2% (1) Non meaningful figure.
June 30, 2018 2017Cash and Equivalents$57,930 $ 55,253Working Capital 115,778 109,188Long-term Debt 51,297 55,763Shareholders’ Equity 175,127 167,549Total Assets 253,983 245,143COMPANY COMMENTS
Jack Kenny, Chief Executive Officer, commented, “We delivered a solid quarter with top- and bottom-line growth in the third quarter. Overall revenues increased 3%, with Diagnostics revenues growing 1% in the quarter year-over-year (flat on a constant currency basis), while Life Science revenues increased 8% (7% on a constant currency basis). Non-GAAP diluted earnings per share increased $0.02 in the quarter, from $0.16 to $0.18. Year-to-date Diagnostics revenues advanced 6% (4% on a constant currency basis), while Life Science revenues increased 8% (6% on a constant currency basis). Non-GAAP diluted earnings per share for the nine-month period were $0.54, compared to $0.53 a year ago.
Our Diagnostics Segment performed respectably during the quarter. Product line highlights include single-digit growth in our *H. pylori* product line, and double-digit growth in our respiratory and Magellan lead testing product lines. This growth was largely offset by declines in our *C. difficile* and foodborne product lines. We are encouraged by the fiscal year-to-date revenue growth of 6% (4% on a constant currency basis). Furthermore, we remain committed to working closely with the FDA regarding the use of venous blood with Magellan’s LeadCare® Testing Systems. Enhancements to Magellan’s quality system continue, as does work with the FDA in efforts to regain our claim for use of venous blood on the testing systems.
Our Life Science Segment continues to perform well, with our molecular and immunological reagents product lines posting revenue growth of 8% and 9%, respectively, in the quarter. Performance in Asia-Pacific markets, led by our growth efforts in China, continues to be strong with revenues in China increasing nearly 20% over the comparable quarter of the prior fiscal year. Life Science is having a good year with revenue growth of 8% (6% on a constant currency basis) year-to-date and is progressing with the reorganization of its commercial units to better leverage the full Life Science menu to customers.
We recently submitted our de novo 510(k) for ***illumi***gene CMV to the FDA, and we expect to launch our ***illumi***gene CMV, the first molecular test to detect cytomegalovirus in newborns, in early calendar year 2019. We continue to work on our *H. pylori*/Clarithromycin resistance assay and have identified improvements that we believe will enhance the workflow and the cost effectiveness of the test for the customer. In light of these changes, we are re-evaluating our clinical trial dates. We are making modifications to our Curian™ offering, which leverages both optical and fluorescent technologies. We believe these modifications will accelerate adoption with an expanded menu of multiple assays, and Curian is now expected to launch in early calendar year 2020.
We have been focused on streamlining the organization and consolidating activities within our two segments, Diagnostics and Life Science. These efforts are starting to yield savings and efficiencies, which we intend to reinvest in the business. We continue to look at opportunities to further improve operational efficiencies across the business. Additionally, we are evaluating and pursuing opportunities to improve and expand our competitive position in both the Diagnostics and Life Science segments. Our research and development program is a critical element of this effort and we are currently evaluating all aspects of our R&D program and are committed to increasing its effectiveness. We look forward to sharing the core results of this process in the fall.”
Mr. Kenny continued, “As we enter the fourth quarter of fiscal 2018, both our Diagnostics and Life Science segments remain on track to perform in-line with expectations. We are reaffirming our revised fiscal 2018 guidance. Looking ahead to fiscal 2019 and beyond, we remain enthusiastic about the prospects for Meridian as we prepare to move forward on a clear growth strategy.”
TAX REFORM IMPACT
Our GAAP net earnings for the year include the effects of the U.S. Tax Cuts and Jobs Acts (the “tax reform act”) signed into law during December 2017. Included therein are (i) a benefit of approximately $2.4 million ($0.05 per diluted share) primarily related to the re-measurement of our U.S. net deferred tax liabilities ($1.7 million, or $0.04 per diluted share, in the first quarter and $0.7 million, or $0.02 per diluted share, in the third quarter); and (ii) a provisional charge of approximately $850,000 ($0.02 per diluted share) in the first quarter for the mandatory U.S. repatriation transition tax. Excluding these items, we are estimating our effective tax rate to be in the range of 27% to 28% on a normalized basis during fiscal 2018. Approximately 25% of our cash is held outside of the U.S. At this time, we do not expect to repatriate large amounts of cash.
Looking to fiscal 2019 and beyond, upon completing strategic planning activities this summer, we will determine the extent to which future savings resulting from tax reform will be utilized to increase R&D spending and for other initiatives, such as to fund increases in entry level wages.
CASH DIVIDEND MATTERS
The Board of Directors declared the regular quarterly cash dividend of $0.125 per share for the third quarter ended June 30, 2018. The dividend is payable on August 20, 2018 to shareholders of record as of the close of business on August 10, 2018. Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings on both a GAAP and non-GAAP basis, cash flow requirements and future business developments, including any acquisitions and other factors deemed relevant by the Board.
FISCAL 2018 GUIDANCE REAFFIRMED
For the fiscal year ending September 30, 2018, management expects net revenues to be in the range of $209 million to $214 million, and non-GAAP net earnings per diluted share to be between $0.69 and $0.72 per share. Non-GAAP earnings per share for fiscal year 2018 excludes the impact of litigation costs, executive transition and realignment costs, potential future costs associated with the realignment of our organizational structure and the one-time benefit of tax reform, namely the re-measurement of deferred tax liabilities and the repatriation transition tax. Several of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided.
These per share estimates assume an increase in average shares outstanding from approximately 42.6 million at fiscal 2017 year-end to approximately 42.8 million at fiscal 2018 year-end.
The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2018.
FINANCIAL CONDITION
The Company’s financial condition remains sound. At June 30, 2018, current assets were $140.2 million compared to current liabilities of $24.4 million, resulting in working capital of $115.8 million and a current ratio of 5.7. Cash and equivalents were $57.9 million, and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations, all of which were incurred in connection with the 2016 acquisition of Magellan, totaled $51.3 million as of June 30, 2018.
INTERIM UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2018 and fiscal 2017.
Three Months Ended Nine Months Ended June 30, June 30, 2018 2017 2018 2017Net revenues$ 51,737 $ 50,140 $ 160,471 $ 151,074Cost of sales 19,781 18,994 62,160 57,412Gross profit 31,956 31,146 98,311 93,662 Operating expenses Research and development 4,259 3,964 13,245 11,512Selling and marketing 8,504 7,961 25,962 23,645General and administrative 8,377 8,289 26,155 23,302Executive transition and realignment costs 913 – 5,105 –Litigation costs 1,168 – 3,370 –Goodwill impairment charge – 6,628 – 6,628Total operating expenses 23,221 26,842 73,837 65,087 Operating income 8,735 4,304 24,474 28,575Other expense, net (115) (358) (972) (780)Earnings before income taxes 8,620 3,946 23,502 27,795Income tax provision 1,795 3,706 5,087 11,964Net earnings$ 6,825 $ 240 $ 18,415 $ 15,831 Net earnings per basic common share$ 0.16 $ 0.01 $ 0.44 $ 0.38Basic common shares outstanding 42,349 42,203 42,307 42,184 Net earnings per diluted common share$ 0.16 $ 0.01 $ 0.43 $ 0.37Diluted common shares outstanding 42,758 42,593 42,712 42,556
The following table sets forth the unaudited segment data for the interim periods in fiscal 2018 and fiscal 2017 (in thousands).
Three Months Ended Nine Months Ended June 30, June 30, 2018 2017 2018 2017 Net revenues Diagnostics$ 36,368 $ 35,949 $ 113,640 $ 107,529 Life Science 15,369 14,191 46,831 43,545 $ 51,737 $ 50,140 $ 160,471 $ 151,074 Operating Income Diagnostics(1)$ 7,166 $ 914 $ 22,926 $ 17,152 Life Science 3,647 3,388 10,007 11,226 Executive Transition and Realignment
Costs, and Litigation Costs (2,081) – (8,475) – Eliminations 3 2 16 197 $ 8,735 $ 4,304 $ 24,474 $ 28,575
(1) Fiscal 2017 periods include a goodwill impairment charge of $6.6 million.
NON-GAAP FINANCIAL MEASURES
In this press release, we have supplemented our reported GAAP financial information with information on net earnings, basic earnings per share and diluted earnings per share excluding the effects of executive transition and realignment costs, litigation costs, goodwill impairment charge, and certain one-time tax effects of the tax reform act. We have provided in the tables below reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of these non-routine items, for the third quarters and nine month periods ended June 30, 2018 and June 30, 2017.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
THIRD QUARTER AND NINE MONTH YEAR-TO-DATE
GAAP TO NON-GAAP RECONCILATION TABLES
(In Thousands, Except per Share Data)
Three Months Nine Months Ended June 30, Ended June 30, 2018 2017 2018 2017 Net Earnings – U.S. GAAP basis$ 6,825 $ 240 $ 18,415 $ 15,831 Executive transition and realignment costs\* 685 – 3,737 – Litigation costs\* 864 – 2,467 – Goodwill impairment charge – 6,628 – 6,628 One-time benefit from tax law change (652) – (2,347) – Repatriation transition tax – – 854 – Adjusted Earnings$ 7,722 $ 6,868 $ 23,126 $ 22,459 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.16 $ 0.01 $ 0.44 $ 0.38 Executive transition and realignment costs 0.02 – 0.09 – Litigation costs 0.02 – 0.06 – Goodwill impairment charge – 0.16 – 0.16 One-time benefit from tax law change (0.02) – (0.06) – Repatriation transition tax – – 0.02 – Adjusted Basic EPS$ 0.18 $ 0.16\*\*$ 0.55 $ 0.53\*\* Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.16 $ 0.01 $ 0.43 $ 0.37 Executive transition and realignment costs 0.02 – 0.09 – Litigation costs 0.02 – 0.06 – Goodwill impairment charge – 0.16 – 0.16 One-time benefit from tax law change (0.02) – (0.05) – Repatriation transition tax – – 0.02 – Adjusted Diluted EPS$ 0.18 $ 0.16\*\*$ 0.54\*\*$ 0.53 \* Net of tax. \*\* Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with the ramp up of new products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs, including legal expenses, and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar, compliance with anti-corruption laws, tariffs, trade wars, and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. Meridian cannot predict the outcome of changes in business strategy or plans, legal proceedings or developments. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=L1MFJh76yZINoe4FzJ0VWkbUrht_PZV9oHukXYJZkCoMgFGGVhLZhJhZqZ6kvClnZ0NyZEmnYdHfgXP2Xj8i8WI-YtwzpsFMn8ygTJ4XWP9Esyqe-5nzuMOXTzb_ON0z "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Third Quarter 2019 Operating Results](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-third-quarter-2019-operating-results/)
**Published:** July 30, 2019
**Author:** hamza
**Content:**
CINCINNATI, Ohio, July 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019.
**Third Quarter 2019 Highlights (Comparison to Third Quarter Fiscal 2018):**
- Consolidated revenue decreased 6% to $48.4 million (5% decrease in constant-currency)
- Diagnostics segment revenues decreased 9% to $33.1 million (8% decrease in constant-currency)
- Life Science segment revenues were flat at $15.3 million (1% growth in constant-currency)
- Reported GAAP operating income of $6.5 million (including $2.5 million of costs associated with acquisition activities, restructuring activities and selected legal proceedings), as compared to $8.7 million last year (which included $2.1 million of costs associated with restructuring activities and selected legal proceedings)
- Reported GAAP EPS of $0.12 per diluted share and Adjusted EPS of $0.16 per diluted share (see non-GAAP financial measure reconciliation below)
- Operating results include one month of activity related to the acquisition of the business of GenePOC, completed on June 3, 2019
**June Year-to-Date Fiscal 2019 Highlights (Comparison to June Year-to-Date Fiscal 2018):**
- Consolidated revenue decreased 6% to $150.2 million (5% decrease in constant-currency)
- Diagnostics segment revenues decreased 9% to $103.3 million (8% decrease in constant-currency)
- Life Science segment revenues were flat at $46.9 million (2% growth in constant-currency)
- Reported GAAP operating income of $26.9 million (including $4.5 million of costs associated with acquisition activities, restructuring activities and selected legal proceedings), as compared to $24.5 million last year (which included $8.5 million of costs associated with restructuring activities and selected legal proceedings)
- Reported GAAP EPS of $0.47 per diluted share and Adjusted EPS of $0.55 per diluted share (see non-GAAP financial measure reconciliation below)
**Third Quarter Fiscal 2019 Results (Comparison to Third Quarter Fiscal 2018)**
Consolidated revenue for the third quarter of fiscal 2019 decreased 6% to $48.4 million, compared to $51.7 million last year. Diagnostics segment revenues were down 9%, while Life Science segment revenues were relatively flat for the third quarter. Our Diagnostics segment experienced continued competitive pressures in a number of our molecular products, particularly *C. difficile*, and volume and pricing declines in certain gastrointestinal products. Our Life Science segment revenues for the quarter reflected double-digit growth in the EMEA region as well as China, but this was offset by softness in the Americas region.
Reported operating income for the third quarter of fiscal 2019 decreased 26% to $6.5 million. SG&A expenses were down $2.1 million, largely due to the effects of last year’s organizational stream-lining activities, lower FDA Quality System remediation costs for our Billerica manufacturing site and lower incentive compensation costs. Research and development expenses increased modestly for the quarter, primarily due to the addition of costs associated with the acquisition of GenePOC’s business. Reported operating income for the quarter also included $2.5 million of costs for acquisition activities, restructuring activities and selected legal proceedings. Excluding the effects of such costs, adjusted operating income achieved a margin of 18%, as compared to 21% on the same basis for the third quarter of fiscal 2018.
GAAP net earnings for the third quarter of fiscal 2019 totaled $5.1 million, or $0.12 per diluted share, down 26% and 25%, respectively. On an adjusted basis (non-GAAP), earnings were $7.0 million, or $0.16 per diluted share, down 10% and 11%, respectively. Adjusted basis excludes the effects of costs of acquisition activities, restructuring activities and selected legal proceedings.
Jack Kenny, Chief Executive Officer, commented, “While we were anticipating a challenging third quarter, our overall sales performance came in at the lower end of our expectations. The Life Science segment was flat in the quarter, which was below our expectations. The Diagnostics segment, which had a 9% revenue decline, was in line with our expectations. Our acquisition of the GenePOC business and the revogene™ molecular diagnostics platform is intended to directly address competitive pressures and trends in the molecular portion of our Diagnostics product portfolio. We are optimistic that our integration activities are on track, and early customer feed-back for the revogene™ molecular diagnostics platform has been positive. Although we are early-on in the process, we are actively converting customers from our alethia™ system to the revogene™ system, and results to-date are ahead of expectations. Our development efforts on our Diagnostics instrument platforms, revogene™, Curian™ and PediaStat™, are making significant progress, and over the next 12-18 months, we expect to submit to the FDA multiple 510k applications to help us drive future growth. For our Life Science segment, despite the relatively flat revenue performance during the quarter and the first nine months, customer order activity in July signals that our fourth quarter will yield positive revenue growth, with strong contributions from China. Our new lyophilization-ready qPCR and RT-qPCR mixes are showing meaningful revenue contributions as customers recognize the advantages of room-temperature shipping and storage and extended shelf life. We continue to refine and optimize our organizational structure for both business segments to ensure customer focus and cost efficiency. We effectively managed our expenses without compromising future growth initiatives, which led to better than expected earnings per share in the quarter.”
**Tax Reform Impact** Our net earnings for both fiscal year-to-date periods include the effects of the tax reform act signed into law during December 2017. The fiscal 2019 year-to-date period reflects the lower U.S. federal tax rate of 21% being fully phased-in, and the first nine months of fiscal 2018 includes: (i) a benefit of $2.3 million ($0.05 per diluted share) primarily related to the re-measurement of U.S. net deferred tax liabilities based on the new federal rate; and (ii) a charge of $0.9 million ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax. The effective tax rates for the third quarter and first nine months of fiscal 2019 were 22%, and 23%, respectively.
**Fiscal 2019 Guidance Including Effects of the Recently Completed Acquisition of GenePOC Business**
For fiscal 2019, we expect our consolidated revenues to be down approximately 6%, with our Diagnostics segment revenues being down high-single-digits and our Life Science segment revenues being up low-single-digits. We expect our adjusted (non-GAAP) operating margin to be approximately 18% to 19%, and our adjusted (non-GAAP) earnings per share on a diluted basis to be $0.63 to $0.65 per share. Adjusted earnings per share on a diluted basis assumes a tax rate of approximately 23%. Adjusted (non-GAAP) operating margin and earnings per share on a diluted basis excludes the effects of costs associated with acquisition activities, restructuring activities and selected legal proceedings. See non-GAAP financial measure reconciliation below.
**Financial Condition**
The Company’s financial condition remains sound. At June 30, 2019, cash and equivalents were $55.2 million and the Company had $49.2 million of borrowing capacity under its $125.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $75.8 million as of June 30, 2019.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Interim Chief Financial Officer and Chief Accounting Officer, will host a conference call on Tuesday, July 30, 2019 beginning at 10:00 a.m. Eastern Time to discuss the third quarter financial results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5392886. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on July 30, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5392886.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2019 and fiscal 2018.
Three Months Ended Nine Months Ended June 30, June 30, 2019 2018 2019 2018 Net revenues$48,440 $51,737 $150,168 $160,471 Cost of sales 20,181 19,775 60,999 61,930 Gross profit 28,259 31,962 89,169 98,541 Operating expenses Research and development 4,594 4,264 12,294 13,159 Selling and marketing 6,747 8,502 21,221 25,963 General and administrative 8,002 8,380 24,288 26,470 Acquisition-related costs 473 – 1,445 – Restructuring costs 1,801 913 1,701 5,105 Litigation costs 178 1,168 1,370 3,370 Total operating expenses 21,795 23,227 62,319 74,067 Operating income 6,464 8,735 26,850 24,474 Other income (expense), net 14 (115) (649) (972) Earnings before income taxes 6,478 8,620 26,201 23,502 Income tax provision 1,399 1,795 5,922 5,087 Net earnings$5,079 $6,825 $20,279 $18,415 Net earnings per basic common share$0.12 $0.16 $0.48 $0.44 Basic common shares outstanding 42,639 42,349 42,526 42,307 Net earnings per diluted common share$0.12 $0.16 $0.47 $0.43 Diluted common shares outstanding 42,910 42,758 42,907 42,712
Three Months Ended Nine Months Ended June 30, June 30, 2019 2018 2019 2018**Adjusted Financial Measures
(see non-GAAP financial measure reconciliation below) Operating income$8,916 $10,816 $31,366 $32,949 Net earnings 6,960 7,722 23,743 23,126 Net earnings per diluted common share$0.16 $0.18 $0.55 $0.54
**Condensed Balance Sheet Data**
June 30, 2019 2018 Cash and equivalents$ 55,192 $ 57,930 Working capital 117,567 115,778 Long-term debt 75,824 51,297 Shareholders’ equity 188,553 175,127 Total assets 322,436 253,983
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2019 and fiscal 2018 (in thousands).
Three Months Ended Nine Months Ended June 30, June 30, 2019 2018 2019 2018 Net Revenues – By Product Platform/Type Diagnostics Molecular assays$5,937 $7,509 $20,371 $26,200 Immunoassays & blood chemistry assays 27,181 28,859 82,912 87,440 Total Diagnostics 33,118 36,368 103,283 113,640Life Science Molecular reagents 5,495 6,049 17,495 17,882 Immunological reagents 9,827 9,320 29,390 28,949 Total Life Science 15,322 15,369 46,885 46,831 Total Net Revenues$48,440 $51,737 $150,168 $160,471
Three Months Ended Nine Months Ended June 30, June 30, 2019 2018 2019 2018 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$17,232 $20,212 $52,024 $59,631 Respiratory illness assays 5,708 5,749 21,242 22,779 Blood chemistry assays 4,750 5,005 13,510 13,528 Other 5,428 5,402 16,507 17,702 Total Diagnostics 33,118 36,368 103,283 113,640 Life Science Americas 4,369 5,500 14,347 15,875 EMEA 6,389 5,756 21,608 18,307 ROW 4,564 4,113 10,930 12,649 Total Life Science 15,322 15,369 46,885 46,831 Total Net Revenues$48,440 $51,737 $150,168 $160,471 OPERATING INCOME Diagnostics$5,078 $8,591 $20,455 $25,701 Life Science 4,289 3,706 14,781 10,286 Corporate (2,926) (3,646) (8,450) (11,744) Eliminations 23 84 64 231 Total Operating Income$6,464 $8,735 $26,850 $24,474 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of acquisition-related costs, restructuring costs, litigation costs, and certain one-time tax effects of the tax reform act, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the third quarters and nine-month periods ended June 30, 2019 and June 30, 2018.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**THIRD QUARTER AND NINE MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Nine Months Ended June 30, Ended June 30, 2019 2018 2019 2018Operating Expenses – U.S. GAAP basis$21,795 $23,227 $62,319 $74,067 Acquisition-related costs (473) – (1,445) – Restructuring costs (1,801) (913) (1,701) (5,105) Litigation costs (178) (1,168) (1,370) (3,370) Adjusted Operating Expenses$19,343 $21,146 $57,803 $65,592 Operating Income – U.S. GAAP basis$6,464 $8,735 $26,850 $24,474 Acquisition-related costs 473 – 1,445 – Restructuring costs 1,801 913 1,701 5,105 Litigation costs 178 1,168 1,370 3,370 Adjusted Operating Income$8,916 $10,816 $31,366 $32,949 Net Earnings – U.S. GAAP basis$5,079 $6,825 $20,279 $18,415 Acquisition-related costs \* 363 – 1,108 – Restructuring costs \* 1,381 685 1,305 3,737 Litigation costs \* 137 864 1,051 2,467 One-time benefit from tax law change – (652) – (2,347) Repatriation transition tax – – – 854 Adjusted Earnings$6,960 $7,722 $23,743 $23,126 \* Net of tax.
Three Months Nine Months Ended June 30, Ended June 30, 2019 2018 2019 2018Net Earnings per Basic Common Share – U.S. GAAP basis$0.12 $0.16 $0.48 $0.44 Acquisition-related costs 0.01 – 0.03 – Restructuring costs 0.03 0.02 0.03 0.09 Litigation costs – 0.02 0.02 0.06 One-time benefit from tax law change – (0.02) – (0.06) Repatriation transition tax – – – 0.02 Adjusted Basic EPS$0.16 $0.18 $0.56 $0.55 Net Earnings per Diluted Common Share – U.S. GAAP basis$0.12 $0.16 $0.47 $0.43 Acquisition-related costs 0.01 – 0.03 – Restructuring costs 0.03 0.02 0.03 0.09 Litigation costs – 0.02 0.02 0.06 One-time benefit from tax law change – (0.02) – (0.05) Repatriation transition tax – – – 0.02 Adjusted Diluted EPS \*\*$0.16 $0.18 $0.55 $0.54 \*\* Diluted EPS for Nine Months Ended June 30, 2018 does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dC4HAJC35xQgDLqq3YNyoKnPbulRV_BpEvmlk1U5DSng24g0CkEN9OY-4kot18qSbdZY6yjdOdQ3efScNBo3UPC3CJQmU5ZIy98apYkqaNCyO4B1uzkK7RlYZNfxTAIg)
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-third-quarter-2019-financial-results-conference-call-on-july-30-2019/)
**Published:** July 10, 2019
**Author:** hamza
**Content:**
CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Interim Chief Financial Officer and Chief Accounting Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5392886.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on July 30, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5392886.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Bryan Baldasare
Interim Chief Financial Officer and Chief Accounting Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=5rA-xClqEGKRx1jmhxA3_JZTmsmyWoW9ZRBUJLNeS2F3Na69RrxwCBjwW27Tiskit708xbKHCBuWaWqHVeUm4Yjm5YUaIrIvzzEnWvdlne0fYbCBwUx8_x_BOFAcgztK "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-closing-of-transaction-to-acquire-business-of-genepoc/)
**Published:** June 3, 2019
**Author:** hamza
**Content:**
CINCINNATI, June 03, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Iwe0jFHkfJWRKHl1LRtJJJIV4t0UkEW7rvoqMsDWEeoVH7cdG2ZgcCA0xi26J2bFp1bMKNaOuatBbefpgxakwWqcP66YXncd-ixM21ePW4pcvQIZYun-_1wEG5EV25mw)
**Categories:** Press Release
---
### [Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-second-quarter-2019-operating-results-suspends-quarterly-cash-dividend-and-provides-fiscal-2019-guidance-for-pending-acquisition/)
**Published:** April 30, 2019
**Author:** hamza
**Content:**
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019.
**Second Quarter 2019 Highlights:**
- Total revenue decreased 11% to $50.2 million, as compared to $56.5 million in the second quarter of fiscal 2018 (10% decrease in constant-currency)
- Diagnostics segment revenues decreased 16% to $33.5 million (15% decrease in constant-currency)
- Life Science segment revenues were flat at $16.7 million (2% growth in constant-currency)
- Reported operating income of $9.8 million (including $1.4 million of costs associated with acquisition activities, restructuring activities and litigation), as compared to $7.7 million in the second quarter of fiscal 2018, which included $4.9 million of costs associated with restructuring activities and litigation
- Reported EPS of $0.17 per diluted share and Adjusted EPS of $0.19 per diluted share (see non-GAAP financial measure reconciliation below)
- Quarterly cash dividend suspended in connection with the announcement of the Company’s agreement to acquire the business of GenePOC Inc. and decision to allocate capital to related and other growth initiatives
**Year-to-Date Fiscal 2019 Highlights:**
- Total revenue decreased 6% to $101.7 million, as compared to $108.7 million in same period of fiscal 2018 (also a 6% decrease in constant-currency)
- Diagnostics segment revenues decreased 9% to $70.2 million (also a 9% decrease in constant-currency)
- Life Science segment revenues were flat at $31.6 million (2% growth in constant-currency)
- Reported operating income of $20.4 million (including $2.1 million of costs associated with acquisition activities, restructuring activities and litigation), as compared to $15.7 million in the fiscal 2018 year-to-date period, which included $6.4 million of costs associated with restructuring activities and litigation
- Reported EPS of $0.35 per diluted share and Adjusted EPS of $0.39 per diluted share (see non-GAAP financial measure reconciliation below)
**Second Quarter 2019 Results**
Total revenue for the second quarter of fiscal 2019 decreased 11% to $50.2 million, compared to $56.5 million in the second quarter of 2018. This decrease was driven by a 16% decrease in Diagnostics business unit revenues from $39.8 million to $33.5 million, as a result of continued competitive pressures in a number of our molecular products, particularly *C. difficile*, weaker respiratory product demand, and volume and pricing declines in certain gastrointestinal products. Life Science business unit revenues were relatively flat at $16.7 million (a 2% increase on a constant-currency basis compared to the second quarter of 2018), as growth in both Americas and EMEA was largely offset by soft customer order activity in China.
Reported operating income for the second quarter of fiscal 2019 increased $2.2 million to $9.8 million from the second quarter of fiscal 2018. This increase resulted from a $7.4 million decrease in operating expenses including a $3.5 million decrease in acquisition, restructuring and litigation costs, more than offsetting the lower amount of gross profit from decreased revenues. Excluding the effects of the acquisition, restructuring and litigation costs in each period, operating income decreased 11% to $11.2 million. R&D spending was down in the quarter compared to second quarter of fiscal 2018, due to the timing of certain product development project expenses including clinical trial expenses incurred in the fiscal 2018 second quarter for the cCMV test, which launched this quarter. Sales and marketing expenses in the quarter were down due to fiscal 2018 organization streamlining initiatives, as well as lower sales commissions as a result of lower revenues. General and administrative expenses were down in the quarter, also due largely to the effects of organizational streamlining initiatives implemented in fiscal 2018, but also due to lower FDA Quality System remediation costs for the Billerica manufacturing facility and lower incentive compensation costs. Fiscal 2019 second quarter operating income in Diagnostics decreased 29%, due entirely to the decrease in revenues, as spending was down significantly. Operating income for the second quarter of fiscal 2019 was up 47% in Life Science, driven by the continued benefit of fiscal 2018 restructuring activities, including a lower-cost commercial organization.
Net earnings for the second quarter of fiscal 2019 totaled $7.1 million, or $0.17 per diluted share, as compared to $5.3 million, or $0.12 per diluted share, for the second quarter of fiscal 2018. On an adjusted basis (non-GAAP), earnings were $8.2 million, or $0.19 per diluted share, as compared to $8.9 million, or $0.21 per diluted share, for the second quarter of fiscal 2018, decreases of 8% and 10%, respectively. Adjusted basis excludes the effect of acquisition transaction and litigation costs in the fiscal 2019 quarter and restructuring and litigation costs in the fiscal 2018 quarter.
Jack Kenny, Chief Executive Officer, commented, “While I am disappointed in our results for the second quarter for both our Diagnostics and Life Science business units, I am excited about the shift that our pending acquisition of GenePOC represents for Meridian. The addition upon closing of GenePOC and its revogene™ molecular diagnostics platform is a critical step in our strategy to invest in new products and technologies. We believe this
transaction and other initiatives are necessary to stabilize our Diagnostics business and re-position the Company for sustainable, long-term growth. The suspension of our quarterly cash dividend represents a change in our capital allocation philosophy to support this strategy and increase re-investment in the business. We recognize the near-term trends and competitive pressures in our business and we have recently reorganized our Diagnostics commercial organization as an additional step to help address these pressures. For our Life Science business unit, we are expecting customer order activity in China to improve over the back half of the year, but not to previously expected levels. Good growth performance this quarter in the Americas and EMEA, however, are evidence that the Life Science business is well-positioned, despite the recent unforeseen weakness in China.”
**Fiscal 2019 First Half Results**
Total revenue for the first half of fiscal 2019 totaled $101.7 million, a 6% decrease from the $108.7 million achieved in fiscal 2018. This decrease reflects a decline of 9% (also 9% on a constant-currency basis) to $70.2 million in Diagnostics, driven largely by competitive pressures in molecular assays, particularly *C. difficile*, volume and pricing declines in gastrointestinal products, and volume declines in respiratory assays. Revenues in the Life Science business unit were relatively flat (up 2% on a constant-currency basis), reflecting softness in customer order activity in China.
During the first half of fiscal 2019, operating income totaled $20.4 million, an increase of 30% or $4.6 million. This increase primarily resulted from lower expenses for restructuring and litigation activities. Excluding the effects of the acquisition, restructuring and litigation costs in each period, operating income increased 1% to $22.5 million compared to the first half of fiscal 2018, despite the decline in revenues. Operating expenses were broadly lower in all categories across both business units, which favorably affected operating income, despite the revenue decline in Diagnostics.
Net earnings totaled $15.2 million, or $0.35 per diluted share, for the first half of fiscal 2019, as compared to $11.6 million, or $0.27 per diluted share, for the same period in fiscal 2018. On an adjusted basis, earnings were $16.8 million, or $0.39 per diluted share, increases of 9% and 8%, respectively, over fiscal 2018’s adjusted earnings of $15.4 million, or $0.36 per diluted share. Adjusted earnings exclude the effect of acquisition transaction and litigation costs in the first half of fiscal 2019, and restructuring and litigation costs, and certain one-time tax effects of the tax reform act, in the same period in fiscal 2018 period (see non-GAAP financial measure reconciliation below).
**Tax Reform Impact**
Our net earnings for both fiscal year-to-date periods include the effects of the tax reform act signed into law during December 2017. The fiscal 2019 year-to-date period reflects the lower U.S. federal tax rate of 21% being fully phased-in, and the first six months of fiscal 2018 includes: (i) a benefit of $1.7 million ($0.04 per diluted share) primarily related to the re-measurement of U.S. net deferred tax liabilities based on the new federal rate;
and (ii) a charge of $0.9 million ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax. The effective tax rate for both the second quarter and first six months of fiscal 2019 was 23%.
**Cash Dividend Matters**
As part of the Company’s regular evaluation of its capital allocation, upon evaluation of earnings, cash flow requirements and future business developments, including the pending acquisition of the business of GenePOC Inc., and other factors deemed relevant, the Board of Directors, at its discretion, suspended the Company’s quarterly cash dividend effective immediately. This action was taken in order to deploy cash into new product development activities for the revogene™ molecular diagnostics platform among other investments and to preserve capital resources and liquidity for general corporate purposes.
**Fiscal 2019 Guidance Including Effects of the Pending Acquisition**
The Company provided revised guidance for full year fiscal 2019 in its press release dated April 2, 2019. Excluding amortization expense, the Company expects the transaction to add approximately $4 million – $5 million in operating expenses in fiscal 2019. The Company currently estimates that the transaction will be dilutive to full year fiscal 2019 EPS by approximately $0.10 to $0.12 per share, based on current purchase accounting estimates.
**Financial Condition**
The Company’s financial condition remains sound. At March 31, 2019, cash and equivalents were $66.1 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility. The Company’s bank-debt obligations totaled $47.9 million as of March 31, 2019.
In connection with the pending acquisition of GenePOC, the Company also expects to execute a new five-year $125 million revolving credit facility that would replace its existing $30 million credit facility. The new credit facility is expected to be secured by substantially all of the Company’s assets and include certain restrictive financial covenants. The Company expects to use this new facility and cash on-hand to repay the existing term loan outstanding at March 31, 2019 and fund the closing payment for the acquisition of GenePOC.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Eric Rasmussen, Chief Financial Officer, will host a conference call on Tuesday, April 30, 2019 beginning at 10:00 a.m. Eastern Time to discuss the second quarter financial results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3893028. A replay will be available for 14 days beginning at 1:00p.m. Eastern Time on April 30, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3893028.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2019 and fiscal 2018.
Three Months Ended Six Months Ended March 31, March 31, 2019 2018 20192018Net revenues$50,248 $56,451 $101,728 $108,734 Cost of sales 20,910 21,882 40,818 42,155 Gross profit 29,338 34,569 60,910 66,579 Operating expenses Research and development 3,816 4,491 7,700 8,895 Selling and marketing 6,911 8,647 14,474 17,461 General and administrative 7,388 8,842 16,286 18,090 Acquisition and restructuring costs 785 3,458 872 4,192 Litigation costs 603 1,453 1,192 2,202 Total operating expenses 19,503 26,891 40,524 50,840 Operating income 9,835 7,678 20,386 15,739 Other expense, net (588) (454) (663) (857)Earnings before income taxes 9,247 7,224 19,723 14,882 Income tax provision 2,153 1,936 4,523 3,292 Net earnings$7,094 $5,288 $15,200 $11,590 Net earnings per basic common share$0.17 $0.12 $0.36 $0.27 Basic common shares outstanding 42,496 42,323 42,472 42,289 Net earnings per diluted common share$0.17 $0.12 $0.35 $0.27 Diluted common shares outstanding 42,946 42,732 42,925 42,693 **Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$11,223 $12,589 $22,450 $22,133 Net earnings 8,159 8,863 16,783 15,404 Net earnings per diluted common share$0.19 $0.21 $0.39 $0.36
**Condensed Balance Sheet Data**
March 31, 2019 2018Cash and equivalents$66,097 $56,400Working capital 120,583 113,691Long-term debt 47,946 52,414Shareholders’ equity 181,645 174,336Total assets 253,964 254,547 **Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2019 and fiscal 2018 (in thousands).
Three Months Ended Six Months Ended March 31, March 31, 2019 2018 2019 2018Net Revenues – By Product Platform/Type Diagnostics Molecular assays$7,132 $9,976 $14,434 $18,692 Immunoassays & blood chemistry assays 26,368 29,806 55,731 58,580 Total Diagnostics 33,500 39,782 70,165 77,272Life Science Molecular reagents 5,390 6,143 11,998 11,832 Immunological reagents 11,358 10,526 19,565 19,630 Total Life Science 16,748 16,669 31,563 31,462 Total Net Revenues$50,248 $56,451 $101,728 $108,734 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$16,177 $19,149 $34,792 $39,419 Respiratory illness assays 7,553 9,543 15,534 17,029 Blood chemistry assays 4,330 4,257 8,760 8,523 Other 5,440 6,833 11,079 12,301 Total Diagnostics 33,500 39,782 70,165 77,272Life Science Americas 5,453 5,121 9,975 10,373 EMEA 7,901 7,478 15,376 12,659 ROW 3,394 4,070 6,212 8,430 Total Life Science 16,748 16,669 31,563 31,462 Total Net Revenues$50,248 $56,451 $101,728 $108,734 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
Three Months Ended Six Months Ended March 31, March 31, 2019 2018 2019 2018OPERATING INCOME Diagnostics $7,561 $10,684 $16,346 $19,310 Life Science 5,361 3,638 10,492 6,580 Corporate (3,101) (6,723) (6,493) (10,334)Eliminations 14 79 41 183 Total Operating Income $9,835 $7,678 $20,386 $15,739
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of acquisition transaction costs, restructuring costs, litigation costs, and certain one-time tax effects of the tax reform act, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the second quarters and six month periods ended March 31, 2019 and March 31, 2018.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**SECOND QUARTER AND SIX MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILATION TABLES**
(In Thousands, Except per Share Data)
Three Months Six Months Ended March 31, Ended March 31, 2019 2018 2019 2018 Operating Expenses – U.S. GAAP basis$19,503 $26,891 $40,524 $50,840 Acquisition and restructuring costs (785) (3,458) (872) (4,192) Litigation costs (603) (1,453) (1,192) (2,202) Adjusted Operating Expenses$18,115 $21,980 $38,460 $44,446 Operating Income – U.S. GAAP basis$9,835 $7,678 $20,386 $15,739 Acquisition and restructuring costs 785 3,458 872 4,192 Litigation costs 603 1,453 1,192 2,202 Adjusted Operating Income$11,223 $12,589 $22,450 $22,133 Net Earnings – U.S. GAAP basis$7,094 $5,288 $15,200 $11,590 Acquisition and restructuring costs \* 602 2,517 669 3,052 Litigation costs\* 463 1,058 914 1,603 One-time benefit from tax law change – – – (1,695) Repatriation transition tax – – – 854 Adjusted Earnings$8,159 $8,863 $16,783 $15,404 Net Earnings per Basic Common Share – U.S. GAAP basis$0.17 $0.12 $0.36 $0.27 Acquisition and restructuring costs 0.01 0.06 0.02 0.07 Litigation costs 0.01 0.02 0.02 0.04 One-time benefit from tax law change – – – (0.04) Repatriation transition tax – – – 0.02 Adjusted Basic EPS$0.19 $0.21 \*\*$0.40 $0.36
Three Months Six Months Ended March 31, Ended March 31, 2019 2018 2019 2018Net Earnings per Diluted Common Share – U.S. GAAP basis$0.17 $0.12 $0.35 $0.27 Acquisition and restructuring costs 0.01 0.06 0.02 0.07 Litigation costs 0.01 0.02 0.02 0.04 One-time benefit from tax law change – – – (0.04) Repatriation transition tax – – – 0.02 Adjusted Diluted EPS$0.19 $0.21 \*\*$0.39 $0.36 \*Net of tax. \*\*Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues,” “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=E0tI4X3CuDmMoFkmu3mCqAKygCcROLxg7Ju63xiig8jlzD4jASbJyqorQ1INmWA8320ESfeBq1ayqQD4zM0Z8B_uvWhJVolZ4P6D0y0iZG70OBgW0SLf-Gm9wjD-0Pxf)
**Categories:** Press Release
---
### [Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-agreement-to-acquire-business-of-genepoc-adds-state-of-the-art-molecular-diagnostics-platform/)
**Published:** April 30, 2019
**Author:** hamza
**Content:**
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. Founded in 2007, GenePOC has approximately 100 employees and generated total revenues of less than $1 million in calendar 2018. Meridian has agreed to make a cash payment at closing of the transaction of $50 million with future payments totaling up to an additional $70 million contingent upon the successful achievement of certain technical development milestones and sales thresholds.
**Strategic Fit and Rationale**
With the acquisition, Meridian will be getting GenePOC’s state-of-the art revogene™ molecular diagnostics platform, which offers sample to result testing for single tests, as well as flexible multiplexing capability. The Company believes revogene™ is a perfect fit with Meridian’s stated strategy to provide gastrointestinal disease and core respiratory illness diagnostics solutions for the diverse needs of complex medical health systems. revogene™ is an FDA-cleared platform that currently has three FDA-cleared assays, including *C. difficile*, Group A *Strep*, and Group B *Strep*. Those three assays comprise a vast majority of Meridian’s current total molecular diagnostics sales, thus enabling it to immediately offer this new platform and technology to existing customers seeking better workflow and less hands-on time than Meridian’s current Alethia™ molecular platform can provide. Over time, through its multiplexing capability, revogene™ is expected to allow Meridian to also offer its customers smart panel solutions currently in development and planning.
Jack Kenny, Chief Executive Officer, commented, “We are very excited to be adding the GenePOC technology and team to Meridian. GenePOC provides an exciting new state-of-the-art molecular diagnostics platform to our Diagnostics portfolio. This is a critical element of our strategy to re-position our Diagnostics business for sustainable long-term growth. GenePOC’s revogene™ platform is an excellent fit for our customers and strategy to offer gastrointestinal-focused and other targeted diagnostic solutions to meet the diverse needs of today’s more complex health care system. We welcome the GenePOC team to the Meridian family and look forward to leveraging Meridian’s strong and established commercial infrastructure to offer revogene™ and its menu of assays to our current and new customers.”
**Summary Transaction Terms and Impact**
The cash-free/debt-free purchase price has a maximum potential value of $120 million, with $50 million to be paid at closing (subject to a holdback and working capital adjustment), subsequent payments of up to $20 million in Meridian’s fiscal 2021 based on the achievement of certain technical development milestones, and a final payment of up to $50 million in fiscal 2023 based on both the sales performance of certain molecular assays and their achievement of minimum profit margin thresholds.
Excluding amortization expense, the Company expects the transaction to add approximately $4 – $5 million in operating expenses in fiscal 2019 and $9 – $10 million in fiscal 2020, both net of planned cost synergies. R&D Teams in both Quebec City and Cincinnati will continue and ramp up work to develop new assays for revogene™ and meaningfully expand the menu of product offerings. As a result, the Company expects R&D expense in the Diagnostics business to increase to the mid-teens as a percent of sales. The Company expects the transaction to provide a net positive contribution to run rate molecular sales and Company EBITDA starting in fiscal 2021.
The transaction is subject to certain closing conditions of a transaction of this nature. PNC Bank has committed financing and will lead with Fifth Third Bank a transaction for a new $125 million revolving line of credit to finance the acquisition and re-finance Meridian’s current outstanding debt. The acquisition will also be financed with cash. The Company expects the transaction to close no later than early fourth quarter of fiscal 2019.
**Conference Call**
Meridian is holding a conference call at 10:00 a.m. Eastern Time today to review the transaction and answer questions, as well as report its fiscal second quarter results. To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3893028. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on April 30, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3893028.
**Cautionary Statement Regarding Forward-Looking Statements**
Certain statements in this communication regarding the proposed acquisition of the business of GenePOC by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding Meridian’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions, and the negative thereof, are intended to identify forward-looking statements.
All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of Meridian, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the diversion of management time on transaction-related issues; ability to successfully integrate the businesses; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian’s filings with the SEC and available through the SEC’s Electronic Data Gathering and Analysis Retrieval system at [www.sec.gov](https://www.globenewswire.com/Tracker?data=HWLLyZYPK8AoGUFkjD-sq2P8VSGnnRtI-D9SB_6opxehWR38RwVLwnjgiTLlI0CoXcsxx6ec85GIx9rZNm85Zg== "www.sec.gov"), including Meridian’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=ikROHhla8jA_Y3yGI3QCpbPS4iaU3-49fMickRqIw0nJP7JVt5q8MJMT8Dkz2GzzKb54IRuAL5ugOdIpTCvgkh-Md5wSB9dcFVOfmhd_DiMVggB_gJbV3i6AQKMub2vz "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples](https://www.meridianbioscience.com/press-release/meridian-launches-a-new-inhibitor-tolerant-qpcr-reagent-to-significantly-simplify-molecular-diagnostic-workflows-from-crude-samples/)
**Published:** April 18, 2019
**Author:** hamza
**Content:**
CINCINNATI, April 18, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of molecular diagnostic products.
A variety of different inhibitors inherent to clinical and environmental samples can negatively impact the sensitivity and accuracy of a molecular assay. To overcome this, specimens often have to undergo extensive processing prior to testing. However, extraction technologies are slow and time consuming, impacting the amount of target nucleic acid available for testing and some enzyme inhibitors can co-elute following purification and induce false-negative assay results.
Inhibitor-tolerant qPCR Mix contains a novel DNA polymerase and buffer system, that is designed to reduce the amount of sample processing required for reliable qPCR analysis and can be used for amplification from crude lysates or inhibitor-rich samples such as urine, saliva, cerebral spinal fluid (CSF), whole blood, serum, plasma, feces and plants samples. This makes Inhibitor-tolerant qPCR Mix ideally suited for applications in cancer research, infectious disease, as well as GMO testing, foodborne and waterborne pathogen detection.
Dr. Florent Chang-Pi-Hin, Director, Research and Development, commented, “With the Inhibitor-tolerant qPCR Mix we are giving our customers a highly sensitive qPCR mix for use on crude samples. Removing the need for DNA purification not only reduces the time to results, but also the cost of extraction, while still allowing detection of very low copy number targets.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=omdg1cCjWJAHzDvAIUMFhsf3i90yOKrUFn4OiyET2vKYFi5xH02Alw94a5Bq4us02oAJJNu2BBeyWHaPhb2z8cd7MeL6V-KbbJ0PKNAJI5MlgTJ3EDt2qttd95hxcq_I "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-second-quarter-2019-financial-results-conference-call-on-april-30-2019/)
**Published:** April 10, 2019
**Author:** hamza
**Content:**
CINCINNATI, April 10, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019.
Jack Kenny, Chief Executive Officer, and Eric Rasmussen, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3893028.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on April 30, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3893028.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Eric Rasmussen
Chief Financial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Q9nIcc63ZpphcBNqZd1pbAnThWp_0Bs8J0fninMJyGcN8Xj5y9TCFBEAn63vxeFcwUdaIHrBGkU4ip4r4tRDl2BvwR1_-GaCdXOFNKZh4GB6oc-SIzB1cQxXWeeOClHC "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-preliminary-second-quarter-2019-revenue-results-updates-fiscal-2019-guidance/)
**Published:** April 2, 2019
**Author:** hamza
**Content:**
CINCINNATI, April 02, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for fiscal 2019.
**Preliminary Second Quarter Results** The Company expects second fiscal quarter 2019 revenues to be approximately $50.0 million, compared to $56.5 million in the second fiscal quarter of 2018. This decline is being driven by Diagnostics segment revenues, which are expected to be down approximately 14% to 16% for the quarter, and relatively flat revenues for the Life Science segment compared to the second fiscal quarter of 2018. The Company expects that the operating income impact of this revenue decline will be offset partially through expense management during the quarter supported by organizational streamlining and other actions initiated in fiscal 2018.
The Diagnostics segment experienced greater than anticipated weakness in the quarter, with revenues for molecular platform products down nearly 30% from the second fiscal quarter of 2018 as a result of increasing competitive pressures and revenues for respiratory assays down approximately 20% from the second fiscal quarter of 2018. The weaker demand for respiratory assays was impacted by a lighter flu season compared to a year ago. *H. pylori* product revenues were consistent with expectations, but continued to reflect price reductions implemented at the end of fiscal 2018.
Revenues for the Life Science segment continued to reflect inconsistent ordering patterns for IVD customers in China that carried over from the first fiscal quarter. The conversion of sample and validation sales into higher volume bulk orders in China has been lower than expected, and there is increasing evidence of heightened competition from local suppliers.
**Revised Full Year Fiscal 2019 Guidance** As a result of expected second quarter results, the Company reevaluated its outlook for fiscal 2019. Although the Company continues to pursue new product and commercial initiatives to improve its performance, competitive pressures in the Diagnostics segment, particularly in molecular products, are expected to persist. Furthermore, the Life Science segment is experiencing more uncertain demand in China than expected and continues to work through integration activities that were initiated late last year. The Company also expects to continue to incur costs for legal, restructuring and other activities it would consider to be non-routine and not representative of on-going operating expenses for the business, and is excluding such costs in its guidance. Revised financial guidance for the fiscal year ending September 30, 2019 is as follows:
Consolidated
- Net revenues: down 3% to 6%
- Non-GAAP operating margin: ~17% to ~18%
- Tax rate: 24.5% to 25%
- Non-GAAP earnings per share: $0.60 to $0.65
Diagnostics
- Net revenues: mid to high-single digit decline
- Operating margin: down from FY2018
Life Science
- Net revenues: low to mid-single digit growth
- Operating margin: significant improvement from FY2018
The Company’s projections for GAAP operating income and GAAP net income are currently being reviewed.
**Magellan Remediation Update** As previously disclosed, Meridian’s subsidiary, Magellan Diagnostics, submitted 510(k) applications in December 2018, seeking to reinstate venous blood sample-types for its LeadCare® II, LeadCare® Plus™ and LeadCare Ultra® testing systems. The FDA has informed Magellan that each of these 510(k) applications has been put on Additional Information (AI) hold. Further, while Magellan’s LeadCare testing systems remain cleared for marketing by the FDA for use with capillary blood samples, the FDA advised that it has commissioned a third-party study of Magellan’s LeadCare testing systems using both venous and capillary blood samples. According to the FDA, the results of the field study will be used in conjunction with other information to determine whether further action by FDA and CDC is necessary to protect the public health. Meridian intends to fully cooperate with the FDA as it completes its third-party study and continues to work to complete remediation actions at Magellan’s blood–chemistry manufacturing facility to the FDA’s full and complete satisfaction. Meridian remains confident in the performance of the LeadCare products and believes that they serve a critical role in promoting the public health.
Jack Kenny, Chief Executive Officer, commented, “Revenue growth in both of our business units has been more challenging than we expected this year. After consolidating activities and driving organizational efficiencies in fiscal 2018, we continue our work to execute our strategy and re-position the Company for sustainable growth. Managing this longer-term imperative while facing increased competitive pressures, particularly in our molecular diagnostics business, is likely to remain a challenge for the Meridian team. We will continue to work to streamline and improve the operations, while maintaining and investing in the business in ways that are expected to positively address our competitive weaknesses and yield future growth. We also continue to implement near-term commercial and product initiatives we believe will help to offset pressure in our Diagnostics business and push our Life Science business back to higher growth expectations consistent with our strategy.”
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues,” “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and if not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=IXvCnn4VVCWmB-M0SYAbufpMduoXUisMoDVs-n7qMQPyVUYwcrzty7kr3unTv4Xn2D9kXWjm84IDFM_KiKf5dL0AeGXTU0CxwUNQYFR_eqrBf5D-OhLmud1BP2fXnnF9 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches New Range of Lyo-Ready PCR Mixes](https://www.meridianbioscience.com/press-release/meridian-launches-new-range-of-lyo-ready-pcr-mixes/)
**Published:** February 7, 2019
**Author:** hamza
**Content:**
CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR. These master mixes offer new solutions for developing freeze-dried multiplex assays that can simultaneously detect both RNA and DNA viruses.
Lyo-Ready One-Step RT-qPCR and Lyo-Ready One-Step Viral RT-qPCR are glycerol-free formulations that contain optimized lyophilization excipients, which have been tested with a range of lyophilization protocols and formats, including cakes and beads. Their high performance in multiplex reactions in combination with very fast rehydration times, make them ideally suited for automated high-throughput platforms. Lyo-Ready One-Step Viral RT-qPCR has been specifically developed for amplification of RNA viruses with a high secondary structure.
Molecular diagnostic tests are progressively moving towards a lyophilized format in order to avoid the need for a cool chain, leading to considerable cost savings during shipment and storage. However, there are significant technical challenges in developing an RT-qPCR lyophilization-compatible mix that has the same highly reproducible performance as a ‘wet’ formulation. Building on its expertise in the field of PCR, the life science division of Meridian Bioscience has successfully developed a range of ready-to-use, lyophilization-compatible products to suit this growing demand within the molecular diagnostics industry.
Dr. Lourdes Weltzien, Executive Vice President of Life Science, commented, “We are delighted to announce the release of our new Lyo-Ready One-Step RT-qPCR master mixes. We now have a range of ready-to-use, lyophilization-friendly solutions for our IVD and biotech customers looking to improve the accuracy of their assays, increase operational efficiencies and reduce their overall costs. We remain committed to bringing innovation and quality products to the IVD community.”
For complete information, please visit meridianlifescience.com/molecular-dx-reagents.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=esCHbTsiB-IoLA0nikLiat_etNS2J2OMGFGneIIhSO2bIjtkz3cNykzKHoPJJYQjIp78kTe5MiEkwEKgUUnUBnqogTN0m2ZBL9DtZJzLHxFZ8TRyGXy5p8tSfb6HTmEh "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-fourth-quarter-and-full-year-fiscal-2019-operating-results-and-provides-fiscal-2020-guidance/)
**Published:** November 7, 2019
**Author:** hamza
**Content:**
CINCINNATI, Nov. 07, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019.
**Fourth Quarter 2019 Highlights (Comparison to Fourth Quarter Fiscal 2018):**
- Consolidated revenue decreased 4% to $50.8 million (3% decrease in constant-currency)
- Diagnostics segment revenues decreased 9% to $33.4 million (also a 9% decrease in constant-currency); note that while Diagnostics segment revenues were down compared to the fourth quarter of fiscal 2018, such revenues were relatively flat with our fiscal 2019 third quarter
- Life Science segment achieved a record quarter, with revenues increasing 7% to $17.4 million (9% growth in constant-currency)
- Reported GAAP Operating Margin of 11.5% and Adjusted Operating Margin of 14.9% for the quarter, which includes a full three months of activities in the Diagnostics segment from the acquisition of the GenePOC business
- Reported GAAP EPS of $0.10 per diluted share and Adjusted EPS of $0.13 per diluted share
- Adjusted Operating Margin and Adjusted EPS on a diluted basis excludes costs associated with acquisition-related activities, restructuring activities and selected legal matters (see non-GAAP financial measure reconciliation below)
**Full Fiscal Year 2019 Highlights (Comparison to Full Year Fiscal 2018):**
- Consolidated revenue decreased 6% to $201.0 million (5% decrease in constant-currency)
- Diagnostics segment revenues decreased 9% to $136.7 million (8% decrease in constant-currency)
- Life Science segment revenues increased 2% to $64.3 million (3% growth in constant-currency)
- Reported GAAP Operating Margin of 16.3% and Adjusted Operating Margin of 19.4%, which includes four months of activities in the Diagnostics segment from the acquisition of the GenePOC business
- Reported GAAP EPS of $0.57 per diluted share and Adjusted EPS of $0.68 per diluted share
- Adjusted Operating Margin and Adjusted EPS on a diluted basis excludes costs associated with acquisition-related activities, restructuring activities and selected legal matters (see non-GAAP financial measure reconciliation below)
**Fourth Quarter Fiscal 2019 Results (Comparison to Fourth Quarter Fiscal 2018)**
Consolidated revenue for the fourth quarter of fiscal 2019 decreased 4% to $50.8 million, compared to $53.1 million last year. Diagnostics segment revenues were down 9%, while Life Science segment revenues were up 7%. Our Diagnostics segment experienced continued competitive pressures in a number of our products, particularly *C. difficile* and foodborne, volume and pricing declines in certain gastrointestinal products, and the effects of initially lighter shipments of respiratory products in advance of the upcoming season. Our Life Science segment revenues for the quarter reflected double-digit growth from IVD customers purchasing immunological reagents in the EMEA region as well as China, but this was offset by softness in the distribution channel in the Americas region.
Reported operating income for the fourth quarter of fiscal 2019 was $5.8 million, including operating costs of $3.5 million for the normal activities from the acquisition of the GenePOC business. SG&A expenses were down $0.9 million, largely due to the effects of last year’s organizational stream-lining activities. Research and development expenses increased $2.0 million for the quarter, primarily due to the addition of costs associated with the acquisition of GenePOC’s business and continued development of two revogene™ assays, as well as the completion of clinical trials for our first Curian™ assay, a stool-antigen test for *H. pylori*. Reported operating income for the quarter also included $1.7 million of costs associated with acquisition-related activities, restructuring activities and selected legal matters. Excluding the effects of such costs, adjusted operating income achieved a margin of 15% (see non-GAAP financial measure reconciliation below).
Jack Kenny, Chief Executive Officer, commented, “We are very pleased with our fourth quarter results, which showed significant progress on our strategic direction for both our Diagnostics and Life Science businesses. For the Diagnostics segment, our overall revenue level stabilized commensurate with our third quarter. Conversion of customers from our alethia™ molecular system to the revogene™ system during the first 120 days exceeded our expectations. Instrument placements were approximately 60 during this time period. The revogene™ platform is helping address competitive pressures and has slowed our account losses. Our new product development efforts on our Diagnostic instrument platforms (revogene™, Curian™ and PediaStat™) continue to make progress, and we submitted our first Curian™ assay, a stool-antigen test for *H. pylori*, to the FDA in September. For the Life Science segment, IVD customer orders for immunological reagents were strong as this segment delivered its best revenue-growth quarter for the year. During the quarter we also made refinements to our organizational structure in both business units in order to improve customer focus and cost efficiencies in fiscal 2020.”
**Full Fiscal Year 2019 Results (Comparison to Full Year Fiscal 2018)**
Consolidated revenue for the fiscal year ended September 30, 2019 decreased 6% to $201.0 million, compared to $213.6 million in fiscal 2018. Revenues for our Diagnostics segment decreased 9% (8% on a constant-currency basis) to $136.7 million, driven largely by declines in gastrointestinal assays, which reflected anticipated pricing declines in our *H. pylori* products and continued competitive pressures in our *C. difficile* and foodborne products. Revenues in our Life Science segment grew 2% (3% on a constant-currency basis), reflecting growth in the EMEA region being partially offset by declines in the Americas and Rest of World. Life Science revenues in China increased by approximately 2% on a full-year basis.
During fiscal 2019, reported operating income was $32.7 million, including operating costs of $4.6 million for the normal activities from the acquisition of the GenePOC business. On an adjusted basis (excludes costs associated with acquisition-related activities, restructuring activities and selected legal matters), operating income was $38.9 million and achieved a margin of 19%, which compares to adjusted operating income of $44.6 million and a margin of 21% in fiscal 2018 (see non-GAAP financial measure reconciliation below).
**Tax Reform Impact** Our net earnings for both fiscal year-to-date periods include the effects of the tax reform act signed into law during December 2017. The fiscal 2019 year-to-date period reflects the lower U.S. federal tax rate of 21% being fully phased-in, and fiscal 2018 includes: (i) a benefit of $2.7 million ($0.06 per diluted share) primarily related to the re-measurement of U.S. net deferred tax liabilities based on the new federal rate; and (ii) a charge of $0.9 million ($0.02 per diluted share) for the mandatory U.S. repatriation transition tax. The effective tax rates for both the fourth quarter and full year fiscal 2019 were 23%.
**Fiscal 2020 Guidance**
Our fiscal 2020 guidance reflects significant investments in new product development to continue to refresh our Diagnostics segment’s product lines, including beginning clinical trials for six assays across three instrument platforms (revogene™, Curian™ and PediaStat™). Our fiscal 2020 guidance noted below for adjusted operating margin and adjusted earnings per share on a diluted basis reflects $27 million to $28 million in Research and Development spending, or 13% to 14% of consolidated revenues, compared to approximately $18 million, or 9% of consolidated revenues in fiscal 2019).
*Revenues*
- Consolidated – flat to down 3%
- Diagnostics segment – down 3% to 5%
- Life Science segment – up 2% to 6%
*Adjusted Operating Margin*
- Consolidated – 9% to 10%
- Diagnostics segment – mid-single-digits (significant research and development spending)
- Life Science segment – 50 to 100 basis-point improvement over 2019
*Effective Tax Rate*
- 23.5% to 24.5%
*Adjusted Earnings Per Share on a Diluted Basis*
- $0.28 to $0.34
Adjusted operating margin and adjusted earnings per share on a diluted basis for fiscal 2020 excludes costs associated with restructuring activities and selected legal matters that we expect to continue in fiscal 2020. In addition, our fiscal 2020 guidance for adjusted operating margin and earnings per share on a diluted basis excludes the medical device excise tax, the moratorium for which is due to expire December 31, 2019, unless Congress chooses to extend such moratorium for a third time, or altogether repeals it.
Although we do expect revenues for our Diagnostics segment to be down low to mid-single-digits for the full fiscal year, we expect revenues for our Diagnostics segment to be down high-single-digits during the first quarter, commensurate with the second half of fiscal 2019. Our revenue expectations for our Diagnostics segment for the first quarter, along with current customer order patterns for our Life Science segment, indicate our consolidated revenues for the first quarter could be down mid-single-digits.
**Financial Condition**
The Company’s financial condition remains sound. At September 30, 2019, cash and equivalents were $62.4 million and the Company had $49.2 million of borrowing capacity under its $125.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $75.8 million as of September 30, 2019.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Thursday, November 7, 2019 beginning at 10:00 a.m. Eastern Time to discuss the fourth quarter and full fiscal year financial results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9471778. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on November 7, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9471778.
**FOURTH QUARTER AND FISCAL 2019 UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim and annual periods of fiscal 2019 and fiscal 2018.
Three Months Ended Twelve Months Ended September 30, September 30, 2019 2018 2019 2018 Net revenues$ 50,846 $ 53,100 $ 201,014 $ 213,571 Cost of sales 21,690 20,944 82,689 82,874 Gross profit 29,156 32,156 118,325 130,697 Operating expenses Research and development 5,654 3,630 17,948 16,789 Selling and marketing 7,225 8,505 28,446 34,468 General and administrative 8,714 8,335 33,002 34,805 Acquisition-related costs 363 – 1,808 – Restructuring costs 1,138 3,601 2,839 8,706 Selected legal costs 213 975 1,583 4,345 Total operating expenses 23,307 25,046 85,626 99,113 Operating income 5,849 7,110 32,699 31,584 Other expense, net (493) (232) (1,142) (1,204) Earnings before income taxes 5,356 6,878 31,557 30,380 Income tax provision 1,253 1,444 7,175 6,531 Net earnings$ 4,103 $ 5,434 $ 24,382 $ 23,849 Net earnings per basic common share$ 0.10 $ 0.13 $ 0.57 $ 0.56 Basic common shares outstanding 42,711 42,391 42,571 42,325 Net earnings per diluted common share$ 0.10 $ 0.13 $ 0.57 $ 0.56 Diluted common shares outstanding 42,916 42,821 42,899 42,754
Three Months Ended Twelve Months Ended September 30, September 30, 2019 2018 2019 2018 **Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$ 7,563 $ 11,686 $ 38,929 $ 44,635 Net earnings 5,399 8,579 29,142 31,705 Net earnings per diluted common share$ 0.13 $ 0.20 $ 0.68 $ 0.74
**Condensed Balance Sheet Data**
September 30, 2019 2018 Cash and equivalents$ 62,397 $ 59,763Working capital 123,847 114,880Long-term debt 75,824 50,180Shareholders’ equity 190,967 175,418Total assets 325,378 251,377
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim and annual periods in fiscal 2019 and fiscal 2018 (in thousands).
Three Months Ended Twelve Months Ended September 30, September 30, 2019 2018 2019 2018 Net Revenues – By Product Platform/Type Diagnostics Molecular assays$ 6,065 $ 7,727 $ 26,231 $ 33,709 Immunoassays & blood chemistry assays 27,334 29,087 110,451 116,745 Total Diagnostics 33,399 36,814 136,682 150,454 Life Science Molecular reagents 5,765 6,650 23,261 24,533 Immunological reagents 11,682 9,636 41,071 38,584 Total Life Science 17,447 16,286 64,332 63,117 Total Net Revenues$ 50,846 $ 53,100 $ 201,014 $ 213,571
Three Months Ended Twelve Months Ended September 30, September 30, 2019 2018 2019 2018 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$ 16,953 $ 19,172 $ 68,977 $78,803 Respiratory illness assays 5,380 6,132 26,622 28,911 Blood chemistry assays 5,572 5,581 19,082 19,109 Other 5,494 5,929 22,001 23,631 Total Diagnostics 33,399 36,814 136,682 150,454Life Science Americas 5,094 5,206 19,443 21,080 EMEA 7,318 6,253 29,157 24,715 ROW 5,035 4,827 15,732 17,322 Total Life Science 17,447 16,286 64,332 63,117 Total Net Revenues$ 50,846 $ 53,100 $ 201,014 $ 213,571 OPERATING INCOME Diagnostics$ 1,944 $ 6,773 $ 22,399 $ 32,569 Life Science 5,791 3,479 20,572 13,799 Corporate (1,923) (3,203) (10,373) (15,076) Eliminations 37 61 101 292 Total Operating Income$ 5,849 $ 7,110 $ 32,699 $ 31,584 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of acquisition-related costs, restructuring costs, selected legal costs, and certain one-time tax effects of the tax reform act, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the fourth quarters and fiscal years ended September 30, 2019 and September 30, 2018.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FOURTH QUARTER AND FISCAL YEAR**
**GAAP TO NON-GAAP RECONCILATION TABLES**
(In Thousands, Except per Share Data)
Three Months Twelve Months Ended September 30, Ended September 30, 2019 2018 2019 2018 Operating Expenses U.S. GAAP basis$23,307 $25,046 $85,626 $99,113 Acquisition-related costs (363) – (1,808) – Restructuring costs (1,138) (3,601) (2,839) (8,706) Selected legal costs (213) (975) (1,583) (4,345) Adjusted Operating Expenses$21,593 $20,470 $79,396 $86,062 Operating Income – U.S. GAAP basis$ 5,849 $ 7,110 $32,699 $31,584 Acquisition-related costs 363 – 1,808 – Restructuring costs 1,138 3,601 2,839 8,706 Selected legal costs 213 975 1,583 4,345 Adjusted Operating Income$7,563 $11,686 $38,929 $44,635 Net Earnings U.S. GAAP basis$ 4,103 $ 5,434 $24,382 $23,849 Acquisition-related costs \* 273 – 1,381 – Restructuring costs \* 864 2,693 2,169 6,430 Selected legal costs \* 159 738 1,210 3,205 One-time benefit from tax law change – (308) – (2,655) Repatriation transition tax – 22 – 876 Adjusted Earnings$ 5,399 $ 8,579 $29,142 $31,705 \* Net of tax.
Three Months Twelve Months Ended September 30, Ended September 30, 2019 2018 2019 2018 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.10 $ 0.13 $ 0.57 $ 0.56 Acquisition-related costs 0.01 – 0.03 – Restructuring costs 0.02 0.06 0.05 0.15 Selected legal costs – 0.02 0.03 0.08 One-time benefit from tax law change – (0.01) – (0.06) Repatriation transition tax – – – 0.02 Adjusted Basic EPS $ 0.13 $ 0.20 $ 0.68 $ 0.75 Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.10 $ 0.13 $ 0.57 $ 0.56 Acquisition-related costs 0.01 – 0.03 – Restructuring costs 0.02 0.06 0.05 0.15 Selected legal costs – 0.02 0.03 0.07 One-time benefit from tax law change – (0.01) – (0.06) Repatriation transition tax – – – 0.02 Adjusted Diluted EPS$ 0.13 $ 0.20 $ 0.68 $ 0.74
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=KCJyEbglMawXGBf7g9KWv8Q9zyJmIO_N9JjXMrT3hIqd0eH5gutcO4Xn59uWJVFz2yDHxe1ThJy8940WKNiSTsq1LTrxkoZOWqYmFdduphHIzKmHJ07IduFzOeJ8Mxa1 "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=VfqZHgbAVCBBPvZ1NtAVOv6x7teE4m51X_LYqDMnhTN4ml9JQhphHGCpzD0lU5HVgKAiDgWYfdx7VjnGL9bXTqshiGQhR4IbwEPo3K9nDg-rT62_0R135Iidtz2Zr7QK "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA](https://www.meridianbioscience.com/press-release/meridian-submits-curian-analyzer-and-the-curian-hpsa-assay-to-the-fda/)
**Published:** November 6, 2019
**Author:** hamza
**Content:**
CINCINNATI, Nov. 06, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. This platform and assay are designed to specifically detect Helicobacter pylori antigens in human stool using fluorescent lateral flow technology. Curian™ HpSA is intended to aid in the diagnosis of H. pylori infection and to monitor response during and post-therapy in patients. The addition of this new platform and assay continues to strengthen Meridian’s strategic positioning in the gastrointestinal disease testing market.
Recent studies have shown that Helicobacter pylori infections are a major public health concern globally. According to the CDC, about two-thirds of the global population is infected with H. pylori. H. pylori infection is considered the leading cause for chronic gastritis and is also considered an etiological agent for gastric cancer (adenocarcinoma) and peptic ulcer disease.1-3 H. pylori infection has also been associated with mucosa-associated lymphoid tissue (MALT) and has been attributed to approximately 89% of gastric cancer diagnoses. 1, 4
Lawrence Mertz, Senior Vice President of Research and Development, stated, “We are excited to be the first to develop a rapid fluorescent lateral flow HpSA assay. The use of fluorescent technology coupled with an automated analyzer readout provides a result that can be read without the risk of subjective analysis by the technician.”
Tony Serafini-Lamanna, Global Vice President and General Manager, said, “The submission of Curian and the Curian HpSA assay is yet another strategic move to maintain our leadership and expertise in gastrointestinal diagnostics testing. Curian is an analyzer that will advance rapid GI disease testing, with HpSA being the first of several tests in development.”
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
1. Hooi James KY, Lai Wan Ying, Ng Wee Khoon, Suen Michael MY. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis, Gastroenterology. 2017; Vol 153, No. 2.
2. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.
3. Wang C, Yuan Y, Hunt RH. The association between *Helicobacter pylori* infection and early gastric cancer: a meta-analysis. Am J Gastroenterol. 2007;102:1789–1798.
4. International Agency for Research on Cancer *Helicobacter pylori* Working Group. *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. (IARC Working Group Reports, No. 8). Lyon, France: International Agency for Research on Cancer, 2014. Available from: [https://publications.iarc.fr/Book-And-Report-Series/Iarc-Working-Group-Reports/-Em-Helicobacter-Pylori-Em-Eradication-As-A-Strategy-For-Preventing-Gastric-Cancer-2014](https://www.globenewswire.com/Tracker?data=F_qgckjwqoHN8kUAPmJjyq_FcrJZz83OIIavXyEVqoYBAu7zrzJ4jvEsVZhsOMiB83U0zmacKojAf8MokcQN7MYmw6AJyk-szJ643qwuTtahX51a6_xckZt8QPxm9YTvI_C0L6WRn7Ej87_fVM2ikMSxx6zmusedW-pxYiHpoPADITUbwNcrtf2Oz__kZedpP0jE1JlFjk3k45ZjRWZLFW-gTR4J3_vrTiIdtTn8yrQe078pW6-v2prGjva89KUMYUEIG4zac1e4GRssMp1RdJlAMTMKXkoA8bSzEaRELURya6wWmLaPKFn29inOVgNvcW94Ncx27tE1aNNvjrQOqHO_RLQMorg7Q4lldkEbu06N54rUYbOXbg3wVt2JV9Wb_Yat1qDJda3iKCSNOhQAWxLFLrjIjCMXFLCa9rHNz4KL5Z5m3mObx5m9cVGP3sfrJq8sbAKaARFF1a2oQyg9Og==). Accessed November 18, 2016.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=4V1v-ZbJXroKy5ulIOIICR9EjFPSjVsqlP3ozA6bOMRKJ7R50wPrMAauZnixzIHAI5hxLQ750jumNFscMa9k7bRvLugE7FRz3WvKB6insRe4AcSgdbrr_Iy-DsB30NQL1RDsv3va0CP6PxePMl4klLlqThoS9AOZxS5gkOIoGRxMlgzMzhhRBQinvfipXoTZXRhjGpZJlJfOVFNSzzirh3eDZfjfBJszN_wB_bWNiwrSUvU5_rQASbOFFcv-KJKBMonlhGuUJjZVm_h-sknt2Rqc0fBlp3kZzwFAkzcxydoMBvg4sBLMTFf4Xlvc26lnMd24Pj3cC93B0FOkUCeUQQpSA0ZowG0tTpA0J1hpuq5-_xqMzFpZpm8jazdWzhtyleTdAUh0B34Pl2ElGszff2EvA7E91wJNE1eo4-l4rj6fSuEJeyQoy_QH7hsdXnb7LpPQU0CIhYCi86xI2e55wDwOStHfzz9l8pIlQxcb7ohrQuHe0kharKiFNgUe5gMB30R1aPnUPWyrmz2F1v22QQ== "www.meridianbioscience.com").
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=UfclQUZL-dKQjX8DQRC6c8AUrsFShSxouvzBdOajQg5BOMgAyST7gYVx1Xfv7nYmXi1QQY6FbdSgfAoEvJDfyfnCKT6JM3PUlNuYlQzsChTRK-8VCwxMgfRabodn6vco "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-fourth-quarter-and-full-year-2019-financial-results-conference-call-on-november-7-2019/)
**Published:** October 16, 2019
**Author:** hamza
**Content:**
CINCINNATI, Oct. 16, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2019 financial results Thursday, November 7, 2019.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9471778.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on November 7, 2019 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9471778.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=0zTbtBFMdCCi9gF892USu8o-hH_vPjtm6ogcJNOTXyXOOSZZMQxJ6LDmJEYm_kDb0Bt0k8shO3AUlKW19X2W0oqXlmxzYYvKEVUM_6BU4eUBFRkub-Oyv10h2A0lx9Lm "www.meridianbioscience.com").
**Contact:**
Bryan Baldasare
Executive Vice President and Chief Financial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=vTay6Aq9tGyn_1fhIi_cIjICFYqfPuZZWIohXLYUG1fjmeHXzSAJnf6WeSInJPS7i4hhLEH91DxS_K78_B7ACY-2gf7HnTcZuPEZOjRYN6c= "mbi@meridianbioscience.om")
**Categories:** Press Release
---
### [Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications](https://www.meridianbioscience.com/press-release/meridian-launched-a-new-high-fidelity-polymerase-to-offer-robust-amplification-for-ngs-and-pcr-applications/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.
High-fidelity amplification is essential for applications whose outcome depends upon the correct DNA sequence, such as next generation sequencing (NGS), cloning, and genotyping. However, results from such amplifications can be compromised by a DNA polymerase incapable of evenly amplifying diverse types of sequences or if samples contain inhibitors.
The Life Science Division of Meridian Bioscience has addressed these challenges by developing High-Specificity Pfu HS Mix as a high-fidelity amplification solution, with market leading properties in terms of inhibitor resistance, multiplexing and low GC bias. It is a perfect tool for NGS technologies applied to the clinical market, especially in the field of genetic testing and cancer screening, i.e., the development of panels for tumor or mutation profiling.
Lourdes Weltzien, Ph.D., Executive Vice President of Life Science, commented, “High-fidelity polymerases have been susceptible to difficulties in PCR amplification of GC-rich or inhibitor-rich DNA. High-Specificity Pfu HS Mix has dramatically reduced these limitations and will increase customers’ testing capabilities.”
“In NGS-based clinical assays, being able to sequence all the DNA regions of the sample independently from GC-content is essential. Using our extensive expertise in enzymes and buffer systems, High-Specificity Pfu HS Mix has been designed to achieve this. From target enrichment to library amplification, it allows better NGS data and more accurate results,” says Florent Chang-Pi-Hin, Ph.D., Senior Director, Research & Development at Meridian.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mrAdC6EUwJ1_KyJrn1kAdVijr5z1-kI034UW8lv2UeB3NQyj_Sry2aOohaxlJrfXSzc49B-5oNTHqpUbeh535d4ADd8Wg_jaPj6OL1GZ9OvTX9-GhyYGuNc07GiLgIWn "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-first-quarter-2020-financial-results-conference-call-on-february-7-2020/)
**Published:** January 15, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 15, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020 financial results Friday, February 7, 2020.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 2496742.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on February 7, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 2496742.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Bryan Baldasare
Executive Vice President and Chief Financial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=soMb0iiMLa7bGpZ8AwQHEBNVFPIuTzSw-M9CDKg5_rdJtRqJCjhcYA-QrEMcmTBFJ0AAgtoBajMxV1jd09blMi1LpY7a5k9Q4Rwz9Co7vtcwscm1zqWZpufb1OOYyM2n "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian lance une nouvelle polymérase haute-fidélité pour fournir une amplification robuste aux applications NGS et PCR](https://www.meridianbioscience.com/press-release/meridian-lance-une-nouvelle-polymerase-haute-fidelite-pour-fournir-une-amplification-robuste-aux-applications-ngs-et-pcr/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, 23 janv. 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ : VIVO) a annoncé aujourd’hui le lancement d’un mélange Pfu HS de haute spécificité qui non seulement fournit une amplification haute-fidélité, mais offre également des produits leaders sur le marché de l’amplification pour le diagnostic compagnon (CDx) et les tests cliniques.
L’amplification haute-fidélité est essentielle pour les applications dont le résultat dépend de la séquence correcte d’ADN, telles que le séquençage de nouvelle génération (NGS), le clonage et le génotypage. Cependant, les résultats de telles amplifications peuvent être faussés par une ADN polymérase incapable d’amplifier uniformément divers types de séquences ou si les échantillons contiennent des inhibiteurs.
La division des sciences de la vie de Meridian Bioscience a relevé ces défis en développant le mélange Pfu HS de haute spécificité en tant que solution d’amplification haute-fidélité, avec des propriétés de pointe sur le marché en termes de résistance aux inhibiteurs, de multiplexage et de faible déviation GC. C’est un outil idéal pour les technologies NGS appliquées au marché clinique, en particulier dans le domaine des tests génétiques et du dépistage du cancer, c’est-à-dire le développement de panels pour le profilage des tumeurs ou des mutations.
Le Dr Lourdes Weltzien, vice-présidente exécutive de la division Sciences de la vie, a déclaré : « Les polymérases haute-fidélité ont été sensibles aux difficultés d’amplification par PCR d’ADN riche en GC ou riche en inhibiteurs. Le mélange Pfu HS de haute spécificité a considérablement réduit ces limitations et augmentera les capacités de test des clients. »
« Dans les essais cliniques basés sur le NGS, il est essentiel de pouvoir séquencer toutes les régions d’ADN de l’échantillon indépendamment du contenu GC. En nous appuyant sur notre vaste expertise en matière d’enzymes et de systèmes tampons, nous avons conçu le mélange Pfu HS de haute spécificité pour y parvenir. De l’enrichissement de la cible à l’amplification de la bibliothèque, il permet d’obtenir de meilleures données NGS et des résultats plus précis », explique le Dr Florent Chang-Pi-Hin, directeur de la Recherche et du développement chez Meridian.
**À propos de Meridian Bioscience, Inc.**
Meridian est une société de sciences de la vie entièrement intégrée qui développe, fabrique, commercialise et distribue une large gamme de produits de diagnostic innovants. Nous nous concentrons sur le développement et la fourniture de meilleures solutions qui apportent des réponses avec rapidité, précision et simplicité et qui redéfinissent les possibilités de la vie depuis la découverte jusqu’au diagnostic. Grâce à la découverte et au développement, nous fournissons des matières premières essentielles aux sciences de la vie utilisées dans les tests immunologiques et moléculaires pour les applications humaines, animales, végétales et environnementales. Grâce au diagnostic, nous fournissons des solutions de diagnostic dans des domaines tels que les infections gastro-intestinales et respiratoires supérieures et les tests de plombémie. Nous établissons des relations et fournissons des solutions aux hôpitaux, laboratoires de référence, centres de recherche, centres de tests vétérinaires, cabinets médicaux, fabricants de diagnostics et entreprises de biotechnologie dans plus de 70 pays à travers le monde.
Les actions de Meridian sont cotées sur le marché NASDAQ Global Select, sous le symbole VIVO. L’adresse du site Web de Meridian est [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RUMuOpqFoL0CFwQptHmBkoRdrxdvDgSSS_3mLSZSbFc3YRMlQD0ALWqpZmjFqFhWoZy7l0GrjOnjYG-ov15VQwJ9Es-duZCqkIHkYWRiVf_j2Xr5xvvkFQiQrcnSqKBc "www.meridianbioscience.com").
**Contact :**
Jack Kenny
Président-directeur général
Meridian Bioscience, Inc.
Téléphone : 513.271.3700
Courriel : [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hOvXhYEc3oaPrs6LJge0iYXDKOnkN64KXK2XTDy9vlPbD8okBvs7iepvvZ7MJlF6NCyx43SoNHviMWSJrWvL-aJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian bietet mit neuer High-Fidelity-Polymerase stabile Amplifikation für NGS- und PCR-Anwendungen](https://www.meridianbioscience.com/press-release/meridian-bietet-mit-neuer-high-fidelity-polymerase-stabile-amplifikation-fur-ngs-und-pcr-anwendungen/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) hat heute die Einführung eines High-Specificity Pfu HS Mix bekanntgegeben, der neben einer High-Fidelity-Amplifikation auch eine branchenführende Amplifikation für Begleitdiagnostika und klinische Tests bietet.
Die High-Fidelity-Amplifikation ist für Anwendungen elementar, deren Ergebnisse von der richtigen DNA-Sequenz abhängen. Hierzu zählen „Next Generation Sequencing“ (NGS), Klonen und Genotypisierung. Die Ergebnisse solcher Amplifikationen können jedoch durch eine DNA-Polymerase beeinträchtigt werden, die nicht in der Lage ist, verschiedene Sequenztypen gleichmäßig zu amplifizieren (vervielfältigen), oder wenn Proben Inhibitoren enthalten.
Die Life Science Division von Meridian Bioscience hat sich diesen Herausforderungen gestellt und einen High-Specificity Pfu HS Mix als Lösung für die High-Fidelity-Amplifikation mit marktführenden Eigenschaften in Bezug auf Inhibitorresistenz, Multiplexing und niedrigen GC-Bias entwickelt. Diese Lösung bietet sich insbesondere für NGS-Technologien im klinischen Bereich an, allen voran in den Bereichen Gentests und Krebsvorsorge, konkret für die Entwicklung von Panels für das Tumor- bzw. Mutations-Profiling.
Lourdes Weltzien, Ph.D., Executive Vice President of Life Science, hierzu: „High-Fidelity-Polymerasen waren bisher anfällig für Schwierigkeiten bei der PCR-Amplifikation GC-reicher bzw. Inhibitor-reicher DNA. Der High-Specificity Pfu HS Mix reduziert diese Einschränkungen erheblich und erhöht die Testmöglichkeiten für Kunden.“
„Bei klinischen NGS-basierten Assays ist es wichtig, alle DNA-Bereiche der Probe unabhängig vom GC-Gehalt sequenzieren zu können. Wir haben hierfür auf unser fundiertes Wissen in den Bereichen Enzyme und Puffersysteme zurückgegriffen, damit wir mit dem High-Specificity Pfu HS Mix genau dies erreichen. Von „Target Enrichment“ bis „Library Amplification“ bietet er bessere NGS-Daten und genauere Ergebnisse“, so Florent Chang-Pi-Hin, Ph.D., Senior Director, Research & Development bei Meridian.
**Über Meridian Bioscience, Inc.**
Meridian ist ein voll integriertes Life-Science-Unternehmen, das eine breite Palette an innovativen Diagnostik-Produkten entwickelt, herstellt, vermarktet und vertreibt. Unsere Mission ist es, bessere Lösungen zu entwickeln und zu bieten, die schnell und einfach genaue Antworten liefern, und so die Möglichkeiten des Lebens neu definieren, von der Entdeckung bis zur Diagnose. Entdeckung und Entwicklung: Wir bieten wichtige Ausgangsmaterialien für den Life-Science-Sektor, die in immunologischen und molekularen Tests für Tier-, Pflanzen- und Umweltanwendungen sowie für Anwendungen am Menschen eingesetzt werden. Diagnostik: Wir bieten Diagnoselösungen für verschiedene Bereiche an, einschließlich gastrointestinale Infektionen und Infektionen der oberen Atemwege, sowie Tests zum Messen der Blutbleiwerte. Zu unseren Kunden zählen Krankenhäuser, Referenzlabore, Forschungszentren, Veterinärprüfzentren, Arztpraxen, Diagnostikahersteller und Biotech-Unternehmen in mehr als 70 Ländern weltweit.
Die Aktien von Meridian werden am NASDAQ Global Select Market, Symbol VIVO, gehandelt. Die Website von Meridian ist www.meridianbioscience.com.
**Kontakt:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Telefon: 513.271.3700
E-Mail: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Meluncurkan Polimerase Fidelitas Tinggi Baru dengan Kemampuan Amplifikasi Canggih bagi Aplikasi NGS dan PCR](https://www.meridianbioscience.com/press-release/meridian-meluncurkan-polimerase-fidelitas-tinggi-baru-dengan-kemampuan-amplifikasi-canggih-bagi-aplikasi-ngs-dan-pcr/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 24, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) hari ini mengumumkan peluncuran High-Specificity Pfu HS Mix yang menyediakan amplifikasi fidelitas tinggi, sekaligus amplifikasi terkemuka di pasaran untuk companion diagnostic (CDx) dan pengujian klinis.
Amplifikasi fidelitas tinggi sangat penting bagi aplikasi yang mengutamakan ketepatan urutan DNA dalam hasilnya, misalnya next generation sequencing (NGS), atau pembuatan klon dan genotipe. Namun, hasil dari amplifikasi dapat terkompromi jika polimerase DNA tidak mampu memperkuat beragam jenis urutan, atau jika sampel mengandung inhibitor.
Untuk mengatasi masalah tersebut, Life Science Division Meridian Bioscience mengembangkan High-Specificity Pfu HS Mix sebagai solusi amplifikasi fidelity tinggi dengan properti terkemuka dalam bidang resistansi inhibitor, multipleks, dan bias GC rendah. Alat ini sempurna bagi teknologi NGS yang diterapkan di pasar klinis, khususnya dalam bidang pengujian genetik dan pemeriksaan kanker, mis., pengembangan panel untuk profil tumor atau mutasi.
Lourdes Weltzien, Ph.D., Executive Vice President Life Science berkomentar, “Polimerase berfidelitas tinggi sulit untuk menerima amplifikasi PCR dari DNA yang mengandung banyak GC atau inhibitor. High-Specificity Pfu HS Mix dapat mengurangi batasan tersebut dan akan meningkatkan kemampuan pengujian pelanggan secara signifikan.”
“Pengujian klinis berbasis NGS sangat mementingkan kemampuan untuk mengurutkan semua wilayah DNA sampel secara independen dari konten GC. Demi mencapai hal tersebut, kami memanfaatkan berbagai keahlian ekstensif dalam bidang enzim dan sistem buffer untuk merancang High-Specificity Pfu HS Mix. Dengan kemampuan mulai dari penyempurnaan target hingga amplifikasi pustaka, alat ini dapat menyediakan data NGS yang lebih baik dan hasil yang lebih akurat,” ujar Florent Chang-Pi-Hin, Ph.D., Direktur Senior di bagian Penelitian & Pengembangan Meridian.
**Tentang Meridian Bioscience, Inc.**
Meridian adalah perusahaan ilmu kehidupan terintegrasi penuh yang mengembangkan, memproduksi, memasarkan, dan mendistribusikan beragam produk diagnostik inovatif. Dengan dedikasi untuk mengembangkan dan menyediakan solusi yang lebih baik, perusahaan ingin menyediakan hasil pengujian yang cepat, akurat, dan sederhana sehingga dapat meningkatkan kemungkinan bertahan hidup dari tahap penemuan hingga diagnosis. Penemuan dan pengembangan kami menyediakan materi sains kritis yang digunakan dalam pengujian imunologi serta molekuler untuk manusia, hewan, tumbuhan, dan aplikasi lingkungan. Diagnosis kami menghadirkan solusi diagnostik dalam berbagai bidang, seperti infeksi saluran cerna dan pernapasan bagian atas, serta pengujian tingkat timbal darah. Kami membangun hubungan dengan, serta menyediakan solusi bagi, rumah sakit, laboratorium rujukan, pusat penelitian, pusat pengujian hewan, kantor dokter, produsen diagnostik, dan perusahaan bioteknologi di lebih dari 70 negara di seluruh dunia.
Saham Meridian diperjualbelikan dalam NASDAQ Global Select Market, simbol VIVO. Alamat situs web Meridian adalah www.meridianbioscience.com.
**Kontak:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Telepon: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [メリディアン、NGSおよびPCRアプリケーション向けの確実な増幅を実現する新しいハイフィデリティ･ポリメラーゼを公開](https://www.meridianbioscience.com/press-release/メリディアン、ngsおよびpcrアプリケーション向けの/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
シンシナティ発, Jan. 24, 2020 (GLOBE NEWSWIRE) — メリディアン･バイオサイエンス (Meridian Bioscience, Inc.、NASDAQ: VIVO) は本日、High-Specificity Pfu HS Mixを発表した。これはハイフィデリティ増幅を実現するだけでなく、コンパニオン診断 (CDx) や臨床試験にも役立つ市場トップレベルの増幅を提供する。
ハイフィデリティ増幅は、その成果がDNA配列の正しさに依存する、次世代シーケンシング (NGS)、クローニング、ジェノタイピングなどのアプリケーションにとって不可欠な要素である。しかし、こうした増幅は、多様なタイプのシーケンスを均等に増幅できないDNAポリメラーゼや、サンプルに阻害剤が含まれている場合、悪影響を受ける可能性がある。
メリディアン･バイオサイエンスのライフサイエンス部門では、こうした課題に対応するため、阻害剤耐性、多重および低GCバイアスに対する最先端の属性を備えた、ハイフィデリティ増幅ソリューションとしてHigh-Specificity Pfu HS Mixを開発した。これは臨床市場におけるNGSテクノロジーにとって完璧なツールであり、とりわけ遺伝子検査や癌のスクリーニング (腫瘍または変異プロファイリングの開発パネルなど) において効果を発揮する。
ライフサイエンス部門のエグゼクティブ･バイス･プレジデントであるローデス･ヴェルトツィエン (Lourdes Weltzien) 博士は、次のように述べている。「ハイフィデリティ･ポリメラーゼは、GCリッチまたは阻害剤リッチなDNAのPCR増幅における困難さの影響を受けてきました。High-Specificity Pfu HS Mixはこうした制限を劇的に減少させ、お客様の試験能力を向上します。」
メリディアンの研究開発部門シニアディレクターであるフローレント･チャンピーヒン (Florent Chang-Pi-Hin) 博士は、次のように述べている。「NGSベースの臨床分析では、GC含量に関係なくサンプルのすべてのDNA領域を解析できることが不可欠です。当社の酵素およびバッファーシステムの専門性を利用するHigh-Specificity Pfu HS Mixは、こうした目標を達成するために設計されています。ターゲットエンリッチメントからライブラリー増幅まで、同製品はより良いNGSデータとより正確な結果をもたらします。」
**メリディアン･バイオサイエンスについて**
メリディアン (Meridian) は、多様かつ革新的な診断用製品の開発、製造、マーケティング、販売に携わる完全統合型ライフサイエンス企業である。発見から診断まで、生存の可能性に影響を及ぼす判断を、迅速、正確、簡単に提供する優れたソリューションの開発および提供に取り組んでいる。同社は、発見および開発に関して、人、動物、植物、環境アプリケーション向けの免疫学および分子レベルの試験で使用される重要なライフサイエンス関連の原材料を提供する。また、診断に関しては、消化器系や上部呼吸器系の感染症および血中鉛濃度の診断試験といった分野の診断ソリューションを提供する。 また、世界の70か国以上の病院、基準試験所、研究センター、獣医検査センター、診療所、診断機器メーカー、バイオテック企業と提携し、提携先にソリューションを提供している。
メリディアンの株式はナスダックのグローバル･セレクト･マーケット (NASDAQ Global Select Market) でシンボル「VIVO」で取引されている。同社のWebサイトはwww.meridianbioscience.comを閲覧されたい。
**問い合わせ先:**
ジャック･ケニー (Jack Kenny)
最高経営責任者
メリディアン･バイオサイエンス
電話: 513.271.3700
メール: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [메리디안, NGS와 PCR 애플리케이션에 강력한 증폭 능력을 제공하는 정확성 높은 중합효소 공개](https://www.meridianbioscience.com/press-release/메리디안-ngs와-pcr-애플리케이션에-강력한-증폭-능력을/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
신시내티, Jan. 24, 2020 (GLOBE NEWSWIRE) — 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ: VIVO)는 정확성 높은 증폭 능력과 함께 동반진단(CDx) 및 임상 테스트용 증폭 능력을 제공하는 High-Specificity Pfu HS Mix를 공개했다.
정확성 높은 증폭 능력은 차세대 시퀀싱(NGS), 클로닝, 유전형질 분석 등 정확한 DNA 시퀀싱이 선행되어야 결과 도출이 가능한 애플리케이션에 필수적이다. 하지만 다양한 시퀀스를 균등하게 증폭하지 못하게 하는 DNA 중합요소, 혹은 샘플이 억제 유전자를 포함하고 있을 경우 증폭 능력이 발현되는 데 제약이 따른다.
메리디안 바이오사이언스 생명과학사업부는 이러한 문제들을 해결하기 위해 억제제 내성, 멀티플렉싱, 낮은 수준의 구아닌시토신(GC) 편향성과 관련된 자체 기술을 활용해 정확성 높은 증폭 솔루션인 High-Specificity Pfu HS Mix를 개발했다. 본 솔루션은 임상 시장에서 사용되는 NGS 기술에 최적화된 도구로 특히 유전자 테스팅과 암 스크리닝, 즉, 종양 및 돌연변이 프로파일링용 패널 개발에 활용될 수 있다.
Lourdes Weltzien 메리디안 생명과학사업부 부사장은 “높은 정확성을 갖춘 중합요소는 GC가 풍부한 PCRdl나 억제 유전자가 많은 DNA 증폭에 민감한 성질을 노출한다. High-Specificity Pfu HS Mix는 이와 같은 단점을 크게 개선하고 고객들의 테스팅 능력을 향상시킬 것”이라고 밝혔다.
Florent Chang-Pi-Hin 메리디안 R&D 사업부 선임 연구원은 “NGS 기반 분석법을 사용할 경우 GC 물질에서 독립된 형태로 모든 DNA에 대한 시퀀싱이 필수적이다. High-Specificity Pfu HS Mix는 효소와 완충계와 관련된 당사의 전문성을 활용해 이 같은 목표를 달성할 수 있도록 개발되었다. 본 솔루션은 타깃 강화부터 라이브러리 증폭 등을 통해 향상된 NGS 데이터를 얻어 내고 정확한 결과를 도출한다”고 말했다.
**메리디안** **바이오사이언스** **(Meridian Bioscience, Inc.) 개요**
메리디안은 완전 통합된 형태의 생명과학 기업으로 광범위한 규모의 혁신적 진단 테스트 키트, 정제시약 및 관련 제품을 개발, 생산, 마케팅 및 유통하고 있으며 생물약제학적 능력을 갖춘 기술을 공급한다. 이러한 제품 및 진단 테스트들은 다양한 기법을 활용해 위장, 바이러스성, 호흡기 감염 등 각종 일반 질병의 조기 진단 및 치료 단계에서 정확성, 단순성 및 신속성을 제공한다. 메리디안의 진단 제품들은 인체 외부에서 사용되며 특수 장비를 거의 요하지 않는다. 당사 제품들은 환자의 웰빙을 증진하는 한편 헬스케어 비용을 감소시킨다. 메리디안은 위장 및 상기도 감염, 그리고 혈청, 기생충 및 진균성 질병의 진단 분야에서 강력한 시장 지위를 가지고 있다. 또한 신약과 백신 개발에 대한 연구를 진행하는 생물약제 기업들이 사용하는 희귀시약과 특수생물학 및 관련기술을 공급하고 있다. 당사는 전세계 70개국 내 병원, 표준실험실, 연구센터, 진단제품 제조업체 및 생명공학기술 기업들을 대상으로 각종 제품과 기술을 내놓고 있다.
당사 주식은 나스닥의 Global Select Market에서 VIVO라는 거래명으로 거래되고 있다. [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RUMuOpqFoL0CFwQptHmBkoRdrxdvDgSSS_3mLSZSbFc3YRMlQD0ALWqpZmjFqFhWoZy7l0GrjOnjYG-ov15VQwJ9Es-duZCqkIHkYWRiVf_j2Xr5xvvkFQiQrcnSqKBc).
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hOvXhYEc3oaPrs6LJge0iYXDKOnkN64KXK2XTDy9vlPbD8okBvs7iepvvZ7MJlF6NCyx43SoNHviMWSJrWvL-aJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Melancarkan Polimerase Fideliti Tinggi Baharu untuk Menawarkan Penguatan Kukuh untuk Aplikasi NGS dan PCR](https://www.meridianbioscience.com/press-release/meridian-melancarkan-polimerase-fideliti-tinggi-baharu-untuk-menawarkan-penguatan-kukuh-untuk-aplikasi-ngs-dan-pcr/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 24, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) hari ini mengumumkan Campuran HS Pfu Spesifikasi Tinggi yang bukan sahaja menyediakan penguatan fideliti tinggi, tetapi turut menawarkan penguatan untuk diagnostik seiring (CDx) dan ujian klinikal.
Penguatan fideliti tinggi adalah penting untuk aplikasi yang hasilnya bergantung kepada jujukan DNA yang betul, seperti penjujukan generasi hadapan (NGS), pengklonan, dan pengenotipan. Namun, keputusan daripada penguatan tersebut boleh dijejaskan oleh polimerase DNA yang tidak mampu menguatkan jenis jujukan yang berbeza secara sama rata atau jika sampel mengandungi perencat.
Bahagian Sains Hayat di Meridian Bioscience telah menangani cabaran ini dengan membangunkan Campuran HS Pfu Spesifikasi Tinggi sebagai penyelesaian penguatan fideliti tinggi, dengan ciri-ciri utama pasaran dari segi ketahanan perencat, pemultipleksan dan bias GC yang rendah. Ini merupakan alat yang sesuai untuk teknologi NGS yang diaplikasikan kepada pasaran klinikal, terutamanya dalam bidang ujian genetik dan penyaringan kanser, iaitu pembangunan panel untuk penyusukan tumor atau mutasi.
Lourdes Weltzien, Ph.D., Naib Presiden Eksekutif Sains Hayat, mengomen, “Polimerase fideliti tinggi telah menjadi rentan kepada kesukaran dalam penguatan PCR dalam DNA penuh GC atau penuh perencat. Campuran HS Pfu Spesifikasi Tinggi telah mengurangkan batasan ini dengan ketara dan akan meningkatkan kemampuan ujian pelanggan.”
“Dalam cerakin klinikal berdasarkan NGS, keupayaan untuk menjujukkan semua bahagian DNA pada sampel secara bebas daripada kandungan GC adalah penting. Dengan kepakaran meluas kami dalam sistem enzim dan penimbal, Campuran HS Pfu Spesifikasi Tinggi telah direka untuk mencapai ini. Daripada pengayaan sasaran sehinggalah penguatan pustaka, ini membolehkan data NGS yang lebih baik dan keputusan lebih tepat,” kata Florent Chang-Pi-Hin, Ph.D., Pengarah Kanan, Penyelidikan & Pembangunan di Meridian.
**Perihal Meridian Bioscience, Inc.**
Meridian ialah syarikat sains hayat bersepadu sepenuhnya yang membangunkan, mengilangkan, memasarkan dan mengagihkan pelbagai produk diagnostik inovatif. Kami berdedikasi dalam membangunkan dan menyampaikan penyelesaian lebih baik yang memberikan jawapan dengan kelajuan, ketepatan dan keringkasan yang membawa perubahan kepada kemungkinan kehidupan bermula dengan penerokaan sehinggalah diagnosis. Menerusi penerokaan dan pembangunan, kami menyediakan bahan mentah sains hayat kritikal yang digunakan dalam ujian imunologi dan molekul untuk aplikasi manusia, haiwan, tumbuhan, dan alam sekitar. Menerusi diagnosis, kami menyediakan penyelesaian diagnostik dalam aspek termasuklah jangkitan gastrousus dan pernafasan atas dan ujian paras plumbum dalam darah. Kami membina hubungan dan menyediakan penyelesaian kepada hospital, makmal rujukan, pusat penyelidikan, pusat ujian veterinar, pejabat pakar perubatan, pengilang diagnostik, dan syarikat bioteknologi di lebih 70 negara di seluruh dunia.
Saham Meridian didagangkan di NASDAQ Global Select Market, simbol VIVO. Laman web Meridian ialah www.meridianbioscience.com.
**Maklumat Hubungan:**
Jack Kenny
Ketua Pegawai Eksekutif
Meridian Bioscience, Inc.
Telefon: 513.271.3700
E-mel: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian lança nova polimerase de alta fidelidade para oferecer amplificação robusta para aplicações NGS e PCR](https://www.meridianbioscience.com/press-release/meridian-lanca-nova-polimerase-de-alta-fidelidade-para-oferecer-amplificacao-robusta-para-aplicacoes-ngs-e-pcr/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) — A Meridian Bioscience, Inc. (NASDAQ: VIVO) anunciou hoje o lançamento do Mix HS de Pfu de Alta Especificidade que além de fornecer amplificação de alta fidelidade também oferece amplificação líder do mercado para diagnóstico complementar (CDx) e testes clínicos.
A amplificação de alta fidelidade é essencial para aplicações cujo resultado depende da sequência de DNA correta, como sequenciamento da próxima geração (NGS), clonagem e genotipagem. No entanto, os resultados de tais amplificações podem ser comprometidos por uma DNA polimerase incapaz de amplificar uniformemente diversos tipos de sequências ou quando as amostras contêm inibidores.
A Divisão de Ciência da Vida da Meridian Bioscience abordou esses desafios desenvolvendo o Mix HS de Pfu de Alta Especificidade como uma solução de amplificação de alta fidelidade, com propriedades líderes de mercado em termos de resistência a inibidores, multiplexação e baixa polarização GC. É uma ferramenta perfeita para tecnologias NGS aplicadas ao mercado clínico, especialmente no campo de testes genéticos e triagem de câncer, ou seja, desenvolvimento de painéis para perfil de tumor ou mutação.
Lourdes Weltzien, Ph.D., Vice-presidente Executiva de Ciência da Vida, comentou, “As polimerases de Alta Fidelidade são suscetíveis às dificuldades na amplificação de PCR do ADN rico ou inibidor-rico de GC. O Mix HS de Pfu de Alta Especificidade reduziu drasticamente essas limitações e aumentará as capacidades de teste dos clientes”.
“Nos ensaios clínicos baseados em NGS, a capacidade de sequenciar todas as regiões de DNA da amostra independentemente do conteúdo de GC é essencial. Usando nossa vasta experiência em enzimas e sistemas reservas, o Mix HS de Pfu de Alta Especificidade foi projetado para alcançar isso. Do enriquecimento do alvo à amplificação da biblioteca, ele permite melhores dados NGS e resultados mais precisos”, disse Florent Chang-Pi-Hin, Ph.D., Diretor Sênior de Pesquisa e Desenvolvimento da Meridian.
**Sobre a Meridian Biosciences, Inc.**
A Meridian é uma empresa de ciências da vida totalmente integrada que desenvolve, fabrica, comercializa e distribui uma ampla gama de produtos de diagnóstico inovadores. Nos dedicamos ao desenvolvimento e entrega de melhores soluções que dão respostas com rapidez, precisão e simplicidade e que estão redefinindo as possibilidades de vida desde a descoberta até o diagnóstico. Através da descoberta e desenvolvimento, fornecemos matérias-primas de ciência da vida essenciais usadas em testes imunológicos e moleculares para aplicações humanas, animais, vegetais e ambientais. Através do diagnóstico, fornecemos soluções de diagnóstico em áreas incluindo infecções gastrointestinais e respiratórias superiores e testes de nível de chumbo no sangue. Criamos relacionamentos e fornecemos soluções para hospitais, laboratórios de referência, centros de pesquisa, centros de testes veterinários, consultórios médicos, fabricantes de diagnósticos e empresas de biotecnologia em mais de 70 países ao redor do mundo.
As ações da Meridian são negociadas na NASDAQ Global Select Market, símbolo VIVO. O website da Meridian é [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RUMuOpqFoL0CFwQptHmBkoRdrxdvDgSSS_3mLSZSbFc3YRMlQD0ALWqpZmjFqFhWoZy7l0GrjOnjYG-ov15VQwJ9Es-duZCqkIHkYWRiVf_j2Xr5xvvkFQiQrcnSqKBc "www.meridianbioscience.com").
**Contato:**
Jack Kenny
CEO
Meridian Bioscience, Inc.
Telefone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hOvXhYEc3oaPrs6LJge0iYXDKOnkN64KXK2XTDy9vlPbD8okBvs7iepvvZ7MJlF6NCyx43SoNHviMWSJrWvL-aJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian lanza nueva polimerasa de alta fidelidad para ofrecer amplificación robusta para aplicaciones NGS y PCR](https://www.meridianbioscience.com/press-release/meridian-lanza-nueva-polimerasa-de-alta-fidelidad-para-ofrecer-amplificacion-robusta-para-aplicaciones-ngs-y-pcr/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) anuncia hoy el lanzamiento de Mix HS de Pfu de Alta Especificidad que además de ofrecer amplificación de alta fidelidad, también ofrece amplificación líder del mercado para diagnóstico complementario (CDx) y ensayos clínicos.
La amplificación de alta fidelidad es esencial para aplicaciones cuyo resultado depende de la secuencia del ADN correcta, como secuenciación de próxima generación (NGS), clonación y genotipeo. Sin embargo, los resultados de tales amplificaciones pueden ser comprometidos por un ADN polimerasa incapaz de amplificar uniformemente los diversos tipos de secuencias o si las muestras contienen inhibidores.
La División de Ciencias Biológicas de Meridian Bioscience abordó esos desafíos desarrollando el Mix HS de Pfu de Alta Especificidad como una solución de amplificación de alta fidelidad, con propiedades líderes de mercado en términos de resistencia a inhibidores, multiplexación y baja polarización GC. Es una herramienta perfecta para las tecnologías NGS aplicadas al mercado clínico, en especial en el campo de ensayos genéticos y diagnóstico de cáncer, i.e., el desarrollo de paneles para perfiles de tumor o mutación.
La Dra. Lourdes Weltzien, Ph.D., vicepresidenta ejecutiva de Ciencias Biológicas, comentó, “las polimerasas de alta fidelidad han sido susceptibles a dificultades en amplificación de PCR del DNA rico o inhibidor rico de GC. El Mix HS de Pfu de Alta Especificidad redujo drásticamente estas limitaciones y aumentará las capacidades de prueba de los clientes”.
“En ensayos clínicos basados en NGS, la capacidad secuenciar todas las regiones de ADN de la muestra independientemente del contenido de GC es esencial. Utilizando nuestra vasta experiencia en enzimas y sistemas reservas, el Mix HS de Pfu de Alta Especificidad ha sido diseñado para lograr esto. Desde el enriquecimiento del objetivo a la amplificación de la biblioteca, permite mejores datos de NGS y resultados más precisos”, dice Florent Chang-Pi-Hin, Ph.D., director senior de investigación y desarrollo de Meridian.
**Acerca de Meridian Bioscience, Inc.**
Meridian es una compañía de ciencias biológicas totalmente integrada dedicada al desarrollo, fabricación, comercialización y distribución de una amplia gama de productos de diagnóstico innovadores. Nos dedicamos al desarrollo y entrega de mejores soluciones que proporcionan respuestas con velocidad, precisión y simplicidad que redefinen las posibilidades de la vida desde el descubrimiento al diagnóstico. A través del descubrimiento y desarrollo, ofrecemos materias primas de ciencias biológicas esenciales utilizadas en pruebas inmunológicas y moleculares para aplicaciones humanas, animales, vegetales y ambientales. A través del diagnóstico, ofrecemos soluciones de diagnóstico en áreas incluyendo infecciones gastrointestinales y de las vías respiratorias superiores y pruebas de nivel de plomo en la sangre. Creamos relaciones y ofrecemos soluciones para hospitales, laboratorios de referencia, centros de investigación, centros de pruebas veterinarias, consultorios médicos, fabricantes de diagnósticos y empresas de biotecnología en más de 70 países en todo el mundo.
Las acciones de Meridian se cotizan NASDAQ Global Select Market, símbolo VIVO. La dirección del sitio web de Meridian es, www.meridianbioscience.com.
**Contacto:**
Jack Kenny
Director de Operaciones
Meridian Bioscience, Inc.
Teléfono: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian เปิดตัวพอลิเมอเรสความแม่นยำสูงแบบใหม่เพื่อให้การเพิ่มจำนวนที่แข็งแกร่งสำหรับประโยชน์ในงานวิเคราะห์ NGS และ PCR](https://www.meridianbioscience.com/press-release/meridian-เปิดตัวพอลิเมอเรสความ/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
ซินซินนาติ, Jan. 24, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) ได้ประกาศในวันนี้ถึงการเปิดตัว High-Specificity Pfu HS Mix ซึ่งไม่เพียงแต่ให้การเพิ่มปริมาณที่มีความแม่นยำสูง แต่ยังส่งมอบการเพิ่มจำนวนชั้นนำในตลาดสำหรับการทำการจำลองทดสอบยา (CDx) และการทดสอบทางคลินิก
การเพิ่มจำนวนที่มีความแม่นยำสูงเป็นสิ่งจำเป็นสำหรับประโยชน์ในงานวิเคราะห์ ซึ่งผลลัพธ์ขึ้นอยู่กับลำดับ DNA ที่ถูกต้อง เช่น เทคโนโลยีถอดรหัสพันธุกรรม (NGS), การโคลนนิ่ง และการจีโนไทป์ อย่างไรก็ตาม ผลลัพธ์จากการเพิ่มจำนวนดังกล่าวสามารถถูกขัดขวางได้โดย DNA พอลิเมอเรสที่ไม่สามารถขยายลำดับรูปแบบที่หลากหลายอย่างเท่าเทียมกัน หรือหากตัวอย่างมีสารยับยั้ง
แผนกวิทยาศาสตร์ชีวภาพแห่ง Meridian Bioscience ได้จัดการกับความท้าทายเหล่านี้โดยการพัฒนา High-Specificity Pfu HS Mix ให้เป็นโซลูชันการเพิ่มจำนวนที่มีความแม่นยำสูง พร้อมด้วยคุณสมบัติชั้นนำของตลาดในด้านการต้านทานสารยับยั้ง การมัลติเพล็กซ์ และความเบี่ยงเบน GC ต่ำ ซึ่งนี่คือเครื่องมือที่สมบูรณ์แบบสำหรับเทคโนโลยี NGS ที่นำไปใช้กับตลาดทางคลินิก โดยเฉพาะอย่างยิ่งในด้านการทดสอบทางพันธุกรรมและการตรวจคัดกรองมะเร็ง เช่น การพัฒนาผู้เชี่ยวชาญด้านเนื้องอก หรือการรวบรวมข้อมูลการกลายพันธุ์
Lourdes Weltzien, Ph.D., รองประธานกรรมการบริหารแผนกวิทยาศาสตร์ชีวภาพได้กล่าวว่า “พอลิเมอเรสความแม่นยำสูงนั้นมีความอ่อนไหวต่ออุปสรรคในการเพิ่มจำนวน PCR ของ DNA ที่อุดมด้วย GC หรือ DNA ที่อุดมไปด้วยสารยับยั้ง High-Specificity Pfu HS Mix ได้ลดข้อจำกัดเหล่านี้ลงอย่างมาก และจะเพิ่มความสามารถในการทดสอบของลูกค้า”
“ในการทดสอบทางคลินิกที่ใช้ NGS นั้น ความสามารถในการจัดลำดับบริเวณของ DNA ทั้งหมดของตัวอย่างอิสระจาก GC-content คือสิ่งที่จำเป็น ด้วยความเชี่ยวชาญที่กว้างขวางของเราเกี่ยวกับเอนไซม์และระบบบัฟเฟอร์ ทำให้ High-Specificity Pfu HS Mix ได้รับการออกแบบมาเพื่อบรรลุเป้าหมายนี้ ตั้งแต่การเพิ่มประสิทธิภาพของเป้าหมายไปจนถึงการเพิ่มจำนวนคลังเก็บ จะช่วยให้ข้อมูล NGS ที่ดีขึ้นและผลลัพธ์ที่แม่นยำยิ่งขึ้น” Florent Chang-Pi-Hin, Ph.D. ผู้อำนวยการอาวุโสฝ่ายการวิจัยและพัฒนาที่ Meridian กล่าว
**เกี่ยวกับ Meridian Bioscience, Inc.**
Meridian เป็นบริษัทด้านชีววิทยาศาสตร์บูรณาการเต็มรูปแบบที่พัฒนา ผลิต ทำการตลาด และจัดจำหน่ายชุดทดสอบสำหรับการวินิจฉัยอันล้ำสมัยหลากหลายประเภท เราทุ่มเทเพื่อการพัฒนาและนำเสนอโซลูชันที่ดีกว่าที่จะให้คำตอบด้วยความเร็ว แม่นยำ และเรียบง่ายที่กำหนดโอกาสรอดชีวิตตั้งแต่การค้นพบ ไปจนถึงการวินิจฉัย เราได้ให้บริการด้านวัตถุดิบทางวิทยาศาสตร์ชีวภาพที่สำคัญ ซึ่งใช้ในการทดสอบด้านภูมิคุ้มกันและโมเลกุลสำหรับการใช้งานสำหรับมนุษย์ สัตว์ พืช และสิ่งแวดล้อมผ่านการค้นพบและการพัฒนา เราให้บริการโซลูชันการวินิจฉัยเฉพาะพื้นที่ รวมถึงการติดเชื้อในทางเดินอาหารและทางเดินหายใจส่วนบน และการทดสอบระดับตะกั่วในเลือดผ่านการวินิจฉัย เราได้สร้างความสัมพันธ์และส่งมอบโซลูชันให้กับโรงพยาบาล ห้องปฏิบัติการอ้างอิง ศูนย์วิจัย ศูนย์ทดสอบสัตวแพทย์ สำนักงานแพทย์ ผู้ผลิตชุดวินิจฉัย และบริษัทด้านเทคโนโลยีชีวภาพในกว่า 70 ประเทศทั่วโลก
หุ้นของบริษัทซื้อขายบนตลาด Global Select Market ของ NASDAQ โดยมีสัญลักษณ์คือ VIVO ที่อยู่เว็บไซต์ของ Meridian คือ www.meridianbioscience.com
**ติดต่อ:**
Jack Kenny
ประธานเจ้าหน้าที่บริหาร
Meridian Bioscience, Inc.
โทร: 513.271.3700
อีเมล: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hN2oc3igQ259Oj8yI1ty7Ytrtz5hiTkFNb-2oEELwsRbeNhKdYR5tG4Fn-fRvU2T0x-M9y09ptWK5JKQ_udOffd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-better-than-expected-preliminary-second-quarter-fiscal-2020-revenue-results-with-double-digit-growth/)
**Published:** April 2, 2020
**Author:** hamza
**Content:**
CINCINNATI, April 02, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020.
**Preliminary Second Quarter Results** The Company expects second quarter of fiscal 2020 revenues to be approximately $57 million, compared to $50.2 million in the second quarter of fiscal 2019. This increase is driven primarily by Life Science segment revenues which are expected to be between $22 and $23 million for the quarter. Continuing its recovery, the Diagnostics segment also contributed to the growth with revenue expected to be between $34 and $35 million for the quarter.
The Life Science segment achieved record sales in the quarter, produced by unprecedented demand for its molecular products, specifically those designed for the detection of RNA viruses such as SARS-CoV-2. Demand continues to accelerate and while the longevity of the COVID-19 pandemic is unclear, increased revenue year-over-year in the third quarter of fiscal 2020 is also expected. Additionally, order patterns from our top IVD manufacturing customers returned to expected volumes in the quarter.
The Diagnostics segment returned to growth in the second quarter of fiscal 2020 after year-over-year declines in each of the previous five quarters. Strong sales of respiratory related products were offset by lower demand for non-critical care related products. The Company also saw continued stabilization of the Molecular business in the quarter. As announced on March 16th, the Diagnostics business also received FDA approval for the Curian® analyzer and the Curian® HpSA® assay, which are expected to begin shipping in the third quarter of fiscal 2020.
“We continue to be proud of the contribution that Meridian is making in the global fight against the COVID-19 pandemic. Our reagents are now included in 35+ diagnostic tests across China, Australia, Europe and the United States, and the Life Science team is working tirelessly to keep up with the demand,” said Jack Kenny, Chief Executive Officer. “Traction in Diagnostics continues and I look forward to more growth in that segment of the business as we bring new products to market over the next 12 – 24 months.”
Meridian is not updating its fiscal year 2020 guidance at this time. The full financial results and any changes to fiscal 2020 guidance will be discussed on our second quarter earnings call, currently scheduled for Friday, May 8, 2020. Exact details for that event will be announced in a future press release.
**Update on Pending Acquisition of Exalenz Bioscience**
Exalenz Bioscience shareholders approved the proposed merger with Meridian on March 31, 2020. While the merger remains subject to the satisfaction of other customary closing conditions, the Company continues to expect to complete the acquisition before June 30, 2020.
**COVID-19 Impacts**
Meridian’s number one focus has been on protecting the health and welfare of the Meridian family, followed closely behind by meeting our commitments as a critical supplier to the health care industry. To date, Meridian has been successful in meeting both objectives.
Meridian has not experienced any material supply chain issues to date. Meridian maintains relationships with a number of critical suppliers operating in countries around the world including areas that are currently under or could be under “shelter in place” or similar orders. Just as Meridian serves as a critical supplier to the health care industry, many of our suppliers also are deemed to be critical businesses, which are generally exempt from governmental orders to temporarily cease operations; however, in some cases our suppliers may still not be able to operate or have reduced capacity due to staff that are unable to report to work for a variety of reasons. In general, Meridian maintains a multi-month inventory of raw materials and other components, and our suppliers continue to meet our demand. Where there has been some disruption or delay in supply, we have qualified backup suppliers and are continuously monitoring our supply chains.
Many of our clinical trial partners have suspended operations, which will likely result in delays for our products in the pipeline. This includes new assays for the revogene® and Curian® platforms, as well as our new PediaStat® system and its initial lead assay. While those new assays were not expected to receive FDA approval and contribute to revenue in fiscal 2020, their ultimate approval and contribution will be delayed, the extent to which remains unknown. For fiscal 2020, we expect this to reduce our R&D spending below our previously communicated amounts.
Meridian’s outlook on future periods and the aforementioned impacts reflect facts, circumstances and the Company’s assumptions as of today. The impacts of COVID-19 are evolving daily and the extent to which COVID-19 impacts Meridian’s business, operations, and financial results, including the duration and magnitude of such impacts, will depend on numerous risks , uncertainties and other factors the Company may not be able to accurately predict, including those discussed in the Risk Factors set forth in Meridian’s Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, those described below.
In this press release we make statements about our expectations relating to the proposed acquisition of Exalenz Bioscience. Risks and uncertainties related to this transaction include, but are not limited to: the parties’ ability to satisfy the terms and conditions of the merger agreement; the diversion of management time on transaction-related issues; Meridian’s ability to successfully integrate the businesses, operations and technology of Exalenz; risk of failure of the acquisition to achieve its plans and objectives generally; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies or cost savings from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products.
With respect to other risks, uncertainties and other factors, Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Investor Relations
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=yJS2LZL0AOmQnU7GT2YsWNq7vdjn1EJflRr1SVAF9t-Ko_uL1gXLkOxz5PQDdD1CafUlIJ4WhtW-Z1KoBRm06_ZQI_u7bUzg2escYsSewPo3qEDC_ULiaPvCLz63lKkY "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation](https://www.meridianbioscience.com/press-release/meridian-bioscience-supports-diagnostic-companies-in-fighting-coronavirus-pandemic-by-providing-zero-cost-proprietary-technology-for-evaluation/)
**Published:** March 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection. By utilizing Meridian’s specialized enzyme formulations (Fast RT-qPCR Mix and Lyo-Ready 1-Step RT-qPCR Mix) it is Meridian’s hope that diagnostic companies around the world will be able to develop COVID-19 detection assays with greater sensitivity, faster run-times and formatted for high throughput testing. In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation. Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.
In a statement earlier today Todd Howren, Ph.D., Vice President of Global Sales of Life Science said the following, “We are excited to partner with molecular diagnostic companies around the world in our common fight against COVID-19. Many Molecular Diagnostic companies in the United States, China, and Europe have already incorporated Meridian’s technologies in their assays. By making these master mixes available at no charge for initial testing and development, it is our hope that we can accelerate the availability of new COVID-19 test kits and that faster, more economical and more sensitive assays will be developed in the fight against this deadly pathogen.”
Meridian is committed to supplying solutions to the diagnostic industry during times of a pandemic health crisis. For more information on receiving an initial evaluation and testing sample please reply by email to info@meridianlifescience.com.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President of Investor Relations
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=2Cq4jzuoUSInF6Vxv9x06FAHYB38Uc6lxvM0fktm84IJm0lLLLn3BX2O3oGSh3rK7XEFn-aTgqgUkNFtGdCQahRUai6OrRRwzMgBFrGSCnk24k_2Ap6gm5gTCxkwSi3s "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-fda-clearance-for-new-curian-analyzer-and-the-curian-hpsa-assay/)
**Published:** March 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay. This analyzer and first assay play an important part in their initiative to maintain leadership in the gastrointestinal disease testing market.
Curian and Curian HpSA are designed to quickly detect *Helicobacter* *pylori* antigens in human stool using immunofluorescent technology. Curian HpSA is intended to aid in the diagnosis of *H. pylori* infection and to demonstrate loss of *H. pylori* antigen following treatment (i.e., confirmation of eradication). With a simple workflow and clean, comfortable sample handling; Curian HpSA provides healthcare systems a platform looking to standardize *H. pylori* testing from the industry’s leading experts in stool handling and testing.
The immunofluorescent technology of the Curian platform provides an objective, rapid *H. pylori* result with state-of-the-art clinical sensitivity, specificity, and a lower limit of detection than traditional rapid immunoassay testing. Combined with LIS connectivity, the Curian solution helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based test results. “This is the first new platform internally developed at Meridian in several years,” said Dr. Larry Mertz, Senior Vice President of Research and Development / Clinical, “and the first of many new products we have in the pipeline continuing Meridian’s rich history of innovation.”
Meridian Bioscience offers an unparalleled *H. pylori* portfolio that accommodates any laboratory setting from low volume rapid testing to high volume automation, including the LIAISON**®** Meridian *H. pylori* SA test. Jack Kenny, Chief Executive Officer, commented “Curian offers both competitive performance and reduced subjectivity with only a three-step workflow. This is yet another step Meridian is taking toward providing diagnostic platforms for healthcare systems looking to standardize testing, improve patient outcomes, and increase clinician satisfaction rates.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President of Investor Relations
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=n2GfYka1cQrmgUdmOwdt6ZVwISV8AiR1yGob38M4EULGYswHFo1eXlvhUMcDk5RrdYji4a9E4ijsYDeU2exXS6moq5JrTeOCK3H_PYLvzOHggZmPkfCEdZ_9Bxmthejr)
**Categories:** Press Release
---
### [Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers](https://www.meridianbioscience.com/press-release/meridians-novel-air-dryable-qpcr-mix-decreases-costs-and-simplifies-workflows-for-molecular-test-manufacturers/)
**Published:** February 26, 2020
**Author:** hamza
**Content:**
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix. This specialized master mix offers a cost-effective and easier alternative to freeze-drying for ambient temperature stable real-time PCR assays.
Meridian’s Air-Dryable qPCR Mix has been designed to simplify assay development and workflow through a magnesium containing formulation allowing air or oven drying protocols. Incorporation of the Air-Dryable qPCR mix in MDx assays allows dry down and test stability at ambient temperature, removing the need for cold chain shipping and storage. The Meridian Air-Dryable qPCR Mix shows exceptionally high performance in multiplex reactions following rehydration, making it ideally suited for automated high-throughput platforms.
Molecular diagnostic tests are progressively moving towards a dried down format; however, there are technical challenges in developing lyophilization-compatible mixes that require expensive lyophilization equipment. Building on its expertise in ready-to-use, lyophilization-compatible products, the Life Science division of Meridian Bioscience has successfully developed a ready-to-use, air-dryable mix to suit a growing demand within the molecular diagnostics industry for less complicated and cost-effective method of drying their assays.
Lourdes Weltzien, PhD, Executive Vice President, commented, “We are proud to announce the release of our new Air-Dryable qPCR Mix. We now have an alternative to our Lyo-Ready qPCR products that is ideal for our IVD and industry customers looking to increase operational efficiencies while reducing their overall costs. We remain committed to bringing innovation and quality products to molecular assay development.”
Florent Chang-Pi-Hin, PhD, Senior Director of Research and Development added, “We have seen a significant increase in demand for our Lyo-Ready mixes, however not all our customers have the expertise in house to do lyophilization. Following increasing customer demands, we have developed the Air-Dryable qPCR Mix as an easier and economic alternative that still provides the high accuracy expected of our qPCR products. The incorporation of magnesium in this optimized formulation is a great achievement and will enable our customers to simplify and speed up their assay development and workflow.”
For complete information, please visit meridianlifescience.com/molecular-dx-reagents.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Meridian Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=40VKAQoTeqUMsmeKLqZicOY0Cv-Yr62vn69SV27oaHWROdmPm2wtAGU2tVS0xM-1fiID4qsprkvN1MWDp_UIPqcT53fhlMWz6RraE41Hy2Qap4VWyFinbqSBpPaDe2AL)
**Categories:** Press Release
---
### [Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform](https://www.meridianbioscience.com/press-release/meridian-bioscience-signs-definitive-agreement-to-acquire-exalenz-bioscience-adds-state-of-the-art-urea-breath-test-diagnostics-platform/)
**Published:** February 19, 2020
**Author:** hamza
**Content:**
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million. The agreement has been approved unanimously by the boards of directors of both companies.
With this acquisition, Meridian will be adding Exalenz’s flagship BreathID® Breath Test Systems, a urea breath test platform for the detection of *Helicobacter pylori*, often associated with peptic ulcers and gastric cancer. BreathID® furthers Meridian’s strategy to be the leading provider of gastrointestinal diagnostic solutions. The platform offers patient-friendly, noninvasive sample collection, along with best in class sensitivity and specificity for both adult and pediatric patients. The point-of-care system delivers immediate results with real-time patient monitoring in a physician office setting, while the lab system facilitates easy patient sample collection at the clinic or patient service center for analysis in the lab. The BreathID® platform compliments Meridian’s stool antigen tests, and leverages Meridian’s existing channel presence to become the leading US company with comprehensive non-invasive diagnostic solutions for *H. pylori*.
Jack Kenny, Chief Executive Officer, commented, “Our focus has been to drive our strategy to re-position our Diagnostics business for sustainable, long-term growth. Exalenz’s BreathID® platform is an excellent fit for our customers, allowing Meridian to offer gastrointestinal testing solutions from low volume point-of-care labs to high volume reference labs. No matter their preference for approach to *H. pylori* diagnosis, our customers will have a solution that meets their needs. We are very excited to be adding yet another state-of-the-art technology to our portfolio and thrilled to welcome Exalenz to the Meridian family.”
“We are excited to contribute our technology to the Meridian portfolio of *H. pylori* products and leverage Meridian’s strong commercial presence to accelerate the penetration of the BreathID® platform in the United States and beyond,” said Raffi Werner, CEO of Exalenz. “We also look forward to collaborating with the Meridian R&D team in our on-going advancement of this leading platform.”
**Summary Transaction Terms and Impact**
Exalenz shareholders will receive ₪6.10 per share in cash under the terms of the merger. This purchase price implies a total equity value of ₪169 million or approximately $49 million at prevailing exchange rates. The transaction will be financed with cash on hand and debt available under Meridian’s credit facility, which is being expanded to $160 million.
The acquisition is subject to Exalenz shareholder approval and other customary closing conditions. Exalenz’s majority shareholder has entered into a voting agreement pursuant to which he has agreed to vote his shares of Exalenz in favor of the merger. A majority of the remaining shareholders of Exalenz must vote in favor of the merger.
The transaction is expected to close in Q2 of calendar year 2020. In 2019, Exalenz generated approximately $14 million in revenue, representing a 5-year CAGR of ~32%, with a gross profit margin of ~50%. Meridian will discuss the fiscal year 2020 financial impact of the transaction during its fiscal Q2 earnings call in May.
Rothschild & Co is acting as exclusive financial advisor and Keating Muething & Klekamp PPL and Amit, Pollak, Matalon & Co are acting as legal counsel to Meridian. William Blair & Co and Poalim Capital Markets are acting as exclusive financial advisors and Meitar Law Offices and Abramson & Co are acting as legal counsel to Exalenz.
**Cautionary Statement Regarding Forward-Looking Statements**
Certain statements in this communication regarding the proposed acquisition of the business of Exalenz Bioscience Ltd. by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company, including its strategies, products and technologies, future financial performance and any other statements regarding Meridian’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions, and the negative versions thereof, are intended to identify forward-looking statements.
Forward-looking statements speak only as of the date they are made. Forward-looking statements are based on Meridian’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Meridian’s control. Such risks and uncertainties could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the parties’ ability to satisfy the terms and conditions of the merger agreement; the diversion of management time on transaction-related issues; Meridian’s ability to successfully integrate the businesses, operations and technology of Exalenz; risk of failure of the acquisition to achieve its plans and objectives generally; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies or cost savings from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations, legislation, and other regulatory actions and initiatives, the regulatory process for new products and indications, manufacturing issues that may arise, stock price volatility, fluctuations in exchange rates for future sales denominated in foreign currency, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian’s filings with the SEC and available through the SEC’s Electronic Data Gathering and Analysis Retrieval system at [www.sec.gov](https://www.globenewswire.com/Tracker?data=seuuYiUFa6a-NrbZ2yORNbAhEuS8HZidq7-eQGkFgJG6P0iNggw3SAE-qLYbYZOmjw88Uj7nwrhbVIt7bXw3xA==), including Meridian’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
**About Exalenz Bioscience Ltd.**
Exalenz Bioscience develops and markets diagnostic tests and monitoring systems that use the breath to diagnose and help manage gastrointestinal and liver conditions. The company’s flagship BreathID® Hp Systems offer the most efficient and accurate test for detection of *H. pylori* bacteria, associated with various illnesses including gastric cancer, and is already in use in over 400 U.S. medical centers and major labs across the country. Exalenz holds regulatory approvals in the United States, Europe, China and Israel for H. pylori detection and is currently evaluating additional applications of the BreathID platform.
Exalenz’s shares are traded on the Tel Aviv Stock Exchange, symbol EXEN. Exalenz’s website is www.exalenz.com.
**Exalenz Contact:**
Hadas Friedman-Zick
Investor Relations
Phone: +972-3-516-7620
Email: [hadas@km-ir.co.il](https://www.globenewswire.com/Tracker?data=AqVEeZueGPbusvA8BAkPnHMm6vuSZPQm1LFqY54rexsADCxYRMmWzGRRkrXlg7K6ORIyePPDFQAU4c_Bfoaceg==)
www.km-ir.co.il
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Meridian Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=HbLlfNMMYwof29On6bafDxVswr-eujFxffDV4pbAXOJ3FqG8HBPm2U3I9uilAvFzQZ24NnTQAKoQg74aEyuC3Y_J6YnsCbkQZlq0WUFJI3-onLRCkbTfQsfpO98IkPTW "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-first-quarter-fiscal-2020-operating-results-and-reaffirms-2020-guidance/)
**Published:** February 7, 2020
**Author:** hamza
**Content:**
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019.
**First Quarter Fiscal 2020 Highlights:**
- Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business;
- Positive customer feedback for our revogene™ molecular diagnostics system continues to build;
- Diagnostics segment new product development spending increased $1 million, as positive progress continues on key new instrument platforms;
- Lower ordering patterns of top IVD manufacturing customers led to lower Life Science revenues, which we expect to turn around over the remainder of the fiscal year;
- Operating results reflect sound financial discipline, while still driving needed investments in the business; and
- Management reaffirms the following consolidated fiscal 2020 guidance, including segment guidance, as set forth in the Company’s November 7, 2019 earnings release:
> –Consolidated Revenues – Flat to down 3%
> –Consolidated Adjusted Operating Margin – 9% to 10%
> –Consolidated Adjusted Earnings Per Share on a Diluted Basis – $0.28 to $0.34
Jack Kenny, Chief Executive Officer, commented, “I am pleased with our first quarter results, particularly for our Diagnostics business, where we achieved our highest revenue since the fiscal 2019 first quarter. We observed dramatically slower customer account losses within our molecular assay products and delivered double-digit revenue growth in our blood chemistry products. We are pleased that our revogene™ molecular system installations reached 114 as of the end of calendar 2019, and we continue to target approximately 20 installations each month. We are currently working operationally to scale up the production capabilities for both revogene™ instruments and consumables. We continue to be encouraged by positive customer feedback on the ease-of-use of this system, as well as customers who choose to add new assays when converting from our alethia™ molecular system. New product development efforts on our three diagnostic instrument platforms (revogene™, Curian™ and PediaStat™) continue with positive progress, and we are standing by our commitment to invest more into organic growth opportunities. For our Life Science business, order patterns with our top IVD manufacturing customers were disappointing, but we believe strongly in our strategy of being the partner of choice for immunoassay and molecular reagents and expect improved performance in the remaining quarters of the fiscal year. Although not included in our first quarter results, in January, we began shipping molecular reagents to IVD manufacturing customers in China to help health care systems in that country combat the Coronavirus outbreak. We are proud that our Life Science division can play a role in efforts to bring the outbreak under control. Finally, as part of our strategy, we continue to explore business development opportunities that could accelerate our return to growth.”
**First Quarter Fiscal 2020 Results (Comparison to First Quarter Fiscal 2019)**
Consolidated revenue for the first quarter of fiscal 2020 decreased 8% to $47.4 million, compared to $51.5 million last year. Diagnostics segment revenues were down 5%, while Life Science segment revenues were down 15%. Our Diagnostics segment experienced 5% declines in both our molecular products and our immunoassay/blood chemistry products. Our molecular business exhibited significant stabilization with customer account losses in our molecular assay products slowing dramatically. We experienced strong customer response to our revogene™ system with the install base reaching 114 systems. Lower contract pricing for certain gastrointestinal products for our National Reference Laboratory customers contributed to the decline in Diagnostics segment revenues. Importantly, double-digit revenue growth was achieved during the quarter for our blood chemistry products. Our Life Science segment revenues for the quarter reflected lower ordering patterns with our top IVD manufacturing customers, which we expect to turn around over the remainder of the fiscal year. Revenue from sales into China remain strong, increasing approximately 70% over the first quarter of fiscal 2019.
Reported operating income for the first quarter of fiscal 2020 was $5.4 million, including: (i) expectedly higher research and development spending in the Diagnostics segment ($1.0 million); (ii) purchase accounting amortization related to the acquisition of the GenePOC business in June 2019 ($0.9 million); and (iii) an increase in the fair value of the earnout obligation for the acquisition of the GenePOC business ($1.2 million). Excluding the effects of the change in the fair value of the contingent consideration obligation for the GenePOC business, restructuring activities, and selected legal matters, adjusted operating income achieved a margin of 15% (see non-GAAP financial measure reconciliation below).
Earnings per diluted share on a reported GAAP basis totaled $0.07 for the first quarter of 2020, and adjusted earnings per diluted share totaled $0.10 for the quarter. Adjusted earnings per diluted share exclude the after tax effect of the change in the fair value of the contingent consideration obligation for the GenePOC business, restructuring activities, and selected legal matters (see non-GAAP financial measure reconciliation below).
**Financial Condition**
At December 31, 2019, cash and equivalents were $68.6 million and the Company had $49.2 million of borrowing capacity under its $125.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $75.8 million as of December 31, 2019.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, February 7, 2020 beginning at 10:00 a.m. Eastern Time to discuss the first quarter financial results and answer questions. A presentation to accompany the first quarter financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=D7q61CJ_aRmf5vY1cy4n4OIawaq09sjXVO-UXcurc7DhTMt7YbfV7mg7QQIsFmbZrCiFFJgrSF0IZ89GLx2OjRGsjMzTD8nVkSFdkp7z0ztAkGTU76Y78Xl4KelFQzhV), on February 7, 2020 prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 2496742. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on February 7, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 2496742.
**FIRST QUARTER FISCAL 2020 UNAUDITED OPERATING RESULTS**(In Thousands, Except per Share Data) The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the first quarters of fiscal 2020 and fiscal 2019. Three Months Ended December 31, 2019 2018 Net revenues$ 47,421 $ 51,480 Cost of sales 19,981 19,908 Gross profit 27,440 31,572 Operating expenses Research and development 4,824 3,967 Selling and marketing 6,684 7,563 General and administrative 8,756 8,902 Change in fair value of contingent consideration obligation 1,187 – Restructuring costs 275 – Selected legal costs 320 589 Total operating expenses 22,046 21,021 Operating income 5,394 10,551 Other expense, net (1,368) (75) Earnings before income taxes 4,026 10,476 Income tax provision 1,199 2,370 Net earnings$ 2,827 $ 8,106 Net earnings per basic common share$ 0.07 $ 0.19 Basic common shares outstanding 42,789 42,446 Net earnings per diluted common share$ 0.07 $ 0.19 Diluted common shares outstanding 42,938 42,905
Three Months Ended December 31, 2019 2018 **Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$ 7,176 $ 11,140 Net earnings 4,179 8,558 Net earnings per diluted common share$ 0.10 $ 0.20
Condensed Balance Sheet Data**
December 31, 2019 2018 Cash and equivalents$ 68,557 $ 61,523 Working capital 117,579 118,924 Long-term debt 75,824 49,063 Shareholders’ equity 197,292 178,642 Total assets 338,128 249,857
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2020 and fiscal 2019 (in thousands).
Three Months Ended December 31, 2019 2018 Net Revenues – By Product Platform/Type Diagnostics Molecular assays$ 6,887 $ 7,231 Immunoassays & blood chemistry assays 27,904 29,434 Total Diagnostics 34,791 36,665 Life Science Molecular reagents 5,357 6,615 Immunological reagents 7,273 8,200 Total Life Science 12,630 14,815 Total Net Revenues$ 47,421 $ 51,480
Three Months Ended December 31, 2019 2018 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$ 16,046 $ 18,615 Respiratory illness assays 7,749 7,981 Blood chemistry assays 5,150 4,430 Other 5,846 5,639 Total Diagnostics 34,791 36,665 Life Science Americas 4,019 4,521 EMEA 4,966 7,363 ROW 3,645 2,931 Total Life Science 12,630 14,815 Total Net Revenues$ 47,421 $ 51,480 OPERATING INCOME Diagnostics$ 4,408 $ 8,786 Life Science 3,061 5,129 Corporate (2,087) (3,391) Eliminations 12 27 Total Operating Income$ 5,394 $ 10,551 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of a change in fair value of contingent consideration obligation, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the first quarters ended December 31, 2019 and December 31, 2018.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FIRST QUARTER** **GAAP TO NON-GAAP RECONCILATION TABLES** (In Thousands, Except per Share Data) Three Months Ended December 31, 2019 2018 Operating Expenses – U.S. GAAP basis$22,046 $21,021 Change in fair value of contingent consideration obligation (1,187) – Restructuring costs (275) – Selected legal costs (320) (589) Adjusted Operating Expenses$20,264 $20,432 Operating Income – U.S. GAAP basis$ 5,394 $10,551 Change in fair value of contingent consideration obligation 1,187 – Restructuring costs 275 – Selected legal costs 320 589 Adjusted Operating Income$7,176 $11,140 Net Earnings – U.S. GAAP basis$ 2,827 $ 8,106 Change in fair value of contingent consideration obligation \* 901 – Restructuring costs \* 208 – Selected legal costs \* 243 452 Adjusted Earnings$ 4,179 $ 8,558 \* Net of tax
Three Months Ended December 31, 2019 2018 Net Earnings per Basic Common Share – U.S. GAAP basis$ 0.07 $ 0.19 Change in fair value of contingent consideration obligation 0.02 – Restructuring costs – – Selected legal costs 0.01 0.01 Adjusted Basic EPS $ 0.10 $ 0.20 Net Earnings per Diluted Common Share – U.S. GAAP basis$ 0.07 $ 0.19 Change in fair value of contingent consideration obligation 0.02 – Restructuring costs – – Selected legal costs 0.01 0.01 Adjusted Diluted EPS$ 0.10 $ 0.20
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Investor Relations
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1dGlyu9TDwMR3IOdtqhfyzccloGEQYrZeEeV_0InUPrzVDwh7hS2IC1aB1h3Hz-bzaMV1KL7zkc65U0hthWN1lEy05s96xYCeb7c3AgHUq95ltBR8G9h1v1ebRsDOiOY "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak](https://www.meridianbioscience.com/press-release/meridian-bioscience-lyo-ready-1-step-rt-qpcr-mix-is-used-in-the-development-of-molecular-diagnostics-for-new-coronavirus-outbreak/)
**Published:** January 27, 2020
**Author:** hamza
**Content:**
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the Chinese city of Wuhan, 56 people have already died and more than 2,000 confirmed infected. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic.
The World Health Organization (WHO) has provided interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with 2019-nCoV. Sequence information from the 2019-nCoV has recently been made available and diagnostic companies and laboratories in China have turned to Meridian’s Lyo-Ready 1-Step RT-qPCR Mix to develop fast and accurate screening assays. Meridian’s manufacturing team is working diligently to meet the supply of critical reagents for the detection of Coronavirus and fast response to the outbreak.
Dr. Liang Zhang, General Manager for Meridian in China, commented, “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run. This means that patients can be screened very quickly to help stop the spread of this virus. We are pleased to have a reagent that works so well and makes economic sense for Coronavirus diagnostics during these times of great urgency.”
Dr. Steve Hawkins, Product Marketing Manager added. “Over the last few days we have seen significant demand for our Lyo-Ready One-Step RT-qPCR Mix. This ready-to-use, lyophilization-friendly mix is designed to improve the accuracy of assays, increase operational efficiencies and reduce their overall costs, making screening fast and affordable, upholding our commit to bringing innovation and quality products to the IVD community, especially in times of need.”
For complete information, please visit meridianlifescience.com/molecular-dx-reagents.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=F6b3ISRxcy3Vt3_Zw_wSDgXXOGKiawPec0fJUq5WZTNia62Xthb9Cf9-obUlH_fLxivspYbt-Kz-rD7g7_O3jteC3NUP4SPBLeeM2QWkow231cZY7s8mpx92PvVZrCtE "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian推出了一种新的高保真聚合酶，为NGS和PCR应用提供稳健的扩增](https://www.meridianbioscience.com/press-release/meridian推出了一种新的高保真聚合酶，为ngs和pcr应用提供/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience，Inc.（纳斯达克：VIVO）今天宣布推出一种高特异性的Pfu-HS组合，不仅提供高保真度扩增，还为伴诊 (CDx) 和临床试验提供市场领先的扩增。
对于结果取决于正确DNA序列的应用（例如下一代测序 (NGS)、克隆和基因分型等）来说，高保真扩增必不可少。然而，如果样本含有无法均匀扩增不同类型的序列的DNA聚合酶或含有抑制剂，这可能会破坏从此类扩增得出的结果。
通过开发高特异性的PFU-HS混合作为高保真的扩增溶液，借助市场领先的抑制剂抗性性能，多路复用和低GC偏置，Meridian Bioscience生命科学部门解决了这些挑战。它是将NGS技术应用于临床市场的完美工具，特别是在基因检测和癌症筛查领域，即开发用于肿瘤或突变图谱分析的图谱。
生命科学执行副总裁Lourdes Weltzien博士评论道：“高保真聚合酶在富含GC或富含抑制剂的DNA进行PCR扩增时容易遇到困难。高特异性的Pfu-HS混合大大减少了这些限制，并将提高客户的测试能力。”
“在基于NGS的临床分析中，能够独立于GC含量对样本的所有DNA区域进行测序至关重要。利用我们在酶和缓冲系统方面的广泛专业知识，我们设计了高特异性Pfu-HS混合物来实现这一目标。从目标富集到文库扩增，它可以提供更好的NGS数据和更准确的结果，”Meridian研究与开发高级主管Florent Chang Pi Hin博士说。
**关于Meridian Bioscience, Inc.**
Meridian是一家开发、制造、销售和分销各种创新诊断产品的综合性生命科学公司。我们致力于开发和提供更好的解决方案，以快速、准确和简单的方式给出答案，重新定义从发现到诊断的生命可能性。通过发现和开发，我们为人类、动物、植物和环境应用提供用于免疫学和分子测试的关键生命科学原材料。通过诊断，我们提供用于胃肠道和上呼吸道感染以及血铅水平检测等领域的诊断解决方案。我们与全球70多个国家的医院、参考实验室、研究中心、兽医检测中心、医师办公室、诊断制造商和生物技术公司建立关系，并为其提供解决方案。
Meridian的股票在纳斯达克全球精选市场交易，股票代码是VIVO。Meridian的网址是 [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RUMuOpqFoL0CFwQptHmBkoRdrxdvDgSSS_3mLSZSbFc3YRMlQD0ALWqpZmjFqFhWoZy7l0GrjOnjYG-ov15VQwJ9Es-duZCqkIHkYWRiVf_j2Xr5xvvkFQiQrcnSqKBc "www.meridianbioscience.com")。
**联系人：**
Jack Kenny
首席执行官
Meridian Bioscience, Inc.
电话：513.271.3700
电子邮箱：[mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hOvXhYEc3oaPrs6LJge0iYXDKOnkN64KXK2XTDy9vlPbD8okBvs7iepvvZ7MJlF6NCyx43SoNHviMWSJrWvL-aJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian 推出一種新的高保真聚合酶，可為 NGS 和 PCR 應用提供可靠的擴增](https://www.meridianbioscience.com/press-release/meridian-推出一種新的高保真聚合酶，可為-ngs-和-pcr-應用提供/)
**Published:** January 23, 2020
**Author:** hamza
**Content:**
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) 今天宣佈推出高特異性 Pfu HS Mix，不但可提供高保真擴增，而且提供具有市場領先地位的擴增，用於伴隨診斷 (CDx) 和臨床測試。
高保真擴增對於結果取決於正確 DNA 序列的應用至關重要，例如下一代測序 (NGS)、複製和基因型分型。但這種擴增的結果可能會因為 DNA 聚合酶無法均勻擴增各類序列或一旦樣本含有抑製劑而受到影響。
Meridian Bioscience 的生命科學部透過研發高特異性 Pfu HS Mix 作為高保真擴增解決方案來解決上述挑戰，在抑製劑抗性、多重性和低 GC 偏倚方面具有市場領先的特性。這是將 NGS 技術應用在臨床市場中的理想工具，尤其是在基因檢測和癌症篩查方面，即研發用於腫瘤或突變圖譜的面板。
Life Science 行政副總裁 Lourdes Weltzien 博士表示：「高保真聚合酶一直非常易受富含 GC 或富含抑製劑 DNA 的 PCR 擴增困擾。高特異性 Pfu HS Mix 大幅降低了這些局限，且將提高客戶的測試能力。」
Meridian 研究與開發高級總監 Florent Chang-Pi-Hin 博士說：「在基於 NGS 的臨床測定中，能夠對樣本為所有 DNA 區域進行獨立於 GC 含量的測序實在非常重要。 利用我們在各種酶和緩衝系統方面的豐富專業知識，高特異性 Pfu HS Mix 經特別設計，以實現這項目標。從標靶增強到文庫擴增，它可以提供更好的 NGS 數據和更準確的結果。」
**關於 Meridian Bioscience, Inc.**
Meridian 是一家完全整合的生命科學公司，致力於開發、製造、營銷和分銷各種創新的診斷產品。我們致力開發和提供更好的解決方案，以快速、準確和簡單的方式帶來答案，重新定義從發現到診斷的生命潛力。透過發現和開發，我們提供用於人類、動物、植物和環境應用的免疫學和分子測試的重要生命科學原材料。透過診斷，我們在腸胃、上呼吸道感染以及血鉛水平測試等方面提供大量診斷解決方案。我們與全球 70 多個國家的醫院、參照實驗室、研究中心、獸醫測試中心、醫生辦公室、診斷製造商和生物技術公司建立緊密關係並提供解決方案。
Meridian 的股票在納斯達克全球精選市場上交易，交易代碼為 VIVO。Meridian 的網站地址是 [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RUMuOpqFoL0CFwQptHmBkoRdrxdvDgSSS_3mLSZSbFc3YRMlQD0ALWqpZmjFqFhWoZy7l0GrjOnjYG-ov15VQwJ9Es-duZCqkIHkYWRiVf_j2Xr5xvvkFQiQrcnSqKBc "www.meridianbioscience.com")。
**聯絡人：**
Jack Kenny
行政總裁
Meridian Bioscience, Inc.
電話：513.271.3700
電郵：[mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h8YaSo1LdriDEhdnQT-HErrtQb3O_hwMrCF7tYK40hOvXhYEc3oaPrs6LJge0iYXDKOnkN64KXK2XTDy9vlPbD8okBvs7iepvvZ7MJlF6NCyx43SoNHviMWSJrWvL-aJ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-second-quarter-2020-operating-results-raises-guidance-on-strength-of-covid-19-related-products/)
**Published:** May 8, 2020
**Author:** hamza
**Content:**
CINCINNATI, May 08, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020.
**Second Quarter Fiscal 2020 Highlights:**
- Consolidated Net Revenue of $57.3 million, up 14% year-over-year
- Life Science segment responded early and swiftly to the COVID-19 pandemic contributing to a record $22.4 million in revenues, up 33% year-over-year
- Diagnostics segment delivered over $34.9 million in revenue, the fifth consecutive quarter above $33 million and year-over-year growth for the first time in five quarters
- During the quarter, the Curian® analyzer and HpSA® assay received FDA clearance, the first internally developed new product in several years and the first of several in development
Jack Kenny, Chief Executive Officer, commented: “We had an extraordinary quarter on many fronts, led by our Life Science team’s rapid response to the COVID-19 pandemic. Our raw materials were included in millions of molecular tests globally and soon will be in millions more rapid antibody tests. Our Diagnostics segment delivered growth, soon to be supplemented with the contribution from our new Curian analyzer and assay. Our strategic initiatives are setting the foundation for growth, and I am excited about what’s to come.”
Bryan Baldasare, Chief Financial Officer, commented: “Despite the turmoil of the COVID-19 pandemic, our financial position remains strong. Demand for our Life Science products is unprecedented. We have confidence in the direction of the business and are raising our guidance for the year.”
**Second Quarter Fiscal 2020 Results (Comparison to Second Quarter Fiscal 2019)**
Consolidated revenue for the second quarter of fiscal 2020 increased 14% to $57.3 million, compared to $50.2 million in the second quarter of 2019. Diagnostics segment revenues were up 4%, while Life Science segment revenues were up 33%. Our Diagnostics segment experienced 2% growth in revenues from our molecular products and revenues from our immunoassay/blood chemistry products grew 5%. Our Life Science segment revenues for the quarter included $5.6 million in revenue from COVID-19 related products.
Reported operating income for the second quarter of fiscal 2020 was $11.8 million, reflecting strong leverage from record sales levels in our Life Science business. Operating expenses include: (i) expectedly higher research and development spending in the Diagnostics segment; (ii) acquisition-related costs in connection with the recent Exalenz acquisition; and (iii) purchase accounting amortization related to the acquisition of the GenePOC business in June 2019, as well as a favorable adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business. On an adjusted basis, operating income was $12.1 million and achieved a margin of 21% (see non-GAAP financial measure reconciliation below).
Earnings per diluted share on a reported GAAP basis totaled $0.22 for the second quarter of 2020, and adjusted earnings per diluted share totaled $0.23 for the quarter (see non-GAAP financial measure reconciliation below).
**Raising Fiscal 2020 Guidance**
Our performance fiscal year-to-date was well above our expectations. We are slightly ahead of last year’s first half revenue and already delivered Adjusted Diluted EPS at the upper end of our original guidance range for the full year. We expect this strong performance to continue, with our Life Science business more than compensating for the temporary reduction in demand for non-urgent care tests in our Diagnostics business, and are raising our guidance for the year.
Net Revenues:
- Consolidated $230 million to $236 million
- Life Science $110 million to $114 million
- Diagnostics $120 million to $122 million
Adjusted Operating Margin: Consolidated 18% to 19%
Adjusted Earnings Per Share on a Diluted Basis: $0.70 to $0.75
The revenue components of this guidance assume that our Life Science business will see COVID-19 related demand for molecular reagents used in PCR tests and immunological reagents used in serology tests ranging from $43 million to $47 million during the second half of our fiscal 2020, peaking in our third fiscal quarter and tapering in our fourth fiscal quarter. For our Diagnostics business, our assumptions include a 40% reduction in volumes for our third fiscal quarter, recovery to a 25% reduction in volumes for our fourth fiscal quarter, partially offset by modest contributions from the Exalenz acquisition and sales of a COVID-19 serology test. Our guidance also considers that our spending on clinical trials in fiscal 2020 will be lower than originally anticipated as the global COVID-19 pandemic has paused most of our clinical trial sites and also affected our ability to collect patient specimens. Overall operating expenses on an adjusted basis in fiscal 2020 are expected to be commensurate with our original expectations as additional cash incentive compensation will offset the lower spending on clinical trials.
This guidance reflects our current visibility into market conditions for our products and our current assumptions about the extent and duration of the impacts from this pandemic. We expect that our visibility will improve throughout the quarter as local governments around the world begin to relax shelter-in-place orders and healthcare systems return to normal operations with respect to diagnostic testing for infectious diseases and blood chemistry.
**Financial Condition**
At March 31, 2020, cash and equivalents were $49.6 million and the Company had $111.2 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $48.8 million as of March 31, 2020.
In connection with the April 30, 2020 acquisition of Exalenz, the Company drew an additional $50 million on the revolving credit facility, increasing the Company’s total bank-debt obligation under the bank credit facility to $98.8 million.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, May 8, 2020 beginning at 10:00 a.m. Eastern Time to discuss the second quarter financial results and answer questions. A presentation to accompany the second quarter financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=aWBj0goqTcWzo2LAADrjKCdBXYcrG5PN94I7xXIkzcq_rqmPasBfpKVMLYqLQIAUWPrKwh9OCs2KRyVYKunJCLfF6J65cJwTpQPPBFa_3QVr3yOJZExqvIQ6ac8Ns5py), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5872319. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on May 8, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5872319.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2020 and fiscal 2019.
Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019Net revenues$57,296 $50,248 $104,717 $101,728 Cost of sales 22,842 20,910 42,823 40,818 Gross profit 34,454 29,338 61,894 60,910 Operating expenses Research and development 5,386 3,816 10,210 7,700 Selling and marketing 6,514 6,911 13,198 14,474 General and administrative 10,480 7,388 19,236 16,286 Acquisition-related costs 1,787 885 1,787 972 Change in fair value of contingent consideration obligation (2,491) – (1,304) – Restructuring costs 252 (100) 527 (100) Selected legal costs 735 603 1,055 1,192 Total operating expenses 22,663 19,503 44,709 40,524 Operating income 11,791 9,835 17,185 20,386 Other income (expense), net 856 (588) (512) (663) Earnings before income taxes 12,647 9,247 16,673 19,723 Income tax provision 3,288 2,153 4,487 4,523 Net earnings$9,359 $7,094 $12,186 $15,200
Net earnings per basic common share$0.22 $0.17 $0.28 $0.36Basic common shares outstanding 42,830 42,496 42,810 42,472 Net earnings per diluted common share$0.22 $0.17 $0.28 $0.35Diluted common shares outstanding 42,968 42,946 42,953 42,925
**Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$12,074 $11,223 $19,250 $22,450 Net earnings 10,004 8,159 14,183 16,783 Net earnings per diluted common share$0.23 $0.19 $0.33 $0.39
**Condensed Balance Sheet Data**
March 31, 2020 2019 Cash and equivalents$49,550 $66,097 Working capital 98,704 120,583 Long-term debt 48,824 47,946 Shareholders’ equity 204,533 181,645 Total assets 319,074 253,964
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2020 and fiscal 2019 (in thousands).
Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 Net Revenues – By Product Platform/Type Diagnostics Molecular assays$7,238 $7,084 $14,077 $14,314 Immunoassays & blood chemistry assays 27,704 26,416 55,656 55,851 Total Diagnostics 34,942 33,500 69,733 70,165 Life Science Molecular reagents 11,534 5,390 16,892 11,998 Immunological reagents 10,820 11,358 18,092 19,565 Total Life Science 22,354 16,748 34,984 31,563 Total Net Revenues$57,296 $50,248 $104,717 $101,728 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$14,014 $16,177 $30,060 $34,792 Respiratory illness assays 10,863 7,553 18,612 15,534 Blood chemistry assays 4,329 4,330 9,479 8,760 Other 5,736 5,440 11,582 11,079 Total Diagnostics 34,942 33,500 69,733 70,165 Life Science Americas 4,612 5,454 8,627 9,976 EMEA 9,946 7,852 14,914 15,213 ROW 7,796 3,442 11,443 6,374 Total Life Science 22,354 16,748 34,984 31,563 Total Net Revenues$57,296 $50,248 $104,717 $101,728 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 OPERATING INCOME Diagnostics$ 3,842 $ 6,676 $ 8,250 $ 15,374 Life Science 10,818 5,361 13,879 10,492 Corporate (2,896) (2,216) (4,983) (5,521) Eliminations 27 14 39 41 Total Operating Income$ 11,791 $9,835 $ 17,185 $20,386
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of acquisition-related costs, a favorable change in fair value of the contingent consideration obligation, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the second quarters and six-month periods ended March 31, 2020 and March 31, 2019.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**SECOND QUARTER AND SIX MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Six Months Ended March 31, Ended March 31, 2020 2019 2020 2019Operating Expenses – U.S. GAAP basis$22,663 $19,503 $44,709 $40,524 Acquisition-related costs (1,787) (885) (1,787) (972) Change in fair value of contingent
consideration obligation 2,491 – 1,304 – Restructuring costs (252) 100 (527) 100 Selected legal costs (735) (603) (1,055) (1,192) Adjusted Operating Expenses$22,380 $18,115 $42,644 $38,460 Operating Income – U.S. GAAP basis$11,791 $9,835 $17,185 $20,386 Acquisition-related costs 1,787 885 1,787 972 Change in fair value of contingent
consideration obligation (2,491) – (1,304) – Restructuring costs 252 (100) 527 (100) Selected legal costs 735 603 1,055 1,192 Adjusted Operating Income$12,074 $11,223 $19,250 $22,450 Net Earnings – U.S. GAAP basis$9,359 $7,094 $12,186 $15,200 Acquisition-related costs \* 1,787 680 1,787 747 Change in fair value of contingent
consideration obligation \* (1,886) – (985) – Restructuring costs \* 190 (78) 398 (78) Selected legal costs \* 554 463 797 914 Adjusted Earnings$10,004 $8,159 $14,183 $16,783 Net Earnings per Basic Common Share – U.S. GAAP basis$0.22 $0.17 $0.28 $0.36 Acquisition-related costs 0.04 0.02 0.04 0.02 Change in fair value of contingent
consideration obligation (0.04) – (0.02) – Restructuring costs – – 0.01 – Selected legal costs 0.01 0.01 0.02 0.02 Adjusted Basic EPS$0.23 $0.19 \*\*$0.33 $0.40
Three Months Six Months Ended March 31, Ended March 31, 2020 2019 2020 2019Net Earnings per Diluted Common Share – U.S. GAAP basis$0.22 $0.17 $0.28 $0.35 Acquisition-related costs 0.04 0.02 0.04 0.02 Change in fair value of contingent
consideration obligation (0.04) – (0.02) – Restructuring costs – – 0.01 – Selected legal costs 0.01 0.01 0.02 0.02 Adjusted Diluted EPS$0.23 $0.19\*\*$0.33 $0.39 \* Net of tax. \*\* Does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dIg8K1wNXteUaEhMwww2W9cTFqhIF6AVhvSnvxfWikYvKMRs8gbOxzdZCbFYVioB5NKHPgMPH28i4z4BMFjqeqpcpAR6YKq6l9-FkFVvBzDIZiiFOTQV7HfbSPliSaXs "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-partners-with-quantumdx-on-covid-19-assay/)
**Published:** May 6, 2020
**Author:** hamza
**Content:**
CINCINNATI, May 06, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.
The QuantuMDx assay incorporates and takes advantage of Meridian’s proprietary Lyo-Ready 1-Step RT-qPCR master mix, allowing for a fast and highly reproducible assay that is stable at ambient temperature. Since the beginning of the coronavirus outbreak, Meridian has enabled the manufacture of millions of COVID-19 assays through its partnerships with over 35 diagnostic companies around the globe. In the last few months, Meridian has multiplied its production capabilities to meet the demand of its customers including QuantuMDx.
“Our partnership with QuantuMDx is a great example of how Meridian’s master mixes can expedite assay development and improve the quality and efficacy of a molecular test,” said Todd Howren, Ph.D., Meridian’s Vice President of Global Sales for Life Science. “We are proud to be a partner with QuantuMDx in addressing the testing needs during this pandemic.”
Colin Toombs, Vice President of Research & Development for QuantuMDx said, “Meridian’s Lyo-Ready Mix was critical to delivering the overall performance, sensitivity, and runtime required for this assay. We look forward to our on-going partnership with Meridian not only during this period of great urgency, but also on future products in our assay pipeline.”
Meridian is committed to suppling innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience, please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=W8KT3t2c_XRYP7Y0NST1VaTPdzEBo33CHiarMChXs6_OzlqIjRe9rTovL0LIHg2fa8_Qsi-zOzfhESRLrQobvAu5t2dS1Scpr8eoKqYgC_E= "meridianlifescience.com") or contact: [todd.howren@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=wa1arTkQnAnzureKvGVW9CsuZDSEEvqimDiXCM5rEcD0A9XX5XJPzdwZIjZzjHFNYcfAaWxAL9kC8nCIIxrQYw_mh5PbFLvCSacJI0Ie5dvpeKZnKouDr2KkhwJaTvg-XHzqZNNcWFbrbSLoYmo6VF0es7FxScqM5biCx78rUbY= "todd.howren@meridianlifescience.com").
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=srvYjguY0qmLx1VXyuf_qsrr9iHg_t7El_w9JMvrNw4wMjNvCd1-3IMmUlfql1MqMCLdzp4xyVAIiZIYlJ_PCGcVX5vTZ5QILl55HaI5bSj02leZ0bwJStb54FMS6bLL).
**About QuantuMDx**
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: [www.quantumdx.com](https://www.globenewswire.com/Tracker?data=YTiO8Tch7PTQa_qEK-T3rJpPvdwWXmlfoNKcKLGvjJyFla4d-UkE0JZ03tSyXtBvEGGo1wr6HusQDSkhJ14kOw==)
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=c7WiA1as4NGunPh6xbDwne6W1rhaRgFsVNMBxrIfabUkBTG9t8a3dF9QhVdqZtYDlh6sqANX1dZ71s4exMzlbzb5_Btn0Fav8s_CMBfioqtHXcvYkoFkB8zReTmdhBQFcysamGBIRkEQ79NbaODQkARLA7-AQ68wc4vnwTJeJToFttLX020qpGB6-HCtzXiKLiWE_e0ZwB9Ycdud5t2dkA== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-closing-of-transaction-to-acquire-exalenz-bioscience/)
**Published:** April 30, 2020
**Author:** hamza
**Content:**
CINCINNATI, April 30, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of *Helicobacter pylori*.
The combination of Meridian’s leading stool antigen tests with the Exalenz BreathID® urea breath test positions Meridian as the only company in the U.S. with a complete offering of non-invasive diagnostic assays for a *H. pylori* active infection. According to the CDC, approximately two thirds of the global population is infected with *H. pylori*, a leading cause of peptic ulcers and gastric cancer. Annually there are between 500,000 and 850,000 new cases of peptic ulcer disease and over one million ulcer-related hospitalizations.
Jack Kenny, Chief Executive Officer, said, “We are excited to complete the acquisition of Exalenz Bioscience Ltd. and its *H. pylori* urea breath testing systems. Despite the turmoil from the COVID-19 pandemic, we continue to execute on our growth strategy, and this acquisition fits squarely with our Diagnostics business unit’s vision of supplying market leading gastrointestinal assays to health systems around the world. We look forward to immediately integrating the BreathID® Systems into our commercial efforts within the U.S. and delivering our innovative non-invasive *H. pylori* testing solutions to our customer base.”
Meridian will provide more background on Exalenz and the strategic rationale on the Company’s earnings call on May 8, 2020 at 10:00am Eastern Time. Please see [investor.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=OL0UP4Ynen8JFvsETsT1lht4bv7ds0nPWFxUH5TovWJLOdXkwQ21zlSjDJv2imAXq99Lcj1JMKc61cvxc-Y_atG07Vq1d922v6VcoZvKRW-6jZ71pgRQOHB46MKlfpC_ "investor.meridianbioscience.com") for the details of how to join the call.
**Cautionary Statement Regarding Forward-Looking Statements**
Certain statements in this communication regarding the acquisition of Exalenz Bioscience Ltd. by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company, including its strategies, products and technologies, future financial performance and any other statements regarding Meridian’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions, and the negative versions thereof, are intended to identify forward-looking statements.
Forward-looking statements speak only as of the date they are made. Forward-looking statements are based on Meridian’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Meridian’s control. Such risks and uncertainties could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the diversion of management time on transaction-related issues; Meridian’s ability to successfully integrate the businesses, operations and technology of Exalenz; risk of failure of the acquisition to achieve its plans and objectives generally; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies or cost savings from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations, legislation, and other regulatory actions and initiatives, the regulatory process for new products and indications, manufacturing issues that may arise, stock price volatility, fluctuations in exchange rates for future sales denominated in foreign currency, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian’s filings with the SEC and available through the SEC’s Electronic Data Gathering and Analysis Retrieval system at [www.sec.gov](https://www.globenewswire.com/Tracker?data=kOxMUp8TqjNMXGJ22REoHl7rLxdzewW0oKu_V1nISgdNj9RqEOUlQ1JmjbprNl84_-VCIYMrK0-HhPfRijIqFA== "www.sec.gov"), including Meridian’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=FsffLrggYIKYNXpuDOL-AYvtF8hwTsiPlIRDSRUxmF_mdTkcfjRtyJQE03tbRx6E_p5pqEsb6JarirFiNgiK14GijBLkyMPmyjrAp0b08MzbV7ccRSYbgGu7tUq7EJEI).
**Meridian Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=cG3cjxN6Ko5_6l_TBEx6EhbohovkklUVB4qkddexDLbexyw4wmVzoCeaUIDGE9_99z79zg6D2wDBl0wvLn1LPU80bX_GfemJ1L-d5XEYdSwDzsQn2G35ry94HCERWVde "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply](https://www.meridianbioscience.com/press-release/meridian-bioscience-simplifies-covid-19-sample-prep-and-eliminates-dependence-on-reagents-in-short-supply/)
**Published:** April 27, 2020
**Author:** hamza
**Content:**
CINCINNATI, April 27, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay. By eliminating this step, total assay cost is lower and processing times for COVID-19 samples can be reduced by as much as 30 minutes per test.
To date, most COVID-19 molecular assays require laboratories to first isolate and purify the SARS-CoV-2 viral RNA from a patient sample (saliva or nasopharyngeal). This step is not only complex and time consuming, but also adds to the overall cost of the COVID-19 assay. In addition, RNA sample extraction kits have not been readily available during this pandemic. To address these shortfalls, scientists at Meridian have successfully developed a proprietary master mix formulation, which when combined with SARS-CoV-2 primers and probes, will enable laboratories to eliminate the SARS-CoV-2 viral RNA purification step. Patient samples will not require complex processing before running the test when using this master mix in the assay. This innovative advancement in master mix formulation has applications not only in today’s COVID-19 assays, but the future of molecular assays as well.
“This new master mix is a paradigm shift in how laboratories will process biological samples for molecular testing,” said Todd Howren, Ph.D., Vice President of Global Sales for Meridian Life Science, in a statement earlier today. “We have already shared this new master mix with nearly 20 early access laboratories around the globe, and their feedback has been quite positive. We are now ready to launch this innovative product to the broader market in hopes of addressing the bottlenecks faced by many labs. To that end, we are looking to align with developers and manufactures of COVID-19 molecular assays in order to quickly bring this novel solution to bear in the fight against COVID-19.”
Meridian is committed to suppling innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=a11ucAvJPYmxKEZ-Px61zNw0NwjQ3jB-zlBR-KyTgSSVbJN9XDAJl5piFYyEJVZFNCHBsiuZKywfxW_oxZmeRFRVrkZWAtfuXQwGNlR2VlA= "meridianlifescience.com") or contact: [todd.howren@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=jBvfTOb1aDfxyQAPUYbPWMKdfRkJdPpKXNTHPNp2MLEVBoCvxMj3U12jJK5X7xLRR-lvoDyAuZTrqn9kDMwpoWM0zDfLAKvHM9vO1VYthFsjXTKVRrEIsX8WVzWcLKuJG1uYnkL5i5BoCf1Gbft1gN_s-OJGxxz6qipE8OQILDOHvnbjQ7bus4QG2aSgoE0t "todd.howren@meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=IyqJJEH83X6Fsy_ZlZaQGSh4CUawmqwJdWQJkUDE9Z9CU7OSCrx5-x6yPUC-2Mj7lFLP2Y29Pm98J1obFgK-DiE0krWGY0s3Uy6y-tXzywC6uOT0Ut79mEJo4f_pb7ZD "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=_prMW1oJ3qqkWGKm8Gk4Gxs0r2cFL3sUSjvL9m4Ksn685HTQzCENqu8DjDi6cP0Kf60bXLPbWu_FV_msFlhx9z6Em_AW7Hc9dHPpy-fGb0z8GWMJhJWgAWlK_0w8Psdx)
**Categories:** Press Release
---
### [Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-second-quarter-2020-financial-results-conference-call-on-may-8-2020/)
**Published:** April 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, April 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5872319.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on May 8, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5872319.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=h3HABQWyGhbmnSIa3dyFvjd7rw02YbVP_DCEHonAeekU-a2qu9uPp_MmjcECJLhE9qDCRY0vxRnqZs2VaHaQXGy4Ln0gKjDMgwL5yGx3jnTN4QWSEt48IU-nlr2AwDYd "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests](https://www.meridianbioscience.com/press-release/meridian-bioscience-offers-sars-cov-2-antigens-for-covid-19-antibody-tests/)
**Published:** April 14, 2020
**Author:** hamza
**Content:**
CINCINNATI, April 14, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19.
Since the emergence of COVID-19 outbreaks in January, Meridian has supported molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 Molecular Diagnostics tests. To meet the massive need for antibody testing, Meridian has now launched a series of recombinant antigens for high sensitivity and specificity IgG/IgM COVID-19 antibody tests. The quality of the antigen can limit the sensitivity of an antibody test, and Meridian is leveraging its proprietary technology to deliver extremely high-quality antigens made in insect cells. This product line includes the spike glycoprotein (S1, S2, RBD, and NTD) and nucleocapsid protein, which can all be manufactured at commercial scale.
Antibodies are produced over days and weeks after infection with a virus. Antibody tests are important in determining those previously infected with the virus, providing researchers a more accurate measure of how many people had COVID-19 and informing decisions on when to ease social distancing rules and allow return to work.
“Widespread COVID-19 antibody testing is essential to understanding the spread of infection, how long immunity to the virus lasts, and in supporting the development of vaccines. We are pleased to continue the fight against this pandemic with high quality recombinant SARS-CoV-2 antigens in commercial scale to support the immediate demand for COVID-19 antibody testing,” commented Lourdes Weltzien, Ph.D., Executive Vice President, Meridian Bioscience – Life Science.
For complete information, please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=0YZL0yrRSjkzLDfd_PIfcmXGt6bjACKUpwx2DrC2G5cSunVix_7iQ57sdXIgtqwkPtGkqCUcKINIBV_XdU06dTHCYj2Yn6oxCBp3LIlrS4Q=) or contact: [Lourdes.Weltzien@MeridianLifeScience.com](https://www.globenewswire.com/Tracker?data=1I-EzPzJ46APRYUc3FIIk46Z5WkkyE1iFOszZLPwF2taVpowWey7-Z4BehvSt1A8mVt5AuFqoMTkcCQhmlv4EeqgSuSswRsLaev5RWWH68UpcQv6umuic43BnKPgeZT6z6uxtpQQCwpcyMSZNqcgSw==)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=YzTZqA2POCQr7HJGEhhmD9HzLLBFlbqqi-yv2qiI43fSFy5Jt2zE3zGaI3D_0QscZqGBWO2d-R3DuPn1MAm2HVe5-F2dUqbconNwDeSaQOods0fch96fPpsfLeUXwUuD).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=VccVowCCbENLelgTx7nCGw2Ks66l2IExXvm_P-zSg-RTTA-fB-gm6FeRRe2-9loTY1h8PrGNlEp33CBrcdRgJ7yLReOrJpUQzaWcK65JCyYFF22cpipd_gRxmSLSu93z "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-launches-a-complete-solution-to-support-liquid-biopsy-cancer-diagnostics/)
**Published:** October 7, 2020
**Author:** hamza
**Content:**
CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct RNA and DNA detection from liquid biopsy samples such as whole blood.
In cancer diagnosis, liquid biopsy has emerged as a fast and sensitive alternative to conventional tissue biopsy, providing a non-invasive approach for the detection and monitoring of circulating cancer biomarkers such as circulating tumour cells (CTC), circulating tumor DNA (ctDNA) or non-coding RNA (ncRNA) in the blood stream. The establishment of molecular assays to detect these biomarkers is usually challenging, especially at low concentrations, due to the sample variability and inhibitory properties of the specimen.
Meridian Bioscience has developed tools to overcome these challenges with two novel inhibitor-resistant qPCR chemistries for the detection of DNA and RNA molecules directly from liquid biopsy samples without the need for nucleic acid extraction. These qPCR mixes are ideal tools for developing sensitive assays and workflows that require fast turnaround times (TAT) and minimal sample processing while ensuring high specificity of the detection.
“The ability of these qPCR mixes to tolerate high level of inhibitors present in blood allows the development of simpler and faster assays, where the limit of detection (LOD) can be improved further by introducing more sample in the reaction,” said Florent Chang-Pi-Hin, Ph.D., Senior Director, Research & Development. “We have seen a dramatic increase in interest in our products used for cancer biomarker detection, not only proving the interest of cancer diagnostic companies in such qPCR mixes but it also highlights the quality of our chemistries. It is important that we continue developing additional tools like these that facilitate cancer prognosis, diagnosis, and therapy.”
Todd Howren, Ph.D., Vice President, Global Sales Life Science, added, “studies have confirmed that our qPCR mixes for liquid biopsy applications exhibit a superior sensitivity compared to other mixes, with earlier Ct values even in difficult conditions such as 20% blood.”
Meridian is committed to suppling innovative solutions to the diagnostic industry to simplify and accelerate development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=A0JuUNY3N25OMse5-oPJlmFI7I6lFPv_u3uzzFaItH6r9qvmetHmWGFK_OjMLpmEKQyDhMnCeA9Tju8qvF9KU3BnQ8TYa37tgWyxl3fnzEA= "meridianlifescience.com") or email [todd.howren@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=84Aeh-OhUhH5arT2xHge_QT0nTMQ5JtmGSzj3owWpyQEyCTAvfRSBa0H6iPDGmCE6iz_TwSWeWsi2nrWLMuutSJPXEt1mLhzzpM7HL9r0yU90LuT0prPl5ztcXmMF40HUmhfDzUxE_8mTW03yvZqUBMIhbd30xkaC1xjE9hUuDxcji5X2-bfkHTOoyulLm7S "todd.howren@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=kphK9m0UFiUxL037aIm_QFuud5DPgURLj72264qn_ZWgvrdUtfswPm0TPNBTtRRlhHxWwg-Yfom50n8zKNIfdT0CNL0lJ5m87DoMjyO_YSCTxQMlZTt6uJwytETyE5Yi "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1Nrcw_vP7FayTXSZKQFSZ3671B5nhlJPpknuTMIfojCOFYHfanTByetPIVASS73rNWpF6OY3xqJRUfpNWJrE8WeR3wvttsfbqY7E8f9P0s4spoP4RGbi_THdySArhBvnAWukLUEVTwpYVTCHhguRciPfs6mD1dzRjA0h7zLArl0= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples](https://www.meridianbioscience.com/press-release/meridian-launches-a-novel-sars-cov-2-antibody-pair-designed-for-developing-highly-sensitive-rapid-antigen-tests-from-saliva-samples/)
**Published:** September 14, 2020
**Author:** hamza
**Content:**
CINCINNATI, Sept. 14, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is pleased to announce the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva. Coronavirus-neutralizing antibodies primarily target the trimeric spike (S) glycoprotein on the viral surface that mediates entry into the host cell. This antibody pair binds to recombinant SARS-CoV-2 trimeric spike protein.
Intentionally designed and screened for the development of rapid saliva antigen tests, these antibodies recognize a linear epitope of the SARS-CoV-S1 trimeric protein. The antibody pair is the first-of-its-kind, having sensitivity down to picograms per milliliter as measured by ELISA. Further, the antibody pair is highly specific to the SARS-CoV-2 trimeric spike protein and does not cross react with other coronaviruses, such as SARS-CoV, HCoV-229F, HCoV-HKUI, HCoV-NL63 and HCoV-OC43.
“Meridian has already enabled the manufacture of millions of COVID-19 assays dating back to the early days of the pandemic. This new antibody pair reflects Meridian’s on-going commitment to be the leading partner to the diagnostics industry through continuous innovation, enhancing the tools R&D teams have to fight this global pandemic,” said Todd Howren, Ph.D., Vice President Global Sales for Meridian Bioscience, Life Science Division. “A rapid COVID-19 antigen assay from saliva, which does not sacrifice sensitivity, is now possible due to this novel antibody pair.”
“Accelerated scale-up efforts of this antibody pair are now in progress and Meridian is excited to partner with our IVD customers to bring rapid antigen COVID-19 assays to market” said Lourdes Weltzien, Ph.D., Executive Vice President for Meridian Bioscience, Life Science Division.
Meridian is committed to supplying innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=aMNemHAdB7izWmzorqemO2jypg7znlxxl6RRn16NFXrRVHpofOMcNAdsCdqfED44G8zM9HozxMdF-pxn-o9CezzOiQ6E5jkIHbq_9VVzIKI= "meridianlifescience.com") or contact: [lourdes.weltzien@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Ho_K0tvSU2tcZerDWxErCg0a1ogDSXvSOLyV2Snadq0Y2Co6bzp9pCYPCmRGRbHHCKxMdhC49vBgv8ywFNL1A-0J0-ns8zUTE2pt1R28sf0cA4GCDXavsxZVhUEFTnFWj2E8-AFR2GR5EFRAjm-ngt3cd295W6pZf5bdJ3W71bSEqJYjGKjYuaYA9gqGxU0XYxFkWD82RzACvs4th4ap6g== "lourdes.weltzien@meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=D9qhBb3Ne3dL1rGXVv7JBmGdxqwcLi1kHLkZaNEGawY84dNiCfnyYUORmCm27lf2tOmRYhxjdBAfL_4CzdFvMw9ZtSMgMlmarAI_1kuAN6838P76Y1UHMQ-Ewj4ghlsR).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=eqv83gDTpwf1l44xVkY8FQQJBfZqLWdjGhbOUcD4LPIos-I2-zTLRYhBHDAla6PWsEY23AmoUlleVap6cXQf8AKL1RxokuriFrewgPLlBSPEwf-ToYGLv5Gd5wyQSlDv "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-present-at-the-h-c-wainright-22nd-annual-global-investment-conference/)
**Published:** August 31, 2020
**Author:** hamza
**Content:**
CINCINNATI, Aug. 31, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET.
To access the live webcast, go the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=Hx_b8s_oinFZqlINyDu2ppoG91hrWWB8jID1GBblkyhGR1CJA6LDiZVLqfbgebgjNkWi0dg67jH-QaNyI0Kv52xAdel9pO-EsRANJvShJAY-oXPlib3qXDqGzWJBdfr4iypUUV1ZLDVyivnHFQh3vA==). Participants should register several minutes in advance of the event’s start time by following the link provided for the event.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=MTkk0u8H1ourjSkggZi0_l0xEyoqgd8y8mu6VjS8HpMTliWp_z7EKfPGbdphXN6tzEO7jidO7yRlG03zxf1UAwma3FXe6b-mKwckUkmLOf266GHHXda0RJsdmW5nmXVl).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=wRe7cSby1O1X8QKdvnW1ISwv7IOvmCSQ8L9X0uZ-3YfLs2egJfwGtDzoDtiBXGgGJ1coC9lS4Iiqt3gnjcV9P2VQwaRWDLGrmf5ultTy-lYPgeD0pn02UiX9NEFljHZZ "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-fiscal-third-quarter-2020-operating-results-best-quarter-in-company-history-raises-full-year-guidance/)
**Published:** August 7, 2020
**Author:** hamza
**Content:**
CINCINNATI, Aug. 07, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020.
**Third Quarter Fiscal 2020 Highlights:**
- Consolidated Net Revenue of $84.8 million, up 75% year-over-year
- Life Science segment delivers record revenue of $63.2 million, up 312% year-over-year, as a result of strong demand for COVID-19 related products
- Broadened the Life Science portfolio of COVID-19 related products to include key reagents used by diagnostics manufacturers to develop rapid antigen tests
- Diagnostics segment limited to $21.6 million in revenue, in line with expectations and a 35% year-over-year decline, as stay-at-home orders reduced demand for non-critical care testing
- Completed assay design lock in the development of a PCR COVID-19 test on the Revogene® system and expecting submission to the FDA for EUA approval this fall
- Re-initiated clinical trials for key GI products (GI panel, *C. diff*, *Campylobacter*), although at a slower-than-normal pace
- Closed the acquisition of Exalenz and the integrated commercial team placed the first BreathID® Smart System since receiving FDA approval in March
Jack Kenny, Chief Executive Officer, commented: “The diversification of our business turned what could have been a challenging quarter into a record for the Company. Our team executed well in the short-term while continuing to invest in our strategy, positioning us well for a strong FY2021.”
Bryan Baldasare, Chief Financial Officer, commented: “Record revenue and strong margins in our Life Science segment drove cash generation, further strengthening our balance sheet. Our unprecedented earnings demonstrates the power of scale in our operations.”
**Third Quarter Fiscal 2020 Results (Comparison to Third Quarter Fiscal 2019)**
Consolidated net revenue for the third quarter of fiscal 2020 increased 75% to $84.8 million, compared to $48.4 million in the third quarter of 2019. Diagnostics segment revenues were down 35%, in line with expectations, while Life Science segment revenues were up 312%. Our Diagnostics segment experienced a 46% decrease in revenues from our molecular products and revenues from our immunoassay/blood chemistry products decreased 32%. Our Life Science segment revenues for the quarter included $47.8 million in revenue from COVID-19 related products with $32.0 million coming from molecular products and $15.8 million coming from immunological products.
Reported operating income for the third quarter of fiscal 2020 was $34.7 million, reflecting strong leverage from record sales levels in our Life Science business. Operating expenses include: (i) expectedly higher research and development spending in the Diagnostics segment; (ii) acquisition-related costs in connection with the recent Exalenz acquisition; and (iii) purchase accounting amortization related to the acquisitions of Exalenz and the GenePOC business in April 2020 and June 2019, respectively, as well as a favorable adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business. On an adjusted basis, operating income was $30.4 million, a margin of 36% (see non-GAAP financial measure reconciliation below).
Earnings per diluted share on a reported GAAP basis totaled $0.64 for the third quarter of 2020, and adjusted earnings per diluted share totaled $0.55 for the quarter (see non-GAAP financial measure reconciliation below).
**Raising Fiscal 2020 Guidance**
Our performance in the third quarter exceeded our expectations and we are raising our guidance for the year.
FY2020 Net Revenues:
- Consolidated $245 million to $250 million
- Life Science $127 million to $130 million
- Diagnostics $118 million to $120 million
FY2020 Adjusted Operating Margin: Consolidated 22% to 23%
FY2020 Adjusted Earnings Per Share on a Diluted Basis: $1.01 to $1.05 (42.2M shares)
The revenue component of this guidance anticipates that our Life Science business will benefit from COVID-19 related demand ranging from $12 million to $15 million in the fourth quarter. As we have only recently begun sampling reagents for use in rapid antigen tests, our revenue guidance for Life Science has a limited contribution from these products. For the Diagnostics business, our guidance assumes continued softness in demand at a 20% reduction in volumes for our fourth fiscal quarter versus the prior year. Overall operating expenses on an adjusted basis for the full year are expected to be commensurate with our original guidance, as additional cash incentive compensation and operating costs of the Exalenz acquisition will offset lower spending on travel and delayed clinical trials. Importantly, we expect spending on clinical trials in the fourth fiscal quarter of approximately $3 million, as trial sites continue to re-start through the quarter.
This guidance reflects our current visibility into market conditions and customer order patterns for our products and our current assumptions about the impacts from resurgence of COVID-19 infections in the U.S. and around the globe.
**Financial Condition**
At June 30, 2020, cash and equivalents were $63.4 million and the Company had $61.2 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $98.8 million as of June 30, 2020.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, August 7, 2020 beginning at 10:00 a.m. Eastern Time to discuss the third quarter financial results and answer questions. A presentation to accompany the third quarter financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SAJGjpEdFVgNpJBEiSTrU_KjnRgXnI54wXYg4TCVN8DDZChv-Un_7NTvQiJSJh-Dwt13LR94XiXMi2Mg0KqBZ5i_euce4OZiA_Thhsd1DxF-jDbUheN3y2hEFLqoijtJ), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9464209. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on August 7, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9464209.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2020 and fiscal 2019.
Three Months Ended Nine Months Ended June 30, June 30, 2020 2019 2020 2019Net revenues$84,797 $48,440 $189,514 $150,168 Cost of sales 28,945 20,181 71,768 60,999 Gross profit 55,852 28,259 117,746 89,169 Operating expenses Research and development 6,743 4,594 16,953 12,294 Selling and marketing 6,261 6,747 19,459 21,221 General and administrative 12,439 8,002 31,675 24,288 Acquisition-related costs 1,641 473 3,428 1,445 Change in fair value of contingent consideration obligation (6,124) – (7,428) – Restructuring costs 93 1,801 620 1,701 Selected legal costs 134 178 1,189 1,370 Total operating expenses 21,187 21,795 65,896 62,319 Operating income 34,665 6,464 51,850 26,850 Other income (expense), net 208 14 (304) (649)Earnings before income taxes 34,873 6,478 51,546 26,201 Income tax provision 7,366 1,399 11,853 5,922 Net earnings$27,507 $5,079 $39,693 $20,279
Basic earnings per common share$0.64 $0.12 $0.93 $0.48 Basic common shares outstanding 42,837 42,639 42,819 42,526 Diluted earnings per common share$0.64 $0.12 $0.92 $0.47 Diluted common shares outstanding 43,273 42,910 43,038 42,907
**Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$30,409 $8,916 $49,659 $31,366 Net earnings 24,014 6,960 38,197 23,743 Diluted earnings per common share$0.55 $0.16 $0.89 $0.55
**Condensed Balance Sheet Data**
June 30, 2020 2019Cash and equivalents$63,445 $55,192Working capital 130,705 117,567Long-term debt 98,824 75,824Shareholders’ equity 233,335 188,553Total assets 419,787 322,436
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2020 and fiscal 2019 (in thousands), noting that “non-molecular assays” is comprised of traditional immunoassays, blood chemistry assays and urea breath assays.
Three Months Ended Nine Months Ended June 30, June 30, 2020 2019 2020 2019Net Revenues – By Product Platform/Type Diagnostics Molecular assays$3,182 $5,894 $17,259 $20,208Non-molecular assays 18,416 27,224 74,072 83,075Total Diagnostics 21,598 33,118 91,331 103,283Life Science Molecular reagents 38,784 5,495 55,691 17,495Immunological reagents 24,415 9,827 42,492 29,390Total Life Science 63,199 15,322 98,183 46,885Total Net Revenues$84,797 $48,440 $189,514 $150,168 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$9,584 $17,232 $39,644 $52,024Respiratory illness assays 5,052 5,708 23,664 21,242Blood chemistry assays 3,364 4,666 12,508 13,364Other 3,598 5,512 15,515 16,653Total Diagnostics 21,598 33,118 91,331 103,283Life Science Americas 22,015 4,369 30,642 14,347EMEA 26,070 6,389 40,977 21,608ROW 15,114 4,564 26,564 10,930Total Life Science 63,199 15,322 98,183 46,885Total Net Revenues$84,797 $48,440 $189,514 $150,168 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
Three Months Ended Nine Months Ended June 30, June 30, 2020 2019 2020 2019OPERATING INCOME Diagnostics$(2,731) $5,731 $6,469 $22,330 Life Science 40,253 3,639 53,182 12,906 Corporate (2,849) (2,929) (7,832) (8,450)Eliminations (8) 23 31 64 Total Operating Income$34,665 $6,464 $51,850 $26,850
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of acquisition-related costs, a favorable change in fair value of the contingent consideration obligation, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the third quarters and nine-month periods ended June 30, 2020 and June 30, 2019.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**THIRD QUARTER AND NINE MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Nine Months Ended June 30, Ended June 30, 2020 2019 2020 2019Operating Expenses – U.S. GAAP basis$21,187 $21,795 $65,896 $62,319 Acquisition-related costs (1,641) (473) (3,428) (1,445)Change in fair value of contingent consideration obligation 6,124 – 7,428 – Restructuring costs (93) (1,801) (620) (1,701)Selected legal costs (134) (178) (1,189) (1,370)Adjusted Operating Expenses$25,443 $19,343 $68,087 $57,803 Operating Income – U.S. GAAP basis$34,665 $6,464 $51,850 $26,850 Acquisition-related costs 1,641 473 3,428 1,445 Change in fair value of contingent consideration obligation (6,124) – (7,428) – Restructuring costs 93 1,801 620 1,701 Selected legal costs 134 178 1,189 1,370 Adjusted Operating Income$30,409 $8,916 $49,659 $31,366 Net Earnings – U.S. GAAP basis$27,507 $5,079 $39,693 $20,279 Acquisition-related costs, including gain on currency hedge of purchase price \* 959 363 2,746 1,108 Change in fair value of contingent consideration obligation \* (4,623) – (5,608) – Restructuring costs \* 70 1,381 468 1,305 Selected legal costs \* 101 137 898 1,051 Adjusted Earnings$24,014 $6,960 $38,197 $23,743 Basic Earnings per Common Share – U.S. GAAP basis$0.64 $0.12 $0.93 $0.48 Acquisition-related costs, including gain on currency hedge of purchase price 0.02 0.01 0.06 0.03 Change in fair value of contingent consideration obligation (0.11) – (0.13) – Restructuring costs – 0.03 0.01 0.03 Selected legal costs – – 0.02 0.02 Adjusted Basic EPS \*\*$0.56 $0.16 $0.89 $0.56
Three Months Nine Months Ended June 30, Ended June 30, 2020 2019 2020 2019Diluted Earnings per Common Share – U.S. GAAP basis$0.64 $0.12 $0.92 $0.47Acquisition-related costs, including gain on currency hedge of purchase price 0.02 0.01 0.06 0.03Change in fair value of contingent consideration obligation (0.11) – (0.13) –Restructuring costs – 0.03 0.01 0.03Selected legal costs – – 0.02 0.02Adjusted Diluted EPS \*\*\*$0.55 $0.16 $0.89 $0.55
\* Net of tax.
\*\* Basic Earnings per Common Share for the three months ended June 30, 2020 does not sum to the total Adjusted Basic EPS due to rounding.
\*\*\* Diluted Earnings per Common Share for the nine months ended June 30, 2020 does not sum to the total Adjusted Diluted EPS due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=8-AeXNmWf-cR4Mw5wgbyN_TN2HRuri--qaAXqTGB2LdPpN3ZQfu-3LVuwHOyRr_KzkPrmndi4alPezl5i2tNNEueHX90Qv50EM2JgrN8P2d2l-zVuIUgvKG9NKmA_3k0 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces New Board Member - Anthony Bihl](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-new-board-member-anthony-bihl/)
**Published:** July 28, 2020
**Author:** hamza
**Content:**
CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.
“We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” said David Phillips, Chairman of Meridian Bioscience. “We were looking to add diagnostics expertise to the board and Tony additionally brings the breadth of leading both large and small public organizations.”
Bihl graduated with distinction from Pennsylvania State University and brings 35 years of leadership experience in global medical device markets, most notably in the diagnostics market. His diagnostics experience began with a broad range of operations and financial roles at Dupont, followed by senior executive roles at Bayer Healthcare’s Diagnostics Division which subsequently led to his becoming CEO of Siemens Medical Solutions Diagnostics, after orchestrating the divestiture to Siemens AG. He joins Meridian’s Board after his retirement in April as CEO and Member of the Board of Managers at Bioventus, LLC. Prior to Bioventus, he served as CEO of American Medical Systems, Inc. Bihl will continue to serve on the boards of Sonendo Inc., Spectral Medical Inc., and the Arthritis Foundation.
“Meridian was an early pioneer in gastrointestinal diagnostics and has stayed true to those roots,” said Bihl. “I have been following their turnaround under Jack Kenny’s leadership and look forward to working with him and the rest of the board as the growth story continues.”
For more information on Meridian, please visit [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=C2e4ROVHeaaYh1_MQwlW0MqN7yZLELOlL5hMCYaQ3WSunogt8vxYHfqJjOPS4oU7tcUFPRic4Be-lYFXEWdLSpPW-av5GABtuTII1sLh65G2xzln7wrV5KO91kRKlfe6 "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=C2e4ROVHeaaYh1_MQwlW0MqN7yZLELOlL5hMCYaQ3WS5sUS46tak9V8jEBVNyxaAqaAGV0qeXgTkyU_aiEEWkinsLMlSTvOy_lmMAcjoZDfAv7p069QyTg44A25ZRhrq).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=2d34LsiS8AZauha2jsKUvk07tjHjpndjXZrw0e0Q4wbOTz6ZXLrH-K6ZL1V0vBAGJ9POh1m6ELqFfpJe0RDTOC-QJK9v86Bkw-wnOrX1ERYGB1aRKg0Z2eIA2mDZnuZV "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-third-quarter-2020-financial-results-conference-call-on-august-7-2020/)
**Published:** July 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, July 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9464209.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on August 7, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9464209.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=pQNj6WNBsgy47r5JVPO4IZC1lCK6B1lbxm-m0Kb8EgUxSQR1muk-ngyr9ikQ8T1-CcKY1pfxy9qaFmBrRIzaRY52YEP3jYnI64DGRM82k0rT46whxMwwsK7s5fSd07DG "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-the-launch-of-a-high-sensitivity-sars-cov-2-nucleocapsid-antibody-pair-for-the-development-of-rapid-covid-19-antigen-assays/)
**Published:** July 13, 2020
**Author:** hamza
**Content:**
CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.
Since the emergence of COVID-19 in January, Meridian has worked side-by-side with molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 molecular diagnostics tests. These tests are typically ultra-sensitive and can diagnose early in the infection, but they must be carried out by trained technicians in a laboratory, delaying diagnosis. To meet the critical need for easier, faster and cheaper screening assays, Meridian has launched a highly sensitive and specific pair of monoclonal antibodies that are ideal for developing reliable and sensitive rapid lateral flow antigen assays for the detection of active COVID-19 infections.
“There are many highly sensitive molecular tests available that can diagnose an infection early, but they require processing in a laboratory and take time to report a result. We now provide an antibody pair that can be used to create fast, point-of-care assays, capable of delivering results in minutes rather than hours,” commented Lourdes Weltzien, Ph.D., Executive Vice President, Life Science. “Although a negative result does not rule out an infection, antigen tests can be a first-line screen to help determine if people are infectious, allowing much faster response to potential outbreaks.”
Dr. Todd Howren, Vice President, Global Sales – Life Science, added, “Since the start of this pandemic, the world has been on the defensive, reacting to the outbreak. With the launch of this antibody pair that can detect as low as 3ng/mL of nucleocapsid in a patient sample and does not cross react with other coronaviruses (except SARS 2003), there is potential to create COVID-19 tests that can be carried out at a point-of-care setting in local communities allowing for more rigorous control.”
Meridian is committed to suppling innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience, please visit [meridianlifescience.com](https://www.globenewswire.com/Tracker?data=VbZj1PWQw5OCLRDu3kGGg0iaTj4o70bRynPet2pH4IA9c2rXeOWnFQyDW1ooFI5Kshvn57-aMHjDrc1LcaVDQKnRsWtDk60w1d3Xka0lnAI= "meridianlifescience.com") or email [Lourdes.Weltzien@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=v9UUCR9wkzbch2Sxb-IidXf5C2_MvPCp7qL6rz4gessuzD3Lbny8G1LRaykqq2JApgl0LLbLgWSgvIPkrtEhkdghb8bLgKdmAibj8tR4Y5DGfjcCoA8l1fvVyHliH97jE4hwzKLnm8CRJPtjDDmeK3ZIu2iNrncg-H6DDn258WzHHvROwUfZ0nxB4D4eFMSM "Lourdes.Weltzien@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=46ux8tXwbtf6Xi0zqXcdDJVi11l7VCvw7oJM3z-cNcUOEhBT8l_1WhoSe3MZ00Y5a2HsRBD5AW1pHpOa-uAv3P4sCADmeRJhMrUczcELfYgH002fLFB3rtH3uUk_2_ZL).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=OTU7VqMSnYQyqYgodGEredEAF5bzlmCztz4gP89TDcFRLFiNbEaHUqCPhj_Uqk7ZGcUT2TS10jS___iHMfGgeub5GGjXEFU0dpJlwpPZ5uP02cZABWdWKbmaehUuIH5nx5VZFOOTYMVlQJUKYjSrNqJCMsmFoyAFGOSUdZKLwiY= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-the-40th-annual-william-blair-growth-stock-conference/)
**Published:** May 29, 2020
**Author:** hamza
**Content:**
CINCINNATI, May 29, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Tuesday, June 9, 2020 at 8:40 AM CT (9:40 AM ET).
To access the live webcast, go the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=SZukd_hWTNkxF7qW23R3WzrRss9qfyfCZdQG7bmM0pDhC_g9TDM0w9XBPE2njaNwZuWAOHyKImgbYiK1lfmraw-GhWcqZdK-KQ8ySf1psR7LDVug18viSs912Krf7QvB21dXAbOhokb3fTm2CwtQ9g==). Participants should register several minutes in advance of the event’s start time by following the link provided for the event.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SjfM-rMtKrxeDTecHZQZqZXKGADhbOjkfXRHZSEaQb6rsSFXJ0upvC-k4WFHkWtTilPMptEQxaARGPt-80oQF4_8hbuCXag75NI-x9_ZxBFm8T8XXvf2c0LIqpGj8dLO).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=5E9qDoI1UjelirBTTe-cPvuxHdZUpKC9_StV9PV531QMMR1BrheMfcV9PT2RvmOPjtqJj76lkiUHavTBBsjBtUwJHm2MpmzL8ZZTmS6Voy8eQgsI2mFi5biNsct_jWczm2TyBZsw4lM0BIN0ybVLFAIw7LpQzvbve9FQqXGUIghulJ5K2mwqmUO2IzQ0xYgTDBZLGKhD2lxqppBQm9m5Hg== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-it-will-supply-reagents-for-the-manufacturing-of-tens-of-millions-of-covid-19-antibody-tests-per-month/)
**Published:** May 26, 2020
**Author:** hamza
**Content:**
CINCINNATI, May 26, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), with projected production schedules of tens of millions of COVID-19 antibody tests per month.
Since the beginning of this public health emergency in January, Meridian has supported over 35 molecular diagnostic companies with critical master mixes and enzymes, enabling over 30 million COVID-19 molecular diagnostic tests. In April, Meridian began offering SARS-CoV-2 recombinant antigens to meet the growing need for antibody testing. Like Meridian’s molecular offerings, this immunological product line was quickly acknowledged for its ability to deliver high sensitivity and specificity assays. This level of quality, coupled with Meridian’s reliability of production and customer service, has led to high demand. Widespread COVID-19 testing, both molecular and antibody, is essential to front-line healthcare workers delivering care, researchers understanding the spread of infection, and scientists developing vaccines and therapies.
Jack Kenny, CEO of Meridian Bioscience commented, “We quickly responded to help test manufacturers around the world meet their COVID-19 testing requirements, through products with exceptional performance and scalable infrastructure. We remain committed to supporting the diagnostic industry during this global health crisis.”
For more information on partnering with Meridian Bioscience, please email [Lourdes.Weltzien@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=lgW5Txpwae_heOHAwwWS4PS7seK5npVEeflI5NIqRrPRYYCY7yjoYDAUiDA7dJpTbpFjbFTHePvVV_-tsoYCp8TNQvRacUz3ogcnsl1H-y48oTaZP2i3Sfl2V0ph6I8FH5BpPmOsM6Us2CUIcBdEervukPXzDe4LYiROM1Z41qrseI-awsSF2flHeqvRTfZf-zxqQQVXAnZ7D0oIgNWDXg== "Lourdes.Weltzien@meridianlifescience.com").
**Forward-Looking Statements** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to projected production schedules, sales, product demand, revenue and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the factors identified from time to time in Meridian’s filings with the Securities and Exchange Commission, particularly those included in the Part I, Item 1A “Risk Factors” section of our most recent Annual Report on Form 10-K which contains a list and description of uncertainties, risks and other matters that may affect Meridian. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RmA57BAkSUBYii9PL17ujp6L-ABQQ9fP4eV73R8CtU-3cWI3bQ6F_h5oGN1aUUPNT8OwGOPDirs7vv4nVIFCKU0SW-NILTo7yBex4ocssPDZ0VWahcROXSqcudLlwzV6).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=uEXOpCXjiDvKw_HcQSIIWuYkDiVCMqFeDIwDOi_gAjPl8HIHSpfiQ43D4CQ5tTiaN1U7FzGjiQvSztTTVyTNADoDyObzHo8x8NLJYXhvsEMNd8rpjh1VxYp7uJdIsISk208IO8uBeqw6dd2YbarKLCsB2HuWpjYvHrytpEpMFZQA0vOYWRhUtWC0XpiN7rUkfeJLTqwWw2Ibp9e3ZcjDHQ== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics](https://www.meridianbioscience.com/press-release/meridian-bioscience-promotes-tony-serafini-lamanna-to-executive-vice-president-of-diagnostics/)
**Published:** May 20, 2020
**Author:** hamza
**Content:**
CINCINNATI, May 20, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics. Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of the Diagnostics division to Mr. Serafini-Lamanna, who becomes an officer of the company. This change was effective May 18, 2020.
David Phillips, Chairman of Meridian Bioscience, said, “Jack’s leadership was critical to the strategic redirection of our Diagnostics division. With the success of Tony’s day-to-day execution, now is the time to pass full control to Tony, freeing Jack to spend more time on the long-term strategic vision and investor engagement.”
Serafini-Lamanna assumes this post from his prior position of Global Vice President and General Manager of Diagnostics, which he held since April 2018. He will continue to report to Kenny. Serafini-Lamanna has 30 years of experience in diagnostics, including, prior to Meridian, over seventeen years with Siemens Healthcare Diagnostics with tenures as General Manager, Diagnostics Canada and subsequently Vice President, Marketing for North America.
Kenny said, “Tony has been my right hand and instrumental in the turnaround of Diagnostics. His depth of experience and broad vision is an ongoing contribution and I am confident in the continued success of the division under his leadership.”
“I am truly honored to assume this leadership role,” said Serafini-Lamanna. “Over the last two years we have rebuilt our strategy with a focus on acquisitions and new product development while we stabilized our molecular business and positioned the division for growth. With the strength of our global team, I look forward to building on the momentum that Jack has created.”
For more information on Meridian, please visit [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=bNknK7ZHHfo5zyUNXSScLzD87-8wVWgsOvTj_At6oWHh-NWTQ8Aje0Qb1CtD_2yfE0Jl8DxomuRq0RnlRxuI33MKgMRtzMz0TralF9K7qv-W4ZU_pJvQhLPEBqFjYQKN "www.meridianbioscience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=bNknK7ZHHfo5zyUNXSScLzD87-8wVWgsOvTj_At6oWG9TWlBs0hTtHUdedvQCXRmRj3eyNQTiG6QemCefMQxNnvYZYMu7fTjSHfjWuoTEi3BkFq8LACgFd1ZkxCWRDSl).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1DE_xvHuZyjcstE24SWe6DaKCmm5nMdK3lZVDtMUvg1Ng0igXU_MSo3LaPGsJxPFbzL6Ou3LnxOYlsZvLvEm1dTBgX2B7IFvCe-E1zDoAdgP9-_oxYZSwMaosFB_PQCl "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Participates in Piper Sandler 32nd Annual Virtual Healthcare Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-participates-in-piper-sandler-32nd-annual-virtual-healthcare-conference/)
**Published:** November 23, 2020
**Author:** hamza
**Content:**
CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020.
To register for access to the pre-recorded fireside chat, go to the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=zSbR7bQxTCZZqS5kmJqB7AsBkA-6QfCamhL-VBmR0hiOLfmbxqlKzp-tbIJK9b_prZeaMnkRN5WjFQAaSCW9Hb03FZEAxNluM8M8OnOjhXNVhPw5fOWlu0D9Op1xa0XAZ1YCLmJvCZWcFjhz-bFDVA==) and follow the link provided for the event. The recording will be available until February 15, 2021.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=PhWoXL8LrxU_TYWwupCTZywYCjtrYFpCJjh4WPyyK6ZwWsZhYGxsrrz9ZOX07dERTEiyDEr5ULtYeCX0aBnWI6gbHTjqkPgmPaXrpOFkBjH4gXVVkmyjQHc_Ij1SOrdg "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=vwWPz2UPy4tajE2sNRZfixcubq3RxOtxF02S0qtiGHZIu6hpBYle4tr7r4sj3QXAjXZcAmXekYyqciVCZHSdJ5OvlxZ_f6eBp2_Io__wtaEaad_KuJEGw_dlKm6_4YNHsCHAEaWA5hnQyjsDsfu2zG07q0Rndj9xFYT8aGFwHotLjTqRtlhVeyCPZJ4lI0Ij "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-canaccord-genuity-virtual-medtech-diagnostics-forum/)
**Published:** November 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET.
To access the live stream, go to the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=PXoF0-YmLJwXjT3iYQsaxxupd1agnFKZhnNxqruLXxaQCJVJhv_Grhn6_O1Z6Qv5LzKR0gbtXv8dvCbAYa6HP978k8aVcGZdJcwpuV_9vTVu0cYMZYbMEhIY5g4ek93kt1eMx_CElICM0wwzywixrw==). Participants should register several minutes in advance of the event’s start time by following the link provided for the event. A webcast recording will be available for a year following the conclusion of the live event.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=rK9BylO4oHsfELBMlOkac59Dm96s8t6WRvEg6OCdgkqjVVWoQ19a4AT7aVuoSE6mjYovTev0OMbgTtrFACQNX83sePKRN2Y9ec62x64ItVP-Jb-UqCW0XOzIFQss7yaL "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RCccVmVRbiZEDqbKyX8R6wl56kwyy2STTVq9MyZs40CHvlgJk0FlXG0ax88KXVt1ds9CKfaerPJAZ55ItfHy18GAcztdH19bkM55-6ycXiszRugVyMqcGL0Q1bVQYGaU2hfQUPI3yaWQ_aKwLPcdDcnNYCxvxXK4ny6Wx9RUnkA= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-strong-fourth-quarter-and-record-full-year-fiscal-2020-operating-results-and-provides-fiscal-2021-guidance/)
**Published:** November 13, 2020
**Author:** hamza
**Content:**
CINCINNATI, Nov. 13, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020.
**Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019):**
- Consolidated Net Revenue of $64.2 million, up 26% year-over-year
- Life Science segment delivers revenue of $34.4 million, up 97% year-over-year
- Diagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger than expected rebound from Q3 FY20, up 38% quarter-over-quarter
- Launched various SARS-CoV-2 antibody pairs, designed for highly sensitive rapid antigen tests (for saliva and nasopharyngeal samples)
**Full Fiscal Year 2020 Highlights (Comparison to Full Year Fiscal 2019):**
- Consolidated Net Revenue of $253.7 million, up 26% year-over-year
- Life Science segment delivers record revenue of $132.5 million, up 106% year-over-year, with the contribution of $71.5 million from COVID-19 related products for immunological and molecular tests
- Diagnostics segment revenues decreased 11% year-over-year to $121.1 million, due to headwinds from COVID-19 pandemic in the second half
- Launched the Curian® analyzer and HpSA® assay, the first internally developed new product in several years
- Completed assay design lock of a PCR COVID-19 test on the Revogene® system and preparing submission to the FDA for Emergency Use Authorization
- Closed the acquisition of Exalenz Bioscience, adding the BreathID® instrument and its Urea Breath Test for *H. pylori* to the diagnostics product portfolio
**Fourth Quarter Fiscal 2020 Results (Comparison to Fourth Quarter Fiscal 2019)**
Consolidated revenue for the fourth quarter of fiscal 2020 increased 26% to $64.2 million, compared to $50.8 million last year. Diagnostics segment revenues rebounded strongly from the pandemic headwinds seen in the third fiscal quarter, but were still down 11% year-over-year. Life Science segment revenues were up 97%. Our Diagnostics segment experienced a 23% decrease in revenues from our molecular products and revenues from our non-molecular assay products decreased 8%. Our Life Science segment revenues for the quarter included $18.1 million in revenue from COVID-19 related products with $14.6 million coming from molecular products and $3.5 million coming from immunological products.
Reported operating income for the fourth quarter of fiscal 2020 was $9.5 million. Operating expenses included: (i) higher research and development spending in the Diagnostics segment; (ii) acquisition-related costs in connection with the recent Exalenz acquisition; and (iii) purchase accounting amortization related to the acquisition of Exalenz in April 2020, as well as an upward adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business in 2019. On an adjusted basis, operating income was $12.0 million, a margin of 19% (see non-GAAP financial measure reconciliation below).
Jack Kenny, Chief Executive Officer, commented, “This was truly a transformative year for Meridian. All our hard work over the previous two years prepared us to both weather the storm in Diagnostics and excel as a critical partner to the IVD industry battling a global pandemic. Heading into fiscal 2021, we will build on the momentum in Diagnostics and continue the strength in Life Science to deliver another record year.”
**Full Fiscal Year 2020 Results (Comparison to Full Year Fiscal 2019)**
Consolidated revenue for the fiscal year ended September 30, 2020 increased 26% to $253.7 million, compared to $201.0 million in fiscal 2019. Diagnostics segment revenues were down 11%, while Life Science segment revenues were up 106%. Our Diagnostics segment experienced a 17% decrease in revenues from our molecular products and revenues from our non-molecular assay products decreased 10%. Our Life Science segment revenues for the fiscal year included $71.5 million in revenue from COVID-19 related products with $52.2 million coming from molecular products and $19.3 million coming from immunological products.
Reported operating income for fiscal 2020 was $61.3 million. Operating expenses included: (i) higher research and development spending in the Diagnostics segment; (ii) acquisition-related costs in connection with the recent Exalenz acquisition; and (iii) purchase accounting amortization related to the acquisitions of Exalenz and the GenePOC business in April 2020 and June 2019, respectively, as well as a net downward adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business. On an adjusted basis, operating income was $61.7 million, a margin of 24% (see non-GAAP financial measure reconciliation below).
Bryan Baldasare, Chief Financial Officer, commented, “Fiscal 2020 marked not only a record year in revenues and earnings, but also cash flows from operations, allowing us to repay borrowings under our revolving credit facility and increase our available credit capacity.”
**Fiscal 2021 Guidance**
Our fiscal 2021 guidance reflects a big rebound of the Diagnostics segment and continued strong demand for our Life Science reagents used in COVID-19 assays. We expect continued headwinds to our core diagnostics products through the first half, with anticipated full recovery in the second half of the fiscal year. COVID-19 related diagnostics products are expected to supplement that recovery in the fiscal second quarter. Life Science demand is expected to be strong throughout fiscal 2021, between $80 and $85 million, albeit, subject to the same quarter-to-quarter volatility that was seen in fiscal 2020. Adjusted operating margin reflects significant investment in R&D and manufacturing, coupled with costs associated with the acquisition of Exalenz and annualization of headcount increases during fiscal 2020. Gross margin is expected to be relatively flat on a consolidated basis, reflecting a modest improvement for Diagnostics driven by higher volumes from rebounding demand, and a modest decline for Life Science driven by investments to fortify capacity for larger scale manufacturing. Diagnostics investment in new product development is forecast to be 18% of Diagnostics revenue as a result of costs for clinical trials delayed from fiscal 2020, which are added to anticipated spend on products advancing through the development pipeline. Life Science is also investing in infrastructure across sales and R&D to support the new scale of the business.
*Revenues*
- Consolidated – $290 to $310 million
- Diagnostics segment – $140 to $150 million
- Life Science segment – $150 to $160 million
*Adjusted Operating Margin*
- Consolidated – 23.5% to 24.5%
*Effective Tax Rate*
- 23% to 24%
*Adjusted Earnings Per Share on a Diluted Basis (based on 44.3M shares)*
- $1.14 to $1.28
The higher tax rate compared to 2020 reflects a larger amount of taxable income coming from the United States. Adjusted operating margin and adjusted earnings per share on a diluted basis for fiscal 2021 exclude costs associated with restructuring activities, changes in the fair value of the earnout obligation and selected legal matters that we expect to continue in fiscal 2021. Current customer order patterns for our Life Science segment coupled with the current trends with the pandemic, indicate revenues for the segment could favor the first half of the fiscal year and are incorporated in our guidance. Finally, this guidance reflects our current line of sight and assumes that we do not encounter any significant reductions in manufacturing capacity as a result of the pandemic causing either partial or full site closures for an extended period of time, or adversely affecting our supply chain for raw materials.
**Financial Condition**
At September 30, 2020, cash and equivalents were $53.5 million and the Company had $91.2 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s bank-debt obligations under the bank credit facility totaled $68.8 million as of September 30, 2020.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, November 13, 2020 beginning at 10:00 a.m. Eastern Time to discuss the fourth quarter and full fiscal year financial results and answer questions. A presentation to accompany the quarterly and full fiscal year financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=VKH9h260aNcVQwQXMjIwrUOhh0mS5NHcgASFy4WCqLinqHBoljk6Zi_RLtR2KlaZc9Vd16W_KzesOlQvtnM_s6cg8PyJXRjVk1w2YHDGnFIl_Y4vDhLanytUZZBh2cvJ), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3958286. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on November 13, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3958286.
**FOURTH QUARTER AND FISCAL 2020 UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim and annual periods of fiscal 2020 and fiscal 2019.
Three Months Ended Twelve Months Ended September 30, September 30, 2020 2019 2020 2019 Net revenues$64,153 $50,846 $253,667 $201,014 Cost of sales 25,822 21,664 97,419 82,286 Gross profit 38,331 29,182 156,248 118,728 Operating expenses Research and development 6,983 5,607 23,729 17,760 Selling and marketing 7,210 7,140 26,486 27,995 General and administrative 12,109 8,872 44,345 34,044 Acquisition-related costs 462 363 3,890 1,808 Change in fair value of contingent consideration obligation 1,135 – (6,293) – Restructuring costs 67 1,138 687 2,839 Selected legal costs 891 213 2,080 1,583 Total operating expenses 28,857 23,333 94,924 86,029 Operating income 9,474 5,849 61,324 32,699 Other expense, net (1,727) (493) (2,031) (1,142) Earnings before income taxes 7,747 5,356 59,293 31,557 Income tax provision 1,254 1,253 13,107 7,175 Net earnings$6,493 $4,103 $46,186 $24,382 Net earnings per basic common share$0.15 $0.10 $1.08 $0.57 Basic common shares outstanding 42,940 42,711 42,855 42,571 Net earnings per diluted common share$0.15 $0.10 $1.07 $0.57 Diluted common shares outstanding 43,642 42,916 43,174 42,899
Three Months Ended Twelve Months Ended September 30, September 30, 2020 2019 2020 2019 **Adjusted Financial Measures** (see non-GAAP financial measure reconciliation below) Operating income$12,029 $7,563 $61,688 $38,929 Net earnings 8,289 5,399 46,301 29,142 Net earnings per diluted common share$0.19 $0.13 $1.07 $0.68
**Condensed Balance Sheet Data**
September 30, 2020 2019Cash and equivalents$53,514 $62,397Working capital 109,666 123,847Long-term debt 68,824 75,824Shareholders’ equity 247,629 190,967Total assets 405,261 325,478
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim and annual periods in fiscal 2020 and fiscal 2019 (in thousands).
Three Months Ended Twelve Months Ended September 30, September 30, 2020 2019 2020 2019
Net Revenues – By Product Platform/Type Diagnostics Molecular assays$4,648 $6,074 $21,907 $26,283 Non-molecular assays 25,153 27,325 99,225 110,399 Total Diagnostics 29,801 33,399 121,132 136,682 Life Science Molecular reagents 22,703 5,764 78,431 23,261 Immunological reagents 11,649 11,683 54,104 41,071 Total Life Science 34,352 17,447 132,535 64,332 Total Net Revenues$64,153 $50,846 $253,667 $201,014
Three Months Ended Twelve Months Ended September 30, September 30, 2020 2019 2020 2019 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$15,396 $16,958 $55,040 $68,982 Respiratory illness assays 3,030 5,380 26,694 26,622 Blood chemistry assays 5,026 5,275 17,534 18,639 Other 6,349 5,786 21,864 22,439 Total Diagnostics 29,801 33,399 121,132 136,682 Life Science Americas 6,795 5,092 37,391 19,441 EMEA 17,115 7,241 58,125 28,850 ROW 10,442 5,114 37,019 16,041 Total Life Science 34,352 17,447 132,535 64,332 Total Net Revenues$64,153 $50,846 $253,667 $201,014 OPERATING INCOME Diagnostics$(4,174) $2,728 $3,885 $25,390 Life Science 17,234 5,007 68,826 17,581 Corporate (3,605) (1,923) (11,437) (10,373) Eliminations 19 37 50 101 Total Operating Income$9,474 $5,849 $61,324 $32,699 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic earnings per share and diluted earnings per share, each on an adjusted basis excluding the effects of acquisition-related costs, changes in fair value of the contingent consideration obligation, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles for the fourth quarters and fiscal years ended September 30, 2020 and September 30, 2019.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FOURTH QUARTER AND FISCAL YEAR**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Twelve Months Ended September 30, Ended September 30, 2020 2019 2020 2019 Operating Expenses – U.S. GAAP basis$28,857 $23,333 $94,924 $86,029 Acquisition-related costs (462) (363) (3,890) (1,808) Change in fair value of contingent
consideration obligation (1,135) – 6,293 – Restructuring costs (67) (1,138) (687) (2,839) Selected legal costs (891) (213) (2,080) (1,583) Adjusted Operating Expenses$26,302 $21,619 $94,560 $79,799 Operating Income – U.S. GAAP basis$9,474 $5,849 $61,324 $32,699 Acquisition-related costs 462 363 3,890 1,808 Change in fair value of contingent
consideration obligation 1,135 – (6,293) – Restructuring costs 67 1,138 687 2,839 Selected legal costs 891 213 2,080 1,583 Adjusted Operating Income$12,029 $7,563 $61,688 $38,929 Net Earnings – U.S. GAAP basis$6,493 $4,103 $46,186 $24,382 Acquisition-related costs, including gain
on currency hedge of purchase price \* 212 273 2,751 1,381 Change in fair value of contingent
consideration obligation \* 867 – (4,726) – Restructuring costs \* 50 864 528 2,169 Selected legal costs \* 667 159 1,562 1,210 Adjusted Earnings$8,289 $5,399 $46,301 $29,142 Basic Earnings per Common Share – U.S. GAAP basis$0.15 $0.10 $1.08 $0.57 Acquisition-related costs, including gain
on currency hedge of purchase price – 0.01 0.06 0.03 Change in fair value of contingent
consideration obligation 0.02 – (0.11) – Restructuring costs – 0.02 0.01 0.05 Selected legal costs 0.02 – 0.04 0.03 Adjusted Basic EPS$0.19 $0.13 $1.08 $0.68
Three Months Twelve Months Ended September 30, Ended September 30, 2020 2019 2020 2019 Diluted Earnings per Common Share – U.S. GAAP basis$0.15 $0.10 $1.07 $0.57 Acquisition-related costs, including gain
on currency hedge of purchase price – 0.01 0.06 0.03 Change in fair value of contingent
consideration obligation 0.02 – (0.11) – Restructuring costs – 0.02 0.01 0.05 Selected legal costs 0.02 – 0.04 0.03 Adjusted Diluted EPS$0.19 $0.13 $1.07 $0.68 \* Net of tax.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=VKH9h260aNcVQwQXMjIwrUOhh0mS5NHcgASFy4WCqLhEZvIyINVd7mWnZzPw2WIyLELLRbJPv6Dq4K1Ow2yJN5u419IS4bD509DrFEyemaM_wcnZYDBWbLPRn8nrtqcQ "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=2zpa21kP6sXMUl5VQr8qIdx3oubCOgGKM1765b01y-rcg4yPMxerX-XACEzJSaxXDectr-YLFfYO0ALVlO1yy8qlj3ttX0_HKVKpoweHB5Vtg6_YZhYx2_Ids8TFBclo "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on November 13, 2020](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-fourth-quarter-and-full-year-2020-financial-results-conference-call-on-november-13-2020/)
**Published:** October 20, 2020
**Author:** hamza
**Content:**
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2020 financial results Friday, November 13, 2020.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3958286.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on November 13, 2020 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3958286.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=m0q49HWtwwCS4KJ3v5rSkdqihOav09TFzyLTlAENVjwp0TzRxZHjMgKGy9CIq1hkXMjxHT6LYVv4aJS4vJVvxiyoRPy5iZp3fRHRXGGfuzQs28d8ZiboRjJf9DUnadxz "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-submits-application-to-fda-for-emergency-use-authorization-for-sars-cov-2-molecular-assay/)
**Published:** December 8, 2020
**Author:** hamza
**Content:**
CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.
The SARS-CoV-2 test is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the causative agent of COVID-19. The COVID-19 global pandemic has resulted in a need for accurate and timely results to quickly determine which patients are infected with COVID-19. With results available as early as 47 minutes, the Revogene® SARS-CoV-2 test will help customers improve their testing capacity and enable healthcare providers to quickly deliver appropriate care and guide infection control measures for patients. The Revogene® is a flexible molecular testing platform that can be easily integrated into any laboratory or health system.
“As this is our first RNA based molecular assay, the Revogene® SARS-CoV-2 test is a significant milestone for the Revogene platform and will open up additional opportunities to grow our respiratory franchise,” said Tony Serafini-Lamanna, Executive Vice President – Diagnostics. “With increased manufacturing capability, and assay performance supported by a good dataset, we believe this is the right COVID-19 assay to offer to our customers.”
For more information on the Revogene® SARS-CoV-2 test, please visit [https://www.meridianbioscience.com/human-condition/respiratory/coronavirus/revogene-sars-cov-2/](https://www.globenewswire.com/Tracker?data=TGk-BrcttVMBpgWbRklfrFSPvxamJ5QsRVG_Ms_cAjBAvO_P3ws5gqJB_4QGL5PLqp-sH6Qy_UnaoiQzNrHOa8cF4sUHLOzQZSd9ZTJE6NTeKHECTEYhw55ILh-5tofazP-F0rhABfBmij4uIVFTjpLkOSCUEr_p_ail7tUAsjJJaM5q1tuL8Gp6ujSyEhEpxGQvE9Z_5tDCPLFWIFkb7Io1slM0FB3JOTRH5qOwQDDOT9mFT-L4gLV6_e-xjIjkirfxaG9bEwLnyQdvuJgKL6JnL9_wQikvTlvQ50LfHAk=).
*The Revogene*® *SARS-CoV-2 Molecular Diagnostic Test has not been FDA cleared or approved.*
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=wly3siqiaL3j6en8tBEuBlnK395mUFEaFLWSpCNIuDoX5v9vcXXqZRBsfKaDON6WWoLoS9mcdvLkve1gw3VEStvtVKyYRUuIzhA26I2-YN9AlId-qcuBsBGk3toAMwJj "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1IVpzbtJlyQrnqrHHJMeF2ptijnOJcjxjMVW4NHIV3EQpHDu7-GMjSp22JPII7dbEc-aVnD0Vj3EmVzp5HcHU5xH1ZHoH13DAgN8Xms_zxaxITgipkCpdI9E4Um90vASEzhKzxNEgYQlcyHIPA0pSh_-_9YrHPT9n3Za1a0LBfRIZURVEBAd-YXRGSgKnBH2 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers](https://www.meridianbioscience.com/press-release/meridian-launches-its-novel-air-dryable-rt-qpcr-mix-further-decreases-costs-and-simplifies-workflows-for-covid-19-molecular-test-manufacturers/)
**Published:** December 3, 2020
**Author:** hamza
**Content:**
CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed for air-drying, a cost-effective and easier alternative to lyophilization. With this new product addition, Meridian has the most comprehensive offering of master mixes for developing both DNA and RNA based molecular diagnostic assays at ambient temperature, removing the need for cold chain shipping and storage.
While molecular diagnostic tests are progressively moving towards a dried-down format, there are technical challenges in developing lyophilization-compatible mixes that require lengthy optimization and expensive lyophilization equipment. Building on its expertise in qPCR chemistries, the Life Science division of Meridian Bioscience has successfully developed a ready-to-use, air-dryable RT-qPCR mix to meet the growing demand within the molecular diagnostics industry for an easier and more cost-effective method of drying RNA assays.
Meridian’s Air-Dryable RT-qPCR Mix has been designed to simplify development, manufacturing and storage of molecular assays while delivering fast detection of RNA targets, an ideal solution for COVID-19 assay development. Its one-tube format chemistry containing all reagents necessary for a RT-qPCR, including magnesium, dNTP and reverse transcriptase, not only shortens assay optimization but is also compatible with air-drying protocols. This new mix shows exceptionally high performance in both singleplex and multiplex reactions following rehydration, making it ideally suited for a wide range of instruments from automated high-throughput platforms to point-of-care devices.
Florent Chang-Pi-Hin, PhD, Senior Director of Research and Development added, “Over the last 12 months, we have seen a significant increase in demand for our Lyo-Ready RT-qPCR mixes; however, not all our customers have the expertise in-house to lyophilize. Building on the launch of our Air-Dryable qPCR Mix earlier this year, our new Air-Dryable RT-qPCR Mix represents a perfect solution for the development of ambient temperature stable assays for RNA targets, which is so important today with the global fight against SARS-CoV-2.”
Meridian is committed to suppling innovative solutions to the diagnostic industry to simplify and accelerate development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit [meridianlifescienc](https://www.globenewswire.com/Tracker?data=RpXW_czUi8fvxOkDXw7_IPK9FrfUv5Sx9eGM6DrxdhiGRY8um5mNJ82jguRUpkOVC0JIKHqn-BElLbqe7ccIbe5uQyYqPnufC8wauJG5iSU= "meridianlifescienc")[e](https://www.globenewswire.com/Tracker?data=bamf-5f8dRdAvCeni7nPFXCGryPZ4PEYuarGaxs10JqCP9tEkppw0a1eXDVusMIexAjTNswLEq-UZ4XFhv5gpg== "e")[.com](https://www.globenewswire.com/Tracker?data=NptZl3sgjTkXezkspwmvR1uDOTRrejKaZdK_xJyqC-lOeyEY5s1rtkUcI2XGxETKo-R7eJJC0ALK0mFGqfGLDA== ".com") or email [lourdes.weltzien@meridia](https://www.globenewswire.com/Tracker?data=KgkDqaYMATYbDEzMqTlo1UltEYjGt-BaZW7rdiUybc4OsT2stWYyEQ2Xa6vQhIOM618popFzGxDWslEfUv_DyomnxPBS3pauWFfGPcOLMDMINQdY7ONrRhaa_Lz5BU9WbTt-rVBynNIcXryvRuqamvQD8GXzqY_5Eg3ZjREwzj-sVhNb5uDoMLb1ERuiIK0kE0qmj7bESrq_e3eRPAKv_w== "lourdes.weltzien@meridia")[n](https://www.globenewswire.com/Tracker?data=QZAzo6_HnTPGJQnyTerm8II4j0kk9LXU9tG9-6lnX_1LRKsZ4f6_XsWdmCpYvTHwLiUU70B3HgyodIXnEG2vNKn13cHQDAugfsEdOgafc7HOo1s5Lv1e6i4qtkhFlGobslKBh60Tsxzko01nWjBPpBj38KWM6dALr-MfpOwm0YA= "n")[lifescience.com](https://www.globenewswire.com/Tracker?data=0mB7srJF_3Gk2T8A0RQpX6FPxeRMR5J0kAdxRAlb2ddAwxehe__SLFzGi8ll8Z-QI-2vdeGgczUCfwysIAVgFPr2YmKw_95lIxQBp6jmIamLPESPFn3aGJWRGpGWD02iH1sv5ePqTjxDpWnrDVGlA-JTcaT58yR-mN9SM4-Av8-2-aHh2MctQBrFV2imATKA "lifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscienc](https://www.globenewswire.com/Tracker?data=fPOVNR85HegDfbGil4PW5zYUXCI9EWCLwcNth0DvzTjHXXdH5KxRmbfUXrhWYZPepsm5HPt6JM5KKv8kXychMiTqqh71JXFdGUVj4htDbao= "www.meridianbioscienc")[e](https://www.globenewswire.com/Tracker?data=kHA3iywf2AXhr1FzMbVF-UAWmI5-16LrTYY4_tR4txiMBiNlkwkemls927g1z9Ok2cK2iemAmlZ_EBCxyaTsbw== "e")[.com](https://www.globenewswire.com/Tracker?data=JWeFgSW4qlRa60RvxDgA_9ZO5s9KB0os_RXL0au3R5t_tIiQUXIHPIiSMCV1r8ZvgwNH2T6O2EkYjMJD5f24Ig== ".com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbio](https://www.globenewswire.com/Tracker?data=AHHVUKAHA-j1_R83D8LdJ51vFlcbvR4kOOyUAj9yS9kKZOM_ZMltds0YRQJUwfoTeAhqkzyVyUpqnYofCDJQkO2s_wp6pluAeYsldzG-0NXoHLo4z1YJj4qc3P8dQ-xJTWcm1IbAnYfoDiG5htigTsITuOa0jHMAarcMEnnORew= "mbi@meridianbio")[s](https://www.globenewswire.com/Tracker?data=aNUPlu3vCiD39zmUmW8stR2ZbnREIgLW3DzCcEDJlqdVjCRQ2HTh5cVpaVlpk8FJKkzvmEsZHS6SWxcuDffo_kw1vF3OQUKn2ZV8JELqRis1Lj9gUolHK89LLvdtbkfNp9MOpvC7gmEqLev0Wbt8GA== "s")[cience.com](https://www.globenewswire.com/Tracker?data=SUZlATca8BQt6kbXZBonPU9A8jTCGoy3rJMfX-_KaIUnnOtp50B9VKerNY3mbdMK_yJK4QsSGU35DmTLDmOfH7aHrKXkS9mhbQchI68NZBEmJtklFZiXLwAb30wnPL7CdiVdZBpJXTjYeEpf7xspiQ== "cience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission](https://www.meridianbioscience.com/press-release/meridian-bioscience-provides-a-further-update-on-the-revogene-sars-cov-2-eua-submission/)
**Published:** February 23, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.
Following the submission of Meridian’s written response to the FDA’s request for additional information on its Revogene® SARS-CoV-2 test on February 16, 2021 and further discussions with the FDA, on February 22, 2021, Meridian Bioscience elected to withdraw its EUA application. Between now and the end of March 2021 and based on guidance from the FDA, Meridian intends to conduct a new clinical validation study and a Limit-of-Detection bridging study, with the intention of re-submitting an EUA application for its SARS-CoV-2 test on the Revogene® platform as soon as possible thereafter. Upon notification to the FDA of its intent to re-submit an EUA application, during its third fiscal quarter, Meridian expects to resume shipping of this test to customers. Any change to our financial guidance will be discussed during our 2021 second fiscal quarter earnings call, scheduled for May 7, 2021, when we have more complete information.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products and emergency use authorization application for the Revogene SARS-CoV-2 test). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1I1MUJvMd5AZizmwsKx6g-t-hI_t8v-rA65ZalEoLLcB2e8RBwmVwExd2o8QGOoneAeKbKwWdv2NJixuQP6vulyckvDIeqdlkNnOmZ3EvmHCpgXj9dMtCupaH_fb8hZF "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Hdt0kuBSyv221ZbuIBFkLStPcxbSMHaY2HHxgJZtTHE2rCBlWemC2KeCSQqFK2lF2LUysyGaqhKSR3P2dr2aSp0Fl4vszSZEROyZ5AOm4FzE1prAj9qvwYRRRqtj76voubnEp66DmWX7setO90KpXw== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission](https://www.meridianbioscience.com/press-release/meridian-bioscience-provides-an-update-on-the-revogene-sars-cov-2-eua-submission/)
**Published:** February 16, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.
In its ongoing discussion with the FDA, late in the day on Friday, February 12, 2021, the Company received further correspondence requesting additional information on the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. Later today, the Company plans to submit a response with additional information to the FDA for its review. The Company has elected to place shipments of the SARS-CoV-2 test kits on hold while it continues to work with the FDA.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products and EUA request for the COVID-19 Revogene product). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=iVz7CC2uGAf-WebrFDDSwTAE-kxm12hMxcdaIKQj6sg_f0ilVmiPDtqOtWcDFj1gFeRuOFrWwj4p1iheJqMKGAb1TsTYx4mG5CjXsVGV8DN9uif5D8oi4cZmYN4Fq4Oq "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=y_05vfNmUai-aZrSbdurZbfr0SgOwlF1t79aYpFSd7_AvfnHIOjsDXM0bWXeyrQ8JmyKjbKi5nwA_uNAjamSuv4SbcWvV3J3byfeiHJfVvYUzEObAWZUKtndUmuBnWcK3IQBxrTf0Rb4_vZdSwtLpA== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Record Setting First Quarter Fiscal 2021 Operating Results and Raises Full Year Fiscal 2021 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-record-setting-first-quarter-fiscal-2021-operating-results-and-raises-full-year-fiscal-2021-guidance/)
**Published:** February 5, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020.
**First Quarter 2021 Highlights (Comparison to First Quarter Fiscal 2020):**
- Consolidated net revenues of $92.9 million, up 96% year-over-year
- Life Science segment delivered net revenues of $62.6 million, up 396% year-over-year
- Diagnostics segment net revenues decreased 13% year-over-year to $30.3 million, up 2% from the fourth quarter of fiscal 2020
- Received a National Institutes of Health Rapid Acceleration of Diagnostics (“RADx”) grant for the development of Revogene® SARS-CoV-2 assay and submitted application to FDA for Emergency Use Authorization
- Launched paradigm-shifting Air-Dryable Master Mix to replace lyophilization in manufacturing of molecular assays
- Launched complete solution of Life Science products to support liquid biopsy cancer molecular diagnostics
**First Quarter Fiscal 2021 Results (Comparison to First Quarter Fiscal 2020)**
Consolidated net revenues for the first quarter of fiscal 2021 increased 96% to $92.9 million, compared to $47.4 million last year. Diagnostics segment net revenues were down 13% year-over-year, but continued its recovery, up 2% from the fourth quarter of fiscal 2020 and up 40% from the low seen in the third quarter of fiscal 2020. Life Science segment revenues were up 396%. Our Life Science segment net revenues for the quarter included $43 million in net revenues from COVID-19 related products with $34 million coming from molecular products and $9 million coming from immunological products. Core (non-COVID-19 related) Life Science segment net revenues were up 55% year-over-year.
Reported operating income for the first quarter of fiscal 2021 was $34.7 million. Operating expenses included: (i) higher research and development spending in the Diagnostics segment; (ii) higher amortization related to the acquisition of Exalenz in April 2020, as well as an upward adjustment in the fair value of the contingent consideration related to the acquisition of the GenePOC business in fiscal 2019. On an adjusted basis, operating income was $36.9 million, a margin of 40% (see non-GAAP financial measure reconciliation below), up from a margin of 15% representing year-over-year growth of over 400%.
Jack Kenny, Chief Executive Officer, commented, “Q1 was another strong performance by the team and its great to have both Life Science and Diagnostics segments contributing to the pandemic. Submission of the Revogene® SARS-CoV-2 assay EUA is the first key milestone in the resurgence of the Diagnostics segment during the remainder of the year.”
Bryan Baldasare, Chief Financial Officer, commented, “Our balance sheet continues to strengthen as a result of the robust cash generation of our business. We look forward to putting that cash generation to work in the coming months as we fortify our Life Science segment production capacity and build out a new production facility for assays on the Revogene® platform.”
**Raising Fiscal 2021 Guidance**
Our performance in the first quarter exceeded our expectations and we are raising our guidance for the year.
FY2021 Net Revenues:
- Consolidated $320 million to $350 million
- Diagnostics segment $140 million to $150 million
- Life Science segment $180 million to $200 million
FY2021 Adjusted Operating Margin: Consolidated 31% to 33%
FY2021 Adjusted Net Earnings Per Share on a Diluted Basis (“EPS”): $1.70 to $1.90 (44.3M shares)
The net revenue component of this guidance anticipates that our Life Science segment will continue to see strong demand in the second quarter, similar to that of the first quarter of fiscal 2021. In Life Science, the forecast for the second half of the year assumes we return to levels similar to the fourth quarter of fiscal 2020 in anticipation of declining infection rates as the COVID-19 vaccines are administered around the world. We anticipate this would still result in Life Science segment net revenues significantly above pre-pandemic levels and the Diagnostics segment contributions from our COVID-19 assays offsetting lingering headwinds from the pandemic. The increased adjusted operating margin and adjusted EPS reflect a flow-through of the additional net revenue and gross profit, as well as lower spending for travel, tradeshows and selected new product development programs.
This guidance reflects our current visibility into market conditions and customer order patterns for our products and our current assumptions about the impacts from the COVID-19 pandemic in the U.S. and around the globe.
**Financial Condition**
At December 31, 2020, cash and cash equivalents were $63.2 million and the Company had $101.2 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s obligations under the commercial bank credit facility totaled $58.8 million as of December 31, 2020.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, February 5, 2021 beginning at 10:00 a.m. Eastern Time to discuss the first quarter financial results and answer questions. A presentation to accompany the quarterly financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=GN4UGuEQipxOx_P2J7ImrDakqtq7yucf_o8ASsnuyS1Qdzglx-fgmi6GI_ned14v4AUBq0Ax-HPpHhoF7-EuNyUO99uAzhsQxOh5GutT5Efm38wTnt-QfMQ3tQCdZuqW "www.meridianbioscience.com"), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5617405. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on February 5, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5617405.
**FIRST QUARTER FISCAL 2021 UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted accounting principles (“GAAP”) basis for the first quarters of fiscal 2021 and fiscal 2020.
Three Months
EndedDecember 31,20202019Net
revenues$92,917$47,421Cost of sales31,36919,770Gross profit61,54827,651Operating expensesResearch and development5,6514,763Selling and marketing7,0216,728General and administrative11,9388,984Change in fair value of acquisitionconsideration1,0471,187Restructuring costs–275Selected legal costs1,227320Total operating expenses26,88422,257Operating income34,6645,394Other expense, net(416)(1,368)Earnings before income taxes34,2484,026Income tax provision7,4691,199Net earnings$26,779$2,827Net earnings per basic common share$0.62$0.07Basic common shares outstanding43,09842,789Net earnings per diluted common share$0.61$0.07Diluted common shares outstanding43,77942,938
Three Months
EndedDecember 31,20202019**Adjusted Financial Measures**(see non-GAAP financial measure
reconciliation below)Operating income$36,938$7,176Net earnings28,4864,179Net earnings per diluted
common share$0.65$0.10
**Condensed Consolidated Balance Sheet Data**
December 31,September 30,20202020Cash and
cash equivalents$63,193$53,514Working capital123,785109,666Long-term debt58,82468,824Shareholders’ equity278,867247,629Total assets423,930405,261
**Segment Data**
The following table sets forth the unaudited revenue and segment data for the interim periods in fiscal 2021 and fiscal 2020 (in thousands).
Three Months EndedDecember 31,20202019Net
Revenues – By Product Platform/TypeDiagnosticsMolecular assays$4,590$6,903Non-molecular assays25,73127,888Total Diagnostics30,32134,791Life ScienceMolecular reagents46,0295,367Immunological reagents16,5677,263Total Life Science62,59612,630Total Net Revenues$92,917$47,421
Three Months EndedDecember 31,20202019Net Revenues – By Disease State/GeographyDiagnosticsGastrointestinal assays$15,452$16,251Respiratory illness assays4,8067,778Blood chemistry assays4,3944,951Other5,6695,811Total Diagnostics30,32134,791Life ScienceAmericas18,7554,012EMEA32,3114,960ROW11,5303,658Total Life Science62,59612,630Total Net Revenues$92,917$47,421OPERATING (LOSS) INCOMEDiagnostics$(1,182)$5,141Life Science39,7972,328Corporate(3,963)(2,087)Eliminations1212Total Operating Income$34,664$5,394Geographic Regions
Americas = North
and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of certain acquisition-related costs, changes in fair value of the acquisition consideration, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three-months ended December 31, 2020 and 2019.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FIRST QUARTER**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three MonthsEnded December 31,20202019Operating Expenses –GAAP basis$26,884$22,257Change in fair value of acquisition consideration(1,047)(1,187)Restructuring costs–(275)Selected legal costs(1,227)(320)Adjusted Operating Expenses$24,610$20,475Operating Income –GAAP basis$34,664$5,394Change in fair value of acquisition consideration1,0471,187Restructuring costs–275Selected legal costs1,227320Adjusted Operating Income$36,938$7,176Net Earnings –GAAP basis$26,779$2,827Change in fair value of acquisition consideration \*786901Restructuring costs \*–208Selected legal costs \*921243Adjusted Net Earnings$28,486$4,179Basic Net Earnings per Common Share (“EPS”) –GAAP basis$0.62$0.07Change in fair value of acquisition
consideration0.020.02Restructuring costs––Selected legal costs0.020.01Adjusted Basic EPS$0.66$0.10
Three Months Ended December 31, 2020 2019 Diluted Net Earnings per Common Share (“EPS”) – GAAP basis$0.61 $0.07 Change in fair value of acquisition consideration 0.02 0.02 Restructuring costs – – Selected legal costs 0.02 0.01 Adjusted Diluted EPS$0.65 $0.10 \* Net of tax.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=SxAr00J6-o5940asmcVyFQLfYq_LsPy8YFvN1I4esWgC_mUgCPAEL9FkAnoT-vA6wjcWJfJq7_0qeVjQxplahIPu5UeHYEg2VraThTCDDkeir5uAkw7_ZzOYkQhzNsd0 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown](https://www.meridianbioscience.com/press-release/meridian-bioscience-expands-production-capacity-with-support-from-nih-jobsohio-and-the-village-of-newtown/)
**Published:** February 3, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company’s SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene® test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the corporate headquarters in the Village of Newtown (Cincinnati, OH). The expansion will be completed in phases over the coming months and is expected to yield a maximum capacity of 800,000 Revogene® tests per month by the end of calendar year 2021.
“We are excited to be in the final stages of bringing the Revogene SARS-CoV-2 assay to market,” said Tony Serafini-Lamanna, Executive Vice President – Diagnostics. “Our customers continue to search for more tests to battle this wave of the coronavirus pandemic and this support from our Federal, State and Local governments will be instrumental in scaling our manufacturing capacity.”
NIH launched the RADxSM initiative to speed innovation in developing, commercializing, and implementing technologies for COVID-19 testing. Meridian Bioscience is one of 27 projects that have moved to Phase 2, with a focus on scaling manufacturing to increase the capacity of testing in the U.S.
NIH Director, Francis S. Collins, M.D., Ph.D. commented during the launch of the RADxSM initiative in April 2020 saying, “Now is the time for that unmatched American ingenuity to bring the best and most innovative technologies forward to make testing for COVID-19 widely available.”
JobsOhio and REDI Cincinnati are partnering with Meridian to support its growth on the Meridian Bioscience campus in Newtown, Ohio. Meridian received a JobsOhio Economic Development Grant as part of its commitment to create 45 new jobs and invest more than $7 million in Ohio. The Village of Newtown has also provided support to the project through tax abatements applied to the buildout of the newly leased facility.
“Meridian Bioscience’s investment near its Cincinnati headquarters is an example of how Ohio healthcare companies are front and center in the battle to defeat COVID-19,” said J.P. Nauseef, JobsOhio President and CEO. “We and our partners at REDI Cincinnati welcome this expansion at Meridian’s Newtown facility, where talented Ohioans will play a critical role bringing the newest advancements in COVID testing to the North American market.”
“Meridian has been a valued, long-term resident of Newtown for over 40 years and is once again expanding their presence through economic investment and the addition of 45 full-time jobs. We are proud of the contribution Meridian is making to the fight against this pandemic and happy we are able to support them in their expansion,” said Mayor of Newtown, Mark Kobasuk.
This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health under Contract No: 75N92021C00003. The current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.
*The Revogene*® *SARS-CoV-2 Molecular Diagnostic Test has not been FDA cleared or approved.*
For more information on the Revogene® SARS-CoV-2 test, please visit [https://www.meridianbioscience.com/human-condition/respiratory/coronavirus/revogene-sars-cov-2/](https://www.globenewswire.com/Tracker?data=NXrvItiHqstaoXE2ZNUaa6kPVyVpr2XXAQdzNkGJ9HfhO36aQamP5uu9L4zQS-FKeDr9Ab1fSpL0NhKkSbQ3-GPQBlxoS4ggF54LlAESQPjOFng7itlbzsAuyAbz0Nv4rjD-qxNXekykUD1yohicwK78DhW_5RRVwNz_H6LiE1cTtQdg6KXRbF1v81u2bwkZl8VB0ViResehDUTQe1mgNAWbvC3F0xnUvV__YVtB0_0ZVTv9ib4lU8AWvbEX59qEnpoUo3BrJwWm0RR_3-XMsraLMASE10ELbTLP6cMICiU=).
**About the National Institutes of Health (NIH) and RADx Initiative**
NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a U.S. Department of Health and Human Services component. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit [www.nih.gov](https://www.globenewswire.com/Tracker?data=fRDVJB32Zpeo8zCNc0UEThjS3KDLpMAfT8AGJ9173MptGWJqIlKKe6QOPOAooR2pEa6hU7d_hA9BVoCwZTxAgg== "www.nih.gov").
The RADx initiative was launched on April 29, 2020, to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The initiative has four programs: RADx Tech, RADx Advanced Technology Platforms, RADx Underserved Populations, and RADx Radical. It leverages the existing NIH Point-of-Care Technology Research Network. The RADx initiative partners with federal agencies, including the Office of the Assistant Secretary of Health, Department of Defense, the Biomedical Advanced Research and Development Authority, and U.S. Food and Drug Administration. Learn more about the RADx initiative and its programs: [https://www.nih.gov/radx](https://www.globenewswire.com/Tracker?data=NXrvItiHqstaoXE2ZNUaa-E6WQ2eBF6GOpIkyWD6v9y17QPXVLUBTvfZlkQpnuWzrFfAx8yshgYcknrmWk4bRXIZdcaP9oG-V5JKjZFZjRA=).
**About JobsOhio**
JobsOhio is a private nonprofit economic development corporation designed to drive job creation and new capital investment in Ohio through business attraction, retention, and expansion. The organization also works to seed talent production in its targeted industries and to attract talent to Ohio through Find Your Ohio. JobsOhio works with six regional partners across Ohio: Dayton Development Coalition, Ohio Southeast Economic Development, One Columbus, REDI Cincinnati, Regional Growth Partnership, and Team NEO. Learn more at [www.jobsohio.com](https://www.globenewswire.com/Tracker?data=QnEvlSFj6wiYYuWhm4joC9URsj5oggLK8eHybqdH2rUCyDCJOovJDX3u18UqGKADRCQ3BSZ5yACf_qq7c_MtNA== "www.jobsohio.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=lvYmGqbo-WMGZIPMQEH4fDPP6IbAW9cr7Vjx_ZyjlbjFCws6hwHhi4ge4mIUzIEoG33HJYMKFruFgqgffPTDupn2u7Df2cn7uT304cqpl5jv42fS_y2XW19nstEFRuPe "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Zgj0feqWGO-p5mHVvKuS3SE_TX-okFSM5uTcHshsZ8DcmBD-tLsvWIHCT2e7uxKXs-V0Q--nG_wz0THW-M6ZL9-BJMFayOpgeriCwAxlXWgaqnljGiyVuQ6lX4SiXW3XIThE16_n5YawSplljI9ggA== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays](https://www.meridianbioscience.com/press-release/meridians-air-dryable-master-mixes-replace-lyophilization-in-the-manufacturing-of-molecular-assays/)
**Published:** February 2, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for manufacturing room-temperature stable molecular diagnostic assays that do not require lyophilization. The conventional approach to manufacture room-temperature stable molecular assay is lyophilization, which is expensive, time consuming, and requires expertise and sophisticated equipment. Meridian’s new air-dryable master mixes for DNA/RNA detection replace the need for lyophilization with a fast, simple and inexpensive oven-drying procedure.
A unique advantage of Meridian’s air-dryable master mixes is their ability to effectively preserve the performance and integrity of the enzymes throughout the oven-drying process. Meridian’s air-dryable master mixes also exhibit higher tolerance to PCR inhibitors, when compared to lyophilized or liquid-formats, regardless of the sample type (e.g., urine, stool, blood, saliva, waste water, plant, etc.) In addition, air-dryable master mixes are ideal for molecular assays that require multiplexing or are price sensitive.
Lourdes Weltzien, PhD, Executive Vice President – Life Science commented, “Air-dryable master mixes create a paradigm shift for molecular assay manufacturers. Room-temperature stable assays can now be created with an optimized master mix that can be oven-dried on site. Manufacturers can save time, reduce cost, and control their entire manufacturing workflow, while delivering the same or better performance as compared to other assay-formats. Our air-dryable master mixes are designed to work with fast protocols, saving time and cost in delivering a diagnosis.”
Morey Setareh, PhD, Sr. Director – Life Science Sales & Marketing added, “To simplify the use of our air-dryable master mixes, we created high concentration mixes in a single tube format for DNA/RNA detection. In addition to molecular testing for human diagnostics, other industries such as agriculture, food, environmental, forensics and animal testing can reduce manufacturing costs while maintaining high assay performance.”
Meridian is committed to suppling innovative solutions to the diagnostic industry to simplify and accelerate development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/air-dryable-mixes](https://www.globenewswire.com/Tracker?data=TQf895uByo69t8dpYmJ2dheE3_cjktfSJZdtPiqaAwVE2Ocq4Ph_Oet6pQI7ZMXepxCPZHqozW625L3h5OymhwpAEIktSBSNU5CgHEEbJWZxkYxC23uZpcQcuDDQW7uoTbb1HimBj-rPLQJdd0qsNT91L6cFhjMJJZeH3I0jui8=) or email [lourdes.weltzien@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=88_c9aaYhKpxuhvvhQzkJ0-ysTcEIq27At7fDslxlSP3SEg4OonydodH23i4ElGGLTjK7G7QdoBJxgUrskZSS9OE13kBLQ5edTSiJD9t5PLYyOwTqQ4qQ9MLEf37bqyvQJTCC-ETNA1yn19zCAz1AsD9srk1aQqLYvWKRHcoRdpUDTQHhhu_cgJztTpVDogR2EfvcSARi7QRhaT6f5MGfg== "lourdes.weltzien@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=plCsAgQGKZx34QVE1kVod1TN569L6i93GrFS86o0PUqAlNBKYASjuR7AdaWAZ08gekmcficb_5NkkXKCfQjSBUrZAzytwkcnpkadAJy4C7f9fYFYGadqH9oIO9nnxN1k "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=0bcjywOxdfkUfIKHXiiGqSlm6f0o3J5RGLc6G4jLjQqS5eLu5v-S7wOEQe-YwqWyE87BaVAxLgxP3FJM4zvgSM7eLSmulbz5rutSenu2K3LxdAICY1axT9qZSkpWEthqcrcvyXo6QOHWyFuvHWMgsYn-AKMwYgQVXG4zOcmUYVE= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold First Quarter Fiscal 2021 Financial Results Conference Call on February 5, 2021](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-first-quarter-fiscal-2021-financial-results-conference-call-on-february-5-2021/)
**Published:** January 13, 2021
**Author:** hamza
**Content:**
CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5617405.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on February 5, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 5617405.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=TJqmS1MY4iQuZ4WPntcAaT8hM7ueVKJ8oCmwmQBHrX6ic9pgB3TTsRUd92fEhvonBevd5DvpKUbFB3VVzq6JaUXccqPYiMcwO7K-ZwFzZmd6lf8U1UfkgxwNSE8cZc55 "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-better-than-expected-preliminary-first-quarter-fiscal-2021-revenue-results/)
**Published:** January 7, 2021
**Author:** hamza
**Content:**
CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021.
**Preliminary First Quarter Fiscal 2021 Results**
The Company expects first quarter of fiscal 2021 revenue to be approximately $92 million, compared to $47.4 million in the first quarter of fiscal 2020, reflecting an increase of approximately 94%. This increase is driven by Life Science segment revenue which is expected to be approximately $62 million for the quarter. Diagnostics segment revenue is expected to be roughly flat compared to the fourth quarter of fiscal 2020, with revenue of approximately $30 million.
Life Science segment revenue in the quarter exceeded expectations due to the high demand for COVID-19 related products. Demand remains robust and, while the longevity of this wave of the COVID-19 pandemic is uncertain, high levels of revenue in the Life Science segment, similar to this quarter, are expected to continue through the second quarter of fiscal 2021.
The Diagnostics segment was seeing continued improvement in the first half of the quarter, but beginning in late November, started to experience headwinds in its recovery as COVID-19 case counts increased in the U.S. and Globally, and intensified lockdowns were put in place.
“We continue to be proud of the contribution that Meridian is making in the global fight against the COVID-19 pandemic,” said Jack Kenny, Chief Executive Officer. “Demand for our Life Science reagents continues to exceed expectations and while the Diagnostics segment saw a setback in its recovery during the quarter, its own contribution to the fight begins in the coming week with initial shipments of the Revogene SARS-CoV-2 assay to select customers expected.”
Meridian has not yet completed preparation of its financial statements for the first quarter of 2021 and the guidance presented herein is a preliminary estimate, subject to change. Furthermore, Meridian is not updating its fiscal year 2021 guidance at this time. The full financial results and any changes to fiscal 2021 guidance will be discussed on our first quarter earnings call, currently scheduled for Friday, February 5, 2021. Exact details for that event will be announced in a future press release.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=P2I0rU-OmqJd-uxerazMWUcr2DcvkphUw06Aj_bbkR8drX2EjJ6h-WElRkEF9H_dw0_CGKfFkEYmpG6A84jdih6bdonsjBZKHZ5NP5jk7Pm0YHkdf_c_1mHXuQj7evIM "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=k19A3ysexJP3gwBpzhRbLH96l4kYd1-MqLIzjusKMAArbRsXzo50EdOfhujZ4jll0e4EErJCAl2VvogcyCsuUnQo2DdwkSk4NEplrKQnW43y1tzGQdyg6pZy8r48Zjy1JVPo1Pu29PaaahAxD0CXDoE2FGUsTxdecPliZSm7gs8= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-h-c-wainright-bioconnect-2021-virtual-conference/)
**Published:** January 6, 2021
**Author:** hamza
**Content:**
CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021.
Jack Kenny will also be participating in a panel discussion hosted by former FDA Commissioner Scott Gottlieb, M.D. on Tuesday, January 12, 2021 from 12:00pm to 1:00pm Eastern Time. The panel is entitled “FDA Regulation (Diagnostics and Devices, Potential Changes to Come).” Panel participants also include Dwight Egan, President & CEO of Co-Diagnostics, Michael Nall, President & CEO of Biocept, Inc., and Dr. Reginald Seeto, President and CEO of CareDx, Inc.
Webcast links to Meridian’s fireside chat and the panel discussion will be available in the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=Foxc9wN2qFXfXvaIcO1A4XHj1OBTsnA4-RxPvuXNJ_rfflRDmkyZjKLCuxDNDRVFVuvnphH4fkw340Kcb31P5fylrzuEGmy9cdU1VN5caPmp627vATVa5wdQLmPRw-qnUL2GWXW9YpUuxMx1YYycog==). The fireside chat will be available for 90 days and the panel discussion will only be available live.
For additional information on the H. C. Wainright Bioconnect 2021 Virtual Conference, please visit [www.h](https://www.globenewswire.com/Tracker?data=IjsoJyBI5A6nudremoSOBaUWCjFuz1GX5z2RI1cwglzwpaPJ84xwq96ZG9KNKw3YD9C70YQkXXTVfKXH-W6Wdg== "www.h")[c](https://www.globenewswire.com/Tracker?data=-YPFBCarwDJvDZgjBYTus0qp7phgKeE7xmYefFdguNxLARh8prS01FcnZBOiXbFXWqkdqwAs7TmuehuuuTdqLA== "c")[w](https://www.globenewswire.com/Tracker?data=AF1EhrOHqf9eNUvCqJFvoVTWxiM8vXgC0L7EzKVhmW4GDqSvluDJo9WnNXdyt0jTKRIx4Q4Jbb4pdWrS1_vm8g== "w")[events.com/bioconnect](https://www.globenewswire.com/Tracker?data=3Vb-C81dU85FUID0QCzf8B5yJbbZJsrc_OdGr-Ie8TlQxNMrwYpkyKXzwpAojiDarGqycObh0Z33rrDo-mj8uFF3D0uFZXZWzTbpBm4I0Vw= "events.com/bioconnect").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=F68NnvJpoy53OlsNQ7o7UzlO1EtCsgmT9yYatAFCbDz2FiU0GDMaYVooFg_BB3wnq5vFxlzJ0kI01YVHGZp-GWv7miB2oz751FyFISZ34XXXVV-cHg-ZfiC10WkgwjJW "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=k8vfn-FK66BynPh_m-P-l7UEi5sdzyoa7tKd2Bp4tyQdsPwI49k5UqWyltOqQgmOakZXI2I20a2fDRfDOuakp0iiOBwKMx3lSeexsJUhmIcr_xPNV2KM_YFipNy34I6YfJRxjLa3RHLMvAiIm8UGeClMrMk8aIdCxdtIMoXmKiN8-9SkZA4xRfuoG5TmRbJg "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2](https://www.meridianbioscience.com/press-release/meridian-bioscience-receives-nih-award-for-supporting-rapid-development-of-revogene-molecular-test-for-sars-cov-2/)
**Published:** December 16, 2020
**Author:** hamza
**Content:**
CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. On December 7, the application for Emergency Use Authorization (EUA) for the Revogene® SARS-CoV-2 assay was submitted to the U.S. Food and Drug Administration (FDA).
NIH funds were critical to support the development of a new assay consumable for the Revogene® platform enabling the detection of RNA targets, such as SARS-CoV-2 genomic RNA, directly from viral transport media without pre-dilution in the sample workflow. To achieve this goal, a new assay formulation was needed to not only optimize the microfluidic properties of our PIE assay device, but to also enable new enzymology and internal processing controls to ensure robust clinical results. The RADxSM initiative further provided access to several experienced consultants and through the Center for Advancing Point of Care Technology (CAPCaT) program, gave us the ability to perform external clinical testing on our SARS-CoV-2 assay.
“The NIH contribution to our SARS-CoV-2 assay was instrumental in our goal achievement, providing a kick-start to meet our product development milestones and helping us create a new generation PIE device for the detection of respiratory viral targets directly from unprocessed specimens,” said Dr. Lawrence Mertz, Senior Vice President, Diagnostics Research & Clinical Development. “We are now using this innovation to expand our respiratory viral menu on the Revogene® platform.”
The RADxSM initiative was launched by NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. Meridian Bioscience is one of forty-seven projects that made the cut and moved to Phase 1, a rigorous four to six-week period of initial technology validation.
This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Federal Award Number U54HL143541.
*The Revogene*® *SARS-CoV-2 Molecular Diagnostic Test has not been FDA cleared or approved.*
For more information on the Revogene® SARS-CoV-2 test, please visit [https://www.meridianbioscience.com/human-condition/respiratory/coronavirus/revogene-sars-cov-2/](https://www.globenewswire.com/Tracker?data=YQ-nOp9DuuS88mV5gnX_sHcHfd3A_bFYjq0SFT2FMcepeOzg7l9Rr6IHFLHo5cLrn0n4p4TYVpLnqkJw70vwN40e35aYfltfy3mBP3RnGB2scYk1shwfWsugQ4n5ZX-wVTRlEGHNYHrBbAy4XYNNnVssc1N56bD45udnO_70VgD-OO5Hj1g1KA2KmEAlcG5PwsGQvZuJZjYaEPrzmLcVnLu84NnJdBkrd8yzd_MxUiz8PmhU2tEwZ6kxCy-oBnHGrmGd7e2UaAzkshXSiIpSDbkBvakJO7Xx0WTa76ZpcRw=).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=dIbl3BpZDYaY6jJXrNhyzWgIR6NlsFGHXqSLR18I8xeOouPIDE4PT3AAW7Zw1NmpRgZ8qDWSYuT1YyEkIhZFFtnasq6KB2t1aAeLwMP9Uq5NVcV00FJi7nQdnIOm5sMo "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=YOANur0E6PiqIs50SaBkWqyJ9LwBOWpiiKncEzPIzVtvD2fYuU8BA1uv7L9TsTyJDEtc3oIF7DiPNF-2c_2xZQykySAG_51IctLLLapc0kkbZMTDVhrd_E78NQFerMlx_YlgwC-PyN0T8M9JXuILRg== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples](https://www.meridianbioscience.com/press-release/meridian-improves-field-testing-in-agbio-with-its-new-air-dryable-qpcr-mix-for-crude-plant-samples/)
**Published:** May 17, 2021
**Author:** hamza
**Content:**
CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Plant Mix. This unique Mix is specifically designed to develop and manufacture multiplexed highly sensitive and economical molecular field-tests in agriculture biotechnology (AgBio).
Increasing global food demand due to the growth in the human population accelerated the need for better crop health monitoring and surveillance. The requirements for constant monitoring of transgenic DNA from genetically modified organisms (GMO), coupled with the need for more reactive crop disease management with fast pathogen detection, led to the adoption of molecular techniques such as qPCR in agricultural diagnostics. While extraction of DNA from the plant sample before qPCR analysis does allow for the removal of various plant metabolites inhibiting the analysis, it is also a laborious and expensive activity. Meridian has developed an innovative solution for direct qPCR workflows using crude plant lysates without nucleic acid purification.
Meridian’s Air-Dryable™ Direct DNA qPCR Plant Mix uses a unique polymerase and buffer system, optimized explicitly for direct amplification from crude plant lysates – removing the need for purification of DNA from the sample. In addition, with its uniquely high 4x concentration format, the Air-Dryable™ Direct DNA qPCR Plant Mix facilitates the development of ambient temperature stable assays without the need for lyophilization – making it ideal for manufacturing field-friendly, highly sensitive, and cost-effective molecular plant assays.
Lourdes Weltzien, PhD, Executive Vice President – Life Science commented, “Air-dryable master mixes create a paradigm shift for molecular assay manufacturers. Room-temperature stable assays can now be created with an optimized master mix that can be oven-dried on site. Manufacturers can save time, reduce cost, and control their entire manufacturing workflow, while delivering the same or better performance as compared to other assay-formats. With the ability to use our Air-Dryable™ Direct DNA qPCR Plant Mix with crude samples, the testing process is faster and more economical than ever before.”
Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior assays. For more information about partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/air-dryable-mixes](https://www.globenewswire.com/Tracker?data=kVi4uG-M_a4FoU1qgDfGGXMfXXJ6HxbSvVjwiX2VoSjDC-WTP0UTl59aV7XfPXUwFehSdRvIG1rIHT5qvEpVvTLxCKCqvIwtwiE8HcF8fzuTf4UZETqf6ZmAS8zA3LMZt5N2u6uXAWMuhxno7Y4nPSGSkZ7JwYVy0YraBLwY5ds=) or contact Morey Setareh, Senior Director, Sales & Marketing at [morey.setareh@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=QsvHUIkECWiReKrse2k1FliBF7uh1Tu64KZuNhTf-Ovzna3EWhjI7T8UW59AgQ5HAm45-nIB3_Mj2QXvK9R0pPx6CDHCjmKYeYppsv5LkwWwwEuqb2V1EZCYcMcCZuLCN1Aah-iuhG2N6Esm1SBT0g== "morey.setareh@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=iKKxF1eBh33o4zHfiamiAlPWLkpDi1BYCDLnCOhu3j97y5PM15HVFbdreTmGybjnxJA8Pls5yNH6zB1dGkUNk0-HIrqlnWg-iuo7uq3LPbQHn31kBBAX9DHMc-w1YbkYGsnFj392N__AIP_hvN9dFWsBytk58CnDMYU2OmsUwFambx_m0eNcmm7xy4KBgYOS "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-strong-growth-in-net-revenues-and-eps-in-second-quarter-fiscal-2021/)
**Published:** May 7, 2021
**Author:** hamza
**Content:**
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
**Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020):**
- Consolidated net revenues of $85.3 million, up 49% year-over-year
- Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year
- Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021
- Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative – $5.5 million for ramping manufacturing of Revogene® SARS-CoV-2 Assay
- Submitted 510(k) for Curian® Campy assay
- Launched first Air-Dryable sample specific Master Mix for Blood
Jack Kenny, Chief Executive Officer, commented, “As we begin the transition into a post-COVID world, we have significant optimism for the future of Meridian. Life Science was transformed by the COVID-19 pandemic and Diagnostics is moving into a position of strength with testing returning to normal and contributions from the investments we have made.”
**Second Quarter Fiscal 2021 Results (Comparison to Second Quarter Fiscal 2020)**
Consolidated net revenues for the second quarter of fiscal 2021 increased 49% to $85.3 million, compared to $57.3 million last year. Diagnostics segment net revenues were down 9% year-over-year, but continued its recovery, up 5% from the first quarter of fiscal 2021 and up 48% from the low seen in the third quarter of fiscal 2020. Life Science segment revenues were up 139% year-over-year including an estimated $31 million in net revenues from COVID-19 related products, with approximately $28 million in molecular products and $3 million in immunological products. This implies core (non-COVID-19 related) Life Science segment net revenues were up over 30% year-over-year.
Reported operating income for the second quarter of fiscal 2021 was $34.2 million. Operating expenses included: (i) higher research and development spending in the Diagnostics segment; (ii) higher amortization related to the acquisition of Exalenz Bioscience Ltd. (Exalenz) in April 2020; (iii) lower acquisition-related expenses associated with the Exalenz transaction; and (iv) a downward adjustment in the fair value of the contingent consideration related to the fiscal 2019 GenePOC transaction. On an adjusted basis, operating income was $32.2 million, a margin of 38% (see non-GAAP financial measure reconciliation below), up from $12.1 million and a margin of 21% in the prior year, representing year-over-year growth of nearly 170%.
**Financial Condition**
At March 31, 2021, cash and cash equivalents were $63.4 million and the Company had $110.0 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s obligations under the commercial bank credit facility totaled $50.0 million as of March 31, 2021.
Bryan Baldasare, Chief Financial Officer, commented, “Our cash generation continues to be a strength and we remain focused on putting our balance sheet to work to drive both organic and inorganic growth opportunities.”
**Adjusting Fiscal 2021 Guidance**
As a result of the voluntary withdrawal of the emergency use authorization (EUA) application for the Revogene SARS-CoV-2 assay in February, Meridian is adjusting the Diagnostics segment guidance and the impact on consolidated operating margin and diluted net earnings per share, both on an adjusted basis.
FY2021 Net Revenues:
- Consolidated $305 million to $335 million
- Diagnostics segment $125 million to $135 million
- Life Science segment $180 million to $200 million
FY2021 Adjusted Operating Margin: Consolidated 30% to 33%
FY2021 Adjusted Net Earnings Per Share on a Diluted Basis (“EPS”): $1.60 to $1.80 (44.3M shares)
While the Life Science segment net revenues were somewhat below the Company’s expectations in the second quarter, we continue to see good demand for its reagents. As a result, guidance for the Life Science segment’s net revenues has not changed. The $15 million reduction in net revenues guidance only reflects the removal of any significant contribution from the Diagnostics segment’s COVID-19 products as a result of our voluntary withdrawal of our Revogene SARS-COV-2 EUA application and expected timing of re-submission, as well as no clear line of sight as to when our current partner will submit its rapid antigen SARS-CoV-2 test for EUA clearance. Adjusted EPS includes the impact of removal of the net revenues from these tests during our second half of fiscal 2021.
This guidance reflects our current visibility into market conditions and customer order patterns for our products and our current assumptions about the impacts from the COVID-19 pandemic in the U.S. and around the globe.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, May 7, 2021 beginning at 10:00 a.m. Eastern Time to discuss the second quarter financial results and answer questions. A presentation to accompany the quarterly financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=9qFpofOLvDy1dlkU6qLy3w4F11GHlqb8Gm5Qn5kD64bGAVf7Ub9xXixJlBHo_1QqhYtRsgoOa0SSwC6Bc4ubcboHDrctLOBMx_2Ty9QrDfR2Hemxja1n2Tx0jDcrEoy5 "www.meridianbioscience.com"), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9948805. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on May 7, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9948805.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted accounting principles (“GAAP”) basis for the interim periods of fiscal 2021 and fiscal 2020.
Three Months Ended Six Months Ended March 31, March 31, 2021 2020 2021 2020Net revenues$85,264 $57,296 $178,181 $104,717 Cost of sales 27,492 22,750 58,861 42,520 Gross profit 57,772 34,546 119,320 62,197 Operating expenses Research and development 6,065 5,315 11,716 10,078 Selling and marketing 6,540 6,529 13,561 13,257 General and administrative 12,925 10,628 24,863 19,612 Acquisition-related costs – 1,787 – 1,787 Change in fair value of acquisition consideration (2,989) (2,491) (1,942) (1,304) Restructuring costs – 252 – 527 Selected legal costs 1,030 735 2,257 1,055 Total operating expenses 23,571 22,755 50,455 45,012 Operating income 34,201 11,791 68,865 17,185 Other income (expense), net (1,149) 856 (1,565) (512) Earnings before income taxes 33,052 12,647 67,300 16,673 Income tax provision 6,750 3,288 14,219 4,487 Net earnings$26,302 $9,359 $53,081 $12,186 Net earnings per basic common share$0.61 $0.22 $1.23 $0.28 Basic common shares outstanding 43,244 42,830 43,171 42,810 Net earnings per diluted common share$0.60 $0.22 $1.21 $0.28 Diluted common shares outstanding 44,122 42,968 43,960 42,953
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
**Condensed Consolidated Balance Sheet Data** (in thousands)
March 31, September 30,2021 2020Cash and cash equivalents$63,374 $53,514 Working capital 137,984 109,666 Long-term debt 50,000 68,824 Shareholders’ equity 309,473 247,629 Total assets 439,169 405,261
**Segment Data**
The following table sets forth the unaudited net revenues and segment data for the interim periods in fiscal 2021 and fiscal 2020 (in thousands):
Three Months Ended Six Months Ended March 31, March 31, 2021 2020 2021 2020 Net Revenues – By Product Platform/Type
Diagnostics Molecular assays$4,395 $7,238 $8,985 $14,077 Non-molecular assays 27,554 27,704 53,285 55,656 Total Diagnostics 31,949 34,942 62,270 69,733 Life Science Molecular reagents 37,752 11,534 83,776 16,902 Immunological reagents 15,563 10,820 32,135 18,082 Total Life Science 53,315 22,354 115,911 34,984 Total Net Revenues$85,264 $57,296 $178,181 $104,717
Three Months Ended Six Months Ended March 31, March 31, 2021 2020 2021 2020 Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$15,666 $14,014 $31,118 $30,060 Respiratory illness assays 3,686 10,863 8,492 18,612 Blood chemistry assays 4,358 4,194 8,753 9,142 Other 8,239 5,871 13,907 11,919 Total Diagnostics 31,949 34,942 62,270 69,733 Life Science Americas 13,550 4,612 32,296 8,623 EMEA 21,773 9,946 54,066 14,907 ROW 17,992 7,796 29,549 11,454 Total Life Science 53,315 22,354 115,911 34,984 Total Net Revenues$85,264 $57,296 $178,181 $104,717 OPERATING INCOME (LOSS) Diagnostics$2,421 $4,729 $1,239 $9,870 Life Science 36,089 9,931 75,886 12,259 Corporate (4,325) (2,896) (8,288) (4,983) Eliminations 16 27 28 39 Total Operating Income$34,201 $ 11,791 $68,865 $17,185
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of certain acquisition-related costs, changes in fair value of the acquisition consideration, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three- and six-month periods ended March 31, 2021 and 2020.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**SECOND QUARTER AND SIX MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Six Months Ended March 31, Ended March 31, 2021 2020 2021 2020 Operating Expenses – GAAP basis$23,571 $22,755 $50,455 $45,012 Acquisition-related costs – (1,787) – (1,787) Change in fair value of acquisition
consideration 2,989 2,491 1,942 1,304 Restructuring costs – (252) – (527) Selected legal costs (1,030) (735) (2,257) (1,055) Adjusted Operating Expenses$25,530 $22,472 $50,140 $42,947 Operating Income – GAAP basis$34,201 $11,791 $68,865 $17,185 Acquisition-related costs – 1,787 – 1,787 Change in fair value of acquisition
consideration (2,989) (2,491) (1,942) (1,304) Restructuring costs – 252 – 527 Selected legal costs 1,030 735 2,257 1,055 Adjusted Operating Income$32,242 $12,074 $69,180 $19,250 Net Earnings – GAAP basis$26,302 $9,359 $53,081 $12,186 Acquisition-related costs – 1,787 – 1,787 Change in fair value of acquisition
consideration \* (2,244) (1,886) (1,458) (985) Restructuring costs \* – 190 – 398 Selected legal costs \* 774 554 1,695 797 Adjusted Earnings$24,832 $10,004 $53,318 $14,183 Basic Earnings per Common Share – GAAP basis$0.61 $0.22 $1.23 $0.28 Acquisition-related costs – 0.04 – 0.04 Change in fair value of acquisition
consideration (0.05) (0.04) (0.03) (0.02) Restructuring costs – – – 0.01 Selected legal costs 0.02 0.01 0.04 0.02 Adjusted Basic EPS \*\*$0.57 $0.23 $1.24 $0.33
Three Months Six Months Ended March 31, Ended March 31, 2021 2020 2021 2020 Diluted Earnings per Common Share – GAAP basis$0.60 $0.22 $1.21 $0.28 Acquisition-related costs – 0.04 – 0.04 Change in fair value of acquisition
consideration (0.05) (0.04) (0.03) (0.02) Restructuring costs – – – 0.01 Selected legal costs 0.02 0.01 0.04 0.02 Adjusted Diluted EPS \*\*\*$0.56 $0.23 $1.21 $0.33
\*Net of tax, as applicable.\*\*Three months ended March 31, 2021 does not sum to total due to rounding.\*\*\*Three and six months ended March 31, 2021 do not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=9qFpofOLvDy1dlkU6qLy3w4F11GHlqb8Gm5Qn5kD64bWi8DApa_YWOOr-KyKEMPH2u-WE4NcY3rSFJTLrlIDqcUdEJI1f4syhpZzrzPJsRg0NIWaRUZ4ukIrNVyNgvpU "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=kUGbidlIO_1RFnF7ioFLNvDGU9j754SQ6QbOq7Zpcsu5PLG_pi3yfs3hP2jFGm0HBoNC66QENuzzBogEe2HO2u1NYYJFYrdbs9LzExYQdwVbUcY_TtS9KS5uRHorOcBF)
**Categories:** Press Release
---
### [Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready LAMP Mix](https://www.meridianbioscience.com/press-release/meridian-simplifies-workflows-for-poc-molecular-tests-with-a-new-lyo-ready-lamp-mix/)
**Published:** April 28, 2021
**Author:** hamza
**Content:**
CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays. The Lyo-Ready DNA LAMP Mix is formulated for rapid, robust, and sensitive DNA amplification through nucleic acid strand displacement.
The COVID-19 pandemic has highlighted the benefit of point-of-care molecular diagnostic testing. LAMP assays are perfectly suited for point-of-care or portable testing because they are performed at one single temperature which reduces the cost and complexity of the device without the requirement of a thermocycler. Additionally, to further support point-of-care testing, molecular diagnostic tests are progressively moving towards formats that avoid cold storage requirements.
To facilitate development of such tests, Meridian designed the new Lyo-Ready DNA LAMP Mix as a glycerol-free, and uniquely high 4x concentration format mix, containing pre-optimized lyo-excipients. Once target-specific primers/probes are added, the mix is ready to be lyophilized, making it ideal for faster development of room temperature stable LAMP assays with superior amplification sensitivity and specificity.
Florent Chang-Pi-Hin, Ph.D., Sr. Director of Research & Development – Life Science, commented, “LAMP is increasingly used in molecular diagnostics as a field-friendly alternative to many other complex molecular methods. We are delighted to announce the release of our new Lyo-Ready LAMP Mix, which outperforms the competition with excellent sensitivity and specificity while also reducing overall assay development and manufacturing costs.”
Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior diagnostic assays. For more information about partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/lyophilization-ready-qpcr-rt-qpcr-mixes](https://www.globenewswire.com/Tracker?data=kHYjtPb3I9Jzy_j0P1KNa-lpl3oAuCpnKLdo14MyjBH-JBjm9unniZzsc3jVBO_yWjeecFZ5B91mKeJuJHZrWp3Msr34-0iBuMzpHjZ12lndAH05BoXGsZYNkRstOIpdd_uBcsDLx7A5dKXT41YSbLZt-hQeCbLr7zDjGAJTrI7afKrF9GDha9rQtNB6t9LVtBlhMXVX42WZm7CRe7pEUiQ3XCDLpsY5rIkMjZ9aTU8=) or contact Dr. Chang-Pi-Hin at [florent.chang-pi-hin@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=imOHcPCBSGHH5lEGpge18JaBLUY9fFtBzYG55jg9Hh11KTnjxkQ4yepAf4uBbdiWcKlqxV0YNViHQ_LiUoj3e-KIe6sP1AA9XF7GbVkStVB4kxY4pX3RYQF8hh4k1sJmoSK9MTrTxuOZzDZemhndANkHQzXiZ5f7xf5v2WJGrmk= "florent.chang-pi-hin@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=39s8umyDCz5UoPojWPkGtTxDmIa6ez4uB9ifqV7fUktgKNjRJCDQjS6P9uoUFqnqG5KN_f4ue3L9bccPYjKavrGnnmysTd6me52Et07RV3sD6bRrziHhUOvDZF6kmIqy "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-second-quarter-fiscal-2021-financial-results-conference-call-on-may-7-2021/)
**Published:** April 19, 2021
**Author:** hamza
**Content:**
CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 9948805.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on May 7, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 9948805.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=LIoIWlSmI2yTzTBN8l99WmpjCPfqb8rZOJRLkdk247SY40j1GPcui_31vx0tLE4VGQ56i7Bbi9pqcOjFLkerqXGJswbB9JWDlBg6VsdKekc5D5EKoKnaFl34sbp5Giz8 "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=RGx9RlYRgzmdakpKZ3x7zTdicfzCDl2IbFpNPHLaGhEqAASnjjivGzr6b3CzjPqoRVATwTRHfBG5W-GN74pTGQApNkibCAN6jgHY44O5sZwyK_PlyB5pXVNCK-HWbv-W "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-fda-submission-for-new-curian-campy-assay/)
**Published:** April 1, 2021
**Author:** hamza
**Content:**
CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s new Curian® Campy assay. This assay is one of many assays in the pipeline that expands the Curian® menu, continuing Meridian’s leadership in the gastrointestinal disease and lateral flow testing market.
Curian® Campy, for use with the Curian® Analyzer, is a rapid, qualitative fluorescent immunoassay for the detection of *Campylobacter* spp. (*C.* *jejuni / C. coli / C. upsaliensis / C. lari*) in human stool. The stool sample may be either unpreserved or preserved in Cary-Blair-based transport media.
The Curian® solution provides objective, rapid test results and helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually-based test results. With a simple workflow and clean, comfortable sample handling, Curian® provides healthcare systems a platform to standardize testing from the industry’s leading experts in stool handling and testing.
For more information on the Curian® platform, please visit [https://www.meridianbioscience.com/platform/immunoassay/curian/](https://www.globenewswire.com/Tracker?data=A5zFtEzBdj0wQRGyf3_1toECLLDBX_ky5JIS3x8Sib4yy6l-yCSgVAu0l9lvVL_4tCmt9JYvxBf1MbJJCwmWSzRtNM_k7b5-0bTNW5E5Bh3HFRKqJavB8NUQFluGdBHYVMDpcbVBbtbP4jA6Oz4XhXeQ2K8vagzbgIDaQEglX09uz_yb_bICU-aAcEUH_OPYN0LLmubDo9XS1qiWaTfc4g==).
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=ZLapTPhQInlyUXwyACTTpmyA5Q6Cwl5jEXwbIcpsAE4lFPhOncSuDQemJ4-Jyvk4V0XkAm-OT8XxfyMftcVThFtx9WX8HFR4nWPNGlSnvBzEadJyLISVlMfLZtoPlYlg "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=4Oet9HjQgav2CeFRxqQhaEnRaW-daeUjz2lxoUAVm_sfplKU7L3eyEDFs0sn9AVkvY8EupHxdkDrcok3HY9arGoaCxqFxg7V4c2ySjux6G3flrHlCYm3EeXb_eOHMYqWCXNDMM_XCBg3ZdEzuUyKJVihHBNmIwwhFdChsLGJUvU= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches its New Air-Dryable Mix for Crude Blood Samples](https://www.meridianbioscience.com/press-release/meridian-launches-its-new-air-dryable-mix-for-crude-blood-samples/)
**Published:** March 8, 2021
**Author:** hamza
**Content:**
CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, serum or plasma.
The National Cancer Institute (NCI) and NHS England have predicted that tens of thousands of excess cancer deaths will occur over the next decade due to missed screenings, delays in diagnosis and reductions in oncology care caused by the COVID-19 pandemic. Blood sample screening provides a faster and more accurate way for early cancer detection compared to single-site tissue sampling. However, PCR inhibitors in blood specimens can lead to false-negative results or reduced sensitivity unless costly and time-consuming DNA purification methods are used. Meridian’s Air-Dryable Direct DNA qPCR Blood Mix uses a specialized polymerase and advanced buffer formulation optimized specifically for whole blood, serum and plasma, without the need for purification of DNA from the sample. In addition, the Air-Dryable Direct DNA qPCR Blood Mix replaces the need for lyophilization with a fast, simple, and inexpensive oven-drying procedure, making it ideal for manufacturing room-temperature stable, highly sensitive and cost-effective molecular diagnostic assays.
Morey Setareh, Ph.D., Sr. Director Sales & Marketing – Life Science commented, “The Air-Dryable Direct DNA qPCR Blood is designed to tolerate a high level of inhibitors present in blood, allowing for the development of simpler and faster assays. With Meridian’s new air-dryable technology, assays can now be oven-dried on site, saving manufacturers’ time and cost, as well as allowing them to control their entire manufacturing workflow.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/air-dryable-mixes](https://www.globenewswire.com/Tracker?data=nrWKm4n3sKz-pBGA3L4fAUdjILhadKW9TpjOPcdxHo7kEpMnTaDqXR5INYkWm70tzbAa631QR6FapXIzjuPhRqK2sSfeO2vTuJS2PuZCBI1CdVHsPnPk4r1pfeC0r3j0jlXJrbwROGCvNcsmci1cBDJo8rlH5D8gTMCPgwqYSQQ=) or email [morey.setareh@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=Hvq_nyX0lvVIDxdloMuDWoHiu2auPDaFppqZhAlaHTFuC4R-b5SVVFO5BySKDjjSGkeG4LqzERUzd1jfa_XZ1Min7hwhr2-wKCVHJOY0Y77dZX8C-p7DslMneXpslfNGeLSErZM1ZR4iAJoJHM1Q-oBFATFU3U8RqUgsfbwOfbf4ujcb6Hq3yjZrMzhiW8s9_XMBxlK0VClIAKCGZCLD5Q== "morey.setareh@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=I4ySNRtD4aBCX6tUDmWybSrEG7JsbQq9NEYboxAPUnvrzERTAf8H29dsbOkHJdtsJ7DCfWajFSHj9d9B_K3m7FvhPI_6HsIHRjDnWpFFrgicozZ5r5QZcL0HqjF7Xmre "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=vEYqRD9dazCxfiZP3lkiYsPdPA-bc5guDbnFii13eRI7ebvrugsP6KRj2i1mTVCisQ-FzdhEnejV4Y-VmloRXVJ-W01UodaoMtSqbe8lBsttkhcE0Rm2TnjmZN5IWMf7LOM-DCWm0Eio7rFHBn0CVmAl1G18YbtpVLlAqLaK_wSsWgm78sVQ6MXGHtxa2oEm "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-h-c-wainwright-global-life-sciences-2021-virtual-conference/)
**Published:** March 4, 2021
**Author:** hamza
**Content:**
CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on March 9, 2021.
A link to access the pre-recorded presentation will be available in the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=fTw1tceLi35YRdntPkZ7a7HrH021K1EXFPwurWxVn3nslbstCkWKXSmBKMFY0Ri6o33YIQschyi9gHen-6C3l5mzj_SNr9Ehjd8HK-3hf2dg4K8NC8H0b7TSdEZ7Wee6JAogcmn8I7y80v1j0PBmlg==) for 90 days.
For additional information on the H.C. Wainwright Global Life Sciences 2021 Virtual Conference, please visit [www.hcwevents.com/globalconference/](https://www.globenewswire.com/Tracker?data=W_l_GgBOrX5da1uk69-DROimPlMAYZ1-Ji71Ffa6s1D3XiSYoiQXZjzvM5OT633oh3U6hVSxgc6GPmRToEGcDHQnRJjL140GP32zBoLpVt_92NTJ3tMsOWYD8lTm6Ga5 "www.hcwevents.com/globalconference/").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=qMIZpZvzp80Ex-t5e0BPHQwSGzPgHy6YEafzsGHf837fyP5sYGLzFPXWg4vtErqmI6C86y2qDAHYt7B4mGkw2ppzBJeBEPBkVvnq5yBe-W4aOsJmxXrMrTjAZ6jw4Tuz "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Wbr5br_Urc8i-digGSP7SGhD8r8hOgqoKOGfgVvAYz_vKdCyV_eVGOKYZ7aVsgbOF-O8o84wMUrf_qHIU-NBN9Wp__yv1EAfZddaB3DSnrWB4iYpiqmemslQleoCHlDUAwKFO0737llIoD-LE3WzV-Tkq1kxXSYHaJfQxQkMccm9oIqughVPkHu2LLbP5GwIM6uj6Ig4yz5QSV4R2tQ6e4A7y8sF19lW1zkq0gl5YCU= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal](https://www.meridianbioscience.com/press-release/meridian-bioscience-corrects-prior-update-regarding-revogene-sars-cov-2-eua-withdrawal/)
**Published:** February 23, 2021
**Author:** hamza
**Content:**
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.
In subsequent communication with the FDA mid-morning on February 23, 2021, the FDA clarified that Meridian will not be able to distribute its SARS-CoV-2 molecular diagnostic test on its Revogene® platform until the test receives EUA approval from the FDA. This corrects the Company’s prior statement that the Company would resume shipping the Revogene® SARS-CoV-2 test to customers upon notification of its intent to re-submit an EUA application.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, revenue, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products and emergency use authorization application for the Revogene SARS-CoV-2 test). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=zs7J_-LbuaMMxBediXmrUEKJCtGkIIBMPAtr_PS2w5phezKz4ox_tcTJmCQXTGUXZijaAFRHLcWJ0Q7n7hNTqXEN3P10UMv6GMgsSauJnK15cfLdGgizINHLCc1rZtaP "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=8_LQhsga8OjjrppmEELj_KB8QqujgymB23YKph-kyDbG-cpZ3ipfiglTtMh9RJ284ozItzFoFhlmzcDvQ7j4qih0NGasE78BcNYWTvfML-kD2BbZUzL7YxU1LdLc8kXDKYDsQBF-39I_Rz0Nn9aCTw== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-the-41st-annual-william-blair-growth-stock-conference-and-jefferies-virtual-healthcare-conference/)
**Published:** May 27, 2021
**Author:** hamza
**Content:**
CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Jack Kenny will also pre-record a presentation for the Jefferies Virtual Healthcare Conference which will be webcast on Friday, June 4, 2021 at 2:00 PM ET.
Jack Kenny will be taking 1×1 meetings at the William Blair conference while Bryan Baldasare, Executive Vice President and Chief Financial Officer, and Charlie Wood, Vice President – Investor Relations, are taking 1×1 meetings at the Jefferies conference.
To access these presentations, go the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://www.globenewswire.com/Tracker?data=9BdI_PNGhxj5EGKXn4I3OQA42JPgVghw-yQGqJzBsltpywtkTAZHY29SPTMDIc3DwhviDvtB43MPq_IMJnW_bn5sDt6Lv1OnuiwQfiQGG53SowBQqpM0OrGTE8Mu6zFWjRoz9ruXwiPCD8pdRdR4VA==). Participants should register several minutes in advance of the William Blair event’s start time by following the link provided for the event. A recording of this event will be available for 30 days. The pre-recorded presentation for the Jefferies event will be made available for 90 days starting June 4.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=tXvEot1SJbP3DDkwsjR7jaLOd2VXVpt-MQHZ6goMku_u0MYhwmzWmwZVs1rVrJrvp3NNlGjbqP0WirSDzGqbrcWKH5FJZI3XG40bJvrGh1ERgBS8C31GHXfcEfBNdMcm "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=laoi3PXKudvlY7jRjpKPMjQzOHukBhZYmqS2TsrWxqGxDAiIHb9bCri0BZ8UK3aoZZ5gVom7UUF14WQ-Nd5ijC0ODh_Cvf-kCKqtaaV4M-7SwqWJNSXzezTpPXO9S8WGFch0vot0Wjefxww6aYRl8WeAnoTmYTeenpRIbXPgkND-aQ4hLmQwZyoPnfhYeDNu "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay](https://www.meridianbioscience.com/press-release/meridian-resubmits-application-to-fda-for-emergency-use-authorization-for-revogene-sars-cov-2-molecular-assay/)
**Published:** June 28, 2021
**Author:** hamza
**Content:**
CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.
On February 22, 2021, Meridian voluntarily withdrew its EUA application in order to conduct additional studies based on guidance from the FDA. Meridian completed the additional studies and re-submitted its EUA application on Friday, June 25, 2021.
Tony Serafini-Lamanna, Executive Vice President – Diagnostics, said, “We are pleased to have completed these studies and resubmitted our EUA application. We look forward to the FDA’s review of the Revogene SARS-CoV-2 assay.”
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=yfp9AXNwePJarQ1yT1mX4TZMWT8bVMaOpBnYuhb4jt9IgVxVheY0M-evnM982WH5FRGf7OBWTBYJqW1b-FyjARD-uNwLgpCykLtl4jv84BbBcOYy_KpqGxp1UV8ocBrC "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=zhX4S4rB6f-LIxQliVDco7BGMxfhxzY1a3dWWeIHqpBlAuAfaWCMvhq4EJ-D29Z6C828Au9-Q43YVmktumoEzBmfb2gOHvo3bEjIJNt6fgGkiCsem9L00jPJ3O4bnZms9riPCk_DvxWgtWBhSVyn1w4Rc9mCWBP5LOvnIXZ7BuXikFmKy3qaZ6d9Pc5Zvj8g)
**Categories:** Press Release
---
### [Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses](https://www.meridianbioscience.com/press-release/meridians-new-master-mix-for-lamp-assays-offers-a-practical-solution-for-poc-molecular-detection-of-rna-viruses/)
**Published:** June 16, 2021
**Author:** hamza
**Content:**
CINCINNATI, June 16, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays. The Lyo-Ready RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruses.
RT-LAMP technology is perfectly suited for point-of-care or portable testing because assays are performed at one single temperature, which reduces the cost and complexity of the device without the requirement of a thermocycler. RT-LAMP has been successfully used in the diagnosis of infectious diseases caused by RNA viruses, such as influenza, hepatitis C, West Nile fever, Dengue virus and Ebola virus. The accuracy and relatively simple equipment requirement makes RT-LAMP the perfect technology for use as a practical solution for point-of-care detection of viruses, particularly in non-standard institutions such as airports, rural hospitals or in the home. Applications for this technology go beyond human diagnostics expanding to veterinary, environmental, AgBio, and food testing.
However, in order to have this wide reach, RT-LAMP diagnostic developers need to eliminate the need for cold storage of the assay. To facilitate development of tests that can be stored at ambient temperature, Meridian has designed the new Lyo-Ready RT-LAMP 1-Step Mix as a glycerol-free, and uniquely high 4x concentration format mix, containing pre-optimized lyo-excipients. Its unique formulation expedites the assay optimization, reducing development time of room temperature stable RT-LAMP assays with superior amplification sensitivity and specificity.
Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development – Life Science, commented, “Our new Lyo-Ready RT-LAMP mix contains all enzymes required for RNA detection with reverse transcriptase and Bst Polymerase in a lyophilization compatible format. With the pressing needs of COVID-19 testing, lyophilization opens the door to a faster and near patient alternative to the diagnosis. We are delighted to announce the release of our new Lyo-Ready LAMP 1-Step Mix, which outperforms the competition with market leading sensitivity and specificity while also enabling point-of-care with ambient temperature storage capability.”
Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior diagnostic assays. For more information about partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/lamp](https://www.globenewswire.com/Tracker?data=vSorDGn6YZg-NvUDdIV090ySU_ndo6zaLbZpCmpo321xdSqKLGavLmlJoLdNyJBC8b1xmguGsNGV79Lh009SAdII3UF6nwFQJsJFF1byBlQI6KEsX3MpcCoXXFMT5lyC) or contact Dr. Chang-Pi-Hin at [florent.chang-pi-hin@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=UdTxaSLBhobr15kP8nCFt4GFnErLMCE7cVBKQyzlpsca83v9fUANtIi3uL_p9_ihxxJE2rPq2hvhtO-eAuvjyCSoo2yDK8oWAdkX9yAMmLb88b1vUWXxflwAaA9rJM6O7ZSPNqiMGtxgKs2GOQbdUXFjE3pvDkuqkIYZUa55zSAU5PuHU_lZEI-KvsO5nl3WimwsXmi9Rn0BXvouaIVK4w== "florent.chang-pi-hin@meridianlifescience.com").
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=iAGjMfVcqO0Scv2P5Y5h9KKQ9W_RlKAbnYTzEGdSY4nHbx6KMkWOzUFJKr_o3dVlw965rSWiHpcOPTeaamYlMS4fkJeOPNGwyNYmFm7Oo7A0BUl18leAxRyLxTqLr7Cv "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=H8C-f0uTNJcMJnjfg5NGbgiNctm7I5FHzUZcBhviwdL_AohQHMoM02EuRX90ZQjJcjc1-e6FxNwvMxO6m3APliX3rH-spxkREy_b6NErlrgYYiVhVZ78xR8uyIWs4zr2blHTX_Yqq13mwolA8WkpS-pRDURDmNJMqL8Ujl5wyBVMw1qZz7w0rNgANWsBmnXR "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches New Air-Dryable™ qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples](https://www.meridianbioscience.com/press-release/meridian-launches-new-air-dryable-qpcr-mix-enabling-direct-detection-of-rna-from-whole-blood-samples/)
**Published:** October 7, 2021
**Author:** hamza
**Content:**
CINCINNATI, Oct. 7, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-launches-new-air-dryable-qpcr-mix-enabling-direct-detection-of-rna-from-whole-blood-samples-301395598.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix. Meridian designed this innovative master mix to develop room-temperature stable molecular diagnostic assays that directly amplify RNA from crude whole blood, serum, or plasma. This new offering adds to the innovative portfolio of sample-specific master mixes that Meridian has created to help molecular diagnostic manufacturers develop assays faster.
The ability of qPCR to screen directly from blood samples provides faster and highly sensitive detection of viral infections such as HIV, HBV, or HCV, but also bacterial infections, hereditary diseases, and forensic analyses. Blood can also be used as a non-invasive liquid biopsy for examining circulating tumor DNA, RNA, or cells, which is essential in cancer management, allowing prognosis, diagnosis, and monitoring following treatment. However, PCR inhibitors often found in blood samples can produce false-negative results or reduced limit-of-detection (“LOD”) unless costly and time-consuming DNA/RNA purification is used. Meridian’s new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix can be used on crude samples and eliminates the need for an extraction step. It uses specialized enzymes and an advanced buffer formulation pre-optimized specifically for whole blood, serum, and plasma. The blood master mix was designed to be compatible with air-drying in an oven while maintaining the highest activity and sensitivity. Air-Dryable technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures, making it ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.
Diane Szydel, Vice President, Global Life Science Commercial Operations at Meridian, commented, “The Air-Dryable™ Direct RNA/DNA qPCR Blood Mix provides a diagnostic developer with a ready to use master mix that has already addressed all the complex inhibitors present in blood, allowing for the development of simpler and faster assays. In addition, Meridian’s air-dryable technology overcomes the time and cost associated with cold storage or lyophilization, allowing manufacturers full control of their entire manufacturing workflow.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on leveraging Air-Dryable™ technology for your assay development, please visit [https://meridianlifescience.com/air-dryable-mixes](https://c212.net/c/link/?t=0&l=en&o=3316730-1&h=1940970879&u=https%3A%2F%2Fmeridianlifescience.com%2Fair-dryable-mixes&a=https%3A%2F%2Fmeridianlifescience.com%2Fair-dryable-mixes) or email .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3316730-1&h=2128603377&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=qPCR%20Blood)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples](https://www.meridianbioscience.com/press-release/meridian-launches-two-new-air-dryable-qpcr-mixes-enabling-direct-detection-of-dna-or-rna-from-stool-samples/)
**Published:** September 9, 2021
**Author:** hamza
**Content:**
CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences from crude stool material.
Many gastrointestinal diagnostic tests use stool samples, including inflammatory bowel disease, gastric or colon cancer, and screening for harmful bacteria, fungi, or viruses. In recent years, molecular diagnostic assays have gained in popularity due to their increased speed and sensitivity; however, using stool samples can be highly complex, as stool includes many inhibitors (e.g., bile salts, polysaccharides, and catabolic substances) that can dramatically reduce assay sensitivity and efficiency. Consequently, expensive and time-consuming extraction steps are often needed.
Meridian’s new Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes remove the need for time-consuming RNA or DNA purification or complex component optimization. They produce faster and more sensitive assays directly from crudely processed stool material. Setting up the assay can be as simple as adding primers and probes. The assay can then be used in a liquid format or dried down in a convection oven to create ambient-temperature stable assays without the need for lyophilization.
Florent Chang-Pi-Hin, Ph.D., Vice President Research & Development – Life Science, commented, “The use of Air-Dryable™ Direct qPCR Stool mixes for both DNA and RNA in the development of point-of-care assays offers easy sample analysis and reduces turnaround time. This increased efficiency can be essential in many applications, for example, bacterial food poisoning, where early detection and treatment can be lifesaving. Air-dryable technology also has the benefit of allowing oven-drying on site, saving manufacturers’ time and cost. It also allows manufacturers to control their entire manufacturing workflow.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on leveraging Air-Dryable™ technology for your assay development, please visit [https://meridianlifescience.com/air-dryable-mixes](https://www.globenewswire.com/Tracker?data=4yZjXR8v152j9jjuSwghSkVDk1QuapSTlvq5d1vrDu7Nr0F3Hg3yt2_2Iq2leRvfy6uNgXxzoW2Dj33gwkzW_GMMJdYwssp88PTTNcca9SSaDCi5BU28GhAbXyVM3P5ngGZ_FGerpk7l2-bVAFVF3oVcJbohN497yUSM87D7s_g=) or email [Liyan.Pang@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=HiBtVd9AwwvSu-f3ivk7S4qII4HWFICEBm6qkTcRDbwQZ8WfbtPv2hGCH4F6Z_f0veTu4TuckDWvnLT05zk1ohw-35Kght6zfm9SOmeFXU11njH22vu43jSm23p4JBoCCie-X_gJiN65A9KQWZYeiw== "Liyan.Pang@meridianlifescience.com").
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=bN3wqrnjkuceanbkWoc6ms6TMTYv4l_UEJ7CvVDhVe5PH4F7izI4lLczQGoMJiPltZG_S1i3jeo27UqM4VJtleEuLgV5zclqJUfkecPQzAi-3I4oEcjnq-93jmaLDSOI "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=Y5gWKKfqDFMXjxpIcqsGvAafc1KXpezLCPFTrQehL4Y_vCOARU0TvqMxIGzTZpHga-0WyFM9K9ZNADMQ3882940OI3mjYLUG-XbvsOUsEIkr4M2vo85SpIlWrUz3TS2yccoWzYMlhzIEI6w_vLM4qQ== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples](https://www.meridianbioscience.com/press-release/meridian-launches-two-new-air-dryable-qpcr-mixes-enabling-direct-detection-of-dna-or-rna-from-saliva-samples/)
**Published:** September 7, 2021
**Author:** hamza
**Content:**
CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum.
Saliva is a complex fluid containing various enzymes, hormones, antibodies, growth factors, enzymes and microbes reflecting the body’s health status. The saliva sample has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (e.g., avian influenza viruses and coronaviruses) and bacterial infections; however, the low concentration of analytes and high concentration of PCR inhibitors have been challenges for assay developers.
Meridian’s new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes have been formulated specifically to overcome the inhibitors found in saliva samples, allowing a diagnosis directly from crudely processed saliva or sputum samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used simply in a wet format or alternatively dried down to create ambient-temperature stable assays without the need for lyophilization.
Dr. Lourdes Weltzien, Executive Vice President – Life Science commented, “The use of Air-Dryable™ Direct qPCR Saliva mixes in the development of point-of-care assays, not only offer painless and quick sample analysis but also lower exposure risk to healthcare workers by reducing the need for sample handling. Our air-dryable technology has proven to save manufacturers’ time and cost, as well as allow them to control their entire manufacturing workflow.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit [https://meridianlifescience.com/air-dryable-mixes](https://www.globenewswire.com/Tracker?data=ZUoJWzKaVe4lOqOFHPAygouvhxbU5Kivp9ubtQoOkodEWp-xYODozPmGg2fTVJkqOYjdOGyIbQuP-ShXznSzNa7AbxtQC12dzAYZ9mEzknTjLh3891ehxuShkO1Ox2VSUoShdvam0fgGw4HU7hBEYJQzPcWLmeTx0w0glRI9_T0=) or email [morey.setareh@meridianlifescience.com](https://www.globenewswire.com/Tracker?data=GjFL6K3rviyTh5u4DFXkRC4XLaRMv3pvWiR2EhP8zCrC8Mijt32cOc062wQ1p7YNhn9-rXttBCrbY22CNAu_dRnMz6KRYVNB3-jDdYe3ovmahBpTsDqIyN7h6WqcctKx-7tfb5DmKZzNnoIhXzzhJA== "morey.setareh@meridianlifescience.com").
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=1gKYlmr7FG0gAETBkyi09Up-xsP2JTdbQjZpPNXLQgi7mrjv4NUts7bJRwO1qiM1rKMaa9Pci5jjzYpoFihVhXtjThibB3N7YqogVJbhNlI_4-oQW38-dUNYWJp8Aohb "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=mqMH1LoTLu4bCzAFQbzKNp8QUbtKf_FMXyW_rZSdnZ3cyxof4STBudbGpKJWWfQUNAHHkjr_juAcwIBZ-91HIk1oBDv9XXtWNsT6bqMjnSWyjQ1bt5s5S8rVJRPZ6P1PPBeovI-3f9172ITkTIjpTA== "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Reports Third Quarter Fiscal 2021 Results](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-third-quarter-fiscal-2021-results/)
**Published:** August 6, 2021
**Author:** hamza
**Content:**
CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021.
**Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):** • Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019
• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million
• Life Science segment net revenues decreased 49% year-over-year to $32.3 million
• Re-Submitted Emergency Use Authorization (“EUA”) with U.S. Food and Drug Administration (“FDA”) for Revogene® SARS-CoV-2 assay
• Launched Lyo-Ready master mixes for loop-mediated isothermal amplification (“LAMP”) technology
• Launched Air-Dryable™ master mixes for saliva and plant-based samples
• Completed remediation of quality system at Billerica manufacturing site – October 2017 FDA warning letter closed
Jack Kenny, Chief Executive Officer, commented, “This quarter is a great demonstration that while Meridian’s performance accelerated during the COVID-19 pandemic, it is not dependent on a resurgence of the pandemic to have a strong business going forward. We have been preparing for a post-pandemic world and this quarter clearly shows the positive direction the business is headed.”
**Third Quarter Fiscal 2021 Results (Comparison to Third Quarter Fiscal 2020)**
Consolidated net revenues for the third quarter of fiscal 2021 decreased 25% to $63.5 million, compared to $84.8 million last year. We believe that a meaningful year-over-year comparison is challenging to understand, since the third quarter of fiscal 2020 was the peak quarter of the COVID-19 pandemic for that fiscal year. Compared to the pre-pandemic period, third quarter of fiscal 2019, consolidated net revenues are up 31%.
Diagnostics segment net revenues were up 44% year-over-year but were negatively impacted by recent supply chain issues and product recall activities related to our LeadCare® products, which resulted in backorders of approximately $1.5 million at the end of the quarter. Life Science segment net revenues were down 49% year-over-year, reflecting the negative impact of the continued reduction in demand for reagents associated with COVID-19 testing, as reported widely across the industry. Also, of note, we had a backorder of approximately $1.0 million affecting our Life Science segment revenues at the end of the quarter related to core (non-COVID-19 related) immunoassay blocking-reagent products. Included within Life Science segment net revenues is an estimated $14.5 million in net revenues from COVID-19 related products, with approximately $12.5 million in molecular products and $2.0 million in immunological products. This implies core Life Science segment net revenues were up approximately 15% year-over-year.
Reported operating income for the third quarter of fiscal 2021 was $15.7 million, down 55% from the prior year, reflecting the lower revenue levels for the quarter. Compared to the pre-pandemic period, third quarter of fiscal 2019, reported operating income is up 143%. Operating expenses included: (i) lower research and development spending in the Diagnostics segment; (ii) lower incentive compensation expenses; (iii) lower acquisition-related expenses associated with the fiscal 2020 Exalenz transaction; and (iv) a downward adjustment in the fair value of the contingent consideration related to the fiscal 2019 GenePOC transaction. On an adjusted basis, operating income was $12.9 million for the third quarter of fiscal 2021, a margin of 20% (see non-GAAP financial measure reconciliation below), down from $30.4 million and a margin of 36% in the prior year.
**Financial Condition**
At June 30, 2021, cash and cash equivalents were $70.0 million and the Company had $110.0 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s obligations under the commercial bank credit facility totaled $50.0 million as of June 30, 2021. Subsequent to the end of the quarter, on July 31, 2021, the Company closed the acquisition of the BreathTek® business from Otsuka America Pharmaceutical, Inc. for approximately $20.0 million, funded out of cash and cash equivalents on hand.
Bryan Baldasare, Chief Financial Officer, commented, “Despite being down from the COVID-19 pandemic highs, the third quarter was a strong quarter for the Company relative to pre-pandemic levels. Our balance sheet remains strong and our cash generation continues to fund opportunities with the potential to deliver strong returns for shareholders.”
**Fiscal 2021 Guidance Reaffirmed with Tighter Range**
Fiscal 2021 Net Revenues:
- Consolidated $308 million to $314 million
- Diagnostics segment $128 million to $130 million
- Life Science segment $180 million to $184 million
Fiscal 2021 Adjusted Operating Margin: Consolidated 30% to 31%
Fiscal 2021 Adjusted Net Earnings Per Share on a Diluted Basis (“EPS”): $1.61 to $1.67 (44.1M shares)
Results for the third quarter were consistent with our expectations of reduced demand for Life Science segment reagents used in COVID-19 testing. As such, we are reaffirming the lower end of our guidance and updating with a tighter range. The guidance was further adjusted to account for the impact of the acquisition of the BreathTek® business. We expect the acquisition to be accretive to Adjusted EPS by approximately $0.01 in the fourth quarter of fiscal 2021.
This guidance reflects our current visibility into market conditions and customer order patterns for our products and our current assumptions about the impacts from the COVID-19 pandemic in the U.S. and around the globe.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, August 6, 2021 beginning at 10:00 a.m. Eastern Time to discuss the third quarter financial results and answer questions. A presentation to accompany the quarterly financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=3U-Qb5Hx8bKUfXZLdTg5bznxARKXdHyDKe2a2OvKkZc0f9s42PNBhqk9IGEu62zJEStOBjZlxTebxkDG-mWsTMNCMdWyBXD1PLSVNOwTTbovocdBsE6s4-jNae7ADHWf "www.meridianbioscience.com"), prior to the conference call.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3074079. A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on August 6, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3074079.
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted accounting principles (“GAAP”) basis for the interim periods of fiscal 2021 and fiscal 2020.
Three Months Ended Nine Months Ended June 30, June 30, 2021 2020 2021 2020 Net revenues$63,511 $84,797 $241,692 $189,514 Cost of sales 26,400 28,814 85,261 71,334 Gross profit 37,111 55,983 156,431 118,180 Operating expenses Research and development 6,083 6,668 17,799 16,746 Selling and marketing 6,209 6,282 19,770 19,539 General and administrative 11,964 12,624 36,827 32,236 Acquisition-related costs 300 1,641 300 3,428 Change in fair value of acquisition consideration (3,563) (6,124) (5,505) (7,428)Restructuring costs – 93 – 620 Selected legal costs 438 134 2,695 1,189 Total operating expenses 21,431 21,318 71,886 66,330 Operating income 15,680 34,665 84,545 51,850 Other income (expense), net (385) 208 (1,950) (304)Earnings before income taxes 15,295 34,873 82,595 51,546 Income tax provision 3,626 7,366 17,845 11,853 Net earnings$11,669 $27,507 $64,750 $39,693 Net earnings per basic common share$0.27 $0.64 $1.50 $0.93 Basic common shares outstanding 43,334 42,837 43,226 42,819 Net earnings per diluted common share$0.26 $0.64 $1.47 $0.92 Diluted common shares outstanding 44,097 43,273 44,006 43,038
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended Nine Months Ended June 30, June 30, 2021 2020 2021 2020Adjusted Operating income$12,855 $30,409 $82,035 $49,659 Adjusted Net earnings 9,547 24,014 62,865 38,197 Adjusted Net earnings per diluted common share$0.22 $0.55 $1.43 $0.89
**Condensed Consolidated Balance Sheet Data** (in thousands)
June 30, September 30, 2021 2020 Cash and cash equivalents$70,012 $53,514 Working capital 158,277 109,666 Long-term debt 50,000 68,824 Shareholders’ equity 322,156 247,629 Total assets 446,570 405,261
**Segment Data**
The following table sets forth the unaudited net revenues and segment data for the interim periods in fiscal 2021 and fiscal 2020 (in thousands):
Three Months Ended Nine Months Ended June 30, June 30, 2021 2020 2021 2020Net Revenues – By Product Platform/Type
Diagnostics Molecular assays$4,383 $3,182 $13,368 $17,259 Non-molecular assays 26,806 18,416 80,091 74,072 Total Diagnostics 31,189 21,598 93,459 91,331 Life Science Molecular reagents 20,385 38,791 104,016 55,703 Immunological reagents 11,937 24,408 44,217 42,480 Total Life Science 32,322 63,199 148,233 98,183 Total Net Revenues$63,511 $84,797 $241,692 $189,514
Three Months Ended Nine Months Ended June 30, June 30, 2021 2020 2021 2020Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$17,844 $9,584 $48,962 $39,644 Respiratory illness assays 3,742 5,052 12,233 23,664 Blood chemistry assays 4,254 3,364 13,006 12,508 Other 5,349 3,598 19,258 15,515 Total Diagnostics 31,189 21,598 93,459 91,331 Life Science Americas 7,419 22,007 39,661 30,638 EMEA 15,723 26,227 70,084 41,305 ROW 9,180 14,965 38,488 26,240 Total Life Science 32,322 63,199 148,233 98,183 Total Net Revenues$63,511 $84,797 $241,692 $189,514 OPERATING INCOME (LOSS) Diagnostics$2,510 $(1,783) $3,749 $8,087 Life Science 16,129 39,305 92,015 51,564 Corporate (2,998) (2,849) (11,286) (7,832)Eliminations 39 (8) 67 31 Total Operating Income$15,680 $34,665 $84,545 $51,850 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of certain acquisition-related costs, changes in fair value of the acquisition consideration, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three- and nine-month periods ended June 30, 2021 and 2020.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**THIRD QUARTER AND NINE MONTH YEAR-TO-DATE**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months Ended Nine Months Ended June 30, June 30, 2021 2020 2021 2020Net Revenues – By Disease State/Geography Diagnostics Gastrointestinal assays$17,844 $9,584 $48,962 $39,644 Respiratory illness assays 3,742 5,052 12,233 23,664 Blood chemistry assays 4,254 3,364 13,006 12,508 Other 5,349 3,598 19,258 15,515 Total Diagnostics 31,189 21,598 93,459 91,331 Life Science Americas 7,419 22,007 39,661 30,638 EMEA 15,723 26,227 70,084 41,305 ROW 9,180 14,965 38,488 26,240 Total Life Science 32,322 63,199 148,233 98,183 Total Net Revenues$63,511 $84,797 $241,692 $189,514 OPERATING INCOME (LOSS) Diagnostics$2,510 $(1,783) $3,749 $8,087 Life Science 16,129 39,305 92,015 51,564 Corporate (2,998) (2,849) (11,286) (7,832)Eliminations 39 (8) 67 31 Total Operating Income$15,680 $34,665 $84,545 $51,850 Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
Three Months Nine Months Ended June 30, Ended June 30, 2021 2020 2021 2020 Diluted Earnings per Common Share – GAAP basis$0.26 $0.64 $1.47 $0.92 Acquisition-related costs 0.01 0.02 0.01 0.06 Change in fair value of acquisition consideration (0.06) (0.11) (0.09) (0.13)Restructuring costs – – – 0.01 Selected legal costs 0.01 – 0.05 0.02 Adjusted Diluted EPS \*\*\*$0.22 $0.55 $1.43 $0.89
\*Net of tax, as applicable.\*\*Three and nine months ended June 30, 2021 and three months ended June 30, 2020 do not sum to total due to rounding.\*\*\*Nine months ended June 30, 2021 and 2020 do not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=pHLGhTnbQ_kPFPbKe9s6iBVU0nGncHQR_aEw-WENIl2o4TxxSOfBgSFpGs8N21p1pRlzjsMXxfr_marvIxYh_sFK_GS51qB_RxQ-VEKGEm9ZYUd49amB-hxstoGPeIq2GaKzX1xV8ez-b115RuzpgaL7I1bGV3D1bsOToN5xN1I=)
**Categories:** Press Release
---
### [Meridian Closes Acquisition of BreathTek® Business](https://www.meridianbioscience.com/press-release/meridian-closes-acquisition-of-breathtek-business/)
**Published:** August 2, 2021
**Author:** hamza
**Content:**
CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021.
Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=aeUgkC0l5JsmGBF7CK8a4DqEK1_fwfwuVGklU8H_oxRDbd42Wo99vQIeEgeaQ-sKuGlBcP2nLhNApAEoyO5Qx4Kjrh4gfePzvHcIkKDXzb4oNSgvngubvRqt4RbjSikt4T2Ti-0Ws4c1uwwrredQJOcehlnu74rvwOnpIPD_Jyk= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.](https://www.meridianbioscience.com/press-release/meridian-signs-definitive-agreement-to-acquire-urea-breath-test-for-h-pylori-from-otsuka-america-pharmaceutical-inc/)
**Published:** July 23, 2021
**Author:** hamza
**Content:**
CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter.
With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek®, a urea breath test for the detection of *Helicobacter pylori*. The acquisition is expected to add more than $20 million of annual revenue, strengthening Meridian’s position as a leading provider of gastrointestinal diagnostic solutions, and is expected to be accretive to earnings and cash immediately.
Jack Kenny, Chief Executive Officer, commented, “This is another example of our strategic use of cash generated during the pandemic to further position the diagnostics segment for sustainable growth. We look forward to supporting Otsuka’s customers with the gastrointestinal expertise and world class customer service Meridian is known for.”
**Cautionary Statement Regarding Forward-Looking Statements**
Certain statements in this communication regarding the proposed acquisition of assets from Otsuka as described above by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding Meridian’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions, and the negative thereof, are intended to identify forward-looking statements.
All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of Meridian, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the diversion of management time on transaction-related issues; ability to successfully integrate the businesses; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian’s filings with the SEC and available through the SEC’s Electronic Data Gathering and Analysis Retrieval system at www.sec.gov, including Meridian’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=MvwgPRChFWR2Pkp6uYkc2XXFwEj7qSyZ_1GFwvduRKasmodFDWH0lZk-2bzqPOsFRVmWjMrzautjEVzto3XdihQgK4Zle1YCmUkBqHot16k1zHtuxrNP_Z5lAwr_WeJN "www.meridianbioscience.com").
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=ebdVLD0W7eMyvL5vCFORE7ByPvh0NK1wtOGwipACAGsku1pVUJeTep6rR_i_8h6koP2965XsJ1RJzT-3EzPONvQ0GP_y2FGQeGsyUanx4f9QgmQMSuEB2Hii4OSN9Ggm25U9oWsKYLgf7h4Vs2FV9LBASWzqIcyedyoq5FfLVrM= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-third-quarter-fiscal-2021-financial-results-conference-call-on-august-6-2021/)
**Published:** July 14, 2021
**Author:** hamza
**Content:**
CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021.
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 3074079.
A replay will be available for 14 days beginning at 1:00 p.m. Eastern Time on August 6, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering pass code 3074079.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=zO0xd9ESFQzWXwbKuvPwyvM3MhuBJfiB3dnsEB0s4TA22td7jFKFuDf95BsKCw5Zq_FszNLYukuSSFCmfhnVv-Lqb0oiNmNbyQKfg5tglzeF9ufXUYl90PWP4iv4Vqrn "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-preliminary-revenue-results-for-fiscal-2021-third-quarter/)
**Published:** July 13, 2021
**Author:** hamza
**Content:**
CINCINNATI, July 13, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021.
Preliminary unaudited revenue for the third quarter of fiscal 2021 is expected to be approximately $63.5 million, below expectations. The Diagnostics segment performance was impacted negatively by recent supply chain issues with our LeadCare reagents that resulted in backorders towards the end of the quarter. The Life Science segment performance was impacted negatively by the continued reduction in demand for reagents associated with COVID-19 testing as reported widely across the industry.
Meridian has not yet completed preparation of its financial statements for the third quarter of 2021 and the information presented herein is a preliminary estimate, subject to change. We will provide full financial results and any changes to fiscal 2021 guidance on our third quarter earnings call, scheduled for Friday, August 6, 2021. We will announce additional information related to the call in a future press release.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, please also refer to additional factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, including in Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K, which contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.globenewswire.com/Tracker?data=n1hYaUuA_ZqPDJ_HifbcZDuS0svAUYu3riQuEYET-vLOq5CMuT9nNDembPf-qOg6q7w3MPnRrBPyPaw5ED7lDRQN408MXWAzTbr477oos_TEmYYEy-napZR1FKxD_XAv "www.meridianbioscience.com").
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](https://www.globenewswire.com/Tracker?data=n_7Yz6uYldxEekPuFSsUyJBtWzeLgDwuiE_UKcbrcrTf8mhz4kpyFhfwQskX4Z6dhsRG1wZGX3XF-m7K2D7YVjI9idOPsEMFmNjhBElXSAFyFlQovKLZ9sXi5BnsKPHx-HBUAOykawr4QEh2GNcEYLJcgsmT7aOhHOQvTclKM5Q= "mbi@meridianbioscience.com")
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-the-2022-h-c-wainwright-bioconnect-virtual-conference/)
**Published:** January 4, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 4, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-to-participate-in-the-2022-h-c-wainwright-bioconnect-virtual-conference-301453854.html#financial-modal)) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H. C. Wainwright Bioconnect Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on January 10, 2022.
Webcast links to Meridian’s presentation will be available in the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://c212.net/c/link/?t=0&l=en&o=3403436-1&h=2126670457&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=https%3A%2F%2Finvestor.meridianbioscience.com%2F). The fireside chat will be available for 90 days.
For additional information on the H. C. Wainwright Bioconnect 2022 Virtual Conference, please visit [www.hcwevents.com/bioconnect](https://c212.net/c/link/?t=0&l=en&o=3403436-1&h=2411954843&u=http%3A%2F%2Fwww.hcwevents.com%2Fbioconnect&a=www.hcwevents.com%2Fbioconnect).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3403436-1&h=3958359187&u=https%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Investor%20Relations%20-%20HCWCo%20Bioconnect)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces Retirement of CFO Bryan Baldasare](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-retirement-of-cfo-bryan-baldasare/)
**Published:** December 2, 2021
**Author:** hamza
**Content:**
CINCINNATI, Dec. 2, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-announces-retirement-of-cfo-bryan-baldasare-301435670.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.
Mr. Baldasare joined Meridian in 2000 and has served as CFO since July 2019. During his tenure, Meridian grew its revenues by over 500%, developed and launched dozens of new products, expanded into a diversified global business with 15 sites in 10 countries, and managed through the COVID-19 pandemic as a much stronger enterprise.
Bryan Baldasare stated, “It has been a pleasure supporting Meridian for the last 21 years, including under the leadership of every CEO dating back to the founder, Bill Motto. This company has grown to be a leader in the healthcare industry, and I am particularly proud of Meridian’s global contribution to fighting the COVID-19 pandemic. Meridian has the strongest balance sheet and most valuable of assets of any time in my tenure, and I look forward to continuing to follow its success.”
Jack Kenny, CEO, said, “Bryan has been a great business partner to me and made a substantial impact on the organization over the years. The broader Meridian team and I will miss him and his leadership. Bryan leaves us with strong finance, accounting, and information technology organizations, which will ensure continuity through this transition. We wish him great success in whatever lies ahead.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3376687-1&h=3642381323&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Mr.%20Baldasare%20Retirement)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces Retirement of Chairman David Phillips](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-retirement-of-chairman-david-phillips/)
**Published:** November 24, 2021
**Author:** hamza
**Content:**
CINCINNATI, Nov. 24, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-announces-retirement-of-chairman-david-phillips-301431176.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips’ term expires and will not replace the vacated seat, which will reduce the number of directors to eight.
Mr. Phillips joined the Meridian Board of Directors in 2000 and has served as chairman since September 2018. During his tenure, Mr. Phillips shepherded the Company through the implementation of Sarbanes-Oxley and numerous acquisitions that form today’s Meridian. The Company has more than twice as many employees and finished fiscal 2021 with net revenues and diluted earnings per share more than five times that of fiscal year 2000.
David Phillips, Chairman of the Board of Directors stated, “It has been an honor to be part of Meridian for the last 21 years. I have witnessed the transformation and globalization of this business and I am proud of the impact the Company continues to make in healthcare. Jack has built the strongest management team since I have been part of the organization, and coupled with the expertise of the other directors, I am excited about what the future holds for the Company.”
Jack Kenny, CEO said, “Dave has dedicated many years to Meridian as an advisor, leader, and friend. His contributions over the years are greatly appreciated and his presence around the office and in the board room will be greatly missed.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3369401-1&h=3096457955&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Mr.%20Phillips%20Retirement)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Participates in Piper Sandler 33rd Annual Virtual Healthcare Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-participates-in-piper-sandler-33rd-annual-virtual-healthcare-conference/)
**Published:** November 18, 2021
**Author:** hamza
**Content:**
CINCINNATI, Nov. 18, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-participates-in-piper-sandler-33rd-annual-virtual-healthcare-conference-301428363.html#financial-modal)) announced today its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1st and 2nd, 2021. Jack Kenny, Chief Executive Officer, pre-recorded a fireside chat on Tuesday, November 16, 2021 which will be available for viewing to registered attendees and through Meridian’s Investor Relations website beginning Monday November 22nd. 1×1 meetings with management may be requested through Piper Sandler.
To register for access to the pre-recorded fireside chat, go to the Events & Presentations section of the Company’s Investor Relations website at [https://investor.meridianbioscience.com/](https://c212.net/c/link/?t=0&l=en&o=3364695-1&h=3615872789&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=https%3A%2F%2Finvestor.meridianbioscience.com%2F) and follow the link provided for the event. The recording will be available until February 13, 2022.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3364695-1&h=1118337535&u=https%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Piper%20Sandler%20Conference)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing](https://www.meridianbioscience.com/press-release/meridian-launches-two-new-air-dryable-mixes-for-isothermal-amplification-powering-shortest-time-to-results-in-point-of-care-testing/)
**Published:** November 17, 2021
**Author:** hamza
**Content:**
CINCINNATI, Nov. 17, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-launches-two-new-air-dryable-mixes-for-isothermal-amplification-powering-shortest-time-to-results-in-point-of-care-testing-301426194.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its Air-Dryable™ LAMP Mix and Air-Dryable™ RT-LAMP 1-Step Mix. These ground-breaking molecular master mixes are specifically designed for fast isothermal amplification of nucleic acid sequences, not only to facilitate the development of point-of-care ambient temperature-stable assays, but also to accelerate diagnosis.
Compared to qPCR, isothermal amplification technologies are used under one single temperature condition, which make them ideal for point-of-care or portable devices; however, one limitation of LAMP assays, specifically, has been the typical 45 minutes it takes to produce a result. Meridian’s innovative Air-Dryable™ LAMP and RT-LAMP 1-Step mixes cut the usual sample-to-result time in half. Using Meridian’s revolutionary new LAMP mixes, test manufacturers can now develop faster than ever assays with improved sensitivity and specificity.
Meridian’s two new mixes not only allow more sample to be added due to their 4x format, but also have incorporated Meridian’s revolutionary Air-Dryable™ technology. This technology works equally well in a liquid format or when oven-dried when an ambient-temperature stabilisation of the assay is needed. As the latest addition to Meridian’s innovative Air-Dryable™ product family, both Air-Dryable™ LAMP mixes contain a pre-optimized buffer system including enzyme(s), stabilizers, enhancers and nucleotides, greatly facilitating the chemistry optimization for assay developers.
The Air-Dryable™ LAMP and Air-Dryable™ RT-LAMP 1-Step mixes expedite assay optimization, reduce development time, and produce superior amplification sensitivity and specificity.
Florent Chang-Pi-Hin, Ph.D., Vice President, Research and Development – Life Science, commented, “We are delighted to release our new Air-Dryable™ LAMP and RT-LAMP 1-Step Mixes. Isothermal amplification methods such as LAMP are increasingly used in molecular diagnostics due to their compatibility with point-of-care devices and fast time to results. We’ve been very successful in the development of these isothermal chemistries and it is a great satisfaction seeing our Air-Dryable™ LAMP mixes outperform the competition with faster time to results and superior amplification sensitivity and specificity. Test manufacturers will also benefit from expedited assay development and reduced manufacturing costs due to the pre-optimized air-dryable formulation. Assay development can be as simple as adding target-specific primers/probes and can be done with either wet or oven-dried formats to create ambient-temperature stable assays without the need for lyophilization.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. Please visit [https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/](https://c212.net/c/link/?t=0&l=en&o=3361998-1&h=3858767854&u=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Fisothermal-amplification%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Fisothermal-amplification%2F) for more information on leveraging isothermal amplification technology for your assay development or contact [Liyan.Pang@meridianlifescience.com](mailto:Liyan.Pang@meridianlifescience.com?subject=Air-Dryable%20LAMP%20Mixes).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3361998-1&h=704727231&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Air-Dryable%20LAMP%20Mixes)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-strong-fourth-quarter-and-record-full-year-fiscal-2021-operating-results-and-provides-fiscal-2022-guidance/)
**Published:** November 12, 2021
**Author:** hamza
**Content:**
CINCINNATI, Nov. 12, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-reports-strong-fourth-quarter-and-record-full-year-fiscal-2021-operating-results-and-provides-fiscal-2022-guidance-301422751.html#financial-modal)) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021.
**Fourth Quarter 2021 Highlights (Comparison to Fourth Quarter Fiscal 2020):**
- Consolidated net revenues of $76.2 million, up 19% year-over-year
- Life Science segment delivered net revenues of $41.9 million, up 22% year-over-year
- Diagnostics segment net revenues increased 15% year-over-year to $34.3 million
- Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LAMP Mix for isothermal amplification
- Received U.S. design patent for Revogene® PIE (Fluidic Centripetal Device)
- Launched new environmentally friendly, REACH compliant, enzymes
- Closed $20 million acquisition of the BreathTek® Urea Breath Test for *H. pylori*
**Full Fiscal Year 2021 Highlights (Comparison to Full Year Fiscal 2020):**
- Consolidated net revenues of $317.9 million, up 25% year-over-year
- Life Science segment delivered record net revenues of $190.1 million, up 43% year-over-year, with $111.9 million from COVID-19 related products for immunological and molecular tests
- Diagnostics segment net revenues increased 5% year-over-year to $127.8 million
- Disrupted molecular reagents market with a comprehensive line of Air-Dryable™ master mixes optimized for specific sample types
- Submitted Curian® Campy 510(k) and Revogene® SARS-CoV-2 Emergency Use Authorization (EUA)
- Awarded $6.5 million in RADx grants for the Revogene® SARS-CoV-2 assay
Jack Kenny, Chief Executive Officer, commented, “All of our hard work over the previous two years prepared us to both weather the storm in Diagnostics and excel in Life Science as a critical partner to the IVD industry battling the global COVID-19 pandemic. We look forward to Diagnostics making its contribution with the Revogene® SARS-CoV-2 assay receiving Emergency Use Authorization earlier this week. Fiscal 2022 will be an exciting year for Meridian and should provide a foundation for future growth.”
**Fourth Quarter Fiscal 2021 Results (Comparison to Fourth Quarter Fiscal 2020)**
Consolidated net revenues for the fourth quarter of fiscal 2021 increased 19% to $76.2 million, compared to $64.2 million last year. Diagnostics segment net revenues increased 15% year-over-year, while Life Science segment net revenues were up 22%. Our Diagnostics segment experienced a 22% increase in net revenues from our molecular products and revenues from our non-molecular assay products increased 14%, despite the impact of the LeadCare® product recall and our pausing of manufacturing and distribution in mid-August. Our Life Science segment net revenues for the quarter included $23.3 million in net revenues from COVID-19 related products, with $18.1 million coming from molecular products and $5.2 million coming from immunological products.
Reported operating income for the fourth quarter of fiscal 2021 was $8.5 million, a margin of 11%. Operating expenses included: (i) $5.6 million of LeadCare® product recall expenses; and (ii) a $4.6 million upward adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business in 2019, in arriving at the $20.0 million fourth quarter settlement of the earnout obligation. On an adjusted basis, operating income was $13.3 million, a margin of 17% (see non-GAAP financial measure reconciliation below).
Net earnings per diluted share for the fourth quarter of fiscal 2021 on a reported GAAP basis totaled $0.15 and adjusted net earnings per diluted share totaled $0.23 (see non-GAAP financial measure reconciliation below).
**Full Fiscal Year 2021 Results (Comparison to Full Year Fiscal 2020)**
Consolidated net revenues for the fiscal year ended September 30, 2021 increased 25% to $317.9 million, compared to $253.7 million in fiscal 2020. Diagnostics segment net revenues were up 5%, while Life Science segment net revenues were up 43%. Our Diagnostics segment experienced a 13% decrease in net revenues from our molecular products, while net revenues from our non-molecular assay products increased 10%. Our Life Science segment net revenues for the fiscal year included $111.9 million in net revenues from COVID-19 related products, with $92.55 million coming from molecular products and $19.35 million coming from immunological products.
Reported operating income for fiscal year ended September 30, 2021 was $93.0 million, a margin of 29%. Operating expenses included: (i) $5.6 million of LeadCare® product recall expenses; (ii) $2.8 million of legal expenses related to the ongoing Magellan Department of Justice investigation; and (iii) a $0.9 million downward adjustment in the fair value of the earnout obligation for the acquisition of the GenePOC business in 2019, in arriving at the $20.0 million fourth quarter settlement of the earnout obligation. On an adjusted basis, operating income was $95.3 million, a margin of 30% (see non-GAAP financial measure reconciliation below).
Net earnings per diluted share for the fiscal year ended September 30, 2021 on a reported GAAP basis totaled $1.62 and adjusted net earnings per diluted share totaled $1.66 (see non-GAAP financial measure reconciliation below).
Bryan Baldasare, Chief Financial Officer, commented, “Fiscal 2021 was another record year financially. With most of the negative impacts of the COVID-19 pandemic behind us, Meridian is a business expected to be 50% greater than the last pre-pandemic period in fiscal 2019, with opportunities to grow.”
**Financial Condition**
At September 30, 2021, cash and cash equivalents were $49.8 million and the Company had $100.0 million of borrowing capacity under its $160.0 million commercial bank credit facility. The Company’s obligations under the commercial bank credit facility totaled $60.0 million as of September 30, 2021. In October 2021, the Company amended its commercial bank credit facility, increasing the limit to $200.0 million, leaving the Company with borrowing capacity of $140.0 million as of November 12, 2021.
**Fiscal 2022 Guidance**
*Net Revenues*
- Consolidated – $285 to $300 million
- Diagnostics segment – $145 to $150 million
- Life Science segment – $140 to $150 million
*Adjusted Operating Margin*
- Consolidated – 21% to 22%
*Effective Tax Rate*
- 23.5%
*Adjusted Earnings Per Share on a Diluted Basis (based on 44.5 million shares)*
- $0.98 to $1.08
Diagnostics segment net revenues are expected to be higher in the second half of the year, reflecting our assumption that we will begin shipping LeadCare® product in April 2022. Life Science segment net revenues contemplate strong double-digit growth for sales of products other than those used in COVID-19 tests, offset by a reduction in demand for its products due to decreases in COVID-19 testing. COVID-19 has become endemic and as such, we expect the impact from related sales to be higher during the respiratory season, in the first half of our fiscal year. The decline in Life Science net revenues between the first and the second half should be less pronounced than in fiscal 2021 and roughly mirror the increase in Diagnostics net revenues expected in the second half of the year.
Life Science segment operating margins are expected to exceed 50% and the Diagnostics segment is expected to have a break-even to low single-digit operating margin. These estimates, coupled with contribution mix changes between the segments, results in the consolidated operating margin forecast of 21% to 22%.
The higher tax rate compared to 2021 reflects a greater percentage of net revenues and taxable income generated in the United States than in fiscal year 2021.
There are a number of unknowns that make setting guidance challenging including, without limitation, the timing of FDA clearance for the Curian® Campy assay, the resolution of the LeadCare® product recall situation, the anticipated demand for COVID-19 testing globally, the inflationary environment and supply chain interruption considerations. The guidance presented above reflects Meridian’s current visibility into these matters and overall market conditions.
**Conference Call Information**
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, November 12, 2021 beginning at 10:00 a.m. Eastern Time to discuss the fourth quarter and full fiscal year financial results and answer questions. A presentation to accompany the quarterly and full fiscal year financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3356852-1&h=1686258822&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com), prior to the conference call.
The Company is introducing a live webcast for this and future earnings calls, with the link to access the webcast being located at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3356852-1&h=3165124294&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com) or directly [here](https://c212.net/c/link/?t=0&l=en&o=3356852-1&h=3082911924&u=https%3A%2F%2Fwww.webcast-eqs.com%2Fmeridianbio_11122021_en&a=here). The webcast will provide the best experience for tuning into the call; however, if you are unable to join via the webcast, you may still participate by telephone from the U.S. by dialing (877) 407-0890, or from outside the U.S., by dialing (201) 389-0918, and enter the audience pass code 13724028. A replay of the conference call will be available by webcast for one year beginning at 1:00 p.m. Eastern Time on November 12, 2021 using the link provided at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3356852-1&h=3165124294&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com).
**FOURTH QUARTER AND FISCAL 2021 UNAUDITED CONDENSED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted accounting principles (GAAP) basis for the interim and annual periods of fiscal 2021 and fiscal 2020.
Three Months Ended
Year Ended
September 30,
September 30,
2021
2020
2021
2020
Net revenues
$
76,204
$
64,153
$
317,896
$
253,667
Cost of sales
31,487
25,822
116,748
97,419
Gross profit
44,717
38,331
201,148
156,248
Operating expenses
Research and development
6,112
6,983
23,911
23,729
Selling and marketing
7,010
7,210
26,780
26,486
General and administrative
12,714
12,109
49,541
44,345
Product recall costs
5,596
–
5,596
–
Selected legal costs
108
891
2,803
2,080
Acquisition-related costs
92
462
392
3,890
Change in fair value of acquisition
consideration
4,596
1,135
(909)
(6,293)
Restructuring costs
–
67
–
687
Total operating expenses
36,228
28,857
108,114
94,924
Operating income
8,489
9,474
93,034
61,324
Other income (expense), net
(633)
(1,727)
(2,583)
(2,031)
Earnings before income taxes
7,856
7,747
90,451
59,293
Income tax provision
1,199
1,254
19,044
13,107
Net earnings
$
6,657
$
6,493
$
71,407
$
46,186
Net earnings per basic common share
$
0.15
$
0.15
$
1.65
$
1.08
Basic common shares outstanding
43,356
42,940
43,259
42,855
Net earnings per diluted common share
$
0.15
$
0.15
$
1.62
$
1.07
Diluted common shares outstanding
44,094
43,642
44,012
43,174
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended
Year Ended
September 30,
September 30,
2021
2020
2021
2020
Adjusted operating income
$
13,285
$
12,029
$
95,320
$
61,688
Adjusted net earnings
10,258
8,289
73,123
46,301
Adjusted net earnings per diluted
common share
$
0.23
$
0.19
$
1.66
$
1.07
**Condensed Consolidated Balance Sheet Data** (in thousands)
September 30,
2021
2020
Cash and equivalents
$
49,771
$
53,514
Working capital
145,650
109,666
Long-term debt
60,000
68,824
Shareholders’ equity
328,302
247,629
Total assets
449,722
405,261
**Segment Data** The following table sets forth the unaudited net revenues and segment data for the interim and annual periods in fiscal 2021 and fiscal 2020 (in thousands).
Three Months Ended
Year Ended
September 30,
September 30,
2021
2020
2021
2020
Net Revenues – By Product Platform/Type
Diagnostics
Molecular assays
$
5,671
$
4,648
$
19,037
$
21,907
Non-molecular assays
28,630
25,153
108,723
99,225
Total Diagnostics
34,301
29,801
127,760
121,132
Life Science
Molecular reagents
26,399
22,703
130,537
78,431
Immunological reagents
15,504
11,649
59,599
54,104
Total Life Science
41,903
34,352
190,136
132,535
Total Net Revenues
$
76,204
$
64,153
$
317,896
$
253,667
Three Months Ended
Year Ended
September 30,
September 30,
2021
2020
2021
2020
Net Revenues – By Disease State/Geography
Diagnostics
Gastrointestinal assays
$
19,838
$
15,396
$
68,890
$
55,040
Respiratory illness assays
5,375
3,030
17,608
26,694
Blood chemistry assays
2,391
5,026
15,398
17,534
Other
6,697
6,349
25,864
21,864
Total Diagnostics
34,301
29,801
127,760
121,132
Life Science
Americas
6,356
6,795
46,063
37,391
EMEA
23,965
17,115
93,655
58,125
ROW
11,582
10,442
50,418
37,019
Total Life Science
41,903
34,352
190,136
132,535
Total Net Revenues
$
76,204
$
64,153
$
317,896
$
253,667
OPERATING INCOME
Diagnostics
$
(11,889)
$
(4,174)
$
(8,140)
$
3,885
Life Science
23,235
17,234
115,250
68,826
Corporate
(2,878)
(3,605)
(14,164)
(11,437)
Eliminations
21
19
88
50
Total Operating Income
$
8,489
$
9,474
$
93,034
$
61,324
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of certain acquisition-related costs, changes in fair value of the acquisition consideration, restructuring costs, and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three-month period and full year ended September 30, 2021 and 2020.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FOURTH QUARTER AND FISCAL YEAR GAAP TO NON-GAAP RECONCILIATION TABLES** (In Thousands, Except per Share Data)
Three Months
Year
Ended September 30,
Ended September 30,
2021
2020
2021
2020
Operating Expenses –
GAAP basis
$
36,228
$
28,857
$
108,114
$
94,924
Selected legal costs
(108)
(891)
(2,803)
(2,080)
Acquisition-related costs
(92)
(462)
(392)
(3,890)
Change in fair value of acquisition
consideration
(4,596)
(1,135)
909
6,293
Restructuring costs
–
(67)
–
(687)
Adjusted Operating Expenses
$
31,432
$
26,302
$
105,828
$
94,560
Operating Income –
GAAP basis
$
8,489
$
9,474
$
93,034
$
61,324
Selected legal costs
108
891
2,803
2,080
Acquisition-related costs
92
462
392
3,890
Change in fair value of acquisition
consideration
4,596
1,135
(909)
(6,293)
Restructuring costs
–
67
–
687
Adjusted Operating Income
$
13,285
$
12,029
$
95,320
$
61,688
Net Earnings –
GAAP basis
$
6,657
$
6,493
$
71,407
$
46,186
Selected legal costs \*
81
667
2,105
1,562
Acquisition-related costs \*
69
212
294
2,751
Change in fair value of acquisition
consideration \*
3,451
867
(683)
(4,726)
Restructuring costs \*
–
50
–
528
Adjusted Net Earnings
$
10,258
$
8,289
$
73,123
$
46,301
Basic Earnings per Common Share –
GAAP basis
$
0.15
$
0.15
$
1.65
$
1.08
Selected legal costs
–
0.02
0.05
0.04
Acquisition-related costs
–
–
0.01
0.06
Change in fair value of acquisition
consideration
0.08
0.02
(0.02)
(0.11)
Restructuring costs
–
–
–
0.01
Adjusted Basic EPS \*\*
$
0.24
$
0.19
$
1.69
$
1.08
Three Months
Year
Ended September 30,
Ended September 30,
2021
2020
2021
2020
Diluted Earnings per Common Share –
GAAP basis
$
0.15
$
0.15
$
1.62
$
1.07
Selected legal costs
–
0.02
0.05
0.04
Acquisition-related costs
–
–
0.01
0.06
Change in fair value of acquisition
consideration
0.08
0.02
(0.02)
(0.11)
Restructuring costs
–
–
–
0.01
Adjusted Diluted EPS
$
0.23
$
0.19
$
1.66
$
1.07
\* Net of tax, as applicable.
\*\* Three months ended September 30, 2021 does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**Revogene® SARS-CoV-2 assay disclaimer**
The Revogene® SARS-CoV-2 assay has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3356852-1&h=1686258822&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=FY21%20Q4%20Earnings%20Release)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-receives-fda-emergency-use-authorization-for-revogene-sars-cov-2-molecular-assay/)
**Published:** November 10, 2021
**Author:** hamza
**Content:**
CINCINNATI, Nov. 10, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-receives-fda-emergency-use-authorization-for-revogene-sars-cov-2-molecular-assay-301420554.html#financial-modal)), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021.
The Revogene® SARS-CoV-2 assay is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the causative agent of COVID-19. The test can return a positive result as soon as 47 minutes from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens and provides impressive clinical performance with a positive predictive agreement (PPA) of 97.7% and a negative predicative agreement (NPA) of 97.7%.
The Revogene® SARS-CoV-2 assay can help laboratories and healthcare systems improve their COVID-19 testing capacity and enable healthcare providers to quickly deliver the appropriate care and guide infection control measures for patients. The flexible Revogene® molecular testing platform can easily integrate into any laboratory or health system. Additional FDA-approved tests on the Revogene® platform include Revogene® C. difficile, Revogene® Strep A, Revogene® GBS LB, and Revogene® Carba C.
“There continues to be high demand for fast, accurate detection of COVID-19 especially considering the upcoming respiratory season and combating the COVID-19 variants that continue to emerge,” said Tony Serafini-Lamanna, Executive Vice President – Diagnostics for Meridian Bioscience. “We believe our Revogene® SARS-CoV-2 assay and growing Revogene® platform can help clinicians and health systems meet these demands now and in the future.”
To learn more about the Revogene® SARS-CoV-2 assay, please visit [https://www.meridianbioscience.com/revogene-sars-cov-2/](https://c212.net/c/link/?t=0&l=en&o=3353694-1&h=1849321197&u=https%3A%2F%2Fwww.meridianbioscience.com%2Frevogene-sars-cov-2%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Frevogene-sars-cov-2%2F). For sales inquiries, please contact Meridian Bioscience at 1-888-763-6769 or [sales@meridianbioscience.com](mailto:sales@meridianbioscience.com?subject=COVID-19%20Antibody%20Test).
**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, including in Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K, which contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3353694-1&h=4151878041&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Revogene%20SARS-CoV-2%20EUA)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples](https://www.meridianbioscience.com/press-release/meridian-launches-innovative-air-dryable-qpcr-mixes-enabling-direct-detection-of-dna-or-rna-from-urine-samples/)
**Published:** October 27, 2021
**Author:** hamza
**Content:**
CINCINNATI, Oct. 27, 2021 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-launches-innovative-air-dryable-qpcr-mixes-enabling-direct-detection-of-dna-or-rna-from-urine-samples-301409805.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples. Meridian developed these unique master mixes specifically to overcome the adverse effect of inhibitors present in crude urine samples that can affect the sensitivity of a molecular assay.
Urine is an abundant biofluid used to diagnose urinary tract infections (UTIs) and sexually transmitted diseases (STDs), and manage bladder, ovarian, prostate, and kidney diseases. Urine-based biopsies are non-invasive and enable convenient at-home self-sampling, consequently increasing patient compliance and satisfaction. Urine contains substances (e.g., urea) that can inhibit the PCR reactions. As such, expensive and time-consuming extraction steps are often needed. Meridian’s new Air-Dryable™ Direct DNA qPCR Urine and Air-Dryable™ Direct RNA/DNA qPCR Urine mixes remove the need for time-consuming RNA or DNA purification or complex component optimization. These mixes produce faster and more sensitive assays directly from urine. Setting up the assay can be as simple as adding primers and probes. Air-Dryable™ technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures. Meridian’s mixes are ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.
Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development at Meridian Life Science, commented, “Urine can be a rich source of material for testing a wide variety of conditions as it is easily accessible and convenient for patients to provide in comparison to other liquid biopsy material such as blood. Interestingly, we have shown that the Air-Dryable™ Direct qPCR Urine mixes are sensitive enough to detect and distinguish co-infecting arboviruses such as Dengue, Zika, and Chikungunya in urine long after the disappearance of viremia in the blood. The Air-Dryable™ Direct qPCR Urine mixes are ideal for developing point-of-care assays with faster workflows and market-leading performance. Meridian’s Air-Dryable™ technology allows oven-drying on-site, saving manufacturing time and expense while allowing control of the entire workflow.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on leveraging Air-Dryable™ technology for your assay development, please visit [https://meridianlifescience.com/air-dryable-mixes](https://c212.net/c/link/?t=0&l=en&o=3336743-1&h=911008608&u=https%3A%2F%2Fmeridianlifescience.com%2Fair-dryable-mixes&a=https%3A%2F%2Fmeridianlifescience.com%2Fair-dryable-mixes) or email [Liyan.Pang@meridianlifescience.com](mailto:Liyan.Pang@meridianlifescience.com?subject=Air-Dryable%20Urine%20Mix).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3336743-1&h=992204526&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Air-Dryable%20Urine%20Mix)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-hold-first-quarter-2022-financial-results-conference-call-on-february-4-2022/)
**Published:** January 10, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 10, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-to-hold-first-quarter-2022-financial-results-conference-call-on-february-4-2022-301457240.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022.
Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
To participate in the live call by webcast, join directly [here](https://c212.net/c/link/?t=0&l=en&o=3407818-1&h=1084169369&u=https%3A%2F%2Fwww.webcast-eqs.com%2Fmeridianbioscience02042022_en%2Fen&a=here) or visit [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3407818-1&h=172071354&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=investor.meridianbioscience.com) for the link.
If you are unable to join the webcast, you may join by telephone. From the U.S., dial (877) 407-0890, or from outside the U.S., dial (201) 389-0918, and provide the code 13726037.
A replay of the conference call will also be available by webcast for one year beginning 1:00 p.m. Eastern Time on February 4, 2022 using the link provided at [investor.meridianbiocience.com](https://c212.net/c/link/?t=0&l=en&o=3407818-1&h=3695049943&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=investor.meridianbiocience.com).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3407818-1&h=3596255477&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-receives-fda-clearance-for-the-curian-campy-assay/)
**Published:** January 5, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 5, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-receives-fda-clearance-for-the-curian-campy-assay-301454661.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance. The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a *Campylobacter*-specific antigen including *C. jejuni*, *C. coli*, *C. upsaliensis*, and *C. lari* in human fecal specimens. The assay was developed to be utilized on the Curian immunofluorescent testing platform.
*Campylobacter* infection, also known as campylobacteriosis, is one of the most widespread infectious diseases worldwide. This gastrointestinal disease presents with symptoms of acute watery or bloody diarrhea, abdominal pain, and fever. The symptoms usually occur 24 to 72 hours after ingestion, and the disease lasts up to six days. The Curian Campy assay features an easy workflow and produces objective results in about 20 minutes. Curian Campy offers clinicians accurate and timely results to deliver appropriate care for patients infected with campylobacteriosis.
The Curian testing platform centers around the innovative Curian analyzer – a compact immunofluorescent instrument that boasts a simple workflow and clean sample handling to provide a rapid result that eliminates the subjectivity of traditional rapid immunoassay diagnostic tests. The platform can be easily integrated into any laboratory or healthcare system. Curian Campy is the second FDA-cleared assay on Meridian’s expanding Curian testing platform. The Curian Analyzer and Curian HpSA® assay received FDA clearance in March 2020.
“Curian Campy follows last year’s successful launch of our Curian HpSA assay and is the next step in expanding our Curian test menu for gastrointestinal infections,” stated Wes Lindsey, Ph.D., Vice President Global Research and Development – Diagnostics. “What is most exciting about this platform is that it paves the way for us to continue to develop easy-to-use lateral flow assays with fluorescent detection on an automated analyzer. This allows for not only increased sensitivity but eliminates the subjectivity that is inherent when manually reading a lateral flow assay.”
To learn more about the Curian testing platform and the Curian Campy assay, please visit [www.meridianbioscience.com/curian](https://c212.net/c/link/?t=0&l=en&o=3404509-1&h=2576851436&u=http%3A%2F%2Fwww.meridianbioscience.com%2Fcurian&a=www.meridianbioscience.com%2Fcurian). For sales inquiries, please contact Meridian Bioscience at 1-888-763-6769 or [sales@meridianbioscience.com](mailto:sales@meridianbioscience.com?subject=Curian%20CAMPY%20FDA%20Approval). For media inquiries, please contact Charlie Wood at [charlie.wood@meridianbioscience.com](mailto:charlie.wood@meridianbioscience.com?subject=Curian%20CAMPY%20FDA%20Approval).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3404509-1&h=3074184959&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President –Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer](https://www.meridianbioscience.com/press-release/meridian-bioscience-names-andy-kitzmiller-as-chief-financial-officer/)
**Published:** February 21, 2022
**Author:** hamza
**Content:**
CINCINNATI, Ohio, Feb. 21, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-names-andy-kitzmiller-as-chief-financial-officer-301486200.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny. He will oversee the global finance organization and financial activities, including accounting and controllership, financial planning and analysis, tax, internal audit, and treasury.
Mr. Kitzmiller joins Meridian from Hillenbrand, Inc., where he was Vice President, Chief Accounting Officer, and Corporate Controller. In that role, he was responsible for all external and internal financial reporting, internal controls over financial reporting and supported the annual budgeting, periodic forecasting, and quaraterly earnings guidance processes. Prior to Hillenbrand, Mr. Kitzmiller was the Vice President of Finance and Corporate Controller of Milacron, spent five years in various global finance roles at GE Aviation, and spent ten years in the audit practice of Deloitte & Touche.
“We are excited to welcome Andy to Meridian to help develop and execute strategies that continue to drive sustainable revenue growth and profitability across the company,” commented Jack Kenny, Chief Executive Officer. “Andy’s diverse experience and strategic finance expertise will be instrumental as we take Meridian into the future.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3449230-1&h=4212828650&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Kitzmiller%20CFO%20Announcement)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits](https://www.meridianbioscience.com/press-release/magellan-diagnostics-resumes-distribution-of-leadcare-ii-test-kits/)
**Published:** February 16, 2022
**Author:** hamza
**Content:**
CINCINNATI, Feb. 16, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/magellan-diagnostics-resumes-distribution-of-leadcare-ii-test-kits-301483264.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits.
The Magellan quality management system identified discrepancies in the performance of LeadCare test kits. It was originally suspected that a defect with the plastic used to manufacture Treatment Reagent tubes was the source of this discrepancy; however, studies have shown that the paperboard material used to package Treatment Reagent tubes is the source of the contaminant. As the issue had the potential to underestimate blood lead levels when processing patient samples, Magellan voluntarily recalled test kits and temporarily suspended shipping. Magellan has conducted numerous studies and experiments to understand the root cause of the issue and has identified suitable replacement materials such that shipments can resume.
Tony Serafini-Lamanna, Executive Vice President – Diagnostics, commented, “LeadCare II is on the frontlines of early diagnosis of childhood lead exposure. Our team is intensely focused on getting LeadCare II testing back into clinician’s offices to help quickly identify and address the effects of lead poisoning.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3445218-1&h=2266449693&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-second-best-quarter-in-company-history/)
**Published:** February 4, 2022
**Author:** hamza
**Content:**
CINCINNATI, Feb. 4, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-reports-second-best-quarter-in-company-history-301475420.html#financial-modal)) today announced financial results for the first quarter ended December 31, 2021.
**First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021):**
- Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations
- Life Science segment delivered net revenues of $55.1 million
- Diagnostics segment net revenues increased 10% year-over-year to $33.2 million
- Launched first Lyo-Ready sample-specific master mix for saliva-based assays
- Received FDA 510(k) clearance for Curian® Campy assay and Emergency Use Authorization for Revogene® SARS-CoV-2 assay
Jack Kenny, Chief Executive Officer, commented, “While disappointed that we are fighting yet another wave of COVID-19 infections across the globe, I am pleased to report that Meridian delivered an outstanding quarter. Continued strength in our Life Science segment, coupled with growing momentum in the Diagnostics segment, is a sign of the Company’s potential in fiscal 2022 and beyond.”
**First Quarter Fiscal 2022 Results (Comparison to First Quarter Fiscal 2021)** Consolidated net revenues for the first quarter of fiscal 2022 were $88.3 million, only 5% below the record $92.9 million in last year’s first quarter. Diagnostics segment net revenues were up 10% year-over-year, while Life Science segment net revenues were down 12% relative to its nearly record quarter in the first quarter of fiscal 2021. Our Diagnostics segment experienced a 4% increase in net revenues from molecular products, and net revenues from non-molecular assay products increased 11% despite the impact of the LeadCare® product recall and the pausing of sales of that product in mid-August 2021. The Life Science segment experienced a dramatic shift in net revenues mix from molecular products (32% decrease) to immunological products (43% increase), driven by the demand for COVID-19 rapid antigen tests relative to molecular test demand experienced in fiscal 2021.
Reported consolidated operating income for the first quarter of fiscal 2022 was $20.3 million. Operating expenses included: (i) increased research and development spending in the Diagnostics segment, reflecting increased clinical trial spending and product development costs; (ii) increased selling and marketing costs in both the Diagnostics and Life Science segments, reflecting filling certain open positions and the easing of certain travel and meeting restrictions imposed during the prior year in connection with the COVID-19 pandemic; and (iii) increased general and administrative costs. On an adjusted basis, consolidated operating income was $20.6 million, a margin of 23%, ahead of expectations, but down from $36.9 million and a margin of 40% in the prior year (see non-GAAP financial measure reconciliation below). This year-over-year margin decrease was driven by revenue mix between segments and lower gross margins for both segments. Gross margin for the Diagnostics segment was negatively impacted by the lack of LeadCare® revenues due to the recall, and for the Life Science segment was negatively impacted by the product mix dynamics mentioned above.
**Financial Condition** At December 31, 2021, cash and cash equivalents were $72.7 million and the Company had $150.0 million of available borrowing capacity under its $200.0 million commercial bank credit facility. The Company’s obligations under the facility totaled $50.0 million as of December 31, 2021.
Julie Smith, Senior Vice President, Controller and Principal Accounting Officer, commented, “The continued strong profitability and cash generation has put Meridian in a net cash position, further strengthening the Company’s ability to take advantage of investment opportunities.”
**Raising Fiscal 2022 Guidance** The performance of both segments in the first quarter exceeded our expectations. Based on these results and current demand for Life Science segment reagents, we are raising our guidance for the full fiscal year.
FY2022 Net Revenues:
- Consolidated $315.0 million to $330.0 million
- Diagnostics segment $145.0 million to $150.0 million (unchanged)
- Life Science segment $170.0 million to $180.0 million
FY2022 Adjusted Operating Margin: Consolidated 21% to 23%
FY2022 Adjusted Net Earnings Per Share on a Diluted Basis (“EPS”): $1.10 to $1.30 (44.5M shares)
The net revenues component of this guidance anticipates that our Life Science segment will continue to see strong demand for its reagents in the second quarter before infection rates decline and demand slows, as they did in 2021. Diagnostics segment guidance anticipates demand for the partner SARS-CoV-2 rapid antigen test, along with the first quarter outperformance, will offset any lost revenue from the delay in shipping the Revogene® SARS-CoV-2 assay. The consolidated adjusted operating margin and adjusted EPS reflect the additional net revenues and gross profit, and take into account the continued inflationary pressure on wages and other expenses, and the expected mix of Life Science segment molecular and immunological reagents.
This guidance reflects our current visibility into market conditions and customer order patterns for our products, and our current assumptions about the impact of the COVID-19 pandemic in the U.S. and around the globe.
**Conference Call Information** Jack Kenny, Chief Executive Officer, and Julie Smith, Senior Vice President, Controller and Principal Accounting Officer, will host a conference call on Friday, February 4, 2022 beginning at 10:00 a.m. Eastern Time to discuss the first quarter financial results and answer questions. A presentation to accompany the quarterly financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3434054-1&h=3898193282&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com), prior to the conference call.
The quarterly earnings call is once again also available via a live webcast, the link for which is located at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3434054-1&h=813434818&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com) or directly [here](https://c212.net/c/link/?t=0&l=en&o=3434054-1&h=2124163566&u=https%3A%2F%2Fwww.webcast-eqs.com%2Fmeridianbioscience02042022_en%2Fen&a=here). The webcast will provide the best experience for tuning into the call; however, if you are unable to join via the webcast, you may still participate by telephone from the U.S. by dialing (877) 407-0890, or from outside the U.S., by dialing (201) 389-0918, and enter the audience pass code 13726037. A replay of the conference call will be available by webcast for one year beginning at 1:00 p.m. Eastern Time on February 4, 2022 using the link provided at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3434054-1&h=813434818&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com).
**FIRST QUARTER FISCAL 2022 UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted
accounting principles (“GAAP”) basis for the first quarters of fiscal 2022 and fiscal 2021.
Three Months Ended
December 31,
2021
2020
Net revenues
$
88,341
$
92,917
Cost of sales
39,182
31,369
Gross profit
49,159
61,548
Operating expenses
Research and development
6,194
5,651
Selling and marketing
7,741
7,021
General and administrative
14,660
11,938
Selected legal costs
281
1,227
Change in fair value of acquisition
consideration
–
1,047
Total operating expenses
28,876
26,884
Operating income
20,283
34,664
Other income (expense), net
(532)
(416)
Earnings before income taxes
19,751
34,248
Income tax provision
4,411
7,469
Net earnings
$
15,340
$
26,779
Net earnings per basic common share
$
0.35
$
0.62
Basic common shares outstanding
43,439
43,098
Net earnings per diluted common share
$
0.35
$
0.61
Diluted common shares outstanding
44,028
43,779
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended
December 31,
2021
2020
Adjusted operating income
$
20,564
$
36,938
Adjusted net earnings
15,551
28,486
Adjusted net earnings per diluted
common share
$
0.35
$
0.65
**Condensed Consolidated Balance Sheet Data** (in thousands)
December 31,
September 30,
2021
2021
Cash and cash equivalents
$
72,729
$
49,771
Working capital
153,707
145,650
Long-term debt
50,000
60,000
Shareholders’ equity
345,219
328,302
Total assets
458,640
449,722
**Segment Data**
The following table sets forth the unaudited net revenues and segment data for the first quarter in fiscal 2022
and fiscal 2021 (in thousands).
Three Months Ended
December 31,
2021
2020
Net Revenues – By Product Platform/Type
Diagnostics
Molecular assays
$
4,752
$
4,590
Non-molecular assays
28,452
25,731
Total Diagnostics
33,204
30,321
Life Science
Molecular reagents
31,488
46,029
Immunological reagents
23,649
16,567
Total Life Science
55,137
62,596
Total Net Revenues
$
88,341
$
92,917
Three Months Ended
December 31,
2021
2020
Net Revenues – By Disease State/Geography
Diagnostics
Gastrointestinal assays
$
21,619
$
15,452
Respiratory illness assays
6,380
4,806
Blood chemistry assays
78
4,394
Other
5,127
5,669
Total Diagnostics
33,204
30,321
Life Science
Americas
8,137
18,755
EMEA
28,648
32,311
ROW
18,352
11,530
Total Life Science
55,137
62,596
Total Net Revenues
$
88,341
$
92,917
OPERATING (LOSS) INCOME
Diagnostics
$
(2,612)
$
(1,182)
Life Science
26,517
39,797
Corporate
(3,637)
(3,963)
Eliminations
15
12
Total Operating Income
$
20,283
$
34,664
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of changes in fair value of acquisition consideration and selected legal costs, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three months ended December 31, 2021 and 2020.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FIRST QUARTER**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Month
Ended December 31,
2021
2020
Operating Expenses –
GAAP basis
$
28,876
$
26,884
Selected legal costs
(281)
(1,227)
Change in fair value of acquisition
consideration
–
(1,047)
Adjusted Operating Expenses
$
28,595
$
24,610
Operating Income –
GAAP basis
$
20,283
$
34,664
Selected legal costs
281
1,227
Change in fair value of acquisition
consideration
–
1,047
Adjusted Operating Income
$
20,564
$
36,938
Net Earnings –
GAAP basis
$
15,340
$
26,779
Selected legal costs \*
211
921
Change in fair value of acquisition
consideration \*
–
786
Adjusted Net Earnings
$
15,551
$
28,486
Basic Net Earnings per Common Share –
GAAP basis
$
0.35
$
0.62
Selected legal costs
–
0.02
Change in fair value of acquisition
consideration
–
0.02
Adjusted Basic EPS \*\*
$
0.36
$
0.66
Three Months
Ended December 31,
2021
2020
Diluted Net Earnings per Common Share –
GAAP basis
$
0.35
$
0.61
Selected legal costs
–
0.02
Change in fair value of acquisition
consideration
–
0.02
Adjusted Diluted EPS
$
0.35
$
0.65
\* Net of tax, as applicable.
\*\* Three months ended December 31, 2021 does not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. healthcare legislation that might be initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**Revogene® SARS-CoV-2 assay disclaimer** The Revogene® SARS-CoV-2 assay has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3434054-1&h=3898193282&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=FY22%20Q1%20Earnings%20Release)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel](https://www.meridianbioscience.com/press-release/meridian-bioscience-receives-additional-nih-award-to-support-the-rapid-development-of-the-revogene-molecular-viral-respiratory-testing-panel/)
**Published:** January 31, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 31, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-receives-additional-nih-award-to-support-the-rapid-development-of-the-revogene-molecular-viral-respiratory-testing-panel-301471612.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has been awarded additional funding in the amount of $2.5M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative. This award expands the scope of the original $5.5M award to help support the research, development, and increased production of the company’s Revogene® molecular viral respiratory diagnostic testing panel.
The funding is provided as part of the RADx Tech program that NIH launched to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The Revogene respiratory panel will simultaneously detect SARS-CoV-2, respiratory synovial virus (RSV), and influenza A/B infections. The expanded NIH investment not only offsets the cost of development but also enables Meridian to enhance its PIE device manufacturing line to increase throughput and improve labor efficiency to meet the expected demand for this viral respiratory panel.
“We are excited and grateful for the continued partnership with NIH and their support of the Revogene testing platform,” said Tony Serafini-Lamanna, Executive Vice President – Diagnostics. “As COVID-19 moves from a pandemic to an endemic public health concern, our customers are requesting highly accurate respiratory testing panels to help speed and differentiate diagnosis so patients can get the best treatment and on the road to wellness. We believe our Revogene viral respiratory panel will meet that need.”
This project has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No:75N92021C00003.
To learn more about the Revogene testing platform, please visit [www.meridianbioscience.com/revogene](https://c212.net/c/link/?t=0&l=en&o=3428770-1&h=2732604516&u=http%3A%2F%2Fwww.meridianbioscience.com%2Frevogene&a=www.meridianbioscience.com%2Frevogene).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3428770-1&h=1522930690&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection](https://www.meridianbioscience.com/press-release/meridian-bioscience-launches-lyo-ready-qpcr-saliva-specific-master-mixes-for-dna-rna-direct-detection/)
**Published:** January 28, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 28, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-launches-lyo-ready-qpcr-saliva-specific-master-mixes-for-dna--rna-direct-detection-301470634.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude saliva samples. These two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix and Lyo-Ready Direct RNA/DNA qPCR Saliva Mix can be used in liquid format or lyophilized. Both mixes accelerate the development of diagnostic assays and improve assay sensitivity using saliva samples with direct qPCR protocols.
Saliva is a non-invasive clinical sample utilized for diagnostic testing across many diseases, including cancer, HIV, and respiratory diseases (e.g., flu, bronchiolitis, pneumonia, and COVID-19). Saliva is one of the easiest samples to collect and handle; however, PCR inhibitors naturally present in high concentrations in the sample create challenges in developing highly sensitive and reliable saliva-based assays.
Similar to the innovative portfolio of Air-Dryable™ sample-specific master mixes, Meridian’s new Lyo-Ready saliva-specific master mixes are optimized for use on crudely processed saliva or sputum samples for enhanced assay sensitivity and flexible protocols. They are “ready-to-use,” with no further optimization required aside from the addition of primers and probes. Additionally, these mixes are stable in a liquid format or can be lyophilized to create ambient temperature-stable assays for point-of-care applications.
Lourdes Weltzien, Ph.D., Executive Vice President – Life Science, commented, “With the surge of COVID-19 infections caused by the Omicron variant along with a rapid increase of other respiratory infections, the need for direct saliva testing has never been greater. Direct RT-qPCR saliva assays offer fast and convenient sample analysis, improve logistics and reduce costs involved in sample handling and transport. We are pleased to be the first to offer a complete solution for anyone developing a saliva-based molecular assay, whether in liquid, lyophilized or air-dried format.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. To learn more about Meridian’s innovative mixes, visit [https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ambient-temperature-rt-qpcr-qpcr-mixes](https://c212.net/c/link/?t=0&l=en&o=3427083-1&h=1670940108&u=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Fambient-temperature-rt-qpcr-qpcr-mixes&a=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Fambient-temperature-rt-qpcr-qpcr-mixes) or email .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3427083-1&h=2589417436&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board](https://www.meridianbioscience.com/press-release/meridian-bioscience-elects-john-c-mcilwraith-new-chairman-of-the-board/)
**Published:** January 27, 2022
**Author:** hamza
**Content:**
CINCINNATI, Jan. 27, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-elects-john-c-mcilwraith-new-chairman-of-the-board-301469984.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effective January 26, 2022. Mr. McIlwraith succeeds David C. Phillips, who retired after serving for more than 21 years on the Meridian Bioscience Board.
Mr. McIlwraith is a Managing Director of Allos Ventures, a venture capital firm, where he leads investments in early-stage technology companies. Prior to co-founding Allos Ventures in 2010, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company. He has served on the board of directors of more than 20 healthcare or information technology companies, including as the Chairman of the Board and later Lead Director of Assurex Health, the provider of a pharmacogenetic test that analyzed genetic variations which impact how patients metabolize and respond to medications that treat mental health conditions. Before joining Blue Chip in 1997, Mr. McIlwraith served as Senior Vice President, Strategic Planning and General Counsel of publicly-traded Quantum Health Resources, Inc., a provider of biologics and other therapies to patients with rare chronic diseases; and was a Partner in the Jones Day law firm. Mr. McIlwraith has served on the Meridian Bioscience Board since 2015.
“John’s broad experience with innovative healthcare and other high growth companies and in driving strategy uniquely positions him to help guide Meridian as we continue to develop innovative diagnostic assays and cutting-edge molecular and immunological reagents,” said Meridian Bioscience CEO, Jack Kenny.
“I am honored to have been elected as the Chairman of the Meridian Bioscience Board of Directors,” said John McIlwraith. “It is with deep gratitude that I assume the role after the steady leadership Dave Phillips provided as a Board Member, Chairman, and friend. I look forward to continuing to partner with Jack Kenny and the company’s other talented Board members as we lead Meridian into the future.”
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3426420-1&h=3023329884&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President –Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-preliminary-results-for-fiscal-2022-third-quarter/)
**Published:** July 7, 2022
**Author:** hamza
**Content:**
CINCINNATI, July 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-announces-preliminary-results-for-fiscal-2022-third-quarter-301582252.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.
For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The Diagnostics segment net revenues are expected to be between $41 million and $43 million. The Life Science segment net revenues are expected to be between $25 million and $26 million, of which sales of immunological reagents accounted for approximately 69% and molecular reagents contributed approximately 31%.
Meridian has not yet completed preparation of its interim financial statements for the third quarter of fiscal 2022 and the information presented herein is a preliminary estimate, subject to change.
**FORWARD-LOOKING STATEMENTS**
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, and in complying with the ongoing investigation of the Department of Justice described in Meridian’s reports filed with the SEC, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian’s operations.
There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian’s results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3587938-2&h=3214648892&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Investor Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
**Media Contact:** Bryan Locke / Monique Sidhom
FGS Global
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays](https://www.meridianbioscience.com/press-release/meridian-launches-new-qpcr-master-mixes-for-stool-samples-to-accelerate-development-of-molecular-assays/)
**Published:** June 20, 2022
**Author:** hamza
**Content:**
CINCINNATI, June 20, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-launches-new-qpcr-master-mixes-for-stool-samples-to-accelerate-development-of-molecular-assays-301570593.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix, and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assays.
Stool samples are used in many gastrointestinal diagnostic tests to screen for harmful bacteria, fungi, viruses, autoimmune conditions, and colorectal cancer (CRC). The fecal occult blood test (FOBT) has been the most widely used gastrointestinal immunoassay to screen CRC for over three decades. However, recent large-scale studies have shown that the FOBT lacks the sensitivity to detect early stages of CRC. Better diagnostic tools are needed to improve assay accuracy, sensitivity, and affordability. Molecular testing is the newest alternative and offers significant improvement in sensitivity and accuracy, especially when multiple targets are detected in the results of a multiplex test. Detection of DNA or RNA from stool is challenging because it contains an array of PCR inhibitors including bile salts, polysaccharides, and catabolic substances. To overcome these challenges, assays typically require expensive and time-consuming sample processing and extraction steps which increase the time to results and cost – ultimately delaying physician diagnosis and patient treatment.
Meridian’s new Lyo-Ready Direct DNA qPCR Stool and Lyo-Ready Direct RNA/DNA qPCR Stool Mixes remove the need for time-consuming nucleic acid extraction or lengthy component optimization. This enables test developers to quickly develop faster and more sensitive assays for stool sample analysis. In addition, the mixes can be used in liquid or lyophilized format when ambient temperature assay stabilization is needed, removing the need for cold storage.
Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development – Life Science, commented, “The use of Lyo-Ready Direct qPCR Stool mixes for DNA and RNA is ideal for cancer biomarker detection, early cancer detection, and cancer treatment monitoring where assay sensitivity can be lifesaving. The specific adaptation of our chemistries to stool specimens makes our master mixes the perfect tool for any developer seeking faster new product introduction, shorter time to results, or the ability to transform a wet assay to an ambient temperature-stable assay with minimum developmental time.”
Meridian is committed to creating innovative solutions that simplify and accelerate the development of superior diagnostic assays. For more information on leveraging of Lyo-Ready technology for your assay development, please visit [https://www.meridianbioscience.com/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/](https://c212.net/c/link/?t=0&l=en&o=3571076-1&h=1751255249&u=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Flyo-ready-air-dryable-master-mixes-reagents%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2Flyo-ready-air-dryable-master-mixes-reagents%2F) or contact .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3571076-1&h=4239984707&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Lyo-Ready%20Stool%20Master%20Mix)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests](https://www.meridianbioscience.com/press-release/meridian-bioscience-responds-to-the-monkeypox-outbreak-with-its-inhibitor-tolerant-qpcr-master-mixes-for-the-development-of-molecular-tests/)
**Published:** May 26, 2022
**Author:** hamza
**Content:**
CINCINNATI, May 26, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-responds-to-the-monkeypox-outbreak-with-its-inhibitor-tolerant-qpcr-master-mixes-for-the-development-of-molecular-tests-301556096.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests.
The recent outbreak of monkeypox has caused global concern due to its unprecedented rapid spread, resulting in what is feared to be the largest outbreak outside of Africa. Monkeypox is an orthopoxvirus first identified in monkeys and has historically only circulated in central and west Africa. Since May 13, 2022, more than 250 monkeypox cases have been reported to the World Health Organization (WHO) from 17 countries outside of Africa, with no known direct travel links to endemic areas.
Screening assays that detect low levels of the virus will be instrumental in helping to contain the outbreak as it continues to spread globally. Monkeypox has a long incubation period of up to three weeks, making traditional viral culture techniques not ideal for testing for monkeypox. Serology testing is also challenging due to the close antigenic relation between surface antigens among the orthopoxviruses. Therefore, confirmation of monkeypox infection requires qPCR detection, which is considered the most rapid, sensitive, and accurate method for viral diagnosis. Meridian has identified its inhibitor-tolerant qPCR master mixes as the best molecular master mixes in the portfolio for the detection of monkeypox. These mixes have versions compatible with either wet or dry assay formats with its Lyo-ready™ (lyophilization ready) or Air-dryable™ technologies.
“With any outbreak, it’s critical to bring accurate testing to healthcare professionals as quickly as possible. Meridian helped bring over 100 COVID-19 tests to market, including dozens in the early months of the pandemic, and is prepared to support diagnostic manufacturers in developing assays for monkeypox,” commented Lourdes Weltzien, Ph.D. Executive Vice President – Life Science. “Our inhibitor-tolerant qPCR mixes are perfect for developing monkeypox assays without the need for further optimization, greatly reducing development time. Our team is standing by to help customers identify the best master mix for their application.”
Meridian continues to be steadfast in its commitment to bringing innovation and quality products to the IVD community, with a focus on developing tools that improve assay accuracy, increase operational efficiencies, and reduce overall costs to enable screening assays that are fast and affordable. To learn more about Meridian’s innovative products, visit [www.meridianlifescience.com/molecular-dx-reagents](https://c212.net/c/link/?t=0&l=en&o=3549766-1&h=921137666&u=http%3A%2F%2Fwww.meridianlifescience.com%2Fmolecular-dx-reagents&a=www.meridianlifescience.com%2Fmolecular-dx-reagents) or contact .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3549766-1&h=944453179&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Monkeypox%20Master%20Mixes)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference](https://www.meridianbioscience.com/press-release/meridian-bioscience-to-participate-in-the-2022-h-c-wainwright-global-investment-conference/)
**Published:** May 23, 2022
**Author:** hamza
**Content:**
CINCINNATI, May 23, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-to-participate-in-the-2022-hc-wainwright-global-investment-conference-301553073.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference. Jack Kenny, Chief Executive Officer, will pre-record the company’s presentation. A link to Mr. Kenny’s presentation will be posted on May 24, 2022, on the Meridian Bioscience website at [https://investor.meridianbioscience.com/news-events/events-presentations/](https://c212.net/c/link/?t=0&l=en&o=3545317-1&h=425943913&u=https%3A%2F%2Finvestor.meridianbioscience.com%2Fnews-events%2Fevents-presentations%2F&a=https%3A%2F%2Finvestor.meridianbioscience.com%2Fnews-events%2Fevents-presentations%2F), and will be accessible for 90 days.
For additional information on the 2022 H.C. Wainwright Global Investment Conference, please visit [www.hcwevents.com/globalconference/](https://c212.net/c/link/?t=0&l=en&o=3545317-1&h=3336925462&u=https%3A%2F%2Fhcwevents.com%2Fglobalconference%2F&a=www.hcwevents.com%2Fglobalconference%2F).
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3545317-1&h=1729231823&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Investor%20Relations%20-%20HCWCo%20Global%20Investment%20Conference)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Launches Lyo-Ready Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays](https://www.meridianbioscience.com/press-release/meridian-bioscience-launches-lyo-ready-saliva-specific-isothermal-amplification-master-mixes-for-direct-detection-of-dna-rna-in-point-of-care-diagnostic-assays/)
**Published:** May 17, 2022
**Author:** hamza
**Content:**
CINCINNATI, May 17, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-launches-lyo-ready-saliva-specific-isothermal-amplification-master-mixes-for-direct-detection-of-dna--rna-in-point-of-care-diagnostic-assays-301549424.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix. The usage of isothermal amplification, such as loop-mediated amplification (LAMP), is increasing globally. The most significant increases are seen in the point of care (POC) molecular diagnostics market and driven in part by the COVID-19 pandemic. The constant arrival of new COVID variants has resulted in a public demand for diagnostic assays that offer short sample-to-result time, high sensitivity, lower cost, and widespread accessibility.
Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix are the first commercially available isothermal mixes designed explicitly for saliva and sputum samples and are compatible with lyophilization. Meridian’s new master mixes combine the benefits of high inhibitor tolerance with fast isothermal amplification to enable ultra-sensitive detection directly from saliva or sputum. The mixes are uniquely designed for extraction-free amplification making them ideal for POC diagnostics. They are compatible with lyophilization to create ambient-temperature stable molecular diagnostic assays, providing significant cost savings and environmental benefits in shipment and storage.
“Isothermal amplification methods such as LAMP are increasingly used in molecular diagnostics due to their compatibility with point-of-care devices and fast time to results. Our newest saliva-specific isothermal mixes are unique in the market and outperform other commercially available master mixes with faster time to results and significantly better amplification in terms of sensitivity and specificity. We are confident they will quickly become market-leading solutions for diagnostic assay developers,” commented Lourdes Weltzien, Ph.D. Executive Vice President – Life Science. “Saliva is an important diagnostic specimen for a broad range of applications for detecting bacterial or viral infections, including respiratory infections such as COVID-19, and STDs such as HIV and herpes. Our new master mixes can help diagnostic companies develop high-performing assays efficiently with lower costs to the bottom line and the environment.”
Meridian is committed to supplying novel solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. To learn more about Meridian’s innovative reagents, visit [https://www.meridianbioscience.com/lifescience/products/molecular-reagents/](https://c212.net/c/link/?t=0&l=en&o=3540015-1&h=2812569494&u=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Flifescience%2Fproducts%2Fmolecular-reagents%2F) or contact .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3540015-1&h=101990573&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Lyo-Ready%20Saliva%20LAMP)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-record-second-quarter-fiscal-2022-operating-results/)
**Published:** May 6, 2022
**Author:** hamza
**Content:**
CINCINNATI, May 6, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-reports-record-second-quarter-fiscal-2022-operating-results-301541477.html#financial-modal)) today announced financial results for the second quarter ended March 31, 2022.
**Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021):**
- Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectations
- Life Science segment delivered record net revenues of $70.1 million
- Diagnostics segment net revenues increased 29% year-over-year to a record $41.1 million
- Launched Lyo-Ready sample specific master mixes for blood
- Resumed shipment of LeadCare® II assay ahead of schedule
Jack Kenny, Chief Executive Officer, commented, “Meridian delivered another strong quarter. For the first time since before the COVID-19 pandemic, both the Diagnostics and Life Science segments outperformed, each posting record quarterly net revenues. This is another sign in the continued progress we are making in building a stronger Meridian.”
**Second Quarter Fiscal 2022 Results (Comparison to Second Quarter Fiscal 2021)** Consolidated net revenues for the second quarter of fiscal 2022 were $111.2 million, up 30% from $85.3 million in last year’s second quarter. Diagnostics segment net revenues were up 29% year-over-year, while Life Science segment net revenues were up 32% year-over-year. Our Diagnostics segment’s net revenues from molecular products were flat compared to the prior year second quarter, and net revenues from non-molecular assay products increased 33%. The Life Science segment experienced a significant shift in net revenues product mix from molecular reagents (7% increase) to immunological reagents (91% increase), driven by a higher demand for COVID-19 rapid antigen tests in fiscal 2022 relative to the molecular test demand experienced in fiscal 2021.
Reported consolidated operating income for the second quarter of fiscal 2022 was $36.1 million compared to $34.2 million in the second quarter of fiscal 2021. Operating expenses included: (i) increased selling and marketing costs in both the Diagnostics and Life Science segments, due, in part, to filling certain open positions and easing of COVID-19 related travel and meeting restrictions; and (ii) increased general and administrative costs primarily due to increases in incentive compensation. On an adjusted basis, consolidated operating income was $36.7 million, reflecting a margin of 33%, up from the prior year’s $32.2 million but down from the prior year margin of 38% (see non-GAAP financial measure reconciliation below). This year-over-year margin decrease was driven by the lower gross margins of each of the segments. Gross margin for the Diagnostics segment was negatively impacted by the partial quarter of LeadCare® II assay shipments, and the Life Science segment, was negatively impacted by the significant shift in product mix mentioned above.
**Financial Condition** At March 31, 2022, cash and cash equivalents were $76.5 million and after the paydown of $25 million, the Company had $175.0 million of available borrowing capacity under its $200.0 million commercial bank credit facility. The Company’s obligations under the facility totaled $25.0 million as of March 31, 2022.
Andy Kitzmiller, Executive Vice President and Chief Financial Officer, commented, “Meridian successfully navigated global supply chain challenges, and was able to meet the unprecedented demand of our customers through effective planning and leveraging the strength of our consolidated balance sheet.”
**Raising Fiscal 2022 Guidance** Based on the strong performance in the second quarter of fiscal 2022 we are raising our guidance for full year fiscal 2022.
FY2022 Net Revenues range:
- Consolidated $330.0 million to $345.0 million
- Diagnostics segment $145.0 million to $150.0 million (unchanged)
- Life Science segment $185.0 million to $195.0 million
FY2022 Adjusted Operating Margin: Consolidated 22.5% to 23.5%
FY2022 Adjusted Net Earnings Per Share on a Diluted Basis (“EPS”): $1.30 to $1.40 (44.3M shares)
Consistent with the Company’s prior remarks on net revenues expectations, the net revenues component of this guidance anticipates that our Life Science segment experiences lower levels of net revenues in the second half of the year driven by decreased demand for its reagents used in COVID-19 tests. The Company expects to see demand similar to that seen in previous quarters where testing levels decreased following a surge in COVID-19 infection rates, such as the fourth quarter of fiscal 2020 or the third quarter of fiscal 2021. The consolidated adjusted operating margin and adjusted EPS reflect the additional net revenues and gross profit and take into account the continued inflationary pressure on wages and other expenses, and the expected mix of Life Science segment molecular and immunological reagents.
This guidance reflects our current visibility into market conditions and customer order patterns for our products, and our current assumptions about the impact of the COVID-19 pandemic in the U.S. and around the globe.
**Conference Call Information** Jack Kenny, Chief Executive Officer, and Andy Kitzmiller, Executive Vice President and Chief Financial Officer, will host a conference call on Friday, May 6, 2022 beginning at 10:00 a.m. Eastern Time to discuss the second quarter financial results and answer questions. A presentation to accompany the quarterly financial results and related discussion will be made available within the Investor Relations section of the Company’s website, [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3528246-1&h=1990864435&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com), prior to the conference call.
The quarterly earnings call is once again also available via a live webcast, the link for which is located at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3528246-1&h=2928647283&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com) or directly [here](https://c212.net/c/link/?t=0&l=en&o=3528246-1&h=1638674437&u=https%3A%2F%2Fwww.webcast-eqs.com%2Fregister%2Fmeridianbio05062022_en%2Fen&a=here). The webcast will provide the best experience for tuning into the call; however, if you are unable to join via the webcast, you may still participate by telephone from the U.S. by dialing (877) 407-0890, or from outside the U.S., by dialing (201) 389-0918, and mention “Meridian Bioscience, Inc.”. A replay of the conference call will be available by webcast for one year beginning at 1:00 p.m. Eastern Time on May 6, 2022 using the link provided at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3528246-1&h=2928647283&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=investor.meridianbioscience.com).
**INTERIM UNAUDITED OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted accounting principles (“GAAP”) basis for the following interim periods:
Three Months Ended
Six Months Ended
March 31,
March 31,
2022
2021
2022
2021
Net revenues
$
111,231
$
85,264
$
199,572
$
178,181
Cost of sales
42,754
27,492
81,936
58,861
Gross profit
68,477
57,772
117,636
119,320
Operating expenses
Research and development
5,691
6,065
11,885
11,716
Selling and marketing
7,514
6,540
15,255
13,561
General and administrative
18,555
12,925
33,215
24,863
Acquisition-related costs
68
–
68
–
Selected legal costs
508
1,030
789
2,257
Change in fair value of acquisition
consideration
–
(2,989)
–
(1,942)
Total operating expenses
32,336
23,571
61,212
50,455
Operating income
36,141
34,201
56,424
68,865
Other income (expense), net
394
(1,149)
(138)
(1,565)
Earnings before income taxes
36,535
33,052
56,286
67,300
Income tax provision
7,783
6,750
12,194
14,219
Net earnings
$
28,752
$
26,302
$
44,092
$
53,081
Net earnings per basic common share
$
0.66
$
0.61
$
1.01
$
1.23
Basic common shares outstanding
43,549
43,244
43,495
43,171
Net earnings per diluted common share
$
0.65
$
0.60
$
1.00
$
1.21
Diluted common shares outstanding
44,262
44,122
44,112
43,960
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended
Six Months Ended
March 31,
March 31,
2022
2021
2022
2021
Adjusted operating income
$
36,717
$
32,242
$
57,281
$
69,180
Adjusted net earnings
29,185
24,832
44,736
53,318
Adjusted net earnings per diluted common share
$
0.66
$
0.56
$
1.01
$
1.21
**Condensed Consolidated Balance Sheet Data** (in thousands)
March 31,
September 30,
2022
2021
Cash and cash equivalents
$
76,487
$
49,771
Working capital
161,095
145,650
Long-term debt
25,000
60,000
Shareholders’ equity
374,632
328,302
Total assets
471,810
449,722
**Segment Data** The following table sets forth the unaudited net revenues and segment data for the following interim periods (in thousands):
Three Months Ended
Six Months Ended
March 31,
March 31,
2022
2021
2022
2021
Net Revenues – By Product Platform/Type
Diagnostics
Molecular assays
$
4,385
$
4,395
$
9,137
$
8,985
Non-molecular assays
36,718
27,554
65,170
53,285
Total Diagnostics
41,103
31,949
74,307
62,270
Life Science
Molecular reagents
40,334
37,752
71,822
83,776
Immunological reagents
29,794
15,563
53,443
32,135
Total Life Science
70,128
53,315
125,265
115,911
Total Net Revenues
$
111,231
$
85,264
$
199,572
$
178,181
Three Months Ended
Six Months Ended
March 31,
March 31,
2022
2021
2022
2021
Net Revenues – By Disease State/Geography
Diagnostics
Gastrointestinal assays
$
20,281
$
15,666
$
41,900
$
31,118
Respiratory illness assays
9,491
3,686
15,871
8,492
Blood chemistry assays
3,425
4,358
3,503
8,753
Other
7,906
8,239
13,033
13,907
Total Diagnostics
41,103
31,949
74,307
62,270
Life Science
Americas
10,377
13,550
18,514
32,296
EMEA
33,246
21,773
61,894
54,066
ROW
26,505
17,992
44,857
29,549
Total Life Science
70,128
53,315
125,265
115,911
Total Net Revenues
$
111,231
$
85,264
$
199,572
$
178,181
OPERATING INCOME (LOSS)
Diagnostics
$
1,589
$
2,641
$
(174)
$
1,683
Life Science
40,286
36,025
66,888
75,754
Corporate
(5,752)
(4,481)
(10,323)
(8,600)
Eliminations
18
16
33
28
Total Operating Income
$
36,141
$
34,201
$
56,424
$
68,865
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of selected legal costs, restructuring costs and changes in fair value of acquisition consideration, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three and six months ended March 31, 2022 and 2021.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**SECOND QUARTER AND SIX MONTH YEAR-TO-DATE GAAP TO NON-GAAP RECONCILIATION TABLES** (In Thousands, Except per Share Data)
Three Months
Six Months
Ended March 31,
Ended March 31,
2022
2021
2022
2021
Operating Expenses –
GAAP basis
$
32,336
$
23,571
$
61,212
$
50,455
Acquisition-related costs
(68)
–
(68)
–
Selected legal costs
(508)
(1,030)
(789)
(2,257)
Change in fair value of acquisition
consideration
–
2,989
–
1,942
Adjusted Operating Expenses
$
31,760
$
25,530
$
60,355
$
50,140
Operating Income –
GAAP basis
$
36,141
$
34,201
$
56,424
$
68,865
Acquisition-related costs
68
–
68
–
Selected legal costs
508
1,030
789
2,257
Change in fair value of acquisition
consideration
–
(2,989)
–
(1,942)
Adjusted Operating Income
$
36,717
$
32,242
$
57,281
$
69,180
Net Earnings –
GAAP basis
$
28,752
$
26,302
$
44,092
$
53,081
Acquisition-related costs \*
51
–
51
–
Selected legal costs \*
382
774
593
1,695
Change in fair value of acquisition
consideration \*
–
(2,244)
–
(1,458)
Adjusted Net Earnings
$
29,185
$
24,832
$
44,736
$
53,318
Basic Earnings per Common Share –
GAAP basis
$
0.66
$
0.61
$
1.01
$
1.23
Acquisition-related costs
–
–
–
–
Selected legal costs
0.01
0.02
0.01
0.04
Change in fair value of acquisition
consideration
–
(0.05)
–
(0.03)
Adjusted Basic EPS \*\*
$
0.67
$
0.57
$
1.03
$
1.24
Three Months
Ended March 31,
Six Months
Ended March 31,
2022
2021
2022
2021
Diluted Earnings per Common Share –
GAAP basis
$
0.65
$
0.60
$
1.00
$
1.21
Acquisition-related costs
–
–
–
–
Selected legal costs
0.01
0.02
0.01
0.04
Change in fair value of acquisition
consideration
–
(0.05)
–
(0.03)
Adjusted Diluted EPS \*\*\*
$
0.66
$
0.56
$
1.01
$
1.21
\*
Net of tax, as applicable.
\*\*
Three months ended March 31, 2021 and six months ended March 31, 2022 do not sum to total due to rounding.
\*\*\*
Three and six months ended March 31, 2021 do not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, and in complying with the ongoing investigation of the Department of Justice described in Meridian’s reports filed with the SEC, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian’s results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.meridianbioscience.com/).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=FY21%20Q3%20Earnings%20Release)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities](https://www.meridianbioscience.com/press-release/meridian-acquires-euprotein-to-further-expand-recombinant-protein-capabilities/)
**Published:** May 2, 2022
**Author:** hamza
**Content:**
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-acquires-euprotein-to-further-expand-recombinant-protein-capabilities-301536950.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022.
EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help Meridian accelerate its pipeline of new immunological reagents while expanding recombinant capabilities.
“We are excited to welcome EUPROTEIN into the Meridian family,” commented Jack Kenny, Meridian Bioscience Chief Executive Officer. “We already extensively work with EUPROTEIN on projects with our Life Science R&D team, and they are well-positioned to help us accelerate our pipeline of new immunological reagents.”
Guangli Wang, Ph.D., Founder, and CEO of EUPROTEIN, remarked, “The EUPROTEIN team is delighted to join Meridian. Combining our products and capabilities with Meridian’s global reach and stellar reputation for providing the highest quality reagents furthers our vision of making a lasting impact on global healthcare.”
Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. Please visit [www.meridianbioscience.com/lifescience](https://c212.net/c/link/?t=0&l=en&o=3521592-1&h=1733213126&u=http%3A%2F%2Fwww.meridianbioscience.com%2Flifescience&a=www.meridianbioscience.com%2Flifescience) to learn more about Meridian’s raw materials designed for diagnostic applications. Or contact Paul Marr at [Paul.Marr@MeridianLifeScience.com](mailto:paul.marr@meridianlifescience.com).
**Cautionary Statement Regarding Forward-Looking Statements** Certain statements in this communication regarding the acquisition of assets from EUPROTEIN as described above by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding Meridian’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions, and the negative thereof, are intended to identify forward-looking statements.
All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of Meridian, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the diversion of management time on transaction-related issues; ability to successfully integrate the businesses; risk that the transaction and its announcement could have an adverse effect on the parties’ ability to retain customers and retain and hire key personnel; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian’s filings with the SEC and available through the SEC’s Electronic Data Gathering and Analysis Retrieval system at [www.sec.gov](https://www.sec.gov/), including Meridian’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3521592-1&h=2348393799&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=EUPROTEIN%20acquisition)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-preliminary-net-revenues-results-for-fiscal-2022-second-quarter/)
**Published:** April 7, 2022
**Author:** hamza
**Content:**
CINCINNATI, April 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-announces-preliminary-net-revenues-results-for-fiscal-2022-second-quarter-301519570.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022.
Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian’s expectations and a record for the Company. Individually, both of the Company’s segments are also expected to have record net revenues in the quarter with the Diagnostics segment net revenues expected to be between $40 million and $42 million and the Life Science segment net revenues expected to be between $69 million and $71 million. Both the return of the LeadCare® product line to market earlier in the quarter than expected and positive demand for the SARS-CoV-2 rapid antigen test contributed to Diagnostics segment results. Strong demand for reagents associated with COVID-19 antigen testing during the recent Omicron wave of infections contributed to Life Science segment results.
Meridian has not yet completed preparation of its interim financial statements for the second quarter of fiscal 2022 and the information presented herein is a preliminary estimate, subject to change. The Company will provide full financial results and any changes to fiscal 2022 guidance during the second quarter earnings call scheduled for 10:00 a.m. Eastern Time on Friday, May 6, 2022. Jack Kenny, Chief Executive Officer, and Andy Kitzmiller, Chief Financial Officer, will host the conference call and answer questions.
To participate in the live call by webcast, join directly [here](https://c212.net/c/link/?t=0&l=en&o=3497412-1&h=2414407265&u=https%3A%2F%2Fwww.webcast-eqs.com%2Fmeridianbio05062022_en%2Fen&a=here) or visit [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3497412-1&h=69627818&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=investor.meridianbioscience.com) for the link.
If you are unable to join the webcast, you may join by telephone. From the U.S., dial (877) 407-0890, or from outside the U.S., dial (201) 389-0918, and mention “Meridian Bioscience, Inc.”
A replay of the conference call will also be available by webcast for one year beginning 1:00 p.m. Eastern Time on May 6, 2022 using the link provided at [investor.meridianbiocience.com](https://c212.net/c/link/?t=0&l=en&o=3497412-1&h=3529116359&u=https%3A%2F%2Finvestor.meridianbioscience.com%2F&a=investor.meridianbiocience.com).
**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian’s results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19. In addition to the factors described in this paragraph, please also refer to additional factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, including in Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K, which contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3497412-1&h=3637752314&u=https%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Launches Lyo-Ready qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection](https://www.meridianbioscience.com/press-release/meridian-bioscience-launches-lyo-ready-qpcr-inhibitor-tolerant-blood-specific-master-mixes-for-dna-rna-direct-detection/)
**Published:** May 29, 2022
**Author:** hamza
**Content:**
CINCINNATI, March 29, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-launches-lyo-ready-qpcr-inhibitor-tolerant-blood-specific-master-mixes-for-dna--rna-direct-detection-301513098.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready Direct DNA qPCR Blood Mix and Lyo-Ready Direct RNA/DNA qPCR Blood Mix, are designed for applications that require ultra-sensitive detection, such as liquid biopsy. This breakthrough technology is the first blood-specific, inhibitor-tolerant, and lyophilizable chemistry that enables extraction-free qPCR/RT-qPCR for liquid biopsy analysis at a performance level on par with traditional qPCR from purified nucleic acids.
Liquid biopsy is a non-invasive alternative to tissue biopsy and offers ultra-sensitive detection of tumor-associated DNA or RNA from biofluids such as blood. Sample types like whole blood, serum, plasma, and the anticoagulants used for specimen stabilization contain PCR inhibitors that can significantly reduce detection sensitivity and may cause false-negative results. Inhibitors are usually removed by DNA/RNA extraction; however, that approach is very inefficient and increases assay time, cost, and the risk of contamination or error. Meridian’s innovative Lyo-Ready Blood-Specific Master Mixes do not require extraction and are proven to excel with crude blood and its derivatives without the need to remove inhibitors. These groundbreaking mixes can help improve patient outcomes by enabling early cancer detection by delivering assay sensitivity down to one copy of DNA. Meridian’s new mixes are formulated with lyophilization excipients, making them compatible with lyophilization to create room-temperature stable molecular diagnostic assays. Not only does this allow maximum sample input in the liquid biopsy analysis, but it also eliminates the need for cold chain storage of the finished test kit, limiting our customer’s environmental impact.
Florent Chang-Pi-Hin, Ph.D., Vice President, Global Research and Development, commented, “We are excited to expand our sample-specific molecular range with the market’s first lyophilizable, and inhibitor-tolerant master mixes designed for direct amplification of nucleic acids from liquid biopsy. It is a truly disruptive technology that makes the early detection of cancer biomarkers directly from liquid biopsy a reality. We are proud of being the technology innovator enabling efficient and more cost-effective diagnostic assay development to help clinicians deliver the quickest, most accurate diagnosis for patients.”
Meridian is committed to supplying novel solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. To learn more about Meridian’s groundbreaking mixes, visit
[https://www.meridianbioscience.com/ambient-temperature-mixes](https://c212.net/c/link/?t=0&l=en&o=3487866-1&h=2319435830&u=https%3A%2F%2Fwww.meridianbioscience.com%2Fambient-temperature-mixes&a=https%3A%2F%2Fwww.meridianbioscience.com%2Fambient-temperature-mixes) or contact .
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries worldwide.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3487866-1&h=1060998907&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Liquid%20Biopsy%20Mix)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-anticipated-closing-date-of-the-pending-merger/)
**Published:** December 12, 2022
**Author:** hamza
**Content:**
CINCINNATI, Dec. 12, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-announces-anticipated-closing-date-of-the-pending-merger-301699917.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian’s pending merger for January 31, 2023.
As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SD Biosensor, Inc., (“SDB”), Columbus Holding Company (“Parent”), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent (“Merger Sub”, and together with SDB and Parent, the “Parent Parties,” and each individually a “Parent Party”). The Merger Agreement provides, among other things, that, upon the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the applicable provisions of the Ohio General Corporation Law, Merger Sub will merge with and into Meridian (the “Merger”), with Meridian surviving the Merger as a direct wholly owned subsidiary of Parent.
On December 9, 2022, Meridian and the Parent Parties, entered into a letter agreement (the “Letter Agreement”), modifying the Merger Agreement. In the Letter Agreement, Meridian and the Parent Parties agreed that all of the conditions to the Parent Parties’ obligations to complete the Merger set forth in the Merger Agreement are satisfied (and are deemed to remain satisfied through the completion of the Merger), provided that the Company is required to comply with certain covenants in the Merger Agreement through the completion of the Merger. Meridian and the Parent Parties also agreed to consummate the Merger on January 31, 2023 and to waive their right to terminate the Merger Agreement if the Merger has not been consummated by 11:59 p.m. Eastern Time on January 6, 2023. In agreeing to consummate the Merger on January 31, 2023, the board of directors of Meridian determined that it is in the best interest of Meridian’s shareholders to provide the Parent Parties additional time to consummate the Merger in order to finalize their financing (which is not a condition to the consummation of the Merger).
Please refer to the 8K filed today for additional details including the full text of the Letter Agreement filed as an exhibit to the 8K.
**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) the anticipated date for completion of the Merger, (2) the risk that any announcements relating to the proposed Merger, including the expected consummation, could have adverse effects on the market price of Meridian’s common stock; (3) economic or other conditions in the markets in which Meridian operates, including as a result of the COVID-19 pandemic or the Russia–Ukraine conflict; (4) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or the Letter Agreement; (5) the risk that the Company may not be able to comply with its ongoing covenants set forth in the Merger Agreement in a timely manner or at all; (6) risks related to distraction of Meridian’s management time from ongoing business operations due to the proposed Merger; (7) the risk of any unexpected costs or expenses resulting from the proposed Merger, the delay thereof or disputes relating thereto; (8) the risk that the outcome of any legal proceedings related to the proposed Merger could be material to Meridian or detrimental to the proposed Merger; (9) the risk that Meridian may be adversely affected by other economic, business, or competitive factors; and (10) the effect of the announcement of the proposed Merger on the ability of Meridian to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Meridian does business, or on the Meridian’s operating results and business generally. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Additional factors that may affect the future results of Meridian are set forth in its filings with the SEC, including Meridian’s most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on Meridian’s website at [investor.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3733812-1&h=3548087045&u=https%3A%2F%2Fmbimgmt-my.sharepoint.com%2Fpersonal%2Fcharlie_wood_meridianbioscience_com%2FDocuments%2FCorporateDevelopment%2FSD%2520Biosensor%2520(Madeira)%2FCommunications%2FPR%2520-%2520Side%2520Letter%2Fwww.investor.meridianbioscience.com&a=investor.meridianbioscience.com) and the SEC’s website at [www.sec.gov](https://c212.net/c/link/?t=0&l=en&o=3733812-1&h=722463105&u=https%3A%2F%2Fmbimgmt-my.sharepoint.com%2Fpersonal%2Fcharlie_wood_meridianbioscience_com%2FDocuments%2FCorporateDevelopment%2FSD%2520Biosensor%2520(Madeira)%2FCommunications%2FPR%2520-%2520Side%2520Letter%2Fwww.sec.gov&a=www.sec.gov), specifically under the heading “Risk Factors.” The risks and uncertainties described above are not exclusive and further information concerning Meridian and its businesses, including factors that potentially could materially affect its businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. The forward-looking statements in this communication speak only as of the date hereof. Except as required by law, Meridian assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3733812-1&h=367823329&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Anticipated%20Closing%20Date%20Announcement)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-third-quarter-fiscal-2022-operating-results/)
**Published:** August 5, 2022
**Author:** hamza
**Content:**
CINCINNATI, Aug. 5, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-reports-third-quarter-fiscal-2022-operating-results-301600577.html#financial-modal)) today announced financial results for the third quarter ended June 30, 2022.
**Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021):**
- Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-year
- Diagnostics segment net revenues increased 36% year-over-year to a record $42.4 million
- Life Science segment delivered net revenues of $25.4 million, a decrease of 22%
**Third Quarter Fiscal 2022 Results (Comparison to Third Quarter Fiscal 2021)** Consolidated net revenues for the third quarter of fiscal 2022 were $67.8 million, up 7% from $63.5 million in last year’s third quarter. Diagnostics segment net revenues were up 36% year-over-year, while Life Science segment net revenues were 22% lower year-over-year. Our Diagnostics segment’s net revenues from molecular products increased 11% compared to the prior year third quarter, and net revenues from non-molecular assay products increased 40%. Key contributors to the non-molecular assay year-over-year increase include the addition of the BreathTek® product line acquired in July 2021 and the increase in sales of LeadCare® products that were not shipping for a portion of the third quarter of fiscal 2021 due to a product recall. The Life Science segment experienced a significant shift in net revenues product mix from molecular reagents (62% decrease) to immunological reagents (48% increase), driven by lower overall demand in fiscal 2022 relative to the strong molecular test demand experienced in fiscal 2021 driven largely by COVID-19 testing.
Reported consolidated operating loss for the third quarter of fiscal 2022 was $6.7 million compared to operating income of $15.7 million in the third quarter of fiscal 2021. The consolidated operating loss was primarily driven by a $10 million estimated expense recorded in the third quarter related to the possible settlement of the previously disclosed and ongoing U.S. Department of Justice legal matter. Operating expenses also included: (i) increased selling and marketing costs in both the Diagnostics and Life Science segments, due, in part, to filling certain open positions and easing of COVID-19 related travel and meeting restrictions; (ii) increased general and administrative costs due, in part, to increased intangible asset amortization resulting from the acquisition of the BreathTek® business in July 2021; (iii) higher acquisition and transaction related expenses in connection with the recently signed definitive merger agreement discussed below; and (iv) the effect of the fiscal 2021 third quarter upward adjustment to the contingent consideration related to the fiscal 2019 acquisition of GenePOC Inc. On an adjusted basis, consolidated operating income was $9.4 million, reflecting a margin of 14%, down from the prior year quarter’s $12.9 million and 20% margin (see non-GAAP financial measure reconciliation below). This year-over-year decrease was driven primarily by the decreased level of net revenues and gross margins within the Life Science segment, which resulted from the overall decline in COVID-19 related net revenues and the significant shift in product mix mentioned above.
Jack Kenny, Chief Executive Officer, commented, “The Diagnostics segment continues to perform well, delivering a third quarter with record net revenues of $42.4 million. As expected, Life Science segment net revenues declined, with reduced demand for COVID-19 related products.”
**Financial Condition** At June 30, 2022, cash and cash equivalents were $83.5 million and the Company had $175.0 million of available borrowing capacity under its $200.0 million commercial bank credit facility. The Company’s obligations under the facility totaled $25.0 million as of June 30, 2022.
**Fiscal 2022 Guidance & Conference Call** As announced on July 7, 2022, the Company entered into a definitive merger agreement whereby a newly formed affiliate vehicle of a Consortium, consisting of SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”), will acquire Meridian. The transaction is expected to close in the fourth calendar quarter of 2022, subject to approval by Meridian shareholders, receipt of required regulatory approvals, the absence of specified material adverse outcomes of the Company’s previously disclosed and ongoing investigation by the U.S. Department of Justice, and other customary closing conditions.
Due to the pending transaction, Meridian will no longer hold conference calls to discuss its quarterly financial results and withdraws its previously issued financial guidance for fiscal year 2022, last updated on May 6, 2022.
**INTERIM UNAUDITED OPERATING RESULTS** (In Thousands, Except per Share Data)
The following table sets forth the unaudited comparative results of Meridian on a U.S. generally accepted
accounting principles (“GAAP”) basis for the following interim periods:
Three Months Ended
Nine Months Ended
June 30,
June 30,
2022
2021
2022
2021
Net revenues
$
67,771
$
63,511
$
267,343
$
241,692
Cost of sales
31,043
26,400
112,979
85,261
Gross profit
36,728
37,111
154,364
156,431
Operating expenses
Research and development
6,043
6,083
17,928
17,799
Selling and marketing
8,178
6,209
23,433
19,770
General and administrative
13,149
11,964
46,364
36,827
Acquisition and transaction related costs
4,227
300
4,295
300
Litigation and select legal costs
11,812
438
12,601
2,695
Change in fair value of acquisition
consideration
–
(3,563)
–
(5,505)
Total operating expenses
43,409
21,431
104,621
71,886
Operating income (loss)
(6,681)
15,680
49,743
84,545
Other income (expense), net
79
(385)
(59)
(1,950)
Earnings (loss) before income taxes
(6,602)
15,295
49,684
82,595
Income tax provision
736
3,626
12,930
17,845
Net earnings (loss)
$
(7,338)
$
11,669
$
36,754
$
64,750
Net earnings (loss) per basic common share
$
(0.17)
$
0.27
$
0.84
$
1.50
Basic common shares outstanding
43,586
43,334
43,526
43,226
Net earnings (loss) per diluted common
share
$
(0.16)
$
0.26
$
0.83
$
1.47
Diluted common shares outstanding
44,474
44,097
44,230
44,006
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended
Nine Months Ended
June 30,
June 30,
2022
2021
2022
2021
Adjusted operating income
$
9,358
$
12,855
$
66,639
$
82,035
Adjusted net earnings
7,197
9,547
51,933
62,865
Adjusted net earnings per diluted
common share
$
0.16
$
0.22
$
1.17
$
1.43
**Condensed Consolidated Balance Sheet Data** (in thousands)
June 30,
September 30,
2022
2021
Cash and cash equivalents
$
83,487
$
49,771
Working capital
152,122
145,650
Long-term debt
25,000
60,000
Shareholders’ equity
365,547
328,302
Total assets
465,928
449,722
**Segment Data** The following table sets forth the unaudited net revenues and segment data for the following interim periods (in
thousands):
Three Months Ended
Nine Months Ended
June 30,
June 30,
2022
2021
2022
2021
Net Revenues – By Product Platform/Type
Diagnostics
Molecular assays
$
4,876
$
4,383
$
14,039
$
13,368
Non-molecular assays
37,533
26,806
102,677
80,091
Total Diagnostics
42,409
31,189
116,716
93,459
Life Science
Molecular reagents
7,743
20,385
79,531
104,016
Immunological reagents
17,619
11,937
71,096
44,217
Total Life Science
25,362
32,322
150,627
148,233
Total Net Revenues
$
67,771
$
63,511
$
267,343
$
241,692
Three Months Ended
Nine Months Ended
June 30,
June 30,
2022
2021
2022
2021
Net Revenues – By Disease State/Geography
Diagnostics
Gastrointestinal assays
$
22,715
$
17,844
$
64,704
$
48,962
Respiratory illness assays
5,488
3,742
21,359
12,233
Blood chemistry assays
6,431
4,254
9,762
13,006
Other
7,775
5,349
20,891
19,258
Total Diagnostics
42,409
31,189
116,716
93,459
Life Science
Americas
7,314
7,419
25,833
39,661
EMEA
8,200
15,723
70,188
70,084
ROW
9,848
9,180
54,606
38,488
Total Life Science
25,362
32,322
150,627
148,233
Total Net Revenues
$
67,771
$
63,511
$
267,343
$
241,692
OPERATING INCOME (LOSS)
Diagnostics
$
3,278
$
2,717
$
3,104
$
4,400
Life Science
9,088
16,078
75,976
91,832
Corporate
(19,084)
(3,154)
(29,407)
(11,754)
Eliminations
37
39
70
67
Total Operating Income (Loss)
$
(6,681)
$
15,680
$
49,743
$
84,545
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income (loss), operating margin, net earnings (loss), basic net earnings (loss) per share and diluted net earnings (loss) per share, each on an adjusted basis excluding the effects of acquisition and transaction related costs, litigation and select legal costs, and changes in fair value of acquisition consideration, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three and nine months ended June 30, 2022 and 2021.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**THIRD QUARTER AND NINE MONTH YEAR-TO-DATE GAAP TO NON-GAAP RECONCILIATION TABLES** (In Thousands, Except per Share Data)
Three Months
Nine Months
Ended June 30,
Ended June 30,
2022
2021
2022
2021
Operating Expenses –
GAAP basis
$
43,409
$
21,431
$
104,621
$
71,886
Acquisition and transaction related costs
(4,227)
(300)
(4,295)
(300)
Litigation and select legal costs
(11,812)
(438)
(12,601)
(2,695)
Change in fair value of acquisition
consideration
–
3,563
–
5,505
Adjusted Operating Expenses
$
27,370
$
24,256
$
87,725
$
74,396
Operating Income (Loss) –
GAAP basis
$
(6,681)
$
15,680
$
49,743
$
84,545
Acquisition and transaction related costs
4,227
300
4,295
300
Litigation and select legal costs
11,812
438
12,601
2,695
Change in fair value of acquisition
consideration
–
(3,563)
–
(5,505)
Adjusted Operating Income
$
9,358
$
12,855
$
66,639
$
82,035
Net Earnings (Loss) –
GAAP basis
$
(7,338)
$
11,669
$
36,754
$
64,750
Acquisition and transaction related costs \*
3,174
225
3,226
225
Litigation and select legal costs \*
11,361
329
11,953
2,024
Change in fair value of acquisition
consideration \*
–
(2,676)
–
(4,134)
Adjusted Net Earnings
$
7,197
$
9,547
$
51,933
$
62,865
Basic Earnings (Loss) per Common Share –
GAAP basis
$
(0.17)
$
0.27
$
0.84
$
1.50
Acquisition and transaction related costs
0.07
0.01
0.07
0.01
Litigation and select legal costs
0.26
0.01
0.27
0.05
Change in fair value of acquisition
consideration
–
(0.06)
–
(0.10)
Adjusted Basic EPS \*\*
$
0.17
$
0.22
$
1.19
$
1.45
Three Months
Nine Months
Ended June 30,
Ended June 30,
2022
2021
2022
2021
Diluted Earnings (Loss) per Common Share –
GAAP basis
$
(0.16)
$
0.26
$
0.83
$
1.47
Acquisition and transaction related costs
0.07
0.01
0.07
0.01
Litigation and select legal costs
0.26
0.01
0.27
0.05
Change in fair value of acquisition
consideration
–
(0.06)
–
(0.09)
Adjusted Diluted EPS \*\*\*
$
0.16
$
0.22
$
1.17
$
1.43
\*
Net of tax, as applicable.
\*\*
Three and nine months ended June 30, 2022 and three and nine months ended June 30, 2021 do not sum to total due to rounding.
\*\*\*
Three months ended June 30, 2022 and nine months ended June 30, 2021 do not sum to total due to rounding.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, and in complying with the ongoing investigation of the Department of Justice described in Meridian’s reports filed with the SEC, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian’s results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to the proposed acquisition by SD Biosensor, Inc., as well as disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.meridianbioscience.com/).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=FY22%20Q3%20Earnings%20Release)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-receives-re-authorization-from-fda-for-its-revogene-sars-cov-2-molecular-assay/)
**Published:** July 29, 2022
**Author:** hamza
**Content:**
CINCINNATI, July 29, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-receives-re-authorization-from-fda-for-its-revogene-sars-cov-2-molecular-assay-301596124.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022.
On November 10, 2021, Meridian announced the Revogene® SARS-CoV-2 assay was granted authorization by the FDA. Subsequent to that, it was determined that the original design of the assay would not detect the Omicron variant and Meridian delayed marketing the assay to modify its design to correct for the detection of the variant. In March, Meridian completed the development work and submitted an initial set of data to the FDA to validate the performance of this revised assay. Over the last few months in consultation with the FDA, Meridian completed additional clinical studies and the FDA has now re-authorized the EUA.
The Revogene® SARS-CoV-2 assay is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens and provides impressive clinical performance with a positive predictive agreement (PPA) of 97.7% and a negative predicative agreement (NPA) of 97.7%.
The Revogene® SARS-CoV-2 assay can help laboratories and healthcare systems improve their COVID-19 testing capacity and enable healthcare providers to quickly deliver the appropriate care and guide infection control measures for patients. The flexible Revogene® molecular testing platform can easily integrate into any laboratory or health system. Additional FDA-approved tests on the Revogene platform include Revogene® *C. difficile*, Revogene® Strep A, Revogene® GBS LB, and Revogene® Carba C.
“There continues to be demand for fast, accurate detection of COVID-19 especially considering the high transmissibility of these new variants and the upcoming respiratory season,” said Tony Serafini-Lamanna, Executive Vice President – Diagnostics for Meridian Bioscience. “We believe our Revogene® SARS-CoV-2 assay and growing Revogene® platform can help clinicians and health systems meet these demands now and in the future.”
To learn more about the Revogene® SARS-CoV-2 assay, please visit [https://www.meridianbioscience.com/revogene-sars-cov-2/](https://c212.net/c/link/?t=0&l=en&o=3607859-1&h=170952285&u=https%3A%2F%2Fwww.meridianbioscience.com%2Frevogene-sars-cov-2%2F&a=https%3A%2F%2Fwww.meridianbioscience.com%2Frevogene-sars-cov-2%2F). For sales inquiries, please contact Meridian Bioscience at 1-888-763-6769 or [sales@meridianbioscience.com](mailto:sales@meridianbioscience.com?subject=Revogene%20SARS-CoV-2%20EUA).
This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.
**FORWARD-LOOKING STATEMENTS** The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, including in Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K, which contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3607859-1&h=2473738537&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=Revogene%20SARS-CoV-2%20EUA)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS](https://www.meridianbioscience.com/press-release/meridian-bioscience-reports-fourth-quarter-and-full-year-fiscal-2022-operating-results/)
**Published:** November 22, 2022
**Author:** hamza
**Content:**
CINCINNATI, Nov. 22, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-reports-fourth-quarter-and-full-year-fiscal-2022-operating-results-301684525.html#financial-modal)) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022.
**Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021):**
- Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-year
- Diagnostics segment net revenues increased 14% year-over-year to $39.2 million
- Life Science segment delivered net revenues of $26.5 million, a decrease of 37%
- Submitted 510(k) for Curian® Shiga Toxin assay
**Full Fiscal Year 2022 Highlights (Comparison to Full Year Fiscal 2021):**
- Consolidated net revenues of $333.0 million, up 5% year-over-year
- Diagnostics segment net revenues increased 22% year-over-year to $155.9 million
- Life Science segment delivered net revenues of $177.1 million, a decrease of 7%
- Established new Life Science recombinant protein R&D facility in New Jersey with assets acquired from EUPROTEIN, Inc.
- Diagnostics segment launched two new products: Curian® Campy and Revogene® SARS-CoV-2 EUA
- Life Science segment launched 17 new molecular products, which completed a full line of sample-specific master mixes for qPCR and LAMP with sensitivity suitable for oncology applications
- Entered into agreement to be acquired by a Korean Consortium for $34.00 per share, which is expected to close before the end of calendar year 2022
**Fourth Quarter Fiscal 2022 Results (Comparison to Fourth Quarter Fiscal 2021)** Consolidated net revenues for the fourth quarter of fiscal 2022 decreased 14% to $65.7 million, compared to $76.2 million last year. Diagnostics segment net revenues increased 14% year-over-year, while Life Science segment net revenues decreased 37%. Growth in the Diagnostics segment was driven by our non-molecular assay products which increased 22%. Key contributors to the non-molecular assay year-over-year increase include organic growth in our BreathID® product line, the addition of the BreathTek® product line acquired in July 2021 and the increase in sales of LeadCare® products that were not shipping for a portion of the fourth quarter of fiscal 2021 due to a product recall. The Life Science segment decline was driven by lower overall demand, primarily from reductions in COVID-19 testing, though more so for molecular reagents (53% decrease) than immunological reagents (8% decrease).
Reported consolidated operating income for the fourth quarter of fiscal 2022 was $4.6 million (7% margin), compared to $8.5 million (11% margin) in the fourth quarter of fiscal 2021. The decrease in consolidated operating income primarily results from the decreased level of net revenues and gross margins within the Life Science segment, which resulted from the overall decline in COVID-19 related net revenues and the significant shift in product mix from the high margin molecular reagents to lower margin immunological reagents (approximately 46% molecular in fiscal 2022 versus approximately 63% in 2021). The effect of these factors was partially offset by the decrease in overall operating expense, most notably due to the $5.6 million of product recall costs in fiscal 2021. On an adjusted basis, consolidated operating income was $9.1 million, reflecting a margin of 14%, down from the prior year quarter’s $13.3 million and 17% margin (see non-GAAP financial measure reconciliation below), reflecting the factors noted above.
**Full Fiscal Year 2022 Results (Comparison to Full Year Fiscal 2021)** Consolidated net revenues for the fiscal year ended September 30, 2022 increased 5% to $333.0 million, compared to $317.9 million in fiscal 2021. Diagnostics segment net revenues were up 22%, while Life Science segment net revenues were down 7%. Our Diagnostics segment experienced a 5% decrease in net revenues from our molecular products, and net revenues from our non-molecular assay products increased 27%, significantly impacted by the current year contributions of the BreathTek product line acquired in July 2021, as well as organic growth of our BreathID products. The Life Science segment experienced a significant shift in net revenues product mix from molecular reagents (30% decrease) to immunological products (43% increase). This shift resulted from lower overall demand for our molecular reagents in fiscal 2022, particularly the second half of the year, relative to the strong demand experienced in fiscal 2021 driven largely by reductions in COVID-19 testing, as well as the shift from molecular testing to rapid antigen testing.
Reported consolidated operating income for the fiscal year ended September 30, 2022 was $54.4 million (16% margin), compared to $93.0 million (29% margin) in fiscal 2021. The decrease in consolidated operating income reflects the impact of decreased level of net revenues and gross margins within the Life Science segment, which resulted from the overall decline in COVID-19 related net revenues and the significant shift in product mix mentioned above (approximately 52% molecular in fiscal 2022 versus approximately 69% in 2021), and increased operating expenses. The increase in operating expenses primarily results from: (i) a $10.0 million estimated expense related to the possible resolution of the previously disclosed and ongoing U.S. Department of Justice legal matter; (ii) higher acquisition and transaction related expenses in connection with the definitive merger agreement signed in July 2022; (iii) increased selling and marketing costs in both the Diagnostics and Life Science segments, due, in part, to filling certain open positions and easing of COVID-19 related travel and meeting restrictions; and (iv) increased general and administrative costs due, in part, to increased incentive compensation expenses and increased intangible amortization resulting from the July 2021 BreathTek acquisition. The effect of these factors was partially offset by a decrease in product recall expenses during fiscal 2022, following the recording of a $5.6 million LeadCare product recall reserve recorded in fiscal 2021. On an adjusted basis, consolidated operating income was $76.0 million, reflecting a margin of 23%, down from the prior year quarter’s $95.3 million and 30% margin (see non-GAAP financial measure reconciliation below), reflecting the factors noted above.
Jack Kenny, Chief Executive Officer, commented, “Meridian delivered strong financial performance for the third straight year, yet again exceeding our expectations going into the year. Our Diagnostics and Life Science segments both performed well, generating positive Operating Income, and I am excited for the future prospects of both businesses.”
**Financial Condition** In fiscal year 2022, the Company generated Cash from Operations of $82.4 million, a 23% increase from $66.9 million in fiscal 2021. This contributed to a cash and cash equivalents balance of $81.5 million at September 30, 2022. The Company’s obligations under its commercial bank credit facility totaled $25.0 million as of September 30, 2022, leaving $175.0 million of available borrowing capacity under the facility.
Andy Kitzmiller, Chief Financial Officer, commented, “Meridian continued its track record of significant cash generation, even on lower operating profit, through its focus on the efficiency of the cash conversion cycle throughout the year. Our strong balance sheet and operating fundamentals position the Company well as we navigate the current macroeconomic uncertainty and establish a new baseline for the Life Science segment in the endemic phase of the COVID-19 pandemic.”
**Subsequent Event** On October 26, 2022, Meridian acquired select assets from Estel Biosciences, Inc., as part of Meridian’s continued investment in its immunological research and development capabilities. Among other assets, the Company acquired intellectual property that will be incorporated into the Life Science operations in North Brunswick, New Jersey and Memphis, Tennessee for the design and manufacture of recombinant proteins using an insect cell expression system.
**Update on the Pending Transaction, Fiscal 2023 Guidance, and Conference Call** As announced on July 7, 2022, the Company entered into a definitive merger agreement (the “Merger Agreement”) whereby a newly formed affiliate vehicle of a Consortium, consisting of SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”), will acquire Meridian (the “Merger”). The closing of the transaction is subject to receipt of required regulatory approvals, the absence of specified material adverse outcomes of the Company’s previously disclosed and ongoing investigation by the U.S. Department of Justice, and other customary closing conditions.
On October 10, 2022, Meridian held a special meeting of its shareholders, at which the Company’s shareholders approved the transaction. As of November 22, 2022, Meridian or the appropriate parties to the Merger Agreement have obtained approval or clearances, as applicable, for all relevant antitrust and foreign direct investment filings, including the filing related to the Committee on Foreign Investment in the United States (“CFIUS”) which was obtained on November 21, 2022. Meridian has not yet reached a resolution with the DOJ with respect to the DOJ legal matter; Meridian continues to actively work with the DOJ to find a resolution to the DOJ legal matter.
As of November 22, 2022, Meridian continues to expect to complete the Merger before the end of calendar year 2022.
Due to the pending transaction, Meridian is no longer holding conference calls to discuss its quarterly financial results and has issued no financial guidance for fiscal year 2023.
**FOURTH QUARTER AND FISCAL 2022 OPERATING RESULTS**
(In Thousands, Except per Share Data)
The following table sets forth the comparative results of Meridian on a U.S. GAAP basis for the interim and
annual periods of fiscal 2022 and fiscal 2021.
(Unaudited)
Three Months Ended
Twelve Months Ended
September 30,
September 30,
2022
2021
2022
2021
Net revenues
$
65,675
$
76,204
$
333,018
$
317,896
Cost of sales
31,683
31,487
144,662
116,748
Gross profit
33,992
44,717
188,356
201,148
Operating expenses
Research and development
6,407
6,112
24,335
23,911
Selling and marketing
7,840
7,010
31,273
26,780
General and administrative
10,982
12,714
57,148
49,541
Product recall costs (adjustment)
(350)
5,596
(350)
5,596
Acquisition and transaction related costs
2,645
92
6,940
392
Litigation and select legal costs
909
108
13,510
2,803
Restructuring costs
911
–
1,109
–
Change in fair value of acquisition
consideration and settlement
–
4,596
–
(909)
Total operating expenses
29,344
36,228
133,965
108,114
Operating income
4,648
8,489
54,391
93,034
Other income (expense), net
(15)
(633)
(74)
(2,583)
Earnings before income taxes
4,633
7,856
54,317
90,451
Income tax provision (benefit)
(1,072)
1,199
11,858
19,044
Net earnings
$
5,705
$
6,657
$
42,459
$
71,407
Net earnings per basic common share
$
0.13
$
0.15
$
0.97
$
1.65
Basic common shares outstanding
43,749
43,356
43,583
43,259
Net earnings per diluted common share
$
0.13
$
0.15
$
0.96
$
1.62
Diluted common shares outstanding
44,732
44,094
44,375
44,012
**Adjusted Financial Measures** (in thousands, except per share data)
(see non-GAAP financial measure reconciliation below)
Three Months Ended
Twelve Months Ended
September 30,
September 30,
2022
2021
2022
2021
Adjusted operating income
$
9,113
$
13,285
$
75,950
$
95,320
Adjusted net earnings
9,090
10,258
61,172
73,123
Adjusted net earnings per diluted
common share
$
0.20
$
0.23
$
1.38
$
1.66
**Condensed Consolidated Balance Sheet Data** (in thousands)
September 30,
2022
2021
Cash and equivalents
$
81,453
$
49,771
Working capital
152,646
145,650
Long-term debt
25,000
60,000
Shareholders’ equity
368,061
328,302
Total assets
463,097
449,722
**Segment Data**
The following table sets forth the revenue and segment data for the interim and annual periods in fiscal 2022
and fiscal 2021 (in thousands).
(Unaudited)
Three Months Ended
Twelve Months Ended
September 30,
September 30,
2022
2021
2022
2021
Net Revenues – By Product Platform/Type
Diagnostics
Molecular assays
$
4,138
$
5,671
$
18,177
$
19,037
Non-molecular assays
35,049
28,630
137,726
108,723
Total Diagnostics
39,187
34,301
155,903
127,760
Life Science
Molecular reagents
12,285
26,399
91,816
130,537
Immunological reagents
14,203
15,504
85,299
59,599
Total Life Science
26,488
41,903
177,115
190,136
Total Net Revenues
$
65,675
$
76,204
$
333,018
$
317,896
(Unaudited)
Three Months Ended
Twelve Months Ended
September 30,
September 30,
2022
2021
2022
2021
Net Revenues – By Disease State/Geography
Diagnostics
Gastrointestinal assays
$
22,864
$
19,838
$
87,568
$
68,890
Respiratory illness assays
5,273
5,375
26,632
17,608
Blood chemistry assays
4,430
2,391
14,189
15,398
Other
6,620
6,697
27,514
25,864
Total Diagnostics
39,187
34,301
155,903
127,760
Life Science
Americas
7,465
6,356
33,062
46,063
EMEA
10,982
23,965
81,305
93,655
ROW
8,041
11,582
62,748
50,418
Total Life Science
26,488
41,903
177,115
190,136
Total Net Revenues
$
65,675
$
76,204
$
333,018
$
317,896
OPERATING INCOME (LOSS)
Diagnostics
$
(122)
$
(11,680)
$
2,982
$
(7,280)
Life Science
10,064
23,182
86,040
115,014
Corporate
(5,300)
(3,034)
(34,707)
(14,788)
Eliminations
6
21
76
88
Total Operating Income
$
4,648
$
8,489
$
54,391
$
93,034
Geographic Regions
Americas = North and Latin America
EMEA = Europe, Middle East and Africa
ROW = Rest of World
**NON-GAAP FINANCIAL MEASURES**
In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of acquisition and transaction related costs, litigation and select legal costs, and changes in fair value of acquisition consideration, each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three- and twelve-month periods ended September 30, 2022 and 2021.
We believe this information is useful to an investor in evaluating our performance because:
1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.
**FOURTH QUARTER AND FISCAL YEAR**
**GAAP TO NON-GAAP RECONCILIATION TABLES**
(In Thousands, Except per Share Data)
Three Months
Twelve Months
Ended September 30,
Ended September 30,
2022
2021
2022
2021
Operating Expenses –
GAAP basis
$
29,344
$
36,228
$
133,965
$
108,114
Acquisition and transaction related costs
(2,645)
(92)
(6,940)
(392)
Litigation and select legal costs
(909)
(108)
(13,510)
(2,803)
Restructuring costs
(911)
–
(1,109)
–
Change in fair value of acquisition
consideration and settlement
–
(4,596)
–
909
Adjusted Operating Expenses
$
24,879
$
31,432
$
112,406
$
105,828
Operating Income –
GAAP basis
$
4,648
$
8,489
$
54,391
$
93,034
Acquisition and transaction related costs
2,645
92
6,940
392
Litigation and select legal costs
909
108
13,510
2,803
Restructuring costs
911
–
1,109
–
Change in fair value of acquisition
consideration and settlement
–
4,596
–
(909)
Adjusted Operating Income
$
9,113
$
13,285
$
75,950
$
95,320
Net Earnings –
GAAP basis
$
5,705
$
6,657
$
42,459
$
71,407
Acquisition and transaction related costs \*
1,986
69
5,212
294
Litigation and select legal costs \*
683
81
12,636
2,105
Restructuring costs \*
716
–
865
–
Change in fair value of acquisition
consideration and settlement \*
–
3,451
–
(683)
Adjusted Net Earnings
$
9,090
$
10,258
$
61,172
$
73,123
Basic Earnings per Common Share –
GAAP basis
$
0.13
$
0.15
$
0.97
$
1.65
Acquisition and transaction related costs
0.05
–
0.12
0.01
Litigation and select legal costs
0.02
–
0.29
0.05
Restructuring costs
0.02
–
0.02
–
Change in fair value of acquisition
consideration and settlement
–
0.08
–
(0.02)
Adjusted Basic EPS \*\*
$
0.21
$
0.24
$
1.40
$
1.69
Three Months
Twelve Months
Ended September 30,
Ended September 30,
2022
2021
2022
2021
Diluted Earnings per Common Share –
GAAP basis
$
0.13
$
0.15
$
0.96
$
1.62
Acquisition and transaction related costs
0.04
–
0.12
0.01
Litigation and select legal costs
0.02
–
0.28
0.05
Restructuring costs
0.02
–
0.02
–
Change in fair value of acquisition
consideration and settlement
–
0.08
–
(0.02)
Adjusted Diluted EPS \*\*\*
$
0.20
$
0.23
$
1.38
$
1.66
\*
Net of tax, as applicable.
\*\*
Three months ended September 30, 2022 and 2021 do not sum to total due to rounding.
\*\*\*
Three months ended September 30, 2022 does not sum to total due to rounding.
REVOGENE® SARS-COV-2 ASSAY DISCLAIMER
The Revogene® SARS-CoV-2 product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can”, “guidance” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. (“Meridian” or “the Company”) expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company’s customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, and in complying with the ongoing investigation of the Department of Justice described in Meridian’s reports filed with the SEC, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian’s results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to the proposed acquisition by SD Biosensor, Inc., as well as disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions. In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company’s filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company’s most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company’s forward-looking statements.
**About Meridian Bioscience, Inc.** Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://www.meridianbioscience.com/).
**Contact:**
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com?subject=FY22%20Q4%20Earnings%20Release)
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
### [Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction](https://www.meridianbioscience.com/press-release/meridian-bioscience-inc-enters-into-agreement-to-be-acquired-by-sd-biosensor-and-sjl-partners-in-1-53-billion-all-cash-transaction/)
**Published:** July 8, 2022
**Author:** hamza
**Content:**
*Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value*
*Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners*
CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: [VIVO](https://www.prnewswire.com/news-releases/meridian-bioscience-inc-enters-into-agreement-to-be-acquired-by-sd-biosensor-and-sjl-partners-in-1-53-billion-all-cash-transaction-301582745.html#financial-modal)), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”) announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.
Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian’s closing stock price on the day before the Consortium’s first offer before the market open on March 18, 2022 (closing price on March 17, 2022 was $25.67) and a premium of 16% based on the one-month average price per share of common stock commencing June 7, 2022.
John C. McIlwraith, Meridian’s Chairman, said, “This announcement follows an extensive and deliberate review of Meridian’s growth and value creation opportunities in the context of the broader macroeconomic and industry environment. In consultation with external financial advisors and following outreach to potential strategic and financial partners, the Board unanimously agreed that this transaction represents the best path forward for Meridian shareholders, providing them with immediate, compelling and certain value, while enabling the Company to benefit from SDB’s and SJL’s capital support, expertise and experience.”
“We are excited to announce this new chapter for Meridian after the many years spent transforming the Company for sustainable growth,” commented Jack Kenny, Meridian’s Chief Executive Officer. “In addition to delivering immediate and significant value to our shareholders, we believe the transaction will enhance our ability to serve customers as we navigate the decline in COVID-19 testing demand and develop new products with the benefit of SDB’s industry expertise and complementary offerings. Current and prospective employees around the world will also benefit from an even stronger Meridian supported by SDB’s and SJL’s financial backing and experience. I look forward to working with SDB and SJL and the rest of our Meridian team to build long-term strength and drive further growth in the diagnostics space.”
Dr. Young Shik Cho, Chairman of SDB, representing the Consortium said, “We are pleased to be a family with Meridian Bioscience as a great partner for accelerating our entry into the U.S. IVD market. I believe that SD Biosensor’s R&D capabilities and mass production know-how, Meridian Bioscience’s U.S. distribution network and expertise in the regulated U.S. market, and SJL Partners’ strong management expertise will enable compelling synergies.”
Steve Sukjung Lim, Chairman and Managing Partner of SJL, said, “We are eager to begin this partnership with the Meridian team. The combination of Meridian’s product commercialization team with deep expertise in the regulated U.S. market, SDB’s broad product portfolio and scale manufacturing expertise, and SJL’s execution experience and partnership model will further position the Company for long-term success.”
**TRANSACTION DETAILS**
Completion of the transaction is not contingent on any financing condition. SDB, which is obligated to ensure that the Consortium funds the acquisition, will do so, together with SJL, through a combination of cash on hand and additional financing capacity, leveraging its strong balance sheet. Under the terms of the merger agreement, which has been unanimously approved by the boards of directors of Meridian and SDB, and the investment committee of SJL, the newly formed vehicle will acquire 100% of the outstanding shares of the Company. The transaction is subject to approval by Meridian shareholders, receipt of required regulatory approvals, the absence of specified materially adverse outcomes of Meridian’s previously disclosed and ongoing investigation by the U.S. Department of Justice, and other customary closing conditions. The transaction is expected to close in the fourth calendar quarter of 2022. Upon completion of the transaction, it is expected that SDB will own approximately 60% and SJL will own approximately 40% of Meridian. Meridian will no longer be traded or listed on any public securities exchange.
The Consortium intends to operate Meridian as an independent entity following the completion of the transaction and the Company’s leadership team and headquarters are expected to remain in place.
**MERIDIAN THIRD QUARTER FISCAL 2022 RESULTS UPDATE**
This morning, Meridian separately announced preliminary results for the third quarter of fiscal 2022. Full financial results for the third quarter of fiscal 2022 will be released before the market opens on August 5, 2022. In light of the transaction with the Consortium, the Company will not host a conference call to discuss fiscal third quarter earnings.
**ADVISORS**
Rothschild & Co is serving as exclusive financial advisor and Jones Day and Keating Muething & Klekamp PLL are serving as legal counsel to Meridian.
Piper Sandler & Co. is serving as exclusive financial advisor and Paul Hastings LLP is serving as legal counsel to the Consortium.
**FORWARD-LOOKING STATEMENTS**
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) economic or other conditions in the markets in which Meridian Bioscience, Inc. (the “Company”) operates, including as a result of the COVID-19 pandemic or the Russia-Ukraine conflict; (2) the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could reduce anticipated benefits or cause the parties to abandon the proposed transaction; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into pursuant to the proposed transaction; (4) the possibility that the Company’s shareholders may not approve the proposed transaction; (5) the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; (6) risks related to disruption of the Company’s management time from ongoing business operations due to the proposed transaction; (7) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock; (8) the risk of any unexpected costs or expenses resulting from the proposed transaction or the delay thereof; (9) the risk that the outcome of any legal proceedings related to the transaction could be material to the Company or detrimental to the proposed transaction; (10) the risk that Company may be adversely affected by other economic, business, or competitive factors; (11) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; and (12) the announcement of the transaction on the ability of the Company to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company does business, or on the Company’s operating results and business generally. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
Additional factors that may affect the future results of the Company are set forth in its filings with the Securities and Exchange Commission (the “SEC”), including the Company’s most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the Company’s website at [www.investor.meridianbioscience.com](https://www.investor.meridianbioscience.com/) and the SEC’s website at [www.sec.gov](https://www.sec.gov/), specifically under the heading “Risk Factors”. The risks and uncertainties described above and in the Company’s most recent Quarterly Report on Form 10-Q are not exclusive and further information concerning the Company and its businesses, including factors that potentially could materially affect its businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that the Company files from time to time with the SEC. The forward-looking statements in these materials speak only as of the date of these materials. Except as required by law, the Company assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
**ADDITIONAL INFORMATION AND WHERE TO FIND IT**
In connection with the proposed transaction, the Company intends to file relevant information with the SEC, including a proxy statement on Schedule 14A. This communication is not a substitute for the Proxy Statement or for any other document that the Company may file with the SEC and send to its shareholders in connection with the proposed transaction. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement to each shareholder entitled to vote at the special meeting relating to the transaction. THE COMPANY’S SHAREHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND THE PARTIES TO THE TRANSACTION. The definitive proxy statement, the preliminary proxy statement, other relevant materials in connection with the transaction (when they become available) and any other documents filed by the Company with the SEC, may be obtained free of charge at the Company’s website ([www.investor.meridianbioscience.com](https://www.investor.meridianbioscience.com/)) or the SEC’s website ([www.sec.gov](https://www.sec.gov/)). These documents may also be obtained free of charge from the Company by requesting them by mail at 3471 River Hills Drive, Cincinnati, OH 45244, Attention: Charlie Wood, Vice President – Investor Relations, or by email at .
**PARTICIPANTS IN THE SOLICITATION**
The Company and its directors and executive officers may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s shareholders in connection with the transaction. You may obtain information about the Company’s executive officers and directors in the Company’s definitive proxy statement for its 2022 annual meeting of shareholders, which was filed with the SEC on December 15, 2021. To the extent holdings of such participants in the Company’s securities are not reported, or have changed since the amounts described in the proxy statement for the 2022 annual meeting of shareholders, such changes have been reflected on the Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. These documents may be obtained free of charge at the Company’s website ([www.investor.meridianbioscience.com](https://www.investor.meridianbioscience.com/)) or the SEC’s website ([www.sec.gov](https://www.sec.gov/)). Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available.
**About SJL Partners**
SJL is a Korea-based private equity investment manager uniquely focused on cross-border partnership investments with market-leading strategic companies to support their inorganic growth in international markets. SJL’s portfolio includes investments into Momentive Performance Materials, a U.S.-based global leader in specialty silicones and silicone derivatives, Momentive Technologies, a leader in fused quartz and ceramic solutions, and Nexeon, a U.K.-based technology leader in anode materials for rechargeable batteries. Additional information is available at [www.sjlpartners.com](https://c212.net/c/link/?t=0&l=en&o=3587938-3&h=4283175555&u=http%3A%2F%2Fwww.sjlpartners.com%2F&a=www.sjlpartners.com).
**About SD Biosensor, Inc.**
SD Biosensor, Inc. is a global in-vitro diagnostics company that contributes to improving quality of life by quickly and accurately diagnosing diseases under the slogan ‘Beginning of all things that protect lives.’ SD Biosensor is a Total Solution Provider in the IVD industry, developing and researching innovative diagnostic platforms. From screening tests that general user can easily purchase and diagnose(use) oneself, such as BGMS and COVID-19 home test kits, to confirmatory tests that can check diseases qualitatively and quantitatively through medical staffs like PCR tests, SD Biosensor has a diverse products portfolio of its full line-up. For further information, refer to the official website.
[https://www.sdbiosensor.com/](https://c212.net/c/link/?t=0&l=en&o=3587938-3&h=2995920245&u=https%3A%2F%2Fwww.sdbiosensor.com%2F&a=https%3A%2F%2Fwww.sdbiosensor.com%2F)
**About Meridian Bioscience, Inc.**
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is [www.meridianbioscience.com](https://c212.net/c/link/?t=0&l=en&o=3587938-3&h=2833298047&u=http%3A%2F%2Fwww.meridianbioscience.com%2F&a=www.meridianbioscience.com).
**Investor Contact:** Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email:
**Media Contact:** Bryan Locke / Monique Sidhom
FGS Global
Email:
SOURCE Meridian Bioscience, Inc.
**Categories:** Press Release
---
## Pages
### [Integrated Diagnostic & Life Science Solutions - Meridian Bioscience - Home](https://www.meridianbioscience.com/)
**Published:** January 22, 2025
**Author:** hamza
**Content:**
###### Life Discovered.
# Life Science
Leading manufacturer of molecular and immunological reagents for diagnostic applications.
[ Explore Life Science ](https://www.meridianbioscience.com/lifescience/)
###### Life Diagnosed.
# Diagnostics
Best-in-class diagnostic platforms, tests, education, and support to help you deliver answers.
[ Explore Diagnostics ](https://www.meridianbioscience.com/diagnostics/)
#### Breaking News!
#### [Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows](/press-release/meridian-bioscience-and-4bases-announce-collaboration-to-enable-rapid-globally-scalable-next-generation-sequencing-workflows/)
[ Read More ](/press-release/meridian-bioscience-and-4bases-announce-collaboration-to-enable-rapid-globally-scalable-next-generation-sequencing-workflows/)
#### Breaking News!
#### [Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay](/press-release/meridian-bioscience-announces-health-canada-license-for-alethia-cmv-assay/)
[ Read More ](/press-release/meridian-bioscience-announces-health-canada-license-for-alethia-cmv-assay/)
### People. Purpose. Progress.
We believe that genuine connections are what make us human. The opportunity to support authentic relationships is what motivates our teams to create accurate solutions that span the range from discovery to diagnosis. We work hard every day to build genuine connections with all of our customers because even in the complex world of healthcare, the solution is simple. We’re here to help people, and we can only do that together.
[ Learn More About Us ](https://www.meridianbioscience.com/about)
### Meridian is a company of collaborators. advocates. thinkers. optimists.
[ Join Our Team ](/careers/)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [AssayProven™ Validated Reagents for your Immunoassay](https://www.meridianbioscience.com/lifescience/assayproven-immunoassay-reagents/)
**Published:** July 7, 2026
**Author:** Hamza Shahzad
**Content:**
## AssayProven™
#### A curated portfolio designed for assay development
###### Start stronger. Develop faster. Build with greater assay confidence.
Assay development often starts with uncertainty. Teams can spend valuable time screening reagent combinations, troubleshooting unexpected performance issues, and generating characterization data before moving forward.
AssayProven™ Validated Reagents help change that starting point. With matched assay components, development-ready performance data, and platform-relevant validation, AssayProven™ helps reduce technical risk, simplify reagent selection, and support a faster path from evaluation to assay optimization.
# AssayProven™ Validated Reagents for your Immunoassay
- Molecular point-of-care testing (qPCR, isothermal amplification, and next-generation sequencing)
- Ambient-stable reagent chemistries (lyophilization, cold-chain free)
- Infectious disease diagnostics
- Decentralized testing & rapid assay development
- Scalability in resource-limited or near-patient settings
**Register Now!** Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
**Speaker:**
William , R&D Team Leader at Meridian Life Science
William is an R&D Team Leader at Meridian Life Science. He earned his PhD in molecular microbiology in 2019, investigating C. difficile pathogenesis at Royal Holloway, University of London, UK. Subsequently, he held the position of Senior Scientist at Sporegen Ltd, leading diverse research projects rooted in recombinant spore technology. With more than 8 years of expertise in developing molecular assays for clinical use, William is a vital asset within Meridian’s R&D team. His role involves spearheading the creation of cutting-edge molecular products for the global diagnostic industry.
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [Diagnostics](https://www.meridianbioscience.com/diagnostics/)
**Published:** February 20, 2025
**Author:** hamza
**Content:**
# Diagnostics Solutions
Meridian Bioscience provides best-in-class diagnostic platforms, tests, education, and support to help you deliver answers.
#### [ Which disease do you need to test for?](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU2OTM5IiwidG9nZ2xlIjpmYWxzZX0%3D)
#### Limited Time Offer!
#### [Stay Ahead of Respiratory Season with StatID PRO™
Buy 4 Kits, Get 1 FREE.](/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
[ Learn More ](/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Fast, reliable answers when every minute matters
## StatID PRO™ COVID-19/Flu A&B
StatID PRO COVID-19/Flu A&B combo rapid test delivers quick, reliable results for COVID-19, influenza A,
and influenza B from a simple anterior nasal swab. FDA-cleared for use in patients 2 years and older, the test
is designed for use within the first five days of symptoms. This easy-to-use rapid assay helps healthcare
providers quickly differentiate between common respiratory infections with similar presentations.
[ Learn More ](/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## [Molecular Testing Platforms](/diagnostics/platforms/solutions/molecular/)
[](https://www.meridianbioscience.com/diagnostics/platforms/molecular/revogene/)### Revogene ®
###### Molecular Testing Platform
Revogene® is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. It’s a flexible platform that is built to grow with you.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/molecular/alethia/)### Alethia®
###### Molecular Testing Platform
Alethia is an affordable LAMP (loop-mediated isothermal amplification) based molecular platform that can generate between 1 and 10 qualitative results in less than 1 hour. Alethia’s flexibility makes it adaptable to almost any workflow.
Learn More
## [Urea Breath Testing Platforms](/diagnostics/platforms/solutions/urea-breath/)
[](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-lab/)### BreathID® Hp Lab
###### Urea Breath Testing Platform
The BreathID® Hp Lab urea breath testing system detects *H. pylori* and confirms eradication for healthcare providers with large patient testing volumes.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-smart/)### BreathID® Smart
###### Urea Breath Testing Platform
The BreathID® Smart urea breath testing platform detects *H. pylori* and confirms eradication for healthcare providers with mid-range patient testing volumes.
Learn More
[](/diagnostics/platforms/urea-breath/breathtek/)### BreathTek®
###### Urea Breath Testing Platform
Effective May 1, 2023, the BreathTek® product is discontinued. The supply of bags and replacement parts are only available while supplies last.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-hp/)### BreathID® Hp
###### Urea Breath Testing Platform
Effective immediately, the BreathID® Hp instrument is discontinued. The purchase of kits and consumables will continue to be available including technical support for current instruments in use.
Learn More
## [Immunoassay Testing Platforms](/diagnostics/platforms/solutions/immunoassay/)
[](/diagnostics/platforms/immunoassay/standard-q/)### Standard Q
###### Immunoassay Testing Platform
Standard Q can be used as an aid in the diagnosis of COVID-19 infection.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/curian/)### Curian®
###### Immunoassay Testing Platform
Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. See how laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care with Curian.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunocard-stat/)### Immunocard STAT®
###### Immunoassay Testing Platform
Immunocard STAT! is a one-step lateral flow immunoassay to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Several of these tests are CLIA waived. Join us as you increase your lab’s efficiencies with trusted results from Immunocard Stat.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunocard/)### Immunocard®
###### Immunoassay Testing Platform
Immunocard can help labs of any size function at their best. With Immunocard your core lab, hospital lab, or reference lab can run more efficiently and deliver accurate results to clinicians and patients. Learn how Immunocard can deliver results in 15-20 minutes.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/premier/)### Premier®
###### Immunoassay Testing Platform
Premier is a multi-step microwell based enzyme immunoassay with detachable microwells to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Learn more about Premier immunoassays from Meridian.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/serology/)### Serology
###### Immunoassay Testing Platform
Unveiling Insights Through Serology: Dive into Meridian Bioscience’s Serology solutions. With our advanced technology, we uncover a deeper understanding of immune responses, aiding in the diagnosis of various conditions. Join us in shaping a healthier future through precise and reliable serological testing.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/latex/)### Latex Agglutination
###### Immunoassay Testing Platform
Latex agglutination is a rapid latex test technology with qualitative and semi-quantitative detection to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/buhlmann/)### BÜHLMANN
###### Immunoassay Testing Platform
BÜHLMANN has launched its first assay for fecal calprotectin testing more than 10 years ago and is today considered as the gold standard. Learn more about the BÜHLMANN fCAL ELISA test for the quantitative determination of fecal calprotectin.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/liaison/)### LIAISON
###### Immunoassay Testing Platform
A chemiluminescent assay for the qualitative determination of Helicobacter pylori antigen in human stool. Test must be performed on the LIAISON® XL Analyzer.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunodiffusion/)### Immunodiffusion
###### Immunoassay Testing Platform
Immunodiffusion & Complement Fixation products, including aspergillus, histoplasma, Coccidioides, and Endo-Staph to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/merifluor/)### Merifluor®
###### Immunoassay Testing Platform
Merifluor is a direct fluorescent technology that is simple to perform and can help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Learn More
[](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/tru/)### Tru®
###### Immunoassay Testing Platform
Tru® is a rapid, easy to run vertical flow immunoassay with a unique closed system feature to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. See how Meridian’s TRU can produce results for your lab in 15-20 minutes
Learn More
## [Blood Chemistry Testing Platforms](/diagnostics/platforms/solutions/blood-chemistry/)
[](https://www.meridianbioscience.com/diagnostics/platforms/blood-chemistry/leadcare/)### LeadCare®
###### Blood Chemistry Testing Platform
Lead poisoning threatens millions of people yet is entirely preventable. Meridian is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure. Join us in preventing lead poisoning.
Learn More
### Revogene® Strep A. SARS-CoV-2 *C. difficile* GBS Carba C
Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. It’s a flexible platform that is built to grow with you.
[ Meet Revogene® ](#)
## Disease Areas
Our passion is to help providers make better diagnostic decisions with a focus on gastrointestinal, neonatal, pediatrics, and respiratory conditions.
[Gastrointestinal](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/)
[Pediatric & Neonatal](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/)
[Respiratory](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/)
[Other](https://www.meridianbioscience.com/diagnostics/disease-areas/other/)
## Distributors
Our global network is eager to answer your questions about our wide range of solutions.
[ Find your distributor ](/diagnostics/distributors/)
## News
Click below to see all the recent great Meridian news!
[ Read all about it! ](/press-release/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Proficiency and Controls](https://www.meridianbioscience.com/about/about-diagnostics/proficiency-and-controls/)
**Published:** February 20, 2025
**Author:** hamza
**Content:**
# Quality Assurance, Testing, and Education
### Microbiology Panels for Quality Assurance, Testing, and Education
The Meridian Bioscience Proficiency & Controls Business Unit (PCBU) has proven expertise in the development and manufacture of a variety of microbiological specimen panels. Maintaining a standard of excellence for more than 25 years, PCBU products help meet requirements for:
- Proficiency testing programs
- Clinical study site qualification
- Product development and manufacture
- New product market introductions and evaluations
- Instruction and training associated with staff performance evaluations and review
- Reference
- Education
Our expertise embraces:
- Virus/Bacteria Culture
- Virus/Bacteria Serology
- Molecular Detection of Infectious Agents
- Diagnostic Immunology
- Parasitology
- Autoimmune Serology
- Enzyme Immunoassay
- Microscopy.
These product formats closely simulate actual analytes encountered in clinical specimens and can be of value in helping laboratorians ensure that regulatory guidelines and compliance with medical quality system regulations are met.
### Product Development and Product Manufacturing Services
The PCBU provides product development and manufacturing services to establish the proficiency of participating clinical trial sites in the performance of laboratory analyses associated with vaccines and other biopharmaceutical products.
Our customer-focused product offerings span the spectrum of biological and non-biological materials in a variety of formats:
- Glass slides
- Dry swabs
- Liquids
- Lyophilized
### Custom Development Services
The PCBU also provides custom development and manufacturing services to meet customer specifications and labeling requirements. A dedicated customer focus combined with unparalleled experience enables the PCBU to develop specialized resources at a favorable cost
### PARA-PANEL®
PARA-PANEL® products contain parasitic organisms preserved in human blood or fecal matter. These products are intended for:
- Educational training
- Proficiency
- Reference use
There are 3 types of panels:
- Blood parasite panels, including malaria, filarial, and trypanosome parasites
- Intestinal parasite panels containing developmental stages of helminths and protozoan parasites and artifacts
- Immunoassay panels with formalin-preserved intestinal protozoan parasites
### Self Assessment Materials
Use of independent materials can be of assistance in monitoring the performance of procedures. These items serve as an aid in identifying errors, trends, and problems within procedures when they occur. External assessment materials serve as an integral component of good laboratory practices in providing a means of assisting in the monitoring of overall laboratory performance.
### BACTQUAL®
BACTQUAL® products contain sets of samples intended for self-assessment when performing laboratory procedures.
**BACTQUAL® GAS – Streptococcus Group A**
- BACTQUAL® GAS Group A Streptococcus is comprised of both Positive and Negative samples in swab format.
- Specimens are to be processed in accordance with instructions and standard procedures for handling biological specimens.
**BACTQUAL® CD – Clostridium difficile**
- BACTQUAL® CD Clostridium difficile is comprised of both positive and negative samples in liquid suspension.
- Specimens are to be processed in accordance with instructions and standard procedures for handling biological specimens.
**PARAQUAL®** PARAQUAL® products contain sets of samples intended for self-assessment when performing laboratory procedures.
PARAQUAL® FSm – Unassayed Microsporidia
- PARAQUAL® FSm – Unassayed Microsporidia is comprised of formalin-preserved fecal smear slides for qualitative determinations.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Experience It for Yourself](https://www.meridianbioscience.com/lifescience/molecular-general-sample/)
**Published:** September 16, 2025
**Author:** hamza
**Content:**
## Discover the Meridian Difference
Meridian’s molecular reagents—enzymes, dNTPs, and master mixes—are engineered for high sensitivity, inhibitor-tolerance, and seamless integration into qPCR, isothermal, and Next Generation Sequencing (NGS) workflows. Backed by decades of diagnostic expertise and global manufacturing, our reagents help streamline development while reducing cold chain challenges and supply chain risks. - **Enzymes:** Optimized for speed, sensitivity, and inhibitor resistance in high-demand molecular applications such as qPCR, LAMP, and NGS
- **dNTPs:** Ultra-pure, glycerol-free, and manufactured in bulk at our ISO 13485 German facility
- **Master Mixes:** Pre-formulated for consistency and ease of use—available in lyo-ready, air-dryable, and inhibitor-tolerant formats for multiplex, RT-qPCR, and isothermal workflows
- **Custom Services:** Tailored glycerol-free formulations and assay development support to help you transition to ambient-stable, workflow-ready solutions
---
### [About Life Science](https://www.meridianbioscience.com/lifescience/about-life-science/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
# About Meridian Life Science
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products and critical raw materials. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that redefine the possibilities of life from discovery to diagnosis.
As the Life Science division of Meridian, our focus is on supporting immunological and molecular test manufacturers with original raw materials for human, animal, plant, and environmental applications. The large portfolio of antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR and isothermal amplification applications are designed to simplify assay design and enable accurate test results.
We strive to provide our customers with solutions they need when they need them – from novel antigens and antibodies to major disease outbreaks such as Zika and SARS-CoV-2 to pioneering the market with our innovative air-dried qPCR/RT-qPCR mixes. We take pride in providing our customers with unparalleled support, customer service, and quality.
[ Explore Life Science Products ](/lifescience/products/)
## It's About Quality & Quantity
The Life Science division of Meridian Bioscience is committed at all levels of our organization to providing the highest quality immunological and molecular biology reagent solutions that deliver value to our stakeholders. Each of our facilities is certified to ISO 13485 and we operate with a high commitment to Quality with an ongoing customer focus.
[ Germany, United Kingdom
ISO13485 Certificate ](https://www.meridianbioscience.com/uploads/ISO13485-2025.pdf)
[ United States (USA)
ISO13485 Certificate ](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/22074520/Certificate-of-Registration_BSI_Expiry-2027-07-31.pdf)
### For Quality Inquiries
**Please contact the Meridian Life Science Quality Team at**
**[MLSQuality@meridianlifescience.com](mailto:mlsquality@meridianlifescience.com)**
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Contact Meridian Bioscience Corporate](https://www.meridianbioscience.com/contact-meridian-bioscience-corporate/)
**Published:** February 5, 2025
**Author:** hamza
**Content:**
# Contact Meridian Bioscience Corporate
Please complete the form below and the appropriate individual will contact you.
Please note: We may share your personal contact data with our distribution partner(s) for the sole purpose of responding and replying to your inquiry. If you do not want your information shared, please contact us directly by emailing info@meridianbioscience.com.
##### USA Headquarters
**Meridian Diagnostics & Corporate Offices**
3471 River Hills Drive
Cincinnati, OH 45244
Email: mbi@meridianbioscience.com
**Meridian Life Science**
5171 Wilfong Road
Memphis, Tennessee 38134-5611
Email: info@meridianlifescience.com
Corporate
Toll Free: 800-696-0739
Tel: +1 513-271-3700
Fax: 513-271-3702
Life Science Customer Service
Tel: +1 901-382-8716
Fax: +1 901-333-8223
Diagnostics Customer Service
Tel: 800-543-1980
Fax: +1 513-271-0124
Diagnostics Technical Services Product Support Center
Tel: 800-343-3858
##### Canada
360 Rue Franquet #3
Québec, QC G1P 4N3
Tel: +1 418-650-3535
Email: info@meridianbioscience.com
##### China
Unit A6, East Tower, 10th Floor
No. 12 B, Jianguomenwai Avenue
Chaoyang District, Beijing, China
Tel : +86 010-85660600
Email: info.cn@meridianlifescience.com
##### Germany
Im Biotechnologiepark, 3
14943 Luckenwalde
Tel: +49 (0)3371 602 2200
Fax: +49 (0)3371 602 2201
Email: info@meridianlifescience.com
##### Israel
4 Ha’maayan St.
Modiin, Israel
Tel: +972 8-973-7500
##### Italy
Via dell’ Industria, 7
20035 Villa Cortese
Milano
Tel: +39 0331 43 36 36
Fax: +39 0331 43 36 16
Email: info@meridianbioscience.eu
##### United Kingdom
Unit 16 The Edge Business Centre
Humber Road
NW2 6EW London
Tel: +44 (0)20 8453 7970
Fax: +44 (0)20 8452 2822
Email: info@meridianlifescience.com
---
### [Michelle Bosch](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/michelle-bosch/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Michelle Bosch
### Vice President, Global Commercial Marketing and Business Management
Michelle Bosch leads Meridian Bioscience’s global commercial marketing and business management functions, bringing more than 20 years of experience with the company in sales, marketing, and business strategy.
Since joining Meridian in 2003, she has advanced through roles in inside sales, product management, and marketing leadership, driving growth through innovative campaigns, product launches, and high-impact sales initiatives.
She began her career as a clinical laboratory professional and holds a Bachelor of Science in Medical Technology from Xavier University.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Pairs Table](https://www.meridianbioscience.com/lifescience/pairs-table/)
**Published:** March 14, 2025
**Author:** hamza
**Content:**
# Pairs Table
**Click on the specificity below to view tested pairs:**
[A](#letter-A)[B](#letter-B)[C](#letter-C)[D](#letter-D)[E](#letter-E)[F](#letter-F)[G](#letter-G)[H](#letter-H)[I](#letter-I)[J](#letter-J)[K](#letter-K)[L](#letter-L)[M](#letter-M)[N](#letter-N)[O](#letter-O)[P](#letter-P)[R](#letter-R)[S](#letter-S)[T](#letter-T)[V](#letter-V)[Y](#letter-Y)[Z](#letter-Z)
### A
- [AFP](https://www.meridianbioscience.com/lifescience/pairs-table/afp)
- [AMH](https://www.meridianbioscience.com/lifescience/pairs-table/amh)
- [Adenovirus](https://www.meridianbioscience.com/lifescience/pairs-table/adenovirus)
- [Adiponectin](https://www.meridianbioscience.com/lifescience/pairs-table/adiponectin)
- [Amphetamine](https://www.meridianbioscience.com/lifescience/pairs-table/amphetamine)
- [Angiostatin](https://www.meridianbioscience.com/lifescience/pairs-table/angiostatin)
- [Astrovirus](https://www.meridianbioscience.com/lifescience/pairs-table/astrovirus)
### B
- [BNP & proBNP](https://www.meridianbioscience.com/lifescience/pairs-table/bnp-probnp)
- [Barbital](https://www.meridianbioscience.com/lifescience/pairs-table/barbital)
- [Barbiturate](https://www.meridianbioscience.com/lifescience/pairs-table/barbiturate)
- [Benzodiazepine](https://www.meridianbioscience.com/lifescience/pairs-table/benzodiazepine)
- [Benzoylecgonine](https://www.meridianbioscience.com/lifescience/pairs-table/benzoylecgonine)
- [Buprenorphine](https://www.meridianbioscience.com/lifescience/pairs-table/buprenorphine)
### C
- [C. difficile](https://www.meridianbioscience.com/lifescience/pairs-table/clostridium-difficile)
- [C. jejuni](https://www.meridianbioscience.com/lifescience/pairs-table/c-jejuni)
- [CA15-3](https://www.meridianbioscience.com/lifescience/pairs-table/ca15-3)
- [CA19-9](https://www.meridianbioscience.com/lifescience/pairs-table/ca19-9)
- [CA72-4](https://www.meridianbioscience.com/lifescience/pairs-table/ca72-4)
- [CEA](https://www.meridianbioscience.com/lifescience/pairs-table/cea)
- [CK-MB](https://www.meridianbioscience.com/lifescience/pairs-table/ck-mb)
- [CK-MM](https://www.meridianbioscience.com/lifescience/pairs-table/ck-mm)
- [CRP](https://www.meridianbioscience.com/lifescience/pairs-table/crp-vet-health)
- [CRP](https://www.meridianbioscience.com/lifescience/pairs-table/crp)
- [Calcitonin](https://www.meridianbioscience.com/lifescience/pairs-table/calcitonin-hormones-steroids)
- [Calprotectin](https://www.meridianbioscience.com/lifescience/pairs-table/calprotectin)
- [Campylobacter](https://www.meridianbioscience.com/lifescience/pairs-table/campylobacter)
- [Candida albicans](https://www.meridianbioscience.com/lifescience/pairs-table/candida-albicans)
- [Canine Coronavirus](https://www.meridianbioscience.com/lifescience/pairs-table/canine-coronavirus)
- [Chlamydia trachomatis](https://www.meridianbioscience.com/lifescience/pairs-table/chlamydia-trachomatis)
- [Cholera](https://www.meridianbioscience.com/lifescience/pairs-table/cholera)
- [Clostridium botulinum](https://www.meridianbioscience.com/lifescience/pairs-table/clostridium-botulinum)
- [Cocaine](https://www.meridianbioscience.com/lifescience/pairs-table/cocaine)
- [Cotinine](https://www.meridianbioscience.com/lifescience/pairs-table/cotinine)
- [Cryptosporidium](https://www.meridianbioscience.com/lifescience/pairs-table/cryptosporidium-2)
- [Cyfra-21-1](https://www.meridianbioscience.com/lifescience/pairs-table/cyfra-21-1)
- [Cystatin C](https://www.meridianbioscience.com/lifescience/pairs-table/cystatin-c)
- [Cystatin C](https://www.meridianbioscience.com/lifescience/pairs-table/cystatin-c-vet-health)
### D
- [D-Dimer](https://www.meridianbioscience.com/lifescience/pairs-table/d-dimer)
- [Dengue](https://www.meridianbioscience.com/lifescience/pairs-table/dengue)
- [Distemper](https://www.meridianbioscience.com/lifescience/pairs-table/canine-distemper-virus)
### E
- [E. coli](https://www.meridianbioscience.com/lifescience/pairs-table/e-coli)
- [EDDP](https://www.meridianbioscience.com/lifescience/pairs-table/eddp)
- [EPSPS](https://www.meridianbioscience.com/lifescience/pairs-table/epsps)
- [Ebola](https://www.meridianbioscience.com/lifescience/pairs-table/ebola)
- [Entamoeba Dispar](https://www.meridianbioscience.com/lifescience/pairs-table/entamoeba-dispar)
- [Entamoeba histolytica](https://www.meridianbioscience.com/lifescience/pairs-table/entamoeba-histolytica)
- [Enterovirus](https://www.meridianbioscience.com/lifescience/pairs-table/enterovirus)
- [Erythropoietin](https://www.meridianbioscience.com/lifescience/pairs-table/epo)
### F
- [FABP](https://www.meridianbioscience.com/lifescience/pairs-table/fabp)
- [FSH](https://www.meridianbioscience.com/lifescience/pairs-table/follicle-stimulating-hormone-fsh)
- [FeLV](https://www.meridianbioscience.com/lifescience/pairs-table/feline-leukemia-virus-felv)
- [Ferritin](https://www.meridianbioscience.com/lifescience/pairs-table/ferritin)
- [Fibrinopeptide](https://www.meridianbioscience.com/lifescience/pairs-table/fibrinopeptide)
### G
- [GFAP](https://www.meridianbioscience.com/lifescience/pairs-table/gfap)
- [Giardia](https://www.meridianbioscience.com/lifescience/pairs-table/giardia)
### H
- [H. Pylori](https://www.meridianbioscience.com/lifescience/pairs-table/h-pylori)
- [HE4](https://www.meridianbioscience.com/lifescience/pairs-table/he4)
- [HIV](https://www.meridianbioscience.com/lifescience/pairs-table/hiv)
- [HPV](https://www.meridianbioscience.com/lifescience/pairs-table/hpv)
- [HSA](https://www.meridianbioscience.com/lifescience/pairs-table/hsa)
- [Hantaan](https://www.meridianbioscience.com/lifescience/pairs-table/hantaan)
- [Heartworm](https://www.meridianbioscience.com/lifescience/pairs-table/canine-heartworm)
- [Hemoglobin](https://www.meridianbioscience.com/lifescience/pairs-table/hemoglobin)
- [Hepatitis A](https://www.meridianbioscience.com/lifescience/pairs-table/hepatitis-a)
- [Hepatitis B](https://www.meridianbioscience.com/lifescience/pairs-table/hepatitis-b)
- [Hepatitis C](https://www.meridianbioscience.com/lifescience/pairs-table/hepatitis-c)
- [hCG](https://www.meridianbioscience.com/lifescience/pairs-table/hcg)
- [hGH](https://www.meridianbioscience.com/lifescience/pairs-table/hgh)
### I
- [IgA](https://www.meridianbioscience.com/lifescience/pairs-table/iga)
- [IgE](https://www.meridianbioscience.com/lifescience/pairs-table/ige)
- [Influenza A](https://www.meridianbioscience.com/lifescience/pairs-table/influenza-a)
- [Influenza B](https://www.meridianbioscience.com/lifescience/pairs-table/influenza-b)
- [Insulin](https://www.meridianbioscience.com/lifescience/pairs-table/insulin)
- [Interferon](https://www.meridianbioscience.com/lifescience/pairs-table/interferon-cardiac-cholesterol-metabolic-markers)
### J
- [JEV](https://www.meridianbioscience.com/lifescience/pairs-table/japanese-encephalitis-jev)
### K
- [K2](https://www.meridianbioscience.com/lifescience/pairs-table/k2)
- [Klebsiella pneumoniae Carbapenemase](https://www.meridianbioscience.com/lifescience/pairs-table/klebsiella-pneumoniae-carbapenemase)
### L
- [LH](https://www.meridianbioscience.com/lifescience/pairs-table/lh)
- [Lactoferrin](https://www.meridianbioscience.com/lifescience/pairs-table/lactoferrin)
- [Lassa](https://www.meridianbioscience.com/lifescience/pairs-table/lassa)
- [Legionella pneumophila](https://www.meridianbioscience.com/lifescience/pairs-table/legionella-pneumophila)
- [Leptospira](https://www.meridianbioscience.com/lifescience/pairs-table/leptospira)
- [Listeria](https://www.meridianbioscience.com/lifescience/pairs-table/listeria)
- [Lp-PLA2](https://www.meridianbioscience.com/lifescience/pairs-table/lp-pla2)
### M
- [MDMA](https://www.meridianbioscience.com/lifescience/pairs-table/mdma-ecstacy)
- [MERS](https://www.meridianbioscience.com/lifescience/pairs-table/mers)
- [Malaria](https://www.meridianbioscience.com/lifescience/pairs-table/malaria)
- [Methadone](https://www.meridianbioscience.com/lifescience/pairs-table/methadone)
- [Methamphetamine](https://www.meridianbioscience.com/lifescience/pairs-table/methamphetamine)
- [Monkeypox](https://www.meridianbioscience.com/lifescience/pairs-table/monkeypox)
- [Morphine](https://www.meridianbioscience.com/lifescience/pairs-table/morphine)
- [Mycobacterium tuberculosis](https://www.meridianbioscience.com/lifescience/pairs-table/mycobacterium-tuberculosis)
- [Mycoplasma genitalium](https://www.meridianbioscience.com/lifescience/pairs-table/mycoplasma-genitalium)
- [Mycoplasma pneumoniae](https://www.meridianbioscience.com/lifescience/pairs-table/mycoplasma-pneumoniae)
- [Myoglobin](https://www.meridianbioscience.com/lifescience/pairs-table/myoglobin)
### N
- [NPR](https://www.meridianbioscience.com/lifescience/pairs-table/npr)
- [NSE](https://www.meridianbioscience.com/lifescience/pairs-table/neuron-specific-enolase-nse)
- [NT-proBNP](https://www.meridianbioscience.com/lifescience/pairs-table/nt-probnp-cardiac-cholesterol-markers)
- [New Delhi metallo-beta-lactamase-1](https://www.meridianbioscience.com/lifescience/pairs-table/new-delhi-metallo-beta-lactamase)
- [Nipah](https://www.meridianbioscience.com/lifescience/pairs-table/nipah-virus)
- [Norovirus](https://www.meridianbioscience.com/lifescience/pairs-table/norovirus)
### O
- [OXA-48](https://www.meridianbioscience.com/lifescience/pairs-table/oxa-48)
- [Osteocalcin](https://www.meridianbioscience.com/lifescience/pairs-table/osteocalcin)
- [Osteopontin](https://www.meridianbioscience.com/lifescience/pairs-table/osteopontin)
- [Oxycodone](https://www.meridianbioscience.com/lifescience/pairs-table/oxycodone)
### P
- [PAPP-A](https://www.meridianbioscience.com/lifescience/pairs-table/papp-a)
- [PEDV](https://www.meridianbioscience.com/lifescience/pairs-table/porcine-epidemic-diarrhea-virus-pedv)
- [PSA](https://www.meridianbioscience.com/lifescience/pairs-table/psa)
- [Parainfluenza](https://www.meridianbioscience.com/lifescience/pairs-table/parainfluenza)
- [Parvovirus](https://www.meridianbioscience.com/lifescience/pairs-table/parvovirus)
- [Procalcitonin](https://www.meridianbioscience.com/lifescience/pairs-table/pct)
- [Prolactin](https://www.meridianbioscience.com/lifescience/pairs-table/prolactin)
### R
- [RSV](https://www.meridianbioscience.com/lifescience/pairs-table/respiratory-syncytial-virus-rsv)
- [Renin](https://www.meridianbioscience.com/lifescience/pairs-table/renin)
- [Retinol Binding Protein](https://www.meridianbioscience.com/lifescience/pairs-table/retinol-binding-protein)
- [Rotavirus](https://www.meridianbioscience.com/lifescience/pairs-table/rotavirus)
- [Rubella](https://www.meridianbioscience.com/lifescience/pairs-table/rubella)
### S
- [S-100](https://www.meridianbioscience.com/lifescience/pairs-table/s100)
- [SAA](https://www.meridianbioscience.com/lifescience/pairs-table/saa)
- [SARS](https://www.meridianbioscience.com/lifescience/pairs-table/sars)
- [SEE](https://www.meridianbioscience.com/lifescience/pairs-table/see)
- [SEG](https://www.meridianbioscience.com/lifescience/pairs-table/seg)
- [Salmonella](https://www.meridianbioscience.com/lifescience/pairs-table/salmonella)
- [Staphylococcus aureus](https://www.meridianbioscience.com/lifescience/pairs-table/staphylococcus-2)
- [Strep A](https://www.meridianbioscience.com/lifescience/pairs-table/streptococcus-group-a)
- [Streptococcus pneumoniae](https://www.meridianbioscience.com/lifescience/pairs-table/streptococcus-pneumoniae)
### T
- [T.Foetus](https://www.meridianbioscience.com/lifescience/pairs-table/trichomonas-foetus)
- [THC](https://www.meridianbioscience.com/lifescience/pairs-table/thc)
- [TNF](https://www.meridianbioscience.com/lifescience/pairs-table/tnf)
- [TPO](https://www.meridianbioscience.com/lifescience/pairs-table/tpo)
- [TSH](https://www.meridianbioscience.com/lifescience/pairs-table/tsh)
- [TSH](https://www.meridianbioscience.com/lifescience/pairs-table/tsh-2)
- [Thyroglobulin](https://www.meridianbioscience.com/lifescience/pairs-table/thyroglobulin)
- [Transferrin](https://www.meridianbioscience.com/lifescience/pairs-table/transferrin)
- [Treponema pallidum](https://www.meridianbioscience.com/lifescience/pairs-table/treponema-pallidum)
- [Trichomonas vaginalis](https://www.meridianbioscience.com/lifescience/pairs-table/trichomonas-vaginalis)
- [Troponin](https://www.meridianbioscience.com/lifescience/pairs-table/troponin)
- [Tsutsugamushi](https://www.meridianbioscience.com/lifescience/pairs-table/tsutsugamushi)
- [tPA](https://www.meridianbioscience.com/lifescience/pairs-table/tpa)
### V
- [Verona Integron Metallo-beta-lactamase](https://www.meridianbioscience.com/lifescience/pairs-table/verona-integron-metallo-beta-lactamase)
- [Vitamin D](https://www.meridianbioscience.com/lifescience/pairs-table/vitamin-d)
### Y
- [Yellow Fever](https://www.meridianbioscience.com/lifescience/pairs-table/yellow-fever)
### Z
- [Zika](https://www.meridianbioscience.com/lifescience/pairs-table/zika-virus)
---
### [Careers](https://www.meridianbioscience.com/careers/)
**Published:** February 3, 2025
**Author:** hamza
**Content:**
# Genuine Connections Are What Make Us Human.
Categories Executive Finance General Administrative Human Resources Information Technology Marketing Operations Quality & Regulatory Affairs Research and Development Sales
Location (Current Location) (Zip Code) CA-QC-Quebec IT-Villa Cortese, MI US-Remote US-FL-Boca Raton US-OH-Cincinnati US-PA-Philadelphia US-TN-Memphis
[View Openings](https://careers-meridianbioscience.icims.com/jobs/search?ss=1&searchLocation=&searchCategory=&hashed=-435711682)
### Join and Achieve Your Dreams With Us.
“The most rewarding part of my job over the past six years has been building genuine relationships with our customers. They truly look forward to hearing from us and value our service. Working within this industry presents new, exciting challenges every day and that’s what helps me stay motivated to do my best work.”
Andrea Fisher
Product Manager, Diagnostics
## Caring for Our Team
Those who care for others deserve to be cared for. See Our Benefits.
##### Total Compensation
Competitive total compensation as it compares to the Diagnostic / Life Science markets, and reward programs that help us attract, retain, and motivate a high-quality workforce.
##### Benefit Programs
Benefit programs that are competitive in the market with respect to time off, wellness, retirement planning, and career growth.
##### Base Pay
Base pay levels that are competitive with the external job market in which we compete for talent and reflect the value of each position.
##### Incentive Bonus
Incentive Bonus Programs commensurate with contribution level and driven by individual and company performance — compensation mix will vary by position.
[ View Benefits ](https://www.meridianbioscience.com/careers/benefits/)
## Our Culture
### Beware of Fraudulent Recruitment Activity
Fraudulent recruitment activity is becoming more sophisticated and may apply to a range of scenarios. Wrongdoers may feature a company’s name and logo without authority, falsely claiming that they represent the company and are interested in hiring individuals. These wrongdoers may offer fraudulent employment opportunities to individuals and often ask for sensitive personal and financial information as a part of their scheme. Meridian Bioscience condemns such fraudulent activity and takes this issue very seriously.
- **[Click to Learn more about the Meridian Candidate Application Process and How to Identify Fraudulent Recruiting](https://www.meridianbioscience.com/careers/candidate-application-process/ "Meridian Bioscience Candidate")**
### EEO Statement
All qualified applicants will receive consideration for employment without regard to race, color, sex, sexual orientation, gender identity, religion, national origin, disability, veteran status, or other legally protected status.
Meridian Bioscience, Inc. is committed to working with and providing reasonable accommodations to individuals with physical and mental disabilities. If you need special assistance or an accommodation while seeking employment, please email . We will make a determination on your request for reasonable accommodation on a case by case basis The law requires Meridian Bioscience to post a notice describing the Federal laws prohibiting job discrimination. For information regarding your legal rights and protections, please click on the following link: [Know Your Rights.](https://kairosservicesinc.com/wp-content/uploads/2022/11/22-088_EEOC_KnowYourRights.pdf)Meridian Bioscience will not discharge or in any other manner discriminate against employees or applicants because they have inquired about, discussed, or disclosed their own pay. Please see the [Pay Transparency Nondiscrimination Provision](https://kairosservicesinc.com/wp-content/uploads/2019/08/PayTransparencyPoster.pdf) for more information. As a federal contractor, Meridian Bioscience is required to participate in the E-Verify Program to confirm eligibility to work in the United States. For information, please click the following link: [E-Verify.](https://kairosservicesinc.com/wp-content/uploads/2019/08/EVerifyParticipationPoster.pdf)
## Join Our Team
[ View Openings ](https://careers-meridianbioscience.icims.com/jobs/search?ss=1&searchLocation=&searchCategory=&hashed=-435711682)
---
### [Leadership Team](https://www.meridianbioscience.com/about/leadership-team/)
**Published:** February 3, 2025
**Author:** hamza
**Content:**
# Corporate Officers
Meridian’s global leadership team is composed of visionary professionals dedicated to advancing human health through innovation and integrity. By fostering a collaborative corporate culture, they bridge the gap between scientific discovery and commercial success. Their commitment to operational excellence ensures that every strategic decision enhances global healthcare accessibility and reliability.
## Our Team
[  ](/about/leadership-team/andy-kitzmiller/)
### Andy Kitzmiller
President and Chief Executive Officer
[ Read Bio ](/about/leadership-team/andy-kitzmiller/)
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/about/leadership-team/julie-smith/)
### Julie Smith
Senior Vice President and Chief Financial Officer
[ Read Bio ](/about/leadership-team/julie-smith/)
[  ](/about/leadership-team/emerson-c-moser/)
### Emerson C. Moser
Senior Vice President and General Counsel
[ Read Bio ](/about/leadership-team/emerson-c-moser/)
[  ](/about/leadership-team/don-oliver/)
### Don Oliver
Senior Director of Global Information Technology
[ Read Bio ](/about/leadership-team/don-oliver/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [Customer Support](https://www.meridianbioscience.com/customer-support/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
# Customer Support
[ Need information about reagents & antibodies?
Contact our Life Science Division ](https://www.meridianbioscience.com/contact-us-life-science/)
[ Need Information about diagnostic assays and platforms?
Contact our Diagnostics Division ](https://www.meridianbioscience.com/contact-us-diagnostics/)
---
### [Rob Stewart](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/rob-stewart/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Rob Stewart
### Senior Vice President, Global Sales and Support
Rob Stewart leads Meridian Bioscience’s global sales and customer support operations, bringing over 20 years of experience in healthcare diagnostics and medical technology.
Since joining Meridian in 2019, he has driven worldwide growth through innovative sales strategies, operational excellence, and strong client partnerships.
Prior to Meridian, Rob held senior roles at McKesson Medical-Surgical, Siemens Healthineers, and Quest Diagnostics.
He holds a Bachelor of Science in Business Administration in Marketing from the University of Arkansas.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Past Events](https://www.meridianbioscience.com/lifescience/past-events/)
**Published:** August 7, 2025
**Author:** hamza
**Content:**
### Events & Tradeshows
[ Upcoming Events ](/lifescience/events/)
[Home](https://www.meridianbioscience.com "Home")» [Life Science](https://www.meridianbioscience.com/lifescience/ "Life Science")» Past Events
[  ](https://www.meridianbioscience.com/lifescience/events/i-mdx-molecular-diagnostics-industry-conference-and-exhibition-2026/)
#### [I-MDX (Molecular Diagnostics Industry Conference and Exhibition)](https://www.meridianbioscience.com/lifescience/events/i-mdx-molecular-diagnostics-industry-conference-and-exhibition-2026/)
Wuhan Crown Plaza, Wuhan, China
Join us at I-MDx 2026, the 8th Annual Molecular Diagnostics Industry Conference and Exhibition. This conference is hosted by Shanghai Truesaw Business Consulting Co., Ltd. and focuses on advancements and innovations in the molecular diagnostics industry. Attendees can expect insightful discussions, networking opportunities, and exhibitions showcasing the latest developments in molecular diagnostics.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/i-mdx-molecular-diagnostics-industry-conference-and-exhibition-2026/)
02 — 03 July 2026
[  ](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2026/)
#### [European Society of Human Genetics Conference (ESHG) 2026](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2026/)
Svenska Mässan, Gothenburg, Sweden
Booth #462
Join us at booth #462 at the European Society of Human Genetics (ESHG) Conference which gathers the world’s leading geneticists, genetics researchers and biotechnology companies to collaborate and discuss the latest cutting-edge advancements in human genetics and genomics. The scientific program features top speakers, symposia, oral presentations, poster presentations and a series of educational sessions.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2026/)
13 — 16 June 2026
[Schedule a Meeting](https://share.hsforms.com/18wXoD8lkSKSaiVm6rCR3ZAc22yq)
[  ](https://www.meridianbioscience.com/lifescience/events/diagmand-ivd-innovation-development-and-upstream-solutions-conference-26/)
#### [Diagmand (IVD Innovation Development and Upstream Solutions Conference)](https://www.meridianbioscience.com/lifescience/events/diagmand-ivd-innovation-development-and-upstream-solutions-conference-26/)
Suzhou Shishan Conference Center, Suzhou, China
The Diagnostics and Manufacturing (Diagmand) Conference is an upcoming event focused on innovations and developments in the in vitro diagnostics (IVD) industry. Scheduled to feature over 80 exhibitors and attract more than 2,500 professionals, the conference will present over 200 topics across various forums. Key areas of discussion include biochemical immunodiagnostics, molecular diagnostics, sequencing technology, automation innovation, microbial diagnostics, and hemagglutination diagnostics. The event aims to bring together leading upstream brands in immunodiagnosis, molecular diagnosis, and molecular point-of-care testing.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/diagmand-ivd-innovation-development-and-upstream-solutions-conference-26/)
29 — 30 May 2026
[  ](https://www.meridianbioscience.com/lifescience/events/immunology-2026/)
#### [IMMUNOLOGY 2026](https://www.meridianbioscience.com/lifescience/events/immunology-2026/)
Thomas M. Menino Convention & Exhibition Center (MCEC), Boston, Massachusetts
Booth #620
Join us at IMMUNOLOGY 2026 at Booth #620, the world’s largest annual all-immunology meeting, bringing together more than 3,500 scientists from over 40 countries. Attendees span all career stages—from international leaders to the next generation of researchers—gathering to share cutting-edge science and explore innovations that advance immunology research.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/immunology-2026/)
15 — 19 April 2026
[Schedule a Meeting](https://share.hsforms.com/1q33eVPGOQvmUzJwJEXjzlwc22yq)
[  ](https://www.meridianbioscience.com/lifescience/events/caclp-2026-china-association-of-clinical-laboratory-practice/)
#### [CACLP 2026 (China Association of Clinical Laboratory Practice)](https://www.meridianbioscience.com/lifescience/events/caclp-2026-china-association-of-clinical-laboratory-practice/)
Xiamen International Expo Center, Xiamen, China
Booth #4-0606
Join us at Booth #4-0606 for CACLP 2026, the 23rd China International In Vitro Diagnostic Expo, taking place 21–23 March 2026 at the Xiamen International Expo Center, Xiamen, China. As one of the largest and most influential IVD exhibitions in China, CACLP provides a comprehensive platform for industry professionals, researchers, and businesses to explore the latest advancements across the diagnostics ecosystem—including diagnostic technologies, medical laboratory equipment, and cutting-edge innovations.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/caclp-2026-china-association-of-clinical-laboratory-practice/)
21 — 23 March 2026
[  ](https://www.meridianbioscience.com/lifescience/events/medica-2025/)
#### [Meridian Life Science at MEDICA 2025](https://www.meridianbioscience.com/lifescience/events/medica-2025/)
Hall 3, Düsseldorf, Germany
Join us at MEDICA, the world’s largest medical industry event, where you can discover the latest innovations in healthcare alongside thousands of exhibitors and attendees from over 70 countries! Connect with global experts to explore advancements in laboratory technology, molecular diagnostics, medical research and devices, and raw materials manufacturing.
Join us at MEDICA 2025 in Hall 3, Booth #3D15-2, to discover next-generation solutions that power precision diagnostics and accelerate your path from concept to commercialization.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/medica-2025/)
17 — 20 November 2025
[Schedule a Meeting](https://share.hsforms.com/10BzTF0eoT22d7hvxHGU4WAc22yq)
[  ](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2025-annual-meeting-expo/)
#### [Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2025-annual-meeting-expo/)
Boston, MA
Booth #1115
Join us at the 31st AMP 2025 - Annual Meeting and Expo, Booth #1115 to discover how our innovative molecular reagents & services are designed to streamline workflows, reduce barriers, and improve test performance across a wide range of applications.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2025-annual-meeting-expo/)
11 — 15 November 2025
[Schedule a Meeting](https://share.hsforms.com/1ox-ZvIJZRZCuOwGBRg8sUQc22yq)
[  ](https://www.meridianbioscience.com/lifescience/events/precision-oncology-diagnostics-2025/)
#### [Precision Oncology & Diagnostics 2025](https://www.meridianbioscience.com/lifescience/events/precision-oncology-diagnostics-2025/)
Jay Conference - Bryant Park, New York, NY
Meridian Life Science is proud to participate in Precision Oncology & Diagnostics 2025, an event developed with the editorial team of Precision Oncology News to spotlight the rapidly evolving field of precision oncology. This meeting will bring together leaders across pharma, biotech, cancer centers, and the research community to discuss strategies and best practices for implementing molecularly guided cancer care.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/precision-oncology-diagnostics-2025/)
05 — 06 November 2025
[Contact Us](https://www.meridianbioscience.com/contact-us-life-science/)
[  ](https://www.meridianbioscience.com/lifescience/events/american-society-of-human-genetics-ashg-2025-annual-meeting/)
#### [American Society of Human Genetics (ASHG) 2025 Annual Meeting](https://www.meridianbioscience.com/lifescience/events/american-society-of-human-genetics-ashg-2025-annual-meeting/)
Boston, MA
Booth #1243
Join us at the American Society of Human Genetics (ASHG 2025) Annual Meeting where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/american-society-of-human-genetics-ashg-2025-annual-meeting/)
14 — 18 October 2025
[  ](https://www.meridianbioscience.com/lifescience/events/nextgen-dx-2025/)
#### [NextGen DX 2025](https://www.meridianbioscience.com/lifescience/events/nextgen-dx-2025/)
Capital Hilton, Washington, D.C.
Cambridge Healthtech Institute is proud to present the Seventeenth Annual Next Generation Dx Summit which will take place at the Capital Hilton in Washington, D.C. on August 18-20, 2025. The Next Generation Dx Summit is the nexus for international thought leaders to discuss diagnostic advancement and technology innovation. This year’s event provides a valuable window on the state-of-the art, forecasting and future trends in point-of-care and decentralized testing, infectious disease, liquid biopsy, multi-cancer early detection, reimbursement, regulation, and companion diagnostics to improve standard of care in medicine. This must-attend Summit offers incomparable networking and complete coverage of the most timely and important topics for the industry.
[ Get Details ](https://www.meridianbioscience.com/lifescience/events/nextgen-dx-2025/)
18 — 20 August 2025
[Schedule a Meeting](https://share.hsforms.com/1JjAdXcrsSne9rl36sfERkQc22yq)
PreviousPage1[Page2](https://www.meridianbioscience.com/lifescience/past-events/2/?doing_wp_cron=1784535480.8002269268035888671875)[Page3](https://www.meridianbioscience.com/lifescience/past-events/3/?doing_wp_cron=1784535480.8002269268035888671875)[Next](https://www.meridianbioscience.com/lifescience/past-events/2/)
---
### [Meridian Bioscience Candidate](https://www.meridianbioscience.com/careers/candidate-application-process/)
**Published:** August 21, 2025
**Author:** hamza
**Content:**
## Meridian Bioscience Candidate Application Process
## What To Expect During The Meridian Candidate Application Process
- Positions are posted only to [MeridianBioscience.com/Careers](https://www.MeridianBioscience.com/Careers)
- Candidates must create an account to apply for positions on this site
- Candidates who apply will receive a confirmation email to acknowledge receipt of the application
- Meridian’s Talent Acquisition department will contact candidates if selected for a phone screen
- Selected candidates will be invited to interview
- The final candidate will be sent an offer by Meridian’s HR and Hiring Manager after completing the required interviews
#### **If you receive anything suspicious or have questions, please contact us at +1 513-271-3700 or email **
## Beware of Fraudulent Recruitment Activity
Fraudulent recruitment activity is becoming more sophisticated and may apply to various scenarios. These schemes may be sent to an individual in multiple formats, including e-mail, text, social media, or a letter. This type of fraud can also be perpetrated through online services with bogus websites with fraudulent domain name URLs or even done through otherwise legitimate online job websites. Wrongdoers may feature a company’s name and logo without authority, falsely claiming that they represent the company and are interested in hiring individuals. These wrongdoers may offer fraudulent employment opportunities to individuals and often ask for sensitive personal and financial information as a part of their scheme. Meridian Bioscience condemns such fraudulent activity and takes this issue very seriously. Below is information to help identify recruitment fraud and some steps you can take to protect yourself. ### How To Identify Fraud
- Fraudulent recruitment e-mail correspondence is often sent from free web-based email accounts such as Gmail, Yahoo, or Hotmail. Meridian Bioscience does not communicate with potential job applicants through these web-based email services.
- There is an early request for personal information or payment.
- You may be referred to an organization that requests fees for processing certain documents, such as work permits, visa applications, or the like.
- The perpetrators frequently (but not necessarily) use mobile or platform telephone numbers beginning with +44(0)70 instead of official company numbers.
- There is an insistence on urgency.
### What Should I Do If I Believe I Have Identified Fraud
#### **DO**
- Save messages from the perpetrator for further investigation, if necessary.
- Contact law enforcement and provide them with all information you may have from the perpetrator so that law enforcement can take any appropriate action.
- If you would like, you may send any relevant information or documents to mbi@meridianbioscience.com. Meridian Bioscience will strive to investigate the situation and take appropriate corrective action. Please note any information or materials provided to us should not include any personal information (e.g., Social Security numbers, driver’s license numbers, bank account details, etc.).
#### **DO NOT**
- Do not disclose your personal or financial details to anyone you do not know.
- Do not send any money to Meridian Bioscience or anyone pretending to be Meridian Bioscience. Meridian Bioscience does not and will not ask for money transfers or payments.
- Do not engage in further communications if you believe the communications may be fraudulent.
For further information, the following webpage from the Federal Trade Commission may be helpful in protecting yourself further: .
##### Caring For Our Team
[ See Benefits ](https://www.meridianbioscience.com/careers/benefits/)
##### Caring For Our Team
[ View Openings ](https://careers-meridianbioscience.icims.com/jobs/intro?hashed=-435711682&mobile=false&width=850&height=500&bga=true&needsRedirect=false&jan1offset=-300&jun1offset=-240)
#### Get In Touch With Us
[ Contact Us ](https://www.meridianbioscience.com/contact-us/)
---
### [Immunoassay Blocking Agents](https://www.meridianbioscience.com/lifescience/immunoassay-blocking-agents/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## Immunoassay Blocking Agents
#### Safeguard your immunoassays with proven blocking agents
Immunoassay blockers are essential tools for reducing false positives caused by non-specific binding and antibody interference—such as HAMA and rheumatoid factor (RF).
[ Request Sample Pack ](/lifescience/blockers-sample-pack-request)
[ View Products Below ](#mouse-serum)
### Tailoring Blocking Solutions to Your Assay Needs
Whether you are developing ELISAs, lateral flow assays (LFA), or chemiluminescent immunoassays (CLIA), Meridian’s blockers are your first line of defense. Our portfolio includes trusted solutions such as:
#### Mouse IgG & Mouse Serum
• Passive blockers that bind HAMA for cleaner results.
• Effective on HAMA but not on other types of HA.
[Learn More](#mouse-serum)
#### TRU Block™ Series
Meridian’s flagship line of universal (active and passive) blockers are designed to address a wide range of assay challenges.
• Ideal for blocking HAAA, HA, and RF.
[Learn More](#tru-block-series)
#### K-BLOCK™
A proprietary blend of recombinant immunoglobulins and proteins that offers broad-spectrum active blocking against HAAAs and RF.
[Learn More](#k-block)
## Request A Blocker Sample Pack
[ Click to contact a specialist and request your sample pack ](/lifescience/blockers-sample-pack-request/)
##### What is antibody interference and how do you prevent it from impacting your assay results?
What is antibody interference and how do you prevent it from impacting your assay results?
### Mouse Serum & Mouse IgG
Mouse IgG and mouse serum are widely used as passive blockers in immunoassays to reduce interference from human anti-mouse antibodies (HAMA) by competitively binding to HAMA. These blockers are simple to use and cost-effective, making them ideal for weakly cross-reactive antibody interference, particularly in assays that use mouse-derived antibodies.
**Mouse Serum** is a broad-spectrum blocker that contains a natural mix of mouse proteins, including immunoglobulins. This makes it ideal for assays where **multiple types of interference** may be present.
**Mouse IgG** is a purified immunoglobulin G derived from mouse serum. It is specifically designed to block **human anti-mouse antibodies (HAMA)**, a common source of interference in immunoassays.
[Learn more](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/?country=US) about our blockers.
[ Request a Sample ](/lifescience/immuno-blocker-sample-request/)
#### Benefits
- Simple to use and cost-effective
- Reduces HA and HAMA interference
- Compatible with ELISA, CLIA, and LFA formats
### TRU Block™ Series
TRU Block™ is an active HAAA (HAMA, HAGA, and HARA) and RF blocker that neutralizes these interfering antibodies, preventing false signal generation and improving assay specificity. It is available in three distinct formulations, each uniquely designed to address a broad spectrum of immunoassay interference. By combining mouse IgG with a proprietary active blocker in optimized ratios, each version is tailored to different levels of antibody interference and assay sensitivity—delivering consistent, high-performance blocking across diverse assay formats.
Each formulation is tailored to varying levels of interference and effectively blocks HA, HAMA, and RF.[Learn more](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/) about our blockers.
[ Request a Sample ](/lifescience/immuno-blocker-sample-request/)
#### Benefits
- Proven HAAA and RF blocking
- Minimal impact on assay kinetics
- Customizable and bulk available
### Understanding Universal (active and passive) Blockers: Targeted Protection Against HAMA and RF
Active blockers prevent immunoassay interference by specifically binding and neutralizing interfering antibodies like HAMA and RF, whereas passive blockers, such as mouse IgG, rely on competitive binding and often require higher concentrations to be effective.
How do active blockers like TRU Block™ provide broader, more efficient protection against antibody interference than traditional options like Mouse IgG?
Read this whitepaper to learn how they improve assay accuracy by directly neutralizing HAMA, RF, and other interfering antibodies.
[ Read the Whitepaper ](https://collateral.meridianlifescience.com/reducing-false-results-white-paper/?__hstc=51647990.26e2792c973c6d98a744bd481f28db83.1754909130320.1756907940809.1757056832760.37&__hssc=51647990.1.1757056832760&__hsfp=464159533)
Has COVID impacted immunoassay interference by increasing the risk of false results from elevated autoantibodies like RF?
Read this blog to learn how elevated autoantibodies like RF could be driving more false results in diagnostics.
[ Read the Blog ](/lifescience-blog/rise-in-antibody-interference-post-covid-impacts-on-diagnostic-assay-developers/)
### K-BLOCK™
Recombinant immunoassay blockers offer key advantages over traditional animal-derived options. Because they are precisely engineered, they deliver high batch-to-batch consistency, more predictable performance, and greater confidence in assay reproducibility—especially important in regulated and high-throughput environments.
**K-BLOCK™** is Meridian’s latest proprietary blocking solution, designed to actively neutralize a broad spectrum of interfering substances—including HAMA, RF, and other HAAAs. Produced through *in vitro* recombinant technology, K-BLOCK™ is entirely animal-free, offering a consistent and scalable solution for interference control.
[Learn more](https://meridianbiostg.wpengine.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/animal-free-blockers/?country=US) about our blockers.
[ Request a Sample ](/lifescience/immuno-blocker-sample-request/)
#### Benefits
- High batch-to-batch consistency with predictable performance
- Actively neutralizes a broad spectrum of interference including HA, HAMA, RF, and other HAAAs
- 100% Animal-free
### Why choose a recombinant blocker over a traditional animal-derived solution?
Recombinant immunoassay blockers offer key advantages over traditional animal-derived solutions. Produced using precise recombinant technology, they provide enhanced specificity, improved batch consistency, and eliminate the ethical and supply concerns of animal-based reagents.
**Watch this webinar to learn the key advantages of recombinant blockers over traditional animal-derived solutions.**Understand how these cutting-edge solutions improve assay accuracy by directly neutralizing HAMA, RF, and other interfering antibodies—without the variability of animal-based blockers.
[ Watch the Webinar ](https://share.hsforms.com/1hqgsJ8dwTZqfsMpEm9JSLgc22yq)
## FAQS
What is the difference between passive and active blockers?
Passive blockers such as mouse serum or Mouse IgG work by binding non-specifically to weakly cross-reactive antibodies, helping to reduce false results. Active blockers like K-BLOCK™ provide more targeted protection, especially against human anti-mouse antibodies (HAMA) and rheumatoid factor (RF). Universal blockers provide both passive and active blocking.
How to determine if I should use TRU Block™ or Mouse IgG?
While mouse IgG can reduce interference from antibodies like HAMA, it typically requires higher concentrations to be effective—potentially affecting the assay signal. TRU Block™, on the other hand, is designed to directly and efficiently block a wider range of interfering antibodies, including both HAMA (and other HAAAs) and rheumatoid factor (RF), even at lower concentrations. For standard tests with low interference risk, mouse IgG may be sufficient. TRU Block™ is the preferred option when working with samples prone to high levels of interference or in high-stakes diagnostic tests—such as those used to detect acute conditions like heart attacks—where reliable and precise results are vital.
Which types of assays are most susceptible to antibody interference?
Assays that rely on antibody–antigen binding—such as sandwich assays, competitive immunoassays, and antibody capture formats—are particularly vulnerable to interference from heterophilic antibodies like HAMA. This is especially true when mouse monoclonal antibodies are used as both capture and detection reagents, as these can be targeted by human anti-animal antibodies present in patient samples.
How do I choose the right blocker for my assay?
Several factors influence blocker selection:
- Host species of the antibodies used
- The immunoassay configuration (e.g., sandwich or competitive)
- Type of biological sample (serum, plasma, etc.)
- Anticipated interference risks (e.g., RF, heterophilic antibodies
If you’re unsure, reach out to Meridian’s technical experts for personalized guidance based on your assay’s parameters.
What are the main types of antibody interference in immunoassays?
One of the most common causes of immunoassay interference is the presence of human anti-mouse antibodies (HAMA), which can bind to mouse-derived assay components and disrupt results.
In addition to HAMA, patients may produce heterophilic antibodies against other animal species (human anti-animal antibodies, or HAAAs) frequently used in assay development—such as goat (HAGA), sheep (HASA), or rabbit (HARA).
Rheumatoid factor (RF), particularly the IgM subtype, is another significant source of interference. It can bind non-specifically to the Fc portion of IgG antibodies, mimicking true analyte signals and potentially causing false positives or negatives.
What is rheumatoid factor (Rf)?
Rheumatoid factor (RF) is an autoantibody that targets the Fc region of IgG antibodies. The most common and clinically significant type in immunoassay interference is IgM RF, which—due to its pentameric structure—is particularly effective at crosslinking antibodies and forming immune complexes. IgM RF is frequently found in individuals with rheumatoid arthritis (present in approximately 50% of cases), but elevated levels can also appear in about 1 in 20 people without the disease, especially among the elderly.
How does rheumatoid factor (RF) cause false signals in immunoassays?
Rheumatoid factor can mimic antigen–antibody binding by bridging capture and detection antibodies, generating artificial signals in immunoassays. It often targets the Fc regions of IgG molecules and may cross-react with antibodies from both human and animal sources.
What can be done to prevent post-COVID interference in immunoassays?
After COVID-19 infection, many individuals exhibit increased levels of polyreactive antibodies, including IgM RF. These immune alterations can interfere with immunoassay performance, leading to inaccurate results. To safeguard assay reliability, it’s essential to validate using post-COVID clinical samples and incorporate high-performance active blockers—such as TRU Block™—to minimize the risk of interference across varied patient populations.
## Get in Touch With Us
[ Contact Us ](/contact-us-life-science/)
---
### [Life Science](https://www.meridianbioscience.com/lifescience/)
**Published:** February 7, 2025
**Author:** hamza
**Content:**
# Life Science molecular biology reagents, antibodies and antigens supplier
Meridian has been providing innovative life science solutions and building trusted partnerships for over 40 years. Our focus is to offer products and services that help to advance the development of diagnostic assays.
###### Find your product by selecting which test you are making:
[ Molecular Diagnosis
](/lifescience/products/molecular-reagents/)
[ Immunoassay Diagnosis
](/lifescience/products/antibodies-antigens)
## Let's discover together! Join our quarterly newsletter for the latest insights in your inbox.
[ Register Today ](/life-science-newsletter-registration)
## NEW! Pioneering Sustainable Innovation in Immuno & Molecular Dx Reagents
[ Learn More ](/lifescience/pioneering-sustainable-innovation-in-immuno-molecular-dx-reagents)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
### Meridian is the complete solution
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
[ See All Product ](/lifescience/products)
### First to market, second to none
Meridian is dedicated to discovering new solutions for old problems. Our team of scientists, with expertise ranging from virology and immunology to enzyme behavior and large-scale protein expression and purification, are at the forefront of developing first to market products for immunoassay and molecular diagnostic tests. As a company, we strive to transform ideas into reality and provide unparalleled products, services, and value to our customers.
[ Learn More ](/lifescience/about-life-science/)
## Meridian Life Science Overview
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products and critical raw materials. As one of the leading reagent companies for antibodies, antigens, blockers, and molecular diagnostic reagent solutions, we are dedicated to delivering answers with speed, accuracy, and simplicity, redefining possibilities from discovery to diagnosis.
As the Life Science division of Meridian, we focus on supporting immunological and molecular test manufacturers, including human, veterinary, plant, and environmental assay developers, with original raw materials and critical reagents. Our extensive portfolio includes antibodies, antigens, molecular enzymes, nucleotides, and optimized mixes for qPCR and isothermal amplification. These solutions are designed to simplify assay design and enable accurate, reliable test results.
Meridian’s expertise spans from antibody development and antibody production services to IVD contract manufacturing and specialized reagents for major disease outbreaks. We have supplied novel antigens and antibodies for emerging pathogens such as Zika and SARS-CoV-2, while pioneering the market with our innovative air-dried qPCR/RT qPCR mixes.
Our brands, including Meridian Bioline and the complete range of Meridian Life Science products, are trusted by leading molecular companies, antibody companies, and diagnostic manufacturers worldwide. Whether for human diagnostics, environmental testing, or veterinary diagnostics, we are committed to delivering high-quality products backed by unmatched technical support and customer service.
At Meridian, we take pride in providing our customers with the solutions they need, when they need them, and focus on helping to advance diagnostic innovation and strengthen global health.
## Get in Touch With Us
[ Contact Us ](/contact-us-life-science/)
---
### [Product Documents](https://www.meridianbioscience.com/product-documents/)
**Published:** June 25, 2025
**Author:** hamza
**Content:**
# Meridian Product Support Documents
To download your product’s supporting documents, please enter the catalog number and/or lot number in the search box below:
Please contact our technical support team if you have any questions or need further assistance regarding your product.
Search Filter by: Document Type Safety Data Sheet User Guide Product Handling Guide Certificate of Analysis Product Information Sheet [Reset](#)
Product Name Title Catalog No. Lot No. Categories Link
---
### [Standards For Suppliers](https://www.meridianbioscience.com/suppliers/)
**Published:** February 4, 2025
**Author:** hamza
**Content:**
## Standards For Suppliers
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. Meridian is dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Meridian has established a reputation for integrity in all business dealings. As Meridian continues to expand our business, it is important to preserve our core values and protect our reputation in selecting where and with whom we do business. The standards set forth herein (the “Supplier Standards”) are the basic minimum standards that all Suppliers must meet in order to conduct business with Meridian Bioscience, Inc. and its subsidiaries and affiliates (collectively, “Meridian”). Meridian recognizes that there are different legal and cultural environments in which our Suppliers operate throughout the world. In the event compliance with the Supplier Standards would cause a violation of applicable law, Meridian expects our Suppliers to behave in a manner consistent with the spirit of the Supplier Standards to the extent possible without violating applicable law
1\. Compliance with Laws
a. General. All Suppliers must comply with all applicable industry standards and legal requirements of the countries in which they do business, including the export control and labor and employment laws of those countries and applicable U.S. laws. All invoices, shipping documents, quotations, bills of lading and other transaction documents prepared by Supplier must comply with all applicable law and these Supplier Standards.
2\. Employment Practices
a. Prison or Forced Labor. Suppliers are not permitted to use prison or forced labor. Suppliers shall maintain employment on a voluntary basis.
b. Human Trafficking. Meridian will not tolerate human trafficking in any of our global operations. Meridian expects our Suppliers to ensure no human trafficking exists within their businesses and supply chain and are committed to complying with applicable laws prohibiting such exploitation.
c. Disciplinary Practices. Suppliers shall treat their employees with respect and dignity. Suppliers must provide a work environment free of harassment, abusive behavior and physical punishment in any form.
d. Child Labor. Suppliers are not permitted to use child labor as defined in Principle Five of the United Nations Global Compact.
e. Working Hours. Suppliers shall maintain reasonable employee work hours in compliance with local standards and all applicable laws. Employees shall not work more hours in one week than allowable under applicable law and shall be properly compensated for overtime work. Employees should be permitted reasonable days off and leave privileges.
f. Employee Training. Suppliers must ensure that personnel are properly and adequately trained to successfully and safely perform their assigned responsibilities.
g. Compensation. Suppliers must pay wages that meet or exceed legally required wages. Suppliers must comply with all applicable local, state, and national wage and hour laws.
h. Non-Discrimination/Human Rights. Suppliers should treat all employees with professionalism and respect. Meridian believes that all terms and conditions of employment should be based upon an individual’s ability to do the job, not on the basis of personal characteristics or beliefs. Suppliers should not discriminate against their employees in hiring practices or any other term or condition of work, on the basis of race, ethnicity, color, religion, sex, national origin, age, sexual orientation, genetic information, disability or any other characteristics protected by law.
i. Workplace Environment. Suppliers shall provide their employees with safe and healthy working conditions, including, for example, reasonable machine guarding, working and accessible fire exits, adequate ventilation, safety equipment, well-lit and comfortable workstations, clean restrooms, adequate living quarters where necessary, and other customary and normal safety business practices. Facilities should be built and maintained in accordance with the standards set by applicable codes and ordinances and workers should be adequately trained to perform their jobs safely.
j. Collective Bargaining. Suppliers shall recognize and respect employee rights to join or not join any lawful organization of their own choosing and be committed to complying with laws pertaining to freedom of association, privacy, and collective bargaining.
3\. Anti-Bribery and Anti-Corruption
Meridian maintains its Corporate Policy Concerning U.S. Foreign Corrupt Practices Act, U.K. Bribery Act and Anti-Corruption Laws prohibiting corruption, including any improper or unethical payments to any person anywhere in the world, with specific focus on the provisions of the United States Foreign Corrupt Practices Act and the UK Bribery Act 2010.
Our policy statement is: No Meridian officer, employee or agent shall, for the purpose of securing an improper advantage for Meridian, offer or promise, or make or facilitate a payment or gift of, anything of value to – or accept anything of value from – any person, including, but not limited to, a foreign government official. Furthermore, every Meridian officer, employee and agent is obligated by Meridian policy and federal law to keep books, records and accounts that accurately and fairly reflect all transactions and any disposition of Meridian assets. This policy is intended to supplement Meridian’s Code of Ethics, which contains provisions governing conduct similar to that addressed in Meridian policies, including provisions regarding bribery, record-keeping and compliance with applicable law.
Meridian likewise expects its suppliers to abide by its policies and not offer, promise, make, or facilitate a payment or gift of anything of value to any person, including any foreign government official.
4\. Environmental Practices
Suppliers should provide products to Meridian and conduct their business operations in a way that protects and sustains the environment in accordance with applicable laws and regulations. Suppliers are expected reduce the total use of substances of concern as well as the adequate treatment of hazardous waste (solid and wastewater) and hazardous air emissions. Suppliers are encouraged to:
reduce excess packaging,
use recycled and non-toxic materials where feasible,
use sustainable manufacturing practices,
promote the efficient and responsible use of products,
take efforts to reduce energy use, and
reduce water consumption.
5\. Conflict Minerals. “Conflict Minerals,” as defined by the US legislation, currently include the metals tantalum, tin, tungsten and gold, which are the extracts of the minerals cassiterite, columbite-tantalite and wolframite, respectively. Suppliers shall ensure they (i) do not use Conflict Minerals in the materials they supply to Meridian, (ii) have no reason to believe the Conflict Minerals they use may have originated in the Covered Countries, and/or (iii) reasonably believe that the Conflict Minerals they use are from recycled or scrap sources.
6\. Competition Law
Suppliers shall not share or exchange any price, cost or other competitive information or engage in any collusive conduct with any third party with respect to any proposed, pending or current Meridian procurement.
7\. Conflicts of Interests
All Meridian employees are expected to avoid any investment, interest or association which interferes, might interfere, or might be thought to interfere with the employee’s independent exercise of judgment in Meridian’s best interest. A conflict of interest may exist where the employee, any member of his or her family or any close personal relation (i) has a significant direct or indirect financial interest in, or obligation to, an actual or potential competitor, Supplier or customer or (ii) is a principal, officer or representative of a Supplier or customer with whom the employee conducts business on Meridian’s behalf. Meridian employees are required to disclose any possible conflicts of interest and report any violations of nonconforming business practices to a member of management. Similarly, Suppliers are required to disclose any possible conflict of interest to the Meridian employee(s) with whom they are negotiating or, if the possible conflict involves such persons, to the appropriate general manager or department head.
8\. Data Privacy and Security
Suppliers shall be individually and separately responsible for complying with the obligations that apply to it as a Controller under Applicable Data Protection Law, including responding to any Data Subject requests to exercise their rights under Applicable Data Protection Law. Each party shall maintain a publicly accessible privacy policy on its website that satisfies the transparency disclosure requirements of Applicable Data Protection Law.
Suppliers shall maintain appropriate documents and records to ensure quality and regulatory compliance.
9\. How to Raise a Question or Concern
Subject to local laws and any legal restrictions applicable to such report, each Supplier is expected to inform Meridian promptly of any concern related to these Standards affecting Meridian, whether or not the concern involves the Supplier, as soon as the Supplier has knowledge of such an occurrence. Meridian prohibits retaliation against any person reporting such a concern. Suppliers must take such steps as Meridian may reasonably request to assist Meridian in the investigation of any such occurrence involving Meridian and the Supplier. A question or concern may be raised as follows:
By discussing it with the Meridian business contact when appropriate
By submitting it online to www.meridianbioscience.ethicspoint.com
By calling the Meridian Ethics Hotline at 1-844-246-9963 (U.S.), or if outside the U.S., you can find your country-specific hotline number at www.meridianbioscience.ethicspoint.com
Rev. 10/2023
[ Download the Meridian Standards for Suppliers ](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/02/04165526/2023-Standards-for-Suppliers-102023.pdf)
---
### [About Diagnostics](https://www.meridianbioscience.com/about/about-diagnostics/)
**Published:** February 3, 2025
**Author:** hamza
**Content:**
# Our path started with a simple vision — to help people.
We believe that genuine connections are what make us human. Those connections motivate our teams to create better solutions that help people from discovery to diagnosis. **We work harder every day to build relationships.**
Working to create healthcare solutions that help save lives will always unite us. We are a company of advocates. Of courageous thinkers. Of compassionate doers who strive to understand, collaborate and simplify an increasingly challenging industry. Each discovery, each diagnosis each answer, every patient, every day.
For all of us, our path started with a simple vision—to help people. No matter how the realities of today push and pull us, we won’t lose sight of that calling.
## Each discovery, each diagnosis, each answer, every patient. parent. neighbor.
[ Meet Our Team ](https://www.meridianbioscience.com/about/leadership-team/)
## Meridian is a company of advocates.
[ Join Our Team ](https://www.meridianbioscience.com/careers/)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Blockers Sample Pack Request](https://www.meridianbioscience.com/lifescience/blockers-sample-pack-request/)
**Published:** April 1, 2026
**Author:** hamza
**Content:**
Our blocker sample pack includes a selection of our most effective immunoassay blockers—designed to help you compare performance, optimize assay conditions, and address interference from HAMA, HA, or RF.
**Included in this kit:**
PRODUCT NAME CAT. NO. VOLUME PROTEIN CONC. BLOCKER TYPE APPLICATIONS Mouse Serum (Heat-Inactivated) 88131 25 mL >5.5 g/dL Passive ELISA, LFA Mouse IgG A66185M 1 mL 50–55 mg/mL Passive ELISA, CLIA TRU BlockTM A66800H 1 mL 24–26 mg/mL Universal (Active + Passive) ELISA, CLIA TRU BlockTM 2 A66802H 1 mL 24–26 mg/mL Universal (Active + Passive) ELISA, CLIA, LFA TRU BlockTM 3 A66803H 1 mL 24–26 mg/mL Universal (Active + Passive) ELISA, CLIA K-BLOCKTM (Recombinant) BN1200 5 mL 5–7 mg/mL Active ELISA, CLIA, LFA ## Simply fill out the form, and our team will be in touch to help you order a sample pack.
---
### [Request A Molecular Reagent Sample](https://www.meridianbioscience.com/lifescience/molecular-reagent-sample/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
Please note: We may share your personal contact data with our distribution partner(s) for the sole purpose of responding and replying to your inquiry. If you do not want your information shared, please contact us directly by emailing .
---
### [About](https://www.meridianbioscience.com/about/)
**Published:** January 30, 2025
**Author:** hamza
**Content:**
# Our path started with a simple vision — to help people.
## About Meridian
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio.
## About our
Diagnostics Division
[](https://www.meridianbioscience.com/about-diagnostics/) [ Learn more about our Diagnostics division ](https://www.meridianbioscience.com/diagnostics/)
## About our
Life Science Division
[ Learn more about our Life Science division ](/lifescience/about-life-science/)
### Meridian is a company of collaborators. advocates. thinkers. optimists.
[ Join Our Team ](https://www.meridianbioscience.com/careers/)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Todd Woodrich](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/todd-woodrich/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Todd Woodrich
### Vice President, Manufacturing
Todd Woodrich is Vice President of Manufacturing at Meridian Bioscience, leading production teams across multiple sites.
Since joining the company in 2004, he has driven operational excellence through process optimization, strategic initiatives, and a culture of collaboration and continuous improvement.
Todd brings over 20 years of leadership experience in production operations and team development.
He holds a Master of Science in Biochemistry from The Ohio State University and an MBA in Operations Management from Northern Kentucky University.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Press Release](https://www.meridianbioscience.com/press-release/)
**Published:** March 19, 2025
**Author:** hamza
**Content:**
## Press Releases
Select Year 2026202520242023202220212020201920182017
### [Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay](https://www.meridianbioscience.com/press-release/meridian-bioscience-announces-health-canada-license-for-alethia-cmv-assay/)
July 8, 2026
### [Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows](https://www.meridianbioscience.com/press-release/meridian-bioscience-and-4bases-announce-collaboration-to-enable-rapid-globally-scalable-next-generation-sequencing-workflows/)
June 10, 2026
### [Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio](https://www.meridianbioscience.com/press-release/meridian-bioscience-achieves-ivdr-certification-for-alethia-molecular-assay-portfolio/)
February 23, 2026
### [Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit.](https://www.meridianbioscience.com/press-release/meridian-life-science-expands-ambient-stable-ngs-portfolio-with-the-launch-of-a-lyophilized-enzymatic-dna-fragmentation-kit/)
February 18, 2026
### [Meridian Bioscience Appoints New CEO and Executive Team to Accelerate Global Growth](https://www.meridianbioscience.com/press-release/meridian-bioscience-appoints-new-ceo-and-executive-team-to-accelerate-global-growth/)
October 16, 2025
### [Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth’s 2025 “Force Of Nature” Award](https://www.meridianbioscience.com/press-release/meridian-bioscience-congratulates-catherine-lufkin-for-receiving-pure-earths-2025-force-of-nature-award/)
March 6, 2025
### [Meridian Bioscience Wins the CDC’s Lead Detect Prize Competition, Building on Decades of Leadership in Blood Lead Testing at the Point of Care](https://www.meridianbioscience.com/press-release/meridian-bioscience-wins-the-cdcs-lead-detect-prize-competition-building-on-decades-of-leadership-in-blood-lead-testing-at-the-point-of-care/)
November 6, 2024
### [Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability](https://www.meridianbioscience.com/press-release/meridian-bioscience-awarded-bronze-medal-by-ecovadis-for-the-second-consecutive-year-in-recognition-of-its-continued-dedication-to-sustainability/)
November 5, 2024
### [Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers](https://www.meridianbioscience.com/press-release/meridian-bioscience-leads-the-way-with-innovative-sustainable-solutions-for-in-vitro-diagnostic-manufacturers/)
July 23, 2024
### [Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage](https://www.meridianbioscience.com/press-release/meridian-bioscience-unveils-industry-first-lyophilized-library-prep-kit-for-next-generation-sequencing-eliminating-the-need-for-cold-chain-shipping-and-storage/)
June 26, 2024
Previous 1 Next
---
### [Life Science Blog](https://www.meridianbioscience.com/lifescience/blog/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
# Diagnostics Dialogue:
### Insights on the Latest Trends and Innovations
in Diagnostic Testing.
[ Subscribe ](/lifescience/life-science-newsletter-registration)
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
### [Liquid Biopsy: Entering a New Phase in Cancer Diagnostics](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
The term liquid biopsy has been part of the oncology research vocabulary for more than twenty years and is now...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Liquid Biopsy](https://www.meridianbioscience.com/category/lifescience-blog/liquid-biopsy/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
#### Featured
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
### [Liquid Biopsy: Entering a New Phase in Cancer Diagnostics](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
The term liquid biopsy has been part of the oncology research vocabulary for more than twenty years and is now...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Liquid Biopsy](https://www.meridianbioscience.com/category/lifescience-blog/liquid-biopsy/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
[  ](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
### [What Would It Take to Bring NGS to the Point of Need](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
NGS Workflows and Centralized Laboratory Challenges Next-generation sequencing has become remarkably powerful but in many ways, it is still designed for...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/), [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/)
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
### [Double Trouble: Viral Co-Infections and Their Role in Cancer Progression](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
Cancer remains one of the world’s most complex diseases, arising from an interplay of genetic, environmental, and infectious factors. While...
- [Immunology](https://www.meridianbioscience.com/category/lifescience-blog/immunology/), [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
[  ](https://www.meridianbioscience.com/lifescience-blog/antigens-native-vs-recombinant-immunoassays/)
### [Antigens Matter: How Native and Recombinant Formats Shape Immunoassay Success](https://www.meridianbioscience.com/lifescience-blog/antigens-native-vs-recombinant-immunoassays/)
In antibody-based immunoassays, antigen selection is the key biological decision driving assay performance. The structure, epitope integrity, and expression format...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/)
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
### [Liquid Biopsy: Entering a New Phase in Cancer Diagnostics](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
The term liquid biopsy has been part of the oncology research vocabulary for more than twenty years and is now...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Liquid Biopsy](https://www.meridianbioscience.com/category/lifescience-blog/liquid-biopsy/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
[  ](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
### [What Would It Take to Bring NGS to the Point of Need](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
NGS Workflows and Centralized Laboratory Challenges Next-generation sequencing has become remarkably powerful but in many ways, it is still designed for...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/), [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/)
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
### [Double Trouble: Viral Co-Infections and Their Role in Cancer Progression](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
Cancer remains one of the world’s most complex diseases, arising from an interplay of genetic, environmental, and infectious factors. While...
- [Immunology](https://www.meridianbioscience.com/category/lifescience-blog/immunology/), [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
[  ](https://www.meridianbioscience.com/lifescience-blog/blog-smarter-library-prep-for-whole-genome-sequencing/)
### [Smarter Library Prep for Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience-blog/blog-smarter-library-prep-for-whole-genome-sequencing/)
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, powering discovery in oncology, infectious disease, inherited disorders, and...
- [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/), [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/), [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/), [POCT](https://www.meridianbioscience.com/category/poct/)
[ View All ](/category/lifescience-blog/)
#### [Immunology](/category/lifescience-blog/immunology/)
### [ Double Trouble: Viral Co-Infections and Their Role in Cancer Progression ](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
Cancer remains one of the world’s most complex diseases, arising from an interplay of genetic, environmental, and infectious factors. While
### [ Rise in Antibody Interference Post-COVID: Impacts on Diagnostic Assay Developers ](https://www.meridianbioscience.com/lifescience-blog/rise-in-antibody-interference-post-covid-impacts-on-diagnostic-assay-developers/)
Since COVID-19, changes in the immune system, specifically increased levels of autoantibodies such as rheumatoid factor (RF), have begun to
### [ 2025 Outlook: Emerging Viruses & Next-Gen Respiratory DX ](https://www.meridianbioscience.com/lifescience-blog/emerging-viruses-next-generation-of-respiratory-diagnostics-2025-outlook/)
The 2025 flu season has been more intense than recent years, with elevated infection rates and notable pressure on healthcare
### [ The Silent Threat of Cancer-Causing Viruses ](https://www.meridianbioscience.com/lifescience-blog/the-silent-threat-of-cancer-causing-viruses/)
The article discusses the underappreciated risks posed by viruses that can lead to cancer. It highlights the significant influence of
#### [Molecular](/category/lifescience-blog/molecular/)
### [ Liquid Biopsy: Entering a New Phase in Cancer Diagnostics ](https://www.meridianbioscience.com/lifescience-blog/blog-liquid-biopsy-entering-a-new-phase-in-cancer-diagnostics/)
The term liquid biopsy has been part of the oncology research vocabulary for more than twenty years and is now
### [ What Would It Take to Bring NGS to the Point of Need ](https://www.meridianbioscience.com/lifescience-blog/what-would-it-take-to-bring-ngs-to-the-point-of-need/)
NGS Workflows and Centralized Laboratory Challenges Next-generation sequencing has become remarkably powerful but in many ways, it is still designed
### [ Double Trouble: Viral Co-Infections and Their Role in Cancer Progression ](https://www.meridianbioscience.com/lifescience-blog/blog-double-trouble-viral-co-infections-and-the-future-of-cancer-diagnostics/)
Cancer remains one of the world’s most complex diseases, arising from an interplay of genetic, environmental, and infectious factors. While
### [ Smarter Library Prep for Whole Genome Sequencing ](https://www.meridianbioscience.com/lifescience-blog/blog-smarter-library-prep-for-whole-genome-sequencing/)
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, powering discovery in oncology, infectious disease, inherited disorders, and
---
### [Kevin Kiser](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/kevin-kiser/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Kevin Kiser
### Senior Vice President, Operations
Kevin Kiser oversees manufacturing, engineering, supply chain, and facilities operations across Meridian Bioscience’s global sites, ensuring quality, efficiency, and compliance.
With more than 25 years in life sciences operations, Kevin has advanced through multiple leadership roles since joining Meridian in 2002, spearheading process improvements and operational growth.
He holds a Bachelor of Science in Biological Sciences from the University of Cincinnati and a Master of Business Administration from Xavier University.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Pioneering Sustainable Innovation In Immuno Molecular Dx Reagents](https://www.meridianbioscience.com/lifescience/pioneering-sustainable-innovation-in-immuno-molecular-dx-reagents/)
**Published:** March 5, 2025
**Author:** hamza
**Content:**
# Pioneering Sustainable Innovation
#### in Immuno & Molecular Dx Reagents
At Meridian, we believe sustainability starts with us. Throughout our entire organization, we are committed to integrating sustainability principles and ethical practices into our business model. Our goal is to provide innovative, eco-conscious and cost-effective products to our customers, empowering them with solutions to increase global access to their tests, reduce waste, and enhance efficiency in their supply chains and assay workflows as they progress toward their sustainability goals.
[ Request Information Now ](#pioneering-page-form)
[ Learn More ](#meridian-offers-leading)
## Meridian offers leading innovative, eco-conscious products designed to enhance your operational efficiency and sustainability.
With increasing pressure to integrate Environmental, Social, and Governance (ESG) sustainability into their operations, diagnostic manufacturers require innovative solutions in raw materials and reagents to reduce the carbon footprint of diagnostic assays (). In response, Meridian has curated a comprehensive portfolio of eco-conscious and cost-efficient solutions designed to meet specific challenges like:
- **Overcoming Cold Chain Logistics Barriers:** Glycerol-free and high-concentration reagents enable the development of ambient temperature stable assays, eliminating cold chain logistics, reducing energy consumption, and minimizing packaging needs.
- **Streamlining Workflows:** Extraction-free and low-temperature solutions streamline workflows, eliminate multiple extraction steps, reduce energy use, and increase throughput for faster turnaround times.
- **Providing Animal-Free Alternatives:** Animal-free recombinant alternatives for immunoassays, offer greater versatility and reproducibility, ensuring supply continuity while addressing ethical concerns.
## Finding Ways to Adopt Sustainable Solutions
Meridian’s product development strategy focuses on sustainable, cost-effective solutions. With a robust pipeline of upcoming
product launches, Meridian aims to boost their partners’ competitive advantage while supporting their objectives in attaining a
more ethical and sustainable future. Sustainable innovative solutions start with us.
Reduce Waste Increase Efficiency Expand Accessibility Use Eco-Conscious Reagents
#### Achieving Waste Reduction
Diagnostic assays produce 10% of all medical waste, most of which is hazardous and cannot be reused or recycled. This waste comes from the assays themselves, specimen collection, and the shipping and storage of reagents.
Meridian’s innovative master mixes and enzymes achieve waste reduction by providing:
- [**High-concentration formats**](/lifescience/products/molecular-reagents/enzyme/)
Reduces the volume of reagents, enabling miniaturization.
- [**Lyo-Ready and Air-Dryable™ options**](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
Provides options for creating ambient-temperature stable assays.
- [**Inhibitor-tolerant mixes**](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
Ensures highly sensitive direct detection.
- [**Specimen-specific solutions**](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
Supports self-sampling using saliva, urine, stool, and capillary blood.
#### Strategies to Improve Efficiency
Simplifying assay development and enhancing workflow efficiency can reduce an assay’s ecological footprint and lower costs. Innovative, sustainable solutions offer a competitive edge and reduce CO2 emissions.
Meridian’s innovative master mixes and enzymes improve efficiencies by providing:
- [**Ready-to-use solutions**](/lifescience/products/molecular-reagents/)
Saves time and resources and only add primers and probes.
- [**Extraction-free mixes**](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
Allows direct detection in crude specimens.
- **[Isothermal applications](/lifescience/products/molecular-reagents/isothermal-amplification/)**
Enables decentralized testing through access to point-of-care.
- [**Ambient-stable formats**](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
Eliminates refrigeration for shipping and storage.
#### Ways to Expand Accessibility
Expanding assay accessibility is essential for equitable healthcare. Barriers include high costs, the need for technical expertise or expensive equipment, and supply chain issues like cold-chain requirements.
Meridian’s innovative master mixes and enzymes expand accessibility by providing:
- [**Isothermal applications**](/lifescience/products/molecular-reagents/isothermal-amplification/)
Enables decentralized testing through access to point-of-care.
- [**Ambient-temperature stable**](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
Eliminates refrigeration for shipping and storage.
- **[Specimen-specific solutions](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)**
Supports self-sampling using saliva, urine, stool, and capillary blood.
#### Benefits to Eco-Conscious Reagents
Eco-conscious reagents optimize resource use and minimize hazardous waste, allowing labs to significantly reduce their carbon footprint.
Meridian’s innovative eco-conscious reagents are:
- [**Animal-free**](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/animal-free-blockers/)
Eliminates the unethical use of animal-derived components, improving the continuity of supply
- **[Point-of-care focused](/lifescience/products/molecular-reagents/isothermal-amplification/)**
Consumes less energy by utilizing lower temperature requirements
- [**Ambient-temperature stable**](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
Removes the need for energy-intensive refrigeration.
- [**Inhibitor-tolerant**](/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
Removes the need for extraction, enabling highly sensitive direct detection.
---
### [Raw Materials for STI Diagnostic Development](https://www.meridianbioscience.com/lifescience/raw-materials-for-sti-diagnostic-development/)
**Published:** March 18, 2026
**Author:** Holger
**Content:**
## Raw Materials for STI Diagnostic Development
Accelerate assay development with validated immunoassay and molecular reagents designed for clinical reliability and scalable manufacturing.
Meridian Life Science partners with diagnostic developers to deliver the critical raw materials needed to build accurate, reproducible STI assays, from high-throughput laboratory systems to rapid point-of-care (POC) platforms.
[ View Resources ](#ViewResources)
[ Contact a Specialist ](https://share.hsforms.com/19sUiIH81SOa3zARMOVqZKQc22yq)
##### **Build Reliable Sexually Transmitted Infection Assays with Confidence**
Accurate, early detection of sexually transmitted infections is critical for effective treatment and prevention of
further transmission. Diagnostic developers need raw materials that perform consistently across diverse sample
types in real-world clinical settings.
Meridian Life Science enables STI diagnostic development with:
- - Well-characterized antibodies and antigens
- A broad portfolio of interference blockers
- Robust molecular reagents for sensitive nucleic acid detection
- Scalable solutions to support development, validation and commercialization
Our solutions enable developers to deliver timely, accurate, and reproducible STI diagnostics across diverse testing platforms and clinical workflows.
[ View Molecular Products ](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/)
[ View Immuno Products ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/)
## Clinically Significant STIs We Support
## Syphilis
Resurgent syphilis rates highlight the need for sensitive, reliable serological testing to support early diagnosis and effective disease monitoring.
Meridian offers a broad range of sensitive antibody and antigen pairs for syphilis, including an innovative T. pallidum P17 + P45 chimeric recombinant antigen pair for lateral flow tests. Additionally, our range of inhibitor-tolerant molecular master mixes and enzymes for qPCR and LAMP amplification allow direct detection from clinical samples, simplifying the workflow for point-of-case assays.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/treponema-pallidum/)
## CT/NG
Rising Chlamydia and Gonorrhea prevalence underscores the need for accessible, high-quality molecular screening.
Meridian enables CT/NG testing with qPCR master mixes for rapid, multiplex detection and minimal processing. Our portfolio includes C. trachomatis MOMP/LPS and N. gonorrhoeae Opa/LOS reagents, ensuring reliable, reproducible assays. Together, these solutions support expanded testing, co-infection detection, and AMR surveillance.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/chlamydia-trachomatis/)
## HBV
The WHO aims to close the global gap in HBV diagnosis and reduce new infections by 90% by 2030.
Meridian offers high-performing HBV antigens and antibodies for HBsAg, anti-HBc, or antiHBs tests, along with molecular master mixes and enzymes for viral load, genotyping, or mutational analysis.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/)
## HSV
Effective diagnostics and disease monitoring are critical to lowering the risk of spreading HSV.
Meridian has high-performing native and recombinant antigens to HSV-1 and HSV-2 that are ideal for serologic HSV IgG type-specific testing. In addition, our inhibitor-tolerant LAMP and qPCR mixes are highly suited to direct detection and differentiation of HSV-1 and HSV-2 DNA from lesion specimens.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/herpes/)
## HPV
The WHO aims to achieve a 70% HPV screening target by 2030 to reduce cervical cancer.
Meridian offers the complete solution to HPV testing, including antibodies and antigens to the high-risk strains HPV 16 & 18 for immunoassays, and innovative qPCR master mixes for molecular testing including a Lyo-Ready Genotyping Direct qPCR Urine Mix is ideal for developing self-collection, PCR-based HPV-type tests.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/hpv/)
## HIV
The WHO and leading global health organizations are working to end the HIV epidemic by 2030.
Meridian’s portfolio of immunoassay HIV reagents includes antigens and sensitive antibody pairs to HIV-p24, HIV-1 gp41 and HIV-2 gp36 for rapid lateral flow assays. In addition, Meridian’s inhibitor-tolerant qPCR and LAMP molecular master mixes are lyophilization capable, ideal for developing ambient-temperature stable assays, and available in specimen-specific formulations for saliva, urine, and blood.
[ Learn More ](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/hiv/)
## Key Testing Techniques
##### ELISA/CLIA
Detects antibodies or antigens for specific STIs, supporting high-throughput clinical screening and monitoring.
##### Lateral Flow
Enable rapid, point-of-care detection of select STIs with easy visual readouts.
##### PCR
Highly sensitive and specific detection of certain STIs, even in low-abundance samples.
##### Isothermal Amplification
Offers rapid nucleic acid detection without thermocycling, ideal for decentralized or nearpatient STI testing.
## Contact a Specialist to Learn More
[ ](/contact-us-life-science/)
## Industry Insights
Access the technical documents, protocols, and scientific support you need to succeed.
## eBook
[  ](https://www.meridianbioscience.com/lifescience/the-evolution-of-sti-testing-a-catalyst-for-modern-diagnostic-technologies/)
[ eBook ](https://www.meridianbioscience.com/lifescience/the-evolution-of-sti-testing-a-catalyst-for-modern-diagnostic-technologies/)
## Webinar
[  ](https://share.hsforms.com/15BVD6PSCS6KQNjSE-V93cQc22yq)
[ Webinar ](https://share.hsforms.com/15BVD6PSCS6KQNjSE-V93cQc22yq)
## Blog
[  ](https://www.meridianbioscience.com/lifescience-blog/revolutionizing-std-testing-navigating-the-advancements-in-molecular-and-immunoassay-techniques/)
[ Blog ](https://www.meridianbioscience.com/lifescience-blog/revolutionizing-std-testing-navigating-the-advancements-in-molecular-and-immunoassay-techniques/)
## Catalogs & Brochures
[Sexually Transmitted Infections (STI)](https://collateral.meridianlifescience.com/view/159653059/) **Sexually Transmitted Infections (STI)**
[Blood Donor Screening](https://collateral.meridianlifescience.com/view/160293564/) **Blood Donor Screening**
[Key STD Molecular & Immuno Solutions](https://collateral.meridianlifescience.com/view/510339704/) **Key STD Molecular & Immuno Solutions**
## FAQs
Do you manufacture diagnostic test kits?
No. Meridian Life Science is a raw material supplier, not a diagnostic test manufacturer. We supply high-quality raw materials including antibodies, antigens, molecular reagents, and interference blockers needed to build and validate diagnostic tests.
What types of STI assays do your materials support?
Our materials support a wide range of assay formats, including ELISA, CLIA, lateral flow assays, PCR/qPCR, and isothermal amplification (e.g., LAMP).
Do you offer both immunoassay and molecular reagents?
Yes. Our portfolio supports both immunoassay development and molecular diagnostics. Our molecular portfolio includes inhibitor-tolerant qPCR and isothermal master mixes designed to deliver reliable performance in complex clinical sample types such as urine, saliva, and swabs.
Can your molecular reagents support direct-from-sample workflows?
Yes. Our inhibitor-tolerant qPCR and isothermal mixes are specially formulated to maintain performance in the presence of substances that can interfere with nucleic acid amplification, such as components found in urine, blood, or swab samples. These mixes help ensure reliable detection even when sample purification is minimal or absent.
Do you provide technical support for assay development?
Yes. Our team offers scientific and technical support to help optimize reagent selection, assay design, and performance.
Are your products manufactured under a quality system?
Yes. Meridian operates under an ISO 13485-certified quality management system to support diagnostic manufacturers.
Can your materials be used in regulated IVD assays?
Our products are supplied as raw materials for research and further manufacturing use. Customers are responsible for validating materials within their specific diagnostic applications and regulatory frameworks.
What makes Meridian different from other reagent suppliers?
Key differentiators include deep expertise in immunoassay and molecular diagnostics, a broad STI-focused (sexually-transmitted infections) portfolio, interference mitigation solutions, scalable manufacturing capabilities, and strong technical support.
Do you offer recombinant or animal-origin-free options?
Yes. We offer recombinant and animal-origin-free reagents where applicable to support consistency, scalability, and regulatory preferences.
### Discover more in our new STI e-Book
- The evolution of STI testing from early assays to next-generation molecular and immunoassay platforms
- How laboratory, point-of-care, at-home, and self-collection models are improving access, privacy and patient engagement
- Key technology trends, including multiplexing, ambient-stable reagents, and digital connectivity
- Real-world insights from a case study highlighting 40 years of innovation in HIV diagnostics
Together, these advances are breaking down barriers to testing, enabling earlier detection, supporting public health initiatives and improving sexual health outcomes globally.
**Download the eBook** to discover how modern STI diagnostics are shaping the future of accessible, patient-centered care.
---
### [The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies](https://www.meridianbioscience.com/lifescience/the-evolution-of-sti-testing-a-catalyst-for-modern-diagnostic-technologies/)
**Published:** February 23, 2026
**Author:** hamza
**Content:**
## The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
### From Early Assays to Next-Gen Platforms: The Molecular and Immunoassay Innovations Shaping Modern Testing
Sexually transmitted infections (STIs) remain among the world’s most preventable and treatable public health challenges, yet global infection rates continue to rise. As the World Health Organization works towards the elimination or significant reduction of key STIs—including syphilis, gonorrhea, chlamydia, and trichomoniasis—by 2030, access to accurate, timely, and scalable diagnostics is critical.
This eBook explores how innovation across immunoassays and molecular diagnostics is transforming STI testing. From high-throughput laboratory assays to point-of-care, at-home, and self-collection models, advances in assay design, reagent stability, and platform integration are expanding access to reliable testing across clinical, community, and decentralized settings.
#### Inside the eBook, you’ll learn about:
- The evolution of STI testing from early assays to next-generation molecular and immunoassay platforms
- How laboratory, point-of-care, at-home, and self-collection models are improving access, privacy and patient engagement
- Key technology trends, including multiplexing, ambient-stable reagents, and digital connectivity
- Real-world insights from a case study highlighting 40 years of innovation in HIV diagnostics
Together, these advances are breaking down barriers to testing, enabling earlier detection, supporting public health initiatives and improving sexual health outcomes globally.
**Download the eBook** to discover how modern STI diagnostics are shaping the future of accessible, patient-centered care.
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [Instructions for Use](https://www.meridianbioscience.com/diagnostics/pi/)
**Published:** February 20, 2025
**Author:** hamza
**Content:**
# Instructions for Use
To download your product’s Instructions For Use, please enter the catalog/reference number in the search box below:
Customers outside of the United States, please note: To receive a translated version of the Revogene® Operator’s Manual,please contact your local distributor or [MBE-TechService@meridianbioscience.eu](mailto:MBE-TechService@meridianbioscience.eu?subject=Revogene%20Operator%27s%20Manual).Revogene assay-specific documentation may be found by searching for the catalog number of each assay in the search box below.
**Example of where the catalog/reference number may be found on the kit box label:**
If you can’t locate the catalog/reference number, or have questions, please contact our Technical Support department at [(+1) 800-343-3858](tel:18003433858) or (USA), or find your Local Technical Support at [meridianbioscience.com/contact-us/](/contact-us/).
Note PDF files require Adobe Acrobat which can be downloaded from the Adobe website.
[Click here to download](https://get.adobe.com/reader/).
[ Distributors ](/diagnostics/distributors/)
[ Resource Videos ](/customer-support/resource-videos/)
---
### [Thank You Speak Specialist](https://www.meridianbioscience.com/thank-you-speak-specialist/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your request has been received.
A Meridian representative will be in contact soon.
###### Thank you!
---
### [Looking to detect SNPs or other point mutations in samples that have a limited number of DNA copies?](https://www.meridianbioscience.com/lifescience/looking-to-detect-snps-or-other-point-mutations-in-samples-that-have-a-limited-number-of-dna-copies/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Emerson C. Moser](https://www.meridianbioscience.com/about/leadership-team/emerson-c-moser/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Emerson C. Moser
### Senior Vice President and General Counsel
Emerson Moser joined Meridian in October 2022 as Senior Vice President and General Counsel. He heads the legal department at Meridian, providing business and legal counsel to the executive leadership team and advising the Company on all legal matters, including mergers and acquisitions, commercial agreements, compliance, litigation, and data privacy. Emerson has significant prior in-house legal experience, having served as General Counsel to Hillenbrand, Inc.’s Milacron group of businesses and as Sr. Vice President, General Counsel, and Corporate Secretary for General Cable Corporation. Emerson began his career in private practice with the law firm, Dinsmore & Shohl LLP, and then served as Assistant General Counsel of NIBCO, INC. He received his law degree from Wake Forest University and undergraduate degrees in Economics and Political Science from Purdue University.
## Get to Know Our Members
[  ](/about/leadership-team/andy-kitzmiller/)
### Andy Kitzmiller
President and Chief Executive Officer
[ Read Bio ](/about/leadership-team/andy-kitzmiller/)
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/about/leadership-team/julie-smith/)
### Julie Smith
Senior Vice President and Chief Financial Officer
[ Read Bio ](/about/leadership-team/julie-smith/)
[  ](/about/leadership-team/don-oliver/)
### Don Oliver
Senior Director of Global Information Technology
[ Read Bio ](/about/leadership-team/don-oliver/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [Multiplexing Respiratory Assay Reagent Solutions](https://www.meridianbioscience.com/multiplexing-respiratory-assay-reagent-solutions/)
**Published:** March 4, 2025
**Author:** hamza
**Content:**
# Amplifying Precision
### High-quality Reagents for Multiplex Respiratory Point-of-Care (POC) Assays
#### Multiplex assays for respiratory diseases are particularly challenging due to the potential for cross-reactivity between pathogens and the high sample complexity. Respiratory specimens often contain various types of cells, mucus, and other components that can interfere with a test and affect assay accuracy.
#### Meridian offers both highly sensitive and specific reagent solutions for rapid immunoassays and molecular (qPCR and LAMP) techniques to meet your needs. Read our whitepaper to learn more through real-world case studies!
## Point-of-Care (POC) Respiratory Testing
The field of Point-of-care (POC) diagnostics for respiratory diseases has experienced rapid advancements, with the COVID-19 pandemic catalyzing the development and widespread adoption of POC respiratory testing. Both paper-based immunodiagnostics and microfluidic molecular devices have received particular attention for the development of POCT assays (https://doi.org/10.1016/j.aca.2023.341283). However, POC multiplex assays for respiratory diseases pose considerable challenges, primarily due to the potential for cross-reactivity among different pathogens and the intricate composition of respiratory specimens.
### Diagnostic Assay Solutions for Top 3 Viral Infections
#### Influenza A/B
Diagnostic influenza (flu) tests include rapid assays (RIDTs), direct fluorescent antibody stains, and molecular assays. Meridian’s flu A antibody pairs have proven high binding affinity for superior performance in lateral flow applications. Saliva-specific master mixes are also ideal for direct detection POC assays.
[ Request a Sample ](/lifescience/products/antibodies-antigens/respiratory-diseases/influenza-a/)
#### SARS-CoV-2
Both rapid antigen and molecular assays are important testing methods for controlling the spread of SARS-CoV-2 (COVID-19). Meridian’s antibodies to SARS-CoV-2 nucleoprotein are found in rapid tests around the world and our inhibitor-tolerant master mixes are ideal for point-of-care direct detection assays.
[ Request a Sample ](/lifescience/products/antibodies-antigens/respiratory-diseases/sars/)
#### RSV
Rapid antigen detection assays supplemented with immunofluorescence to confirm diagnosis is a common testing algorithm for RSV. Molecular testing is also popular and provides very sensitive and specific results. Meridian’s paired RSV antibodies and qPCR and LAMP master mixes provide ideal solutions for either test type.
[ Request a Sample ](/lifescience/products/antibodies-antigens/respiratory-diseases/respiratory-syncytial-virus-rsv/)
### Multiplex Rapid Lateral Flow Assays
Multiplex rapid lateral flow assays for respiratory infections such as the flu, COVID, and RSV offer an efficient testing solution. However, due to differences in the viral strains, viral loads, and sample types, balancing high assay sensitivity and specificity can be complex, especially if the viruses share genetic or antigenic similarities, leading to potential cross-reactivity.
Meridian’s monoclonal antibodies for Flu A, Flu B, COVID, and RSV are designed for low cross-reactivity and high sensitivity, ideal for lateral flow rapid multiplex tests for COVID/FLU/RSV.
[ Find Out More ](https://info.meridianbioscience.com/respiratoryantibodypairs?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741068401818.1741082312147.10&__hssc=51647990.1.1741082312147&__hsfp=1480098718&_gl=1*8uqlkx*_gcl_au*MTU2MTA1NzgzNi4xNzQwMDMyNTIx)
### Molecular Respiratory Assays
Multiplex molecular assays are challenging to develop as the assay must detect different targets to the same level of accuracy and sensitivity as a single test. Meridian specializes in enzymes and master mixes for RT-qPCR and RT-LAMP that are designed for fast and sensitive amplification over a wide dynamic range. The key difference in Meridian’s molecular reagents is their optimization for top performance in the presence of PCR inhibitors. By enhancing inhibitor tolerance of the mixes and enzymes, Meridian’s reagents can achieve higher sensitivity and greater assay reliability.
[ Find Out More ](https://info.meridianbioscience.com/respiratorymolecularsolutions?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741068401818.1741082312147.10&__hssc=51647990.1.1741082312147&__hsfp=1480098718&_gl=1*y5belo*_gcl_au*MTU2MTA1NzgzNi4xNzQwMDMyNTIx)
[  ](https://share.hsforms.com/1okNGuxxBRAivRK7MqDbZQwc22yq?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741068401818.1741082312147.10&__hssc=51647990.1.1741082312147&__hsfp=1480098718)
#### Interested to learn more about COVID/Flu/RSV multiplex testing?
[ Download Whitepaper ](https://share.hsforms.com/1okNGuxxBRAivRK7MqDbZQwc22yq?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741068401818.1741082312147.10&__hssc=51647990.1.1741082312147&__hsfp=1480098718)
---
### [Jeremy Schroeder](https://www.meridianbioscience.com/lifescience/lifescience-leadership-team/jeremy-schroeder/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Jeremy Schroeder
### Vice President, Global Commercial Operations
Jeremy C. Schroeder is Vice President of Global Commercial Operations at Meridian Life Science, where he leads global commercial execution, sales operations, and go-to-market strategy. He brings more than 20 years of leadership experience across life sciences and diagnostics, with a proven track record of building high-performing global teams and scalable commercial models.
Prior to joining Meridian, Jeremy spent over 19 years at Thermo Fisher Scientific in senior commercial leadership roles across the enterprise, consistently delivering revenue growth and operational excellence. He holds an MBA from Johns Hopkins University and a Bachelor of Science in Biological Sciences from the University of Michigan.
## Get to Know Our Members
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
### Florent Chang-Pi-Hin, PhD
Vice President, R&D, Life Science – UK Site Leader
[ Read Bio ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
[  ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
### Jason Klemke, PhD
Vice President, Global Manufacturing and Technical Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Life Science Leadership Team](https://www.meridianbioscience.com/lifescience/lifescience-leadership-team/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
[Home](/) » [About](/about/) » [Team](/about/leadership-team/) » Life Science Leadership
# Life Science Leadership
Our Management Team leverages their deep industry experience, data-driven insights and strategic innovation to empower our team of advocates who deliver novel healthcare solutions that help customers succeed in an increasingly challenging business climate.
## Our Team
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
### Florent Chang-Pi-Hin, PhD
Vice President, R&D, Life Science – UK Site Leader
[ Read Bio ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
[  ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
### Jason Klemke, PhD
Vice President, Global Manufacturing and Technical Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
[  ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
### Jeremy Schroeder
Vice President, Global Commercial Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Carrière](https://www.meridianbioscience.com/carriere/)
**Published:** February 3, 2025
**Author:** hamza
**Content:**
# Ce sont les liens que nous créons qui nous rendent humains.
[ Consulter les offres d’emploi ](https://careersquebec-meridianbioscience.icims.com/jobs/intro?hashed=-435711682)
Nous sommes fiers de dire que nous sommes une entreprise composée de penseurs créatifs qui ne reculent devant aucun défi. Avez-vous ce qu’il faut pour être l’un des cerveaux de Meridian? Si contribuer à repousser les limites des découvertes aux diagnostics vous passionne, nous aimerions vous connaître.
« J’ai su que Meridian était lieu de travail spécial dès mon premier entretien avec la directrice financière. Un moment dont je me souviens depuis le début de ma carrière chez Meridian il y a de cela 19 ans est lorsqu’elle a dit : “Nous sauvons des vies ici; je ne veux pas que vous perdiez cela de vue”. Aussi importants que soient la réalisation des objectifs commerciaux, l’augmentation de la valeur actionnariale et le développement de l’entreprise, il est essentiel de comprendre et de saisir l’impact que nous avons sur les soins de santé et les gens. »
**Lance Connor**
Director, Revenue Analysis, DIAGNOSTICS
## Prendre soin de notre équipe
Ceux qui prennent soin des autres méritent qu’on prenne soin d’eux. Consultez nos avantages sociaux.
[ Consulter les avantages sociaux ](/careers/benefits/)
## Rejoindre notre équipe
Penseurs créatifs et gens d’action qui font preuve de compassion : postulez ici
[ Consulter les offres d’emploi ](https://careers-meridianbioscience.icims.com/jobs/search?ss=1&searchLocation=12955-12966-Quebec)
### Nous sommes une entreprise de penseurs de gens d’action qui ne recule devant aucun défi
[ Découvrir notre culture d’entreprise ](#)
---
### [Jason Klemke, PhD](https://www.meridianbioscience.com/lifescience/lifescience-leadership-team/jason-klemke-phd/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Jason Klemke, PhD
### Vice President, Global Manufacturing and Technical Operations
Jason Klemke leads Global Manufacturing and Technical Operations functions for the Life Science division, bringing over 20 years of expertise in biochemical research, product development, process engineering, and scalable manufacturing. Since joining Meridan in 2006, he has advanced through a series of leadership roles in R&D, where he contributed to the development of blockers, antibodies, and antigens, and led contract manufacturing efforts for vaccines, gene therapies, and challenge viruses. In 2020, Jason transitioned into manufacturing leadership, serving as Senior Director of Manufacturing and Technical Operations at the U.S. Life Science facilities. In this role, he has championed operational excellence, driving improvements in efficiency, quality, and scalability.
Jason holds a PhD in Chemistry from the University of Pennsylvania and a B.A. in Chemistry from Wabash College.
## Get to Know Our Members
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
### Florent Chang-Pi-Hin, PhD
Vice President, R&D, Life Science – UK Site Leader
[ Read Bio ](/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
[  ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
### Jeremy Schroeder
Vice President, Global Commercial Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Catalogs Literature](https://www.meridianbioscience.com/lifescience/catalogs-literature/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
# Catalogs & Literature
##### Learn more about us and our products by clicking on the catalogs below.
### About Meridian Life Science
[ Meridian Life Science Company Overview ](https://collateral.meridianlifescience.com/view/1015735341/) **Meridian Overview
Brochure**
[Immunoassay Full Product Catalog](https://collateral.meridianlifescience.com/view/1015303046/)**Antigen/AntibodyProduct Catalog**
[ Reagent Solutions for Molecular Diagnostics ](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics
Catalog**
[ Molecular Overview ](https://collateral.meridianlifescience.com/view/736341769/) **Molecular Overview**
[Immuno Overview](https://collateral.meridianlifescience.com/view/972086005/)**Immuno Overview**
[Novel RT-qPCR Reagents](https://collateral.meridianlifescience.com/view/475510132/)**Novel RT-qPCR ReagentsCatalog**
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR/RT-qPCRCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCR Catalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
### Immunoassay Blocking Reagents
[TRU Block](https://collateral.meridianlifescience.com/view/190586606/)**TRU Block™Catalog**
[Immunoassay Blocking Agents Catalog](https://collateral.meridianlifescience.com/view/537560556/)**Immunoassay Blocking Agents Catalog**
[TRU Block Ultra](https://collateral.meridianlifescience.com/view/190593767/)**TRU Block™ UltraCatalog**
[Meridian Immunoassay Blockers for Heterophilic Interference](https://collateral.meridianlifescience.com/view/462794126/)**Meridian Immunoassay Blockers for Heterophilic Interference**
[Meridian K-Block Catalog](https://collateral.meridianlifescience.com/view/118170593/)**Meridian K-Block Catalog**
[Mouse-FREE IgG](https://collateral.meridianlifescience.com/view/790577272/)**Mouse-FREE IgG**
### Infectious Disease
[Infectious Diseases & Toxins](https://collateral.meridianlifescience.com/view/159860758/)**Infectious Diseases & ToxinsCatalog**
[ToRCH & Childhood Diseases](https://collateral.meridianlifescience.com/view/923314182/)**ToRCH & Childhood DiseasesCatalog**
[ToRCH IgG/IgM Assay Development Guide](https://collateral.meridianlifescience.com/view/922874448/)**ToRCH Reagents GuideCatalog**
[Rubella IgM MAX Antigen](https://collateral.meridianlifescience.com/view/159717506/)**Rubella IgM MAX™ AntigenCatalog**
[Sexually Transmitted Diseases (STDs)](https://collateral.meridianlifescience.com/view/159653059/)**Sexually Transmitted Diseases (STD)Catalog**
[Viral Hepatitis](https://collateral.meridianlifescience.com/view/159945696/)**Viral HepatitisCatalog**
[Tropical & Vector-Borne Diseases](https://collateral.meridianlifescience.com/view/923135831/)**Tropical & Vector- Borne DiseasesCatalog**
[Zika Virus](https://collateral.meridianlifescience.com/view/923687354/)**ZikaCatalog**
[Nipah Virus G Proteins](https://collateral.meridianlifescience.com/view/923766223/)**Nipah Catalog**
[Respiratory Diseases](https://collateral.meridianlifescience.com/view/455424416/)**Respiratory Catalog**
[Leading Respiratory Products/Pairs](https://collateral.meridianlifescience.com/view/455625468/)**Leading Respiratory Products/PairsCatalog**
[Gastrointestinal Pathogens for Stool Testing](https://collateral.meridianlifescience.com/view/455381450/)**Gastrointestinal Pathogens for Stool TestingCatalog**
[Blood Donor Screening](https://collateral.meridianlifescience.com/view/160293564/)**Blood Donor ScreeningCatalog**
[Cancer-causing Viruses](https://collateral.meridianlifescience.com/view/788698881/)**Cancer-causing VirusesCatalog**
[Key STD Molecular & Immuno Solutions](https://collateral.meridianlifescience.com/view/510339704/)**Key STD Molecular & Immuno SolutionsCatalog**
[New HCV Chimeric Antigen](https://collateral.meridianlifescience.com/view/143770016/)**New HCV Chimeric AntigenCatalog**
### Cancer & Tumor Markers
[Cancer & Tumor Markers Catalog](https://collateral.meridianlifescience.com/view/592341234/)**Cancer and Tumor Markers Catalog**
[Cancer Products Pairs flyer](https://collateral.meridianlifescience.com/view/592174495/)**Cancer Products Pairs Brochure**
### Cardiac
[Cardiac & Metabolic Markers](https://collateral.meridianlifescience.com/view/591795949/)**Cardiac & Metabolic MarkersCatalog**
[Cardiac Pairs](https://collateral.meridianlifescience.com/view/592204925/)**Cardiac PairsCatalog**
[](https://www.meridianbioscience.com/lifescience/tech-note-high-sensitivity-cardiac-monoclonal-antibody-pairs/)**High-Sensitivity Cardiac Monoclonal Antibody Pairs**
### Bone Health
[Vitamin D Flyer](https://collateral.meridianlifescience.com/view/592376020/)**Vitamin DBrochure**
### Hormones & Steroids
[Hormones & Steroids](https://collateral.meridianlifescience.com/view/189848031/)**Hormones and Steroids Brochure**
[Anti-Müllerian Hormone (AMH)](https://collateral.meridianlifescience.com/view/190454639/)**Anti-Müllerian Hormone (AMH)Brochure**
### Drug of Abuse
[Drug Testing Reagents for Commercial Assay Development](https://collateral.meridianlifescience.com/view/591826635/)**Drug Testing Reagents for Commercial Assay DevelopmentCatalog**
### Autoimmune & Allergy
[Autoimmune Flyer](https://collateral.meridianlifescience.com/view/591745596/)**AutoimmuneCatalog**
### Contract Manufacturing
[Meridian Contract Manufacturing](https://collateral.meridianlifescience.com/view/592363736/)**Contract ManufacturingBrochure**
### Veterinary and Animal Health
[Veterinary & Animal Health](https://collateral.meridianlifescience.com/view/591812349/)**Veterinary & Animal HealthCatalog**
[African Swine Fever Virus (ASFV)](https://collateral.meridianlifescience.com/view/591560695/)**African Swine Fever Virus (ASFV)Catalog**
[Veterinary Health](https://collateral.meridianlifescience.com/view/999379633/)**Veterinary HealthCatalog**
### COVID-19
[COVID-19](https://collateral.meridianlifescience.com/view/33597782/)**COVID-19**
[Multiplex Respiratory Assays – RSV, Flu and COVID](https://collateral.meridianlifescience.com/view/795558266/)**Multiplex Respiratory Assays – RSV, Flu and COVID**
[MAb Pair to SARS-CoV-2 NP](https://collateral.meridianlifescience.com/view/475150359/)**High-Sensitivity SARS-CoV-2 Nucleoprotein Antibody PairCatalog**
[SARS-CoV-2 Recombinant Antigens](https://collateral.meridianlifescience.com/view/875184270/)**SARS-CoV-2 Recombinant AntigensCatalog**
### Molecular Dx Reagents
#### Polymerases
[Glycerol‑Free Taq HS](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HSCatalog**
[Aptamer Taq HS](https://collateral.meridianlifescience.com/view/33669388/)**Aptamer Taq HS (Glycerol-Free)Catalog**
[Bacterial and Fungal DNA Amplification](https://collateral.meridianlifescience.com/view/33644836/)**Bacterial & Fungal DNA AmplificationCatalog**
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase & Optimized Reaction Buffers for Isothermal AssaysCatalog**
[High-performing DNA polymerases](https://collateral.meridianlifescience.com/view/664490484/)**High-performing DNA polymerasesCatalog**
[Glycerol-Free Tth DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/751572112/)**Glycerol-Free Tth DNA Polymerase (HC)Catalog**
#### Mixes
[Liquid Stable Flex DNA qPCR Mix](https://collateral.meridianlifescience.com/view/676462519/)**Liquid Stable Flex DNA qPCR Mix (MDX360)**
[Meridian Liquid Stable Ready DNA qPCR Mix (MDX364)](https://collateral.meridianlifescience.com/view/677153002/)**Meridian Liquid Stable Ready DNA qPCR Mix (MDX364)**
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR/RT-qPCRCatalog**
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable™ Direct SalivaCatalog**
[Meridian Air Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable™ Direct StoolCatalog**
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
[Unlocking Precision in Liquid Biopsy with High-Sensitivity qPCR](https://collateral.meridianlifescience.com/view/648087398/)**Unlocking Precision in Liquid Biopsy with High-Sensitivity qPCR**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[Air-Dryable Direct Urine](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct UrineCatalog**
[Air-Dryable Direct Plant](https://collateral.meridianlifescience.com/view/397948458/)**Air-Dryable Direct PlantCatalog**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable AssaysCatalog**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HSCatalog**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMPCatalog**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMPCatalog**
[Lyo-Ready Direct Saliva](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct SalivaCatalog**
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCRCatalog**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCRCatalog**
[Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix, 4xCatalog**
[Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Saliva Master Mixes](https://collateral.meridianlifescience.com/view/180412872/)**Lyo-Ready Direct LAMP Saliva MixesCatalog**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://collateral.meridianlifescience.com/view/111612146/)**Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes**
[Lyo-Ready Direct LAMP Urine Mixes](https://collateral.meridianlifescience.com/view/940080326/)**Lyo-Ready Direct LAMP Urine Mixes**
[Specimen-specific™ and Universal qPCR & LAMP Master Mixes for Ultra-Sensitive Detection](https://collateral.meridianlifescience.com/view/205757818/)**Specimen-specific™ and Universal qPCR & LAMP Master Mixes for Ultra-Sensitive Detection**
[Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes](https://collateral.meridianlifescience.com/view/206034024/)**Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/)**Lyo-Ready Genotyping Direct DNA qPCR Urine**
[Lyo-Ready Genotyping Direct qPCR Stool](https://collateral.meridianlifescience.com/view/967751022/)**Lyo-Ready Genotyping Direct qPCR Stool**
[Lyo-Ready Direct Blood Mixes](https://collateral.meridianlifescience.com/view/222789736/)**Lyo-Ready Direct Blood Mixes**
[Lyo-Ready Direct qPCR Urine Mixes](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct qPCR Urine Mixes**
[Lyo-Ready Genotyping Direct qPCR Blood](https://collateral.meridianlifescience.com/view/330386481/)**Lyo-Ready Genotyping Direct qPCR Blood**
[Lyo-Ready Genotyping Direct qPCR FFPE](https://collateral.meridianlifescience.com/view/487986445/)**Lyo-Ready Genotyping Direct qPCR FFPE**
### General Reagents
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Solutions for Next Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Solutions for Next Generation Sequencing (NGS)Catalog**
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction ControlsCatalog**
[VLP-RNA Extraction Control](https://collateral.meridianlifescience.com/view/33936393/)**VLP-RNA Extraction ControlCatalog**
[dNTPs](https://collateral.meridianlifescience.com/view/864093733/)**dNTPs (Deoxynucleotide triphosphates)Catalog**
[Food Safety Testing](https://collateral.meridianlifescience.com/view/34018489/)**Food Safety TestingCatalog**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)Catalog**
[Reverse transcriptases](https://collateral.meridianlifescience.com/view/1040476064/)**Reverse transcriptases Catalog**
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080)**Glycerol-Free T7 RNA Polymerase Catalog**
### Custom Services
[Immuno Contract Manufacturing Services](https://collateral.meridianlifescience.com/view/592363736/)**Immuno Contract Manufacturing ServicesCatalog**
[Custom Oligonucleotide Manufacturing](https://collateral.meridianlifescience.com/view/1069600406/)**Custom Oligonucleotide ManufacturingCatalog**
[Molecular Custom Assay Development Services Flyer](https://collateral.meridianlifescience.com/view/341387842/)**Molecular Custom Assay Development Services Flyer**
[Lateral Flow Services](https://collateral.meridianlifescience.com/view/1069892597/)**Lateral Flow ServicesCatalog**
#### Quick Links
[About Meridian Life Science](#about-life-science)
[Immunoassay Blocking Reagents](#blockers)
[Infectious Disease](#infectious-disease)
[Cancer & Tumor Markers](#cancer)
[Cardiac](#cardiac)
[Bone Health](#bone-health)
[Hormones & Steroids](#hormones)
[Drug of Abuse](#drugs)
[Autoimmune & Allergy](#autoimmune)
[Contract Manufacturing](#contract-manufacturing)
[Veterinary and Animal Health](#vet)
[COVID-19](#covid)
[Molecular Dx Reagents](#molecular)
[Polymerases](#polymerases)
[Mixes](#mixes)
[General Reagents](#general)
[Custom Services](#custom)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/about/lifescience/)
---
### [High-Sensitivity Cardiac Monoclonal Antibody Pairs](https://www.meridianbioscience.com/lifescience/tech-note-high-sensitivity-cardiac-monoclonal-antibody-pairs/)
**Published:** December 11, 2025
**Author:** Holger
**Content:**
# High-Sensitivity Cardiac
Monoclonal Antibody Pairs
[High-Sensitivity Cardiac Monoclonal Antibody Pairs](https://collateral.meridianlifescience.com/view/710252173/)**High-Sensitivity Cardiac Monoclonal Antibody Pairs**
[ Back to White Papers ](#)
---
### [Harald Ottenhof](https://www.meridianbioscience.com/about/leadership-team/harald-ottenhof/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Harald Ottenhof, PhD
### Executive Vice President, Life Science Meridian Bioscience
Harald Ottenhof serves as Executive Vice President of the Life Science business at Meridian Bioscience, where he leads global strategy, commercial execution, and operational excellence across the company’s Life Science portfolio. With more than a decade in progressive leadership roles at Meridian, Harald has been instrumental in strengthening the organization’s operational capabilities, expanding global market reach, and driving high-performance culture across teams and geographies.
Since joining Meridian in 2018, Harald has held several key leadership positions, including Vice President of Commercial Operations, General Manager of the Memphis Life Science site, Vice President of Global Operations, and Senior Vice President of Global Commercial & Operations. His deep industry expertise and results-oriented leadership have helped position Meridian as a trusted global partner for diagnostic innovators and biopharmaceutical manufacturers.
Harald’s leadership philosophy emphasizes clarity, accountability, and alignment around shared goals. Known for building collaborative, empowered teams, he is recognized for his ability to translate complex market and operational dynamics into actionable strategies that deliver sustainable growth. His global background—spanning the U.S., U.K., Europe, and Asia-Pacific—further informs his approach to scaling organizations and fostering customer-focused innovation.
Before joining Meridian, Harald spent more than a decade at Thermo Fisher Scientific (including Life Technologies), where he advanced through commercial and product management roles across the Life Sciences Solutions and Laboratory Equipment businesses. Earlier in his career, he held a postdoctoral research position at the University of Melbourne, building on his scientific training.
Harald holds a Doctor of Philosophy in Genetics and Biochemistry from the University of Cambridge and a Bachelor of Science (Hons) in Genetics from the University of Nottingham. He continues to guide Meridian’s Life Science business with a commitment to operational rigor, commercial excellence, and strategic growth on a global scale.
## Get to Know Our Members
[  ](/about/leadership-team/andy-kitzmiller/)
### Andy Kitzmiller
President and Chief Executive Officer
[ Read Bio ](/about/leadership-team/andy-kitzmiller/)
[  ](/about/leadership-team/julie-smith/)
### Julie Smith
Senior Vice President and Chief Financial Officer
[ Read Bio ](/about/leadership-team/julie-smith/)
[  ](/about/leadership-team/emerson-c-moser/)
### Emerson C. Moser
Senior Vice President and General Counsel
[ Read Bio ](/about/leadership-team/emerson-c-moser/)
[  ](/about/leadership-team/don-oliver/)
### Don Oliver
Senior Director of Global Information Technology
[ Read Bio ](/about/leadership-team/don-oliver/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [John R. Lewis, Jr.](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# John R. Lewis, Jr.
### Vice President, Quality Operations
John R. Lewis, Jr. leads Meridian Bioscience’s quality operations, ensuring the highest standards of product quality, compliance, and operational excellence across the organization.
Since joining Meridian in 2012, he has advanced through roles as Director, Senior Director, and now Vice President of Quality Operations, guiding quality systems and processes that support the company’s growth and regulatory success.
John holds both a Bachelor’s and Master’s degree in Ecology and Evolutionary Biology / Molecular Genetics from the University of Cincinnati.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Urea Breath Marketing](https://www.meridianbioscience.com/urea-breath-marketing/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
## *H. pylori* Testing for Healthcare Providers & Laboratories
Detect *Helicobacter pylori* with confidence using our FDA-approved urea breath test (UBT) kits. Our market-leading diagnostic solutions offer unparalleled accuracy for both initial detection and post-treatment confirmation, ensuring superior patient care in medical and laboratory settings.
[ Request a Quote ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU5Mzk5IiwidG9nZ2xlIjpmYWxzZX0%3D)
#### Unmatched Accuracy in *H. pylori* Detection
The state-of-the-art BreathID® Smart urea breath test platform for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with efficient automation for maximizing mid-range testing throughput. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
##### Unparalleled Performance
- 100% Sensitivity
- 97.9% Specificity
##### Intuitive Efficiency
Automated data input and batch analysis to reduce human error and simplify reporting
##### Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
### From Scan to Results in 3 Steps
2 minutes to diagnose *H. pylori*
### Your trusted partner in diagnostic accuracy and compact operational efficiencies
### The BreathID® Platform Advantage
The BreathID® platform can be used in conjunction with other Meridian *H. pylori* platforms for a total testing solution across the healthcare system that offers:
- Flexibility in testing options to support near-patient testing or centralized testing in a core lab
- The ability for system administrators to be responsive to changes in testing requirements and demand fluctuations within the health network
- An unparalleled *H. pylori* portfolio that accommodates any laboratory setting, from low-volume rapids to high-volume automation
- A choice of testing methods for physicians to accurately diagnose active H. pylori infection
- Improved operational efficiencies and the capability to deliver standardization across the network by consolidating testing to one trusted partner
#### Why use BreathID®? Smart urea breath test platform for *H. pylori*?
- **Non-Invasive Breath Testing –** A patient-friendly alternative for clinics, hospitals, and diagnostic laboratories, suitable for both adults and children.
- **Rapid & Reliable Results –** Use the urea breath test (UBT) for fast 2 minutes to diagnosis to ensure the most effective diagnostic workflow. Rapid results in just 2 minutes, ensuring an efficient and effective diagnostic workflow.
- **Clinically Validated Accuracy –** Our urea breath test is trusted by leading gastroenterology practices, hospitals, and research institutions for *H. pylori* detection and confirmation of eradication.
- **Seamless Laboratory Integration –** Our test kits support high-throughput lab processing, minimizing turnaround time and maximizing operational efficiency.
#### Scalable Solutions for Medical Facilities & Laboratories
[ Order UBT Kits ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU5Mzk5IiwidG9nZ2xlIjpmYWxzZX0%3D)
- **Ensure uninterrupted supply for clinical use, hospital networks, and diagnostic laboratories..**
- **Expand Your Testing Services –** Partner with Meridian to offer urea breath testing at your facility, increasing patient access to non-invasive *H. pylori* diagnostics.
- **Clinical Partnerships & Provider Network –** We collaborate with gastroenterology centers, diagnostic labs, and primary care providers to streamline *H. pylori* detection and treatment decisions.
#### Science-Backed Accuracy for Precision Testing
Our 13C-urea breath test is gastroenterologist-recommended for its high sensitivity and specificity. Equip your facility with the best test for *H. pylori*, backed by clinical guidelines.
#### Optimize *H. pylori* in Your Practice
- Support effective treatment decisions with early, accurate detection.
- Reduce unnecessary antibiotic prescriptions by confirming eradication post-treatment.
- Enhance patient care & clinical outcomes with streamlined, non-invasive testing solutions.
### Partner with Us Today
Contact us to discuss ordering, laboratory partnerships, or clinical integration of *H. pylori* urea breath test solutions. Let’s improve gastrointestinal health diagnostics together.
#### Are you a Healthcare Professional?
As a healthcare professional, you’re dedicated to providing accurate and timely results. Click below to connect with our specialists for expert guidance and additional resources.
[ Contact a Specialist ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU5NDAxIiwidG9nZ2xlIjpmYWxzZX0%3D)
#### Are you a Patient?
Your health matters, and getting the right information is key. Click below to learn more and take the next step towards understanding your health better.
[Visit our Resource Center](/h-pylori-patients-resources/)
---
### [News & Updates](https://www.meridianbioscience.com/news-updates/)
**Published:** January 22, 2025
**Author:** hamza
---
### [Corporate Social Responsibility](https://www.meridianbioscience.com/about/corporate-social-responsibility/)
**Published:** February 4, 2025
**Author:** hamza
**Content:**
# Building a Healthier Future Through Sustainability and With Integrity
We are committed to fostering a sustainable future grounded in ethical business practices and supply chain accountability. We prioritize integrity, innovation, and community engagement to positively impact public health, protect the environment, and nurture the wellbeing of our employees.
#### Together, let’s make a difference.
#### Advancing Human Health Through Sustainability
At Meridian Bioscience, sustainability is a fundamental part of our mission to improve human health. We are committed to creating lasting value that goes beyond our products, with a focus on environmental stewardship and responsible operations. By prioritizing sustainability, we aim to meet international standards and contribute to the global push for a more sustainable future. Our ongoing efforts are designed to make a positive impact on our employees, communities, and the planet, ensuring we operate with responsibility and integrity.
### Our Mission to Improve Human Health
At Meridian Bioscience, our commitment to sustainability and Corporate Social Responsibility (CSR) is at the core of our mission to improve human health. We believe in creating value that endures beyond our products—our commitment to environmental stewardship, ethical operations, fair labor practices, and a responsible supply chain is embedded in our corporate ethos. By prioritizing these key areas, we not only strive to meet international sustainability standards but also contribute to the global agenda for a sustainable future. Our ongoing efforts are aimed at creating a positive impact on our employees, communities, and planet as we work to ensure that we operate responsibly and with integrity.
### Unwavering Dedication to Corporate Social Responsibility
At Meridian Bioscience, our commitment to sustainability and Corporate Social Responsibility (CSR) is at the core of our mission to improve human health. We believe in creating value that endures beyond our products—our commitment to environmental stewardship, ethical operations, fair labor practices, and a responsible supply chain is embedded in our corporate ethos. By prioritizing these key areas, we not only strive to meet international sustainability standards but also contribute to the global agenda for a sustainable future. Our ongoing efforts are aimed at creating a positive impact on our employees, communities, and planet as we work to ensure that we operate responsibly and with integrity.
[ Download Our EcoVadis Sustainability Performance Overview ](/uploads/MERIDIAN_BIOSCIENCE_INC_(GROUP)_CSR_Performance_Overview_2025_10_13.pdf)
### Upholding the Highest Standards of Ethics
We uphold the highest standards of ethics by fostering a culture of integrity, transparency, and accountability. Our commitment to ethical practices is reflected in our interactions with stakeholders, adherence to regulatory compliance, and dedication to responsible sourcing. We believe that ethical conduct not only drives our success but also builds trust within the communities we serve, ensuring that our mission to improve health and well-being is achieved with the utmost integrity.
If you have any concerns about the actions (or inactions) of Meridian, its employees or its partners/representatives, we encourage you to submit your concern through our EthicsPoint Compliance Helpline. Your voice matters in maintaining our commitment to ethics.
[ Download Meridian's Code of Ethics and Business Conduct ](/uploads/2024-Code-of-Conduct-vFinal-Public-Policy.pdf)
### Standards for Suppliers
We prioritize strong partnerships with suppliers who share our commitment to quality, sustainability, and ethical practices. Learn about our supplier requirements, and how we collaborate to ensure the highest standards in delivering innovative diagnostic solutions that improve human health globally.
[ Read our Standards for Suppliers ](https://www.meridianbioscience.com/suppliers/)
### Meridian's Anti-Trafficking and Modern Slavery Commitment
Meridian Bioscience, Inc., together with its global subsidiaries (collectively, “Meridian”) does not tolerate or condone modern slavery in any form, including, but not limited to, forced labor, child labor, indentured servitude, and/or human trafficking (collectively, “Modern Slavery”). Through Meridian’s policies and procedures, Meridian is committed to ensuring that there is no Modern Slavery in its business or supply chain. Meridian will comply with all applicable laws and regulations concerning the identification and prevention of Modern Slavery.
[ Read Our Anti-Trafficking and Modern Slavery Commitment ](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/01143708/Modern-Slavery-Commitment.pdf)
### Meridian's Responsible Materials Policy
Meridian Bioscience, Inc. and its global subsidiaries are committed to sourcing minerals responsibly and ensuring that its supply chain does not contribute to human rights abuses, environmental harm, or armed conflict. This policy establishes our commitment to ethical sourcing, due diligence, and compliance with international standards as set by OECD Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas (OECD Due Diligence Guidance), and also addressed by the legislators in various regions, including the United States of America and the European Union.We prioritize strong partnerships with suppliers who share our commitment to quality, sustainability, and ethical practices. Learn about our supplier requirements, and how we collaborate to ensure the highest standards in delivering innovative diagnostic solutions that improve human health globally.
[ Read our Responsible Minerals Policy ](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/10/29144150/Responsible-Minerals-Policy-11.1.25-Public.pdf)
### Have a Corporate Social Responsibility, or Sustainability Question?
Please complete the form to the right to contact the Meridian Sustainability Team.
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Andy Kitzmiller](https://www.meridianbioscience.com/about/leadership-team/andy-kitzmiller/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Andy Kitzmiller
### President and Chief Executive Officer
As President and Chief Executive Officer of Meridian Bioscience, Andy Kitzmiller leads a global organization of more than 800 employees dedicated to advancing diagnostic and life science solutions that improve health and well-being around the world.
Since joining Meridian in February 2022, Kitzmiller has helped align the company’s operational and financial strategies, strengthen execution, and define the four strategic pillars that continue to guide Meridian’s long-term value creation plan. Prior to his current role, he served as Chief Operating Officer and Chief Financial Officer, partnering closely with teams across Meridian, its shareholders, investors, and affiliates—including SD Biosensor and Bionote—to drive growth, integration, and innovation.
Kitzmiller’s leadership philosophy is grounded in collaboration, transparency, and disciplined execution. He is deeply committed to cross-functional teamwork and to connecting strategic vision with meaningful outcomes for employees, customers, and shareholders alike.
Earlier in his career, Kitzmiller held senior finance and operational leadership roles at Hillenbrand, Milacron, and GE Aviation (now GE Aerospace), and began his professional journey in Deloitte’s audit practice in Cincinnati, Ohio. Across his career, he has been passionate about developing teams, delivering sustainable results, and building global organizations that thrive through both performance and purpose.
## Get to Know Our Members
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/about/leadership-team/julie-smith/)
### Julie Smith
Senior Vice President and Chief Financial Officer
[ Read Bio ](/about/leadership-team/julie-smith/)
[  ](/about/leadership-team/emerson-c-moser/)
### Emerson C. Moser
Senior Vice President and General Counsel
[ Read Bio ](/about/leadership-team/emerson-c-moser/)
[  ](/about/leadership-team/don-oliver/)
### Don Oliver
Senior Director of Global Information Technology
[ Read Bio ](/about/leadership-team/don-oliver/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [Contact our Diagnostics Division](https://www.meridianbioscience.com/contact-us-diagnostics/)
**Published:** February 5, 2025
**Author:** hamza
**Content:**
# Contact Our Diagnostics Division
We’re here to assist you with any inquiries or support you need regarding our diagnostic solutions. Whether you have questions about our products, need technical assistance, or require specific information, our expert team is ready to help. If you prefer not to have your information shared, contact us directly at [info@meridianbioscience.com.](mailto:info@meridianbioscience.com)
##### USA Headquarters
**Meridian Diagnostics & Corporate Offices**
3471 River Hills Drive
Cincinnati, OH 45244
Email: mbi@meridianbioscience.com
**Meridian Life Science**
5171 Wilfong Road
Memphis, Tennessee 38134-5611
Email: info@meridianlifescience.com
Corporate
Toll Free: 800-696-0739
Tel: +1 513-271-3700
Fax: 513-271-3702
Life Science Customer Service
Tel: +1 901-382-8716
Fax: +1 901-333-8223
Diagnostics Customer Service
Tel: 800-543-1980
Fax: +1 513-271-0124
Diagnostics Technical Services Product Support Center
Tel: 800-343-3858
##### Canada
360 Rue Franquet #3
Québec, QC G1P 4N3
Tel: +1 418-650-3535
Email: info@meridianbioscience.com
##### China
Unit A6, East Tower, 10th Floor
No. 12 B, Jianguomenwai Avenue
Chaoyang District, Beijing, China
Tel : +86 010-85660600
Email: info.cn@meridianlifescience.com
##### Germany
Im Biotechnologiepark, 3
14943 Luckenwalde
Tel: +49 (0)3371 602 2200
Fax: +49 (0)3371 602 2201
Email: info@meridianlifescience.com
##### Israel
4 Ha’maayan St.
Modiin, Israel
Tel: +972 8-973-7500
##### Italy
Via dell’ Industria, 7
20035 Villa Cortese
Milano
Tel: +39 0331 43 36 36
Fax: +39 0331 43 36 16
Email: info@meridianbioscience.eu
##### United Kingdom
Unit 16 The Edge Business Centre
Humber Road
NW2 6EW London
Tel: +44 (0)20 8453 7970
Fax: +44 (0)20 8452 2822
Email: info@meridianlifescience.com
---
### [Antibodies Antigens](https://www.meridianbioscience.com/antibodies-antigens/)
**Published:** January 23, 2025
**Author:** hamza
---
### [Cal Check Video IT](https://www.meridianbioscience.com/cal-check-video-it/)
**Published:** February 12, 2026
**Author:** Moaaz Ahmad
**Content:**
---
### [Don Oliver](https://www.meridianbioscience.com/about/leadership-team/don-oliver/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Don Oliver
### Senior Director of Global Information Technology
Leads global information technology operations at Meridian, bringing more than 25 years of experience delivering enterprise technology, business transformation, and cybersecurity solutions. Known for leading large-scale transformational initiatives, he has successfully modernized enterprise platforms, strengthened cybersecurity capabilities, and built high-performing global teams that enable innovation and operational excellence.
He partners closely with executive leadership to shape and execute Meridian’s technology strategy, with responsibility for global IT operations, budgeting, project and portfolio management, IT governance, cybersecurity, and enterprise risk management. Throughout his career, he has championed initiatives that align technology investments with business priorities, improve organizational agility, and drive measurable value across the enterprise.
Looking ahead, he is focused on transforming Meridian’s technology ecosystem to support the company’s next phase of growth, advancing scalable digital platforms, modern data and analytics capabilities, and resilient infrastructure that enables faster innovation and stronger collaboration across the organization. By continuing to invest in talent, modern architecture, and strategic partnerships, he is helping position Meridian Bioscience to operate with greater speed, scalability, and global impact.
## Get to Know Our Members
[  ](/about/leadership-team/andy-kitzmiller/)
### Andy Kitzmiller
President and Chief Executive Officer
[ Read Bio ](/about/leadership-team/andy-kitzmiller/)
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/about/leadership-team/julie-smith/)
### Julie Smith
Senior Vice President and Chief Financial Officer
[ Read Bio ](/about/leadership-team/julie-smith/)
[  ](/about/leadership-team/emerson-c-moser/)
### Emerson C. Moser
Senior Vice President and General Counsel
[ Read Bio ](/about/leadership-team/emerson-c-moser/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [Contact our Life Science Division](https://www.meridianbioscience.com/contact-us-life-science/)
**Published:** February 5, 2025
**Author:** hamza
**Content:**
# Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
Please note: We may share your personal contact data with our distribution partner(s) for the sole purpose of responding and replying to your inquiry. If you do not want your information shared, please contact us directly by emailing: .
## Let's discover together! Join our quarterly newsletter for the latest insights in your inbox.
[ Life Science Newsletter Registration ](https://www.meridianbioscience.com/lifescience/life-science-newsletter-registration/)
##### USA Headquarters
**Meridian Diagnostics & Corporate Offices**
3471 River Hills Drive
Cincinnati, OH 45244
Email: mbi@meridianbioscience.com
**Meridian Life Science**
5171 Wilfong Road
Memphis, Tennessee 38134-5611
Email: info@meridianlifescience.com
Corporate
Toll Free: 800-696-0739
Tel: +1 513-271-3700
Fax: 513-271-3702
Life Science Customer Service
Tel: +1 901-382-8716
Fax: +1 901-333-8223
Diagnostics Customer Service
Tel: 800-543-1980
Fax: +1 513-271-0124
Diagnostics Technical Services Product Support Center
Tel: 800-343-3858
##### Canada
360 Rue Franquet #3
Québec, QC G1P 4N3
Tel: +1 418-650-3535
Email: info@meridianbioscience.com
##### China
Unit A6, East Tower, 10th Floor
No. 12 B, Jianguomenwai Avenue
Chaoyang District, Beijing, China
Tel : +86 010-85660600
Email: info.cn@meridianlifescience.com
##### Germany
Im Biotechnologiepark, 3
14943 Luckenwalde
Tel: +49 (0)3371 602 2200
Fax: +49 (0)3371 602 2201
Email: info@meridianlifescience.com
##### Israel
4 Ha’maayan St.
Modiin, Israel
Tel: +972 8-973-7500
##### Italy
Via dell’ Industria, 7
20035 Villa Cortese
Milano
Tel: +39 0331 43 36 36
Fax: +39 0331 43 36 16
Email: info@meridianbioscience.eu
##### United Kingdom
Unit 16 The Edge Business Centre
Humber Road
NW2 6EW London
Tel: +44 (0)20 8453 7970
Fax: +44 (0)20 8452 2822
Email: info@meridianlifescience.com
---
### [New Air-Dryable Technology, an Advanced Alternative to Lyophilization for Molecular Assays](https://www.meridianbioscience.com/lifescience/new-air-dryable-technology-an-advanced-alternative-to-lyophilization-for-molecular-assays/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## New Air-Dryable Technology, an Advanced Alternative to Lyophilization for Molecular Assays
[ Back to White Papers ](#)
---
### [The COVID Aftermath: Rising Immunoassay Interference in Diagnostic Immunoassays](https://www.meridianbioscience.com/lifescience/rising-immunoassay-interference-immunoassays-webinar/)
**Published:** November 13, 2025
**Author:** Moaaz Ahmad
**Content:**
# The COVID Aftermath:
### Rising Immunoassay Interference in Diagnostic Immunoassays
The COVID-19 pandemic has left a lasting impact on diagnostic immunoassays, with emerging evidence linking SARS-CoV-2 infection to increased antibody-mediated immunoassay interference. This presentation explores the rise in interference, particularly from rheumatoid factor (Rf), and its implications for assay accuracy. Post-COVID immune dysregulation has led to elevated levels of autoantibodies, including polyreactive RF, which significantly increase the risk of false results in immunoassays.
# Attendees will learn about:
- Mechanisms of antibody interference
- The post-COVID increase in interference challenges
- Practical strategies to mitigate interference and protect assay performance
The session will also explore the role of passive, active, and universal blockers in neutralizing interfering antibodies, highlighting Meridian Life Science’s portfolio of solutions designed to improve reliability across ELISA, CLIA, and LFA platforms.
**Register Now! Join us for this webinar to stay ahead of post-COVID interference challenges!**
**Speaker Bio:**
John Francois, Product Manager
John Francois brings a unique blend of academic and industry expertise to the immunodiagnostics field. He earned his PhD in Biology from Rutgers University, where he also taught biology courses for several years. Driven by a passion for bridging science and business, he pursued an MBA from Rutgers Business School before transitioning into the life sciences industry. John began his corporate career at VWR (part of Avantor) as a Life Science Product Manager, where he led product strategy for six years. In 2025, he joined Meridian Life Science as Product Manager for the Immunology portfolio, focusing on innovative solutions for assay interference and diagnostic accuracy.
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [Transforming Cancer Detection with Liquid Biopsy](https://www.meridianbioscience.com/lifescience/transforming-cancer-detection-with-liquid-biopsy/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Diagnostics Team Members](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
[Home](/) » [About](/about/) » [Team](/about/leadership-team/) » Diagnostics Leadership
# Diagnostics Leadership
The Diagnostics team focuses on empowering clinicians with fast, accurate answers. Specialized in gastrointestinal, respiratory, and blood lead testing, these compassionate doers utilize advanced platforms like Revogene and Curian. By simplifying complex diagnostic processes, they help healthcare providers make confident decisions that identify risks and improve patient outcomes every day.
## Our Team
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Products](https://www.meridianbioscience.com/lifescience/products/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
- [Home](https://www.meridianbioscience.com)
- »
- Products
# Products
Diagnostic assays that deliver the best patient outcomes rely on high-quality reagents. Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 disease targets and an extensive range of specialty qPCR master mixes and molecular enzymes manufactured under ISO13485 regulations. Meridian offers diagnostic manufacturers the complete solution.
[ Contact a Specialist ](#contactsales)
[ View Products Below ](#products)
### Molecular Reagents & Service
- [Custom Services](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/services/)
- [noun\_pollen\_3843579 copy 22DNA-RNA Extraction Controls](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)
- [ Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/)
- [Isothermal Amplification](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/)
- [Lyo-Ready & Air-Dryable Master Mixes & Reagents](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
- [ NGS Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes/)
- [Nucleotides](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/nucleotides/)
- [qPCR and RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/)
- [noun\_pollen\_3843579 copy 22Reaction Buffers](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/reaction-buffers/)
- [RNase Inhibitors](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/rnase-inhibitor/)
- [Specimen-specific™ Inhibitor Tolerant Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
#### Antibodies, Antigens, Blockers & Services
- [ Allergens](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/allergens/)
- [ Antimicrobial Resistance](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/)
- [ Autoimmune](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/)
- [ Blockers & Immunoglobulins](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/)
- [ Cancer Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/)
- [ Cardiac, Cholesterol, & Metabolic Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/)
- [Custom Antibody & Protein Manufacturing Services](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/custom-antibody-protein-manufacturing-services/)
- [ DOA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/)
- [Enzymes](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/enzymes/)
- [ Food & Water Testing](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/)
- [ Gastrointestinal Pathogens](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/)
- [ Hormones & Steroids](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/)
- [ Microbial Detection](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/)
- [ Miscellaneous Reagents](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/)
- [ Neurological Diseases & Trauma](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/)
- [Pfu Enzyme](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/pfu-enzyme/)
- [ Renal Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/renal-diseases/)
- [ Respiratory Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/)
- [ Sexually Transmitted Infections (STIs)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/)
- [ ToRCH & Childhood](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/)
- [ Toxins & Biowarfare](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/toxins-biowarfare/)
- [ Tropical & Vector-Borne Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/)
- [ Vet Health](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/)
- [ Viral Hepatitis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/)
## Why We Are Second To None
We strive to provide our customers with solutions they need when they need it – from novel antigens and antibodies to major disease outbreaks such as Zika and SARS-CoV-2 to pioneering the market with our innovative air-dried qPCR/RT-qPCR mixes. We take pride in providing our customers with unparalleled support, customer service, and quality.
Path Copy
Quality
Path
Scale
Speed
Dependability
## Air-Dryable™ qPCR
[ Contact Sales ](#contactsales)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our[ Privacy Statement.](/privacy/)
## Learn More About Us
[ Learn More ](/about/lifescience/)
---
### [Contact Us](https://www.meridianbioscience.com/contact-us/)
**Published:** February 7, 2025
**Author:** hamza
**Content:**
# Contact Us
[](/contact-us-life-science/)#### Contact Life Science Division
Need information about reagents & antibodies?
[ Contact Us ](/contact-us-life-science/)
[](/contact-us-diagnostics/)#### Contact Diagnostics Division
Need Information about diagnostic assays and platforms?
[ Contact Us ](/contact-us-diagnostics/)
[](/contact-meridian-bioscience-corporate/)#### Contact Meridian Corporate
Need to contact our corporate team?
[ Contact Us ](/contact-meridian-bioscience-corporate/)
##### USA Headquarters
**Meridian Diagnostics & Corporate Offices**
3471 River Hills Drive
Cincinnati, OH 45244
Email: mbi@meridianbioscience.com
**Meridian Life Science**
5171 Wilfong Road
Memphis, Tennessee 38134-5611
Email: info@meridianlifescience.com
Corporate
Toll Free: 800-696-0739
Tel: +1 513-271-3700
Fax: 513-271-3702
Life Science Customer Service
Tel: +1 901-382-8716
Fax: +1 901-333-8223
Diagnostics Customer Service
Tel: 800-543-1980
Fax: +1 513-271-0124
Diagnostics Technical Services Product Support Center
Tel: 800-343-3858
##### Canada
360 Rue Franquet #3
Québec, QC G1P 4N3
Tel: +1 418-650-3535
Email: info@meridianbioscience.com
##### China
Unit A6, East Tower, 10th Floor
No. 12 B, Jianguomenwai Avenue
Chaoyang District, Beijing, China
Tel : +86 010-85660600
Email: info.cn@meridianlifescience.com
##### Germany
Im Biotechnologiepark, 3
14943 Luckenwalde
Tel: +49 (0)3371 602 2200
Fax: +49 (0)3371 602 2201
Email: info@meridianlifescience.com
##### Israel
4 Ha’maayan St.
Modiin, Israel
Tel: +972 8-973-7500
##### Italy
Via dell’ Industria, 7
20035 Villa Cortese
Milano
Tel: +39 0331 43 36 36
Fax: +39 0331 43 36 16
Email: info@meridianbioscience.eu
##### United Kingdom
Unit 16 The Edge Business Centre
Humber Road
NW2 6EW London
Tel: +44 (0)20 8453 7970
Fax: +44 (0)20 8452 2822
Email: info@meridianlifescience.com
---
### [Florent Chang-Pi-Hin, PhD](https://www.meridianbioscience.com/lifescience/lifescience-leadership-team/florent-chang-pi-hin-phd/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Florent Chang-Pi-Hin, PhD
### Vice President, R&D, Life Science – UK Site Leader
Florent Chang-Pi-Hin leads research and development for Meridian Bioscience’s Life Science division and serves as UK site leader. He brings more than 20 years of experience in molecular biology, biochemistry, and product innovation. Since joining Meridian in 2011 through its Bioline business, Florent has advanced through leadership roles in R&D, driving the development of innovative molecular tools and technologies.
Florent previously conducted postdoctoral research at University College London and Université catholique de Louvain. Florent holds a PhD in Biochemistry and Molecular Biology from Université de Reims Champagne-Ardenne, as well as master’s and bachelor’s degrees in Biochemistry and Molecular Biology from Aix-Marseille University.
## Get to Know Our Members
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
### Jason Klemke, PhD
Vice President, Global Manufacturing and Technical Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jason-klemke-phd/)
[  ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
### Jeremy Schroeder
Vice President, Global Commercial Operations
[ Read Bio ](/lifescience/lifescience-leadership-team/jeremy-schroeder/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Lead Poisoning Resource Center for Healthcare Providers](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-healthcare-providers/)
**Published:** September 29, 2025
**Author:** hamza
**Content:**
# Growing children don’t have time to wait.
Early diagnosis helps to quickly address the effects of lead exposure. Learn more about how you can protect your patients from the dangers of lead.
## Who is at Risk
### Lead is especially dangerous tochildren under the age of 6.
**Children are considered at risk if any of the following are true:**
- Child lives or frequently visits a home built before 1978. \[1 in 4 children live in a home built before 1978\]
- Child’s parent or primary caregiver works with lead.
Examples include: battery recycling or manufacturing, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacturers.
- Child has a sibling or frequent playmate with elevated blood lead levels.
- Child is a recent immigrant, refugee, or foreign adoptee.
- Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member).
## Lifelong consequences of lead exposure include:1,2
**Six times** higher likelihood of having a reading disability.
**Seven times**more likely to drop out of high school.
**Lower scores** on tests for math, reading, nonverbal reasoning and short-term memory.
**Decline in IQ**with every 1.0 μg/dL increase in blood lead.
## Have you found the children at risk in your practice?
**1 in 38 U.S.** children has harmful blood lead levels. Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.
**No safe levels.** Evidence continues to grow that blood lead levels as low as 3.5 ug/dL may impair cognition, with no minimum threshold yet identified.
**Early diagnosis** helps to quickly address the effects of lead exposure and provides an impetus for lead abatement in homes.
## How is the testing performed?
A small amount of blood is taken from the finger, heel, or arm and tested for lead during a blood lead test.
**A finger-prick (capillary)** sample is usually the first step to determine if a child has lead in their blood. A capillary test is typically performed at the point of care, enabling the physician to act early should the test result come back elevated. A capillary test that generates an elevated lead level should be confirmed with a venous blood sample.
**A venous blood draw** takes blood from the child’s vein. It may take several days to receive results from the laboratory. Providers may order a venous blood draw to confirm the blood lead level seen in an initial capillary test.
All blood lead test results must be reported to the appropriate state or federal agency. The office/lab performing the test is responsible for reporting.
## Point-of-care testing reaches those at risk, eliminating the need for follow-up.
Testing at the point of care enables you to detect harmful blood lead levels and take swift action in just one office visit.
Developed in collaboration with the CDC, LeadCare II is the only CLIA-waived system that allows you to test, educate, and intervene on the spot. Point-of-care testing makes it easy to comply with federal and state mandates. A LeadCare II test is also reimbursable, improving economics for your practice.
**Lead results in 3 minutes.**
**2 drops of blood. 1 visit. Zero loose ends.**
[Learn more about LeadCare II](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/?_gl=1*1er06ij*_gcl_au*ODQwMzE5NjYyLjE3NTkxMzAwODA.)
## What’s a Blood Lead Reference Value?
**No level of lead in the blood is safe. In October 2021, the Centers for Disease Control and Prevention (CDC) updated the blood lead reference value from 5 ug/dL to 3.5 ug/dL.**
CDC’s blood lead reference value of 3.5 µg/dL is a screening tool to identify children who have higher levels of lead in their blood compared with most children. The reference value is not health-based and is not a regulatory standard.
States independently determine action thresholds based on state laws, regulations, and resource availability. [Learn more about CDC’s Blood Lead Reference Value.](https://www.cdc.gov/lead-prevention/php/data/blood-lead-surveillance.html?CDC_AAref_Val=https://www.cdc.gov/nceh/lead/data/blood-lead-reference-value.htm)
CDC encourages healthcare providers and public health professionals to follow the recommended follow-up actions based on confirmed blood lead levels.
## Learn about your lead testing requirements
### The CDC provides resources to state and local health departments to support childhood lead poisoning prevention activities and strengthen testing efforts.
Click on a state below to visit your state’s Childhood Lead Poisoning Prevention Program webpage.
Select state Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
## Resources for your Practice
- [6 Lead Facts to Know Poster](/uploads/Lead-Poisoning-Education-6-Facts-to-Know_v0.1.pdf)
- [Surprising Sources of Lead Poster](/uploads/Lead-Sources-Education-Poster.pdf)
- [Happy, Healthy, Lead-Free Me! Book](https://cribsforkids.org/happy-healthy-lead-free-me/)
- [Lead Quantity Poster](/uploads/Lead-Quantity-Education-Poster.pdf)
- [6 Lead Facts to Know Poster (Spanish)](/uploads/M-0011-S-Rev-00-DYK-Fact-Sheet-Spanish.pdf)
Frequently asked questions about lead exposure
What is lead?
Lead is a naturally occurring metal used in various products and materials. Exposure to lead, even in small amounts, can affect multiple body systems and be particularly harmful to young children.
How does lead exposure occur?
Lead exposure occurs when someone inhales lead-containing fumes or dust or swallows something that contains lead. Lead-based paint and lead-contaminated dust are the primary sources of exposure for U.S. children. Despite significant progress, lead poisoning remains a top childhood environmental health problem. (Source: Healthy Homes)
Why are children especially vulnerable?
Toddlers and young children explore with their hands and frequently put them in their mouths. As young children crawl on the floor and reach windows, railings, and walls, they may inhale dust from peeling and chipping lead-based paint or ingest paint chips.
Furthermore, children under six years of age are biologically more sensitive to lead due to rapid brain and organ development, when the body readily takes up lead—mistaking it for calcium. Therefore, children who are low in calcium or have iron-deficient anemia may have an ever-greater lead uptake.
Are adults affected by lead poisoning?
Adults can become lead poisoned, most frequently from the workplace and hobbies. Lead in adults can affect the central nervous and gastrointestinal systems and can cause chronic kidney disease as well as other health problems.
Is there any safe level of lead?
No level of lead in the blood can be defined as safe. An advisory panel of the CDC now recommends that children with blood levels as low as 3.5 μg/dL be identified as having elevated levels and be monitored. Even such low levels may harm a child’s cardiovascular, immunological, and endocrine health, with consequences for that individual and overall public health. While the effects of lead appear to be irreversible, eliminating lead exposure can reduce further damage.
What can I do to prevent lead poisoning?
The best way to prevent lead poisoning among young children is to remove the lead source. To prevent exposure, especially in homes built before 1978, the CDC recommends:
- Contact your local health department about testing paint and dust from your home.
- Ensure a child cannot access peeling paint or chewable surfaces painted with lead-based paint.
- Create barriers between children and lead sources until clean-up is complete.
- Regularly wet mop floors, damp sponge walls, and all horizontal surfaces and vacuum with a high-efficiency particulate air vacuum (HEPA vac). Cleaning is a temporary solution until the lead can be completely removed.
- Pregnant women and children should avoid pre-1978 homes if a renovation is underway.
- Regularly wash children’s hands, especially before eating.
- Regularly wash children’s toys.
- Prevent children from playing in bare soil, opting for sandboxes or planting grass. This is especially true of areas that are within one block of a major highway or busy street, as lead that was once in gasoline may have accumulated in the soil.
- Give your children foods that are high in calcium and iron, such as meat, beans, spinach, and low-fat dairy products. This can help reduce the amount of lead absorbed by the body.
*Source: https://www.cdc.gov/nceh/features/leadpoisoning/index.html*
References:
1\.
2\.
## Stay in the loop
Receive information regarding lead consumer alerts, policy updates, educational tools, and more!
---
### [Urea Breath test Marketing](https://www.meridianbioscience.com/urea-breath-test-marketing/)
**Published:** November 17, 2025
**Author:** Moaaz Ahmad
**Content:**
# *H. pylori* Testing for Healthcare Providers & Laboratories
Detect *Helicobacter pylori* with confidence using our FDA-approved urea breath test (UBT) kits. Our market-leading diagnostic solutions offer unparalleled accuracy for both initial detection and post-treatment confirmation, ensuring superior patient care in medical and laboratory settings.
#### Unparalleled Performance
- 100% Sensitivity
- 97.9% Specificity
#### Intuitive Efficiency
Automated data input and batch analysis to reduce human error and simplify reporting
#### Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
#### Contact a Specialist
I am a Healthcare Professional I am a Patient
For clinical guidance on H. pylori testing and treatment, please consult your doctor or healthcare professional. To learn more about H. pylori, please visit our Resource Center below for additional educational resources.
[Visit our Resource Center](/lead-poisoning-resource-center-for-families-and-parents/)
#### Unmatched Accuracy in *H. pylori* Detection
The state-of-the-art BreathID® Smart urea breath test platform for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with efficient automation for maximizing mid-range testing throughput. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
### From Scan to Results in 3 Steps
2 minutes to diagnose *H. pylori*
## Your trusted partner in diagnostic accuracy and compact operational efficiencies
### The BreathID® Platform Advantage
The BreathID® platform can be used in conjunction with other Meridian *H. pylori* platforms for a total testing solution across the healthcare system that offers:
- Flexibility in testing options to support near-patient testing or centralized testing in a core lab
- The ability for system administrators to be responsive to changes in testing requirements and demand fluctuations within the health network
- An unparalleled *H. pylori* portfolio that accommodates any laboratory setting, from low-volume rapids to high-volume automation
- A choice of testing methods for physicians to accurately diagnose active H. pylori infection
- Improved operational efficiencies and the capability to deliver standardization across the network by consolidating testing to one trusted partner
#### Why use BreathID®? Smart urea breath test platform for *H. pylori*?
- **Non-Invasive Breath Testing –** A patient-friendly alternative for clinics, hospitals, and diagnostic laboratories, suitable for both adults and children.
- **Rapid & Reliable Results –** Use the urea breath test (UBT) for fast 2 minutes to diagnosis to ensure the most effective diagnostic workflow. Rapid results in just 2 minutes, ensuring an efficient and effective diagnostic workflow.
- **Clinically Validated Accuracy –** Our urea breath test is trusted by leading gastroenterology practices, hospitals, and research institutions for *H. pylori* detection and confirmation of eradication.
- **Seamless Laboratory Integration –** Our test kits support high-throughput lab processing, minimizing turnaround time and maximizing operational efficiency.
#### Scalable Solutions for Medical Facilities & Laboratories
[ Order UBT Kits ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU3NDM5IiwidG9nZ2xlIjpmYWxzZX0%3D)
- **Ensure uninterrupted supply for clinical use, hospital networks, and diagnostic laboratories..**
- **Expand Your Testing Services –** Partner with Meridian to offer urea breath testing at your facility, increasing patient access to non-invasive *H. pylori* diagnostics.
- **Clinical Partnerships & Provider Network –** We collaborate with gastroenterology centers, diagnostic labs, and primary care providers to streamline *H. pylori* detection and treatment decisions.
#### Science-Backed Accuracy for Precision Testing
Our 13C-urea breath test is gastroenterologist-recommended for its high sensitivity and specificity. Equip your facility with the best test for *H. pylori*, backed by clinical guidelines.
#### Optimize *H. pylori* in Your Practice
- Support effective treatment decisions with early, accurate detection.
- Reduce unnecessary antibiotic prescriptions by confirming eradication post-treatment.
- Enhance patient care & clinical outcomes with streamlined, non-invasive testing solutions.
### Partner with Us Today
Contact us to discuss ordering, laboratory partnerships, or clinical integration of *H. pylori* urea breath test solutions. Let’s improve gastrointestinal health diagnostics together.
I am a Healthcare Professional I am a Patient
For clinical guidance on H. pylori testing and treatment, please consult your doctor or healthcare professional. To learn more about H. pylori, please visit our Resource Center below for additional educational resources.
[Visit our Resource Center](/lead-poisoning-resource-center-for-families-and-parents/)
---
### [privacy](https://www.meridianbioscience.com/privacy/)
**Published:** August 12, 2025
**Author:** hamza
**Content:**
# PRIVACY STATEMENT
**EFFECTIVE December 1, 2020**
Meridian Bioscience, Inc. and subsidiaries (“Meridian”), which include Meridian Life Science, Bioline, Magellan Diagnostics, Meridian Bioscience Canada (GenePOC), and Exalenz Bioscience, have created the following Privacy Policy to describe how we use information and data we collect. This Privacy Policy applies to the websites of Meridian and its subsidiaries. It explains how Meridian collects, uses, and discloses information regarding your access and use of the websites.
This Privacy Policy only applies to Meridian websites and not third-party websites and applications. Meridian websites may contain links to third-party websites and applications that may interest you. Meridian is not responsible for the collection, processing, and use of your data by websites or applications that Meridian does not operate; furthermore, Meridian is not responsible for their content. For information on the processing of your data, please refer to the data privacy policies of the respective parties.
We recommend that you read this Privacy Policy in its entirety to ensure you are fully informed. If you have any questions about this Privacy Policy or Meridian’s data collection, use, and disclosure practices, please contact our Privacy Officer, Emerson Moser, at privacy@meridianbioscience.com or by mail or phone using the information in Section 6.
**DATA WE COLLECT**
The data we collect may include Personally Identifiable Information (“PII”). This consists of the following types of data.
Identity Data includes first and last name.
Contact Data: includes email addresses.
Technical Data: includes Internet protocol (IP) address, browser type and version, time zone and location, browser plug-in types and versions, operating system and platform, and other technology on the devices you use to access this website.
Usage Data: includes information about how you use our website.
Communications Data: includes your preferences in receiving news alerts.
We may use the data we collect in various ways, as outlined below.
Direct Marketing Purposes: including providing you with relevant product and company news.
Providing Product and Services, You Request: including the collection of data required to process product orders, sample requests, and provide technical support services and other instructions to Meridian.
Custom User Experiences: including data to allow you to personalize how aspects of our website function for you.
Site Analytics and Improvement: to monitor site traffic patterns and preferences for site improvement, analytics, and optimization.
Job Application Collection: to receive online job applications.
We do not sell your personal information. We do not share your personal data with any third-party advertisers for their advertising.
Where applicable, for example, where PII is provided for Direct Marketing Purposes, we will ask for your consent to use the data for the proposed purpose(s).
This website is not intended for children under 18 years old, and we do not knowingly collect data relating to children.
**COOKIES**
We may use technologies such as cookies, pixel tags, browser analysis tools, server logs, and web beacons which automatically collect certain information from you. We use these cookies for various purposes, including activity that is strictly necessary for the Site to function and for analytics and advertising. For example, we may use this information for purposes including but not limited to servicing your specific requests for functionality, such as displaying the correct content for your region, local pricing, currency, and shipping charges, as well as any additional user and account specific functionality; validating your identity and for capacity management, including monitoring the number of people using the site and how they are using and navigating the site; helping us recognize you when you return to the Site; improving the quality of our service when you visit our Site; diagnosing problems with the Site; administering the website; tailoring our advertising to suit your interests; or processing your requests for information.
You may control cookies, including preventing or stopping the installation and storage of cookies, through your browser settings and other tools. If you do so, our Site may not function correctly. Please refer to the Help feature of your browser for information on disabling cookies.
[Click here for a complete list of the cookies we use on meridianbioscience.com](https://www.meridianbioscience.com/cookie-list/?country=US&_gl=1*1h7c5bu*_gcl_au*MjMxNTIwMjgzLjE3NTE5NjI5MTAuMTc0NTk4NjYxNC4xNzU0OTk1MzY0LjE3NTQ5OTUzNjQ.)
**2.1 First-Party Cookies**
First-party cookies are cookies that are set by the domain, or a sub-domain, of the site you are visiting. Meridian websites use cookies to provide you with the best user experience possible. The Meridian website domains serve our customers internationally, and cookies are necessary to ensure that we can serve you with the right content for your region, country, or locality. To ensure the maximum level of privacy for all our customers and website users, no personally identifying information is stored or transmitted in cookies set by Meridian websites. We always endeavor to set only cookies that are strictly necessary to service your specific requests for functionality.
You may refuse to use first-party cookies by selecting the appropriate settings in your browser. However, please note that if you do this and do not make exceptions for Meridian’s websites and any other domains listed in this document, you may not be able to use the full functionality of our websites.
**2.2 Google Analytics**
Meridian utilizes the services of Google Analytics, a web analytics service provided by Google, Inc. We use information collected by Google Analytics for site maintenance, management, monitoring, and capacity planning. Google Analytics uses cookies to compile the data about browser sessions and site traffic, enabling us to analyze how customers and other users use this website.
Analytics data will be transmitted to and stored by Google. Google will use this information to evaluate your website use, compiling summary reports on website activity and providing other services relating to website activity and Internet usage. Google may also transfer this information to third parties where required to do so by law or where such third parties process the information on Google’s behalf.
Because of how Google Analytics functions, cookies set by this site reporting technology are set by the Meridian website domains.
**2.3 Third-Party Cookies**
Third-party cookies are those set when you visit a website but do not originate from the first party whose site you are visiting. It is possible to configure your browser to disallow the setting of third-party cookies automatically. Doing so means your browser will only accept cookies from the first-party domain you visit.
We may occasionally utilize third-party services to provide additional site functionality, and these third-party services may attempt to set cookies on your browsing device.
**YouTube**
Some pages on this website contain embedded videos that we host on YouTube. Depending on your configuration, YouTube.com may set a cookie on your browsing device when you access pages on which a video is embedded. For more information about YouTube and its privacy policy, please see the links below.
**Site:** YouTube / YouTube No Cookie **Domain:** https://www.youtube.com/t/about\_youtube **About:** https://www.youtube.com/t/about\_youtube **Privacy Policy:** https://www.google.co.uk/intl/en/policies/privacy/
To protect your privacy, YouTube videos are embedded using the youtube-nocookie.com version of YouTube, which does not automatically set a cookie on your machine when you load a page on the Meridian website that features an embedded video. A cookie may be placed on your device if allowed by your configuration when you play the video.
**Vimeo**
Some Meridian’s websites’ pages contain embedded videos we host with Vimeo. Depending on your configuration, Vimeo.com may set a cookie on your browsing device when you access pages on which a video is embedded. Please see the links below for more information about Vimeo and its privacy policy.
**Site:** Vimeo **Domain:** https://www.vimeo.com **About:** https://www.vimeo.com/about **Privacy Policy:** https://www.vimeo.com/features/video-privacy, https://vimeo.com/cookie\_policy
**SFDC (SalesForce.com)**
We may use SFDC, a Salesforce Company, for assistance with marketing initiatives on our websites. SFDC deploys cookies for monitoring browsing information and allows us to collect PII through forms and landing pages. Please refer to SFDC’s Privacy Policy for details on data storage and security. Also, read “How Does SFDC Track Activities” for details on their use of cookies. Please see the links below for more information about SFDC and its privacy policy.
**Site:** SFDC **Domain:** https://www.salesforce.com/gdpr/overview/ **About:** https://www.salesforce.com/company/about-us/ **Privacy Policy:** https://www.salesforce.com/uk/company/privacy/
**Hubspot**
We may use Hubspot, Inc. for assistance with marketing initiatives on our websites. Hubspot deploys cookies for monitoring browsing information and allows us to collect PII through forms and landing pages. Please refer to Hubspot’s Privacy Policy for data storage and security information. Also, read “Cookies Policy” for details on their use of cookies. Please see the links below for more information about Hubspot and its privacy policy.
**Site:** Hubspot **Domain:** https://www.hubspot.com/ **About:** https://www.hubspot.com/our-story **Privacy Policy:** https://legal.hubspot.com/privacy-policy
**Hotjar**
We may use Hotjar Ltd for assistance with marketing initiatives on our websites. Hotjar deploys cookies for monitoring browsing information and allows us to collect PII through forms and surveys. Please refer to Hotjar’s Privacy Policy for data storage and security information. Also, read “Cookies Policy” for details on their use of cookies. Please see the links below for more information about Hotjar and its privacy policy.
**Site:** Hotjar **Domain:** https://www.hotjar.com **About:** https://www.hotjar.com/about-us/ **Privacy Policy:** https://www.hotjar.com/legal/policies/privacy/
**2.4 Do Not Track**
“Do Not Track” is a privacy preference that you can set in your Internet search browser that signals to a website that you do not want the website operator to track certain browsing information about you. However, because our sites are not configured to detect Do Not Track signals from a user’s computer, we cannot respond to Do Not Track requests.
**PROTECTING THE DATA WE COLLECT**
**3.1 Security**
We take commercially reasonable precautions such as policy-based access control to protect data in our possession from loss, misuse, and unauthorized access. We follow generally accepted industry standards to protect the data, both during transmission and once received by Meridian. However, no method of transmission over the Internet or method of electronic storage is guaranteed to be 100% secure.
**3.2 Data retention**
We retain personal information we collect from you where we have an ongoing legitimate business need (for example, to provide you with a service you have requested or to comply with applicable legal requirements). When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it or, if this is not possible (for example, because your personal data has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
**3.3 Information Shared with Third Parties**
The data we collect may be shared with third parties as necessary to operate our business and protect our interests and legal rights. This includes vendors and suppliers and our affiliated companies. We use a limited number of third-party processors to store and process the data we collect on our behalf. We will not authorize these parties to use your PII for any purpose that is not related to Meridian’s business operations.
In certain limited circumstances, we may need to disclose PII to comply with a legal obligation or demand. Additionally, in certain circumstances in connection with a change-in-control or change in control sale of a portion of the business, PII may be shared with a third-party seeking to acquire all or a portion of Meridian.
We do not sell your personal information. We do not share your personal data with any third-party advertisers for their advertising.
**3.4 International Data Transfers**
As an enterprise serving users in many countries, we may transfer personal information to countries other than the country in which the data was originally collected. This includes transfers within Meridian and to independent third parties. For users in the European Economic Area (EEA) which includes countries in the European Union, along with Iceland, Liechtenstein and Norway, when we transfer your personal information to other countries, we select data processors that contractually comply with EU Data Protection regulations, including the GDPR.
**YOUR RIGHTS**
**4.1 EU or EEA Residents**
If you are in the EU or EEA, you may have the following rights.
**Right of Access**
You have the right to obtain from us confirmation as to whether-or-not personal data concerning you are processed, and, where that is the case, you have the right to request and get access to that personal data.
**Right to Rectification**
You have the right to obtain from us the rectification of inaccurate personal data and you have the right to provide additional personal data to complete any incomplete personal data.
**Right to Erasure (“Right to be Forgotten”)**
In certain cases, including where you have provided personal information for direct marketing purposes, you have the right to obtain from us the erasure of your personal data.
**Right to Restriction of Processing**
You have the right to obtain from us restriction of processing, applicable for a certain period and/or for certain situations.
**Right to Data Portability**
You have the right to receive from us in a structured format your personal data and you have the right to (allow us) transmit such personal data to another controller.
**Right to Object**
You have the right to object to the further processing of your personal data in so far as such data have been collected for direct marketing purposes.
**Right to Withdraw Consent**
You have the right to withdraw any consent you have previously given us to handle your personal information. If you withdraw your consent, this will not affect the lawfulness of our use of your personal information prior to the withdrawal of your consent.
**Right to File a Complaint**
You have the right to file a complaint with a data protection authority.
In response to a request, we will ask you to verify your identity if we need to and to provide information that helps us to understand your request better. If we do not comply with your request, whether in whole or in part, we will explain why.
To exercise your rights or make a request in connection with our Privacy Statement, please contact us using one of the options in 6. How to Contact Us.
**4.2 California Residents**
If you are a California consumer, you may have certain rights under the California Consumer Privacy Act (Act) relating to your personal information, as defined under the Act. For additional information, please use the contact information in 6. How to Contact Us.
We do not sell the personal information of California consumers, including information we collect about individuals acting within the context of a business-to-business relationship with Meridian.
**Amendment of Privacy Statement**
We may update our Privacy Statement from time to time. Updates of our Privacy Statement will be published on our website. Any amendments become effective upon publication on our website. Any PII will be collected upon your continued use of Meridian’s sites will be handled in accordance with the currently-posted Privacy Statement. Therefore, we recommend that you regularly review the posted Privacy Statement.
**How to Contact Us**
If you have any questions regarding this Privacy Policy or wish to submit a request regarding rights outlined in 4. Your Rights, you may contact us at:
**Email Address** privacy@meridianbioscience.com
**Mailing Address** Meridian Bioscience, Inc. Privacy Office 3471 River Hills Drive Cincinnati, Ohio 45244
**Phone Number** +1.513.271.3700 (Meridian Corporate Office) 844.246.9963 (U.S. toll-free)
**Cookie List**
A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:
**Functional Cookies**
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.
**Functional Cookies****Cookie Subgroup****Cookies****Cookies used**www.meridianbioscience.com[stg\_debug](https://cookiepedia.co.uk/cookies/stg_debug)First Partyinvestor.meridianbioscience.com[hubspotutk](https://cookiepedia.co.uk/cookies/hubspotutk), [DrupalVisitorMobile](https://cookiepedia.co.uk/cookies/DrupalVisitorMobile)First Partymeridianbioscience.com[bm\_mi](https://cookiepedia.co.uk/cookies/bm_mi), [ak\_bmsc](https://cookiepedia.co.uk/cookies/ak_bmsc), [bm\_sv](https://cookiepedia.co.uk/cookies/bm_sv)First Party[globenewswire.com](https://cookiepedia.co.uk/host/globenewswire.com)incap\_ses\_\*, nlbi\_XXXXXXX, visid\_incap\_XXXXXXThird Party[api.nasdaqomx.wallst.com](https://cookiepedia.co.uk/host/api.nasdaqomx.wallst.com)4341%5F0, 4228%5F1, 4341%5F1, 4228%5F0Third Party[js.hs-analytics.net](https://cookiepedia.co.uk/host/js.hs-analytics.net)\_\_hstc, \_\_hssrc, \_\_hsscThird Party[www.rumiview.com](https://cookiepedia.co.uk/host/www.rumiview.com)\_pk\_ses.{id}, \_pk\_id.{id}Third Party[js.hs-banner.com](https://cookiepedia.co.uk/host/js.hs-banner.com)\_\_hstc, \_\_hssc, hubspotutkThird Party[vimeo.com](https://cookiepedia.co.uk/host/vimeo.com)vuidThird Party**Social Media Cookies**
These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.
**Social Media Cookies****Cookie Subgroup****Cookies****Cookies used**[www.linkedin.com](https://cookiepedia.co.uk/host/www.linkedin.com)bscookieThird Party[linkedin.com](https://cookiepedia.co.uk/host/linkedin.com)bcookie, lidc, langThird Party[ads.linkedin.com](https://cookiepedia.co.uk/host/ads.linkedin.com)langThird Party**Targeting Cookies**
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Targeting Cookies**Cookie Subgroup****Cookies****Cookies used**www.meridianbioscience.com[stg\_last\_interaction](https://cookiepedia.co.uk/cookies/stg_last_interaction), [stg\_utm\_campaign](https://cookiepedia.co.uk/cookies/stg_utm_campaign), [stg\_traffic\_source\_priority](https://cookiepedia.co.uk/cookies/stg_traffic_source_priority)First Partyinvestor.meridianbioscience.com[stg\_externalReferrer](https://cookiepedia.co.uk/cookies/stg_externalReferrer), [stg\_returning\_visitor](https://cookiepedia.co.uk/cookies/stg_returning_visitor), [stg\_debug](https://cookiepedia.co.uk/cookies/stg_debug)First Partymeridianbioscience.com[AMCVS\_](https://cookiepedia.co.uk/cookies/AMCVS_), [AMCV\_](https://cookiepedia.co.uk/cookies/AMCV_)First Party[api.nasdaqomx.wallst.com](https://cookiepedia.co.uk/host/api.nasdaqomx.wallst.com)GZIPThird Party[www.globenewswire.com](https://cookiepedia.co.uk/host/www.globenewswire.com)GNWTracker, ASP.NET\_SessionIdThird Party[js.hs-analytics.net](https://cookiepedia.co.uk/host/js.hs-analytics.net)hubspotutkThird Party[www.rumiview.com](https://cookiepedia.co.uk/host/www.rumiview.com)stg\_utm\_campaign, stg\_returning\_visitor, stg\_traffic\_source\_priority, stg\_last\_interaction, stg\_externalReferrerThird Party[youtube.com](https://cookiepedia.co.uk/host/youtube.com)VISITOR\_INFO1\_LIVE, CONSENT, YSCThird Party[simpli.fi](https://cookiepedia.co.uk/host/simpli.fi)suid\_legacy, suidThird Party[hubspot.com](https://cookiepedia.co.uk/host/hubspot.com)\_\_cf\_bmThird Party[linkedin.com](https://cookiepedia.co.uk/host/linkedin.com)li\_gc, UserMatchHistory, AnalyticsSyncHistoryThird Party[demdex.net](https://cookiepedia.co.uk/host/demdex.net)demdexThird Party[js.hs-banner.com](https://cookiepedia.co.uk/host/js.hs-banner.com)\_\_hssrcThird Party[www.googletagmanager.com](https://cookiepedia.co.uk/host/www.googletagmanager.com)stg\_externalReferrerThird Party[meridianbioscience.gcs-web.com](https://cookiepedia.co.uk/host/meridianbioscience.gcs-web.com)DrupalVisitorMobileThird Party[doubleclick.net](https://cookiepedia.co.uk/host/doubleclick.net)test\_cookie, IDEThird Party**Performance Cookies**
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
**Performance Cookies****Cookie Subgroup****Cookies****Cookies used**www.meridianbioscience.com[\_\_hstc](https://cookiepedia.co.uk/cookies/__hstc), [\_\_hssrc](https://cookiepedia.co.uk/cookies/__hssrc), [\_pk\_id.{id}](https://cookiepedia.co.uk/cookies/_pk_id.%7Bid%7D)First Partyinvestor.meridianbioscience.com[\_pk\_ses.{id}](https://cookiepedia.co.uk/cookies/_pk_ses.%7Bid%7D), [\_\_hssc](https://cookiepedia.co.uk/cookies/__hssc)First Partymeridianbioscience.com[test](https://cookiepedia.co.uk/cookies/test), [\_ga](https://cookiepedia.co.uk/cookies/_ga), [\_mkto\_trk](https://cookiepedia.co.uk/cookies/_mkto_trk), [\_gid](https://cookiepedia.co.uk/cookies/_gid), [\_gclxxxx](https://cookiepedia.co.uk/cookies/_gclxxxx), [\_gat\_UA-](https://cookiepedia.co.uk/cookies/_gat_UA-), [s\_xxxx](https://cookiepedia.co.uk/cookies/s_xxxx)First Party[adobe.com](https://cookiepedia.co.uk/host/adobe.com)s\_xxxxThird Party[nr-data.net](https://cookiepedia.co.uk/host/nr-data.net)JSESSIONIDThird Party**Strictly Necessary Cookies**
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
**Strictly Necessary Cookies****Cookie Subgroup****Cookies****Cookies used**.meridianbioscience.com[OptanonConsent](https://cookiepedia.co.uk/cookies/OptanonConsent), [OptanonAlertBoxClosed](https://cookiepedia.co.uk/cookies/OptanonAlertBoxClosed)First Party
---
### [H. pylori Patients Resources](https://www.meridianbioscience.com/h-pylori-patients-resources/)
**Published:** October 1, 2025
**Author:** hamza
**Content:**
- [Home](https://www.meridianbioscience.com/h-pylori-resource-home/)
- *[H. pylori](#hpylori)*
- [Symptoms](#symptoms)
- [Testing](#testing)
- [FAQ](#faqs)
- [Resources](#resource)
## Suffering from heartburn, indigestion, stomach pain?
These symptoms are usually blamed on things such as stress, diet, or lifestyle choices. When symptoms don’t go away and disrupt your daily life, it could be something more serious called a Helicobacter pylori infection; also known as *H. pylori*.
It’s important to learn about the risks of having *H. pylori* and when it’s time to talk with your doctor.
[View Justin’s Journey with *H. pylori* ](#)
[](#)
## There is no single symptom of *H. pylori.*3
### Common symptoms include:
       
Indigestion (dyspepsia) ›
Indigestion – also called dyspepsia or an upset stomach – is discomfort in your upper abdomen.
Stomach or abdominal pain ›
Abdominal pain can be mild or severe. It may be continuous or come and go. Abdominal pain can be short-lived (acute) or occur over weeks, months, or years (chronic).
Bloating ›
Bloating is the sensation of having a full stomach. Distension is a visible or measurable increase in abdominal size.
Nausea/Vomiting ›
Nausea and vomiting are common signs and symptoms that can be caused by numerous conditions.
Regurgitation ›
Regurgitation is the spitting up of food from the esophagus or stomach without nausea or forceful contractions of the abdominal muscles.
Heartburn ›
Heartburn is a burning pain in your chest, just behind your breastbone. The pain is often worse after eating, in the evening, or when lying down or bending over.
Flatulence ›
Intestinal gas, a buildup of air in the digestive tract, is usually not noticed until you burp or pass it rectally (flatulence).
Belching ›
Belching is commonly known as burping. It’s your body’s way of expelling excess air from your upper digestive tract.
This list is non-exhaustive; provided for information purposes. It is recommended to consult your doctor.
## Relieving symptoms is your #1 priority.
Many over-the-counter medications, and even some prescriptions to manage stomach symptoms can provide immediate relief making them easy to take every day. Unfortunately, these medications only provide temporary relief and may hide what’s really going on, such as an *H. pylori* infection.
### Common over-the-counter medications used to relieve symptoms can include:
Zantac® (ranitidine)
Pepcid® (famotidine)
Prilosec OTC® (omeprazole)
Prevacid® (lansoprazole)
Tagamet® (cimetidine)
Axid® (nizatidine)
Nexium® (esomeprazole)
\* All registered marks are the property of their respective owners.
## What you need to know about *H. pylori.*
***Helicobacter pylori* (hell-ee-ko-back-ter pie-lore-ee)**
*Helicobacter pylori*, commonly referred to as *H. pylori*, is a bacteria (germ) that lives in the lining of the stomach and it’s one of the world’s most common bacterial infections.4
There are simple ways to diagnose and treat *H. pylori*. When *H. pylori* infections are not diagnosed and treated by a doctor, they can cause sores in the lining of the stomach known as ulcers.
Therefore, it’s important to speak with your doctor to understand if an *H. pylori* infection is responsible for your stomach symptoms.
**1 in 3 Americans** are infected with *H. pylori.*1
**25 million Americans** suffer from ulcers.5
**9 out of 10 ulcers**
are caused by untreated *H. pylori* infections.5
## Learn more about H. pylori
Quick Facts about *H. pylori*
[Get the Fact Sheet](/uploads/MBI_6_Facts_Hpylori.pdf)
*H. pylori* Education
[Get the Brochure](/uploads/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
[Take control of your symptoms – talk to your doctor](#)
## Start the conversation
Talk with your doctor about your stomach symptoms and simple testing options for *H. pylori*. The only way to know if *H. pylori* is responsible for your stomach symptoms is to get tested.
If *H. pylori* is the cause of your stomach symptoms, your doctor will decide on a treatment plan and medications.
## Finish medications as prescribed
If you have an *H. pylori* infection, your doctor will likely prescribe medications such as antibiotics and/or medication to reduce stomach acid. These medications help heal your stomach and get rid of the infection.
**It’s important to follow your doctor’s treatment plan and take all the medications as directed.**
## Follow-up to get tested again
**It’s important to follow up with your doctor after finishing your medications.** In some cases, you may be required to complete more than one round of treatment (antibiotics) to take care of the infection. Therefore, your doctor should order a second test once you have completed your medications to confirm the *H. pylori* infection is gone.
**This is the ONLY way to know the infection has been treated successfully; even if your symptoms have gone away.**
## Tools to help you prepare for your next appointment
Click to get the tools to start a conversation with your doctor.
[Symptoms Checklist](/uploads/H.-pylori-Symptoms-Checklist.pdf)
[Patient Educational Brochure](/uploads/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
## Frequently Asked Questions
What are the symptoms of *H. pylori?*
There is no single symptom of *H. pylori*. Symptoms of *H. pylori* include:3
- Heartburn/reflux
- Nausea
- Flatulence
- Belching
- Indigestion
- Stomach or abdominal discomfort
- Stomach or abdominal pain
- Bloating
- Vomiting
- Regurgitation
What is *H. pylori?*
*Helicobacter pylori* (hell-ee-ko-back-ter pie-lore-ee), commonly referred to as *H. pylori*, is a bacteria (germ) that lives in the lining of the stomach and is one of the world’s most common bacterial infections.
How do you get *H. pylori?* Is it contagious?
Most people contract *H. pylori* when they are children and, if left untreated, the infection can last a lifetime. *H. pylori* can be easily passed from one household member to the next, for example by sharing food. If you or a family member tests positive, the entire family should get tested.
Why should you get tested and treated for *H. pylori?* Won’t it go away on its own?
The only way to know if you have an *H. pylori* infection is to get tested. If you test positive, it is important to get treatment. Untreated *H. pylori* infections can lead to ulcers and is one of the strongest known risk factors for stomach cancer.
What is an ulcer?
An ulcer is a sore or hole in the lining of the stomach or the first part of the small intestine (duodenum). People of any age can get an ulcer and women are affected just as often as men.
How do you get tested for *H. pylori?*
Getting tested for *H. pylori* is simple. Talk with your doctor about your symptoms. Your doctor will determine if you need a test for *H. pylori* and provide you with options for testing.
How is an *H. pylori* infection treated?
*H. pylori* infections can be treated with medications such as antibiotics and medications to reduce stomach acid.
Why is it important to finish prescribed medications, even if symptoms have gone away?
It’s important to follow all medication instructions as prescribed by your doctor. Your symptoms may come back, the infection may not be cured or treated, and it could require taking a second dose of medications. If you have trouble with your treatment plan, contact your doctor for advice.
After finishing treatment, why should you follow up with your doctor to take another test?
Sometimes *H. pylori* infections are difficult to cure. Taking a second test to confirm that you are cured will help you feel confident that the infection is gone. A second test can reduce the risk of developing ulcers and prevent symptoms from returning.
Is there a vaccine?
There is currently no vaccine to protect against *H. pylori* infection.
References
1\. Fennerty, M. B. Helicobacter pylori: why it still matters in 2005. Cleveland Clinic Journal of Medicine, 2005; 72(Suppl\_2), S1-7. https://doi.org/10.3949/ccjm.72.suppl\_2.s1.
2\. American Cancer Society. Key Statistics for Stomach Cancer. Available at https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html. Accessed June 9, 2022.
3\. Helicobacter pylori (H. pylori) infection – Symptoms and causes. (2022, May 5). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/h-pylori/symptoms-causes/syc-20356171
4\. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 2018; 113(7), p1102. doi: 10.1038/s41395-018-0132-6
5\. Centers for Disease Control. MMWR (October 1997) Knowledge About Causes of Peptic Ulcer Disease—United States, March-April 1997. https://www.cdc.gov/mmwr/preview/mmwrhtml/00049679.htm. Accessed June 9, 2022.
## Resources
Justin’s journey with *H. pylori*
[Watch the Video](#justin-video)
*H. pylori* Facts
[Get the Fact Sheet](/uploads/MBI_6_Facts_Hpylori.pdf)
Symptoms Checklist
[Get the Checklist](/uploads/H.-pylori-Symptoms-Checklist.pdf)
*H. pylori* Education
[Get the Brochure](/uploads/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
## Stay in the Loop
**Receive information regarding *H. pylori*, policy updates, educational tools, and more!**
[Back To Top](#)
---
### [H. Pylori Resource Home](https://www.meridianbioscience.com/h-pylori-resource-home/)
**Published:** September 24, 2025
**Author:** Moaaz Ahmad
**Content:**
- [Home](https://www.meridianbioscience.com/h-pylori-resource-home/)
- [Patient Resources](https://www.meridianbioscience.com/h-pylori-patients-resources/)
- [Healthcare Professionals](https://www.meridianbioscience.com/h-pylori-health-care-professional-resources/)
## Looking for answers?
Chronic stomach symptoms such as heartburn, indigestion
(dyspepsia), and stomach pain, are usually blamed on things such
as stress, diet, or lifestyle choices.
Did you know these symptoms could be caused by *H. pylori*, a
common bacterial infection that affects 1 out of 3 people?1
##### Click to learn how to take control
of your symptoms.
[ Explore Answers for Patients ](https://www.meridianbioscience.com/h-pylori-patients-resources/)
##### Click to learn why you should
rule out *H. pylori* first.
[ Explore Answers for Healthcare Professionals ](https://www.meridianbioscience.com/h-pylori-health-care-professional-resources/)
## It could be more than just heartburn or indigestion.
#### Medicines that reduce stomach acid only provide temporary relief.
Common over-the-counter medications may be treating the symptoms, and not what’s causing your pain and discomfort. Often these symptoms are caused by a common infection that is easily treatable.
[ Explore Answers for Patients ](https://www.meridianbioscience.com/h-pylori-patients-resources/)
#### The right diagnosis could change lives.
*H. pylori* can be found in 1 in 3 people and its symptoms resemble many other common gastrointestinal (GI) conditions.1 Differentiating between GI conditions can be frustrating for both physicians and patients.
[ Explore Answers for Healthcare Professionals ](https://www.meridianbioscience.com/h-pylori-health-care-professional-resources/)
### Welcome to the *H. pylori* resource center.
Our mission is to raise awareness and provide education about *Helicobacter pylori* (*H. pylori*). *H. pylori* is one of the world’s most common bacterial infections. If left untreated, *H. pylori* can cause long-term infection and is one of the strongest known risk factors for gastric cancer.2
### Stay in the Loop
Receive information regarding *H. pylori*, policy updates, educational tools, and more!
**References:**
1. Fennerty, M. B. Helicobacter pylori: why it still matters in 2005. Cleveland Clinic Journal of Medicine, 2005; 72(Suppl_2), S1-7. https://doi.org/10.3949/ccjm.72.suppl_2.s1.
2. American Cancer Society. Key Statistics for Stomach Cancer. Available at https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html. Accessed June 9, 2022. [Back To Top](#)
---
### [H. Pylori Health Care Professional Resources](https://www.meridianbioscience.com/h-pylori-health-care-professional-resources/)
**Published:** September 30, 2025
**Author:** hamza
**Content:**
- [Home](https://www.meridianbioscience.com/h-pylori-resource-home/)
- *[H. pylori](#hpylori)*
- [Symptoms](#symptoms)
- [Testing](#test)
- [Resources](#resource)
## Do you see patients presenting with symptoms such as
- Heartburn
- Dyspepsia
- Stomach Pain
- Bloating
- Indigestion
These symptoms can be caused by several gastrointestinal (GI) conditions such as peptic ulcer disease (PUD), gastritis, GERD, or even gastric cancer. It could also be something more common, like H. pylori; which affects 1 in 3 people.1
Differentiating between GI conditions that share similar symptoms can be frustrating for both physicians and patients.
Listen to Dr. Ali’s advice
[](#)
Dr. M. Aamir Ali, MD, AGAF speaks about *H. pylori* and the need for testing
## *H. pylori*
Helicobacter pylori (H. pylori) bacterium is found in the lining of the stomach. An infection with H. pylori is linked to several important upper gastrointestinal (GI) conditions, including chronic gastritis, peptic ulcer disease, and gastric cancer.5
## The consequences can be serious
**1 in 3 Americans** are infected with *H. pylori.*1
**9 in 10 ulcers** are caused by untreated *H. pylori* infections.2
**Gastric Cancer risk is 6 times** higher in *H. pylori*-infected individuals.3
## Dyspepsia
Dyspepsia is used to describe what many people refer to as stomach pain or abdominal pain centered in the upper abdomen. A common cause of dyspepsia is an infection with H. pylori.5
## Patients with dyspepsia and no alarm symptoms should undergo initial testing and treatment for *H. pylori.*4
## Symptoms of
*H. pylori*
- Stomach or abdominal discomfort
- Stomach or abdominal pain
- Bloating
- Vomiting
- Regurgitation
- Heartburn/reflux
- Nausea
- Flatulence
- Belching
- Indigestion
## Dyspepsia Alarm
Symptoms
- Age older than 60 years with new-onset dyspepsia
- Family history of upper gastrointestinal cancer
- Unintended weight loss
- Gastrointestinal bleeding
- Progressive dysphagia
- Odynophagia
- Unexplained iron-deficiency anemia
- Persistent vomiting
- Palpable mass or lymphadenopathy
- Jaundice
## Learn more about H. pylori
*H. pylori* Education
[Get the Brochure](/uploads/MBI_H.-pylori-Provider-Brochure_2022-06.pdf)
*H. pylori* Facts
[Get the Fact Sheet](/uploads/MBI_H.-pylori-HCP-Fact-Sheet_2022-06.pdf)
## Treat the infection, not the symptoms
- Proton pump inhibitors (PPIs) are commonly used to alleviate symptoms and discomfort in patients but may mask and prolong an *H. pylori* infection.
- Performing an *H. pylori* test before writing a PPI prescription can help identify *H. pylori*-positive individuals, allow treatment, and prevent chronic PPI use.
- Prolonged PPI (prescription and/or OTC) use is associated with increased risk of fractures and kidney disease.6
- The American Gastroenterology Association (AGA) and the American College of Gastroenterology (ACG) recommend a test, treat, and retest approach to confirm eradication with an active infection test prior to prescribing a proton pump inhibitor.4,7
## Test for *H. pylori* before prescribing a PPI
Approximately 60% of adult patients are already taking a PPI when they initially present with GI symptoms.8
One out of every 4 patients on PPI therapy is *H. pylori*-positive and can potentially be removed from PPI.7
Annual expenditure on PPIs in the US is $11 Billion.9
## Prescribing PPIs? Get the facts.
[Proton Pump Inhibitor Facts](/uploads/MBI_H.-pylori-PPI-Fact-Sheet_2022-06.pdf)
[AGA Update: De-prescribing PPIs](/uploads/AGA-Update-De-Prescribing-PPIs.pdf)
## Clinical guidelines: Test. Treat. Test again.
## Test
Guidelines by both ACG and AGA recommend to test, treat, and retest to confirm eradication with a non-invasive active infection test for patients under the age of 60, with no alarm symptoms.4,7 **Stool antigen and urea breath tests are recommended.**
Patients over the age of 60, or under 60 with alarm symptoms, should be tested with an endoscopy.4,7
AGA and ACG state serology (antibody) testing, which does not test for an active *H. pylori* infection, should no longer be used.4,7
**“A positive serology test is no better than a coin toss in predicting the presence of active infection.”5**
## Fast Facts
Serology cannot distinguish active *H. pylori* from past infection.10
Serology antibody testing is not recommended and is not reimbursed by most insurance companies.4,7,11
The sensitivity and specificity of serology for the detection of *H. pylori* infection are too poor to be recommended as the initial screening test.10
## H. pylori testing Guidelines and Recommendations
[ACG Guidelines](/uploads/H.-pylori-ACG-Guidelines-2017.pdf)
[Houston Consensus](/uploads/HpSA-Article-Houston-Consensus-Conference-2018.pdf)
[H. pylori Managed Care Map](/uploads/Hpylori-Managed-Care-Map-Digital-Version.pdf)
[AGA Guidelines](/uploads/H.-pylori-AGA-Technical-Review-on-Evaluation-of-Dyspepsia-2005.pdf)
[Facts on serology testing](/uploads/MBI_H.-pylori-Serology-Fact-Sheet_2022-06.pdf)
## Treat
If *H. pylori* is detected, initiate treatment. Although several treatment regimens for *H. pylori* infections have been identified, none has yet emerged as superior. Variables such as cost, tolerability, ease of administration, and patient adherence should be considered when prescribing therapy.12
## Get info on treating H. pylori
[Rational Helicobacter pylori therapy](/uploads/Rational-Helicobacter-pylori-Therapy.pdf)
[Update on triple therapy for eradication of *Helicobacter pylori*](/uploads/Update-on-triple-therapy-for-eradication-of-Helicobacter-pylori.pdf)
## Test Again
Confirmatory testing is a good standard of care.
Repeat testing after *H. pylori* eradication therapy—the “test-treat-retest” strategy—should be offered to all patients to confirm that the infection has been cured.13
## Fast Facts
*H. pylori* eradication therapy fails in 1 out of 4 patients.12
Antibiotic resistance, poor compliance—or both—are considered the most common causes of *H. pylori* treatment failure.5
Antibiotic resistance may be the strongest predictor of treatment failure.14
## Rule out *H. pylori* first
Testing for *H. pylori* first has many advantages such as:
- Decreased complications associated with untreated, long-term *H. pylori* infections.
- Reduced risks associated with chronic PPI use among patients.15
- Promoting antibiotic stewardship by appropriately treating patients.
**If you suspect an *H. pylori* infection, here are some tools to educate patients about *H. pylori***
[Patient Education Brochure](/uploads/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
[Symptoms Checklist](/uploads/H.-pylori-Symptoms-Checklist-1.pdf)
[6 facts to know](/uploads/MBI_6_Facts_Hpylori.pdf)
## Resources
Educational Materials
- [Dr. Ali video](#dr-ali)
- [*H. pylori* Education](/uploads/MBI_H.-pylori-Provider-Brochure_2022-06.pdf)
- [*H. pylori* Facts ](/uploads/MBI_H.-pylori-HCP-Fact-Sheet_2022-06.pdf)
- [Proton Pump Inhibitor Facts](/uploads/MBI_H.-pylori-PPI-Fact-Sheet_2022-06.pdf)
- [Serology Facts](/uploads/MBI_H.-pylori-Serology-Fact-Sheet_2022-06.pdf)
- [Patient Education](/uploads/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
- [Symptom Checklist](/uploads/H.-pylori-Symptoms-Checklist.pdf)
- [*H. pylori* 6 Facts to Know](/uploads/MBI_6_Facts_Hpylori.pdf)
- [Webinar: Current Trends in *H. pylori* Testing](https://meridianbiostg.wpengine.com/about-diagnostics/events-webinars/?display-webinars=55&country=US#hpylori)
- [*H. pylori* Managed Care Map](/uploads/Hpylori-Managed-Care-Map-Digital-Version.pdf)
Articles/Journals
- [AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors](/uploads/AGA-Update-De-Prescribing-PPIs.pdf)
- [ACG Guidelines](/uploads/H.-pylori-ACG-Guidelines-2017.pdf)
- [AGA Guidelines](/uploads/H.-pylori-AGA-Technical-Review-on-Evaluation-of-Dyspepsia-2005.pdf)
- [Houston Consensus Conference on Testing for *Helicobacter pylori* Infection in the United States](/uploads/HpSA-Article-Houston-Consensus-Conference-2018.pdf)
- [Rational *Helicobacter pylori* Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence.](/uploads/Rational-Helicobacter-pylori-Therapy.pdf)
- [Update on triple therapy for eradication of *Helicobacter pylori*: current status of the art](/uploads/Update-on-triple-therapy-for-eradication-of-Helicobacter-pylori.pdf)
References
1\. Fennerty, M. B. *Helicobacter pylori: why it still matters in 2005*. Cleveland Clinic Journal of Medicine, 2005; 72(Suppl\_2), S1-7. [https://doi.org/10.3949/ccjm.72.suppl\_2.s1](https://doi.org/10.3949/ccjm.72.suppl_2.s1).
2\. Centers for Disease Control. MMWR (October 1997) *Knowledge About Causes of Peptic Ulcer Disease—United States, March-April 1997*. . Accessed June 9, 2022.
3\. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 Sep;49(3):347-53. doi: 10.1136/gut.49.3.347. PMID: 11511555; PMCID: PMC1728434.
4\. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. *American College of Gastroenterology Clinical Guideline: Treatment of Helicobacter pylori Infection*. American Journal of Gastroenterology, 2018; 113(7), p1102. doi: 10.1038/s41395-018-0132-6
5\. Chey WD & Wong BCY. *Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection*. Am J Gastroenterol, 2007; 102(8):1808-1825.
6\. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. *Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease*. JAMA Intern Med, 2016;176(2):238–246. doi:10.1001/jamainternmed.2015.7193
7\. Talley, N. J. *American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia*. Gastroenterology, 2005; 129(5):1753–1755.
8**.** Data on file. Otsuka America Pharmaceutical, Inc.
9\. Heidelbaugh JJ, et al. *Overutilization of proton-pump inhibitors: what the clinician needs to know*. Therap Adv Gastroenterol, 2012 Jul; 5(4): 219-232.
10\. Vakil, N., & Fendrick, A. M. (2005). *How to test for Helicobacter pylori in 2005*. Cleveland Clinic Journal of Medicine, 72(Suppl\_2), S8. [https://doi.org/10.3949/ccjm.72.suppl\_2.s8](https://doi.org/10.3949/ccjm.72.suppl_2.s8).
11\. Hashem B. El-Serag, John Y. Kao, Fasiha Kanwal, Mark Gilger, Frank LoVecchio, Steven F. Moss, Sheila Crowe, Adam Elfant, Thomas Haas, Ronald J. Hapke, and David Y. Graham. *Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States*. Clinical Gastroenterology and Hepatology, 2018; 16:992–1002.
12\. Urgesi R, Ciaci R, Ricconi ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol, 2012;5:151-157.
13\. American Family Physician, *Practice Guidelines: H.pylori Infection: ACG Updates Treatment Recommendations*, January 2018; 97(2):137.
14\. Vakil, N., & Megraud, F. (2007). Eradication Therapy for Helicobacter pylori. Gastroenterology, 133(3), 985–1001.
15\. Acid-reducing medicines may lead to dependency; EurekAlert! The Global Source for Science News, AGA 2009. Available at: [https://www.eurekalert.org/pub\_releases/2009-07/aga-amm062909.php](https://www.eurekalert.org/pub_releases/2009-07/aga-amm062909.php)
## Stay in the Loop
**Receive information regarding H. pylori, policy updates, educational tools, and more!**
[Back To Top](#)
---
### [Resource Videos](https://www.meridianbioscience.com/customer-support/resource-videos/)
**Published:** February 5, 2025
**Author:** hamza
**Content:**
# Resource Videos
## BreathID®
Introduction to Meridian BreathID® Urea Breath Testing with BreathID® Smart
BreathID® Smart Workflow
H. pylori Education – BreathID® Hp Lab
## BreathTek®
BreathTek® UBT for H. pylori How to Administer The Test
## Revogene®
Getting Ready for Revogene®
How to unpack and install Revogene®
Revogene® Workflow
Revogene® Workflow C. difficile
Revogene® SARS-CoV-2 Workflow
Revogene® Strep A Workflow
## Alethia®
Alethia® Malaria Workflow
## Curian®
Curian® Campy Workflow
Curian® HpSA® Workflow
Curian® Shiga Toxin Workflow
## Curian® User's Guide
Curian® Package
Initial Installation and Set up
Install Power Adapter
Plug In and Power Up
Install Ferrite Core
Admin Log-on
Basic Navigation
Additional Users
Import and Export User List
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Lead Poisoning Resource Center for Families and Parents](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-families-and-parents/)
**Published:** September 24, 2025
**Author:** Moaaz Ahmad
**Content:**
## Don't be “mislead". Know the facts about lead exposure.
## Lead exposure
### The impact of lead poisoning on children
Lead is one of the most prevalent environmental health risks for children, with lifelong repercussions. Symptoms are not usually apparent and can mimic other everyday ailments like a headache or the flu. Even small quantities of lead in the bloodstream can affect a child’s learning capabilities, attention span and academic performance.
A blood test is the only way to diagnose lead exposure; followed by actions to mitigate the effects. The source of lead exposure should be quickly identified and the child should be isolated from it as soon as possible.
One of the key pieces to fighting this silent poison is creating more awareness for families ― empowering them to understand where lead lurks in the environment and to ask to get their children tested without depending on someone to tell them they’re at risk.
It only takes this much lead to poison a child.
There is NO safe level of lead in the blood.
## Sources of lead exposure
###### Most children are exposed to lead from paint in homes built before 1978.1
###### 1 in 4 children live in a home old enough to have lead paint.2
###### It’s more than lead paint. 30% of children are exposed to lead by additional sources.3
### Possible lead exposure sources include:
30-70 Section Windows and Doors Toys and Jewelry Drinking Water Pottery Soil Hobby / Work
## Windows and Doors
A home, school, or daycare built before 1978 may have lead paint on the windows, trim, etc. When the paint peels and cracks, it creates harmful lead dust, which can be inhaled by little ones in your household.
## Toys and Jewelry
Lead can be found in imported and antique toys, costume jewelry and trinkets.
## Drinking Water
Older plumbing may contain lead which can contaminate tap water.
## Pottery
Imported, old, and handmade pottery may have been made with leaded glaze.
## Soil
Soil near busy streets or pre-1978 buildings can contain high lead concentrations.
## Hobby / Work
A hobby or job can bring home lead dust on shoes and clothing (examples include: hunting, fishing, shooting, construction work, remodeling, welding, auto repair, etc.).
## Routes of exposure
### Both adults and children can become exposed to lead through occupational and environmental sources
- **Ingestion** of lead-contaminated dust, water (from leaded pipes), and food (from lead-glazed or lead-soldered containers).
- **Inhalation** of lead particles generated by burning materials containing lead, for example during smelting, recycling, stripping leaded paint, and using leaded aviation fuel
#### Don’t be “mislead” about lead…
Learn how a simple blood lead test at your child’s next pediatrician’s visit can provide answers.
[ 6 Facts to Know Sheet ](/uploads/Lead-Poisoning-Education-6-Facts-to-Know_v0.1.pdf)
[ Sources of Lead Poster ](/uploads/Lead-Sources-Education-Poster.pdf)
[ Happy, Healthy, Lead-Free Me! Book ](https://leadfreekidsnh.org/happy-healthy-lead-free-me-resources/)
## Learn about Lead
#### The impact of lead on little ones
###### Many lead-poisoned children do not show any signs of exposure. If gone undetected, lead may cause:
- learning delays
- damage to a child’s body, including brain, kidney, and nervous system
- hearing loss
- hyperactivity and behavior challenges
- delayed growth and development
- lower IQ and lower achievement in school
- seizures
- death
#### How do I know if my child has been exposed?
###### A blood lead test is the only way to know if your child has been exposed to lead.
- Children enrolled in Medicaid are required to get tested for lead at ages 1 and 2 or up to the age of 6 if they have no record of ever being tested.
- For children not enrolled in Medicaid, the CDC recommends focusing testing efforts on high-risk neighborhoods and children. These include children who:
- live or spend time in a house or building built before 1978
- are from low-income households
- are immigrants, refugees, or recently adopted from less developed countries
- live or spend time with someone who works with lead or has hobbies that may expose them to lead
#### How do I know if my child has been exposed?
###### A blood lead test is the only way to know if your child has been exposed to lead.
- live or spend time in a house or building built before 1978
- are from low-income households
- are immigrants, refugees, or recently adopted from less developed countries
- live or spend time with someone who works with lead or has hobbies that may expose them to lead
## How is the testing performed?
A blood test can be performed at the doctor’s office, local health department, clinic, or hospital. A healthcare provider will test a child’s blood for lead. A small amount of blood is taken from the finger, heel, or arm and tested for lead during a blood lead test.
**A finger-prick (capillary)** sample is usually the first step to determine if a child has lead in their blood. A finger-prick test that shows a blood lead level at or above the CDC’s blood lead reference value is usually followed by a second test to confirm it.
**A venous blood draw** takes blood from the child’s vein. It may take a few days to receive results from the laboratory. A healthcare provider may order a venous blood draw to confirm the blood lead level seen in an initial capillary test.
## Frequently asked questions about lead exposure
What is lead?
Lead is a naturally occurring metal used in various products and materials. Exposure to lead, even in small amounts, can affect multiple body systems and be particularly harmful to young children.
How does lead exposure occur?
Lead exposure occurs when someone inhales lead-containing fumes or dust or swallows something that contains lead. Lead-based paint and lead-contaminated dust are the primary sources of exposure for U.S. children. Despite significant progress, lead poisoning remains a top childhood environmental health problem. (Source: Healthy Homes)
Is there any safe level of lead?
No level of lead in the blood can be defined as safe. An advisory panel of the CDC now recommends that children with blood levels as low as 3.5 μg/dL be identified as having elevated levels and be monitored. Even such low levels may harm a child’s cardiovascular, immunological, and endocrine health, with consequences for that individual and overall public health. While the effects of lead appear to be irreversible, eliminating lead exposure can reduce further damage.
Why are children especially vulnerable?
Toddlers and young children explore with their hands and frequently put them in their mouths. As young children crawl on the floor and reach windows, railings, and walls, they may inhale dust from peeling and chipping lead-based paint or ingest paint chips.
Furthermore, children under six years of age are biologically more sensitive to lead due to rapid brain and organ development, when the body readily takes up lead—mistaking it for calcium. Therefore, children who are low in calcium or have iron-deficient anemia may have an ever-greater lead uptake.
Are adults affected by lead poisoning?
Adults can become lead poisoned, most frequently from the workplace and hobbies. Lead in adults can affect the central nervous and gastrointestinal systems and can cause chronic kidney disease as well as other health problems.
What can I do to prevent lead poisoning?
The best way to prevent lead poisoning among young children is to remove the lead source. To prevent exposure, especially in homes built before 1978, the CDC recommends:
- Contact your local health department about testing paint and dust from your home.
- Ensure a child cannot access peeling paint or chewable surfaces painted with lead-based paint.
- Create barriers between children and lead sources until clean-up is complete.
- Regularly wet mop floors, damp sponge walls, and all horizontal surfaces and vacuum with a high-efficiency particulate air vacuum (HEPA vac). Cleaning is a temporary solution until the lead can be completely removed.
- Pregnant women and children should avoid pre-1978 homes if a renovation is underway.
- Regularly wash children’s hands, especially before eating.
- Regularly wash children’s toys.
- Prevent children from playing in bare soil, opting for sandboxes or planting grass. This is especially true of areas that are within one block of a major highway or busy street, as lead that was once in gasoline may have accumulated in the soil.
- Give your children foods that are high in calcium and iron, such as meat, beans, spinach, and low-fat dairy products. This can help reduce the amount of lead absorbed by the body.
Source: https://www.cdc.gov/nceh/features/leadpoisoning/index.html
References:
1\. The Centers for Disease Control and Prevention (CDC) estimate that 29 million housing units have deteriorated lead paint and elevated levels of lead-contaminated house dust – about 1 in every 3 U.S. housing units may have lead paint hazards.
2\. Levin R. Lead Exposures in US Children, 2008: Implications for Prevention. *Env. Health Perspect.*2008;116(10):1285-93.
3\. Brown, M.J. (2012). Lead in Drinking Water and Human Blood Lead Levels in the United States. Morbidity and Mortality Weekly Report, August 10 Supplement, 61, 1-9
#### Stay in the loop
Receive information regarding lead consumer alerts, policy updates, educational tools, and more!
---
### [Susan Bogar](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/susan-bogar/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Susan Bogar
### Vice President, Regulatory Affairs
Susan Bogar leads Meridian Bioscience’s regulatory affairs function, ensuring product compliance across all stages of the lifecycle and supporting the company’s global quality and licensing strategy.
Since joining Meridian in 2006, she has advanced through leadership roles in regulatory affairs, design quality assurance, and product quality, contributing to successful product launches and regulatory submissions worldwide.
Susan began her career as a microbiologist and holds a Bachelor of Arts in Microbiology from Miami University and a Certificate of Graduate Study in Medical Device Leadership from Xavier University.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Life Science Newsletter Registration](https://www.meridianbioscience.com/lifescience/life-science-newsletter-registration/)
**Published:** January 23, 2025
**Author:** hamza
**Content:**
#### Let’s discover together! Join our quarterly newsletter for the latest insights in your inbox.
# Register to receive our newsletter
---
### [Getting Started with Curian® Shiga Toxin](https://www.meridianbioscience.com/getting-started-with-curian-shiga-toxin/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
## Getting Started with Curian® Shiga Toxin
Use the training videos below to help get you started implementing Curian.
**Click on the links below to access the training videos available:**
[**Installation Videos**](https://meridianbiostg.wpengine.com/getting-started-with-curian/getting-started-with-curian-shiga-toxin/?country=US#videos) – these videos support setting up the Curian analyzer and basic navigation.
[**Training Video**](https://meridianbiostg.wpengine.com/getting-started-with-curian/getting-started-with-curian-shiga-toxin/?country=US#videos) –this video demonstrates the Curian Shiga Toxin assay procedure according to the package insert.
### Curian® Shiga Toxin Training Resources
The below documents can assist with the training and implementation of Curian Shiga Toxin.
Please reach out to our [Technical Services Team](https://meridianbiostg.wpengine.com/contact-us/?country=US) or call: [+1 800-343-3858](tel:18003433858) if you have any questions.
#### Downloadable PDFs
- **[Curian Shiga Toxin Training Checklist](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-Training-Checklist.docx)**
- **[Curian Shiga Toxin Assay Training Quiz](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-Assay-Training-Quiz-.docx)**
- **[Curian Shiga Toxin Assay Training Quiz Key](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-Assay-Training-Quiz-Key.docx)**
- **[Curian Shiga Toxin IQCP Template](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-IQCP-Template.xlsx)**
- **[Curian Shiga Toxin CLSI](https://meridianbiostg.wpengine.com/uploads/760630_clsi.doc)**
- **[Curian Shiga Toxin Validation Plan – Mac Broth](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-Validation-Plan-_Mac-Broth.docx)**
- **[Curian Shiga Toxin Validation Plan – GN Broth](https://meridianbiostg.wpengine.com/uploads/Curian-Shiga-Toxin-Validation-Plan_GN-Broth.docx)**
## Training Videos
#### Installation Videos
Watch the videos above to learn more about installing Curian.
#### Training Video
Running Curian Campy is easy! See for yourself in the video above.
## Still Need Assistance?
[ Call our support line at 800.343.3858 ](/contact-us/)
---
### [Case Study - From Concept to Clinic: Rapid Sepsis Detection Enabled by ddPCR and Lyophilized PCR Chemistry](https://www.meridianbioscience.com/lifescience/case-study-from-concept-to-clinic/)
**Published:** March 2, 2026
**Author:** Holger
**Content:**
## From Concept to Clinic
#### Rapid Sepsis Detection Enabled by ddPCR and Lyophilized PCR Chemistry
[From Concept to Clinic: Rapid Sepsis Detection Enabled by ddPCR and Lyophilized PCR Chemistry](https://collateral.meridianlifescience.com/view/367137942/)
[ Back to White Papers ](/lifescience/posters-and-articles/)
---
### [Getting Started with Curian® Campy](https://www.meridianbioscience.com/getting-started-with-curian-campy/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
## Getting Started with Curian® Campy
Use the training videos below to help get you started implementing Curian.
**Click on the links below to access the training videos available:**
[**Installation Videos**](#videos) – these videos support setting up the Curian analyzer and basic navigation
[**Software Update Video**](#videos) – this video demonstrates how to update Curian software prior to running patient testing.
Choose your Curian assay below to access training and implementation documents to begin testing. We are here to support you through this process. If you have any difficulty accessing training resources, please reach out to the [Technical Services Team](https://www.meridianbioscience.com/contact-us/) (+1 800.343.3858).
### Curian® Campy
Training Resources
The below documents can assist with the training and implementation of Curian Campy.
Please reach out to our [Technical Services Team](https://meridianbiostg.wpengine.com/contact-us/?country=US) or call: [+1 800-343-3858](tel:18003433858) if you have any questions.
#### Downloadable PDFs
- **[Curian Campy Training Checklist](https://www.meridianbioscience.com/uploads/Curian-Campy-Training-Checklist.docx)**
- **[Curian Campy Assay Training Quiz](https://www.meridianbioscience.com/uploads/CURIAN-CAMPY-TRAINING-Quiz.docx)**
- **[Curian Campy Assay Training Quiz Key](https://www.meridianbioscience.com/uploads/CURIAN-CAMPY-TRAINING-Quiz-Key.docx)**
- **[Curian Campy IQCP Template](https://www.meridianbioscience.com/uploads/Curian-Campy-IQCP-template.xlsx)**
- **[Curian Campy Validation Plan](https://www.meridianbioscience.com/uploads/Curian-Campy-Method-Validation.docx)**
- **[CLSI – Curian Campy ](https://www.meridianbioscience.com/uploads/760730_CLSI.doc)**
- **[Procedure Card – Curian Campy](https://www.meridianbioscience.com/uploads/760730_pc.pdf)**
- **[Proficiency Surveys for Curian Assays](https://www.meridianbioscience.com/uploads/Curian-Proficiency-surveys-10.2022.pdf)**
## Training Videos
#### Installation Videos
Watch the videos above to learn more about installing Curian.
#### Training Video
Running Curian Campy is easy! See for yourself in the video above.
## Still Need Assistance?
[ Call our support line at 800.343.3858 ](/contact-us/)
---
### [Benefits](https://www.meridianbioscience.com/careers/benefits/)
**Published:** February 4, 2025
**Author:** hamza
**Content:**
# Caring for Our Team
**Meridian is committed to attracting and retaining individuals who are capable of exceptional performance and dedication. We reward employees for the value of their accomplishments.**
Our compensation philosophy supports our mission and business strategy to align with the organization goals.
Meridian has established a performance-based compensation program — including base pay, annual bonuses, and recognition awards that reinforce our brand values.
#### Total Compensation
Competitive total compensation as it compares to the Diagnostic / Life Science markets, and reward programs that help us attract, retain, and motivate a high-quality workforce.
#### Benefit Programs
Benefit programs that are competitive in the market with respect to time off, wellness, retirement planning, and career growth.
#### Base Pay
Base pay levels that are competitive with the external job market in which we compete for talent and reflect the value of each position.
#### Incentive Bonus Programs
Incentive Bonus Programs commensurate with contribution level and driven by individual and company performance — compensation mix will vary by position.
We are proud to say that we are a company of thinkers and problem solvers.
If you have a passion to help redefine the possibilities from discovery to diagnosis, we’d like to hear from you. Start your journey by clicking below to see our current openings.
### We are a company of thinkers doers
[ See our current open positions ](https://careers-meridianbioscience.icims.com/jobs/intro?hashed=-435711682&mobile=false&width=850&height=500&bga=true&needsRedirect=false&jan1offset=-300&jun1offset=-240)
---
### [From Sample to Insight: Technologies Driving the Future of Precision Oncology Assay](https://www.meridianbioscience.com/lifescience/gen-precision-oncology-ebook-download/)
**Published:** November 17, 2025
**Author:** Moaaz Ahmad
**Content:**
## From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
### Discover how molecular diagnostics are transforming cancer detection, treatment, and monitoring.
[Precision oncology](/lifescience/products/molecular/precision-oncology-solutions-driving-the-future-of-cancer-diagnostics/) is reshaping how cancer is diagnosed and treated, with molecular technologies at the center of this transformation. From early detection and tumor profiling to real-time treatment monitoring and recurrence tracking, these tools are guiding clinical decisions across the entire patient journey.
**Discover What’s Next in Precision Oncology**
From scalable qPCR mixes to ambient-stable NGS reagents, Meridian’s molecular and immunoassay technologies are advancing cancer diagnostics — driving progress from early detection to precision treatment.
[Explore our Precision Oncology Solutions](/lifescience/products/molecular/precision-oncology-solutions-driving-the-future-of-cancer-diagnostics/)
#### Inside the eBook, you’ll learn:
- Molecular insights: How genomic profiling uncovers the mutations driving tumor progression—enabling more targeted therapies.
- Technology in action: The roles of qPCR, targeted NGS, and whole-genome sequencing in delivering accurate, scalable, and clinically relevant results.
- The future of oncology assays: Why workflow-optimized, scalable solutions are essential to expand access to precision medicine worldwide.
As cancer prevalence continues to rise, the demand for practical, high-performance diagnostic solutions is greater than ever. This eBook explores the diagnostic platforms and innovations powering the next generation of oncology assays—and what they mean for the future of cancer care. **Download your free copy today and gain insights into how precision oncology is being transformed by technology.**
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [Dan Siman-Tov](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/dan-siman-tov/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Dan Siman-Tov, PhD
### Vice President, Diagnostics Research and Development
Dan Siman-Tov, Ph.D., MBA, serves as Vice President of Research and Development, Diagnostics at Meridian Bioscience.
With more than 20 years of experience in in vitro diagnostic (IVD) device development , Dr. Siman-Tov leads the company’s global diagnostics R&D organization across multiple sites and diagnostic platforms, driving the development of innovative assays from concept through regulatory approval and commercial launch.
Since joining Meridian in 2018, he has brought an innovative and creative approach to the R&D organization, coupled with strong leadership and a clear strategic vision that continues to empower and align global teams.
Throughout his career, he has led cross-functional teams in delivering FDA-cleared and CE-marked products and advancing instrument-based platforms, while shaping R&D portfolio strategy and long-term business planning .
A passionate advocate for scientific excellence and organizational growth, he plays a key role in defining the strategic vision of the business and ensuring the successful execution of Meridian’s global diagnostic innovation agenda.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/andy-hiar/)
### Andy Hiar
Vice President, Diagnostics Clinical Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/andy-hiar/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Thank You For Newsletter Signup](https://www.meridianbioscience.com/thank-you-for-newsletter-signup/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your submission has been received.
Thank you for connecting! Look forward to the latest news & and insights to accelerate your diagnostics development.
###### Thank you!
[Home](https://www.meridianbioscience.com "Home")» Thank You For Newsletter Signup
# Thank You For Newsletter
Signup
Diagnostic assays that deliver the best patient outcomes rely on high-quality reagents. Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 disease targets and an extensive range of specialty qPCR master mixes and molecular enzymes manufactured under ISO13485 regulations. Meridian offers diagnostic manufacturers the complete solution.
[ Contact a Specialist ](#contact-a-specialist)
[ View Products Below ](#products1)
- [#### Antibodies, Antigens & Blockers
](/lifescience/products/antibodies-antigens/)
- [#### Molecular Reagents
](/lifescience/products/molecular-reagents/)
Not seeing what you’re looking for? [Inquire about a new product](https://meridianbiostg.wpengine.com/thank-you-for-requesting-a-sample-mdx/?country=CU#form-anchor)
---
### [Experience It for Yourself](https://www.meridianbioscience.com/lifescience/immuno-blocker-sample-request/)
**Published:** September 16, 2025
**Author:** hamza
**Content:**
## Discover the Meridian Difference
Meridian offers a broad range of high-performance immunoassay blockers to help reduce interference from HAMA, RF, and other heterophilic antibodies—supporting more accurate and reliable assay results across ELISA, CLIA, and lateral flow formats.
Please select the blocker you would like to evaluate using the form below and a representative will be in touch to help you with your order.
---
### [Julie Smith](https://www.meridianbioscience.com/about/leadership-team/julie-smith/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Julie Smith
### Senior Vice President and Chief Financial Officer
Julie Smith serves as Senior Vice President and Chief Financial Officer at Meridian Bioscience, where she leads global financial strategy, planning, and reporting. With more than 20 years at Meridian, Julie has been instrumental in driving financial performance, supporting strategic growth initiatives, and ensuring transparency across the organization.
Throughout her tenure, Julie has held key leadership roles, including Vice President of Finance and Senior Vice President, Controller, and Principal Accounting Officer. Her deep institutional knowledge and steady leadership have strengthened Meridian’s financial foundation and aligned finance operations with long-term strategic priorities.
Julie’s leadership philosophy emphasizes integrity, collaboration, and disciplined execution. She is recognized for translating complex financial data into actionable insights and fostering cross-functional partnerships that advance organizational success.
Before joining Meridian, Julie built her expertise in audit, consulting, and nonprofit management. She began her career at PwC as an Audit Manager and later specialized in controllership and finance consulting, focusing on internal controls, Sarbanes-Oxley implementation, and audit readiness.
Julie holds a Bachelor of Science in Accounting and an MBA from the University of Dayton. She continues to guide Meridian’s finance organization with a focus on sustainable growth, operational excellence, and long-term value creation.
## Get to Know Our Members
[  ](/about/leadership-team/andy-kitzmiller/)
### Andy Kitzmiller
President and Chief Executive Officer
[ Read Bio ](/about/leadership-team/andy-kitzmiller/)
[  ](/about/leadership-team/harald-ottenhof/)
### Harald Ottenhof, PhD
Executive Vice President, Life Science Meridian Bioscience
[ Read Bio ](/about/leadership-team/harald-ottenhof/)
[  ](/about/leadership-team/emerson-c-moser/)
### Emerson C. Moser
Senior Vice President and General Counsel
[ Read Bio ](/about/leadership-team/emerson-c-moser/)
[  ](/about/leadership-team/don-oliver/)
### Don Oliver
Senior Director of Global Information Technology
[ Read Bio ](/about/leadership-team/don-oliver/)
## Experts driving diagnostic innovation
[ View Diagnostics Leadership Team ](/diagnostics/diagnostics-team-members/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
---
### [Diagnostics Blog](https://www.meridianbioscience.com/diagnostics/diagnostics-blog/)
**Published:** March 17, 2025
**Author:** hamza
**Content:**
# Diagnostics Dialogue:
### Insights on the Latest Trends and Innovations in
Diagnostic Testing.
[  ](https://www.meridianbioscience.com/diagnostics-blog/understanding-lead-poisoning-a-comprehensive-guide-to-blood-lead-testing/)
### [Understanding Lead Poisoning: A Comprehensive Guide to Blood Lead Testing](https://www.meridianbioscience.com/diagnostics-blog/understanding-lead-poisoning-a-comprehensive-guide-to-blood-lead-testing/)
Lead poisoning remains a significant public health concern, particularly affecting young children. With symptoms ranging from abdominal pain and developmental...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [LeadCare](https://www.meridianbioscience.com/category/diagnostics-blog/leadcare/), [Pediatric & Neonatal](https://www.meridianbioscience.com/category/diagnostics-blog/pediatric-neonatal/)
#### Featured
[  ](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
### [Rethinking *Campylobacter*: Fast, Accurate Diagnostics for Better GI Outcomes](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
What Is Campylobacter and How Is It Transmitted? Campylobacter is a genus of bacteria and one of the most common causes...
- [campylobacter](https://www.meridianbioscience.com/category/diagnostics-blog/campylobacter/), [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
### [Understanding *H. pylori*: Why Timely Testing and Retesting Matters](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
What Is H. pylori and How Is It Transmitted? Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that infects the stomach...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/), [H. pylori](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/h-pylori/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
### [Shiga Toxin-Producing E. coli: The Urgent Need for Accurate, Antibiotic-Free Management](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
What Is E. coli? Understanding STEC and How It Spreads Escherichia coli (E. coli) is a diverse group of bacteria that...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [E. coli](https://www.meridianbioscience.com/category/diagnostics-blog/e-coli/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/why-modern-labs-are-moving-beyond-visual-interpretation-in-diagnostic-testing/)
### [Why Modern Labs Are Moving Beyond Visual Interpretation in Diagnostic Testing](https://www.meridianbioscience.com/diagnostics-blog/why-modern-labs-are-moving-beyond-visual-interpretation-in-diagnostic-testing/)
Colorimetric lateral flow assays (LFAs) have long been trusted in point-of-care and laboratory diagnostics due to their simplicity, low cost,...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/outdated-and-ineffective-why-its-time-to-say-goodbye-to-serology-for-h-pylori-testing/)
### [Outdated and Ineffective: Why It’s Time to Say Goodbye to Serology for H. pylori Testing](https://www.meridianbioscience.com/diagnostics-blog/outdated-and-ineffective-why-its-time-to-say-goodbye-to-serology-for-h-pylori-testing/)
Helicobacter pylori (H. pylori) is a widespread bacterial infection that affects the stomach lining and is a leading cause of...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
### [Rethinking *Campylobacter*: Fast, Accurate Diagnostics for Better GI Outcomes](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
What Is Campylobacter and How Is It Transmitted? Campylobacter is a genus of bacteria and one of the most common causes...
- [campylobacter](https://www.meridianbioscience.com/category/diagnostics-blog/campylobacter/), [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
### [Understanding *H. pylori*: Why Timely Testing and Retesting Matters](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
What Is H. pylori and How Is It Transmitted? Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that infects the stomach...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/), [H. pylori](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/h-pylori/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
### [Shiga Toxin-Producing E. coli: The Urgent Need for Accurate, Antibiotic-Free Management](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
What Is E. coli? Understanding STEC and How It Spreads Escherichia coli (E. coli) is a diverse group of bacteria that...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/), [E. coli](https://www.meridianbioscience.com/category/diagnostics-blog/e-coli/), [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
[  ](https://www.meridianbioscience.com/diagnostics-blog/why-modern-labs-are-moving-beyond-visual-interpretation-in-diagnostic-testing/)
### [Why Modern Labs Are Moving Beyond Visual Interpretation in Diagnostic Testing](https://www.meridianbioscience.com/diagnostics-blog/why-modern-labs-are-moving-beyond-visual-interpretation-in-diagnostic-testing/)
Colorimetric lateral flow assays (LFAs) have long been trusted in point-of-care and laboratory diagnostics due to their simplicity, low cost,...
- [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/)
[ View All ](/category/diagnostics-blog)
#### [Gastrointestinal](/category/diagnostics-blog/gastrointestinal/)
### [ Rethinking *Campylobacter*: Fast, Accurate Diagnostics for Better GI Outcomes ](https://www.meridianbioscience.com/diagnostics-blog/rethinking-campylobacter-fast-accurate-diagnostics-for-better-gi-outcomes/)
What Is Campylobacter and How Is It Transmitted? Campylobacter is a genus of bacteria and one of the most common
### [ Understanding *H. pylori*: Why Timely Testing and Retesting Matters ](https://www.meridianbioscience.com/diagnostics-blog/understanding-h-pylori-why-timely-testing-and-retesting-matters/)
What Is H. pylori and How Is It Transmitted? Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that infects the
### [ Shiga Toxin-Producing E. coli: The Urgent Need for Accurate, Antibiotic-Free Management ](https://www.meridianbioscience.com/diagnostics-blog/shiga-toxin-producing-e-coli-the-urgent-need-for-accurate-antibiotic-free-management/)
What Is E. coli? Understanding STEC and How It Spreads Escherichia coli (E. coli) is a diverse group of bacteria
### [ Unveiling H. pylori Trends: Updates on Diagnosis and Management ](https://www.meridianbioscience.com/diagnostics-blog/unveiling-h-pylori-trends-updates-on-diagnosis-and-management/)
As the battle against Helicobacter pylori continues to evolve, healthcare professionals are increasingly turning to advanced diagnostic tools and innovative
#### [CMV](/category/diagnostics-blog/cmv/)
### [ Navigating Congenital Cytomegalovirus: Latest Trends in Prevention and Care ](https://www.meridianbioscience.com/diagnostics-blog/navigating-congenital-cytomegalovirus-latest-trends-in-prevention-and-care/)
Congenital cytomegalovirus (CMV) is a critical public health issue with significant implications for unborn babies. As the leading non-genetic cause
### [ Understanding Congenital Cytomegalovirus: Risks, Symptoms, and Management ](https://www.meridianbioscience.com/diagnostics-blog/understanding-congenital-cytomegalovirus-risks-symptoms-and-management/)
Understanding the Risks and Management of Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus (CMV) poses significant risks to unborn children, marking it
### [ Emerging Strategies in Congenital Cytomegalovirus Management: A Comprehensive Guide ](https://www.meridianbioscience.com/diagnostics-blog/emerging-strategies-in-congenital-cytomegalovirus-management-a-comprehensive-guide/)
Exploring the Frontier of Congenital CMV Management
Congenital cytomegalovirus (CMV) infection, a significant challenge in public health, has far-reaching implications
### [ New Frontiers in Congenital Cytomegalovirus Research: Current Developments and Future Prospects ](https://www.meridianbioscience.com/diagnostics-blog/new-frontiers-in-congenital-cytomegalovirus-research-current-developments-and-future-prospects/)
Leading the Fight Against Congenital CMV: New Strategies and Hope
As one of the leading causes of sensory and neurological
---
### [Point of Care Assay Development Challenges and Solutions: LAMP vs. qPCR](https://www.meridianbioscience.com/lifescience/point-of-care-assay-development-challenges-and-solutions-lamp-vs-qpcr/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## Point of Care Assay Development Challenges and Solutions: LAMP vs. qPCR
[ Back to White Papers ](#)
---
### [Inside an Assay Developer’s Initial Study Comparing qPCR Mixes for Targeted NGS](https://www.meridianbioscience.com/lifescience/inside-an-assay-developers-initial-study-comparing-qpcr-mixes-for-targeted-ngs/)
**Published:** December 12, 2025
**Author:** Holger
**Content:**
# Inside an Assay Developer’s Initial Study Comparing qPCR Mixes for Targeted NGS
[tNGS App Note - Inside a Developer's Study](https://collateral.meridianlifescience.com/view/369412383/)**tNGS App Note - Inside a Developer's Study**
[ Back to White Papers ](/lifescience/products/molecular/white-papers-conference-posters/)
---
### [Reducing False Results in Immunoassay Testing](https://www.meridianbioscience.com/lifescience/whitepaper-reducing-false-results-in-immuno-testing/)
**Published:** December 12, 2025
**Author:** Holger
**Content:**
# Reducing False Results
in Immunoassay Testing
[Whitepaper: Reducing False Results in Immunoassay Testing](https://collateral.meridianlifescience.com/view/812878521/)**Whitepaper: Reducing False Results in Immunoassay Testing**
[ Back to White Papers ](/lifescience/products/molecular/white-papers-conference-posters/)
---
### [Andy Hiar](https://www.meridianbioscience.com/diagnostics/diagnostics-team-members/andy-hiar/)
**Published:** March 12, 2026
**Author:** hamza
**Content:**
# Andy Hiar
### Vice President, Diagnostics Clinical Affairs
Andy Hiar serves as Vice President, Diagnostics Clinical Affairs at Meridian Bioscience.
With more than 20 years of experience with in-vitro diagnostic (IVD) device clinical trial leadership and execution, Andy leads the company’s global Clinical Affairs team.
Since joining Meridian in 2024, Andy has brought an innovative and creative approach to Clinical Affairs, coupled with strong leadership and strategic vision, he has positioned his team to support Meridian’s new product development initiatives.
Throughout his career, he has led Clinical Affairs teams in delivering successful clinical trials to support FDA, CE-Mark and IVDR product registrations.
Andy holds a Bachelor of Science in Biology from the University of St. Francis and a Master of Public Health degree from Benedictine University.
## Get to Know Our Members
[  ](/diagnostics/diagnostics-team-members/kevin-kiser/)
### Kevin Kiser
Senior Vice President, Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/kevin-kiser/)
[  ](/diagnostics/diagnostics-team-members/rob-stewart/)
### Rob Stewart
Senior Vice President, Global Sales and Support
[ Read Bio ](/diagnostics/diagnostics-team-members/rob-stewart/)
[  ](/diagnostics/diagnostics-team-members/susan-bogar/)
### Susan Bogar
Vice President, Regulatory Affairs
[ Read Bio ](/diagnostics/diagnostics-team-members/susan-bogar/)
[  ](/diagnostics/diagnostics-team-members/michelle-bosch/)
### Michelle Bosch
Vice President, Global Commercial Marketing and Business Management
[ Read Bio ](/diagnostics/diagnostics-team-members/michelle-bosch/)
[  ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
### John R. Lewis, Jr.
Vice President, Quality Operations
[ Read Bio ](/diagnostics/diagnostics-team-members/john-r-lewis-jr/)
[  ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
### Dan Siman-Tov, PhD
Vice President, Diagnostics Research and Development
[ Read Bio ](/diagnostics/diagnostics-team-members/dan-siman-tov/)
[  ](/diagnostics/diagnostics-team-members/todd-woodrich/)
### Todd Woodrich
Vice President, Manufacturing
[ Read Bio ](/diagnostics/diagnostics-team-members/todd-woodrich/)
## Leaders shaping Meridian’s vision
[ View Lifescience Leadership Team ](/lifescience/lifescience-leadership-team/)
## Leaders guiding company strategy
[ View Corporate Officers ](/about/leadership-team/)
---
### [Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/webinar-shaping-the-future-of-precision-oncology/)
**Published:** September 17, 2025
**Author:** Moaaz Ahmad
**Content:**
#### NGS
##### [2025 Outlook: Emerging Viruses & Next-Gen Respiratory DX](/2025-outlook-emerging-viruses-next-gen-respiratory-dx/)
The 2025 flu season has been more intense than recent years, with elevated infection rates and notable pressure on healthcare…
##### [Solving Enzyme Stability by Tackling Glycerol-Free Formulation Challenges](/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/)
Imagine diagnostic assays that can be shipped and stored at room temperature, removing the need for freezing or refrigeration while…
##### [The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS](/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/)
The world of diagnostics is evolving rapidly, driven by the growing need for personalized healthcare solutions. For decades, qPCR has…
##### [Next-Gen Synergies: Innovating POCT and NGS for Enhanced Molecular Diagnostics](/next-gen-synergies-innovating-poct-and-ngs-for-enhanced-molecular-diagnostics/)
In recent years, point-of-care testing (POCT) and next-generation sequencing (NGS) have undergone remarkable advancements, establishing themselves as fundamental tools in…
---
### [Highly sensitive qPCR detection of biomarkers from liquid biopsies](https://www.meridianbioscience.com/lifescience/highly-sensitive-qpcr-detection-of-biomarkers-from-liquid-biopsies/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Ebook The Evolution of STI Testing](https://www.meridianbioscience.com/lifescience/ebook-the-evolution-of-sti-testing/)
**Published:** February 24, 2026
**Author:** Holger
**Content:**
## The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
#### From Early Assays to Next-Gen Platforms: The Molecular and Immunoassay Innovations Shaping Modern Testing
[The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies](https://collateral.meridianlifescience.com/view/482457839/)
[ Back to eBooks ](/lifescience/posters-and-articles/)
---
### [Increasing Access to Point of Care Diagnostics through Innovative Advances in Molecular Reagents](https://www.meridianbioscience.com/lifescience/increasing-access-to-point-of-care-diagnostics-through-innovative-advances-in-molecular-reagents/)
**Published:** December 22, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [BreathID® IDkit Hp®Two](https://www.meridianbioscience.com/idkit-two-video-it/)
**Published:** February 11, 2026
**Author:** hamza
**Content:**
## ### BreathID® IDkit Hp® Two
---
### [Getting Started with Curian® HpSA®](https://www.meridianbioscience.com/getting-started-with-curian-hpsa/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
## Getting Started with Curian® HpSA®
Use the training videos below to help get you started implementing Curian.
**Click on the links below to access the training videos available:**
[**Installation Videos**](https://meridianbiostg.wpengine.com/getting-started-with-curian/getting-started-with-curian-hpsa/?country=US#videos) – these videos support setting up the Curian analyzer and basic navigation
[**Training Video**](https://meridianbiostg.wpengine.com/getting-started-with-curian/getting-started-with-curian-hpsa/?country=US#videos) –this video demonstrates the Curian® HpSA® assay procedure according to the package insert.
### Curian® HpSA Training Resources
The below documents can be used to assist with the training and implementation of Curian HpSA.
Please reach out to our [Technical Services Team](https://meridianbiostg.wpengine.com/contact-us/?country=US) or call: [+1 800-343-3858](tel:18003433858) if you have any questions.
#### Downloadable PDFs
- **[Curian HpSA Training Checklist](https://meridianbiostg.wpengine.com/uploads/Curian-Training-Checklist.docx)**
- **[Curian HpSA Assay Training Quiz](https://meridianbiostg.wpengine.com/uploads/Curian-HpSA-assay-training-quiz.docx)**
- **[Curian HpSA Assay Training Quiz Key](https://meridianbiostg.wpengine.com/uploads/Curian-HpSA-assay-training-quiz-key.docx)**
- **[Curian HpSA IQCP Template](https://meridianbiostg.wpengine.com/uploads/Curian-HpSA-IQCP-template.xlsx)**
- **[Curian HpSA Validation Plan](https://meridianbiostg.wpengine.com/uploads/Curian-HpSA-Method-Validation-with-patients.docx)**
- **[CLSI – Curian HpSA](https://meridianbiostg.wpengine.com/uploads/760130_clsi.doc)**
- **[Procedure Card – Curian HpSA](https://meridianbiostg.wpengine.com/uploads/760130_pc.pdf)**
- **[Proficiency Surveys for Curian Assays](https://meridianbiostg.wpengine.com/uploads/Curian-Proficiency-surveys-10.2022.pdf)**
## Training Videos
#### Installation Videos
Watch the videos above to learn more about installing Curian.
#### Training Video
Running Curian Campy is easy! See for yourself in the video above.
## Still Need Assistance?
[ Call our support line at 800.343.3858 ](/contact-us/)
---
### [LeadCare® II Marketing](https://www.meridianbioscience.com/leadcare-ii-marketing/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
##### LeadCare® II
## Blood Lead Testing Made Easy
Lead exposure poses serious health risks across all age groups. LeadCare II® is the only FDA-cleared, CLIA-waived point-of-care blood lead test that delivers lab-accurate results in minutes with a simple fingerstick.
[ Request a Quote ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU3NDM5IiwidG9nZ2xlIjpmYWxzZX0%3D)
Take action before health and learning suffer.
Early diagnosis helps to quickly address the effects of lead exposure. Learn more about how you can protect your child from lead poisoning.
- Group 12Created with Sketch. Results in 3 minutes
- Group 19Created with Sketch. Easy to use - CLIA-waived
- Group 13Created with Sketch. Boosts compliance
- tech\_icon2 A single visit and a simple fingerstick test
## Why Test for Lead?
Lead exposure is a significant health concern for pediatrics as well as adults exposed through occupational settings. Most lead exposed children have no obvious or immediate symptoms. Early detection is essential to prevent long-term health effects in:
- **Young children (ages 1-6):** A vital period for brain and physical development, where lead exposure can cause irreversible harm.
- **Adults in high-risk jobs:** Workers in construction, manufacturing, mining, and other industries with lead exposure face increased health risks.
- **Prenatal and maternal health:** Monitoring lead levels in expectant mothers is essential to protecting both maternal well-being and fetal development.
## LeadCare® II Product Description
Lead is an invisible neurotoxin lurking throughout our environment, posing the greatest risk to children living in homes built before 1978. In just three minutes, LeadCare® II detects lead exposure. CLIA-waived LeadCare® II is used in thousands of practices because it’s easy to use, provides an accurate test result and fits seamlessly into office workflow. Parents value the convenience of a single doctor’s visit, a quick fingerstick, and same day test results.
#### Analyzer Kit
The analyzer kit contains the analyzer, power cord, and instructions. Test kits must be ordered separately.
**Catalog Number: 70-6760**
#### Test Kit
Contains reagents, capillary tubes, plungers and transfer droppers for 48 tests; two levels of quality control and a calibration button.
**Catalog Number: 70-6762**
### Benefits of LeadCare® II
- **Rapid blood lead level** testing at the point-of-care with results in 3 minutes
- **FDA-cleared & CLIA-waived** for use in physician offices, hospitals or public health settings
- **Fingerstick sample** requires just 2 drops of blood
- **Portable blood lead analyzer** provides same day test results ensuring faster and more efficient testing with the patient in-office
## How It Works
**Testing is As Easy As 1, 2, 3**
1. Collect a fingerstick sample using the capillary tube provided
2. Add sample to treatment reagent and mix thoroughly
3. Insert a sensor into the analyzer and apply the sample
## Blood Lead Testing Made Easy
- Easy test procedure provides a quick and accurate way to help identify children and adults at risk for lead exposure
- Point-of-care lead testing increases testing compliance for healthcare providers
- Aligned with CDC recommendations for blood lead testing
### Order Your CLIA-Waived Lead Test Kit Today
Equip your physician’s office with fast, dependable blood lead level test kits for quick patient testing. LeadCare® II plays a crucial role in identifying those most at risk for lead poisoning, helping to prevent further exposure to this dangerous neurotoxin and ensuring better health outcomes.
#### Are you a Healthcare Professional?
As a healthcare professional, you play a critical role in identifying and preventing lead exposure. Click below to connect with our specialists for expert guidance and helpful resources.
[ Contact a Specialist ](#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU5NDAzIiwidG9nZ2xlIjpmYWxzZX0%3D)
#### Are you a Patient?
Lead exposure can be harmful, but understanding the facts is the first step to protecting yourself and your family. Click below to visit our Resource Center for education on lead poisoning prevention.
[Visit Our Resource Center](/lead-poisoning-resource-center-for-families-and-parents/)
---
### [LeadCare® II Product Marketing](https://www.meridianbioscience.com/leadcare-ii-product-marketing/)
**Published:** November 17, 2025
**Author:** Moaaz Ahmad
**Content:**
# Blood Lead Testing Made Easy
Lead exposure poses serious health risks for people of all ages, especially children. LeadCare II® is the only FDA-cleared, CLIA-waived point-of-care blood lead test that provides accurate results in minutes from a simple fingerstick.
- Group 12Created with Sketch. Results in 3 minutes
- Group 19Created with Sketch. CLIA-waived and FDA-cleared
- Group 13Created with Sketch. Capillary sample, just 2 drops of blood
- tech\_icon2 Easy to use – no validation required
#### Contact a Specialist
I am a Healthcare Professional I am a Patient
For guidance on lead testing and prevention, please consult your doctor or pediatrician. To learn more about lead poisoning prevention, visit our Resource Center below for additional educational resources.
[Visit our Resource Center](/lead-poisoning-resource-center-for-families-and-parents/)
## LeadCare® II Product Description
Lead is an invisible neurotoxin found throughout our environment, posing the greatest risk to children during critical stages of growth and development. With LeadCare® II, detecting blood lead levels is fast, accurate, and easy. In just three minutes, this CLIA-waived system delivers reliable results from a simple fingerstick sample — right in your office.
Used in thousands of healthcare practices nationwide, LeadCare® II integrates seamlessly into your workflow, empowering clinicians to make informed decisions during a single patient visit. Parents appreciate the speed and convenience of same day results without the need for follow up appointments.
LeadCare® II — the trusted solution for lead testing when every minute matters.
### Analyzer Kit
The analyzer kit contains the analyzer, power cord, and instructions. Test kits must be ordered separately.
**Catalog Number: 70-6760**
### Test Kit
Contains reagents, capillary tubes, plungers and transfer droppers for 48 tests; two levels of quality control and a calibration button.
**Catalog Number: 70-6762**
### Benefits of LeadCare® II
- **Rapid blood lead level** testing at the point-of-care with results in 3 minutes
- **FDA-cleared & CLIA-waived** for use in physician offices, hospitals or public health settings
- **Fingerstick sample** requires just 2 drops of blood
- **Portable blood lead analyzer** provides same day test results ensuring faster and more efficient testing with the patient in-office
## Why Test for Lead?
Lead exposure is a significant health concern for pediatrics as well as adults exposed through occupational settings. Most lead exposed children have no obvious or immediate symptoms. Early detection is essential to prevent long-term health effects in:
- **Young children (ages 1-6):** A vital period for brain and physical development, where lead exposure can cause irreversible harm.
- **Adults in high-risk jobs:** Workers in construction, manufacturing, mining, and other industries with lead exposure face increased health risks.
- **Prenatal and maternal health:** Monitoring lead levels in expectant mothers is essential to protecting both maternal well-being and fetal development.
## How It Works
**Testing is As Easy As 1, 2, 3**
1. Collect a fingerstick sample using the capillary tube provided
2. Add sample to treatment reagent and mix thoroughly
3. Insert a sensor into the analyzer and apply the sample
## Blood Lead Testing Made Easy
- Easy test procedure provides a quick and accurate way to help identify children and adults at risk for lead exposure
- Point-of-care lead testing increases testing compliance for healthcare providers
- Aligned with CDC recommendations for blood lead testing
### Order Your CLIA-Waived Lead Test Kit Today
Equip your physician’s office with fast, dependable blood lead level test kits for quick patient testing. LeadCare® II plays a crucial role in identifying those most at risk for lead poisoning, helping to prevent further exposure to this dangerous neurotoxin and ensuring better health outcomes.
I am a Healthcare Professional I am a Patient
For guidance on lead testing and prevention, please consult your doctor or pediatrician. To learn more about lead poisoning prevention, visit our Resource Center below for additional educational resources.
[Visit our Resource Center](/lead-poisoning-resource-center-for-families-and-parents/)
---
### [From Single Mutations to Whole Genomes: Molecular Technologies Shaping Precision Oncology Diagnostics](https://www.meridianbioscience.com/lifescience/white-paper-from-single-mutations-to-whole-genomes/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
# From Single Mutations to Whole Genomes: Molecular Technologies Shaping Precision Oncology Diagnostics
## A Comparison of qPCR, Targeted NGS, and Whole Genome Sequencing
[From Single Mutations to Whole Genomes: Molecular Technologies Shaping Precision Oncology Diagnostics](https://collateral.meridianlifescience.com/view/270528439/)
[ Back to White Papers ](#)
---
### [Getting Started with Curian®](https://www.meridianbioscience.com/getting-started-with-curian/)
**Published:** September 8, 2025
**Author:** Moaaz Ahmad
**Content:**
Curian
## Getting Started with Curian®
Use the training videos below to help get you started implementing Curian.
**Click on the links below to access the training videos available:**
[**Installation Videos**](#videos) – these videos support setting up the Curian analyzer and basic navigation.
[**Software Update Video**](#videos) – this video demonstrates how to update Curian software prior to running patient testing.
Choose your Curian assay below to access training and implementation documents to begin testing. We are here to support you through this process. If you have any difficulty accessing training resources, please reach out to the [Technical Services Team](https://www.meridianbioscience.com/contact-us/) (+1 800.343.3858).
[](/getting-started-with-curian-hpsa/)## curian®
###### Curian® HpSA®
Improves healthcare system efficiencies by providing a rapid, accurate result for *H. pylori* active infection and confirmation of eradication while removing subjectivity and transcription error. [Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/getting-started-with-curian-campy/)## curian®
###### Curian® Campy
A rapid, qualitative fluorescent immunoassay for the direct detection of a Campylobacter-specific antigen in stool specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/getting-started-with-curian-shiga-toxin/) [](/diagnostics/platforms/urea-breath/breathid-smart/)## curian®
###### Curian® Shiga Toxin
A rapid, fluorescent immunoassay for the detection of Shiga toxin 1 and 2 produced by enterohemorrhagic *E. coli* (EHEC) from stool specimens in broth enrichment. [Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
### Training Videos
#### How to Install Curian
Watch the videos above to learn more about installing Curian.
#### How to Update Software
Watch the videos above to learn more about installing Curian.
##### [Curian Platform Brochure](/uploads/Curian-Platform-Brochure_v1.0-1.pdf)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [The COVID Aftermath: Rising Immunoassay Interference in Diagnostic Immunoassays](https://www.meridianbioscience.com/lifescience/webinar-video-rising-immunoassay-interference-immunoassays/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## The COVID Aftermath: Rising Immunoassay Interference in Diagnostic Immunoassays
#### NGS
[](/smarter-library-prep-for-whole-genome-sequencing/)##### Smarter Library Prep for Whole Genome Sequencing
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, powering discovery in oncology, infectious disease, inherited disorders, and…
[](/2025-outlook-emerging-viruses-next-gen-respiratory-dx/)##### 2025 Outlook: Emerging Viruses & Next-Gen Respiratory DX
The 2025 flu season has been more intense than recent years, with elevated infection rates and notable pressure on healthcare…
[](/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/)##### Solving Enzyme Stability by Tackling Glycerol-Free Formulation Challenges
Imagine diagnostic assays that can be shipped and stored at room temperature, removing the need for freezing or refrigeration while…
[](/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/)##### The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS
The world of diagnostics is evolving rapidly, driven by the growing need for personalized healthcare solutions. For decades, qPCR has…
---
### [Cal Check Video Lab](https://www.meridianbioscience.com/cal-check-video-lab/)
**Published:** November 25, 2025
**Author:** hamza
**Content:**
---
### [Cal Check Video](https://www.meridianbioscience.com/cal-check-video/)
**Published:** November 25, 2025
**Author:** hamza
**Content:**
---
### [Top Reasons for Using Animal-Free HAMA/RF Immunoassay Interference Blockers](https://www.meridianbioscience.com/lifescience/top-reasons-for-using-animal-free-hama-rf-immunoassay-interference-blockers/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Meridian’s solution to detecting DNA or RNA directly from whole blood](https://www.meridianbioscience.com/lifescience/meridians-solution-to-detecting-dna-or-rna-directly-from-whole-blood/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [From Extraction to Result: Applying VLP Controls for Comprehensive Performance Validation Across Each Stage of an MDx Assay](https://www.meridianbioscience.com/lifescience/from-extraction-to-result-applying-vlp-controls-for-comprehensive-performance-validation-across-each-stage-of-an-mdx-assay/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [The evolution of STI at-home testing solutions: Exploring key advancements in molecular and immunoassay testing for STI at-home kits](https://www.meridianbioscience.com/lifescience/the-evolution-of-sti-at-home-testing-solutions-exploring-key-advancements-in-molecular-and-immunoassay-testing-for-sti-at-home-kits/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Breaking Down Barriers: Revolutionizing Next Generation Sequencing Accessibility by Innovating Reagent Logistics](https://www.meridianbioscience.com/lifescience/breaking-down-barriers-revolutionizing-next-generation-sequencing-accessibility-by-innovating-reagent-logistics/)
**Published:** December 23, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Advances in HPV Diagnostic Testing: Technologies Enhancing Detection of High-Risk Strains Linked to Cervical Cancer](https://www.meridianbioscience.com/lifescience/webinar-advances-in-hpv-diagnostic-testing/)
**Published:** September 16, 2025
**Author:** hamza
**Content:**
## Advances in HPV Diagnostic Testing: Technologies Enhancing Detection of High-Risk Strains Linked to Cervical Cancer
[ Back to Webinars ](https://www.meridianbioscience.com/lifescience/life-science-webinars/)
---
### [Ultra-fast Point-of-Care MDx development with new, sensitive LAMP master mixes](https://www.meridianbioscience.com/lifescience/ultra-fast-point-of-care-mdx-development-with-new-sensitive-lamp-master-mixes/)
**Published:** December 22, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Ebook From Sample to Insight](https://www.meridianbioscience.com/lifescience/ebook-from-sample-to-insight/)
**Published:** November 18, 2025
**Author:** hamza
**Content:**
## From Sample to Insight
#### Technologies Driving the Future of Precision Oncology Assays
[From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays](https://collateral.meridianlifescience.com/view/592614364/)
[ Back to White Papers ](/lifescience/posters-and-articles/)
---
### [Inside an Assay Developer’s Initial Study Comparing qPCR Mixes for Targeted NGS](https://www.meridianbioscience.com/lifescience/app-note-inside-an-assay-developers-initial-study-comparing-qpcr-mixes-for-targeted-ngs/)
**Published:** November 24, 2025
**Author:** Holger
**Content:**
## Application Note
[Inside an Assay Developers Initial Study Comparing qPCR Mixes for Targeted NGS](https://collateral.meridianlifescience.com/view/369412383/)
---
### [Driving Sustainability in the IVD Industry: Key Market Trends and Strategic Approaches](https://www.meridianbioscience.com/lifescience/white-paper-driving-sustainability-in-the-ivd-industry/)
**Published:** March 5, 2025
**Author:** hamza
**Content:**
## Driving Sustainability in the IVD Industry: Key Market Trends and Strategic Approaches
[Meridian Growing Demand for Sustainability in IVD industry …](https://collateral.meridianlifescience.com/view/548875924/)
[ Back to White Papers ](/lifescience/posters-and-articles/)
---
### [The Future of Molecular POC Testing: Low Cost and Highly-Sensitive Isothermal Amplification](https://www.meridianbioscience.com/lifescience/the-future-of-molecular-poc-testing-low-cost-and-highly-sensitive-isothermal-amplification/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## The Future of Molecular POC Testing: Low Cost and Highly-Sensitive Isothermal Amplification
[ Back to White Papers ](#)
---
### [Meridian Sample Specific Master Mixes – Breakthrough Innovation in MDx Development](https://www.meridianbioscience.com/lifescience/meridian-sample-specific-master-mixes-breakthrough-innovation-in-mdx-development/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## Meridian Sample Specific Master Mixes – Breakthrough Innovation in MDx Development
[ Back to White Papers ](#)
---
### [Direct Genotyping from Blood & FFPE Biopsies: Novel Inhibitor-Tolerant Master Mixes & Their Applications in Molecular Diagnosis](https://www.meridianbioscience.com/lifescience/direct-genotyping-from-blood-ffpe-biopsies-novel-inhibitor-tolerant-master-mixes-their-applications-in-molecular-diagnosis/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## Direct Genotyping from Blood & FFPE Biopsies: Novel Inhibitor-Tolerant Master Mixes & Their Applications in Molecular Diagnosis
[ Back to White Papers ](#)
---
### [Novel Solutions for Improved Process Control in Your Molecular IVD Assays](https://www.meridianbioscience.com/lifescience/novel-solutions-for-improved-process-control-in-your-molecular-ivd-assays/)
**Published:** September 18, 2025
**Author:** Moaaz Ahmad
**Content:**
[ Back to Webinars ](/lifescience-webinar/)
---
### [Empowering Molecular Point-of-Care Diagnostics with Timesaving, Cost-Effective, and Ambient-Stable Chemistries](https://www.meridianbioscience.com/lifescience/presentation-empowering-molecular-poc-diagnostics/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
## Empowering Molecular Point-of-Care Diagnostics with Timesaving, Cost-Effective, and Ambient-Stable Chemistries
#### NGS
[](/smarter-library-prep-for-whole-genome-sequencing/)##### Smarter Library Prep for Whole Genome Sequencing
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, powering discovery in oncology, infectious disease, inherited disorders, and…
[](/2025-outlook-emerging-viruses-next-gen-respiratory-dx/)##### 2025 Outlook: Emerging Viruses & Next-Gen Respiratory DX
The 2025 flu season has been more intense than recent years, with elevated infection rates and notable pressure on healthcare…
[](/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/)##### Solving Enzyme Stability by Tackling Glycerol-Free Formulation Challenges
Imagine diagnostic assays that can be shipped and stored at room temperature, removing the need for freezing or refrigeration while…
[](/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/)##### The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS
The world of diagnostics is evolving rapidly, driven by the growing need for personalized healthcare solutions. For decades, qPCR has…
---
### [Pairs Table Category](https://www.meridianbioscience.com/lifescience/pairs-table/pairs-table-category/)
**Published:** March 18, 2025
**Author:** hamza
**Content:**
Please select a category in the widget settings.
---
### [Life Science Newsletter Registration](https://www.meridianbioscience.com/life-science-newsletter-registration/)
**Published:** November 24, 2025
**Author:** hamza
---
### [The Viral Connection: When Co-Infections Become Catalysts for Cancer](https://www.meridianbioscience.com/lifescience/the-viral-connection-when-co-infections-become-catalysts-for-cancer/)
**Published:** November 19, 2025
**Author:** Moaaz Ahmad
**Content:**
## The Viral Connection:
### When Co-Infections Become Catalysts for Cancer
Cancer is one of the leading causes of death worldwide, and its origins are as diverse as the disease itself, ranging from inherited mutations to viral infection. Fundamentally, cancer arises when the body’s regulatory systems fail to keep cell growth and repair in balance, leading to uncontrolled proliferation. This breakdown can be driven by genetic mutations (inherited or acquired), environmental exposures such as radiation or carcinogenic chemicals, and lifestyle factors like smoking, alcohol use, diet, and obesity. Meridian Life Science, a leader in [ambient-temperature–stable reagent](/lifescience/products/molecular-reagents/liquid-ambient-stable-master-mixes/) technologies, supports this mission with solutions that advance both [immunoassay](/lifescience/products/antibodies-antigens/) and [molecular diagnostics](/lifescience/products/molecular-reagents/). Infectious causes of cancer, particularly viruses known as oncoviruses, are less widely recognized but increasingly important. Globally, about 1 in 6 cancers (12–20%) are linked to viral infections1, making infection the third leading cause of cancer worldwide. While lifestyle-related and environmental/genetic factors typically drive cancer through mutations, they can also induce epigenetic changes—such as silencing of tumor suppressor genes—that contribute to cancer development.
## The Role of Oncoviruses
Epstein–Barr virus (EBV) was the first virus confirmed to cause human cancer, and it remains one of the best-studied examples of viral oncogenesis. Today, the International Agency for Research on Cancer (IARC) identifies seven viruses as Group 1 carcinogens: HPV, HBV, HCV, EBV, Kaposi sarcoma–associated herpesvirus (KSHV/HHV-8), HTLV-1, and HIV. Collectively, these viruses are linked to cancers including hepatocellular carcinoma, [gastric cancer](/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/), [cervical cancer](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/), nasopharyngeal carcinoma, Kaposi sarcoma, lymphoma, and adult T-cell leukemia/lymphoma2. Most people will contract at least one oncogenic virus during their lifetime, and in most cases these infections resolve within months without progressing to cancer. However, some oncoviruses establish lifelong infections and, under certain conditions such as immune suppression, chronic inflammation, or exposure to co-oncogenic factors, infected cells can acquire malignant traits that drive cancer development. Malignant transformation can occur through direct pathways, including viral gene integration into the host genome, disruption of tumor suppressor genes, activation of oncogenes, and interference with cell-cycle regulation. Indirect mechanisms include the establishment of persistent infections that promote chronic inflammation, immune suppression, and genomic instability, all of which create a permissive environment for oncogenesis. Despite significant advances, the molecular mechanisms underlying viral oncogenesis remain only partially understood, underscoring the complexity of virus–host interactions.
**An overview of viral oncogenic mechanisms.**
Oncoviruses transform host cells by disrupting normal controls—activating oncogenes, silencing tumor suppressors, driving chronic inflammation, and evading immune responses. Together, these mechanisms promote tumor development and metastasis: direct oncogenesis and indirect oncogenesis. This figure was adapted from:
### The Global Burden of Oncoviruses and Co-Infections
Oncoviruses are responsible for approximately 2 million new cancer cases annually3, with the heaviest burden in low- and middle-income countries where vaccination and screening remain limited. Of the seven viruses as Group 1 carcinogens:
- **[HPV](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/hpv/)** accounts for ~5% of cancers worldwide, driving cervical cancer and contributing to anal, oropharyngeal, penile, vulvar, and vaginal cancers
- **[HBV](/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-b/) and [HCV](/lifescience/pairs-table/hepatitis-c-virus/)** together cause up to 80% of hepatocellular carcinoma, one of the deadliest cancers, often diagnosed at late stages
- **[EBV](/lifescience/products/antibodies-antigens/torch-childhood/epstein-barr-virus-ebv/)**, carried by over 90% of people globally, is linked to lymphomas and nasopharyngeal carcinoma
- **HHV-8** causes Kaposi’s sarcoma, particularly in HIV-positive individuals
- **HTLV-1** is less common but can trigger aggressive adult T-cell leukemia/lymphoma
- **Merkel cell polyomavirus (MCPyV)** is the main cause of Merkel cell carcinoma, a rare but highly lethal skin cancer
- **[HIV](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/human-immunodeficiency-virus-hiv/)** although not oncogenic, causes immune suppression that magnifies the risk of cancers caused by these viruses
While each of these viruses pose significant risks on their own, the danger can escalate when two or more infections occur together. Co-infections are relatively common in regions where multiple viruses are endemic or in populations with weakened immune systems. For example, among the 38 million people living with HIV worldwide, up to half are co-infected with another oncogenic virus such as HPV, HBV, HCV, or HHV-8, which dramatically elevates their cancer risk. In Asia and sub-Saharan Africa, HBV and HCV co-infection affects up to 15% of chronic hepatitis patients, doubling the likelihood of liver cancer compared to infection with a single virus. Similarly, in regions of Africa where EBV and malaria overlap, children experience some of the world’s highest rates of Burkitt lymphoma. As multiple infections increasingly shape cancer risk, the role of diagnostics in detecting, differentiating, and monitoring oncoviruses is both a challenge and an opportunity—one that will define the future of cancer prevention. 
Figure 1. Schematic of potential commonalities in the molecular mechanisms between HPV and HBV in tumorigenesis.
### Co-Infections and Viral Synergy
Co-infections create unique biological conditions in which viruses can act synergistically, even without infecting the same cell. Virus-infected cells release cytokines, chemokines, exosomes, and other signaling molecules that reshape the tumor microenvironment and influence neighboring cells.
One example is the interaction between HIV and HHV-8: HIV-induced immune suppression provides the ideal environment for HHV-8 to drive Kaposi’s sarcoma. Similarly, patients infected with both HBV and HCV face a much greater risk of liver cancer than those with either virus alone, as HBV integrates into host DNA while HCV promotes chronic inflammation creating two complementary pathways to tumor formation. HIV can also worsen HPV-driven cancers, including cervical and anal cancer, by reducing the body’s ability to clear precancerous lesions.
Adding to this complexity, research suggests that some co-infections may influence cancer development even without the continued presence of the second pathogen—a phenomenon described as the “hit-and-run” theory (). This highlights the potential for viral synergy, where, in this case, individuals with HPV who also carry other oncoviruses face not only an increased risk of HPV-associated cancers but also additional malignancies.
Complicating matters further, emerging evidence indicates that SARS-CoV-2, though not itself an oncovirus, can reactivate latent oncoviruses such as EBV and HHV-84. The immune dysregulation triggered by SARS-CoV-2 appears capable of awakening dormant viruses, indirectly elevating cancer risk in vulnerable populations. These findings illustrate how interactions between oncogenic and non-oncogenic viruses can further shape cancer development and outcomes, underscoring the complexity of virus-driven oncogenesis.
### Prevention and Diagnosis of Virus-Driven Cancers
Preventing and diagnosing oncovirus-driven cancers requires a different approach than treating traditional cancers. For patients with viral co-infections, the prognosis is often worse than with single infections. These cancers develop faster, are diagnosed later, and respond less well to treatment. Vaccination programs against HPV and HBV have already shown dramatic reductions in infection rates and related cancers, but broader coverage, especially in low-resource regions, is essential. For viruses without vaccines, such as HCV or EBV, early screening and antiviral therapies play a critical role in lowering long-term cancer risk. On the diagnostic side, relying on single-pathogen testing is often inadequate when multiple infections may be present. Instead, syndromic and multiplex panels that can detect several viruses at once, give clinicians a clearer picture of a patient’s risk and enable earlier intervention. Combined with better surveillance and education, these tools make it possible to not only prevent many viral cancers but also catch them before they progress to late, hard-to-treat stages.
Commercial immunoassay technologies that enable multiplex detection are already available, though most are still geared toward research rather than clinical diagnostics. Platforms such as [Bio-Rad’s Bio-Plex](https://www.bio-rad.com/en-au/category/bio-plex-multiplex-immunoassay-system), [Meso Scale Discovery (MSD) kits](https://www.mesoscale.com/en/applications/oncology_and_cancer), and [Merck’s Milliplex assays](https://www.sigmaaldrich.com/AU/en/technical-documents/product-supporting/milliplex/multiplex-cancer-assays-for-cancer-biomarker-detection?srsltid=AfmBOor7SmqVgJA_HGv9ux7yRyHfjr41DvEAJxNVnik6wzHfCM3dBHUg) allow simultaneous measurement of multiple viral or cancer-related biomarkers from a single sample, while [Randox’s STI Array](https://www.randox.com/sti-array/) demonstrates how syndromic panels can be applied clinically by detecting up to ten sexually transmitted pathogens at once. However, fully validated immunoassays that specifically combine oncoviruses and co-infection panels for cancer risk assessment remain limited, with most solutions currently used in research, surveillance, or specialized testing settings. This highlights both the technical feasibility of multiplex immunoassays and the urgent need to expand them into routine cancer diagnostics.
For immunoassays, the future is moving toward portable, multiplex-capable formats that bring testing closer to patients. One example is the development of “lab-in-a-box” platforms which are compact, self-contained systems that automate sample preparation, detection, and readout making syndromic viral panels feasible even in low-resource settings. Sensitivity is also being advanced through new labeling technologies, including [fluorescent nanoparticles](https://www.sciencedirect.com/science/article/abs/pii/S0165993623005289), [quantum dots](https://pmc.ncbi.nlm.nih.gov/articles/PMC9497919/), and [magnetic particles](https://pmc.ncbi.nlm.nih.gov/articles/PMC7278001/), which help reduce background noise. At the same time, smartphone-based readers and portable optical devices are being paired with strips to minimize user interpretation errors and deliver semi-quantitative results5.
Further gains are being made in assay reliability, with improvements in membrane chemistry and [blocking agents](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/) enhancing reproducibility6 and accuracy while the integration of [isothermal amplification](/lifescience/products/molecular-reagents/isothermal-amplification/) and CRISPR-based methods7 is dramatically boosting sensitivity. Taken together, these innovations are transforming lateral flow from a simple yes/no test into a powerful multiplexed platform for near-patient diagnostics, capable of tackling complex challenges like viral co-infections.
### Co-Infections and Viral Synergy
Co-infections create unique biological conditions in which viruses can act synergistically, even without infecting the same cell. Virus-infected cells release cytokines, chemokines, exosomes, and other signaling molecules that reshape the tumor microenvironment and influence neighboring cells. One example is the interaction between HIV and HHV-8: HIV-induced immune suppression provides the ideal environment for HHV-8 to drive Kaposi’s sarcoma. Similarly, patients infected with both HBV and HCV face a much greater risk of liver cancer than those with either virus alone, as HBV integrates into host DNA while HCV promotes chronic inflammation creating two complementary pathways to tumor formation. HIV can also worsen HPV-driven cancers, including cervical and anal cancer, by reducing the body’s ability to clear precancerous lesions. Adding to this complexity, research suggests that some co-infections may influence cancer development even without the continued presence of the second pathogen—a phenomenon described as the “hit-and-run” theory (). This highlights the potential for viral synergy, where, in this case, individuals with HPV who also carry other oncoviruses face not only an increased risk of HPV-associated cancers but also additional malignancies. Complicating matters further, emerging evidence indicates that SARS-CoV-2, though not itself an oncovirus, can reactivate latent oncoviruses such as EBV and HHV-84. The immune dysregulation triggered by SARS-CoV-2 appears capable of awakening dormant viruses, indirectly elevating cancer risk in vulnerable populations. These findings illustrate how interactions between oncogenic and non-oncogenic viruses can further shape cancer development and outcomes, underscoring the complexity of virus-driven oncogenesis. ### Prevention and Diagnosis of Virus-Driven Cancers
Preventing and diagnosing oncovirus-driven cancers requires a different approach than treating traditional cancers. For patients with viral co-infections, the prognosis is often worse than with single infections. These cancers develop faster, are diagnosed later, and respond less well to treatment. Vaccination programs against HPV and HBV have already shown dramatic reductions in infection rates and related cancers, but broader coverage, especially in low-resource regions, is essential. For viruses without vaccines, such as HCV or EBV, early screening and antiviral therapies play a critical role in lowering long-term cancer risk. On the diagnostic side, relying on single-pathogen testing is often inadequate when multiple infections may be present. Instead, syndromic and multiplex panels that can detect several viruses at once, give clinicians a clearer picture of a patient’s risk and enable earlier intervention. Combined with better surveillance and education, these tools make it possible to not only prevent many viral cancers but also catch them before they progress to late, hard-to-treat stages. Commercial immunoassay technologies that enable multiplex detection are already available, though most are still geared toward research rather than clinical diagnostics. Platforms such as [Bio-Rad’s Bio-Plex](https://www.bio-rad.com/en-au/category/bio-plex-multiplex-immunoassay-system), [Meso Scale Discovery (MSD) kits](https://www.mesoscale.com/en/applications/oncology_and_cancer), and [Merck’s Milliplex assays](https://www.sigmaaldrich.com/AU/en/technical-documents/product-supporting/milliplex/multiplex-cancer-assays-for-cancer-biomarker-detection?srsltid=AfmBOor7SmqVgJA_HGv9ux7yRyHfjr41DvEAJxNVnik6wzHfCM3dBHUg) allow simultaneous measurement of multiple viral or cancer-related biomarkers from a single sample, while [Randox’s STI Array](https://www.randox.com/sti-array/) demonstrates how syndromic panels can be applied clinically by detecting up to ten sexually transmitted pathogens at once. However, fully validated immunoassays that specifically combine oncoviruses and co-infection panels for cancer risk assessment remain limited, with most solutions currently used in research, surveillance, or specialized testing settings. This highlights both the technical feasibility of multiplex immunoassays and the urgent need to expand them into routine cancer diagnostics. For immunoassays, the future is moving toward portable, multiplex-capable formats that bring testing closer to patients. One example is the development of “lab-in-a-box” platforms which are compact, self-contained systems that automate sample preparation, detection, and readout making syndromic viral panels feasible even in low-resource settings. Sensitivity is also being advanced through new labeling technologies, including [fluorescent nanoparticles](https://www.sciencedirect.com/science/article/abs/pii/S0165993623005289), [quantum dots](https://pmc.ncbi.nlm.nih.gov/articles/PMC9497919/), and [magnetic particles](https://pmc.ncbi.nlm.nih.gov/articles/PMC7278001/), which help reduce background noise. At the same time, smartphone-based readers and portable optical devices are being paired with strips to minimize user interpretation errors and deliver semi-quantitative results5. Further gains are being made in assay reliability, with improvements in membrane chemistry and [blocking agents](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/) enhancing reproducibility6 and accuracy while the integration of [isothermal amplification](/lifescience/products/molecular-reagents/isothermal-amplification/) and CRISPR-based methods7 is dramatically boosting sensitivity. Taken together, these innovations are transforming lateral flow from a simple yes/no test into a powerful multiplexed platform for near-patient diagnostics, capable of tackling complex challenges like viral co-infections.
### Conclusion
Viral co-infections represent a hidden multiplier of cancer risk, underscoring the need for innovative tools that extend beyond conventional diagnostics. At Meridian, we support both [immunoassay](/lifescience/products/antibodies-antigens/) and [molecular diagnostics](/lifescience/products/molecular-reagents/) across a broad range of cancer biomarkers and oncovirus targets ([EBV](/lifescience/products/antibodies-antigens/torch-childhood/epstein-barr-virus-ebv/), [HBV](/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-b/), [HCV](/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-c/), [HPV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/hpv/), [HTLV-1](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/htlv/), and [HIV](/lifescience/products/antibodies-antigens/sexually-transmitted-diseases/human-immunodeficiency-virus-hiv/)), providing assay developers with the reagents needed to improvehttps://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-c/ sensitivity, specificity, and reliability.
Our portfolio spans a comprehensive range of antigens, antibodies, enzymes, and master mixes, complemented by interference [blockers](/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/) that enhance assay precision and reproducibility. These reagents support a wide spectrum of diagnostic applications, including point-of-care multiplex lateral flow and LAMP assays to high-throughput immunoassays and molecular qPCR, facilitating the creation of robust, scalable assays for cancer biomarker detection.
As a leader in [ambient-temperature–stable molecular technologies](/lifescience/products/molecular-reagents/liquid-ambient-stable-master-mixes/), including first-to-market master mixes and enzymes, Meridian enables assay developers to design reliable, high-performance assays that eliminate cold-chain requirements, improving accessibility and cost efficiency. By advancing diagnostic innovation, Meridian supports global efforts to improve early detection, expand access, and strengthen surveillance of virus-driven cancers.
**References:**
1\. Dai, L., Wilson, L. G., Nakagawa, M., & Qin, Z. (2024). Coinfections with additional oncoviruses in HPV+ individuals: Status, function, and potential clinical implications. *Journal of Medical Virology,* 96(1), e29363. [https://doi.org/10.1002/jmv.29363 ](https://doi.org/10.1002/jmv.29363)
2\. Xiao, Q., Liu, Y., Li, T., & et al. (2025). Viral oncogenesis in cancer: From mechanisms to therapeutics. *Signal Transduction and Targeted Therapy, 10*, 151. [https://doi.org/10.1038/s41392-025-02197-9](https://doi.org/10.1111/prd.12566)
3\. Contreras, A., Amaya Sánchez, S., Rodríguez-Medina, C., & Botero, J. E. (2024). The role and impact of viruses on cancer development. *Periodontology 2000*. Advance online publication.
4\. Park, J. (2022). Lateral flow immunoassay reader technologies for quantitative point-of-care testing. Sensors, 22(19), 7398.
5\. Khatmi, G., Klinavičius, T., Simanavičius, M., et al. (2024). Lateral flow assay sensitivity and signal enhancement via laser µ-machined constrains in nitrocellulose membrane. *Scientific Reports*, 14, 22936. [https://doi.org/10.1038/s41598-024-61891-0 ](https://doi.org/10.1038/s41598-024-61891-0)
6. Yigci, D., Atçeken, N., Yetisen, A. K., et al. (2023). Loop-mediated isothermal amplification-integrated CRISPR methods for infectious disease diagnosis at point of care. *ACS Omega, 8*(46), 43357–43373. [https://doi.org/10.1021/acsomega.3c04422 ](https://doi.org/10.1021/acsomega.3c04422)
---
### [From Sample to Sequence: Why Smarter Library Prep is Critical for Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/short-report-sample-prep-in-wgs/)
**Published:** November 18, 2025
**Author:** hamza
**Content:**
## From Sample to Sequence:
### Why Smarter Library Prep is Critical for Whole Genome Sequencing
Whole genome sequencing (WGS) has become a cornerstone of modern genomics, with applications spanning oncology, infectious disease and rare inherited disorders. Beyond human health, it is equally valuable for sequencing agriculturally important species—including livestock, crops and disease-associated microbes. WGS provides complete genomic coverage, capturing both exonic (coding) and intronic (non-coding) regions, enabling the detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs) and large structural rearrangements. This makes it particularly well-suited for discovery-driven applications such as novel variant identification and de novo genome assembly. In the United States, WGS-based tests are not yet FDA-approved for routine clinical use, however, many laboratories have adopted them as laboratory developed tests (LDTs) under Clinical Laboratory Improvement Amendments (CLIA) oversight. In Europe, where companion diagnostics are not as tightly bound to drug approvals by the European Medicines Agency (EMA), there is greater flexibility in implementing genomic assays. This has enabled wider adoption of WGS-based LDTs in accredited laboratories, with validated pipelines supporting clinical decision-making.1 Despite its transformative potential and expanding clinical acceptance, the practical implementation of WGS still faces significant challenges. As sequencing costs decline and platform throughput increases, broader adoption is increasingly limited by a persistent bottleneck: library preparation.2 Traditional workflows are labor-intensive, reagent-heavy and often require skilled personnel to ensure consistency and data integrity. In response, [next-generation](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes/) library preparation methods have emerged, aiming to improve efficiency, scalability and reproducibility. Many of these workflows are now compatible with automation, minimizing manual handling and inter-sample variability—key advancements for scaling WGS in high-throughput research, clinical diagnostics and decentralized testing environments. In parallel, the use of lyophilized, [glycerol-free reagents](https://www.meridianbioscience.com/lifescience-blog/solving-enzyme-stability-by-tackling-glycerol-free-formulation-challenges/) enables room-temperature shipping and storage, simplifies logistics and improves consistency by reducing freeze-thaw variability and supporting pre-plated, ready-to-use formats for automated systems. ## Why Sample Preparation Matters
Sample types with limited input, compromised quality, or complex biological origins are now increasingly being addressed through the broader adoption of WGS. This presents a key challenge as sequencing performance is highly dependent on the integrity and consistency of the input-DNA. While qPCR and targeted panels may tolerate minor degradation or contaminants, they can critically impair WGS performance, resulting in uneven coverage, elevated duplicate rates and contamination artifacts. To ensure reliable results, the upstream preparation process must deliver clean, high-quality libraries that support accurate and reproducible sequencing across diverse applications.
### The Whole Genome Sequencing Workflow
In WGS, library preparation involves the critical process of converting extracted DNA into a format compatible with sequencing platforms. While every stage of the WGS workflow contributes to overall data quality, library preparation sits at the core, bridging sample integrity with sequencing performance. From nucleic acid extraction to final purification and quality control, each step must be carefully optimized to ensure accuracy, precision and completeness of genomic coverage. In the sections below, we outline the key stages of the WGS library prep workflow: **Step 1: Nucleic Acid Extraction**The WGS workflow begins with isolating high-quality DNA (or RNA) from biological samples such as blood, tissue, cultured cells, saliva or urine. The integrity and purity of this genetic material is critical, as contaminants, degradation or low yields at this stage can compromise every step that follows. As WGS is increasingly applied to more challenging specimens, effective extraction and upstream quality control become imperative to ensure reliable sequencing outcomes. **Step 2: Library Preparation**To be compatible with sequencing platforms, extracted nucleic acids must be converted into a sequencing-ready format. This process involves fragmenting the DNA to a defined size range and ligating adapters to the fragment ends. These adapters often contain unique barcodes (indexes) to enable multiplexing of multiple samples in a single sequencing run. Fragmentation can be performed using mechanical methods (e.g., sonication) or enzymatic approaches (e.g., fragmentase or transposase-based), each with distinct trade-offs in precision, bias and scalability. The efficiency and consistency of this step have a direct impact on library complexity, coverage uniformity and overall data quality. **Step 3: Amplification (Optional)**Depending on the input amount and application, PCR amplification may be used to increase library yield prior to sequencing. While PCR enables analysis of low-input samples, it can also introduce bias and duplicates if not properly controlled. For WGS, where coverage uniformity is critical, minimizing amplification bias is essential, especially when working with GC-rich regions or degraded templates. **Step 4: Purification and Quality Control**Library purification removes unwanted byproducts such as free adapters, enzymes or improperly sized fragments. Many sequencing platforms have optimal library size ranges, so size selection (typically bead-based or gel-based) is used to enrich appropriately sized fragments. Final quality control assesses library concentration and size distribution, often via fluorometry and capillary electrophoresis, to ensure samples meet input criteria for sequencing. Rigorous QC here prevents expensive sequencing failures and ensures confidence in downstream analyses. Together, these steps form an interconnected process with multiple critical control points where variability can arise and compromise downstream outcomes. For instance, DNA extraction methods influence yield and fragment length; an inconsistent shearing step can skew fragment sizes; suboptimal ligation can reduce library diversity and excessive PCR amplification can lead to high duplicate rates and coverage bias. Quality issues introduced early in the workflow will compound through subsequent steps—once sample integrity is compromised, even the most advanced sequencer cannot recover lost data quality. ### Advances in Library Preparation for WGS
[Library preparation](https://www.meridianbioscience.com/lifescience/ngs-enzymes/lyophilized-ngs-library-preparation-kit/) protocols for whole genome sequencing are inherently complex and the multistep design introduces multiple opportunities for sample loss, cross-contamination and operator-induced variability, especially in manual workflows. In addition, the cumulative use of high-cost reagents and extended hands-on time increases the operational burden and cost. Recent innovations in library preparation have aimed to address these challenges through multiple strategies: **1. Integrated Enzymatic Workflows**Newer kits leverage enzymatic fragmentation combined with simultaneous end-repair and A-tailing, enabling DNA fragmentation and polishing to occur in a single reaction tube. This reduces hands-on time, minimizes DNA loss, and is more forgiving for fragmented or damaged templates (e.g., FFPE-derived DNA). Some platforms also include integrated damage repair enzymes to restore nicks or abasic (apurinic/apyrimidinic) sites prior to ligation – improving performance with compromised samples. **2. Lyophilized and Ambient-Stable Reagents**Lyophilized formulations are increasingly adopted to improve reagent stability, consistency and ease of use. By removing glycerol and freeze-drying enzymes, these kits can be stored and shipped at ambient temperatures, eliminating cold chain requirements and reducing the risk of reagent degradation. This enhances reproducibility by avoiding freeze-thaw cycles, streamlines logistics, and enables broader deployment in decentralized or resource-limited settings. Additionally, lyophilized kits support pre-plated, single-use formats that are well-suited for automation and high-throughput workflows. **3. PCR-Free and Low-Bias Amplification Options**PCR amplification, though often necessary for low-input samples, introduces GC bias and duplicates, which reduce library complexity and can skew variant allele frequencies. To minimize these effects, many workflows offer PCR-free protocols for high-input samples (≥500 ng), producing libraries with greater uniformity and more accurate representation of the genome. For applications requiring amplification, engineered high-fidelity polymerases are now available that tolerate high-GC content and reduce amplification bias. **4. Dual-Indexing and Unique Molecular Identifiers (UMIs)**Modern [library preparation kits](https://www.meridianbioscience.com/lifescience/ngs-enzymes/lyophilized-ngs-library-preparation-kit/) often include dual index barcoding to mitigate index hopping, a known artifact in high throughput multiplexed sequencing. More advanced workflows incorporate unique molecular identifiers (UMIs) during adapter ligation. These short, random sequences uniquely tag each original DNA molecule, allowing downstream bioinformatics pipelines to distinguish true variants from PCR duplicates or sequencing errors. This enhances analytical accuracy in demanding applications such as somatic variant detection and liquid biopsy analysis. **5. Automation-Ready and Miniaturized Protocols**Scalability is a growing concern as labs process more samples for large-scale studies or clinical WGS. Many library prep kits are now designed to be automation-friendly, with reduced pipetting steps, pre-aliquoted reagents and magnetic bead-based cleanup compatible with robotic systems. Protocols are also being miniaturized to work in reduced volumes (e.g., <10 µL reactions), which lowers reagent costs without sacrificing performance—especially beneficial in population genomics and high-throughput diagnostic workflows. By integrating smarter enzymology, stabilization technologies workflow simplification, today’s [library prep solutions](https://www.meridianbioscience.com/lifescience/ngs-enzymes/lyophilized-ngs-library-preparation-kit/) are not only improving data quality but also lowering the barriers to implementing WGS across diverse lab environments. ### Meridian’s Library Preparation Solutions
Meridian’s [Lyophilized Next-Generation Library Preparation Kit](https://www.meridianbioscience.com/lifescience/ngs-enzymes/lyophilized-ngs-library-preparation-kit/) (MDX219) simplifies the core library construction steps of end-repair, A-tailing, adapter ligation and optional amplification, while maintaining high enzymatic performance and producing high-quality libraries. The kit contains three separate, lyophilized components: an end-repair/dA-tailing mix, a ligase with buffer and a high-fidelity PCR master mix. This format ensures ambient-temperature stability, allowing for room-temperature shipping and storage without the need for refrigeration, removing cold chain requirements and easing logistical burdens. Designed for ease of use—just add fragmented DNA—the kit is automation-compatible and supports high-throughput workflows with reduced hands-on time. It delivers performance equivalent to traditional liquid reagents while improving consistency and minimizing variability. For assay developers seeking a robust, scalable and stable solution for whole genome sequencing, Meridian’s kit offers an efficient path forward.
[](https://www.meridianbioscience.com/lifescience/ngs-enzymes/lyophilized-ngs-library-preparation-kit/?_gl=1*5xzcm9*_gcl_au*NDg1NjQyMzQwLjE3NTkyMjg1NTEuNDgwMjc2MDA5LjE3NjM0NTE2MzEuMTc2MzQ1MTY0OA..)
**References:**1. Meggendorfer, M., *et al.* (2022). Analytical demands to use whole-genome sequencing in precision oncology. *Seminars in Cancer Biology, 84,* 16–22. 2. Hess, J. F., *et al.* (2020). Library preparation for next generation sequencing: A review of automation strategies. *Biotechnology Advances, 41,* 107537.
---
### [IDkit Two Video](https://www.meridianbioscience.com/idkit-two-video/)
**Published:** November 17, 2025
**Author:** hamza
---
### [BreathID® IDkit Hp™ Two](https://www.meridianbioscience.com/breathid-idkit-hp-two/)
**Published:** November 17, 2025
**Author:** hamza
**Content:**
---
### [pi](https://www.meridianbioscience.com/pi/)
**Published:** November 17, 2025
**Author:** hamza
---
### [Posters and Articles](https://www.meridianbioscience.com/lifescience/posters-and-articles/)
**Published:** February 11, 2025
**Author:** hamza
**Content:**
# White Papers and Conference Posters
## White Papers
[](/lifescience/products/molecular/request-precision-oncology-white-paper/)
[](https://share.hsforms.com/1Lx9uB8m6TMS6xHZyy2qd8Qc22yq)
[Develop highly sensitive monkeypox MDx assays using Specimen-specific Master Mixes](https://collateral.meridianlifescience.com/view/1058482020/)**Develop highly sensitive monkeypox MDx assays using Specimen-specific Master Mixes**
[Reducing False Results in Immunoassay Testing](https://collateral.meridianlifescience.com/view/812878521/)**Reducing False Results in Immunoassay Testing**
[Benefits of multiplex testing for the differential diagnosis of COVID-19, Flu and RSV in a busy flu season](https://collateral.meridianlifescience.com/view/293344079/)**Benefits of multiplex testing for the differential diagnosis of COVID-19, Flu and RSV in a busy flu season**
[Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples](https://collateral.meridianlifescience.com/view/1070676719/)**Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples**
[Liquid Biopsy for Cancer Detection](https://collateral.meridianlifescience.com/view/655471428/)**Advances in qPCR-based liquid biopsy for cancer detection**
[Direct detection from crude cell lysate](https://collateral.meridianlifescience.com/view/789926652/)**Direct Detection from crude cell lysate: Obesity marker study**
## Conference Posters
[ECCMID 2023 Poster](https://collateral.meridianlifescience.com/view/1020429880/)**AMP 2024 Poster “The Latest Molecular Diagnostics Technologies to Accelerate Development and Stabilize at Room Temperature qPCR, LAMP and NGS Workflows”**
[TriCon 2023 Exhibit Poster "From Urine Samples to Diagnosis"](https://collateral.meridianlifescience.com/view/630490657/)**TriCon 2023 Exhibit Poster "From Urine Samples to Diagnosis"**
[TriCon 2023 Poster "SNPs & DNA Methylation Detection"](https://collateral.meridianlifescience.com/view/630891945/)**TriCon 2023 Poster "SNPs & DNA Methylation Detection"**
[ECCMID 2023 Poster](https://collateral.meridianlifescience.com/view/58821890/)**ECCMID 2023 Poster “Direct Detection of Viral SNPs & Antibiotic Resistance Markers”**
---
### [Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/webinars-precision-oncology-may-2025/)
**Published:** November 13, 2025
**Author:** Moaaz Ahmad
**Content:**
## Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing
# On Demand!
IN THIS WEBINAR YOU WILL LEARN:
- How qPCR, targeted NGS, and whole-genome sequencing compare in precision medicine applications such as liquid biopsy, MRD monitoring, mutation detection, and hereditary disease screening.
- The advantages and limitations of each approach, including key considerations for sensitivity, throughput, cost, and data requirements.
- Real-world assay examples demonstrating how these technologies are applied in clinical oncology settings.
Register Now! Join us to gain a deeper understanding of these powerful technologies and how Meridian can support your assay development with innovative solutions tailored to your needs.
**Speaker:**
Dale Clash, Marketing Manager
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [View our Featured Presentation from Next Gen Dx](https://www.meridianbioscience.com/lifescience/featured-presentation-from-next-gen-dx/)
**Published:** November 13, 2025
**Author:** Moaaz Ahmad
**Content:**
## View our Featured Presentation from Next Gen Dx
##### Empowering Molecular Point-of-Care Diagnostics with Timesaving, Cost-Effective, and Ambient-Stable Chemistries
Point-of-care diagnostics are reshaping how and where patients access healthcare. However, challenges around enzyme stabilization, cost, and logistics can limit their reach.
In this presentation, William Ferreira explores how established and emerging molecular techniques—like qPCR, isothermal amplification, and NGS—can be adapted using ambient-stable reagents to enable rapid, scalable, and cost-effective testing at the point of care. Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
# Learn more about our solutions for:
- Molecular point-of-care testing (qPCR, isothermal amplification, and next-generation sequencing)
- Ambient-stable reagent chemistries (lyophilization, cold-chain free)
- Infectious disease diagnostics
- Decentralized testing & rapid assay development
- Scalability in resource-limited or near-patient settings
**Register Now!** Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
**Speaker:**
William , R&D Team Leader at Meridian Life Science
William is an R&D Team Leader at Meridian Life Science. He earned his PhD in molecular microbiology in 2019, investigating C. difficile pathogenesis at Royal Holloway, University of London, UK. Subsequently, he held the position of Senior Scientist at Sporegen Ltd, leading diverse research projects rooted in recombinant spore technology. With more than 8 years of expertise in developing molecular assays for clinical use, William is a vital asset within Meridian’s R&D team. His role involves spearheading the creation of cutting-edge molecular products for the global diagnostic industry.
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
---
### [Thank you](https://www.meridianbioscience.com/thank-you-ls/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your submission has been received.
A Meridian representative will be in contact soon.
###### Thank you!
[Home](https://www.meridianbioscience.com "Home")» Thank you
# Thank you
Diagnostic assays that deliver the best patient outcomes rely on high-quality reagents. Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 disease targets and an extensive range of specialty qPCR master mixes and molecular enzymes manufactured under ISO13485 regulations. Meridian offers diagnostic manufacturers the complete solution.
[ Contact a Specialist ](#contact-a-specialist)
[ View Products Below ](#products1)
- [#### Antibodies, Antigens & Blockers
](/lifescience/products/antibodies-antigens/)
- [#### Molecular Reagents
](/lifescience/products/molecular-reagents/)
Not seeing what you’re looking for? [Inquire about a new product](https://meridianbiostg.wpengine.com/thank-you-for-requesting-a-sample-mdx/?country=CU#form-anchor)
---
### [Thank you](https://www.meridianbioscience.com/thank-you-ls-immuno-services/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your submission has been received.
A Meridian representative will be in contact soon.
###### Thank you!
---
### [Thank you for Requesting a Sample](https://www.meridianbioscience.com/thank-you-ls-sample-immuno/)
**Published:** November 7, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your request has been received.
A Meridian representative will be in contact soon.
###### If you require immediate assistance, please call +1 901-382-8716
---
### [Thank you for Requesting a Sample](https://www.meridianbioscience.com/thank-you-for-requesting-a-sample-mdx/)
**Published:** November 7, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your request has been received.
A Meridian representative will be in contact soon.
###### If you require immediate assistance, please call +1 901-382-8716
[Home](https://www.meridianbioscience.com "Home")» Thank you for Requesting a Sample
# Thank you for Requesting a Sample
Diagnostic assays that deliver the best patient outcomes rely on high-quality reagents. Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 disease targets and an extensive range of specialty qPCR master mixes and molecular enzymes manufactured under ISO13485 regulations. Meridian offers diagnostic manufacturers the complete solution.
[ Contact a Specialist ](#contact-a-specialist)
[ View Products Below ](#products1)
- [#### Antibodies, Antigens & Blockers
](/lifescience/products/antibodies-antigens/)
- [#### Molecular Reagents
](/lifescience/products/molecular-reagents/)
Not seeing what you’re looking for? [Inquire about a new product](https://meridianbiostg.wpengine.com/thank-you-for-requesting-a-sample-mdx/?country=CU#form-anchor)
---
### [Thank you for Requesting Corporate](https://www.meridianbioscience.com/thank-you-contact-meridian-corporate/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your request has been received.
A Meridian representative will be in contact soon.
###### If you require immediate assistance, please call +1 513-271-3700
[Home](https://www.meridianbioscience.com "Home")» Thank you for Requesting Corporate
# Thank you for Requesting Corporate
Diagnostic assays that deliver the best patient outcomes rely on high-quality reagents. Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 disease targets and an extensive range of specialty qPCR master mixes and molecular enzymes manufactured under ISO13485 regulations. Meridian offers diagnostic manufacturers the complete solution.
[ Contact a Specialist ](#contact-a-specialist)
[ View Products Below ](#products1)
- [#### Antibodies, Antigens & Blockers
](/lifescience/products/antibodies-antigens/)
- [#### Molecular Reagents
](/lifescience/products/molecular-reagents/)
Not seeing what you’re looking for? [Inquire about a new product](https://meridianbiostg.wpengine.com/thank-you-for-requesting-a-sample-mdx/?country=CU#form-anchor)
---
### [Thank you](https://www.meridianbioscience.com/thank-you-ls-mdx-services/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Your submission has been received.
A Meridian representative will be in contact soon.
###### Thank you!
---
### [Thank you](https://www.meridianbioscience.com/thank-you-dx/)
**Published:** November 10, 2025
**Author:** Moaaz Ahmad
**Content:**
## Thank you!
Your submission has been received.
---
### [DDW Marketing](https://www.meridianbioscience.com/ddw-marketing/)
**Published:** September 5, 2025
**Author:** Moaaz Ahmad
**Content:**
### Meet us at DDW®!
Join Meridian at Digestive Disease Week® (DDW®) 2024 and immerse yourself in the forefront of innovation. Meet our team and explore BreathID® and Curian®, two revolutionary solutions reshaping digestive disease diagnosis and management.
Experience personalized demos, gain insights into the latest *H. pylori* testing recommendations, and elevate your practice to new heights. Don’t miss out — reserve your spot today!
[ Reserve your spot ](#)
### Meridian Team
###### Marcelo Sigal
###### Manager, Business Development Latin America
###### Michael Baez
###### Director of Distribution Americas
###### Tyler Liem
###### Account Executive DC, MD, VA & DE
## Contact Us
Digestive Disease Week® and DDW® are registered trademarks of DDW LLC.
---
### [Lead Poisoning Resource Center](https://www.meridianbioscience.com/lead-poisoning-resource-center/)
**Published:** September 5, 2025
**Author:** Moaaz Ahmad
**Content:**
- [Home](/lead-poisoning-resource-center/)
- [Parents/Families Resources](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-families-and-parents/)
- [Healthcare Professional Resources](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-healthcare-providers/)
## Get Ahead of Lead
#### Welcome to the Lead Poisoning Resource Center
A one-stop shop to drive awareness and provide education about the dangers of lead poisoning. Lead exposure remains one of the top childhood environmental health problems today.1 The good news is that lead poisoning is 100% preventable. Explore our resource center to learn more about common sources of lead and how to avoid exposure.
#### Explore resources for:
[ Parents/Families ](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-families-and-parents/)
[ Healthcare Professionals ](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-healthcare-providers/)
### Don’t leave it to chance.
In most cases, lead exposure is completely asymptomatic and irreversible. A blood test is the only way to find out if your child has been exposed to lead. Talk to your child’s doctor about having your child tested.
[ Resources for Parents ](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-families-and-parents/)
### The right diagnosis could change lives.
Over 535,000 children have an elevated blood lead level annually. Federal and state blood lead testing recommendations have been put into place to ensure every child reaches their full potential.
[ Resources for Healthcare Professionals ](https://www.meridianbioscience.com/lead-poisoning-resource-center-for-healthcare-providers/)
### What is lead and why is it harmful?
Lead is a naturally occurring heavy metal found in the earth’s crust. While it has some beneficial uses from an industrial sense, it can be extremely toxic to humans and animals. Lead is a powerful neurotoxin – meaning continuous exposure can cause permanent health consequences.
Almost everyone has come in contact with lead at some point in their life. Lead can be found in all parts of our environment, including our home. The truth is you never know where insidious lead will appear. The most important step that families, healthcare providers, and public health professionals can take is to prevent lead exposure before it occurs.
#### Stay in the loop
Receive information regarding lead consumer alerts, policy updates, educational tools, and more!
References:
1\. U.S. Department of Housing and Urban Development, Office of Healthy Homes and Lead Hazard Control; [www.hud.gov/offices/lead](https://www.hud.gov/offices/lead)
---
### [H. pylori Diagnostic Solutions](https://www.meridianbioscience.com/h-pylori-diagnostic-solutions/)
**Published:** September 5, 2025
**Author:** Moaaz Ahmad
**Content:**
## Revolutionize *H. pylori* Detection with Cutting-Edge Testing Solutions
##### Non-Invasive, Accurate, and Efficient Deliver Better Patient Outcomes with Our *H. pylori* Diagnostic Tests.
[ Request a Free Consultation ](#contact)
## Why Choose Our *H. pylori* Testing Solutions?
**Innovative Solutions for Accurate *H. pylori* Detection**
- Non-Invasive Testing: Easy for both patients and clinicians.
- High Accuracy: Reliable results with a proven track record.
- Fast Turnaround: Timely results for better patient management.
#### Spotlight on BreathID® Urea Breath Testing for *H. pylori*
The BreathID® Urea Breath Test (UBT) is a quick, noninvasive method for diagnosing *H. pylori* infection. It requires a simple breath sample and provides results within minutes, helping healthcare professionals make informed treatment decisions.
[  ](https://player.vimeo.com/video/491846234)
#### Learn more about Meridian’s full portfolio of non-invasive testing solutions
[  ](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/09/05141813/H.-pylori-Product-Portfolio-Brochure.pdf)
Click the image above to download the brochure.
### Contact Us
##### Want to learn more about our *H. pylori* diagnostic testing solutions?
Complete the form to the right and your Meridian representative will contact you.
## Get in Touch With Us
[ Contact Us ](/contact-us-life-science/)
---
### [Resource Videos for Life Science](https://www.meridianbioscience.com/lifescience/resource-videos-for-life-science/)
**Published:** February 7, 2025
**Author:** hamza
**Content:**
# Resource Videos for Life Science
## Custom Solutions
**Partnering for Diagnostic Success with Meridian’s Custom Solutions**
In this behind-the-scenes video, we showcase how our deep scientific expertise and collaborative approach help diagnostic developers bring innovative assays to life. Led by Florent Chang-Pi-Hin, PhD, VP of R&D, the video highlights Meridian’s decades of experience in stabilizing and optimizing enzyme systems for qPCR, isothermal amplification, and NGS. What sets Meridian apart is not just our technical capabilities, but our close partnership with customers, from early-stage development through scale-up and manufacturing. With flexible, responsive support and a commitment to quality, Meridian’s custom solutions are designed to accelerate your path to market.
## Contamination Control Solutions
Streamlined dUTP Workfllow
## Specimen-Specific Molecular Solutions
Isothermal Mixes for LAMP
## Air-Dryable™ Technology
**What is Air-Dryable™ Technology**
**How to Air Dry using Air-Dryable™ Mixes**
**Air-Dryable™ DNA qPCR Plant Mix**
## Immunoassay Blockers
**TRU Block™ HAMA Blocker**
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Past Events](https://www.meridianbioscience.com/diagnostics/past-events/)
**Published:** August 8, 2025
**Author:** hamza
**Content:**
### Events & Tradeshows
[ Upcoming Events ](/diagnostics/events)
[Home](https://www.meridianbioscience.com "Home")» [Diagnostics](https://www.meridianbioscience.com/diagnostics/ "Diagnostics")» Past Events
[  ](https://www.meridianbioscience.com/diagnostics/event/amp-2025-annual-meeting-expo/)
#### [AMP 2025 Annual Meeting & Expo](https://www.meridianbioscience.com/diagnostics/event/amp-2025-annual-meeting-expo/)
Boston, Massachusetts, USA
Booth 1115
Join us at the 31st AMP Annual Meeting & Expo, where over 3,000 professionals from over 200 companies in the molecular diagnostics industry come together to collaborate on the latest advancements in molecular diagnostics and medicine. Attendees of this event seek the newest information and the latest advances to enhance their ability to provide the best patient care.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/amp-2025-annual-meeting-expo/)
11 — 15 November 2025
[Schedule a Demo](https://share.hsforms.com/1QPUVyimyQ7u6pe40erXiDQsx55t)
[  ](https://www.meridianbioscience.com/diagnostics/event/aap-experience-2025/)
#### [AAP Experience 2025](https://www.meridianbioscience.com/diagnostics/event/aap-experience-2025/)
Colorado Convention Center, Denver, CO
Booth #553
The American Academy of Pediatrics (AAP) invites you to join us for the 2025 National Conference & Exhibition, taking place September 26–30 in Denver, Colorado. This flagship event brings together thousands of pediatric healthcare professionals from around the globe to explore the latest clinical advances, research developments, and policy updates shaping the future of pediatric medicine.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/aap-experience-2025/)
26 — 30 September 2025
[Schedule a Demo](https://share.hsforms.com/1LtjiqKl7Rz2c_g5MW9DUgQsx55t?__hstc=92816578.ecb3c7e11ec351e06e52226ae12d05ae.1756308219808.1756308219808.1756308219808.1&__hssc=92816578.5.1756318129256&__hsfp=1286964747)
[  ](https://www.meridianbioscience.com/diagnostics/event/2025-community-health-institute-chi-expo/)
#### [2025 Community Health Institute (CHI) & Expo](https://www.meridianbioscience.com/diagnostics/event/2025-community-health-institute-chi-expo/)
Hyatt Regency, Chicago, IL
Booth 121
Join Meridian Bioscience at the 2025 Community Health Institute (CHI) & EXPO, August 17–19 in Chicago, Illinois.
Hosted by the National Association of Community Health Centers (NACHC), CHI is the premier annual gathering for community health professionals, convening over 2,300 executives, clinicians, administrators, and board members from health centers nationwide.
This year’s conference will take place at the Hyatt Regency Chicago, offering attendees insights into the latest in science, education, practice, and policy essential for health centers to remain competitive and financially stable.
As a trusted partner in diagnostic solutions, Meridian Bioscience is proud to exhibit at CHI 2025. Visit our booth to explore our latest innovations designed to support early detection, accurate results, and improved patient outcomes in community health settings.
Don’t miss this opportunity to connect with industry leaders, discover new products and technologies, and collaborate on strategies to enhance care delivery and health center operations.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/2025-community-health-institute-chi-expo/)
17 — 19 August 2025
[  ](https://www.meridianbioscience.com/diagnostics/event/adlm-2025/)
#### [ADLM 2025](https://www.meridianbioscience.com/diagnostics/event/adlm-2025/)
Chicago, IL, USA
Booth 3620
Join us at booth #3620 at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting, formerly known as AACC. This cornerstone event for professionals in diagnostics and laboratory medicine offers over 250 educational opportunities, including plenary sessions, scientific presentations, and roundtable discussions, covering cutting-edge topics such as artificial intelligence, nanotechnology, mass spectrometry, and diagnostic innovation. Don’t miss out on the opportunity to explore the Clinical Lab Expo, featuring more than 850 exhibitors and over 200 new products and services.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/adlm-2025/)
27 — 31 July 2025
[Schedule A Meeting or Demo](https://share.hsforms.com/1m3CueKtcRhO3wQCK5-AwXAsx55t)
[  ](https://www.meridianbioscience.com/diagnostics/event/behind-the-guidelines-h-pylori-management-in-2025/)
#### [Behind the Guidelines: H. pylori Management in 2025](https://www.meridianbioscience.com/diagnostics/event/behind-the-guidelines-h-pylori-management-in-2025/)
Webinar, Online
Join Meridian Bioscience for an exclusive, expert-led webinar based around the American College of Gastroenterology (ACG) 2024 clinical guideline on the management of *H. pylori* infection.
**P.A.C.E.-Accredited Webinar**
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/behind-the-guidelines-h-pylori-management-in-2025/)
24 June 2025
[  ](https://www.meridianbioscience.com/diagnostics/event/asm-2025/)
#### [ASM 2025](https://www.meridianbioscience.com/diagnostics/event/asm-2025/)
Los Angeles,USA
Booth 1101
ASM Microbe 2025 brings together thousands of scientists, researchers, and healthcare professionals for the world’s largest microbial sciences gathering. The conference will feature over 200 unique sessions across eight scientific tracks, covering topics from basic microbiology to artificial intelligence research (AI). Attendees can engage in cutting-edge scientific sessions and explore curated itineraries on interdisciplinary topics. Key focus areas include antimicrobial resistance, clinical microbiology, environmental and applied microbiology, microbial ecology and evolution, host-microbe biology, and microbial therapeutics and vaccines.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/asm-2025/)
19 — 23 June 2025
[Schedule A Meeting or Demo](https://share.hsforms.com/15P8LEaqdRyWh8Xqbh18fPgsx55t)
[  ](https://www.meridianbioscience.com/diagnostics/event/ddw2025-digestive-disease-week/)
#### [DDW2025, Digestive Disease Week®](https://www.meridianbioscience.com/diagnostics/event/ddw2025-digestive-disease-week/)
San Diego Convention Center, San Diego, CA
Booth 4556
Join Meridian at Digestive Disease Week® (DDW®) 2025 and immerse yourself in the forefront of innovation. Meet our team and explore BreathID®, a revolutionary solution reshaping digestive disease diagnosis and management.
Experience personalized demos, gain insights into the latest *H. pylori* testing recommendations, and elevate your practice to new heights. Don’t miss out — reserve your spot today!
Note: Digestive Disease Week® and DDW® are registered trademarks of DDW LLC.
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/ddw2025-digestive-disease-week/)
03 — 06 May 2025
[Schedule a demo](https://share.hsforms.com/1urfzVdxYSkqZ5yM5Bcc24Qsx55t)
[  ](https://www.meridianbioscience.com/diagnostics/event/medlab-middleeast-2025/)
#### [MedLab MiddleEast 2025](https://www.meridianbioscience.com/diagnostics/event/medlab-middleeast-2025/)
Dubai World Trade Centre
Booth Z5.C11
[ Get Details ](https://www.meridianbioscience.com/diagnostics/event/medlab-middleeast-2025/)
03 — 06 February 2025
---
### [Life Science Webinars](https://www.meridianbioscience.com/lifescience/life-science-webinars/)
**Published:** February 11, 2025
**Author:** hamza
**Content:**
## Life Science Webinars
Please click on the link below to view our educational webinars.
## Life Science Webinars in English
[ View Our Educational Webinars ](/lifescience/webinars)
## 视频直播
[ 观看线上讲座 ](/lifescience/webinar-cn)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
---
### [Custom Formulation Services](https://www.meridianbioscience.com/lifescience/services/)
**Published:** March 5, 2025
**Author:** hamza
**Content:**
# Custom Formulation Services
Glycerol-Free Reagent Development for qPCR, Isothermal Amplifications and NGS
[ Request Information ](#formulation-service-form-sec)
## Meridian’s Approach to Ambient-Temperature Stabilization
At Meridian, we are known for delivering high-performance molecular reagents and innovative solutions, to fit the diverse needs of our IVD customers. Our specialized molecular services include custom glycerol-free formulations to enable lyophilization and air-dryable formats of key molecular reagents. Our stabilization technologies ensure ambient-temperature shipping and storage, extending shelf life and enhancing sustainability without compromising on performance, vital for both point-of-care and high-throughput applications in the IVD market.
## Why Choose Meridian?
- Seamless Chemistry Integration: Ensure perfect compatibility between the reagents and your platform.
- Reduce Development Time: Accelerate your molecular assay development with expert support and cutting-edge technologies.
- Boost Performance: Improve the reliability, sensitivity, and stability of your assays through optimized formulations.
- Enhance Sustainability: Minimize shipping costs and environmental impact with lyophilization and ambient-temperature storage.
### Request Information About Meridian's Custom Services for Ambient-Temperature Stabilization
[ Contact an Expert ](#formulation-service-form-sec)
### Glycerol-Free Enzyme Development
Glycerol is commonly used to stabilize enzymes during their storage to prevent damage; however, it can interfere with lyophilization. Glycerol-free formulations are used to ensure compatibility with lyophilization or air-drying while preserving the performance and stability of the enzyme activity to facilitate storage and transport conditions, allowing more flexibility during development and cost saving during commercialization.
At Meridian, we have many years of expertise in developing glycerol-free enzymes for qPCR, LAMP and NGS. We can take an existing enzyme from our catalog, source an enzyme, or take one of your proprietary enzymes and create a glycerol-free format using your own specifications.
### Custom Master Mix Optimization
We can take any of Meridian’s master mixes and further optimize it to your specific workflow and assay, and if required even transforming the assay into an ambient temperature stable format.
For example:
- For lyophilization
- For air-drying
- Incorporation of dUTP
- Integration to platform
Whatever the technology is, qPCR, LAMP, NGS, NASBA etc.
## Learn more about Meridian's Custom Formulation Services
---
### [Custom Antibody & Protein Manufacturing Services](https://www.meridianbioscience.com/lifescience/custom-antibody-protein-manufacturing-services/)
**Published:** March 10, 2025
**Author:** hamza
**Content:**
# Custom Antibody & Protein Manufacturing Services
Conversion to Animal-Free and Large-Scale Manufacturing
[ Request Information ](#request)
## Meridian’s Approach to Custom Manufacturing Services
At Meridian, we specialize in custom antibody and protein manufacturing services, delivering high-performance reagents tailored to meet the diverse needs of our IVD customers. Our services include hybridoma conversion to animal-free formats, animal IgG conversion to a recombinant Animal-Origin-Free (AOF) alternative, and large-scale production of antibodies, antigens, and enzymes. Transitioning to animal-free manufacturing is a vital step toward more efficient, lower-risk, and better sustainable bioproduction methods.
### What is Animal-Origin-Free (AOF)?
Animal origins free (AOF) means that the product does not contain materials derived from eukaryotic animals. Animal cell lines adapted to animal-free, chemically defined media are included.
## Why Choose Meridian?
- Increased Flexibility : Customize your protein design without the constraints typically linked to animal-derived products.
- Boost Performance: Improve your assays' reliability, safety, and sustainability through animal-free formulations.
- Large-Scale Production: Capacity up to 2,000L ensures consistent quality (ISO 13485), efficiency, and seamless scalability every step of the way.
- Faster Time to Market: Leverage our expertise, cutting-edge technologies and proven processes to accelerate your development and production timeline, bringing your products to the market faster.
### Request Information About Meridian's Custom Antibody & Protein Manufacturing Services
[ Contact an Expert ](#request)
### Conversion to Animal-Free
Recombinant antibodies offer numerous advantages over traditional hybridoma antibodies and can be produced using non-animal-derived materials. Our services include the conversion of your hybridoma-derived antibodies, or animal-derived blocker (e.g., goat IgG), into a recombinant, animal-free format. We provide a comprehensive solution encompassing sequencing, cloning, verification, expression, purification, and production, ensuring a seamless transition to a more ethical, stable, and efficient antibody source.
#### Advantages to Recombinant, Animal-Free Formats
- For lyophilization
- For air-drying
- Incorporation of dUTP
- Integration to platform
### Large-Scale Manufacturing from Sequence or Clone (ISO 13485)
Discover Meridian’s tailored protein manufacturing solutions, which offer customizable packages to suit your project’s unique needs. We provide large-scale production of recombinant antigens, antibodies, and enzymes in quantities up to gram-scale for commercial applications.
Scaling up production involves utilizing adaptable methodologies to enhance expression capacity and meet increasing demands. Our commitment to quality is underscored by stringent quality control measures and compliance with industry standards, ensuring that every product meets the highest specifications for reliability and performance.
### Our Cell Culture and Fermentation Equipment
Our facility is equipped with state-of-the-art cell culture and fermentation equipment, including single-use bioreactors and traditional stirred tank reactors with capacities up to 2,000L. Complimentary downstream processing equipment for protein purification and fill-and-finish operations is also available.
### Protein Manufacturing Services (Up to 2,000L) Versatile Expression Systems: E. coli, Yeast, Insect, CHO, HEK
#### Cell Culture
Fermenter
Single-use Bioreactor
Glass Bioreactor
Biostat® C-PLUS
Biostat® RM
CELBIC 25
Multi-shaker
CO2 incubator
#### Purification
ÄKTA Prime
ÄKTA Pilot
ÄKTA Avant
Sartoflow® Advanced
ÄKTA Flux
Chromatography Columns & Resins
#### QC & Fill and Finish
SDS-PAGE
CE-PAGE
HPLC (SEC, RP)
IEF
Western Blot
Bioburden
Concentration
Others – Functional or binding assays
## Learn more about Meridian's Custom Antibody & Protein Manufacturing Services
---
### [Air-Dryable Direct DNA qPCR Plant Mix](https://www.meridianbioscience.com/lifescience/plant-specimen-specific/)
**Published:** March 7, 2025
**Author:** hamza
**Content:**
# Air-Dryable TM Direct DNA qPCR Plant Mix
#### Air-Dryable™ Direct qPCR Plant is the first commercially available mix designed for developing room-temperature stable assays for the direct quantitation of DNA from plants. It is suitable for direct detection from leaf, root, seeds and soil samples.
#### Direct DNA Detection
Avoid labor and time-intensive DNA extraction by using direct detection methods. Air-Dryable™ Direct DNA qPCR Plant Mix is optimized for robust, sensitive amplification straight from plant lysate. Just add your primers and probes!
#### Sensitive Amplification
Detect DNA down to a single copy using Air-Dryable™ Direct DNA qPCR Plant Mix. The mix’s high inhibitor tolerance enables ultra-sensitive amplification, even from crude plant lysate. Early detection of plant diseases can save significant costs.
#### Room-Temperature Stable
Air-Dryable™ Direct DNA qPCR Plant Mix can be used to create room-temperature stable assays that have a shelf-life of +12 months. The mixes contain a blend of additives that are optimized for oven or air drying.
### Ultra-Sensitive Detection from Crude Lysate
#### Detect Down to 1 Copy of DNA
**Detection down to 1 copy of Rice ATPe in tomato lysate using Air-Dryable™ Direct DNA qPCR Plant Mix.** Air-Dryable™ Direct DNA qPCR Plant Mix was air dried with rice ATPe primers and probe. The dried material was reconstituted in 40% tomato leaf alkaline lysate containing 1,000 copies (brown), 100 copies (amber), 10 copies (green) and 1 copy (blue) genome equivalents per reaction of Rice gDNA.
### Diagnostic Assay Solutions for Top 3 Viral Infections
##### Read the Flyer
Review additional data and information in the Air-Dryable™ Direct DNA qPCR Plant Mix flyer. Compare the performance of liquid vs dried mix, and multiplexing assay straight from 25% tomato leaf lysate.
[ Download Flyer ](https://collateral.meridianlifescience.com/view/397948458/?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741258701586.1741343291715.19&__hssc=51647990.12.1741343291715&__hsfp=1480098718)
##### Watch a Short Video
Curious to learn more about the benefits of room-temperature stable assays? Watch this video to find out how dried assay formats can extend an assay’s shelf-life, and reduce and shipping and storage costs.
[ Watch Video ](https://vimeo.com/578099542/e46f0d4739)
##### Try an Award-Winning Product
Air-Dryable™ Direct qPCR Plant was named one of the Top 10 most innovative products for 2021 by SeedWorld. To learn more, watch the SeedWorld Innovation Series webinar: “Speed up Agbio testing with Ambient temperature stable direct qPCR”.
[ Watch Webinar ](https://youtu.be/q5rcgvbf8ho)
### Experience a Faster Workflow with Direct Detection
By removing the DNA or RNA extraction step, there is less hands-on labor, reduced risk of cross-contamination and sample loss, and a significantly faster assay turnaround time.
#### Want to learn more? Visit the [product page](/lifescience/products/molecular-reagents/ambient-temperature-rt-qpcr-qpcr-mixes/air-dryable-direct-dna-qpcr-plant/?__hstc=51647990.6ad31c1e3db54db646b8a455f24021a3.1740032524073.1741258701586.1741343291715.19&__hssc=51647990.13.1741343291715&__hsfp=1480098718&_gl=1*up2t89*_gcl_au*MTU2MTA1NzgzNi4xNzQwMDMyNTIxLjkzMTY2MjUyNS4xNzQxMzQzMzM1LjE3NDEzNDQxMzM.) or contact us for more information.
[ Contact Us for more information ](/contact-us-life-science/)
---
### [Reagent Solutions for SARS-CoV-2 Assays](https://www.meridianbioscience.com/lifescience/reagent-solutions-for-sars-cov-2-assays/)
**Published:** March 6, 2025
**Author:** hamza
**Content:**
## Reagent Solutions for SARS-CoV-2 Diagnostic Assays
Diagnostic testing for the new coronavirus strain SARS-CoV-2 can be carried out through molecular or immunoassays and can distinguish between active and past infections. For active infections, the presence of the virus can be detected by molecular RT-qPCR assay or by rapid antigen testing. The main benefits of RT-qPCR are sensitivity and the ability to detect transmission of the disease at a very early stage of the infection. However, these tests must be carried out in a laboratory using sophisticated equipment. Rapid antigen assays, in contrast, use monoclonal antibodies to SARS-CoV-2 in a lateral flow format and can be employed in the field to deliver immediate results. For past infections, the virus is no longer present but antibodies to SARS-CoV-2 continue to circulate after an infection has cleared, which can be detected using serology testing. These tests are useful tools for monitoring the evolution of an outbreak and for identifying previously undiagnosed infections in the asymptomatic population that is critical for seroprevalence studies.
Meridian provides a comprehensive solution to each type of COVID-19 assay. Our range of optimized RT-qPCR mixes are ideal for fast and accurate molecular testing and include options for direct detection on clinical samples. For immunoassays, Meridian has several pairs of high-performing monoclonal antibodies to SARS-CoV-2 and a range of recombinant antigens including a panel of antigens that represent the different World Health Organization’s Variants of Concern. The nucleoprotein MAb pair (9547/9548) is currently used in several commercial rapid assays and is capable of detecting the major variant strains circulating globally (e.g. Alpha, Beta, Delta, Omicron).
### Reagent Solutions for SARS-CoV-2 Assays
##### [Reagents for Molecular Diagnostics](/lifescience/molecular-reagents-for-sars-cov-2-assays/)
##### [MAbs for Rapid Antigen Testing](/lifescience/monoclonals-to-sars-cov-2/)
##### [Antigens for Serology Testing](/lifescience/sars-cov-2-recombinant-antigens/)
---
### [New Services Offered By the Life Science Division of Meridian Bioscience](https://www.meridianbioscience.com/lifescience/new-life-science-services/)
**Published:** March 5, 2025
**Author:** hamza
**Content:**
## The Life Science Division of Meridian is proud to offer two new services.
##### Learn more by clicking on the videos below.
#### Lateral Flow Production
#### Lyophilization Services (Lyo-Beads)
---
### [Distributors](https://www.meridianbioscience.com/diagnostics/distributors/)
**Published:** February 20, 2025
**Author:** hamza
---
## Diagnostics Events & Tradeshows
### [ADLM 2026](https://www.meridianbioscience.com/diagnostics/event/adlm-2026/)
**Published:** March 26, 2026
**Author:** Holger
**Content:**
Join us at booth #3265 at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting, formerly known as AACC. This cornerstone event for professionals in diagnostics and laboratory medicine offers over 250 educational opportunities, including plenary sessions, scientific presentations, and roundtable discussions, covering cutting-edge topics such as artificial intelligence, nanotechnology, mass spectrometry, and diagnostic innovation. Don’t miss out on the opportunity to explore the Clinical Lab Expo, featuring more than 850 exhibitors and over 200 new products and services.
**Regions:** North America
**Types:** Trade Show
---
### [AAP Experience 2026](https://www.meridianbioscience.com/diagnostics/event/aap-experience-2026/)
**Published:** March 26, 2026
**Author:** Holger
**Content:**
The American Academy of Pediatrics (AAP) invites you to join us for the 2026 National Conference & Exhibition, taking place October 2–6 in San Diego, California. This flagship event brings together thousands of pediatric healthcare professionals from around the globe to explore the latest clinical advances, research developments, and policy updates shaping the future of pediatric medicine.
**Regions:** North America
**Types:** Trade Show
---
### [AMP 2025 Annual Meeting & Expo](https://www.meridianbioscience.com/diagnostics/event/amp-2025-annual-meeting-expo/)
**Published:** February 18, 2025
**Author:** hamza
**Content:**
Join us at the 31st AMP Annual Meeting & Expo, where over 3,000 professionals from over 200 companies in the molecular diagnostics industry come together to collaborate on the latest advancements in molecular diagnostics and medicine. Attendees of this event seek the newest information and the latest advances to enhance their ability to provide the best patient care.
**Regions:** North America
**Types:** Trade Show
---
### [AAP Experience 2025](https://www.meridianbioscience.com/diagnostics/event/aap-experience-2025/)
**Published:** April 18, 2025
**Author:** hamza
**Content:**
The American Academy of Pediatrics (AAP) invites you to join us for the 2025 National Conference & Exhibition, taking place September 26–30 in Denver, Colorado. This flagship event brings together thousands of pediatric healthcare professionals from around the globe to explore the latest clinical advances, research developments, and policy updates shaping the future of pediatric medicine.
**Regions:** North America
**Types:** Trade Show
---
### [2025 Community Health Institute (CHI) & Expo](https://www.meridianbioscience.com/diagnostics/event/2025-community-health-institute-chi-expo/)
**Published:** April 18, 2025
**Author:** hamza
**Content:**
Join Meridian Bioscience at the 2025 Community Health Institute (CHI) & EXPO, August 17–19 in Chicago, Illinois.
Hosted by the National Association of Community Health Centers (NACHC), CHI is the premier annual gathering for community health professionals, convening over 2,300 executives, clinicians, administrators, and board members from health centers nationwide.
This year’s conference will take place at the Hyatt Regency Chicago, offering attendees insights into the latest in science, education, practice, and policy essential for health centers to remain competitive and financially stable.
As a trusted partner in diagnostic solutions, Meridian Bioscience is proud to exhibit at CHI 2025. Visit our booth to explore our latest innovations designed to support early detection, accurate results, and improved patient outcomes in community health settings.
Don’t miss this opportunity to connect with industry leaders, discover new products and technologies, and collaborate on strategies to enhance care delivery and health center operations.
---
### [MedLab MiddleEast 2025](https://www.meridianbioscience.com/diagnostics/event/medlab-middleeast-2025/)
**Published:** February 18, 2025
**Author:** hamza
**Regions:** EMEA
**Types:** Trade Show
---
### [ASM 2025](https://www.meridianbioscience.com/diagnostics/event/asm-2025/)
**Published:** February 18, 2025
**Author:** hamza
**Content:**
ASM Microbe 2025 brings together thousands of scientists, researchers, and healthcare professionals for the world’s largest microbial sciences gathering. The conference will feature over 200 unique sessions across eight scientific tracks, covering topics from basic microbiology to artificial intelligence research (AI). Attendees can engage in cutting-edge scientific sessions and explore curated itineraries on interdisciplinary topics. Key focus areas include antimicrobial resistance, clinical microbiology, environmental and applied microbiology, microbial ecology and evolution, host-microbe biology, and microbial therapeutics and vaccines.
**Regions:** North America
**Types:** Trade Show
---
### [ADLM 2025](https://www.meridianbioscience.com/diagnostics/event/adlm-2025/)
**Published:** February 18, 2025
**Author:** hamza
**Content:**
Join us at booth #3620 at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting, formerly known as AACC. This cornerstone event for professionals in diagnostics and laboratory medicine offers over 250 educational opportunities, including plenary sessions, scientific presentations, and roundtable discussions, covering cutting-edge topics such as artificial intelligence, nanotechnology, mass spectrometry, and diagnostic innovation. Don’t miss out on the opportunity to explore the Clinical Lab Expo, featuring more than 850 exhibitors and over 200 new products and services.
**Regions:** North America
**Types:** Trade Show
---
### [DDW2025, Digestive Disease Week®](https://www.meridianbioscience.com/diagnostics/event/ddw2025-digestive-disease-week/)
**Published:** March 24, 2025
**Author:** hamza
**Content:**
Join Meridian at Digestive Disease Week® (DDW®) 2025 and immerse yourself in the forefront of innovation. Meet our team and explore BreathID®, a revolutionary solution reshaping digestive disease diagnosis and management.
Experience personalized demos, gain insights into the latest *H. pylori* testing recommendations, and elevate your practice to new heights. Don’t miss out — reserve your spot today!
Note: Digestive Disease Week® and DDW® are registered trademarks of DDW LLC.
---
### [Behind the Guidelines: H. pylori Management in 2025](https://www.meridianbioscience.com/diagnostics/event/behind-the-guidelines-h-pylori-management-in-2025/)
**Published:** May 8, 2025
**Author:** hamza
**Content:**
Join Meridian Bioscience for an exclusive, expert-led webinar based around the American College of Gastroenterology (ACG) 2024 clinical guideline on the management of *H. pylori* infection.
**P.A.C.E.-Accredited Webinar**
**Types:** Webinar
---
## Disease Areas
### [H. pylori](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/)
**Published:** May 24, 2024
**Author:** hamza
**Content:**
# *Helicobacter Pylori* (*H. pylori*) Tests
## Prevent the Preventable. Manage the Manageable.
*H. pylori* is 1 of 4 common infections that can lead to cancer- it is preventable with early detection.4
## *Helicobacter Pylori* (*H. pylori*)
*H. pylori* is one of the most prevalent bacterial infections globally, characterized by typical gastrointestinal discomfort symptoms that can be treated. An *H. pylori* test is essential for accurate diagnosis and early intervention. When an *H. pylori* test is not conducted and the infection remains untreated, it may lead to the development of chronic gastritis, peptic ulcer disease, and even gastric cancer.5.
**1 in 3 Americans** are infected with *H. pylori*.1
**9 in 10 ulcers** are caused by untreated *H. pylori* infections.2
**Gastric Cancer** risk is 6 times higher in *H. pylori*-infected individuals.3
## What is an *H. pylori* Test?
An *H. pylori* test is essential for detecting *H. pylori*, a bacteria linked to ulcers, gastritis, and stomach cancer. Early diagnosis with an *H. pylori* test helps prevent serious complications and ensures timely treatment. This *H. pylori* test is a simple, non-invasive procedure that provides accurate results for effective medical management. Regular *H. pylori* testing is recommended for individuals experiencing persistent digestive issues, as an *H. pylori* test can lead to early intervention and improved gut health.
## Urea Breath Test Solution for *H. pylori* Detection
#### Noninvasive *H. pylori* test from a simple breath sample
Meridian Bioscience’s urea breath test platforms provide unparalleled flexibility and scalability for *H. pylori* test applications across diverse clinical settings. Discover customized *H. pylori* test solutions designed to meet the needs of high-volume reference laboratories or compact, near-patient clinical environments.
[](/diagnostics/platforms/urea-breath/breathid-lab/)### BreathID® Hp Lab
The BreathID® Hp Lab urea breath testing system detects *H. pylori* and confirms eradication for healthcare providers with large patient testing volumes.
Learn More
[](/diagnostics/platforms/urea-breath/breathid-smart/)### BreathID® Smart
The BreathID® Smart urea breath testing platform detects *H. pylori* and confirms eradication for healthcare providers with mid-range patient testing volumes.
Learn More
[](/diagnostics/platforms/urea-breath/breathid-smart-eu/)### BreathID® Smart (EU)
The BreathID® Smart urea breath testing platform detects *H. pylori* and confirms eradication for healthcare providers with mid-range patient testing volumes.
Learn More
## Only Meridian Provides a Complete *H. pylori* Active Infection Testing Solution
Meridian Bioscience provides the complete *H. pylori* testing solution that aligns with diagnostic standards set by the European *Helicobacter* and Microbiota Study Group (EHMSG) and Maastricht Consensus Reports9 and the American College of Gastroenterology (ACG)10, and other clinical guidelines. Our comprehensive testing menu includes non-invasive tests for active infection like the BreathID® urea breath test (UBT) and stool antigen tests, empowering healthcare professionals with accurate tools for diagnosing and managing *H. pylori* infections. Choose Meridian Bioscience for a dependable and efficient testing solution tailored to your needs.
## Stool Antigen Test Solutions for *H. pylori*
#### Noninvasive testing for the detection of *H. pylori* antigens in stool specimens
Meridian Bioscience’s stool antigen testing solutions for *H. pylori* detection provide reliable, patient-friendly results without invasive procedures. As a leader in cutting-edge medical diagnostics, the Meridian stool antigen portfolio provides a precise and comprehensive method for identifying Helicobacter pylori infection, a critical factor in the prevention and management of gastritis and ulcers.
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)#### Curian®HpSA®
Improves healthcare system efficiencies by providing a rapid, accurate result for *H. pylori* active infection and confirmation of eradication while removing subjectivity.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/?country=US)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)#### Immunocard STAT!® HpSA®
A CLIA waived one-step lateral flow immunoassay for the direct detection of *Helicobacter pylori* antigens in stool specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/?country=US)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)#### Premier® HpSA® Flex
A streamlined, highly sensitive enzyme immunoassay for the detection of *H. pylori* antigens in fresh (unpreserved) and preserved stool specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/?country=US)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)#### Premier®Platinum HpSA® PLUS
A streamlined, highly sensitive enzyme immunoassay for the detection of *H. pylori* antigens in fresh (unpreserved) stool specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/?country=US)
## Learn More About *H. pylori*
*H. pylori* is one of the world’s most common bacterial infections and has common GI distress symptoms that are curable. If left untreated, an *H. pylori* infection can cause chronic gastritis, peptic ulcer disease and even gastric cancer.
## Education and Outreach tools to learn more about *H. pylori* testing
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
*H. pylori* Fact Sheet
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/22121434/MBI_H.-pylori-HCP-Fact-Sheet_2022-06.pdf) [ 
*H. pylori* Patient Education Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/22121250/MBI_H.-pylori-Patient-Education-Brochure_2022-06.pdf)
## FAQs
What is *H. pylori* ?
*H. pylori*, or *Helicobacter pylori*, is a type of bacteria that infects the stomach lining and can lead to various digestive issues, including gastritis and peptic ulcers.
What is Dyspepsia?
Dyspepsia, commonly known as indigestion, refers to discomfort or pain in the upper abdomen, often accompanied by symptoms like bloating, belching, and nausea. It can be caused by various factors, including overeating, eating too quickly, consuming fatty or spicy foods, stress, or underlying digestive disorders. Dyspepsia can sometimes be a symptom of an *H. pylori* infection or other gastrointestinal conditions. If symptoms persist or worsen, it’s important to consult a healthcare provider for proper evaluation and management.
How is *H. pylori* transmitted?
*H. pylori* is usually transmitted through contaminated food, water, or utensils. It can also spread through close contact with an infected person’s saliva or vomit.
What are the symptoms of an *H. pylori* infection?
Individuals experiencing persistent abdominal pain, bloating, or other symptoms suggestive of a stomach ulcer or gastritis should consider getting tested for *H. pylori*. Those with a family history of stomach cancer or peptic ulcers may also benefit from *H. pylori* testing.
Why is it important to test for *H. pylori*
Approximately 50% of the world is infected with *H. pylori*. When left untreated, patients with *H. pylori* are at risk for long-term consequences such as ulcers and gastric cancer. Gastric cancer accounts for about 1.5% of all new cancers diagnosed in the United States each year. Early detection of *H. pylori* is vital in establishing appropriate treatment.1,6,7
Why test for using urea breath tests or stool antigen tests?
Guidelines from AGA and ACG recommend a test, treat, and retest approach to confirm the eradication of *H. pylori*. Active infection tests such as 13C-urea breath tests or stool antigens are recommended rather than serology (antibody). Serology tests cannot determine active *H. pylori* infection and are no better than a coin toss in predicting the presence of active infection.5,7,8
What is the treatment for an *H. pylori* infection?
A healthcare provider will determine the most appropriate treatment for *H. pylori*. However, treatment may typically involve a combination of antibiotics and acid-suppressing medications to eradicate the bacteria and heal any resulting ulcers. The specific regimen may vary depending on the individual’s health and other factors determined by their healthcare provider.
Why test for *H. pylori* again after treatment?
The ACG/AGA guidelines emphasize the need to test for diagnosis, treatment, and retest to confirm eradication using a non-invasive active infection test for *H. pylori* infection. *H. pylori* eradication therapy fails in 1 out of 4 patients. Antibiotic resistance and poor compliance are considered the most common causes of *H. pylori* treatment failure. There are ways to detect active infection and confirm infection eradication of an *H. pylori*infection with our non-invasive active infection tests that deliver trusted results – for lifelong impact.5
Can *H. pylori* infections recur after treatment?
Yes, *H. pylori* infections can recur, especially if the initial treatment was not successful or if the individual is re-exposed to the bacteria. Follow-up testing may be recommended to ensure the infection has been completely eradicated as determined by a healthcare provider.
Is there anything I can do to prevent *H. pylori* infection?
While it’s not always possible to prevent *H. pylori* infection, practicing good hygiene, avoiding contaminated food and water, and adopting safe food handling practices can reduce the risk of transmission. Additionally, avoiding close contact with individuals who have active *H. pylori* infections may help lower the risk.
### References:
1. Fennerty, M. B. *Helicobacter pylori*: why it still matters in 2005. Cleveland Clinic Journal of Medicine, 2005; 72(Suppl\_2), S1-7. https://doi.org/10.3949/ccjm.72.suppl\_2.s1.
2. Centers for Disease Control. MMWR (October 1997) Knowledge About Causes of Peptic Ulcer Disease—United States, March-April 1997. https://www.cdc.gov/mmwr/preview/mmwrhtml/00049679.htm. Accessed June 9, 2022.
3. Helicobacter and Cancer Collaborative Group. Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 Sep;49(3):347-53. doi: 10.1136/gut.49.3.347. PMID: 11511555; PMCID: PMC1728434.
4. The Lancet. Chronic Disease Management in Aging Populations. Available at https://www.thel ancet.com/journals/lancet/article/PIIS0140-6736(12)60790-9/fulltext. Accessed on June 9, 2022.
5. Chey WD & Wong BCY. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. Am J Gastroenterol, 2007; 102(8):1808-1825
6. American Cancer Society. Key Statistics for Stomach Cancer. Available at https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html Accessed June 9, 2022
7. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. American Journal of Gastroenterology, 2018; 113(7), p1102. doi: 10.1038/s41395-018-0132-6
8. Talley, N. J. American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia. Gastroenterology, 2005; 129(5):1753–1755. https://doi.org/10.1053/j.gastro.2005.09.019
## Get In Touch With A Specialist
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [StatID PRO™ COVID-19/Flu A&B External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/statid-pro-covid-19-flu-ab-external-controls/)
**Published:** October 9, 2025
**Author:** hamza
**Content:**
# StatID PRO™ COVID-19/Flu A&B External Controls
Catalog Number: 783010
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[Support & Documents](#support-documents)
#### Limited Time Offer!
#### Stay Ahead of Respiratory Season with StatID PRO™
Buy 4 Kits, Get 1 FREE.
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ StatID PRO™ COVID-19/Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_pi.pdf)
[ Safety Data Sheet - Kit StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_kit_sds.pdf)
[ Safety Data Sheet - Positive Control StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_positive_control_sds.pdf)
[ Safety Data Sheet (OSHA)- Positive Control StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_positive_control_osha.pdf)
[ Safety Data Sheet - Negative Control StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_negative_control_sds.pdf)
[ Safety Data Sheet (OSHA) - Negative Control StatID PRO COVID-19/Flu A&B External Controls ](/uploads/783010_negative_control_osha.pdf)
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [BreathID® Hp Lab - IDkit Hp® Two](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two/)
**Published:** April 30, 2020
**Author:** hamza
**Content:**
# BreathID® Hp Lab – IDkit Hp® Two
A non-invasive urea breath test for the detection of *H. pylori* and confirmation of eradication.
Catalog Number: AC00063
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Kit Components
- Blue BASELINE breath bag
- Gray POST-INGESTION breath bag
- 75mg 13C-urea tablet
- 4.3g package of Citrica (citric acid)
- Straw
- Drinking Cup
- User Guide
- 4 labels
- Sample transport bag
- Package Insert
## Support & Documents
#### Downloadable PDFs
[ Product Brochure IDkit Hp Two ](/uploads/MBI_IDKit_Hp_Two_SS_2026-01.pdf)
[ Package Insert IDkit Hp Two ](/uploads/ac00063_pi.pdf)
[ Package Insert - ES IDkit Hp Two ](/uploads/ac00063_pi_es.pdf)
[ Procedure Card IDkit Hp Two ](/uploads/ac00063_pc.pdf)
[ Guía rápida Prueba De Aliento Para Detectar H. pylori ](/uploads/mbi_breathid_idkit-two-quick-guide_es_2020-08.pdf)
[ Safety Data Sheet (SDS) IDkit Hp ](/uploads/50402-100_sds.pdf)
#### Webinars & Videos
- [UBT versus Serology](https://youtu.be/unTrKNznOzM)
- [Why test for *H. pylori*](https://youtu.be/HkOrGwEhLUY)
- [How To Administer
The BreathID IDkit Hp Two Test](https://vimeo.com/543605576)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Immunocard STAT!® C. difficile GDH AB External Control Set](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
**Published:** September 26, 2023
**Author:** hamza
**Content:**
## Immunocard STAT!® C. difficile GDH AB External Control Set
External Controls to be used with Immunocard STAT!® *C. difficile* GDH AB.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 750501
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - External Control Set Immunocard STAT! C. difficile GDH-AB ](/uploads/750501_pi.pdf)
[ Safety Data Sheet - Immunocard STAT! GDH Positive Control ](/uploads/750501_positive_control_sds.pdf)
[ Safety Data Sheet - Immunocard STAT! GDH Negative Control ](/uploads/750501_negative_control_sds.pdf)
[ Safety Data Sheet - Immunocard STAT! 2A-B Cdiff Positive Control ](/uploads/750501_2ab_cdiff_positive_control_sds.pdf)
[ Safety Data Sheet - Immunocard STAT! 2A-B Cdiff Negative Control ](/uploads/750501_2ab_cdiff_negative_control_sds.pdf)
[ Safety Data Sheet - Immunocard STAT! C. difficile GDH-AB External Control Set Kit ](/uploads/750501_kit_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Cryptococcal Antigen Latex Agglutination System (CALAS®)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/cryptococcal-antigen-latex-agglutination-system/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Cryptococcal Antigen Latex Agglutination System (CALAS®)
Latex agglutination test for the detection of *Cryptococcus neoformans* antigen in serum or CSF
Catalog Number: 140100
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ CALAS® Pronase ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/calas-pronase/)
Pediatric & Neonatal
[ Monospot® Latex ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/monospot-latex/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert CALAS ](/uploads/140100_140050_pi.pdf)
[ CLSI CALAS ](/uploads/140100_clsi.doc)
[ Procedure Card CALAS ](/uploads/140100_pc.pdf)
[ Reaction Card CALAS ](/uploads/140100_rc.pdf)
[ Safety Data Sheet (OSHA) - Antibody Control ](/uploads/1405_osha.pdf)
[ Safety Data Sheet (OSHA) - Control Latex ](/uploads/1402_osha.pdf)
[ Safety Data Sheet (OSHA)- Detection Latex ](/uploads/1401_osha.pdf)
[ Safety Data Sheet (OSHA) - Negative Control ](/uploads/1032_osha.pdf)
[ Safety Data Sheet (OSHA) - Positive Control ](/uploads/1404_osha.pdf)
[ Safety Data Sheet - Pronase Reagent ](/uploads/1408_sds.pdf)
[ Safety Data Sheet (OSHA) - Pronase Reagent ](/uploads/1408_osha.pdf)
[ Safety Data Sheet (OSHA) - Sample Diluent ](/uploads/1403_osha.pdf)
[ Safety Data Sheet - CALAS Kit ](/uploads/140100_kit_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Cryptosporidium/Giardia](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Parasitology
# Cryptosporidium/Giardia
Our *Cryptosporidium/Giardia* testing portfolio is flexible to match the way your organization works. Pick your platform below.
[](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls) 
###### Immunocard STAT!®Crypto/Giardia
Controls
External Controls to be used with Immunocard STAT!® Crypto/Giardia.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia) 
###### merifluor® Cryptosporidium/Giardia
Direct fluorescent assay for the detection of *Cryptosporidium* and *Giardia*. A simple, highly sensitive stain to detect *Cryptosporidium* and *Giardia*.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides) 
###### merifluor® C/G Treated Microscope
Slides
Direct fluorescent assay for the detection of *Cryptosporidium* and *Giardia*. A simple, highly sensitive stain to detect *Cryptosporidium* and *Giardia*.
Learn More
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/) 
###### Immunocard STAT!®Crypto/Giardia
Rapid lateral flow immunoassay for the differentiated detection of *Cryptosporidium* and *Giardia lamblia* from stool specimens.
Learn More
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Parasitology
---
### [Alethia® Group A Streptococcus](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
**Published:** March 5, 2019
**Author:** hamza
**Content:**
## Alethia® Group A Streptococcus
Molecular assay for the detection of Group A Streptococcus. Alethia® provides a quick, accurate and reliable molecular assay for Group A Strep detection.
Catalog Number: 480150
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Group A Streptococcus ](/uploads/480150_product_brochure.pdf)
[ Package Insert - Alethia Group A Streptococcus ](/uploads/480150_pi.pdf)
[ Safety Data Sheet - Alethia Group A Strep Kit ](/uploads/480150_kit_sds.pdf)
[ CLSI - Alethia Group A Streptococcus ](/uploads/480150_clsi.doc)
[ Safety Data Sheet - Control Bead Alethia Group A Streptococcus ](/uploads/2860_control_bead_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia Group A Streptococcus ](/uploads/2860_control_bead_osha.pdf)
[ Safety Data Sheet - Test Bead Alethia Group A Streptococcus ](/uploads/2860_test_bead_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) Alethia Group A Streptococcus ](/uploads/2860_test_bead_osha.pdf)
[ Safety Data Sheet - Sample Preparation Apparatus ](/uploads/2864_2792_sds.pdf)
[ Safety Data Sheet (OSHA) - Sample Preparation Apparatus ](/uploads/2864_2792_osha.pdf)
[ Procedure Card (EN) - Alethia Group A Streptococcus ](/uploads/480150_pc.pdf)
[ Procedure Card (DE) - Alethia Group A Streptococcus ](/uploads/480150_pc_de.pdf)
[ Procedure Card (FR) - Alethia Group A Streptococcus ](/uploads/480150_pc_fr.pdf)
#### Webinars & Videos
#### [Group A Strep - Taking the Guesswork out of Strep Testing](https://vimeo.com/148628975)
#### [Group A Streptococcus - The Benefits of Molecular Detection](https://vimeo.com/57132605)
#### [LEANING The Diagnosis Of Group A Strep & The Diagnostic Challenges of Bordetella pertussis](https://vimeo.com/97717981)
#### FAQs
What are the advantages of molecular amplification for Group A Strep testing?
98% sensitivity means increased detection of positives with fewer false negatives – Eliminates subjectivity related to traditional culture methods – Rapid turn around time in comparison to 48 hours for culture, allowing for proper patient management and appropriate antibiotic treatment.
Culture is the preferred method. What are the drawbacks?
Traditional culture sensitivity is as low as 90% with optimal technique – Overgrowth of normal flora –
Variability in how the specimen is attained affecting amount of streptococci growth.
Can molecular testing be done directly from a throat swab?
Yes, a Flocked Nylon, Polyester, or Rayon swab in either Liquid Stuart or Liquid Amies, without charcoal is appropriate.
Why is Empiric Therapy to be avoided?
Unnecessary antibiotic treatment exposes patients to the expense and hazards which can lead to the development of antimicrobial resistance among common pathogens1. Up to 70% of patients receive antibiotic therapy while only 20%-30% have Group A Strep pharyngitis1. Estimated economic costs of pediatric streptococcal pharyngitis in the U.S. range from $224M to $539M per year.
What is the suggested CPT Code?
Alethia® Group A Strep – 87651
References:
1\. Shulman et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis:2012 Update by the Infectious Diseases Society of America.
2\. Alethia Group A Streptococcus Package Insert, SN11022.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [BreathID® Smart - IDkit Hp® Two](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-la/)
**Published:** June 30, 2026
**Author:** Hamza Shahzad
**Content:**
# BreathID® Smart – IDkit Hp® Two
A non-invasive urea breath test for the detection of *H. pylori* and confirmation of eradication.
Catalog Number: AC00078
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Kit Components
- 100 Tablets 13C Urea, 75mg
- 100 Packets Citrica Powder, 4.3g
- 100 Blue BASELINE Breath Sample Bags
- 100 Gray POST INGESTION Breath Sample Bags
- 100 Drinking Straws
- 100 Cups
- 1 Package Insert
## Support & Documents
#### Downloadable PDFs
[ Package Insert - ES IDkit Hp Two ](/uploads/MLD01021-ES%20Rev%207.3%20IDkit%20Hp%20Two%20AC00078%20Package%20Insert%20in%20Spanish%20-%20A4.pdf)
[ Guía rápida Prueba De Aliento Para Detectar H. pylori ](/uploads/mbi_breathid_idkit-two-quick-guide_es_2020-08.pdf)
[ Safety Data Sheet (SDS) IDkit Hp ](/uploads/50402-100_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [BreathID® Smart - IDkit Hp® Two (EU)](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-eu/)
**Published:** June 30, 2026
**Author:** Hamza Shahzad
**Content:**
# BreathID® Smart – IDkit Hp® Two
A non-invasive urea breath test for the detection of *H. pylori* and confirmation of eradication.
Catalog Number: AC00050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Kit Components
- 20 Baseline Breath Sample Bags
- 20 Post Ingestion Breath Sample Bags
- 20 Straws
## Support & Documents
#### Downloadable PDFs
[ Package Insert IDkit Hp Two ](/uploads/MLD00023%20Rev.%2005%20-%20EU%205%20lang%20IFU%20A3%201.1.26%20PRNT.pdf)
[ Quick Guide IDkit Hp Two ](/uploads/ac00063_pc.pdf)
[ Quick Guide IDkit Hp Two – Italian ](/uploads/MLD00031-IT%20REV-06%20IDKit%20Two%20Quick%20Guide%20Italian.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Merifluor® Cryptosporidium/Giardia](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Merifluor® Cryptosporidium/Giardia
Direct fluorescent assay for the detection of *Cryptosporidium* and *Giardia*. A simple, highly sensitive stain to detect *Cryptosporidium* and *Giardia*.
Catalog Number: 250050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Parasitology
[ Merifluor® C/G Treated Microscope Slides ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/)
Respiratory
[ Merifluor® Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)
Sexual Health
[ Merifluor® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/)
[ Merifluor® VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### SVT Stool Transport
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/svt/)
[  ](https://www.meridianbioscience.com/para-pak/svt/)
### EcoFix® Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/ecofix/)
[  ](https://www.meridianbioscience.com/para-pak/ecofix/)
### SAF Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/saf/)
[  ](https://www.meridianbioscience.com/para-pak/saf/)
### 10% Formalin Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
[  ](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
### Immunocard STAT!® Crypto/Giardia
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Merifluor Cryptosporidium/Giardia ](/uploads/250050_pi.pdf)
[ CLSI - Merifluor Cryptosporidium/Giardia ](/uploads/250050_clsi%20(1).doc)
[ Procedure Card - Merifluor Cryptosporidium/Giardia ](/uploads/250050_pc.pdf)
[ Reaction Card - Merifluor Cryptosporidium/Giardia ](/uploads/250050_rc.pdf)
[ Safety Data Sheet - Counterstain ](/uploads/2502_sds.pdf)
[ Safety Data Sheet (OSHA) - Counterstain ](/uploads/2502_osha.pdf)
[ Safety Data Sheet - Detection Antibody ](/uploads/2501_sds.pdf)
[ Safety Data Sheet (OSHA) - Detection Antibody ](/uploads/2501_osha.pdf)
[ Safety Data Sheet - Mounting Medium ](/uploads/8002_sds.pdf)
[ Safety Data Sheet (OSHA) - Mounting Medium ](/uploads/8002_osha.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/2504_sds.pdf)
[ Safety Data Sheet (OSHA) - Positive Control ](/uploads/2504_osha.pdf)
[ Safety Data Sheet - Negative Control ](/uploads/2505_sds.pdf)
[ Safety Data Sheet (OSHA) - Negative Control ](/uploads/2505_osha.pdf)
[ Safety Data Sheet - Wash Buffer ](/uploads/2503_sds.pdf)
[ Safety Data Sheet (OSHA) - Wash Buffer ](/uploads/2503_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Parasitology
---
### [Alethia® CMV](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
**Published:** March 6, 2019
**Author:** hamza
**Content:**
## Alethia® CMV
Molecular assay for the detection of congenital Cytomegalovirus (CMV). Alethia® provides a quick, accurate and reliable molecular assay for congenital CMV detection.
Catalog Number: 481325
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Alethia CMV ](/uploads/481325_ss.pdf)
[ Package Insert Alethia CMV ](/uploads/481325_pi.pdf)
[ Procedure Card Alethia CMV ](/uploads/481325_pc.pdf)
[ Procedure Card - French Alethia CMV ](/uploads/481325_pc_fr.pdf)
[ Sample Collection Guide Alethia CMV ](/uploads/Alethia_CMV_SC_Guide_481325.pdf)
[ CLSI Alethia CMV ](/uploads/481325_clsi.doc)
[ Safety Data Sheet - Buffer I Alethia CMV ](/uploads/2901_sds.pdf)
[ Safety Data Sheet - Buffer I (OSHA) Alethia CMV ](/uploads/2901_osha.pdf)
[ Safety Data Sheet - Buffer II Alethia CMV ](/uploads/2779_sds.pdf)
[ Safety Data Sheet - Buffer II (OSHA) Alethia CMV ](/uploads/2779_osha.pdf)
[ Safety Data Sheet - Test Bead Alethia CMV ](/uploads/2835_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) Alethia CMV ](/uploads/2835_osha.pdf)
[ Safety Data Sheet Control Bead ](/uploads/2835_2875_2876_sds.pdf)
[ Safety Data Sheet (OSHA) Control Bead ](/uploads/2835_2875_2876_osha.pdf)
[ Safety Data Sheet Alethia CMV Kit ](/uploads/481325_kit_sds.pdf)
#### FAQs
What is a CPT code for cCMV testing?
- The CPT code for Alethia cCMV is 87496.
Why saliva?
- Saliva is an easy to collect sample, a swab moistened with saliva is enough to run the test (do not need any more than a flocked swab moistened with saliva)
- Antigen rich sample due to the fact that CMV replicates in the salivary glands, high level of shedding
- Recommended sample by the CMV consensus guidelines
How does it compare to urine?
- In studies, saliva performs equal or better than urine in the detection of congenital CMV
- Urine collection can be a challenge, squeezing diapers or having to put a catheter is more complicated than collecting a saliva sample
What are the clinical performance characteristics of Alethia CMV?
- Compared to 2 PCR’s and bi-directional sequencing the performance was: PPA 100% and NPA 99.8% with a population > 1,400 samples.
How is the sample transported? And/or how stable is the sample?
- Saliva samples after collection on a flocked swab can be transported as is (I.E., dry) or put in viral transport media (1mL, VTM, or UTM)
- It can last 48 hrs at room temperature, 7 days at 2-8C, or 14 days at -20C
What is Alethia CMV detecting?
- Alethia CMV detects the presence of the CMV virus in newborns younger than 21 days, hence determining if the newborn has a congenital infection, meaning the fetus was infected during pregnancy
- A positive result after 21 days may no longer be considered congenital, but an acquired infection after birth
What about transmission through breastmilk?
- It is indicated that the saliva samples should be collected 1 hr after breastfeeding
- Transmission of CMV through breastmilk is not a congenital infection, but an acquired infection after birth
Why is important to test for congenital CMV?
- Because 1 in 200 babies are born with congenital CMV, making it the most common congenital infection in newborns
- It is the number one cause of non-genetic deafness in children
- 1 in 5 babies will develop health problems and complications, therefore early diagnosis and proper treatment are important to the physician and the family
- Alethia CMV provides results in less than 1 hr, which empowers physicians with actionable results that can positively impact patient care
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [StatID PRO™ COVID-19/Flu A&B](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
**Published:** August 26, 2025
**Author:** Moaaz Ahmad
**Content:**
# StatID PRO™ COVID-19/Flu A&B
The StatID PRO COVID-19/Flu A&B is a lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of influenza A, and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection.
Catalog Number: 783025
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[Support & Documents](#support-documents)
#### Limited Time Offer!
#### Stay Ahead of Respiratory Season with StatID PRO™
Buy 4 Kits, Get 1 FREE.
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why StatID PRO
COVID-19/Flu A&B?
StatID PRO COVID-19/Flu A&B combo rapid test delivers quick, reliable results for COVID-19, influenza A, and influenza B from a simple anterior nasal swab. FDA-cleared for use in patients 2 years and older, the test is designed for use within the first five days of symptoms. This easy-to-use rapid assay helps healthcare providers quickly differentiate between common respiratory infections with similar presentations.
One swab, three answers — COVID-19, Flu A, and Flu B antigen results
FDA-cleared, not EUA — trusted regulatory approval with proven reliability
Approved for use in patients 2 years and older
15-minute visual results for immediate decision-making
Workflow flexibility — specimens may be held in extraction tube for up to 1 hour before testing
## Related Tests
Respiratory
[ StatID PRO™ COVID-19/Flu A&B External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/statid-pro-covid-19-flu-ab-external-controls/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure StatID PRO COVID-19/Flu A&B ](/uploads/StatID-PRO-COVID-19_Flu-AB-Sales-Sheet.pdf)
[ Package Insert StatID PRO COVID-19/Flu A&B ](/uploads/783025_pi.pdf)
[ Quick Reference Instructions StatID PRO COVID-19/Flu A&B ](/uploads/783025_qri.pdf)
[ Safety Data Sheet - Extraction Buffer StatID PRO COVID-19/Flu A&B ](/uploads/783025_sds.pdf)
[ Safety Data Sheet (OSHA) - Extraction Buffer StatID PRO COVID-19/Flu A&B ](/uploads/783025_osha.pdf)
[ Safety Data Sheet (OSHA) - Extraction Buffer StatID PRO COVID-19/Flu A&B ](/uploads/783025_osha.pdf)
[ CLSI - StatID PRO COVID-19/Flu A&B ](/uploads/783025_clsi.doc)
FAQs
What sample types can be used?
Anterior nasal swab sample type can be used with StatID PRO COVID-19/Flu A&B
Can samples in transport media be used?
No. For use with anterior nasal swab specimens only and not for use with viral transport media (VTM)
Does the StatID PRO COVID-19/Flu A&B kit include External Controls?
External controls are sold separately ([StatID PRO COVID-19/Flu A&B Controls, Cat. #783010](/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/statid-pro-covid-19-flu-ab-external-controls/))
What is the suggested CPT code?
It is suggested to use CPT 87428, and for the CLIA waiver, add a QW designator
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Revogene® SARS-CoV-2](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
**Published:** November 24, 2021
**Author:** hamza
**Content:**
# Revogene® SARS-CoV-2
A real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) qualitative test run on the Revogene® instrument for the detection of SARS-CoV-2 nucleic acid from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens.
Catalog Number: 410700
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Revogene SARS-CoV-2?
The Revogene® SARS-CoV-2 assay is a real-time RT-PCR test intended for the qualitative detection of RNA from SARS-CoV-2 in nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet requirements to perform high or moderate complexity tests.
Revogene’s fully automated molecular platform can help optimize the laboratory’s COVID-19 testing capacity with its time-saving, press-and-walk-away efficiencies in just 2 steps. This test can provide final results in as early as 47 minutes for positive specimens.\*
\*E-PRO: Early Positive Result Outcome. Positive results in ~47 minutes for highly positive specimens and negative results in 85 minutes.
- Automated, streamlined workflow – sample to result in 2 easy steps
- Time-saving, walk-away efficiencies with little hands-on-time
- Advanced molecular diagnostic accuracy – 97.7% PPA , 97.7% NPA
- Platform for growth – Single analyte and multiplex testing capability
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
As per the CDC, PCR tests are the ”gold standard” for COVID-19 tests. They are more likely to detect the virus than antigen tests.
Reference: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Products
### StatID PRO™ COVID-19/Flu A&B
Your country: US
Mode: Include
Countries: 1
US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Revogene SARS-CoV-2 ](/uploads/410700_ss.pdf)
[ Package Insert - Revogene SARS-CoV-2 ](/uploads/410700_pi.pdf)
[ CLSI - Revogene SARS-CoV-2 ](/uploads/410700_clsi.doc)
[ Safety Data Sheet - Revogene SARS-CoV-2 ](/uploads/410700_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene SARS-CoV-2 ](/uploads/410700_osha.pdf)
[ Procedure Card - Revogene SARS-CoV-2 ](/uploads/410700_pc.pdf)
[ Healthcare Provider Fact Sheet - Revogene SARS-CoV-2 ](/uploads/410700_healthcare-provider-fact-sheet.pdf)
[ Patient Fact Sheet - Revogene SARS-CoV-2 ](/uploads/410700_patient-fact-sheet.pdf)
#### FAQs
What is the suggested CPT code for the Revogene SARS-CoV-2 assay?
CPT Code 87635
What sample types can be used with the Revogene SARS-CoV-2 assay?
Nasopharyngeal, anterior nasal, mid-turbinate nasal, or oropharyngeal swab specimens collected according to standard technique and placed in 3 mL of transport media according to manufacturer’s instructions.
What are the storage and stability specifications for specimens and the Revogene SARS-CoV-2 assay?
Swab specimens collected in VTM/UTM can be stored at 2-8 C for up to seven (7) days before being tested with the Revogene SARS-CoV-2 assay. Specimens collected in CDC media, MicroTest™ M4RT® (Remel), or saline may be stored up to 72 hours at 2-8 C before use.
The Revogene SARS-CoV-2 kit can be stored at 2-8 C. The expiration date is indicated on the kit box label. For more information, please refer to the Revogene SARS-CoV-2 package insert.
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Merifluor® VZV](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
# Merifluor® VZV
Direct fluorescent assay that detects Varicella-Zoster virus in vesicle smears, biopsies, VZV cell culture.
Catalog Number: 500113
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Parasitology
[ Merifluor® C/G Treated Microscope Slides ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/)
[ Merifluor® Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
Respiratory
[ Merifluor® Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)
Sexual Health
[ Merifluor® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Merifluor VZV ](/uploads/500113_pi.pdf)
[ Safety Data Sheet - Detection Reagent Merifluor VZV ](/uploads/5014_sds.pdf)
[ Safety Data Sheet - Mounting Medium Merifluor ](/uploads/5010_sds.pdf)
[ Safety Data Sheet (OSHA) - Detection Reagent Merifluor VZV ](/uploads/5014_osha.pdf)
[ Safety Data Sheet (OSHA) - Mounting Media Merifluor ](/uploads/5010_osha.pdf)
[ Safety Data Sheet Merifluor VZV Kit ](/uploads/500113_kit_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Sexual Health
---
### [Merifluor® Pneumocystis](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Merifluor® Pneumocystis
Immunofluorescent assay for detection of *Pneumocystis carinii*.
Catalog Number: 222030
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Parasitology
[ Merifluor® C/G Treated Microscope Slides ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/)
[ Merifluor® Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
Respiratory
Sexual Health
[ Merifluor® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/)
[ Merifluor® VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Merifluor Pneumocystis ](/uploads/222030_pi.pdf)
[ Procedure Card - Merifluor Pneumocystis ](/uploads/222030_pc.pdf)
[ Reaction Card - Merifluor Pneumocystis ](/uploads/222030_rc.pdf)
[ Safety Data Sheet - Detection Antibody Merifluor Pneumocystis ](/uploads/2220_sds.pdf)
[ Safety Data Sheet - Mounting Medium Merifluor Pneumocystis ](/uploads/8002_sds.pdf)
[ Safety Data Sheet (OSHA) - Mounting Medium Merifluor Pneumocystis ](/uploads/8002_osha.pdf)
[ Safety Data Sheet (OSHA) - Detection Antibody Merifluor Pneumocystis ](/uploads/2220_osha.pdf)
[ Safety Data Sheet Merifluor Pneumocystis Kit ](/uploads/222030_kit_sds.pdf%20)
#### FAQs
Is culture confirmation required in negative samples?
Yes, the recommendation is that negative samples be followed up with culture or a more sensitive method like a molecular test.
What is the suggested CPT code?
Merifluor® Pneumocystis – 87281
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Anti-Coccidioides “TP” Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “TP” (early) antibodies.
Catalog Number: 103101
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Anti-Coccidioides "TP" Control Serum ](/uploads/1031_sds.pdf)
[ Safety Data Sheet (OSHA) -Anti-Coccidioides "TP" Control Serum ](/uploads/1031_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Coccidioides "TP" Antigen for Fungal Immunodiffusion](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Coccidioides “TP” Antigen for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “TP” (early) antibodies.
Catalog Number: 103001
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Coccidioides "TP" Antigen ](/uploads/1030_sds.pdf)
[ Safety Data Sheet (OSHA) -Coccidioides "TP" Antigen ](/uploads/1030_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
## Anti-Coccidioides “F” Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
Catalog Number: 100801
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Anti-Coccidioides "F" Control Serum ](/uploads/1008_sds.pdf)
[ Safety Data Sheet (OSHA) -Anti-Coccidioides "F" Control Serum ](/uploads/1008_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Histoplasma capsulatum* and *Coccidioides immitis*.
Catalog Number: 100601
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Anti-Histoplasma Control Serum ](/uploads/1006_sds.pdf)
[ Safety Data Sheet (OSHA) -Anti-Histoplasma Control Serum ](/uploads/1006_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Coccidioides “F” Antigen for Fungal Immunodiffusion (5 ml)
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
Catalog Number: 100405
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Coccidioides "F" Antigen ](/uploads/1004_sds.pdf)
[ Safety Data Sheet (OSHA) -Coccidioides "F" Antigen ](/uploads/1004_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Histoplasma Antigen for Fungal Immunodiffusion](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Histoplasma Antigen for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Histoplasma capsulatum* and *Coccidioides immitis.*
Catalog Number: 100201
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Histoplasma ID Antigen ](/uploads/1002_sds.pdf)
[ Safety Data Sheet (OSHA) - Histoplasma ID Antigen ](/uploads/1002_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Premier® EHEC](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Premier® EHEC
A microwell enzyme immunoassay for the detection of Shiga toxin 1 and 2 produced by *enterohemorrhagic E. coli* (EHEC) from stool specimens
Catalog Number: 608096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Premier® CAMPY
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Premier® EHEC ](/uploads/608096_ss.pdf)
[ Package Insert Premier® EHEC ](/uploads/608096_pi.pdf)
[ CLSI Premier® EHEC ](/uploads/608096_clsi.doc)
[ Procedure Card Premier® EHEC ](/uploads/608096_pc.pdf)
[ Safety Data Sheet - Detection Antibody Premier® EHEC ](/uploads/8603_sds.pdf)
[ Safety Data Sheet - Enzyme Conjugate Premier® EHEC ](/uploads/8604_sds.pdf)
[ Safety Data Sheet - Negative Control Premier® EHEC ](/uploads/1603_sds.pdf)
[ Safety Data Sheet - Positive Control Premier® EHEC ](/uploads/8601_sds.pdf)
[ Safety Data Sheet - Sample Diluent Premier® EHEC ](/uploads/8602_sds.pdf)
[ Safety Data Sheet - Stop Solution II Premier® EHEC ](/uploads/1601_sds.pdf)
[ Safety Data Sheet - Wash Buffer II Premier® ](/uploads/2607_sds.pdf)
[ Safety Data Sheet Premier Substrate II ](/uploads/3606_sds.pdf)
[ Safety Data Sheet - Wash Buffer II Premier (OSHA) ](/uploads/2607_osha.pdf)
#### FAQs
Does Premier EHEC only test for E. coli O157 strains?
No, this test detects Shiga toxin 1 and 2, even from non-O157 strains! Studies show an EIA for EHEC Shiga Toxin detects approximately 40% more EHEC O157-H7 than conventional culture, and it is also able to detect an additional 20% more Shiga-toxin producing E.coli that are non-O157-H7.
Why use a shiga toxin test for the non-O157 strains?
It is known that culture will miss ALL non-O157 strains. It is also known that the sensitivity for culture detecting the O-157 strains is low. The documented infection rate is about 50:50 for O157 strains vs. non-O157 strains. You should be testing for both!
References:
1. https://www.nphl.org/documents/ShigaToxinTestingRecommendations.pdf
2. CDC Recommendations and Reports MMWR October 16, 2009 / 58(RR12);1-14
3. Morbidity and Mortality Weekly Report. 2013;62(50):1029-1031
What is the suggested CPT Code?
Premier™ EHEC – 87427
Broth Enrichment – 87015
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Immunocard® C. difficile GDH](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Immunocard® C. difficile GDH
A rapid, sensitive enzyme immunoassay for the detection of *Clostridium difficile* antigen (GDH) in stool specimens.
Catalog Number: 716050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-h-pylori/)
Healthcare Acquired Infections
[ Immunocard® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
Respiratory
[ Immunocard® Mycoplasma ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Revogene® C. difficile
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
### Immunocard® Toxins A&B
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
### Alethia® C. difficile
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Immunocard C. difficile GDH ](/uploads/716050_pi.pdf)
[ CLSI Immunocard C. difficile GDH ](/uploads/716050_clsi.doc)
[ Procedure Card Immunocard C. difficile GDH ](/uploads/716050_pc.pdf)
[ Safety Data Sheet - Enzyme Conjugate Immunocard C. difficile GDH ](/uploads/7120_sds.pdf)
[ Safety Data Sheet - Positive Control Immunocard C. difficile GDH ](/uploads/7122_sds.pdf)
[ Safety Data Sheet - Positive Control (OSHA) Immunocard C. difficile GDH ](/uploads/7122_osha.pdf)
[ Safety Data Sheet - Sample Diluent Immunocard C. difficile GDH ](/uploads/7121_sds.pdf)
[ Safety Data Sheet ImmunoCard Wash Buffer I ](/uploads/7103_sds.pdf)
[ Safety Data Sheet ImmunoCard Substrate I ](/uploads/11372_sds.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard Substrate I ](/uploads/11372_osha.pdf)
[ Safety Data Sheet (OSHA) C. difficile GDH Enzyme Conjugate ](/uploads/7120_osha.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard C. difficile GDH Sample Diluent/Negative Control ](/uploads/7121_osha.pdf)
#### FAQs
What is the suggested CPT Code
Immunocard® *C. difficile* GDH – 87449
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [ImmunoCard STAT!® HpSA® (EU)](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
# ImmunoCard STAT!® HpSA® (EU)
A CLIA waived one-step lateral flow immunoassay for the direct detection of *Helicobacter pylori* antigens in stool specimens.
Catalog Number: 750720
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert ImmunoCard STAT!® HpSA® (EU) ](/uploads/750720_pi.pdf)
[ Procedure Card ImmunoCard STAT!® HpSA® (EU) ](/uploads/750720_pc.pdf)
[ Positive Control SDS ImmunoCard STAT!® HpSA® (EU) ](/uploads/750720_positive_control_sds.pdf)
[ Sample Diluent SDS ImmunoCard STAT!® HpSA® (EU) ](/uploads/750720_sample_diluent_sds.pdf)
#### FAQs
What causes ulcers?
Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that 9 out of 10 ulcers are caused by H.pylori. Medicines that reduce stomach acid may make you feel better, but your symptoms may come back. Here’s the good news – since most ulcers are caused by this bacterial infection, it can be cured with the right antibiotics.
How can your health care provider tell if you have H. pylori?
There are 3 types of recommended tests:
- Stool Test: Provide a small stool specimen (an easy-to-use collection system can be provided for this purpose). The doctor will conduct the test in his office or send it to a laboratory. HpSA is the #1 stool antigen test in the USA.
- Breath Test: In this test, you have to fast then a breath sample is taken after you wait and drink a 13C-labeled urea mix. The breath sample collected is then analyzed in the office or sent out to a laboratory.
- Endoscopy: This is a test in which a small tube with a camera inside is inserted through the mouth an into the stomach to look for ulcers. During The endoscopy, small samples of the stomach lining can be obtained and tested for H. pylori.
What is the recommended testing algorithm for Helicobacter pylori?
Please refer to our H. pylori Learning Center website to view the AGA/ACG Guideline flowchart at [www.hpylorilearningcenter.com/Testing](https://www.hpylorilearningcenter.com/Testing/#agaacg-chart-caption)
How do I know therapy is working or the patient is cured?
Test it. Treat it. Test it again – all with one easy stool test. The HpSA test is the only CLIA-waived FDA cleared 3-in-1 test able to diagnose H. pylori, monitor if therapy is working and test for eradication.
Can stools in Cary Blair be used for HpSA testing?
No, only fresh or frozen stool samples. The product is not validated for the use of samples in Cary Blair. The 1:4 dilution of Cary Blair increases the Limit of Detection and could cause false negative results.
References:
1. https://www.nphl.org/documents/ShigaToxinTestingRecommendations.pdf
2. CDC Recommendations and Reports MMWR October 16, 2009 / 58(RR12);1-14
3. Morbidity and Mortality Weekly Report. 2013;62(50):1029-1031
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Immunocard STAT!® HpSA®](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® HpSA®
A CLIA waived one-step lateral flow immunoassay for the direct detection of *Helicobacter pylori* antigens in stool specimens.
Catalog Number: 750220
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT! HpSA ](/uploads/750220_ss.pdf.pdf)
[ Package Insert Immunocard STAT! HpSA ](/uploads/750220_pi.pdf)
[ Procedure Card Immunocard STAT! HpSA ](/uploads/750220_pc.pdf)
[ CLSI Immunocard STAT! HpSA ](/uploads/750220_clsi%20(1).doc)
[ Safety Data Sheet - Kit Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_kit_sds.pdf)
[ Safety Data Sheet - Sample Diluent (OSHA) Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_sample_diluent_osha.pdf)
[ Safety Data Sheet - Positive Control Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_positive_control_sds.pdf)
[ Safety Data Sheet - Positive Control (OSHA) ImmunoCard STAT! HpSA HD ](/uploads/750005_750020_750220_positive_control_osha.pdf)
[ Safety Data Sheet - Sample Diluent ImmunoCard STAT! HpSA HD ](/uploads/750005_750020_750220_sample_diluent_sds.pdf)
#### Webinars & Videos
- [Today’s Trend in H. pylori Testing and Treatment](https://vimeo.com/165932421)
- [H. pylori Active Infection Testing vs. Passive](https://vimeo.com/35531028)
#### FAQs
What causes ulcers?
*Helicobacter pylori* (*H. pylori*) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that 9 out of 10 ulcers are caused by *H. pylori*. Medicines that reduce stomach acid may make you feel better, but your symptoms may come back. Here’s the good news – since most ulcers are caused by this bacterial infection, it can be cured with the right antibiotics.
How can your health care provider tell if you have *H. pylori*?
There are 3 types of recommended tests:
- Stool Test: Provide a small stool specimen (an easy-to-use collection system can be provided for this purpose). The doctor will conduct the test in his office or send it to a laboratory. HpSA is the #1 stool antigen test in the USA.
- Breath Test: In this test, you have to fast then a breath sample is taken after you wait and drink a 13C-labeled urea mix. The breath sample collected is then analyzed in the office or sent out to a laboratory.
- Endoscopy: This is a test in which a small tube with a camera inside is inserted through the mouth and into the stomach to look for ulcers. During The endoscopy, small samples of the stomach lining can be obtained and tested for *H. pylori*.
What is the recommended testing algorithm for *Helicobacter pylori*?
Visit the [*H. pylori* resource center]() to learn more about guideline recommended testing.
How do I know therapy is working or the patient is cured?
Test it. Treat it. Test it again – all with one easy stool test. The HpSA test is the only CLIA-waived FDA cleared 3-in-1 test able to diagnose H. pylori, monitor if therapy is working and test for eradication.
Can stools in Cary Blair be used for HpSA testing?
No, only fresh or frozen stool samples. The product is not validated for the use of samples in Cary Blair. The 1:4 dilution of Cary Blair increases the Limit of Detection and could cause false negative results.
What is the suggested CPT Code?
Immunocard STAT!® HpSA® – 87338
References:
1. https://www.nphl.org/documents/ShigaToxinTestingRecommendations.pdf
2. CDC Recommendations and Reports MMWR October 16, 2009 / 58(RR12);1-14
3. Morbidity and Mortality Weekly Report. 2013;62(50):1029-1031
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Direct Detect® Stool Transport
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
[  ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### BreathID® Smart – IDkit Hp® Two
Your country: US
Mode: Include
Countries: 2
US CA
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Strep Pneumo](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
###### Respiratory - Respiratory
# Strep Pneumo
[](/diagnostics/disease-areas/respiratory/strep-pneumo/operon-lateral-flow-reader/)#### Simple Strep pneumo-Legio
###### Operon Lateral Flow Reader
The Operon Lateral Flow Reader allows objective reading and interpretation of the results obtained with Operon Simple rapid tests.
[Learn more](#)
[](/diagnostics/disease-areas/respiratory/strep-pneumo/positive-control-strep-pneumo-legio/)#### Simple Strep pneumo-Legio
###### Positive Control Strep pneumo-Legio
Operon Positive Control Strep pneumo-Legio is an external liquid control reagent to be used with Operon Simple Strep pneumo-Legio as part of a routine quality control program.
[Learn more](#)
[](/diagnostics/disease-areas/respiratory/strep-pneumo/simple-strep-pneumo-legio/)#### Simple Strep pneumo-Legio
###### Simple Strep pneumo-Legio
Operon Simple Strep pneumo-Legioa one-step is an immunochromatographic qualitative test for the detection of Streptococcus pneumoniae and Legionella pneumophila serogroup 1 antigens in human urine.
[Learn more](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [TRU Strep Pneumo™](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/tru-strep-pneumo/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# TRU Strep Pneumo™
A Rapid Immunoassay for the Detection of *Streptococcus pneumoniae* in Human Urine and Cerebrospinal Fluid Specimens.
Catalog Number: 752330
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Respiratory
[ RSV Positive Control ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/)
[ TRU Legionella® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/tru-legionella/)
[ TRU RSV® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/tru-rsv/)
## Support & Documents
#### Downloadable PDFs
[ Tru Strep Pneumo Product Brochure ](/uploads/MBI_TRU_Legionella_StrepPneumo_SS_EU_2020-08_v6.pdf)
[ Procedure Card TRU Strep Pneumo ](/uploads/752330_pc.pdf)
[ Safety Data Sheet Conjugate Bead ](/uploads/7980_SDS.pdf)
[ Safety Data Sheet Sample Diluent ](/uploads/7979_SDS.pdf)
[ Safety Data Sheet Positive Control ](/uploads/7982_sds.pdf)
[ Safety Data Sheet Premier Substrate ](/uploads/Elenco-Centri-Antiveleno-CAV_rev.0923.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Monospot® Latex](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/monospot-latex/)
**Published:** March 15, 2019
**Author:** hamza
**Content:**
# Monospot® Latex
Latex agglutination test for the rapid detection of infectious mononucleosis in serum or plasma samples
Catalog Number: 776150
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ CALAS® Pronase ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/calas-pronase/)
[ Cryptococcal Antigen Latex Agglutination System (CALAS®) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/cryptococcal-antigen-latex-agglutination-system/)
Pediatric & Neonatal
## Support & Documents
#### Downloadable PDFs
[ Package Insert Monospot Latex ](/uploads/776150_pi.pdf)
[ Procedure Card Monospot Latex ](/uploads/776150_pc.pdf)
[ CLSI Monospot Latex ](/uploads/776150_clsi%20(1).doc)
[ Safety Data Sheet - Detection Latex Monospot Latex ](/uploads/20140_sds.pdf)
[ Safety Data Sheet - Negative Control Monospot Latex ](/uploads/20141_sds.pdf)
[ Safety Data Sheet - Positive Control Monospot Latex ](/uploads/20142_sds.pdf)
#### FAQs
What is the suggested CPT Code
MONOSPOT® Latex – 86403
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Pediatric & Neonatal
---
### [Immunocard STAT!® Mono](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
## Immunocard STAT!® Mono
A CLIA waived one-step dipstick lateral flow immunoassay for the detection of infectious mononucleosis from serum, plasma, or whole blood specimens.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 755725
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert/Procedure Card Immunocard STAT! Mono ](/uploads/755725_pc.pdf)
[ CLSI Immunocard STAT! Mono ](/uploads/755725_clsi%20(1).doc)
[ Safety Data Sheet - Diluent Immunocard STAT! Mono ](/uploads/755725_diluent_sds.pdf)
[ Safety Data Sheet - Negative Control Immunocard STAT! Mono ](/uploads/755725_negative_control_sds.pdf)
[ Safety Data Sheet - Positive Control Immunocard STAT! Mono ](/uploads/755725_positive_control_sds.pdf)
#### FAQs
What is the suggested CPT Code
Immunocard STAT!® MONO – 86308
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Pediatric & Neonatal
---
### [Premier® Cryptococcal Antigen](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Premier® Cryptococcal Antigen
An enzyme immunoassay for the detection of Cryptococcal Antigen in serum and cerebrospinal fluid (CSF).
Catalog Number: 602096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Premier Cryptococcal Antigen ](/uploads/602096_pi.pdf)
[ CLSI - Premier Cryptococcal Antigen ](/uploads/602096_clsi%20(1).doc)
[ Procedure Card - Premier Cryptococcal Antigen ](/uploads/602096_pc.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/2602_sds.pdf)
[ Safety Data Sheet - Enzyme Conjugate ](/uploads/2604_sds.pdf)
[ Safety Data Sheet - Wash Buffer II Premier® ](/uploads/2607_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/2609_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet - Wash Buffer II Premier (OSHA) ](/uploads/2607_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [CALAS® Pronase](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/calas-pronase/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# CALAS® Pronase
Pre-treatment reagent to reduce non-specific interference with Cryptococcal Antigen Latex test.
Catalog Number: 140050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Cryptococcal Antigen Latex Agglutination System (CALAS®) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/cryptococcal-antigen-latex-agglutination-system/)
Pediatric & Neonatal
[ Monospot® Latex ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/monospot-latex/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert CALAS ](/uploads/140100_140050_pi.pdf)
[ Safety Data Sheet - Pronase Reagent ](/uploads/1408_sds.pdf)
[ Safety Data Sheet - Pronase Reagent (OSHA) ](/uploads/1408_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Coccidioides “F” Antigen for Fungal Immunodiffusion (1 ml)
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
Catalog Number: 100401
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Coccidioides "F" Antigen ](/uploads/1004_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Immunocard STAT!® Rota-Adeno-Noro2](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
## Immunocard STAT!® Rota-Adeno-Noro2
An immunoassay for the qualitative detection, in separate bands, of Rotavirus, Adenovirus and Norovirus genogroup I (GI) and genogroup II (GII) antigens in human stool.
Catalog Number: 750320
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - ImmunoCard STAT! Rota-Adeno-Noro2 ](/uploads/750320_pi.pdf)
[ Package Insert (CZ) - ImmunoCard STAT! Rota-Adeno-Noro2 ](/uploads/750320_pi_CZ.pdf)
[ Procedure Card - ImmunoCard STAT! Rota-Adeno-Noro2 ](/uploads/750320_pc.pdf)
[ Safety Data Sheet - ImmunoCard STAT! Rota-Adeno-Noro2 Sample Diluent ](/uploads/750320_sds.pdf)
[ Buckslip - ImmunoCard STAT! Rota-Adeno-Noro2 ](/uploads/750320_buckslip.pdf)
#### FAQs
What is the suggested CPT Code
CPT 87425 — Infectious agent antigen detection by immunoassay with direct optical observation; rotavirus
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Revogene® Carba C](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
**Published:** July 2, 2019
**Author:** hamza
**Content:**
## Revogene® Carba C
The Revogene Carba C assay provides healthcare systems with a diagnostic solution to enable early detection and management of Carbapenem-Resistant *Enterobacterales* (CRE) from isolated colonies of *Enterobacteriaceae, Acinetobacter baumannii,* or *Pseudomonas aeruginosa*.
Catalog Number: 410500
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Document ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Revogene Carba C?
Carbapenem-Resistant *Enterobacterales* (CRE) infections are hazardous to our patients and alarming for healthcare systems. The CDC has deemed CRE an urgent public health threat that requires immediate and aggressive action. 1
Early identification and isolation of colonized or infected patients is key to limiting the spread of these organisms in healthcare settings and to help in better guidance of treatment.
1\. https://www.cdc.gov/drugresistance/biggest\_threats.html
- sample\_result\_icon
Efficient workflow – Sample to result in 3 easy steps
- assay\_flexibility\_icon
Detects and differentiates the 5 known gene sequences (PC, NDM, VIM, OXA-48-like, IMP) associated with carbapene resistance.
- expansion\_icon
Platform for growth – Single analyte and multiplex testing capability
- tech\_icon2
Helps respond quickly to the threat of carbapenemase-producing organisms by providing results in 70 min.
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
[  ](https://www.youtube.com/watch?v=4ZeGeBdVkeU)
Early detection is key for CRE infection prevention and control. The CDC recommends “detecting and protecting” through early identification of CRE carriers, followed by prevention of transmission through implementation of infection control precautions.
CDC recommends “detecting and protecting”
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Revogene Carba C ](/uploads/410500_pi.pdf)
[ CLSI - Revogene Carba C ](/uploads/410500_clsi.doc)
[ Safety Data Sheet - Revogene Carba C (kit) ](/uploads/410500_kit_sds.pdf)
[ Safety Data Sheet - Revogene Carba C ](/uploads/410500_sds.pdf)
[ Safety Data Sheet - Revogene Carba C (OSHA) ](/uploads/410500_osha.pdf)
[ Safety Data Sheet - Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene Sample Buffer ](/uploads/4101_4102_4103_4104_4105_6102_osha.pdf)
[ Procedure Card - EN Revogene Carba C ](/uploads/410500_pc.pdf)
[ Procedure Card DE Revogene Carba C ](/uploads/410500_pc_de.pdf)
[ Procedure Card ES Revogene Carba C ](/uploads/410500_pc_es.pdf)
[ Procedure Card FR Revogene Carba C ](/uploads/410500_pc_fr.pdf)
[ Procedure Card IT Revogene Carba C ](/uploads/410500_pc_it.pdf)
[ Procedure Card NL Revogene Carba C ](/uploads/410500_pc_nl.pdf)
[ Package Insert - Revogene Mock Pie ](/uploads/610208_pi.pdf)
## FAQs
What is the suggested CPT Code?
Revogene Carba C – 87150 x 5
##### References
1\. https://www.cdc.gov/drugresistance/biggest\_threats.html
2\. https://www.cdc.gov/hai/organisms/cre/index.html
3\. https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html
4\. Neuner, E. & Gallagher J., 2017. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 8(4):440-452.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Healthcare Acquired Infections
---
### [Alethia® Chlamydia](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
## Alethia® Chlamydia
Molecular assay for the detection of *Chlamydia trachomatis*. Alethia provides a quick, accurate and reliable molecular assay for *Chlamydia trachomatis* detection.
Catalog Number: 480450
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia® Chlamydia ](/uploads/480450_pi.pdf)
[ Procedure Card - Swab ](/uploads/480450_480850_swab_pc.pdf)
[ Safety Data Sheet Alethia Chlamydia Kit ](/uploads/480450_kit_sds.pdf)
[ Safety Data Sheet - Assay Control ](/uploads/4823_sds.pdf)
[ Safety Data Sheet - Assay Control (OSHA) ](/uploads/4823_osha.pdf)
[ Safety Data Sheet - Mineral Oil Alethia Pertussis ](/uploads/14298_sds.pdf)
[ Safety Data Sheet - Mineral Oil (OSHA) Alethia Pertussis ](/uploads/14298_osha.pdf)
[ Safety Data Sheet - Test Bead ](/uploads/2810_test_bead_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) ](/uploads/2810_test_bead_osha.pdf)
[ Safety Data Sheet - Control Bead Alethia ](/uploads/2830_2810_2790_2865_2870_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia ](/uploads/2830_2810_2790_2865_2870_osha.pdf)
[ Procedure Card - Alethia Chlamydia ](/uploads/480450_480850_pc.pdf)
[ Safety Data Sheet Alethia Chlamydia Kit ](/uploads/480450_kit_sds.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Sexual Health
---
### [Premier® Coccidioides](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Premier® Coccidioides
An enzyme immunoassay that detects IgM and IgG antibodies directed at the TP and CG antigens of *Coccidioides immitis* in serum and cerebrospinal fluid (CSF).
Catalog Number: 603096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Premier Coccidioides ](/uploads/603096_pi.pdf)
[ Procedure Card Premier Coccidioides ](/uploads/603096_pc.pdf)
[ CLSI - Premier Coccidioides ](/uploads/603096_clsi%20(1).doc)
[ Safety Data Sheet - Enzyme Conjugate IgG ](/uploads/3604_sds.pdf)
[ Safety Data Sheet - Enzyme Conjugate IgM ](/uploads/3603_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/3602_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/3609_sds.pdf)
[ Safety Data Sheet - Wash Buffer II Premier® ](/uploads/2607_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet Wash Buffer II Premer (OSHA) ](/uploads/2607_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [BreathID® Smart - IDkit Hp® Two](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
**Published:** April 30, 2020
**Author:** hamza
**Content:**
# BreathID® Smart – IDkit Hp® Two
A non-invasive urea breath test for the detection of *H. pylori* and confirmation of eradication.
Catalog Number: AC00063
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Kit Components
- Blue BASELINE breath bag
- Gray POST-INGESTION breath bag
- 75mg 13C-urea tablet
- 4.3g package of Citrica (citric acid)
- Straw
- Drinking Cup
- User Guide
- 4 labels
- Sample transport bag
- Package Insert
## Support & Documents
#### Downloadable PDFs
[ Product Brochure IDkit Hp Two ](/uploads/MBI_IDKit_Hp_Two_SS_2020-05.pdf)
[ Package Insert IDkit Hp Two ](/uploads/ac00063_pi.pdf)
[ Package Insert - ES IDkit Hp Two ](/uploads/ac00063_pi_es.pdf)
[ Quick Guide IDkit Hp Two ](/uploads/ac00063_pc.pdf)
[ Guía rápida Prueba De Aliento Para Detectar H. pylori ](/uploads/mbi_breathid_idkit-two-quick-guide_es_2020-08.pdf)
[ Safety Data Sheet (SDS) IDkit Hp ](/uploads/50402-100_sds.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Pregnancy](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# Pregnancy
[](/diagnostics/disease-areas/other/pregnancy-2/osom-hcg-combo-test)#### Immunocard
STAT!®
###### OSOM hCG Combo Test
The OSOM® hCG Combo Test is a rapid immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine or serum as an aid in the early determination of pregnancy. This test is for professional use in physicians’ offices and clinical laboratories.
[Learn More](#)
[](/diagnostics/disease-areas/other/pregnancy-2/immunocard-stat-hcg)#### Immunocard
STAT!®
###### Immunocard STAT!® hCG
A CLIA waived one step lateral flow Immunoassay for the direct detection of human chorionic gonadotropin (hCG) in urine and serum samples.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [Immunocard STAT!® hCG](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# OSOM hCG Combo Test
The OSOM® hCG Combo Test is a rapid immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine or serum as an aid in the early determination of pregnancy. This test is for professional use in physicians’ offices and clinical laboratories.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 124
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert OSOM hCG Combo Test ](/uploads/124_Package-Insert.pdf)
#### FAQs
What is the suggested CPT Code
Serum – 84703
Urine – 81025
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Sexual Health
---
### [OSOM hCG Combo Test](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# OSOM hCG Combo Test
The OSOM® hCG Combo Test is a rapid immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine or serum as an aid in the early determination of pregnancy. This test is for professional use in physicians’ offices and clinical laboratories.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 124
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert OSOM hCG Combo Test ](/uploads/124_Package-Insert.pdf)
#### FAQs
What is the suggested CPT Code
Serum – 84703
Urine – 81025
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Sexual Health
---
### [Rapid Strip Rota/Adeno](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/rapid_strip-rota_adeno/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
## Rapid Strip Rota/Adeno
The Rapid Strip ROTA/ADENO is a rapid and simple in vitro qualitative test for the detection of Rotavirus and Adenovirus antigens in feces.
Catalog Number: 751120
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
Sexual Health
[ OraQuick® HCV Rapid Antibody Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hcv/oraquick-hcv-rapid-antibody-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Rapid Strip ROTA/ADENO ](/uploads/751120_pi.pdf)
[ 751120\_SDS ](/uploads/751120_SDS.pdf)
[ Buckslip Rapid Strip ROTA/ADENO ](/uploads/751120_buckslip.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [LIAISON® Meridian H. pylori SA](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/liaison_meridian_h-pylori-sa/)
**Published:** March 15, 2019
**Author:** hamza
**Content:**
## LIAISON® Meridian *H. pylori* SA
A chemiluminescent assay for the qualitative determination of *Helicobacter pylori* antigen in human stool.
Test must be performed on the LIAISON® XL analyzer.
Catalog Number: 318200
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Gastrointestinal
## Support & Documents
#### [For supporting documents, including SDS and Package Insert (IFU), please click here to visit DiaSorin Assay Info](https://assayinfo.diasorin.com/login)
#### Downloadable PDFs
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [SAS™ Adeno Test](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/sas-adeno-test/)
**Published:** March 18, 2019
**Author:** hamza
**Content:**
## SAS™ Adeno Test
The SAS™ Adeno Immunoassay is a rapid and simple qualitative test for the reliable detection of adenovirus antigens in human specimens.
Catalog Number: 067020
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
## Support & Documents
#### Downloadable PDFs
[ Safety Data Sheet ](/uploads/067020_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Positive Control Strep pneumo-Legio](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/positive-control-strep-pneumo-legio/)
**Published:** November 10, 2025
**Author:** hamza
**Content:**
# Positive Control Strep pneumo-Legio
Operon Positive Control Strep pneumo-Legio is an external liquid control reagent to be used with Operon Simple Strep pneumo-Legio as part of a routine quality control program.
Catalog Number: 9.108.001.37.000
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ Operon Lateral Flow Reader ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/operon-lateral-flow-reader/)
[ Simple Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/simple-strep-pneumo-legio/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Operon Simple Strep pneumo-Legio ](/uploads/MBI_Simple-Strep-pneumo-Legio_Operon_SS_2025-07.pdf)
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [MSwab® for Meridian Bioscience Europe](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
**Published:** March 15, 2019
**Author:** hamza
**Content:**
## MSwab® for Meridian Bioscience Europe
The MSwab collection kit is used to collect, transport and preserve clinical specimens from the collection site to the testing laboratory.
Catalog Number: 6E028N.MER
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert ](/uploads/6e028nmer_pi.pdf)
[ Safety Data Sheet ](/uploads/6u019n_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Operon Lateral Flow Reader](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/operon-lateral-flow-reader/)
**Published:** November 10, 2025
**Author:** hamza
**Content:**
# Operon Lateral Flow Reader
The Operon Lateral Flow Reader allows objective reading and interpretation of the results obtained with Operon Simple rapid tests.
Catalog Number: 9.901.001.90.000
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ Positive Control Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/positive-control-strep-pneumo-legio/)
[ Simple Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/simple-strep-pneumo-legio/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Operon Simple Strep pneumo-Legio ](/uploads/MBI_Simple-Strep-pneumo-Legio_Operon_SS_2025-07.pdf)
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Analytical Services](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
**Published:** March 30, 2019
**Author:** hamza
**Content:**
## Analytical Services
A simple solution for any lab – whether you run blood lead testing with GFAAS or send samples out to a reference laboratory.
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Rapid, reliable and confidential results for industrial clients
We are dedicated to the highest levels of personal service, accurate results, and reliable turnaround times. Let us provide you with details and pricing.
- Group 12 Created with Sketch.
Over 40 years of industrial hygiene accreditation by the AIHA-LAP, LLC
- Group 19 Created with Sketch.
CLIA-certified laboratory (CLIA ID #22D0650073)
- Group 13 Created with Sketch.
OSHA approved through the Pennsylvania DOH blood lead survey program
- Group 19 Created with Sketch.
Participant in the WSLH blood lead proficiency testing program
## Related Tests
Pediatric & Neonatal
[ LeadCare Plus® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)
[ LeadCare Ultra® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)
[ LeadCare® II ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [Fungals](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Other - Other
# Fungals
[](/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series)#### immunodiffusion
###### Fungal Immunodiffusion Plates, 1
Series
Immunodiffusion Plate for the detection of circulating antibody to common systemic pathogens.
[Learn More](#)
[](/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series)#### immunodiffusion
###### Fungal Immunodiffusion Plates, 4 Series
Immunodiffusion Plate for the detection of circulating antibody to common systemic pathogens.
[Learn More](#)
[](/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion)#### immunodiffusion
###### Histoplasma Antigen
for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Histoplasma capsulatum* and *Coccidioides immitis.*
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401)#### immunodiffusion
###### Coccidioides "F" Antigen for Fungal
Immunodiffusion (1 ml)
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion)#### immunodiffusion
###### Coccidioides "TP" Antigen for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “TP” (early) antibodies.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)#### immunodiffusion
###### Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “TP” (early) antibodies.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion)#### immunodiffusion
###### Anti-Coccidioides "F" Control Serum
(Goat or Human or Rabbit) for
Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405)#### immunodiffusion
###### Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml)
Purified preparation for the determination of precipitating antibodies to *Coccidioides immitis*. Reagents for detection of “F” (late) antibodies.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion)#### immunodiffusion
###### Anti-Histoplasma Control Serum
(Goat) for Fungal Immunodiffusion
Purified preparation for the determination of precipitating antibodies to *Histoplasma capsulatum* and *Coccidioides immitis*.
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen)#### premier®
###### Premier!® Cryptococcal Antigen
An enzyme immunoassay for the detection of Cryptococcal Antigen in serum and cerebrospinal fluid (CSF).
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/premier-coccidioides)#### premier
###### Premier® Coccidioides
An enzyme immunoassay that detects IgM and IgG antibodies directed at the TP and CG antigens of *Coccidioides immitis* in serum and cerebrospinal fluid (CSF).
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/cryptococcal-antigen-latex-agglutination-system)#### Latex Agglutination
###### Cryptococcal Antigen Latex
Agglutination System (CALAS®)
Latex agglutination test for the detection of *Cryptococcus neoformans* antigen in serum or CSF
[Learn More ](#)
[](/diagnostics/disease-areas/other/fungals/calas-pronase)#### Latex Agglutination
###### CALAS® Pronase
Pre-treatment reagent to reduce non-specific interference with Cryptococcal Antigen Latex test.
[Learn More ](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Other
---
### [TRU RSV®](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/tru-rsv/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# TRU RSV®
A rapid immunoassay for the detection of respiratory syncytial virus (RSV) antigens in nasal wash. NP aspirate, NP swab and nasal swab samples.
Catalog Number: 751330
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#Support%20and%20Documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Respiratory
[ RSV Positive Control ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/)
[ TRU Legionella® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/tru-legionella/)
[ TRU Strep Pneumo™ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/tru-strep-pneumo/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure TRU RSV ](/uploads/751330_ss.pdf)
[ Package Insert TRU RSV ](/uploads/751330_pi.pdf)
[ Procedure Card TRU RSV ](/uploads/751330_pc.pdf)
[ Safety Data Sheet - Conjugate Bead TRU RSV ](/uploads/7921_sds.pdf)
[ Safety Data Sheet – Conjugate Bead OSHA TRU RSV ](/uploads/7921_osha.pdf)
[ Safety Data Sheet - Sample Diluent TRU RSV ](/uploads//7910_sds.pdf)
[ Safety Data Sheet – Sample Diluent OSHA TRU RSV ](/uploads/7910_osha.pdf)
[ Safety Data Sheet TRU RSV Kit ](/uploads/751330_kit_sds.pdf)
[ CLSI TRU RSV ](/uploads/751330_clsi.doc)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Respiratory Syncytial Virus (RSV)](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Respiratory - Respiratory
# Respiratory Syncytial Virus (RSV)
[](/diagnostics/disease-areas/respiratory/rsv/tru-rsv/)#### Tru®
###### TRU RSV ®
A rapid immunoassay for the detection of respiratory syncytial virus (RSV) antigens in nasal wash, NP aspirate, NP swab and nasal swab samples.
[Learn More](#)
[](/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/)#### Tru®
###### RSV Positive Control
An external liquid control reagent to be used with TRU RSV® as part of a routine quality control program
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [Simple Strep pneumo-Legio](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/simple-strep-pneumo-legio/)
**Published:** November 10, 2025
**Author:** hamza
**Content:**
# Simple Strep pneumo-Legio
Operon Simple Strep pneumo-Legioa one-step is an immunochromatographic qualitative test for the detection of Streptococcus pneumoniae and Legionella pneumophila serogroup 1 antigens in human urine.
Catalog Number: 9.108.020.46.000
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ Operon Lateral Flow Reader ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/operon-lateral-flow-reader/)
[ Positive Control Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/positive-control-strep-pneumo-legio/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Operon Simple Strep pneumo-Legio ](/uploads/MBI_Simple-Strep-pneumo-Legio_Operon_SS_2025-07.pdf)
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Flu](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/)
**Published:** February 23, 2019
**Author:** hamza
**Content:**
# Influenza A & B Testing
### Flu Testing and Early Detection: Protecting Your Health
Flu, or influenza, is a contagious respiratory illness caused by influenza viruses, and early flu testing is essential to ensure timely treatment and prevent the spread of the disease. There are several diagnostic tools available for accurate flu detection, which can quickly confirm the presence of influenza in patients.
## Influenza Testing and Early Detection: Protecting Your Health
Influenza (Flu) is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and lungs. There are two main types of influenza, Type A and Type B, both responsible for the seasonal flu epidemics each year. Early flu testing is essential to ensure timely treatment and prevent the spread of the disease. Several diagnostic tools are available for accurate flu detection, including the highly sensitive Immunocard Flu A&B test, which quickly confirms the presence of influenza in patients, allowing for prompt and effective treatment.
CDC estimates that between 9.3 million – 41 million people are affected by the flu in US each year. 1
On average, there are 405 million hospitalizations and 28 million deaths annually due to Influenza. 1
Children younger than 18 years old are 2X more likely to get the flu than adults older than 65 years old. 2
## Testing Solutions for Influenza Detection
**Immunocard STAT! Flu A&B** directly impacts patient care by providing healthcare systems an opportunity to detect influenza A and B quickly and accurately from a nasal swab. Fast actionable results enable physicians to make informed decisions about patient management and treatment.
[](/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)#### Immunocard STAT!® Flu A&B
A CLIA waived lateral flow immunoassay for the detection of Flu A & B from nasal & NP swab. Can also be used to test nasal aspirate/wash specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)#### Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit
Accessory kit for the Immunocard STAT!® Flu A&B kit to use with nasopharyngeal aspirates/washes specimens [Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)#### StatID PRO™ COVID-19/Flu A&B
The StatID PRO COVID-19/Flu A&B is a lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of influenza A, and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Education Resources About Influenza Testing
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
Immunocard STAT! Flu A&BProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21105149/IC-STAT-FLU-Sales-Brochure-1-1.pdf) [ 
Respiratory FamilyProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102229/Respiratory-Family-Product-Brochure.pdf)
#### Frequently Asked Questions About Flu A&B Testing
What is Influenza A & B?
Influenza (Flu) is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and lungs. The most common strains are Flu A and Flu B. Flu A viruses are associated with causing a Flu pandemic.3
Is Influenza A & B treatable?
Yes, you can be treated with anti-viral medication, but the treatment works best if given within two days after Flu symptoms begin.4
Why is testing for Flu important?
Certain groups of people are at a higher risk of developing Flu complications. These groups include children younger than 5 years, adults 65 or older, pregnant women, and people with certain chronic health conditions.5
### References:
1.
2. [https://www.cdc.gov/flu/about/keyfacts.htm](https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu/about/keyfacts.htm)
3.
4.
5.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [Coronavirus (COVID-19)](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/)
**Published:** August 21, 2020
**Author:** hamza
**Content:**
###### Respiratory - Respiratory
# Coronavirus (COVID-19)
[](/diagnostics/disease-areas/statid-pro-covid-19-flu-ab/)#### statID PRO
###### StatID PRO™ COVID-19/Flu A&B
The StatID PRO COVID-19/Flu A&B is a lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of influenza A, and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection.
[Learn More](#)
[](https://www.meridianbioscience.com//diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-ag-test-2-0/)#### Standard™ Q
COVID-19 Ag Test 2.0
###### Standard™ Q COVID-19 Ag Test 2.0
Standard™ Q COVID-19 Ag Test 2.0 is a rapid test for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swabs from individuals suspected of being infected with SARS-CoV-2 by their healthcare provider within the first 6 days of onset of symptoms or from individuals without symptoms or for serial screening. Emergency Use Authorization (EUA) approved.
[Learn More](#)
[](https://www.meridianbioscience.com//diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)#### revogene
###### Revogene® SARS-CoV-2
A real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) qualitative test run on the Revogene® instrument for the detection of SARS-CoV-2 nucleic acid from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens.
[Learn More](#)
Revogene SARS-CoV-2 assay – This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Standard™ Q COVID-19 Ag Test 2.0 Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-controls/)
**Published:** November 12, 2024
**Author:** hamza
**Content:**
# Standard™ Q COVID-19 Ag Test 2.0 Controls
Catalog Number: 10COVC14J
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Support & Documents
#### Downloadable PDFs
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics)
## Related Tests
Respiratory
[ Standard™ Q COVID-19 Ag Test 2.0 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-ag-test-2-0/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Standard™ Q COVID-19 Ag Test 2.0](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-ag-test-2-0/)
**Published:** June 1, 2024
**Author:** hamza
**Content:**
# Standard™ Q COVID-19 Ag Test 2.0
Standard™ Q COVID-19 Ag Test 2.0 is a rapid test for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swabs from individuals suspected of being infected with SARS-CoV-2 by their healthcare provider within the first 6 days of onset of symptoms or from individuals without symptoms or for serial screening. Emergency Use Authorization (EUA) approved.
Catalog Number: 09COV174D
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigens, which is generally detectable in anterior nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of disease. All negative results are presumptive and may be confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be considered in the context of an patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19. Testing of anterior nasal swab specimens is limited to laboratories certified under CLIA that meet the requirements to perform moderate, high, or waived complexity tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
## Why Standard™ Q COVID-19 Ag Test 2.0?
Standard Q COVID-19 Ag Test 2.0 offers detection of active infection caused by SARS-CoV-2 in 20 minutes.
- Provides direct detection of SARS-CoV-2 antigens from nasal swabs
- A qualitative immunoassay that offers reliable results in as little as 20 min
- Standard Q COVID-19 Ag Test 2.0 allows for near patient testing without the need of instrumentation or special equipment
## Ready to get a handle on COVID-19 testing? Let’s talk.
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Respiratory
[ Standard™ Q COVID-19 Ag Test 2.0 Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-controls/)
## Related Products
### StatID PRO™ COVID-19/Flu A&B
Your country: US
Mode: Include
Countries: 1
US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Standard Q COVID-19 Ag Test 2.0 ](/uploads/Standard-Q-COVID-19-Ag-Test-2.0-Product-Brochure.pdf)
[ Package Insert Standard Q COVID-19 Ag Test 2.0 ](/uploads/09cov174d_pi.pdf)
[ Safety Data Sheet Standard Q COVID-19 Ag Test 2.0 ](/uploads/09cov174d_sds.pdf)
[ Fact Sheet for Healthcare Providers Standard Q COVID-19 Ag Test 2.0 ](/uploads/09cov174d_hcp.pdf)
[ Fact Sheet for Patients Standard Q COVID-19 Ag Test 2.0 ](/uploads/09cov174d_patient.pdf)
FAQs
What sample types can be used?
Nasal Swab sample type can be used with Standard Q COVID-19 Ag Test 2.0
Can samples in transport media be used?
It is not recommended to use transport media with nasal swabs.
Does the Standard Q COVID-19 Ag Test 2.0 kit include External Controls?
Yes, the Standard Q COVID-19 Ag Test 2.0 kit includes 1 positive and 1 negative control swab.
What is the suggested CPT code?
It is suggested to use CPT 87811, and for the CLIA waiver, add a QW designator.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Premier® Platinum HpSA® PLUS](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Premier® Platinum HpSA® PLUS
A streamlined, highly sensitive enzyme immunoassay for the detection of *H. pylori* antigens in fresh (unpreserved) stool specimens.
Catalog Number: 601396
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### Direct Detect® Stool Transport
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
[  ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
### BreathID® Smart – IDkit Hp® Two
Your country: US
Mode: Include
Countries: 2
US CA
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Premier Platinum HpSA PLUS ](/uploads/601396_pi.pdf)
[ CLSI Premier Platinum HpSA PLUS ](/uploads/601396_clsi.doc)
[ Procedure Card Premier Platinum HpSA PLUS ](/uploads/601396_pc.pdf)
[ Safety Data Sheet Premier HpSA Kit ](/uploads/619096_601396_kit_sds.pdf)
[ Safety Data Sheet Premier Enzyme Conjugate ](/uploads/6620_6623_sds.pdf)
[ Safety Data Sheet Premier Positive Control ](/uploads/6614_6622_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier 20X Wash Buffer I ](/uploads/1607_sds.pdf)
[ Safety Data Sheet Premier 20X Wash Buffer I (OSHA) ](/uploads/1607_osha.pdf)
[ Safety Data Sheet Premier Positive Control (OSHA) ](/uploads/6614_6622_osha.pdf)
[ Safety Data Sheet Premier Enzyme Conjugate (OSHA) ](/uploads/6620_6623_osha.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet Premier Sample Diluent / Negative Control (OSHA) ](/uploads/6616_osha.pdf)
[ Safety Data Sheet Premier Sample Diluent / Negative Control ](/uploads/6616_sds.pdf)
#### FAQs
What causes ulcers?
*Helicobacter pylori* (*H. pylori*) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that 9 out of 10 ulcers are caused by *H.pylori*. Medicines that reduce stomach acid may make you feel better, but your symptoms may come back. Here’s the good news – since most ulcers are caused by this bacterial infection, it can be cured with the right antibiotics.
How can your health care provider tell if you have H. pylori ?
There are 3 types of recommended tests:
- Stool Test: Provide a small stool specimen (an easy-to-use collection system can be provided for this purpose). The doctor will conduct the test in his office or send it to a laboratory. HpSA is the #1 stool antigen test in the USA.
- Breath Test: In this test, you have to fast then a breath sample is taken after you wait and drink a 13C-labeled urea mix. The breath sample collected is then analyzed in the office or sent out to a laboratory.
- Endoscopy: This is a test in which a small tube with a camera inside is inserted through the mouth an into the stomach to look for ulcers. During The endoscopy, small samples of the stomach lining can be obtained and tested for *H. pylori*.
What is the recommended testing algorithm for Helicobacter pylori ?
Visit the [*H. pylori* resource center](/h-pylori-resource-home/) to learn more about guideline recommended testing.
How do I know therapy is working or the patient is cured?
Test it. Treat it. Test it again – all with one easy stool test. HpSA test is an FDA cleared 3-in-1 test able to diagnose *H. pylori*, monitor, if therapy is working and test for eradication.
Can stools in Cary Blair be used for HpSA testing?
No, only fresh or frozen stool samples may be used. If you require preserved stool specimens, [Premier® HpSA® Flex](/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/) is approved for use with preserved stool samples.
References:
- Centers for Disease Control and Prevention. Helicobacter pylori and Peptic Ulcer Disease. Available at . Accessed on November 28, 2018.
- American Gastroenterological Association medical position statement: evaluation of dyspepsia: Gastroenterology. 2005;129:1756- 1780.
- Chey WD, Wong BCY, and the Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
- NIH National Cancer Institute. Helicobacter pylori and Cancer. Available at: . Accessed February 12, 2016.
- AGA Board, American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia, Nov 2005, page 1754. ACG Clinical Guideline: Management of Crohn’s Disease in Adults” Gary R. Lichtenstein, et al. Am J Gastroenterol 2018; 113:481–517; doi: 10.1038/ajg.2018.27; published online 27 March 2018.
- Premier Platinum HpSA® Plus Package insert
What is the suggested CPT Code?
- Premier® Platinum HpSA® PLUS – 87338
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Premier® HpSA® Flex](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
**Published:** August 24, 2023
**Author:** hamza
**Content:**
# Premier® HpSA® Flex
A streamlined, highly sensitive enzyme immunoassay for the detection of *H. pylori* antigens in fresh (unpreserved) and preserved stool specimens.
Catalog Number: 619096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### Direct Detect® Stool Transport
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
[  ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
### BreathID® Smart – IDkit Hp® Two
Your country: US
Mode: Include
Countries: 2
US CA
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Premier HpSA Flex ](/uploads/619096-brochure.pdf)
[ Safety Data Sheet Premier HpSA Kit ](/uploads/619096_601396_kit_sds.pdf)
[ Safety Data Sheet Premier Enzyme Conjugate ](/uploads/6620_6623_sds.pdf)
[ Safety Data Sheet Premier Positive Control ](/uploads/6614_6622_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier 20X Wash Buffer I ](/uploads/1607_sds.pdf)
[ Safety Data Sheet Premier 20X Wash Buffer I (OSHA) ](/uploads/1607_osha.pdf)
[ Safety Data Sheet Premier Positive Control (OSHA) ](/uploads/6614_6622_osha.pdf)
[ Safety Data Sheet Premier Enzyme Conjugate (OSHA) ](/uploads/6620_6623_osha.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet Premier Sample Diluent / Negative Control (OSHA) ](/uploads/6616_osha.pdf)
[ Safety Data Sheet Premier Sample Diluent / Negative Control ](/uploads/6616_sds.pdf)
[ Package Insert Premier HpSA Flex ](/uploads/619096_pi.pdf)
[ Procedure Card Premier HpSA Flex ](/uploads/619096_pc.pdf)
#### FAQs
What causes ulcers?
*Helicobacter pylori* (*H. pylori*) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that 9 out of 10 ulcers are caused by *H.pylori*. Medicines that reduce stomach acid may make you feel better, but your symptoms may come back. Here’s the good news – since most ulcers are caused by this bacterial infection, it can be cured with the right antibiotics.
How can your health care provider tell if you have *H. pylori*?
There are 3 types of recommended tests:
- Stool Test: Provide a small stool specimen (an easy-to-use collection system can be provided for this purpose). The doctor will conduct the test in his office or send it to a laboratory. HpSA is the #1 stool antigen test in the USA.
- Breath Test: In this test, you have to fast then a breath sample is taken after you wait and drink a 13C-labeled urea mix. The breath sample collected is then analyzed in the office or sent out to a laboratory.
- Endoscopy: This is a test in which a small tube with a camera inside is inserted through the mouth an into the stomach to look for ulcers. During The endoscopy, small samples of the stomach lining can be obtained and tested for *H. pylori*.
What is the recommended testing algorithm for *Helicobacter pylori*?
Visit the [*H. pylori* resource center](https://www.meridianbioscience.com/h-pylori-resource-home/?country=US%23agaacg-chart-caption%23agaacg-chart-caption#agaacg-chart-caption) to learn more about guideline recommended testing.
How do I know therapy is working or the patient is cured?
Test it. Treat it. Test it again – all with one easy stool test. HpSA test is an FDA cleared 3-in-1 test able to diagnose *H. pylori*, monitor, if therapy is working and test for eradication.
Can stools in Cary Blair be used for HpSA testing?
Yes, Premier HpSA Flex is FDA-cleared for use with preserved stools in Cary Blair or C&S in addition to fresh or frozen unpreserved samples.
What is the suggested CPT Code?
Premier HpSA Flex – 87338
References:
- Centers for Disease Control and Prevention. Helicobacter pylori and Peptic Ulcer Disease. Available at . Accessed on November 28, 2018.
- American Gastroenterological Association medical position statement: evaluation of dyspepsia: Gastroenterology. 2005;129:1756-
1780.
- Chey WD, Wong BCY, and the Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
- NIH National Cancer Institute. Helicobacter pylori and Cancer. Available at:
. Accessed February 12, 2016.
- AGA Board, American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia, Nov 2005, page 1754.
ACG Clinical Guideline: Management of Crohn’s Disease in Adults” Gary R. Lichtenstein, et al. Am J Gastroenterol 2018; 113:481–517; doi: 10.1038/ajg.2018.27; published online 27 March 2018.
- Premier HpSA Flex Package Insert
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Other](https://www.meridianbioscience.com/diagnostics/disease-areas/other/)
**Published:** January 4, 2019
**Author:** hamza
**Content:**
# Other Human Conditions
Our passion is to help providers make better diagnostic decisions with a focus on other conditions such as fungals, sexual health and tropical diseases.
##### Healthcare Acquired Infections
- [ Carbapenem-resistant Enterobacteriaceae (CRE) ](https://www.meridianbioscience.com/diagnostics/disease-areas/cre/)
##### Sexual Health
- [ Pregnancy ](https://www.meridianbioscience.com/diagnostics/disease-areas/pregnancy/)
- [ Phosphate Buffered Saline ](https://www.meridianbioscience.com/diagnostics/disease-areas/pbs/)
- [ Viral Transport ](https://www.meridianbioscience.com/diagnostics/disease-areas/viral-transport/)
- [ HCV ](https://www.meridianbioscience.com/diagnostics/disease-areas/hcv/)
- [ HIV ](https://www.meridianbioscience.com/diagnostics/disease-areas/hiv/)
- [ VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/vzv/)
- [ Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/chlamydia/)
- [ Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/gonorrhea/)
- [ HSV 1&2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/hsv-12/)
- [ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
##### Other
- [ Serology ](https://www.meridianbioscience.com/diagnostics/disease-areas/serology/)
- [ Fungals ](https://www.meridianbioscience.com/diagnostics/disease-areas/fungals/)
##### Tropical Diseases
- [ Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/malaria/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [TRU Legionella®](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/tru-legionella/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Tru® Legionella
A rapid immunoassay for the detection of *Legionella pneumophila* serogroup 1 antigens in human urine specimens.
Catalog Number: 751930
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Respiratory
[ RSV Positive Control ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/)
[ TRU RSV® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/tru-rsv/)
[ TRU Strep Pneumo™ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/tru-strep-pneumo/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Tru Legionella ](/uploads/MBI_Tru-Legionella_Sales_Sheet_2026-03.pdf)
[ Package Insert Tru Legionella ](/uploads/751930_pi.pdf)
[ CLSI Tru Legionella ](/uploads/751930_clsi%20(1).doc)
[ Procedure Card Tru Legionella ](/uploads/751930_pc.pdf)
[ Safety Data Sheet - Conjugate Bead Tru Legionella ](/uploads/7947_sds.pdf)
[ Safety Data Sheet - Positive Control Tru Legionella ](/uploads/7949_sds.pdf)
[ Safety Data Sheet - Sample Diluent Tru Legionella ](/uploads/7950_sds.pdf)
#### FAQs
What is the suggested CPT Code
87449
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Curian® Shiga Toxin](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
**Published:** April 18, 2023
**Author:** hamza
**Content:**
# Curian® Shiga Toxin
A rapid, fluorescent immunoassay for the detection of Shiga toxin 1 and 2 produced by enterohemorrhagic *E. coli* (EHEC) from stool specimens in broth enrichment.
Catalog Number: 760630
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Curian Shiga Toxin?
Curian® Shiga Toxin offers clinicians accurate and timely results to deliver appropriate care for patients infected with Shiga toxin-producing *E. coli*. The Curian testing platform centers around the innovative Curian analyzer – a compact immunofluorescent instrument that boasts a simple workflow and clean sample handling to provide rapid, definitive results. Coupling Curian Shiga Toxin with an automated analyzer readout provides a result that can be read without the risk of subjective analysis by the technologist. Curian’s platform flexibility can help standardize testing throughout the health system by bringing testing closer to the patient resulting in improved clinical efficiencies.
- sample\_result\_icon
Standardized workflow – simple 3-step workflow with standardized assay-to-assay sample prep
- Group 13 Created with Sketch.
Focused menu – removes subjectivity for enhanced performance from the industry's leading experts in stool handling and testing
- assay\_flexibility\_icon
Total solution – flexible testing options allow the platform to fit any laboratory workload
- Group 19 Created with Sketch.
Trusted partner – enables healthcare systems to efficiently maximize resources to deliver standardized care and improve patient outcomes
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Curian® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
[ Curian® Campy ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Curian® Campy
Your country: US
Mode: Include
Countries: 189
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
### Curian® HpSA®
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Curian Shiga Toxin ](/uploads/MBI_Curian-ShigaToxin_Sales_Sheet_2026-03.pdf)
[ Package Insert Curian Shiga Toxin ](/uploads/760630_pi.pdf)
[ Procedure Card Curian Shiga Toxin ](/uploads/760630_pc.pdf)
[ Safety Data Sheet Curian Shiga Toxin Kit ](/uploads/760630_kit_sds.pdf)
[ Safety Data Sheet (OSHA) Sample Diluent Buffer Aioprep ](/uploads/7174_osha.pdf)
[ Safety Data Sheet Curian Shiga Toxin Positive Control GHS ](/uploads/7175_sds.pdf)
[ Safety Data Sheet (OSHA) Positive Control ](/uploads/7175_osha.pdf)
[ CLSI Curian Shiga Toxin ](/uploads/760630_clsi%20(1).doc)
[ Safety Data Sheet Curian Shiga Toxin Sample Diluent Buffer Aioprep GHS ](/uploads/7174_sds-1.pdf)
#### Training Video
[Curian® Shiga Toxin Workflow](https://vimeo.com/809131067)
#### FAQs
What types of specimens can be used?
The Curian Shiga Toxin test is intended for use with broth cultures derived from unpreserved stool or stool preserved in Cary-Blair or C&S transport media.
Why should I use a rapid Shiga toxin test to detect non-O157 strains?
It is known that culture will miss all non-O157 strains. The documented infection rate is about 50:50 for O157 strains vs. non-O157 strains. You should be testing for all Shiga toxin-producing *E. coli.*
Does this test require a broth enrichment step?
Yes, CDC Guidelines recommend Shiga toxin testing be performed on growth from broth culture because this method is more sensitive and specific than direct testing of stool. In addition, because the amount of free fecal Shiga toxin in stools is often low, FIA testing of broth enrichment from stool is recommended rather than direct testing.
What are the suggested CPT Codes for Curian Shiga Toxin testing?
Curian Shiga Toxin provides triple reimbursement by incorporating 3 CPT codes: - Broth enrichment: 87015
- FIA identification Stx 1: 87427
- FIA identification Stx 2: 87427-59
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Curian® Campy](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
**Published:** February 22, 2022
**Author:** hamza
**Content:**
# Curian® Campy
A rapid, qualitative fluorescent immunoassay for the direct detection of a *Campylobacter*-specific antigen in stool specimens.
Catalog Number: 760730
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Curian Campy?
Curian Campy offers clinicians accurate and timely results to deliver appropriate care for patients infected with campylobacteriosis. The Curian testing platform centers around the innovative Curian analyzer – a compact immunofluorescent instrument that boasts a simple workflow and clean sample handling to provide rapid, definitive results. Coupling Curian Campy with an automated analyzer readout provides a result that can be read without the risk of subjective analysis by the technologist. Curian’s platform flexibility can help standardize testing throughout the health system by bringing testing closer to the patient resulting in improved clinical efficiencies.
- sample\_result\_icon
Standardized workflow – simple 3-step workflow with standardized assay-to-assay sample prep
- Group 13 Created with Sketch.
Focused menu – removes subjectivity for enhanced performance from the industry's leading experts in stool handling and testing
- assay\_flexibility\_icon
Total solution – flexible testing options allow the platform to fit any laboratory workload
- Group 19 Created with Sketch.
Trusted partner – enables healthcare systems to efficiently maximize resources to deliver standardized care and improve patient outcomes
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Curian® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
[ Curian® Shiga Toxin ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Curian® HpSA®
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### Curian® Shiga Toxin
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Curian Campy ](/uploads/MBI_Curian-Campy_Sales_Sheet_2026-03.pdf)
[ Package Insert Curian Campy ](/uploads/760730_pi.pdf)
[ Procedure Card Curian Campy ](/uploads/760730_pc.pdf)
[ CLSI Curian Campy ](/uploads/760730_CLSI.doc)
[ Safety Data Sheet Positive Control Curian Campy ](/uploads/7172_ghs.pdf)
[ Safety Data Sheet (OSHA) Positive Control Curian Campy ](/uploads/7172_osha.pdf)
[ Safety Data Sheet Sample Diluent Buffer Curian Campy ](/uploads/7171_ghs.pdf)
[ Safety Data Sheet (OSHA) Sample Diluent Buffer Curian Campy ](/uploads/7171_osha.pdf)
#### FAQs
What is a *Campylobacter* infection?
*Campylobacter* infection, or campylobacteriosis, is caused by ingestion of *Campylobacter* bacteria. It is the most common bacterial cause of diarrheal illness in the United States. People with a Campy infection usually have diarrhea (often bloody), fever, and stomach cramps. The CDC estimates *Campylobacter* infection affects 1.5 million U.S. residents every year.
What *Campylobacter* species does Curian Campy target?
Curian Campy is intended to detect *C. jejuni*, *C. coli*, *C. upsaliensis,* and *C. lari* in human stool from patients with signs and symptoms of gastroenteritis. Over 90% of *Campylobacter* infections are caused by *C. jejuni*, about 5% by *C. coli* and the remainder by other *Campylobacter* species, such as *C. lari* or *C. upsaliensis*. There is increasing acknowledgment of the clinical importance of *Campylobacter* species other than *C. jejuni* and *C. coli*, due to the recognition of these species as emerging human and animal pathogens.
What types of specimens can be used?
The test is intended for use with unpreserved fecal specimens or preserved fecal specimens in transport media (Cary-Blair or C&S).
What is the suggested CPT Code?
87449
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [CMV](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# Congenital CMV Testing
#### Prevent the Preventable. Manage the Manageable.
1 out 3 pregnant women who become infected with CMV will pass the virus to their unborn child. 1 in 200 babies are born with congenital CMV each year, and 1 in 5 will have health complications.1
## Congenital Cytomegalovirus (cCMV)
*Congenital Cytomegalovirus* is the most common virus passed from mothers to babies during pregnancy. It can cause developmental disabilities such as hearing and vision loss, cerebral palsy, mental disability, and, in rare cases, death.
CMV is the #1 cause of non-genetic deafness in children.2
90% of congenital CMV positive babies are born asymptomatic, yet 10-15% will go on to develop hearing loss.2 2
CMV is the most common congenital infection and yet, the majority of women have never heard of it.3
#### Molecular testing solutions for congenital CMV
The First FDA Cleared Molecular Test for cCMV in Saliva That Provides Results in Less Than 1 Hour
Alethia CMV provides fast, actionable results before the baby goes home. Accurate results are obtained in less than 1 hour by using an easy to collect, non-invasive saliva sample.
[](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)#### Alethia® CMV
Molecular assay for the detection of congenital Cytomegalovirus (CMV). Alethia® provides a quick, accurate and reliable molecular assay for congenital CMV detection.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
### Learn More About Congenital CMV Infection
CMV is one of the world’s most prevalent viral infections, often presenting with mild symptoms that can be managed. If left untreated, a CMV infection can lead to serious health issues such as hearing loss, vision impairment, and even developmental disabilities.
#### Congenital Cytomegalovirus: A Silent Risk to Newborns
Shannon A Ross MD, MSPH Pediatric Infectious Diseases The University of Alabama at Birmingham
#### Education Resources About CMV testing
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
CMV Educational Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/20122355/CMV_Brochure_6pg-1.pdf) [ 
Sample Collection Guide Alethia CMV
](/uploads/Alethia_CMV_Sample%20Collection_Guide_481325.pdf) [ 
Parent Educational Brochure Alethia CMV
](/uploads/Alethia_CMV_Parent_Educational_Brochure.pdf) [ 
Educational Brochure Alethia CMV
](/uploads/Alethia_CMV_Educational_Brochure.pdf)
Learn More About Congenital Cytomegalovirus (cCMV)
What is Congenital CMV Testing?
Congenital CMV testing involves screening newborns for Cytomegalovirus (CMV) shortly after birth to detect infections that occurred during pregnancy. This testing is critical for early intervention and management of potential health issues.4
What constitutes a comprehensive CMV Diagnostic Solution for newborns?
A comprehensive CMV diagnostic solution includes a variety of tests such as CMV PCR Test, CMV DNA Testing, and CMV Serology Test to detect the presence of the virus or antibodies produced in response, providing a complete assessment of the infection status.4
Why is Congenital CMV Screening crucial for newborns?
Congenital CMV screening is essential as it can help prevent long-term health effects such as hearing loss or developmental delays by facilitating early detection and treatment of CMV infections.4
What are the primary methods used in CMV Detection for newborns?
The primary methods for CMV detection in newborns include CMV PCR Test and CMV DNA Testing, which are highly sensitive techniques for identifying the virus in body fluids like urine or saliva.4
What is the difference between CMV DNA Testing and CMV Antibody Testing in newborns?
CMV DNA Testing detects the genetic material of the virus, confirming active infection, while CMV Antibody Testing looks for antibodies (such as CMV IgM and CMV IgG), which can indicate an immune response to the virus but may not distinguish between maternal antibodies and those produced by the newborn.4
What role does the CMV PCR Test play in diagnosing congenital CMV?
The CMV PCR Test plays a critical role in diagnosing congenital CMV by detecting CMV DNA in samples from newborns, offering a rapid and accurate diagnosis essential for early therapeutic interventions.4
#### References
1.
2.
3. Doutre, S.M. et al., (2016) Losing Ground: Awareness of congenital CMV in the United States. Journal of Early Hearing Detection and Intervention, 1(2), 39-48
4.
## Get In Touch With A Specialist
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Pediatric & Neonatal
---
### [Pneumocystis](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
###### Respiratory - Respiratory
# Pneumocystis
[](/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)#### merifluorTM
###### Merifluor® Pneumocystis
Immunofluorescent assay for detection of *Pneumocystis carinii*.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Pertussis](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# Bordetella Pertussis Testing
### Prevent the Preventable. Manage the Manageable.
Bordetella Pertussis (B. pertussis) infection incidence is on the rise, returning to pre-pandemic patterns with more than 10,000 cases per year. 1
## Pertussis Testing and Diagnosis: Ensuring Early Detection
*Bordetella Pertussis (B. pertussis)* causes whooping cough, a respiratory infectious disease that can cause severe illness in children younger than 5 years. Pertussis is characterized by frequent cough attacks that can leave the patients out of breath. Pneumonia complications among young infants is the cause of most pertussis-associated deaths.2
Of the pertussis-associated deaths, 84% are children younger than 2 months of age.3
Pertussis is highly contagious, so early diagnosis is important in order to prevent the spread of disease. 3
Pertussis remains a major health problem worldwide, with an estimated 24M cases globally among children younger than 5 years.3
## Alethia Pertussis Testing Solutions for B. Pertussis (Whooping cough)
#### Molecular Testing is Recommended, as B. Pertussis is Difficult to Culture and Lacks Sensitivity
Meridian Bioscience diagnostic solution for the detection of *B. Pertussis*, which provides an accurate and reliable molecular assay from an NP swab in less than 1 hour.
[](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)#### Alethia® Pertussis
Molecular assay for the detection of Bordetella pertussis. Alethia® provides a quick, accurate and reliable molecular assay for Bordetella pertussis detection.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
## Educational Resources About B. Pertussis Testing
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
Alethia PertussisProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102956/MBI_Alethia_Pertussis_Product_Brochure.pdf) [ 
Respiratory FamilyPortfolio Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102229/Respiratory-Family-Product-Brochure.pdf)
#### Frequently Asked Questions About B. Pertussis Testing
What is whooping cough?
Whooping cough is an acute infectious disease cause by *Bordetella Pertussis*.2
What are some clinical features of B. pertussis infection?
The infection is characterized by a cough that gradually becomes more severe, with burst of numerous, rapid coughs usually accompanied by a characteristic high-pitched whoop.2
What is the recommended test?
Molecular testing is recommended for the diagnosis of *B. pertussis*. These tests are sensitive and provide prompt, accurate results that can help with early treatment. A nasopharyngeal swab should be taken 0 to 3 weeks following cough onset.4
## References:
1.
2.
3.
4. [https://www.cdc.gov/pertussis/about/index.html#cdc\_disease\_basics\_testing\_screening-testing-and-diagnosis](https://www.cdc.gov/pertussis/about/index.html#cdc_disease_basics_testing_screening-testing-and-diagnosis)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Mycoplasma](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# Mycoplasma Testing
#### Prevent the Preventable. Manage the Manageable.
It is estimated that over 2 million people in the United States are infected annually with *Mycoplasma pnuemoniae*.
## Mycoplasma Testing: Accurate Detection for Early Intervention
*Mycoplasma pneumoniae* is a bacterium that causes respiratory tract infections known as “walking pneumonia. ” It primarily spreads through respiratory droplets from coughing and sneezing. *Mycoplasma pneumoniae* is one of the main causes of atypical pneumonia in the U.S., and it is associated with 40% of community-acquired pneumonia cases. Early detection is critical for ensuring timely treatment and preventing the spread of infection, particularly in healthcare and community settings.
Causes upper and lower respiratory infection in all age groups, particularly in patients 5 years or older.2
The annual incidence in the U.S. is 24.8 cases per 10,000 adults. 2
Mortality rate is as high as 23% for patients admitted to the intensive care unit for severe pneumonia..2
## Molecular Testing Solutions for *Mycoplasma pneumoniae* Respiratory Infections
#### A More Sensitive and Targeted Testing Method Compared to X-ray, Serology and Multiplex Molecular
Alethia Mycoplasma Direct is a molecular assay for the detection of *Mycoplasma pneumoniae*, a standalone test that provides an accurate and reliable result from a throat swab in less than 1 hour.
[](https://www.meridianbioscience.com//diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)#### Alethia® Mycoplasma Direct
Alethia provides a quick, accurate and reliable molecular assay for *Mycoplasma pneumoniae* detection. [Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
## Immunoassay Testing Solutions for *Mycoplasma pneumoniae* Respiratory Infections
Immunocard Mycoplasma is a rapid sensitive enzyme immunoassay for the detection of IgM antibody to *Mycoplasma pneumoniae* which allows for the identification of early/acute illness and proper treatment selection.
[](https://www.meridianbioscience.com//diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/)#### Immunocard® Mycoplasma
A rapid, sensitive enzyme immunoassay for the detection of IgM to *Mycoplasma pneumoniae* in human serum.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
## Educational Resources for Mycoplasma Testing Insights
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
Alethia Mycoplasma DirectProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102536/480250_product_brochure-1.pdf) [ 
Immunocard Mycoplasma Product Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102430/MBI_IC_Myco_SS_2020-04-1.pdf) [ 
Respiratory FamilyProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102229/Respiratory-Family-Product-Brochure.pdf)
#### Frequently Asked Questions About Mycoplasma Testing
What is *Mycoplasma pneumoniae* and how does it spread?
*Mycoplasma pneumoniae* is a bacterium that causes respiratory tract infections known as “walking pneumonia,” primarily spreading through respiratory droplets from coughing and sneezing. It frequently affects school-aged children and young adults but can occur in all age groups.3,4
What are common symptoms of *Mycoplasma pneumoniae* infection?
Symptoms of *Mycoplasma pneumoniae* include tiredness, fever, headaches, a slowly worsening cough, and sore throat. In severe cases, it may lead to pneumonia with symptoms like shortness of breath and chills. Younger children may experience symptoms like diarrhea, runny nose, or vomiting.3
How is *Mycoplasma pneumoniae* diagnosed and treated?
Diagnosis of *Mycoplasma pneumoniae* often involves clinical examination, chest x-rays, and specific lab tests such as Alethia Mycoplasma Direct and Immunocard Mycoplasma to identify the bacteria. Treatment generally includes antibiotics, although some strains show resistance to macrolide antibiotics, and symptom management with over-the-counter medications.5
What complications can arise from *Mycoplasma pneumoniae* infections?
While most cases are mild, complications can include asthma exacerbations, encephalitis, hemolytic anemia, renal dysfunction, and severe pneumonia. Rarely, it can lead to Stevens-Johnson syndrome or mycoplasma-induced rash and mucositis (MIRM).5
## References:
1. [Mycoplasma Pneumonia – StatPearls – NCBI Bookshelf (nih.gov)](https://www.ncbi.nlm.nih.gov/books/NBK430780/#:~:text=Estimates%20show%20that%20around%201%25%20of%20the%20population,cause%20milder%20disease%20that%20does%20not%20require%20hospitalization.)
2. Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 | MMWR (cdc.gov)
3.
4.
5.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [Legionella](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Respiratory - Respiratory
# Legionella
[](/diagnostics/disease-areas/respiratory/legionella/tru-legionella)#### Tru®
###### Tru® Legionella
A rapid immunoassay for the detection of *Legionella pneumophila* serogroup 1 antigens in human urine specimens.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [Group A Streptococcus](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# Group A Streptococcus Testing
#### Group A Streptococcus Testing: Accurate Detection for Early Intervention
The signs and symptoms of GAS pharyngitis overlap extensively with other infectious causes, making it difficult to diagnose based solely on clinical findings. Accurate diagnosis of Group A Strep is important as it can help prevent unnecessary antibiotic treatment, which can lead to the development of antimicrobial resistance, especially in young children.
## Group A Streptococcus Testing: Accurate Detection for Early Intervention
*Group A Streptococcus* (GAS) is a bacteria responsible for a variety of infections, ranging from mild illnesses like strep throat to more severe conditions such as rheumatic fever. Early *Group A Streptococcus* (GAS) is critical for ensuring timely treatment and preventing the spread of infection, particularly in healthcare and community settings.
Up to 70% of patients receive antibiotic therapy, while only 20%-30% have Group A Strep pharyngitis.1
Pharyngitis affects 20%-30% of children and 5%-15% of adults, with an average economic impact of $381M per year. 2
Group A Strep, if left untreated, can cause invasive disease, which can have a 25% – 30% mortality rate.3
## Molecular Testing Solutions for Group A Strep
#### Meridian Offers Multiple Platforms to Best Fit Your Needs.
Meridian Bioscience’s molecular diagnostic solutions offer the direct detection of Streptococcus pyogenes (Group A β-hemolytic Streptococcus; GAS) from throat swab specimens obtained from patients with signs and symptoms of pharyngitis.
[](/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)#### Revogene® Strep A
A precise diagnostic test for detection of Group A *Streptococcus* (GAS) from throat swab specimens
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)#### Alethia® Group A Streptococcus
Molecular assay for the detection of Group A Streptococcus. A quick, accurate and reliable molecular assay for Group A Strep detection.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)#### Immunocard STAT!® Strep A
A CLIA waived one step lateral flow immunoassay for the direct detection of Group A Streptococcal antigens from throat swabs specimens.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
## Education Resources About Group A Strep Testing
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
Alethia Group A StrepProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21103404/480150_product_brochure-1.pdf) [ 
Revogene Group A StrepProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21103601/MBI_Revogene_Strep_A_SS-1.pdf) [ 
Respiratory FamilyProduct Brochure
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102229/Respiratory-Family-Product-Brochure.pdf)
#### Frequently Asked Questions About Group A Streptococcus Testing
What is Group A Strep or Strep Throat?
Strepococcus pyogenese, also known as Group A Strep is the primary cause of acute *pharyngitis* (Strep Throat) in children and adults. It is characterized by symptoms like sore throat, fever, tonsil inflammation, headache.2
Why it is important to test for Group A Strep?
Infections with Group A Strep can lead to complications like acute rheumatic fever or *glomerulonephritis*. It can also lead to invasive infections that can have a mortality rate of 25%-30%.4
Why is antibiotic stewardship important?
Studies show that of the 70% of the patients that receive antibiotics only 20%-30% actually need it. Over prescription of antibiotic is of concern especially in young children, since over use of antibiotics can increase the potential for resistance.1
### References:
1. Shulman et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America
2. Clinical Infectious Diseases, Volume 55, Issue 10, 15 November 2012, Pages e86–e102
3. [https://www.cdc.gov/group-a-strep/about/?CDC\_AAref\_Val](https://www.cdc.gov/group-a-strep/about/?CDC_AAref_Val)
4. Kanwal S, Vaitla P. Streptococcus Pyogenes. \[Updated 2023 Jul 31\]. In: StatPearls \[Internet\]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Respiratory
---
### [Mononucleosis](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Pediatric & Neonatal - Pediatric & Neonatal
# Mononucleosis
[](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/monospot-latex/)## Latex Agglutination
###### Monospot® Latex
Latex agglutination test for the rapid detection of infectious mononucleosis in serum or plasma samples
Learn More
[](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)## immunocard STAT!
###### Immunocard STAT!® Mono
A CLIA waived one-step dipstick lateral flow immunoassay for the detection of infectious mononucleosis from serum, plasma, or whole blood specimens.
Learn More
[](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)## Alethia
###### MSwab® for Meridian Bioscience Europe
The MSwab collection kit is used to collect, transport and preserve clinical specimens from the collection site to the testing laboratory.
Learn More
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Pediatric & Neonatal
---
### [Lead Poisoning](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# Lead Poisoning Detection & Prevention
Lead poisoning is a serious condition, especially in children, affecting brain development and overall health. Even low lead levels can cause harm, making early detection through testing crucial for timely intervention and treatment.
### Reliable Lead Poisoning Tests for Accurate Diagnosis
Meridian’s reliable lead poisoning tests play a crucial role in early detection and prevention, ensuring timely medical intervention. These tests provide an accurate diagnosis, helping to safeguard children, adults, and at-risk populations from harmful exposure. With quick and precise results, healthcare providers can take necessary steps to reduce long-term health risks. Regular testing with Meridian’s advanced solutions is essential for maintaining overall well-being and preventing complications.
### Take Action Before Health and Learning Suffer
Approximately 1 in 3 children worldwide are affected by lead poisoning, making early detection crucial. A blood lead test is the only definitive way to diagnose lead exposure, allowing for timely intervention to reduce long-term health risks. Young children under 6 years old are particularly vulnerable, as lead exposure can impact their development and cognitive growth. Pregnant women should also undergo testing to prevent lead transfer to the unborn child, ensuring a healthier start to life. Additionally, workers in industrial and construction settings are at higher risk and should be regularly tested to mitigate potential health complications.
## How Lead Poisoning Affects Health: Key Sources and Risks
Lead Poisoning occurs when individuals come into contact with lead-contaminated sources such as dust, soil, paint, and water. It can impair cognitive development, damage vital organs, and affect overall well-being, especially in children, posing significant public health challenges on a global scale.
**LeadCare Blood Lead Testing is a reliable solution for the early detection of lead poisoning in pediatric and neonatal patients.**
It’s more than lead paint. 30% of children are exposed to lead by additional sources..2
There is NO safe level of lead in the blood. Exposure to even small amounts of lead can cause irreversible damage to one’s health. 2
In the U.S., about 1 in every 3 housing units may have lead paint hazards..3
#### Key Advantages of LeadCare Blood Lead Testing
● Fast and accurate results
● Early detection of lead exposure in children
● Easy-to-use testing kits for healthcare providers
#### Testing Solutions for Lead Poisoning
Point-of-Care Lead Testing Reaches those at Risk, Eliminating the Need for Follow-up.
Meridian Bioscience’s LeadCare platform, a trusted point-of-care testing solution for over 20 years, offers fast and accurate blood lead results in three minutes. Developed in collaboration with the CDC, this portable instrument ensures early detection of lead exposure, facilitating timely intervention to safeguard children’s health and prevent long-term developmental and neurological impacts. Early detection through blood lead testing significantly contributes to uncovering those at risk and mitigates ongoing exposure to this harmful neurotoxin.
[](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)#### LeadCare® II
LeadCare II is the only CLIA waived point-of-care test for blood lead poisoning. It can screen in a single visit with a simple finger-stick.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)#### LeadCare Plus®
A simple solution for labs with smaller volumes that want the convenience and control of performing lead testing in house
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)#### LeadCare Ultra®
A simple solution for any lab – whether you run blood lead testing with GFAAS or send samples out to a reference laboratory.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
### Learn More About Lead Poisoning
#### Advancing Lead Poisoning Testing & Prevention for a Healthier Future
At Meridian, we are committed to raising awareness and enhancing early detection through lead poisoning testing and prevention. Lead exposure, especially in children and pregnant women, can cause severe health complications, including developmental delays and neurological issues. Our advanced lead poisoning test solutions provide accurate and timely detection, helping healthcare providers take proactive measures. Beyond diagnostics, we offer educational resources and expert insights to improve testing utilization and public health awareness. By leveraging our expertise, we empower clinicians, laboratories, and communities to combat lead poisoning effectively. Early lead testing is crucial in preventing long-term harm and ensuring a healthier future. Explore our lead poisoning prevention tools and testing solutions to make a meaningful impact. (µg/dl).
#### Educational Resources for Lead Testing & Prevention
As dedicated partners in enhancing patient care, we take pride in our diverse diagnostic portfolio and go further by offering educational content and tools, leveraging our expertise to boost testing utilization and support our partners comprehensively.
[ 
Lead Poisoning Resource Center
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21102430/MBI_IC_Myco_SS_2020-04-1.pdf) [ 
6 Lead Facts to Know Poster
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21104430/Lead-Poisoning-Education-6-Facts-to-Know_v0.1.pdf) [ 
Lead Quantity Poster
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21104538/Lead-Quantity-Education-Poster.pdf) [ 
Surprising Sources of Lead Poster
](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/21104720/Lead-Sources-Education-Poster.pdf)
### Frequently Asked Questions About Lead Testing
What is lead?
Lead is a naturally occurring heavy metal used in various products and materials. Exposure to lead, even in small amounts, can affect multiple body systems and be particularly harmful to young children.5
How does lead exposure occur?
Lead exposure occurs when someone inhales lead-containing dust or swallows something that contains lead. Lead-based paint and lead-contaminated dust are the primary sources of exposure for U.S. children. Despite significant progress, lead poisoning remains a top childhood environmental health problem.6
Is there any safe level of lead exposure?
No level of lead in the blood can be defined as safe. An advisory panel of the CDC now recommends that children with blood levels as low as 3.5 μg/dL be identified as having elevated levels and be monitored. Even such low levels may harm a child’s cardiovascular, immunological, and endocrine health, with consequences for that individual and overall public health. While the effects of lead appear to be irreversible, eliminating lead exposure can reduce further damage.7
Why are children especially vulnerable?
Toddlers and young children explore with their hands and frequently put them in their mouths. As young children crawl on the floor and reach windows, railings, and walls, they may inhale dust from peeling and chipping lead-based paint or ingest paint chips. Children under six years of age are biologically more sensitive to lead due to rapid brain and organ development, when the body readily takes up lead—mistaking it for calcium. Therefore, children who are low in calcium or have iron-deficient anemia may have an ever-greater lead uptake.8
Are adults impacted by lead poisoning?
Adults can become lead poisoned, most frequently from the workplace and hobbies. Lead in adults can affect the central nervous and gastrointestinal systems and can cause chronic kidney disease as well as other health problems.9
How is lead exposure diagnosed?
Lead exposure is diagnosed through blood lead testing, which measures the amount of lead in the bloodstream. A small blood sample is taken from the finger, heel, or arm. The results indicate the level of lead in the blood, typically measured in micrograms per deciliter (µg/dL). In the United States, federal law requires all Medicaid-enrolled children to be tested at ages 1 and 2 and up to the age of 6 if they have not been tested previously. Beyond this federal requirement, state mandates and guidelines vary. High-risk children, such as those living in older homes or those with a history of pica (eating non-food items), may need more frequent testing.10
What happens if my blood lead level is elevated?
If your blood lead level is elevated, several actions may be taken depending on the severity of the exposure and your individual health status. It’s important to follow your healthcare provider’s recommendations closely if you have an elevated blood lead level to protect your health and prevent potential long-term complications associated with lead poisoning.11
- **Medical Evaluation:** Your healthcare provider will likely conduct further tests and assessments to confirm the elevated blood lead level and evaluate any symptoms or health effects.
- **Identifying the Source of Exposure:** It’s crucial to identify and eliminate the source of lead exposure. This may involve testing your home, workplace, or other environments where you spend time to pinpoint sources of lead contamination.
- Monitoring: You may require regular blood lead testing to monitor your levels over time and assess the effectiveness of interventions to reduce exposure.
- **Treatment if Necessary:** In some cases of high blood lead levels or symptoms of lead poisoning, treatments such as chelation therapy may be considered under medical supervision. Chelation therapy involves medications that bind to lead and help remove it from the body.
- **Health Management:** Your healthcare provider may recommend dietary changes or supplements that can help support overall health and reduce the absorption of lead in your body.
### References:
1.
2. Brown, M.J. (2012). Lead in Drinking Water and Human Blood Lead Levels in the United States. Morbidity and Mortality Weekly Report, August 10 Supplement, 61, 1-9
3.
4.
5.
6.
7.
8. [https://www.cdc.gov/lead-prevention/risk-factors/index.html](https://www.cdc.gov/lead-prevention/risk-factors/index.html#:~:text=Children%20less%20than%20six%20years,other%20objects%20into%20their%20mouths)
9.
10.
11.
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Pediatric & Neonatal
---
### [Group B Strep](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Pediatric & Neonatal - Pediatric & Neonatal
# Group B Strep
[](https://www.meridianbioscience.com//diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)## revogene
###### Revogene® GBS LB
A precise diagnostic test for detection of Group B *Streptococcus* (GBS) from Lim Broth samples
Learn More
[](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)## alethia
###### Alethia® Group B Streptococcus
Molecular assay for the detection of Group B Streptococcus. Alethia provides a quick, accurate and reliable molecular assay for Group B Strep detection.
Learn More
[](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)## revogene
###### Revogene® GBS DS
A precise diagnostic test for detection of Group B Streptococcus (GBS) from direct swab samples
Learn More
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Pediatric & Neonatal
---
### [VZV](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# VZV
[](/diagnostics/disease-areas/other/vzv/merifluor-vzv/)#### merifluor
###### Merifluor® VZV
Direct fluorescent assay that detects Varicella-Zoster virus in vesicle smears, biopsies, VZV cell culture.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [Viral Transport](https://www.meridianbioscience.com/diagnostics/disease-areas/other/viral-transport/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# Viral Transport
[](/diagnostics/disease-areas/other/viral-transport/meridian-viral-transport)#### Serology
###### Meridian Viral Transport
Meridian Viral Transport is a system which contains all materials necessary to collect and transport clinical specimens for viral isolation.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Sexual Health
---
### [Malaria](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Other - Tropical Diseases
# Malaria
[](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria)#### Alethia®
###### Alethia® Malaria
Molecular assay for the detection of *Plasmodium sp.* Alethia provides a quick, accurate and reliable molecular assay for *Plasmodium sp.* detection.
[Learn More](#)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)#### Alethia®
###### Alethia® Malaria External Controls
An enzyme immunoassay for the direct detection of adenovirus antigen in human fecal specimens and for the confirmation of Adenovirus in cell culture.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Tropical Diseases
---
### [HSV 1&2](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# HSV 1&2
[](/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12)#### Alethia®
###### Alethia® HSV 1&2
Molecular assay for the detection of herpes simplex virus (HSV) type 1 & 2. Alethia provides a quick, accurate and reliable molecular assay for HSV 1&2 detection.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [Gonorrhea](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# Gonorrhea
[](/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)#### alethia®
###### Alethia® Gonorrhea
Molecular assay for the detection of Neisseria gonorrhoeae . Alethia provides a quick, accurate and reliable molecular assay for Neisseria gonorrhoeae detection.
[Learn more](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [Chlamydia](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# Chlamydia
[](/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia)#### Merifluor®
###### Merifluor® Chlamydia
Direct fluorescent assay for the detection of chlamydia in McCoy cells.
[Learn More](#)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)#### alethia®
###### alethia® Chlamydia
Molecular assay for the detection of Chlamydia trachomatis. Alethia provides a quick, accurate and reliable molecular assay for Chlamydia trachomatis detection.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [Carbapenem-resistant Enterobacteriaceae (CRE)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/)
**Published:** July 24, 2019
**Author:** hamza
**Content:**
###### Other - Healthcare Acquired Infections
# Carbapenem-resistant Enterobacteriaceae (CRE)
[](/diagnostics/disease-areas/other/cre/carba)#### revogene®
###### Revogene® Carba C
The Revogene Carba C assay provides healthcare systems with a diagnostic solution to enable early detection and management of Carbapenem-Resistant *Enterobacterales* (CRE) from isolated colonies of *Enterobacteriaceae, Acinetobacter baumannii,* or *Pseudomonas aeruginosa*.
[Learn More](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Healthcare Acquired Infections
---
### [Rotavirus/Adenovirus/Norovirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Gastrointestinal
# Rotavirus/Adenovirus/Norovirus
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)#### immunocard STAT!
###### Immunocard STAT!® Rota-Adeno-Noro2
An immunoassay for the qualitative detection, in separate bands, of Rotavirus, Adenovirus and Norovirus genogroup I (GI) and genogroup II (GII) antigens in human stool.
[Learn more](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)#### immunocard STAT!
###### Immunocard STAT!® Rota-Adeno-Noro2 External Control Set
External Controls to be used with Immunocard STAT Rota-Adeno-Noro2 External Control Set
[Learn more](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [Rotavirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Gastrointestinal
# Rotavirus
[](/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus)#### immunocard STAT!
###### Immunocard STAT!® rotavirus
One step lateral flow immunoassay for the direct detection of rotavirus antigen in human stool.
[Learn more](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone)
[](/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone)#### premier®
###### Premier® Rotaclone®
An Enzyme Immunoassay for the detection of rotavirus antigen in human fecal samples.
[Learn more](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [BreathTek® UBT for H. pylori](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/breathtek-ubt-for-h-pylori/)
**Published:** September 21, 2021
**Author:** hamza
**Content:**
## BreathTek® UBT for *H. pylori*
**Effective July 1, 2024, the BreathTek® product line is discontinued. The supply of bags and replacement products will no longer be available.**
Catalog Number: 8209
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
Get started with BreathID®
for *H. pylori* testing today
[](/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41)#### premier®
###### Premier® Adenoclone® 40/41
An Enzyme Immunoassay for the detection of Adenovirus Serotypes 40 and 41 in human fecal samples.
[Learn more](#)
## Support & Documents
#### Downloadable PDFs
[ BreathTek Package Insert ](/uploads/BreathTek-PI.pdf)
[ Patient Preparation Card ](/uploads/patient-preparation-card.pdf)
[ Consumer Brief Summary about BreathTek UBT ](/uploads/hcc-brief-summary.pdf)
[ Pediatric UHR Card ](/uploads/pediatric-uhr-card.pdf)
[ Safety Data Sheet BreathTek CO2 Trapping Cartridge ](/uploads/002213_ghs.pdf)
[ Safety Data Sheet (OSHA) BreathTek CO2 Trapping Cartridge ](/uploads/002213_osha.pdf)
#### FAQs
What if I have a complaint or need to report an issue with the test?
Please contact Meridian Bioscience Technical Support at +1 888.343.3858.
I'm interested in learning about all of my *H. pylori* testing options now that BreathTek is part of Meridian.
Please contact us at +1 888.763.6769 or
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [E. coli](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# *E. coli* Infection
## Trusted Results for Urgent *E. coli* Diagnosis
*Escherichia coli (E. coli)* are bacteria commonly found in the environment, food, and intestines of people and animals. Some strains, like Shiga toxin-producing *E. coli* (STEC), cause severe foodborne illness. These strains release Shiga toxins, which can lead to severe complications like hemolytic uremic syndrome (HUS). Early detection and prompt intervention are essential for protecting patients and preventing outbreaks.
## *E. coli* Testing Solutions
Meridian Bioscience offers a suite of *E. coli* testing solutions designed for rapid and accurate detection of Shiga toxin-producing *E. coli* (STEC) strains. These solutions are tailored to meet the needs of clinical laboratories and healthcare providers, ensuring timely diagnosis and effective patient management.
[](/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)#### Curian® Shiga Toxin
A rapid, fluorescent immunoassay for the detection of Shiga toxin 1 and 2 produced by enterohemorrhagic *E. coli* (EHEC) from stool specimens in broth enrichment.
[Learn More](/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
[](/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)#### Immunocard STAT!® EHEC
Rapid lateral flow immunoassay for the detection of Shiga toxin 1 and 2 produced by *enterohemorraghic E. coli* (EHEC) from stool specimens in broth enrichment.
[Learn More](/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[](/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)#### Premier® EHEC
A microwell enzyme immunoassay for the detection of Shiga toxin 1 and 2 produced by *enterohemorrhagic E. coli* (EHEC) from stool specimens.
[Learn More](/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/?country=PK)
[](/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)#### Immunocard STAT!® E. coli O157
Rapid lateral flow immunoassay for the detection of Shiga toxin-producing *E. coli* O157 in stool specimens and culture.
[Learn More](/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/?country=PK)
## Shiga Toxin *E. coli* Symptoms
### Diarrhea
Often watery or bloody, one of the most common early symptoms.
### Abdominal Pain
Severe cramping and pain, especially in the lower abdomen.
### Fever
Mild to moderate fever may accompany other symptoms.
### Nausea & Vomiting
May occur in early stages or alongside other digestive symptoms.
These symptoms typically appear 3 to 4 days after exposure and can last about a week. While many recover without treatment, some infections can lead to severe conditions such as hemolytic uremic syndrome (HUS), a serious complication that can cause kidney failure.
## Shiga Toxin *E. coli* Treatment
Treatment for Shiga toxin-producing *E. coli* infections primarily involves supportive care, including hydration and rest. Antibiotics are generally not recommended, as they may increase the risk of hemolytic uremic syndrome (HUS), a life threatening complication that can lead to kidney failure and permanent health conditions. Shiga toxin-producing *E. coli* is the most common cause of HUS.
## FAQs
What is Shiga toxin-producing *E. coli* (STEC)?
STEC stands for Shiga toxin-producing *Escherichia coli*, a group of bacteria known for producing toxins called Shiga toxins.
How do people get infected with Shiga toxin-producing *E. coli* ?
Infections typically occur through consumption of contaminated food or water, especially undercooked ground beef, unpasteurized milk or juice, raw fruits and vegetables, and through contact with animals or their environments.
What are the symptoms of a Shiga toxin-producing *E. coli* infection?
Symptoms can range from mild to severe and may include diarrhea (often bloody), abdominal cramps, nausea, and vomiting. In some cases, especially in children, it can lead to hemolytic uremic syndrome (HUS), a serious condition involving kidney failure
How is Shiga toxin-producing *E. coli* diagnosed?
Diagnosis is usually confirmed by testing a stool sample for the presence of the bacteria and their toxins. Sometimes, additional confirmatory testing may be conducted to identify specific strains.
How is Shiga toxin-producing *E. coli* treated?
Treatment is primarily supportive, focusing on maintaining hydration and electrolyte balance. Antibiotics are not recommended for routine treatment because they can increase the risk of developing hemolytic uremic syndrome (HUS).
Are there outbreaks of Shiga toxin *E. coli* (STEC) infections?
Yes, outbreaks of STEC infection can occur, often linked to contaminated food or water sources. Public health authorities monitor and investigate outbreaks to prevent further spread.
## References
1. [https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Shiga-toxin-producing-Escherichia-coli.aspx#:~:text=It%20is%20estimated%20that%20as,appear%2C%20when%20diarrhea%20is%20improving](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Shiga-toxin-producing-Escherichia-coli.aspx#:~:text=It%20is%20estimated%20that%20as,appear%2C%20when%20diarrhea%20is%20improvinghttps://epi.dph.ncdhhs.gov/CD/diseases/ecoli.htmlhttps://my.clevelandclinic.org/health/diseases/16638-e-coli-infection)
2. [https://epi.dph.ncdhhs.gov/CD/diseases/ecoli.html](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Shiga-toxin-producing-Escherichia-coli.aspx#:~:text=It%20is%20estimated%20that%20as,appear%2C%20when%20diarrhea%20is%20improvinghttps://epi.dph.ncdhhs.gov/CD/diseases/ecoli.htmlhttps://my.clevelandclinic.org/health/diseases/16638-e-coli-infection)
3. [https://my.clevelandclinic.org/health/diseases/16638-e-coli-infection](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Shiga-toxin-producing-Escherichia-coli.aspx#:~:text=It%20is%20estimated%20that%20as,appear%2C%20when%20diarrhea%20is%20improvinghttps://epi.dph.ncdhhs.gov/CD/diseases/ecoli.htmlhttps://my.clevelandclinic.org/health/diseases/16638-e-coli-infection)
## Get In Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [Campylobacter](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# *Campylobacter* Infection
## Causes and Transmission of *Campylobacter* Infection
*Campylobacter* infection, or campylobacteriosis, is one of the leading causes of foodborne illness in the United States. *Campylobacter* infections often present with symptoms similar to many gastrointestinal illnesses making clinical differentiation challenging. Accurate and timely diagnosis is essential to identify the true cause, guide appropriate treatment, and prevent the spread of infection.
## *Campylobacter* Testing Solutions
We provide advanced diagnostic solutions for *Campylobacter* infection—one of the leading causes of bacterial gastroenteritis worldwide. Powered by trusted technologies from Meridian Bioscience, including Curian® and Immunocard® STAT! Campy immunoassays, our solutions deliver rapid, accurate, and reliable detection of *Campylobacter* species from stool specimens.
[](/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)#### Curian® Campy
A rapid, qualitative fluorescent immunoassay for the direct detection of a *Campylobacter*-specific antigen in stool specimens.
[Learn More](/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
[](/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)#### Immunocard STAT!® CAMPY
Rapid lateral flow immunoassay for the direct detection of *Campylobacter* antigens from stool specimens.
[Learn More](/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[](/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)#### Premier® CAMPY
A microwell enzyme immunoassay for the detection of *Campylobacer* antigens from stool specimens.
[Learn More](/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
## *Campylobacter* Symptoms
*Campylobacter* symptoms typically manifest within two to five days after exposure to the bacteria and can include:
### Diarrhea
Often watery or bloody, a common symptom of *Campylobacter* infection.
### Abdominal Pain
Cramping or pain in the abdomen that may accompany diarrhea.
### Fever
A moderate fever is commonly observed during infection.
### Nausea & Vomiting
These symptoms can occur early in the infection phase.
These symptoms usually last about a week. While most recover without treatment, some may develop complications such as irritable bowel syndrome, arthritis, or Guillain-Barré syndrome—a rare neurological condition causing muscle weakness and paralysis.
## Treatment of *Campylobacter* Infection
Most *Campylobacter* infections are self-limiting and resolve without the need for antibiotics. Supportive care, including staying hydrated and resting, is usually sufficient. However, antibiotics may be prescribed in severe cases or for patients at higher risk of complications.
## FAQs
What is *Campylobacter*?
*Campylobacter* is a genus of bacteria that is one of the most common causes of foodborne illness. The most common species is *Campylobacter jejuni*, followed by *Campylobacter coli*, *Campylobacter upsaliensis* and *Campylobacter lari*.
How do people get infected with *Campylobacter* ?
*Campylobacter* infection is commonly contracted through the consumption of undercooked poultry, unpasteurized milk, contaminated water, or contact with infected animals.
What are the symptoms of *Campylobacter* infection?
Symptoms include diarrhea (often bloody), abdominal cramps, fever, nausea, and vomiting.
How is *Campylobacter* infection diagnosed?
Diagnosis is usually confirmed by testing a stool sample for the presence of *Camplyobacter* bacteria. Sometimes, additional confirmatory testing may be conducted to identify specific species.
How can *Campylobacter* infection be prevented?
Preventive measures include proper cooking of poultry, avoiding unpasteurized milk, practicing good hygiene, and preventing cross-contamination in the kitchen.
## References
-
- [https://pubmed.ncbi.nlm.nih.gov/11283810/](https://pubmed.ncbi.nlm.nih.gov/11283810/)
## Get In Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [C. difficile](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
# *Clostridioides difficile* (*Clostridium difficile*)
## *C. difficile* Infection Statistics and Recurrence
*Clostridioides difficile* (formerly *Clostridium difficile*, also known as *C. difficile or C. diff* ) is a bacterium that causes diarrhea and colitis (inflammation of the colon). It’s estimated that *C.diff* causes nearly half a million infections in the U.S. annually, with around 1 in 6 patients experiencing reinfection within 2–8 weeks. This organism is the most common cause of healthcare-associated diarrhea, especially in hospitalized and long-term care patients.¹
## *C. difficile* Infection Testing Platforms
Our complete testing solution for *Clostridioides difficile (Clostridium difficile) (C.diff)* is designed to support a range of testing approaches and workflows. Whether you require rapid molecular diagnostics or a multi-step testing algorithm, we offer flexible solutions to help minimize the impact of *C. difficile* in your healthcare setting.
## Revogene®
### Fully Automated Molecular Platform with Minimal Hands-On Time
Revogene® delivers an accurate, molecular-based *Clostridioides difficile test* with minimal hands-on time. This platform helps healthcare providers detect *C. diff* quickly and accurately, reducing missed cases and enabling faster, evidence-based patient management. Results from the Revogene® *C. difficile test* can reduce unnecessary isolation, optimize antibiotic use, and improve overall healthcare efficiency.
[ Learn More ](/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[](/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh)#### Premier® *C. difficile* GDH
Enzyme immunoassay for the detection of *Clostridium difficile* GDH in stool specimens.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)#### Immunocard® Toxins A&B
A rapid, sensitive enzyme immunoassay for the detection of *Clostridium difficile* toxins A and B in stool specimens.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab)#### Premier® Toxins A&B
Enzyme Immunoassay for the detection of *Clostridium difficile* toxin A and toxin B in stool specimens.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)#### Alethia® *C. difficile*
Molecular assay for the detection of *C. difficile*. Alethia® provides a quick, accurate and reliable molecular assay for C. difficile detection.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)#### Immunocard® *C. difficile* GDH
A rapid, sensitive enzyme immunoassay for the detection of *Clostridium difficile* antigen (GDH) in stool specimens.
Learn More
## Choosing the Right *C. diff* Test Strategy
Up to 50% of hospital antibiotic use is unnecessary or misapplied.2 Effective use of *C. diff* tests helps reduce this burden and supports better patient outcomes.
## One-Step
### Molecular Testing
Utilize a single molecular-based
*C. difficile* test to reduce the chance of missing a true positive case.
## Two-Step
### Testing Solutions
Screen with a GDH antigen test and confirm with a molecular assay. Alternatively, start with molecular detection of *C. diff*, followed by confirmation using a Toxin A & B immunoassay.
## Three-Step
### Testing Algorithm
Incorporate GDH, toxin, and molecular *C. diff* tests for the most comprehensive diagnostic approach. This algorithm can reduce costs by quickly eliminating negative samples and customizing the second and third steps to your facility’s needs.
## *Clostridioides difficile* (*Clostridium difficile*) Treatment
Approximately 20% of infections resolve within 2–3 days after discontinuing the inciting antibiotic. Most *C. difficile infections* are treated with a 10-day course of oral vancomycin or fidaxomicin.
Retesting is not typically needed if symptoms have resolved, as patients may remain colonized without symptoms.⁴
## FAQs
How is *C. difficile* testing performed?
*C. difficile* testing typically involves collecting a stool sample from the patient and analyzing it for the presence of *C. difficile* toxins or genetic material.
What are the symptoms of *C. difficile* infection?
Symptoms of *C. difficile* infection may include diarrhea, abdominal pain, fever, nausea, and loss of appetite.
Who should undergo *C. difficile* testing?
Individuals with symptoms suggestive of *C. difficile* infection, particularly those who have been recently hospitalized or have taken antibiotics, should undergo *C. difficile* testing.
What are the different types of *C. difficile* tests available?
Common types of *C. difficile* tests include enzyme immunoassays (EIAs), polymerase chain reaction (PCR) tests, and cell culture cytotoxicity assays.
How accurate are *C. difficile* tests?
*C. difficile* tests vary in accuracy depending on the method used, with molecular tests generally considered to be the most sensitive and specific.
How long does it take to get *C. difficile* test results?
Turnaround time for *C. difficile* test results varies depending on the testing method and laboratory processing time, but results are typically available within a few days.
What is the treatment for *C. difficile* infection?
Treatment for *C. difficile* infection may involve antibiotics such as vancomycin or fidaxomicin, as well as supportive measures to manage symptoms and prevent dehydration.
## Resources:
- [Enzyme immunoassay for the detection of Clostridium difficile GDH in stool specimens](/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
- [Actionable results for the detection of Clostridium difficile infection (CDI)](/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
- [C. difficile. Alethia® provides a quick, accurate and reliable molecular assay for C. difficile detection](/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
- [Enzyme immunoassay for the detection of Clostridium Difficile antigen (GDH) in stool specimens](/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
## References
1.
2.
3. [https://www.meridianbioscience.com/uploads/616096\_pi.pdf](/uploads/616096_pi.pdf)
4. [https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/?utm\_source=chatgpt.com&country=US](/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Healthcare Acquired Infections
---
### [Adenovirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Gastrointestinal
# Adenovirus
Our rapid test for the detection of Adenovirus provides results intended to aid in the diagnosis of adenovirus-associated gastroenteritis. Click for product information below.
[](/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone)#### premier®
###### Premier® Adenoclone®
An enzyme immunoassay for the direct detection of adenovirus antigen in human fecal specimens and for the confirmation of Adenovirus in cell culture.
[Learn more](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone)
[](/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41)#### premier®
###### Premier® Adenoclone® 40/41
An Enzyme Immunoassay for the detection of Adenovirus Serotypes 40 and 41 in human fecal samples.
[Learn more](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [Revogene® GBS DS](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
**Published:** September 9, 2019
**Author:** hamza
**Content:**
## Revogene® GBS DS
A precise diagnostic test for detection of Group B *Streptococcus* (GBS) from direct swab samples
Catalog Number: 410100
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Revogene® GBS DS?
The Revogene GBS DS assay is a qualitative in vitro diagnostic test to detect Group B *Streptococcus* (GBS) from vaginal/rectal swab samples from pregnant women. Performing this test enables healthcare professionals to detect the presence of GBS within 70 minutes. The assay provides physicians with accurate and reliable results, allowing for appropriate treatment decisions of the mother at the time of delivery, ensuring the best outcome for the baby.
- Efficient workflow - Sample to result in 3 easy steps
- Flexible platform - Run multiple assays with different sample types on a single run
- Platform for growth - Single analyte and multiplex testing capability
- Total solution - Can be paired with Meridian immunoassays for a scalable testing solution
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Revogene GBS DS ](/uploads/410100_pi.pdf)
[ Package Insert - Revogene Mock Pie ](/uploads/610208_pi.pdf)
[ Safety Data Sheet - Revogene GBS DS Kit ](/uploads/410100_kit_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene GBS DS ](/uploads/410100_osha.pdf)
[ Safety Data Sheet - Revogene GBS DS GHS ](/uploads/410100_sds.pdf)
[ Safety Data Sheet DS - Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_sds.pdf)
[ Safety Data Sheet (OSHA) - GBS DS Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_osha.pdf)
[ Procedure Card EN - Revogene GBS DS ](/uploads/410100_pc.pdf)
[ Procedure Card DE Revogene GBS DS ](/uploads/410100_pc_de.pdf)
[ Procedure Card ES - Revogene GBS DS ](/uploads/410100_pc_es.pdf)
[ Procedure Card FR - Revogene GBS DS ](/uploads/410100_pc_fr.pdf)
#### FAQs
If I don’t have eight samples to fulfill the carousel to perform a complete run, what alternatives do I have?
Revogene MOCK PIEs can be used when less than eight samples are available to perform a run. In case you don’t have any MOCK PIEs, assay PIEs filled with Sample Buffer or External Controls may also be used.
What is the ideal temperature to store Revogene GBS DS kits?
Revogene GBS DS kits can be stored at 2-25°C.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Revogene Mock PIE](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
**Published:** August 12, 2020
**Author:** hamza
**Content:**
## Revogene Mock PIE
Catalog Number: 610208
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Revogene Mock Pie ](/uploads/610208_pi.pdf)
[ Safety Data Sheet Revogene Mock Pie Kit (OSHA) ](/uploads/610208_kit_osha.pdf)
[ Safety Data Sheet Revogene Mock Pie Kit ](/uploads/610208_kit_sds.pdf)
For Additional Support Please Contact Technical Support
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Other
---
### [Revogene® Check](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
**Published:** December 24, 2020
**Author:** hamza
**Content:**
## Revogene® Check
The Revogene instrument requires periodic verification of optical and thermal parameters, through a Revogene Check run, to confirm they are within specifications.
Catalog Number: 610220
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Revogene Check ](/uploads/610220_pi.pdf)
[ Procedure Card Revogene Check ](/uploads/610220_pc.pdf)
[ Safety Data Sheet Revogene Check PIE ](/uploads/610220_sds.pdf)
[ Safety Data Sheet (OSHA) Revogene Check PIE ](/uploads/610220_osha.pdf)
[ Safety Data Sheet Revogene Sample Buffer ](/uploads/410100_410200_410300_410400_410500_610220_sds.pdf)
[ Safety Data Sheet (OSHA) Revogene Sample Buffer ](/uploads/410100_410200_410300_410400_410500_610220_osha.pdf)
[ Safety Data Sheet Revogene Check Kit ](/uploads/610220_kit_sds.pdf)
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Immunocard STAT!® Crypto/Giardia Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Crypto/Giardia Controls
External Controls to be used with Immunocard STAT!® Crypto/Giardia.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 750820
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Immunocard STAT! Crypto/Giardia ](/uploads/750820_pi.pdf)
[ Safety Data Sheet - Cryptosporidium Positive Control Immunocard STAT! Crypto/Giardia ](/uploads/750820_cryptosporidium_positive_control_sds.pdf)
[ Safety Data Sheet - Giardia Positive Control Immunocard STAT! Crypto/Giardia ](/uploads/750820_giardia_positive_control_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Parasitology
---
### [Immunocard® Toxins A&B](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Immunocard® Toxins A&B
A rapid, sensitive enzyme immunoassay for the detection of *Clostridium difficile* toxins A and B in stool specimens.
Catalog Number: 712050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-h-pylori/)
Healthcare Acquired Infections
[ Immunocard® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
Respiratory
[ Immunocard® Mycoplasma ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Immunocard® C. difficile GDH
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
### Revogene® C. difficile
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
### Alethia® C. difficile
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure ImmunoCard Toxins A&B ](/uploads/712050_ss.pdf)
[ Package Insert ImmunoCard Toxins A&B ](/uploads/712050_pi.pdf)
[ Procedure Card ImmunoCard Toxins A&B ](/uploads/712050_pc.pdf)
[ CLSI ImmunoCard Toxins A&B ](/uploads/712050_clsi.doc)
[ Safety Data Sheet ImmunoCard Enzyme Conjugate ](/uploads/7101_sds.pdf)
[ Data Sheet (OSHA) ImmunoCard Enzyme Conjugate ](/uploads/7101_osha.pdf)
[ Safety Data Sheet ImmunoCard Sample Diluent ](/uploads/7102_sds.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard Sample Diluent ](/uploads/7102_osha.pdf)
[ Safety Data Sheet ImmunoCard Wash Buffer I ](/uploads/7103_sds.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard Wash Buffer I ](/uploads/7103_osha.pdf)
[ Safety Data Sheet ImmunoCard Positive Control ](/uploads/7104_sds.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard Positive Control ](/uploads/7104_osha.pdf)
[ Safety Data Sheet (OSHA) ImmunoCard Substrate I ](/uploads/11372_osha.pdf)
[ Safety Data Sheet ImmunoCard Substrate I ](/uploads/11372_sds.pdf)
#### FAQs
What is the suggested CPT Code
Immunocard® Toxins A&B – 87324
References:
- [https://www.cdc.gov/cdiff/clinicians/faq.html#anchor\_1529601758264](https://www.cdc.gov/cdiff/clinicians/faq.html#anchor_1529601758264)
- L Clifford McDonald, Dale N Gerding, Stuart Johnson, Johan S Bakken, Karen C Carroll, Susan E Coffin, Erik R Dubberke, Kevin W Garey, Carolyn V Gould, Ciaran Kelly, Vivian Loo, Julia Shaklee Sammons, Thomas J Sandora, Mark H Wilcox; Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clinical Infectious Diseases, Volume 66, Issue 7, 19 March 2018, Pages e1–e48,
- [https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO\_CDADcurrent.pdf](https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Immunocard STAT!® HpSA® HD](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
## Immunocard STAT!® HpSA® HD
A second generation rapid lateral flow immunoassay that utilizes a monoclonal anti-*H. pylori* antibody.
Catalog Number: 750020
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT! HpSA HD ](/uploads/750020_ss.pdf)
[ Package Insert Immunocard STAT! HpSA HD ](/uploads/750020_pi.pdf)
[ Procedure Card Immunocard STAT! HpSA HD ](/uploads/750020_pc.pdf)
[ Safety Data Sheet - Kit Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_kit_sds.pdf)
[ Safety Data Sheet - Sample Diluent (OSHA) Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_sample_diluent_osha.pdf)
[ Safety Data Sheet - Positive Control Immunocard STAT! HpSA HD ](/uploads/750005_750020_750220_positive_control_sds.pdf)
[ Safety Data Sheet - Sample Diluent ImmunoCard STAT! HpSA HD ](/uploads/750005_750020_750220_sample_diluent_sds.pdf)
[ Safety Data Sheet - Positive Control (OSHA) ImmunoCard STAT! HpSA HD ](/uploads/750005_750020_750220_positive_control_osha.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [IDkit Hp® One](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-one/)
**Published:** April 30, 2020
**Author:** hamza
**Content:**
# IDkit Hp® One
**Effective immediately, the BreathID Hp instrument is discontinued. The purchase of kits and consumables will continue to be available including technical support for current instruments in use.**
Catalog Number: AC00051
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
#### Continous flow specimen collection allows for improved patient satisfaction and compliance.
##### For use with BreathID® Hp
## Related Tests
Gastrointestinal
## Kit Components
- Nasal cannula
- 75mg 13C-urea tablet
- 4.3g package of Citrica (citric acid)
- Drinking straw
- Package insert
## Support & Documents
#### Downloadable PDFs
[ Product Brochure IDkit Hp One ](/uploads/MBI_IDKit_Hp_One_SS_2020-11_v2.pdf)
[ Package Insert IDkit Hp One ](/uploads/ac00051_pi.pdf)
[ Safety Data Sheet (SDS) IDkit Hp ](/uploads/50402-100_sds.pdf)
[ Inserción de Paquetes IDkit Hp One para el Sistema ](/uploads/mld00024_pi_es.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Merifluor® C/G Treated Microscope Slides](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Merifluor® C/G Treated Microscope Slides
Direct fluorescent assay for the detection of *Cryptosporidium* and *Giardia*. A simple, highly sensitive stain to detect *Cryptosporidium* and *Giardia*.
Catalog Number: R2206
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Parasitology
[ Merifluor® Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
Respiratory
[ Merifluor® Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)
Sexual Health
[ Merifluor® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/)
[ Merifluor® VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Parasitology
---
### [LeadCare Plus®](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)
**Published:** March 30, 2019
**Author:** hamza
**Content:**
## LeadCare Plus®
A simple solution for labs with smaller volumes that want the convenience and control of performing lead testing in house
Catalog Number: 70-6760
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## LeadCare Plus® Product Descriptions
Lead is an invisible neurotoxin lurking throughout our environment. Children in homes built before 1978 are at highest risk. LeadCare Plus is based on anodic stripping voltammetry (ASV), an electrochemical technique that’s been used in clinical laboratories for decades.
### Analyzer Kit (82-0001)
The kit contains the analyzer, power cord, and instructions. Test kits must be ordered separately.
### Test Kit (82-0004)
Contains ready to use reagents, controls, and calibration for 96 tests
### Data Management System (82-0003) (optional)
Data Management System allows the collection, storage, sorting, and printing of results and facilitates the transmission of results to an LIS/EMR system using an HL7 interface.
## Related Tests
Pediatric & Neonatal
[ Analytical Services ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
[ LeadCare Ultra® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)
[ LeadCare® II ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)
## Because blood lead tests aren’t the only thing you’re sending out.
LeadCare Plus is the ideal stand-alone, single-channel analyzer for labs with small to midsize sample volumes. The Data Management System offers easy integration with your laboratory’s LIS (optional).
- Group 19 Created with Sketch.
FDA cleared - No method development required
- Group 13 Created with Sketch.
User friendly - Plug in and go! No setup or maintenance costs
- Group 12 Created with Sketch.
Electronic calibration - Seconds to complete, no standards, no drift
- Group 19 Created with Sketch.
Quantitative results - Compares to GFAAS
## Support & Documents
#### [Click here to access all LeadCare Plus product support materials.](https://www.magellandx.com/leadcare-products/leadcare-plus/support/getting-started/)
#### FAQs
What is the CLIA complexity of the LeadCare Plus Blood Lead Testing System?
The LeadCare Plus Blood Lead Testing System is cleared by the FDA with a moderately complex classification.
Is annual maintenance required for the LeadCare Plus Blood Lead Testing System?
Although annual maintenance is not required, your lab’s procedures may call for weekly, monthly, or annual maintenance. Refer to the Maintenance chapter of your LeadCare Plus User’s Guide for additional information on cleaning your analyzer.
What is the suggest CPT Code?
LeadCare Plus Assay – 83655, Collection of capillary blood – 36416
Does the LeadCare Plus test kit need to be refrigerated?
No. All components of the test kit should be stored at room temperature. Refer to the LeadCare Plus package insert included with your test kit for more information.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [Immunocard STAT!® Flu A&B](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
**Published:** March 18, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Flu A&B
A CLIA waived lateral flow immunoassay for the detection of Flu A & B from nasal & NP swab. Can also be used to test nasal aspirate/wash specimens.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 782030
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Related Products
### StatID PRO™ COVID-19/Flu A&B
Your country: US
Mode: Include
Countries: 1
US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Support & Documents
#### Downloadable PDFs
[ ImmunoCard STAT! Flu Brochure ](/uploads/IC-STAT-FLU-Sales-Brochure-.pdf)
[ Package Insert - Immunocard STAT! Flu A&B ](/uploads/782030_pi.pdf)
[ CLSI - Immunocard STAT! Flu A&B ](/uploads/782030_clsi.doc)
[ Procedure Card - Immunocard STAT! Flu A&B ](/uploads/782030_pc.pdf)
[ Safety Data Sheet - Extraction Reagent ](/uploads/781130_782030_sds.pdf)
[ Safety Data Sheet - Extraction Reagent (OSHA) ](/uploads/781130_782030_osha.pdf)
[ 2024 Annual Reactivity Testing Results ](/uploads/P-52770-F-ImmunoCard-STAT-Flu-2021-2023-2024-Annual-Reactivity-Testing-Results-appendix.pdf)
#### FAQs
What sample types can be used?
CLIA waived for Nasal and NP swabs, Moderately complex for Nasal washes and aspirates
Can samples in transport media be used?
Samples in transport media have to be processed following the procedure for apirates/washes. Need to use the Accessory Kit
Does the kit includes External Controls?
Yes, each kit includes 1 Positive control and 1 Negative control swab
Does the kit include everything you need?
Yes if running Nasal or NP swabs. If running nasal aspirate/wahes an Accessory Kit is required to go with the main kit.
References
Immunocard STAT!® FLU A&B Package Insert
What is the suggested CPT Code?
- Flu A – 87804QW (swabs)
- Flu A – 87804
- Flu B – 87804QW-59 (swabs)
- Flu B – 87804
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
**Published:** March 18, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit
Accessory kit for the Immunocard STAT!® Flu A&B kit to use with nasopharyngeal aspirates/washes specimens ##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 781130 (Accessory Kit)
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Related Products
### StatID PRO™ COVID-19/Flu A&B
Your country: US
Mode: Include
Countries: 1
US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/)
## Support & Documents
#### Downloadable PDFs
[ Procedure Card ](/uploads/781130_pc.pdf)
[ Safety Data Sheet - Extraction Reagent (OSHA) ](/uploads/781130_782030_osha.pdf)
[ Safety Data Sheet - Extraction Reagent ](/uploads/781130_782030_sds.pdf)
#### FAQs
What sample types can be used?
CLIA waived for Nasal and NP swabs, Moderately complex for Nasal washes and aspirates
Can samples in transport media be used?
Samples in transport media have to be processed following the procedure for apirates/washes. Need to use the Accessory Kit
Does the kit includes External Controls?
Yes, each kit includes 1 Positive control and 1 Negative control swab
Does the kit include everything you need?
Yes if running Nasal or NP swabs. If running nasal aspirate/wahes an Accessory Kit is required to go with the main kit.
References
Immunocard STAT!® FLU A&B Nasopharyngeal Wash/Aspirate Accessory Kit
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Curian® HpSA®](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/)
**Published:** May 1, 2020
**Author:** hamza
**Content:**
# Curian® HpSA®
Improves healthcare system efficiencies by providing a rapid, accurate result for *H. pylori* active infection and confirmation of eradication while removing subjectivity.
Catalog Number: 760130
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Curian HpSA?
Curian provides healthcare systems an opportunity to accurately diagnose *H. pylori* active infections according to guideline standards. Curian HpSA is intended to aid in the diagnosis of *H. pylori* infection and demonstrate loss of *H. pylori* antigen following treatment. Coupling Curian HpSA with an automated analyzer readout provides a result that can be read without the risk of subjective analysis by the technologist. Curian’s platform flexibility can help standardize testing throughout a health system by bringing testing closer to the patient resulting in improved clinical efficiencies.
- sample\_result\_icon
Standardized workflow – simple 3-step workflow with standardized assay-to-assay sample prep
- Group 13 Created with Sketch.
Focused menu – removes subjectivity for enhanced performance from the industry's leading experts in stool handling and testing
- assay\_flexibility\_icon
Total solution – Meridian offers additional *H. pylori* platforms for a total testing solution
- Group 19 Created with Sketch.
Trusted partner – 20 years of experience in the *H. pylori* business with best-in-class technical support
## Related Tests
Gastrointestinal
[ Curian® Shiga Toxin ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
[ Curian® Campy ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Curian® Campy
Your country: US
Mode: Include
Countries: 189
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
### Curian® Shiga Toxin
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### BreathID® Smart – IDkit Hp® Two
Your country: US
Mode: Include
Countries: 2
US CA
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Curian HpSA ](/uploads/760130-brochure.pdf)
[ Package Insert Curian HpSA ](/uploads/760130_pi.pdf)
[ Procedure Card Curian HpSA ](/uploads/760130_pc.pdf)
[ CLSI Curian HpSA ](/uploads/760130_clsi%20(1).doc)
[ Safety Data Sheet Curian HpSA Positive Control ](/uploads/7140_sds.pdf)
[ Safety Data Sheet Curian HpSA Sample Diluent (OSHA) ](/uploads/7139_osha.pdf)
[ Safety Data Sheet Curian HpSA Sample Diluent ](/uploads/7139_sds.pdf)
[ Safety Data Sheet Curian HpSA Positive Control (OSHA) ](/uploads/7140_osha.pdf)
#### Webinars & Videos
##### [Curian® HPSA® Workflow](https://youtu.be/ZcfIDpMTI3s)
#### FAQs
What causes stomach ulcers?
*Helicobacter pylori* is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that 9 out of 10 ulcers are caused by *H. pylori*. Medicines that reduce stomach acid may make you feel better, but your symptoms may come back. Here’s the good news – since most ulcers are caused by this bacterial infection, it can be cured with the right antibiotics.
What types of tests are used for diagnosing *H. pylori*?
There are 3 types of recommended tests:
**Stool Antigen Test:** Provide a small stool specimen in an easy-to-use collection device. The doctor will conduct the test in his office or send it to a laboratory for analysis.
**Urea Breath Test**: In this test, two breath samples are taken – one prior to ingesting a 13C-labeled urea drink and one after. The breath samples are then analyzed in the office or sent out to a laboratory.
**Endoscopy**: This is an invasive test in which a small tube with a camera inside is inserted through the mouth and into the stomach to look for ulcers. During the endoscopy, small samples of the stomach lining can be obtained and tested for *H. pylori*.
Can stools in Cary Blair be used for HpSA testing?
No, only fresh or frozen stool samples. The product is not validated for the use of samples in Cary-Blair. The 1:4 dilution of Cary Blair increases the limit of detection and could cause false negative results.
Why may a laboratory see an increase in positives with Curian HpSA vs. Immunocard STAT HpSA?
Curian HpSA offers improved performance over Immunocard STAT HpSA. Curian offers the lowest LoD (limit of detection) on the market at 2 ng/mL. Immunocard STAT HpSA has an LoD of 64 ng/mL, which means that any low-level sample between 2-64 ng/mL will be called a false negative by Immunocard STAT HpSA. Curian HpSA and Immunocard STAT HpSA were both compared to the Premier HpSA assay. Curian has higher PPA (96.1%) and NPA (97.0%) values than Immunocard STAT (86.5% and 94.2% respectively).
What is the suggested CPT Code?
Curian® HpSA – 87338
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Immunocard STAT!® Strep A](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Strep A
A CLIA waived one step lateral flow immunoassay for the direct detection of Group A Streptococcal antigens from throat swabs specimens.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 755250
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Group A Streptococcus ](/uploads/480150_product_brochure.pdf)
[ CLSI Immunocard STAT! Strep A ](/uploads/755250_clsi%20(1).doc)
[ Package Insert / Procedure Card Immunocard STAT! Strep A ](/uploads/755250_pi.pdf)
[ Safety Data Sheet – Kit Immunocard STAT! Strep A ](/uploads/755250_kit_sds.pdf)
[ Safety Data Sheet - Negative Control Immunocard STAT! Strep A ](/uploads/755250_negative_control_sds.pdf)
[ Safety Data Sheet - Positive Control Immunocard STAT! Strep A ](/uploads/755250_positive_control_sds.pdf)
[ Safety Data Sheet - Reagent 1 Immunocard STAT! Strep A ](/uploads/755250_reagent_1_sds.pdf)
[ Safety Data Sheet - Reagent 2 Immunocard STAT! Strep A ](/uploads/755250_reagent_2_sds.pdf)
[ Safety Data Sheet – Positive Control (OSHA) Immunocard STAT! Strep A ](/uploads/755250_positive_control_osha.pdf)
[ Safety Data Sheet – Negative Control (OSHA) Immunocard STAT! Strep A ](/uploads/755250_negative_control_osha.pdf)
[ Safety Data Sheet – Reagent 1 (OSHA) Immunocard STAT! Strep A ](/uploads/755250_reagent_1_osha.pdf)
[ Safety Data Sheet – Reagent 2 (OSHA) Immunocard STAT! Strep A ](/uploads/755250_reagent_2_osha.pdf)
#### Webinars & Videos
##### [LEANING The Diagnosis Of Group A Strep & The Diagnostic Challenges of Bordetella pertussis](https://vimeo.com/97717981)
#### FAQs
Is confirmation recommended for negative results with a rapid test?
Yes, the recommendation is that negative results be confirmed with a more sensitive method like culture or a molecular test. Meridian offers two molecular options for Group A Strep testing, [Alethia](https://meridianbiostg.wpengine.com/human-condition/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/) and Revogene. Both platforms offer rapid turn around times and definitive results without the subjectivity of culture.
What is the best use of the rapid Group A Strep test?
Rapid tests can be used for near-patient testing, and are best when paired with a molecular test. Ask about Meridian’s Best of Both Worlds program and how your lab can provide same day results for better patient care.
Reference:
1\. Shulman et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis:2012 Update by the Infectious Diseases Society of America
What is the suggested CPT Code?
Immunocard STAT!® Strep A – 87880
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Immunocard STAT!® EHEC](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® EHEC
Rapid lateral flow immunoassay for the detection of Shiga toxin 1 and 2 produced by *enterohemorraghic E. coli* (EHEC) from stool specimens in broth enrichment.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 751630
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Immunocard STAT!® CAMPY
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard Stat! EHEC ](/uploads/ImmunoCard-STAT-EHEC.pdf)
[ Product Brochure Immunocard STAT! EHEC & CAMPY Combo ](/uploads/ImmunoCard-STAT-EHEC-CAMPY-Combo-Product-Brochure-1.pdf)
[ Package Insert Immunocard STAT! EHEC ](/uploads/751630_pi.pdf)
[ Procedure Card Immunocard STAT! EHEC ](/uploads/751630_pc.pdf)
[ Safety Data Sheet Immunocard STAT! EHEC – Kit ](/uploads/751630_kit_sds.pdf)
[ CLSI Immunocard STAT! EHEC ](/uploads/751630_clsi%20(1).doc)
[ Safety Data Sheet – Sample Diluent Immunocard STAT! EHEC ](/uploads/751630_sample_diluent_sds.pdf)
[ Safety Data Sheet – Sample Diluent (OSHA) Immunocard STAT! EHEC ](/uploads/751630_sample_diluent_osha.pdf)
[ Safety Data Sheet – Positive Control Immunocard STAT! EHEC ](/uploads/751630_positive_control_sds.pdf)
[ Safety Data Sheet – Positive Control (OSHA) Immunocard STAT! EHEC ](/uploads/751630_positive_control_osha.pdf)
#### Webinars & Videos
##### [How does a false negative EHEC test result put your hospital and your patients at risk?](https://vimeo.com/91626476)
##### [Shiga Toxingenic E. coli: A Fully Emerged, Still Underappreciated Pathogen](https://vimeo.com/44872112)
#### FAQs
Does Immunocard STAT! EHEC only test for *E. coli* O157 strains?
No, Immunocard STAT! EHEC detects ALL Shiga toxin-producing *E. coli*, not just *E. coli* O157. Laboratories that are testing with culture will miss all non-O157 strains. Immunocard STAT! EHEC provides more comprehensive results along with increased sensitivity by testing for all Shiga toxin-producing *E. coli*.
Does this test require a broth enrichment step?
Yes, CDC Guidelines recommend Shiga Toxin testing be performed on growth from broth culture because this method is more sensitive and specific than direct testing of stool. In addition, because the amount of free fecal Shiga toxin in stools is often low, EIA testing of broth enrichments from stools is recommended rather than direct testing.
Why use a Shiga Toxin test for the non-O157 strains?
It is known that culture will miss ALL non-O157 strains. It is also known that the sensitivity for culture detecting the O-157 strains is low. The documented infection rate is about 50:50 for O157 strains vs. non-O157 strains. You should be testing for both!
References:
1. https://www.nphl.org/documents/ShigaToxinTestingRecommendations.pdf
2. CDC Recommendations and Reports MMWR October 16, 2009 / 58(RR12);1-14
3. Morbidity and Mortality Weekly Report. 2013;62(50):1029-1031.
What is the suggested CPT Code?
Immunocard STAT!® EHEC – STX I 87899 , STX II 87899-59
Broth Enrichment – 87015
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Immunocard STAT!® CGE](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
## Immunocard STAT!® CGE
A rapid in vitro qualitative immunoassay that simultaneously detects and distinguishes between *Cryptosporidium parvum*, *Giardia lamblia* and *Entamoeba histolytica* antigens in human stool.
Catalog Number: 751420
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Immunocard STAT!® CGE ](/uploads/751420_pi.pdf)
[ Safety Data Sheet Sample Diluent ](/uploads/751420_sample_diluent_sds.pdf)
[ Platform Brochure ](/uploads/MBI_ICS_CGE_SS_EU_2021-06_v3.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [RSV Positive Control](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/)
**Published:** March 22, 2019
**Author:** hamza
**Content:**
# RSV Positive Control
An external liquid control reagent to be used with TRU RSV® as part of a routine quality control program.
Catalog Number: 751110
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Respiratory
[ TRU Legionella® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/tru-legionella/)
[ TRU RSV® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/tru-rsv/)
[ TRU Strep Pneumo™ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/tru-strep-pneumo/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert RSV Positive Control ](/uploads/751110_pi.pdf)
[ Safety Data Sheet RSV Positive Control ](/uploads/7922_sds.pdf)
[ Safety Data Sheet RSV Positive Control OSHA ](/uploads/7922_osha.pdf)
[ Safety Data Sheet Premier Substrate ](/uploads/Elenco-Centri-Antiveleno-CAV_rev.0923.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [Immunocard STAT!® Crypto/Giardia](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Crypto/Giardia
Rapid lateral flow immunoassay for the differentiated detection of *Cryptosporidium* and *Giardia lamblia* from stool specimens.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 750830
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### SVT Stool Transport
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/svt/)
[  ](https://www.meridianbioscience.com/para-pak/svt/)
### SAF Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/saf/)
[  ](https://www.meridianbioscience.com/para-pak/saf/)
### 10% Formalin Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
[  ](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### Merifluor® Cryptosporidium/Giardia
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT! Crypto/Giardia ](/uploads/750830_ss.pdf)
[ Package Insert Immunocard STAT! Crypto/Giardia ](/uploads/750830_pi.pdf)
[ CLSI Immunocard STAT! Crypto/Giardia ](/uploads/750830_clsi.doc)
[ Safety Data Sheet - Conjugate Reagent A Immunocard STAT! Crypto/Giardia ](/uploads/750830_conjugate_reagent_a_sds.pdf)
[ Safety Data Sheet - Conjugate Reagent B Immunocard STAT! Crypto/Giardia ](/uploads/750830_conjugate_reagent_b_sds.pdf)
[ Safety Data Sheet - Sample Treatment Immunocard STAT! Crypto/Giardia ](/uploads/750830_sample_treatment_sds.pdf)
#### FAQs
What are the acceptable specimen collection devices?
Cary-Blair, C&S, 10% Formalin, SAF, MIF, and Stuart Transport Media. Fresh (unpreserved) samples must be diluted 1:4 into an acceptable transport media. [Explore our Para-Pak product page to learn more.](https://www.meridianbioscience.com/para-pak/)
Reference:
1. Immunocard STAT!® Crypto/Giardia Package Insert, 0095023
What are the suggested CPT codes?
Cryptosporidium – 87328
Giardia – 87329
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Parasitology
---
### [Immunocard STAT!® E. coli O157 Plus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® E. coli O157 Plus
Rapid lateral flow immunoassay for the detection of Shiga toxin-producing *E. coli* O157 in stool specimens and culture.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 750530
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Curian® Shiga Toxin
Your country: US
Mode: Include
Countries: 161
AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/)
### Curian® Campy
Your country: US
Mode: Include
Countries: 189
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Brochure Immunocard STAT! E. coli O157 Plus ](/uploads/750530_ss.pdf)
[ Package Insert Immunocard STAT! E. coli O157 Plus ](/uploads/750530_pi.pdf)
[ Procedure Card Immunocard STAT! E. coli O157 Plus ](/uploads/750530_pc.pdf)
[ CLSI Immunocard STAT! E. coli O157 Plus ](/uploads/750530_clsi.doc)
[ Safety Data Sheet - Negative Control Immunocard STAT! E. coli O157 Plus ](/uploads/7887_sds.pdf)
[ Safety Data Sheet - Positive Control Immunocard STAT! E. coli O157 Plus ](/uploads/7886_sds.pdf)
[ Safety Data Sheet - Sample Diluent Immunocard STAT! E. coli O157 Plus ](/uploads/7895_sds.pdf)
#### FAQs
What is the suggested CPT Code
ImmunoCard STAT!® E.coli O157 Plus – 87335
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Immunocard STAT!® C. difficile GDH-AB](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
**Published:** March 19, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® C. difficile GDH-AB
A rapid, qualitative, immunochromatographic assay for the simultaneous detection, in human stool, of *Clostridium difficile* Glutamate Dehydrogenase antigen (GDH, also called “common antigen”) and *Clostridium difficile* Toxins A and B.
Catalog Number: 750520
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT! C. difficile GDH-AB ](/uploads/MBE009e_ICSGT_BROCHURE_REV0119_ENG.pdf)
[ Package Insert Immunocard STAT! C. difficile GDH-AB ](/uploads/750520_pi.pdf)
[ Package Insert (Czech) Immunocard STAT! C. difficile GDH-AB ](/uploads/750520_pi_CZ.pdf)
[ Procedure Card Immunocard STAT! C. difficile GDH-AB ](/uploads/750520_pc.pdf)
[ Safety Data Sheet - Sample Diluent Immunocard STAT! C. difficile GDH-AB ](/uploads/750520_sample_diluent_sds.pdf)
[ Buckslip Immunocard STAT! C. difficile GDH-AB ](/uploads/750520_buckslip.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Immunocard STAT!® Rota-Adeno-Noro2 External Control Set](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
**Published:** September 26, 2023
**Author:** hamza
**Content:**
## Immunocard STAT!® Rota-Adeno-Noro2 External Control Set
External Controls to be used with Immunocard STAT Rota-Adeno-Noro2 External Control Set
Catalog Number: 750301
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Immunocard STAT!® Rotavirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Immunocard STAT!® Rotavirus
One step lateral flow immunoassay for the direct detection of rotavirus antigen in human stool.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 750030
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT!® Rotavirus ](/uploads/750030_ss.pdf)
[ Package Insert Immunocard STAT!® Rotavirus ](/uploads/750030_pi.pdf)
[ Procedure Card Immunocard STAT!® Rotavirus ](/uploads/750030_pc.pdf)
[ CLSI Immunocard STAT!® Rotavirus ](/uploads/750030_clsi.doc)
[ Safety Data Sheet - Positive Control ](/uploads/7881_sds.pdf?)
[ Safety Data Sheet - Sample Diluent ](/uploads/7845_sds.pdf)
#### FAQs
What is the suggested CPT Code
Immunocard STAT!® Rotavirus – 87899
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Immunocard® H. pylori](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-h-pylori/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Immunocard® H. pylori
A rapid, sensitive enzyme immunoassay for the detection of IgG to *Helicobacter pylori* in human serum, plasma and whole blood.
Catalog Number: 710030
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
Healthcare Acquired Infections
[ Immunocard® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
[ Immunocard® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
Respiratory
[ Immunocard® Mycoplasma ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/)
## Support & Documents
#### Downloadable PDFs
[ CLSI Immunocard® H. pylori ](/uploads/710030_clsi%20(1).doc)
[ Package Insert Immunocard® H. pylori ](/uploads/710030_pi.pdf)
[ Procedure Card Immunocard® H. pylori ](/uploads/710030_pc.pdf)
[ Safety Data Sheet Enzyme Conjugate ](/uploads/7851_sds.pdf)
[ Safety Data Sheet Negative Control ](/uploads/7853_sds.pdf)
[ Safety Data Sheet Positive Control ](/uploads/7852_sds.pdf)
[ Safety Data Sheet Sample Diluent ](/uploads/7856_sds.pdf)
[ Safety Data Sheet - Wash Buffer Immunocard Mycoplasma ](/uploads/7847_sds.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Gastrointestinal
---
### [Immunocard® Mycoplasma](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Immunocard® Mycoplasma
A rapid, sensitive enzyme immunoassay for the detection of IgM to *Mycoplasma pneumoniae* in human serum.
Catalog Number: 709030
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-h-pylori/)
Healthcare Acquired Infections
[ Immunocard® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
[ Immunocard® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
Respiratory
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Immunocard Mycoplasma ](/uploads/MBI_IC_Myco_SS_2020-04.pdf)
[ Package Insert - Immunocard Mycoplasma ](/uploads/709030_pi.pdf)
[ Procedure Card - Immunocard Mycoplasma ](/uploads/709030_pc.pdf)
[ CLSI- Immunocard Mycoplasma ](/uploads/709030_clsi.doc)
[ Safety Data Sheet - Enzyme Conjugate Immunocard Mycoplasma ](/uploads/7846_sds.pdf)
[ Safety Data Sheet - Negative Control Immunocard Mycoplasma ](/uploads/7819_sds.pdf)
[ Safety Data Sheet - Positive Control Immunocard Mycoplasma ](/uploads/7848_sds.pdf)
[ Safety Data Sheet - Wash Buffer Immunocard Mycoplasma ](/uploads/7847_sds.pdf)
[ Safety Data Sheet - ImmunoCard Substrate Reagent ](/uploads/7801_sds.pdf)
#### FAQs
What is the suggested CPT Code
Immunocard® Mycoplasma – 86738
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Respiratory
---
### [LeadCare Ultra®](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)
**Published:** March 30, 2019
**Author:** hamza
**Content:**
## LeadCare Ultra®
### Big results from a small footprint.
A simple solution for any lab – whether you run blood lead testing with GFAAS or send samples out to a reference laboratory.
Catalog Number: 70-8040 Lead Testing System
Catalog Number: 70-8098 Test Kit
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## LeadCare Ultra® Product Description
LeadCare Ultra is based on anodic stripping voltammetry (ASV), an electrochemical technique that’s been used in clinical laboratories for decades. Offering throughput and convenience for high volume labs.
### Lead Testing System (70-8040)
The kit contains the 6 port analyzer, PC, barcode scanner, and instructions. Test kits must be ordered separately.
### Test Kit (70-8098)
Contains ready to use reagents, controls, and calibration for 192 tests.
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Pediatric & Neonatal
[ Analytical Services ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
[ LeadCare Plus® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)
[ LeadCare® II ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)
## User friendly, ultra simple interface
LeadCare Ultra is the first plug-and-play, benchtop solution for blood lead testing, offering users calibration at the touch of a button and results in 3 minutes.
- Group 12 Created with Sketch.
3-minute sample analysis
- Group 19 Created with Sketch.
FDA cleared - No method development required
- Group 13 Created with Sketch.
Electronic calibration - Seconds to complete, no standards, no drift
- Group 19 Created with Sketch.
No maintenance plan required
## Support & Documents
#### [Click here to access all LeadCare Ultra product support materials.](https://www.magellandx.com/leadcare-products/leadcare-ultra/support/getting-started/)
#### FAQs
What is the CLIA complexity of the LeadCare Ultra Blood Lead Testing System?
The LeadCare Ultra Blood Lead Testing System is cleared by the FDA with a moderately complex classification.
Is annual maintenance required for the LeadCare Ultra Blood Lead Testing System?
Although annual maintenance is not required, your lab’s procedures may call for weekly, monthly, or annual maintenance. Refer to the Maintenance chapter of your LeadCare Ultra User’s Guide for additional information on cleaning your analyzer.
What is the suggested CPT Code?
LeadCare Ultra Assay – 83655, Collection of capillary blood – 36416
Does the LeadCare Ultra test kit need to be refrigerated?
No. All components of the test kit should be stored at room temperature. Refer to the LeadCare Ultra package insert included with your test kit for more information.
Where can I purchase linearity samples?
Wisconsin State Laboratory of Hygiene (WSLH) offers linearity samples. Visit our [Validation ](https://magellandx.wpengine.com/leadcare-products/leadcare-ultra/support/validation/)webpage for more information.
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [LeadCare® II](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)
**Published:** March 15, 2019
**Author:** hamza
**Content:**
## LeadCare® II
#### The easiest way to test for lead.
LeadCare II is the only CLIA waived point-of-care test for blood lead poisoning. It can screen in a single visit with a simple finger-stick.
Catalog Number: 70-6760, 70-6762
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## LeadCare® II Product Description
Lead is an invisible neurotoxin lurking throughout our environment. Children in homes built before 1978 are at highest risk. In 3 minutes, LeadCare II identifies them. CLIA-waived LeadCare II is used in thousands of practices because it’s easy to use, provides an accurate result and fits seamlessly into the office workflow. Parents appreciate a single visit, a simple fingerstick, and an answer in just 3 minutes.
### Analyzer Kit (70-6760)
The kit contains the analyzer, power cord, and instructions. Test kits must be ordered separately.
### Test Kit (70-6762)
Contains reagents, capillary tubes, plungers and transfer droppers for 48 tests; two levels of quality control and a calibration button.
## Related Tests
Pediatric & Neonatal
[ Analytical Services ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
[ LeadCare Plus® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)
[ LeadCare Ultra® ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)
## Take action before health and learning suffer.
Early diagnosis helps to quickly address the effects of lead exposure. Learn more about how you can prevent your child from lead poisoning.
- Group 12 Created with Sketch.
Results in 3 minutes
- Group 19 Created with Sketch.
Easy to use - CLIA-waived
- Group 13 Created with Sketch.
Accurate
- tech\_icon2
A single visit and a simple fingerstick test
## 1 in 38 US children has an elevated blood lead level
[ Get started today ](/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
#### [Click here to access all LeadCare II product support materials.](https://www.magellandx.com/leadcare-products/leadcare-ii/support/getting-started/)
#### FAQs
What is the LeadCare II Blood Lead Testing System?
LeadCare II is the only CLIA-waived, point-of-care blood lead testing system. The system includes the LeadCare II Blood Lead Analyzer and the LeadCare II Test Kit and is designed for the quantitative measurement of lead in fresh whole blood.
How does the LeadCare II system work?
The LeadCare II relies on electrochemistry (Anodic Stripping Voltammetry or ASV) and a unique sensor to detect lead in whole blood. Most lead is carried within red blood cells. When a sample of whole blood is mixed with treatment reagent, the red blood cells are lysed and the lead becomes available for detection. When a test is run, the analyzer applies an electrical potential that causes the lead to collect on the sensor. After 3 minutes, the analyzer measures the amount of lead on the sensor and displays the result in micrograms per deciliter (µg/dl).
Can the LeadCare II test for other things?
No, the LeadCare II Test Kit is specific for the analysis of lead only.
How does LeadCare II differ from other blood lead tests?
LeadCare II is the only CLIA-waived, point-of-care blood lead testing system. The test can be performed on site, requires only two drops of blood, and provides a quantitative blood lead result in 3 minutes.
In contrast, traditional lead testing methods require sending the test to an outside lab. With traditional tests, a blood sample (capillary or venous) is collected in the doctor’s office or clinic and sent out for testing at a reference lab, or the child is sent to another laboratory to have their blood collected and then sent out for analysis. Traditional testing methods require physicians to wait days to weeks for results, and parents must be called back for follow up. With LeadCare II, testing is performed while the parent and child are in the office, providing the perfect opportunity for education and intervention all in one visit.
What is involved in performing a test with the LeadCare II?
Lead analysis is performed in three simple steps:
The user collects 50 µl (approximately 2 drops) of whole blood from the patient’s fingertip, using a capillary tube provided in the test kit.
The user mixes the patient sample with prepackaged treatment reagent. A chemical reaction liberates the free lead from the red blood cells.
Using a transfer dropper supplied in the kit, the user places a drop of the test mixture on a disposable sensor that has been placed in the analyzer. Lead analysis begins automatically and the result is displayed 3 minutes later.
Is the LeadCare II test reimbursable?
Yes, blood lead testing is reimbursable using CPT code 83655 (‘QW’ modifier may be required). Reimbursement varies by state and insurance plan. For information to assist you regarding reimbursement in your state, contact .
What is the suggested CPT code?
- LeadCare II Kit – 83655
- Collection of capillary blood – 36416
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [Premier® Adenoclone®](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Premier® Adenoclone®
An enzyme immunoassay for the direct detection of adenovirus antigen in human fecal specimens and for the confirmation of Adenovirus in cell culture.
Catalog Number: 696007
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Premier Adenoclone ](/uploads/696007_pi.pdf)
[ CLSI Premier Adenoclone ](/uploads/696007_clsi.doc)
[ Safety Data Sheet - Enzyme Conjugate ](/uploads/6019_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/6061_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/6002_sds.pdf)
[ Safety Data Sheet - Stop Solution ](/uploads/6003_sds.pdf)
[ Safety Data Sheet - Substrate A ](/uploads/6032_sds.pdf)
[ Safety Data Sheet - Substrate B ](/uploads/6033_sds.pdf)
#### FAQs
What is the suggested CPT Code
Premier® Adenoclone® – 87301
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Premier® Adenoclone® 40/41](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Premier® Adenoclone® 40/41
An Enzyme Immunoassay for the detection of Adenovirus Serotypes 40 and 41 in human fecal samples.
Catalog Number: 696006
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ CLSI ](/uploads/696006_clsi.doc)
[ Package Insert Premier Adeoclone 40/41 ](/uploads/696006_pi.pdf)
[ Safety Data Sheet - Enzyme Conjugate ](/uploads/6021_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/6061_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/6002_sds.pdf)
[ Safety Data Sheet - Stop Solution ](/uploads/6003_sds.pdf)
[ Safety Data Sheet - Substrate A ](/uploads/6032_sds.pdf)
[ Safety Data Sheet - Substrate B ](/uploads/6033_sds.pdf)
#### FAQs
What is the suggested CPT code?
Premier® Adenoclone® 40/41 – 87301
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Premier® Rotaclone®](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
# Premier® Rotaclone®
An Enzyme Immunoassay for the detection of rotavirus antigen in human fecal samples.
Catalog Number: 696004
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Premier Rotaclone ](/uploads/696004_pi.pdf)
[ CLSI - Premier Rotaclone ](/uploads/696004_clsi.doc)
[ Safety Data Sheet - Enzyme Conjugate ](/uploads/6018_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/6006_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/6002_sds.pdf)
[ Safety Data Sheet - Stop Solution ](/uploads/6003_sds.pdf)
[ Safety Data Sheet – Substrate A ](/uploads/6032_sds.pdf)
[ Safety Data Sheet – Substrate B ](/uploads/6033_sds.pdf)
#### FAQs
What is the suggested CPT Code
Premier® Rotaclone® – 87899
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Premier® Toxins A&B](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# Premier® Toxins A&B
Enzyme Immunoassay for the detection of *Clostridium difficile* toxin A and toxin B in stool specimens.
Catalog Number: 616096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Alethia® C. difficile
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
### Revogene® C. difficile
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
### Premier® C. difficile GDH
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Premier Toxins A&B ](/uploads/616096_pi.pdf)
[ CLSI Premier Toxins A&B ](/uploads/616096_clsi.doc)
[ Procedure Card Premier Toxins A&B ](/uploads/616096_pc.pdf)
[ Safety Data Sheet - Enzyme Conjugate Premier Toxins A&B ](/uploads/6057_sds.pdf)
[ Safety Data Sheet - Positive Control Premier Toxins A&B ](/uploads/6058_sds.pdf)
[ Safety Data Sheet - Sample Diluent Premier Toxins A&B ](/uploads/6056_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet - Wash Buffer II Premier® ](/uploads/2607_sds.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet - Wash Buffer II Premier (OSHA) ](/uploads/2607_osha.pdf)
#### FAQs
What is the suggested CPT Code
Premier® Toxins A&B – 87324
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Premier® C. difficile GDH](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
**Published:** March 15, 2019
**Author:** hamza
**Content:**
# Premier® C. difficile GDH
Enzyme immunoassay for the detection of *Clostridium difficile* GDH in stool specimens
Catalog Number: 611096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Premier® Toxins A&B
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
### Revogene® C. difficile
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
### Alethia® C. difficile
Your country: US
Mode: Include
Countries: 192
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU BR CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Premier C. difficile GDH ](/uploads/611096_pi.pdf)
[ Procedure Card Premier C. difficile GDH ](/uploads/611096_pc.pdf)
[ Safety Data Sheet - Enzyme Conjugate Premier® ](/uploads/6087_sds.pdf)
[ CLSI Premier C. difficile GDH ](/uploads/611096_clsi.doc)
[ Safety Data Sheet - Positive Control Premier® ](/uploads/6088_sds.pdf)
[ Safety Data Sheet - Sample Diluent Premier® ](/uploads/6086_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet - Wash Buffer II Premier® ](/uploads/2607_sds.pdf)
[ Safety Data Sheet - Wash Buffer II (OSHA) ](/uploads/2607_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
#### FAQs
What is the suggested CPT Code
Premier® C. difficile GDH – 87449
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Premier® H. pylori](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
## Premier® H. pylori
A streamlined enzyme immunoassay for the detection of IgG antibodies to *Helicobacter pylori* in human serum and plasma.
Catalog Number: 606096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Premier H. pylori ](/uploads/606096_pi.pdf)
[ Procedure Card - Premier H. pylori ](/uploads/606096_pc.pdf)
[ CLSI - Premier H. pylori ](/uploads/606096_clsi.doc)
[ Safety Data Sheet - Enzyme Conjugate ](/uploads/6603_sds.pdf)
[ Safety Data Sheet - Negative Control ](/uploads/6602_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/6601_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/4609_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet Premier Wash Buffer I (OSHA) ](/uploads/1607_osha.pdf)
[ Safety Data Sheet Premier Wash Buffer I ](/uploads/1607_sds.pdf)
#### Webinars & Videos
##### [H. pylori: Active Infection Testing vs. Passive, Invasive or Pharma Approach for 55 and Younger](https://vimeo.com/35531028)
##### [Today's Trend in H. pylori Testing and Treatment](https://vimeo.com/165932421)
#### FAQs
What is the suggested CPT Code
Premier® *H. pylori* – 86677
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Alethia® Malaria](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
## Alethia® Malaria
Molecular assay for the detection of *Plasmodium sp.* Alethia provides a quick, accurate and reliable molecular assay for *Plasmodium sp.* detection.
Catalog Number: 480925
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Alethia® Malaria ](/uploads/MBI_Alethia_Malaria_SS_2019-04.pdf)
[ Package Insert Alethia Malaria ](/uploads/480925_pi.pdf)
[ Procedure Card Alethia Malaria ](/uploads/480925_pc.pdf)
[ Safety Data Sheet Buffer 1 ](/uploads/2904_2932_2933_sds.pdf)
[ Safety Data Sheet (OSHA) Buffer 1 ](/uploads/2904_2932_2933_osha.pdf)
[ Safety Data Sheet Control Bead ](/uploads/2835_2875_2876_sds.pdf)
[ Safety Data Sheet (OSHA) Control Bead ](/uploads/2835_2875_2876_osha.pdf)
[ Safety Data Sheet Alethia Malaria Test Kit ](/uploads/480925_kit.sds_.pdf)
[ Safety Data Sheet Sample Prep IV ](/uploads/2777_2778_2824_sds.pdf)
[ Safety Data Sheet (OSHA) Sample Prep IV ](/uploads/2777_2778_2824_osha.pdf)
[ Safety Data Sheet Test Bead ](/uploads/2875_2876_test_bead_sds.pdf)
[ Safety Data Sheet (OSHA) Test Bead ](/uploads/2875_2876_test_bead_osha.pdf)
[ Procedure Card Spanish ](/uploads/480925_PC_ES-1.pdf)
[ Procedure Card French ](/uploads/480925_PC_FR-1.pdf)
[ Procedure Card Italian ](/uploads/480925_PC_IT-1.pdf)
[ Procedure Card German ](/uploads/480925_PC_DE-1.pdf)
[ Safety Data Sheet Alethia Malaria Kit ](/uploads/480925_kit_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Tropical Diseases
---
### [Alethia® Gonorrhea](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
## Alethia® Gonorrhea
Molecular assay for the detection of *Neisseria gonorrhoeae*. Alethia provides a quick, accurate and reliable molecular assay for *Neisseria gonorrhoeae* detection.
Catalog Number: 480850
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Safety Data Sheet Alethia Gonorrhea Kit ](/uploads/480850_kit_sds.pdf)
[ Procedure Card - Swab ](/uploads/480450_480850_swab_pc.pdf)
[ Safety Data Sheet - Assay Control ](/uploads/4823_sds.pdf)
[ Safety Data Sheet - Assay Control (OSHA) ](/uploads/4823_osha.pdf)
[ Safety Data Sheet - Mineral Oil Alethia Pertussis ](/uploads/14298_sds.pdf)
[ Safety Data Sheet - Mineral Oil (OSHA) Alethia Pertussis ](/uploads/14298_osha.pdf)
[ Safety Data Sheet - Test Bead (OSHA) ](/uploads/2790_test_bead_osha.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia ](/uploads/2830_2810_2790_2865_2870_osha.pdf)
[ Safety Data Sheet - Control Bead Alethia ](/uploads/2830_2810_2790_2865_2870_sds.pdf)
[ Package Insert - Alethia Gonorrhea ](/uploads/480850_pi.pdf)
[ Procedure Card - Alethia Gonorrhea ](/uploads/480450_480850_pc.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Sexual Health
---
### [Alethia® Pertussis](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
## Alethia® Pertussis
Molecular assay for the detection of *Bordetella pertussis*. Alethia® provides a quick, accurate and reliable molecular assay for *Bordetella pertussis* detection.
Catalog Number: 480750
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Alethia® Pertussis ](/uploads/MBI_Alethia_Pertussis_Product_Brochure.pdf)
[ Package Insert Alethia® Pertussis ](/uploads/480750_pi.pdf)
[ Procedure Card Alethia® Pertussis ](/uploads/480750_pc.pdf)
[ Procedure Card - Pretreatment Alethia® Pertussis ](/uploads/480750_pre_pc.pdf)
[ Safety Data Sheet Alethia® Pertussis ](/uploads/480750_kit_sds.pdf)
[ CLSI Alethia® Pertussis ](/uploads/480750_clsi%20(1).doc)
[ Safety Data Sheet - Control Bead Alethia® Pertussis ](/uploads/2820_control_bead_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia® Pertussis ](/uploads/2820_control_bead_osha.pdf)
[ Safety Data Sheet - Mineral Oil Alethia Pertussis ](/uploads/14298_sds.pdf)
[ Safety Data Sheet - Mineral Oil (OSHA) Alethia Pertussis ](/uploads/14298_osha.pdf)
[ Safety Data Sheet - Assay Control Alethia Pertussis ](/uploads/2806_sds.pdf)
[ Safety Data Sheet - Assay Control (OSHA) Alethia Pertussis ](/uploads/2806_osha.pdf)
[ Safety Data Sheet - Pretreatment Alethia® Pertussis ](/uploads/1411_sds.pdf)
[ Safety Data Sheet - Pretreatment (OSHA) Alethia® Pertussis ](/uploads/1411_osha.pdf)
[ Safety Data Sheet - Sample Buffer Alethia® Pertussis ](/uploads/2811_sds.pdf)
[ Safety Data Sheet - Sample Buffer (OSHA) Alethia® Pertussis ](/uploads/2811_osha.pdf)
[ Safety Data Sheet - Test Bead Alethia® Pertussis ](/uploads/2820_test_bead_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) Alethia® Pertussis ](/uploads/2820_test_bead_osha.pdf)
[ Procedure Card - French Alethia® Pertussis ](/uploads/480750_PC_FR-1.pdf)
[ Procedure Card Pretreatment - French Alethia® Pertussis ](/uploads/480750_PC_FR2-1.pdf)
[ Procedure Card - Italian Alethia® Pertussis ](/uploads/480750_PC_IT-1.pdf)
[ Procedure Card Pretreatment - Italian Alethia® Pertussis ](/uploads/480750_PC_IT2-1.pdf)
[ Procedure Card - German Alethia® Pertussis ](/uploads/480750_PC_DE-1.pdf)
#### Webinars & Videos
##### [The Importance of Diagnostics in Pertussis Outbreak Situations](https://vimeo.com/204238411)
##### [The Diagnostic Challenges of Bordetella pertussis](https://vimeo.com/154082412)
#### FAQs
Why test for pertussis?
Early symptoms of Bordetella pertussis (B. pertussis) are nonspecific and can resemble many other infections, like the common cold. An early and accurate diagnosis is necessary to treat the patient appropriately to lessen the severity of illness and prevent the spread of infection to others.
What is the difference between Bordetella pertussis and Bordetella parapertussis?
- Bordetella parapertussis (B. parapertussis) is a bacteria like B. pertussis and causes pertussis-like symptoms, but it does not produce the pertussis toxin. The symptoms of B. parapertussis are typically milder and have a shorter duration than what is seen with B. pertussis.
- Unlike B. pertussis, B. parapertussis is not a nationally notifiable disease, so there is no specific case definition, and there are no national guidelines for the treatment or public health management of B. parapertussis infection. – Like B. pertussis, B. parapertussis is susceptible to macrolides and trimethoprim-sulfamethoxazole. Therefore, treatment is the same for both organisms
Culture is a recommended method of detection. What are the drawbacks?
While highly specific, culture for B. pertussis has a variable sensitivity, because fastidious growth requirements make it difficult to transport and isolate the organism. Culture sensitivity typically ranges from 12% to 60% and declines with the duration of illness. Culture is usually much less sensitive than molecular assays, in part because the organism is highly labile and does not survive well during specimen transport. Additionally, culture can typically take 1-2 weeks to finalize a result.
What are the advantages of molecular testing for Bordetella pertussis?
- Recommended by the CDC and IDSA
- Rapid results allow clinicians to collect, test and treat patients the same day, resulting in decreased severity of symptoms and prevention of additional cases
- Does not require viable (live) bacteria in the specimen in order to detect the presence of B. pertussis.
- Increased sensitivity means fewer false negatives
How is Bordetella pertussis treated?
The recommended antimicrobial agents for treatment of pertussis are azithromycin, clarithromycin and erythromycin. Trimethoprim-sulfamethoxasole can also be used.
References
1\. https://www.cdc.gov/pertussis/about/faqs.html
2\. Wedelboe, Aaron Mark, and Annilies Van Rie. “Diagnosis of pertussis: a historical review and recent developments.”(2006): 857-864.
3\. Loeffelholz.M. Towards Improved Accuracy of Bordetella pertussis Nucleic Acid Amplification Tests. J. Clin. Microbiol.2012, 50(7):2186.
What is the suggested CPT Code?
Alethia® Pertussis – 87798
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Alethia® HSV 1 & 2](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
**Published:** March 6, 2019
**Author:** hamza
**Content:**
## Alethia® HSV 1 & 2
Molecular assay for the detection of herpes simplex virus (HSV) type 1 & 2. Alethia provides a quick, accurate and reliable molecular assay for HSV 1 & 2 detection.
Catalog Number: 480650
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Alethia HSV 1&2 ](/uploads/480650_Brochure.pdf)
[ Package Insert Alethia HSV 1&2 ](/uploads/480650_pi.pdf)
[ Procedure Card Alethia HSV 1&2 ](/uploads/480650_pc.pdf)
[ CLSI Alethia HSV 1&2 ](/uploads/480650_clsi%20(1).doc)
[ Safety Data Sheet - Control Bead Alethia ](/uploads/2830_2810_2790_2865_2870_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia ](/uploads/2830_2810_2790_2865_2870_osha.pdf)
[ Safety Data Sheet - Mineral Oil Alethia Pertussis ](/uploads/14298_sds.pdf)
[ Safety Data Sheet - Mineral Oil (OSHA) Alethia Pertussis ](/uploads/14298_osha.pdf)
[ Safety Data Sheet - SMP PREP III (OSHA) Alethia HSV 1&2 ) ](/uploads/2864_2792_osha.pdf)
[ Safety Data Sheet - SMP PREP III Alethia HSV 1&2 ](/uploads/2864_2792_sds-1.pdf)
[ Procedure Card - German Alethia HSV 1&2 ](/uploads/480650_PC_DE-1.pdf)
[ Procedure Card - French Alethia HSV 1&2 ](/uploads/480650_PC_FR-1.pdf)
[ Safety Data Sheet Alethia HSV 1&2 Kit ](/uploads/480650_kit_sds.pdf)
#### FAQs
What are the drawbacks of traditional methods?
- Viral culture: has a low sensitivity, especially for recurrent lesions, and declines rapidly as lesions begin to heal. This test method may take up to 7 days.
- Cytology: is an insensitive and nonspecific method of diagnosis that can be quite time consuming for genital lesions and therefore should not be relied on.
- Type-specific serology: type-specific glycoprotein G (gG)- based serologic assays should only be requested. False negative results might be more frequent at early stages of infection and this test method does not indicate an active infection.
How should I handle an immunocompromised patient with suspected skin lesions?
The CDC guidelines recommend that the clinical diagnosis of genital herpes be confirmed by type-specific laboratory testing. Mucocutaneous manifestations of HSV-2 may have an atypical location or appearance which makes it important to perform a differential diagnosis of HSV-2 lesions including ulcerative sexually transmitted infections such as syphilis, chancroid, staphylococcal and other bacterial infections, pyoderma gangrenosum, squamous cell carcinoma and Behcet’s disease.
How should I diagnose a neonate with suspected HSV infection?
AAP indicates that the majority of infants (~73%) with HSV infection have lesions. Without lesions, the diagnosis of neonatal HSV infection is difficult. Swab specimens from cutaneous and mucocutaneous lesions should be tested before CSF and whole blood.
How should I handle a patient with skin lesions?
The CDC guidelines recommend that the clinical diagnosis of genital herpes be confirmed by type-specific laboratory testing.
The CDC recommends that all pregnant women be asked if they have a history of genital herpes, questioned carefully about symptoms of genital herpes at the onset of labor and examined carefully for herpetic lesions.2
What are the manifestations of HSV in a newborn?
AAP states that:
- 25% of infected infants have disseminated disease involving multiple organs
- 30% of infected infants have localized central nervous system disease (CNS)
- 45% of infected infants have disease localized to the skin, eyes and/or mouth (SEM disease)
What is Suggested CPT Code?
HSV 1 – 87529
HSV 2 – 87529-59
References:
1 Alethia HSV 1&2 Package Insert, SN11028.
2\. Department of Health and Human Services, Centers for Disease Control and Prevention,Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR 2015:64
3\. American Academy of Pediatrics. 2015 Report of the Committee on Infectious Disease. Red Book, 30th Edition. Herpes Simplex p. 432-445. https://redbook.solutions.aap.org/chapter.aspx?sectionid=88187163&bookid=1484
“Sending testing out greatly increases the number of errors and complaints from our customers. By bringing in HSV 1&2 we were able to eliminate these complaints to provide better customer service.”
Regional Reference Lab
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Sexual Health
---
### [Alethia® Group B Streptococcus](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
**Published:** March 6, 2019
**Author:** hamza
**Content:**
## Alethia® Group B Streptococcus
Molecular assay for the detection of Group B Streptococcus. Alethia provides a quick, accurate and reliable molecular assay for Group B Strep detection.
Catalog Number: 480350
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Alethia Group B Streptococcus ](/uploads/480350_product_brochure.pdf)
[ Package Insert Alethia Group B Streptococcus ](/uploads/480350_pi.pdf)
[ Safety Data Sheet Alethia Group B Strep Kit ](/uploads/480350_kit_sds.pdf)
[ CLSI Alethia Group B Streptococcus ](/uploads/480350_clsi.doc)
[ Safety Data Sheet - Control Alethia ](/uploads/4825_sds.pdf)
[ Safety Data Sheet - Control (OSHA) Alethia ](/uploads/4825_osha.pdf)
[ Safety Data Sheet - Control Bead Alethia ](/uploads/2830_2810_2790_2865_2870_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia ](/uploads/2830_2810_2790_2865_2870_osha.pdf)
[ Safety Data Sheet - Test Bead Alethia ](/uploads/2830_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) Alethia ](/uploads/2830_osha.pdf)
[ Safety Data Sheet - Reaction Buffer Alethia ](/uploads/2801_sds.pdf)
[ Safety Data Sheet - Reaction Buffer (OSHA) Alethia ](/uploads/2801_osha.pdf)
[ Procedure Card Alethia Group B Streptococcus ](/uploads/480350_pc.pdf)
[ Procedure Card (FR) Alethia Group B Streptococcus ](/uploads/480350_pc_fr.pdf)
#### FAQs
When is the best time to screen for GBS in pregnancy?
Studies have shown that testing within four weeks of delivery is most accurate at predicting GBS colonization status at delivery. The 2020 guidelines published by the American College of Obstetricians and Gynecologists (ACOG) state that screening should be done between 36-38 weeks of gestation.
The broth enrichment step delays the result by 24 hours. What advantage does it offer?
Broth enrichment greatly enhances the recovery of GBS thus improving the sensitivity. The 2010 CDC guidelines state that all samples must be enriched in broth media for 18-24 hours. For GBS disease, an accurate screening result is far more important than a rapid screening result.
Culture is the preferred method. What are the drawbacks?
The majority of infants that develop GBS disease are born to mothers who tested negative for Group B Streptococcus. This is due in large part to false-negative culture results. The sensitivity of culture is unreliable and is documented to be as low as 42%. The lack of sensitivity can be attributed to several factors including: Subjectivity, 4% of GBS isolates are nonhemolytic and therefore are undetectable on the culture plate, Overgrowth of normal flora can inhibit the ability to identify GBS colonies.
Can a molecular test be done directly from a prenatal swabs?
Based on the recommendations of the CDC, all vaginal-rectal swabs must be inoculated in selective enrichment broth first and incubated for 18-24 hours prior to performing any molecular test.
What are the advantages of molecular testing for Group B Streptococcus?
Recommended by CDC guidelines:
- Sensitivity of 98.6% means fewer false negatives
- Eliminates all subjectivity related to traditional culture methods
- Definitive, accurate answers mean appropriate therapy can be administered at delivery, if needed
What is the suggested CPT code?
Alethia Group B Streptococcus – 87653
Broth Culture – 87081
References:
1.Department of Health and Human Services, Centers for DiseaseControl and Prevention. Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010.MMWR 2010;59.
2.M. Van Dyke, Ph.D., et al. 2009. Evaluation of Universal Antenatal Screening for Group B Streptococcus. The New England Journal of Medicine. 360: pp. 2626-2636.
3.F. Rallu, P. Barriga, C. Scrivo, V. Martel-Laferriere, and C. Laferriere.2006. Sensitivities of Antigen Detection and PCR assays Greatly Increased Compared to that of the Standard Culture Method for Screening for Group B Streptococcus Carriage in Pregnant Women.Journal of Clinical Microbiology. 44: pp. 725-728.
4.CDC website, https://www.cdc.gov/groupbstrep/clinicians/QAs-obstetric.htm
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Pediatric & Neonatal
---
### [Alethia® Mycoplasma Direct](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
## Alethia® Mycoplasma Direct
Molecular assay for the detection of Mycoplasma pneumoniae. Alethia provides a quick, accurate and reliable molecular assay for Mycoplasma pneumoniae detection.
Catalog Number: 480250
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Alethia Mycoplasma Direct ](/uploads/480250_product_brochure.pdf)
[ Package Insert - Alethia Mycoplasma Direct ](/uploads/480250_pi.pdf)
[ CLSI - Alethia Mycoplasma Direct ](/uploads/480250_clsi.doc)
[ Safety Data Sheet - Alethia Mycoplasma Direct Kit ](/uploads/480250_kit_sds.pdf)
[ Safety Data Sheet - Test Bead Alethia Mycoplasma Direct ](/uploads/2855_test_bead_sds.pdf)
[ Safety Data Sheet (OSHA)- Test Bead Alethia Mycoplasma Direct ](/uploads/2855_test_bead_osha.pdf)
[ Safety Data Sheet - Control Bead Alethia Mycoplasma Direct ](/uploads/2855_control_bead_sds.pdf)
[ Safety Data Sheet (OSHA) - Control Bead Alethia Mycoplasma Direct ](/uploads/2855_control_bead_osha.pdf)
[ Safety Data Sheet - Sample Preparation Apparatus Alethia ](/uploads/2864_2792_sds.pdf)
[ Safety Data Sheet (OSHA) - Sample Preparation Apparatus Alethia ](/uploads/2864_2792_osha.pdf)
[ Procedure Card (EN) - Alethia Mycoplasma Direct ](/uploads/480250_pc.pdf)
[ Procedure Card (DE) - Alethia Mycoplasma Direct ](/uploads/480250_pc_de.pdf)
[ Procedure Card (FR) - Alethia Mycoplasma Direct ](/uploads/480250_pc_fr.pdf)
[ Procedure Card (IT) - Alethia Mycoplasma Direct ](/uploads/480250_pc_it.pdf)
[ Procedure Card (NL) - Alethia Mycoplasma Direct ](/uploads/480250_pc_nl.pdf)
[ Procedure Card (RO) - Alethia Mycoplasma Direct ](/uploads/480250_pc_ro.pdf)
#### FAQs
Why test for Mycoplasma pneumoniae?
- 40% of all community-acquired pneumonia is associated with Mycoplasma pneumoniae
- An estimated 2 million cases of Mycoplasma pneumoniae occur annually in the US
- IDSA guidelines for community-acquired pneumonia recommend immediate antibiotic therapy
- Typical antibiotics for respiratory infections including penicillin are ineffective in treating Mycoplasma pneumoniae due to the lack of cell wall, Chronic Mycoplasma pneumoniae infection may be linked to chronic asthma, Empiric treatment may lead to antimicrobial resistance
What are the drawbacks of X-Rays?
No distinctive X-Ray pattern of Mycoplasma pneumoniae has been found and marked differences exist in its radiographic appearance, making it an insufficient diagnostic tool with as low as 29% sensitivity.
What are the drawbacks of serology?
- Serology may only detect 25% of positives during the first week and 56% of positives during the second week of infection.
- IgM antibodies may not be produced:
- Until 1-2 weeks after symptom onset
- On reinfection
- In very young children.
How is Mycoplasma pneumoniae treated?
- Macrolides are the treatment of choice for Mycoplasma pneumoniae
- Tetracyclines and fluoroquinolones are also effective in the treatment of Mycoplasma pneumoniae in adults, however, they are not recommended for children under normal circumstances.
What are the advantages of stand alone molecular testing of Mycoplasma pneumoniae?
- Targeted detection for targeted treatment
- Simple sample preparation from throat swabs
- Positive agreement of 96.0% means fewer false negatives
- Direct molecular methods detect up to 4X more positives than serology
What is the suggested CPT Code?
Alethia® Mycoplasma Direct – 87581
References
1\. Waites, K.B., Mitchell F.B., and Atkinson, T.P. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiology (2008): 635-648.
2\. Centers for Disease Control and Prevention: National Center for Immunization and Respiratory Diseases, Division of Bacterial Disease. Mycoplasma pneumoniae Infection: History and Disease (2016). https://www.cdc.gov/pneumonia/atypical/mycoplasma/about/index.html
3\. Mandell et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. CID 2007; 44(S27-72).
4\. Martin, R.J., J.M., Kraft, M., Chu., H.W. et al. A link between chronic asthma and chronic infection. Journal of Allergy and Clinical Immunology 107.4 (2001): 595-601.
5\. Centers for Disease Control and Prevention: National Center for Immunization and Respiratory
10\. Nilsson, A.C., Björkman, P., and Persson, K.. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiology 8.1 (2008): 93.
11\. Loens, K., & Ieven, M. Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics. Frontiers in Microbiology 7.448 (2016)
12\. Graffelman, A. W., Willemssen, F. E., Zonderland, H. M., et al. Limited value of chest radiography in predicting aetiology of lower respiratory tract infection in general practice. The British Journal of General Practice, 58.547 (2008): 93–97.13. Medjo, B., Atanaskovic-Mark
13\. Medjo, B., Atanaskovic-Markovic, M., Radic, S., et al. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Italian Journal of Pediatrics. 40.104 (2014).
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [Alethia® C. difficile](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
**Published:** August 27, 2019
**Author:** hamza
**Content:**
## Alethia® *C. difficile*
Molecular assay for the detection of *C. difficile*. Alethia® provides a quick, accurate and reliable molecular assay for C. difficile detection.
Catalog Number: 480050
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Immunocard® Toxins A&B
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
### Immunocard® C. difficile GDH
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Alethia C. difficile ](/uploads/480050_product_brochure.pdf)
[ Package Insert - Alethia C. difficile ](/uploads/480050_pi.pdf)
[ CLSI - Alethia C. difficile ](/uploads/480050_clsi.doc)
[ Safety Data Sheet - Alethia C. difficile Kit ](/uploads/480050_kit_sds.pdf)
[ Safety Data Sheet - Control Bead Alethia C. difficile ](/uploads/2850_control_bead_sds.pdf)
[ Safety Data Sheet - Control Bead (OSHA) Alethia C. difficile ](/uploads/2850_control_bead_osha.pdf)
[ Safety Data Sheet - Sample Prep Alethia C. difficile ](/uploads/2849_sds.pdf)
[ Safety Data Sheet - Sample Prep (OSHA) Alethia C. difficile ](/uploads/2849_osha.pdf)
[ Safety Data Sheet - Reaction Buffer Alethia ](/uploads/2801_sds.pdf)
[ Safety Data Sheet - Reaction Buffer (OSHA) Alethia ](/uploads/2801_osha.pdf)
[ Safety Data Sheet - Test Bead Alethia C. difficile ](/uploads/2850_test_bead_sds.pdf)
[ Safety Data Sheet - Test Bead (OSHA) Alethia C. difficile ](/uploads/2850_test_bead_osha.pdf)
[ Procedure Card (EN) - Alethia C. difficile ](/uploads/480050_pc.pdf)
[ Procedure Card (DE) - Alethia C. difficile ](/uploads/480050_PC_DE.pdf)
[ Procedure Card (FR) - Alethia C. difficile ](/uploads/480050_PC_FR.pdf)
[ Procedure Card (IT) - Alethia C. difficile ](/uploads/480050_PC_IT.pdf)
#### FAQs
What are the differences between colonization and infection?
Colonization is more common than C. diff infection. The patient exhibits no clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.
What is the best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant C. difficile infection in commonly submitted stool specimens?
Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase \[GDH\] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test \[NAAT\]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.
What is the most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms?
Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.
Does detection of fecal lactoferrin or another biologic marker improve the diagnosis of CDI over and above the detection of toxigenic C. difficile? Can such a subset predict a more ill cohort?
There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.
What were the recent changes to the CDI LabID Event Reporting?
The 2018 MDRO/CDI Protocol states that the results of the final tests that are placed in the patient’s medical record should be used to determine whether or not the event meets the CDI LabID Event definition. That means that facilities using a multi-step testing algorithm for C. difficile will be entering LabID events in NHSN based on the results of the final test in the algorithm. In 2017, the CDI testing algorithm of “NAAT plus EIA, if NAAT-positive” received the “NAAT” level of risk adjustment. Now the CDI testing algorithm of “NAAT plus EIA, if NAAt-positive” is assigned the “EIA” level of risk adjustment. Facilities using this algorithm should only enter CDI LabID events into NHSN if the results from the EIA test are positive.
What is the suggested CPT Code?
Alethia®*C. difficile* – 87493
References
1. [https://www.cdc.gov/cdiff/clinicians/faq.html#anchor\_1529601758264](https://www.cdc.gov/cdiff/clinicians/faq.html#anchor_1529601758264)
2. L Clifford McDonald, Dale N Gerding, Stuart Johnson, Johan S Bakken, Karen C Carroll, Susan E Coffin, Erik R Dubberke, Kevin W Garey, Carolyn V Gould, Ciaran Kelly, Vivian Loo, Julia Shaklee Sammons, Thomas J Sandora, Mark H Wilcox; Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clinical Infectious Diseases, Volume 66, Issue 7, 19 March 2018, Pages e1–e48,
3. [https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO\_CDADcurrent.pdf](https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Alethia® Malaria External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia® Malaria External Controls
An enzyme immunoassay for the direct detection of adenovirus antigen in human fecal specimens and for the confirmation of Adenovirus in cell culture.
Catalog Number: 479970
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia Malaria External Controls ](/uploads/479970_pi.pdf)
[ Safety Data Sheet - Alethia Malaria Control Kit ](/uploads/479970_kit_sds.pdf)
[ Safety Data Sheet - Alethia Malaria Positive Control ](/uploads/4795_4799_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Malaria Positive Control ](/uploads/4795_4799_osha.pdf)
[ Safety Data Sheet - Alethia Malaria Negative Control ](/uploads/4776_4796_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Malaria Negative Control ](/uploads/4776_4796_osha.pdf)
#### FAQs
What is the suggested CPT Code
87798 – Molecular Malaria Test
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Alethia® HSV 1&2 External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia® HSV 1&2 External Controls
Catalog Number: 479960
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia HSV 1&2 External Controls ](/uploads/479960_pi.pdf)
[ Safety Data Sheet - Alethia HSV 1&2 External Control Kit ](/uploads/479960_kit_sds.pdf)
[ Safety Data Sheet - Alethia HSV 1&2 Positive Control ](/uploads/4791_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia HSV 1&2 Positive Control ](/uploads/4791_osha.pdf)
[ Safety Data Sheet - Alethia HSV 1&2 Negative Control ](/uploads/4816_2907_2962_2963_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia HSV 1&2 Negative Control ](/uploads/4816_2907_2962_2963_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Alethia® Pertussis External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
**Published:** July 15, 2020
**Author:** hamza
**Content:**
## Alethia® Pertussis External Controls
Catalog Number: 479930
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - External Controls Alethia Pertussis ](/uploads/479930_pi.pdf)
[ Safety Data Sheet - Alethia Pertussis Positive Control ](/uploads/4807_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Pertussis Positive Control ](/uploads/4807_osha.pdf)
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Alethia® C. difficile External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia® C. difficile External Controls
Catalog Number: 479920
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia C. difficile External Controls ](/uploads/479920_pi.pdf)
[ Safety Data Sheet - Alethia C. difficile External Controls Kit ](/uploads/479920_kit_sds.pdf)
[ Safety Data Sheet - Alethia Negative Control ](/uploads/4803_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Negative Control ](/uploads/4803_osha.pdf)
[ Safety Data Sheet - Alethia C. Difficile Positive Control ](/uploads/4802_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia C. Difficile Positive Control ](/uploads/4802_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Alethia® Group A Streptococcus External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
**Published:** July 7, 2020
**Author:** hamza
**Content:**
## Alethia® Group A Streptococcus External Controls
Catalog Number: 479910
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia Group A Streptococcus External Controls ](/uploads/479910_pi.pdf)
[ Safety Data Sheet - Positive Control Alethia Group A Streptococcus ](/uploads/4804_sds.pdf)
[ Safety Data Sheet - Positive Control (OSHA) Alethia Group A Streptococcus ](/uploads/4804_osha.pdf)
[ Safety Data Sheet - Negative Control Alethia Group A Streptococcus ](/uploads/2806_sds.pdf)
[ Safety Data Sheet - Negative Control (OSHA) Alethia Group A Streptococcus ](/uploads/2806_osha.pdf)
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Alethia® Group B Streptococcus External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia® Group B Streptococcus External Controls
Catalog Number: 479900
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia Group B Streptococcus External Controls ](/uploads/479900_pi.pdf)
[ Safety Data Sheet - Alethia Group B Streptococcus External Controls Kit ](/uploads/479900_kit_sds.pdf)
[ Safety Data Sheet - Alethia Group B Streptococcus Positive Control GHS ](/uploads/4822_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Group B Streptococcus Positive Control ](/uploads/4822_osha.pdf)
[ Safety Data Sheet - Alethia Group B Streptococcus Negative Control GHS ](/uploads/4803_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia Group B Streptococcus Negative Control ](/uploads/4803_osha.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Alethia® Mycoplasma Direct External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia® Mycoplasma Direct External Controls
Catalog Number: 479890
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - External Controls Alethia Mycoplasma Direct ](/uploads/479890_pi.pdf)
[ Safety Data Sheet - Positive Control Alethia Mycoplasma Direct ](/uploads/4794_sds.pdf)
[ Safety Data Sheet (OSHA) - Positive Control Alethia Mycoplasma Direct ](/uploads/4794_osha.pdf)
[
For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/?country=PK)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Alethia CMV External Controls](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
**Published:** October 28, 2020
**Author:** hamza
**Content:**
## Alethia CMV External Controls
Catalog Number: 479880
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - Alethia CMV External Controls Kit ](/uploads/479880_pi.pdf)
[ Safety Data Sheet - Alethia CMV External Controls Kit ](/uploads/479880_kit_sds.pdf)
[ Safety Data Sheet - Alethia CMV Positive Control GHS ](/uploads/2797_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia CMV Positive Control ](/uploads/2797_osha.pdf)
[ Safety Data Sheet - Alethia CMV Negative Control GHS ](/uploads/2798_sds.pdf)
[ Safety Data Sheet (OSHA) - Alethia CMV Negative Control ](/uploads/2798_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Revogene® C. difficile](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
**Published:** May 22, 2019
**Author:** hamza
**Content:**
## Revogene® C. difficile
Improves satisfaction among patients and physicians by providing rapid, accurate, actionable results for the detection of *Clostridium difficile* infection (CDI)
Catalog Number: 410300
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Why Revogene C. difficile?
Revogene provides healthcare systems an opportunity to minimize the overall burden of *C. difficile* through improved care and efficiency by helping to reduce the risk of missing a true positive with the accuracy of molecular. Fast, actionable results enable physicians to make informed decisions about patient management and treatment resulting in reduced healthcare costs associated with isolation and antibiotics. Revogene is a flexible, reliable molecular platform that allows health systems to provide testing closer to the patient and advance the quality of care through simplified sample processing and efficient workflow.
Efficient workflow – Sample to result in 3 easy steps
Flexible platform – Run multiple assays with different sample types on a single run
Platform for growth – Single analyte and multiplex testing capability
Total solution – Can be paired with Meridian immunoassays for a scalable testing solution
## Related Tests
Healthcare Acquired Infections
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
### The system is very easy to work with, I was able to start and run an experiment after only 5 minutes of training!
Ingrid Op den Buijs
Senior technician molecular diagnostics
PAMM Laboratories
Veldhoven, Netherlands
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Revogene C. difficile ](/uploads/410300_ss.pdf)
[ Package Insert - Revogene C. difficile ](/uploads/410300_pi.pdf)
[ CLSI - Revogene C. difficile ](/uploads/410300_clsi.doc)
[ Safety Data Sheet - Revogene C. difficile Kit ](/uploads/410300_kit_sds.pdf)
[ Safety Data Sheet - Revogene C. difficile ](/uploads/410300_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene C difficile ](/uploads/410300_osha.pdf)
[ Safety Data Sheet - Revogene Sample Buffer ](/uploads/4101_4102_4103_4104_4105_6102_sds.pdf)
[ Safety Data Sheet - Revogene Sample Buffer (OSHA) ](/uploads/4101_4102_4103_4104_4105_6102_osha.pdf)
[ Procedure Card - EN Revogene C. difficile ](/uploads/410300_pc.pdf)
[ Procedure Card DE Revogene C. difficile ](/uploads/410300_pc_de.pdf)
[ Procedure Card ES - Revogene C. difficile ](/uploads/410300_pc_es.pdf)
[ Procedure Card FR - Revogene C. difficile ](/uploads/410300_pc_fr.pdf)
[ Procedure Card IT - Revogene C. difficile ](/uploads/410300_pc_it.pdf)
[ Procedure Card NL - Revogene C. difficile ](/uploads/410300_pc_nl.pdf)
[ Package Insert - Revogene Mock Pie ](/uploads/610208_pi.pdf)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Immunocard® Toxins A&B
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/)
### Immunocard® C. difficile GDH
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
#### FAQs
What are the differences between colonization and infection?
Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.
What is the best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant C. difficile infection in commonly submitted stool specimens?
Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase \[GDH\] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test \[NAAT\]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.
What is the most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms?
Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.
Does detection of fecal lactoferrin or another biologic marker improve the diagnosis of CDI over and above the detection of toxigenic C. difficile? Can such a subset predict a more ill cohort?
There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.
What is the suggested CPT Code?
Revogene *C. difficile* – 87493
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Healthcare Acquired Infections
---
### [Revogene® GBS LB](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
**Published:** May 22, 2019
**Author:** hamza
**Content:**
## Revogene® GBS LB
A precise diagnostic test for detection of Group B *Streptococcus* (GBS) from Lim Broth samples
Catalog Number: 410200
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Revogene GBS LB ](/uploads/MBI_Revogene_GBS_LB_Product_Brochure.pdf)
[ Procedure Card Revogene GBS LB ](/uploads/410200_pc.pdf)
[ Package Insert Revogene GBS LB ](/uploads/410200_pi.pdf)
[ CLSI Revogene GBS LB ](/uploads/410200_clsi.doc)
[ Safety Data Sheet Revogene GBS LB ](/uploads/410200_sds.pdf)
[ Package Insert Revogene Mock Pie ](/uploads/610208_pi.pdf)
[ Safety Data Sheet Revogene GBS LB Kit ](/uploads/410200_kit_sds.pdf)
[ Safety Data Sheet (OSHA) Revogene GBS LB ](/uploads/410200_osha.pdf)
[ Safety Data Sheet (OSHA) DS Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_osha.pdf)
[ Safety Data Sheet DS Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_sds.pdf)
#### FAQs
Can direct swab specimen be used with the Revogene GBS LB assay?
Only enriched specimen with LIM Broth has been validated for this test. Samples from a direct swab are not compatible with the Revogene GBS LB assay.
Which enrichment media is compatible with the Revogene GBS LB assay?
Only enriched specimen with LIM Broth has been validated for this test. Other enrichment media must be evaluated.
If I don’t have eight samples to fulfill the carousel to perform a complete run, what alternatives do I have?
Revogene MOCK PIEs can be used when less than eight samples are available to perform a run. In case you don’t have any MOCK PIEs, assay PIEs filled with Sample Buffer or External Controls may also be used.
What is the ideal temperature to store Revogene GBS LB kits?
Revogene GBS LB kits can be stored at 2-25°C.
What is the suggested CPT Code?
Revogene GBS LB – 87081, 87653
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Pediatric & Neonatal
---
### [Fungal Immunodiffusion Plates, 1 Series](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Fungal Immunodiffusion Plates, 1 Series
Immunodiffusion Plate for the detection of circulating antibody to common systemic pathogens.
Catalog Number: 101012
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Immunodiffusion Plates ](/uploads/101009_101012_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Other
---
### [Fungal Immunodiffusion Plates, 4 Series](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Fungal Immunodiffusion Plates, 4 Series
Immunodiffusion Plate for the detection of circulating antibody to common systemic pathogens.
Catalog Number: 101009
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/)
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/)
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/)
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/)
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/)
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Fungal Immunodiffusion Reagents ](/uploads/100201_100401_100405_100601_100801_101009_101012_103001_103101_pi.pdf)
[ Safety Data Sheet Immunodiffusion Plates ](/uploads/101009_101012_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Other
---
### [Immunocard STAT!® CAMPY](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
## Immunocard STAT!® CAMPY
Rapid lateral flow immunoassay for the direct detection of ,Campylobacter antigens from stool specimens.
##### NOTE: Actual product may vary from image displayed. Please refer to the package insert for complete information.
Catalog Number: 751530
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/)
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/)
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/)
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/)
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/)
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/)
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/)
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/)
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/)
Parasitology
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/)
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/)
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/)
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/)
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/)
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/)
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/)
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/)
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Immunocard STAT!® EHEC
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Immunocard STAT! EHEC & CAMPY Combo ](/uploads/ImmunoCard-STAT-EHEC-CAMPY-Combo-Product-Brochure-1.pdf)
[ Package Insert Immunocard STAT! CAMPY ](/uploads/751530_pi.pdf)
[ Procedure Card Immunocard STAT! CAMPY ](/uploads/751530_pc-1.pdf)
[ Safety Data Sheet Immunocard STAT! Campy – Kit ](/uploads/751530_kit_sds.pdf)
[ CLSI Immunocard STAT! CAMPY ](/uploads/751530_clsi%20(1).doc)
[ Safety Data Sheet – Positive Control ImmunoCard STAT! Campy ](/uploads/751530_positive_control_sds.pdf)
[ Safety Data Sheet -Positive Control Immunocard STAT! CAMPY (OSHA) ](/uploads/751530_positive_control_osha.pdf)
[ Safety Data Sheet - Sample Diluent Negative Control ImmunoCard STAT! Campy ](/uploads/751530_sample_diluent_negative_control_sds.pdf)
[ Safety Data Sheet -Sample Diluent Negative Control Immunocard STAT! CAMPY (OSHA) ](/uploads/751530_sample_diluent_negative_control_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Premier® CAMPY](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# Premier® CAMPY
A microwell enzyme immunoassay for the detection of *Campylobacer* antigens from stool specimens
Catalog Number: 618096
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/)
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/)
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/)
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/)
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/)
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/)
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/)
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/)
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/)
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/)
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Related Products
### Premier® EHEC
Your country: US
Mode: Include
Countries: 190
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
[  ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/)
### Clean Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[  ](https://www.meridianbioscience.com/para-pak/clean-vial/)
### C&S Stool Transport
Your country: US
Mode: Include
Countries: 191
AT BE BG HR CY CZ DK EE FI FR DE GR HU IE IT LV LT LU MT NL PL PT RO SK SI ES SE CH AD AF AL DZ AO AG AR AM AZ BS BH BD BB BY BZ BJ BT BO BA BW BN BF BI CV KH CM CF TD CL CN CO KM CG CD CR CU DJ DM DO EC EG SV GQ ER ET FJ GA GM GE GH GD GT GN GW GY HT VA HN IS IN ID IR IQ IL JM JO KZ KE KI KP KR KW KG XK LB LS LR LY LI MG MW MY MV ML MH MR MU MX FM MD MC MN ME MA MZ MM NA NR NP NZ NI NE NG NO OM PK PW PS PA PG PY PE PH QA RU RW KN LC VC WS SM ST SA SN RS SC SL SG SB SO ZA SS LK SD SR SY TW TJ TZ TH TL TG TO TT TN TR TM TV UG UA AE UY UZ VU VE VN YE ZM ZW GB AU CA US
✓ Available in your country
[ Learn More ⟶ ](https://www.meridianbioscience.com/para-pak/cs/)
[  ](https://www.meridianbioscience.com/para-pak/cs/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure Premier CAMPY ](/uploads/618096_ss.pdf)
[ Package Insert Premier CAMPY ](/uploads/618096_pi.pdf)
[ CLSI Premier CAMPY ](/uploads/618096_clsi.doc)
[ Procedure Card Premier CAMPY ](/uploads/618096_pc.pdf)
[ Safety Data Sheet - Enzyme Conjugate Premier CAMPY ](/uploads/6079_sds.pdf)
[ Safety Data Sheet - Positive Control Premier CAMPY ](/uploads/6078_sds.pdf)
[ Safety Data Sheet - Sample Diluent / Negative Control Premier Campy ](/uploads/6076_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I Premier® ](/uploads/8613_sds.pdf)
[ Safety Data Sheet Premier Stop Solution I (OSHA) ](/uploads/8613_osha.pdf)
[ Safety Data Sheet - Wash Buffer III Premier CAMPY ](/uploads/6067_sds.pdf)
[ Safety Data Sheet Premier Substrate I ](/uploads/11371_sds.pdf)
[ Safety Data Sheet Premier Substrate I (OSHA) ](/uploads/11371_osha.pdf)
[ Safety Data Sheet - Wash Buffer III Premier Campy (OSHA) ](/uploads/6067_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Meridian Viral Transport](https://www.meridianbioscience.com/diagnostics/disease-areas/other/viral-transport/meridian-viral-transport/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
## Meridian Viral Transport
Meridian Viral Transport is a system which contains all materials necessary to collect and transport clinical specimens for viral isolation.
Catalog Number: 505021
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
[ ANA Test | ANA Screening ELISA ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/serology/ana-screening-elisa/)
Sexual Health
## Support & Documents
#### Downloadable PDFs
[ Package Insert ](/uploads/505021_pi.pdf)
[ Safety Data Sheet ](/uploads/505021_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Merifluor® Chlamydia](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/)
**Published:** March 14, 2019
**Author:** hamza
**Content:**
# Merifluor® Chlamydia
Direct fluorescent assay for the detection of chlamydia in McCoy cells.
Catalog Number: 500111
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Parasitology
[ Merifluor® C/G Treated Microscope Slides ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/)
[ Merifluor® Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/)
Respiratory
[ Merifluor® Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/)
Sexual Health
[ Merifluor® VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert Merifluor Chlamydia ](/uploads/500111_pi.pdf)
[ Safety Data Sheet - Detection Reagent Merifluor Chlamydia ](/uploads/5011_sds.pdf)
[ Safety Data Sheet - Mounting Medium Merifluor ](/uploads/5010_sds.pdf)
#### FAQs
What is the suggested CPT Code
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Sexual Health
---
### [Revogene® Strep A](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/)
**Published:** June 19, 2019
**Author:** hamza
**Content:**
## Revogene® Strep A
A precise diagnostic test for detection of Group A *Streptococcus* (GAS) from throat swab specimens
Catalog Number: 410400
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ FAQs ](#faqs)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Why Revogene Strep A?
The Revogene Strep A assay is for the direct detection of *Streptococcus pyogenes* (Group A β-hemolytic *Streptococcus*; GAS) from throat swab specimens obtained from patients with signs and symptoms of pharyngitis. The signs and symptoms of GAS pharyngitis overlap extensively with other infectious causes, making it difficult to diagnose based solely on clinical findings. However, an accurate diagnosis is necessary to promptly and adequately treat the disease with antibiotics and avoid possible serious complications such as rheumatic fever. This test can provide final results in as early as 42 minutes for positive specimens.\*
\*E-PRO: Early Positive Result Outcome. Positive results in ~42 minutes for highly positive specimens and negative results in ~70 minutes.)
- Efficient workflow - Sample to result in 3 easy steps
- Flexible platform - Run multiple assays with different sample types on a single run
- Platform for growth - Single analyte and multiplex testing capability
- Total solution - Can be paired with Meridian immunoassays for a scalable testing solution
## Related Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/)
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/)
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/)
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/)
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/)
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/)
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/)
“Revogene Strep A demonstrated good performance during our evaluation and is a promising alternative to replace throat culture and RADT for Streptococcal pathogens detection in a patient presenting with pharyngitis symptoms.
Improved detection and rapid results have the potential to improve antibiotic utilization in the emergency department.”
Amanda Harrington, PhD Loyola University
Chicago, Illinois, USA
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Support & Documents
#### Downloadable PDFs
[ Product Brochure - Revogene Strep A ](/uploads/MBI_Revogene_Strep_A_SS.pdf)
[ Package Insert - Revogene Strep A ](/uploads/410400_pi.pdf)
[ CLSI - Revogene Strep A ](/uploads/410400_clsi.doc)
[ Safety Data Sheet - Revogene Strep A Kit ](/uploads/410400_kit_sds.pdf)
[ Safety Data Sheet - Revogene Strep A ](/uploads/410400_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene Strep A ](/uploads/410400_osha.pdf)
[ Safety Data Sheet - Revogene Sample Buffer GHS ](/uploads/4101_4102_4103_4104_4105_6102_sds.pdf)
[ Safety Data Sheet (OSHA) - Revogene Sample Buffer ](/uploads/4101_4102_4103_4104_4105_6102_osha.pdf)
[ Procedure Card - EN Revogene Strep A ](/uploads/410400_pc.pdf)
[ Procedure Card DE Revogene Strep A ](/uploads/410400_pc_de.pdf)
[ Procedure Card ES Revogene Strep A ](/uploads/410400_pc_es.pdf)
[ Procedure Card FR Revogene Strep A ](/uploads/410400_pc_fr.pdf)
[ Procedure Card IT Revogene Strep A ](/uploads/410400_pc_it.pdf)
[ Procedure Card NL Revogene Strep A ](/uploads/410400_pc_nl.pdf)
[ Package Insert Revogene Mock Pie ](/uploads/610208_pi.pdf)
#### FAQs
What is the suggested CPT Code
Revogene® Strep A – 87651
[For Additional Support Please Contact Technical Support](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
**Conditions:** Respiratory
---
### [M-prep](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/)
**Published:** March 8, 2019
**Author:** hamza
**Content:**
# M-prep
Sample Preparation Kit for use with the Alethia assays. This product is intended for use in conjunction with in vitro diagnostic medical devices.
Catalog Number: 281110
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/)
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/)
Pediatric & Neonatal
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/)
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/)
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/)
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/)
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/)
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/)
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/)
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/)
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/)
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/)
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/)
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/)
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/)
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/)
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/)
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/)
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/)
Other
## Para-Pak
The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.
[ Learn More ](/para-pak)
## Support & Documents
#### Downloadable PDFs
[ Package Insert - M-prep ](/uploads/281110_pi.pdf)
[ Safety Data Sheet M-Prep Kit ](/uploads/281110_kit_sds.pdf)
[ Safety Data Sheet Buffer 1 ](/uploads/2904_2932_2933_sds.pdf)
[ Safety Data Sheet (OSHA) Buffer 1 ](/uploads/2904_2932_2933_osha.pdf)
[ Safety Data Sheet - Buffer II ](/uploads/2906_2923_2942_2943_sds.pdf)
[ Safety Data Sheet - Buffer II (OSHA) ](/uploads/2906_2923_2942_2943_osha.pdf)
[ Safety Data Sheet M-prep Column ](/uploads/2905_2905ctng_2908_2909_2922_sds.pdf)
[ Safety Data Sheet (OSHA) M-prep Column ](/uploads/2905_2905ctng_2908_2909_2922_osha.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Pediatric & Neonatal](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/)
**Published:** January 4, 2019
**Author:** hamza
**Content:**
Prevent the Preventable. Manage the Manageable.
Prevent the Preventable. Manage the Manageable.
Prevent the Preventable. Manage the Manageable.
Prevent the Preventable. Manage the Manageable.
Prevent the Preventable. Manage the Manageable.
## Pediatric & Neonatal
Our passion is to help providers make better diagnostic decisions for preventable and manageable neonatal and pediatric illnesses – like congenital Cytomegalovirus (cCMV), lead poisoning, and Group B Streptococcus (GBS) to name a few. Together, we can make a difference through diagnostic knowledge empowering needed intervention shaping lives today and tomorrow.
[](https://www.meridianbioscience.com/diagnostics/disease-areas/cmv/)##### CMV
[](https://www.meridianbioscience.com/diagnostics/disease-areas/leadcare/)##### Lead Poisoning
[](https://www.meridianbioscience.com/diagnostics/disease-areas/group-b-strep/)##### Group B Strep
[](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)##### Mononucleosis
## Pediatric & Neonatal Resources
Congenital CMV – A Silent Risk to Newborns
Newborn Saliva Sample Collection for CMV Testing
Meet LeadCare II
Meet Revogene
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Rotavirus/Adenovirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/)
**Published:** February 22, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Gastrointestinal
# Rotavirus/Adenovirus
[](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/rapid_strip-rota_adeno/)#### Rapid Strip Rota/Adeno
The Rapid Strip ROTA/ADENO is a rapid and simple in vitro qualitative test for the detection of Rotavirus and Adenovirus antigens in feces.
[Learn More](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/rapid_strip-rota_adeno/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [Serology](https://www.meridianbioscience.com/diagnostics/disease-areas/other/serology/)
**Published:** March 6, 2019
**Author:** hamza
**Content:**
###### Other - Other
# Serology
[](/diagnostics/disease-areas/other/serology/ana-screening-elisa/)#### Serology
###### ANA Test | ANA Screening ELISA
An Antinuclear Antibody Enzyme Immunoassay Screening Test that detects presence of antinuclear antibodies in human serum.
[Learn More](https://meridianbiostg.wpengine.com/diagnostics/disease-areas/other/serology/ana-screening-elisa/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Other
---
### [ANA Test | ANA Screening ELISA](https://www.meridianbioscience.com/diagnostics/disease-areas/other/serology/ana-screening-elisa/)
**Published:** March 11, 2019
**Author:** hamza
**Content:**
# ANA Test | ANA Screening ELISA
An Antinuclear Antibody Enzyme Immunoassay Screening Test that detects presence of antinuclear antibodies in human serum.
Catalog Number: 4884261
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
[ Support & Documents ](#support-documents)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Other
Sexual Health
[ Meridian Viral Transport ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/viral-transport/meridian-viral-transport/)
## Support & Documents
#### Downloadable PDFs
[ Package Insert ](/uploads/4884261_pi-1.pdf)
[ Safety Data Sheet - Conjugate ](/uploads/4884261_conjugate_sds.pdf)
[ Safety Data Sheet - Negative Control ](/uploads/4884261_negative_control_sds.pdf)
[ Safety Data Sheet - Positive Control ](/uploads/4884261_positive_control_sds.pdf)
[ Safety Data Sheet - Sample Diluent ](/uploads/4884261_sample_diluent_sds.pdf)
[ Safety Data Sheet - Stop Solution ](/uploads/4884261_stop_solution_sds.pdf)
[ Safety Data Sheet - Wash Concentrate ](/uploads/4884261_wash_concentrate_sds.pdf)
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [HIV](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hiv/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# HIV
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [HCV](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hcv/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
###### Other - Sexual Health
# HCV
[](/diagnostics/disease-areas/other/hcv/oraquick-hcv-rapid-antibody-test/)#### Immunoassay®
###### OraQuick® HCV Rapid Antibody Test
An immunoassay for the qualitative detection of IgG antibodies to Hepatitis C Virus in oral fluid, fingerstick whole blood, venipuncture whole blood, serum and plasma specimens.
[Learn more](#)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Sexual Health
---
### [statID PRO™](https://www.meridianbioscience.com/diagnostics/disease-areas/statid-pro/)
**Published:** October 9, 2025
**Author:** Moaaz Ahmad
**Conditions:** Respiratory
---
### [OraQuick® HCV Rapid Antibody Test](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hcv/oraquick-hcv-rapid-antibody-test/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
## OraQuick® HCV Rapid Antibody Test
An immunoassay for the qualitative detection of IgG antibodies to Hepatitis C Virus in oral fluid, fingerstick whole blood, venipuncture whole blood, serum and plasma specimens.
Catalog Number: 1001-0270
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
Gastrointestinal
[ Rapid Strip Rota/Adeno ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/rapid_strip-rota_adeno/)
Sexual Health
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [OraQuick ADVANCE® HIV -1/2 Rapid Antibody Test](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hiv/oraquick-advance-hiv-1-2-rapid-antibody-test/)
**Published:** March 20, 2019
**Author:** hamza
**Content:**
## OraQuick ADVANCE® HIV -1/2 Rapid Antibody Test
An immunoassay for the qualitative detection of antibodies to HIV-1 and HIV-2 in oral fluid, fingerstick whole blood, venipuncture whole blood and plasma specimens.
**For Professional Users Only**
Catalog Number: 1001-0284
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Test Details ](#product-info)
- [ Related Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ FAQs ](#faqs)
- [ Pricing ](#pricing)
## Definitive answers, confidence in results
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
## Related Tests
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Respiratory](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/)
**Published:** January 4, 2019
**Author:** hamza
**Content:**
# Respiratory Human Conditions
Our passion is to help providers make better diagnostic decisions with a focus on respiratory conditions.
##### Respiratory
- [ Coronavirus (COVID-19) ](/diagnostics/disease-areas/respiratory/coronavirus)
- [ Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/pneumocystis/)
- [ Mycoplasma ](https://www.meridianbioscience.com/diagnostics/disease-areas/mycoplasma/)
- [ Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/pertussis/)
- [ Respiratory Syncytial Virus (RSV) ](https://www.meridianbioscience.com/diagnostics/disease-areas/rsv/)
- [ Legionella ](https://www.meridianbioscience.com/diagnostics/disease-areas/legionella/)
- [ Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/group-a-streptococcus/)
- [ Flu ](https://www.meridianbioscience.com/diagnostics/disease-areas/flu/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
---
### [Norovirus](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/norovirus/)
**Published:** March 6, 2019
**Author:** hamza
**Content:**
###### Gastrointestinal - Gastrointestinal
## Norovirus
Our rapid test for the detection of Norovirus provides results intended to aid in the diagnosis of Norovirus associated gastroenteritis. Click for
product information below.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics)
**Conditions:** Gastrointestinal
---
### [Gastrointestinal](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/)
**Published:** January 4, 2019
**Author:** hamza
**Content:**
# Gastrointestinal Human Conditions
Our passion is to help providers make better diagnostic decisions with a focus on gastrointestinal conditions.
##### Gastrointestinal
- [ Calprotectin ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/calprotectin/)
- [ H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [ Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/)
- [ E. coli ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/)
- [ Adenovirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/)
- [ Rotavirus/Adenovirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus/)
- [ Norovirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/norovirus/)
- [ Rotavirus/Adenovirus/Norovirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/)
- [ Campylobacter ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/)
##### Healthcare Acquired Infections
- [ C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/healthcare-acquired-infections/c-difficile/)
##### Parasitology
- [ Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/parasitology/cryptosporidium-giardia/)
- [ Para Pak ](https://www.meridianbioscience.com/diagnostics/disease-areas/parasitology/para-pak/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Gastrointestinal
---
### [Para Pak](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/para-pak/)
**Published:** February 23, 2019
**Author:** hamza
**Conditions:** Parasitology
---
### [Phosphate Buffered Saline](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pbs/)
**Published:** March 7, 2019
**Author:** hamza
**Content:**
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Conditions:** Sexual Health
---
## Distributors
### [Fort Richard Laboratories](https://www.meridianbioscience.com/diagnostics/distributor/southern-cross-diagnostics-scd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** New Zealand
---
### [Edwards Co Group](https://www.meridianbioscience.com/diagnostics/distributor/edwards-co-group/)
**Published:** October 6, 2025
**Author:** Moaaz Ahmad
**Country:** Australia
---
### [Phu Gia Medical Trading Co. Ltd](https://www.meridianbioscience.com/diagnostics/distributor/phu-gia-medical-trading-co-ltd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Vietnam
---
### [McKesson](https://www.meridianbioscience.com/diagnostics/distributor/mckesson/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United States of America
---
### [Minh Long Technologies JSC](https://www.meridianbioscience.com/diagnostics/distributor/minh-long-technologies-jsc/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Vietnam
---
### [CIENVAR S.A.](https://www.meridianbioscience.com/diagnostics/distributor/cienvar-s-a/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Venezuela
---
### [ENOL S.A (for Lead Care products)](https://www.meridianbioscience.com/diagnostics/distributor/enol-s-a-for-lead-care-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Uruguay
---
### [Biocor](https://www.meridianbioscience.com/diagnostics/distributor/biocor/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Uruguay
---
### [Launch Diagnostics Limited](https://www.meridianbioscience.com/diagnostics/distributor/launch-diagnostics-limited/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United Kingdom
---
### [Medline](https://www.meridianbioscience.com/diagnostics/distributor/medline/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United States of America
---
### [Thermo Fisher](https://www.meridianbioscience.com/diagnostics/distributor/thermo-fisher/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United States of America
---
### [Cardinal](https://www.meridianbioscience.com/diagnostics/distributor/cardinal/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United States of America
---
### [Henry Schein](https://www.meridianbioscience.com/diagnostics/distributor/henry-schein/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United States of America
---
### [Al-Hayat Pharmaceuticals](https://www.meridianbioscience.com/diagnostics/distributor/al-hayat-pharmaceuticals/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** United Arab Emirates
---
### [Rapport Co Ltd](https://www.meridianbioscience.com/diagnostics/distributor/rapport-co-ltd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Thailand
---
### [Bencard AG](https://www.meridianbioscience.com/diagnostics/distributor/bencard-ag/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Switzerland
---
### [Aidian Sweden AB](https://www.meridianbioscience.com/diagnostics/distributor/aidian-sweden-ab/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Sweden
---
### [Grifols](https://www.meridianbioscience.com/diagnostics/distributor/grifols/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Spain
---
### [Woongbee MeDiTech Inc](https://www.meridianbioscience.com/diagnostics/distributor/woongbee-meditech-inc/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** South Korea
---
### [Separation Scientific SA (Pty) Ltd](https://www.meridianbioscience.com/diagnostics/distributor/separation-scientific-sa-pty-ltd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** South Africa
---
### [All Eights (Singapore) Pte Ltd](https://www.meridianbioscience.com/diagnostics/distributor/all-eights-singapore-pte-ltd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Singapore
---
### [Aidian Oy](https://www.meridianbioscience.com/diagnostics/distributor/aidian-oy/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Slovak Republic
---
### [Abdulla Fouad Holding Company Medical Supplies Division](https://www.meridianbioscience.com/diagnostics/distributor/abdulla-fouad-holding-company-medical-supplies-division/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Saudi Arabia
---
### [MEDIS D.O.O.](https://www.meridianbioscience.com/diagnostics/distributor/medis-d-o-o/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Slovenia
---
### [ReMaS d.o.o.](https://www.meridianbioscience.com/diagnostics/distributor/remas-d-o-o/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Slovenia
---
### [S.C. DIAMEDIX IMPEX SA](https://www.meridianbioscience.com/diagnostics/distributor/s-c-diamedix-impex-sa/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Romania
---
### [Novaintermed](https://www.meridianbioscience.com/diagnostics/distributor/novaintermed/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Romania
---
### [Ali Al-Suwaidi Trading Establishment](https://www.meridianbioscience.com/diagnostics/distributor/ali-al-suwaidi-trading-establishment/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Qatar
---
### [Bionuclear Puerto Rico](https://www.meridianbioscience.com/diagnostics/distributor/bionuclear-puerto-rico/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Puerto Rico
---
### [Puerto Rico Hospital Supply](https://www.meridianbioscience.com/diagnostics/distributor/puerto-rico-hospital-supply/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Puerto Rico
---
### [Diagnostika Pilipinas Inc.](https://www.meridianbioscience.com/diagnostics/distributor/diagnostika-pilipinas-inc/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Philippines
---
### [Simed Corp](https://www.meridianbioscience.com/diagnostics/distributor/simed-corp/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Peru
---
### [Argenta Sp. z o.o.](https://www.meridianbioscience.com/diagnostics/distributor/argenta-sp-z-o-o/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Poland
---
### [Bioportugal](https://www.meridianbioscience.com/diagnostics/distributor/bioportugal/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Portugal
---
### [Cardinal PR](https://www.meridianbioscience.com/diagnostics/distributor/cardinal-pr/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Puerto Rico
---
### [Innovative Medical Tech](https://www.meridianbioscience.com/diagnostics/distributor/innovative-medical-tech/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Puerto Rico
---
### [Labdepot S.A (for Lead Care products)](https://www.meridianbioscience.com/diagnostics/distributor/labdepot-s-a-for-lead-care-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Peru
---
### [TECNOFAST S.A. (for BreathID)](https://www.meridianbioscience.com/diagnostics/distributor/tecnofast-s-a-for-breathid/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Paraguay
---
### [El Alamo (Lead Care products)](https://www.meridianbioscience.com/diagnostics/distributor/el-alamo-lead-care-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Paraguay
---
### [GT Scientific (MBI Products)](https://www.meridianbioscience.com/diagnostics/distributor/gt-scientific-mbi-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Paraguay
---
### [Servi Lab](https://www.meridianbioscience.com/diagnostics/distributor/servi-lab/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Panama
---
### [Sure Bio Diagnostics](https://www.meridianbioscience.com/diagnostics/distributor/sure-bio-diagnostics/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Pakistan
---
### [Aidian Norway AS](https://www.meridianbioscience.com/diagnostics/distributor/aidian-norway-as/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Norway
---
### [Tecnodiagnostica SA](https://www.meridianbioscience.com/diagnostics/distributor/tecnodiagnostica-sa/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Nicaragua
---
### [Comercial Biomedico](https://www.meridianbioscience.com/diagnostics/distributor/comercial-biomedico/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Mexico
---
### [Aidian Netherlands BV](https://www.meridianbioscience.com/diagnostics/distributor/aidian-netherlands-bv/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Netherlands
---
### [Abalat](https://www.meridianbioscience.com/diagnostics/distributor/abalat/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Mexico
---
### [All Eights (Malaysia)](https://www.meridianbioscience.com/diagnostics/distributor/all-eights-malaysia/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Malaysia
---
### [Aidian Belgium BV](https://www.meridianbioscience.com/diagnostics/distributor/aidian-belgium-bv/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Luxembourg
---
### [Saramed](https://www.meridianbioscience.com/diagnostics/distributor/saramed/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Lebanon
---
### [Advanced Technology Company (ATC)](https://www.meridianbioscience.com/diagnostics/distributor/advanced-technology-company-atc/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Kuwait
---
### [Tectron Electronic Appliances](https://www.meridianbioscience.com/diagnostics/distributor/tectron-electronic-appliances/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Kuwait
---
### [Diab Establishment](https://www.meridianbioscience.com/diagnostics/distributor/diab-establishment/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Jordan
---
### [Pt.Inti Makmur Meditama](https://www.meridianbioscience.com/diagnostics/distributor/pt-inti-makmur-meditama/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Indonesia
---
### [Accusay Diagnostics](https://www.meridianbioscience.com/diagnostics/distributor/accusay-diagnostics/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Ireland
---
### [Meridian Bioscience](https://www.meridianbioscience.com/diagnostics/distributor/meridian-bioscience/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Italy
---
### [Spark Services](https://www.meridianbioscience.com/diagnostics/distributor/spark-services/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** India
---
### [Anand Brothers](https://www.meridianbioscience.com/diagnostics/distributor/anand-brothers/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** India
---
### [MEDOR hf.](https://www.meridianbioscience.com/diagnostics/distributor/medor-hf/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Iceland
---
### [Wenlin Company](https://www.meridianbioscience.com/diagnostics/distributor/wenlin-company/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Hong Kong
---
### [Representaciones Caceres](https://www.meridianbioscience.com/diagnostics/distributor/representaciones-caceres/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Honduras
---
### [Servilab S.A](https://www.meridianbioscience.com/diagnostics/distributor/servilab-s-a/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Guatemala
---
### [Gold Standard Diagnostics Frankfurt GmBH](https://www.meridianbioscience.com/diagnostics/distributor/gold-standard-diagnostics-frankfurt-gmbh/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Germany
---
### [LAUNCH Diagnostics France SAS](https://www.meridianbioscience.com/diagnostics/distributor/launch-diagnostics-france-sas/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** France
---
### [Aidian Germany GmbH](https://www.meridianbioscience.com/diagnostics/distributor/aidian-germany-gmbh/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Germany
---
### [VARELAS S.A. – Chemicals and Diagnostics](https://www.meridianbioscience.com/diagnostics/distributor/varelas-s-a-chemicals-and-diagnostics/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Greece
---
### [Arquisa](https://www.meridianbioscience.com/diagnostics/distributor/arquisa/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Guatemala
---
### [Reactlab Import S.A (for LeadCare® and Revogene® products)](https://www.meridianbioscience.com/diagnostics/distributor/reactlab-import-s-a-for-leadcare-and-revogene-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Ecuador
---
### [Medilabor S.A (for Alethia products)](https://www.meridianbioscience.com/diagnostics/distributor/medilabor-s-a-for-alethia-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Ecuador
---
### [Bionuclear S.A](https://www.meridianbioscience.com/diagnostics/distributor/bionuclear-s-a/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Dominican Republic
---
### [Tecnodiagnostica S.A.](https://www.meridianbioscience.com/diagnostics/distributor/tecnodiagnostica-s-a/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** El Salvador
---
### [Aidian Denmark ApS](https://www.meridianbioscience.com/diagnostics/distributor/aidian-denmark-aps/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Denmark
---
### [BIOGEN d.o.o.](https://www.meridianbioscience.com/diagnostics/distributor/biogen-d-o-o/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Croatia
---
### [Farminpex NV](https://www.meridianbioscience.com/diagnostics/distributor/farminpex-nv/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Curacao
---
### [Scientronics Ltd](https://www.meridianbioscience.com/diagnostics/distributor/scientronics-ltd/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Cyprus
---
### [Annar Diagnóstica Import S.A.S](https://www.meridianbioscience.com/diagnostics/distributor/annar-diagnostica-import-s-a-s/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Colombia
---
### [Quimiolab SAS](https://www.meridianbioscience.com/diagnostics/distributor/quimiolab-sas/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Colombia
---
### [Prolab (for Alethia, BreathID and Rapids)](https://www.meridianbioscience.com/diagnostics/distributor/prolab-for-alethia-breathid-and-rapids/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Chile
---
### [MICROBAC SpA (for Revogene and LeadCare)](https://www.meridianbioscience.com/diagnostics/distributor/microbac-spa-for-revogene-and-leadcare/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Chile
---
### [Caribbean Diagnostics](https://www.meridianbioscience.com/diagnostics/distributor/caribbean-diagnostics/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Cayman Islands
---
### [Somagen](https://www.meridianbioscience.com/diagnostics/distributor/somagen/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Canada
---
### [MeDilem EOOD](https://www.meridianbioscience.com/diagnostics/distributor/medilem-eood/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Bulgaria
---
### [NL Comercio](https://www.meridianbioscience.com/diagnostics/distributor/nl-comercio/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Brazil
---
### [Q&Q MEDICAL LTDA.](https://www.meridianbioscience.com/diagnostics/distributor/qq-medical-ltda/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Bolivia
---
### [Szabo-Scandic HandelsgmbH & Co KG](https://www.meridianbioscience.com/diagnostics/distributor/szabo-scandic-handelsgmbh-co-kg/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Austria
---
### [Mercury Marketing W.L.L](https://www.meridianbioscience.com/diagnostics/distributor/mercury-marketing-w-l-l/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Bahrain
---
### [AsC SRL](https://www.meridianbioscience.com/diagnostics/distributor/asc-srl/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Bolivia
---
### [GEMATEC S.A. (For Alethia and rapids)](https://www.meridianbioscience.com/diagnostics/distributor/gematec-s-a-for-alethia-and-rapids/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Argentina
---
### [Biomed Medical Devices SRL (for LeadCare® products)](https://www.meridianbioscience.com/diagnostics/distributor/biomed-medical-devices-srl-for-leadcare-products/)
**Published:** February 27, 2025
**Author:** hamza
**Country:** Argentina
---
## Documents
### [BIO-39044S_DMS-313103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044s_dms-313103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO61270.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo61270-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO59170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo59170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO54630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo54630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO50690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo50690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO46860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo46860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO41740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo41740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO37360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo37360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO33240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo33240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO30460.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo30460-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO27190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo27190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO27170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo27170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO23800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo23800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-BO21970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-bo21970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B077300.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b077300-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B077050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b077050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B073750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b073750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B069150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b069150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B065900.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b065900-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-B019080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-b019080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-313111_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-313111_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-313111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-313111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-313108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-313108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-313103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-313103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_DM408-213202.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_dm408-213202-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39044_1000_DM648-313109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39044_1000_dm648-313109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO62700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo62700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO62420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo62420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO52040.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo52040-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO52030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo52030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO47120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo47120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO46990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo46990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO44000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo44000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO43580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo43580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO38370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo38370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO38100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo38100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO35210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo35210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO30990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo30990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO25610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo25610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO23200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo23200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-BO20290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-bo20290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-B079180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-b079180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-B073480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-b073480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-B073210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-b073210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-B072100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-b072100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-B071840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-b071840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-213210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-213210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-213207.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-213207-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM410-213202.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm410-213202-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043_DM4-212I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043_dm4-212i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39043 DM410-BO52020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39043-dm410-bo52020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DUM-013101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dum-013101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO59800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo59800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO57180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo57180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO55010.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo55010-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO52620.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo52620-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO51850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo51850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO51320.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo51320-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO47870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo47870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO44880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo44880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO38400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo38400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO34940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo34940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO30970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo30970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO26650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo26650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO24120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo24120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO21410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo21410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-BO16140_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-bo16140_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B080010.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b080010-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B076740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b076740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B076520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b076520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B072330.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b072330-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B072280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b072280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-B040940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-b040940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-013110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-013110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-013108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-013108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39041_DM414-013104.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39041_dm414-013104-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO61260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo61260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO54410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo54410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO50130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo50130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO43730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo43730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO39840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo39840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO33600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo33600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO28530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo28530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO23650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo23650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO21810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo21810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-BO21580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-bo21580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-B080170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-b080170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-B075550.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-b075550-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-B065400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-b065400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-B031890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-b031890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39039_DS419-913107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39039_ds419-913107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO63670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo63670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO52690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo52690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO50120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo50120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO43720.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo43720-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO33590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo33590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-BO30750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-bo30750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-B078740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-b078740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-B078240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-b078240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39038_DS418-B069230.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39038_ds418-b069230-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO63660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo63660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO60440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo60440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO52680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo52680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO43740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo43740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO38590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo38590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO33580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo33580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO28860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo28860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-BO28750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-bo28750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-B073370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-b073370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-213109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-213109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39037_DS417-213106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39037_ds417-213106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO63650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo63650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO59050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo59050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO55620.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo55620-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO55570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo55570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO52130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo52130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO46350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo46350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO43710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo43710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO39820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo39820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO35580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo35580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO33570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo33570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO28740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo28740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-BO23640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-bo23640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-B079240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-b079240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-B078820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-b078820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-B077870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-b077870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-B076580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-b076580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-B031880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-b031880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-313109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-313109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39036_DS416-013204.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39036_ds416-013204-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO64750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo64750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO61120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo61120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO56810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo56810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO56140.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo56140-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO50520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo50520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO45530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo45530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO43760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo43760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO39810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo39810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO32990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo32990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO30980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo30980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [Bio-39035_DS415-BO29420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo29420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO24590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo24590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-BO21510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-bo21510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B081070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b081070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B080060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b080060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B076810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b076810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B075290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b075290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B071090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b071090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-B067600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-b067600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-914101_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-914101_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-914101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-914101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-913111_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-913111_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-913111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-913111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-913106_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-913106_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39035_DS415-913106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39035_ds415-913106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029-DM412-BO17630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029-dm412-bo17630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029-500ML_dNTP_Mix_100mM_#313308.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029-500ml_dntp_mix_100mm_313308-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM-313510_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm-313510_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM-313510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm-313510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO59600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo59600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO56960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo56960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO49500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo49500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO45420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo45420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO39830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo39830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO35650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo35650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO32980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo32980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO28260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo28260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO26710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo26710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO24040.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo24040-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-BO20880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-bo20880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-B080860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-b080860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-B075280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-b075280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-B074290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-b074290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-B072420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-b072420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-B065700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-b065700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-313612_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-313612_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-313612.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-313612-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-313307.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-313307-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_DM412-213305.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_dm412-213305-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_500ML_DM-313509_2.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_500ml_dm-313509_2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_500ML_DM-313509.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_500ml_dm-313509-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39029_50_ml_DM-313611.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39029_50_ml_dm-313611-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028CUS_DM1-312K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028cus_dm1-312k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM670-BO22530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm670-bo22530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO61060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo61060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO55710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo55710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO51730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo51730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO45010.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo45010-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO39870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo39870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO34580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo34580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO30360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo30360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO26890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo26890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO22610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo22610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-BO18990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-bo18990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-B078200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-b078200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-B076980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-b076980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-B073360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-b073360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-B071080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-b071080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-B066760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-b066760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-314601_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-314601_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-314601.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-314601-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-313509.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-313509-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-313105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-313105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_DM411-213302.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_dm411-213302-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39028_CUS_DM1-513H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39028_cus_dm1-513h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39027_DS500-310113.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39027_ds500-310113-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39027_DS406-BO20680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39027_ds406-bo20680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39027_DS406-060813.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39027_ds406-060813-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO62150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo62150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO55810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo55810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO52610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo52610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO52490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo52490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO48690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo48690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO42910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo42910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO38580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo38580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO35910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo35910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO30840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo30840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO28410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo28410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO23660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo23660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-BO19910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-bo19910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-B081370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-b081370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-B073400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-b073400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-B067150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-b067150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-091213_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-091213_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-091213.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-091213-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39026_DS404-010813.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39026_ds404-010813-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO61250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo61250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO55350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo55350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO52120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo52120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO48080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo48080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO41860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo41860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO36120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo36120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO32290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo32290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO28770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo28770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO25000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo25000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO22090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo22090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-BO19090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-bo19090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-B076610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-b076610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-B074280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-b074280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-B070860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-b070860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-B066250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-b066250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-092013.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-092013-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_DS403-030613.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_ds403-030613-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-39025_30ml_080313.pdf](https://www.meridianbioscience.com/lifescience/document//bio-39025_30ml_080313-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38049_REC610-BO07150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38049_rec610-bo07150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38049_REC610-05116B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38049_rec610-05116b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38049_REC610-05116A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38049_rec610-05116a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38049_REC610-05115K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38049_rec610-05115k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38049_CT566-BO10540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38049_ct566-bo10540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38048_REC610-01115F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38048_rec610-01115f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_REC560-05213F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_rec560-05213f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_REC560-05115J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_rec560-05115j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO13290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo13290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO13080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo13080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO12770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo12770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO11190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo11190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO09850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo09850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO09680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo09680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO06890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo06890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38045_CT568-BO06680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38045_ct568-bo06680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044S_REC560-S113I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044s_rec560-s113i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044_S_REC560-S112J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044_s_rec560-s112j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044_REC560-01213H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044_rec560-01213h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044_REC560-01115I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044_rec560-01115i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044_REC560-01115I (2).pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044_rec560-01115i-2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38044_REC560-01115F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38044_rec560-01115f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_REC670-BO10090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_rec670-bo10090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_REC670-05215J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_rec670-05215j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_REC670-05116C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_rec670-05116c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_REC670-05115J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_rec670-05115j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO13280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo13280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO13070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo13070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO12680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo12680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO12300.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo12300-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO11610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo11610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO11070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo11070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO11010.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo11010-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10890 (2).pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10890-2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10830 (2).pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10830-2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO10410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo10410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO09770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo09770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO08690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo08690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO08670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo08670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO08560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo08560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO08090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo08090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38041_CT564-BO07980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38041_ct564-bo07980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_S_RECs-312E.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_s_recs-312e-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_S_REC670-S112J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_s_rec670-s112j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC670-22116B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec670-22116b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC670-01316C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec670-01316c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC670-01216C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec670-01216c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC670-01115I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec670-01115i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC670-01115H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec670-01115h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_REC01-113B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_rec01-113b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_CT563-BO07440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_ct563-bo07440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_CT563-BO07310.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_ct563-bo07310-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38040_CT563-BO07080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38040_ct563-bo07080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS-315K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts-315k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS-218H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts-218h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS-213I_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts-213i_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS-213I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts-213i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS-119F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts-119f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS2-314F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts2-314f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS2-213I_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts2-213i_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_TS2-114A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_ts2-114a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_315K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_315k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_314F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_314f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_312K_Feb.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_312k_feb-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_312K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_312k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_216K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_216k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_216G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_216g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_215G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_215g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_212J.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_212j-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_212I_March.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_212i_march-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_212I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_212i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_118A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_118a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_117G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_117g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_116E.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_116e-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_115A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_115a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38033_113C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38033_113c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032S_111B_March.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032s_111b_march-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032S_111B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032s_111b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS-218H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts-218h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS-216K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts-216k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS-119F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts-119f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS-113C_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts-113c_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS-113C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts-113c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS1-314F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts1-314f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS1-114A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts1-114a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_TS1-113C_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_ts1-113c_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_314F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_314f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_218H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_218h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_216K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_216k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_215G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_215g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_211K_March.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_211k_march-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_211K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_211k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_118A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_118a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_117G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_117g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_113C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_113c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_112K.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_112k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032_111B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032_111b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38032 TS-116E.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38032-ts-116e-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38031_RA400-BO2130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38031_ra400-bo2130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38031_RA400-113H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38031_ra400-113h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38030_RA399-BO21290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38030_ra399-bo21290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38030_RA399-BO18880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38030_ra399-bo18880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38030_RA399-314101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38030_ra399-314101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38030_RA399-313109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38030_ra399-313109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38030_RA399-112D.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38030_ra399-112d-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO63930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo63930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO61500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo61500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO53050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo53050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO49490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo49490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO41690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo41690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO40200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo40200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO32460.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo32460-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO29930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo29930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO24690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo24690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-BO22080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-bo22080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-B078730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-b078730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-B073390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-b073390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-B069220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-b069220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-014101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-014101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-013110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-013110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38029_RA398-013109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38029_ra398-013109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO64210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo64210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO62160.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo62160-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO59390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo59390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO55760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo55760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO51410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo51410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO51170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo51170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO44430.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo44430-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO39050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo39050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO33560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo33560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO31530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo31530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO28190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo28190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO24670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo24670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO21870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo21870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-BO20270.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-bo20270-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B080930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b080930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B078850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b078850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B074920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b074920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B070850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b070850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B069560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b069560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B067770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b067770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B067470.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b067470-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-B066360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-b066360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-113209.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-113209-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-38028_RA397-113107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-38028_ra397-113107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37115_ES551-113111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37115_es551-113111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37115_ES551-113107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37115_es551-113107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37115_ES551-113102.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37115_es551-113102-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37114_ES550-113208.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37114_es550-113208-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37114_ES550-113207.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37114_es550-113207-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO64200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo64200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO59960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo59960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO56540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo56540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO51680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo51680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO46000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo46000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO41850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo41850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO40180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo40180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO36680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo36680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO33400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo33400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO29740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo29740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO22640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo22640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-BO21060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-bo21060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-B077040.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-b077040-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-B075300.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-b075300-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-B069210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-b069210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-B067060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-b067060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-213105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-213105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37112_ES549-113102.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37112_es549-113102-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO63350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo63350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO58060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo58060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO56550.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo56550-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO52670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo52670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO47410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo47410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO46870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo46870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO43430.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo43430-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO43080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo43080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO39380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo39380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO37850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo37850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO22740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo22740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO21820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo21820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-BO19880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-bo19880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-B074730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-b074730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-B072480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-b072480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-B071790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-b071790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_ES548-213205.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_es548-213205-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37111_25ml_MTB-212J_oct.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37111_25ml_mtb-212j_oct-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO54650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo54650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO54400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo54400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO50590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo50590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO48710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo48710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO43980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo43980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO43290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo43290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_ES546-BO33650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_es546-bo33650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37102_BO21050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37102_bo21050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37101_ES545-BO41640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37101_es545-bo41640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37101_ES545-BO32560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37101_es545-bo32560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO60670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo60670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO55230.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo55230-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO51930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo51930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO51310.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo51310-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO50240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo50240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO47500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo47500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO46080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo46080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO45830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo45830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO42760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo42760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO39080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo39080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO38030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo38030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO36240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo36240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO33910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo33910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO32480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo32480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO31150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo31150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO30600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo30600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO30450.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo30450-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO28940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo28940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO26700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo26700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO22180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo22180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-BO21760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-bo21760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-B076690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-b076690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-B076100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-b076100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-B070650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-b070650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-B066240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-b066240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-313110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-313110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37085_ES538-313106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37085_es538-313106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES538-BO33770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es538-bo33770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES538-BO28800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es538-bo28800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES538-BO21880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es538-bo21880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO64390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo64390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO62400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo62400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO59160.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo59160-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO56130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo56130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO53400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo53400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO50970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo50970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO47880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo47880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO44030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo44030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO40190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo40190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO37570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo37570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO30730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo30730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO28760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo28760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO25910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo25910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO22840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo22840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-BO20120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-bo20120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B079030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b079030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B074950.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b074950-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B074100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b074100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B073770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b073770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B071610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b071610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-B068930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-b068930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-313212.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-313212-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-313105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-313105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37084_ES537-213202.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37084_es537-213202-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-BO20620_V2.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-bo20620_v2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-313412_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-313412_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-313412.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-313412-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-313309.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-313309-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-313205.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-313205-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37080_ES540-113C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37080_es540-113c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO65380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo65380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO62780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo62780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO61880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo61880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO59000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo59000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO58410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo58410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO58050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo58050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO56830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo56830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO54390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo54390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO51880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo51880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO50290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo50290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO49920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo49920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO42610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo42610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO32000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo32000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO31960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo31960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO30000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo30000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO29990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo29990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO26990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo26990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO24860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo24860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO24030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo24030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO22030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo22030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO21680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo21680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-BO19900.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-bo19900-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B080490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b080490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B079520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b079520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B078180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b078180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B076730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b076730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B076530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b076530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B076020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b076020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B075090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b075090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B073270.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b073270-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B073250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b073250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B070520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b070520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B070140.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b070140-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B069300.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b069300-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-B067480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-b067480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-913108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-913108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-913103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-913103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37075_ES539-913102.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37075_es539-913102-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37070_ES453-013110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37070_es453-013110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37070_ES453-013107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37070_es453-013107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37070_ES453-013105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37070_es453-013105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37070_ES453-013101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37070_es453-013101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_HLBR-213104.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_hlbr-213104-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_HLBR-213101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_hlbr-213101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-BO33760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-bo33760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-BO28280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-bo28280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-BO24850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-bo24850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-BO23790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-bo23790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-B019870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-b019870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37068_ES452-213106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37068_es452-213106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_QCP25-113101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_qcp25-113101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_QC-913103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_qc-913103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO64810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo64810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO64400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo64400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO62390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo62390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO59140.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo59140-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO56940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo56940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO56820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo56820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO50510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo50510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO46180.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo46180-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO42620.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo42620-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO40470.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo40470-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO37780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo37780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO37710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo37710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO33920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo33920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO33500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo33500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO28980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo28980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO27500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo27500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO24330.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo24330-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO22150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo22150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-BO21000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-bo21000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B080340.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b080340-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B077960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b077960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B075100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b075100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B074720.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b074720-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B068600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b068600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-B053790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-b053790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-313112_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-313112_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-313112.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-313112-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-313108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-313108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37048_ES491-113105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37048_es491-113105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO65570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo65570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO60660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo60660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO57890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo57890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO55100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo55100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO49790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo49790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO49480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo49480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO45050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo45050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO41840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo41840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO38270.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo38270-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO35200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo35200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO32700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo32700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO30350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo30350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO26240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo26240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO24640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo24640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO21480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo21480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-BO20090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-bo20090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-B079170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-b079170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-B075030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-b075030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-313112_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-313112_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-313112.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-313112-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-313110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-313110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-313108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-313108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-113105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-113105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047_ES490-113104.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047_es490-113104-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047 ES490-BO57780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047-es490-bo57780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047 ES490-B070510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047-es490-b070510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37047 ES490-B070310.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37047-es490-b070310-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045-ES451-BO17490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045-es451-bo17490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO64620.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo64620-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO61040.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo61040-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO57530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo57530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO52870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo52870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO48070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo48070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO45650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo45650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO42390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo42390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO39690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo39690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO36220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo36220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO32210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo32210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO30100.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo30100-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO27380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo27380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO25080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo25080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO23080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo23080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-BO20810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-bo20810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-B076970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-b076970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-B073410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-b073410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-B071600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-b071600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-B067450.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-b067450-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-313111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-313111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-313108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-313108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-313105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-313105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37045_ES451-313103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37045_es451-313103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041S_PM-013103.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041s_pm-013103-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-314101_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-314101_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-314101.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-314101-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-313107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-313107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-013105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-013105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-013104.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-013104-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37041_ES553-013102.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37041_es553-013102-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_PK10-114H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_pk10-114h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO62740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo62740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO62560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo62560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO58440-October 2020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo58440-october-2020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO58440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo58440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO58340.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo58340-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO58330.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo58330-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO52310-June 2020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo52310-june-2020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO52310.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo52310-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO50860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo50860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO48440_Nov19.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo48440_nov19-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO48440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo48440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO45670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo45670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO45670 v04.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo45670-v04-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO45670 v03.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo45670-v03-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO45670 v02.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo45670-v02-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO42670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo42670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO38350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo38350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO38350 v04.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo38350-v04-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO38350 v03.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo38350-v03-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO38350 v02.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo38350-v02-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO32520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo32520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO30010.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo30010-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO28510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo28510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO26740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo26740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-BO22700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-bo22700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-B076640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-b076640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-B072540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-b072540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-B067700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-b067700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-B067680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-b067680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-B066120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-b066120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_ES534-113G_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_es534-113g_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37039_DEN_PK-113J_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37039_den_pk-113j_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO67610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo67610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO60930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo60930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO38340.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo38340-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO38340 Nov 2019.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo38340-nov-2019-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO38340 Mar 2020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo38340-mar-2020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO32530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo32530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO21920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo21920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-BO18930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-bo18930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-B076650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-b076650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-B073800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-b073800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-B060930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-b060930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-B029770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-b029770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-B025570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-b025570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-113K_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-113k_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37037_ES533-113E_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37037_es533-113e_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO64570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo64570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO60940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo60940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO58070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo58070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO55000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo55000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO53210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo53210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO50960.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo50960-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO47620.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo47620-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO42940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo42940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO38380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo38380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO35000.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo35000-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO31260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo31260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO27770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo27770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO25850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo25850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-BO24200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-bo24200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-B077860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-b077860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-B074940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-b074940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-B072250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-b072250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-B069280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-b069280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37036_ES532-B067590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37036_es532-b067590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO61890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo61890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO55850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo55850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO50950.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo50950-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO45290.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo45290-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO34990.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo34990-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO26500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo26500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-BO20900.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-bo20900-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-B074480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-b074480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37035_ES531-B070250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37035_es531-b070250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES544-113107.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es544-113107-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO64080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo64080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO60330.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo60330-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO58740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo58740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO55690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo55690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO55340.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo55340-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO54590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo54590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO52860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo52860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO50110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo50110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO46020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo46020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO43360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo43360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO42070.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo42070-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO38570.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo38570-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO37320.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo37320-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO33890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo33890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO31510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo31510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO28930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo28930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO26410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo26410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO22380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo22380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-BO20540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-bo20540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B081080.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b081080-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B076430.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b076430-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B073810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b073810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B071260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b071260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B071250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b071250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B070840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b070840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B066790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b066790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-B033890.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-b033890-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026_ES543-113111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026_es543-113111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37026 ES543-BO18740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37026-es543-bo18740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_NH-213202_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_nh-213202_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO64090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo64090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO63360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo63360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO62430.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo62430-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO59130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo59130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO54200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo54200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO50500.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo50500-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO45520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo45520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO44150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo44150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO38560.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo38560-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO32800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo32800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO32040.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo32040-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO31750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo31750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO30710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo30710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO26510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo26510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-BO20820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-bo20820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-B077460.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-b077460-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-B074710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-b074710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-B069550.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-b069550-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-314101_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-314101_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-213202.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-213202-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-37025_ES541-213106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-37025_es541-213106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO11910.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo11910-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO11520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo11520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO10750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo10750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO10750 (2).pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo10750-2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO09840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo09840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO09140.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo09140-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO08680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo08680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35034_CT562-BO08640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35034_ct562-bo08640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-BO10520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-bo10520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-BO08370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-bo08370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-BO07200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-bo07200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-BO06840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-bo06840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-05115H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-05115h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_DEC610-05112C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_dec610-05112c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_CT561-BO11660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_ct561-bo11660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_CT561-BO09220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_ct561-bo09220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35033_BO06700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35033_bo06700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35032_CT560-BO13230.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35032_ct560-bo13230-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35032_CT560-BO10900.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35032_ct560-bo10900-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_DEC560-05214H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_dec560-05214h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_DEC560-05115L.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_dec560-05115l-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_DEC560-05115F.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_dec560-05115f-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_DEC560-05113H.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_dec560-05113h-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_DEC560-05112I.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_dec560-05112i-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT5589-BO11510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct5589-bo11510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT5589-BO11420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct5589-bo11420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT5589-BO11200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct5589-bo11200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT5589-BO10230.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct5589-bo10230-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT5589-BO08580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct5589-bo08580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO13220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo13220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO13090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo13090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO12690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo12690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO12260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo12260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO11700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo11700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO08720.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo08720-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO08720 v04.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo08720-v04-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO08720 v2.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo08720-v2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO06920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo06920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35031_CT559-BO06870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35031_ct559-bo06870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_DEC670-20113E.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_dec670-20113e-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO13530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo13530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO12420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo12420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO11940.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo11940-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO11600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo11600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO10460.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo10460-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO10260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo10260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35029_CT558-BO07630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35029_ct558-bo07630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05216B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05216b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05215G.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05215g-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05116B.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05116b-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05116A.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05116a-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05115L.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05115l-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO35028_DEC670-05115K.pdf](https://www.meridianbioscience.com/lifescience/document//bio35028_dec670-05115k-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_DEC670-05112C.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_dec670-05112c-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO13240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo13240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO12840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo12840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO12760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo12760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO12200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo12200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO11410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo11410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO11170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo11170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO10640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo10640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO10640 (2).pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo10640-2-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO09150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo09150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO08930.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo08930-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO07210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo07210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35028_CT557-BO06860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35028_ct557-bo06860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO63610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo63610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO60650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo60650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO59030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo59030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO57380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo57380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO54120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo54120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO53600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo53600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO51870.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo51870-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO49260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo49260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO47640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo47640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO42400.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo42400-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO39090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo39090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO33390.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo33390-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO30420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo30420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO28490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo28490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO27440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo27440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO26140.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo26140-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO26050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo26050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO23260.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo23260-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO20320.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo20320-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-BO18980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-bo18980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-B071060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-b071060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-B066150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-b066150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-B065710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-b065710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-314101_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-314101_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-313111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-313111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025_CT554-313108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025_ct554-313108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35025 CT554-BO16920.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35025-ct554-bo16920-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35020_SF703-BO42160.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35020_sf703-bo42160-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35020_SF703-BO38440.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35020_sf703-bo38440-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35020_SF703-B019680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35020_sf703-b019680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35020 SF703-B034470.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35020-sf703-b034470-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35005_SF702-BO38430.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35005_sf702-bo38430-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35005_SF702-B041220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35005_sf702-b041220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35005_SF702-B019690.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35005_sf702-b019690-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-35002_SF701-B019700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-35002_sf701-b019700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO65060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo65060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO55800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo55800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO54660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo54660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO52110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo52110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO49680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo49680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO47970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo47970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO38830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo38830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO32350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo32350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO27640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo27640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34005_SF699-B019650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34005_sf699-b019650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33062_MW436-213109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33062_mw436-213109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33062_MW463-213106.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33062_mw463-213106-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-B064580.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-b064580-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-B071050.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-b071050-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-BO22860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-bo22860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-BO27510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-bo27510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-BO36780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-bo36780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-BO47630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-bo47630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33066_MW449-BO58280.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33066_mw449-bo58280-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33068_MW442-BO19190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33068_mw442-bo19190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34002_SF698-B019660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34002_sf698-b019660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33071_MX445-BO19200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33071_mx445-bo19200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34005_SF699-BO38820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34005_sf699-bo38820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34005_SF699-BO40810.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34005_sf699-bo40810-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34005_SF699-BO41950.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34005_sf699-bo41950-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34005_SF699-BO42750.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34005_sf699-bo42750-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-B019640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-b019640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO22880.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo22880-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-34020_SF700-BO24020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-34020_sf700-bo24020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33062 MW436-BO32710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33062-mw436-bo32710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO65370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo65370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO60170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo60170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO57520.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo57520-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO52660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo52660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO48060.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo48060-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO41630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo41630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO37090.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo37090-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO33550.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo33550-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO28730.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo28730-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO26640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo26640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO23220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo23220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-BO19170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-bo19170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-B081360.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-b081360-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-B071030.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-b071030-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-B070770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-b070770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-213112_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-213112_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33057_MW433-213108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33057_mw433-213108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO333250.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo333250-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO62410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo62410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO59680.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo59680-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO59590.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo59590-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO56120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo56120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO52850.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo52850-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO49470.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo49470-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO46170.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo46170-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO42600.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo42600-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO37820.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo37820-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO36190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo36190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO30410.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo30410-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO28240.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo28240-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO25830.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo25830-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO23950.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo23950-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-BO22220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-bo22220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B079160.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b079160-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B078710.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b078710-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B075660.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b075660-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B073780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b073780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B069200.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b069200-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-B065860.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-b065860-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO35380.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo35380-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B074470.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b074470-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B078670.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b078670-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO19160.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo19160-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO24130.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo24130-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO24980.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo24980-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO26630.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo26630-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO27970.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo27970-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO30530.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo30530-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO32270.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo32270-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO38020.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo38020-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO40800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo40800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO48490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo48490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO52840.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo52840-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO55610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo55610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO59120.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo59120-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-BO61490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-bo61490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-213105.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-213105-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-213108.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-213108-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33056_MW430-213111.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33056_mw430-213111-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO44420.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo44420-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO35370.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo35370-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO37700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo37700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO41540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo41540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO47610.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo47610-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO50490.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo50490-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO53780.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo53780-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO57510.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo57510-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO60640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo60640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO64190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo64190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-213209.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-213209-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-213210.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-213210-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-214201.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-214201-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-214201_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-214201_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B004800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b004800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B0045190.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b0045190-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B066230.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b066230-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B067540.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b067540-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-B070760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-b070760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33054_MW424-213207.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33054_mw424-213207-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-B080790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-b080790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO53350.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo53350-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO55640.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo55640-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO57770.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo57770-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO61900.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo61900-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO64480.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo64480-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33046_MW438-BO64700.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33046_mw438-bo64700-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-113206.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-113206-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-313109.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-313109-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-313112.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-313112-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-313112_0414.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-313112_0414-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-B072800.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-b072800-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO32220.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo32220-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO29950.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo29950-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO26760.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo26760-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO24650.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo24650-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO19150.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo19150-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-BO21740.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-bo21740-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-B068790.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-b068790-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
### [BIO-33053_MW421-B077110.pdf](https://www.meridianbioscience.com/lifescience/document//bio-33053_mw421-b077110-pdf/)
**Published:** July 20, 2026
**Author:** Hamza Shahzad
---
## Immuno Products
### [MHP18-601CC](https://www.meridianbioscience.com/lifescience-product/mhp18-601cc/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C-Peptide, Hormones & Steroids
---
### [88131](https://www.meridianbioscience.com/lifescience-product/88131/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Serum
---
### [8120](https://www.meridianbioscience.com/lifescience-product/8120/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [7749](https://www.meridianbioscience.com/lifescience-product/7749/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [7705](https://www.meridianbioscience.com/lifescience-product/7705/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [7309](https://www.meridianbioscience.com/lifescience-product/7309/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [7305](https://www.meridianbioscience.com/lifescience-product/7305/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [W41604G](https://www.meridianbioscience.com/lifescience-product/w41604g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W01256R](https://www.meridianbioscience.com/lifescience-product/w01256r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W01252G](https://www.meridianbioscience.com/lifescience-product/w01252g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [W01251G](https://www.meridianbioscience.com/lifescience-product/w01251g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [VTI540](https://www.meridianbioscience.com/lifescience-product/vti540/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [VTI530](https://www.meridianbioscience.com/lifescience-product/vti530/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [VTI520](https://www.meridianbioscience.com/lifescience-product/vti520/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [VTI510](https://www.meridianbioscience.com/lifescience-product/vti510/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [VTI360](https://www.meridianbioscience.com/lifescience-product/vti360/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [VTI340](https://www.meridianbioscience.com/lifescience-product/vti340/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R8A404](https://www.meridianbioscience.com/lifescience-product/r8a404/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R8A403](https://www.meridianbioscience.com/lifescience-product/r8a403/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R8A114](https://www.meridianbioscience.com/lifescience-product/r8a114/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R8A120](https://www.meridianbioscience.com/lifescience-product/r8a120/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R8A101](https://www.meridianbioscience.com/lifescience-product/r8a101/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R65911](https://www.meridianbioscience.com/lifescience-product/r65911/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R18830](https://www.meridianbioscience.com/lifescience-product/r18830/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R18530](https://www.meridianbioscience.com/lifescience-product/r18530/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [R18410](https://www.meridianbioscience.com/lifescience-product/r18410/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R18350](https://www.meridianbioscience.com/lifescience-product/r18350/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [R18152](https://www.meridianbioscience.com/lifescience-product/r18152/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [R18142](https://www.meridianbioscience.com/lifescience-product/r18142/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [R14710](https://www.meridianbioscience.com/lifescience-product/r14710/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Candida albicans, Sexually Transmitted Infections (STIs)
---
### [R02121](https://www.meridianbioscience.com/lifescience-product/r02121/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [R01783](https://www.meridianbioscience.com/lifescience-product/r01783/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01715](https://www.meridianbioscience.com/lifescience-product/r01715/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [R01705](https://www.meridianbioscience.com/lifescience-product/r01705/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01682](https://www.meridianbioscience.com/lifescience-product/r01682/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01681](https://www.meridianbioscience.com/lifescience-product/r01681/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01673](https://www.meridianbioscience.com/lifescience-product/r01673/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [R01665](https://www.meridianbioscience.com/lifescience-product/r01665/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01631](https://www.meridianbioscience.com/lifescience-product/r01631/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01627](https://www.meridianbioscience.com/lifescience-product/r01627/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01626](https://www.meridianbioscience.com/lifescience-product/r01626/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01625](https://www.meridianbioscience.com/lifescience-product/r01625/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01606](https://www.meridianbioscience.com/lifescience-product/r01606/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01594](https://www.meridianbioscience.com/lifescience-product/r01594/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [R01593](https://www.meridianbioscience.com/lifescience-product/r01593/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01583](https://www.meridianbioscience.com/lifescience-product/r01583/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01582](https://www.meridianbioscience.com/lifescience-product/r01582/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01547](https://www.meridianbioscience.com/lifescience-product/r01547/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01529](https://www.meridianbioscience.com/lifescience-product/r01529/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01528](https://www.meridianbioscience.com/lifescience-product/r01528/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [R01508](https://www.meridianbioscience.com/lifescience-product/r01508/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01507](https://www.meridianbioscience.com/lifescience-product/r01507/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01454](https://www.meridianbioscience.com/lifescience-product/r01454/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [R01434](https://www.meridianbioscience.com/lifescience-product/r01434/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [R01433](https://www.meridianbioscience.com/lifescience-product/r01433/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [R01429](https://www.meridianbioscience.com/lifescience-product/r01429/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [R01428](https://www.meridianbioscience.com/lifescience-product/r01428/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [R01276](https://www.meridianbioscience.com/lifescience-product/r01276/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [N64250P](https://www.meridianbioscience.com/lifescience-product/n64250p/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Serum
---
### [N64007B](https://www.meridianbioscience.com/lifescience-product/n64007b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Serum
---
### [N14010M](https://www.meridianbioscience.com/lifescience-product/n14010m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Serum
---
### [N01269H](https://www.meridianbioscience.com/lifescience-product/n01269h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [M66281M](https://www.meridianbioscience.com/lifescience-product/m66281m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M66280M](https://www.meridianbioscience.com/lifescience-product/m66280m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M66279M](https://www.meridianbioscience.com/lifescience-product/m66279m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M66278M](https://www.meridianbioscience.com/lifescience-product/m66278m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M66113M](https://www.meridianbioscience.com/lifescience-product/m66113m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M66112M](https://www.meridianbioscience.com/lifescience-product/m66112m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M66108M](https://www.meridianbioscience.com/lifescience-product/m66108m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [M66105M](https://www.meridianbioscience.com/lifescience-product/m66105m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Osteopontin
---
### [M66103M](https://www.meridianbioscience.com/lifescience-product/m66103m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Osteopontin
---
### [M66102M](https://www.meridianbioscience.com/lifescience-product/m66102m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Osteopontin
---
### [M01333C](https://www.meridianbioscience.com/lifescience-product/m01333c/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01295M](https://www.meridianbioscience.com/lifescience-product/m01295m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [MEM11-767](https://www.meridianbioscience.com/lifescience-product/mem11-767/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Sialyl Lewis
---
### [MDM04-710](https://www.meridianbioscience.com/lifescience-product/mdm04-710/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MDF07-037](https://www.meridianbioscience.com/lifescience-product/mdf07-037/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [MCT04-001](https://www.meridianbioscience.com/lifescience-product/mct04-001/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MCT02-011](https://www.meridianbioscience.com/lifescience-product/mct02-011/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Thyroxine (T4)
---
### [MCF02-011](https://www.meridianbioscience.com/lifescience-product/mcf02-011/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAZ23-741](https://www.meridianbioscience.com/lifescience-product/maz23-741/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** FITC, Miscellaneous Reagents
---
### [MAV56-981T](https://www.meridianbioscience.com/lifescience-product/mav56-981t/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV56-981](https://www.meridianbioscience.com/lifescience-product/mav56-981/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV56-965](https://www.meridianbioscience.com/lifescience-product/mav56-965/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV56-271](https://www.meridianbioscience.com/lifescience-product/mav56-271/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV56-267](https://www.meridianbioscience.com/lifescience-product/mav56-267/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV56-013](https://www.meridianbioscience.com/lifescience-product/mav56-013/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [MAV133-236](https://www.meridianbioscience.com/lifescience-product/mav133-236/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ricin, Toxins & Biowarfare
---
### [MAV100-265](https://www.meridianbioscience.com/lifescience-product/mav100-265/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, H. Pylori
---
### [MAV07-743](https://www.meridianbioscience.com/lifescience-product/mav07-743/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [MAV07-347](https://www.meridianbioscience.com/lifescience-product/mav07-347/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [MAV06-086](https://www.meridianbioscience.com/lifescience-product/mav06-086/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [MAT04-252](https://www.meridianbioscience.com/lifescience-product/mat04-252/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-127](https://www.meridianbioscience.com/lifescience-product/mat04-127/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-006](https://www.meridianbioscience.com/lifescience-product/mat04-006/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-005](https://www.meridianbioscience.com/lifescience-product/mat04-005/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-003](https://www.meridianbioscience.com/lifescience-product/mat04-003/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-001](https://www.meridianbioscience.com/lifescience-product/mat04-001/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT03-612](https://www.meridianbioscience.com/lifescience-product/mat03-612/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TBG
---
### [MAT02-525](https://www.meridianbioscience.com/lifescience-product/mat02-525/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Thyroxine (T4)
---
### [MAT01-237](https://www.meridianbioscience.com/lifescience-product/mat01-237/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Triiodothyronine
---
### [MAT01-121](https://www.meridianbioscience.com/lifescience-product/mat01-121/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Triiodothyronine
---
### [MAS01-501](https://www.meridianbioscience.com/lifescience-product/mas01-501/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cortisol, Hormones & Steroids
---
### [MARG16-125](https://www.meridianbioscience.com/lifescience-product/marg16-125/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [MAM42-801](https://www.meridianbioscience.com/lifescience-product/mam42-801/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, p53
---
### [MAM26-014](https://www.meridianbioscience.com/lifescience-product/mam26-014/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Desmin
---
### [MAM23-741](https://www.meridianbioscience.com/lifescience-product/mam23-741/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Epithelial MuCIn
---
### [MAM21-964](https://www.meridianbioscience.com/lifescience-product/mam21-964/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, PCNA
---
### [MAM10-810](https://www.meridianbioscience.com/lifescience-product/mam10-810/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Sialyl Lewis
---
### [MAM04-710](https://www.meridianbioscience.com/lifescience-product/mam04-710/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MAM04-187](https://www.meridianbioscience.com/lifescience-product/mam04-187/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MAM04-175](https://www.meridianbioscience.com/lifescience-product/mam04-175/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MAM04-030](https://www.meridianbioscience.com/lifescience-product/mam04-030/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MAM04-010](https://www.meridianbioscience.com/lifescience-product/mam04-010/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [MAM02-881](https://www.meridianbioscience.com/lifescience-product/mam02-881/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [MAM02-009](https://www.meridianbioscience.com/lifescience-product/mam02-009/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [MAM02-008](https://www.meridianbioscience.com/lifescience-product/mam02-008/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [MAM02-007](https://www.meridianbioscience.com/lifescience-product/mam02-007/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [MAM01-210](https://www.meridianbioscience.com/lifescience-product/mam01-210/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [MAL08-804](https://www.meridianbioscience.com/lifescience-product/mal08-804/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [MAG40-231](https://www.meridianbioscience.com/lifescience-product/mag40-231/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [MAG40-002](https://www.meridianbioscience.com/lifescience-product/mag40-002/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [MAGG16-264](https://www.meridianbioscience.com/lifescience-product/magg16-264/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [MAF10-710](https://www.meridianbioscience.com/lifescience-product/maf10-710/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [MAF10-245](https://www.meridianbioscience.com/lifescience-product/maf10-245/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [MAF10-216](https://www.meridianbioscience.com/lifescience-product/maf10-216/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [MAF10-145](https://www.meridianbioscience.com/lifescience-product/maf10-145/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [MAF07-412](https://www.meridianbioscience.com/lifescience-product/maf07-412/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [MAG40-132](https://www.meridianbioscience.com/lifescience-product/mag40-132/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, IgE
---
### [MAF07-226](https://www.meridianbioscience.com/lifescience-product/maf07-226/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [MAC20-029](https://www.meridianbioscience.com/lifescience-product/mac20-029/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [L62905G](https://www.meridianbioscience.com/lifescience-product/l62905g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Lambda Light Chain
---
### [L62805G](https://www.meridianbioscience.com/lifescience-product/l62805g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Kappa Light Chains
---
### [L15905G](https://www.meridianbioscience.com/lifescience-product/l15905g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Lambda Light Chain
---
### [L15805G](https://www.meridianbioscience.com/lifescience-product/l15805g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Kappa Light Chains
---
### [L04330G](https://www.meridianbioscience.com/lifescience-product/l04330g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Macroglobulin
---
### [L01237G](https://www.meridianbioscience.com/lifescience-product/l01237g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [K24124M-LQ](https://www.meridianbioscience.com/lifescience-product/k24124m-lq/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Vitamin D
---
### [K24123M](https://www.meridianbioscience.com/lifescience-product/k24123m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Vitamin D
---
### [K04365G](https://www.meridianbioscience.com/lifescience-product/k04365g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Lambda Light Chain
---
### [K01395C](https://www.meridianbioscience.com/lifescience-product/k01395c/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [J16430D](https://www.meridianbioscience.com/lifescience-product/j16430d/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [J16200D](https://www.meridianbioscience.com/lifescience-product/j16200d/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HRP, Miscellaneous Reagents
---
### [H86922M](https://www.meridianbioscience.com/lifescience-product/h86922m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, sLOX
---
### [H86502M](https://www.meridianbioscience.com/lifescience-product/h86502m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, sGC
---
### [H86262M](https://www.meridianbioscience.com/lifescience-product/h86262m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [H01413M](https://www.meridianbioscience.com/lifescience-product/h01413m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [H01396M](https://www.meridianbioscience.com/lifescience-product/h01396m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [H01394M](https://www.meridianbioscience.com/lifescience-product/h01394m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [H01388M](https://www.meridianbioscience.com/lifescience-product/h01388m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Hemoglobin
---
### [H01384M](https://www.meridianbioscience.com/lifescience-product/h01384m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, SAA
---
### [H01380R](https://www.meridianbioscience.com/lifescience-product/h01380r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [H01379R](https://www.meridianbioscience.com/lifescience-product/h01379r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, SAA
---
### [H01375M](https://www.meridianbioscience.com/lifescience-product/h01375m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Adiponectin, Cardiac, Cholesterol, & Metabolic Markers
---
### [H01373M](https://www.meridianbioscience.com/lifescience-product/h01373m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Hemoglobin
---
### [H01372M](https://www.meridianbioscience.com/lifescience-product/h01372m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [H01363M](https://www.meridianbioscience.com/lifescience-product/h01363m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [H01354M](https://www.meridianbioscience.com/lifescience-product/h01354m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** NT-proBNP, Vet Health
---
### [H01348M](https://www.meridianbioscience.com/lifescience-product/h01348m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Hemoglobin
---
### [H01347M](https://www.meridianbioscience.com/lifescience-product/h01347m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [H01343M](https://www.meridianbioscience.com/lifescience-product/h01343m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [H01310G](https://www.meridianbioscience.com/lifescience-product/h01310g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [G5C21-766](https://www.meridianbioscience.com/lifescience-product/g5c21-766/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [G5C20-766](https://www.meridianbioscience.com/lifescience-product/g5c20-766/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [G31234M](https://www.meridianbioscience.com/lifescience-product/g31234m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Carbamazepine, DOA
---
### [GB9521](https://www.meridianbioscience.com/lifescience-product/gb9521/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [GB9520](https://www.meridianbioscience.com/lifescience-product/gb9520/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [E20630M](https://www.meridianbioscience.com/lifescience-product/e20630m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [E20122M](https://www.meridianbioscience.com/lifescience-product/e20122m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [EV9287](https://www.meridianbioscience.com/lifescience-product/ev9287/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C86943M](https://www.meridianbioscience.com/lifescience-product/c86943m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C86921P](https://www.meridianbioscience.com/lifescience-product/c86921p/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ricin, Toxins & Biowarfare
---
### [C86867M](https://www.meridianbioscience.com/lifescience-product/c86867m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [C86863M](https://www.meridianbioscience.com/lifescience-product/c86863m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C86820M](https://www.meridianbioscience.com/lifescience-product/c86820m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycobacterium tuberculosis, Respiratory Diseases
---
### [C86791M](https://www.meridianbioscience.com/lifescience-product/c86791m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [C86718M](https://www.meridianbioscience.com/lifescience-product/c86718m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [C86636M](https://www.meridianbioscience.com/lifescience-product/c86636m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C86634M](https://www.meridianbioscience.com/lifescience-product/c86634m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C86420M](https://www.meridianbioscience.com/lifescience-product/c86420m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [C86328M](https://www.meridianbioscience.com/lifescience-product/c86328m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C86319P](https://www.meridianbioscience.com/lifescience-product/c86319p/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [C86319M](https://www.meridianbioscience.com/lifescience-product/c86319m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [C86308B](https://www.meridianbioscience.com/lifescience-product/c86308b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Toxins & Biowarfare, Yersinia
---
### [C86302M](https://www.meridianbioscience.com/lifescience-product/c86302m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C86180M](https://www.meridianbioscience.com/lifescience-product/c86180m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ebola, Tropical & Vector-Borne Diseases
---
### [C86135B](https://www.meridianbioscience.com/lifescience-product/c86135b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Legionella pneumophila, Respiratory Diseases
---
### [C86109M](https://www.meridianbioscience.com/lifescience-product/c86109m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [C86036M](https://www.meridianbioscience.com/lifescience-product/c86036m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Diphtheria, Tropical & Vector-Borne Diseases
---
### [C86013M](https://www.meridianbioscience.com/lifescience-product/c86013m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HPV, Sexually Transmitted Infections (STIs)
---
### [C8A401H](https://www.meridianbioscience.com/lifescience-product/c8a401h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C8A020M](https://www.meridianbioscience.com/lifescience-product/c8a020m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C8A015M](https://www.meridianbioscience.com/lifescience-product/c8a015m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C70517M](https://www.meridianbioscience.com/lifescience-product/c70517m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [C66513M](https://www.meridianbioscience.com/lifescience-product/c66513m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Giardia
---
### [C66512M](https://www.meridianbioscience.com/lifescience-product/c66512m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cryptosporidium, Gastrointestinal Pathogens
---
### [C66510M](https://www.meridianbioscience.com/lifescience-product/c66510m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, SLT
---
### [C66509M](https://www.meridianbioscience.com/lifescience-product/c66509m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [C66503M](https://www.meridianbioscience.com/lifescience-product/c66503m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [C66501M](https://www.meridianbioscience.com/lifescience-product/c66501m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C66496M](https://www.meridianbioscience.com/lifescience-product/c66496m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [C66441M](https://www.meridianbioscience.com/lifescience-product/c66441m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cryptococcus, Respiratory Diseases
---
### [C66436M](https://www.meridianbioscience.com/lifescience-product/c66436m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C66435M](https://www.meridianbioscience.com/lifescience-product/c66435m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C66432M](https://www.meridianbioscience.com/lifescience-product/c66432m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [C66431M](https://www.meridianbioscience.com/lifescience-product/c66431m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [C66405M](https://www.meridianbioscience.com/lifescience-product/c66405m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [C66150M](https://www.meridianbioscience.com/lifescience-product/c66150m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C66130M](https://www.meridianbioscience.com/lifescience-product/c66130m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Rotavirus
---
### [C65941M](https://www.meridianbioscience.com/lifescience-product/c65941m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C65912M](https://www.meridianbioscience.com/lifescience-product/c65912m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C65911M](https://www.meridianbioscience.com/lifescience-product/c65911m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C65901M](https://www.meridianbioscience.com/lifescience-product/c65901m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C65815M](https://www.meridianbioscience.com/lifescience-product/c65815m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C65690M](https://www.meridianbioscience.com/lifescience-product/c65690m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C65675M](https://www.meridianbioscience.com/lifescience-product/c65675m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Trichomonas vaginalis
---
### [C65499M](https://www.meridianbioscience.com/lifescience-product/c65499m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C65302M](https://www.meridianbioscience.com/lifescience-product/c65302m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C65206M](https://www.meridianbioscience.com/lifescience-product/c65206m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C65168M](https://www.meridianbioscience.com/lifescience-product/c65168m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C65116M](https://www.meridianbioscience.com/lifescience-product/c65116m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C65115M](https://www.meridianbioscience.com/lifescience-product/c65115m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C55580M](https://www.meridianbioscience.com/lifescience-product/c55580m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neisseria gonorrhoeae, Sexually Transmitted Infections (STIs)
---
### [C18386M](https://www.meridianbioscience.com/lifescience-product/c18386m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C11999M](https://www.meridianbioscience.com/lifescience-product/c11999m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01859M](https://www.meridianbioscience.com/lifescience-product/c01859m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C01848C](https://www.meridianbioscience.com/lifescience-product/c01848c/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01847C](https://www.meridianbioscience.com/lifescience-product/c01847c/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01845R](https://www.meridianbioscience.com/lifescience-product/c01845r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Candida albicans, Sexually Transmitted Infections (STIs)
---
### [C01820M](https://www.meridianbioscience.com/lifescience-product/c01820m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neisseria gonorrhoeae, Sexually Transmitted Infections (STIs)
---
### [C01819M](https://www.meridianbioscience.com/lifescience-product/c01819m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neisseria gonorrhoeae, Sexually Transmitted Infections (STIs)
---
### [C01818M](https://www.meridianbioscience.com/lifescience-product/c01818m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neisseria gonorrhoeae, Sexually Transmitted Infections (STIs)
---
### [C01706M](https://www.meridianbioscience.com/lifescience-product/c01706m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [C01668M](https://www.meridianbioscience.com/lifescience-product/c01668m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma genitalium, Sexually Transmitted Infections (STIs)
---
### [C01667M](https://www.meridianbioscience.com/lifescience-product/c01667m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma genitalium, Sexually Transmitted Infections (STIs)
---
### [C01666M](https://www.meridianbioscience.com/lifescience-product/c01666m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma genitalium, Sexually Transmitted Infections (STIs)
---
### [C01665M](https://www.meridianbioscience.com/lifescience-product/c01665m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma genitalium, Sexually Transmitted Infections (STIs)
---
### [C01657M](https://www.meridianbioscience.com/lifescience-product/c01657m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01656M](https://www.meridianbioscience.com/lifescience-product/c01656m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01655M](https://www.meridianbioscience.com/lifescience-product/c01655m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01653M](https://www.meridianbioscience.com/lifescience-product/c01653m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01577M](https://www.meridianbioscience.com/lifescience-product/c01577m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01576M](https://www.meridianbioscience.com/lifescience-product/c01576m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [C01571M](https://www.meridianbioscience.com/lifescience-product/c01571m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Trichomonas vaginalis
---
### [C01568M](https://www.meridianbioscience.com/lifescience-product/c01568m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Trichomonas vaginalis
---
### [C01567M](https://www.meridianbioscience.com/lifescience-product/c01567m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Trichomonas vaginalis
---
### [C01566M](https://www.meridianbioscience.com/lifescience-product/c01566m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C01565M](https://www.meridianbioscience.com/lifescience-product/c01565m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C01461M](https://www.meridianbioscience.com/lifescience-product/c01461m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma hominis, Sexually Transmitted Infections (STIs)
---
### [C01365M](https://www.meridianbioscience.com/lifescience-product/c01365m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [C01292M](https://www.meridianbioscience.com/lifescience-product/c01292m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C01291M](https://www.meridianbioscience.com/lifescience-product/c01291m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [C01290M](https://www.meridianbioscience.com/lifescience-product/c01290m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [B65961P](https://www.meridianbioscience.com/lifescience-product/b65961p/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [B65961G](https://www.meridianbioscience.com/lifescience-product/b65961g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [B65961B](https://www.meridianbioscience.com/lifescience-product/b65961b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [B65411R](https://www.meridianbioscience.com/lifescience-product/b65411r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Candida albicans, Sexually Transmitted Infections (STIs)
---
### [B65411F](https://www.meridianbioscience.com/lifescience-product/b65411f/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Candida albicans, Sexually Transmitted Infections (STIs)
---
### [B65411B](https://www.meridianbioscience.com/lifescience-product/b65411b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Candida albicans, Sexually Transmitted Infections (STIs)
---
### [B65253R](https://www.meridianbioscience.com/lifescience-product/b65253r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [B65252R](https://www.meridianbioscience.com/lifescience-product/b65252r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [B65252G](https://www.meridianbioscience.com/lifescience-product/b65252g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia trachomatis, Sexually Transmitted Infections (STIs)
---
### [B65210R](https://www.meridianbioscience.com/lifescience-product/b65210r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [B65205R](https://www.meridianbioscience.com/lifescience-product/b65205r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [B65134G](https://www.meridianbioscience.com/lifescience-product/b65134g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [B65133G](https://www.meridianbioscience.com/lifescience-product/b65133g/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [B65121S](https://www.meridianbioscience.com/lifescience-product/b65121s/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [B65111R](https://www.meridianbioscience.com/lifescience-product/b65111r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Neisseria gonorrhoeae, Sexually Transmitted Infections (STIs)
---
### [B65107R](https://www.meridianbioscience.com/lifescience-product/b65107r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Herpes, Sexually Transmitted Infections (STIs)
---
### [BN1266](https://www.meridianbioscience.com/lifescience-product/bn1266/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [BN1264](https://www.meridianbioscience.com/lifescience-product/bn1264/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HTLV, Sexually Transmitted Infections (STIs)
---
### [BN1220](https://www.meridianbioscience.com/lifescience-product/bn1220/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [BN1046](https://www.meridianbioscience.com/lifescience-product/bn1046/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1043](https://www.meridianbioscience.com/lifescience-product/bn1043/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1044](https://www.meridianbioscience.com/lifescience-product/bn1044/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1045](https://www.meridianbioscience.com/lifescience-product/bn1045/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1041](https://www.meridianbioscience.com/lifescience-product/bn1041/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1042](https://www.meridianbioscience.com/lifescience-product/bn1042/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1039](https://www.meridianbioscience.com/lifescience-product/bn1039/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1040](https://www.meridianbioscience.com/lifescience-product/bn1040/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1030](https://www.meridianbioscience.com/lifescience-product/bn1030/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1038](https://www.meridianbioscience.com/lifescience-product/bn1038/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Sexually Transmitted Infections (STIs), Treponema pallidum
---
### [BN1026](https://www.meridianbioscience.com/lifescience-product/bn1026/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1027](https://www.meridianbioscience.com/lifescience-product/bn1027/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1028](https://www.meridianbioscience.com/lifescience-product/bn1028/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1025](https://www.meridianbioscience.com/lifescience-product/bn1025/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1023](https://www.meridianbioscience.com/lifescience-product/bn1023/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1024](https://www.meridianbioscience.com/lifescience-product/bn1024/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1021](https://www.meridianbioscience.com/lifescience-product/bn1021/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1022](https://www.meridianbioscience.com/lifescience-product/bn1022/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1020](https://www.meridianbioscience.com/lifescience-product/bn1020/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1018](https://www.meridianbioscience.com/lifescience-product/bn1018/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [BN1019](https://www.meridianbioscience.com/lifescience-product/bn1019/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** HIV, Sexually Transmitted Infections (STIs)
---
### [A66400S](https://www.meridianbioscience.com/lifescience-product/a66400s/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [A66441S](https://www.meridianbioscience.com/lifescience-product/a66441s/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [A66190M-NA](https://www.meridianbioscience.com/lifescience-product/a66190m-na/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66200H](https://www.meridianbioscience.com/lifescience-product/a66200h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [A66189M](https://www.meridianbioscience.com/lifescience-product/a66189m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66186M-NA](https://www.meridianbioscience.com/lifescience-product/a66186m-na/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66187M](https://www.meridianbioscience.com/lifescience-product/a66187m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66185M-NA](https://www.meridianbioscience.com/lifescience-product/a66185m-na/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66186M](https://www.meridianbioscience.com/lifescience-product/a66186m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66181M](https://www.meridianbioscience.com/lifescience-product/a66181m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A66185M](https://www.meridianbioscience.com/lifescience-product/a66185m/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [A62934H](https://www.meridianbioscience.com/lifescience-product/a62934h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [A38980H](https://www.meridianbioscience.com/lifescience-product/a38980h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [A41182R](https://www.meridianbioscience.com/lifescience-product/a41182r/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [A38558H](https://www.meridianbioscience.com/lifescience-product/a38558h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, LDH
---
### [A38270H](https://www.meridianbioscience.com/lifescience-product/a38270h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [A38454H](https://www.meridianbioscience.com/lifescience-product/a38454h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, LDH
---
### [A38131H](https://www.meridianbioscience.com/lifescience-product/a38131h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Myoglobin
---
### [A38195H](https://www.meridianbioscience.com/lifescience-product/a38195h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Ferritin, Hormones & Steroids
---
### [A32502H](https://www.meridianbioscience.com/lifescience-product/a32502h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [A38104H](https://www.meridianbioscience.com/lifescience-product/a38104h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, MPO
---
### [A32340H](https://www.meridianbioscience.com/lifescience-product/a32340h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Cyfra-21-1
---
### [A32231H](https://www.meridianbioscience.com/lifescience-product/a32231h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA15-3, Cancer Markers
---
### [A32260H](https://www.meridianbioscience.com/lifescience-product/a32260h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [A32030H](https://www.meridianbioscience.com/lifescience-product/a32030h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [A32180H](https://www.meridianbioscience.com/lifescience-product/a32180h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA125, Cancer Markers
---
### [A32000H](https://www.meridianbioscience.com/lifescience-product/a32000h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA15-3, Cancer Markers
---
### [A01707N](https://www.meridianbioscience.com/lifescience-product/a01707n/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Yersinia Enterocolitica
---
### [A01708N](https://www.meridianbioscience.com/lifescience-product/a01708n/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Yersinia Enterocolitica
---
### [A01695H](https://www.meridianbioscience.com/lifescience-product/a01695h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [A01694D](https://www.meridianbioscience.com/lifescience-product/a01694d/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Vitamin D
---
### [A01690H](https://www.meridianbioscience.com/lifescience-product/a01690h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA125, Cancer Markers
---
### [A01683H](https://www.meridianbioscience.com/lifescience-product/a01683h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Elastase
---
### [A01678H](https://www.meridianbioscience.com/lifescience-product/a01678h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, BPI Protein
---
### [A01679H](https://www.meridianbioscience.com/lifescience-product/a01679h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Cathepsin G
---
### [A01672B](https://www.meridianbioscience.com/lifescience-product/a01672b/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, GBM
---
### [A01458H](https://www.meridianbioscience.com/lifescience-product/a01458h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [A01467H](https://www.meridianbioscience.com/lifescience-product/a01467h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [A01447H](https://www.meridianbioscience.com/lifescience-product/a01447h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Beta 2 Microglobulin, Cancer Markers
---
### [A01451H](https://www.meridianbioscience.com/lifescience-product/a01451h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Microglobulin, Renal Diseases
---
### [A01444H](https://www.meridianbioscience.com/lifescience-product/a01444h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [A01406H](https://www.meridianbioscience.com/lifescience-product/a01406h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [A01273H](https://www.meridianbioscience.com/lifescience-product/a01273h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Hemoglobin
---
### [A01366C](https://www.meridianbioscience.com/lifescience-product/a01366c/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [A01264H](https://www.meridianbioscience.com/lifescience-product/a01264h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** CA50, Cancer Markers
---
### [A01238H](https://www.meridianbioscience.com/lifescience-product/a01238h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [A01250H](https://www.meridianbioscience.com/lifescience-product/a01250h/)
**Published:** February 23, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [BN1300](https://www.meridianbioscience.com/lifescience-product/bn1300/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Animal-Free, Recombinant Immunoassay Blockers, Blockers, Blockers & Immunoglobulins
---
### [BN1200](https://www.meridianbioscience.com/lifescience-product/bn1200/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Animal-Free, Recombinant Immunoassay Blockers, Blockers, Blockers & Immunoglobulins
---
### [9635](https://www.meridianbioscience.com/lifescience-product/9635/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Imipenem
---
### [9632](https://www.meridianbioscience.com/lifescience-product/9632/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Imipenem
---
### [9631](https://www.meridianbioscience.com/lifescience-product/9631/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Verona Integron Metallo-beta-lactamase
---
### [9630](https://www.meridianbioscience.com/lifescience-product/9630/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Verona Integron Metallo-beta-lactamase
---
### [9629](https://www.meridianbioscience.com/lifescience-product/9629/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Verona Integron Metallo-beta-lactamase
---
### [9628](https://www.meridianbioscience.com/lifescience-product/9628/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Verona Integron Metallo-beta-lactamase
---
### [9627](https://www.meridianbioscience.com/lifescience-product/9627/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, New Delhi metallo-beta-lactamase-1
---
### [9626](https://www.meridianbioscience.com/lifescience-product/9626/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, New Delhi metallo-beta-lactamase-1
---
### [9624](https://www.meridianbioscience.com/lifescience-product/9624/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, New Delhi metallo-beta-lactamase-1
---
### [9623](https://www.meridianbioscience.com/lifescience-product/9623/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, New Delhi metallo-beta-lactamase-1
---
### [9622](https://www.meridianbioscience.com/lifescience-product/9622/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, New Delhi metallo-beta-lactamase-1
---
### [9621](https://www.meridianbioscience.com/lifescience-product/9621/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Klebsiella pneumoniae Carbapenemase
---
### [9620](https://www.meridianbioscience.com/lifescience-product/9620/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Klebsiella pneumoniae Carbapenemase
---
### [9619](https://www.meridianbioscience.com/lifescience-product/9619/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Klebsiella pneumoniae Carbapenemase
---
### [9618](https://www.meridianbioscience.com/lifescience-product/9618/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, Klebsiella pneumoniae Carbapenemase
---
### [9617](https://www.meridianbioscience.com/lifescience-product/9617/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, OXA-48
---
### [9616](https://www.meridianbioscience.com/lifescience-product/9616/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, OXA-48
---
### [9615](https://www.meridianbioscience.com/lifescience-product/9615/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Antimicrobial Resistance, OXA-48
---
### [9607](https://www.meridianbioscience.com/lifescience-product/9607/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, SOD
---
### [9606](https://www.meridianbioscience.com/lifescience-product/9606/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9605](https://www.meridianbioscience.com/lifescience-product/9605/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ASFV, Vet Health
---
### [9603](https://www.meridianbioscience.com/lifescience-product/9603/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [9604](https://www.meridianbioscience.com/lifescience-product/9604/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [9602](https://www.meridianbioscience.com/lifescience-product/9602/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [9599](https://www.meridianbioscience.com/lifescience-product/9599/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9597](https://www.meridianbioscience.com/lifescience-product/9597/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, Strep A
---
### [9598](https://www.meridianbioscience.com/lifescience-product/9598/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9596](https://www.meridianbioscience.com/lifescience-product/9596/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [9595](https://www.meridianbioscience.com/lifescience-product/9595/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [9594](https://www.meridianbioscience.com/lifescience-product/9594/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [9592](https://www.meridianbioscience.com/lifescience-product/9592/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [9593](https://www.meridianbioscience.com/lifescience-product/9593/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [9591](https://www.meridianbioscience.com/lifescience-product/9591/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Calprotectin, Gastrointestinal Pathogens
---
### [9589](https://www.meridianbioscience.com/lifescience-product/9589/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [9590](https://www.meridianbioscience.com/lifescience-product/9590/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [9588](https://www.meridianbioscience.com/lifescience-product/9588/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [9587](https://www.meridianbioscience.com/lifescience-product/9587/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [9585](https://www.meridianbioscience.com/lifescience-product/9585/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Rotavirus
---
### [9586](https://www.meridianbioscience.com/lifescience-product/9586/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [9584](https://www.meridianbioscience.com/lifescience-product/9584/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [9582](https://www.meridianbioscience.com/lifescience-product/9582/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Elastase
---
### [9583](https://www.meridianbioscience.com/lifescience-product/9583/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [9581](https://www.meridianbioscience.com/lifescience-product/9581/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Elastase
---
### [9578](https://www.meridianbioscience.com/lifescience-product/9578/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Entamoeba histolytica, Gastrointestinal Pathogens
---
### [9580](https://www.meridianbioscience.com/lifescience-product/9580/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Elastase
---
### [9577](https://www.meridianbioscience.com/lifescience-product/9577/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Entamoeba histolytica, Gastrointestinal Pathogens
---
### [9575](https://www.meridianbioscience.com/lifescience-product/9575/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [9576](https://www.meridianbioscience.com/lifescience-product/9576/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [9574](https://www.meridianbioscience.com/lifescience-product/9574/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [9572](https://www.meridianbioscience.com/lifescience-product/9572/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9573](https://www.meridianbioscience.com/lifescience-product/9573/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [9569](https://www.meridianbioscience.com/lifescience-product/9569/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9567](https://www.meridianbioscience.com/lifescience-product/9567/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9568](https://www.meridianbioscience.com/lifescience-product/9568/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9566](https://www.meridianbioscience.com/lifescience-product/9566/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9560](https://www.meridianbioscience.com/lifescience-product/9560/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9565](https://www.meridianbioscience.com/lifescience-product/9565/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9559](https://www.meridianbioscience.com/lifescience-product/9559/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9558](https://www.meridianbioscience.com/lifescience-product/9558/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9556](https://www.meridianbioscience.com/lifescience-product/9556/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9557](https://www.meridianbioscience.com/lifescience-product/9557/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9555](https://www.meridianbioscience.com/lifescience-product/9555/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ACE2, Cardiac, Cholesterol, & Metabolic Markers
---
### [9552](https://www.meridianbioscience.com/lifescience-product/9552/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9554](https://www.meridianbioscience.com/lifescience-product/9554/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9551](https://www.meridianbioscience.com/lifescience-product/9551/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9549](https://www.meridianbioscience.com/lifescience-product/9549/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9550](https://www.meridianbioscience.com/lifescience-product/9550/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9548](https://www.meridianbioscience.com/lifescience-product/9548/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9544](https://www.meridianbioscience.com/lifescience-product/9544/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9547](https://www.meridianbioscience.com/lifescience-product/9547/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, SARS
---
### [9278](https://www.meridianbioscience.com/lifescience-product/9278/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, NGAL
---
### [9050](https://www.meridianbioscience.com/lifescience-product/9050/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Tropical & Vector-Borne Diseases, Zika
---
### [8303](https://www.meridianbioscience.com/lifescience-product/8303/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** MAPT, Neurological Diseases & Trauma
---
### [8505](https://www.meridianbioscience.com/lifescience-product/8505/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis A, Viral Hepatitis
---
### [8302](https://www.meridianbioscience.com/lifescience-product/8302/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, UCHL1
---
### [8300](https://www.meridianbioscience.com/lifescience-product/8300/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Distemper, Vet Health
---
### [8301](https://www.meridianbioscience.com/lifescience-product/8301/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** GFAP, Neurological Diseases & Trauma
---
### [8202](https://www.meridianbioscience.com/lifescience-product/8202/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [8198](https://www.meridianbioscience.com/lifescience-product/8198/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis A, Viral Hepatitis
---
### [8175](https://www.meridianbioscience.com/lifescience-product/8175/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [8185](https://www.meridianbioscience.com/lifescience-product/8185/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [8160](https://www.meridianbioscience.com/lifescience-product/8160/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [8159](https://www.meridianbioscience.com/lifescience-product/8159/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [8158](https://www.meridianbioscience.com/lifescience-product/8158/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [8099](https://www.meridianbioscience.com/lifescience-product/8099/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mumps, ToRCH & Childhood
---
### [7844](https://www.meridianbioscience.com/lifescience-product/7844/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Rotavirus
---
### [7740](https://www.meridianbioscience.com/lifescience-product/7740/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [7604](https://www.meridianbioscience.com/lifescience-product/7604/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Measles, ToRCH & Childhood
---
### [7600](https://www.meridianbioscience.com/lifescience-product/7600/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [7517](https://www.meridianbioscience.com/lifescience-product/7517/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [7511](https://www.meridianbioscience.com/lifescience-product/7511/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [7507](https://www.meridianbioscience.com/lifescience-product/7507/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [7504](https://www.meridianbioscience.com/lifescience-product/7504/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [7209](https://www.meridianbioscience.com/lifescience-product/7209/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [7201](https://www.meridianbioscience.com/lifescience-product/7201/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [6300](https://www.meridianbioscience.com/lifescience-product/6300/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [6123](https://www.meridianbioscience.com/lifescience-product/6123/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [6200](https://www.meridianbioscience.com/lifescience-product/6200/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [6076](https://www.meridianbioscience.com/lifescience-product/6076/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [6075](https://www.meridianbioscience.com/lifescience-product/6075/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Rubella, ToRCH & Childhood
---
### [Z87304M](https://www.meridianbioscience.com/lifescience-product/z87304m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [Z86411M](https://www.meridianbioscience.com/lifescience-product/z86411m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [Z86412M](https://www.meridianbioscience.com/lifescience-product/z86412m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z86213M](https://www.meridianbioscience.com/lifescience-product/z86213m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z86140M](https://www.meridianbioscience.com/lifescience-product/z86140m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z86102M](https://www.meridianbioscience.com/lifescience-product/z86102m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z86104M](https://www.meridianbioscience.com/lifescience-product/z86104m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [Z86101P](https://www.meridianbioscience.com/lifescience-product/z86101p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z86002M](https://www.meridianbioscience.com/lifescience-product/z86002m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z01252M](https://www.meridianbioscience.com/lifescience-product/z01252m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Kappa Light Chains
---
### [Z01253M](https://www.meridianbioscience.com/lifescience-product/z01253m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgA
---
### [Z01251M](https://www.meridianbioscience.com/lifescience-product/z01251m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Lambda Light Chain
---
### [Z01249M](https://www.meridianbioscience.com/lifescience-product/z01249m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [Z01250M](https://www.meridianbioscience.com/lifescience-product/z01250m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgA
---
### [Z01248M](https://www.meridianbioscience.com/lifescience-product/z01248m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z01247M](https://www.meridianbioscience.com/lifescience-product/z01247m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Z01235M](https://www.meridianbioscience.com/lifescience-product/z01235m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [Z01236M](https://www.meridianbioscience.com/lifescience-product/z01236m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [Y82250B](https://www.meridianbioscience.com/lifescience-product/y82250b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Oxycodone
---
### [Y82230P](https://www.meridianbioscience.com/lifescience-product/y82230p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Testosterone
---
### [Y82135P](https://www.meridianbioscience.com/lifescience-product/y82135p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Methamphetamine
---
### [Y49125B](https://www.meridianbioscience.com/lifescience-product/y49125b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, THC
---
### [Y01302B](https://www.meridianbioscience.com/lifescience-product/y01302b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, K2
---
### [Y01305B](https://www.meridianbioscience.com/lifescience-product/y01305b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, EDDP
---
### [Y01301B](https://www.meridianbioscience.com/lifescience-product/y01301b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amphetamine, DOA
---
### [Y01299B](https://www.meridianbioscience.com/lifescience-product/y01299b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Oxycodone
---
### [Y01298B](https://www.meridianbioscience.com/lifescience-product/y01298b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Methadone
---
### [Y01297B](https://www.meridianbioscience.com/lifescience-product/y01297b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Morphine
---
### [Y01295B](https://www.meridianbioscience.com/lifescience-product/y01295b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Morphine
---
### [Y01296B](https://www.meridianbioscience.com/lifescience-product/y01296b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Morphine
---
### [Y01294B](https://www.meridianbioscience.com/lifescience-product/y01294b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Methamphetamine
---
### [Y01293B](https://www.meridianbioscience.com/lifescience-product/y01293b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Benzoylecgonine, DOA
---
### [Y01291B](https://www.meridianbioscience.com/lifescience-product/y01291b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Buprenorphine, DOA
---
### [Y01292B](https://www.meridianbioscience.com/lifescience-product/y01292b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Benzoylecgonine, DOA
---
### [Y01290B](https://www.meridianbioscience.com/lifescience-product/y01290b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Benzodiazepine, DOA
---
### [Y01287B](https://www.meridianbioscience.com/lifescience-product/y01287b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amphetamine, DOA
---
### [Y01280B](https://www.meridianbioscience.com/lifescience-product/y01280b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Methadone
---
### [Y01285B](https://www.meridianbioscience.com/lifescience-product/y01285b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Barbiturate, DOA
---
### [Y01276B](https://www.meridianbioscience.com/lifescience-product/y01276b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Morphine
---
### [Y01273B](https://www.meridianbioscience.com/lifescience-product/y01273b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, THC
---
### [Y01241B](https://www.meridianbioscience.com/lifescience-product/y01241b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Ketamine
---
### [Y01268B](https://www.meridianbioscience.com/lifescience-product/y01268b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, THC
---
### [W99613B](https://www.meridianbioscience.com/lifescience-product/w99613b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W99245P](https://www.meridianbioscience.com/lifescience-product/w99245p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W99591G](https://www.meridianbioscience.com/lifescience-product/w99591g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [W99180B](https://www.meridianbioscience.com/lifescience-product/w99180b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W99114C](https://www.meridianbioscience.com/lifescience-product/w99114c/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W99154A](https://www.meridianbioscience.com/lifescience-product/w99154a/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [W99101G](https://www.meridianbioscience.com/lifescience-product/w99101g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W99020C](https://www.meridianbioscience.com/lifescience-product/w99020c/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [W99036P](https://www.meridianbioscience.com/lifescience-product/w99036p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [W90010F](https://www.meridianbioscience.com/lifescience-product/w90010f/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgA
---
### [W41250G](https://www.meridianbioscience.com/lifescience-product/w41250g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W41502G](https://www.meridianbioscience.com/lifescience-product/w41502g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W41202G](https://www.meridianbioscience.com/lifescience-product/w41202g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [W01262FL](https://www.meridianbioscience.com/lifescience-product/w01262fl/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [W03900G](https://www.meridianbioscience.com/lifescience-product/w03900g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [W01260AF](https://www.meridianbioscience.com/lifescience-product/w01260af/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [W01259G](https://www.meridianbioscience.com/lifescience-product/w01259g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [W01258G](https://www.meridianbioscience.com/lifescience-product/w01258g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [W01254G](https://www.meridianbioscience.com/lifescience-product/w01254g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [VTI880](https://www.meridianbioscience.com/lifescience-product/vti880/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, EGF
---
### [V8Z21-271](https://www.meridianbioscience.com/lifescience-product/v8z21-271/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Miscellaneous Reagents, Streptavidin
---
### [VTI850](https://www.meridianbioscience.com/lifescience-product/vti850/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [VTI840](https://www.meridianbioscience.com/lifescience-product/vti840/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MB
---
### [VTI830](https://www.meridianbioscience.com/lifescience-product/vti830/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-BB
---
### [VTI810](https://www.meridianbioscience.com/lifescience-product/vti810/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MB
---
### [VTI820](https://www.meridianbioscience.com/lifescience-product/vti820/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [VTI710](https://www.meridianbioscience.com/lifescience-product/vti710/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [VTI610](https://www.meridianbioscience.com/lifescience-product/vti610/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [T59107R](https://www.meridianbioscience.com/lifescience-product/t59107r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Collagen
---
### [T40331R](https://www.meridianbioscience.com/lifescience-product/t40331r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Collagen
---
### [R92101](https://www.meridianbioscience.com/lifescience-product/r92101/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, H. Pylori
---
### [T40263R](https://www.meridianbioscience.com/lifescience-product/t40263r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Collagen
---
### [R88640](https://www.meridianbioscience.com/lifescience-product/r88640/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R88340](https://www.meridianbioscience.com/lifescience-product/r88340/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R88540](https://www.meridianbioscience.com/lifescience-product/r88540/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R88240](https://www.meridianbioscience.com/lifescience-product/r88240/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R88245](https://www.meridianbioscience.com/lifescience-product/r88245/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R88235](https://www.meridianbioscience.com/lifescience-product/r88235/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86874](https://www.meridianbioscience.com/lifescience-product/r86874/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86900](https://www.meridianbioscience.com/lifescience-product/r86900/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [R86872](https://www.meridianbioscience.com/lifescience-product/r86872/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R86783](https://www.meridianbioscience.com/lifescience-product/r86783/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R86870](https://www.meridianbioscience.com/lifescience-product/r86870/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R86480](https://www.meridianbioscience.com/lifescience-product/r86480/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86350](https://www.meridianbioscience.com/lifescience-product/r86350/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [R86380](https://www.meridianbioscience.com/lifescience-product/r86380/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86288](https://www.meridianbioscience.com/lifescience-product/r86288/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86310](https://www.meridianbioscience.com/lifescience-product/r86310/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [R86280](https://www.meridianbioscience.com/lifescience-product/r86280/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R86250](https://www.meridianbioscience.com/lifescience-product/r86250/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [R8A560](https://www.meridianbioscience.com/lifescience-product/r8a560/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Tropical & Vector-Borne Diseases, West Nile
---
### [R8A442](https://www.meridianbioscience.com/lifescience-product/r8a442/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R8A320](https://www.meridianbioscience.com/lifescience-product/r8a320/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis E, Viral Hepatitis
---
### [R8A330](https://www.meridianbioscience.com/lifescience-product/r8a330/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis E, Viral Hepatitis
---
### [R8A310](https://www.meridianbioscience.com/lifescience-product/r8a310/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis E, Viral Hepatitis
---
### [R8A123](https://www.meridianbioscience.com/lifescience-product/r8a123/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R8A131](https://www.meridianbioscience.com/lifescience-product/r8a131/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R8A116](https://www.meridianbioscience.com/lifescience-product/r8a116/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R8A115](https://www.meridianbioscience.com/lifescience-product/r8a115/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R8A104](https://www.meridianbioscience.com/lifescience-product/r8a104/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Tropical & Vector-Borne Diseases, West Nile
---
### [R65914](https://www.meridianbioscience.com/lifescience-product/r65914/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R65915](https://www.meridianbioscience.com/lifescience-product/r65915/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R65360](https://www.meridianbioscience.com/lifescience-product/r65360/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FIV, Vet Health
---
### [R5V100-754](https://www.meridianbioscience.com/lifescience-product/r5v100-754/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Microbial Detection, Staphylococcus aureus
---
### [R5SG10-048](https://www.meridianbioscience.com/lifescience-product/r5sg10-048/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgG
---
### [R18800](https://www.meridianbioscience.com/lifescience-product/r18800/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18560](https://www.meridianbioscience.com/lifescience-product/r18560/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R18740](https://www.meridianbioscience.com/lifescience-product/r18740/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R18541](https://www.meridianbioscience.com/lifescience-product/r18541/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18523](https://www.meridianbioscience.com/lifescience-product/r18523/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18512](https://www.meridianbioscience.com/lifescience-product/r18512/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R18426](https://www.meridianbioscience.com/lifescience-product/r18426/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R18412](https://www.meridianbioscience.com/lifescience-product/r18412/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R18420](https://www.meridianbioscience.com/lifescience-product/r18420/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis D, Viral Hepatitis
---
### [R18358](https://www.meridianbioscience.com/lifescience-product/r18358/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18401](https://www.meridianbioscience.com/lifescience-product/r18401/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [R18306](https://www.meridianbioscience.com/lifescience-product/r18306/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R18330](https://www.meridianbioscience.com/lifescience-product/r18330/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [R18250](https://www.meridianbioscience.com/lifescience-product/r18250/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis E, Viral Hepatitis
---
### [R18206](https://www.meridianbioscience.com/lifescience-product/r18206/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18190](https://www.meridianbioscience.com/lifescience-product/r18190/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R18113](https://www.meridianbioscience.com/lifescience-product/r18113/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R18102](https://www.meridianbioscience.com/lifescience-product/r18102/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R17900](https://www.meridianbioscience.com/lifescience-product/r17900/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Coxsackie, ToRCH & Childhood
---
### [R18082](https://www.meridianbioscience.com/lifescience-product/r18082/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** TBE, Tropical & Vector-Borne Diseases
---
### [R17160](https://www.meridianbioscience.com/lifescience-product/r17160/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Coxsackie, ToRCH & Childhood
---
### [R14800](https://www.meridianbioscience.com/lifescience-product/r14800/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [R14900](https://www.meridianbioscience.com/lifescience-product/r14900/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. jejuni, Gastrointestinal Pathogens
---
### [R14720](https://www.meridianbioscience.com/lifescience-product/r14720/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma pneumoniae, Respiratory Diseases
---
### [R14610](https://www.meridianbioscience.com/lifescience-product/r14610/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Legionella pneumophila, Respiratory Diseases
---
### [R14101](https://www.meridianbioscience.com/lifescience-product/r14101/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, H. Pylori
---
### [R02902](https://www.meridianbioscience.com/lifescience-product/r02902/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parainfluenza, Respiratory Diseases
---
### [R14041](https://www.meridianbioscience.com/lifescience-product/r14041/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, VZV
---
### [R02721](https://www.meridianbioscience.com/lifescience-product/r02721/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Adenovirus, Respiratory Diseases
---
### [R02310](https://www.meridianbioscience.com/lifescience-product/r02310/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [R02620](https://www.meridianbioscience.com/lifescience-product/r02620/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Chlamydia pneumoniae, Respiratory Diseases
---
### [R02220](https://www.meridianbioscience.com/lifescience-product/r02220/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R02102](https://www.meridianbioscience.com/lifescience-product/r02102/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma pneumoniae, Respiratory Diseases
---
### [R02100](https://www.meridianbioscience.com/lifescience-product/r02100/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R02002](https://www.meridianbioscience.com/lifescience-product/r02002/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parainfluenza, Respiratory Diseases
---
### [R02001](https://www.meridianbioscience.com/lifescience-product/r02001/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01807](https://www.meridianbioscience.com/lifescience-product/r01807/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Monkeypox, Tropical & Vector-Borne Diseases
---
### [R01806](https://www.meridianbioscience.com/lifescience-product/r01806/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Monkeypox, Tropical & Vector-Borne Diseases
---
### [R01805](https://www.meridianbioscience.com/lifescience-product/r01805/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Monkeypox, Tropical & Vector-Borne Diseases
---
### [R01803](https://www.meridianbioscience.com/lifescience-product/r01803/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R01802](https://www.meridianbioscience.com/lifescience-product/r01802/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, THBD
---
### [R01801](https://www.meridianbioscience.com/lifescience-product/r01801/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** BVDV, Vet Health
---
### [R01797](https://www.meridianbioscience.com/lifescience-product/r01797/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R01800](https://www.meridianbioscience.com/lifescience-product/r01800/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, tTG
---
### [R01794](https://www.meridianbioscience.com/lifescience-product/r01794/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R01793](https://www.meridianbioscience.com/lifescience-product/r01793/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ASFV, Vet Health
---
### [R01776](https://www.meridianbioscience.com/lifescience-product/r01776/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Leukemia, Vet Health
---
### [R01774](https://www.meridianbioscience.com/lifescience-product/r01774/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** SAA, Vet Health
---
### [R01775](https://www.meridianbioscience.com/lifescience-product/r01775/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Beta 2 Microglobulin, Cancer Markers
---
### [R01773](https://www.meridianbioscience.com/lifescience-product/r01773/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** SAA, Vet Health
---
### [R01772](https://www.meridianbioscience.com/lifescience-product/r01772/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CRP, Vet Health
---
### [R01771](https://www.meridianbioscience.com/lifescience-product/r01771/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** SAA, Vet Health
---
### [R01767](https://www.meridianbioscience.com/lifescience-product/r01767/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01770](https://www.meridianbioscience.com/lifescience-product/r01770/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, Vet Health
---
### [R01765](https://www.meridianbioscience.com/lifescience-product/r01765/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01763](https://www.meridianbioscience.com/lifescience-product/r01763/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01764](https://www.meridianbioscience.com/lifescience-product/r01764/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01746](https://www.meridianbioscience.com/lifescience-product/r01746/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01741](https://www.meridianbioscience.com/lifescience-product/r01741/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** E. coli, Gastrointestinal Pathogens
---
### [R01742](https://www.meridianbioscience.com/lifescience-product/r01742/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** E. coli, Gastrointestinal Pathogens
---
### [R01740](https://www.meridianbioscience.com/lifescience-product/r01740/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [R01739](https://www.meridianbioscience.com/lifescience-product/r01739/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [R01737](https://www.meridianbioscience.com/lifescience-product/r01737/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01738](https://www.meridianbioscience.com/lifescience-product/r01738/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. difficile, Gastrointestinal Pathogens
---
### [R01736](https://www.meridianbioscience.com/lifescience-product/r01736/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01734](https://www.meridianbioscience.com/lifescience-product/r01734/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [R01735](https://www.meridianbioscience.com/lifescience-product/r01735/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01733](https://www.meridianbioscience.com/lifescience-product/r01733/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [R01732](https://www.meridianbioscience.com/lifescience-product/r01732/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** E. coli, Gastrointestinal Pathogens
---
### [R01730](https://www.meridianbioscience.com/lifescience-product/r01730/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [R01731](https://www.meridianbioscience.com/lifescience-product/r01731/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Norovirus
---
### [R01729](https://www.meridianbioscience.com/lifescience-product/r01729/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Astrovirus, Gastrointestinal Pathogens
---
### [R01724](https://www.meridianbioscience.com/lifescience-product/r01724/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Calprotectin, Gastrointestinal Pathogens
---
### [R01728](https://www.meridianbioscience.com/lifescience-product/r01728/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Rotavirus
---
### [R01723](https://www.meridianbioscience.com/lifescience-product/r01723/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Giardia
---
### [R01721](https://www.meridianbioscience.com/lifescience-product/r01721/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C. jejuni, Gastrointestinal Pathogens
---
### [R01722](https://www.meridianbioscience.com/lifescience-product/r01722/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Giardia
---
### [R01720](https://www.meridianbioscience.com/lifescience-product/r01720/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Campylobacter, Gastrointestinal Pathogens
---
### [R01719](https://www.meridianbioscience.com/lifescience-product/r01719/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Entamoeba Dispar, Gastrointestinal Pathogens
---
### [R01718](https://www.meridianbioscience.com/lifescience-product/r01718/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Entamoeba histolytica, Gastrointestinal Pathogens
---
### [R01714](https://www.meridianbioscience.com/lifescience-product/r01714/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Respiratory Diseases, RSV
---
### [R01712](https://www.meridianbioscience.com/lifescience-product/r01712/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [R01713](https://www.meridianbioscience.com/lifescience-product/r01713/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AMH, Hormones & Steroids
---
### [R01710](https://www.meridianbioscience.com/lifescience-product/r01710/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01707](https://www.meridianbioscience.com/lifescience-product/r01707/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01701](https://www.meridianbioscience.com/lifescience-product/r01701/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycoplasma pneumoniae, Respiratory Diseases
---
### [R01699](https://www.meridianbioscience.com/lifescience-product/r01699/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01698](https://www.meridianbioscience.com/lifescience-product/r01698/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01695](https://www.meridianbioscience.com/lifescience-product/r01695/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, SmD2
---
### [R01693](https://www.meridianbioscience.com/lifescience-product/r01693/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, snRNPC
---
### [R01694](https://www.meridianbioscience.com/lifescience-product/r01694/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, P1
---
### [R01689](https://www.meridianbioscience.com/lifescience-product/r01689/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01688](https://www.meridianbioscience.com/lifescience-product/r01688/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01686](https://www.meridianbioscience.com/lifescience-product/r01686/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01687](https://www.meridianbioscience.com/lifescience-product/r01687/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01685](https://www.meridianbioscience.com/lifescience-product/r01685/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01684](https://www.meridianbioscience.com/lifescience-product/r01684/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01679](https://www.meridianbioscience.com/lifescience-product/r01679/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CCL
---
### [R01677](https://www.meridianbioscience.com/lifescience-product/r01677/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, SCCA
---
### [R01678](https://www.meridianbioscience.com/lifescience-product/r01678/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CCL
---
### [R01676](https://www.meridianbioscience.com/lifescience-product/r01676/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Interleukin
---
### [R01675](https://www.meridianbioscience.com/lifescience-product/r01675/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Miscellaneous Reagents, Protein A
---
### [R01671](https://www.meridianbioscience.com/lifescience-product/r01671/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01672](https://www.meridianbioscience.com/lifescience-product/r01672/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01670](https://www.meridianbioscience.com/lifescience-product/r01670/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01669](https://www.meridianbioscience.com/lifescience-product/r01669/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01668](https://www.meridianbioscience.com/lifescience-product/r01668/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycobacterium tuberculosis, Respiratory Diseases
---
### [R01663](https://www.meridianbioscience.com/lifescience-product/r01663/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01661](https://www.meridianbioscience.com/lifescience-product/r01661/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01662](https://www.meridianbioscience.com/lifescience-product/r01662/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01660](https://www.meridianbioscience.com/lifescience-product/r01660/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01658](https://www.meridianbioscience.com/lifescience-product/r01658/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01659](https://www.meridianbioscience.com/lifescience-product/r01659/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01657](https://www.meridianbioscience.com/lifescience-product/r01657/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01656](https://www.meridianbioscience.com/lifescience-product/r01656/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01654](https://www.meridianbioscience.com/lifescience-product/r01654/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Chikungunya, Tropical & Vector-Borne Diseases
---
### [R01655](https://www.meridianbioscience.com/lifescience-product/r01655/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Transferrin
---
### [R01653](https://www.meridianbioscience.com/lifescience-product/r01653/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Chikungunya, Tropical & Vector-Borne Diseases
---
### [R01652](https://www.meridianbioscience.com/lifescience-product/r01652/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01649](https://www.meridianbioscience.com/lifescience-product/r01649/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Ro52
---
### [R01648](https://www.meridianbioscience.com/lifescience-product/r01648/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, PCNA
---
### [R01647](https://www.meridianbioscience.com/lifescience-product/r01647/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, LC-1
---
### [R01646](https://www.meridianbioscience.com/lifescience-product/r01646/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, CENP-B
---
### [R01644](https://www.meridianbioscience.com/lifescience-product/r01644/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01643](https://www.meridianbioscience.com/lifescience-product/r01643/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01642](https://www.meridianbioscience.com/lifescience-product/r01642/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01641](https://www.meridianbioscience.com/lifescience-product/r01641/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01640](https://www.meridianbioscience.com/lifescience-product/r01640/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01639](https://www.meridianbioscience.com/lifescience-product/r01639/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01638](https://www.meridianbioscience.com/lifescience-product/r01638/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01637](https://www.meridianbioscience.com/lifescience-product/r01637/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Parvovirus, ToRCH & Childhood
---
### [R01636](https://www.meridianbioscience.com/lifescience-product/r01636/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Tropical & Vector-Borne Diseases, Zika
---
### [R01635](https://www.meridianbioscience.com/lifescience-product/r01635/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Tropical & Vector-Borne Diseases, Zika
---
### [R01623](https://www.meridianbioscience.com/lifescience-product/r01623/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01619](https://www.meridianbioscience.com/lifescience-product/r01619/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, SAA
---
### [R01617](https://www.meridianbioscience.com/lifescience-product/r01617/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, FABP
---
### [R01616](https://www.meridianbioscience.com/lifescience-product/r01616/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, NT-proBNP
---
### [R01615](https://www.meridianbioscience.com/lifescience-product/r01615/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Interleukin
---
### [R01614](https://www.meridianbioscience.com/lifescience-product/r01614/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [R01610](https://www.meridianbioscience.com/lifescience-product/r01610/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01609](https://www.meridianbioscience.com/lifescience-product/r01609/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01605](https://www.meridianbioscience.com/lifescience-product/r01605/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HER2
---
### [R01604](https://www.meridianbioscience.com/lifescience-product/r01604/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01603](https://www.meridianbioscience.com/lifescience-product/r01603/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01602](https://www.meridianbioscience.com/lifescience-product/r01602/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01601](https://www.meridianbioscience.com/lifescience-product/r01601/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01599](https://www.meridianbioscience.com/lifescience-product/r01599/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R01600](https://www.meridianbioscience.com/lifescience-product/r01600/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R01598](https://www.meridianbioscience.com/lifescience-product/r01598/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01596](https://www.meridianbioscience.com/lifescience-product/r01596/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01597](https://www.meridianbioscience.com/lifescience-product/r01597/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01595](https://www.meridianbioscience.com/lifescience-product/r01595/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01590](https://www.meridianbioscience.com/lifescience-product/r01590/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycobacterium tuberculosis, Respiratory Diseases
---
### [R01587](https://www.meridianbioscience.com/lifescience-product/r01587/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01589](https://www.meridianbioscience.com/lifescience-product/r01589/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01586](https://www.meridianbioscience.com/lifescience-product/r01586/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01581](https://www.meridianbioscience.com/lifescience-product/r01581/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R01575](https://www.meridianbioscience.com/lifescience-product/r01575/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01576](https://www.meridianbioscience.com/lifescience-product/r01576/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01574](https://www.meridianbioscience.com/lifescience-product/r01574/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Leishmania, Tropical & Vector-Borne Diseases
---
### [R01571](https://www.meridianbioscience.com/lifescience-product/r01571/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01573](https://www.meridianbioscience.com/lifescience-product/r01573/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** ToRCH & Childhood, Toxoplasma gondii
---
### [R01570](https://www.meridianbioscience.com/lifescience-product/r01570/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01565](https://www.meridianbioscience.com/lifescience-product/r01565/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01569](https://www.meridianbioscience.com/lifescience-product/r01569/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enterovirus, Gastrointestinal Pathogens
---
### [R01563](https://www.meridianbioscience.com/lifescience-product/r01563/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01564](https://www.meridianbioscience.com/lifescience-product/r01564/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01561P](https://www.meridianbioscience.com/lifescience-product/r01561p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01561](https://www.meridianbioscience.com/lifescience-product/r01561/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CMV, ToRCH & Childhood
---
### [R01559](https://www.meridianbioscience.com/lifescience-product/r01559/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01560](https://www.meridianbioscience.com/lifescience-product/r01560/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** NT-proBNP, Vet Health
---
### [R01558](https://www.meridianbioscience.com/lifescience-product/r01558/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01556](https://www.meridianbioscience.com/lifescience-product/r01556/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01557](https://www.meridianbioscience.com/lifescience-product/r01557/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01554](https://www.meridianbioscience.com/lifescience-product/r01554/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01555](https://www.meridianbioscience.com/lifescience-product/r01555/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01552](https://www.meridianbioscience.com/lifescience-product/r01552/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01553](https://www.meridianbioscience.com/lifescience-product/r01553/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Dengue, Tropical & Vector-Borne Diseases
---
### [R01550](https://www.meridianbioscience.com/lifescience-product/r01550/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Chikungunya, Tropical & Vector-Borne Diseases
---
### [R01538](https://www.meridianbioscience.com/lifescience-product/r01538/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Food & Water Testing, Leptospira
---
### [R01537](https://www.meridianbioscience.com/lifescience-product/r01537/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Aflatoxin, Food & Water Testing
---
### [R01526](https://www.meridianbioscience.com/lifescience-product/r01526/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01523](https://www.meridianbioscience.com/lifescience-product/r01523/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01525](https://www.meridianbioscience.com/lifescience-product/r01525/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01522](https://www.meridianbioscience.com/lifescience-product/r01522/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** EBV, ToRCH & Childhood
---
### [R01518](https://www.meridianbioscience.com/lifescience-product/r01518/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis C, Viral Hepatitis
---
### [R01521](https://www.meridianbioscience.com/lifescience-product/r01521/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Borrelia, Tropical & Vector-Borne Diseases
---
### [R01517](https://www.meridianbioscience.com/lifescience-product/r01517/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Coxsackie, ToRCH & Childhood
---
### [R01513](https://www.meridianbioscience.com/lifescience-product/r01513/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Leishmania, Tropical & Vector-Borne Diseases
---
### [R01478](https://www.meridianbioscience.com/lifescience-product/r01478/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01456](https://www.meridianbioscience.com/lifescience-product/r01456/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Mycobacterium tuberculosis, Respiratory Diseases
---
### [R01439](https://www.meridianbioscience.com/lifescience-product/r01439/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [R01436](https://www.meridianbioscience.com/lifescience-product/r01436/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01421](https://www.meridianbioscience.com/lifescience-product/r01421/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01423](https://www.meridianbioscience.com/lifescience-product/r01423/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01403](https://www.meridianbioscience.com/lifescience-product/r01403/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01419](https://www.meridianbioscience.com/lifescience-product/r01419/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01401](https://www.meridianbioscience.com/lifescience-product/r01401/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01364](https://www.meridianbioscience.com/lifescience-product/r01364/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** T. cruzi (Chagas), Tropical & Vector-Borne Diseases
---
### [R01372](https://www.meridianbioscience.com/lifescience-product/r01372/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Clostridium botulinum, Gastrointestinal Pathogens
---
### [R01290](https://www.meridianbioscience.com/lifescience-product/r01290/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01289](https://www.meridianbioscience.com/lifescience-product/r01289/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hepatitis B, Viral Hepatitis
---
### [R01250](https://www.meridianbioscience.com/lifescience-product/r01250/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01248](https://www.meridianbioscience.com/lifescience-product/r01248/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [R01249](https://www.meridianbioscience.com/lifescience-product/r01249/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [R01247](https://www.meridianbioscience.com/lifescience-product/r01247/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [R01246](https://www.meridianbioscience.com/lifescience-product/r01246/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza B, Respiratory Diseases
---
### [RM1003](https://www.meridianbioscience.com/lifescience-product/rm1003/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [R01245](https://www.meridianbioscience.com/lifescience-product/r01245/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Influenza A, Respiratory Diseases
---
### [RM1000](https://www.meridianbioscience.com/lifescience-product/rm1000/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [Q88600R](https://www.meridianbioscience.com/lifescience-product/q88600r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q86610M](https://www.meridianbioscience.com/lifescience-product/q86610m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [Q86006M](https://www.meridianbioscience.com/lifescience-product/q86006m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [Q86403M](https://www.meridianbioscience.com/lifescience-product/q86403m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [Q86003M](https://www.meridianbioscience.com/lifescience-product/q86003m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [Q67973M](https://www.meridianbioscience.com/lifescience-product/q67973m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q67497M](https://www.meridianbioscience.com/lifescience-product/q67497m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q67594M](https://www.meridianbioscience.com/lifescience-product/q67594m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q67350M](https://www.meridianbioscience.com/lifescience-product/q67350m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q4A132R](https://www.meridianbioscience.com/lifescience-product/q4a132r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Dopamine
---
### [Q2B100G](https://www.meridianbioscience.com/lifescience-product/q2b100g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Amyloid, Neurological Diseases & Trauma
---
### [Q2B060G](https://www.meridianbioscience.com/lifescience-product/q2b060g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, Presenilin
---
### [Q06604M](https://www.meridianbioscience.com/lifescience-product/q06604m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Synuclein
---
### [Q01235M](https://www.meridianbioscience.com/lifescience-product/q01235m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, SNAP
---
### [Q01236M](https://www.meridianbioscience.com/lifescience-product/q01236m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Neurological Diseases & Trauma, SNAP
---
### [Q01234M](https://www.meridianbioscience.com/lifescience-product/q01234m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Myelin, Neurological Diseases & Trauma
---
### [Q01119M](https://www.meridianbioscience.com/lifescience-product/q01119m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Map-2
---
### [P91235M](https://www.meridianbioscience.com/lifescience-product/p91235m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P86842M](https://www.meridianbioscience.com/lifescience-product/p86842m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Interferon
---
### [P86424M](https://www.meridianbioscience.com/lifescience-product/p86424m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Interferon
---
### [P86210M](https://www.meridianbioscience.com/lifescience-product/p86210m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CD Markers
---
### [P86106M](https://www.meridianbioscience.com/lifescience-product/p86106m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CD Markers
---
### [P86020M](https://www.meridianbioscience.com/lifescience-product/p86020m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Erythropoietin
---
### [P86010M](https://www.meridianbioscience.com/lifescience-product/p86010m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Erythropoietin
---
### [P42764M](https://www.meridianbioscience.com/lifescience-product/p42764m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P42118M](https://www.meridianbioscience.com/lifescience-product/p42118m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P42117M](https://www.meridianbioscience.com/lifescience-product/p42117m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P24141M](https://www.meridianbioscience.com/lifescience-product/p24141m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Defensin
---
### [P24011M](https://www.meridianbioscience.com/lifescience-product/p24011m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Defensin
---
### [P18422M](https://www.meridianbioscience.com/lifescience-product/p18422m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Interleukin
---
### [P01309M](https://www.meridianbioscience.com/lifescience-product/p01309m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Interferon
---
### [P01287M](https://www.meridianbioscience.com/lifescience-product/p01287m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P01204M](https://www.meridianbioscience.com/lifescience-product/p01204m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Interleukin
---
### [P01158B](https://www.meridianbioscience.com/lifescience-product/p01158b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [P01150B](https://www.meridianbioscience.com/lifescience-product/p01150b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [N86925M](https://www.meridianbioscience.com/lifescience-product/n86925m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86925B](https://www.meridianbioscience.com/lifescience-product/n86925b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86802H](https://www.meridianbioscience.com/lifescience-product/n86802h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [N86710M](https://www.meridianbioscience.com/lifescience-product/n86710m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Fibrinopeptide
---
### [N86583H](https://www.meridianbioscience.com/lifescience-product/n86583h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, NT-proBNP
---
### [N86580H](https://www.meridianbioscience.com/lifescience-product/n86580h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Myoglobin
---
### [N86500M](https://www.meridianbioscience.com/lifescience-product/n86500m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86436M](https://www.meridianbioscience.com/lifescience-product/n86436m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86429M](https://www.meridianbioscience.com/lifescience-product/n86429m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Fibrinopeptide
---
### [N86413M](https://www.meridianbioscience.com/lifescience-product/n86413m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Fibrinogen
---
### [N86403M](https://www.meridianbioscience.com/lifescience-product/n86403m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86352M](https://www.meridianbioscience.com/lifescience-product/n86352m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86340M](https://www.meridianbioscience.com/lifescience-product/n86340m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86304M](https://www.meridianbioscience.com/lifescience-product/n86304m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86043M](https://www.meridianbioscience.com/lifescience-product/n86043m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N86002H](https://www.meridianbioscience.com/lifescience-product/n86002h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [N63913M](https://www.meridianbioscience.com/lifescience-product/n63913m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Malaria, Tropical & Vector-Borne Diseases
---
### [N55199M](https://www.meridianbioscience.com/lifescience-product/n55199m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Prekallikrein
---
### [N55198M](https://www.meridianbioscience.com/lifescience-product/n55198m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Factor XII
---
### [N42409M](https://www.meridianbioscience.com/lifescience-product/n42409m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [N42165F](https://www.meridianbioscience.com/lifescience-product/n42165f/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [N42145M](https://www.meridianbioscience.com/lifescience-product/n42145m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [N01276M](https://www.meridianbioscience.com/lifescience-product/n01276m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, tPA
---
### [N01274M](https://www.meridianbioscience.com/lifescience-product/n01274m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N01273M](https://www.meridianbioscience.com/lifescience-product/n01273m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N01272M](https://www.meridianbioscience.com/lifescience-product/n01272m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Angiostatin, Autoimmune
---
### [N01271M](https://www.meridianbioscience.com/lifescience-product/n01271m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Angiostatin, Autoimmune
---
### [N01270M](https://www.meridianbioscience.com/lifescience-product/n01270m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [N01267R](https://www.meridianbioscience.com/lifescience-product/n01267r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, Serum
---
### [N01265M](https://www.meridianbioscience.com/lifescience-product/n01265m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, D-Dimer
---
### [M92986M](https://www.meridianbioscience.com/lifescience-product/m92986m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M92396P](https://www.meridianbioscience.com/lifescience-product/m92396p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M92396M](https://www.meridianbioscience.com/lifescience-product/m92396m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86842M](https://www.meridianbioscience.com/lifescience-product/m86842m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M86842F](https://www.meridianbioscience.com/lifescience-product/m86842f/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M86806M](https://www.meridianbioscience.com/lifescience-product/m86806m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86641M](https://www.meridianbioscience.com/lifescience-product/m86641m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [M86599M](https://www.meridianbioscience.com/lifescience-product/m86599m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86520M](https://www.meridianbioscience.com/lifescience-product/m86520m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, NSE
---
### [M86506P](https://www.meridianbioscience.com/lifescience-product/m86506p/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86506M](https://www.meridianbioscience.com/lifescience-product/m86506m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86501M](https://www.meridianbioscience.com/lifescience-product/m86501m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [M86433M](https://www.meridianbioscience.com/lifescience-product/m86433m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86429M](https://www.meridianbioscience.com/lifescience-product/m86429m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA125, Cancer Markers
---
### [M86429B](https://www.meridianbioscience.com/lifescience-product/m86429b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA125, Cancer Markers
---
### [M86416M](https://www.meridianbioscience.com/lifescience-product/m86416m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, NPR
---
### [M86406M](https://www.meridianbioscience.com/lifescience-product/m86406m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, NPR
---
### [M86306B](https://www.meridianbioscience.com/lifescience-product/m86306b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA125, Cancer Markers
---
### [M86304M](https://www.meridianbioscience.com/lifescience-product/m86304m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [M86209M](https://www.meridianbioscience.com/lifescience-product/m86209m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M86201M](https://www.meridianbioscience.com/lifescience-product/m86201m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, NSE
---
### [M86141M](https://www.meridianbioscience.com/lifescience-product/m86141m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, NSE
---
### [M86101M](https://www.meridianbioscience.com/lifescience-product/m86101m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, NSE
---
### [M86007M](https://www.meridianbioscience.com/lifescience-product/m86007m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M86005M](https://www.meridianbioscience.com/lifescience-product/m86005m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M86003M](https://www.meridianbioscience.com/lifescience-product/m86003m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M75301M](https://www.meridianbioscience.com/lifescience-product/m75301m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, SCLC
---
### [M66276M](https://www.meridianbioscience.com/lifescience-product/m66276m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M66107M](https://www.meridianbioscience.com/lifescience-product/m66107m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [M66106M](https://www.meridianbioscience.com/lifescience-product/m66106m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [M1M20-912](https://www.meridianbioscience.com/lifescience-product/m1m20-912/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, PCNA
---
### [M01348M](https://www.meridianbioscience.com/lifescience-product/m01348m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CRP, Vet Health
---
### [M01347M](https://www.meridianbioscience.com/lifescience-product/m01347m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CRP, Vet Health
---
### [M01346M](https://www.meridianbioscience.com/lifescience-product/m01346m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CRP, Vet Health
---
### [M01345M](https://www.meridianbioscience.com/lifescience-product/m01345m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CRP, Vet Health
---
### [M01342M](https://www.meridianbioscience.com/lifescience-product/m01342m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA72-4, Cancer Markers
---
### [M01341M](https://www.meridianbioscience.com/lifescience-product/m01341m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA72-4, Cancer Markers
---
### [M01340M](https://www.meridianbioscience.com/lifescience-product/m01340m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA72-4, Cancer Markers
---
### [M01331M](https://www.meridianbioscience.com/lifescience-product/m01331m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01330M](https://www.meridianbioscience.com/lifescience-product/m01330m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01329M](https://www.meridianbioscience.com/lifescience-product/m01329m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [M01326M](https://www.meridianbioscience.com/lifescience-product/m01326m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Cyfra-21-1
---
### [M01323M](https://www.meridianbioscience.com/lifescience-product/m01323m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HE4
---
### [M01322M](https://www.meridianbioscience.com/lifescience-product/m01322m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HE4
---
### [M01321M](https://www.meridianbioscience.com/lifescience-product/m01321m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HE4
---
### [M01320M](https://www.meridianbioscience.com/lifescience-product/m01320m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HE4
---
### [M01319M](https://www.meridianbioscience.com/lifescience-product/m01319m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01310M](https://www.meridianbioscience.com/lifescience-product/m01310m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, EpCAM
---
### [M01300M](https://www.meridianbioscience.com/lifescience-product/m01300m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Cyfra-21-1
---
### [M01299M](https://www.meridianbioscience.com/lifescience-product/m01299m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HER2
---
### [M01298M](https://www.meridianbioscience.com/lifescience-product/m01298m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HER2
---
### [M01297M](https://www.meridianbioscience.com/lifescience-product/m01297m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HER2
---
### [M01296M](https://www.meridianbioscience.com/lifescience-product/m01296m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, HER2
---
### [M01294M](https://www.meridianbioscience.com/lifescience-product/m01294m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA15-3, Cancer Markers
---
### [M01292M](https://www.meridianbioscience.com/lifescience-product/m01292m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA15-3, Cancer Markers
---
### [M01289M](https://www.meridianbioscience.com/lifescience-product/m01289m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA15-3, Cancer Markers
---
### [M01256M](https://www.meridianbioscience.com/lifescience-product/m01256m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [M01255M](https://www.meridianbioscience.com/lifescience-product/m01255m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [M01254M](https://www.meridianbioscience.com/lifescience-product/m01254m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [M01250M](https://www.meridianbioscience.com/lifescience-product/m01250m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [M01246M](https://www.meridianbioscience.com/lifescience-product/m01246m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CEA
---
### [M01243M](https://www.meridianbioscience.com/lifescience-product/m01243m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01239M](https://www.meridianbioscience.com/lifescience-product/m01239m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01238M](https://www.meridianbioscience.com/lifescience-product/m01238m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CRP
---
### [M01237M](https://www.meridianbioscience.com/lifescience-product/m01237m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** CA19-9, Cancer Markers
---
### [M01236M](https://www.meridianbioscience.com/lifescience-product/m01236m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [MKT02-007](https://www.meridianbioscience.com/lifescience-product/mkt02-007/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Thyroxine (T4)
---
### [MHP18-6014](https://www.meridianbioscience.com/lifescience-product/mhp18-6014/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C-Peptide, Hormones & Steroids
---
### [MEM24-211](https://www.meridianbioscience.com/lifescience-product/mem24-211/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, S-100
---
### [MDX003](https://www.meridianbioscience.com/lifescience-product/mdx003/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Enzymes, Pfu Enzyme
---
### [MCP17-301](https://www.meridianbioscience.com/lifescience-product/mcp17-301/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Beta 2 Microglobulin, Cancer Markers
---
### [MCF06-610](https://www.meridianbioscience.com/lifescience-product/mcf06-610/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hGH, Hormones & Steroids
---
### [MAV66-310](https://www.meridianbioscience.com/lifescience-product/mav66-310/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** E. coli, Gastrointestinal Pathogens
---
### [MAV152-165](https://www.meridianbioscience.com/lifescience-product/mav152-165/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Gastrointestinal Pathogens, Lactoferrin
---
### [MAT04-410](https://www.meridianbioscience.com/lifescience-product/mat04-410/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT04-176](https://www.meridianbioscience.com/lifescience-product/mat04-176/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TSH
---
### [MAT03-439](https://www.meridianbioscience.com/lifescience-product/mat03-439/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, TBG
---
### [MAT02-641](https://www.meridianbioscience.com/lifescience-product/mat02-641/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Thyroxine (T4)
---
### [MAT02-011](https://www.meridianbioscience.com/lifescience-product/mat02-011/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Thyroxine (T4)
---
### [MAS04-267](https://www.meridianbioscience.com/lifescience-product/mas04-267/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Estradiol, Hormones & Steroids
---
### [MAM22-871](https://www.meridianbioscience.com/lifescience-product/mam22-871/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** BrdU, Miscellaneous Reagents
---
### [MAM07-234](https://www.meridianbioscience.com/lifescience-product/mam07-234/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, PSA
---
### [MAM01-301](https://www.meridianbioscience.com/lifescience-product/mam01-301/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** AFP, Cancer Markers
---
### [MAL59-043](https://www.meridianbioscience.com/lifescience-product/mal59-043/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [MAL43-059](https://www.meridianbioscience.com/lifescience-product/mal43-059/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [MAL105-226](https://www.meridianbioscience.com/lifescience-product/mal105-226/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [MAG40-368](https://www.meridianbioscience.com/lifescience-product/mag40-368/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [MAG40-348](https://www.meridianbioscience.com/lifescience-product/mag40-348/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgE
---
### [MAF10-111](https://www.meridianbioscience.com/lifescience-product/maf10-111/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Prolactin
---
### [MAF07-037](https://www.meridianbioscience.com/lifescience-product/maf07-037/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [MAF07-036](https://www.meridianbioscience.com/lifescience-product/maf07-036/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, LH
---
### [MAF06-610](https://www.meridianbioscience.com/lifescience-product/maf06-610/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hGH, Hormones & Steroids
---
### [MAF06-212](https://www.meridianbioscience.com/lifescience-product/maf06-212/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hGH, Hormones & Steroids
---
### [MAF06-210](https://www.meridianbioscience.com/lifescience-product/maf06-210/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hGH, Hormones & Steroids
---
### [MAF06-154](https://www.meridianbioscience.com/lifescience-product/maf06-154/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hGH, Hormones & Steroids
---
### [MAF05-627](https://www.meridianbioscience.com/lifescience-product/maf05-627/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF05-043](https://www.meridianbioscience.com/lifescience-product/maf05-043/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF05-025](https://www.meridianbioscience.com/lifescience-product/maf05-025/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF05-023](https://www.meridianbioscience.com/lifescience-product/maf05-023/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF05-020](https://www.meridianbioscience.com/lifescience-product/maf05-020/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF05-019](https://www.meridianbioscience.com/lifescience-product/maf05-019/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** hCG, Hormones & Steroids
---
### [MAF02-275](https://www.meridianbioscience.com/lifescience-product/maf02-275/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAF02-264](https://www.meridianbioscience.com/lifescience-product/maf02-264/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAF02-243](https://www.meridianbioscience.com/lifescience-product/maf02-243/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAF02-155](https://www.meridianbioscience.com/lifescience-product/maf02-155/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAF02-145](https://www.meridianbioscience.com/lifescience-product/maf02-145/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FSH, Hormones & Steroids
---
### [MAD64-052](https://www.meridianbioscience.com/lifescience-product/mad64-052/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Tobramycin
---
### [MAD63-003](https://www.meridianbioscience.com/lifescience-product/mad63-003/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Theophylline
---
### [MAD53-310C](https://www.meridianbioscience.com/lifescience-product/mad53-310c/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Digoxin, DOA
---
### [MAD53-212](https://www.meridianbioscience.com/lifescience-product/mad53-212/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Digoxin, DOA
---
### [MAD53-122](https://www.meridianbioscience.com/lifescience-product/mad53-122/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Digoxin, DOA
---
### [MAD12-066](https://www.meridianbioscience.com/lifescience-product/mad12-066/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, THC
---
### [MAD09-034](https://www.meridianbioscience.com/lifescience-product/mad09-034/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** DOA, Morphine
---
### [MAC23-035](https://www.meridianbioscience.com/lifescience-product/mac23-035/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [MAC23-031](https://www.meridianbioscience.com/lifescience-product/mac23-031/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [MAC20-001](https://www.meridianbioscience.com/lifescience-product/mac20-001/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [MAC02-512](https://www.meridianbioscience.com/lifescience-product/mac02-512/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [MAC02-186](https://www.meridianbioscience.com/lifescience-product/mac02-186/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [MAC01-288](https://www.meridianbioscience.com/lifescience-product/mac01-288/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-BB
---
### [MAB07-510](https://www.meridianbioscience.com/lifescience-product/mab07-510/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [L66644G](https://www.meridianbioscience.com/lifescience-product/l66644g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, C4
---
### [L66633G](https://www.meridianbioscience.com/lifescience-product/l66633g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, C3
---
### [L66607G](https://www.meridianbioscience.com/lifescience-product/l66607g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers & Immunoglobulins, IgM
---
### [L15752G](https://www.meridianbioscience.com/lifescience-product/l15752g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, C4
---
### [L15408G](https://www.meridianbioscience.com/lifescience-product/l15408g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [L15406G](https://www.meridianbioscience.com/lifescience-product/l15406g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Blockers, Blockers & Immunoglobulins
---
### [L01243G](https://www.meridianbioscience.com/lifescience-product/l01243g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, C4
---
### [L01240G](https://www.meridianbioscience.com/lifescience-product/l01240g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, C3
---
### [K97113R](https://www.meridianbioscience.com/lifescience-product/k97113r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K97112R](https://www.meridianbioscience.com/lifescience-product/k97112r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K97110S](https://www.meridianbioscience.com/lifescience-product/k97110s/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K88201R](https://www.meridianbioscience.com/lifescience-product/k88201r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CX3CR1
---
### [K86503M](https://www.meridianbioscience.com/lifescience-product/k86503m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FITC, Miscellaneous Reagents
---
### [K86130M](https://www.meridianbioscience.com/lifescience-product/k86130m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Miscellaneous Reagents, Streptavidin
---
### [K86005M](https://www.meridianbioscience.com/lifescience-product/k86005m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, MPO
---
### [K8A069M](https://www.meridianbioscience.com/lifescience-product/k8a069m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, CD Markers
---
### [K74190G](https://www.meridianbioscience.com/lifescience-product/k74190g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K74180B](https://www.meridianbioscience.com/lifescience-product/k74180b/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K67902M](https://www.meridianbioscience.com/lifescience-product/k67902m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, EGFR
---
### [K67190M](https://www.meridianbioscience.com/lifescience-product/k67190m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, EGFR
---
### [K67123M](https://www.meridianbioscience.com/lifescience-product/k67123m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, EGFR
---
### [K65811R](https://www.meridianbioscience.com/lifescience-product/k65811r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Microbial Detection, Saccharomyces
---
### [K65701R](https://www.meridianbioscience.com/lifescience-product/k65701r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FITC, Miscellaneous Reagents
---
### [K65700R](https://www.meridianbioscience.com/lifescience-product/k65700r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** FITC, Miscellaneous Reagents
---
### [K63964R](https://www.meridianbioscience.com/lifescience-product/k63964r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Vitronectin
---
### [K63250R](https://www.meridianbioscience.com/lifescience-product/k63250r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, tPA
---
### [K63235R](https://www.meridianbioscience.com/lifescience-product/k63235r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Fibrinogen
---
### [K63142S](https://www.meridianbioscience.com/lifescience-product/k63142s/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Renin
---
### [K63132R](https://www.meridianbioscience.com/lifescience-product/k63132r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, PAI-1
---
### [K62200G](https://www.meridianbioscience.com/lifescience-product/k62200g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K55170M](https://www.meridianbioscience.com/lifescience-product/k55170m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, IGF
---
### [K4A670R](https://www.meridianbioscience.com/lifescience-product/k4a670r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [K4A660R](https://www.meridianbioscience.com/lifescience-product/k4a660r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** BNP & proBNP, Cardiac, Cholesterol, & Metabolic Markers
---
### [K4A361R](https://www.meridianbioscience.com/lifescience-product/k4a361r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Leptin
---
### [K31342G](https://www.meridianbioscience.com/lifescience-product/k31342g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [K31341G](https://www.meridianbioscience.com/lifescience-product/k31341g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Troponin
---
### [K31315G](https://www.meridianbioscience.com/lifescience-product/k31315g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, CK-MM
---
### [K24211R](https://www.meridianbioscience.com/lifescience-product/k24211r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Hormones & Steroids, Relaxin
---
### [K24124M](https://www.meridianbioscience.com/lifescience-product/k24124m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cardiac, Cholesterol, & Metabolic Markers, Vitamin D
---
### [K23600G](https://www.meridianbioscience.com/lifescience-product/k23600g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K23300R](https://www.meridianbioscience.com/lifescience-product/k23300r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K23001R](https://www.meridianbioscience.com/lifescience-product/k23001r/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
### [K11444M](https://www.meridianbioscience.com/lifescience-product/k11444m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Biotin, Miscellaneous Reagents
---
### [K11333M](https://www.meridianbioscience.com/lifescience-product/k11333m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Cancer Markers, Hemocyanin
---
### [K11111M](https://www.meridianbioscience.com/lifescience-product/k11111m/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** HRP, Miscellaneous Reagents
---
### [K07112H](https://www.meridianbioscience.com/lifescience-product/k07112h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, dsDNA
---
### [K07111H](https://www.meridianbioscience.com/lifescience-product/k07111h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Histone
---
### [K07110H](https://www.meridianbioscience.com/lifescience-product/k07110h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, St Autoimmune
---
### [K07108H](https://www.meridianbioscience.com/lifescience-product/k07108h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Sm Antigen
---
### [K07105H](https://www.meridianbioscience.com/lifescience-product/k07105h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Scl-70
---
### [K07104H](https://www.meridianbioscience.com/lifescience-product/k07104h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, SS-B
---
### [K07103H](https://www.meridianbioscience.com/lifescience-product/k07103h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Ro (SS-A)
---
### [K07102H](https://www.meridianbioscience.com/lifescience-product/k07102h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, RNP
---
### [K07101H](https://www.meridianbioscience.com/lifescience-product/k07101h/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Autoimmune, Jo-1
---
### [K04341G](https://www.meridianbioscience.com/lifescience-product/k04341g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** C-1 Inhibitor, Cancer Markers
---
### [K04323G](https://www.meridianbioscience.com/lifescience-product/k04323g/)
**Published:** January 19, 2026
**Author:** hamza
**Antibodies & Antigens:** Apolipoprotein, Cardiac, Cholesterol, & Metabolic Markers
---
## Lifescience Chinese Webinars
### [主题：宫颈癌风险防控：HPV检测技术及最新解决方案](https://www.meridianbioscience.com/lifescience-chinese/主题：宫颈癌风险防控：hpv检测技术及最新解决方/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 免疫
---
### [主题：分子POCT行业临床应用及市场前言动态](https://www.meridianbioscience.com/lifescience-chinese/主题：分子poct行业临床应用及市场前言动态/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** Point-of-Care, 分子
---
### [主题：精准诊断:呼吸道传染病多重检测及POCT的全面解决方案](https://www.meridianbioscience.com/lifescience-chinese/主题：精准诊断呼吸道传染病多重检测及poct的全面/)
**Published:** May 28, 2025
**Author:** hamza
---
### [主题：赋能肿瘤学：从高通量到POC不同场景的超灵敏SNP分子检测](https://www.meridianbioscience.com/lifescience-chinese/主题：赋能肿瘤学：从高通量到poc不同场景的超灵/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** Point-of-Care|分子, 分子, 癌症研究
---
### [主题：新一代NGS建库解决方案：告别冷链，促进测序技术推广和POC设备的整合](https://www.meridianbioscience.com/lifescience-chinese/主题：新一代ngs建库解决方案：告别冷链，促进测/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** NGS, 分子
---
### [主题：性传染病居家自检：市场发展最新进展及分子和免疫检测全面解决方案](https://www.meridianbioscience.com/lifescience-chinese/主题：性传染病居家自检：市场发展最新进展及分/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 免疫
---
### [主题：高性能分子酶引领分子诊断：无甘油酶，打造未来分子诊断新生态](https://www.meridianbioscience.com/lifescience-chinese/主题：高性能分子酶引领分子诊断：无甘油酶，打/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** Point-of-Care, 分子, 分子核心酶
---
### [主题：天然抗原在免疫诊断检测中的应用及挑战](https://www.meridianbioscience.com/lifescience-chinese/主题：天然抗原在免疫诊断检测中的应用及挑战/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 免疫, 天然抗原
---
### [主题：分子POC检测的未来：低成本和高灵敏的等温扩增 LAMP & NASBA](https://www.meridianbioscience.com/lifescience-chinese/主题：分子poc检测的未来：低成本和高灵敏的等温/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** Point-of-Care, 分子
---
### [主题： 冻干和风干qPCR / RT-qPCR试剂在分子检测中的应用 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：-冻干和风干qpcr-rt-qpcr试剂在分子检测中的应用-直/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 常温稳定
---
### [主题：酶力无穷：赋能卓越的分子诊断性能](https://www.meridianbioscience.com/lifescience-chinese/主题：酶力无穷：赋能卓越的分子诊断性能/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 分子核心酶
---
### [直播内容简介 Introduction:](https://www.meridianbioscience.com/lifescience-chinese/直播内容简介-introduction/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 分子检测质控
---
### [主题：迈迪安公司优生优育ToRCH原料及其他相关原料介绍 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：迈迪安公司优生优育torch原料及其他相关原料/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 优生优育, 免疫
---
### [主题：呼吸道感染检测的完整解决方案 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：呼吸道感染检测的完整解决方案-直播内容简/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 传染病, 分子
---
### [主题：可风干qPCR试剂解决方案开发常温稳定试剂 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：可风干qpcr试剂解决方案开发常温稳定试剂-直/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 常温稳定|分子, 癌症研究
---
### [主题：血液和FFPE活检样本的直接基因分型：新型抗抑性分子原料及其在DNA突变分子诊断中的应用](https://www.meridianbioscience.com/lifescience-chinese/主题：血液和ffpe活检样本的直接基因分型：新型抗/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 癌症研究
---
### [新型可风干技术： 为开发常温稳定的干燥型分子检测提供全新的解决方案](https://www.meridianbioscience.com/lifescience-chinese/新型可风干技术：-为开发常温稳定的干燥型分子检/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 常温稳定
---
### [主题： 分子POCT诊断试剂研发面临的挑战及解决方案:LAMP vs. qPCR 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：-分子poct诊断试剂研发面临的挑战及解决方案lamp/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** Point-of-Care, 分子
---
### [主题： 免核酸提取直扩：让分子诊断更简单快速 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：-免核酸提取直扩：让分子诊断更简单快速-直/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 抗抑性直扩
---
### [主题： LAMP试剂开发技巧及关键原料选择 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：-lamp试剂开发技巧及关键原料选择-直播内容简/)
**Published:** May 28, 2025
**Author:** hamza
---
### [主题：针对特定样本的分子检测试剂-分子诊断开发的突破性创新](https://www.meridianbioscience.com/lifescience-chinese/主题：针对特定样本的分子检测试剂-分子诊断开发/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 抗抑性直扩
---
### [主题：样本类型不同，试剂配发就该不同！](https://www.meridianbioscience.com/lifescience-chinese/主题：样本类型不同，试剂配发就该不同！/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 抗抑性直扩
---
### [主题：产前生殖检测和优生优育诊断检测的原料选择](https://www.meridianbioscience.com/lifescience-chinese/主题：产前生殖检测和优生优育诊断检测的原料选/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 优生优育, 免疫
---
### [主题：血液分子诊断的创新型原料](https://www.meridianbioscience.com/lifescience-chinese/主题：血液分子诊断的创新型原料/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 抗抑性直扩
---
### [主题：呼吸道传染病检测免疫/分子整体解决方案](https://www.meridianbioscience.com/lifescience-chinese/主题：呼吸道传染病检测免疫-分子整体解决方案-2/)
**Published:** May 28, 2025
**Author:** hamza
---
### [主题：呼吸道传染病检测免疫/分子整体解决方案](https://www.meridianbioscience.com/lifescience-chinese/主题：呼吸道传染病检测免疫-分子整体解决方案/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 传染病, 分子
---
### [主题：癌症检测的变革：液体活检](https://www.meridianbioscience.com/lifescience-chinese/主题：癌症检测的变革：液体活检/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 癌症研究
---
### [主题：揭秘免疫阻断剂：提高免疫诊断的准确性 直播内容简介 Introduction：](https://www.meridianbioscience.com/lifescience-chinese/主题：揭秘免疫阻断剂：提高免疫诊断的准确性-直/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 免疫, 免疫阻断剂
---
### [主题：中国IVD诊断走向世界机遇、挑战及原料选择](https://www.meridianbioscience.com/lifescience-chinese/主题：中国ivd诊断走向世界机遇、挑战及原料选择/)
**Published:** May 28, 2025
**Author:** hamza
**Topics:** 分子, 常温稳定
---
## Lifescience Events & Tradeshows
### [The Association for Diagnostics & Laboratory Medicine – (ADLM | AACC) 2026](https://www.meridianbioscience.com/lifescience/events/the-association-for-diagnostics-laboratory-medicine-adlm-aacc-2026/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at Booth #3265 at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting, formerly known as AACC. This premier event brings together professionals in diagnostics and laboratory medicine for more than 250 educational opportunities, including plenary sessions, scientific presentations, and roundtable discussions. Attendees will explore cutting-edge topics such as artificial intelligence, nanotechnology, mass spectrometry, and diagnostic innovation, and can visit the Clinical Lab Expo featuring over 850 exhibitors and more than 200 new products and services.
**Content:**
###### Something New Is Coming to ADLM 2026! Join Meridian at Booth #3265 for an Exclusive Look.
Meridian Bioscience is excited to exhibit at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Clinical Lab Expo—the leading global event for laboratory diagnostics and clinical innovation.
Visit booth #3265 to explore Meridian’s end-to-end immunoassay and molecular reagent solutions. Be among the first to preview new offerings for assay developers, including a solution designed to simplify master mix storage and shipping plus a new product series that helps accelerate immunoassay reagent selection and assay development.
**Comprehensive Reagent Solutions for Molecular and Immunoassay Development**
Whether you’re advancing infectious disease testing, oncology panels, or point-of-care diagnostics, our reagents are designed to optimize performance, simplify workflows, and reduce supply chain risk.
**Molecular Diagnostic Reagents & Custom Services**
Streamline your workflow with a comprehensive portfolio of molecular components for qPCR, isothermal amplification, and NGS applications.
•
**Enzymes & Polymerases –** Glycerol-free, inhibitor-tolerant enzymes engineered for high performance in challenging clinical samples (e.g., FFPE, plasma)
•
**Master Mixes –** Highly sensitive, lyophilization-ready mixes optimized for qPCR, LAMP, and NGS
•
**Nucleotides & Oligos –** Ultra-pure dNTPs for reliable amplification and assay consistency
•
**Extraction & Process Controls –** Designed to verify sample integrity, monitor workflow efficiency, and ensure result traceability across diverse sample types
**Immunoassay Reagents & Custom Services**
Build sensitive, reliable immunoassays with lot-to-lot consistency using immunodiagnostic components manufactured to exacting quality standards.
**We have everything you need to:**
•
**Paired Antibodies –** High-affinity antibodies for over 150 disease targets
•
**Native & Recombinant Antigens –** Optimized for sensitive detection of IgG and IgM antibody responses
•
**Immunoassay Blockers –** Minimize false results from HAMA, RF, and heterophilic antibody interference
•
**Custom Antibody & Protein Services –** Flexible development and scalable manufacturing tailored to your assay needs
### Why partner with Meridian?
•
**Decades of Enzyme Expertise –** Proven know-how to make your enzyme glycerol-free
•
**Single Source Solution –** All your assay reagents from one trusted partner
•
**Immunoassay Blockers –** Minimize false results from HAMA, RF, and heterophilic antibody interference
•
**Flexible Customization Services –** We extend your R&D capacity with scalable, fit-for-purpose solutions
**Categories:** Immuno, Molecular
**Regions:** North America
---
### [18th Annual NextGen DX 2026](https://www.meridianbioscience.com/lifescience/events/18th-annual-nextgen-dx-2026/)
**Published:** June 5, 2026
**Author:** Hamza Shahzad
**Excerpt:** Cambridge Healthtech Institute will host the 18th Annual Next Generation Dx Summit at the Capital Hilton in Washington, D.C., on August 24–26, 2026. The Next Generation Dx Summit brings together global thought leaders to discuss diagnostic advancement, emerging technologies and innovation across the diagnostics industry. This year’s program will provide a valuable look at state-of-the-art technologies, forecasting and future trends in point-of-care and at-home testing, infectious disease, multi-cancer early detection, single-cancer early detection, reimbursement, regulation and companion diagnostics to improve the standard of point-of-care medicine.
Meridian Life Science will participate in the Summit with a featured presentation, “Advancing Point-of-Care Diagnostics through Lyophilization-Ready Isothermal Amplification Technologies,” presented by Rosa Maria Porreca, PhD.
**Content:**
## 18th Annual NextGen DX 2026
August 24-26, 2026
Capital Hilton, Washington, DC
Join Meridian Life Science at the 18th Annual Next Generation Dx Summit, hosted by Cambridge Healthtech Institute. The summit brings together global diagnostics leaders to discuss emerging technologies, future trends and advances in point-of-care testing, oncology, infectious disease, reimbursement, regulation and companion diagnostics shaping the future of healthcare.
**Categories:** Molecular
---
### [CACLP 2026 (China Association of Clinical Laboratory Practice)](https://www.meridianbioscience.com/lifescience/events/caclp-2026-china-association-of-clinical-laboratory-practice/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at Booth #4-0606 for CACLP 2026, the 23rd China International In Vitro Diagnostic Expo, taking place 21–23 March 2026 at the Xiamen International Expo Center, Xiamen, China. As one of the largest and most influential IVD exhibitions in China, CACLP provides a comprehensive platform for industry professionals, researchers, and businesses to explore the latest advancements across the diagnostics ecosystem—including diagnostic technologies, medical laboratory equipment, and cutting-edge innovations.
**Content:**
Join us at Booth #4-0606 for CACLP 2026, the 23rd China International In Vitro Diagnostic Expo, taking place 21–23 March 2026 at the Xiamen International Expo Center, Xiamen, China.
As one of the largest and most influential IVD exhibitions in China, CACLP provides a comprehensive platform for industry professionals, researchers, and businesses to explore the latest advancements across the diagnostics ecosystem—including diagnostic technologies, medical laboratory equipment, and cutting-edge innovations.
At CACLP 2026, we are proud to launch our **newest liquid ambient-stable qPCR and RT-qPCR mixes**, delivering outstanding performance and stability without the need for cold-chain logistics. We will also introduce our **recombinant HAMA blockers**, specifically engineered to reduce assay interference and enhance result reliability.
Discover our comprehensive portfolio of molecular and immunoassay solutions, thoughtfully designed to simplify assay development and support more sustainable workflows. Our offerings include high-quality antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications. Visit our booth and attend our seminar presentation to learn how these innovations can advance your diagnostic development programs.
This is a unique opportunity to **connect, collaborate, and stay ahead** in the rapidly evolving diagnostics landscape—**don’t miss it！**
**Categories:** Immuno, Molecular
**Regions:** Asia Pacific
**Types:** Trade Show
---
### [European Society of Human Genetics Conference (ESHG) 2026](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2026/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at booth #462 at the European Society of Human Genetics (ESHG) Conference which gathers the world’s leading geneticists, genetics researchers and biotechnology companies to collaborate and discuss the latest cutting-edge advancements in human genetics and genomics. The scientific program features top speakers, symposia, oral presentations, poster presentations and a series of educational sessions.
**Content:**
Join us at the ESHG 2026 conference to explore how our latest ambient temperature-stable assay technologies are advancing molecular diagnostics.
**Categories:** Molecular
**Regions:** EMEA, Europe
---
### [IMMUNOLOGY 2026](https://www.meridianbioscience.com/lifescience/events/immunology-2026/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at IMMUNOLOGY 2026 at Booth #620, the world’s largest annual all-immunology meeting, bringing together more than 3,500 scientists from over 40 countries. Attendees span all career stages—from international leaders to the next generation of researchers—gathering to share cutting-edge science and explore innovations that advance immunology research.
**Content:**
## Why Meet Us at IMMUNOLOGY 2026?
**Join us at IMMUNOLOGY 2026 at Booth #620** to explore Meridian’s immunoassay-first reagent portfolio—featuring innovative antibodies, antigens, blockers, and molecular reagents, including enzymes, nucleotides, and master mixes. Designed to streamline workflows, reduce barriers, and improve assay performance, our solutions support academic research, translational science, and industrial assay development across human, animal, plant, and environmental applications—from early discovery and proof-of-concept through validation and commercialization.
**Categories:** Immuno
**Regions:** North America
---
### [I-MDX (Molecular Diagnostics Industry Conference and Exhibition)](https://www.meridianbioscience.com/lifescience/events/i-mdx-molecular-diagnostics-industry-conference-and-exhibition-2026/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at I-MDx 2026, the 8th Annual Molecular Diagnostics Industry Conference and Exhibition. This conference is hosted by Shanghai Truesaw Business Consulting Co., Ltd. and focuses on advancements and innovations in the molecular diagnostics industry. Attendees can expect insightful discussions, networking opportunities, and exhibitions showcasing the latest developments in molecular diagnostics.
**Content:**
Join us at I-MDx 2026, thee 8th Annual Molecular Diagnostics Industry Conference and Exhibition. This conference is hosted by Shanghai Truesaw Business Consulting Co., Ltd. and focuses on advancements and innovations in the molecular diagnostics industry. Attendees can expect insightful discussions, networking opportunities, and exhibitions showcasing the latest developments in molecular diagnostics.
**Categories:** Molecular
**Regions:** Asia Pacific
**Tags:** Molecular
**Types:** Trade Show
---
### [Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2026-annual-meeting-expo/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at the 32nd AMP 2026 - Annual Meeting and Expo, Booth #645 to discover how our innovative molecular reagents & services are designed to streamline workflows, reduce barriers, and improve test performance across a wide range of applications.
**Content:**
Join us at the 32st **AMP 2026 – Annual Meeting and Expo, Booth #1115 to discover how our innovative molecular reagents & services** are designed to streamline workflows, reduce barriers, and improve test performance across a wide range of applications.
**Explore Our Molecular Solutions:**
- •
**[Ambient-Temperature Stable Master Mixes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/liquid-ambient-stable-master-mixes)**
From liquid ambient-stable master mixes to lyophilization-ready and air-dryable formats, discover solutions that remove cold-chain constraints and simplify workflows.
- •
**[Isothermal Enzymes & Master Mixes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/)**
Optimized solutions for LAMP and NASBA enabling rapid, sensitive detection with simple workflows that are ideal for point-of-care and decentralized testing.
- •
**[High-Concentration, Glycerol-Free Enzymes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/)**
Flexible formulations for seamless integration into automated workflows, while eliminating cold chain constraints for easier handling and shipping.
- •
**[Inhibitor-Tolerant Formulations:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)**
Designed for robust performance with crude or complex samples, reducing the risk of false negatives and ensuring highly reproducible results.
**Categories:** Molecular
**Regions:** North America
---
### [American Society of Human Genetics (ASHG) 2026 Annual Meeting](https://www.meridianbioscience.com/lifescience/events/american-society-of-human-genetics-ashg-2026-annual-meeting/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** Join us at the American Society of Human Genetics (ASHG 2026) Annual Meeting at Booth #1109, where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
**Content:**
Join us at the American Society of Human Genetics (ASHG 2026) Annual Meeting where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
**Advancing Molecular Diagnostics with Smarter Reagent Solutions**
We’ll be showcasing a comprehensive portfolio of high-performance enzymes and master mixes designed for reliability, sensitivity, and workflow efficiency across applications such as liquid biopsy, tNGS, NGS, and genotyping.
**Our Reagent Solutions Are Engineered To:**
• Enhance stability, even under variable temperature conditions
• Improve sensitivity for accurate, reproducible results
• Streamline workflows to save hands-on time and reduce complexity
**Categories:** Immuno, Molecular
**Regions:** North America
---
### [Diagmand (IVD Innovation Development and Upstream Solutions Conference)](https://www.meridianbioscience.com/lifescience/events/diagmand-ivd-innovation-development-and-upstream-solutions-conference-26/)
**Published:** January 28, 2026
**Author:** Holger
**Excerpt:** The Diagnostics and Manufacturing (Diagmand) Conference is an upcoming event focused on innovations and developments in the in vitro diagnostics (IVD) industry. Scheduled to feature over 80 exhibitors and attract more than 2,500 professionals, the conference will present over 200 topics across various forums. Key areas of discussion include biochemical immunodiagnostics, molecular diagnostics, sequencing technology, automation innovation, microbial diagnostics, and hemagglutination diagnostics. The event aims to bring together leading upstream brands in immunodiagnosis, molecular diagnosis, and molecular point-of-care testing.
**Content:**
The Diagnostics and Manufacturing (Diagmand) Conference is an upcoming event focused on innovations and developments in the in vitro diagnostics (IVD) industry. Scheduled to feature over 80 exhibitors and attract more than 2,500 professionals, the conference will present over 200 topics across various forums. Key areas of discussion include biochemical immunodiagnostics, molecular diagnostics, sequencing technology, automation innovation, microbial diagnostics, and hemagglutination diagnostics. The event aims to bring together leading upstream brands in immunodiagnosis, molecular diagnosis, and molecular point-of-care testing.
**Categories:** Immuno, Molecular
**Regions:** Asia Pacific
**Types:** Trade Show
---
### [Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/events/shaping-the-future-of-precision-oncology-a-comparative-analysis-of-qpcr-targeted-ngs-and-whole-genome-sequencing/)
**Published:** April 1, 2025
**Author:** hamza
**Content:**
In our webinar, explore the role of qPCR, targeted NGS, and whole-genome sequencing in precision oncology. Learn how these technologies compare in applications like liquid biopsy, MRD monitoring, and mutation detection, along with their advantages, limitations, and key considerations for sensitivity, cost, and data analysis. Gain insights from real-world assay examples and discover how Meridian can support your assay development with innovative, tailored solutions.
**Categories:** Molecular
**Types:** Webinar
---
### [Precision Oncology & Diagnostics 2025](https://www.meridianbioscience.com/lifescience/events/precision-oncology-diagnostics-2025/)
**Published:** October 31, 2025
**Author:** Holger
**Excerpt:** Meridian Life Science is proud to participate in Precision Oncology & Diagnostics 2025, an event developed with the editorial team of Precision Oncology News to spotlight the rapidly evolving field of precision oncology.
This meeting will bring together leaders across pharma, biotech, cancer centers, and the research community to discuss strategies and best practices for implementing molecularly guided cancer care.
**Content:**
Meridian Life Science is proud to participate in Precision Oncology & Diagnostics 2025, an event developed with the editorial team of Precision Oncology News to spotlight the rapidly evolving field of precision oncology.
This meeting will bring together leaders across pharma, biotech, cancer centers, and the research community to discuss strategies and best practices for implementing molecularly guided cancer care.
---
### [Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2025-annual-meeting-expo/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at the 31st AMP 2025 - Annual Meeting and Expo, Booth #1115 to discover how our innovative molecular reagents & services are designed to streamline workflows, reduce barriers, and improve test performance across a wide range of applications.
**Content:**
Join us at the 31st **AMP 2025 – Annual Meeting and Expo, Booth #1115 to discover how our innovative molecular reagents & services** are designed to streamline workflows, reduce barriers, and improve test performance across a wide range of applications.
**Explore Our Molecular Solutions:**
- •
**[Ambient-Temperature Stable Master Mixes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/liquid-ambient-stable-master-mixes)**
From liquid ambient-stable master mixes to lyophilization-ready and air-dryable formats, discover solutions that remove cold-chain constraints and simplify workflows.
- •
**[Isothermal Enzymes & Master Mixes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/)**
Optimized solutions for LAMP and NASBA enabling rapid, sensitive detection with simple workflows that are ideal for point-of-care and decentralized testing.
- •
**[High-Concentration, Glycerol-Free Enzymes:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/)**
Flexible formulations for seamless integration into automated workflows, while eliminating cold chain constraints for easier handling and shipping.
- •
**[Inhibitor-Tolerant Formulations:](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)**
Designed for robust performance with crude or complex samples, reducing the risk of false negatives and ensuring highly reproducible results.
**Categories:** Molecular
**Regions:** North America
---
### [Meridian Life Science at MEDICA 2025](https://www.meridianbioscience.com/lifescience/events/medica-2025/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at MEDICA, the world’s largest medical industry event, where you can discover the latest innovations in healthcare alongside thousands of exhibitors and attendees from over 70 countries! Connect with global experts to explore advancements in laboratory technology, molecular diagnostics, medical research and devices, and raw materials manufacturing.
Join us at MEDICA 2025 in Hall 3, Booth #3D15-2, to discover next-generation solutions that power precision diagnostics and accelerate your path from concept to commercialization.
**Content:**
Discover how Meridian’s molecular and immunoassay reagent technologies are accelerating the development of next-generation diagnostic assays. From liquid ambient-stable qPCR master mixes to paired, high-sensitivity antibodies for a wide range of diseases, Meridian’s portfolio is engineered to enhance sensitivity, consistency, and scalability across diagnostic applications—including high-throughput, point-of-care, and at-home testing.
Join us at MEDICA 2025 in Hall 3, Booth #3D15-2, to discover next-generation solutions that power precision diagnostics and accelerate your path from concept to commercialization.
**Innovating Diagnostics. Accelerating Discovery.**
We’re advancing the science behind diagnostics through innovative reagent solutions that enable accuracy, speed, and sensitivity in molecular and immunoasssay workflows. Visit our booth to learn how our technologies support reliable performance across diverse technologies, including qPCR, LAMP, NGS, CLIA, ELISA and lateral flow.
**Featured innovations include:**
- •
**[Ambient-stable molecular chemistries](https://www.meridianbioscience.com/liquid-ambient-stable-qpcr-mixes/)** for qPCR, LAMP, and NGS
- •
**[Recombinant blockers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/)** proven to reduce immunoassay interference
- •
**[Custom Reagent Services](https://meridianbiostg.wpengine.com/lifescience/products/molecular-reagents/services/)** – designed your way: sustainable, cold-chain free, and animal-free
- •
**[Enzymes and master mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/)** for molecular assays
- •
**[Nucleotides and oligos](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/nucleotides/)**
Our molecular and immunoassay reagents are designed to improve reproducibility, simplify workflow integration, and expand accessibility across global markets. From cold-chain-free molecular mixes that streamline transport and scale-up to paired antibodies and animal-free blockers that enhance sensitivity and reduce background in lateral flow and ELISA formats, Meridian enables faster, more reliable assay development—helping diagnostic innovators bring better tests to more people, everywhere.
### Let’s Connect – Meet Our Experts
Our team, including R&D and business leaders will be available throughout the show to discuss your unique development goals.
Plan your visit or [Schedule a Meeting](https://share.hsforms.com/10BzTF0eoT22d7hvxHGU4WAc22yq) in advance.
Stop by Booth #3D15-2 in Hall 3 to see how Meridian can help advance your next innovation in diagnostics
**Categories:** Immuno, Molecular
**Regions:** EMEA, Europe
---
### [American Society of Human Genetics (ASHG) 2025 Annual Meeting](https://www.meridianbioscience.com/lifescience/events/american-society-of-human-genetics-ashg-2025-annual-meeting/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at the American Society of Human Genetics (ASHG 2025) Annual Meeting where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
**Content:**
Join us at the American Society of Human Genetics (ASHG 2025) Annual Meeting where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
**Advancing Molecular Diagnostics with Smarter Reagent Solutions**
We’ll be showcasing a comprehensive portfolio of high-performance enzymes and master mixes designed for reliability, sensitivity, and workflow efficiency across applications such as liquid biopsy, tNGS, NGS, and genotyping.
**Our Reagent Solutions Are Engineered To:**
• Enhance stability, even under variable temperature conditions
• Improve sensitivity for accurate, reproducible results
• Streamline workflows to save hands-on time and reduce complexity
**Categories:** Immuno, Molecular
**Regions:** North America
---
### [NextGen DX 2025](https://www.meridianbioscience.com/lifescience/events/nextgen-dx-2025/)
**Published:** March 14, 2025
**Author:** hamza
**Excerpt:** Cambridge Healthtech Institute is proud to present the Seventeenth Annual Next Generation Dx Summit which will take place at the Capital Hilton in Washington, D.C. on August 18-20, 2025. The Next Generation Dx Summit is the nexus for international thought leaders to discuss diagnostic advancement and technology innovation. This year’s event provides a valuable window on the state-of-the art, forecasting and future trends in point-of-care and decentralized testing, infectious disease, liquid biopsy, multi-cancer early detection, reimbursement, regulation, and companion diagnostics to improve standard of care in medicine. This must-attend Summit offers incomparable networking and complete coverage of the most timely and important topics for the industry.
**Content:**
Join Meridian Bioscience at the Next Generation Dx Summit, hosted by the Cambridge Healthtech Institute which unites global leaders driving innovation in diagnostics. This year’s program covers a wide range of breakthrough areas—from liquid biopsy and infectious disease testing to companion diagnostics, clinical microbiology, and decentralized testing.
**Categories:** Immuno, Molecular
**Regions:** North America
**Types:** Trade Show
---
### [ASHG 2024 Annual Meeting](https://www.meridianbioscience.com/lifescience/events/ashg-2024-annual-meeting/)
**Published:** October 8, 2024
**Author:** hamza
**Excerpt:** Join us at booth #385 at the American Society of Human Genetics (ASHG 2024) Annual Meeting where the world’s leading geneticists, genetics research and biotechnology companies will be gathered to collaborate and discuss the latest cutting-edge advancements in the human genetics and genomics industry.
**Content:**
# Discover Meridian’s innovative molecular reagents and services for qPCR and NGS!
Visit us at booth #385 to meet our experts who will share insights on the latest technological advancements in NGS and qPCR for precision diagnostics. Learn about our new glycerol-free NGS enzymes that enable lyophilization, removing the constraint of cold-chain logistics. This is an industry first for ambient temperature shipping and storage, helping to make NGS technology more accessible and supporting Meridian’s commitment to sustainability.
**Categories:** Immuno
**Regions:** North America
**Types:** Trade Show
---
### [MEDICA 2024](https://www.meridianbioscience.com/lifescience/events/medica-2024/)
**Published:** October 8, 2024
**Author:** hamza
**Excerpt:** Join us at MEDICA, the world’s largest medical industry event, where you can discover the latest innovations in healthcare alongside thousands of exhibitors and attendees from over 70 countries! Connect with global experts to explore advancements in laboratory technology, molecular diagnostics, medical research and devices, and raw materials manufacturing.
**Content:**
# Learn more about Meridian’s portfolio of innovative solutions for molecular diagnostics and immunoassays
Stop by our booth, #3D19-1, to check out our innovative solutions in molecular and immunoassay reagents, designed to simplify assay design, eliminate cold-chain logistics, and improve sustainability. We have a large portfolio of antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications for the IVD industry as well as animal, plant, and environmental areas. This is a fantastic opportunity to network and collaborate at the forefront of innovation—don’t miss out!
**Categories:** Immuno, Molecular
**Regions:** EMEA
**Types:** Trade Show
---
### [Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo](https://www.meridianbioscience.com/lifescience/events/association-for-molecular-pathology-amp-2024-annual-meeting-expo/)
**Published:** October 9, 2024
**Author:** hamza
**Excerpt:** Join us at booth #1519 at the 30th AMP Annual Meeting & Expo, where over 3,000 professionals from over 200 companies in the molecular diagnostics industry come together to collaborate on the latest advancements in molecular diagnostics and medicine. Attendees of this event seek the newest information and the latest advances to enhance their ability to provide the best patient care.
**Content:**
## Discover Meridian’s Latest Molecular Solutions Advancing Point-of-Care Applications!
Visit us at booth #1519 to learn about our latest molecular reagent solutions that advance point-of-care (POC) applications. From glycerol-free enzymes to lyophilization-ready master mixes for LAMP and qPCR, our solutions support sustainable POC assay development that can increase the efficiency and accessibility of your assays.
**Categories:** Molecular
**Regions:** North America
**Types:** Trade Show
---
### [Increasing Access to Point-of-Care Diagnostics Through Innovative Advances in Molecular Reagents for Assay Development](https://www.meridianbioscience.com/lifescience/events/increasing-access-to-point-of-care-diagnostics-through-innovative-advances-in-molecular-reagents-for-assay-development/)
**Published:** November 25, 2024
**Author:** hamza
**Content:**
ON DEMAND
Despite gaining traction in diagnostics, molecular Point-of-Care (POC) tests face challenges related to accessibility, stability, and ease of workflow.
Due to infrastructure limitations, especially in remote areas, there is often a lack of necessary resources for appropriately storing reagents, and complex workflows are frequently difficult to implement in non-laboratory settings.
**VIEW THIS WEBINAR TO LEARN ABOUT:**
• Innovative molecular reagents that simplify assay workflow using direct detection
• Benefits to eliminating cold-chain through ambient temperature assay stability
• Advances in qPCR and isothermal technologies tailored for point-of-care use
Don’t miss this opportunity to gain valuable insights from experts in molecular reagent development.
**Categories:** Molecular
**Types:** Webinar
---
### [CACLP 2025 (China Association of Clinical Laboratory Practice)](https://www.meridianbioscience.com/lifescience/events/caclp-2025-china-association-of-clinical-laboratory-practice/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at booth #4-E0401 for CACLP 2025, the 22nd China International In Vitro Diagnostic Expo, taking place from 22–24 March 2025 at the Hangzhou Grand Convention & Exhibition Center, Zhejiang, China. As one of the largest IVD exhibitions in China, CACLP offers a comprehensive platform to explore innovations across the diagnostics ecosystem.
**Content:**
**Advancing Diagnostics with Meridian’s Trusted Life Science Solutions!**
Join us at Booth #4-E0401 for CACLP 2025, the 22nd China International In Vitro Diagnostic Expo, taking place from March 22–24, 2025, at the Hangzhou Grand Convention & Exhibition Center in Zhejiang, China.
As one of the largest and most influential exhibitions in China, CACLP 2025 provides a comprehensive platform for industry professionals, researchers, and businesses to explore the latest advancements in diagnostic technologies, medical laboratory equipment, and cutting-edge innovations.
Explore our cutting-edge solutions in molecular and immunoassays, designed to streamline assay development, eliminate cold-chain requirements, and enhance sustainability. Our extensive portfolio includes antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications.
This is a unique opportunity to connect, collaborate, and stay ahead in the ever-evolving diagnostics landscape—don’t miss out!
**Categories:** Immuno, Molecular
**Regions:** Asia Pacific
**Types:** Trade Show
---
### [European Society of Human Genetics Conference (ESHG) 2025](https://www.meridianbioscience.com/lifescience/events/european-society-of-human-genetics-conference-eshg-2025/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at booth #280 at the European Society of Human Genetics (ESHG) Conference, a major scientific and professional event where the world’s leading geneticists, genetics researchers, and biotechnology companies will gather to collaborate and discuss the latest cutting-edge advancements in human genetics and genomics. The scientific program features top speakers, symposia, oral presentations, poster presentations, and a series of educational sessions.
**Content:**
Join us at the ESHG 2025 conference to explore how our latest ambient temperature-stable assay technologies are advancing molecular diagnostics.
We will be showcasing our comprehensive suite of high-performance enzymes that drive workflow solutions, including a panel of lyophilized NGS library prep reagents.
All of our ambient-stable solutions are engineered to:
- Strengthen assay stability
- Improve sensitivity
- Simplify workflows
These innovations help you accelerate development timelines, reduce cold-chain dependency, and move faster from R&D to market launch — while expanding the global reach of next-generation diagnostics for precision medicine.
Visit us at Booth #280 to discover how our technologies can simplify your workflows, cut operational complexity, and power the next breakthroughs in molecular diagnostics and genetic research.
**Categories:** Molecular
**Regions:** EMEA, Europe
---
### [The Association for Diagnostics & Laboratory Medicine – (ADLM | AACC) 2025](https://www.meridianbioscience.com/lifescience/events/the-association-for-diagnostics-laboratory-medicine-adlm-aacc-2025/)
**Published:** December 16, 2024
**Author:** hamza
**Excerpt:** Join us at booth #3620 at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting, formerly known as AACC. This cornerstone event for professionals in diagnostics and laboratory medicine offers over 250 educational opportunities, including plenary sessions, scientific presentations, and roundtable discussions, covering cutting-edge topics such as artificial intelligence, nanotechnology, mass spectrometry, and diagnostic innovation. Don’t miss out on the opportunity to explore the Clinical Lab Expo, featuring more than 850 exhibitors and over 200 new products and services.
**Content:**
**Join Meridian Bioscience at ADLM 2025 at booth #3620**
Meridian Bioscience is excited to exhibit at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 Clinical Lab Expo—the leading global event for laboratory diagnostics and clinical innovation. Drop by our booth, #3620 to explore Meridian’s end-to-end immunoassay and molecular reagent solutions—powering assay development from early-stage design through to commercialization.
**Comprehensive Reagent Solutions for Molecular and Immunoassay Development**
Whether you’re advancing infectious disease testing, oncology panels, or point-of-care diagnostics, our reagents are designed to optimize performance, simplify workflows, and reduce supply chain risk.
**Molecular Diagnostic Reagents & Custom Services**
Streamline your workflow with a comprehensive portfolio of molecular components for qPCR, isothermal amplification, and NGS applications.
•
**Enzymes & Polymerases –** Glycerol-free, inhibitor-tolerant enzymes engineered for high performance in challenging clinical samples (e.g., FFPE, plasma)
•
**Master Mixes –** Highly sensitive, lyophilization-ready mixes optimized for qPCR, LAMP, and NGS
•
**Nucleotides & Oligos –** Ultra-pure dNTPs for reliable amplification and assay consistency
•
**Extraction & Process Controls –** Designed to verify sample integrity, monitor workflow efficiency, and ensure result traceability across diverse sample types
**Immunoassay Reagents & Custom Services**
Develop highly sensitive immunoassay assays with lot-to-lot consistency with immunodiagnostic components manufactured to exacting quality standards. Build sensitive, reliable immunoassays with lot-to-lot consistency using components manufactured to the highest quality standards.
**We have everything you need to:**
•
**Paired Antibodies –** High-affinity antibodies for over 150 disease targets
•
**Native & Recombinant Antigens –** Optimized for sensitive detection of IgG and IgM antibody responses
•
**Immunoassay Blockers –** Minimize false results from HAMA, RF, and heterophilic antibody interference
•
**Custom Antibody & Protein Services –** Flexible development and scalable manufacturing tailored to your assay needs
### Why partner with Meridian?
•
**Decades of Enzyme Expertise –** Proven know-how to make your enzyme glycerol-free
•
**Single Source Solution –** All your assay reagents from one trusted partner
•
**Immunoassay Blockers –** Minimize false results from HAMA, RF, and heterophilic antibody interference
•
**Flexible Customization Services –** We extend your R&D capacity with scalable, fit-for-purpose solutions
**Categories:** Immuno, Molecular
**Regions:** North America
---
### [I-MDX (Molecular Diagnostics Industry Conference and Exhibition)](https://www.meridianbioscience.com/lifescience/events/i-mdx-molecular-diagnostics-industry-conference-and-exhibition/)
**Published:** March 12, 2025
**Author:** hamza
**Excerpt:** The I-MDx 2025, the 7th Annual Molecular Diagnostics Industry Conference and Exhibition, will be held at a five-star hotel in Nanjing, Jiangsu, China. Hosted by Shanghai Truesaw Business Consulting Co., Ltd., this event focuses on advancements and innovations in the molecular diagnostics industry. Attendees can expect insightful discussions, networking opportunities, and exhibitions showcasing the latest developments in molecular diagnostics.
**Content:**
The I-MDx 2025, the 7th Annual Molecular Diagnostics Industry Conference and Exhibition, will be held at a five-star hotel in Nanjing, Jiangsu, China. Hosted by Shanghai Truesaw Business Consulting Co., Ltd., this event focuses on advancements and innovations in the molecular diagnostics industry. Attendees can expect insightful discussions, networking opportunities, and exhibitions showcasing the latest developments in molecular diagnostics.
**Categories:** Molecular
**Regions:** Asia Pacific
**Tags:** Molecular
**Types:** Trade Show
---
### [Diagmand (IVD Innovation Development and Upstream Solutions Conference)](https://www.meridianbioscience.com/lifescience/events/diagmand-ivd-innovation-development-and-upstream-solutions-conference/)
**Published:** March 12, 2025
**Author:** hamza
**Excerpt:** The Diagnostics and Manufacturing (Diagmand) Conference is an upcoming event focused on innovations and developments in the in vitro diagnostics (IVD) industry. Scheduled to feature over 80 exhibitors and attract more than 2,500 professionals, the conference will present over 200 topics across various forums. Key areas of discussion include biochemical immunodiagnostics, molecular diagnostics, sequencing technology, automation innovation, microbial diagnostics, and hemagglutination diagnostics. The event aims to bring together leading upstream brands in immunodiagnosis, molecular diagnosis, and molecular point-of-care testing (POCT).
**Content:**
The Diagnostics and Manufacturing (Diagmand) Conference is an upcoming event focused on innovations and developments in the in vitro diagnostics (IVD) industry. Scheduled to feature over 80 exhibitors and attract more than 2,500 professionals, the conference will present over 200 topics across various forums. Key areas of discussion include biochemical immunodiagnostics, molecular diagnostics, sequencing technology, automation innovation, microbial diagnostics, and hemagglutination diagnostics. The event aims to bring together leading upstream brands in immunodiagnosis, molecular diagnosis, and molecular point-of-care testing (POCT).
**Categories:** Immuno, Molecular
**Regions:** Asia Pacific
**Types:** Trade Show
---
### [Annual Veterinary Diagnostic Conference (AVDC)](https://www.meridianbioscience.com/lifescience/events/annual-veterinary-diagnostic-conference-avdc/)
**Published:** March 12, 2025
**Author:** hamza
**Excerpt:** The 6th edition of the International Veterinary Testing and Diagnosis Conference is a leading professional event dedicated to advancing animal health and food safety through veterinary diagnostics. It has become the largest conference of its kind in Asia and brings together over 3,000 delegates to discuss the latest advancements in veterinary testing, including molecular diagnostics, microbiology, and laboratory quality management. The conference brings the latest developments in the global veterinary testing industry to the delegates and shares the latest international information and research results in the fields of experimental pathology, molecular diagnosis, virology/serology, microbiology, certification of veterinary testing, rapid on-site testing, laboratory safety, and laboratory quality management.
**Content:**
The 6th edition of the International Veterinary Testing and Diagnosis Conference is a leading professional event dedicated to advancing animal health and food safety through veterinary diagnostics. It has become the largest conference of its kind in Asia and brings together over 3,000 delegates to discuss the latest advancements in veterinary testing, including molecular diagnostics, microbiology, and laboratory quality management. The conference brings the latest developments in the global veterinary testing industry to the delegates and shares the latest international information and research results in the fields of experimental pathology, molecular diagnosis, virology/serology, microbiology, certification of veterinary testing, rapid on-site testing, laboratory safety, and laboratory quality management.
**Categories:** Immuno, Molecular
**Regions:** Asia Pacific
**Types:** Trade Show
---
### [ASM Microbe](https://www.meridianbioscience.com/lifescience/events/asm-microbe/)
**Published:** March 12, 2025
**Author:** hamza
**Excerpt:** ASM Microbe 2025 brings together thousands of scientists, researchers, and healthcare professionals for the world’s largest microbial sciences gathering. The conference will feature over 200 unique sessions across eight scientific tracks, covering topics from basic microbiology to artificial intelligence research (AI). Attendees can engage in cutting-edge scientific sessions and explore curated itineraries on interdisciplinary topics. Key focus areas include antimicrobial resistance, clinical microbiology, environmental and applied microbiology, microbial ecology and evolution, host-microbe biology, and microbial therapeutics and vaccines.
**Content:**
**Join us at ASM Microbe 2025 at booth# 1402**, and explore how our integrated reagent solutions can power your next immunoassay or molecular diagnostic breakthrough. From enzymes to master mixes and blockers, we support assay development with the performance, flexibility, and reliability needed from concept to commercialization.
**Discover How to De-risk, Simplify, and Streamline Your Reagents.**
Stop by our booth #1402 to meet our experts and learn how our high-performance reagents and custom services support the advancement of infectious disease diagnostics and microbiology research:
- •
**Molecular Assay Reagents**
Optimized master mixes and enzymes for qPCR, isothermal amplification, and next-gen diagnostics—designed for precision and reproducibility.
- •
**Cold-Chain Free Options**
Stabilize your molecular assays with glycerol-free and lyophilization-ready formulations—ideal for ambient-temperature storage and global distribution.
- •
**Custom Enzyme Formulation & Development Services**
Collaborate with our experts to convert your enzymes or master mixes into glycerol-free or lyo-ready formats, tailored to your assay’s specifications and stability needs.
- •
**Immunoassay Blockers**
Eliminate false results with blockers targeting HAMA, rheumatoid factor (RF), and heterophilic antibodies (HA)—ideal for complex clinical samples.
**Why It Matters at ASM Microbe**
Microbiology is evolving fast. Whether you’re developing rapid diagnostics for antimicrobial resistance or novel detection platforms for emerging pathogens, your reagents need to keep up.
We have everything you need to:
- •**De-risk your supply chain** with proven, scalable solutions
- •**Simplify development** with expert formulation and support
- •**Innovate confidently** with reagents built for clinical impact
**Categories:** Immuno, Molecular
**Regions:** North America
---
## Lifescience Webinars
### [Top Reasons for Using Animal-Free HAMA/RF Immunoassay Interference Blockers](https://www.meridianbioscience.com/lifescience/webinars/top-reasons-for-using-animal-free-hama-rf-immunoassay-interference-blockers/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Immunoassay interference can cause false-positive and false-negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA are the most prevalent and are identified in up to 25% of the patient population. Combined with HA, they represent the most significant factors leading to false positive immunoassay results.
Avoiding immunoassay interference requires blockers to be included in every immunoassay. Historically, animal-based interference blockers have been used to improve assay accuracy; however, they are susceptible to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages – as seen during the COVID-19 pandemic. Meridian’s new animal-free commercial blockers, K-BlockTM and Mouse-FREE IgG, are the next-generation solution for blocking HAMA/RF/HA that overcomes the ethical concerns and supply problems in using animal-derived blockers.
In this webinar you will learn the advantages of using animal-free immunoassay blockers and their performance.
**Speakers:**
Ryan Hughes Ph.D., (Life Science Immunology Product Manager, Meridian Bioscience)
Andy Gaspar Ph.D., (Life Science Technical Operations and Development Manager, Meridian Bioscience)
**Moderator:**
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
**Topics:** Blockers, Immunology
---
### [Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/webinars/webinars-precision-oncology-may-2025/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
## On Demand!
IN THIS WEBINAR YOU WILL LEARN:
- How qPCR, targeted NGS, and whole-genome sequencing compare in precision medicine applications such as liquid biopsy, MRD monitoring, mutation detection, and hereditary disease screening.
- The advantages and limitations of each approach, including key considerations for sensitivity, throughput, cost, and data requirements.
- Real-world assay examples demonstrating how these technologies are applied in clinical oncology settings.
Register Now! Join us to gain a deeper understanding of these powerful technologies and how Meridian can support your assay development with innovative solutions tailored to your needs.
**Speaker:**
Dale Clash, Marketing Manager
**Topics:** Molecular, Point-of-Care
---
### [The Future of Molecular POC Testing: Low Cost and Highly-Sensitive Isothermal Amplification](https://www.meridianbioscience.com/lifescience/webinars/the-future-of-molecular-poc-testing-low-cost-and-highly-sensitive-isothermal-amplification/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
The recent pandemic and increasing frequency of infectious disease outbreaks due to climate change, urbanization, and increased human migration have drawn significant attention to nucleic acid amplification-based diagnostic technologies (NAAT). Currently, these technologies are mainly accessible only to trained workers in centralized facilities. There is a growing demand for home-based, extraction-free testing using crude samples, however, there are significant challenges in assay development for these point-of-care (POC) applications.
In this upcoming webinar, you will learn:
- Advances in isothermal amplification as an alternative to the current qPCR gold standard
- Advantages of loop-mediated isothermal amplification (LAMP) and nucleic acid sequence-based amplification (NASBA) for the development of the next generation of sensitive, affordable, mobile POC devices
**Speakers:**
William Ferreira, Ph.D., R&D Team Leader
Steve Hawkins, Ph.D., Product Marketing Manager
**Topics:** Molecular
---
### [Speed Up AgBio Testing with Ambient Temperature Stable Direct qPCR Assay](https://www.meridianbioscience.com/lifescience/webinars/webinar-agbio/)
**Published:** December 2, 2025
**Author:** Holger
**Content:**
### Learn more about our solutions for:
- Molecular point-of-care testing (qPCR, isothermal amplification, and next-generation sequencing)
- Ambient-stable reagent chemistries (lyophilization, cold-chain free)
- Infectious disease diagnostics
- Decentralized testing & rapid assay development
- Scalability in resource-limited or near-patient settings
**Register Now!** Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
**Speaker:**
William , R&D Team Leader at Meridian Life Science
William is an R&D Team Leader at Meridian Life Science. He earned his PhD in molecular microbiology in 2019, investigating C. difficile pathogenesis at Royal Holloway, University of London, UK. Subsequently, he held the position of Senior Scientist at Sporegen Ltd, leading diverse research projects rooted in recombinant spore technology. With more than 8 years of expertise in developing molecular assays for clinical use, William is a vital asset within Meridian’s R&D team. His role involves spearheading the creation of cutting-edge molecular products for the global diagnostic industry.
**Topics:** Molecular
---
### [Diagnostic Immunoassays](https://www.meridianbioscience.com/lifescience/webinars/rising-immunoassay-interference-immunoassays-webinar/)
**Published:** October 9, 2025
**Author:** Moaaz Ahmad
**Content:**
### Attendees will learn about:
- Mechanisms of antibody interference
- The post-COVID increase in interference challenges
- Practical strategies to mitigate interference and protect assay performance
The session will also explore the role of passive, active, and universal blockers in neutralizing interfering antibodies, highlighting Meridian Life Science’s portfolio of solutions designed to improve reliability across ELISA, CLIA, and LFA platforms.
**Register Now! Join us for this webinar to stay ahead of post-COVID interference challenges!**
**Speaker Bio:**
John Francois, Product Manager
John Francois brings a unique blend of academic and industry expertise to the immunodiagnostics field. He earned his PhD in Biology from Rutgers University, where he also taught biology courses for several years. Driven by a passion for bridging science and business, he pursued an MBA from Rutgers Business School before transitioning into the life sciences industry. John began his corporate career at VWR (part of Avantor) as a Life Science Product Manager, where he led product strategy for six years. In 2025, he joined Meridian Life Science as Product Manager for the Immunology portfolio, focusing on innovative solutions for assay interference and diagnostic accuracy.
**Topics:** Immunology
---
### [View our Featured Presentation from Next Gen Dx](https://www.meridianbioscience.com/lifescience/webinars/featured-presentation-from-next-gen-dx/)
**Published:** October 21, 2025
**Author:** Moaaz Ahmad
**Content:**
### Learn more about our solutions for:
- Molecular point-of-care testing (qPCR, isothermal amplification, and next-generation sequencing)
- Ambient-stable reagent chemistries (lyophilization, cold-chain free)
- Infectious disease diagnostics
- Decentralized testing & rapid assay development
- Scalability in resource-limited or near-patient settings
**Register Now!** Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
**Speaker:**
William , R&D Team Leader at Meridian Life Science
William is an R&D Team Leader at Meridian Life Science. He earned his PhD in molecular microbiology in 2019, investigating C. difficile pathogenesis at Royal Holloway, University of London, UK. Subsequently, he held the position of Senior Scientist at Sporegen Ltd, leading diverse research projects rooted in recombinant spore technology. With more than 8 years of expertise in developing molecular assays for clinical use, William is a vital asset within Meridian’s R&D team. His role involves spearheading the creation of cutting-edge molecular products for the global diagnostic industry.
**Topics:** Molecular
---
### [From Extraction to Result: Applying VLP Controls for Comprehensive Performance Validation Across Each Stage of an MDx Assay](https://www.meridianbioscience.com/lifescience/webinars/from-extraction-to-result-applying-vlp-controls-for-comprehensive-performance-validation-across-each-stage-of-an-mdx-assay/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
As regulations tighten, find out how to improve process control through every step of a molecular assay, from samples to results!
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
**Speakers:**
Steve Hawkins, Ph.D., Product Marketing Manager
**Topics:** Molecular, Molecular Dx Controls
---
### [Direct Genotyping from Blood & FFPE Biopsies: Novel Inhibitor-Tolerant Master Mixes & Their Applications in Molecular Diagnosis](https://www.meridianbioscience.com/lifescience/webinars/direct-genotyping-from-blood-ffpe-biopsies-novel-inhibitor-tolerant-master-mixes-their-applications-in-molecular-diagnosis/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
**Speakers:**
Mihai-Nicolae Podaru, PhD (R&D Senior Scientist, Meridian Bioscience)
**Moderator:**
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
**Topics:** Inhibitor Tolerance, Molecular
---
### [Transforming Cancer Detection with Liquid Biopsy](https://www.meridianbioscience.com/lifescience/webinars/transforming-cancer-detection-with-liquid-biopsy/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Liquid biopsy is fast becoming the method of choice for cancer diagnosis in the field of precision medicine, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure. Liquid biopsy utilizes bodily fluids such as blood, stool, urine and saliva to detect cancer biomarkers earlier than conventional methods such as tissue biopsy. It is also useful to screen for drug-resistant subpopulations, micro-metastases, minimum residual disease and disease relapse. The non-invasive approach of liquid biopsies enables samples to be taken easily and repeatedly over the course of a patient’s treatment, overcoming the inherent shortcomings and risks of surgical tissue biopsies. This panel discussion will review how liquid biopsy is opening up new avenues in cancer detection and continuous monitoring for personalized cancer treatment, as well as the screening of cancer markers for therapeutic resistance. Four industrial leaders in the field of molecular diagnostics will come together to discuss the current status of liquid biopsy for cancer screening, as well as how modern technologies are changing the landscape of cancer detection and CDx.
**Panelists:**
Chris Sale (CEO, Nonacus, UK)
Shidong Jia, PhD (CEO, Predicine, USA)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)
**Moderator:**
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
**Topics:** Cancer Research, Molecular
---
### [Increasing Access to Point-of-Care Diagnostics Through Innovative Advances in Molecular Reagents for Assay Development](https://www.meridianbioscience.com/lifescience/webinars/increasing-access-to-point-of-care-diagnostics-through-innovative-advances-in-molecular-reagents-for-assay-development/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Despite gaining traction in diagnostics, molecular Point-of-Care (POC) tests face challenges related to accessibility, stability, and ease of workflow.
Due to infrastructure limitations, especially in remote areas, there is often a lack of necessary resources for appropriately storing reagents, and complex workflows are frequently difficult to implement in non-laboratory settings.
VIEW THIS WEBINAR TO LEARN ABOUT:
- Innovative molecular reagents that simplify assay workflow using direct detection
- Benefits to eliminating cold-chain through ambient temperature assay stability
- Advances in qPCR and isothermal technologies tailored for point-of-care use
**Don’t miss this opportunity to gain valuable insights from experts in molecular reagent development.**
**Topics:** Molecular, Point-of-Care
---
### [Advances in HPV Diagnostic Testing: Technologies Enhancing Detection of High-Risk Strains Linked to Cervical Cancer](https://www.meridianbioscience.com/lifescience/webinars/advances-in-hpv-diagnostic-testing-technologies-enhancing-detection-of-high-risk-strains-linked-to-cervical-cancer/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
With over 12 different types of human papilloma virus (HPV) that can cause cancer, it is the leading cause of cervical cancer in women. The HPV/Pap smear co-test has improved the accuracy of cervical cancer screening; however the test has several limitations. Recent advancements in molecular diagnostics have led to the development of genotype-specific HPV tests that accurately detect and differentiate HPV strains, including high-risk oncogenic types such as HPV-16 and HPV-18.
In this webinar you will:
- Learn about HPV type-specific testing
- Explore the recent trends in HPV diagnostics
- Discover urine-specific genotyping chemistry, which can provide a non-invasive, sensitive method for HPV detection
**Speaker:** Steve Hawkins, Ph.D., Meridian Life Science Molecular Product Manager
**Topics:** Immunology, STDs
---
### [Breaking Down Barriers: Revolutionizing Next Generation Sequencing Accessibility by Innovating Reagent Logistics](https://www.meridianbioscience.com/lifescience/webinars/breaking-down-barriers-revolutionizing-next-generation-sequencing-accessibility-by-innovating-reagent-logistics/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
This webinar explores the groundbreaking impact of innovative next-generation sequencing (NGS) enzymes, library preparation kits and services on reshaping the sequencing landscape and accelerating the democratization of NGS in diagnostics. Learn about the newest eco-conscious and cost-effective solutions in NGS reagents, that eliminate cold-chain requirements and decrease NGS workflow-associated carbon footprint.
IN THIS WEBINAR, YOU WILL LEARN ABOUT:
- Logistical barriers to NGS democratization: Challenges due to shipping and storage of reagent kits under refrigeration conditions
- Technological advancements in NGS chemistries: Learn about the latest enzymatic solutions increasing the affordability and accessibility of NGS
- Meridian’s new glycerol-free enzymes: Discover how they enable lyophilization of the library preparation and amplification kits and eliminate the need for energy-intensive transportation and storage conditions
- The first-to-market lyophilized NGS library preparation kit: An introduction to the first commercially available kit of its kind
- High-concentration format: Understand the benefit of high-concentration enzymes that meet the demand for miniaturization, often required for point-of-care devices, and maximize sample input quantity to improve assay sensitivity.
**Speakers:**
Michele Amasio, Ph.D., Senior Manager, R&D – Molecular
Lina Gasiūnaitė, Ph.D., Team Leader, R&D – Molecular
**Topics:** Molecular
---
### [The evolution of STI at-home testing solutions: Exploring key advancements in molecular and immunoassay testing for STI at-home kits](https://www.meridianbioscience.com/lifescience/webinars/the-evolution-of-sti-at-home-testing-solutions-exploring-key-advancements-in-molecular-and-immunoassay-testing-for-sti-at-home-kits/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
With the global increase of sexually transmitted infections (STIs), the need for accessible and accurate STI diagnostic solutions has never been more critical. Traditional testing methods are hindered by several barriers, including limited accessibility and STI-related stigma. This is further compounded by the challenge of asymptomatic infections, which deter initial testing. However, the unprecedented adoption of at-home testing and telemedicine that developed during the COVID-19 pandemic has facilitated the expansion of at-home and self-collection assays for several diseases, such as STIs. Join us as we delve into the changing landscape of STI testing, highlighting the new developments in at-home testing and the molecular and immunoassay reagent solutions for developing new STI assays.
IN THIS WEBINAR, YOU WILL LEARN ABOUT:
- What has changed in STI testing in the post-COVID market and the key differences between home-testing vs. self-collection assays
- Innovative molecular chemistries that enable sensitive direct detection using crude samples
- High-performing immuno-reagents ideal for rapid lateral flow tests
- The future direction of STI screening: trends and growth predictions
**Speakers:**
Steve Hawkins, Ph.D., Merdian Life Science Molecular Product Manager
Ryan Hughes, Ph.D, Merdian Life Science Immuno Product Manager
**Topics:** Immunology|Molecular, Infectious Disease
---
### [Ultra-fast Point-of-Care MDx development with new, sensitive LAMP master mixes](https://www.meridianbioscience.com/lifescience/webinars/ultra-fast-point-of-care-mdx-development-with-new-sensitive-lamp-master-mixes/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
The COVID-19 pandemic accelerated the adoption of point-of-care molecular technologies that offer quick sample to results, high sensitivity, lower cost and widespread accessibility.
This webinar will cover new market-leading reagent solutions for loop-mediated isothermal amplification (LAMP) assays, which simplify assay development, speed up assay turnaround time, and deliver highly sensitive and specific amplification without DNA or RNA extraction.
**Presenters**
Elda Iljazi Ph.D.
Senior Scientist Meridian Bioscience
**Topics:** Molecular, Point-of-Care
---
### [Looking to detect SNPs or other point mutations in samples that have a limited number of DNA copies?](https://www.meridianbioscience.com/lifescience/webinars/looking-to-detect-snps-or-other-point-mutations-in-samples-that-have-a-limited-number-of-dna-copies/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Join our in-house experts William Ferreira, Ph.D. and Steve Hawkins, Ph.D., for their latest webinar where they share their insights on the newest range of Lyo-Ready Genotyping Direct qPCR Master mixes that support commercial assays designed to detect mutations.
In this presentation, you will learn how to detect single nucleotide polymorphisms (SNPs) directly from blood, plasma, urine, stool or FFPE tissue (down to 1 copy/reaction) using a simplified workflow that eliminates the need for nucleic acid extraction.
**Speakers:**
William Ferreira, Ph.D., R&D Team Leader
Steve Hawkins, Ph.D., Product Marketing Manager
**Topics:** Cancer Research|Molecular, Molecular, Point-of-Care
---
### [The Future of Molecular Reagent Technologies: Transforming Infectious Disease Testing](https://www.meridianbioscience.com/lifescience/webinars/the-future-of-molecular-reagent-technologies-transforming-infectious-disease-testing/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
The molecular diagnostic approach for infectious disease such as STDs, tropical, and respiratory disease has seen significant development in the past twelve months, driven by a demand for better, faster, higher sensitivity assays, that can detect asymptomatic carriers. Traditionally, lab-based tests using blood samples have been the mainstay for molecular testing, however home-based, extraction-free tests, using alternative sample types (saliva, urine, stool) are now highly sought after, but pose significant challenges in assay development for both lab-based and point of care (POC) applications.
In this webinar you will learn about:
- New nucleic acid amplification chemistries that simplify direct detection
- Optimizing assay performance per sample types (e.g. blood, saliva, urine, stool)
- The latest technologies that can reduce your cold-chain management
**Presenters**
Michele Amasio, Ph.D.
Research and Development Senior Manager
Steve Hawkins
Ph.D. – Product Marketing Manager
**Topics:** Infectious Disease, Molecular
---
### [Novel Solutions for Improved Process Control in Your Molecular IVD Assays](https://www.meridianbioscience.com/lifescience/webinars/novel-solutions-for-improved-process-control-in-your-molecular-ivd-assays/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
As the IVD industry continues to evolve, new regulations frequently come into place to better control an innovative and growing industry. Molecular IVDs in particular are experiencing tighter regulations regarding the presence of appropriate controls within the assay. All tests must include both positive and negative controls which are subjected to the whole testing process, including the extraction step. Novel co-extracted exogenous controls are providing cutting edge solutions for monitoring RNA or DNA analysis including the detection of potential inhibition. These controls can be used across a variety of sample types and assays, representing a significant advantage over traditional spike-in controls.
**Speakers:**
Michele Amasio, Ph.D. (Research and Development Senior Manager, Meridian Bioscience)
**Moderator:**
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
**Topics:** Molecular, Molecular Dx Controls
---
### [New Air-Dryable Technology, an Advanced Alternative to Lyophilization for Molecular Assays](https://www.meridianbioscience.com/lifescience/webinars/new-air-dryable-technology-an-advanced-alternative-to-lyophilization-for-molecular-assays/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
qPCR and RT-qPCR are widely used in the development of molecular diagnostic assays with applications in human diagnostics, animal health, environmental, plant and food testing.
Lyophilization is a common technique used for creating ambient temperature stable PCR assays. However, the process is time consuming, complex to optimize and requires expensive equipment. Meridian’s new air-dryable technology replaces lyophilization with a fast, simple, and inexpensive oven-drying process, making it ideal for manufacturing room-temperature stable, highly sensitive and cost-effective molecular diagnostic assays.
**This webinar will cover:**
- How Meridian’s new air-dryable technology compares to traditional lyophilization
- The impact of the air-drying process on qPCR performance
- The combination of air-drying with inhibitor tolerance technology in qPCR assays
**Presenters:**
Dr Steve Hawkins – Product Marketing Manager
Dr Michele Amasio – Research and Development Manager
**Topics:** Ambient Temperature Shipping and Storage, Molecular
---
### [Point of Care Assay Development Challenges and Solutions: LAMP vs. qPCR](https://www.meridianbioscience.com/lifescience/webinars/point-of-care-assay-development-challenges-and-solutions-lamp-vs-qpcr/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Molecular point of care (POC) tests are rapidly gaining traction in the diagnostic market, especially for infectious diseases. While LAMP and qPCR testing share common advantages such as quick turnaround time and high sensitivity and specificity, LAMP has additional benefits, making it possible for testing to be carried out essentially anywhere – from an airport to school, to a remote medical clinic.
**In this webinar you will learn about:**
- The new advances in the LAMP and qPCR assay development for POC
- How to speed up sample-to-result and eliminate the need for cold-chain management
**Speakers:**
Elda Iljazi, Ph.D. – R&D Senior Scientist, Meridian Bioscience
Dr. Michele Amasio – Research and Development Manager
**Topics:** Molecular, Point-of-Care
---
### [Meridian Sample Specific Master Mixes – Breakthrough Innovation in MDx Development](https://www.meridianbioscience.com/lifescience/webinars/meridian-sample-specific-master-mixes-breakthrough-innovation-in-mdx-development/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Traditionally, qPCR and RT-qPCR diagnostic assays include DNA/RNA extraction and purification steps to remove inhibitors from the PCR reactions, to meet the assay specificity and sensitivity. However, these steps are laborious, expensive, and time-consuming. To overcome this, Meridian has developed inhibitor tolerant mixes specifically for blood, saliva, urine, and stool. Meridian’s Direct Sample-Specific qPCR Mixes are the first mixes on the market overcoming the limitations of inhibitors inherent in the various clinical specimens, for ultimate assay sensitivity and specificity.
**In this webinar our speakers will discuss:**
The optimization strategy and methodology that have led to the development of these specimen-specific mixes, which have superior performance compared to other products on the market and enable faster, more sensitive, and cost-effective diagnostic assays.
**Speakers:**
Dr. Rachel Currier- Acting Team Leader, Research & Development
Dr. Thomas Fouqueau- Acting Team Leader, Research & Development
**Moderator**
Dr. Steve Hawkins, Product Marketing Manager
**Topics:** Inhibitor Tolerance, Molecular
---
### [Meridian’s solution to detecting DNA or RNA directly from whole blood](https://www.meridianbioscience.com/lifescience/webinars/meridians-solution-to-detecting-dna-or-rna-directly-from-whole-blood/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Direct qPCR has many advantages over traditional qPCR workflows that involve DNA/RNA extraction. However, achieving high sensitivity with direct qPCR using whole blood samples has been challenging due to the presence of qPCR inhibitors within the sample (such as heme, salts, and proteins), and preservatives or anti-coagulants that are added during the sample collection process. The inhibitors can negatively impact the performance of the enzymes used in qPCR and RT-qPCR and they limit the amount of sample that can be added to the reaction, overall reducing the assay sensitivity and accuracy. In this talk, we will be discussing Meridian’s novel solution to overcome PCR inhibitors in direct qPCR and RT-qPCR, enabling greater sensitivity for direct detection from whole blood, improving assay reproducibility, and reducing assay development time.
**Presenters**
Thomas Fouqueau, PhD
Acting Team Leader, R&D, Meridian Life Science
Rachel Currier, PhD
Acting Team Leader, R&D, Meridian Life Science
**Topics:** Inhibitor Tolerance, Molecular
---
### [Highly sensitive qPCR detection of biomarkers from liquid biopsies](https://www.meridianbioscience.com/lifescience/webinars/highly-sensitive-qpcr-detection-of-biomarkers-from-liquid-biopsies/)
**Published:** May 26, 2025
**Author:** hamza
**Content:**
Liquid biopsy is a non-invasive alternative to tissue biopsy based on ultra-sensitive detection of tumor-derived material such as ctRNA and ctDNA from biofluids, including blood, urine, stool, saliva, and sputum. qPCR based liquid biopsy possesses several advantages in cost and throughput, when compared to other technologies like NGS and ddPCR. In this talk, we will discuss Meridian’s new advances in inhibitor tolerant qPCR based liquid biopsy, that reduces the cost and complexity of these assays, while enabling ultra-sensitive detection from very low concentration cancer markers.
**Presenters**
Steve Hawkins
Ph.D. – Product Marketing Manager
Michele Amasio, Ph.D.
Research and Development Senior Manager
**Topics:** Cancer Research, Molecular
---
## Molecular Products
### [MDX988](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx988/)
**Published:** July 9, 2026
**Author:** Hamza Shahzad
**Molecular Reagents:** Liquid Ambient-Stable Master Mixes
---
### [MDX998](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx998/)
**Published:** July 9, 2026
**Author:** Hamza Shahzad
**Molecular Reagents:** Liquid Ambient-Stable Master Mixes
---
### [MDX364](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx364/)
**Published:** September 18, 2025
**Author:** Moaaz Ahmad
**Molecular Reagents:** Liquid Ambient-Stable Master Mixes, qPCR and RT-qPCR Master Mixes
---
### [MDX362](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx362/)
**Published:** June 10, 2026
**Author:** Hamza Shahzad
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX200](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx200/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX174](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx174/)
**Published:** May 1, 2026
**Author:** Holger
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX024](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx024/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX021](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx021/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX173](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx173/)
**Published:** April 30, 2026
**Author:** Holger
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX302](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx302/)
**Published:** April 17, 2026
**Author:** Holger
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo Ready Air Dryer Master Mixes Reagents
---
### [MDX241](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx241/)
**Published:** April 14, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX252](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx253/)
**Published:** March 2, 2026
**Author:** Holger
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX039](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx039/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX224](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx224/)
**Published:** February 2, 2026
**Author:** Moaaz Ahmad
**Molecular Reagents:** Enzymes, fragmentation
---
### [MDX095](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx095/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX082](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx082/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX016](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx016/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX032](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx032/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX105](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx105/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX220](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx220/)
**Published:** April 14, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX221](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx221/)
**Published:** April 14, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX223](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx223/)
**Published:** April 14, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX222](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx222/)
**Published:** April 14, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX058](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx058/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX051](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx051/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX050](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx050/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX096](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx096/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX086](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx086/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX084](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx084/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX083](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx083/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX155](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx155/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX154](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx154/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX360](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx360/)
**Published:** September 17, 2025
**Author:** Moaaz Ahmad
**Molecular Reagents:** Liquid Ambient-Stable Master Mixes, qPCR and RT-qPCR Master Mixes
---
### [MDX301](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx301/)
**Published:** November 19, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo Ready Air Dryer Master Mixes Reagents
---
### [MDX352](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx352/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX046](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx046/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Nucleotides
---
### [MDX219-B](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx219-b/)
**Published:** May 23, 2025
**Author:** hamza
---
### [MDX242](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx242/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX003](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx003/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX008](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx008/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX009](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx009/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX011](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx011/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX012](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx012/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification
---
### [MDX014](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx014/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX015](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx015/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX001](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx001/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX018](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx018/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX042](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx042/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX043](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx043/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX044](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx044/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX054](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx054/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX055](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx055/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX117](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx117/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX201](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx201/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX202](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx202/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX203](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx203/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX205](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx205/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX206](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx206/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX170](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx170/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX207](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx207/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX208](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx208/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX216](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx216/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX217](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx217/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes
---
### [MDX218](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx218/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX240](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx240/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Enzymes, Enzymes, Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX029](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx029/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX028](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx028/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX027](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx027/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX026](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx026/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX069](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx069/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX068](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx068/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [MDX007](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx007/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX004](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx004/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX002](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx002/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX034](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx034/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX033](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx033/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX075](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx075/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Reaction Buffers
---
### [MDX020](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx020/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX019](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx019/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Reaction Buffers
---
### [MDX080](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx080/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Reaction Buffers
---
### [MDX076](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx076/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Reaction Buffers
---
### [MDX078](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx078/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Reaction Buffers
---
### [MDX049](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx049/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX048](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx048/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX047](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx047/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX063](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx063/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX059](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx059/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Nucleotides
---
### [MDX013](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx013/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX006](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx006/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX025](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx025/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX030](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx030/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX031](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx031/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX060](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx060/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX072](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx072/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX073](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx073/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [MDX023](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx023/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX022](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx022/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Reaction Buffer
---
### [MDX061](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx061/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Reaction Buffer
---
### [MDX052](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx052/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Reaction Buffer
---
### [MDX062](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx062/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX119](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx119/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX118](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx118/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX113](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx113/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX108](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx108/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX097](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx097/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Isothermal Master Mix, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [MDX185](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx185/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX184](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx184/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, qPCR and RT-qPCR Master Mixes
---
### [MDX116](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx116/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX121](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx121/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX122](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx122/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX123](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx123/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX124](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx124/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX092](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx092/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX141](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx141/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX140](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx140/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX135](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx135/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX134](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx134/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX133](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx133/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX132](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx132/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX131](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx131/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX130](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx130/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX128](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx128/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX126](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx126/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX125](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx125/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX142](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx142/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX144](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx144/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX145](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx145/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Isothermal Amplification, Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX148](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx148/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX153](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx153/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX150](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx150/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX151](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx151/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX152](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx152/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX143](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx143/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX168](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx168/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX158](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx158/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX322](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx322/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX323](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx323/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX332](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx332/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX333](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx333/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX353](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx353/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents, Specimen Specific Master Mix
---
### [MDX219-A](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx219-a/)
**Published:** May 23, 2025
**Author:** hamza
---
### [MDX120](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx120/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** RNase Inhibitor
---
### [MDX056](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx056/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** RNase Inhibitor
---
### [MDX041](https://www.meridianbioscience.com/lifescience/products/molecular-reagent/mdx041/)
**Published:** May 23, 2025
**Author:** hamza
**Molecular Reagents:** General Reagent
---
## Platforms
### [Curian®](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/curian/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Curian®
Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. See how laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care with Curian.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Curian Diagnostic Solution
Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.
- sample\_result\_icon Fluorescent analyzer – improved performance with no subjectivity
- Group 12Created with Sketch. Intuitive user interface – intuitive, fast, and easy-to-use improves productivity
- expansion\_icon Easy, standardized workflow – implement and train only once
- expansion\_icon Simple sample prep – clean, comfortable handling of samples
### Curian has a standardized assay-to-assay workflow
##### Sample to result in 3 easy steps with less than 1-minute hands-on time
##### Flexible testing options allow the platform to fit any laboratory workload
##### Analyze Now – available for batch testing
##### Incubate & Analyze – load and walk away
## Tests
Gastrointestinal
[ Curian® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/curian-hpsa/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Curian® Shiga Toxin ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/curian-shiga-toxin/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB Detecting...
[ Curian® Campy ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/curian-campy/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Support & Documents
##### Downloadable PDFs
-  [Curian Platform Brochure](/uploads/Curian-Platform-Brochure_v1.0-1.pdf)
##### FAQs
What is the difference between fluorometric and colorimetric?
Curian uses a fluorometric technology that requires analysis using a UV light in order to interpret results. There will not be a visible line on the test card for positive results, unlike colorimetric assays which produce a color change when positive.
What are the benefits of fluorometric assays?
Fluorometric assays often achieve a higher sensitivity and specificity over colorimetric assays, along with a lower limit of detection (LoD). Fluorometric assays remove subjectivity, so technologists don’t need ask around to see if a line is truly present – the analyzer will do that for them.
What is dual mode capability?
Curian has dual mode capability. The first mode is Analyze Now – this is the best option for batch testing. Multiple test cards can be incubated on the bench top for 20 minutes. Then the test cards are read one-by-one by inserting into the analyzer. The second mode is Incubate & Analyze. This is convenient for single patient samples when a laboratory is running samples as they come in. The test card is immediately inserted into the analyzer after sample prep and the analyzer will automatically read the card after a 20-minute incubation. This allows the technologist to walk away and perform other duties while test is running. These two options provide flexibility to meet specific laboratory workflow demands.
What are the data management options for Curian?
Curian has 4 data management options. You can choose to print results via an ancillary printer, export results via a USB, store results on board and retrieve when needed, or transmit results via an LIS connection.
What ancillary items are included with Curian?
A barcode scanner is included with the purchase of a Curian analyzer. The keyboard and printer are optional for an additional charge.
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [BreathID Hp Lab VS02000W](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-lab/)
**Published:** June 2, 2025
**Author:** hamza
**Content:**
# BreathID® Hp Lab
The BreathID® Hp Lab urea breath testing system detects *H. pylori* and confirms eradication for healthcare providers with large patient testing volumes.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## BreathID® Hp Lab: Advanced Detection Platform
The state-of-the-art BreathID® Hp Lab urea breath test system for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
- Group 13Created with Sketch. Unparalleled Diagnostic Performance
100% Sensitivity
97.9% Specificity
- sample\_result\_icon Intuitive Efficiency
Automated data input and batch analysis to reduce human error and simplify reporting
- assay\_flexibility\_icon Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
### Press and walk away automation
#### Built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling.
##### BreathID® Hp Lab System
## Tests
Gastrointestinal
[ BreathID® Hp Lab - IDkit Hp® Two ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two/) Available in: CA, US, GB, EU Detecting...
## Definitive answers, confidence in results
[ Contact Sales ](/contact-us-diagnostics/)
## Support & Documents
##### Downloadable PDFs
-  [Platform Brochure BreathID Hp Lab](/uploads/BreathID-Hp-Lab-Platform-Brochure.pdf)
-  [Procedure Card BreathID Hp Lab](/uploads/vs01082_pc.pdf)
-  [Calibration Procedure Card BreathID Hp Lab](/uploads/vs01082_cpc.pdf)
##### Webinars & Videos
- [ BreathID® Hp Lab for *H. pylori* Detection ](https://youtu.be/k4oIxWQeh8w)
- [ UBT Versus Serology ](https://youtu.be/B-8kZGgWLF8?si=pgg9SIWGUqP4IBi2)
##### FAQs
What is the suggested CPT code?
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Urea Breath
---
### [StatID PRO™](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/statid-pro/)
**Published:** October 9, 2025
**Author:** hamza
**Content:**
# StatID PRO™
StatID PRO™ are lateral flow immunochromatographic assays
[ Contact Sales ](https://www.meridianbioscience.com/contact-us-diagnostics/)
- [ Product Details ](#)
- [ Tests ](#tests)
- [ Disease Areas ](#)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ StatID PRO™ COVID-19/Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/) Available in: US Detecting...
[ StatID PRO™ COVID-19/Flu A&B External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/statid-pro-covid-19-flu-ab/statid-pro-covid-19-flu-ab-external-controls/) Available in: US Detecting...
## Pricing
To order, contact your regional sales representative or use the following contact information: - **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics)
**Solutions:** Immunoassay
---
### [LeadCare®](https://www.meridianbioscience.com/diagnostics/platforms/blood-chemistry/leadcare/)
**Published:** June 4, 2025
**Author:** hamza
**Content:**
# LeadCare®
Lead poisoning threatens millions of people yet is entirely preventable. Meridian is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure. Join us in preventing lead poisoning.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#test)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Efficient Blood Lead Testing Solutions
LeadCare® can help labs of any size function at their best. With LeadCare your core lab, hospital lab, reference lab, or physician’s office lab can run more efficiently and deliver accurate results to clinicians and patients. Deliver results in minutes.
- sample\_result\_icon Results in 3 minutes
- Group 12Created with Sketch. Easy to use - CLIA-waived
- A single visit and a simple fingerstick test
- Accurate
## LeadCare® II
CLIA-waived LeadCare II is used in thousands of practices
[ Learn More ](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ii/)
## LeadCare Plus®
Simplicity and control for any lab with smaller volumes
[ Learn More ](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-plus/)
## LeadCare Ultra®
A simple solution, offering throughput and convenience of high volume
[ Learn More ](/diagnostics/disease-areas/pediatric-neonatal/leadcare/leadcare-ultra/)
#### Analytical Services
#### [A simple solution for any lab – whether you run blood lead testing with GFAAS or send samples out to a reference laboratory.](/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
[ Contact Us ](/diagnostics/disease-areas/pediatric-neonatal/leadcare/analytical-services/)
## LeadCare®: The easiest way to test for lead
LeadCare® is a blood lead test platform that provides a stand-alone system and features the only CLIA waived system to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Pediatric & Neonatal Human Conditions
## Support & Documents
- [ Please visit www.LeadCare2.com to learn more about our lead testing products. ](https://www.leadcare2.com/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Blood Chemistry
---
### [BreathID® Smart VS07000 (EU)](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-smart-eu/)
**Published:** June 30, 2026
**Author:** Hamza Shahzad
**Content:**
# BreathID® Smart
The BreathID® Smart urea breath testing platform detects *H. pylori* and confirms eradication for healthcare providers with mid-range patient testing volumes.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Unmatched Accuracy in *H. pylori* Detection
The state-of-the-art BreathID® Smart urea breath test platform for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with efficient automation for maximizing mid-range testing throughput. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
- Group 13Created with Sketch. Unparalleled Diagnostic Performance (If used with 75mg C13-urea + 4g citric acid)
100% Sensitivity
97.9% Specificity
- sample\_result\_icon Intuitive Efficiency
Automated data input and batch analysis to reduce human error and simplify reporting
- assay\_flexibility\_icon Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
### Automated Efficiency.
##### BreathID® Smart
## Tests
Gastrointestinal
[ BreathID® Smart - IDkit Hp® Two (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-eu/) Available in: NZ, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Definitive answers, confidence in results
[ Contact Sales ](/contact-us-diagnostics/)
## Support & Documents
##### Downloadable PDFs
-  [Platform Brochure BreathID Smart](/uploads/MBE091e_BreathID_Smart_Platform_Brochure_EU_Rev052026_EN.pdf)
-  [Platform Brochure BreathID Smart – Italian](/uploads/MTD00358-IT%20MBI_BreathID_Smart_Platform_Brochure_EU_2025-10_Digital_IT.pdf)
-  [Platform Brochure BreathID Smart – Spanish](/uploads/MBI_BreathID_Smart_Platform_Brochure%20MTD00358-ES%20Rev%2003.02.pdf)
-  [Procedure card BID smart English](/uploads/vs07000_pc.pdf)
-  [Procedura Del Test BreathID Smart - Italian](/uploads/vs07000_pc_it.pdf)
-  [Procedimiento BreathID Smart Spanish](/uploads/vs07000_pc_es.pdf)
-  [Calibration Procedure Card BreathID Smart](/uploads/vs07000_cpc.pdf)
-  [Calibration Procedure Card BreathID Smart – Italian](/uploads/MLD01059-IT%20Rev%201%20Smart%20SystemTest_Calibration%20Check%20Procedure%20Card%20Italian.pdf)
##### Webinars & Videos
- [ UBT Versus Serology ](https://youtu.be/B-8kZGgWLF8?si=pgg9SIWGUqP4IBi2)
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Urea Breath
---
### [BreathID® Smart VS07000W](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-smart/)
**Published:** June 2, 2025
**Author:** hamza
**Content:**
# BreathID® Smart
The BreathID® Smart urea breath testing platform detects *H. pylori* and confirms eradication for healthcare providers with mid-range patient testing volumes.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Unmatched Accuracy in *H. pylori* Detection
The state-of-the-art BreathID® Smart urea breath test platform for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with efficient automation for maximizing mid-range testing throughput. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
- Group 13Created with Sketch. Unparalleled Diagnostic Performance
100% Sensitivity
97.9% Specificity
- sample\_result\_icon Intuitive Efficiency
Automated data input and batch analysis to reduce human error and simplify reporting
- assay\_flexibility\_icon Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
### Automated Efficiency.
##### BreathID® Smart
## Tests
Gastrointestinal
[ BreathID® Smart - IDkit Hp® Two ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/) Available in: US, CA Detecting...
## Definitive answers, confidence in results
[ Contact Sales ](/contact-us-diagnostics/)
## Support & Documents
##### Downloadable PDFs
-  [Platform Brochure BreathID Smart](/uploads/BreathID-Smart-Platform-Brochure.pdf)
-  [Procedure Card BreathID Smart](/uploads/vs07000_pc.pdf)
-  [Calibration Procedure Card BreathID Smart](/uploads/vs07000_cpc.pdf)
-  [Procedimiento BreathID Smart](/uploads/vs07000_pc_es.pdf)
-  [Procedura Del Test BreathID Smart](/uploads/vs07000_pc_it.pdf)
##### Webinars & Videos
- [ UBT Versus Serology ](https://youtu.be/B-8kZGgWLF8?si=pgg9SIWGUqP4IBi2)
##### FAQs
What is the suggested CPT code?
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Urea Breath
---
### [Revogene](https://www.meridianbioscience.com/diagnostics/platforms/molecular/revogene/)
**Published:** May 30, 2025
**Author:** hamza
**Content:**
# Revogene®
Revogene® is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. It’s a flexible platform that is built to grow with you.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Introducing Revogene
Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. It’s a flexible platform that is built to grow with you.
- sample\_result\_icon Automated, streamlined workflow with minimal steps
- Group 12Created with Sketch. Time-Saving, Walk-Away Efficiencies with so little hands-on-time
- expansion\_icon Flexible platform
#### It’s minimal hands-on-time with Revogene. Samples in and walk away.
##### Minimal workflow. Minimal hands-on time.
## Tests
Healthcare Acquired Infections
[ Revogene® C. difficile ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/revogene-c-difficile/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Revogene® Carba C ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/carba/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Revogene Mock PIE ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-mock-pie/) Available in: AU, BR, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Revogene® Check ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/revogene-check/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Revogene® GBS DS ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-ds/) Available in: AU, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Pediatric & Neonatal
[ Revogene® GBS LB ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/revogene-gbs-lb/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Respiratory
[ Revogene® SARS-CoV-2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/revogene-sars-cov-2/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
[ Revogene® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/revogene-strep-a/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## What disease area do you need to test for?
Revogene is a flexible molecular diagnostic solution with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
[ ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/)
[ Gastrointestinal Human Conditions ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/)
Healthcare Acquired Infections
- [C. difficile](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/)
- [C. difficile](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/)
[ ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/)
[ Pediatric & Neonatal Human Conditions ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/)
Pediatric & Neonatal
- [Group B Strep](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/)
- [Group B Strep](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/)
[ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/)
[ Respiratory Human Conditions ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/)
Respiratory
- [Coronavirus (COVID-19)](/diagnostics/disease-areas/respiratory/coronavirus/)
- [Group A Streptococcus](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
- [Coronavirus (COVID-19)](/diagnostics/disease-areas/respiratory/coronavirus/)
- [Group A Streptococcus](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
[ ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/)
[ Other Human Conditions ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/)
Healthcare Acquired Infections
- [Carbapenem-resistant Enterobacteriaceae (CRE)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/)
- [Carbapenem-resistant Enterobacteriaceae (CRE)](https://www.meridianbioscience.com/diagnostics/disease-areas/other/cre/)
## Support & Documents
##### Downloadable PDFs
-  [Revogene Reference Guide Procedure Card](/uploads/610210_pi.pdf)
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Molecular
---
### [BreathID® Hp](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathid-hp/)
**Published:** June 2, 2025
**Author:** hamza
**Content:**
# BreathID® Hp
Effective immediately, the BreathID® Hp instrument is discontinued. The purchase of kits and consumables will continue to be available including technical support for current instruments in use.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## BreathID® Hp: Leading *H. pylori* Detection Solutions
The state-of-the-art BreathID® Hp urea breath test system for *H. pylori* detection intuitively combines market-leading diagnostic accuracy with real-time results and convenient follow-up testing in a clinic or point-of-care setting. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics.
- Group 19 Created with Sketch.
Unparalleled Diagnostic Performance
100% Sensitivity
99.2% Specificity
- Group 13 Created with Sketch.
Intuitive Efficiency
Real-time results enable providers to test and treat at the point of care
- sample\_result\_icon
Trusted Partner
Meridian offers additional *H. pylori* platforms for a total testing solution
- Unparalleled Diagnostic Performance 100% Sensitivity 99.2% Specificity
- Group 12Created with Sketch. Intuitive Efficiency Real-time results enable providers to test and treat at the point of care
- expansion\_icon Trusted Partner Meridian offers additional *H. pylori* platforms for a total testing solution
### In-office BreathID® Hp
##### Quickly and easily perform UBT right in your office or clinic.
## Tests
Gastrointestinal
[ IDkit Hp® One ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-one/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
## Definitive answers, confidence in results
[ Contact Sales ](/contact-us-diagnostics/)
## Support & Documents
##### Downloadable PDFs
-  [Platform Brochure BreathID Hp (POC)](/uploads/BreathID-Hp-POC-Platform-Brochure.pdf)
-  [Evaluation of BreathID Hp 2015](/uploads/Evaluation-of-Exalenz-breathID.pdf)
##### FAQs
What is the suggested CPT code?
*H. pylori* urea breath test analysis — 83013
*H. pylori* urea breath test collection — 83014
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Urea Breath
---
### [Simple Strep pneumo-Legio](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/simple-strep-pneumo-legio/)
**Published:** November 10, 2025
**Author:** hamza
**Content:**
# Simple Strep pneumo-Legio
Operon Simple Strep pneumo-Legio is a one-step immunochromatographic qualitative test for the detection of Streptococcus pneumoniae and Legionella pneumophila serogroup 1 antigens in human urine.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Related Tests
Respiratory
[ Operon Lateral Flow Reader ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/operon-lateral-flow-reader/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, EU Detecting...
[ Positive Control Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/positive-control-strep-pneumo-legio/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, EU Detecting...
[ Simple Strep pneumo-Legio ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/simple-strep-pneumo-legio/) Available in: EU Detecting...
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Alethia](https://www.meridianbioscience.com/diagnostics/platforms/molecular/alethia/)
**Published:** June 2, 2025
**Author:** hamza
**Content:**
# Alethia®
Alethia is an affordable LAMP (loop-mediated isothermal amplification) based molecular platform that can generate between 1 and 10 qualitative results in less than 1 hour. Alethia’s flexibility makes it adaptable to almost any workflow.
[ Contact Sales ](/contact-us-diagnostics/)
## Alethia Test Menu
Alethia’s LAMP technology provides powerful accuracy for physicians and a reliable workflow for laboratories. Alethia produces results in less than one hour to quickly respond to ER requests and can simultaneously process both batch and STAT requests.
- sample\_result\_icon Fast
- Group 12Created with Sketch. Accurate
- expansion\_icon Reliable
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Healthcare Acquired Infections
[ Alethia® *C. difficile* ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Alethia CMV External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/alethia-cmv-external-controls/) Available in: BR, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® C. difficile External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/alethia-c-difficile/alethia-c-difficile-external-controls/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Group A Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/alethia-group-a-streptococcus-external-control-kit/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Group B Streptococcus External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/alethia-group-b-streptococcus-external-controls/) Available in: BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® HSV 1&2 External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/alethia-hsv-12-external-controls/) Available in: BR, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Malaria External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/alethia-malaria-external-controls/) Available in: AU, BR, CA, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Mycoplasma Direct External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/alethia-mycoplasma-direct-package-insert-external-controls/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Pertussis External Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/alethia-pertussis-external-control-kit/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ M-prep ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/alethia-mprep/) Available in: BR, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ MSwab® for Meridian Bioscience Europe ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/mswab-for-meridian-bioscience-europe/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, EU Detecting...
Pediatric & Neonatal
[ Alethia® Group B Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/alethia-group-b-streptococcus/) Available in: BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® CMV ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/cmv/alethia-cmv/) Available in: BR, US, CA, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Respiratory
[ Alethia® Group A Streptococcus ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/alethia-group-a-streptococcus/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Mycoplasma Direct ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Pertussis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pertussis/alethia-pertussis/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Sexual Health
[ Alethia® HSV 1 & 2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/hsv-12/alethia-hsv-12/) Available in: BR, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/alethia-chlamydia/) Available in: BR, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Alethia® Gonorrhea ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/gonorrhea/alethia-gonnorrhea/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Tropical Diseases
[ Alethia® Malaria ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/malaria/alethia-malaria/) Available in: AU, BR, CA, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Alethia Diagnostic Platform
Alethia® is an affordable LAMP (loop-mediated isothermal amplification) based molecular platform with a simple to use instrument that can generate between 1 and 10 qualitative results in less than 1 hour. Alethia’s flexibility makes it adaptable to almost any workflow.
Gastrointestinal Human Conditions Healthcare Acquired Infections
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
Pediatric & Neonatal Human Conditions Pediatric & Neonatal
- [CMV](/diagnostics/disease-areas/pediatric-neonatal/cmv/)
- [Group B Strep](/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/)
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
- [CMV](/diagnostics/disease-areas/pediatric-neonatal/cmv/)
- [Group B Strep](/diagnostics/disease-areas/pediatric-neonatal/group-b-strep/)
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
Respiratory Human Conditions Respiratory
- [Mycoplasma](/diagnostics/disease-areas/respiratory/mycoplasma/)
- [Pertussis](/diagnostics/disease-areas/respiratory/pertussis/)
- [Group A Streptococcus](/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
- [Mycoplasma](/diagnostics/disease-areas/respiratory/mycoplasma/)
- [Pertussis](/diagnostics/disease-areas/respiratory/pertussis/)
- [Group A Streptococcus](/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
Other Human Conditions Sexual Health
- [Chlamydia](/diagnostics/disease-areas/other/chlamydia/)
- [Gonorrhea](/diagnostics/disease-areas/other/gonorrhea/)
- [HSV 1&2](/diagnostics/disease-areas/other/hsv-12/)
- [Chlamydia](/diagnostics/disease-areas/other/chlamydia/)
- [Gonorrhea](/diagnostics/disease-areas/other/gonorrhea/)
- [HSV 1&2](/diagnostics/disease-areas/other/hsv-12/)
Tropical Diseases
- [Malaria](/diagnostics/disease-areas/other/malaria/)
- [Malaria](/diagnostics/disease-areas/other/malaria/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Molecular
---
### [Tru](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/tru/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Tru®
Tru® is a rapid, easy to run vertical flow immunoassay with a unique closed system feature to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. See how Meridian’s TRU can produce results for your lab in 15-20 minutes.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Respiratory
[ RSV Positive Control ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/flu-rsv-positive-control/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ TRU Legionella® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/legionella/tru-legionella/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ TRU RSV® ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/rsv/tru-rsv/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ TRU Strep Pneumo™ ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/strep-pneumo/tru-strep-pneumo/) Not available in: US, BR, CA, JP, AU, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Tru® Vertical Flow Rapid Tests
Tru® is a rapid, easy to run vertical flow immunoassay with a unique closed system feature to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Results in 15-20 minutes.
Respiratory Human Conditions Respiratory
- [Strep Pneumo](/diagnostics/disease-areas/respiratory/strep-pneumo/)
- [Respiratory Syncytial Virus (RSV)](/diagnostics/disease-areas/respiratory/rsv/)
- [Legionella](/diagnostics/disease-areas/respiratory/legionella/)
- [Strep Pneumo](/diagnostics/disease-areas/respiratory/strep-pneumo/)
- [Respiratory Syncytial Virus (RSV)](/diagnostics/disease-areas/respiratory/rsv/)
- [Legionella](/diagnostics/disease-areas/respiratory/legionella/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Merifluor](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/merifluor/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Merifluor®
Merifluor is a direct fluorescent technology that is simple to perform and can help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Parasitology
[ Merifluor® C/G Treated Microscope Slides ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-c-g-treated-microscope-slides/) Available in: AU, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Merifluor® Cryptosporidium/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/merifluor-cryptosporidium-giardia/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Respiratory
[ Merifluor® Pneumocystis ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/pneumocystis/merifluor-pneumocystis/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Sexual Health
[ Merifluor® Chlamydia ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/chlamydia/merifluor-chlamydia/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
[ Merifluor® VZV ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/vzv/merifluor-vzv/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Efficient Fluorescent Testing with Merifluor
Merifluor is a direct fluorescent technology that is simple to perform and can help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Gastrointestinal Human Conditions Parasitology
- [Cryptosporidium/Giardia](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/)
- [Cryptosporidium/Giardia](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/)
Respiratory Human Conditions Respiratory
- [Pneumocystis](/diagnostics/disease-areas/respiratory/pneumocystis/)
- [Pneumocystis](/diagnostics/disease-areas/respiratory/pneumocystis/)
Other Human Conditions Sexual Health
- [VZV](/diagnostics/disease-areas/other/vzv/)
- [VZV](/diagnostics/disease-areas/other/vzv/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Immunocard STAT®](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunocard-stat/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Immunocard STAT®
Immunocard STAT! is a one-step lateral flow immunoassay to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Several of these tests are CLIA waived. Join us as you increase your lab’s efficiencies with trusted results from Immunocard Stat.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Immunocard STAT Test Menu
Immunocard STAT!® can help labs of any size function at their best. With Immunocard STAT! your core lab, hospital lab, reference lab, or physician’s office lab can run more efficiently and deliver accurate results to clinicians and patients. Deliver results in 5-15 minutes.
- Group 12 Created with Sketch.
Rapid
- Group 13 Created with Sketch.
Accurate
- Group 19 Created with Sketch.
Reliable
## Tests
Gastrointestinal
[ Immunocard STAT!® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-ehec/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® E. coli O157 Plus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/immunocard-stat-e-coli-o157-plus/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® HpSA® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ ImmunoCard STAT!® HpSA® (EU) ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-stat-hpsa-eu/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, EU Detecting...
[ Immunocard STAT!® Rotavirus ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/immunocard-stat-rotavirus/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Healthcare Acquired Infections
[ Immunocard STAT!® C. difficile GDH-AB ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh-2/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Immunocard STAT!® C. difficile GDH AB External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/immunocard-stat-c-difficile-gdh-ab-external-control-set/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/immunocard-stat-campy/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® CGE ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-cge/) Available in: AU, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® HpSA® HD ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/immunocard-stat-hpsa-hd/) Available in: GB, EU Detecting...
[ Immunocard STAT!® Rota-Adeno-Noro2 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® Rota-Adeno-Noro2 External Control Set ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/immunocard-stat-rota-adeno-noro2-external-control-set/) Available in: AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Parasitology
[ Immunocard STAT!® Crypto/Giardia ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard STAT!® Crypto/Giardia Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/immunocard-stat-crypto-giardia-controls/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Pediatric & Neonatal
[ Immunocard STAT!® Mono ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/immunocard-stat-mono/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Respiratory
[ Immunocard STAT!® Flu A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
[ Immunocard STAT!® Flu A&B Nasopharyngeal Wash/Aspirate Accessory Kit ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/flu/immunocard-stat-flu-ab-nasopharyngeal-wash-aspirate-accessory-kit/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
[ Immunocard STAT!® Strep A ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/group-a-streptococcus/immunocard-stat-strep-a/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Sexual Health
[ Immunocard STAT!® hCG ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/immunocard-stat-hcg/) Available in: US Detecting...
[ OSOM hCG Combo Test ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/pregnancy/osom-hcg-combo-test/) Available in: US Detecting...
## Immunocard STAT!® Rapid Tests
Immunocard STAT!® is a one-step lateral flow immunoassay to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Several of these tests are CLIA waived.
Gastrointestinal Human Conditions Gastrointestinal
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [Rotavirus](/diagnostics/disease-areas/gastrointestinal/rotavirus/)
- [E. coli](/diagnostics/disease-areas/gastrointestinal/e-coli/)
- [Rotavirus/Adenovirus/Norovirus](/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/)
- [Campylobacter](/diagnostics/disease-areas/gastrointestinal/campylobacter/)
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [Rotavirus](/diagnostics/disease-areas/gastrointestinal/rotavirus/)
- [E. coli](/diagnostics/disease-areas/gastrointestinal/e-coli/)
- [Rotavirus/Adenovirus/Norovirus](/diagnostics/disease-areas/gastrointestinal/rotavirus-adenovirus-norovirus/)
- [Campylobacter](/diagnostics/disease-areas/gastrointestinal/campylobacter/)
Healthcare Acquired Infections
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
Parasitology
- [Cryptosporidium/Giardia](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/)
- [Cryptosporidium/Giardia](/diagnostics/disease-areas/gastrointestinal/cryptosporidium-giardia/)
Pediatric & Neonatal Human Conditions Pediatric & Neonatal
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
Respiratory Human Conditions Respiratory
- [Group A Streptococcus](/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
- [Flu](/diagnostics/disease-areas/respiratory/flu/)
- [Group A Streptococcus](/diagnostics/disease-areas/respiratory/group-a-streptococcus/)
- [Flu](/diagnostics/disease-areas/respiratory/flu/)
Other Human Conditions Sexual Health
- [Pregnancy](/diagnostics/disease-areas/other/pregnancy/)
- [Pregnancy](/diagnostics/disease-areas/other/pregnancy/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [BÜHLMANN](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/buhlmann/)
**Published:** June 4, 2025
**Author:** hamza
**Content:**
# BÜHLMANN
BÜHLMANN has launched its first assay for fecal calprotectin testing more than 10 years ago and is today considered as the gold standard. Learn more about the BÜHLMANN fCAL ELISA test for the quantitative determination of fecal calprotectin.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## BÜHLMANN
BÜHLMANN has launched its first assay for fecal calprotectin testing more than 10 years ago and is today considered as the gold standard.
## Why BÜHLMANN fCAL®
- sample\_result\_icon Rapid
- Group 12Created with Sketch. Reliable
- expansion\_icon Accurate
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Breathtek](https://www.meridianbioscience.com/diagnostics/platforms/urea-breath/breathtek/)
**Published:** August 1, 2025
**Author:** hamza
**Content:**
# BreathTek®
**Effective May 1, 2023, the BreathTek® product is discontinued. The supply of bags and replacement parts are only available while supplies last**
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
Get started with BreathID for H. pylori testing today
[](/diagnostics/disease-areas/gastrointestinal/h-pylori/breathtek-ubt-for-h-pylori/)### BreathTek® UBT for H. pylori
Effective July 1, 2024, the BreathTek® product line is discontinued. The supply of bags and replacement products will no longer be available.
Learn More
[](/diagnostics/disease-areas/gastrointestinal/h-pylori/idkit-hp-two-2/)### BreathID® Smart - IDkit Hp
A non-invasive urea breath test for the detection of H. pylori and confirmation of eradication.
Learn More
## Definitive answers, confidence in results
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Urea Breath
---
### [Immunodiffusion](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunodiffusion/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Immunodiffusion
Immunodiffusion & Complement Fixation products, including aspergillus, histoplasma, Coccidioides, and Endo-Staph to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Other
[ Anti-Coccidioides "TP" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Anti-Histoplasma Control Serum (Goat) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-histoplasma-control-serum-goat-for-fungal-immunodiffusion/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (1 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-tp-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion-401/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Coccidioides "F" Antigen for Fungal Immunodiffusion (5 ml) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-f-antigen-for-fungal-immunodiffusion-405/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Coccidioides "TP" Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/coccidioides-tp-antigen-for-fungal-immunodiffusion/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Fungal Immunodiffusion Plates, 1 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-1-series/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Fungal Immunodiffusion Plates, 4 Series ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/fungal-immunodiffusion-plates-4-series/) Available in: AU, US, CA, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Histoplasma Antigen for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/histoplasma-antigen-for-fungal-immunodiffusion/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Anti-Coccidioides "F" Control Serum (Goat or Human or Rabbit) for Fungal Immunodiffusion ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/anti-coccidioides-f-control-serum-goat-or-human-or-rabbing-for-fungal-immunodiffusion/) Available in: AU, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Immunodiffusion Testing
Immunodiffusion & Complement Fixation products, including aspergillus, histoplasma, Coccidioides, and Endo-Staph to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Other Human Conditions Other
- [Fungals](/diagnostics/disease-areas/other/fungals/)
- [Fungals](/diagnostics/disease-areas/other/fungals/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Latex Agglutination](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/latex/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Latex Agglutination
Latex agglutination is a rapid latex test technology with qualitative and semi-quantitative detection to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Other
[ CALAS® Pronase ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/calas-pronase/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Cryptococcal Antigen Latex Agglutination System (CALAS®) ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/cryptococcal-antigen-latex-agglutination-system/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Pediatric & Neonatal
[ Monospot® Latex ](https://www.meridianbioscience.com/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/monospot-latex/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Latex Agglutination Tests
Latex agglutination is a rapid latex test technology with qualitative and semi-quantitative detection to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently.
Pediatric & Neonatal Human Conditions Pediatric & Neonatal
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
- [Mononucleosis](/diagnostics/disease-areas/pediatric-neonatal/mononucleosis/)
Other Human Conditions Other
- [Fungals](/diagnostics/disease-areas/other/fungals/)
- [Fungals](/diagnostics/disease-areas/other/fungals/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Premier®](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/premier/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Premier®
Premier is a multi-step microwell based enzyme immunoassay with detachable microwells to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Learn more about Premier immunoassays from Meridian.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Gastrointestinal
[ Premier® Adenoclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® Adenoclone® 40/41 ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/adenovirus/premier-adenoclone-40-41/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® CAMPY ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/campylobacter/premier-campy/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® EHEC ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/e-coli/premier-ehec/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® Platinum HpSA® PLUS ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-platinum-hpsa-plus/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® Rotaclone® ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/rotavirus/premier-rotaclone/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Healthcare Acquired Infections
[ Premier® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-c-difficile-gdh/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/premier-toxins-ab/) Available in: AU, BR, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Premier® Coccidioides ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-coccidioides/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® Cryptococcal Antigen ](https://www.meridianbioscience.com/diagnostics/disease-areas/other/fungals/premier-cryptococcal-antigen/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Other
[ Premier® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/premier-h-pylori/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Premier® HpSA® Flex ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/premier-hpsa-flex/) Available in: US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW Detecting...
## Premier Microwell Testing
Premier® is a multi-step microwell based enzyme immunoassay with detachable microwells to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently. Results in 60-90 minutes.
###
Gastrointestinal Human Conditions Gastrointestinal
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [Rotavirus](/diagnostics/disease-areas/gastrointestinal/rotavirus/)
- [E. coli](/diagnostics/disease-areas/gastrointestinal/e-coli/)
- [Adenovirus](/diagnostics/disease-areas/gastrointestinal/adenovirus/)
- [Campylobacter](/diagnostics/disease-areas/gastrointestinal/campylobacter/)
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [Rotavirus](/diagnostics/disease-areas/gastrointestinal/rotavirus/)
- [E. coli](/diagnostics/disease-areas/gastrointestinal/e-coli/)
- [Adenovirus](/diagnostics/disease-areas/gastrointestinal/adenovirus/)
- [Campylobacter](/diagnostics/disease-areas/gastrointestinal/campylobacter/)
Healthcare Acquired Infections
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
Other Human Conditions Other
- [Fungals](/diagnostics/disease-areas/other/fungals/)
- [Fungals](/diagnostics/disease-areas/other/fungals/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Immunocard](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/immunocard/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Immunocard®
Immunocard can help labs of any size function at their best. With Immunocard your core lab, hospital lab, or reference lab can run more efficiently and deliver accurate results to clinicians and patients. Learn how Immunocard can deliver results in 15-20 minutes.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Immunocard Test Menu
Immunocard® can help labs of any size function at their best. With Immunocard your core lab, hospital lab, or reference lab can run more efficiently and deliver accurate results to clinicians and patients. Deliver results in 15-20 minutes.
- sample\_result\_icon Rapid
- Group 12Created with Sketch. Accurate
- expansion\_icon Reliable
## Tests
Gastrointestinal
[ Immunocard® H. pylori ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/h-pylori/immunocard-h-pylori/) Available in: CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Healthcare Acquired Infections
[ Immunocard® C. difficile GDH ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-c-difficile-gdh/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
[ Immunocard® Toxins A&B ](https://www.meridianbioscience.com/diagnostics/disease-areas/gastrointestinal/c-difficile/immunocard-toxins-ab/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
Respiratory
[ Immunocard® Mycoplasma ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/immunocard-mycoplasma/) Available in: AU, CA, US, AD, AF, AL, DZ, AO, AG, AR, AM, AZ, BS, BH, BD, BB, BY, BZ, BJ, BT, BO, BA, BW, BN, BF, BI, CV, KH, CM, CF, TD, CL, CN, CO, KM, CG, CD, CR, CU, DJ, DM, DO, EC, EG, SV, GQ, ER, ET, FJ, GA, GM, GE, GH, GD, GT, GN, GW, GY, HT, VA, HN, IS, IN, ID, IR, IQ, IL, JM, JO, KZ, KE, KI, KP, KR, KW, KG, XK, LB, LS, LR, LY, LI, MG, MW, MY, MV, ML, MH, MR, MU, MX, FM, MD, MC, MN, ME, MA, MZ, MM, NA, NR, NP, NZ, NI, NE, NG, NO, OM, PK, PW, PS, PA, PG, PY, PE, PH, QA, RU, RW, KN, LC, VC, WS, SM, ST, SA, SN, RS, SC, SL, SG, SB, SO, ZA, SS, LK, SD, SR, SY, TW, TJ, TZ, TH, TL, TG, TO, TT, TN, TR, TM, TV, UG, UA, AE, UY, UZ, VU, VE, VN, YE, ZM, ZW, GB, EU Detecting...
## Immunocard
Immunocard® is a rapid, multi-step membrane immunoassay to help your core lab, hospital lab, reference lab, or physician’s office lab run more efficiently
Gastrointestinal Human Conditions Gastrointestinal
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
- [H. pylori](/diagnostics/disease-areas/gastrointestinal/h-pylori/)
Healthcare Acquired Infections
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
- [C. difficile](/diagnostics/disease-areas/gastrointestinal/c-difficile/)
Respiratory Human Conditions Respiratory
- [Mycoplasma](/diagnostics/disease-areas/respiratory/mycoplasma/)
- [Mycoplasma](/diagnostics/disease-areas/respiratory/mycoplasma/)
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Standard Q](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/standard-q/)
**Published:** June 3, 2025
**Author:** hamza
**Content:**
# Standard Q
Standard Q can be used as an aid in the diagnosis of COVID-19 infection.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Tests
Respiratory
[ Standard™ Q COVID-19 Ag Test 2.0 ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-ag-test-2-0/) Available in: US Detecting...
[ Standard™ Q COVID-19 Ag Test 2.0 Controls ](https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/coronavirus/standard-q-covid-19-controls/) Available in: US Detecting...
## Pricing
To order, contact your regional sales representative or use the following contact information:
- **Email:**
- **Phone:** [+1 800 696-0739](tel:+18006960739)
- **International Sales Extension:** [+1 513 271-3000](tel:+15132713000)
[ Contact Sales ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Quantum Blue](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/quantum-blue/)
**Published:** August 1, 2025
**Author:** hamza
**Content:**
# Quantum Blue®
Quantum Blue®
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## Quantum Blue
Quantum Blue® Calprotectin is a rapid, sensitive and non-invasive test that provides a valid aid in the diagnosis of chronic inflammatory bowel diseases (MICI).
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
### [Serology](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/serology/)
**Published:** June 4, 2025
**Author:** hamza
**Content:**
# Serology
Unveiling Insights Through Serology: Dive into Meridian Bioscience’s Serology solutions. With our advanced technology, we uncover a deeper understanding of immune responses, aiding in the diagnosis of various conditions. Join us in shaping a healthier future through precise and reliable serological testing.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
**Solutions:** Immunoassay
---
### [LIAISON](https://www.meridianbioscience.com/diagnostics/platforms/immunoassay/liaison/)
**Published:** June 4, 2025
**Author:** hamza
**Content:**
# LIAISON
A chemiluminescent assay for the qualitative determination of Helicobacter pylori antigen in human stool. Test must be performed on the LIAISON® XL Analyzer.
[ Contact Sales ](/contact-us-diagnostics/)
- [ Product Details ](#product-info)
- [ Tests ](#tests)
- [ Disease Areas ](#disease-area)
- [ Support and Documents ](#support-documents)
- [ Pricing ](#pricing)
## LIAISON
A chemiluminescent assay for the qualitative determination of Helicobacter pylori antigen in human stool. Test must be performed on the LIAISON® XL Analyzer.
## Get in Touch With Us
[ Contact Us ](/contact-us-diagnostics/)
**Solutions:** Immunoassay
---
## Product Landing Pages
### [Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
**Published:** April 25, 2025
**Author:** hamza
**Content:**
# Taq DNA Polymerase
Taq DNA Polymerase is a combination of next-generation DNA polymerase and a novel buffer system that has been designed to deliver very high yield, fast PCR amplification over a wide range of PCR templates. It has been developed to give very robust amplification, allowing it to perform well with most PCR testing, including challenging templates and in the presence of PCR inhibitors.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Taq DNA Polymerase
- Fast DNA polymerase, delivers high yield even with limiting amounts of template
- Robust PCR amplification in the presence of inhibitors and with even the most challenging targets
- Novel optimized buffer system maximizes efficiency of PCR amplification, eliminate the need for long optimization, saving time, effort, and cost
- Developed to give sensitive, reproducible, robust amplification with very fast PCR cycling conditions
## Robust PCR amplification of GC-rich human genomic DNA
A serial dilution in duplicate of human genomic DNA (1 μg, 200 ng, 100 ng, 50 ng, 25 ng and 12.5 ng, 1-6 respectively) was used with primers and Taq DNA Polymerase to amplify a 450 bp fragment of the human myc gene. The section of gene used has 61% GC content and was selected to demonstrate the high yield and sensitivity of the Taq DNA Polymerase, making it the perfect choice for the amplification of complex PCR templates.
### Taq DNA Polymerase, MDX001
**Application:** PCR**Specimen Type:** DNA Polymerase**Concentration:** 5 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Very high yield, high-performance polymerase, to give fast, superior amplification, even with challenging templates and in the presence of PCR inhibitors.
Available in 0.5 mL (500 Units) or 10 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX001-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX001-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX001.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX001)
## Description
Taq DNA Polymerase is provided with an optimized buffer system containing dNTP, MgCl2, stabilizers, and PCR enhancers at optimal concentrations which eliminates the need for optimization. The DNA polymerase has been developed to give more robust amplification than other polymerases allowing it to perform well with challenging templates in the presence of PCR inhibitors, making it ideal for fast PCR reactions across a range of templates, without compromising specificity or yield.
## Specifications
DescriptionVery high-performance polymerase, supplied with an optimized, novel buffer system, containing dNTPs, MgCl2 and enhancers, to give superior amplification.Concentration5 U/µLAppearanceClear, colorless solutionHot StartNoneApplicationPCR, qPCRSample typecDNA, DNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionalityPCR with a dilution series of human genomic DNA, single, distinct band was observedDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[Taq HS Antibody](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-antibody/)
## FAQs: Taq HS DNA Polymerase
If my PCR testing is being impeded by too many PCR inhibitors, what can I do for optimization?
Decreasing the template concentration will help to minimize the concentration of inhibitors, the amount of DNA polymerase and primer can also be increased. In some cases you may also have to add a pre-treatment step if the DNA is not accessible.
What do the terms yield, fidelity, processivity and specificity actually mean?
These terms refer to parameters to be considered when performing PCR testing.
Yield: The amount of DNA produced in a PCR reaction. High yield increases sensitivity.
Fidelity: The accuracy of the enzyme at incorporating the correct dNTP to the elongating DNA strand. For standard PCR this is not important, but for sequencing or expression a high-fidelity mix (such as High-Specificity Pfu HS Mix (MDX006)) may be required.
Processivity: The length of time a polymerase is associated with the template and therefore the size of fragment which can be amplified (the amplicon). Taq HS DNA Polymerase will work with amplicons up to 5 kb.
Specificity: A measure of the unwanted by-products generated in a reaction. This is the reason for having hot start PCR, this prevents miss-priming at low temperatures and non-specific amplification
What applications can Taq DNA Polymerase be used for?
Taq DNA Polymerase has been validated with a broad range of PCR templates including DNA extracted from human, animal and plant samples, making it the ideal choice for the following applications:
• End-point PCR testing
• High-yield PCR testing
• Fast PCR testing
• Multiplex PCR testing
• qPCR and RT-qPCR testing
Can Taq DNA Polymerase be used for qPCR?
Yes, Taq DNA Polymerase can be used for quantitative PCR amplification (qPCR), but it will require a hot-start antibody (MDX014), qPCR buffer such as Fast qPCR Buffer, 4x (MDX033), or for RT-qPCR, a one-step buffer such as 1-Step qPCR Buffer, 4x (MDX034) and reverse transcriptase such as MMLV-RT (MDX044).
How fast is Taq DNA Polymerase?
This depends on the length of the amplicon and the complexity of the template. For fast PCR, the initial denaturation will remain 1 minute, but with low complexity template such as plasmid DNA, an annealing of 5 seconds and extension time of 10 seconds is sufficient for amplicons up to 1 kb. In order to find the fastest optimal condition, for more complex or longer amplicons, we suggest incrementally increasing the extension time successively up to 30 s/kb.
Can Taq Polymerase be used for difficult samples like GC rich or bisulfite converted DNA?
Yes, Taq DNA Polymerase works very well with difficult samples like GC rich or bisulfite converted DNA. However a hot-start to the PCR (such as MDX014) is important, as it decreases primer dimer and unspecific amplification.
If optimization is required, we would suggest starting with the annealing temperature and with bisulfite conversion, the process can fragment the DNA, so it may be useful to increase the amount of template and polymerase.
What is the error rate of Taq DNA Polymerase?
The enzyme has an error rate of approximately 1 error per 2.0 x 10⁵ nucleotides incorporated. If you are looking for a DNA polymerase with a lower error rate, for next-generation sequencing (NGS) library or expression a high-fidelity DNA polymerase (such as High-Fidelity Pfu (MDX003)) or mix (such as High-Specificity Pfu HS Mix (MDX006)) should be used.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
**Published:** April 25, 2025
**Author:** hamza
**Content:**
# Taq PCR Buffer, 5x
Taq PCR Buffer, 5x is a novel buffer system that has been designed to be combined with a high quality Taq DNA polymerase such as MDX001 or MDX008, to deliver very high yield PCR amplification over a wide range of PCR templates and has been developed to give very robust amplification allowing it to perform well with challenging templates in the presence of PCR inhibitors.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Taq PCR Buffer, 5x
- Delivers high yield PCR amplification even with limiting amounts of template
- Robust PCR amplification in the presence of inhibitors
- Optimized to maximize PCR amplification, eliminating the need for long optimization, saving time, effort, and cost
- Developed to give sensitive, reproducible, robust amplification with very fast PCR cycling conditions
## Robust PCR amplification of GC-rich human genomic DNA
A serial dilution in duplicate of human genomic DNA (1 μg, 200 ng, 100 ng, 50 ng, 25 ng and 12.5 ng, 1-6 respectively) was used with primers and Taq DNA Polymerase to amplify a 450 bp fragment of the human myc gene. The section of gene used has 61% GC content and was selected to demonstrate the high yield and sensitivity of the Taq DNA Polymerase, making it the perfect choice for the amplification of complex PCR templates.
### Taq PCR Buffer, 5x, MDX002
**Application:** PCR**Specimen Type:** Buffer**Concentration:** 5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
An optimized, novel buffer system, containing dNTPs, MgCl2 and enhancers, to give superior amplification, making it the perfect choice for complex templates.
Available in 2 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX002-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX002-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX002.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX002)
## Description
Taq PCR Buffer is a combination of the latest advances in buffer chemistry together with enhancers, stabilizers, dNTPs, and MgCl2 at optimal concentrations. Taq PCR Buffer has been designed for superior fast amplification across a range of templates.
## Specifications
DescriptionAn optimized, novel buffer system, containing dNTPs, MgCl2 and enhancers, to give superior amplification, making it the perfect choice for complex templates.Concentration5xAppearanceClear, colorless solutionApplicationPCR, qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelFunctionalityPCR with a dilution series of human genomic DNA, single, distinct band was observedDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Taq HS Antibody](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-antibody/)
## FAQs: Taq DNA Buffer
What applications can Taq DNA Buffer be used for?
Taq DNA Buffer has been validated for use with a broad range of PCR templates including DNA extracted from human, animal and plant samples, making it the ideal choice for the following applications:
• End-point PCR testing
• High-yield PCR testing
• Fast PCR testing
• Multiplex PCR testing
Can Taq DNA Buffer be used for qPCR?
For qPCR we recommend the use of Fast qPCR Buffer, 4x (MDX033) as it has been optimized for this application.
How fast is Taq DNA Buffer?
This depends on the polymerase used as well as the length of the amplicon and the complexity of the template. For fast PCR, with Taq HS DNA polymerase (MDX008), the initial denaturation is 1 minute, but with low complexity template such as plasmid DNA, an annealing of 5 seconds and extension time of 10 seconds is sufficient for amplicons up to 1 kb. In order to find the fastest optimal condition, for more complex or longer amplicons, we suggest incrementally increasing the extension time successively up to 30 s/kb.
If my PCR testing is being impeded by too many PCR inhibitors, what can I do for optimization?
Decreasing the template concentration will help to minimize the concentration of inhibitors, the amount of DNA polymerase and primer can also be increased. In some cases, you may also have to add a pre-treatment step if the DNA is not accessible.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [High-Fidelity Pfu](https://www.meridianbioscience.com/lifescience/products/molecular/high-fidelity-pfu/)
**Published:** April 25, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » High-Fidelity Pfu
# High-Fidelity Pfu
PCR is used for the amplification of a next-generation sequencing (NGS) library. In addition to increasing the amount of DNA, the PCR amplification step is also used for DNA target enrichment for fragments that have an adaptor-ligated to each end. These will be the fragments that attach to the flow cell and will be sequenced, so it is important that this PCR amplification step does not introduce mutations to the NGS library, as a lower error rate means that less sequence coverage is required, saving expense and time.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's High-Fidelity Pfu
- Antibody hot-start Pfu polymerase for increased specificity
- An error rate of 3.0 x 10-6
- Ideal for NGS library amplification
- Provided with 10x buffer and 50mM MgCl2
## NGS library amplification
Four NGS libraries were created using E. coli DNA. These libraries were amplified using High-Fidelity Pfu prior to being placed on flow cells and being sequenced. For each sample, the fraction of uniquely mapped (mapped to only one place on a reference sequence), ambiguously mapped and unmapped reads relative to the total number of reads per sample is shown. The results illustrate that with E. coli DNA, High-Fidelity Pfu allowed for over 90% unique reads that could be aligned to the reference sequence and as such these libraries are considered very good libraries.
### High-Fidelity Pfu, MDX003
**Application:** PCR,NGS**Specimen Type:** DNA**Concentration:** 2 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Thermostable high fidelity Hot Start DNA polymerase, generates blunt-ended amplicons up to 5 kb in length making it ideal for high yields in NGS library amplification.
Available in 2 mL (500 Units) or 10 mL (25,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX003-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX003-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX003.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX003)
## Description
High-Fidelity Pfu is a thermostable high fidelity DNA polymerase enzyme, isolated from *Pyrococcus furiosus*. The Pfu polymerase enzyme replicates DNA in the 5´→3´ direction in the presence of magnesium, but also possesses 3´→5´ exonuclease (proofreading) activity. Base misincorporations that may occur during polymerization are rapidly excised by this proofreading activity. High-Fidelity has an error rate of 3.0 x 10-6 generating blunt-ended amplicons up to 5 kb in length.
## Specifications
DescriptionHigh-fidelity hot start Taq DNA polymerase with separate 10x Pfu Reaction Buffer and MgCl2.Concentration2 U/µLAppearanceClear, colorless solutionHot Startantibody mediatedApplicationPCR, NGS library preparation, cloning, protein expressionSample typecDNA, DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HSCatalog**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
[NGS High-Fidelity Pfu Buffer, 10x](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-high-fidelity-pfu-buffer-10x/)
## FAQs: High-Fidelity Pfu
What is proofreading polymerase?
In nature, the ability of a DNA polymerase to correct misincorporation of nucleotides in the DNA strand being elongated is often crucial to the survival of the host organism. This ability is termed “proofreading activity” and occurs in the 3′ to 5′ direction. This activity also leads to the polymerase removing unpaired nucleotides overhanging at the 3’end (A-overhangs), creating blunt ends.
My DNA sample contains PCR inhibitors, will the High-Fidelity Pfu still work?
If possible, we would recommend an additional clean-up of affected samples, alternatively High-Specificity Pfu HS Mix (MDX006) would be recommended, as it is designed to work in the presence of inhibitors.
How long a fragment will this High-Fidelity Pfu polymerase amplify?
High-Fidelity Pfu has been validated for templates up to 5 kb.
What is DNA target enrichment?
DNA target enrichment is a pre-sequencing DNA preparation step where DNA sequences are either directly amplified (multiplex PCR-based) or captured (hybrid capture-based). These enriched DNA fragments can then be sequenced using DNA sequencers.
What are the advantages of a hot-start polymerase?
During PCR amplification setup at room temperature, standard polymerases will have some activity. When using a hot-start polymerase, this enzyme will have no activity at room temperature, thus reducing the risk of unspecific products in the reaction due to these mis-primed oligonucleotides. This feature makes this type of polymerase ideally suited to high-throughput applications, where the reactions may be left sitting at room temperature for prolonged periods of time.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Tissue Extract-PCR Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/tissue-extract-pcr-buffers/)
**Published:** April 25, 2025
**Author:** hamza
**Content:**
# Tissue Extract-PCR Buffers
Many DNA tissue extraction methods can be laborious and time-consuming or involve the use of hazardous chemicals. Tissue Extract-PCR Buffers offer a rapid, easy, and safer alternative for the extraction of DNA from a variety of tissue types, particularly solid tissues such as mouse tail or mouse ear. Combined with a high-quality inhibitor-tolerant polymerase, they maximize sensitivity and speed while minimizing contamination risks to deliver greater experiment success rates.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Tissue Extract-PCR Buffers
- Produces high yield, PCR-ready DNA in as little as 15 minutes
- Reduces the risk of sample loss and contamination and minimizes manual effort
- Use with high quality Taq HS DNA Polymerase (MDX008) for improving yield of even the most challenging targets
- No need for hazardous chemicals or multiple washing steps
## Sex determination in neonate mice
Mouse (Mus musculus) tail tissue placed into equal volumes of Buffer A and Buffer B and incubated at 75°C for 5 minutes, followed by deactivation at 95°C for 10 minutes. Taq DNA Polymerase (MDX008) and X- and Y- chromosome-specific gene were added, amplified and the PCR products loaded onto an agarose gel. A single band is seen in five of the nine reactions (Lanes 1, 3, 5, 7 and 9) correspond to the XX (female chromosomes) and a doublet in the other four (Lanes 2, 4, 6, and 8) correspond to the XY (male chromosomes). The PCR product sizes were checked and corresponded exactly to a visual determination of the sex of the individual mice.
### Tissue Extract-PCR Buffers, MDX004
**Application:** Extraction**Specimen Type:** Buffer**Concentration:** 5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Convenient, fast and efficient method for the extraction of DNA from a variety of mammalian tissues in a single tube, without the need for multiple washing steps for use directly in a PCR reaction.
Available in 1 mL (1,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX004-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX004-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX004.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX004)
## Description
Tissue Extract-PCR Buffer offers a convenient, fast and efficient method for the extraction of DNA from a variety of mammalian tissues, particularly from rodent tail or ear samples. The DNA extractions are performed in a single tube, without the need for multiple washing steps, greatly reducing the risk of sample loss and contamination, and can be used directly in a PCR reaction.
## Specifications
DescriptionA convenient, fast and efficient method for the extraction of DNA from a variety of mammalian tissues in a single tube, without the need for multiple washing steps for use directly in a PCR reaction.Concentration5xAppearanceClear, colorless solutionApplicationPCR, RT-PCR, qPCR, RT-qPCR, LAMPSample typecDNA, DNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelSensitivityPCR with a dilution series of extracted DNA, to determine specific product at limiting template concentrationDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Taq HS Antibody](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-antibody/)
## FAQs: Tissue Extract-PCR Buffers
Is it critical to deactivate at 95°C for ten minutes?
Yes, if it is not properly deactivated through the heat denaturation step, it could quickly degrade the polymerase during the PCR step.
Can the tissue extract be used for qPCR?
Yes, the lysate can be used directly in a qPCR reaction, we recommend using the inhibitor-tolerant or Specimen-specific™ mixes.
Can the tissue extract be stored?
Yes, the tissue extract can be stored at -20°C in the short term but for long term storage, we recommend purifying the DNA and re-suspending it in a standard buffer.
What sample types can be used with the Tissue Extract-PCR Buffers?
The Tissue Extract-PCR Buffers has been tested with cell cultures, tissues (tail, ear, kidney, liver, blood and FFPE), buccal swabs, stool samples, gram positive bacteria and hair follicles.
Is centrifugation a requirement prior to PCR?
Depending on the sample type, it is possible to omit the centrifugation step after the extraction reaction, however pelleting the debris will result in a more reliable PCR.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
**Published:** April 28, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » High-Specificity Pfu HS Mix
# High-Specificity Pfu HS Mix
A high-fidelity DNA polymerase (higher than 130x Taq fidelity), High-Specificity Pfu HS Mix is highly suited to DNA target enrichment, NGS library amplification, and cloning applications. High-Specificity Pfu HS Mix provides high yield and sensitivity, as well as superior amplification of GC- and AT-rich targets. The hot-start aptamer binds reversibly to the high-fidelity DNA polymerase which inhibits its activity at ambient temperatures and improves the specificity of the amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's High-Specificity Pfu HS Mix
- Aptamer hot start for increased specificity
- Inhibitor-tolerant (tolerates up to 20% whole blood)
- Robust amplification across different GC-content (29% - 65%)
- High-fidelity reduces errors for NGS library amplification
### High-Specificity Pfu HS Mix, MDX006
**Application:** PCR,NGS**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
High concentration, high-fidelity Taq DNA polymerase used for the amplification of a next-generation sequencing (NGS) library.
Available in 0.025 mL (500 Units) or 1 mL (20,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX006-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX006-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX006.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX006)
High-Specificity Pfu HS Mix is a combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, together with an aptamer-mediated hot-start polymerase, dNTPs, and MgCl2. The advanced buffer chemistry has been developed for fast, highly reproducible, multiplex PCR and is designed for superior sensitivity and specificity, making High-Specificity Pfu HS Mix perfect for DNA target enrichment and NGS library amplification.
## Catalogs & Brochures
[High-Specificity Pfu HS Catalog](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Catalog**
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[High-Fidelity Pfu](https://www.meridianbioscience.com/lifescience/products/molecular/high-fidelity-pfu/)
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
[NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
[NGS High-Fidelity Pfu Buffer, 10x](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-high-fidelity-pfu-buffer-10x/)
## FAQs: High-Specificity Pfu HS Mix
What is a proofreading polymerase?
In nature, the ability of a DNA polymerase to correct misincorporation of nucleotides in the DNA strand being elongated is often crucial to the survival of the host organism. This ability is termed “proofreading activity” and occurs in the 3′ to 5′ direction. This activity also leads to the polymerase removing unpaired nucleotides overhanging at the 3’end (A-overhangs), creating blunt ends.
How was the fidelity of High-Specificity Pfu HS Mix calculated?
High-Specificity Pfu HS Mix fidelity was determine using the method developed by Lee et al. ( Mapping DNA polymerase errors by single-molecule sequencing. Lee F. D., et al. Nucleic Acids Research, 44 (13) e118 2016 (doi: 10.1093/nar/gkw436)) using a barcode strategy and NGS to characterize the average error rate, error hotspots and lesion bypass fidelity of the DNA polymerase.
My DNA sample contains PCR inhibitors, will the High-Specificity Pfu HS Mix still work?
High-Specificity Pfu HS Mix is designed to work in the presence of inhibitors. If there is too much interference the concentration of magnesium can be increased, for example, up to 4 mM (in the final reaction) should be added in presence of more than 10% of whole blood.
How long a fragment will this high-fidelity DNA polymerase amplify?
High-Specificity Pfu HS Mix has been validated for templates up to 5 kb.
What is DNA target enrichment?
DNA target enrichment is a pre-sequencing DNA preparation step where DNA sequences are either directly amplified (multiplex PCR-based) or captured (hybrid capture-based). These enriched DNA fragments can then be sequenced using DNA sequencers.
What are the advantages of an aptamer-mediated hot-start polymerase?
Aptamers are engineered oligonucleotides that bind to the active site of the high-fidelity DNA polymerase but are denatured and released as the temperature is increased during the PCR amplification cycle. This aptamer-mediated inhibition/activation process is however fully reversible, and so at the end of thermal cycling, when the temperature of the reaction is decreased, the aptamer refolds and rebinds to high-fidelity DNA polymerase, inhibiting any further activity in the sample. This has proven to be important in workflows where undesired polymerase activity after reaction completion can disturb baseline readings, such as NGS following amplification of a library.
Does the aptamer get sequenced in the NGS process?
No, the ends of the aptamer are blocked to prevent them being sequences.
What are the storage conditions of High-Specificity Pfu HS Mix?
High-Specificity Pfu HS Mix should be stored at -20°C for optimal retention of activity. We do not recommend the storage of High-Specificity Pfu HS Mix at -80 °C as ice crystals could form on the active site, which may affect or destroy the activity of the enzyme.
Specifications:
Description: High-fidelity PCR master mix containing a reversible, temperature-dependent hot start Taq DNA polymerase and buffer
Concentration: 2 x
Appearance: Clear, colorless solution
Hot Start. Aptamer mediated
Application: PCR, NGS target enrichment, NGS library preparation
Sample type: cDNA, DNA
Presentation: 1 vial
Storage: -20 °C
Mix stability: See outer label
Consistency: ± 0.5 Ct variance between test and reference sample
DNA Contamination: None detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.
DNase Contamination: No detectable degradation
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Taq Dilution Buffer](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dilution-buffer/)
**Published:** April 28, 2025
**Author:** hamza
**Content:**
# Taq Dilution Buffer
Taq Dilution is an optimized buffer system that has been designed to conferring long-term stability at -20 °C to high-quality Taq DNA polymerase such as MDX001 or MDX008.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Taq Dilution Buffer
- Combination of the latest advances in buffer chemistry.
- Optimized buffer system for storage of polymerases, conferring long-term stability at -20 °C.
### Robust PCR amplification of GC-rich human genomic DNA
A serial dilution in duplicate of human genomic DNA (1 μg, 200 ng, 100 ng, 50 ng, 25 ng and 12.5 ng, 1-6 respectively) was used with primers and Taq DNA Polymerase to amplify a 450 bp fragment of the human myc gene. The section of gene used has 61% GC content and was selected to demonstrate the high yield and sensitivity of the Taq DNA Polymerase, making it the perfect choice for the amplification of complex PCR templates.
### Taq Dilution Buffer, MDX007
**Application:** PCR**Specimen Type:** DNA**Concentration:** 1x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Taq Dilution is an optimized buffer system that has been designed to conferring long-term stability at -20 °C to high-quality Taq DNA polymerase.
Available in 2 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX007-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX007-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX007.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX007)
## Description
Taq Dilution Buffer requires the addition of a polymerase and a reaction buffer, dNTPs, and MgCl2, together with primers and templates.
## Specifications
DescriptionTaq HS Antibody is a mix of anti-Taq monoclonal antibodies designed to inhibit Taq DNA polymerase activity at room temperature. It is used in the preparation of hot-start PCR or qPCR master mixes and helps to prevent nonspecific amplification and primer-dimer formation, increasing specificity and sensitivity, while allowing assembly of reactions at ambient temperatures.Concentration10 mg/mL ≤ 5%AppearanceClear, colorless solutionApplicationPCR, multiplex PCR, qPCR, multiplex qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelSensitivityqPCR with a dilution series of human genomic DNA, to determine specific product at limiting template concentrationEfficiency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[dNTP Mix, 100mM (Lithium)](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-lithium/)
## FAQs: Taq Dilution Buffer
What concentration of Taq should be used?
We generally recommend using Taq DNA Polymerase at a concentration of 25 units/mL (1.25 units/50 μL reaction). However, the optimal concentration of Taq DNA Polymerase may range from 5–50 units/mL (0.25–2.5 units/50 μL reaction) in specialized applications.
What happens if you add too much Taq polymerase in a reaction?
Too much Taq will result in an excessive background of unwanted DNA fragments (a smear on a gel) while a huge excess may cause the reaction to fail with no product being detected.
Why should I use a Taq Dilution Buffer?
Due to the difficulties in pipetting small volumes of enzyme, Taq DNA Polymerase can be diluted in Taq Dilution Buffer. Unlike Taq Reaction Buffer, the Taq Dilution Buffer can then be used to store the Taq DNA polymerases, conferring long-term stability at -20 °C.
If my PCR testing is being impeded by too many PCR inhibitors, what can I do for optimization?
Decreasing the template concentration will help to minimize the concentration of inhibitors, the amount of DNA polymerase and primer can also be increased. In some cases you may also have to add a pre-treatment step if the DNA is not accessible.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-µl/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Low DNA Taq HS 5 U/µL
Low DNA Taq HS, 5 U/µL is a highly purified chemically modified hot start Taq DNA polymerase and buffer system, with separate magnesium. It has been developed for low bioburden and very high sensitivity over a wide range of PCR templates.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Low DNA Taq HS, 5 U/µL
- Chemical hot start Taq polymerase
- Reduced effects of primer dimerization or mispriming that causes pcr nonspecific bands
- Reduced effects of primer dimerization or mispriming that causes pcr nonspecific bands
- Reduced effects of primer dimerization or mispriming that causes pcr nonspecific bands
### High sensitivity and specificity using Low DNA Taq HS
A 10-fold dilution of DNA was used in a qPCR assay using Low DNA Taq HS and an intercalating dye. Each dilution was run in triplicate using standard reaction conditions. A/ The amplification curve demonstrates the reproducibility and sensitivity of the Low DNA Taq HS and B/ The single distinct peak in the melt curve illustrates the products are a single discrete species, with no additional bands or primer/dimers.
### Low DNA Taq HS 5 U/µL, MDX009
**Application:** PCR**Specimen Type:** DNA**Concentration:** 5 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Highly purified Taq DNA polymerase with low DNA background and stringent chemical hot-start properties, ideal for PCR of low-copy bacterial targets to avoid false-positive amplification, such as in water testing.
Available in 0.1 mL (500 Units) or 10 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX009-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX009-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX009.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX009)
## Description
A chemical moiety is attached to Low DNA Taq HS, 5 U/µL making it inactive at ambient temperature, avoiding extension of non-specifically annealed primers or primer dimers and providing higher specificity of DNA amplification. Low DNA Taq HS, 5 U/µL catalyzes 5′-3′ synthesis and possesses low 5′-3′ exonuclease activity, however these are not detectable before activation, enhancing PCR sensitivity. The functional activity of the enzyme is restored during a 10-minute incubation at 95 °C. The low DNA background and stringent hot-start properties of Low DNA Taq HS, 5 U/µL are ideal for PCR of low-copy bacterial targets and avoiding false-positive amplification, such as in water testing.
## Specifications
DescriptionA highly purified Taq DNA polymerase. The low DNA background and stringent hot-start properties are ideal for PCR of low-copy bacterial targets and avoiding false-positive amplification, such as in water testing.Concentration5 U/µLAppearanceClear, colorless solutionHot StartChemicalPurity>90%ApplicationPCR, two-step RT-PCRPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
## Related Products
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
[Low DNA Taq HS 10 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-10-u-%c2%b5l/)
## FAQs: Low DNA qPCR mix
What are the advantages and considerations of a chemical hot start Taq polymerase?
With a chemical hot start Taq polymerase, the polymerase is covalently linked with chemical groups to block enzyme activity at room temperature.
Advantages
• More stringent than antibody hot-start methods, so there is no activity even for long periods at room temperature, minimizes non-specific amplification
• Low bioburden, as it is free of animal and bacterial-origin components
Considerations
• Longer activation time required for the polymerase to become fully active
Does Low DNA Taq HS, 5 U/µL have exonuclease activities?
Low DNA Taq HS, 5 U/µL lacks a 3′ – 5′ exonuclease activity. However, the enzyme does have 5 ‘ – 3′ nuclease activity. During the extension step of a PCR amplification, the enzyme will hydrolyze any blocking strand starting from its 5’ end.
Does Low DNA Taq HS, 5 U/µL add on extra A to the PCR product?
Low DNA Taq HS, 5 U/µL lacks proofreading activity, so it will leave a 3′-overhang which can be used with TA cloning. In order to drive the reaction to the extra A state, a final extension time at 72°C should be increased to 15-30 minutes.
Does Low DNA Taq HS, 5 U/µL remain in an active state once it is activated?
Yes, once activated, Low DNA Taq HS, 5 U/µL remains active. Lowering the temperature will not inactivate Low DNA Taq HS, 5 U/µL.
Does the activation of Low DNA Taq HS, 5 U/µL at 95°C for 10 minutes interfere with the half-life of the enzyme?
No the 10-minute activation will the enzyme, it will remain fully functional during the subsequent cycling.
Can Low DNA Taq HS, 5 U/µL be used for multiplex PCR?
Multiplex PCR involves the co-amplification of multiple amplicons in a single PCR. Since several sets of primers are being added to a single reaction, the potential for primer dimer formation or mispriming and so loss of specificity and so a decrease in yield of specific product exists. Because Low DNA Taq HS, 5 U/µL remains active has no activity prior to the hot start PCR, the multiple primers do not have the possibility to react with themselves, dramatically increasing specific product yield.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [Bst DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/bst-dna-polymerase/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Bst DNA Polymerase
Bst DNA Polymerase is an enzyme derived from the large fragment of *Bacillus stearothermophilus* DNA Polymerase I. It contains 5´- 3´ DNA polymerase activity and strong strand displacement activity but lacks 5´- 3´ exonuclease activity. The strong strand displacement activity enables Bst DNA Polymerase to synthesize DNA at a constant temperature making it an ideal enzyme for isothermal amplification, including HDA, MCA, and Loop-Mediated Isothermal DNA Amplification (LAMP).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Bst DNA Polymerase
- Optimized for isothermal amplification such as LAMP.
- Designed for fast polymerization and so faster time to results.
- Supplied with a reaction buffer and enzyme dilution buffer.
### Bst DNA Polymerase, MDX012
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 8 units/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
DNA polymerase (exo-), with strand-displacement properties. used for Isothermal DNA amplification such as LAMP (Loop-mediated Isothermal Amplification).
Available in 1 mL or 10 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX012-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX012-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX012.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX012)
## Description
Bst DNA Polymerase (8 U/µL) is supplied with an Enzyme Dilution Buffer and a Bst Reaction Buffer formulated to deliver the fastest amplification speed (time-to-results), yield, salt tolerance, and sensitivity, speeding up your product development time and allowing you to commercialize your new products faster. For the most difficult templates, an Inhibitor-Tolerant Bst Buffer is available that is specifically designed for high performance when using crude samples such as sputum or saliva.
## Specifications
DescriptionDNA polymerase (exonuclease minus), with strand-displacement properties. Bst DNA Polymerase is used for Isothermal DNA amplification and LAMP (Loop-mediated Isothermal Amplification).Concentration10 units/µL +/-10% measured against a standardAppearanceClear, colorless solutionApplicationLoop-mediated isothermal amplificationSample typecDNA, DNAPresentation3 vialsStorage-20 °CStabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/buffers/)
## FAQs: Bst DNA Polymerase
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
Is Meridian’s Bst DNA Polymerase warm/hot start?
No Meridian’s Bst DNA Polymerase does not come with warm or hot start; instead, the reaction buffer does not contain magnesium and so the enzyme is completely inactive until magnesium is added. If you are concerned about setting your reaction up at room temperature, we recommend adding the magnesium last, just before running the experiment and it will prevent non-specific amplification.
Can LAMP be used for a multiplex assay?
Yes, it is possible to design a multiplex LAMP test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Can Bst DNA Polymerase be used in place of other DNA polymerases for thermal cycling?
No, the reaction temperatures are too high for enzyme stability.
Does Bst DNA polymerase have reverse transcriptase activity?
Yes, Bst DNA polymerase does have some reverse transcriptase activity, however for robust and consistent reactions we recommend the addition of a reverse transcriptase.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [Taq HS Antibody](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-antibody/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Taq HS Antibody
Taq HS Antibody binds Taq DNA polymerase and inhibits its activity until reaction temperature is elevated at the start of a PCR (hot start PCR). At that point, the Taq Antibody is denatured and releases its hold on Taq DNA polymerase, allowing DNA synthesis to proceed. This enhances the specificity and sensitivity of PCR by preventing primer-dimer formation and non-specific amplification at lower temperatures.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Taq HS Antibody
- Anti-Taq antibody for hot start PCR.
- Helps to prevent mispriming and non-specific amplification derived from primer dimers.
- Can be used under conventional PCR conditions.
- Glycerol-free, ideal for preparation of dried-down PCR tests.
## Efficient and sensitive amplification with both wet (black) and lyophilized (blue) PCR tests
Glycerol-Free Taq HS, 50 U/µL (MDX011) was mixed with Taq HS Antibody and lyophilized (blue) or left as a wet mix (black), these were used with a 10-fold serial dilution of template. Results illustrate that lyophilization of Taq HS Antibody with the Glycerol-Free Taq HS does not have an effect on the quality of the qPCR, as both the assays demonstrate identical efficiency and sensitivity.
### Taq HS Antibody, MDX014
**Application:** PCR**Specimen Type:** Others**Concentration:** 50 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Mix of anti-Taq monoclonal antibodies designed to block Taq DNA polymerase activity at room temperature. Used in the preparation of hot-start PCR or qPCR master mixes.
Available in 20 µL (1,000 Units) or 250 µL (12,500 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX014-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX014-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX014.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX014)
## Description
Taq HS Antibody is a mix of anti-Taq antibodies designed to inhibit Taq DNA polymerase activity at room temperature. It is used in the preparation of hot-start PCR or qPCR master mixes and helps to prevent nonspecific amplification and primer-dimer formation, increasing specificity and sensitivity while allowing assembly of reactions at ambient temperatures. Inhibition is reversed when the temperature is raised during the first denaturing step of thermal cycling.
## Specifications
DescriptionA mix of anti-Taq monoclonal antibodies designed to block Taq DNA polymerase activity at room temperature. Used in the preparation of hot-start PCR or qPCR master mixes, it helps to prevent nonspecific amplification and primer-dimer formation, increasing specificity and sensitivity, while allowing assembly of reactions at ambient temperatures.Concentration10 mg/mL ≤ 5%AppearanceClear, colorless solutionApplicationPCR, multiplex PCR, qPCR, multiplex qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelSensitivityqPCR with a dilution series of human genomic DNA, to determine specific product at limiting template concentrationEfficiency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/mmlv-rt/)
## FAQs: Taq HS Antibody
What do the terms specificity mean?
Specificity is a measure of the unwanted by-products generated in a reaction. This is the reason for having hot start PCR, this prevents miss-priming at low temperatures and non-specific amplification.
Will Taq HS Antibody work with any standard Taq DNA polymerase?
Yes, however we recommend using a high-quality polymerase such as Taq DNA Polymerase (MDX001).
Taq HS Antibody be used with high-fidelity Taq DNA polymerase?
No, Taq HS Antibody is designed for standard Taq DNA polymerases, not high-fidelity Taq DNA polymerases.
Is Taq HS Antibody a monoclonal antibody?
Taq HS Antibody is a mix of monoclonal anti-Taq antibodies, with different isotypes, this ensures that the Taq DNA polymerase remains inactive at room temperature.
Can Taq HS Antibody be used for lyophilization?
Yes, Taq HS Antibody can be added to a glycerol-free Taq DNA polymerase and lyophilized.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA Polymerases ](/lifescience/products/molecular-reagents/dna-polymerases/)»Aptamer Taq HS (Glycerol-Free)
# Aptamer Taq HS (Glycerol-Free)
Aptamer Taq HS (glycerol-free) is a fast, high concentration, glycerol-free DNA polymerase containing a DNA aptamer that is designed to reversibly block the DNA polymerase and so work as a temperature-dependent hot start system. The glycerol-free formulation can be used to produce lyophilized or air-dried, ambient-temperature stable PCR or qPCR reagents and exhibit the same high performance before and after drying, offering greater flexibility for assay design and format.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Aptamer Taq HS (Glycerol-Free)
- The DNA aptamer hot start suited to multiplex, high-throughput assays requiring high specificity
- Glycerol-Free DNA polymerase ideal for creating ambient temperature stable assays
- Provided as 50U/µL hot start Taq and enzyme dilution buffer
- Allows convenient room temperature reaction set-up
## Compatible with highly sensitive reverse transcription
Four viral sequences, two DNA (Cytomegalovirus (green line) and Adenovirus (blue line)) and two RNA (Rotavirus (orange line) and Norovirus (red line)) were amplified using A/ Aptamer Taq HS (glycerol-free) (MDX015) or B/ Roche AptaTaq DNA Polymerase, with Lyo-Ready qPCR Buffer (MDX022) and RNase-Tolerant MMLV-RT (MDX043) in quadruplex qPCR probe assays. The data demonstrates both DNA and RNA templates are amplified with equal sensitivity using Aptamer Taq HS (glycerol-free), unlike the AptaTaq DNA Polymerase that gave very poor results with the RNA templates.
### Aptamer Taq HS (Glycerol-Free), MDX015
**Application:** PCR**Specimen Type:** DNA**Concentration:** 50 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration hot-start Taq DNA polymerase, suitable for difficult, multiplex molecular tests that require fast amplification.
Available in 20 ?L (1,000 Units) or 1 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX015-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX015-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX015.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX015-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX015)
## Description
Traditional hot start PCR methods that are antibody or chemically mediated require a long activation time at very high temperatures. In contrast, DNA aptamers disassociate from the enzyme (e.g. activate) at relatively lower temperatures (45 °C), allowing for room temperature assay set-up, fast PCR reaction protocols and better assay specificity. Aptamer Taq HS (glycerol-free) is therefore suitable for difficult, multiplex PCR tests that require fast amplification whilst maintaining both high specificity and sensitivity.
## Specifications
DescriptionGlycerol-free high concentration hot-start Taq DNA polymerase, suitable for difficult, multiplex molecular tests that require fast amplification, while maintaining both high specificity and sensitivity.ConcentrationBetween 50 and 60 U/µL (see CoA)AppearanceClear, colorless solutionHot StartReversible, temperature-dependent aptamer mediatedApplicationPCR, real-time PCR, two-step RT-qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following air-drying or lyophilizationPurity>50 % as measured as a percentage of total protein by quantitative gel electrophoresis on Bioanalyzer (Agilent)DNA contaminationNone detected in qPCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.
## Catalogs & Brochures
[Aptamer Taq HS](https://collateral.meridianlifescience.com/view/33669388/)**Aptamer Taq HS (Glycerol-Free)Catalog**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready qPCR Buffer w/o Excipients, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-w-o-excipients-4x/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
## FAQs: Aptamer Taq HS (glycerol-free)
What are the advantages of an aptamer-mediated hot-start DNA polymerase?
DNA aptamers are engineered oligonucleotides that bind to the active site of the DNA polymerase but are denatured and released as the temperature is increased during the PCR amplification cycle. This aptamer-mediated inhibition/activation process is however fully reversible, and so at the end of thermal cycling, when the temperature of the reaction is decreased, the DNA aptamer refolds and rebinds to DNA polymerase, inhibiting any further activity in the sample. This has proven to be important in workflows where undesired polymerase activity after reaction completion can disturb baseline readings, such as with high-throughput automated systems.
Does Aptamer Taq HS (glycerol-free) require an initial incubation to activate the polymerase?
No, the DNA aptamer-based hot start PCR mechanism does not require an initial incubation. The aptamer is released from the DNA polymerase during normal cycling conditions, so Standard Taq protocols can be used.
Can the DNA aptamer be confused as a primer during the PCR?
No, the ends of the DNA aptamer are blocked to prevent them being used as primers during amplification.
What are the advantages of a 10x DNA polymerase?
Aptamer Taq HS (glycerol-free) is at 50 U/µL for PCR kit manufactures and DNA testing facilities, requiring large amounts of DNA polymerases. The highly concentrated Aptamer Taq HS (glycerol-free) allows for concentrated bulk production of PCR master mixes.
Concentrated bulks in glycerol-free formats are also attractive when using automated pipetting robots and other applications where accurate pipetting of small volumes is crucial, as glycerol makes the solution more viscous, the aptamer has the additional advantage of also allowing convenient room temperature reaction set-up.
Concentrated PCR master mixes are easier to lyophilize due to the reduced volume of the concentrated mix.
What are the storage conditions and stabilities of Aptamer Taq HS (glycerol-free)?
Glycerol is a cryoprotectant and is normally part of the storage buffer, where it serves to protect Taq DNA polymerase during freezing conditions. The high concentration of Aptamer Taq HS (glycerol-free) means that you get the same protection to freeze/thawing as a DNA polymerase that contains glycerol.
After drying for how long will the lyophilized PCR tests stay stable to use?
A lyophilized PCR molecular test will remain stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Can Aptamer Taq HS (glycerol-free) be used to create quantitative PCR tests?
Yes, Glycerol-Free Taq HS 50 U/µL is ideal for any multiplex PCR assays, particularly quantitative PCR molecular tests that require fast PCR amplification, whilst maintaining both high specificity and sensitivity.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [qPCR and RT-qPCR Master Mixes ](/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/)» Fast qPCR Mix
# Fast qPCR Mix
Fast qPCR master mix contains Taq polymerase, reaction buffer, dNTP, MgCl2, stabilizers, and PCR enhancers. It is ideal for developing multiplex qPCR diagnostic tests and is suited for high-throughput, automated platforms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Fast qPCR Mix
- Create ultra-sensitive qPCR assays to deliver reproducible results from low copy number targets
- Robust formulation delivers consistent, reliable qPCR performance in fast cycling conditions
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High qPCR efficiency, giving excellent performance in multiplex qPCR assays
## Standard qPCR (black) and fast qPCR (blue) of a ten-fold serial dilution of template DNA
DNA target was amplified using standard qPCR cycling conditions (2 min @ 95ºC, 40 cycles of 10 sec @ 95ºC and 25 sec @ 60ºC) and the fast cycling conditions (2 min @ 95ºC, 40 cycles of 1 sec @ 95ºC and 10 sec @ 60ºC). The results illustrate the higher performance and end-fluorescence of the Fast qPCR Mix in both standard (blue) and fast (black) qPCR cycling conditions.
### Fast qPCR Mix, MDX020
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
The latest advances in buffer chemistry and PCR enhancers and stabilizers, together with a hot-start polymerase, dNTPs and MgCl2, for highly reproducible, accurate assay results under fast thermal cycling conditions.
Available in 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX020-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX020-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX020.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX020)
### Fast qPCR Mix, 5x, MDX072
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
The latest advances in buffer chemistry and PCR enhancers and stabilizers, together with a hot-start polymerase, dNTPs and MgCl2, for highly reproducible, accurate assay results under fast thermal cycling conditions.
Available in 2 mL (500 Rxns) or 40 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX072-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX072-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX072.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX072)
## Description
Fast qPCR Mix has been designed with a highly optimized buffer chemistry and hot-start DNA polymerase, to give highly sensitive qPCR efficiency, even from low abundance targets and scarce samples. With high processivity and robustness, it delivers excellent results in both singleplex and multiplex qPCR assays and confers superior assay performance under fast thermal cycling conditions, allowing more samples to be run in a day with the highest confidence, ideal for high‑throughput assays. Fast qPCR Mix is available as a standard 2x and 5x formulation, offering flexible reaction setups and protocols.
## Specifications
DescriptionThe latest advances in buffer chemistry and PCR enhancers and stabilizers, together with a hot-start polymerase, dNTPs and MgCl2, for highly reproducible, accurate assay results under fast thermal cycling conditions, ideal for automated, high-throughput systems.Concentration2x and 5xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, qPCR, two-step RT-qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## FAQs: Fast qPCR Mix
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
What are the advantages of using a two-step qPCR mix over a one-step RT-qPCR mix?
• Two buffers optimized for independent RT and real-time PCR
• Highly sensitive
• Recommended when the reaction is performed with a limiting amount of starting material
• More efficient because random primers and oligo d(T) can be used
• Possibility to stock cDNA to quantify several targets
When performing a reverse transcription reaction for a two-step quantitative PCR assay, it is possible to use different primer strategies. Random hexamer primers, which bind anywhere on the RNA allow full coverage of total RNA (including ribosomal, bacterial and viral RNA), oligo d(T)n (or anchored oligo d(T)n), which binds to the poly-A tail of the mRNA which is located at the extremity of the transcript, leading to full transcripts, a mixture of random hexamer and oligo d(T)n that reduces the risk of bias in cDNA synthesis and specific primers, which bind to the transcript of interest.
The ability to optimize both cDNA and quantitative PCR reactions separately and the higher cDNA yields, two-step reactions can be more sensitive than one-step reactions. The ability to separately optimize these reactions is also beneficial when performing multiplex qPCR on challenging sequences.
What are the considerations of using a two-step qPCR mix?
With two-step quantitative PCR, the use of several tubes means that it is more time consuming and less adaptable to liquid handling robotics and so more difficult to adopt for high throughput
screening assays. The use of several tubes and pipetting steps also exposes the reaction to a greater risk of DNA contamination.
What probes can be used in quantitative PCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors, including:
• Hydrolysis (TaqMan) probes
• Molecular beacons
• Dual hybridization probes
• Eclipse probes
• Amplifluor assays
• Scorpions PCR primers
• LUX PCR primers
• QZyme PCR primers
The two most commonly used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Do you sell qPCR mixes that use intercalating dyes such as SYBR Green?
No, intercalating dyes bind into all DNA, this means that they cannot be used for multiplex qPCR, as different amplicons cannot be distinguished, whereas different dyes can be used on probes for different amplicons. This also makes probe-based systems more specific; only detect the gene of interest, even making it possible to distinguish between similar sequences with small differences like SNPs or mutations. In general, probe assays need less optimization, and they can be used for multiplex qPCR.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Lyo-Ready qPCR Buffer, 2.5x
Molecular diagnostic tests are progressively moving towards lyophilized. There are several advantages for this, including room temperature shipping and storage, extended shelf-life and increased flexibility in sample volume. In order to be compatible with drying however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to freezing, vacuum and dehydration.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready qPCR Buffer, 2.5x
- Used to create ultra-sensitive qPCR assays
- Formulated with a specialized blend of lyo-excipients, compatible with lyophilization into beads or cakes
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High efficiency, giving excellent performance in multiplex qPCR assays
## Powerful multiplexing capacity
Three viral sequences, Cytomegalovirus (CMV) Adenovirus, Epstein-Barr Virus (EBV) and a DNA Extraction Control were amplified with equal efficiency from synthetic DNA templates with Lyo-Ready qPCR Mix in a quadruplex qPCR probe assay. The result illustrates that all three viruses were amplified with high efficiency and sensitivity, demonstrating the ability of Lyo-Ready qPCR Mix to detect low-copy number DNA targets simultaneously from a single sample.
### Lyo-Ready qPCR Buffer, 2.5x, MDX022
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2.5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free qPCR reaction buffer containing lyo-excipients, designed to deliver highly reproducible, accurate qPCR assay results under fast thermal cycling conditions.
Available in 8 mL (500 Rxns) or 100 mL (12,500 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX022-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX022-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX022.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX022-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX022)
## Description
Lyo-Ready qPCR Buffer 2.5x is a glycerol-free qPCR reaction buffer containing lyo-excipients, designed to deliver highly reproducible, accurate qPCR assay results under fast thermal cycling conditions. In order to produce lyophilized, ambient-temperature stable qPCR reagents, dNTP, MgCl2 and glycerol-free Taq DNA polymerase (such as MDX011 or MDX015) must be added prior to lyophilization.
## Specifications
DescriptionA glycerol-free qPCR reaction buffer containing lyo-excipients. In order to produce room temperature lyophilized qPCR reagents, a lyo-compatible Taq DNA polymerase, assay specific primers and probes are added for subsequent lyophilization.Concentration2.5xAppearanceClear, colorless solutionApplicationFast qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[Lyo-Ready qPCR Buffer w/o Excipients, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-w-o-excipients-4x/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
## FAQs: Lyo-Ready qPCR Mix 2.6x
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
What probes can be used in qPCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Lyo-Ready qPCR Buffer, 2.6x be used with crude samples?
The Lyo-Ready qPCR Buffer, 2.6x has some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we recommend using are optimized Lyo-Ready Specimen-specific™ (blood, saliva, urine, stool, and plant) qPCR and LAMP mixes.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo-Ready qPCR Mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
Do you supply lyo-excipients separately?
No, our lyo-excipients are proprietary, if you require a buffer that does not contain lyo-excipients, we have the Lyo-Ready qPCR Buffer w/o Excipients, 4x (MDX061), but you will need to supply your own excipients.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Lyo-Ready qPCR Mix, 2.6x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Lyo-Ready qPCR Mix, 2.6x
Meridians Lyo-Ready mixes are glycerol-free mixes, ideal for developing ambient temperature, lyophilized, multiplex qPCR molecular diagnostic tests and are suited for high-throughput, automated platforms or microfluidic qPCR platforms requiring millisecond rehydration times.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready qPCR Mix, 2.6x
- Very fast reaction kinetics – ideal for multiplex qPCR assays and low-copy number targets
- Glycerol-free mixes are pre-formulated with a specialized blend of lyo-excipients, compatible with lyophilization into beads or cakes
- Higher concentration makes it ideal for molecular diagnostic tests on microfluidic qPCR platforms
## Powerful multiplexing capacity
Three viral sequences, Cytomegalovirus (CMV) Adenovirus, Epstein-Barr Virus (EBV) and a DNA Extraction Control were amplified with equal efficiency from synthetic DNA templates with Lyo-Ready qPCR Mix in a quadruplex qPCR probe assay. The result illustrates that all three viruses were amplified with high efficiency and sensitivity, demonstrating the ability of Lyo-Ready qPCR Mix to detect low-copy number DNA targets simultaneously from a single sample.
### Lyo-Ready qPCR Mix 2.6x, MDX023
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2.6x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free Taq polymerase, reaction buffer, dNTP, MgCl2, and lyo-excipients, ideal for developing room temperature, lyophilized, multiplex qPCR assays.
Available in 8 mL (500 Rxns) or 100 mL (12,500 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX023-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX023-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX023.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX023-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX023)
## Description
Molecular diagnostic tests are progressively moving towards lyophilized formats. There are several advantages for this, including ambient temperature shipping and storage, extended shelf-life, reduced operating steps and potential errors and increased flexibility in sample volume. In order to be compatible with drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to various conditions including freezing, vacuum, and dehydration.
Lyo-Ready qPCR Mix 2.6x is used for the development of DNA based multiplex qPCR tests, enabling highly sensitive detection of target DNA, at a slightly higher concentration than the Lyo-Ready qPCR Mix (MDX021), the Lyo-Ready qPCR Mix 2.6x Mix is for use with microfluidic qPCR, where the initial volume needs to be smaller.
## Specifications
DescriptionGlycerol-free master mix containing Taq polymerase, reaction buffer, dNTP, MgCl2 and lyo-excipients, for highly reproducible, accurate assay results under fast thermal cycling conditions, use with microfluidic instruments.Concentration2.6xFormatClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following lyophilizationConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR MixesCatalog**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR MixCatalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
## FAQs: Lyo-Ready qPCR Mix 2.6x
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
What probes can be used in qPCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Lyo-Ready qPCR Mix, 2.6x be used with crude samples?
The Lyo-Ready qPCR Mix, 2.6x has some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we have the universal Inhibitor-Tolerant qPCR mixes (MDX013 and MDX073) and for even greater sensitivity, we have the sample specific (blood, saliva, urine, stool, and plant) qPCR and LAMP mixes.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo-Ready qPCR Mix, 2.6x is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Low LOD 1-Step RT-qPCR Master Mix
Low LOD 1-Step RT-qPCR Mix is fast, highly reproducible real-time PCR master mix that has been designed with a highly optimized buffer chemistry and hot-start DNA polymerase, to deliver excellent results and very low background, allowing greater sensitivity.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Low LOD 1-Step RT-qPCR Master Mix
- Suitable for detecting purified RNA and DNA viruses at very low titers.
- High efficiency, giving excellent performance in multiplex qPCR assays.
- Prevents carry-over contamination.
## Low limit of detection (LOD) for both RNA and DNA viruses
24 replicates of purified blood viral extracts were tested in singleplex qPCR reactions using the Low LOD 1-Step RT-qPCR Mix at the indicated IU/mL. The singleplex reactions were HCV, HIV-1, HIV-2 and Parvovirus B19. The amplification curve results illustrate that Low LOD 1-Step RT-qPCR Mix can be used with both RNA and DNA viruses as low as 5 IU/mL
### Low LOD 1-Step RT-qPCR Mix, MDX025
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
RT-qPCR mix a dNTP/dUTP mix, designed for stringent amplification of highly structured and very low copy-number RNA and DNA targets.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots.
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX025-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX025-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX025.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX025)
## Description
Low LOD 1-Step RT-qPCR master mix contains Taq DNA polymerase, reaction buffer, dNTP, MgCl2, stabilizers, and PCR enhancers, and a separate RNase tolerant reverse transcriptase mix. However, the dTTP in the dNTPs has been substituted for dUTP, so that Uracil DNA Glycosylase (UDGase) (MDX054) can be added to remove background PCR product contamination. This makes Low LOD 1-Step RT-qPCR ideal for developing highly sensitive RT-qPCR diagnostic tests, such as for detecting RNA and DNA viruses at very low levels in blood banks or transplant viral testing.
## Specifications
DescriptionRT-qPCR mix containing Taq polymerase, reaction buffer, MgCl2 and optimized dNTP/dUTP mix, and separate reverse transcriptase/RNase inhibitor mix, designed for stringent amplification of highly structured and very low copy-number RNA and DNA targets.Concentration2xAppearanceClear, colorless solutionHot StartAntibody mediateddUTPPresence of dUTP checked by reverse-phase HPLC separationApplicationProbe-based, one-step RT-qPCRSample typeRNA and DNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR Mix**
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR Mixes**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
## FAQs: Low LOD 1-Step RT-qPCR Mix
What is one-step RT-qPCR and two-step qPCR?
In one-step RT-qPCR or reverse transcription qPCR, cDNA synthesis and qPCR are performed in a single reaction tube. In two-step qPCR, cDNA is synthesized in one reaction tube, and aliquots of the cDNA is then used for a subsequent qPCR experiment.
What are the advantages of using a one-step RT-PCR mix?
• Accurate representation of target copy number
• Simple and rapid
• Fewer pipetting steps (reducing possible errors and contamination)
• Best option for high-throughput screening
• Best method when only a few assays are run repeatedly
• Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample
There are several other advantages of one-step reactions, these include limited sample handling and reduced bench time, which helps to decrease chances for pipetting errors and cross contamination between reverse transcription and qPCR steps. This method is quick to set up and makes processing multiple RNA samples easy (especially when using liquid handling robotics), when you are amplifying only a few genes of interest. It is therefore ideal for high throughput screening laboratories where only a few reverse transcription qPCR assays are run repeatedly, using well-established reaction conditions, with the added advantage that multiplex qPCR of the gene of interest and control genes can be done in single well, from same RNA sample.
What are the considerations of using a one-step RT-PCR mix?
Gene-specific primers are required for generating the cDNA and for subsequent amplification in one tube, however this reduces experimental variation, since both enzymatic reactions take place under the same conditions, making one-step qPCR highly reproducible.
One-step RT-PCR requires careful evaluation to prevent primer dimer formation, because the primers will be present during the lower temperature conditions of the RT reaction as well as the qPCR cycling. This is particularly important in multiplex qPCR assays.
How is Uracil DNA Glycosylase used in RT-qPCR?
As qPCR can amplify tiny amounts of DNA, preventing contamination is essential, as even small amounts of qPCR contamination can produce false positives. qPCR contamination can include cross-contamination from other samples, contamination from elsewhere in the laboratory, and carryover contamination from amplification products and primers used in prior qPCR experiments. The latter causes most of the false positive results seen in qPCR. Preventing contamination can be difficult and so laboratory procedures must be in place to ensure DNA from one assay is not re-amplified in subsequent assay.
Uracil DNA Glycosylase can specifically degrade products that have already been through the qPCR process and have incorporated dUTP, leaving native nucleic acid templates intended for amplification intact. Uracil DNA Glycosylase activation occurs as the first step of qPCR at a 50°C incubation for 2 minutes and then the Uracil DNA Glycosylase is denatured when the temperature increases to 95°C during hot-start activation.
What is the difference between UDG and UNG?
Uracil-DNA glycosylase (UDG or UDGase) is a family of enzymes comprising six sub-families. Family I UDGase enzymes are called UNG (uracil-N-glycosylase gene), so there is no difference, the terms UDG and UNG are commonly used interchangeably because they perform the same function in qPCR—namely to prevent carryover qPCR contamination.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [qPCR Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/qpcr-extraction-control-red/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA-RNA Extraction Controls ](/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)» qPCR Extraction Control Red
# qPCR Extraction Control Red
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s qPCR Extraction Control Red uses E. coli cells of a known concentration that contain quantitative PCR positive control DNA sequence (with no known homology to any organism, so that it does not interfere with the detection of the sample target DNA). Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of a qPCR assay from lysis/extraction to amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's qPCR Extraction Control Red
- Extraction control undergoes the same processing as test sample
- Confirms successes of extraction step and monitors co-purification of PCR inhibitors
- Probe based designed specifically for multiplex quantitative PCR assays
- Quantitative PCR positive control sequence is unique with no homology to any organism
## Workflow
### qPCR Extraction Control Red, MDX026
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 25x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Control used to monitor the success of a qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample DNA.
Available in 10 mL (2,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX026-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX026-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX026.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX026)
## Description
qPCR Extraction Control Red comprises internal control DNA sequence in *E. coli* cells and a control mix (containing specific primer and probe (emission wavelength = 670nm)) for qPCR detection. The cells are added to the sample and lysed and extracted with the sample DNA for downstream amplification by qPCR. The detection of qPCR Extraction Control acts as a PCR positive control and confirms the success of the extraction and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionControl used to monitor the success of a qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample DNA.Concentration25xAppearanceClear, colorless solutionInternal Control DNAIn *E. coli* cells (genotype: F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-argF)U169Ф80lacZΔ15λ–pBR322 (ranseqb1 AmpR)).Control MixPrimers and Quasar® 670 labeled probeApplicationProbe-based, qPCRSample typeTissue, cellsPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionaity/ ConsistencyCt of 29 ± 1.6. The difference between test and history is less than 1 Ct.
## Catalogs & Brochures
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction Controls**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
[Low DNA qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-qpcr-mix/)
## FAQs: qPCR Extraction Control
What are the differences / advantages in comparison with internal control or spike in controls?
The benefit of the artificial qPCR Extraction Control cells in evaluation of the extraction process is the possibility to validate sample extraction process. Signal derived from the qPCR Extraction Control confirms the success of the extraction step and monitors co-purification of PCR inhibitors that may cause biased or PCR false negative results. Housekeeping genes or spike in controls do not monitor the whole extraction process, especially the lysis step and in the case of housekeeping genes, low extraction efficiency and degraded samples.
What is internal DNA control in DNA extraction?
When performing DNA extraction, it is often advantageous to have an exogenous source of DNA template that is spiked into the sample prior to lysis. This control DNA is then co-purified with the sample DNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
Can the E. coli interfere with screening for DNA from other bacteria?
Yes, it is possible that some of the genes will be the similar, the genotype of the *E. coli* that we use is F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ- pBR322 (ranseqb1 AmpR). You will need to check before using the qPCR Extraction Control with other bacteria.
Do I need to supply the primers and probe for the qPCR DNA Extraction Control?
The primers and probe for the qPCR Extraction Controls are in the Control Mix.
Would it be possible to use a different PCR detection method than recommended in the manual?
We recommend using the probe-based detection method for quantification of DNA extraction controls, but it would be possible to use other PCR applications for detection of the extraction controls, such as an intercalating dye such as SYBR® Green (but this would be singleplex), or endpoint PCR.
Why are there two colors for the qPCR Extraction Controls?
The two colors are for the fluorescent dyes on the qPCR Extraction Control probe. Control Mix Red (Cy5 – emission wavelength = 670nm) and Control Mix Orange (HEX – emission wavelength = 560nm). This allows you to chose one that will fit with your existing protocol in a multiplex qPCR assay.
Do I need a specific DNA extraction method for the qPCR Extraction Control?
No, the qPCR Extraction Control will work with any commercially available DNA extraction method, such as silica-membrane extraction kits, magnetic bead-based extraction, phenol-based extraction and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [qPCR Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/qpcr-extraction-control-orange/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA-RNA Extraction Controls ](/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)» qPCR Extraction Control Orange
# qPCR Extraction Control Orange
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s qPCR Extraction Control Orange uses *E. coli* cells of a known concentration that contain quantitative PCR positive control DNA sequence (with no known homology to any organism, so that it does not interfere with the detection of the sample target DNA). Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of a qPCR assay from lysis/extraction to amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's qPCR Extraction Control Orange
- Extraction control undergoes the same processing as test sample
- Confirms successes of extraction step and monitors co-purification of PCR inhibitors
- Probe based designed specifically for multiplex quantitative PCR assays
- Quantitative PCR positive control sequence is unique with no homology to any organism
## Workflow
### qPCR Extraction Control Orange, MDX027
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 25x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Control used to monitor the success of a qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample DNA.
Available in 10 mL (2,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX027-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX027-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX027.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX027)
## Description
qPCR Extraction Control Orange comprises internal control DNA sequence in *E. coli* cells and a control mix (containing specific primer and probe (emission wavelength = 560nm)) for qPCR detection. The cells are added to the sample and lysed and extracted with the sample DNA for downstream amplification by qPCR. The detection of qPCR Extraction Control acts as a PCR positive control and confirms the success of the extraction and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionControl used to monitor the success of a qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample DNA.Concentration25xAppearanceClear, colorless solutionInternal Control DNAIn *E. coli* cells (genotype: F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-argF)U169Ф80lacZΔ15λ–pBR322 (ranseqb1 AmpR)).Control MixPrimers and Cal Fluor® Orange 560 labeled probeApplicationProbe-based, qPCRSample typeTissue, cellsPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionaity/ ConsistencyCt of 29 ± 1.6. The difference between test and history is less than 1 Ct.
## Catalogs & Brochures
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction Controls**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
[Low DNA qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-qpcr-mix/)
## FAQs: qPCR Extraction Control
What are the differences / advantages in comparison with internal control or spike in controls?
The benefit of the artificial qPCR Extraction Control cells in evaluation of the extraction process is the possibility to validate sample extraction process. Signal derived from the qPCR Extraction Control confirms the success of the extraction step and monitors co-purification of PCR inhibitors that may cause biased or PCR false negative results. Housekeeping genes or spike in controls do not monitor the whole extraction process, especially the lysis step and in the case of housekeeping genes, low extraction efficiency and degraded samples.
What is internal DNA control in DNA extraction?
When performing DNA extraction, it is often advantageous to have an exogenous source of DNA template that is spiked into the sample prior to lysis. This control DNA is then co-purified with the sample DNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
Can the E. coli interfere with screening for DNA from other bacteria?
Yes, it is possible that some of the genes will be the similar, the genotype of the *E. coli* that we use is F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ pBR322 (ranseqb1 AmpR). You will need to check before using the qPCR Extraction Control with other bacteria.
Do I need to supply the primers and probe for the qPCR DNA Extraction Control?
The primers and probe for the qPCR Extraction Controls are in the Control Mix.
Would it be possible to use a different PCR detection method than recommended in the manual?
We recommend using the probe-based detection method for quantification of DNA extraction controls, but it would be possible to use other PCR applications for detection of the extraction controls, such as an intercalating dye such as SYBR® Green (but this would be singleplex), or endpoint PCR.
Why are there two colors for the qPCR Extraction Controls?
The two colors are for the fluorescent dyes on the qPCR Extraction Control probe. Control Mix Red (Cy5 – emission wavelength = 670nm) and Control Mix Orange (HEX – emission wavelength = 560nm). This allows you to choose one that will fit with your existing protocol in a multiplex qPCR assay.
Do I need a specific DNA extraction method for the qPCR Extraction Control?
No, the qPCR Extraction Control will work with any commercially available DNA extraction method, such as silica-membrane extraction kits, magnetic bead-based extraction, phenol-based extraction and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [Air-Dryable Direct DNA qPCR Plant, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-plant-4x/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA qPCR Plant Master Mix
Air-Dryable™ Direct DNA qPCR Plant is a glycerol-free mix that contain optimized excipients compatible with air and oven drying. It has been designed for the development of qPCR assays for direct detection of plant DNA from crude lysate without extraction. **Can also be used wet and/or with purified nucleic acid.**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Air-Dryable™ Direct DNA qPCR Plant
- For ultra-sensitive direct qPCR plant DNA testing using crude lysate samples.
- Simplify plant DNA testing, by removing the DNA extraction step and shortening the sample-to-result workflows.
- Designed for genotyping, transgene plant detection, GMO testing and knockout analysis.
- Can be used wet or it can be dried, for developing an ambient-temperate stable assay.
## Detection down to a single copy of Rice ATPe in tomato lysate with high reaction efficiency
Air-Dryable™ Direct DNA qPCR Plant Mix was air dried with rice ATPe primers and probe. The dried material was reconstituted in 40% tomato leaf alkaline lysate containing 1,000 copies (brown), 100 copies (amber), 10 copies (green) and 1 copy (blue) genome equivalents per reaction of Rice gDNA.
The results illustrate the sensitivity of the Air-Dryable™ Direct DNA qPCR Plant Mix to (A) detection down to 1 copy of Rice ATPe in tomato lysate with (B) 100% reaction efficiency.
### Air-Dryable Direct DNA qPCR Plant, 4x, MDX116
**Application:** qPCR**Specimen Type:** Plant,DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
No need for extraction, compatible with 25% Plant lysate (SDS, NaOH). Perfect for multiplexing and fast cycling conditions for in-field qPCR testing. Used for genotyping and transgene or pathogenic detection.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX116-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX116-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX116.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX116-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX116)
#### Meridian Life Science Division's Air-Dryable™ Plant Mix was recently named one of the Top 10 most innovative products for 2021 by SeedWorld.
Meridian has developed a new Air-Dryable™ Direct DNA qPCR Plant mix, which is inhibitor tolerant and can be used with crude extracts of plant samples. It’s also air-drying compatible for creating ambient-temperature stable assays.
Click the “Play Button” on the left to learn more.
## Description
The introduction of genetically modified organisms (GMO) in the last 20 or so years and the demand for more precise and reliable techniques to detect foreign (transgenic or pathogenic) DNA in edible plants have been the driving force for the introduction of qPCR techniques in plant research. Direct amplification of crudely lysed plant DNA samples is a fast and convenient technique that avoids the need for laborious, time-consuming, and expensive nucleic acid extractions prior to qPCR. Air-Dryable™ Direct qPCR Plant is the first commercially available mix designed for developing ambient-temperature stable assays for the direct quantitation of DNA from plants. It combines the benefits of inhibitor tolerance with air-drying to create highly sensitive and cost-effective plant assays.
## Specifications
DescriptionGlycerol-free qPCR mix containing Taq polymerase, reaction buffer, dNTPs, MgCl2 and air-dry compatible excipients, developed to tolerate the effects of the inhibitors present in plant lysate.Concentration4xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based real-time PCR, Direct PCR from plant lysatesSample typeCrude or purified DNA from plant tissuePresentation1 vialStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following air-dryingConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Air Dryable Direct DNA qPCR Plant](https://collateral.meridianlifescience.com/view/397948458/)**Air Dryable Direct DNA qPCR Plant**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
## FAQs: qPCR Plant Test
What types of PCR inhibitors are found in plant tissues?
Plant tissue can contain humic acids, pectin, polyphenols, complex polysaccharides, tannins and xylan
What is your recommendation to take a sample from plant for Direct qPCR?
In order to obtain best results for plant DNA testing, it is important to use a very small amount of starting materials. The recommended size is 1.2 mm in diameter single leaf punch (0.1 mg).
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is a pre-treatment needed for the plant material?
That will depend on the plant tissue, for soft leaf samples a direct heat lysis can be applied, a single leaf punch (leaf disc of ø1,2 mm or approximately 0.1 mg) is heated at 95 °C for 5 min in 20 µL water. For tougher tissue a SDS lysis (A single leaf punch is heated at 95 °C for 5 min in 26 µL SDS Lysis Buffer (0.1% SDS)) or alkaline lysis (A single leaf punch was heated at 95 °C for 5 minutes in 20 µL alkaline Lysis Buffer (0.2 M NaOH) and neutralised using 6 µL 2 M Tris-HCl, pH 7.5 (Total lysate volume per leaf punch = 26 µL)) may be necessary.
Is qPCR a validated GMO test?
In the European Union (EU), labelling of any food and feed product containing or consisting of genetically modified organisms (GMOs) is mandatory (Regulation No 1830; Regulation No 1829). In order to comply with existing legislation, analytical methods for GMO quantification and detection must be available. Currently, qPCR is the technique of choice for GMO determination. qPCR can also be used to determine copy number in a transgenic plant (as multiple transgenes tend to be unstable and the plants more difficult to commercialize, qPCR screening for single copies can therefore save time and resources in future generations).
Are reaction conditions the same for air-dried and liquid mixes?
Yes, the Air-Dryable™ Direct DNA qPCR Plant be used as a liquid mix or air/oven dried and stored for up to 24 months without needing to change the reaction conditions and air drying/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [RT-qPCR Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/rt-qpcr-extraction-control-red/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA-RNA Extraction Controls ](/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)» RT-qPCR Extraction Control Red
# RT-qPCR Extraction Control Red
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s RT-qPCR Extraction Control Red uses artificial micelles of a known concentration that contain quantitative PCR positive control RNA sequence (with no known homology to any organism, so that it does not interfere with the detection of the sample target RNA). Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of an RT-qPCR assay from lysis/extraction to reverse transcription and amplification
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's RT-qPCR Extraction Control Red
- Extraction control undergoes the same processing as test sample
- Confirms successes of extraction step and monitors co-purification of PCR inhibitors
- Probe based designed specifically for multiplex quantitative PCR assays
- Quantitative PCR positive control sequence is unique with no homology to any organism
## Workflow
### RT-qPCR Extraction Control Red, MDX028
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 25x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Control used to monitor the success of an RT-qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample RNA.
Available in 1 mL (500 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX028-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX028-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX028.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX028)
## Description
RT-qPCR Extraction Control Red contains an internal control RNA sequence, with no known homology to any organism, in an artificial cell. The RT-qPCR Extraction Control is spiked in the with lysis buffer into the sample prior to RNA extraction. Following RNA extraction, the control mix (containing specific primers and probe (emission wavelength = 670nm)) is added to the extracted RNA prior to amplification. The detection of RT-qPCR Extraction Control acts as a PCR positive control and confirms the success of the extraction, reverse transcription, and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionControl used to monitor the success of an RT-qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample RNA.Concentration25xAppearanceClear, colorless solutionInternal Control RNAIn micellsControl MixPrimers and Quasar® 670 labeled probeApplicationProbe-based, one-step RT-qPCRSample typeTissue, cellsPresentation3 vialsStorage-80 °CMix stabilitySee outer labelFunctionaity/ ConsistencyCt of 27 – 30. The difference between test and history is less than 1 Ct.
## Catalogs & Brochures
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction Controls**
## Related Products
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
## FAQs: RT-qPCR Extraction Control
What are the differences / advantages in comparison with other methods like measurement of housekeeping gene, internal control / spike in controls?
The benefit of the artificial RT-qPCR Extraction Control in evaluation of the extraction process is the possibility to validate sample extraction process. Signal derived from the RT-qPCR Extraction Control confirms the success of the extraction step and monitors co-purification of PCR inhibitors that may cause biased or PCR false negative results. Housekeeping genes or spike in controls do not monitor the whole extraction process, especially the lysis step and in the case of housekeeping genes, extraction efficiency and degraded samples as well as the possibility of the housekeeping gene expression level changing.
What is internal RNA control in RNA extraction?
When performing RNA extraction, it is often advantageous to have an exogenous source of RNA template that is spiked into the sample prior to lysis. This control RNA is then co-purified with the sample RNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
How careful do I need to be with the RT-qPCR Extraction Control?
The RT-qPCR Extraction Controls are in micelles and so care needs to be taken when handling them. We recommend storing the RT-qPCR Extraction Control at -80 ᵒC and adding it to the lysis buffer before adding to the sample.
Do I need to supply the primers and probe for the RT-qPCR RNA Extraction Control?
The primers and probe for the RT-qPCR Extraction Controls are in the Control Mix.
Why are there two colors for the RT-qPCR Extraction Controls?
The two colors are for the fluorescent dyes on the RT-qPCR Extraction Control probe. Control Mix Red (Cy5 – emission wavelength = 670nm) and Control Mix Orange (HEX – emission wavelength = 560nm). This allows you to chose one that will fit with your existing protocol in a multiplex RT-qPCR assay.
Do I need a specific extraction method for the RT-qPCR Extraction Control?
No, the RT-qPCR Extraction Control will work with commercially available silica-membrane extraction kits and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [RT-qPCR Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/rt-qpcr-extraction-control-orange/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA-RNA Extraction Controls ](/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)» RT-qPCR Extraction Control Orange
# RT-qPCR Extraction Control Orange
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s RT-qPCR Extraction Control Orange uses artificial micelles of a known concentration that contain quantitative PCR positive control RNA sequence (with no known homology to any organism, so that it does not interfere with the detection of the sample target RNA). Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of an RT-qPCR assay from lysis/extraction to reverse transcription and amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's RT-qPCR Extraction Control Orange
- Extraction control undergoes the same processing as test sample
- Confirms successes of extraction step and monitors co-purification of PCR inhibitors
- Probe based designed specifically for multiplex quantitative PCR assays
- Quantitative PCR positive control sequence is unique with no homology to any organism
## Workflow
### RT-qPCR Extraction Control Orange, MDX029
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 25x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Control used to monitor the success of an RT-qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample RNA.
Available in 1 mL (500 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX029-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX029-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX029.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX029)
## Description
RT-qPCR Extraction Control Orange contains an internal control RNA sequence, with no known homology to any organism, in an artificial cell. The RT-qPCR Extraction Control is spiked in the with lysis buffer into the sample prior to RNA extraction. Following RNA extraction, the control mix (containing specific primers and probe (emission wavelength = 560nm)) is added to the extracted RNA prior to amplification. The detection of RT-qPCR Extraction Control acts as a PCR positive control and confirms the success of the extraction, reverse transcription, and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionControl used to monitor the success of an RT-qPCR assay from lysis/extraction to amplification and reduces the chance of obtaining false negative results from the sample RNA.Concentration25xAppearanceClear, colorless solutionInternal Control RNAIn micellsControl MixPrimers and Cal Fluor® Orange 560 labeled probeApplicationProbe-based, one-step RT-qPCRSample typeTissue, cellsPresentation3 vialsStorage-80 °CMix stabilitySee outer labelFunctionaity/ ConsistencyCt of 27 – 30. The difference between test and history is less than 1 Ct.
## Catalogs & Brochures
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction Controls**
## Related Products
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: RT-qPCR Extraction Control
What are the differences / advantages in comparison with other methods like measurement of housekeeping gene, internal control / spike in controls?
The benefit of the artificial RT-qPCR Extraction Control in evaluation of the extraction process is the possibility to validate sample extraction process. Signal derived from the RT-qPCR Extraction Control confirms the success of the extraction step and monitors co-purification of PCR inhibitors that may cause biased or PCR false negative results. Housekeeping genes or spike in controls do not monitor the whole extraction process, especially the lysis step and in the case of housekeeping genes, extraction efficiency and degraded samples as well as the possibility of the housekeeping gene expression level changing.
What is internal RNA control in RNA extraction?
When performing RNA extraction, it is often advantageous to have an exogenous source of RNA template that is spiked into the sample prior to lysis. This control RNA is then co-purified with the sample RNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
How careful do I need to be with the RT-qPCR Extraction Control?
The RT-qPCR Extraction Controls are in micelles and so care needs to be taken when handling them. We recommend storing the RT-qPCR Extraction Control at -80 ᵒC and adding it to the lysis buffer before adding to the sample.
Do I need to supply the primers and probe for the RT-qPCR RNA Extraction Control?
The primers and probe for the RT-qPCR Extraction Controls are in the Control Mix.
Why are there two colors for the RT-qPCR Extraction Controls?
The two colors are for the fluorescent dyes on the RT-qPCR Extraction Control probe. Control Mix Red (Cy5 – emission wavelength = 670nm) and Control Mix Orange (HEX – emission wavelength = 560nm). This allows you to chose one that will fit with your existing protocol in a multiplex RT-qPCR assay.
Do I need a specific extraction method for the RT-qPCR Extraction Control?
No, the RT-qPCR Extraction Control will work with commercially available silica-membrane extraction kits and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Hi-throughput dUTP qPCR Mix Master Mix
Hi-throughput dUTP qPCR Mix is fast, highly reproducible real-time PCR master mix that has been designed with a highly optimized buffer chemistry and hot-start DNA polymerase, to deliver excellent results and very low background, allowing greater sensitivity.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Hi-throughput dUTP qPCR Mix Master Mix
- Optimized dTTP to dUTP ratio for high sensitivity and specificity.
- High efficiency, giving excellent performance in multiplex qPCR assays.
- Prevents carry-over qPCR contamination.
## High efficiency and sensitivity with DNA viruses
Amplification of a 10-fold serial dilution of Parvovirus B19 from inactivated crude viral lysates was tested using Hi-throughput dUTP qPCR Mix and primers and probe for Parvovirus B19. Four replicated are shown in the amplification curve, illustrate the reproducibility, efficiency and sensitivity of Hi-throughput dUTP qPCR Mix.
### Hi-throughput dUTP qPCR Mix, MDX031
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
qPCR mix containing Taq polymerase, reaction buffer, dNTP/dUTP mix and MgCl2, developed to remove background PCR product contamination.
Available in 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX031-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX031-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX031.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX031)
## Description
Hi-throughput dUTP qPCR Mix contains Taq DNA polymerase, reaction buffer, dNTP, MgCl2, stabilizers and PCR enhancers. However, some of the dTTPs in the dNTP mix has been substituted for dUTP, so that Uracil DNA Glycosylase (UDGase) (MDX054) can be added to carry-over qPCR contamination. This makes Hi-throughput dUTP qPCR ideal for multiplex assays on open, automated, high-throughput instruments.
## Specifications
DescriptionqPCR mix containing Taq polymerase, reaction buffer, dNTP/dUTP mix and MgCl2, developed to remove background PCR product contamination.Concentration2 xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationHigh throughput qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics Catalog](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics Catalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
[Hi-throughput dUTP qPCR Lo-ROX](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-lo-rox/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
## FAQs: Hi-throughput dUTP qPCR Mix
What is carryover qPCR contamination?
As qPCR can amplify tiny amounts of DNA, preventing contamination is essential, as even small amounts of qPCR contamination can produce false positives. Cross-over qPCR contamination can include cross-contamination from other samples, contamination from elsewhere in the laboratory, and carryover qPCR contamination from amplification products and primers used in prior qPCR experiments. The latter causes most of the false positive results seen in qPCR. Preventing contamination can be difficult and so laboratory procedures must be in place to ensure DNA from one assay is not re-amplified in subsequent assay.
How is Uracil DNA Glycosylase used in qPCR?
Uracil DNA Glycosylase can specifically degrade products that have already been through the qPCR process and have incorporated dUTP, leaving native nucleic acid templates intended for amplification intact. Uracil DNA Glycosylase activation occurs as the first step of qPCR at a 50°C incubation for 2 minutes and then the Uracil DNA Glycosylase is denatured when the temperature increases to 95°C during hot-start activation.
What is the difference between UDG and UNG?
Uracil-DNA glycosylase (UDG or UDGase) is a family of enzymes comprising six sub-families. Family I UDGase enzymes are called UNG (uracil-N-glycosylase gene), so there is no difference, the terms UDG and UNG are commonly used interchangeably because they perform the same function in qPCR—namely to prevent carryover qPCR contamination.
Why is dUTP not used for all qPCR assays?
Total elimination of contaminants is not always accomplished using this technique, particularly where PCR product length is short, which is a common situation in qPCR assays. In addition, there is the possibility, particularly when the initial sample contains only one or a few target molecules, that inclusion of UDG may reduce amplification efficiency and thereby delay detection and so reduce sensitivity.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Fast 1-Step RT-qPCR Mix
Fast 1-Step RT-qPCR master mix contains Taq polymerase, reaction buffer, dNTP, MgCl2, stabilizers, PCR enhancers, and separate reverse transcriptase and RNase inhibitor. It is ideal for developing multiplex one-step qPCR diagnostic tests and is suited for high-throughput, automated platforms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Fast 1-Step RT-qPCR Mix
- Create ultra-sensitive RT-qPCR assays to deliver reproducible results from low copy number RNA targets
- Robust formulation delivers consistent, reliable one-step RT-PCR performance in fast cycling conditions
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High efficiency, giving excellent performance in multiplex qPCR assays
## Fast, singleplex (red) and multiplex qPCR (blue) of a ten-fold serial dilution of an RNA target
A 10-fold serial dilution of human cDNA amplified with four different probes; both in singleplex reactions (blue line) and quadruplex reaction (the red line displayed is for the same primers as for the singleplex). Five replicates were run (10 min 45°C followed by 2 min 95°C and 45 cycles 95°C 5s, 20°C 10s) and the results illustrate the high sensitivity, excellent reproducibility and Ct values for both the singleplex and multiplex reactions with no reduction of efficiency that is often associated with multiplexing.
### Fast 1-Step RT-qPCR Mix, MDX032
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
A combination of the latest advances in buffer chemistry and PCR enhancers, together with a hot-start polymerase, dNTPs and MgCl2 and separate reverse transcriptas, ideal for fast, accurate, highly reproducible RT-qPCR.
Available in 1 mL (100 Rxns), 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX032-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX032-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX032.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX032)
## Description
Fast 1-Step RT-qPCR Mix is a one-step RT-PCR master mix that has been designed with a highly optimized buffer chemistry, hot-start DNA polymerase, and reverse transcriptase, to give fast, efficient, reliable amplification of your low-copy RNA targets and subsequent highly sensitive, reproducible one-step RT-qPCR in a single tube. With high processivity and robustness, it delivers excellent results in both singleplex and multiplex qPCR assays and confers superior assay performance under fast thermal cycling conditions, allowing more samples to be run in a day with the highest confidence, ideal for high‑throughput assays.
## Specifications
DescriptionThe latest advances in buffer chemistry and PCR enhancers and stabilizers, together with a hot-start polymerase, dNTPs and MgCl2 and separate reverse transcriptase and RNase inhibitor, for highly reproducible, accurate assay results under fast thermal cycling conditions, ideal for automated, high-throughput systems.Concentration2xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, one-step RT-qPCRSample typeRNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics Catalog](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics Catalog**
## Related Products
[Lyo-Ready qPCR Mix, 2.6x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## FAQs: Fast 1-Step RT-qPCR Mix
What is one step qPCR and two step qPCR?
In one-step qPCR or reverse transcription qPCR, cDNA synthesis and qPCR are performed in a single reaction tube. In two-step qPCR, cDNA is synthesized in one reaction tube, and aliquots of the cDNA is then used for a subsequent RT-qPCR experiments.
What are the advantages of using a 1-step RT-PCR mix?
• Accurate representation of target copy number
• Best option for high-throughput screening
• Simple and rapid
• Fewer pipetting steps (reducing possible errors and contamination)
• Best method when only a few assays are run repeatedly
• Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample
There are several other advantages of one-step reactions, these include limited sample handling and reduced bench time, which helps to decrease chances for pipetting errors and cross contamination between reverse transcription and qPCR steps. This method is quick to set up and makes processing multiple RNA samples easy (especially when using liquid handling robotics), when you are amplifying only a few genes of interest. It is therefore ideal for high throughput screening laboratories where only a few reverse transcription qPCR assays are run repeatedly, using well-established reaction conditions, with the added advantage that multiplex qPCR of the gene of interest and control genes can be done in single well, from same RNA sample.
What are the considerations of using a 1-step RT-PCR mix?
Gene-specific primers are required for generating the cDNA and for subsequent amplification in one tube, however this reduces experimental variation, since both enzymatic reactions take place under the same conditions, making one-step qPCR highly reproducible.
One-step RT-PCR requires careful evaluation to prevent primer dimer formation, because the primers will be present during the lower temperature conditions of the RT reaction as well as the qPCR cycling. This is particularly important in multiplex qPCR assays.
How can amplification of genomic DNA in RNA samples be avoided?
There are several ways to avoid genomic contamination with reverse transcription qPCR. Firstly, design forward and reverse primers in exons upstream and downstream of a large intron. This strategy favors the smaller amplicon and will prevent the genomic DNA from being amplified.
Secondly, for genes that lack introns or when the genomic structure is unknown, pre-treat the RNA with DNase I to remove genomic DNA.
Do you sell RT-qPCR mixes that use intercalating dyes such as SYBR Green?
No, intercalating dyes bind into all DNA, this means that they cannot be used for multiplex qPCR, as different amplicons cannot be distinguished, whereas different dyes can be used on probes for different amplicons. This also makes probe-based systems more specific; only detect the gene of interest, even making it possible to distinguish between similar sequences with small differences like SNPs or mutations. In general, probe assays need less optimization, and they can be used for multiplex qPCR.
In a 1-step RT-PCR is it preferable to use elevated temperature in the RT step?
When template RNA has stable secondary structures and when doing multiplex qPCR, it can be beneficial to extend the reaction time up to 20 minutes and/or the temperature use elevated temperatures (up to 48°C) in the reverse transcription reaction. If the RNA contains a lot of stable secondary structures (often seen in RNA viruses), we recommend using an RT-qPCR mix with a thermostable reverse transcriptase, such as Inhibitor-Tolerant RT-qPCR Mix (MDX016), where the reverse transcription reaction time can be extended up to 55° C.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Reverse Transcriptases ](/lifescience/products/molecular-reagents/reverse-transcriptases/)» Lyo-Compatible MMLV-RT
# Lyo-Compatible MMLV-RT
Lyo-Compatible MMLV-RT is a high concentration reverse transcriptase and dilution buffer. Lyo-Compatible MMLV-RT is added to a glycerol free qPCR mix to create a Lyo-ready 1-step RT-qPCR mix for subsequent lyophilization.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Compatible MMLV-RT
- Highly sensitive cDNA synthesis, even low concentrations of template RNA
- Thermostability up to 45°C, for more challenging transcripts
- High-quality, first-strand cDNA synthesis ideal for most one-step RT-PCR and RT-qPCR applications
- Ideal for creating ambient-temperature stable assays.
### Lyo-Compatible MMLV-RT, MDX042
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** > 165 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free high concentration reverse transcriptase and dilution buffer. Can be used to create 1-step RT-qPCR mixes for subsequent lyophilization.
Available in 8 µL (1,000 Rxns) or 80 µL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX042-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX042-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX042.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX042-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX042)
List of Lot-Specific Enzyme Concentrations
**Reverse transcriptase activity:**
**356.0 U/µL Lot Numbers:** EM032-B069810 , EM033-B075830, EM032-B079280, EN055-B075840, EM032-B070090, EM033-B078120, EM033-B079610, EN055-B077220, EM032-B078560 , EM033-B078550, EN054-B069830 , EM033-B072620, EM116-B079090, EN055-B071120
**Reverse transcriptase activity:**
**820.6 U/µL Lot Numbers:** EM116-B079670, EM033-B079680, EM032-B079780, EM033-B079960, EN055-B081110, EN055-B081180, EN055-B081460
**Reverse transcriptase activity:**
**676.6 U/µL Lot Numbers:** EN055-B095790, EN055-B102520
**Reverse transcriptase activity:**
**591 U/µL Lot Numbers:** EN055-B099440, EN054-B085190, EN055-B092750, EN054-B088060, EN054-B088340, EN054-B088440, EN055-B092210, EN055-B095500, EN055-B096450, EN055-B097970, EN055-B097120, EN055-B097760
**Reverse transcriptase activity:**
501 U/µL Lot Numbers: EN055-B103720, EN055-B103930, EN054-B105000, EN055-B107580, EN055-B118430
**966.0 U/µL Lot Numbers:** EN055-B127580, EN054-B129970, EN054-B131550
## Description
Lyo-Compatible MMLV-RT is a high-concentration, Moloney Murine Leukemia Virus (MMLV) Reverse Transcriptase (RT) with reduced RNase H activity, which exhibits high sensitivity and efficiency for cDNA synthesis and is suitable for incorporation into wet or lyophilized multiplex RT-PCR assays, allowing high sensitivity detection of low copy number RNA targets.
## Specifications
DescriptionHigh concentration reverse transcriptase and dilution buffer. Can be used to create 1-step RT-qPCR mixes for subsequent lyophilization.Concentration> 165 U/µL (see List of Lot-Specific Enzyme Concentrations)AppearanceClear, colorless solutionApplicationcDNA synthesis, RT-PCR, PCR, two-step RT-qPCR, one-step RT-qPCRSample typeRNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelDNA contaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[RNase-Tolerant MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/rnase-tolerant-mmlv-rt/)
[MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/mmlv-rt/)
[55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
## FAQs: Lyo-compatible MMLV-RT
I want to use viral RNA with very high secondary structure for cDNA synthesis, can I use Lyo-compatible MMLV-RT?
For RNA with very high secondary structure, we recommend using 55C MMLV-RT (MDX117), this is a glycerol-free reverse transcriptase can be used at temperatures up to 60°C which improves the cDNA yield from difficult RNA targets that require higher temperature to denature strong secondary structures.
Can I improve the yield when using Lyo-compatible MMLV-RT?
Avoiding ribonuclease contamination is of primary concern since high quality template RNA is required. You can add RNase Inhibitor (MDX056).
What buffer do you recommend using with Lyo-Compatible MMLV-RT?
The Lyo-Compatible MMLV-RT is supplied with an enzyme dilution buffer, but if you are going to make cDNA, you will also require a buffer that contains 0.2 mM each dATP, dCTP, dGTP & dTTP, 10 mM DTT (dithiothreitol), 25 mM KCl, 3.5 mM MgCl2 and 50 mM Tris–HCl (7.5). However, if you want to do RT-qPCR, we recommend Lyo-Ready 1-Step RT-qPCR Buffer (MDX052).
How is Lyo-Compatible MMLV-RT inactivated?
The reverse transcriptase can be inactivated by adding a chelating agent such as EDTA or heating to 70°C or higher for 10 min.
Does Lyo-Compatible MMLV-RT need a primer?
Yes, to initiate cDNA synthesis, the Lyo-Compatible MMVL-RT reverse transcriptase requires a primer to bind to its complementary sequences on the RNA template and serve as a starting point for synthesis of a new strand. For general cDNA synthesis, random hexamer primers and oligo(dT) primers can be used either separately or mixed. For RT-PCR and RT-qPCR gene-specific primers should be used.
What is the error rate of Lyo-Compatible MMLV-RT?
Unlike eukaryotic replicative polymerases, reverse transcriptase lacks exonuclease activity and so is error prone. MMLV-based reverse transcriptase has been reported to have an error rate in the range of 1.1 × 10−4 to 4.8 × 10−4.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reverse Transcriptases
---
### [MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/mmlv-rt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# MMLV-RT
Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV RT) is an RNA-dependent DNA polymerase that can be used for cDNA synthesis and subsequent PCR or qPCR in one-step or two-step RT-PCR or RT-qPCR assays.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's MMLV-RT
- Highly sensitive, even with low concentrations of template RNA
- Thermostability up to 45°C, for more challenging transcripts
- High-quality, first-strand cDNA ideal for most RT-PCR and RT-qPCR applications
- Lower RNase H activity for high yield
### MMLV-RT, MDX044
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 100x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
For cDNA synthesis and subsequent PCR or qPCR in a one-step or two-step assay.
Available in 200 µL (1,000 Rxns) or 2 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX044-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX044-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX044.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX044)
## Description
MMLV-RT is a high-quality reverse transcriptase that synthesizes a complementary DNA (cDNA) strand from mRNA or total RNA. With higher thermostability and reduced RNase H activity, it can be used for synthesis with long messenger RNA templates with high sensitivity and efficiency and is ideal for detecting low-level target genes.
## Specifications
DescriptionMMLV-RT (Moloney Murine Leukemia Virus Reverse Transcriptase) is used for cDNA synthesis and subsequent PCR or qPCR in a one-step or two-step assay.Concentration100xAppearanceClear, colorless solutionApplicationcDNA synthesis, RT-PCR, PCR, two-step RT-qPCR, one-step RT-qPCRSample typeRNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA contaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[RNase-Tolerant MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/rnase-tolerant-mmlv-rt/)
## FAQs: MMLV-RT
I want to generate cDNA from viral RNA with very high secondary structure, can I use MMLV-RT?
For RNA with very high secondary structure we recommend using 55C MMLV-RT (MDX117), this reverse transcriptase can be used at temperatures up to 60°C which improves the cDNA yield from difficult RNA targets that require higher temperature to denature strong secondary structures.
Can I improve the yield when using MMLV-RT?
Avoiding ribonuclease contamination is of primary concern since high quality template RNA is required. You can add RNase Inhibitor (MDX056), alternatively we also have RNase-Tolerant MMLV-RT (MDX043) which includes an RNase inhibitor.
What buffer do you recommend using with MMLV-RT?
If you are going to make cDNA, you will require a buffer that contains 0.2 mM each dATP, dCTP, dGTP & dTTP, 10 mM DTT (dithiothreitol), 25 mM KCl, 3.5 mM MgCl2 and 50 mM Tris–HCl (7.5). However if you want to do RT-qPCR, we recommend 1-Step qPCR Buffer, 4x (MDX034) or Lyo-Ready 1-Step RT-qPCR Buffer (MDX052).
How is MMLV-RT inactivated?
The reverse transcriptase can be inactivated by adding a chelating agent such as EDTA or heating to 70°C or higher for 10 min.
Does MMLV-RT need a primer?
Yes, to initiate reverse transcription, the MMVL-RT reverse transcriptase require a primer to bind to its complementary sequences on the RNA template and serve as a starting point for synthesis of a new strand. For general cDNA synthesis, random hexamer primers and oligo(dT) primers can be used either separately or mixed. For RT-PCR and RT-qPCR gene-specific primers should be used.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reverse Transcriptases
---
### [dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dCTP, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure Deoxycytidine triphosphate (dCTP), 100mM solution, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's dCTP, 100mM, Lithium Salt
- Greater than 99 % purity, ideal for use in qPCR applications
- Free from PCR inhibitors for maximum assay performance
- nzymatically synthesized from premium quality raw materials
- Free from DNase, RNase and Nickases
## Highly sensitive multiplex qPCR reaction
A 10-fold serial dilution of human genomic DNA amplified with four different probes, both in singleplex reactions (blue line) and quadruplex reaction (red line) using dATP, dCTP, dGTP and dTTP in lithium salt. The results illustrate the same high sensitivity, excellent reproducibility and Ct values for both the singleplex and multiplex reactions with no reduction of efficiency often associated with multiplexing.
### dCTP, 100mM (Lithium), MDX047
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dCTP (2’-Deoxycytidine-5’-Triphosphate) lithium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX047-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX047-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX047.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX047)
## Description
dCTP, 100mM, Lithium Salt is of the highest quality, with minimal batch-to-batch variations. It is manufactured to the highest purity standards and is perfectly suited for even the most demanding applications, such as long next-generation sequencing, long PCR, and highly sensitive qPCR.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dNTP Mix, 100mM (Lithium)](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-lithium/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dNTP Mix, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure Deoxynucleotide triphosphate (dNTP) mix, 25 mM each of dATP, dCTP, dGTP and dTTP solution (100 mM total), supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's dNTP Mix, 100mM, Lithium Salt
- Greater than 99 % purity, ideal for use in qPCR applications
- Free from PCR inhibitors for maximum assay performance
- Enzymatically synthesized from premium quality raw materials
- Free from DNase, RNase and Nickases
## Highly sensitive multiplex qPCR reaction
A 10-fold serial dilution of human genomic DNA amplified with four different probes, both in singleplex reactions (blue line) and quadruplex reaction (red line) using dATP, dCTP, dGTP and dTTP in lithium salt. The results illustrate the same high sensitivity, excellent reproducibility and Ct values for both the singleplex and multiplex reactions with no reduction of efficiency often associated with multiplexing.
### dNTP Mix, 100mM (Lithium), MDX051
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure mix of dATP, dGTP, dCTP, and dTTP in lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 5 mL or larger aliquots (please enquire)
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX051-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX051-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX051.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX051)
## Description
Ultra-pure dNTP (dATP (2’-Deoxyadenosine-5’-Triphosphate), dCTP (2’-Deoxycytidine-5’-Triphosphate), dGTP (2’-Deoxyguanosine-5’-Triphosphate) and dTTP (2’-Deoxythymidine-5’-Triphosphate)) lithium salt solution is enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities.
## Specifications
escriptionUltra-pure dNTP (dATP (2’-Deoxyadenosine-5’-Triphosphate), dCTP (2’-Deoxycytidine-5’-Triphosphate), dGTP (2’-Deoxyguanosine-5’-Triphosphate) and dTTP (2’-Deoxythymidine-5’-Triphosphate)) lithium salt solution is enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. dATPdCTPdGTPdTTPCompositionC10H12N5O12P3Li4,C10H12N3O13P3Li4C10H12N5O13P3Li4C10H13N2O14P3Li4Molecular weight514.916 g/mol490.891 g/mol530.916 g/mol505.903 g/molλmax (at pH 7.0)259 ± 1 nm272 ± 1 nm252 ± 1 nm267 ± 1 nmA250/A2600.78 ± 0.030.82 ± 0.031.16 ± 0.050.65 ± 0.03A280/A2600.15 ± 0.020.98 ± 0.030.66 ± 0.030.73 ± 0.02Concentration25 mM ± 5%(at λmax, pH 7.0, ԑ = 15.4 E x mmol-1 x cm-1)
25 mM ± 5%(at λmax, pH 7.0, ԑ = 9.1 E x mmol-1 x cm-1)
25 mM ± 5%(at λmax, pH 7.0, ԑ = 13.7 E x mmol-1 x cm-1)
25 mM ± 5%(at λmax, pH 7.0, ԑ = 9.5 E x mmol-1 x cm-1)
Presentation1 vialspH of Solution (at 20°C)7.5 – 8.0AppearanceClear, colorless solutionApplicationcDNA synthesis, PCR, long-range PCR (>20 kb), high fidelity PCR, RT-PCR, qPCR, RT-qPCR, LAMP, microarrays, long NGSConsistencySingle band with PCR amplification of a 3 kb amplicon with a serial dilution of dNTP.DNA contaminationNone detected in qPCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase/RNase/Nickase activityNone detectedPurity dNTP(HPLC Area % at λmax)
≥99%dNDP + dNMP(HPLC Area % at λmax)
<1%DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
[dNTPs](https://collateral.meridianlifescience.com/view/864093733/)**dNTPs (Deoxynucleotide triphosphates)Catalog**
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dNTP Mix, 100mM
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs is normally used in a PCR?
The standard concentration of a dNTP for PCR reactions is 0.2 mM. If the starting stock is a 25 mM solution of each dNTP in a 100mM dNTP Mix, you need to add 0.5 µL to a 50 µL standard PCR reaction.
Can I increase the DNA yield by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield, but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The sodium salt dNTP products are a standard grade and so we recommend these dNTPs for PCR. For more sophisticated reactions such as amplification of long templates, real-time PCR and NGS, we recommend lithium salt dNTP products.
Is the pH of the dATP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.0-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dATPs (deoxyadenosine triphosphate) to dADPs (deoxyadenosine diphosphates) and dAMPs (deoxyadenosine monophosphates), rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dATP solution can differ from the pH at 20°C. Sodium salts are temperature sensitive, so care needs to be taken when repeatedly frozen and thawed and sodium salt dATP is better aliquoted into smaller volumes and kept frozen in order to extend their shelf life.
What are the advantages of enzymic synthesis over chemical synthesis of dNTPs?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
Are the concentrations of the dNTPs each or total?
The concentration of our dNTP Mix are total – 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using molecular biology or PCR grade water.
Can your dNTP Mix be used for lyophilization?
Yes, all of our dNTPs are glycerol-free and so can be lyophilized.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Lyo-Ready 1-Step RT-qPCR Buffer](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-buffer/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Lyo-Ready 1-Step RT-qPCR Buffer
Molecular diagnostic tests are progressively moving towards lyophilization. There are several advantages for this, including room temperature shipping and storage, extended shelf-life and increased flexibility in sample volume. In order to be compatible with drying however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to freezing, vacuum and dehydration.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready 1-Step RT-qPCR Buffer
- Used to create ultra-sensitive RT-qPCR assays
- Formulated with a specialized blend of lyo-excipients, compatible with lyophilization into beads or cakes
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High efficiency, giving excellent performance in multiplex RT-qPCR assays
## Retention of reverse transcriptase activity following lyophilization
Glycerol-Free Taq HS 50 U/µL (MDX011), 100x Lyo-compatible MMLV-RT (MDX042), primers and probes were added to Lyo-Ready 1-Step RT-qPCR Buffer (MDX052), dried down and rehydrated (red) and tested against a freshly prepared wet mix (blue), in a triplex probe RT-qPCR assay on mouse RNA. The results demonstrate the same reverse transcriptase and polymerase enzyme activity before and following lyophilization.
### Lyo-Ready 1-Step RT-qPCR Buffer, MDX052
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free RT-qPCR reaction buffer containing lyo-excipients, designed to deliver highly reproducible, accurate RT-qPCR assay results under fast thermal cycling conditions.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX052-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX052-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX052.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX052-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX052)
## Description
Lyo-Ready 1-Step RT-qPCR Buffer is a glycerol-free qPCR mix containing RNase Inhibitor, reaction buffer, dNTP, MgCl2 and lyo-excipients. In order to produce room temperature lyophilized RT-qPCR reagents, Reverse Transcriptase, Taq polymerase, assay specific primers and probes are added to Lyo-Ready 1-Step RT-qPCR Buffer for subsequent lyophilization.
## Specifications
DescriptionA glycerol-free RT-qPCR reaction buffer containing lyo-excipients. In order to produce room temperature lyophilized qPCR reagents, a lyo-compatible Taq DNA polymerase, assay specific primers and probes are added for subsequent lyophilization.Concentration2xAppearanceClear, colorless solutionApplicationRT-qPCRSample typeRNA, cDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradationRNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[dNTP Mix, 100mM (Lithium)](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-lithium/)
## FAQs: Lyo-Ready 1-Step RT-qPCR Buffer
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex RT-qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
What probes can be used in RT-qPCR?
Many fluorescent RT-qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most used are:
– Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
– Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Lyo-Ready 1-Step RT-qPCR Buffer be used with crude samples?
The Lyo-Ready 1-Step RT-qPCR Buffer has some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we recommend using are optimized Lyo-Ready Specimen-specific™ (blood, saliva, urine, stool, and plant) RT-qPCR and RT-LAMP mixes.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo-Ready RT-qPCR Mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
Do you supply lyo-excipients separately?
No, our lyo-excipients are proprietary.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Uracil DNA Glycosylase](https://www.meridianbioscience.com/lifescience/products/molecular/uracil-dna-glycosylase/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Uracil DNA Glycosylase
Uracil DNA Glycosylase (UDG) is an enzyme used to eliminate carryover polymerase chain reaction (PCR) products in qPCR and RT-qPCR. This is done by incorporating dUTP in all qPCR products, so any residual products from previous PCR amplifications will contain dUs and can be digested by pre-treating with UDG enzyme. \*Not available for sale in the United States
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Uracil DNA Glycosylase
- Optimized dTTP to dUTP ratio for high sensitivity and specificity.
- High efficiency, giving excellent performance in multiplex qPCR assays.
- Novel optimizedaPrevents carry-over qPCR contamination. buffer system maximizes efficiency of PCR amplification, eliminate the need for long optimization, saving time, effort, and cost
- UDGase is also available as glycerol-free, high concentration and heat-labile.
## High efficiency and sensitivity with DNA viruses
Amplification of a 10-fold serial dilution of Parvovirus B19 from inactivated crude viral lysates was tested using Hi-throughput dUTP qPCR Mix (MDX031) and primers and probe for Parvovirus B19 and Uracil DNA Glycosylase (MDX054). Four replicated are shown in the amplification curve, illustrate the reproducibility, efficiency and sensitivity of Hi-throughput dUTP qPCR Mix.
### Uracil DNA Glycosylase, MDX054
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 1 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Used to eliminate carryover polymerase chain reaction (PCR) products in qPCR and RT-qPCR,by incorporating dUTP in reactions, so residual products from previous PCR amplifications containing dUs can be digested.
Available in 10 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX054-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX054-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX054.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX054)
## Description
Uracil DNA Glycosylase (UDG) catalyzes the release of uracil from uracil-containing single or double-stranded DNA, but not from RNA or oligonucleotides (6 or fewer bases). UDG is active over a broad pH range with an optimum at pH 8.0, does not require a divalent cation, and is inhibited by high ionic strength (>200 mM).
## Specifications
DescriptionUracil DNA Glycosylase (UDG) removes uracil residues from the sugar moiety of single- and double-stranded DNA without destroying the phosphodiester backbone, preventing its use as a hybridization target or as a template for DNA polymerases. UDG will not remove uracil from RNA.ConcentrationUracil DNA Glycosylase, MDX054 = 1 U/µL in 50% glycerolUnit DefinitionOne unit is the amount of enzyme that catalyses the release of 60 pmol of uracil per minute from double stranded, uracil-containing DNA. Activity was measured by release of \[3H\]-uracil in a 50 µL reaction mix containing 0.2 mg DNA (104-105 cpm/mg) in 30 minutes at 37 °C.SourceMDX054 is recombinant *E. coli* strains carrying the over-expressed modified gene of Uracil DNA Glycosylase.FormatClear, colorless solution10x reaction buffer0.25 M Tris-Cl, 1 mM EDTA, 10 mM DTT, pH 8.0.ApplicationHigh throughput, PCR, qPCRSample typecDNA, DNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionalitydUTP PCR products are degraded on the addition of UDGase to give single, distinct bands on an agarose gel.DNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR Mix**
## Related Products
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[dUTP Mix, 50mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-mix-50mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: Uracil DNA Glycosylase
How does Uracil DNA Glycosylase work?
During PCR, misincorporation of uracil during DNA synthesis or spontaneous cytosine deamination in the DNA strand can occur. UDG enzyme catalyzes the excision of uracil nucleobases (dUTPs) to prevent mutagenesis, allowing for targeted, more reliable PCR assays.
What is the difference between UDG enzyme and UNG enzyme?
UDG refers to a superfamily of enzymes that includes family I UDG enzyme called UNG, after the uracil-N-glycosylase gene, so the terms UDG enzyme (UDGase) and UNG enzyme are commonly used interchangeably because they perform the same function in qPCR, by preventing carryover contamination.
Does Uracil DNA Glycosylase remove uracil from RNA?
Uracil DNA Glycosylase (UDG) catalyzes the release of uracil from uracil-containing single or double-stranded DNA, but not from RNA or oligonucleotides (6 or fewer bases).
Which pH range is Uracil DNA Glycosylase active over?
UDG is active over a broad pH range with an optimum at pH 8.0, does not require a divalent cation, and is inhibited by high ionic strength (>200 mM).
At what temperature is Uracil DNA Glycosylase inactivated?
The UDG enzyme has activity below 55°C, so this should be the minimum annealing temperature for qPCR amplification, to avoid degradation of newly synthesized dU-containing qPCR products.
How is Uracil DNA Glycosylase tested for purity?
Uracil DNA Glycosylase is tested for purity (run on SDS-PAGE gel), presence and absence of endonucleases, nickases, exonucleases and RNases.
What is the source of the Uracil DNA Glycosylase?
The Uracil DNA Glycosylase is sourced from a recombinant E. coli strain carrying the over-expressed modified UDG gene.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Lyo-Ready 1-Step RT-qPCR Virus Master Mix
Lyo-Ready 1-Step RT-qPCR Virus Mix is a glycerol-free mix, ideal for developing ambient temperature, lyophilized, multiplex qPCR and RT-qPCR molecular diagnostic tests, particularly for RNA viruses, and is suited for high-throughput, automated platforms or microfluidic qPCR platforms requiring millisecond rehydration times. **Can also be used wet**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready 1-Step RT-qPCR Virus Master Mix
- Specifically optimized for amplification of RNA viruses with a high secondary structure (reverse transcriptase remains active at 55-60 °C)
- Very fast reaction kinetics – ideal for multiplex qPCR assays and low-copy number targets
- Glycerol-free mixes are pre-formulated with a specialized blend of lyo-excipients, compatible with lyophilization into beads or cakes
- Mixes can used as a wet mix, or lyophilized to create fast, highly reproducible, ambient temperature stable molecular diagnostic tests
## High efficiency and sensitivity from both DNA (red) and RNA (blue) templates
Amplification of both Rotavirus A (dsRNA) and Adenovirus (dsDNA) in a single multiplexed RT-qPCR assay, from inactivated crude viral lysates. The result illustrates that both the DNA and RNA viruses were amplified with high efficiency and sensitivity, demonstrating the ability of Lyo-Ready 1-Step RT-qPCR Virus Mix to detect low-copy number RNA and DNA targets simultaneously from a single sample.
### Lyo-Ready 1-Step RT-qPCR Virus Mix, MDX062
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Taq polymerase, RNase inhibitor, reaction buffer, dNTP, MgCl2 and lyo-excipients and separate reverse transcriptase, optimized for amplification of RNA with high secondary structure.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX062-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX062-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX062.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX062-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX062)
## Description
Molecular diagnostic tests are progressively moving towards lyophilized formats. There are several advantages for this, including ambient temperature shipping and storage, extended shelf-life, reduced operating steps and potential errors and increased flexibility in sample volume. In order to be compatible with drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to various conditions including freezing, vacuum, and dehydration.
Lyo-Ready 1-Step RT-qPCR Virus Mix is a 2x RT-qPCR master mix and can be used for the development of both RNA and DNA based molecular diagnostic tests, it contains a separate lyo-compatible MMLV-RT and enzyme dilution buffer. The Lyo-Ready 1-Step RT-qPCR Virus Mix reverse transcriptase is also thermostable and has been optimized for amplification of DNA or RNA viruses with a high secondary structure (reverse transcriptase remains active at 55-60 °C).
## Specifications
DescriptionGlycerol-free master mix containing Taq polymerase, RNase inhibitor, reaction buffer, dNTP, MgCl2 and lyo-excipients and separate reverse transcriptase and dilution buffer. Optimized for amplification of RNA high secondary structure from either extracted or intact virus samples.Concentration2xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typeRNA and/or DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following lyophilizationConsistency±0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR Mixes**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR Mix**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## FAQs: Lyo-Ready 1-Step RT-qPCR Virus Mix
What causes low efficiency in RT-qPCR?
Slope of standard 10-fold dilution curve indicates RT-qPCR efficiency. The efficiency of the RT-qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your RT-qPCR primer and/or probe design may not be optimal.
What are the advantages and considerations of using a one-step mix?
One-step reaction
• Accurate representation of target copy number
• Simple and rapid
• Fewer pipetting steps (reducing possible errors and contamination)
• Best option for high-throughput screening
• Best method when only a few assays are run repeatedly
• Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample
Considerations
• Usually less sensitive as it is impossible to optimize the two reactions separately
• Difficult to troubleshoot RT step
• No stock of cDNA
So, one-step workflows are commonly favoured in molecular diagnostic tests, where archiving of cDNA is not required.
Are reaction conditions the same for lyophilized and liquid mix?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex RT-qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
What probes can be used RT-qPCR reactions?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most commonly used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex RT-qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Lyo-Ready 1-Step RT-qPCR Virus Mix be used with crude samples?
The Lyo-Ready 1-Step RT-qPCR Virus Mix is inhibitor tolerance, but for even greater sensitivity, we have the sample specific (blood, saliva, urine and stool) mixes.
Should I include a No-RT control reaction with my RT-qPCR?
No-RT control reactions are useful for determining issues that may arise from the amplification of genomic DNA that may be present in a sample. However, many RNA transcripts are present at low abundance and for these transcripts, it is recommended to perform a No-RT control reaction if primer sets do not span exon-exon junctions. If the primers do span exon-exon junctions, or genomic DNA is not likely to interfere (when looking at RNA viruses in a sample for example) a No-RT control is not required.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo‑Ready™ 1-Step RT-qPCR Virus Mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Inhibitor-Tolerant PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-pcr-buffer-5x/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Inhibitor Tolerant qPCR Buffer, 5x
A variety of PCR inhibitors inherent to clinical and environmental samples can negatively impact the sensitivity and accuracy of a molecular assay. Conventionally, to overcome this, specimens undergo processing before testing. However, extraction technologies are not 100% efficient and can impact the amount of target nucleic acid available for testing. Some PCR inhibitors can also co-elute following purification, reducing the efficiency, particularly in quantitative PCR multiplex assays and may even induce false-negative assay results.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Inhibitor Tolerant qPCR Buffer, 5x
- Ready-to-use qPCR buffer engineered for amplification from crude samples without the need for complex or time-consuming extraction
- 5x concentration buffer allows for greater sample volume, simply add DNA polymerase, dNTPs, MgCl2, primers, probes and clinical samples
- Ideal for developing quantitative PCR assays where sample is limited
### Inhibitor-Tolerant PCR Buffer, 5x, MDX075
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Reaction buffer, enhancers and stabilizers, dNTPs and MgCl2, designed to be used in PCR reactions for highly reproducible, accurate assay results in the presence of inhibitors.
Available in 2 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX075-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX075-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX075.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX075)
## Description
Meridian’s universal Inhibitor-Tolerant qPCR Buffer is designed for developing qPCR multiplex assays that require minimal sample processing and fast turn-around times (TAT). Because the buffer is highly resistant to various qPCR inhibitors, it can be used with crude lysates or inhibitor-rich samples, to directly detect pathogens, including viruses and bacteria, in various biological specimens and to analyze gene expression in cells.
## Specifications
DescriptionReaction buffer, enhancers and stabilizers, dNTPs and MgCl2, designed to be used in PCR reactions for highly reproducible, accurate assay results in the presence of inhibitors, such as human and animal blood.Concentration5 xAppearanceClear, colorless solutionApplicationInhibitor tolerant PCRSample typecDNA, crude or purified DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR/RT-qPCRCatalog**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
## FAQs: Inhibitor-Tolerant qPCR Buffer, 5x
What sample types can be used with the Inhibitor-Tolerant qPCR Buffer, 5x?
We have tested whole human and bovine blood, saliva, sputum, urine, cerebrospinal fluid (CSF), cow milk, stool sample and plant lysate, other types of samples can be used, but we would recommend testing different concentrations to determine the concentrations that can be tolerated.
Do I need to add magnesium to the reaction?
Yes, Inhibitor-Tolerant Buffer, 5x requires the addition of DNA polymerase, dNTPs, MgCl2, primers, probes and clinical samples.
Can Inhibitor-Tolerant qPCR Buffer be dried down for room temperature storage?
The Inhibitor-Tolerant qPCR Buffer can be dried down, but it will require the addition of excipients and glycerol-free polymerase.
Where do I begin with optimization of crude samples or crude extracts?
We would recommend using a range of crude sample concentrations or extract volumes to ascertain at what point unacceptable PCR inhibition starts to take place. This will vary as some sample types, such as blood and stool material typically have more inhibition.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# dNTP Mix, 100mM, Sodium Salt
A mix of ready-to-use general grade dNTPs containing dATP, dGTP, dCTP, and dTTP (100mM total), supplied as sodium salts in purified water at pH 7.5, or sodium salts in purified water at pH 7.0, enzymatically synthesized from quality raw materials, using highly specific production systems. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's dNTP Mix
- Greater than 99 % purity, ideal for use in PCR and qPCR applications
- Free from PCR inhibitors for maximum assay performance
- Ready-to-use pre-blended dNTP mixes
- Enzyme free: DNase, RNase and Nickase free
### dNTP Mix, 10mM (Lithium), MDX086
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 10 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure mix 2.5 mM each of dATP, dGTP, dCTP, and dTTP in lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 10 mL or larger aliquots (please enquire)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX086)
## Description
The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC).
## Catalogs & Brochures
[dNTPs](https://collateral.meridianlifescience.com/view/864093733/)**dNTPs (Deoxynucleotide triphosphates)Catalog**
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
[dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
## FAQs: dNTP Mix, 100mM
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs is normally used in a PCR?
The standard concentration of a dNTP for PCR reactions is 0.2 mM. If the starting stock is a 25 mM solution of each dNTP in a 100mM dNTP Mix, you need to add 0.5 µL to a 50 µL standard PCR reaction.
Can I increase the DNA yield by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield, but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The sodium salt dNTP products are a standard grade and so we recommend these dNTPs for PCR. For more sophisticated reactions such as amplification of long templates, real-time PCR and NGS, we recommend lithium salt dNTP products.
What are the advantages of enzymic synthesis over chemical synthesis of dNTPs?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
Are the concentrations of the dNTPs each or total?
The concentration of our dNTP Mix are total – 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using molecular biology or PCR grade water.
Can your dNTP Mix be used for lyophilization?
Yes, all of our dNTPs are glycerol-free and so can be lyophilized.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA and RNA/DNA qPCR Blood Master Mixes
Air-Dryable™ Direct DNA qPCR and RNA/DNA qPCR Blood mixes are glycerol-free mixes that contain optimized excipients compatible with air and oven drying and they are designed for the direct molecular quantitation of DNA and RNA from whole blood, serum, or plasma. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Air-Dryable™ Direct DNA and RNA/DNA qPCR Blood Master Mixes
- Create ultra-sensitive multiplex direct blood qPCR tests using whole blood, serum or plasma.
- Simplify the development of quantitative PCR blood tests, by removing the nucleic acid extraction step and shortening the sample-to-result workflows.
- Validated for detection of blood pathogens and liquid biopsy applications.
- Can be used wet or air-dried for developing ambient-temperature stable assays.
### Air-Dryable Direct DNA qPCR Blood, 4x, MDX092
**Application:** qPCR**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 20% whole blood, 20% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX092-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX092-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX092.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX092-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX092)
### Air-Dryable Direct RNA/DNA qPCR Blood, 4x, MDX121
**Application:** RT-qPCR**Specimen Type:** Blood, Plasma, Serum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 10% whole blood, 10% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX121-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX121-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX121.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX121-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX121)
## Description
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for evaluating the function of vital organs (kidneys, liver, thyroid, and heart) and for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders such as diabetes. However, whole blood specimens, serum, and plasma contain a number of inherent PCR inhibitors including immunoglobulin G, hemoglobin, lactoferrin, and leukocyte DNA. In addition, PCR inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin). Traditional methods have relied on removing these inhibitors by DNA or RNA extraction prior to testing, however, these methods are problematic, can cause sample loss, and are not 100% effective at removing all the inhibitors.
Air-Dryable™ DNA qPCR Blood is a 4x qPCR master mix for the development of DNA blood tests, enabling highly sensitive detection of target DNA from whole blood, plasma, and serum samples. Air-Dryable™ RNA/DNA qPCR Saliva is a 4x qPCR master mix and can be used for the development of both DNA and RNA blood tests from whole blood, plasma, and serum samples. These mixes have been formulated specifically to overcome the inhibitors found in blood samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or oven dried to create ambient-temperature stable whole blood tests, plasma tests or serum tests.
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: qPCR Blood Test
What are the advantages of using blood over other sample types?
Blood contains abundant information about the health status of the organism, it can be used to evaluate organ function, detect proteins, nucleic acids, metabolites, infectious diseases and can be used for diagnosis of cancer (liquid biopsy), heart disease, diabetes. DNA and RNA Blood tests are a simple and easily accessible (low-invasive) method to assess and monitor health.
What qPCR inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of qPCR in blood, as it can bind to single-stranded genomic DNA, leading to increased Ct values in a quantitative PCR blood test. The other two main inhibitors in blood are hemoglobin and lactoferrin that affect the DNA polymerase activity and thus lower the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM, although this should not affect the Ct value. In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
What is the maximum volume of whole blood you can use in PCR blood Tests?
We have used up to 20% whole blood with our mix, higher concentrations cause to solution to become viscous and difficult to work with.
Do you use a mutant polymerase to overcome inhibitors?
We use our own proprietary Taq polymerase and a highly optimized buffer system to overcome inhibition.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is it possible to detect cell free RNA/DNA from blood serum using these kits?
Yes, the Air-Dryable™ qPCR Blood kits can be used to detect both cfDNA and cfRNA, making it ideal for liquid biopsy.
Is a pre-treatment needed if you want to detect the DNA of gram-positive bacteria?
Yes, it is possible that you may need to pre-treat the blood in order to release the DNA from the gram-positive bacteria. In some cases a heat shock is sufficient, this will depend on the bacteria being examined.
What is the performance difference for DNA when using the DNA-specific blood mix versus the DNA/RNA blood mix?
We do not see a performance difference between the two mixes, which is why we call the Air-Dryable Direct RT-qPCR Blood mix – Air-Dryable™ Direct RNA/DNA qPCR Blood mix, as it can be used for both.
Can the blood with or without anticoagulant be store before the qPCR? How long? At what temperature?
It can be stored frozen or following the instructions from the storage buffer manufacturer.
Do the new master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some optimization may be required for the amount of blood that is needed for qPCR blood tests.
Do I need to elute dried blood spots, or can they be used directly?
You should elute in water, or TE buffer.
Are reaction conditions the same for air-dried and liquid mixes?
Yes, the Air-Dryable™ Direct DNA qPCR Blood and Air-Dryable™ Direct RNA/DNA qPCR Blood can be used as a liquid mix or air/oven dried and stored for up to 24 months without needing to change the reaction conditions and air drying/ambient temperature storage will not affect the sensitivity of the test.
What type of pre-treatment is compatible with the inhibitor tolerant blood mixes (detergents, preheating mix enzyme/plasma 95°C 5 min in the PCR instrument)?
We advise not using Triton; however, heat treatment is ok.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Lyo-Ready LAMP/RT-LAMP Mixes
Meridian’s Lyo-Ready LAMP/RT-LAMP Mixes are ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as Loop mediated isothermal amplification (LAMP), designed to dramatically speed up assay development time and reduce time to results. Loop mediated isothermal amplification is a highly sensitive nucleic acid amplification method that has gained popularity in recent years due to its advantages over qPCR, such as quicker time to results, simple assay workflow, and point-of-care usability. However, the initial assay design and development can be more complex with 4 to 6 primers which are used in combination to generate a robust, fast, and sensitive result. Through extensive R&D research, Meridian has discovered a blend of bst DNA polymerase, reverse transcriptase, dNTPs, Mg2+, excipients, and stabilizers that are used with customer-selected primers and probes for creating any custom DNA or RNA LAMP test. Experimental data on both RNA and DNA templates demonstrate that the mixes are up to 2x faster than other suppliers, generating results in half the time. In addition, the mixes incorporate Meridian’s Lyo-Ready technology and can be used in a liquid format or lyophilized to create an ambient-temperature stable assay (please see the product guide and FAQs for recommendations on lyophilization parameters). By using a ready-to-use master mix such as Lyo-Ready LAMP Mix or Lyo-Ready RT-LAMP Mix, LAMP test assay development is faster, simpler, and more efficient, speeding up your product development time and allowing you to commercialize your new products faster. Can also be used wet
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Lyo-Ready RT-LAMP 1-Step Mix, 4x, MDX108
**Application:** RT-LAMP**Specimen Type:** RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free mix for isothermal applications such as RT-LAMP, containing Bst DNA polymerase, reverse transcriptase, reaction buffer, dNTPs and lyo-compatible excipients, ideal for developing ambient temperature, LAMP assays.
Available in 5 mL (800 Rxns) or 50 mL (8,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX108-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX108-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX108.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX108-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX108)
## Description
The Lyo-Ready LAMP Mixes are 4x master mix formulated with excipients optimized for freeze-drying to create ambient-temperature stable assays. Given cold chain management is a major limiting factor in resource-limited settings, ambient-temperature stable point-of-care tests (POCT) offer several advantages, including no refrigeration, reduced shipping, and handling costs, and extended shelf-life. By using Meridian’s Lyo-Ready LAMP Mixes, the process of developing a sensitive and high-performing assay is made significantly easier, with the added flexibility of using the mix in a wet or dried-down format.
## Catalogs & Brochures
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/159769789)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
## Related Products
[Bst DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/bst-dna-polymerase/)
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
## FAQs: Lyo-Ready LAMP Mixes
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
How can I increase the sensitivity of my DNA or RNA test?
Lyo-Ready LAMP and Lyo-Ready RT-LAMP 1-Step Mix can both be used directly as a liquid mix, or lyophilized, without changing the sensitivity of the assay. The master mixes are 4x concentration, this means that in a 20 L reaction, 5 L the master mix and 1 L of primers and probes are used allowing for up to 14 L of sample to be added, however if the master mix, primers, and probes are lyophilized, then up to 20 L of sample can be added.
Can LAMP be used for a multiplex assay?
Yes, it is possible to designed a multiplex LAMP test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready LAMP and Lyo-Ready RT-LAMP 1-Step Mix can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and this drying/ambient temperature storage will not affect the sensitivity of the POCT.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready dUTP 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-dutp-1-step-rt-qpcr-mix/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Lyo-Ready dUTP 1-Step RT-qPCR Master Mix
Meridians Lyo-Ready dUTP 1-Step RT-qPCR Mix is a glycerol-free mix, ideal for developing ambient temperature, lyophilized, multiplex qPCR and RT-qPCR molecular diagnostic tests and are suited for high-throughput, automated platforms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready dUTP 1-Step RT-qPCR Master Mix
- Very fast reaction kinetics – ideal for multiplex one-step RT-qPCR assays and low-copy number targets.
- Glycerol-free mixes are pre-formulated with a specialized blend of lyo-excipients, compatible with lyophilization into beads or cakes.
- Mixes can be lyophilized to create fast, highly reproducible, ambient temperature stable molecular diagnostic tests.
- Prevents carry-over qPCR contamination.
## High efficiency and sensitivity from both DNA (red) and RNA (blue) templates
Amplification of both Rotavirus A (dsRNA) and Adenovirus (dsDNA) in a single multiplexed RT-qPCR assay, from inactivated crude viral lysates. The result illustrates that both the DNA and RNA viruses were amplified with high efficiency and sensitivity, demonstrating the ability of Lyo-Ready 1-Step RT-qPCR Virus Mix to detect low-copy number RNA and DNA targets simultaneously from a single sample.
### Lyo-Ready dUTP 1-Step RT-qPCR Mix, MDX113
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free mix containing Taq polymerase, RNase Inhibitor, reaction buffer, dNTP/dUTP mix, MgCl2 and lyo-excipients and separate reverse transcriptase , developed to remove background PCR product contamination.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX113-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX113.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX113)
## Description
Molecular diagnostic tests are progressively moving towards lyophilized formats. There are several advantages for this, including ambient temperature shipping and storage, extended shelf-life, reduced operating steps and potential errors and increased flexibility in sample volume. In order to be compatible with drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to various conditions including freezing, vacuum, and dehydration.
Lyo-Ready dUTP 1-Step RT-qPCR Mix is a 2x RT-qPCR master mixes and can be used for the development of RNA based molecular diagnostic tests, it contains a separate lyo-compatible MMLV-RT and enzyme dilution buffer. The dTTP in the dNTPs has been substituted for dUTP, so that Uracil DNA Glycosylase (UDGase) (MDX054) can be added to remove background PCR product contamination. This makes Lyo-Ready dUTP 1-Step RT-qPCR Mix ideal for developing highly sensitive RT-qPCR diagnostic tests, such as for detecting RNA viruses at very low levels.
## Specifications
DescriptionGlycerol-free master mix containing Taq polymerase, RNase Inhibitor, reaction buffer, dNTP/dUTP mix, MgCl2 and lyo-excipients and separate reverse transcriptase and dilution buffer, developed to remove background PCR product contamination.Concentration2xFormatClear, colorless solutionHot StartAntibody mediatedApplicationHigh throughput, qPCR, two-step RT-qPCRSample typecDNA, DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following lyophilizationConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR Mixes**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR Mix**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
## FAQs: Lyo-Ready qPCR and RT-qPCR Master Mixes
What is one-step RT-qPCR and two-step qPCR?
In one-step RT-qPCR or reverse transcription qPCR, cDNA synthesis and qPCR are performed in a single reaction tube. In two-step qPCR, cDNA is synthesized in one reaction tube, and aliquots of the cDNA is then used for a subsequent qPCR experiment.
What are the advantages of using a one-step RT-PCR mix?
• Accurate representation of target copy number
• Simple and rapid
• Fewer pipetting steps (reducing possible errors and contamination)
• Best option for high-throughput screening
• Best method when only a few assays are run repeatedly
• Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample
There are several other advantages of one-step reactions, these include limited sample handling and reduced bench time, which helps to decrease chances for pipetting errors and cross contamination between reverse transcription and qPCR steps. This method is quick to set up and makes processing multiple RNA samples easy (especially when using liquid handling robotics), when you are amplifying only a few genes of interest. It is therefore ideal for high throughput screening laboratories where only a few reverse transcription qPCR assays are run repeatedly, using well-established reaction conditions, with the added advantage that multiplex qPCR of the gene of interest and control genes can be done in single well, from same RNA sample.
What are the considerations of using a one-step RT-PCR mix?
Gene-specific primers are required for generating the cDNA and for subsequent amplification in one tube, however this reduces experimental variation, since both enzymatic reactions take place under the same conditions, making one-step qPCR highly reproducible.
One-step RT-PCR requires careful evaluation to prevent primer dimer formation, because the primers will be present during the lower temperature conditions of the RT reaction as well as the qPCR cycling. This is particularly important in multiplex qPCR assays.
How is Uracil DNA Glycosylase used in RT-qPCR?
As qPCR can amplify tiny amounts of DNA, preventing contamination is essential, as even small amounts of qPCR contamination can produce false positives. qPCR contamination can include cross-contamination from other samples, contamination from elsewhere in the laboratory, and carryover contamination from amplification products and primers used in prior qPCR experiments. The latter causes most of the false positive results seen in qPCR. Preventing contamination can be difficult and so laboratory procedures must be in place to ensure DNA from one assay is not re-amplified in subsequent assay.
Uracil DNA Glycosylase can specifically degrade products that have already been through the qPCR process and have incorporated dUTP, leaving native nucleic acid templates intended for amplification intact. Uracil DNA Glycosylase activation occurs as the first step of qPCR at a 50°C incubation for 2 minutes and then the Uracil DNA Glycosylase is denatured when the temperature increases to 95°C during hot-start activation.
What is the difference between UDG and UNG?
Uracil-DNA glycosylase (UDG or UDGase) is a family of enzymes comprising six sub-families. Family I UDGase enzymes are called UNG (uracil-N-glycosylase gene), so there is no difference, the terms UDG and UNG are commonly used interchangeably because they perform the same function in qPCR—namely to prevent carryover qPCR contamination.
Should I include a No-RT control reaction with my RT-qPCR?
No-RT control reactions are useful for determining issues that may arise from the amplification of genomic DNA that may be present in a sample. However, many RNA transcripts are present at low abundance and for these transcripts, it is recommended to perform a No-RT control reaction if primer sets do not span exon-exon junctions. If the primers do span exon-exon junctions, or genomic DNA is not likely to interfere (when looking at RNA viruses in a sample for example) a No-RT control is not required.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo‑Ready™ 1-Step RT-qPCR Virus Mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Reverse Transcriptases ](/lifescience/products/molecular-reagents/reverse-transcriptases/)» 55C MMLV-RT
# 55C MMLV-RT
Meridian’s 55C MMLV-RT is a highly robust, thermostable reverse transcriptase, ideal for cDNA synthesis from RNA with a high secondary structure such as viral RNA genomes.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's 55C MMLV-RT
- Thermostable reverse transcriptase activity up to 60°C
- Ideal for cDNA synthesis from RNA with high secondary structure such as viral RNA genomes
- Sensitive detection of low copy number RNA targets
- Perfect for developing fast, highly reproducible RT-qPCR assays
### 55C MMLV-RT, MDX117
**Application:** RT-qPCR,RT-LAMP**Specimen Type:** RNA**Concentration:** 200 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Highly robust, thermostable reverse transcriptase, ideal for cDNA synthesis from RNA with a high secondary structure such as viral RNA genomes.
Available in 50 µL (10,000 Units), 200 µL (40,000 Units) or 1 mL (200,000 Units) aliquot
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX117-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX117-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX117.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX117)
## Description
Traditional Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) is not thermostable and can only maintain its enzymatic activity at relatively low temperatures (up to 50°C). However, for cDNA synthesis, a higher reaction temperature is sometimes desirable as it reduces RNA secondary structures which can inhibit reverse transcription and it minimizes nonspecific primer binding. 55C MMLV-RT is a highly thermostable reverse transcriptase with reduced RNase H activity, that allows very efficient first-strand cDNA synthesis at temperatures up to 60°C. This improves the cDNA yield from difficult RNA targets, such as viral RNA genomes, that require higher temperature to denature strong RNA secondary structure.
## Specifications
DescriptionDeveloped to reduce RNase H activity and increase thermal stability, 55C MMLV-RT can be used at temperature up to 60°C, enabling melting of areas of secondary structure in RNA, improving cDNA yield and sensitivity from difficult RNA targets such viral genomes.Concentration≥ 200 U/µLSpecific Activity≥ 300,000 U/mgPurity> 95% (densitometric analysis of SDS-Page)AppearanceClear, colorless solutionApplicationcDNA synthesis, RT-PCR, PCR, two-step RT-qPCR, one-step RT-qPCRSample typeRNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelDNA contaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[55C MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RT**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[RNase-Tolerant MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/rnase-tolerant-mmlv-rt/)
## FAQs: 55C MMLV-RT
I want to generate cDNA from viral RNA with very high secondary structure, can I use 55C MMLV-RT?
Yes, for RNA with very high secondary structure we recommend using 55C MMLV-RT, this thermostable reverse transcriptase can be used at temperatures up to 60°C which improves the cDNA yield from difficult RNA targets (such as viral RNA) that require higher temperature to denature strong RNA secondary structures.
Is 55C MMLV-RT RNase H minus?
55C MMLV-RT does contain the domain for RNase H, but it has been inactivated, so that there is no detectable RNase H activity.
Should I treat the cDNA with RNase H prior to further downstream processing?
If you are going to do RT-PCR or RT-qPCR, this is unnecessary, RNA:DNA duplex after cDNA synthesis are melted during the 95°C denaturing step at the start of the PCR reaction. For cloning of larger fragments, RNase H treatment can be beneficial.
How is 55C MMLV-RT inactivated?
The reverse transcriptase can be inactivated by adding a chelating agent such as EDTA or heating to 70°C or higher for 10 min.
Can 55C MMLV-RT be used for long transcripts?
55C MMLV can be used for first-strand cDNA synthesis at temperatures up to 60°C, providing increased specificity, higher yields and can generate cDNA up to 12 kb.
Does MMLV-RT need a primer?
Yes, to initiate reverse transcription, the MMLV-RT reverse transcriptase require a primer to bind to its complementary sequences on the RNA template and serve as a starting point for synthesis of a new strand. For general cDNA synthesis, random hexamer primers and oligo(dT) primers can be used either separately or mixed. For RT-PCR and RT-qPCR gene-specific primers should be used.
What is the error rate of 55C MMLV-RT?
55C MMLV-based reverse transcriptase has an error rate in the range of about 4.8 × 10−5.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Air-Dryable™ LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-lamp-rt-lamp-mixes/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ LAMP/RT-LAMP Mixes
Meridian’s Air-Dryable™ DNA LAMP and RNA/DNA LAMP Mixes are ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as LAMP, designed to dramatically speed up assay development time and reduce TTR by 50%. Isothermal amplification is a highly sensitive nucleic acid amplification method that has gained popularity in recent years due to its advantages over qPCR, such as quicker time to results, simple assay workflow, and point-of-care usability. However, the initial assay design and development can be more complex with 4 to 6 primers which are used in combination to generate a robust, fast, and sensitive result. Through extensive R&D research, Meridian has discovered a blend of enzymes, dNTPs, Mg2+, excipients, and stabilizers that are used with customer-selected primers and probes for creating any custom DNA or RNA LAMP assay. Experimental data on both RNA and DNA templates demonstrate that the mixes are up to 2x faster than other suppliers, generating results in half the time. In addition, the mixes incorporate Meridian’s new Air-Dryable™ technology and can be used in a liquid format or oven-dried to create an ambient-temperature stable assay (please see the product guide and FAQs for recommendations on oven drying parameters). By using a ready-to-use master mix such as Air-Dryable™ DNA LAMP or RNA/DNA LAMP, assay development is faster, simpler, and more efficient, speeding up your product development time and allowing you to commercialize your new products faster. **Can also be used wet**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Results in half the time - Fastest reaction kinetics on the market.
Air-Dryable™ RNA/DNA LAMP mix was air-dried with Dengue type 2 primers at 50°C for 80 mins. The sensitivity of air-dried Air-Dryable™ RNA/DNA LAMP mix (red) was compared to its liquid (blue) format and NEB WarmStart® (orange) in a serial dilution of the target RNA (Dengue type 2 crude lysate). Reactions were incubated at 65°C for 60 min and TTR were measured at 1:10 of end fluorescence. Error bars represent standard deviation over 4 technical replicates. The results illustrate that the speed of the Air-Dryable™ RNA/DNA LAMP mix is twice as fast as a NEB WarmStart® in either the dry or liquid format.
### Air-Dryable RT-LAMP 1-Step Mix, 4x, MDX118
**Application:** RT-LAMP**Specimen Type:** RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Glycerol-free mix for isothermal applications such as RT-LAMP, containing Bst DNA polymerase, reverse transcriptase, reaction buffer, dNTPs and air-dryable excipients, ideal for developing ambient temperature, LAMP assays.
Available in 5 mL (800 Rxns) or 50 mL (8,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX118-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX118-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX118.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX118-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX118)
### Air-Dryable DNA LAMP, MDX119
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Glycerol-free mix for isothermal applications such as LAMP, containing Bst DNA polymerase, reaction buffer, dNTPs and air-dryable excipients, ideal for developing ambient temperature, LAMP assays.
Available in 5 mL (800 Rxns) or 50 mL (8,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX119-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX119.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX119-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX119)
## Catalogs & Brochures
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready Genotyping Direct qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Lyo-Ready & Air-Dryable Master Mixes & Reagents ](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)» Lyo-Ready Genotyping Direct qPCR Blood
# Lyo-Ready Genotyping Direct qPCR Blood
Lyo-Ready Genotyping Direct qPCR Blood has been optimized to provide highly specific allelic discrimination as demonstrated by excellent cluster separation, even in the presence of PCR inhibitors found in blood, serum or plasma. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Genotyping Direct qPCR Blood
- Ultra-sensitive detection down to less than 1 copy using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in whole blood, serum, plasma.
- Tight fluorescence clusters with clear allele discrimination, perfect for difficult SNPs.
- Can be used as a liquid or lyophilized, ideal for high-throughput or POC testing.
### Lyo-Ready Genotyping Direct qPCR Blood, 4x, MDX128
**Application:** SNP Genotyping**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 10% whole blood, 20% plasma. Compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide and copy number variants, to give highly reproducible allelic discrimination.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX128-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX128-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX128.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX128-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX128)
## Description
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cystic fibrosis screening. Clinical screening of SNPs requires large-scale multiplexed genotyping, which traditionally relies on DNA extraction from complex samples such as blood, to achieve sensitive DNA amplification. However, blood contains several PCR inhibitors that can inhibit the reaction or reduce a reaction’s efficiency.
Meridian’s Lyo-Ready Genotyping Direct qPCR Blood is a 4x inhibitor-resistant mix designed for highly specific and sensitive amplification for genotyping sequence variants, even in the presence of PCR inhibitors found in blood, serum or plasma, to give exceptional cluster resolution with clear allele discrimination, even with challenging SNP targets. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
## Catalogs & Brochures
[Lyo-Ready Genotyping Direct qPCR Blood](https://collateral.meridianlifescience.com/view/330386481/)**Lyo-Ready Genotyping Direct qPCR Blood**
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood**
[Lyo-Ready Direct Blood Mixes](https://collateral.meridianlifescience.com/view/222789736/)**Lyo-Ready Direct Blood Mixes**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: Lyo-Ready Genotyping Direct qPCR Blood
What is allele discrimination?
Allelic discrimination are methods to discriminate between two or more sequence changes at a particular gene locus. Typically, one allele (“wild type” DNA sequence) is common, and the other allele (mutation) is rare. In a SNP there are 3 genotypes: – a diploid homozygote (two wild type alleles (PP)), a diploid homozygote (two mutant alleles (pp)) and a heterozygote (one wild type allele and one mutant allele (Pp)).
Why do we screen for SNPs?
SNPs (single nucleotide polymorphisms) help predict an individual’s resistance or susceptibility to certain drugs (pharmacogenetics), susceptibility to environmental factors such as toxins, and risk of developing diseases. SNPs can also be used to track the inheritance of disease-associated genetic variants within families.
What are the advantages of using qPCR for genotyping?
qPCR (Real-time PCR) enables you to screen known SNPs. The benefits of qPCR are that it is easy, accurate, and can scale to high throughput. The bioinformatic analysis is also less complex than for other technologies, such as sequencing and microarrays.
5′-nuclease (TaqMan) allelic discrimination uses a primer pair to amplify the target area and two allele-specific probes to detect your target SNP alleles and report the genotypes of your samples. Unlike normal qPCR, in genotyping the fluorescence level is only measured at the end of the PCR and the results are displayed on a scatter plot, allowing hundreds of assays to be run and analysed in parallel.
What qPCR inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of qPCR in blood, as it can bind to single-stranded genomic DNA, leading to increased Ct values and a lower signal. The other two main inhibitors in blood are hemoglobin and lactoferrin that affect the DNA polymerase activity and thus lowered the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM. In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Genotyping Direct qPCR Blood can be used as a liquid mix or lyophilized and stored at ambient temperature without needing to change the reaction conditions and lyophilization/storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva Master Mix
Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Saliva mixes are glycerol-free mixes that contain optimized excipients compatible with freezing and lyophilization and they designed for the direct quantitative PCR saliva testing of DNA and RNA. **Can also be used wet and/or with purified nucleic acid.**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva Master Mix
- Create ultra-sensitive single plex or multiplex saliva qPCR tests on a broad range of platforms.
- Simplify the development of your quantitative PCR saliva test, by eliminating the nucleic acid extraction steps.
- Can be used wet or lyophilized, reducing the cost and complexity of developing an ambient-temperate stable assay.
### Lyo-Ready Direct DNA qPCR Saliva, 4x, MDX132
**Application:** qPCR**Specimen Type:** Saliva, Sputum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX132-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX132-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX132.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX132-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX132)
### Lyo-Ready Direct RNA/DNA qPCR Saliva, 4x, MDX133
**Application:** RT-qPCR**Specimen Type:** Saliva, Sputum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX133-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX133-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX133.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX133-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX133)
## Description
Over the last decade, saliva has been extensively studied as a diagnostic specimen due to its non-invasive and simple sample collection/logistics. Like serum, saliva contains hormones, antibodies, growth factors, enzymes, microbes that can be used as biomarkers for disease detection. However, there have been challenges in adopting a saliva qPCR test for molecular diagnostics due to the low concentration of analytes and high concentration of PCR inhibitors in saliva, which typically requires cumbersome sample preparation steps to homogenize the specimen and purify the DNA/RNA.
Lyo-Ready Direct DNA qPCR Saliva is a 4x master mix for the development of DNA saliva testing, enabling highly sensitive detection of target DNA from crudely processed saliva or sputum samples. Lyo-Ready Direct RNA/DNA qPCR Saliva is 4x master mix and can be used for the development of both RNA and DNA saliva testing from crudely processed saliva or sputum samples. These mixes have been formulated to overcome the inhibitors specifically found in saliva samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or lyophilized to create ambient-temperature stable saliva tests or sputum tests.
## Catalogs & Brochures
[Lyo-Ready Direct Saliva](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct Saliva**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct Saliva**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: qPCR Saliva Assays
What are the advantages of using saliva over other sample types?
Saliva testing is compliance with painless, non-invasive sample collection from the patient, making it ideal for use with children or patients that will not comply with blood collections or even intrusive nasal swabs. Saliva tests and sputum tests also increase the efficiency of collection while minimizing sample handling and reducing handling errors.
What can saliva be used to test?
Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antimicrobial constituents, hormones, cytokines, and antibodies. Its composition virtually reflects the entire state of health and disease in a body, and it has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (avian influenza viruses and coronaviruses) and bacterial infections.
What are the advantages of using a saliva mix over a universal inhibitor tolerant mix?
Universal inhibitor tolerant mixes and universal inhibitor resistant mixes are designed to tolerate inhibitors from a wide range of sample types from blood to plants. In adjusting the composition of these mixes to fit all of these sample types, some compromise is required, and this leads to a reduction in the sensitivity (Ct values). In designing the saliva specific mixes, we have not had to make these compromises and so the sensitivity is the same as if the nucleic acid had been purified, enabling assay sensitivity down to as low as 1 copy of DNA.
What are the advantages of using saliva or sputum directly in a qPCR assay?
You will have faster time to results, no extraction is necessary.
You will get better sensitivity, for low copy number samples.
Less cross contamination, everything is done in a single tube, so there is less chance of mixing labels or adding materials into the wrong tubes.
More convenient, the dried assay can be stored at room temperature and the sample added directly and run.
Reduced cost, there are no extraction costs or cold storage and cold transport costs.
How sensitive is a direct quantitative PCR saliva test?
With the Lyo-Ready Direct DNA qPCR Saliva and Lyo-Ready Direct RNA/DNA qPCR Saliva, you can see down to less than 10 copies in a 20 L reaction.
What concentration of saliva or sputum can be used directly in an assay?
For a DNA assay up to 60% saliva or sputum can be used and for an RNA assay up to 50% saliva or sputum can be used.
How can I increase the sensitivity of my assay?
The Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva can both be used directly as a liquid mix, or lyophilized, without changing the sensitivity of the assay. The master mixes are 4x concentration, this means that in a 20 L reaction, 5 L the master mix and 1 L of primers and probes are used allowing for up to 14 L of saliva or sputum to be added, however if the master mix, primers, and probes are lyophilized, then up to 20 L of saliva or sputum can be added.
Do I need to pre-treat my saliva or sputum to use it in a direct assay?
This will depend on what you are testing for and the amount, for example with SARS-CoV-2 heating to 95°C for 10 minutes has been shown to be beneficial, particularly with low viral loads, however Zika virus does not need pre-treatment, whereas some bacteria may require strong pre-treatment (such as proteinase K and heat inactivation).
Does universal transport media (UTM) affect the qPCR reaction?
Up to 50% UTM swab containing sputum can be used in the quantitative PCR saliva test without affecting the sensitivity of the assay.
Can crude saliva samples or sputum samples be used in multiplex assays?
Yes, the Lyo-Ready Direct DNA qPCR Saliva and Lyo-Ready Direct RNA/DNA qPCR Saliva can both be used in multiplex qPCR and RT-qPCR saliva test or sputum test.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA qPCR Saliva and Lyo-Ready Direct RNA/DNA qPCR Saliva can be used as a liquid mix or lyophilized and stored for more than 24 months without needing to change the reaction conditions and this drying/ambient temperature storage will not affect the sensitivity of the assays.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Lyo-Ready Genotyping Direct qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-stool/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Genotyping Direct qPCR Stool
Lyo-Ready Genotyping Direct qPCR Stool has been optimized to provide highly specific allelic discrimination as demonstrated by excellent cluster separation, even in the presence of PCR inhibitors found in crude human stool samples. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Genotyping Direct qPCR Stool
- Ultra-sensitive detection down to less than 1 copy using direct amplification protocols
- Inhibitor-tolerant to PCR inhibitors found in stool
- Tight fluorescence clusters with clear allele discrimination, perfect for difficult SNPs
- Can be used as a liquid or lyophilized, ideal for high-throughput or POC testing
## 20 mg/mL Human Stool and Gastric Cancer-Associated p53 Target
Detection of colorectal cancer-associated p53 mutation (SNP accession number: rs1042522) was performed using A) Lyo-Ready Genotyping Direct qPCR Stool, B) Kapa Probe Force, C) TaqPath™ and D) Type-it Fast Kits, in presence of 20 mg/mL human stool. Homozygous Allele C (red) and allele G (blue) and heterozygous samples for allele C/G (green) were compared with a NTC (black) and x for undetermined. The results illustrate the ability of Lyo-Ready Genotyping Direct qPCR Stool to form tight clusters and to achieve accurate allelic discrimination of clinically relevant mutations directly from crude human stool samples.
### Lyo-Ready Genotyping Direct qPCR Stool, 4x, MDX148
**Application:** SNP Genotyping**Specimen Type:** Stool, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% stool. Compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide and copy number variants, to give highly reproducible allelic discrimination.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX148-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX148.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX148)
## Description
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cancer screening. Clinical screening of SNPs requires large-scale multiplexed genotyping, which traditionally relies on DNA extraction from complex samples such as blood, to achieve sensitive DNA amplification. However, blood collection is invasive and requires a professional, stool on the other hand is non-invasive, safe, less expensive and easy to do at home, making it ideal for POC and frequent sampling.
Meridian’s new Lyo-Ready Genotyping Direct qPCR Stool is a mix that is designed for fast, precise, and reproducible allelic discrimination and cluster separation. Its advanced formulation enables highly sensitive amplification of SNPs and other point mutations from stool samples and overcomes inhibitors such as bile salts that can damage DNA and inhibit PCR reactions. Furthermore, it can be used in a wet format or lyophilized to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
## Catalogs & Brochures
[Lyo-Ready Genotyping Direct qPCR Stool](https://collateral.meridianlifescience.com/view/967751022/)**Lyo-Ready Genotyping Direct qPCR Stool**
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://collateral.meridianlifescience.com/view/111612146/)**Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes**
[Meridian Air Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable™ Direct StoolCatalog**
## Related Products
- [ Specimen-specific™ Inhibitor Tolerant Master Mixes ](/lifescience/molecular-products/reagents/specimen-specific-master-mix/)
- [ qPCR and RT-qPCR Master Mixes ](/lifescience/molecular-products/reagents/qpcr-and-rt-qpcr-master-mixes/)
- [ Lyo-Ready & Air-Dryable Master Mixes & Reagents ](/lifescience/molecular-products/reagents/lyo-ready-air-dryable-master-mixes-reagents/)
## FAQs: Lyo-Ready Genotyping Direct qPCR Stool
What is allele discrimination?
Allelic discrimination are methods to discriminate between two or more sequence changes at a particular gene locus. Typically, one allele (“wild type” DNA sequence) is common, and other alleles (mutation) is rare. In a SNP there are 3 genotypes: – a diploid homozygote (two wild type alleles (PP)), a diploid homozygote (two mutant alleles (pp)) and a heterozygote (one wild type allele and one mutant allele (Pp)).
Why do we screen for SNPs?
SNPs (single nucleotide polymorphisms) help predict an individual’s resistance or susceptibility to certain drugs (pharmacogenetics), susceptibility to environmental factors such as toxins, and risk of developing diseases. SNPs can also be used to track the inheritance of disease-associated genetic variants within families.
What are the advantages of using qPCR for genotyping?
qPCR (real-time PCR) enables you to screen known SNPs. The benefits of qPCR are that it is easy, accurate, and can scale to high throughput. The bioinformatic analysis is also less complex than for other technologies, such as sequencing and microarrays.
5′-nuclease (TaqMan) allelic discrimination uses a primer pair to amplify the target area and two allele-specific probes to detect your target SNP alleles and report the genotypes of your samples. Unlike normal qPCR, in genotyping the fluorescence level is only measured at the end of the PCR and the results are displayed on a scatter plot, allowing hundreds of assays to be run and analysed in parallel.
What qPCR inhibitors are found in stool?
Fecal matter is a highly complex, heterogenous material that contains PCR inhibitors including bile salts, polysaccharides, hematin and catabolic substances.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Genotyping Direct qPCR Stool can be used as a liquid mix or lyophilized and stored at ambient temperature without needing to change the reaction conditions and lyophilization/storage will not affect the sensitivity of the test.
What types of cancer SNPs can be found in stool?
SNP biomarkers have been used for the detection of gastric, pancreatic, and colorectal cancers.
What carrier buffer do you recommend?
There are several buffers on the market that can be used for stool testing, they include phosphate-buffered saline (PBS), Cary-Blair Medium, Stool Transport and Recovery (STAR) buffer and DNA/RNA Shield.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready Genotyping Direct qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Genotyping Direct qPCR Urine
Lyo-Ready Genotyping Direct qPCR Urine has been optimized to provide highly specific allelic discrimination as demonstrated by excellent cluster separation, even in the presence of PCR inhibitors found in crude human urine samples. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Genotyping Direct qPCR Urine
- Ultra-sensitive detection down to less than 1 copy using direct amplification protocols
- Inhibitor-tolerant to PCR inhibitors found in urine
- Can be used as a liquid or lyophilized, ideal for high-throughput or POC testing
- Mixes can be used in liquid or lyophilized formats to extend assay shelf-life
## 30% Pooled Human Urine and Bladder Cancer Associated Targets
Detection of bladder cancer-associated PAI1 mutation (SNP accession number: rs7242) , in presence of 30% pooled human urine with A/ Lyo-Ready Genotyping Direct qPCR Urine Mix, B/ Roche Kapa Probe Force, C/ ThermoFisher TaqPath™ and D/ Qiagen Type-it Fast SNP Probe PCR Kits. Homozygous samples for allele T (red) and allele G (blue) and heterozygous samples for allele T/G (green) were compared with a NTC (black) and x for undetermined. The results illustrate ability of Lyo-Ready Genotyping Direct qPCR Urine to form tight clustering and so accurate allelic discrimination in the presence of 30% crude urine unlike the other mixes.
### Lyo-Ready Genotyping Direct qPCR Urine, 4x, MDX158
**Application:** SNP Genotyping**Specimen Type:** Urine, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% urine. Compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide and copy number variants, to give highly reproducible allelic discrimination.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX158-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX158-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX158.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX158)
## Description
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cancer screening. Clinical screening of SNPs requires large-scale multiplexed genotyping, which traditionally relies on DNA extraction from complex samples such as blood, to achieve sensitive DNA amplification. However, blood collection is invasive and requires a professional, urine on the other hand is an extremely non-invasive process, that is safe, less expensive and easy to do at home, making it ideal for large population or frequent sampling, particularly when children or people that will not comply with blood collections.
Meridian’s Lyo-Ready Genotyping Direct qPCR Urine is a 4x inhibitor-resistant mix designed for highly specific and sensitive amplification for genotyping sequence variants, even in the presence of PCR inhibitors found in crude urine samples, to give exceptional cluster resolution with clear allele discrimination, even with challenging SNP targets. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
## Catalogs & Brochures
[Meridian Air Dryable Direct Urine](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine**
[Lyo-Ready Direct LAMP Urine Mixes](https://collateral.meridianlifescience.com/view/940080326/)**Lyo-Ready Direct LAMP Urine Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/)**Lyo-Ready Genotyping Direct DNA qPCR Urine**
## Related Products
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
[Lyo-Ready Genotyping Direct qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)
## FAQs: Lyo-Ready Genotyping Direct qPCR FFPE
What is allele discrimination?
Allelic discrimination are methods to discriminate between two or more sequence changes at a particular gene locus. Typically, one allele (“wild type” DNA sequence) is common, and other alleles (mutation) is rare. In a SNP there are 3 genotypes: – a diploid homozygote (two wild type alleles (PP)), a diploid homozygote (two mutant alleles (pp)) and a heterozygote (one wild type allele and one mutant allele (Pp)).
Why do we screen for SNPs?
SNPs (single nucleotide polymorphisms) help predict an individual’s resistance or susceptibility to certain drugs (pharmacogenetics), susceptibility to environmental factors such as toxins, and risk of developing diseases. SNPs can also be used to track the inheritance of disease-associated genetic variants within families.
What are the advantages of using qPCR for genotyping?
qPCR (real-time PCR) enables you to screen known SNPs. The benefits of qPCR are that it is easy, accurate, and can scale to high throughput. The bioinformatic analysis is also less complex than for other technologies, such as sequencing and microarrays.
5′-nuclease (TaqMan) allelic discrimination uses a primer pair to amplify the target area and two allele-specific probes to detect your target SNP alleles and report the genotypes of your samples. Unlike normal qPCR, in genotyping the fluorescence level is only measured at the end of the PCR and the results are displayed on a scatter plot, allowing hundreds of assays to be run and analysed in parallel.
What qPCR inhibitors are found in urine?
Urea, metabolites and electrolytes, beta-human chorionic gonadotropin, volatile organic compounds.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Genotyping Direct qPCR Urine can be used as a liquid mix or lyophilized and stored at ambient temperature without needing to change the reaction conditions and lyophilization/storage will not affect the sensitivity of the test.
What types of cancer SNPs can be found in urine?
SNP biomarkers for the urogenital tract cancers such as, ovarian, colorectal, prostate, cervical & endometrial, renal and bladder cancer, and other cancers, such as thyroid, lung, liver, breast, gastric and pancreatic cancer.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Lyo-Ready Genotyping Direct qPCR FFPE](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-ffpe/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Genotyping Direct qPCR FFPE
Lyo-Ready Genotyping Direct qPCR FFPE is a glycerol-free, one tube formulation compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide variants and copy number variations.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Genotyping Direct qPCR FFPE
- Ultra-sensitive detection down to less than 1 copy using direct amplification protocols
- Inhibitor-tolerant to PCR inhibitors found in FFPE tissue
- Tight fluorescence clusters with clear allele discrimination, perfect for difficult SNPs identification
- Mixes can be used in liquid or lyophilized formats to extend assay shelf-life
## Screening FFPE lung tissue for tumor associated PDGFRA1 gene mutations
Healthy FFPE lung tissue (WT) and lung tumor tissue containing the tumor angiogenesis associated PDGFRA1 mutation were run with A/ Lyo-Ready Genotyping Direct qPCR FFPE (MDX168) following extraction with the extraction buffers provided or purified using Qiagen QIAamp DNA FFPE Tissue Extraction Kit and analysed with B/ KAPA Probe Force qPCR Mix (Roche) and C/ TaqPath ProAmp Multiplex Master Mix (ThermoFisher). Homozygous Allele G (red) and allele A (blue) and heterozygous Allele G/A (green) with a NTC (black) and x for undetermined. The results illustrate that MDX168 shows greater allelic discrimination and tighter clustering even in the presence of crude FFPE tissue extracts in comparison to other commercially available master mixes using purified gDNA.
### Lyo-Ready Genotyping Direct qPCR FFPE, 4x, MDX168
**Application:** SNP Genotyping**Specimen Type:** FFPE, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Better extraction buffers and greater tolerance to crude FFPE samples. Compatible with all dual-label probe chemistries for detection of genetic variants, such as single nucleotide and copy number variants, to give highly reproducible allelic discrimination.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX168-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX168.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX168-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX168)
## Description
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cystic fibrosis screening. Although blood is an ideal source for genotyping analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissues are also widely used and constitute valuable resources for retrospective studies due to the possibility of long-term storage at room temperature. Despite the extremely time-consuming and labour-intensive workflows, success rate of genotyping assays using DNA purified from such samples remains low.
To minimize the workflow to isolate DNA from FFPE tissue, Meridian has created the Lyo-Ready Genotyping Direct qPCR FFPE, this allows digestion of the tissue in a single tube, without the need for purification, greatly reducing the risk of sample damage, loss and contamination whilst simplifying and accelerating the analysis process. Furthermore, it can be used in a liquid format or lyophilized format to create ambient-temperature stable assays, making it ideal for high throughput.
## Catalogs & Brochures
[Lyo-Ready Genotyping Direct DNA qPCR FFPE](https://collateral.meridianlifescience.com/view/487986445/)**Lyo-Ready Genotyping Direct DNA qPCR FFPE**
[Lyo-Ready Genotyping Direct qPCR Blood](https://collateral.meridianlifescience.com/view/330386481/)**Lyo-Ready Genotyping Direct qPCR Blood**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Lyo-Ready Genotyping Direct qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)
## FAQs: Lyo-Ready Genotyping Direct qPCR FFPE
What is allele discrimination?
Allelic discrimination are methods to discriminate between two or more sequence changes at a particular gene locus. Typically, one allele (“wild type” DNA sequence) is common, and other alleles (mutation) is rare. In a SNP there are 3 genotypes: – a diploid homozygote (two wild type alleles (PP)), a diploid homozygote (two mutant alleles (pp)) and a heterozygote (one wild type allele and one mutant allele (Pp)).
Why do we screen for SNPs?
SNPs (single nucleotide polymorphisms) help predict an individual’s resistance or susceptibility to certain drugs (pharmacogenetics), susceptibility to environmental factors such as toxins, and risk of developing diseases. SNPs can also be used to track the inheritance of disease-associated genetic variants within families.
What are the advantages of using qPCR for genotyping?
qPCR (Real-time PCR) enables you to screen known SNPs. The benefits of qPCR are that it is easy, accurate, and can scale to high throughput. The bioinformatic analysis is also less complex than for other technologies, such as sequencing and microarrays.
5′-nuclease (TaqMan) allelic discrimination uses a primer pair to amplify the target area and two allele-specific probes to detect your target SNP alleles and report the genotypes of your samples. Unlike normal qPCR, in genotyping the fluorescence level is only measured at the end of the PCR and the results are displayed on a scatter plot, allowing hundreds of assays to be run and analysed in parallel.
What effects the quality and integrity of DNA in FFPE samples?
FFPE specimens are affected by numerous factors including fixative pH (that can lead to cross-linking of the DNA), duration of tissue fixation, age and storage condition of tissue blocks. This leading to extremely time-consuming, labour-intensive workflows that all result in fragmented DNA and consequently, the success rate of genotyping DNA purified from such samples is low.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Genotyping Direct qPCR FFPE can be used as a liquid mix or lyophilized and stored at ambient temperature without needing to change the reaction conditions and lyophilization/storage will not affect the sensitivity of the test.
Can I buy the extraction buffers separately?
Yes, we sell these as MDX004 Tissue Extract-PCR Buffers.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Glycerol-Free Taq HS High Conc. DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-high-conc-dna-polymerase/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA Polymerases ](/lifescience/products/molecular-reagents/dna-polymerases/)» Glycerol-Free Taq HS High Conc. DNA Polymerase
# Glycerol-Free Taq HS High Conc. DNA Polymerase
Glycerol-Free Taq HS High Conc. (50 U/µL) has been optimized to deliver excellent, stable performance without glycerol, meaning it is also compatible with lyophilization, as a stand-alone enzyme, or when combined with additional assay components in a reaction mix.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free Taq HS High Conc. DNA Polymerase
- High concentration of Taq DNA Polymerase allowing for concentrated bulk production of PCR master mixes.
- Highly concentrated Taq DNA Polymerase allows for concentrated bulk production of PCR master mixes
- Retains the same reproducible performance as with conventional formats.
- Glycerol-free solution, ideal for preparation of dried-down PCR tests.
## Efficient and sensitive amplification with both wet (black) and lyophilized (blue) PCR tests
A 10-fold serial dilution of template DNA was used to set up two sets of qPCR assays. One set was lyophilized (blue) and the other left as a wet mix (black). Results illustrate that lyophilization of Glycerol-Free Taq HS High Conc. does not have an effect on the quality of the qPCR, as both the assays demonstrate identical efficiency and sensitivity.
### Glycerol-Free Taq HS High Conc. DNA Polymerase, MDX170
**Application:** PCR, NGS**Specimen Type:** DNA**Concentration:** 50 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration, high fidelity DNA polymerase with separate dilution and reaction buffer, ideal for NGS library amplification and gene expression. Ideal for lyophilization.
Available in 0.025 mL (1,000 Units) or 0.5 mL (25,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX170-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX170-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX170.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX170)
## Description
Glycerol-Free Taq HS High Conc. is supplied as a blend of high‑performance glycerol‑free Taq DNA Polymerase with a Taq hot-start antibody and is suitable for difficult, multiplex PCR that require fast amplification, whilst maintaining both high specificity and sensitivity.
Glycerol-Free Taq HS High Conc. is ideal for PCR kit manufactures and PCR molecular test facilities, requiring large amounts of DNA polymerases. The highly concentrated Glycerol-Free Taq HS High Conc. allows for concentrated bulk production of PCR master mixes and the glycerol free format is useful when using automated pipetting robots and other applications where accurate pipetting of small volumes is crucial.
## Specifications
DescriptionA lyophilization-compatible Taq DNA polymerase with Taq antibody, suitable for difficult, multiplex molecular tests that require fast amplification, whilst maintaining both high specificity and sensitivity.ConcentrationBetween 50 and 60 U/µL (see CoA)Purity>50 % (as a percentage of total protein)Glycerol content<0.02 %AppearanceClear, colorless solutionHot StartAntibody mediatedApplicationPCR, real-time PCR, two-step RT-qPCRSample typecDNA, DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Glycerol-Free Taq HS ](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HS**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[dNTP Mix, 100mM (Lithium)](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-lithium/)
[Lyo-Ready qPCR Buffer w/o Excipients, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-w-o-excipients-4x/)
## FAQs: Glycerol-Free Taq HS High Conc.
How is Glycerol-Free Taq HS High Conc. supplied?
Glycerol-Free Taq HS High Conc. is supplied as a glycerol-free blend of Taq DNA polymerase with Taq hot-start antibody at 50 U/μL. We also have MDX011 Glycerol-Free Taq HS 50 U/µL that has the glycerol‑free Taq DNA polymerase and a separate glycerol‑free Taq antibody and enzyme dilution buffer, to allow greater flexibility in developing PCR tests.
What are the advantages of a 10x DNA polymerase?
Glycerol-Free Taq HS High Conc. (50 U/µL) is ideal for PCR kit manufactures and DNA testing facilities, requiring large amounts of DNA polymerases. The highly concentrated enzyme allows for concentrated bulk production of PCR master mixes.
Concentrated bulks in glycerol-free formats are also attractive when using automated pipetting robots and other applications where accurate pipetting of small volumes is crucial, as glycerol makes the solution more viscous.
Concentrated PCR master mixes are easier to lyophilize due to the reduced volume of the concentrated mix.
What are the storage conditions and stabilities of Glycerol-Free Taq HS High Conc.?
Glycerol is a cryoprotectant and is normally part of the storage buffer, where it serves to protect Taq DNA polymerase during freezing conditions. The high concentration of Glycerol-Free Taq HS 50 U/µL means that you get the same protection to freeze/thawing as a DNA polymerase that contains glycerol.
After drying for how long will the lyophilized PCR tests stay stable to use?
A lyophilized PCR molecular test will remain stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Can Glycerol-Free Taq HS High Conc. be used to create quantitative PCR tests?
Yes, Glycerol-Free Taq HS High Conc. is ideal for any multiplex PCR assays, particularly quantitative PCR molecular tests that require fast amplification, whilst maintaining both high specificity and sensitivity.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [Lyo-Ready Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-inhibitor-tolerant-qpcr-rt-qpcr-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes
A variety of PCR inhibitors inherent to clinical and environmental samples can negatively impact the sensitivity and accuracy of a molecular assay. Conventionally, to overcome this, specimens undergo processing before testing. However, extraction technologies are not 100% efficient and can impact the amount of target nucleic acid available for testing. Some PCR inhibitors can also co-elute following purification, reducing the efficiency, particularly in quantitative PCR multiplex assays and may even induce false-negative assay results.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes
- Ready-to-use lyo-ready qPCR master mixes engineered for amplification from crude samples without the need for complex or time-consuming extraction
- 4x concentration master mix allows for greater sample volume, simply add primers, probes and clinical samples
- Mixes can be lyophilized to create fast, highly reproducible, ambient temperature stable molecular diagnostic tests
## Lyo-Ready Inhibitor-Tolerant qPCR Mix, 4x
Liquid (black), lyophilized (red) and lyophilized with 5% stool extract (yellow) formats of Lyo-Ready Inhibitor-Tolerant RT-qPCR Mix, (MDX185). The results demonstrate the lyophilized mixes retain the ability to efficiently amplify to the same level as the liquid mix, even in the presence of inhibitors, with the same reproducibility.
### Lyo-Ready Inhibitor-Tolerant qPCR Mix, MDX184
**Application:** qPCR**Specimen Type:** Blood, saliva, urine, stool, tissue, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Universal, high concentration, inhibitor tolerant qPCR master mix, for direct amplification from crude lysates or inhibitor-rich samples such as urine, cerebral spinal fluid (CSF), blood, sputum, saliva and stool.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX184-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX184-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX184.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX184)
### Lyo-Ready Inhibitor-Tolerant RT-qPCR Mix, MDX185
**Application:** RT-qPCR**Specimen Type:** Blood, saliva, urine, stool, tissue, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Universal, high concentration, inhibitor tolerant RT-qPCR master mix, for direct amplification from crude lysates or inhibitor-rich samples such as urine, cerebral spinal fluid (CSF), blood, sputum, saliva and stool.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX185-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX185-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX185.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX185)
## Description
Molecular diagnostic tests are progressively moving towards lyophilized formats. Meridian’s universal Lyo-Ready Inhibitor-Tolerant qPCR/RT-qPCR formulations are ready-to-use quantitative PCR supermixes, containing all components except primers, probes, and template for direct qPCR and RT-qPCR. They are also glycerol-free and include specialized excipients that preserve the mixture as it is exposed to various conditions including freezing, vacuum, and dehydration during lyophilization. After lyophilization they can be shipped and storage at ambient temperature, extended shelf-life, reduced operating steps and potential errors and increased flexibility in sample volume. They are designed for developing qPCR multiplex assays that require minimal sample processing and fast turn-around times (TAT) without compromising sensitivity, for low copy number samples.
## Specifications
DescriptionA combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, together with high quality enzymes, dNTPs, MgCl2 and lyophilization compatible excipients. Designed to be used in PCR reactions for highly reproducible, accurate assay results in the presence of inhibitors, even after lyophilization.Concentration4xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typecDNA, crude or purified RNA and/or DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5/1 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR & RT-qPCR Mixes**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable AssaysCatalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: Inhibitor-Tolerant Mixes
What sample types can be used with the Inhibitor-Tolerant qPCR Mixes?
We have tested whole human and bovine blood, saliva, sputum, urine, cerebrospinal fluid (CSF), cow milk, stool sample, and plant lysate; other types of samples can be used but we would recommend testing different concentrations to determine the concentrations that can be tolerated. We also recommend you try out our specimen-specific qPCR/RT-qPCR master mixes specially designed for each specimen type, such as blood, saliva/sputum, urine, stool, or plant.
Do I need to add additional magnesium to the reaction?
The Inhibitor-Tolerant RT-qPCR mixes have been optimized for magnesium, dNTPs, stabilizers, and enhancers, resulting in highly reproducible, accurate RNA and DNA target amplification under fast thermal cycling conditions, delivering excellent results in qPCR multiplex assays, even in the presence of difficult PCR inhibitors. So we do not recommend adding any additional material, only the primers, probe(s), and sample.
What are the recommended reaction conditions for qPCR multiplex assays?
When multiplexing, standard conditions can be used, however, if necessary, the reverse transcription reaction time can be extended up to 20 minutes and/or the temperature can be increased up to 55° C and the annealing/extension time can be extended up to 60 seconds and/or the temperature can be increased up to 65° C, but this will need to be tested during optimization.
Do you use a mutant polymerase to overcome inhibitors?
We use our own proprietary Taq polymerase and a highly optimized buffer system to overcome inhibition.
Can these mixes be dried down for room temperature storage?
These mixes contain glycerol and so cannot be dried down; see our specimen-specific range of inhibitor-tolerant quantitative PCR mixes for lyophilized or air-dried.
Where do I begin with optimization of crude samples or crude extracts?
We would recommend using a range of crude sample concentrations or extract volumes to ascertain at what point unacceptable PCR inhibition starts to take place. This will vary as some sample types, such as blood and stool specimens typically contain more inhibitors for qPCR/RT-qPCR reactions.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Glycerol-Free DNA Pol I Klenow Fragment (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Enzymes ](/lifescience/products/molecular-reagents/enzyme/)» Glycerol-Free DNA Pol I Klenow Fragment (HC)
# Glycerol-Free DNA Pol I Klenow Fragment (HC)
Glycerol-Free DNA Pol I Klenow Fragment (HC) is an N-terminal truncation of E.coli DNA Polymerase I which retains polymerase and 3’➔ 5’ exonuclease activity but has lost 5’➔ 3’ exonuclease activity. It is designed for DNA blunting by 3’ overhang removal and fill-in of 5’ overhangs for adapter ligation.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free DNA Pol I Klenow Fragment (HC)
- dA- and dT-tailing for next-generation sequencing (NGS) adapter ligation
- Labeling by fill-in 5'-overhangs of dsDNA
- DNA sequencing by the Sanger method
- Glycerol-free, for lyophilization and ambient temperature storage
### Glycerol-Free DNA Pol I Klenow Fragment (HC), MDX208
**Application:** NGS**Specimen Type:** DNA**Concentration:** 50 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration DNA polymerase used for generating blunt ends on any duplex DNA molecule, used in next-generation sequencing (NGS) library preparation. Ideal for lyophilization.
Available in 200 µL (10,000 Units) or 1 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX208-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX208-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX208.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX208)
## Description
Glycerol-Free DNA Pol I Klenow Fragment (HC) is a high concentration enzyme (50 U/µL) and is mainly used in next-generation sequencing (NGS) library preparation, where it can be used separately or as part of an End-Repair Mix, for double stranded DNA blunting by 3’ overhang removal and fill-in of 5’ overhangs for subsequent ligation of adaptors by T4 DNA Ligase. The enzyme displays moderate strand displacement activity and can also be used to generate probes using random primers, dideoxy sequencing and random priming labelling. Glycerol-Free DNA Pol I Klenow Fragment (HC) is in a glycerol-free storage buffer and is supplied with a Lyo-Ready Klenow Reaction Buffer and has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components, such as point-of-care NGS.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics
Catalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Mix**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[Glycerol-Free T4 DNA Ligase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free T4 Polynucleotide Kinase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-polynucleotide-kinase-hc/)
[Glycerol-Free T4 DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-polymerase-hc/)
## FAQs: Glycerol-Free DNA Pol I Klenow Fragment (HC)
Can DNA Pol I Klenow Fragment be used to remove 3' overhangs?
No, DNA polymerases cannot remove 3′ overhangs, 3′ overhangs are removed by T4 DNA Polymerase (MDX207).
What is the optimum temperature for DNA Pol I Klenow Fragment?
We recommend 25°C, higher temperatures can cause excessive 3’ ➔ 5’ exonuclease degradation, which eliminates blunt end formation.
What is a Klenow Fragment?
Klenow Fragment is the large fragment of DNA Polymerase I that retains its 5’➔3′ polymerase, 3’➔5′ exonuclease and strand displacement activities. The enzyme lacks the powerful 5’➔3′ exonuclease activity of intact DNA polymerase I. Klenow retains the polymerization fidelity of the holoenzyme without degrading 5′ termini.
What is the difference between Klenow Fragment and T4 DNA polymerase?
Klenow Fragment can be used at 25°C or room temperature, but T4 DNA Polymerase must be used at 12°C due to its robust exonuclease activity.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Glycerol-Free T4 DNA Ligase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Enzymes ](/lifescience/products/molecular-reagents/enzyme/)» Glycerol-Free T4 DNA Ligase (HC)
# Glycerol-Free T4 DNA Ligase (HC)
Glycerol-Free T4 DNA Ligase (HC) is a glycerol-free, high concentration enzyme (50U/µL) that catalyzes the formation of a phosphodiester bond between adjacent 5ʹ phosphate and 3′ hydroxyl groups in duplex DNA or RNA. The enzyme efficiently joins blunt and cohesive ends and repairs single stranded nicks in duplex DNA, RNA or DNA/RNA hybrids.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free T4 DNA Ligase (HC)
- Efficiently joins blunt and cohesive ends.
- Repairs single-stranded nicks in duplex DNA, RNA and DNA/RNA hybrids.
- Joins double-stranded oligonucleotide linkers or adaptors to DNA, for use in NGS library construction and cloning.
- Glycerol-free, for lyophilization and ambient temperature storage, ideal for point of care (POC) assays.
## Lyophilized Glycerol-free T4 DNA Ligase (HC) maintains its activity
Stability of Glycerol-free T4 DNA Ligase (HC) at room temperature in liquid or lyophilized format. For each condition, 330 units of T4 DNA Ligase was assessed for its ability to ligate 750 ng HindIII digested λ DNA in a standard ligation reaction for 1 hour at RT which was subsequently run on an agarose gel. ImageJ analysis was used to assess ligation efficiency relative to T4 DNA Ligase (T0). The results demonstrate that Glycerol-free T4 DNA Ligase (HC) is not affected by lyophilization and retains its activity when rehydrated.
### Glycerol-free T4 DNA Ligase (HC), MDX200
**Application:** NGS**Specimen Type:** DNA**Concentration:** 50 Weiss unit/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration enzyme that efficiently joins blunt and cohesive ends and repairs single stranded nicks in duplex DNA, RNA or DNA/RNA hybrids. Ideal for lyophilization.
Available in 1,000 Unit or 10,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX200-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX200-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX200.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX200)
## Description
Glycerol-free T4 DNA Ligase (HC) requires a ligase reaction buffer. The concentration of Glycerol-free T4 DNA Ligase (HC) (in Weiss units) is higher than the concentration of other ligases on the market and can be lyophilized, making it ideal for microfluidics and point of care testing.
## Catalogs & Brochures
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Mix**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
## FAQs: Glycerol-free T4 DNA Ligase (HC)
When should T4 DNA Ligase be the enzyme of choice?
T4 DNA Ligase should be used to ligate cohesive ends (10 minutes at room temperature) or blunt ends (2 hours at room temperature) or if the ligation is to be done overnight. T4 DNA Ligase should be used if heat inactivation is required. Concentrated T4 DNA Ligase is suggested for ligating single base overhangs.
What is the definition of a Weiss Unit?
One Weiss unit is defined as the amount of enzyme required to convert 1 nmol of 32P-labeled inorganic pyrophosphate into Norit adsorbable material (activated carbon) in 20 minutes at 37°C, using specified reaction conditions (Weiss, B., et al., J. Biol. Chem., 243, 4543 (1968)).
However, as the Weiss unit is not a direct measurement of DNA ligation, but an indirect measurement of the enzyme adenylation reaction, followed by determining ATP-PPi exchange, Cohesive End Unit is also used, as this is the direct measurement of DNA ligation (a Cohesive End Unit deing defined as the amount of enzyme required to give 50% ligation of Hind III fragments of lambda DNA in 20 µL of 1X T4 DNA Ligase Buffer in 30 minutes at 16°C). One Cohesive End Unit equals 0.015 Weiss units, or one Weiss unit equals 67 Cohesive End Units.
Can T4 DNA Ligase be heat inactivated?
Yes, heat at 65 °C for 10 minutes.
What is required in the ligase reaction buffer?
The general formulation of a 1x ligase reaction buffer is 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM DTT and 10 mM ATP.
Both Mg and ATP are an essential cofactor for the reaction, two ATP molecules are consumed for each phosphodiester bond formed.
Why is Glycerol-free T4 DNA Ligase (HC) at such a high concentration?
The increased concentration of the T4 DNA ligase is helpful in lower volume reactions where reagent volumes are limited, such as in microfluidic and cassettes in point of care devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Glycerol-Free T7 RNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Enzymes ](/lifescience/products/molecular-reagents/enzymes/)» Glycerol-Free T7 RNA Polymerase (HC)
# Glycerol-Free T7 RNA Polymerase (HC)
T7 RNA Polymerase is a DNA-dependant RNA Polymerase originating from the T7 bacteriophage and is the industry standard enzyme for *in vitro* transcription (IVT). Not only does T7 RNA Polymerase provide for mRNA vaccine production, but it can also be used for other RNA-based therapeutic and research applications, including miRNA and siRNA synthesis for RNA interference drugs, synthesis of sgRNA for the CRISPR/Cas9 system and in isothermal diagnostic methods, such as nucleic acid sequence-based amplification (NASBA).
[Request a Sample](https://meridianbiostg.wpengine.com/lifescience/products/molecular-reagents/enzymes/glycerol-free-t7-rna-polymerase-hc/?country=US#ls_sample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free T7 RNA Polymerase (HC)
- Synthesis of RNA (including mRNA and sgRNA)
- Synthesis of RNA probes for hybridization or RNA templates for in vitro RNA translation
- Radiolabelled/fluorescently labelled RNA probe preparation
- Nucleic acid sequence-based amplification (NASBA)
## RNA Yield and Integrity
*In vitro* transcription reactions were assembled, according to the manufacturer’s recommended protocol, using 0.1 ng of dsDNA template encoding a 1 kb or 4.5 kb RNA. The reactions were incubated at 37°C for up to 8 hours with lyophilized Glycerol-Free T7 RNA Polymerase (HC) (MDX201) (red), NEB T7 RNA Polymerase (orange) and ThermoFisher T7 RNA Polymerase (black). These samples were tested by performing *In vitro* transcription reactions against MDX201 before lyophilization, NEB T7 RNA Polymerase and ThermoFisher T7 RNA Polymerase. Transcription reactions were purified using a column-based RNA purification kit and quantified on spectrophotometer. These results demonstrate that a considerably higher yield of RNA was synthetized using MDX201, and that MDX201 provide a greater transcript integrity after extended duration of RNA synthesis reactions compared to other manufacturers’ kit.
### Glycerol-Free T7 RNA Polymerase (HC), MDX201
**Application:** NASBA**Specimen Type:** RNA**Concentration:** 1,000 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration DNA-dependant RNA Polymerase that requires a T7 promoter sequence, it an ideal enzyme for in-vitro synthesis of labeled or unlabeled RNA for research, diagnostic or clinical applications. Ideal for lyophilization.
Available in 50,000 Unit or 500,000 Unit aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX201-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX201-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX201.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX201)
## Description
Glycerol-Free T7 RNA Polymerase (HC) is a high concentration (1,000 U/µL) DNA-dependent RNA Polymerase with very high specificity for the T7 phage double-stranded promoter sequence. The enzyme catalyzes the 5’→3’ synthesis of RNA on either single-stranded DNA or double-stranded DNA downstream from the promoter. Glycerol-Free T7 RNA Polymerase (HC) has been optimized to deliver excellent, stable performance without glycerol, allowing you to develop *in vitro* transcription workflows with a high-quality enzyme that delivers reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store reaction mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components.
## Catalogs & Brochures
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080)**Glycerol-Free T7 RNA Polymerase**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: Glycerol-Free T7 RNA Polymerase (HC)
Why use an RNA Polymerase from a T7 bacteriophage?
RNA polymerase from a T7 bacteriophage is very selective and efficient, resulting in a high frequency of transcription initiation and effective elongation. These features result in an RNA elongation that is approximately five-fold faster than for *E. coli* RNA polymerase; hence, the T7 promoter is a much stronger promoter than the *E. coli* promoter.
What is the promoter sequence of T7 RNA Polymerase?
T7 Promoter
5′ TAATACGACTCACTATAG 3′
T7 RNA polymerase is very selective and efficient, resulting both in a high frequency of transcription initiation and effective elongation. T7 RNA polymerase starts transcription at the underlined G in the promoter sequence. The polymerase then transcribes using the opposite strand as a template from 5’->3’. The first base in the transcript will be a G.
The DNA contacts made by T7 RNA polymerase have been mapped during binding and during the subsequent initiation of transcription. The RNA polymerase alone protects 19 bases in a region from -21 to -3. The reason for some literature suggesting additional bases after this G is because synthesis of the hexanucleotide mRNA (TAATACGACTCACTATAGGGAGA), expands the length of the sequence protected by the RNA polymerase to 32 bases and stabilizes the complex1.
1\. Ikeda R. A. and Richardson C. C. Interactions of the RNA polymerase of bacteriophage T7 with its promoter during binding and initiation of transcription PNAS USA 83 (11): 3614-8 (1986).
Does the T7 RNA Polymerase require a primer?
No, the T7 RNA Polymerase recognizes the T7 Promoter sequence and then transcribes using the final G of the promoter as the first base to transcribe the opposite strand as a template from 5’->3’.
What can I do to optimize RNA yield using T7 RNA Polymerase?
Higher yields of RNA may be obtained by raising rNTP concentrations and Mg2+ concentration (to 4 mM above the total NTP concentration) or increasing the plasmid DNA concentration (these would need to be titrated to determine the correct concentrations).
Additionally, inorganic pyrophosphatase can also be added to a final concentration of 4 units/mL to try to lower feedback inhibition caused by the build-up of pyrophosphates that bind and precipitate Mg2+ ions.
RNases are ubiquitous in the environment and a significant risk factor during RNA production. The activity of RNases is blocked using RNase inhibitor. We recommend using RNase inhibitor (MDX056) in the reaction.
What are the main causes of reaction failure with T7 RNA Polymerase?
Degraded the RNA product caused by RNase contamination is often the main cause. We recommend using RNase inhibitor (MDX056) in the reaction. The DNA should also be prepared free of NaCl, as T7 RNA Polymerase is sensitive to NaCl inhibition (concentration should not exceed 20 mM).
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Glycerol-Free T4 DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-polymerase-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [NGS Enzymes ](/lifescience/products/molecular-reagents/ngs-enzymes/)» Glycerol-Free T4 DNA Polymerase (HC)
# Glycerol-Free T4 DNA Polymerase (HC)
Glycerol-Free T4 DNA Polymerase (HC) is a template dependent DNA polymerase that catalyzes 5′-3′ synthesis from primed single-stranded DNA and possess a 3´➔ 5´ exonuclease activity but lacks a 5´➔ 3´ exonuclease activity. Glycerol-Free T4 DNA Polymerase (HC) can be used for generating blunt ends on any duplex DNA molecule and for labelling DNA by replacement synthesis.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free T4 DNA Polymerase (HC)
- Blunting of DNA ends by "fill in" or "polish" the ends of double-stranded DNA fragments, for cloning or generating NGS libraries.
- Oligonucleotide-directed site-directed mutagenesis.
- Sanger sequencing, to remove fluorescent dye-labeled nucleotides as they are incorporated into the growing DNA strand.
- Glycerol-free, for lyophilization and ambient temperature storage
### Glycerol-Free T4 DNA Polymerase (HC), MDX207
**Application:** NGS**Specimen Type:** DNA**Concentration:** 20 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration DNA polymerase used for generating blunt ends on any duplex DNA molecule, used in next-generation sequencing (NGS) library preparation. Ideal for lyophilization.
Available in 50 µL (500 Units) or 500 µL (5,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX207-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX207-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX207.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX207)
## Description
Glycerol-Free T4 DNA Polymerase (HC) is supplied at 10 U/µL and catalyzes the addition of nucleotides to the 3′ end of a DNA strand, extending it in the 5′ to 3′ direction. It also possesses 3′ to 5′ exonuclease activity, allowing it to remove nucleotides from the 3′ end of DNA strands. This activity is useful in various DNA manipulation techniques, such as DNA sequencing, site-directed mutagenesis, and DNA repair studies. In addition, it has 5′ to 3′ exonuclease activity, enabling it to remove nucleotides from the 5′ end of DNA molecules.
It is used in next-generation sequencing (NGS) library preparation, where it can be used separately or as part of an End-Repair Mix, where it can blunt DNA ends of double-stranded DNA fragments for subsequent ligation of adaptors by T4 DNA Ligase.
Glycerol-Free T4 DNA Polymerase (HC) is in a glycerol-free storage buffer and is supplied with a reaction buffer and has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components, such as point-of-care NGS.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics
Catalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Mix**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[Glycerol-Free T4 DNA Ligase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free DNA Pol I Klenow Fragment (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-hc/)
## FAQs: Glycerol-Free T4 DNA Polymerase (HC)
Can T4 DNA Polymerase be used to remove 5' overhangs?
No, DNA polymerases cannot remove 5′ overhangs, 5′ overhangs (3′ recessed ends) are filled in and 3′ overhangs will be removed.
Can T4 DNA Polymerase be used in labeling reactions?
The 3’→5′ exonuclease of T4 DNA Polymerase makes these reactions difficult to control. We recommend Glycerol-Free DNA Pol I Klenow Fragment exo- (HC) (MDX208) for these applications.
What is the optimum temperature for T4 DNA Polymerase?
We recommend 12°C, at higher temperatures the exonuclease activity can remove nucleotides past blunt.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** NGS Enzymes
---
### [Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Lyo-Ready qPCR Mix
Molecular diagnostic tests are progressively moving towards lyophilization. There are several advantages for this, including room temperature shipping and storage, extended shelf-life, and increased flexibility in sample volume. In order to be compatible with drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to freezing, vacuum, and dehydration. An ideal lyophilization formulation, for example, should stabilize an enzyme in a freeze-dried format and allow very fast rehydration and reactivation of the enzyme preparations without impacting its performance post rehydration.
Can also be used wet and/or with purified nucleic acid.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Lyo-Ready qPCR Mix, MDX021
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:**
Glycerol-free Taq polymerase, reaction buffer, dNTP, MgCl2, and lyo-excipients, ideal for developing room temperature, lyophilized, multiplex qPCR assays.
Available in 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX021-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX021-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX021.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX021-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX021)
### Lyo-Ready qPCR ROX Mix, MDX173
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:**
Glycerol-free Taq polymerase, reaction buffer, dNTP, MgCl2, a passive reference dye and lyo-excipients, ideal for developing room temperature, lyophilized, multiplex qPCR assays.
Available in 1 mL (200 Rxns), 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX173-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX173.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX173)
Lyo-Ready qPCR master mix is a glycerol-free formulation that contains Taq polymerase, reaction buffer, dNTP, MgCl2, and lyo-excipients. It is ideal for developing room temperature, lyophilized, multiplex qPCR diagnostic tests and is suited for high-throughput, automated platforms requiring milli-second rehydration times.
## Catalogs & Brochures
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR Mixes Catalog**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR Mix Catalog**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays Catalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix, 2.6x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready Non-Bac DNA qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-non-bac-dna-qpcr-mix/)
**Published:** June 10, 2026
**Author:** Hamza Shahzad
**Content:**
# Lyo-Ready Non-Bac DNA qPCR Mix
Lyo-Ready Non-Bac DNA qPCR Mix is specifically designed to minimize carryover DNA contamination associated with recombinant enzyme production, ensuring highly sensitive and reproducible results. Produced using a eukaryotic expression system, this mix eliminates residual *E. coli* DNA contamination, making it ideal for low-copy target detection and multiplex assays, where false positives pose a significant risk. Optimized for both liquid use and lyophilization, it enables the development of ambient-stable molecular assays for decentralized and point-of-care applications.
[ Request a Sample ](#product)
[ Contact Us ](#contact-a-specialist)
## Key Product Features
- **Manufactured to minimize background DNA contamination**
- **Reliable detection of low-copy targets**
- **Improved signal-to-noise ratio**
- **Enhanced assay specificity**
## Description
Lyo-Ready Non-Bac DNA qPCR Mix is a one-tube, animal-origin-free formulation containing optimized buffer chemistry, PCR enhancers, dNTPs (including dUTP), MgCl₂, and Glycerol-Free Non-Bac HS Taq polymerase (HC). The polymerase is recombinantly produced in a eukaryotic system, significantly reducing bacterial DNA contamination and minimizing false positives, particularly critical when targeting prokaryotic genomes. This makes the mix highly suitable for low-abundance targets and multiplex PCR, delivering high sensitivity, specificity and reproducibility.
The formulation is glycerol-free and includes specialized excipients to support lyophilization. After freeze-drying, assays can be shipped and stored at ambient temperature, enabling: - Extended shelf life
- Simplified workflows
- Reduced risk of handling errors
- Greater flexibility in assay deployment
### Key points:
- Supports the development of clinical, microbiome, environmental, water and food assays
- Enables highly sensitive multiplex detection of low-copy targets
- Reduces false positives caused by background bacterial DNA
- Flexible format: use as a liquid or lyophilize for ambient-stable assays
Reagent Name Volume Lyo-Ready Non Non-Bac DNA qPCR Mix, 4x 5 μL Primer-Probe Mix, 20x 1 μL Water Up to 10 μL
Figure 1. Lyo-Ready Non-Bac DNA qPCR Mix. Combine reagents as shown for a total reaction volume of 20 μL. Briefly vortex and spin down briefly in a microcentrifuge. Incubate the reaction for 2 minutes at 95°C and then cycle for 5 seconds at 95°C and 20 seconds at 60°C for 45 cycles.
### Lyo-Ready Non-Bac DNA qPCR Mix, MDX362
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** No**Dryable:** Lyo-Ready**Sustainability:** Yes
Produced in a eukaryotic system to eliminate E. coli DNA contamination this glycerol-free, bacteria-free, qPCR master mix designed for highly sensitive, low-copy and multiplex qPCR, enabling with reduced false positives.
Available in 1 mL (200 Rxns), 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX362-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX362.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX362-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX362)
## Catalogs & Brochures
[](https://collateral.meridianlifescience.com/view/539655632/)
**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays 4x**
[](https://collateral.meridianlifescience.com/view/268380769/)
**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
- [ Glycerol-Free Non-Bac Taq Polymerase (HC) ](/lifescience/products/molecular/glycerol-free-non-bac-taq-hs-polymerase-hc/)
- [ Lyo-Ready AOF dUTP DNA qPCR Saliva, 4x ](/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-saliva/)
- [ Lyo-Ready AOF dUTP DNA qPCR Blood, 4x ](/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-blood/)
- [ Lyo-Ready AOF dUTP DNA qPCR Urine, 4x ](/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-urine/)
## FAQs: Lyo-Ready Non-Bac DNA qPCR Mix
What does “Non-Bac” mean in this qPCR mix?
“Non-Bac” refers to a low bacterial DNA (low bioburden) formulation. The polymerase is produced in a eukaryotic expression system, minimizing residual *E. coli* DNA contamination that can lead to false positives, particularly when detecting bacterial or low-copy targets.
Why is low bioburden important for qPCR?
Background bacterial DNA can be amplified during qPCR, especially in highly sensitive or multiplex assays. Reducing this contamination improves assay specificity, confidence in low-copy detection and reproducibility across runs
Is this mix suitable for detecting bacterial targets?
Yes. It is specifically designed for applications where bacterial DNA detection is required, as the low bioburden formulation minimizes the risk of false positives from contaminating DNA.
Can this mix be used for multiplex qPCR?
Yes. The optimized buffer chemistry and enzyme system support highly sensitive multiplex assays, enabling reliable detection of multiple targets within a single reaction.
What is the advantage of using a eukaryotic expression system?
Producing the polymerase in a eukaryotic system reduces carryover of bacterial DNA from host cells. This results in lower background contamination, improved assay sensitivity and greater confidence in results involving prokaryotic targets
Is the mix compatible with lyophilization?
Yes. The formulation is lyophilization-ready, containing excipients that preserve enzyme activity during freeze-drying and rehydration.
Can the mix be used in liquid format as well?
Yes. The mix is designed for dual use as a standard liquid qPCR master mix and as a lyophilized reagent for ambient-stable workflow
What are the benefits of lyophilizing this mix?
Lyophilization enables ambient temperature storage and shipping, extended shelf life, reduced cold chain requirements and simplified assay workflows.
Does the mix contain dUTP?
Yes. The inclusion of dUTP supports carryover contamination control systems (e.g., UNG-based workflows), helping to prevent amplicon contamination between runs.
Is UDGase supplied in the mix?
No, UDGase (Uracil DNA Glycosylase) needs to be added separately where there is a greater risk of false positives from cross-over contamination.
Is the formulation animal-origin-free?
Yes. The mix is animal-origin-free, supporting regulatory and quality requirements for diagnostic assay development.
What applications is this mix best suited for?
Typical applications include molecular diagnostics development, environmental and wastewater testing, microbiome research, food safety testing and any assay requiring low background DNA contamination.
Does the mix improve detection of low-copy targets?
Yes. The combination of low bioburden and optimized chemistry improves sensitivity and reduces background noise, making it well suited for low-copy number detection.
Can this mix help reduce false positives?
Yes. By minimizing contaminating bacterial DNA and supporting dUTP/UNG workflows, the mix helps reduce false positives caused by both environmental contamination and PCR carryover.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ Learn More ](/lifescience/about-life-science/)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-urine/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Urine
Urine Mixes are glycerol-free, inhibitor-tolerant formulations optimized for high-throughput qPCR applications. Made from animal-origin-free (AOF) ingredients, these mixes are specifically designed to tolerate/withstand carryover contamination, ensuring reproducible results. They are highly effective with both crude and purified urine samples, making them versatile and reliable for a variety of diagnostic applications.
[ Product Support Material ](#requestasample)
## Key Product Features
- Highly sensitive detection of RNA/DNA, even in crude whole blood, serum and plasma samples
- Compatible with lyophilization for developing ambient-temperature stable assays
- Incorporates dUTP, making it ideal for high-throughput and multiplex assays
- Animal origin-free and sustainable, designed to reduce environmental impact while aligning with future eco-regulations
## Description
Lyo-Ready AOF dUTP DNA qPCR Urine (MDX352) uses an advanced one-tube formulation, incorporating the latest innovations in buffer chemistry and PCR enhancers, along with an optimized concentration of recombinant antibody-mediated hot-start polymerase, dNTPs (including dUTP), and MgCl2. Lyo-Ready AOF dUTP RNA/DNA qPCR Urine, (MDX353) also includes reverse transcriptase and RNase inhibitor for comprehensive nucleic acid detection.
Lyo-Ready AOF dUTP DNA/RNA qPCR mixes utilize the dUTP/UDGase system to prevent carryover contamination, minimizing false positives and ensuring accurate results, especially in high-throughput workflows. BSA-free and sustainable, these mixes also align with evolving regulatory trends toward in vitro systems, reducing reliance on animal-sourced reagents while offering cost-effective, room-temperature stability through their lyophilization-ready formulation.
Urine, a versatile and non-invasive clinical specimen, is increasingly used for diagnosing infectious diseases, metabolic disorders, cancer, and drug monitoring. However, inhibitors like urea and nucleases can impact accuracy. Our inhibitor-tolerant Lyo-Ready mixes ensure sensitive RNA/DNA detection, even in crude urine samples, providing reliable results for diverse diagnostic applications.
### Key points:
- Supports the development of urine-based screening assays, such as assays detecting sexually transmitted diseases (STDs) or urinary tract infections (UTIs)
- Enables highly sensitive detection of low-copy number bacteria, viruses, and cell-free nucleic acids directly from crude urine samples.
- Facilitates quick and accurate identification of slow-growing and hard-to-culture microorganisms, reducing ambiguous results.
- Offers the flexibility to remain as a liquid mix or be lyophilized, creating ambient-temperature stable assays with extended shelf life.
Four sexually transmitted pathogens (*Mycoplasma genitalium, Treponema pallidum* (Syphilis), *Chlamydia trachomatis* and *Neisseria gonorrhoeae*) were amplified in a quadruplex reaction in 20% human urine using MDX352 in lyophilized format (red) and compared to other supplier’s master mixes (grey, green and black). Results demonstrate that Lyo-Ready AOF dUTP DNA qPCR Urine has higher multiplexing capabilities and better reproducibility than other supplier qPCR mixes.
### Lyo-Ready AOF dUTP DNA qPCR Urine, MDX352
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
An optimized qPCR master mix tolerant to inhibitors in urine. Perfect for multiplexing, high throughput assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX352-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX352-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX352.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX352-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX352)
## Catalogs & Brochures
[Air-Dryable Direct Urine Catalog](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine Catalog**
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
## FAQs: qPCR Urine Test
What does Animal origin–free (AOF) mean?
Does not contain materials derived from eukaryotic animals.
#####
Is UDGase supplied in the mixes?
No, UDGase (Uracil DNA Glycosylase) needs to be added separately where there is a greater risk of false positives from cross-over contamination.
#####
What are the advantages of using urine over other sample types?
The advantages of a quantitative PCR urine test are that it is completely non-invasive, and it can be self-sampled in large quantities. Urine testing is used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs) and for monitoring recreational drug use.
#####
What types of infectious diseases can urine detect?
The most common infections are urinary tract infections (UTIs), most commonly *Escherichia coli, Protus mirabilis, Enterococcus faecalis, Staphylococcus saprophyticus and Klebsiella pneumoniae*. Several other infections can be diagnosed by urine DNA and urine RNA tests including community-acquired pneumonia (CAP), legionellosis, tuberculosis, congenital cytomegalovirus (CMV) infection, and arboviruses, such as Chikungunya virus, dengue virus and Zika virus. Parasites can also be diagnosed from urine testing for the detection of eggs from *Schistosoma haematobium*. Furthermore, urine has been used for screening of different sexually transmitted diseases (STD) such as *Neisseria gonorrhoeae* and *Chlamydia trachomatis*.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-blood/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Blood
Lyo-Ready AOF dUTP DNA qPCR and RNA/DNA qPCR Blood Mixes are glycerol-free, inhibitor-tolerant formulations optimized for high-throughput qPCR applications. Made from animal origin-free (AOF) reagents, these mixes are specifically designed to tolerate/withstand carryover contamination, ensuring reproducible results. They are highly effective with both crude and purified blood samples, making them versatile and reliable for a variety of diagnostic applications.
[ Product Support Material ](#requestasample)
## Key Product Features
- Highly sensitive detection of RNA/DNA, even in crude whole blood, serum and plasma samples
- Compatible with lyophilization for developing ambient-temperature stable assays
- Incorporates dUTP, making it ideal for high-throughput and multiplex assays
- Animal origin-free and sustainable, designed to reduce environmental impact while aligning with future eco-regulations
## Description
Lyo-Ready AOF dUTP DNA qPCR Blood Mix (MDX322) uses an advanced one-tube formulation, incorporating the latest innovations in buffer chemistry and PCR enhancers, along with an optimized concentration of recombinant antibody-mediated hot-start polymerase, dNTPs (including dUTP), and MgCl2. Lyo-Ready AOF dUTP RNA/DNA qPCR Blood Mix, (MDX323) also includes reverse transcriptase and RNase inhibitor for comprehensive nucleic acid detection.
Lyo-Ready AOF dUTP DNA/RNA qPCR mixes utilize the dUTP/UDGase system to prevent carryover contamination, minimizing false positives and ensuring accurate results, especially in high-throughput workflows. BSA-free and sustainable, these mixes also align with evolving regulatory trends toward in vitro systems, reducing reliance on animal-sourced reagents while offering cost-effective, ambient-temperature stability through their lyophilization-ready formulation.
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for evaluating the function of vital organs (kidneys, liver, thyroid, and heart) and for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders such as diabetes. However, inhibitors like immunoglobulin G, hemoglobin and lactoferrin can impact accuracy. Our inhibitor-tolerant Lyo-Ready mixes ensure sensitive RNA/DNA detection, even in crude whole blood, serum and plasma samples, providing reliable results for diverse diagnostic applications.
### Key points:
- Supports the development of blood-based screening assays, such as assays detecting cancer or infections.
- Enables highly sensitive detection of low-copy number bacteria, viruses, and cell-free nucleic acids directly from crude whole blood, serum and plasma samples.
- Validated for detection of blood pathogens and liquid biopsy applications.
- Offers the flexibility to remain as a liquid mix or be lyophilized, creating ambient-temperature stable assays with extended shelf life.
#### Enhanced Performance in Anticoagulants
Whole human blood at concentrations of 2%, 5%, and 10% were tested with K2-EDTA, sodium heparin and sodium citrate using A) MDX322 and B) MDX323 and compared with other supplier’s master mixes. The results demonstrate Lyo-Ready AOF dUTP Blood mix’s ability to maintain higher performance and consistently earlier Ct values in the presence of inhibitors in high concentrations of blood containing common anticoagulants, ensuring reliable amplification even under challenging conditions.
### Lyo-Ready AOF dUTP DNA qPCR Blood, MDX322
**Application:** qPCR**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
An optimized qPCR master mix tolerant to inhibitors in whole blood and plasma and compatible with all anticoagulants. Perfect for multiplexing, high throughput assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX322-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX322-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX322.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX322-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX322)
### Lyo-Ready AOF dUTP RNA/DNA qPCR Blood, MDX323
**Application:** RT-qPCR**Specimen Type:** Blood, Plasma, Serum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
An optimized RT-qPCR master mix tolerant to inhibitors in whole blood and plasma and compatible with all anticoagulants. Perfect for multiplexing, high throughput assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX323-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX323-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX323.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX323-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX323)
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Blood Mix
What does Animal origin–free (AOF) mean?
Does not contain materials derived from eukaryotic animals.
Is UDGase supplied in the mixes?
No, UDGase (Uracil DNA Glycosylase) needs to be added separately where there is a greater risk of false positives from cross-over contamination.
What are the advantages of using blood over other sample types?
Blood contains abundant information about the health status of the organism, it can be used to evaluate organ function, detect proteins, nucleic acids, metabolites, infectious diseases and can be used for diagnosis of cancer (liquid biopsy), heart disease, diabetes. Blood tests are a simple and easily accessible (low-invasive) method to assess and monitor health.
What types of infectious diseases can blood detect?
Blood-based quantitative PCR (qPCR) can detect a wide variety of infectious diseases by identifying the genetic material (DNA or RNA) of pathogens, including viruses, bacteria, and parasites. The technique is highly sensitive and specific, making it an essential tool for diagnosing infectious diseases, such as: Viral Infections, including HIV/AIDS, Epstein-Barr Virus (EBV), Herpes Simplex Virus (HSV) and Human Papillomavirus (HPV). Bacterial Infections, including Tuberculosis (TB), Sepsis (organisms like *Staphylococcus aureus, Escherichia coli, or Klebsiella* species) and Meningococcal Infections (Neisseria meningitidis DNA in blood, especially in septicemia). Parasitic Infections, including *Plasmodium species*, *Toxoplasma gondii* and *Leishmaniasis*.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-aof-dutp-dna-and-rna-dna-qpcr-saliva/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Saliva
Lyo-Ready AOF dUTP DNA qPCR and RNA/DNA qPCR Saliva Mixes are glycerol-free, inhibitor-tolerant formulations optimized for high-throughput qPCR applications. Made from animal-origin-free (AOF) ingredients, these mixes are specifically designed to tolerate/withstand carryover contamination, ensuring reproducible results. They are highly effective with both crude and purified saliva samples, making them versatile and reliable for a variety of diagnostic applications.
[ Product Support Material ](#requestasample)
## Key Product Features
- Highly sensitive detection of RNA/DNA, even in crude whole blood, serum and plasma samples
- Compatible with lyophilization for developing ambient-temperature stable assays
- Incorporates dUTP, making it ideal for high-throughput and multiplex assays
- Animal origin-free and sustainable, designed to reduce environmental impact while aligning with future eco-regulations
## Description
Lyo-Ready AOF dUTP DNA qPCR Saliva (MDX332) uses an advanced one-tube formulation, incorporating the latest innovations in buffer chemistry and PCR enhancers, along with an optimized concentration of recombinant antibody-mediated hot-start polymerase, dNTPs (including dUTP), and MgCl2. Lyo-Ready AOF dUTP RNA/DNA qPCR Saliva, (MDX333) also includes reverse transcriptase and RNase inhibitor for comprehensive nucleic acid detection.
Lyo-Ready AOF dUTP DNA/RNA qPCR mixes utilize the dUTP/UDGase system to prevent carryover contamination, minimizing false positives and ensuring accurate results, especially in high-throughput workflows. BSA-free and sustainable, these mixes also align with evolving regulatory trends toward in vitro systems, reducing reliance on animal-sourced reagents while offering cost-effective, room-temperature stability through their lyophilization-ready formulation.
Saliva, a non-invasive and easily accessible diagnostic specimen, is gaining attention for detecting various diseases. Like serum, it contains hormones, antibodies, growth factors, enzymes, and microbes that serve as biomarkers. However, challenges arise when using saliva for molecular diagnostics due to low analyte concentrations and high levels of PCR inhibitors, which require complex sample preparation to purify DNA/RNA. Our inhibitor-tolerant Lyo-Ready mixes enable sensitive RNA/DNA detection, even in crude saliva and sputum samples, ensuring accurate results across a wide range of diagnostic applications.
### Key points:
- Supports the development of saliva-based screening assays, such as assays detecting COVID, influenza, RSV and tuberculosis.
- Suitable for singleplex or multiplex assays detecting RNA or DNA pathogens at very low titers from saliva or sputum samples.
- Validated for detection of saliva viruses and pathogens.
- Offers the flexibility to remain as a liquid mix or be lyophilized, creating ambient-temperature stable assays with extended shelf life.
#### Lyo-Ready AOF dUTP DNA and RNA/DNA qPCR Saliva (MDX333)
Influenza A, RSV A and Adenovirus were amplified in a triplex reaction using MDX333 (red) and compared with other supplier’s master mixes (purple and black) in the presence of 50% UTM swab containing sputum. The results illustrate that dry Lyo-Ready Direct RNA/DNA qPCR Saliva has higher multiplexing capabilities, inhibitor tolerance and better reproducibility than other supplier’s inhibitor tolerant mixes.
### Lyo-Ready AOF dUTP DNA qPCR Saliva, MDX332
**Application:** qPCR**Specimen Type:** Saliva, Sputum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
An optimized qPCR master mix tolerant to inhibitors in saliva and sputum. Perfect for multiplexing, high throughput assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX332-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX332-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX332.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX332-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX332)
### Lyo-Ready AOF dUTP RNA/DNA qPCR Saliva, MDX333
**Application:** RT-qPCR**Specimen Type:** Saliva, Sputum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
An optimized RT-qPCR master mix tolerant to inhibitors in saliva and sputum. Perfect for multiplexing, high throughput assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX333-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX333-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX333.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX333-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX333)
## Catalogs & Brochures
[ Lyo-Ready Direct Saliva ](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct SalivaCatalog**
[ Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable MixesCatalog**
[ Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct SalivaCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: qPCR Saliva Test
What does Animal origin–free (AOF) mean?
Does not contain materials derived from eukaryotic animals.
Is UDGase supplied in the mixes?
No, UDGase (Uracil DNA Glycosylase) needs to be added separately where there is a greater risk of false positives from cross-over contamination.
What are the advantages of using saliva over other sample types?
Saliva testing is compliance with painless, non-invasive sample collection from the patient, making it ideal for use with children or patients that will not comply with blood collections or even intrusive nasal swabs. Saliva tests and sputum tests also increase the efficiency of collection while minimizing sample handling and reducing handling errors.
What types of infectious diseases can saliva detect?
Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antimicrobial constituents, hormones, cytokines, and antibodies. Its composition virtually reflects the entire state of health and disease in a body, and it has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (avian influenza viruses and coronaviruses) and bacterial infections.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Lyo-Ready 1-Step RT-qPCR Mix
Molecular diagnostic tests are progressively moving towards lyophilized. There are several advantages for this, including room temperature shipping and storage, extended shelf-life and increased flexibility in sample volume. In order to be compatible with drying however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to freezing, vacuum and dehydration. An ideal lyophilization formulation for example, should stabilize an enzyme in a freeze-dried format and allow very fast rehydration and reactivation of the enzyme preparations, without impacting its performance post rehydration. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Lyo-Ready 1-Step RT-qPCR Mix, MDX024
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free Taq polymerase, reaction buffer, dNTP, MgCl2, and lyo-excipients, and separate thermostable reverse transcriptase, ideal for developing room temperature, lyophilized, multiplex qPCR assays.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX024-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX024-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX024.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX024-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX024)
### Lyo-Ready 1-Step RT-qPCR ROX Mix, MDX174
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Glycerol-free Taq polymerase, reaction buffer, reverse transcriptase, dNTP, MgCl2, and lyo-excipients, ideal for developing room temperature, lyophilized, multiplex qPCR assays.
Available in 1 mL (200 Rxns), 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX174-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX174.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX174)
### Enzyme Concentrations
Reverse transcriptase activity: 820.6 U/μL
Lot Number: B081920, EM032-B081100, EM033-B080040, EM033-B079850, EM033-B079960, EM032-B079780, EM033-B079680, EM116-B079670
Reverse transcriptase activity: 535 U/μL
Lot Number: EM033-B083980, EM033-B082210, EM033-B081850, EM033-B083810, EM033-B083820, EM033-B084440, EM033-B084430, EM033-B082220, EM033-B082230, EM033-B083750
Reverse transcriptase activity: 591 U/μL
Lot Number: EM033-B099400, EM033-B098680, EM033-B087450, EM033-B088470, EM033-B090230, EM032-B084980, EM033-B093180, EM033-B092850, EM032-B092190, B022175O, EM033-B095190, EM033-B095290, EM033-B095840, EM033-B088570, EM033-B096220, EM033-B096240, EM033-B096320, EM032-B097820, EM033-B097830, EM033-B098070, B095730, EM033-B097720, EM033-B097770, EM032-B102770, EM032-B103150
Reverse transcriptase activity: 501 U/μL
Lot Number: EM032-B090890, EM033-B090880, EM033-B104330, EM033-B104160, EM033-B105100, EM033-B106390, EM033-B107620, EM032-B107730, EM033-B107570, EM032-B107560, EM032-B110340, MDX024_EM032-B120020, EM033-B120950
Reverse transcriptase activity: 676.6 U/μL
Lot Number: EM033-B090910, EM032-B090900, B022176O, EM033-B100340, EM033-B100490, EM033-B100900, EM033-B101440, B102820, EM033-B103530, EM033-B103860
Reverse transcriptase activity: 966 U/μL
Lot Number: MDX024_EM032-B130110, EM032-B130170
---
## Description
Lyo-Ready 1-Step RT-qPCR Mix is a glycerol-free formulation that contains Taq polymerase, reaction buffer, dNTP, MgCl2, lyo-excipients, and separate thermostable reverse transcriptase and dilution buffer. It is ideal for developing room temperature, lyophilized, multiplex RT-qPCR diagnostic tests and is suited for high-throughput, automated platforms requiring milli-second rehydration times.
## Catalogs & Brochures
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCR MixesCatalog**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCR MixCatalog**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable AssaysCatalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready AOF dUTP DNA and RNA/DNA LAMP](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-aof-dutp-dna-lamp/)
**Published:** November 18, 2025
**Author:** hamza
**Content:**
# Lyo-Ready AOF dUTP DNA and RNA/DNA LAMP
Lyo-Ready AOF dUTP DNA LAMP and Lyo-Ready AOF dUTP RNA/DNA LAMP are glycerol-free, ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as loop-mediated isothermal amplification (LAMP), designed to speed up assay development time and reduce time to results. The glycerol-free mixes contain optimized excipients compatible with freezing and lyophilization, making them ideal for point-of-care testing (POCT). Made from animal-origin-free (AOF) ingredients, these mixes are specifically designed to prevent carryover contamination, ensuring reproducible results.
[ Product Support Material ](#product)
[ Contact Us ](#contact-a-specialist)
## Key Product Features
- **Animal-origin free and sustainable, reducing environmental impact and aligning with future eco-regulations**
- **Optimized for fast, highly sensitive detection of DNA**
- **Compatible with lyophilization for developing ambient-temperature stable assays**
## Description
Lyo-Ready AOF dUTP DNA LAMP combines the latest advances in buffer chemistry and reaction enhancers, together with an optimized concentration of strand-displacing polymerase, dNTPs and proprietary lyo-excipients allowing ambient temperature stabilization through lyophilization and Lyo-Ready AOF dUTP RNA/DNA LAMP also contains reverse transcriptase. dUTP and has been added, for fast, sensitive and highly reproducible DNA and RNA target amplification. In order to produce lyophilized ambient-temperature stable assays, specific primers need to be added to the LAMP mixes prior to lyophilization and Magnesium prior to amplification. The mixes do not contain animal-derived components, aligning with evolving regulatory trends toward more sustainable *in vitro* systems, reducing reliance on animals while offering cost-effective, room-temperature stability through a lyophilization-ready formulation. ### Key points:
- Ideal for point of care diagnostic platforms.
- Reduce risk of carryover contamination.
- Concentrated 4x master mix.
- Contains all the required excipients for subsequent lyophilization.
#### Faster time-to-result (TTR) and better reproducibility
A) Lyo-Ready AOF dUTP DNA LAMP (MDX301)
B) Lyo-Ready AOF dUTP RNA/DNA LAMP (MDX302)
A) Lyo-Ready AOF dUTP DNA LAMP (MDX301) was amplified with BRCA1, (1,000 copies), *Mycoplasma pneumoniae* (100 copies) and *Trichomonas vaginalis* (100 copies) and B) Lyo-Ready AOF dUTP RNA/DNA LAMP (MDX302) (blue) was amplified with Hepatitis C Virus (100 copies), West Nile Virus (100 copies) and Chikungunya (1,000 copies). They were compared to the same samples amplified with NEB WarmStart® Multi-Purpose LAMP/RT-LAMP 2X Master Mix (with UDG) (orange). The results demonstrate the faster speed (time to results) and better reproducibility (shorter error bars) of the Lyo-Ready AOF dUTP LAMP mixes compared to other suppliers.
### Lyo-Ready AOF dUTP DNA LAMP, MDX301
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** No**Dryable:** **Sustainability:**
Glycerol-free mix for isothermal applications such as LAMP, containing Bst DNA polymerase, reaction buffer, dNTPs and lyo excipients. Perfect for LAMP assays where there is a greater risk of false positives from cross-over contamination.
Available in 5 mL (800 Rxns) or 50 mL (8,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX301-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX301.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX301-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX301)
### Lyo-Ready AOF dUTP RNA/DNA LAMP, MDX302
**Application:** RT-LAMP**Specimen Type:** RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** No**Dryable:** Lyo-Ready**Sustainability:** Yes
Glycerol-free mix for isothermal applications such as RT-LAMP, containing Bst DNA polymerase, reverse transcriptase, reaction buffer, dNTPs and lyo-compatible excipients. Perfect for LAMP assays where there is a greater risk of false positives.
Available in 5 mL (800 Rxns) or 50 mL (8,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX302-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX302.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX302-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX302)
## Catalogs & Brochures
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMPCatalog**
[Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix, 4xCatalog**
## Related Products
- [ Glycerol-Free High-Fidelity Pfu (HC) ](/lifescience/products/molecular/high-conc-glycerol-free-bst/)
- [ Bst DNA Polymerase ](/lifescience/products/molecular/bst-dna-polymerase/)
## FAQs: Lyo-Ready AOF dUTP DNA LAMP
How is isothermal amplification different from qPCR?
The key difference between loop-mediated isothermal amplification (LAMP) and quantitative PCR (qPCR) lies in how DNA amplification is achieved. LAMP operates at a constant temperature, eliminating the need for thermal cycling. In contrast, qPCR requires precise cycling through multiple temperature stages using a thermocycler.
Instead of using high temperatures to denature DNA, LAMP relies on specialized polymerases, such as Bst DNA polymerase, that have strong strand displacement activity. This allows DNA amplification to occur rapidly and efficiently at a single temperature. As a result, LAMP can produce detectable amounts of DNA in under an hour, and sometimes in as little as 10 minutes.
Can LAMP be used for a multiplex assay?
Yes, it is possible to design a multiplex LAMP test using different primers and probes.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready LAMP and Lyo-Ready RT-LAMP 1-Step Mixes (including Lyo-Ready AOF dUTP DNA LAMP) can be used as a liquid mix or lyophilized and stored for up to 24 months without affecting the sensitivity of the tests.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ Learn More ](/lifescience/about-life-science/)
---
### [PCR and qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/pcr-and-qpcr-master-mixes/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » PCR and qPCR Master Mixes
# PCR and qPCR Master Mixes
Ready-to-use PCR master mixes and qPCR master mixes have been developed for fast cycling and are designed for superior sensitivity and specificity. A combination of the latest advances in buffer chemistry and PCR enhancers, in conjunction with an antibody or chemical-mediated DNA polymerase promote rapid, consistently accurate detection of the intended targets, even with multiplex assays.
[ Contact a Specialist ](#requestasample)
[ View Products Below ](#products)
## PCR/qPCR
[Fast qPCR Mix ](/lifescience/products/molecular/fast-qpcr-mix/)
[Low DNA qPCR Mix](/lifescience/products/molecular/low-dna-qpcr-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Air-Dryable™ qPCR and RT-qPCR Mixes Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready qPCR Mix](/lifescience/products/molecular/lyo-ready-qpcr-mix/)[Lyo-Ready qPCR Mix, 2.6x](/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Genotyping Direct qPCR FFPE](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-ffpe/)[Lyo-Ready Genotyping Direct qPCR Blood](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)[Lyo-Ready Genotyping Direct qPCR Urine](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)[High-Specificity Pfu HS Mix](/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
## PCR and qPCR Master Mixes for Fast, Sensitive Assays
PCR and qPCR Master Mixes are essential tools for developing fast, reliable, and highly sensitive assays in molecular diagnostics. Designed for exceptional performance, these master mixes optimize DNA amplification, enabling precise detection and quantification of genetic material. Whether in research or clinical settings, PCR and qPCR Master Mixes ensure consistent results, even in challenging applications, by providing robust amplification and minimal error rates.
At Meridian Bioscience, our PCR and qPCR Master Mixes are tailored to meet the diverse needs of molecular workflows, ensuring reproducibility, speed, and sensitivity. We support advancements in genetic testing, infectious disease research, and personalized medicine with high-quality reagents. Discover how our PCR and qPCR Master Mixes can elevate the accuracy and efficiency of your molecular assays.
**Key Features:**
- Enhanced specificity for accurate amplification.
- Optimized for fast cycling and superior sensitivity.
- Suitable for a wide range of molecular applications.
Make every assay count with PCR and qPCR Master Mixes designed to deliver precise and reliable outcomes.
## Catalogs & Brochures
[High-Specificity Pfu HS](https://collateral.meridianlifescience.com/view/34570908/) **High-Specificity Pfu HS**
[Lyo-Ready Genotyping Direct qPCR Blood **Lyo-Ready Genotyping Direct qPCR Blood** ](https://collateral.meridianlifescience.com/view/330386481/)
[Lyo-Ready Genotyping Direct DNA qPCR Stool](https://collateral.meridianlifescience.com/view/967751022/) **Lyo-Ready Genotyping Direct DNA qPCR Stool**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/) **Lyo-Ready Genotyping Direct DNA qPCR Urine**
[Air-Dryable Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/33571180/) **Air-Dryable Direct Blood Master Mixes**
[Lyo-Ready Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/222789736/) **Lyo-Ready Direct Blood Master Mixes**
[Lyo-Ready Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/931223153/) **Lyo-Ready Direct Saliva Master Mixes**
[Air-Dryable Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/856384693/) **Air-Dryable Direct Saliva Master Mixes**
[Air-Dryable Direct Stool Master Mixes](https://collateral.meridianlifescience.com/view/140230454/) **Air-Dryable Direct Stool Master Mixes**
[Lyo-Ready Genotyping Direct qPCR FFPE](https://collateral.meridianlifescience.com/view/487986445/) **Lyo-Ready Genotyping Direct qPCR FFPE**
[Lyo-Ready Direct Stool Master Mixes](https://collateral.meridianlifescience.com/view/322486879/) **Lyo-Ready Direct Stool Master Mixes**
[Air-Dryable Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/1027741197/) **Air-Dryable Direct Urine Master Mixes**
[Lyo-Ready Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/) **Lyo-Ready Direct Urine Master Mixes**
[Lyo-Ready Direct LAMP Urine Mixes](https://collateral.meridianlifescience.com/view/940080326/) **Lyo-Ready Direct LAMP Urine Mixes**
## Related Products
[High-Fidelity Pfu](https://www.meridianbioscience.com/lifescience/products/molecular/high-fidelity-pfu/)
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready qPCR Mix, 2.6x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
[qPCR Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/qpcr-extraction-control-red/)
[qPCR Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/qpcr-extraction-control-orange/)
[Low DNA qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-qpcr-mix/)
[Fast qPCR Buffer, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-buffer-4x/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
[Lyo-Ready Genotyping Direct qPCR FFPE](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-ffpe/)
[Lyo-Ready Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-inhibitor-tolerant-qpcr-rt-qpcr-master-mixes/)
[Air-Dryable Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-master-mixes/)
## FAQs
What are the advantages of using a two-step qPCR master mix over a one-step RT-qPCR mix?
1/ Two buffers optimized for independent RT and real-time PCR 2/ Highly sensitive 3/ Recommended when the reaction is performed with a limiting amount of starting material 4/ More efficient because random primers and oligo d(T) can be used 5/ Possibility to stock cDNA to quantify several targets.
When performing a reverse transcription reaction for a two-step quantitative PCR assay, it is possible to use different primer strategies. Random hexamer primers, which bind anywhere on the RNA allow full coverage of total RNA (including ribosomal, bacterial and viral RNA), oligo d(T)n (or anchored oligo d(T)n), which binds to the poly-A tail of the mRNA which is located at the extremity of the transcript, leading to full transcripts, a mixture of random hexamer and oligo d(T)n that reduces the risk of bias in cDNA synthesis and specific primers, which bind to the transcript of interest. The ability to optimize both cDNA and quantitative PCR reactions separately and the higher cDNA yields, two-step reactions can be more sensitive than one-step reactions. The ability to separately optimize these reactions is also beneficial when performing multiplex qPCR on challenging sequences.
What are the advantages and considerations of a chemical hot-start DNA polymerase?
With a chemical hot-start DNA polymerase, the polymerase is covalently linked with chemical groups to block enzyme activity at room temperature. Advantages 1/ More stringent than antibody hot-start methods, so there is no activity even for long periods at room temperature, minimizes non-specific amplification 2/ Low bioburden, as it is free of animal and bacterial-origin components Considerations 3/ Longer activation time required for the polymerase to become fully active.
What are the advantages of an aptamer-mediated hot-start polymerase?
Aptamers are engineered oligonucleotides that bind to the active site of the high-fidelity DNA polymerase but are denatured and released as the temperature is increased during the PCR amplification cycle. This aptamer-mediated inhibition/activation process is however fully reversible, and so at the end of thermal cycling, when the temperature of the reaction is decreased, the aptamer refolds and rebinds to high-fidelity DNA polymerase, inhibiting any further activity in the sample. This has proven to be important in workflows where undesired polymerase activity after reaction completion can disturb baseline readings, such as NGS following amplification of a library.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
How long are the lyophilized/air-dried mixes stable for at ambient temperature?
Following drying in the presence or absence of primers and probes, they are stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [White Papers, eBooks & Conference Posters](https://www.meridianbioscience.com/lifescience/products/molecular/white-papers-conference-posters/)
**Published:** August 27, 2025
**Author:** Moaaz Ahmad
**Content:**
# White Papers, eBooks & Conference Posters
## White Papers
[](https://www.meridianbioscience.com/lifescience/request-precision-oncology-white-paper/)**From Single Mutations to Whole Genomes: Molecular Technologies Shaping Precision Oncology Diagnostics**
[](https://share.hsforms.com/1Lx9uB8m6TMS6xHZyy2qd8Qc22yq)**Driving Sustainability in the IVD Industry: Key Market Trends and Strategic Approaches**
[Develop highly sensitive monkeypox MDx assays using Specimen-specific Master Mixes](https://collateral.meridianlifescience.com/view/1058482020/)**Develop highly sensitive monkeypox MDx assays using Specimen-specific Master Mixes**
[Reducing False Results in Immunoassay Testing](https://collateral.meridianlifescience.com/view/812878521/)**Reducing False Results in Immunoassay Testing**
[Benefits of multiplex testing for the differential diagnosis of COVID-19, Flu and RSV in a busy flu season](https://collateral.meridianlifescience.com/view/293344079/)**Benefits of multiplex testing for the differential diagnosis of COVID-19, Flu and RSV in a busy flu season**
[Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples](https://collateral.meridianlifescience.com/view/1070676719/)**Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples**
[Liquid Biopsy for Cancer Detection](https://collateral.meridianlifescience.com/view/655471428/)**Advances in qPCR-based liquid biopsy for cancer detection**
[Direct detection from crude cell lysate](https://collateral.meridianlifescience.com/view/789926652/)**Direct Detection from crude cell lysate: Obesity marker study**
## eBooks
[](/lifescience/gen-precision-oncology-ebook-download/)**From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays**
[](/lifescience/the-evolution-of-sti-testing-a-catalyst-for-modern-diagnostic-technologies/)**The Evolution of STI Testing:
A Catalyst for Modern Diagnostic Technologies**
## Application Note & Case Study
[](https://share.hsforms.com/110y8C2aIQrOdqqNcwAsPtgc22yq)**Inside an Assay Developer's Initial Study Comparing qPCR Mixes for Targeted NGS**
[](/lifescience/products/molecular/rapid-sepsis-detection-enabled-by-ddpcr-and-lyophilized-pcr-chemistry-case-study/)**From Concept to Clinic: Rapid Sepsis Detection Enabled by ddPCR and Lyophilized PCR Chemistry**
## Conference Posters
[Democratizing Access to NGS for Precision Oncology Through Ambient-Stable Library Preparation Reagents](https://collateral.meridianlifescience.com/view/544738633/)**Democratizing Access to NGS for Precision Oncology Through Ambient-Stable Library Preparation Reagents**
[ECCMID 2023 Poster](https://collateral.meridianlifescience.com/view/1020429880/)**AMP 2024 Poster “The Latest Molecular Diagnostics Technologies to Accelerate Development and Stabilize at Room Temperature qPCR, LAMP and NGS Workflows”**
[TriCon 2023 Exhibit Poster "From Urine Samples to Diagnosis"](https://collateral.meridianlifescience.com/view/630490657/)**TriCon 2023 Exhibit Poster "From Urine Samples to Diagnosis"**
[TriCon 2023 Poster "SNPs & DNA Methylation Detection"](https://collateral.meridianlifescience.com/view/630891945/)**TriCon 2023 Poster "SNPs & DNA Methylation Detection"**
[ECCMID 2023 Poster](https://collateral.meridianlifescience.com/view/58821890/)**ECCMID 2023 Poster “Direct Detection of Viral SNPs & Antibiotic Resistance Markers”**
---
### [Glycerol-Free Non-Bac Taq HS Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-non-bac-taq-hs-polymerase-hc/)
**Published:** February 27, 2026
**Author:** Holger
**Excerpt:** Meridian Bioscience’s high-concentration Glycerol-Free Non-Bac Taq HS Polymerase is designed to ensure accurate detection of low-abundance bacterial targets.
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA Polymerases ](/lifescience/products/molecular-reagents/dna-polymerases/)» Glycerol-Free Taq HS High Conc. DNA Polymerase
# Glycerol-Free Non-Bac Taq HS Polymerase (HC)
Meridian Bioscience’s high-concentration Glycerol-Free Non-Bac Taq HS Polymerase is designed for sensitive PCR and multiplex applications, ensuring accurate detection even at ultra-low target copy numbers. Produced using a recombinant eukaryotic expression system, it is completely free of *E. coli* DNA, eliminating false positives from bacterial contamination.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Key Product Features
- Bacterial DNA-free – eliminates background and false positives.
- High sensitivity & specificity – reliable low-copy, multiplex detection.
- Highly concentration – ideal for bulk.
- Glycerol-free – ready for lyophilized, ambient-stable qPCR.
## Sensitive detection of Bacterial DNA
The activity of the Glycerol-Free Non-Bac HS Taq Polymerase (HC) was tested in a triplex qPCR assay targeting marker genes from three bacteria (16s rRNA gene from *Enterococcus*, Mip gene from *Legionella pneumophila* and ToxA gene from *Pseudomonas aeruginosa*), using 10-fold serial dilution of the bacterial genomic DNAs. The result shows that Glycerol-Free Non-Bac HS Taq Polymerase (HC) can successfully detect multiple targets down to 1 copy of DNA in multiplex assays.
### Glycerol-Free Non-Bac Taq HS Polymerase (HC), MDX252
**Application:** PCR**Specimen Type:** DNA**Concentration:** 50 µg/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Requires Excipients**Air-Dryable:** Requires Excipients**Dryable:** Requires excipients**Sustainability:** Yes
Lyophilization-compatible, high concentration, polymerase, designed to ensuring accurate detection of low-abundance bacterial targets.
Available in 0.02 mL (1,000 Units), 0.5 mL (25,000 Units) or 5 mL (250,000 Units) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX252-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX252.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX252)
## Description
Glycerol-Free Non-Bac Taq HS Polymerase (HC) is a high concentration (50 U/µL) thermostable DNA polymerase and is supplied as a high-performance glycerol-free Taq DNA Polymerase premixed with a Taq hot start antibody. Ideal for sensitive or multiplex PCR, delivering high specificity and zero bacterial DNA.
The glycerol-free formulation can be used to produce lyophilized or air-dried, ambient-temperature stable PCR or qPCR reagents and exhibits the same high performance before and after drying, offering greater flexibility for assay design and format.
## Catalogs & Brochures
[Glycerol-Free Taq HS ](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HS**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
## FAQs: Glycerol-Free Non-Bac Taq HS Polymerase (HC)
What does “Non-Bac” mean?
“Non-Bac” refers to the enzyme’s non-bacterial expression system. Unlike traditional Taq polymerase produced in E. coli, this polymerase is expressed in a recombinant eukaryotic system, ensuring it is free from bacterial (E. coli) DNA contamination.
Why is bacterial DNA contamination a problem in PCR?
Trace bacterial DNA can act as an unintended template, leading to false positives, particularly in assays targeting bacterial or microbial DNA. This is especially critical for low-copy detection, multiplex PCR and environmental or diagnostic testing.
Is Glycerol-Free Non-Bac Taq HS Polymerase (HC) suitable for multiplex PCR?
Yes. Glycerol-Free Non-Bac Taq HS Polymerase (HC) is specifically designed for difficult and multiplex PCR applications, delivering high specificity and sensitivity even when amplifying multiple low-abundance targets in the same reaction.
Why is glycerol-free formulation important?
Glycerol-free enzymes are better suited for lyophilization and ambient storage, enabling cold-chain-free shipping and supporting point-of-care and decentralized testing applications.
Is there a difference between the polymerase with glycerol and glycerol-free formulation?
No, the Glycerol-Free Non-Bac Taq HS Polymerase (HC) can be used in exactly the same way as a glycerol-containing enzyme, however it allows the assay to be future-proofed, should you consider lyophilization and ambient storage, enabling cold-chain-free shipping and supporting point-of-care and decentralized testing applications.
What types of applications is Glycerol-Free Non-Bac Taq HS Polymerase (HC) best suited for?
It is ideal for applications where contamination control and sensitivity are critical, including:
- Pathogen and infectious disease diagnostics
- Environmental and water testing
- Pharmaceutical and food safety screening
- Point-of-care and near-patient testing
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes, Enzymes, Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# dUTP, 100mM, Sodium Salt
dUTP, 100mM, Sodium Salt achieves high dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest standards and are perfectly suited for even the most demanding applications, such as highly sensitive qPCR.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dUTP, 100mM (Sodium), MDX096
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dUTP (2’-Deoxyuridine-5’-Triphosphate) sodium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 20 mL or larger aliquots (please enquire)
##### Documents & Resources
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX096.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX096)
Ready-to-use general grade ultra-pure dUTP, 100mM solution, supplied as lithium salts in purified water at pH 7.5,, or sodium salts in purified water at pH 7.0, enzymatically synthesized from quality raw materials, using highly specific production systems. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC).
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
[dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dATP, 100mM, Sodium Salt
Ready-to-use general grade ultra-pure dATP, 100 mM solution, supplied as sodium salts in purified water at pH 7.5, or sodium salts in purified water at pH 7.0, enzymatically synthesized from quality raw materials, using highly specific production systems. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dATP, 100mM (Sodium), MDX063
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dATP (2’-Deoxyadenosine-5’-Triphosphate) sodium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 20 mL or larger aliquots (please enquire)
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX063-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX063-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX063.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX063)
## Description
dATP Mix, 100mM, Sodium Salt achieves high dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest standards and are perfectly suited for even the most demanding applications, such as highly sensitive qPCR.
## Related Products
[dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
[dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [dNTP Mix, 40mM Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-40mm-sodium-salt/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# dNTP Mix, 40mM, Sodium Salt
A mix of ready-to-use general grade dNTPs containing dATP, dGTP, dCTP, and dTTP (40mM total), supplied as lithium salts in purified water at pH 7.5, or sodium salts in purified water at pH 7.0, enzymatically synthesized from quality raw materials, using highly specific production systems. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dNTP Mix, 40mM (Sodium), MDX083
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 40 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure mix 10 mM each of dATP, dGTP, dCTP, and dTTP in sodium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 10 mL or larger aliquots (please enquire)
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX083-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX083.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX083)
## Description
dNTP Mix, 40mM, Sodium Salt achieves high dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest standards and are perfectly suited for even the most demanding applications, such as Long PCR or highly sensitive qPCR
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
[dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [LAMP Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lamp-master-mixes/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
# LAMP Master Mixes
Loop mediated isothermal amplification (LAMP) is a amplification technique that has played an increasingly important role in point-of-care (POC) diagnostics. It offers several advantages over qPCR and other amplification techniques in terms of sample-to-answer time, sensitivity, specificity, cost, robustness, and accessibility, making it ideal for field-deployable diagnostics in resource-limited regions.
[ Contact a Specialist ](#requestasample)
## High-Sensitivity LAMP Master Mixes for Rapid POCT Development
- Inhibitor-tolerant isothermal mix designed for direct isothermal amplification from crude samples.
- Very fast reaction kinetics – ideal for point of care testing.
- Fully optimized, just add custom primers and probes.
LAMP master mixes enabling highly sensitive detection of target DNA or RNA. Meridian has also developed sample specific inhibitor tolerant LAMP mixes, designed to be used for direct amplification from crude lysates or inhibitor-rich samples, with the ability to tolerate even higher levels of inhibitors present in samples. In addition, these mixes can be used as wet mixes or dried by lyophilization or air-drying for room temperature shipping and storage, extended shelf-life, and increased flexibility in sample volume, making them ideal for POCT development where minimal sample processing and fast turn-around times are essential.
## Bst.Enzymes & Buffers
[Bst DNA Polymerase](/lifescience/products/molecular/bst-dna-polymerase/)[High Conc. Glycerol-Free Bst](/lifescience/products/molecular/high-conc-glycerol-free-bst/)[Buffers](/lifescience/products/molecular/buffers/)
## LAMP Mixes
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)[Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)[Air-Dryable LAMP/RT-LAMP Mixes](/lifescience/products/molecular/air-dryable-lamp-rt-lamp-mixes/)
Not seeing what you’re looking for? [Inquire about a new product](#requestasample)
## Catalogs & Brochures
[Lyo-Ready LAMP Master Mix](https://collateral.meridianlifescience.com/view/33803663/) **Lyo-Ready LAMP Master Mix**
[Lyo-Ready Direct DNA LAMP Blood Master Mixes](https://collateral.meridianlifescience.com/view/683928362/) **Lyo-Ready Direct DNA LAMP Blood Master Mixes**
[Lyo-Ready Direct Stool Urine LAMP Master Mixes](https://collateral.meridianlifescience.com/view/111612146/) **Lyo-Ready Direct Stool LAMP Master Mixes**
[Specimen-specific and Universal qPCR & LAMP Master Mixes](https://collateral.meridianlifescience.com/view/205757818/) **Specimen-specific and Universal qPCR & LAMP Master Mixes**
[Lyo-Ready RT-LAMP 1-Step Master Mix](https://collateral.meridianlifescience.com/view/159769789/) **Lyo-Ready RT-LAMP 1-Step Master Mix**
[Lyo-Ready Direct LAMP Saliva Master Mixes](https://collateral.meridianlifescience.com/view/180412872/) **Lyo-Ready Direct LAMP Saliva Master Mixes**
## Related Products
[Bst DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/bst-dna-polymerase/)
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Glycerol-Free T7 RNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
## FAQs
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
Can LAMP be used for a multiplex assay?
Yes, it is possible to design a multiplex LAMP test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
What is the performance difference for DNA when using the DNA-specific product versus the DNA/RNA product?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-LAMP Blood mix – Lyo-Ready Direct RNA/DNA LAMP Blood mix, as it can be used for both.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the LAMP and RT-LAMP master mixes can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and this drying/ambient temperature storage will not affect the sensitivity of the POCT.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [From Concept to Clinic: Rapid Sepsis Detection Enabled by ddPCR and Lyophilized PCR Chemistry](https://www.meridianbioscience.com/lifescience/products/molecular/rapid-sepsis-detection-enabled-by-ddpcr-and-lyophilized-pcr-chemistry-case-study/)
**Published:** February 26, 2026
**Author:** Holger
**Content:**
In this paper, we present a case study from Pilot Gene (Hangzhou, China) evaluating Meridian’s Lyo-Ready qPCR Mix (MDX024) on a ddPCR platform for sepsis testing. The study demonstrates rapid and accurate pathogen detection, highlighting the ability to detect pathogens within 24 hours, provide early sepsis warning, and enable precise quantitative monitoring throughout the course of sepsis.
The report also compares Meridian’s Lyo-Ready qPCR Mix (MDX024) with a reference mix, showing improved amplification efficiency, specificity, inhibitor tolerance and compatibility with lyophilization.
---
### [Lyophilized NGS Library Preparation Kit](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-library-preparation-kit/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [NGS Enzymes ](/lifescience/products/molecular-reagents/ngs-enzymes/)» Lyophilized NGS Library Preparation Kit
# Lyophilized NGS Library Preparation Kit
Our Lyophilized NGS Library Preparation Kit is a ready-to-use complete solution for sequencing-by-synthesis (SBS) protocols. It removes the need for cold chain shipping and storage and increases the accessibility of NGS reagents and applications.
[ Explore Our Products ](#support-documents)
[ Contact A Specialist ](#contact-a-specialist)
## Lyophilized NGS Library Preparation Kit
The Lyophilized NGS Library Preparation Kit is a ready-to-use lyophilized next-generation sequencing library preparation kit for SBS protocols that can be shipped and stored at ambient temperature for at least 12 months.
- Dried reactions packed in sealed pouches for ambient temperature stability, transport and storage
- Ready-to-use, just add DNA solution
- Cost-effective, sustainable and accessible testing for NGS
## Lyophilized NGS Library Preparation Kit
#### Lyophilized reactions in tubes, packed in sealed pouches for ambient temperature stability
Three tubes consisting of the lyophilized components for end-repair and A-tailing, ligation, and library amplification. These can be stored at ambient temperature and are ready to use, just add DNA solution.
#### Workflow
The straightforward design ensures that the NGS library preparation process is fast and convenient, contributing to cost-effective, sustainable, and accessible NGS technology.
### Lyophilized NGS Library Preparation Kit (PCR-Free), MDX219-A
**Application:** NGS**Specimen Type:** DNA**Concentration:** N/A**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Requires excipients**Air-Dryable:** Lyo-Ready**Dryable:** Lyo-Ready**Sustainability:** Glycerol-Free
Lyophilized components for end-repair and A-tailing, ligation, and optionally library amplification. These can be stored at ambient temperature and are ready to use, just add DNA solution.
Available as 8 reactions, with and without PCR amplification
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX219-A-MSDS.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX219-A.pdf)
- [Product Manual](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-pm/MDX219-A-pm.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX219-A)
### Lyophilized NGS Library Preparation Kit, MDX219-B
**Application:** NGS**Specimen Type:** DNA**Concentration:** N/A**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Glycerol-Free
Lyophilized components for end-repair and A-tailing, ligation, and optionally library amplification. These can be stored at ambient temperature and are ready to use, just add DNA solution.
Available as 8 reactions, with and without PCR amplification
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX219-B-MSDS.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX219-B.pdf)
- [Product Manual](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-pm/MDX219-B-pm.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX219-B)
## Description
Lyophilized NGS Library Preparation Kit, MDX219, consists of an end repair/dA-tailing mix module that combines the enzymes and buffers required for end-repair and dA-tailing to convert fragmented DNA into 5ʹ-phosphorylated and 3ʹ-dA-tailed DNA fragments, a ligase and buffer, enabling direct ligation of sequencing adapters and a high-fidelity PCR dried master mix for library amplification. The kit is designed to be straight forward and to demonstrate that the lyophilized kit can produce libraries equivalent to those achieved with traditional liquid formats.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)Catalog**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HSCatalog**
## Related Products
[Glycerol-Free T4 DNA Ligase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free T4 DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-polymerase-hc/)
[Glycerol-Free DNA Pol I Klenow Fragment (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-hc/)
[Lyophilized NGS Enzymatic DNA Fragmentation Kit](https://www.meridianbioscience.com/lifescience/products/molecular/lyophilized-ngs-enzymatic-dna-fragmentation-kit/)
- [ NGS Library Quantification ](/lifescience/products/molecular-reagents/ngs-library-quantification/)
## Next Generation Sequencing
- [ Learn more about Meridian NGS products ](/lifescience/products/molecular-reagents/ngs-enzymes/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** NGS Enzymes
---
### [Experience It for Yourself](https://www.meridianbioscience.com/lifescience/products/molecular/experience-it-for-yourself/)
**Published:** September 3, 2025
**Author:** Moaaz Ahmad
**Content:**
## Discover the Meridian Difference
Meridian offers a broad range of high-performance immunoassay blockers to help reduce interference from HAMA, RF, and other heterophilic antibodies—supporting more accurate and reliable assay results across ELISA, CLIA, and lateral flow formats.
Please select the blocker you would like to evaluate using the form below and a representative will be in touch to help you with your order.
---
### [Request Precision Oncology White Paper](https://www.meridianbioscience.com/lifescience/products/molecular/request-precision-oncology-white-paper/)
**Published:** August 27, 2025
**Author:** Moaaz Ahmad
**Content:**
As cancer care becomes increasingly personalized, choosing the right molecular technology is more critical than ever. Meridian’s latest white paper, From Single Mutations to Whole Genomes, offers a comparative look at qPCR, targeted NGS, and whole-genome sequencing—highlighting their roles in enabling earlier detection, therapy selection, and long-term monitoring across the cancer care continuum.
This paper outlines the key technical trade-offs and emerging trends shaping oncology assay design. It explores how precision oncology is transforming cancer care—driving demand for highly sensitive, accurate assays across the care continuum. To meet these evolving needs, the next generation of diagnostics will rely on flexible, scalable platforms and ambient-temperature stable reagents that deliver reliable performance wherever testing is needed.
---
### [Precision Oncology Solutions Driving the Future of Cancer Diagnostics](https://www.meridianbioscience.com/lifescience/products/molecular/precision-oncology-solutions-driving-the-future-of-cancer-diagnostics/)
**Published:** August 28, 2025
**Author:** Moaaz Ahmad
**Content:**
## Precision Oncology Solutions Driving the Future of Cancer Diagnostics
##### Early detection demands more. Meridian delivers.
Meridian’s high-performance reagents enable exceptional sensitivity, specificity, and scalability—supporting precision oncology assays across qPCR, targeted NGS, and WGS.
[ View Resources ](#resource)
[ Request Technical Consultation ](https://share.hsforms.com/1kilAJUigQrKVIzea0seqkQc22yq?__hstc=51647990.b0fa2ffb6065e12c59b74669d987437b.1756124777317.1756911524303.1756997980731.16&__hssc=51647990.1.1756997980731&__hsfp=2732387906)
#### From Targeted to Comprehensive:
### Molecular Tools Driving Cancer Detection
Choosing the right molecular technology in oncology testing involves balancing sensitivity, depth of analysis, turnaround time, and cost. From targeted mutation detection to comprehensive genomic insights, each method offers distinct advantages based on clinical needs and assay complexity.
##### qPCR: A Frontline Tool in Precision Oncology
A fast, sensitive, and cost-effective method for detecting known cancer mutations
[ Explore our qPCR Solutions](/lifescience/products/molecular/rt-pcr-rt-qpcr-master-mixes/)
qPCR offers speed, sensitivity, and a strong regulatory track record—ideal for targeted applications like companion diagnostics, liquid biopsy, MRD testing, and treatment selection. It enables high-sensitivity detection even in low-input samples like plasma-derived ctDNA, integrates easily into automated, high-throughput workflows, and delivers results within hours. qPCR offers speed, sensitivity, and a strong regulatory track record—ideal for targeted applications like companion diagnostics, liquid biopsy, MRD testing, and treatment selection.
###### Used in FDA-approved diagnostics for:
- EGFR – NSCLC
- BRAF – melanoma
- KRAS – colorectal cancer
##### tNGS: Multiplex Power for Broad Cancer Profiling
A flexible, scalable solution for broad mutation detection`
[ Talk to Meridian Expert](https://share.hsforms.com/1kilAJUigQrKVIzea0seqkQc22yq?__hstc=51647990.26e2792c973c6d98a744bd481f28db83.1754909130320.1756404966892.1756793989001.31&__hssc=51647990.2.1756793989001&__hsfp=464159533)
Targeted next-generation sequencing (tNGS) enables simultaneous analysis of dozens to hundreds of genes—offering broader coverage than single-target assays. Commonly used in tumor profiling, MRD monitoring, and therapy selection, tNGS strikes a balance between depth and practicality in liquid biopsy and panel-based testing.
###### Two main approaches:
- Amplicon-based – fast, focused, and cost-effective
- Hybrid-capture – greater sensitivity and detection of complex variants
Meridian supports amplicon-based workflows with modular, glycerol-free reagents for sensitive amplification, efficient clean-up, and precise quantification—reducing hands-on time and improving assay consistency. From amplification through to library prep, our solutions integrate seamlessly into your pipeline:
##### WGS: Unbiased Insight for Complex and Rare Cancer Cases
A comprehensive method for decoding the entire cancer genome in a single assay.
[ Explore NGS Library Prep Solutions](/lifescience/products/molecular-reagents/ngs-enzymes/)
Whole genome sequencing (WGS) provides a comprehensive, base-by-base view of the entire genome – capturing all variant types, including SNVs, indels, CNVs, structural variants, and non-coding mutations.
WGS requires no prior mutation knowledge, making it valuable for rare, treatment-resistant, or complex cancers. It’s used in translational research, clinical trials, and national precision medicine programs, with strong relevance in pediatric and hematologic oncology.
While powerful, WGS adoption is limited by cost, turnaround time, and the need for advanced bioinformatics.
NGS library preparation is a key step, directly impacting data quality, yield, and consistency. With limited or low-quality samples, efficient library prep is essential to maximize usable data and ensure reliable variant detection—especially in challenging applications like FFPE or liquid biopsy. 
### Resources
Explore our resources for expert insights, technical guides, and other educational materials—all in one place to keep you informed and stay ahead.
- [ Video ](#Video)
- [ Ebook ](#Ebook)
- [ Webinar/White Paper ](#Webinar)
- [ Blog ](#Blog)
- [ Catalog/Flyers ](#Catalog)
- [ FAQs ](#Faq)
### Video
##### Learn About Meridian’s Custom Reagent Solutions Supporting Precision Oncology
Click the play button on the left to go behind the scenes with our R&D team to see how Meridian partners with developers to deliver customized, high-performance solutions – from early biomarker discovery to clinical validation and manufacturing scale-up.
### eBook
Discover What’s Next in Precision Oncology
[ Download the eBook ](/lifescience/gen-precision-oncology-ebook-download/)
### Webinar / White Paper
Explore how qPCR, tNGS, and WGS are driving today’s most impactful cancer diagnostics.
[ View Webinar ](/lifescience/webinars/webinars-precision-oncology-may-2025/)
[ Download White Paper ](/lifescience/products/molecular/request-precision-oncology-white-paper/)
### Blog
Uncover the Next Wave of Innovation in Molecular Diagnostics.
[ Read the Blog ](/next-gen-synergies-innovating-poct-and-ngs-for-enhanced-molecular-diagnostics/)
### Catalogue / Flyers
Download our product flyers to explore tailored solutions for Liquid Biopsy and NGS applications—featuring high-performance reagents designed for sensitivity, stability, and scalability.
[ Download Flyer ](https://collateral.meridianlifescience.com/view/34525896/?__hstc=51647990.f95f46cc4c3213a038e387e205a28ba7.1759228558452.1763468678794.1763533676255.80&__hssc=51647990.2.1763533676255&__hsfp=1619854557)
[ Download Flyer ](https://collateral.meridianlifescience.com/view/648087398/?__hstc=51647990.f95f46cc4c3213a038e387e205a28ba7.1759228558452.1763468678794.1763533676255.80&__hssc=51647990.2.1763533676255&__hsfp=1619854557)
## FAQs
Are the lyo kits compatible to automation?
Yes, the sudden hydration guarantees compatibility with all the main automation platforms.
Do you have a module target enrichment by hybridization capture?
Not at the moment, but the kit can be integrated with hybridization capture probes.
Do you have an enzymatic fragmentation module?
Coming soon –expected at the end of 2025.
Is the kit compatible to Oxford Nanopore Technologies and with long reads?
Yes, but some optimization is required.
## Contact A specialist to Learn More
[ ](/contact-us-life-science/)
---
### [Resource Videos for Life Science](https://www.meridianbioscience.com/lifescience/products/molecular/resource-videos-for-life-science/)
**Published:** September 3, 2025
**Author:** Moaaz Ahmad
**Content:**
# Resource Videos for Life Science
## Custom Solutions
##### Partnering for Diagnostic Success with Meridian’s Custom Solutions
In this behind-the-scenes video, we showcase how our deep scientific expertise and collaborative approach help diagnostic developers bring innovative assays to life. Led by Florent Chang-Pi-Hin, PhD, VP of R&D, the video highlights Meridian’s decades of experience in stabilizing and optimizing enzyme systems for qPCR, isothermal amplification, and NGS. What sets Meridian apart is not just our technical capabilities, but our close partnership with customers, from early-stage development through scale-up and manufacturing. With flexible, responsive support and a commitment to quality, Meridian’s custom solutions are designed to accelerate your path to market.
## Contamination Control Solutions
##### Streamlined dUTP Workfllow
## Specimen-Specific Molecular Solutions
##### Isothermal Mixes for LAMP
## Air-Dryable™ Technology
## Immunoassay Blockers
##### TRU Block™ HAMA Blocker
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine Master Mixes
Air-Dryable™ Direct DNA qPCR and RNA/DNA qPCR Urine mixes are glycerol-free mixes that contain optimized excipients compatible with air and oven drying. The mixes have been designed for the development of quantitative PCR urine test assays for direct detection of DNA and RNA from human urine specimens without extraction. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine Master Mixes
- Create your ultra-sensitive multiplex direct quantitative PCR urine test using crude urine samples.
- Simplify qPCR urine testing, by removing the nucleic acid extraction step or inhibitor carryover during purification, shortening sample-to-result and reproducibility.
- Designed for the direct detection of bacteria and cell-free nucleic acids at very low titers.
- Can be used wet or it can be dried, for developing an ambient-temperate stable assay.
## High performance (sensitivity and reproducibility) in the presence of 5% human urine
Activity of air-dried Air-Dryable™ Direct RNA/DNA qPCR Urine (red) was compared to Reliance 1-Step Multiplex RT-qPCR Supermix (purple) for their ability to amplify a 1,000-fold dilution of an RNA target (10,000 and 10 copies respectively) in the presence of 5% human urine. The results illustrate that the dried mixes maintain the same high performance as the liquid mixes and shows much higher sensitivity than Reliance 1-Step Multiplex RT-qPCR Supermix.
### Air-Dryable Direct DNA qPCR Urine, 4x, MDX150
**Application:** qPCR**Specimen Type:** Urine, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 60% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX150-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX150-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX150.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX150)
### Air-Dryable Direct RNA/DNA qPCR Urine, 4x, MDX151
**Application:** RT-qPCR**Specimen Type:** Urine, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 20% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX151-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX151-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX151.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX151-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX151)
## Description
Urine is an ideal clinical specimen because it is excreted in large quantities is non-invasive, and it can be self-sampled. Currently, urine specimens are used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs), and for monitoring recreational drug use. However, urine contains substances such as urea and nucleases that can damage DNA or inhibit the PCR reaction.
Meridian’s new Air-Dryable™ Direct Urine molecular mixes are unique in that they enable the highly sensitive, very fast detection of target DNA or RNA directly from high concentrations of urine and are sensitive enough to detect arboviruses, such as Chikungunya virus. These mixes have been formulated specifically to overcome the inhibitors found in urine – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or dried down by oven or air drying to create ambient-temperature stable assays.
## Specifications
DescriptionGlycerol-free qPCR and RT-qPCR mix containing Taq polymerase, reverse transcriptase, reaction buffer, dNTPs, MgCl2 and air-dry compatible excipients, developed to tolerate the effects of the inhibitors present in urine samples.Concentration4xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typecDNA, crude or purified RNA and/or DNA from human stoolPresentation1 vialStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following air-drying.Consistency± 0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Meridian Air Dryable Direct Urine](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
[Lyo-Ready Direct LAMP Urine Mixes](https://collateral.meridianlifescience.com/view/940080326/)**Lyo-Ready Direct LAMP Urine Mixes**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## FAQs: qPCR Urine Test
What are the advantages of using urine over other sample types?
The advantages of a quantitative PCR urine test are that it is completely non-invasive, and it can be self-sampled in large quantities. Urine testing is used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs) and for monitoring recreational drug use.
What types of infectious diseases can urine detect?
The most common infections are urinary tract infections (UTIs), most commonly Escherichia coli, Protus mirabilis, Enterococcus faecalis, Staphylococcus saprophyticus and Klebsiella pneumoniae. Several other infections can be diagnosed by urine DNA and urine RNA tests including community-acquired pneumonia (CAP), legionellosis, tuberculosis, congenital cytomegalovirus (CMV) infection, and arboviruses, such as Chikungunya virus, dengue virus and Zika virus. Parasites can also be diagnosed from urine testing for the detection of eggs from Schistosoma haematobium. Furthermore, urine has been used for screening of different sexually transmitted diseases (STD) such as Neisseria gonorrhoeae and Chlamydia trachomatis.
What type of cancer can be detected in urine?
Cancer cells or their DNA or RNA are too big to pass through the kidneys and will have to come from the bladder or ureters, so bladder cancer is the most obvious urine cancer, however prostate and cervical cancer are also detectable.
What is the maximum volume of urine you can use in a quantitative PCR urine test?
We have used up to 25% human urine with our mix.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is a pre-treatment needed if you want to detect bacteria in urine?
That will depend on the bacteria, for some bacteria you may not need to do any pre-treatment, however some may require heating to 95°C for 5 min and for some tougher bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific urine mix versus the DNA/RNA urine mix?
We do not see a performance difference between the two mixes, which is why we call the Air-Dryable Direct RT-qPCR Urine mix – Air-Dryable™ Direct RNA/DNA qPCR Urine mix, as it can be used for both.
Are reaction conditions the same for air-dried and liquid mixes?
Yes, the Air-Dryable™ Direct DNA qPCR Urine and Air-Dryable™ Direct RNA/DNA qPCR Urine can be used as a liquid mix or air/oven dried and stored for up to 24 months without needing to change the reaction conditions and air drying/ambient temperature storage will not affect the sensitivity of the test.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Isothermal Amplification ](/lifescience/products/molecular-reagents/isothermal-amplification/)» Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes
# Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes
Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Blood mixes are ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as loop-mediated isothermal amplification (LAMP) on blood. They are designed to dramatically speed up assay development time and reduce time to results. The glycerol-free mixes contain optimized excipients compatible with freezing and lyophilization, making them ideal for POC blood testing. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes
- Develop ultra-sensitive LAMP blood tests from whole blood, plasma, and serum samples.
- Shorten the time to results by removing the nucleic acid extraction.
- Simplify the development of POC blood testing by just adding primers and probes.
- Can be used wet or it lyophilized, ideal for developing blood pathogen and liquid biopsy assay.
### Lyo-Ready Direct DNA LAMP Blood, 4x, MDX124
**Application:** LAMP**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% whole blood, 20% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX124-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX124-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX124.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX124-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX124)
### Lyo-Ready Direct RNA/DNA LAMP Blood, 4x, MDX125
**Application:** RT-LAMP**Specimen Type:** Blood, Plasma, Serum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 10% whole blood, 10% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX125-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX125-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX125.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX125-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX125)
## Description
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders such as diabetes. However, whole blood specimens, serum, and plasma contain a number of inherent PCR inhibitors including immunoglobulin G, hemoglobin, lactoferrin, and leukocyte DNA. In addition, PCR inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin). Isothermal amplification such as LAMP is very tolerant to inhibitors and so is ideal for point of care (POC) testing, the simple workflow allows fast, sensitive and reliable results in clinical diagnosis.
The Lyo-Ready Direct DNA LAMP Blood and Lyo-Ready RNA/DNA LAMP Blood mixes combine even greater tolerance with fast, robust isothermal amplification to enable highly sensitive direct detection using crudely processed whole blood, plasma, or serum samples. The mixes are uniquely designed to overcome much higher concentrations of inhibitors, and so do not require a DNA or RNA purification step to concentrate and purify a patient sample. Very fast reaction kinetics result in faster time to results and superior amplification sensitivity and specificity. In addition, the 4x concentrated master mixes are formulated with lyo-excipients which are optimized for freeze-drying to create ambient-temperature stable assays, making them ideal for POC blood testing.
## Catalogs & Brochures
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## FAQs: LAMP Blood Tests
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
What are the advantages of using blood over other sample types?
Blood contains abundant information about the health status of the organism, it can be used to evaluate organ function, detect proteins, nucleic acids, metabolites, infectious diseases and can be used for diagnosis of cancer (liquid biopsy), heart disease, diabetes. For POC Blood testing it is a simple and easily accessible (low-invasive) method to for monitor health.
What LAMP inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of LAMP in blood, as it can bind to single-stranded genomic DNA, reducing the sensitivity of the whole blood test. The other two main inhibitors in blood are hemoglobin and lactoferrin that affected the Bst DNA polymerase activity and thus lowered the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM, although this should not affect the time to results (TTR). In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
What is the maximum volume of whole blood you can use in a LAMP test.
We have used up to 20% whole blood with our mix, higher concentrations cause the solution to become viscous and difficult to work with.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is it possible to detect cell free RNA/DNA from blood serum using these kits?
Yes, the Lyo-Ready LAMP Blood kits can be used to detect both cfDNA and cfRNA.
Is a pre-treatment needed if you want to detect the DNA of gram-positive bacteria?
Yes, it is possible that you may need to pre-treat the blood in order to release the DNA from the gram-positive bacteria. In some cases a heat shock is sufficient, this will depend on the bacteria being examined.
What is the performance difference for DNA when using the DNA-specific product versus the DNA/RNA product?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-LAMP Blood mix – Lyo-Ready Direct RNA/DNA LAMP Blood mix, as it can be used for both.
Can LAMP mixes be used for a multiplex assay?
Yes, it is possible to create a multiplex LAMP whole blood test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Do the master mixes need any changes in LAMP protocol or are they compatible with my current setup?
They are compatible with standard isothermal amplification protocols; however some optimization may be required for the amount of blood plasma or serum samples that is needed for the blood tests.
Do I need to elute dried blood spots, or can they be used directly?
You should elute in water, or TE buffer.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA LAMP Blood and Lyo-Ready Direct RNA/DNA LAMP Blood can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes
Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Stool mixes are ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as loop-mediated isothermal amplification (LAMP) on stool samples, designed to dramatically speed up assay development time and reduce time to results. The glycerol-free mixes contain optimized excipients compatible with freezing and lyophilization, making them ideal for POC stool testing. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes
- Develop rapid enteric pathogenic LAMP stool tests.
- Shorten the time to result by removing the nucleic acid extraction step.
- Validated for detection of enteric pathogens in crude samples.
- Can be used wet or lyophilized, ideal for developing ambient-temperature stable POC assays.
### Lyo-Ready Direct DNA LAMP Stool, 4x, MDX144
**Application:** LAMP**Specimen Type:** Stool, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX144-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX144-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX144.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX144-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX144)
### Lyo-Ready Direct RNA/DNA LAMP Stool, 4x, MDX145
**Application:** RT-LAMP**Specimen Type:** Stool, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 5% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX145-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX145-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX145.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX145-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX145)
## Description
Diarrhoeal disease is the 8th leading cause of death globally and the 2nd leading cause of death in children under the age of five. It is caused by a variety of bacterial, viral and parasitic organisms and is usually spread through the fecal-oral route or by foodborne transmission. Diagnostic tests, especially point-of-care (POC), are essential to enable the rapid identification of gastrointestinal infections and provide the right treatment to prevent serious complications and prevent its spread. Ideally, POC diagnostics are simple to use, involve minimal-to-no-sample pre-processing, do not require cold room storage and are as sensitive and specific as laboratory-based tests. Assays using stool as a specimen can pose a substantial challenge for POC assays as stool samples can be complex, containing food debris, desquamated epithelial cells and mucus, and potential PCR inhibitors such as bile salts, polysaccharides, hematin and catabolic substances. Typically, complex samples require pre-processing to extract the DNA or RNA prior to testing.
The Lyo-Ready Direct DNA LAMP Stool and Lyo-Ready RNA/DNA LAMP Stool mixes combine even greater tolerance with fast, robust isothermal amplification to enable highly sensitive direct detection using crudely processed stool samples. The mixes are uniquely designed to overcome much higher concentrations of inhibitors and so do not require a DNA or RNA purification step to purify a patient sample. Very fast reaction kinetics result in faster time to results and superior amplification sensitivity and specificity. In addition, the 4x concentrated master mixes are formulated with lyo-excipients which are optimized for freeze-drying to create ambient-temperature stable assays, making them ideal for POC stool testing.
## Catalogs & Brochures
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://collateral.meridianlifescience.com/view/111612146/)**Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## FAQs: LAMP Stool Test
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
What is the maximum volume of fecal material you can use in a LAMP stool test.
We have used up to 20 mg/mL human stool with our mix, this is homogenized, and clarified by centrifugation and some pre-treatment may be required.
What carrier buffer do you recommend?
There are several buffers on the market that can be used for stool testing, they include phosphate-buffered saline (PBS), Cary-Blair Medium, Stool Transport and Recovery (STAR) buffer and DNA/RNA Shield.
After lyophilization for how long will the mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is stool DNA always present?
Yes, most of it comes from bacteria and viruses, however there are also human cells that are sloughed into the lumen after cells die and are replaced, these cells go through apoptosis, releasing the DNA. Tumor cells may be present, but they will normally be less than 1% of the total human DNA fragments present in the overall stool sample.
Is a pre-treatment needed?
Pre-treatment will depend on what you are looking at, you may need to heat to 95°C for 5 min and for some bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific stool mix versus the DNA/RNA stool mix?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-LAMP Stool mix – Lyo-Ready Direct RNA/DNA LAMP Stool mix, as it can be used for both.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA LAMP Stool and Lyo-Ready Direct RNA/DNA LAMP Stool can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes
Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Urine mixes are glycerol-free mixes that contain optimized excipients compatible with lyophilization. The mixes have been designed for the development of quantitative PCR urine test assays for direct detection of DNA and RNA from crudely processed human urine specimens. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes
- Ideal for developing screening assays for sexually transmitted diseases (STDs) and urinary tract infections (UTIs)
- Very sensitive detection of low copy number bacteria, viruses and cell-free nucleic acids from crude urine samples
- Quickly and accurately detect slow-growing and difficult-to-culture microorganisms, removing ambiguous results
- Can be kept as a liquid mix or lyophilized to create ambient-temperature stable assays with an extended shelf-life
### Lyo-Ready Direct DNA qPCR Urine, 4x, MDX152
**Application:** qPCR**Specimen Type:** Urine, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX152-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX152.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX152-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX152)
### Lyo-Ready Direct RNA/DNA qPCR Urine, 4x, MDX153
**Application:** RT-qPCR**Specimen Type:** Urine, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX153-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX153.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX153-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX153)
## Description
Urine is an ideal clinical specimen because it is excreted in large quantities, is non-invasive, and it can be self-sampled. Urine specimens are used in the diagnosis and management of infectious diseases, bladder cancer and urinary tract infections (UTIs). However, urine contains substances such as urea and nucleases that can damage DNA or inhibit the PCR reaction.
Meridian’s new Lyo-Ready Direct Urine molecular mixes are unique in that they enable highly sensitive, very fast detection of target DNA or RNA directly from high concentrations of urine. With the CDC reporting a 30% increase in reportable sexually transmitted disease (STDs) between 2015 and 2019, these direct urine molecular mixes are ideal, as they allow less invasive sample collection (than a cervical or urethra swab) and encourage routine screening. They have been formulated specifically to overcome the inhibitors found in urine – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or dried down by lyophilization to create ambient-temperature stable assays.
## Catalogs & Brochures
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable Direct Urine Catalog](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine Catalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## FAQs: qPCR Urine Test
What are the advantages of using urine over other sample types?
The advantages of a quantitative PCR urine test are that it is completely non-invasive, and it can be self-sampled in large quantities. Urine testing is used in the diagnosis and management of infectious diseases (including STDs), urinary tract infections (UTIs) and bladder cancer.
What types of infectious diseases can urine detect?
The most common infections are urinary tract infections (UTIs), most commonly E. coli, P. mirabilis, Enterococcus, Staphylococcus and Klebsiella. This is followed by sexually transmitted diseases (STDs) such as syphilis, gonorrhoea, chlamydia, trichomoniasis, hepatitis B (HBV), herpes simplex virus (HSV), HIV and human papillomavirus (HPV). Several other infections can be diagnosed by urine DNA and urine RNA tests including community-acquired pneumonia (CAP), legionellosis, tuberculosis, congenital cytomegalovirus (CMV) infection, and arboviruses, such as Chikungunya virus, dengue virus and Zika virus. Parasites can also be diagnosed from urine testing for the detection of eggs from *Schistosoma haematobium*.
What type of cancer can be detected in urine?
Cancer cells or their DNA or RNA are too big to pass through the kidneys and will have to come from the bladder or ureters, so bladder cancer is the most obvious urine cancer, however prostate and cervical cancer are also detectable.
What is the maximum volume of urine you can use in a quantitative PCR urine test.
We have used up to 25% human urine with our mix.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is a pre-treatment needed if you want to detect bacteria in urine?
That will depend on the bacteria, for some bacteria you may not need to do any pre-treatment, however some may require heating to 95°C for 5 min and for some tougher bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific urine mix versus the DNA/RNA urine mix?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-qPCR Urine mix – Lyo-Ready Direct RNA/DNA qPCR Urine mix, as it can be used for both.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA qPCR Urine and Lyo-Ready Direct RNA/DNA qPCR Urine can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes
Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Urine mixes are ready-to-use, 4x concentrated, fully optimized mixes for isothermal amplification methods such as loop mediated isothermal amplification (LAMP) on urine samples, designed to dramatically speed up assay development time and reduce time to results. The glycerol-free mixes contain optimized excipients compatible with freezing and lyophilization, making them ideal for POC urine testing. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes
- Ideal for developing screening assays for sexually transmitted diseases (STDs) and urinary tract infections (UTIs).
- Very sensitive detection of low copy number bacteria, viruses and cell-free nucleic acids from crude urine samples.
- Quickly and accurately detect slow-growing and difficult-to-culture microorganisms, removing ambiguous results.
- Can be used wet or lyophilized, ideal for developing ambient-temperature stable POC assays.
### Lyo-Ready Direct DNA LAMP Urine, 4x, MDX154
**Application:** LAMP**Specimen Type:** Urine, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX154-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX154-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX154.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX154-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX154)
### Lyo-Ready Direct RNA/DNA LAMP Urine, 4x, MDX155
**Application:** RT-LAMP**Specimen Type:** Urine, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% urine. Perfect for multiplexing and fast cycling conditions. Used in the detection of urinary track infections, STD, tropical diseases, cancer screening, bladder and prostate cancer.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX155-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX155-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX155.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX155-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX155)
## Description
Urinary tract infections (UTIs) affect over 150 million people worldwide and are the second most common cause of infection in primary and secondary care and most women experience at least one episode of acute uncomplicated cystitis in their lifetime. UTIs are responsible for a major part of antibiotic prescriptions, accounting for up to 15% of antimicrobial use in the community, with antibiotic use been described as one of the main factors contributing to the emergence of antimicrobial resistance. With the stigma attached to sexually transmitted diseases (STDs), and with their rapid spread in the last few years, there is also a need for discrete, fast and accurate point-of-care (POC) tests as well.
The Lyo-Ready Direct DNA LAMP Urine and Lyo-Ready RNA/DNA LAMP Urine mixes combine even greater tolerance with fast, robust isothermal amplification to enable highly sensitive direct detection using crude urine samples. The mixes are uniquely designed to overcome much higher concentrations of inhibitors, and so do not require a urine DNA or urine RNA purification step to analyze a patient sample. Very fast reaction kinetics result in faster time to results and superior amplification sensitivity and specificity. In addition, the 4x concentrated master mixes are formulated with lyo-excipients which are optimized for freeze-drying to create ambient-temperature stable assays, making them ideal for POC urine testing.
## Catalogs & Brochures
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable Direct Urine Catalog](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine Catalog**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
## FAQs: LAMP Urine Test
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
What are the advantages of using urine over other sample types?
The advantages of an isothermal amplification urine test is that it is completely non-invasive, and it can be self-sampled in large quantities. Urine testing is used in the diagnosis and management of infectious diseases (including STDs) and urinary tract infections (UTIs).
What types of infectious diseases can urine detect?
The most common infections are urinary tract infections (UTIs), most commonly *E. coli, P. mirabilis, Enterococcus, Staphylococcus and Klebsiella*. This is followed by sexually transmitted diseases (STDs) such as *syphilis, gonorrhoea, chlamydia, trichomoniasis, hepatitis B (HBV)*, herpes simplex virus (HSV), HIV and human papillomavirus (HPV). Several other infections can be diagnosed by urine DNA and urine RNA tests including community-acquired pneumonia (CAP), legionellosis, tuberculosis, congenital cytomegalovirus (CMV) infection, and arboviruses, such as Chikungunya virus, dengue virus and Zika virus. Parasites can also be diagnosed from urine testing for the detection of eggs from *Schistosoma haematobium*.
What is the maximum volume of urine you can use in an isothermal amplification urine test.
We have used up to 30% human urine with our mix.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is a pre-treatment needed if you want to detect bacteria in urine?
That will depend on the bacteria, for some bacteria you may not need to do any pre-treatment, however some may require heating to 95°C for 5 min and for some tougher bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific urine mix versus the DNA/RNA urine mix?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-LAMP Urine mix – Lyo-Ready Direct RNA/DNA LAMP Urine mix, as it can be used for both.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA LAMP Urine and Lyo-Ready Direct RNA/DNA LAMP Urine can be used as a liquid mix or lyophilization and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Glycerol-Free DNA Helicase (HC) Kit](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-helicase-hc-kit/)
**Published:** August 27, 2025
**Author:** Moaaz Ahmad
**Content:**
# Glycerol-Free DNA Helicase (HC) Kit
Glycerol-Free DNA Helicase (HC) is a high-concentration, glycerol-free mix multi-domain DNA Helicase enzyme that uses ATP hydrolysis to unwind DNA duplexes with 3’ to 5’ polarity. It functions with the addition of the accessory protein, MutL, supplied with the kit. It is active on a wide range of DNA substrates and is compatible with lyophilization, making it ideal for use in point-of-care applications.
[ Product Support Material ](#requestasample)
## Key Product Features
- Unwinds double-stranded DNA
- Operates at 37°C, ideal for mesophilic diagnostic workflows
- Glycerol-free, for developing lyophilized assays
## Description
Glycerol-Free DNA Helicase (HC) Kit (MDX241) is a multi-domain enzyme with both ATPase and helicase activities. It unwinds double-stranded DNA with 3’ to 5’ with respect to the bound strand and initiates unwinding most effectively when a single-stranded region is present. Helicase works in coordination with an accessory protein, methyl-directed mismatch repair (MutL) protein that stimulates the helicase activity.
Glycerol-Free DNA Helicase (HC) has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components, such as point-of-care assays.
Schematic of helicase-dependent amplification using Helicase, Mutl, DNA polymerase, primers and dNTPs with temperatures up to 37°C.
### Glycerol-Free DNA Helicase (HC), MDX241
**Application:** LAMP,RPA,RCA,SDA**Specimen Type:** DNA**Concentration:** 50 µg/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration enzyme used to unwind double-stranded DNA with the help of an accessory protein, allowing you to deliver reliable results with the added capability for lyophilization. MutL
Available in 20 µL (1 µg) or 200 µL (10 µg) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX241-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX241-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX241.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX241)
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase & Optimized Reaction Buffers for Isothermal AssaysCatalog**
[Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes](https://collateral.meridianlifescience.com/view/206034024/)**Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Glycerol-Free Taq HS High Conc. DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-high-conc-dna-polymerase/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free Thermostable DNA Helicase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-thermostable-dna-helicase-hc/)
## FAQs: Glycerol-Free DNA Helicase (HC) Kit
Do I need to add ATP for Glycerol-Free Thermostable DNA Helicase (HC) activity?
The Lyo-Ready Thermostable DNA Helicase Reaction Buffer, 5x contains ATP.
Does Glycerol-Free Thermostable DNA Helicase (HC) require a particular DNA structure to unwind the strands?
No, Glycerol-Free Thermostable DNA Helicase (HC) can unwind any dsDNA structure.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
**Published:** April 28, 2025
**Author:** hamza
**Content:**
# Taq HS DNA Polymerase
Taq HS DNA Polymerase is a combination of next-generation DNA polymerase and novel buffer system that has been designed to deliver very high yield, Fast PCR amplification over a wide range of PCR templates. It has been developed to give very robust amplification, allowing it to perform well with most PCR testing, including challenging templates and in the presence of PCR inhibitors.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Taq HS DNA Polymerase
- Antibody-mediated DNA polymerase for hot start PCR, to deliver high yield even with limiting amounts of template
- Robust PCR amplification in the presence of inhibitors and with even the most challenging DNA targets
- Novel optimized buffer system maximizes efficiency of PCR amplification, eliminate the need for long optimization, saving time, effort, and cost
- Developed to give sensitive, reproducible, robust amplification with very fast PCR cycling conditions
### Taq HS DNA Polymerase, MDX008
**Application:** PCR**Specimen Type:** DNA**Concentration:** 5 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Very high yield, high-performance, antibody-mediated hot-start polymerase, to give fast, superior amplification, even with challenging templates and in the presence of PCR inhibitors.
Available in 0.1 mL (500 Units) or 10 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX008-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX008-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX008.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX008)
## Description
Taq HS DNA Polymerase is an antibody-mediated hot-start DNA polymerase provided with an optimized buffer system containing dNTP, MgCl2, stabilizers, and PCR enhancers at optimal concentrations which eliminates the need for optimization. The DNA polymerase has been developed to give more robust amplification than other polymerases allowing it to perform well with challenging templates in the presence of PCR inhibitors, making it ideal for fast PCR reactions across a range of templates, without compromising specificity or yield.
## Specifications
DescriptionVery high-performance, antibody-mediated hot-start polymerase, supplied with an optimized, novel buffer system, containing dNTPs, MgCl2 and enhancers, to give superior amplification, making it the perfect choice for complex templates.Concentration5 U/µLAppearanceClear, colorless solutionHot StartAntibodyApplicationPCR, qPCRSample typecDNA, DNAPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionalityMultiplex PCR with a dilution series of human genomic DNA, single, distinct bands were observedDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
## Related Products
[Taq DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-dna-polymerase/)
[Taq PCR Buffer, 5x](https://www.meridianbioscience.com/lifescience/products/molecular/taq-pcr-buffer-5x/)
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
## FAQs: Taq HS DNA Polymerase
If my PCR testing is being impeded by too many PCR inhibitors, what can I do for optimization?
Decreasing the template concentration will help to minimize the concentration of inhibitors, the amount of DNA polymerase and primer can also be increased. In some cases you may also have to add a pre-treatment step if the DNA is not accessible.
What do the terms yield, fidelity, processivity and specificity actually mean?
These terms refer to parameters to be considered when performing PCR testing. Yield: The amount of DNA produced in a PCR reaction. High yield increases sensitivity. Fidelity: The accuracy of the enzyme at incorporating the correct dNTP to the elongating DNA strand. For standard PCR this is not important, but for sequencing or expression a high-fidelity mix (such as High-Specificity Pfu HS Mix (MDX006)) may be required. Processivity: The length of time a polymerase is associated with the template and therefore the size of fragment which can be amplified (the amplicon). Taq HS DNA Polymerase will work with amplicons up to 5 kb. Specificity: A measure of the unwanted by-products generated in a reaction. This is the reason for having hot start PCR, this prevents miss-priming at low temperatures and non-specific amplification
What applications can Taq DNA Polymerase be used for?
Taq DNA Polymerase has been validated with a broad range of PCR templates including DNA extracted from human, animal and plant samples, making it the ideal choice for the following applications: • End-point hot start PCR • High-yield PCR • Fast PCR • Multiplex PCR • qPCR and RT-qPCR
How fast is Taq HS DNA Polymerase?
This depends on the length of the amplicon and the complexity of the template. For fast PCR, the initial denaturation will remain 1 minute, but with low complexity template such as plasmid DNA, an annealing of 5 seconds and extension time of 10 seconds is sufficient for amplicons up to 1 kb. In order to find the fastest optimal condition, for more complex or longer amplicons, we suggest incrementally increasing the extension time successively up to 30 s/kb.
Can Taq HS Polymerase be used for difficult samples like GC rich or bisulfite converted DNA?
Yes, Taq HS DNA Polymerase works very well with difficult samples like GC rich or bisulfite converted DNA. The hot start PCR is especially important, as it decreases primer dimer and unspecific amplification. If optimization is required, we would suggest starting with the annealing temperature and with bisulfite conversion, the process can fragment the DNA, so it may be useful to increase the amount of template and polymerase.
What is the error rate of Taq DNA Polymerase?
The enzyme has an error rate of approximately 1 error per 2.0 x 10⁵ nucleotides incorporated. If you are looking for a DNA polymerase with a lower error rate, for next-generation sequencing (NGS) library or expression a high-fidelity DNA polymerase (such as High-Fidelity Pfu (MDX003)) or mix (such as High-Specificity Pfu HS Mix (MDX006)) should be used.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-µl/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA Polymerases ](/lifescience/products/molecular-reagents/dna-polymerases/)» Glycerol-Free Taq HS, 50 U/µL
# Glycerol-Free Taq HS 50U/µL
Glycerol-Free Taq HS 50U/µL has been optimized to deliver excellent, stable performance without glycerol, meaning it is also compatible with lyophilization, as a stand-alone enzyme, or when combined with additional assay components in a reaction mix.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free Taq HS DNA Polymerase
- High concentration of Taq DNA Polymerase allowing for concentrated bulk production of PCR master mixes.
- Retains the same reproducible performance as with conventional formats.
- Separate Taq, antibody and enzyme dilution buffer, for greater assay development flexibility.
- Glycerol-free solution, ideal for preparation of dried-down PCR tests.
### Efficient and sensitive amplification with both wet (black) and lyophilized (blue) PCR tests
A 10-fold serial dilution of template DNA was used to set up two sets of qPCR assays. One set was lyophilized (blue) and the other left as a wet mix (black). Results illustrate that lyophilization of Glycerol-Free Taq HS does not have an effect on the quality of the qPCR, as both the assays demonstrate identical efficiency and sensitivity.
### Glycerol-Free Taq HS, 50 U/µL, MDX011
**Application:** PCR**Specimen Type:** DNA**Concentration:** 50 U/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Lyophilization-compatible high-performance Taq DNA polymerase, separate Taq antibody and enzyme dilution buffer, suitable for difficult, multiplex tests that require fast amplification, whilst maintaining high specificity and sensitivity.
Available in 0.02 mL (1,000 Units) or 0.5 mL (25,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX011-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX011-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX011.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX011-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX011)
## Description
Glycerol-Free Taq HS 50U/µL is supplied as a separate 10x, high‑performance glycerol‑free Taq DNA Polymerase, glycerol‑free Taq antibody, and glycerol‑free enzyme dilution buffer. Separating these components allows greater flexibility in assay development, making Glycerol-Free Taq HS 50 U/µL suitable for difficult, multiplex PCR that require fast amplification, whilst maintaining both high specificity and sensitivity.
Glycerol-Free Taq HS 50U/µL is ideal for PCR kit manufactures and PCR molecular test facilities, requiring large amounts of DNA polymerases. The highly concentrated Glycerol-Free Taq HS 50U/µL allows for concentrated bulk production of PCR master mixes and the glycerol free format is useful when using automated pipetting robots and other applications where accurate pipetting of small volumes is crucial.
## Specifications
DescriptionA lyophilization-compatible Taq DNA polymerase, separate Taq antibody and enzyme dilution buffer, suitable for difficult, multiplex molecular tests that require fast amplification, whilst maintaining both high specificity and sensitivity.ConcentrationBetween 50 and 60 U/µL (see CoA)Purity>50 % (as a percentage of total protein)Glycerol content<0.02 %AppearanceClear, colorless solutionHot StartAntibody mediatedApplicationPCR, real-time PCR, two-step RT-qPCRSample typecDNA, DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Glycerol-Free Taq HS ](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HS**
## FAQs: Glycerol-Free Taq HS
How is Glycerol-Free Taq HS 50U/µL supplied?
Glycerol-Free Taq HS 50U/µL is supplied as a separate 50 U/μL, high‑performance glycerol‑free Taq DNA polymerase, glycerol‑free Taq antibody and glycerol‑free enzyme dilution buffer. Separating these components allows greater flexibility in developing PCR tests.
What are the advantages of a 10x DNA polymerase?
Glycerol-Free Taq HS 50 U/µL is ideal for PCR kit manufactures and DNA testing facilities, requiring large amounts of DNA polymerases. The highly concentrated Glycerol-Free Taq HS 50 U/µL allows for concentrated bulk production of PCR master mixes.
Concentrated bulks in glycerol-free formats are also attractive when using automated pipetting robots and other applications where accurate pipetting of small volumes is crucial, as glycerol makes the solution more viscous.
Concentrated PCR master mixes are easier to lyophilize due to the reduced volume of the concentrated mix.
What are the storage conditions and stabilities of Glycerol-Free Taq HS 50 U/µL?
Glycerol is a cryoprotectant and is normally part of the storage buffer, where it serves to protect Taq DNA polymerase during freezing conditions. The high concentration of Glycerol-Free Taq HS 50 U/µL means that you get the same protection to freeze/thawing as a DNA polymerase that contains glycerol.
After drying for how long will the lyophilized PCR tests stay stable to use?
A lyophilized PCR molecular test will remain stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Can Glycerol-Free Taq HS 50 U/µL be used to create quantitative PCR tests?
Yes, Glycerol-Free Taq HS 50 U/µL is ideal for any multiplex PCR assays, particularly quantitative PCR molecular tests that require fast amplification, whilst maintaining both high specificity and sensitivity.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [DNA Polymerases ](/lifescience/products/molecular-reagents/dna-polymerases/)» High Conc. Glycerol-Free Bst
# High Conc. Glycerol-Free Bst
High Conc. Glycerol-Free Bst is an enzyme derived from the large fragment of Bacillus stearothermophilus DNA Polymerase I. It contains 5´- 3´ DNA polymerase activity and strong strand displacement activity but lacks 5´- 3´ exonuclease activity. The strong strand displacement activity enables Bst DNA Polymerase to synthesize DNA at a constant temperature making it an ideal enzyme for isothermal amplification, including HDA, MCA and, Loop-Mediated Isothermal DNA Amplification (LAMP).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's High Conc. Glycerol-Free Bst
- Optimized for isothermal amplification such as LAMP test.
- Designed for fast polymerization and so faster time to results.
- Supplied with a reaction buffer and enzyme dilution buffer.
- Ideal for creating lyophilized POCT assays.
### High Conc. Glycerol-Free Bst, MDX018
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 100 units/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
High concentration glycerol-free DNA polymerase (exo-), with strand-displacement properties. used for Isothermal DNA amplification such as LAMP (Loop-mediated Isothermal Amplification).
Available in 80 µL or 800 µL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX018-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX018-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX018.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX018)
## Description
High Conc. Glycerol-Free Bst (100 U/µL) is supplied with an Enzyme Dilution Buffer and a Bst Reaction Buffer formulated to deliver the fastest amplification speed (time-to-results), yield, salt tolerance, and sensitivity, speeding up your product development time and allowing you to commercialize your new products faster. High Conc. Glycerol-Free Bst is also lyophilization-compatible, making it ideal for the development of point of care test (POCT) assays that require ambient temperature shipping and storage.
## Specifications
DescriptionHigh concentration glycerol-free DNA polymerase (exonuclease minus), with strand-displacement properties. Bst DNA Polymerase is used for Isothermal DNA amplification and LAMP (Loop-mediated Isothermal Amplification).Concentration>100 units/µL measured against a standardAppearanceClear, colorless solutionApplicationLoop-mediated isothermal amplificationSample typecDNA, DNAPresentation3 vialsStorage-20 °CEnzyme StabilitySee outer labelAssay StabilityUp to 24 months at ambient temperature following air-drying or lyophilizationDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Bst DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/bst-dna-polymerase/)
[Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/buffers/)
## FAQs: High Conc. Glycerol-Free Bst
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification (LAMP) and qPCR is that in a LAMP test, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
Is Meridian’s Bst DNA Polymerase warm/hot start?
No Meridian’s Bst DNA Polymerase does not come with warm or hot start; instead, the reaction buffer does not contain magnesium and so the enzyme is completely inactive until magnesium is added. If you are concerned about setting your reaction up at room temperature, we recommend adding the magnesium last, just before running the experiment and it will prevent non-specific amplification.
Why is Meridian’s Glycerol-Free Bst DNA Polymerase only sold at high-concentration?
Repeated freeze-thawing of Bst DNA polymerase will damage the enzyme due to crystal formation and so glycerol is normally added to prevent this crystal formation. Making the Bst high concentration also stops crystal formation, so that the glycerol can be removed, and this allows the Bst to be lyophilized.
Can LAMP be used for a multiplex assay?
Yes, it is possible to design a multiplex LAMP test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Can Glycerol-Free Bst DNA Polymerase be used in place of other DNA polymerases for thermal cycling?
No, the reaction temperatures are too high for enzyme stability.
Does Glycerol-Free Bst DNA Polymerase have reverse transcriptase activity?
Yes, Glycerol-Free Bst DNA Polymerase does have some reverse transcriptase activity, however for robust and consistent reactions we recommend the addition of a reverse transcriptase.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [RNase-Tolerant MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/rnase-tolerant-mmlv-rt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » RNase-Tolerant MMLV-RT
# RNase-Tolerant MMLV-RT
RNase-Tolerant MMLV-RT is a reverse transcriptase/RNase inhibitor mix optimized for one-step RT-qPCR. RNase-Tolerant MMLV-RT is used for the detection of RNA at very low levels, it can also be used with a broader temperature range, making it ideal for applications such as blood bank or transplant viral testing.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's RNase-Tolerant MMLV-RT
- Highly sensitive cDNA synthesis, even low concentrations of template RNA
- Broader temperature range, up to 50°C, for more challenging transcripts
- High efficiency where samples are likely to contain inhibitors
- High-quality, first-strand cDNA synthesis ideal for most one-step RT-qPCR
### RNase-Tolerant MMLV-RT, MDX043
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 100x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
For the detection of RNA at very low levels, it can also be used with a broader temperature range, making it ideal for applications such as blood bank or transplant viral testing.
Available in 200 µL (1,000 Rxns) or 2 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX043-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX043-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX043.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX043)
## Description
A Moloney Murine Leukemia Virus (MMLV) Reverse Transcriptase (RT), which exhibits high sensitivity and efficiency, and RNase Inhibitor (Ribonuclease Inhibitor) which inhibits a broad spectrum of eukaryotic RNases, including RNases A, B and C. RNase-Tolerant MMLV-RT shows no inhibition of polymerase or reverse transcriptase activity, so can be used in cDNA synthesis or one-step RT-qPCR reactions. RNase-Tolerant MMLV-RT is useful in any applications where the presence of RNases is a potential problem.
## Specifications
DescriptionRNase-Tolerant MMLV-RT (Moloney Murine Leukemia Virus Reverse Transcriptase) for the detection of RNA at very low levels, it can also be used with a broader temperature range, making it ideal for applications such as blood bank or transplant viral testing.Concentration100xAppearanceClear, colorless solutionApplicationcDNA synthesis, RT-PCR, PCR, two-step RT-qPCR, one-step RT-qPCRSample typeRNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA contaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/mmlv-rt/)
[55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
## FAQs: RNase-Tolerant MMLV-RT
I want to use viral RNA with very high secondary structure for cDNA synthesis, can I use RNase-Tolerant MMLV-RT?
For RNA with very high secondary structure, we recommend using 55C MMLV-RT (MDX117), this is a glycerol-free reverse transcriptase can be used at temperatures up to 60°C which improves the cDNA yield from difficult RNA targets that require higher temperature to denature strong secondary structures. You can add RNase Inhibitor (MDX056) to increase the RNase tolerance.
What buffer do you recommend using with RNase-Tolerant MMLV-RT?
If you are going to make cDNA, you will require a buffer that contains 0.2 mM each dATP, dCTP, dGTP & dTTP, 10 mM DTT (dithiothreitol), 25 mM KCl, 3.5 mM MgCl2 and 50 mM Tris–HCl (7.5). However, if you want to do RT-qPCR, we recommend 1-Step RT-qPCR Buffer (MDX034).
How is RNase-Tolerant MMLV-RT inactivated?
The reverse transcriptase can be inactivated by adding a chelating agent such as EDTA or heating to 70°C or higher for 10 min.
Does RNase-Tolerant MMLV-RT need a primer?
Yes, to initiate cDNA synthesis, the RNase-Tolerant MMLV-RT reverse transcriptase requires a primer to bind to its complementary sequences on the RNA template and serve as a starting point for synthesis of a new strand. For general cDNA synthesis, random hexamer primers and oligo(dT) primers can be used either separately or mixed. For RT-PCR and RT-qPCR gene-specific primers should be used.
What is the error rate of RNase-Tolerant MMLV-RT?
Unlike eukaryotic replicative polymerases, reverse transcriptase lacks exonuclease activity and so is error prone. MMLV-based reverse transcriptase has been reported to have an error rate in the range of 1.1 × 10−4 to 4.8 × 10−4.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reverse Transcriptases
---
### [Proteinase K](https://www.meridianbioscience.com/lifescience/products/molecular/proteinase-k/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Proteinase K
Proteinase K is a highly active serine protease (MW 28,500 Da) isolated from the fungus Tritirachium album. The enzyme exhibits broad cleavage specificity on native and denatured proteins and is widely used in the purification of native RNA and DNA from tissues or cell lines. Because the solution is tested for the absence of RNases and DNases, it is especially suitable for isolating qPCR and RT-qPCR templates.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Proteinase K Solution, MDX055
**Application:** Extraction**Specimen Type:** Proteins**Concentration:** 20 mg/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Proteinase K Solution is an enzyme used to digest most proteins in molecular biological techniques.
Available in 25 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX055-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX055-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX055.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX055)
## Description
Proteinase K Solution is an enzyme used to digest most proteins in molecular biological techniques. The enzyme may be used at 56 °C for up to 4 hours or 37 °C for overnight incubations. Proteinase K Solution is a stabilized stock solution (20 mg/mL), stabilized with a specially formulated buffer, and can be used directly from the freezer.
## Related Products
- [ Tissue Extract-PCR Buffer ](/lifescience/products/molecular/tissue-extract-pcr-buffers/)
- [ qPCR/RT-qPCR Extraction Controls ](/lifescience/products/molecular/lyo-ready-inhibitor-tolerant-qpcr-rt-qpcr-master-mixes/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Glycerol-Free RNase H (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-rnase-h-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Enzymes ](/lifescience/products/molecular-reagents/enzymes/)» Glycerol-Free RNase H (HC)
# Glycerol-Free RNase H (HC)
Glycerol-Free RNase H (HC) is an RNA-specific endonuclease that hydrolyzes the phosphodiester bonds of RNA, when hybridized to DNA and produces 5´ phosphate-terminated oligoribonucleotides and single-stranded DNA. It does not hydrolyze the phosphodiester bonds within single-stranded and double-stranded DNA and RNA.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free RNase H (HC)
- Removal of RNA template following second-strand cDNA synthesis
- Removal of mRNA poly(A) sequence after hybridization with oligo(dT)
- Ideal for nucleic acid sequence-based amplification (NASBA)
## Reaction Rate: RFU/s
Glycerol-Free RNase H (HC) was lyophilized at 0.2 U in 20 µL of 1x Lyo-Ready RNase H Reaction Buffer and stored in strips of 8 x 200-µL tubes. After 4 weeks, reactions stored at ambient temperature (orange line) and 37 °C (brown line) were reconstituted in 20 µL of DEPC-treated water and 5 µL of fluorescently labelled RNA-DNA hybrid was added. The rate at which fluorescence was released was compared to a wet reaction (blue line) prepared using the same concentration of Glycerol-Free RNase H (HC) and substrate (control – no RNase H added black line)).
### Glycerol-Free RNase H (HC), MDX202
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 50 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration RNA-specific endonuclease that hydrolyzes the phosphodiester bonds of RNA, when hybridized to DNA. Ideal for lyophilization.
Available in 100 µL (2,500 Unit) or 250 µL (12,500 Unit) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX202-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX202.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX202)
## Description
Glycerol-Free RNase H (HC) is a high concentration (50 U/µL) RNA-specific endonuclease that hydrolyzes the phosphodiester bonds of RNA, when hybridized to DNA and produces 5´ phosphate-terminated oligoribonucleotides and single-stranded DNA. It does not hydrolyze the phosphodiester bonds within single-stranded and double-stranded DNA and RNA. Glycerol-Free RNase H (HC) has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store reaction mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Glycerol-Free T7 RNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
## FAQs: Glycerol-Free RNase H (HC)
What is RNase H used for?
RNase H is an integral part of most RNA amplification and NASBA (nucleic acid sequence-based amplification) protocols. It can be used to degrade specific RNAs when the complementary DNA oligo is hybridized, such as poly(A) tail removal from mRNA hybridized to oligo(dT). If the RNA template is not degraded after first strand cDNA synthesis, it can bind to the newly synthesized cDNA and restrict the accessibility of primers during subsequent PCR amplification, so it can also be used for removal of RNA template after first strand cDNA synthesis for RT-PCR and RT-qPCR. RNase H is an important component in fragment analysis of capped reverse transcribed mRNA molecules, a key step in the development of an mRNA vaccine.
How does RNase H cut RNA?
RNase H cleaves the RNA backbone phosphodiester bonds to leave a 3′ hydroxyl and a 5′ phosphate group.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [NGS Enzymes ](/lifescience/products/molecular-reagents/ngs-enzymes/)»Glycerol-Free High-Fidelity Pfu (HC)
# Glycerol-Free High-Fidelity Pfu (HC)
PCR is used for the amplification of a next-generation sequencing (NGS) library. In addition to increasing the amount of DNA, the PCR amplification step is also used for DNA target enrichment for fragments that have an adaptor-ligated to each end. These will be the fragments that attach to the flow cell and will be sequenced, so it is important that this PCR amplification step does not introduce mutations to the NGS library, as a lower error rate means that less sequence coverage is required, saving expense and time.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact a Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free High-Fidelity Pfu (HC)
- High concentration Pfu polymerase allowing for bulk production of PCR master mixes
- An error rate of 3.0 x 10-6
- Ideal for NGS library amplification
- Glycerol-free for preparation of dried-down PCR tests
## Multiplex amplification
Glycerol-Free High-Fidelity Pfu (HC), was lyophilized with Lyo-Ready Pfu Reaction Buffer, 5x and stored at 37°C for 7 and 28 days. Lyophilization samples were tested in multiplexed PCR amplification of 7 targets (793 bp, 649 bp, 548 bp, 418 bp, 332 bp, 196 bp, 135 bp) against the same enzyme and reaction buffer without lyophilization (Wet Reference) to demonstrate stable after lyophilization allowing for extended storage periods and use in NGS library amplification.
### Glycerol-Free High-Fidelity Pfu (HC), MDX203
**Application:** PCR**Specimen Type:** DNA**Concentration:** 20 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration, high fidelity DNA polymerase with separate dilution and reaction buffer, ideal for NGS library amplification and gene expression. Ideal for lyophilization.
Available in 0.025 mL (500 Units) or 1 mL (20,000 Units) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX203-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX203.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX203)
## Description
High-Fidelity Pfu is a thermostable high fidelity DNA polymerase enzyme, isolated from *Pyrococcus furiosus*. The Pfu polymerase enzyme replicates DNA in the 5´→3´ direction in the presence of magnesium, but also possesses 3´→5´ exonuclease (proofreading) activity. Base misincorporations that may occur during polymerization are rapidly excised by this proofreading activity. High-Fidelity has an error rate of 3.0 x 10-6 generating blunt-ended amplicons up to 5 kb in length. Glycerol-Free High-Fidelity Pfu (HC) is supplied in a glycerol-free storage buffer and is accompanied by a 5x Reaction Buffer that contains magnesium, dNTPs and excipients required for lyophilization.
## Specifications
DescriptionHigh concentration, high-fidelity Taq DNA polymerase with separate Pfu Polymerase Dilution Buffer and10x Pfu Reaction Buffer.Concentration20 U/µLAppearanceClear, colorless solutionApplicationPCR, NGS library preparation, cloning, protein expressionSample typecDNA, DNAPresentation3 vialsStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HSCatalog**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
[NGS High-Fidelity Pfu Buffer, 10x](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-high-fidelity-pfu-buffer-10x/)
## FAQs: High-Fidelity Pfu
What is proofreading polymerase?
In nature, the ability of a DNA polymerase to correct misincorporation of nucleotides in the DNA strand being elongated is often crucial to the survival of the host organism. This ability is termed “proofreading activity” and occurs in the 3′ to 5′ direction. This activity also leads to the polymerase removing unpaired nucleotides overhanging at the 3’end (A-overhangs), creating blunt ends.
My DNA sample contains PCR inhibitors, will the High-Fidelity Pfu still work?
If possible, we would recommend an additional clean-up of affected samples, alternatively High-Specificity Pfu HS Mix (MDX006) would be recommended, as it is designed to work in the presence of inhibitors.
How long a fragment will this High-Fidelity Pfu polymerase amplify?
High-Fidelity Pfu has been validated for templates up to 5 kb.
What is DNA target enrichment?
DNA target enrichment is a pre-sequencing DNA preparation step where DNA sequences are either directly amplified (multiplex PCR-based) or captured (hybrid capture-based). These enriched DNA fragments can then be sequenced using DNA sequencers.
After drying for how long will the lyophilized PCR tests stay stable to use?
A lyophilized PCR molecular test will remain stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** NGS Enzymes
---
### [Glycerol-Free HS Tth DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-hs-tth-dna-polymerase-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Enzymes ](/lifescience/products/molecular-reagents/enzymes/)» Glycerol-Free HS Tth DNA Polymerase (HC)
# Glycerol-Free HS Tth DNA Polymerase (HC)
*Thermus thermophilus* (Tth) DNA Polymerase is a thermostable DNA polymerase with intrinsic reverse transcriptase (RT) activity. The enzyme is a highly processive 5′-3′ DNA polymerase and lacks 3′-5′ exonuclease activity (proof reading). It possesses a very efficient intrinsic reverse transcriptase (RT) activity in the presence of manganese ions and unlike other RT enzymes, it is not associated with RNase H activity.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free HS Tth DNA Polymerase (HC)
- PCR amplification of DNA and one-step RT-PCR of RNA.
- PCR amplification of RNA and DNA templates having a high degree of secondary structure present in RNA.
- No association with RNase H activity
- Higher tolerance to PCR inhibitors
## Maintains Thermostability at 95°C for 10 Minutes
Performance of Glycerol-Free HS Tth DNA Polymerase (MDX205, red), an MMLV-RT (blue) and an AMV-RT (black) after pre-incubation from 40°C to 95°C for 10 mins, in a multiplex one-step RT-qPCR assay on mouse RNA. ΔCt values were calculated against the Ct value produced by the same enzyme stored at -20 °C. The data illustrates that MDX205 maintains its full performance even after 10 min at 95°C, in contrast to MMLV-RT and AMV-RT which are inactivated above 55°C and 60°C, respectively.
### Glycerol-Free HS Tth DNA Polymerase (HC), MDX205
**Application:** RT-qPCR**Specimen Type:** DNA,RNA**Concentration:** 200 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration, thermostable DNA polymerase with intrinsic reverse transcriptase (RT) activity and unlike other RT enzymes, it is not associated with RNase H activity. Ideal for lyophilization.
Available in 50 µL (4,000 Unit) or 500 µL (100,000 Unit) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX205-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX205-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX205.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX205)
## Description
Glycerol-Free Tth DNA Polymerase (HC) is a high concentration (200 U/µL) thermostable DNA polymerase with intrinsic reverse transcriptase (RT) activity. The elevated temperatures of Tth DNA Polymerase activity overcomes the problems posed by RNA secondary structure. Resulting cDNA can be amplified by PCR using the same enzyme in the presence of Mg2+ ions. The ability of Tth DNA Polymerase to perform both reverse transcription and DNA amplification at elevated temperatures allows this enzyme to be used for quantitative RT-PCR, cloning, and gene expression analysis of cellular and viral RNA.
Glycerol-Free HS Tth DNA Polymerase uses antibody-mediated hot start technology that enhances the specificity and sensitivity of PCR. It is supplied with a 5x Reaction Buffer that contains dNTPs and excipients required for lyophilization. Glycerol-Free HS Tth DNA Polymerase enables flexible and scalable reaction volumes and is suitable for applications such as fast RT-qPCR amplification of difficult templates from crude samples.
## Catalogs & Brochures
[Glycerol-Free Tth DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/751572112/)**Glycerol-Free Tth DNA Polymerase (HC)Catalog**
[Glycerol‑Free Taq HS](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HSCatalog**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
[A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)](https://collateral.meridianlifescience.com/view/268380769/)**Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
## FAQs: Glycerol-Free Tth DNA Polymerase (HC)
What is the function of Tth polymerase?
Tth DNA Polymerase is a thermostable DNA Polymerase with intrinsic reverse transcriptase activity for RT-PCR amplification. Thia allows one-step PCR or RT-PCR at much higher temperatures, overcoming problems typically associated with the high degree of secondary structure present in RNA.
What is the error rate of Tth polymerase?
Tth Polymerase error rate is 3.0 x 10-5 so it is very similar to Taq DNA polymerase.
What is the optimum temperature for Glycerol-Free Tth DNA Polymerase?
Temperature optimum for elongation with Mg2+ is approximately +72°C and for reverse transcription with Mn2+.is approximately +60 to +70°C
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Glycerol-Free T4 Polynucleotide Kinase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-polynucleotide-kinase-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [NGS Enzymes ](/lifescience/products/molecular-reagents/ngs-enzymes/)» Glycerol-Free T4 Polynucleotide Kinase (HC)
# Glycerol-Free T4 Polynucleotide Kinase (HC)
T4 Polynucleotide Kinase is widely used to phosphorylate the 5’ end of both DNA and RNA during labeling and ligation by catalyzing the transfer of the γ-phosphate from ATP to the 5´ hydroxyl of single stranded and double stranded DNA, RNA, and nucleoside 3´ monophosphates. T4 Polynucleotide Kinase also catalyzes the hydrolytic removal of the 3´ phosphate from 3´-phosphoryl polynucleotides, deoxyribonucleoside 3´ monophosphates, and deoxyribonucleoside-3´,5´-diphosphates to form a 3´-hydroxyl group.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free T4 Polynucleotide Kinase (HC)
- 5' phosphorylation for subsequent ligation for NGS
- End-labeling for probes and oligodeoxynucleotide primers
- Removes 3′ phosphoryl groups from DNA and RNA
- Glycerol-free, for lyophilization and ambient temperature storage
### Glycerol-Free T4 Polynucleotide Kinase (HC), MDX206
**Application:** NGS**Specimen Type:** DNA**Concentration:** 20 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free enzyme used to phosphorylate the ends of both DNA and RNA during labeling and ligation, mainly used in next-generation sequencing (NGS) library preparation. Ideal for lyophilization.
Available in 25 µL (500 Units) or 250 µL (5,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX206-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX206-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX206.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX206)
## Description
Glycerol-Free T4 Polynucleotide Kinase (HC) is supplied at 20 U/µL and is mainly used in next-generation sequencing (NGS) library preparation, where it can be used separately or as part of an End-Repair Mix, where phosphates are added to the 5′-hydroxyl terminus of double stranded DNA for subsequent ligation of adaptors by T4 DNA Ligase. Glycerol-Free T4 Polynucleotide Kinase (HC) is in a glycerol-free storage buffer and is supplied with a Lyo-Ready reaction buffer and has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components, such as point-of-care NGS.
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Mix**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[Glycerol-Free T4 DNA Ligase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free T4 DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-polymerase-hc/)
[Glycerol-Free DNA Pol I Klenow Fragment (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-hc/)
## FAQs: Glycerol-Free T4 Polynucleotide Kinase
Can I use T4 Polynucleotide Kinase and T4 DNA Ligase in the same reaction?
Yes, but not for radioactive labelling reactions as the non-radioactive ATP from the T4 Ligase buffer will interfere.
Can I inactivate T4 Polynucleotide Kinase?
Yes, incubation for 20 minutes at 65°C completely inactivates T4 Polynucleotide Kinase.
What are the advantages of a high-concentration enzyme?
High-concentration enzymes help reduce volumes when drying down, making the process faster, they also reduce volumes in microfluidic, cartridges and point of care (POC) devices, allowing for more sample to be added. They facilitate optimization and can speed up the reaction (as long as there is substrate available to bind to), increasing sensitivity and yield, as a result, they can be employed in a wide range of assay formats, allowing more flexibility for development and cost saving during commercialization.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** NGS Enzymes
---
### [Glycerol-Free DNA Pol I Klenow Fragment exo- (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-exo-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Glycerol-Free DNA Pol I Klenow Fragment exo- (HC)
Glycerol-Free DNA Pol I Klenow Fragment exo- (HC) is a high concentration N-terminal truncation of *E.coli* DNA Polymerase I which retains polymerase activity, but has lost 5’-3’ exonuclease activity and has mutations (D355A, E357A) which eliminates the 3’-5’ exonuclease activity. It is designed for dA and dT tailing for adapter ligation in next generation sequencing library preparation.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free DNA Pol I Klenow Fragment exo- (HC)
- dA- and dT-tailing for next-generation sequencing (NGS) adapter ligation
- Labeling by fill-in 5'-overhangs of dsDNA
- DNA sequencing by the Sanger method
- Isothermal DNA amplification SDA (Strand Displacement Amplification)
### Glycerol-Free DNA Pol I Klenow Fragment exo- (HC), MDX218
**Application:** NGS**Specimen Type:** DNA**Concentration:** 20 U/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration DNA Pol I Klenow Fragment exo-, designed for dA- and dT-tailing for next-generation sequencing (NGS) adapter ligation and DNA sequencing by the Sanger method.
Available in 50 µL (10,000 Units) or 1 mL (50,000 Units) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX218-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX218-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX218.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX218)
## Description
Glycerol-Free DNA Pol I Klenow Fragment exo- (HC) is as a glycerol-free, high concentration enzyme (50 U/L) and is mainly used in next-generation sequencing (NGS) library preparation, where it can be used separately or as part of an End-Repair Mix, for double stranded DNA blunting by 3’ overhang removal and fill-in of 5’ overhangs for subsequent ligation of adaptors by T4 DNA Ligase. The enzyme displays moderate strand displacement activity and can also be used to generate probes using random primers, dideoxy sequencing and random priming labelling.
Glycerol-Free DNA Pol I Klenow Fragment exo- (HC) is in a glycerol-free storage buffer and is supplied with a Lyo-Ready Klenow Reaction Buffer (5x) and has been optimized to deliver excellent, stable performance without glycerol, allowing you to deliver reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components, such as point-of-care NGS.
## Catalogs & Brochures
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS Mix**
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
## Related Products
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
[Glycerol-Free T4 Polynucleotide Kinase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-polynucleotide-kinase-hc/)
[Glycerol-Free T4 DNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t4-dna-polymerase-hc/)
[Glycerol-Free DNA Pol I Klenow Fragment (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-dna-pol-i-klenow-fragment-hc/)
## FAQs: Glycerol-Free DNA Pol I Klenow Fragment exo- (HC)
What is the difference between DNA Pol I Klenow Fragment and DNA Pol I Klenow Fragment exo-?
Just as the 5′ – 3′ exonuclease activity of DNA polymerase I from E.coli can be undesirable, the 3′ – 5′ exonuclease activity of Klenow fragment can also be undesirable for certain applications. This problem can be overcome by introducing mutations in the gene that encodes Klenow. This results in forms of the enzyme being expressed that retain 5′ – 3′ polymerase activity but lack any exonuclease activity (5′ – 3′ or 3′ – 5′).
Can DNA Pol I Klenow Fragment exo- be used to fill in 3' overhangs?
No, DNA Pol I Klenow Fragment exo- cannot fill in 3′ overhangs. To create blunt ends 3′ overhangs must be removed. Glycerol-Free DNA Pol I Klenow Fragment (HC) (MDX208) and T4 DNA Polymerase (MDX207), are the best choices to remove 3′ overhangs.
Can DNA Pol I Klenow Fragment exo- be used to label dsDNA?
Yes, DNA Pol I Klenow Fragment exo- is ideal for this application, it does so by filling in 5’ overhangs, and the lack of 3’→5′ exonuclease activity prevents the labeled nucleotides from being removed after they are incorporated by the polymerase.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [1-Step qPCR Buffer, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/1-step-qpcr-buffer-4x/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# 1-Step qPCR Buffer, 4x
1-Step qPCR Buffer, 4x is a novel buffer system that has been designed for highly reproducible, accurate reverse transcription followed by qPCR in a single tube under fast thermal cycling conditions, delivering excellent results in fast RT-qPCR assays.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's 1-Step qPCR Buffer, 4x
- Used to create ultra-sensitive RT-qPCR assays to deliver reproducible results from even very low copy number RNA targets
- Robust formulation delivers consistent, reliable one-step RT-PCR performance in fast cycling conditions
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High efficiency, giving excellent performance in multiplex qPCR assays
### 1-Step qPCR Buffer, 4x, MDX034
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
For highly reproducible, accurate assay results under fast thermal cycling conditions, delivering excellent results in fast qPCR assays.
Available in 2.5 mL (500 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX034-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX034-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX034.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX034)
## Description
1-Step qPCR Buffer is a combination of the latest advances in buffer chemistry together with enhancers and stabilizers. The final mix still requires the addition of dNTPs and MgCl2.
## Related Products
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/mmlv-rt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Fast qPCR Buffer, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-buffer-4x/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Fast qPCR Buffer, 4x
Fast qPCR Buffer, 4x is a novel buffer system that has been designed to be combined with a high-quality hot-start Taq DNA polymerase such as MDX008, to deliver highly reproducible, accurate assay results under fast thermal cycling conditions, delivering excellent results in fast qPCR assays.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Fast qPCR Buffer, 4x, MDX033
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
For highly reproducible, accurate assay results under fast thermal cycling conditions, delivering excellent results in fast RT-qPCR assays.
Available in 2.5 mL (500 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX033-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX033-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX033.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX033)
## Description
Fast qPCR Buffer is a combination of the latest advances in buffer chemistry together with enhancers and stabilizers. The final mix still requires the addition of dNTPs and MgCl2.
## Related Products
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/buffers/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
# Buffers
Bst DNA Polymerase is an enzyme derived from the large fragment of *Bacillus stearothermophilus* DNA Polymerase I. It contains 5´- 3´ DNA polymerase activity and strong strand displacement activity but lacks 5´- 3´ exonuclease activity. The strong strand displacement activity enables Bst DNA Polymerase to synthesize DNA at a constant temperature making it an ideal enzyme for isothermal amplification, including HDA, MCA, and for Loop-Mediated Isothermal DNA Amplification (LAMP).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### High Conc. Glycerol-Free Bst, MDX018
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 100 units/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
High concentration glycerol-free DNA polymerase (exo-), with strand-displacement properties. used for Isothermal DNA amplification such as LAMP (Loop-mediated Isothermal Amplification).
Available in 80 µL or 800 µL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX018-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX018-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX018.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX018)
### Inhibitor-Tolerant Bst Buffer, MDX019
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 10x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Inhibitor-Tolerant Bst Buffer is specially designed to overcome the inhibition present in samples in direct LAMP reactions.
Available in 2 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX019-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX019-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX019.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX019)
### Bst Reaction Buffer, 10x, MDX076
**Application:** LAMP**Specimen Type:** DNA**Concentration:** 10x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Reaction Buffer optimized for use with Bst DNA Polymerase.
Available in 5 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX076-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX076-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX076.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX076)
### Enzyme Dilution Buffer, 1x, MDX078
**Application:** PCR**Specimen Type:** DNA**Concentration:** 1x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Glycerol containing1x dilution buffer, for the dilution of enzymes to reaction concentration.
Available in 5 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX078-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX078-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX078.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX078)
### Enzyme Dilution Buffer, 10x (Glycerol free), MDX080
**Application:** PCR**Specimen Type:** DNA**Concentration:** 10x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Glycerol-free,10x dilution buffer, for the dilution of enzymes to reaction concentration.
Available in 5 mL or 100 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX080-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX080-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX080.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX080)
## Catalogs & Brochures
[ Bst DNA Polymerase ](https://collateral.meridianlifescience.com/view/33751484/)
Isothermal amplification such as loop-mediated isothermal amplification (LAMP) is a DNA amplification technique that can be performed at a single temperature. LAMP is currently considered one of the most powerful isothermal amplification techniques, relying on a strand-displacement polymerase combined with four to six primers. These primers recognize several specific regions in the target DNA and two of the primers form loop structures to facilitate subsequent rounds of amplification producing high levels of DNA.
Meridian’s Bst polymerases have strong strand displacement activity, fast polymerization, and enhanced inhibitor and salt tolerance when used with the specialized Inhibitor-Tolerant reaction buffer. The 100x high-concentration, glycerol-free BST enzyme was specifically designed to maximize assay flexibility for LAMP diagnostic test developm
## Related Products
- [ Lyo-Ready LAMP Mix ](/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: Taq HS DNA Polymerase
If my PCR testing is being impeded by too many PCR inhibitors, what can I do for optimization?
Decreasing the template concentration will help to minimize the concentration of inhibitors, the amount of DNA polymerase and primer can also be increased. In some cases you may also have to add a pre-treatment step if the DNA is not accessible.
What do the terms yield, fidelity, processivity and specificity actually mean?
These terms refer to parameters to be considered when performing PCR testing.
Yield: The amount of DNA produced in a PCR reaction. High yield increases sensitivity.
Fidelity: The accuracy of the enzyme at incorporating the correct dNTP to the elongating DNA strand. For standard PCR this is not important, but for sequencing or expression a high-fidelity mix (such as High-Specificity Pfu HS Mix (MDX006)) may be required.
Processivity: The length of time a polymerase is associated with the template and therefore the size of fragment which can be amplified (the amplicon). Taq HS DNA Polymerase will work with amplicons up to 5 kb.
Specificity: A measure of the unwanted by-products generated in a reaction. This is the reason for having hot start PCR, this prevents miss-priming at low temperatures and non-specific amplification
What applications can Taq DNA Polymerase be used for?
Taq DNA Polymerase has been validated with a broad range of PCR templates including DNA extracted from human, animal and plant samples, making it the ideal choice for the following applications:
• End-point PCR testing
• High-yield PCR testing
• Fast PCR testing
• Multiplex PCR testing
• qPCR and RT-qPCR testing
Can Taq DNA Polymerase be used for qPCR?
Yes, Taq DNA Polymerase can be used for quantitative PCR amplification (qPCR), but it will require a hot-start antibody (MDX014), qPCR buffer such as Fast qPCR Buffer, 4x (MDX033), or for RT-qPCR, a one-step buffer such as 1-Step qPCR Buffer, 4x (MDX034) and reverse transcriptase such as MMLV-RT (MDX044).
How fast is Taq DNA Polymerase?
This depends on the length of the amplicon and the complexity of the template. For fast PCR, the initial denaturation will remain 1 minute, but with low complexity template such as plasmid DNA, an annealing of 5 seconds and extension time of 10 seconds is sufficient for amplicons up to 1 kb. In order to find the fastest optimal condition, for more complex or longer amplicons, we suggest incrementally increasing the extension time successively up to 30 s/kb.
Can Taq Polymerase be used for difficult samples like GC rich or bisulfite converted DNA?
Yes, Taq DNA Polymerase works very well with difficult samples like GC rich or bisulfite converted DNA. However a hot-start to the PCR (such as MDX014) is important, as it decreases primer dimer and unspecific amplification.
If optimization is required, we would suggest starting with the annealing temperature and with bisulfite conversion, the process can fragment the DNA, so it may be useful to increase the amount of template and polymerase.
What is the error rate of Taq DNA Polymerase?
The enzyme has an error rate of approximately 1 error per 2.0 x 10⁵ nucleotides incorporated. If you are looking for a DNA polymerase with a lower error rate, for next-generation sequencing (NGS) library or expression a high-fidelity DNA polymerase (such as High-Fidelity Pfu (MDX003)) or mix (such as High-Specificity Pfu HS Mix (MDX006)) should be used.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dTTP, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure dTTP, 100 mM solution, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dTTP, 100mM (Lithium), MDX049
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dTTP (2’-Deoxythymidine-5’-Triphosphate) lithium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX049-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX049-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX049.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX049)
## Description
dTTP, 100mM, Lithium Salt is of the highest quality, with minimal batch-to-batch variations. It is manufactured to the highest purity standards and is perfectly suited for even the most demanding applications, such as long next-generation sequencing, long PCR, and highly sensitive qPCR.
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dTTP
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs to dNDPs and dNMPs, rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. The pH for lithium salt solutions is not as temperature-dependent as with sodium salts, hence where lithium salts are used, no dramatic shifts in pH occur when dNTPs are repeatedly frozen and thawed. This results in the dNTP preparation being more stable and, consequently, having a much longer shelf life than with sodium salts.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dGTP, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure dGTP, 100mM solution, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dGTP, 100mM (Lithium), MDX048
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dGTP (2’-Deoxyguanosine-5’-Triphosphate) lithium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX048-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX048-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX048.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX048)
## Description
dGTP, 100mM, Lithium Salt is of the highest quality, with minimal batch-to-batch variations. It is manufactured to the highest purity standards and is perfectly suited for even the most demanding applications, such as long next-generation sequencing, long PCR, and highly sensitive qPCR.
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dATP, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure Deoxyadenosine triphosphate (dATP), 100 mM solution, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's dATP, 100mM, Lithium Salt
- Greater than 99 % purity, ideal for use in qPCR applications
- Free from PCR inhibitors for maximum assay performance
- Enzymatically synthesized from premium quality raw materials
- Free from DNase, RNase and Nickases
## Highly sensitive multiplex qPCR reaction
A 10-fold serial dilution of human genomic DNA amplified with four different probes, both in singleplex reactions (blue line) and quadruplex reaction (red line) using dATP, dCTP, dGTP and dTTP in lithium salt. The results illustrate the same high sensitivity, excellent reproducibility and Ct values for both the singleplex and multiplex reactions with no reduction of efficiency often associated with multiplexing.
### dATP, 100mM (Lithium), MDX046
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dATP (2’-Deoxyadenosine-5’-Triphosphate) lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX046-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX046-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX046.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX046)
## Description
dATP, 100mM, Lithium Salt achieves high dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest standards and are perfectly suited for even the most demanding applications, such as highly sensitive qPCR.
## Specifications
DescriptionUltra-pure dATP (2’-Deoxyadenosine-5’-Triphosphate) lithium salt solution is enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities.CompositionC10H12N5O12P3Li4Molecular weight514.916 g/molConcentration (at λmax, pH 7.0, ԑ = 15.4 E x mmol-1 x cm-1)100 mM ± 5%AppearanceClear, colorless solutionApplicationcDNA synthesis, PCR, long-range PCR (>20 kb), high fidelity PCR, RT-PCR, qPCR, RT-qPCR, LAMP, microarrays, long NGSPresentation1 vialpH of Solution (at 20°C)7.5 – 8.0λmax (at pH 7.0)259 ± 1 nmA250/A2600.78 ± 0.03A280/A2600.15 ± 0.02ConsistencySingle band with PCR amplification of a 3 kb amplicon with a serial dilution of dATP.DNA contaminationNone detected in qPCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase/RNase/Nickase activityNone detectedPurity dATP(HPLC Area % at λmax)≥99%dNDP + dNMP(HPLC Area % at λmax)<1%DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dATP, 100mM, Lithium Salt
Why is the purity of dATP important?
dATPs or adenosine triphosphate is a “building blocks” for DNA. Purity and stability of all of the dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTPs for PCR preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dATP is normally used in a PCR?
The standard concentration of a dATP for PCR reactions is 0.2 mM. If you add equal volumes of 100 mM dATP, dCTP, dGTP and dTTP, the final stock is a 25 mM of each dNTP, which corresponds to a 100x working concentration, so you need to add 0.2 µL to a 20 µL standard PCR reaction.
Can I increase the DNA yield by adding higher concentrations of dNTPs for PCR?
It depends. You probably can increase the DNA yield, but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The sodium salt dNTP products are a standard grade and so we recommend these dNTPs for PCR. For more sophisticated reactions such as amplification of long templates, real-time PCR and NGS, we recommend lithium salt dNTP products.
Is the pH of the dATP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.0-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dATPs (deoxyadenosine triphosphate) to dADPs (deoxyadenosine diphosphates) and dAMPs (deoxyadenosine monophosphates), rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dATP solution can differ from the pH at 20°C. Sodium salts are temperature sensitive, so care needs to be taken when repeatedly frozen and thawed and sodium salt dATP is better aliquoted into smaller volumes and kept frozen in order to extend their shelf life.
What are the advantages of enzymic synthesis over chemical synthesis of dNTPs?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
I need to dilute my dATPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dATP using molecular biology or PCR grade water.
Can your dATP be used for lyophilization?
Yes, all of our dNTPs are glycerol-free and so can be lyophilized.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dUTP, 100mM, Lithium Salt
Ready-to-use sequencing grade ultra-pure dUTP, 100 mM solution, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dUTP, 100 mM (Lithium), MDX059
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure dUTP (2’-Deoxyuridine-5’-Triphosphate) lithium salt solution is enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX059-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX059-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX059.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX059)
## Description
dUTP, 100mM, Lithium Salt is of the highest quality, with minimal batch-to-batch variations. It’s manufactured to the highest purity standards and is perfectly suited for even the most demanding applications, such as long PCR or highly sensitive qPCR
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP Mix, 50mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-mix-50mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dUTP Mix
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs to dNDPs and dNMPs, rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. The pH for lithium salt solutions is not as temperature-dependent as with sodium salts, hence where lithium salts are used, no dramatic shifts in pH occur when dNTPs are repeatedly frozen and thawed. This results in the dNTP preparation being more stable and, consequently, having a much longer shelf life than with sodium salts.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dUTP Mix, 50mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-mix-50mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dUTP Mix, 50mM, Lithium Salt
A mix of ready-to-use sequencing grade ultra-pure dNTPs containing 10 mM dATP, dGTP, dCTP and 20 mM dU, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dUTP Mix, 50 mM (Lithium), MDX058
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 50 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure mix of 10 mM dATP, dGTP, dCTP and 20 mM dU in lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 50 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX058-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX058-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX058.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX058)
## Description
dUTP Mix, 50mM, Lithium Salt achieve the highest dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest purity standards and are perfectly suited for even the most demanding applications, such as next-generation sequencing (NGS), long PCR, or highly sensitive qPCR.
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dUTP Mix
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs to dNDPs and dNMPs, rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. The pH for lithium salt solutions is not as temperature-dependent as with sodium salts, hence where lithium salts are used, no dramatic shifts in pH occur when dNTPs are repeatedly frozen and thawed. This results in the dNTP preparation being more stable and, consequently, having a much longer shelf life than with sodium salts.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# dNTP Set, 100mM, Lithium Salt
A set of ready-to-use sequencing grade ultra-pure dNTPs consisting of 4 separate 100 mM solutions of dATP, dGTP, dCTP, and dTTP, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from premium quality raw materials, using highly specific production systems in our purpose-built facilities. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dNTP Set, 100mM (Lithium), MDX050
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 100 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure 100 mM solutions of dATP, dGTP, dCTP, and dTTP in lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 4 x 250 µL (1 mL) or 4 x 50 mL (500 mL) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX050-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX050-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX050.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX050)
## Description
dNTP Set, 100mM, Lithium Salt achieves the highest dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest purity standards and are perfectly suited for even the most demanding applications, such next generation sequencing (NGS), long PCR, or highly sensitive qPCR.
## Related Products
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs: dNTP Set
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs to dNDPs and dNMPs, rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. The pH for lithium salt solutions is not as temperature-dependent as with sodium salts, hence where lithium salts are used, no dramatic shifts in pH occur when dNTPs are repeatedly frozen and thawed. This results in the dNTP preparation being more stable and, consequently, having a much longer shelf life than with sodium salts.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [dNTP Mix, 10mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-10mm-lithium-salt/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# dNTP Mix, 10mM, Lithium Salt
A mix of ready-to-use high-quality grade dNTPs containing dATP, dGTP, dCTP, and dTTP (10 mM total), supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from quality raw materials, using highly specific production systems. The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### dNTP Mix, 10mM (Lithium), MDX086
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 10 mM**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Ultra-pure mix 2.5 mM each of dATP, dGTP, dCTP, and dTTP in lithium salt solution, enzymatically synthesized from premium quality raw materials.
Available in 10 mL or larger aliquots (please enquire)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX086)
## What is dNTP
dNTP Mix, 10mM, lithium Salt achieve high dNTP quality, with minimal batch-to-batch variations. They are manufactured to the highest standards and are perfectly suited for even the most demanding applications, such as long PCR or highly sensitive qPCR.
## Related Products
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
What concentration of dNTPs should I use in PCR?
The standard concentration of each dNTP in a PCR reaction is 0.2 mM. If the starting stock is a 100 mM solution of each dNTP, you need to add 0.1 µL of each nucleotide to a 50 µL standard PCR reaction. Since this is not convenient, it is recommended to prepare mixes: If the 100 mM dNTP stock solutions are mixed in equimolar amounts, the concentration of the mix will be 100 mM total or 25 mM of each nucleotide. From a 100x stock, you need to add 0.5 µL to a 50 µL reaction. Meridian also offers more diluted mixes of 40mM total (10mM each), which is a 50x stock solution and 10 mM total (2.5 mM each) 10x working stock.
Can I increase the DNA yield in my PCR by adding higher concentrations of dNTPs?
It depends. You probably can increase the DNA yield but you will have to optimize the complete PCR reaction, adjust the buffer, the Mg2+ and so on. It is not a matter pertaining only to nucleotides.
Does dNTP quality affect processivity?
Yes. The quality of dNTPs is especially important for sophisticated reactions such as amplification of long templates and real-time PCR. Methylated and deaminated nucleotides exhibit inferior results with proofreading DNA polymerases.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs to dNDPs and dNMPs, rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. The pH for lithium salt solutions is not as temperature-dependent as with sodium salts, hence where lithium salts are used, no dramatic shifts in pH occur when dNTPs are repeatedly frozen and thawed. This results in the dNTP preparation being more stable and, consequently, having a much longer shelf life than with sodium salts.
What are the advantages of enzymatic synthesis over chemical synthesis of dNTP?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
What are the advantages of dNTPs being presented in lithium salts as opposed to sodium salts?
Reference was made earlier to the greater solubility of dNTPs in lithium salts than in sodium salts. Also, dNTPs presented in lithium salts are more resistant to repeated freezing and thawing than those presented in sodium salts. Furthermore, they remain sterile during the entire storage period (the lithium ion has been shown to have significant bacteriostatic activity towards various microorganisms). Finally, using lithium-salt nucleotide preparations reduces salt-induced artifacts and increases the legibility of sequencing gels. Lithium salts are highly suited to PCR sequencing and labeling applications.
Are the concentrations of your dNTP Mixes each, or total?
All the concentrations of our dNTP Mixes are totaled, e.g. our 100 mM dNTP Mix is made up of 25 mM of each dNTP (dATP, dCTP, dGTP and dTTP).
I wish to prevent carry-over contamination of my PCR product using dUTP and UDGase, how does this work and which products are suitable?
When dUTP is used in place of or in conjunction with dTTP, the resulting PCR product is a suitable substrate for Uracil DNA Glycosylase (UDGase), which allows the user to completely destroy any contaminating DNA from a previous PCR reaction prior to commencing the current amplification. At Meridian we provide dUTP both as a stand-alone product and as part of a dUTP Mix.
I need to dilute my dNTPs to a different concentration, what should I use as a diluent?
We recommend that you dilute your dNTPs using Molecular Biology or PCR Grade Water.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Nucleotides
---
### [Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [Lyo-Ready & Air-Dryable Master Mixes & Reagents ](/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)» Lyo-Ready Direct DNA and RNA/DNA qPCR Blood Master
# Lyo-Ready Direct DNA and RNA/DNA qPCR Blood Master Mixes
Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Blood mixes are glycerol-free mixes that contain optimized excipients compatible with freezing and lyophilization and they designed for the direct molecular quantitation of DNA and RNA from whole blood, serum, or plasma. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA qPCR Blood Master Mixes
- Create ultra-sensitive multiplex direct blood qPCR tests using whole blood, serum or plasma.
- Simplify the development of quantitative PCR blood tests, by removing the nucleic acid extraction step and shortening the sample-to-result workflows.
- Validated for detection of blood pathogens and liquid biopsy applications.
- Can be used in liquid format or it can be lyophilized, for developing an ambient-temperate stable assay.
## Significantly greater tolerance to inhibitors found in whole blood and anticoagulants
### Lyo-Ready Direct DNA qPCR Blood, 4x, MDX122
**Application:** qPCR**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% whole blood, 20% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX122-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX122-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX122.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX122-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX122)
### Lyo-Ready Direct RNA/DNA qPCR Blood, 4x, MDX123
**Application:** RT-qPCR**Specimen Type:** Blood, Plasma, Serum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 10% whole blood, 10% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX123-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX123-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX123.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX123-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX123)
## Description
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for evaluating the function of vital organs (kidneys, liver, thyroid, and heart) and for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders such as diabetes. However, whole blood specimens, serum, and plasma contain a number of inherent PCR inhibitors including immunoglobulin G, hemoglobin, lactoferrin, and leukocyte DNA. In addition, PCR inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin). Traditional methods have relied on removing these inhibitors by DNA or RNA extraction prior to testing, however, these methods are problematic, can cause sample loss, and are not 100% effective at removing all the inhibitors.
Lyo-Ready DNA qPCR Blood is a 4x qPCR master mix for the development of DNA blood tests, enabling highly sensitive detection of target DNA from whole blood, plasma, and serum samples. Lyo-Ready RNA/DNA qPCR Saliva is 4x qPCR master mix and can be used for the development of both RNA and DNA blood tests from whole blood, plasma, and serum samples. These mixes have been formulated specifically to overcome the inhibitors specifically found in blood samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or lyophilized to create ambient-temperature stable whole blood tests, plasma tests or serum tests.
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
[Lyo-Ready Direct Blood Mixes](https://collateral.meridianlifescience.com/view/222789736/)**Lyo-Ready Direct Blood Mixes**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: qPCR Blood Test
What are the advantages of using blood over other sample types?
Blood contains abundant information about the health status of the organism, it can be used to evaluate organ function, detect proteins, nucleic acids, metabolites, infectious diseases and can be used for diagnosis of cancer (liquid biopsy), heart disease, diabetes. Blood tests are a simple and easily accessible (low-invasive) method to assess and monitor health.
What qPCR inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of qPCR in blood, as it can bind to single-stranded genomic DNA, leading to increased Ct values in a quantitative PCR blood test. The other two main inhibitors in blood are hemoglobin and lactoferrin that affected the DNA polymerase activity and thus lowered the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM, although this should not affect the Ct value. In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
What is the maximum volume of whole blood you can use in PCR blood Test?
We have used up to 20% whole blood with our mix, higher concentrations cause to solution to become viscous and difficult to work with.
Do you use a mutant polymerase to overcome inhibitors?
We use our own proprietary Taq polymerase and a highly optimized buffer system to overcome inhibition.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is it possible to detect cell free RNA/DNA from blood serum using these kits?
Yes, the Lyo-Ready qPCR Blood mixes can be used to detect both cfDNA and cfRNA.
Is a pre-treatment needed if you want to detect the DNA of gram-positive bacteria?
Yes, it is possible that you may need to pre-treat the blood in order to release the DNA from the gram-positive bacteria. In some cases a heat shock is sufficient, this will depend on the bacteria being examined.
What is the performance difference for DNA when using the DNA-specific product versus the DNA/RNA product?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-qPCR Blood mix – Lyo-Ready Direct RNA/DNA qPCR Blood mix, as it can be used for both.
Can the blood with or without anticoagulant can be store before the qPCR? How long? At what temperature?
It can be stored frozen or following the instructions from the storage buffer manufacturer.
Do the new master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some optimization may be required for the amount of blood that is needed for the qPCR blood test.
Do I need to elute dried blood spots, or can they be used directly?
You should elute in water, or TE buffer.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA qPCR Blood and Lyo-Ready Direct RNA/DNA qPCR Blood can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
What type of pre-treatment is compatible with the inhibitor tolerant blood mixes (detergents, preheating mix enzyme/plasma 95°C 5 min? in the PCR instrument)?
We advise not using Triton; however, heat treatment is ok.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » NGS Clean and Select Beads
# NGS Clean and Select Beads
Paramagnetic SPRI beads designed for clean-up and size selection of DNA fragments or next generation sequencing (NGS) libraries. Paramagnetic beads selectively bind DNA fragments based on the volume ratio of bead suspension and sample. They are capable of delivering highly purified DNA fragments and efficiently removing contaminants, such as nucleotides, primers, adapters, enzymes, buffer additives, and salts.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's NGS Clean and Select Beads
- Consistent bead diameter for highly reproducible selection of the user-defined fragment size range
- Excellent recovery of fragments greater than 100 bp and efficient removal of all contaminants
- Eliminates centrifugation or filtration steps for fast manual processing and simple integration with automated liquid handling platforms
- Bead composition specifically developed to withstand the rigours of the NGS workflow
## Description
NGS Clean and Select Beads is an efficient NGS library preparation clean-up and selection system based on paramagnetic beads. It is designed for the removal of salts, primers, and dNTPs and size selection of DNA fragments that can be used directly for downstream applications. The protocol can be used manually or adapted for liquid handling workstations.
### NGS Clean and Select Beads, MDX041
**Application:** NGS**Specimen Type:** DNA**Concentration:** N/A**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Efficient NGS library preparation clean-up and size selection system based on paramagnetic beads, designed for manually or adaptable for liquid handling workstations.
Available in 50 mL and 500 mL aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX041-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX041-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX041.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX041)
## Catalogs & Brochures
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
## Related Products
[High-Fidelity Pfu](https://www.meridianbioscience.com/lifescience/products/molecular/high-fidelity-pfu/)
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[1-Step qPCR Buffer, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/1-step-qpcr-buffer-4x/)
[NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Lithium Salt dNTPs](https://www.meridianbioscience.com/lifescience/products/molecular/lithium-salt-dntps/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
# Lithium Salt dNTPs
Ready-to-use high quality nucleotides and mixes, supplied as lithium salts in purified water at pH 7.5, enzymatically synthesized from quality raw materials, using highly specific production systems.
[ Contact a Specialist ](#requestasample)
## Sequencing Grade Ultra-Pure Nucleotides
- Greater than 99 % purity, ideal for use in qPCR applications
- Free from PCR inhibitors for maximum assay performance
- Enzymatically synthesized from premium quality raw materials
The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC). Lithium salts have greater resistance to repeated freezing and thawing cycles than sodium salts, and lithium salt dNTP preparations remain sterile over the entire shelf-life due to the bacteriostatic activity of lithium towards various microorganisms.
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[dATP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-lithium-salt/)
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[dUTP Mix, 50mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-mix-50mm-lithium-salt/)
[dUTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-lithium-salt/)
[dNTP Mix, 10mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-10mm-lithium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
Does dNTP quality affect processivity?
Yes. The sodium salt dNTP products are a standard grade and so we recommend these dNTPs for PCR. For more sophisticated reactions such as amplification of long templates, real-time PCR and NGS, we recommend lithium salt dNTP products.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs (deoxynucleotide triphosphates) to dNDPs (deoxynucleotide diphosphates) and dNMPs (deoxynucleotide monophosphates), rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. Sodium salts are temperature sensitive, so care needs to be taken when repeatedly frozen and thawed and sodium salt dNTPs are better aliquoted into smaller volumes and kept frozen in order to extend their shelf life.
What are the advantages of enzymic synthesis over chemical synthesis of dNTPs?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [VLP-RNA Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-red/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# VLP-RNA Extraction Control Red
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s VLP-RNA Extraction Controls offer a simple and effective way to reduce false-negative results in RT-qPCR assays. The biomimetic controls are composed of virus-like particle (VLP) shells packaged with a defined number of copies of target RNA molecules. Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of an RT-qPCR assay from lysis/extraction to reverse transcription and amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's VLP-RNA Extraction Control Red
- Contains a defined number of copies of target RNA molecules, encapsidated within a virus-like particle (VLP).
- Closely mimics the test sample, undergoing the same processing from lysis and extraction to RT-qPCR detection.
- Non-infectious material for ease of handling and shipping.
- Compatible with commonly used RNA extraction methods and lyophilization for creating freeze-dried mixes.
## Why use VLP-RNA Extraction Controls in an RT-qPCR assay?
Possible causes of negative detection in an RT-qPCR
Spike-In internal controls are RNA molecules added between the nucleic acid isolation and the detection, they do not monitor the extraction and lysis steps. Mimics internal controls are RNA molecules provided in a format resembling a biological sample (i.e. micelles) and are added just before lysis, but do not allow long incubation with the sample. VLP-RNA Extraction Control have better nuclease resistance, for long incubation with the sample, better quantification for consistent input in MDx processes and are easier to ship and store, ensuring that the MDx process provides reliable results by questioning each step of the process from lysis, through extraction to detection.
### VLP-RNA Extraction Control Red, MDX068
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 10^4 copies/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
An Internal Control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle and a VLP Detection Mix containing primers and probe to the internal control RNA sequence.
Available in 1 mL (~1×10^4 copies/µL) and 20 mL (~1×10^4 copies/µL) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX068-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX068-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX068.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX068)
## Description
VLP-RNA Extraction Control Red contains an internal control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle. The VLP-RNA Extraction Control is spiked in the sample prior to RNA extraction. Following RNA extraction, VLP-RNA Extraction Control can be detected in RT-qPCR by adding the VLP Detection Mix (containing specific primers and probe (emission wavelength = 670nm)) to the reaction mix. The detection of VLP-RNA Extraction Control acts as a PCR positive control and confirms the success of the extraction, reverse transcription, and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionAn Internal Control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle and a VLP Detection Mix containing primers and probe to the internal control RNA sequence, used to confirms the success of the extraction, reverse transcription, and amplification stepsConcentration104 copies/µLDetection MixPrimers and Cy5 labeled probe (absorption λmax = 647 nm and emission λmax = 670 nm)Applicationone-step RT-qPCRSample typeTissue, cellsPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionality testVLP Detection Mix tested in an RT-qPCR of a serial dilution of Internal Control RNA.
## Catalogs & Brochures
[VLP RNA Extraction Control Custom Project](https://collateral.meridianlifescience.com/view/564722040/)**VLP RNA Extraction Control Custom Project**
[VLP-RNA Extraction Control](https://collateral.meridianlifescience.com/view/33936393/)**VLP-RNA Extraction Control Catalog**
## Related Products
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[VLP-RNA Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-orange/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## FAQs: VLP-RNA Extraction Control
What is internal RNA control in RNA extraction?
When performing RNA extraction, it is often advantageous to have an exogenous source of RNA template that is spiked into the sample prior to lysis. This control RNA is then co-purified with the sample RNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
Can the VLP interfere with screening for other RNA viruses?
The VLP-RNA Extraction Controls are in plant based VLPs, so there is no animal/human viruses used within the process, so there is no possibility of the VLP-RNA Extraction Control giving false positive results.
How careful do I need to be with the VLP-RNA Extraction Control?
The VLP-RNA Extraction Controls are extremely robust and stable quantitative PCR positive control, we have tested then for 20 cycles of freeze thawing, storage at ambient temperature for one month, heating to 50 ᵒC for 10 minutes, lyophilization and nuclease treatment without seeing any change in Ct values.
Can the VLP interfere with RNA extraction from other viruses?
The VLP-RNA Extraction Controls are in plant based VLPs, so there is no animal/human viruses used within the process, so there is no possibility of the VLP-RNA Extraction Control giving false positive results.
Do I need to supply the primers and probe for the VLP-RNA Extraction Control?
The primers and probe for the VLP-RNA Extraction Control are in the VLP Detection Mix for VLP-RNA Extraction Control Red, MDX068 and VLP-RNA Extraction Control Orange, MDX069. However we do not supply the primers and probe for the custom VLP-RNA Extraction Control, MDX071.
Why are there two colors for the VLP-RNA Extraction Controls?
The two colors are for the fluorescent dyes on the VLP-RNA Extraction Control probe. VLP Detection Mix Red (Cy5 – emission wavelength = 670nm) and VLP Detection Mix Orange (HEX – emission wavelength = 555nm). This allows you to choose one that will fit with your existing protocol in a multiplex RT-qPCR assay.
Do I need a specific extraction method for the VLP-RNA Extraction Control?
No, the VLP-RNA Extraction Control will work with commercially available silica-membrane extraction kits and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [Sodium Salt dNTPs](https://www.meridianbioscience.com/lifescience/products/molecular/sodium-salt-dntps/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
# Sodium Salt dNTPs
Ready-to-use general grade nucleotides and mixes, supplied as sodium salts in purified water at pH 7.5, enzymatically synthesized from quality raw materials, using highly specific production systems.
[ Contact a Specialist ](#request-a-sample)
## PCR Grade Ultra-Pure Nucleotides
- Greater than 99 % purity, ideal for use in qPCR applications
- Free from PCR inhibitors for maximum assay performance
- Enzymatically synthesized from premium quality raw materials
The manufacturing process eliminates impurities and PCR-specific inhibitors such as modified nucleotides, tetraphosphates, and pyrophosphates commonly observed in other commercially available dNTP products (>99% purity determined by quantitative HPLC).
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[dCTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dctp-100mm-lithium-salt/)
[dGTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dgtp-100mm-lithium-salt/)
[dTTP, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dttp-100mm-lithium-salt/)
[dATP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/datp-100mm-sodium-salt/)
[dNTP Mix, 40mM Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-40mm-sodium-salt/)
[dNTP Mix, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-sodium-salt/)
[dUTP, 100mM, Sodium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dutp-100mm-sodium-salt/)
## FAQs
Why is the purity of dNTPs important?
dNTPs or deoxynucleotide triphosphates are the “building blocks” for DNA. Purity and stability of dNTPs are two of the essential factors to achieve a successful PCR. The use of a highly purified dNTP preparation is particularly recommended for sensitive techniques such as long-range PCR, RT-PCR, multiplex PCR, mutagenesis experiments and real-time applications. The purity of dNTPs is also important when the starting amount of template is minimal.
Does dNTP quality affect processivity?
Yes. The sodium salt dNTP products are a standard grade and so we recommend these dNTPs for PCR. For more sophisticated reactions such as amplification of long templates, real-time PCR and NGS, we recommend lithium salt dNTP products.
Is the pH of the dNTP solution important for stability?
Yes. The optimal pH for storage of nucleotides is from pH 7.5-8.2 (pH at 20°C). An acidic pH will cause hydrolysis of dNTPs (deoxynucleotide triphosphates) to dNDPs (deoxynucleotide diphosphates) and dNMPs (deoxynucleotide monophosphates), rendering them less suitable for PCR applications. During freezing/thawing cycles, the pH of the dNTP solutions can differ from the pH at 20°C. Sodium salts are temperature sensitive, so care needs to be taken when repeatedly frozen and thawed and sodium salt dNTPs are better aliquoted into smaller volumes and kept frozen in order to extend their shelf life.
What are the advantages of enzymic synthesis over chemical synthesis of dNTPs?
The enzymatic synthesis of dNTPs uses highly specific enzymatic systems which eliminate impurities and PCR inhibitors, such as modified nucleotides, PPi and deoxynucleoside tetraphosphates. PCR reactions are impeded by the presence of contaminants resulting from chemical manufacturing processes, such as traces of dNDPs, pyrophosphates or other ionic species (e.g. acetate). Such contamination may lead to poor yields or to no PCR product at all. Unless thoroughly purified, chemically synthesized dNTPs often contain deoxynucleoside tetraphosphates which are powerful PCR inhibitors. Chemical synthesis can also lead to deamination and other nucleotide modifications whereas enzymatic synthesis of dNTPs bypasses these risks.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Blood PCR Master Mixes for Serum and Plasma Tests](https://www.meridianbioscience.com/lifescience/products/molecular/blood-pcr-master-mixes-for-serum-and-plasma-tests/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Blood PCR Master Mixes for Serum and Plasma Tests
# Blood PCR Master Mixes for Serum and Plasma Tests
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders. However, whole blood specimens, serum and plasma contain a number of PCR inhibitors including immunoglobulin G, hemoglobin, lactoferrin and leukocyte DNA.
[ Contact a Specialist ](#requestasample)
**Not seeing what you’re looking for? [Inquire about a new product](#contact-specialist)**
## Meridian’s Blood PCR Master Mix: Inhibitor Solutions
In addition, PCR inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate or heparin). Traditional methods have relied on removing these inhibitors by DNA or RNA extraction prior to testing, however, these methods are problematic, can cause sample loss and are not 100% effective at removing all the inhibitors.
Meridian’s direct blood master mixes are designed to specifically overcome the inhibitors found in blood samples. As a result, they are capable of highly sensitive detection in multiplex assays, either using extracted DNA or RNA or crudely processed samples. No further optimization is required aside from the addition of primers and probes.
- Ultra-sensitive detection down to less than 10 copies of DNA or RNA using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in whole blood, serum, plasma (20%) and anticoagulants (e.g. 20% EDTA).
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian offers ready to use blood, 4x concentrated, glycerol-free master mixes for PCR and isothermal amplification, that have been formulated for direct use with crude lysates that can be used in a wet format or lyophilized and air-dried to create fast, ultra-sensitive ambient-temperature stable assays.
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Blood Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Blood Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Blood](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)
## Related Products
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)
## FAQs
What inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of qPCR or LAMP in blood, as it can bind to single-stranded genomic DNA, leading to increased Ct values or time to results. The other two main inhibitors in blood are hemoglobin and lactoferrin that affect the polymerase activity and thus lower the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM, although this should not affect the speed or Ct value. In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
What is the maximum volume of whole blood you can use with blood master mixes?
We have used up to 20% whole blood with our blood master mixes, higher concentrations cause the solution to become viscous and difficult to work with.
Is it possible to detect cell free RNA/DNA from blood serum using blood master mixes?
Yes, the blood master mixes can be used to detect both cfDNA and cfRNA, making it ideal for liquid biopsy.
What is the performance difference for DNA when using the DNA-specific blood master mixes versus the DNA/RNA blood master mixes?
With Meridian’s direct blood master mixes, you can see down to less than 10 copies.
How sensitive is a direct molecular assay?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of blood that is needed for a molecular assay.
Do the blood master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of blood that is needed for a molecular assay.
After drying for how long will the master mixes stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [FFPE Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/ffpe-master-mix/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » FFPE Master Mix
# FFPE Master Mix
SNPs (single nucleotide polymorphisms) or point mutations comprise the major part of the phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease, consequently, once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics.
[ Contact a Specialist ](#requestasample)
## Enhanced FFPE Master Mix for High-Sensitivity Genotyping Assays
Formalin-fixed paraffin-embedded (FFPE) tumor tissues constitute a valuable resource for retrospective studies due to long-term storage, however, DNA yield and quality, may be poor due to cross-linking of the DNA and its fragmentation and success rate of genotyping assays using DNA purified from such samples remains low.
Meridian’s Lyo-Ready Genotyping Direct qPCR FFPE allows digestion of the tissue, without the need for purification, greatly reducing the risk of sample damage, loss and contamination while simplifying and accelerating the analysis process.
- Ultra-sensitive detection down to less than 1 copy of DNA using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in FFPE tissue to give tight fluorescence clusters with clear allele discrimination
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Lyo-Ready Genotyping Direct qPCR FFPE combines the latest advances in buffer chemistry and PCR enhancers, together with an optimized antibody-mediated hot-start polymerase, dNTPs and MgCl2, along with a two-tube tissue extraction buffer, to release the DNA, for fast, precise, and highly reproducible allelic discrimination and cluster separation with SNP detection assays, even in the presence of PCR inhibitors presence in crude FFPE tissue extracts.
- [Lyo-Ready™ Genotyping Direct qPCR FFPE](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-ffpe/)
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Lyo-Ready Genotyping Direct qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)
[Lyo-Ready Genotyping Direct qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-stool/)
[Lyo-Ready Genotyping Direct qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)
## FAQs
What are the advantages of using qPCR for genotyping?
qPCR enables you to screen known SNPs. The benefits of qPCR are that it is easy, accurate, and can scale to high throughput. The bioinformatic analysis is also less complex than for other technologies, such as sequencing and microarrays.
5′-nuclease (TaqMan) allelic discrimination uses a primer pair to amplify the target area and two allele-specific probes to detect your target SNP alleles and report the genotypes of your samples. Unlike normal qPCR, in genotyping the fluorescence level is only measured at the end of the PCR and the results are displayed on a scatter plot, allowing hundreds of assays to be run and analysed in parallel.
What effects the quality and integrity of DNA in FFPE samples?
FFPE specimens are affected by numerous factors including fixative pH (that can lead to cross-linking of the DNA), duration of tissue fixation, age and storage condition of tissue blocks. This leading to extremely time-consuming, labour-intensive workflows that all result in fragmented DNA and consequently, the success rate of genotyping DNA purified from such samples is low.
Can I buy the extraction buffers separately?
Yes, we sell these as MDX004 Tissue Extract-PCR Buffers.
How sensitive is a direct molecular assay?
With Meridian’s Lyo-Ready Genotyping Direct qPCR FFPE, you can see down to 1 copy.
After drying for how long will the master mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Plant Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/plant-master-mix/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Plant Master Mix
# Plant Master Mix
The introduction of genetically modified organisms (GMO) and the demand for more precise and reliable techniques to detect foreign (transgenic or pathogenic) DNA in edible plants, have been the driving force for the introduction of molecular assays in plant research. Direct amplification of DNA from plant samples is a fast and convenient technique which avoids the need for laborious, time-consuming, and expensive nucleic acid extractions prior to qPCR.
[ Contact a Specialist ](#requestasample)
## High-Sensitivity Plant Master Mixes for PCR and qPCR Assays
However, obtaining consistency and sensitivity can be challenging, given the wide diversity in plant physiology. It is not just the physical challenge to release the DNA, but once the cell has been lysed, but also all the metabolites and cell constituents that can also pose inhibition problems such as complex carbohydrates and phenolic compounds.
Meridian’s direct plant master mix is designed to specifically overcome the inhibitors found in plant samples. As a result, it is capable of highly sensitive detection in multiplex assays, either using extracted DNA or RNA or crudely processed samples. No further optimization is required aside from the addition of primers and probes.
- Ultra-sensitive detection down to 1 copy of DNA or using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in plant lysates, direct or treated with SDS or NaOH.
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian offers a ready to use plant, 4x concentrated, glycerol-free master mix for qPCR amplification, that has been formulated for direct use with crude lysates that can be used in a wet format or lyophilized and air-dried to create fast, ultra-sensitive ambient-temperature stable assays.
- [Lyo-Ready™ Direct DNA qPCR Plant Master Mix](/lifescience/products/molecular/air-dryable-direct-dna-qpcr-plant-4x/)
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
## FAQs
What type of plants can be tested?
Most plant tissue can be used, the Air-Dryable Direct Plant Master Mix has been designed to cope with most of the PCR inhibitors are found in plant tissues, including humic acids, pectin, polyphenols, complex polysaccharides, tannins and xylan.
How sensitive is a direct molecular assay?
With Meridian’s direct plant master mix, you can see down to 1 copy.
Is a pre-treatment needed for the plant material?
That will depend on the plant tissue, for soft leaf samples a direct heat lysis can be applied, a single leaf punch (leaf disc of ø1,2 mm or approximately 0.1 mg) is heated at 95 °C for 5 min in 20 µL water. For tougher tissue a SDS lysis (A single leaf punch is heated at 95 °C for 5 min in 26 µL SDS Lysis Buffer (0.1% SDS)) or alkaline lysis (A single leaf punch was heated at 95 °C for 5 minutes in 20 µL alkaline Lysis Buffer (0.2 M NaOH) and neutralised using 6 µL 2 M Tris-HCl, pH 7.5 (Total lysate volume per leaf punch = 26 µL)) may be necessary.
Does the plant master mix need any changes in PCR protocol or is it compatible with the current setup?
It is compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of plant lysate that is needed for a molecular assay.
After drying for how long will the master mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Stool Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/stool-master-mixes/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Stool Master Mixes
# Stool Master Mixes
Urine is an ideal clinical specimen because it is excreted in large quantities is non-invasive, and it can be self-sampled. Currently, urine specimens are used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs) and for monitoring recreational drug use. However, urine contains substances such as urea and nucleases that can damage DNA or inhibit the PCR reaction.
[ Contact a Specialist ](#requestasample)
## Effective Stool Master Mixes for PCR and Isothermal Amplification
Meridian’s direct stool master mixes are designed to specifically overcome the inhibitors found in stool samples. As a result, they are capable of highly sensitive detection in multiplex assays, either using extracted DNA or RNA or crudely processed samples. No further optimization is required aside from the addition of primers and probes.
- Ultra-sensitive detection down to less than 10 copies of DNA or RNA using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in human stool (10%), bile salt (2mg/mL) and Cary-Blair transport media (40%)
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian offers ready to use stool, 4x concentrated, glycerol-free master mixes for PCR and isothermal amplification, that have been formulated for direct use with crude lysates that can be used in a wet format or lyophilized and air-dried to create fast, ultra-sensitive ambient-temperature stable assays.
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Stool Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Stool Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Stool ](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-stool/)
## Catalogs & Brochures
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
## Related Products
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Air-Dryable™ Direct DNA LAMP Blood Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-lamp-blood-master-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
## FAQs
What can stool be used to test?
Stool tests can allow identification of enteric pathogens such as harmful bacteria, fungi, viruses, or parasites down to the genus or species level, fast and accurately in a few hours, rather than the culture-based stool testing that can take several days. They can also be used as a non-invasive method for screening autoimmune conditions and cancer.
What is the advantage over a fecal occult blood test?
The fecal occult blood test (FOBT) has been the most widely used gastrointestinal immunoassay to screen colorectal cancer (CRC) for over three decades, however, recent large-scale studies have shown that the FOBT lacks the sensitivity to detect early stages of CRC. A molecular cancer stool test is a better diagnostic tool as it offers significant improvement in sensitivity and accuracy and can be used to screen for multiple targets and so speed up diagnosis, therefore improving prognosis.
How sensitive is a direct molecular assay?
With Meridian’s direct stool master mixes, you can see down to less than 10 copies.
What carrier buffer do you recommend?
There are several buffers on the market that can be used for stool testing, they include phosphate-buffered saline (PBS), Cary-Blair Medium, Stool Transport and Recovery (STAR) buffer and DNA/RNA Shield.
Is a pre-treatment needed if you want to detect human stool DNA?
Pre-treatment will depend on what you are looking at, cfDNA may not need pre-treatment, but you may need to heat to 95°C for 5 min and for some bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific urine master mixes versus the DNA/RNA stool master mixes?
We do not see a performance difference between the two master mixes.
Do the stool master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of urine that is needed for a molecular assay.
After drying for how long will the master mixes stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/urine-master-mixes/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Urine Master Mixes
# Urine Master Mixes
Urine is an ideal clinical specimen because it is excreted in large quantities is non-invasive, and it can be self-sampled. Currently, urine specimens are used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs) and for monitoring recreational drug use. However, urine contains substances such as urea and nucleases that can damage DNA or inhibit the PCR reaction.
[ Contact a Specialist ](#requestasample)
## Innovative Urine Master Mixes for PCR and Isothermal Amplification
Meridian’s direct urine master mixes are designed to specifically overcome the inhibitors found in urine samples. As a result, they are capable of highly sensitive detection in multiplex assays, either using extracted DNA or RNA or crudely processed samples. No further optimization is required aside from the addition of primers and probes.
- Ultra-sensitive detection down to less than 10 copies of DNA or RNA using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in human urine (30%).
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian offers ready to use urine, 4x concentrated, glycerol-free master mixes for PCR and isothermal amplification, that have been formulated for direct use with crude lysates that can be used in a wet format or lyophilized and air-dried to create fast, ultra-sensitive ambient-temperature stable assays.
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Urine Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Urine Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Urine](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)
## Catalogs & Brochures
[Air-Dryable Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine Master Mixes**
[Lyo-Ready Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct Urine Master Mixes**
[Lyo-Ready Direct LAMP Urine Master Mixes](https://collateral.meridianlifescience.com/view/940080326/)**Lyo-Ready Direct LAMP Urine Master Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/)**Lyo-Ready Genotyping Direct DNA qPCR Urine**
## Related Products
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Air-Dryable™ Direct DNA LAMP Blood Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-lamp-blood-master-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
## FAQs
What can urine be used to test?
Urine is an ideal clinical specimen because it is excreted in large quantities is non-invasive, and it can be self-sampled. Currently, urine specimens are used in the diagnosis and management of infectious diseases (including STDs), hormone and metabolic disorders, renal diseases, bladder cancer, urinary tract infections (UTIs), and for monitoring recreational drug use.
What types of infectious diseases can urine detect?
The most common infections are urinary tract infections (UTIs), most commonly *Escherichia coli*, *Protus mirabilis*, *Enterococcus faecalis*, *Staphylococcus saprophyticus* and *Klebsiella pneumoniae*. Several other infections can be diagnosed by urine DNA and urine RNA tests including community-acquired pneumonia (CAP), legionellosis, tuberculosis, congenital cytomegalovirus (CMV) infection, and arboviruses, such as Chikungunya virus, dengue virus and Zika virus. Parasites can also be diagnosed from urine testing for the detection of eggs from *Schistosoma haematobium*. Furthermore, urine has been used for screening of different sexually transmitted diseases (STD) such as *Neisseria gonorrhoeae* and *Chlamydia trachomatis*.
How sensitive is a direct molecular assay?
With Meridian’s direct urine master mixes, you can see down to less than 10 copies.
Is a pre-treatment needed if you want to detect bacteria in urine?
That will depend on the bacteria, for some bacteria you may not need to do any pre-treatment, however some may require heating to 95°C for 5 min and for some tougher bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary
What is the performance difference for DNA when using the DNA-specific urine master mixes versus the DNA/RNA urine master mixes?
We do not see a performance difference between the two master mixes.
Do the urine master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of urine that is needed for a molecular assay.
After drying for how long will the master mixes stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Saliva, Sputum Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/saliva-sputum-master-mixes/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Saliva, Sputum Master Mixes
# Saliva, Sputum Master Mixes
Saliva has been extensively studied as a diagnostic specimen due to its non-invasive and simple sample collection/logistics and similar to serum, saliva contains hormones, antibodies, growth factors, enzymes, microbes that can be used as biomarkers for disease detection. However, there have been challenges adopting saliva for molecular assay diagnostics due to the low concentration of analytes and high concentration of PCR inhibitors in saliva.
[ Contact a Specialist ](#requestasample)
**Not seeing what you’re looking for? [Inquire about a new product](#requestasample)**
## Enhanced Saliva and Sputum Master Mix Solutions
Cumbersome sample preparation steps have been required to homogenize the specimen and adequately purify the DNA/RNA.
Meridian’s direct saliva master mixes are designed to specifically overcome the inhibitors found in saliva and sputum samples. As a result, they are capable of highly sensitive detection in multiplex assays, either using extracted DNA or RNA or crudely processed samples. No further optimization is required aside from the addition of primers and probes.
- Ultra-sensitive detection down to less than 10 copies of DNA or RNA using direct amplification protocols.
- Inhibitor-tolerant to PCR inhibitors found in saliva (60%) and Universal Transport Medium – UTM (50%).
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian offers ready to use saliva, 4x concentrated, glycerol-free master mixes for PCR and isothermal amplification, that have been formulated for direct use with crude lysates that can be used in a wet format or lyophilized and air-dried to create fast, ultra-sensitive ambient-temperature stable assays.
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Saliva Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
## Catalogs & Brochures
[Air-Dryable Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct Saliva Master Mixes**
[Lyo-Ready Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct Saliva Master Mixes**
[Lyo-Ready Direct LAMP Saliva Master Mixes](https://collateral.meridianlifescience.com/view/180412872/)**Lyo-Ready Direct LAMP Saliva Master Mixes**
[Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples](https://collateral.meridianlifescience.com/view/1070676719/)**Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples**
## Related Products
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Air-Dryable™ Direct DNA LAMP Blood Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-lamp-blood-master-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
## FAQs
What can saliva be used to test?
Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antimicrobial constituents, hormones, cytokines, and antibodies. Its composition virtually reflects the entire state of health and disease in a body, and it has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (avian influenza viruses and coronaviruses) and bacterial infections.
What are the advantages of using saliva over other sample types?
Saliva testing is compliance with painless, non-invasive sample collection from the patient, making it ideal for use with children or patients that will not comply with blood collections or even intrusive nasal swabs. Saliva tests and sputum tests also increase the efficiency of collection while minimizing sample handling and reducing handling errors..
How sensitive is a direct molecular assay?
With Meridian’s direct saliva master mixes, you can see down to less than 10 copies.
Do I need to pre-treat my saliva or sputum to use it in a direct assay?
This will depend on what you are testing for and the amount, for example with SARS-CoV-2 heating to 95°C for 10 minutes has been shown to be beneficial, particularly with low viral loads, however Zika virus does not need pre-treatment, whereas some bacteria may require strong pre-treatment (such as proteinase K and heat inactivation).
What is the performance difference for DNA when using the DNA-specific saliva master mixes versus the DNA/RNA saliva master mixes?
We do not see a performance difference between the two master mixes.
Do the saliva master mixes need any changes in PCR protocol or are they compatible with the current setup?
They are compatible with standard cycling conditions and can also be used with very fast cycling conditions, however some assay development may be required for the volume of saliva that is needed for a molecular assay.
After drying for how long will the mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Low DNA qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [qPCR and RT-qPCR Master Mixes ](/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/)» Low DNA qPCR Mix
# Low DNA qPCR Mix
Low DNA qPCR Mix is a fast, highly reproducible real-time PCR master mix that has been designed with a highly optimized buffer chemistry and chemical hot-start DNA polymerase, to deliver excellent results and very low background, allowing greater sensitivity.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Low DNA qPCR Mixes
- Reproducible detection of low-copy number templates
- Proprietary hot-start modification minimizes non-specific amplification for improved assay reliability in high-throughput assays
- Consistent results between technical replicates ideal for multiplexing, gene expression analysis and genotyping
- Reliable, accurate detection of DNA and cDNA targets from a broad range of sample types
## Sensitivity with fast cycling conditions
A 100-fold dilution of human cDNA was used in a multiplex assay with Low DNA qPCR Mix (red) and another supplier of chemical hot-start qPCR mixes (black) with fast cycling conditions (10 minutes 95°C followed by 40 cycles 95°C 10 seconds, 60°C 10 seconds). The results illustrate Low DNA qPCR Mix is more sensitive than other suppliers of chemical hot-start qPCR mixes in fast cycling conditions.
### Low DNA qPCR Mix, MDX030
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Highly purified qPCR master mix with stringent chemical hot-start properties and low bioburden, ideal for PCR of low-copy bacterial targets to avoid false-positive amplification.
Available in 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX030-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX030-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX030.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX030)
## Description
Low DNA qPCR master mix contains a chemical hot-start Taq polymerase and highly optimized reaction buffer with dNTPs, MgCl2, stabilizers, and PCR enhancers. The Taq polymerase is purified twice, before and after the addition of the chemical hot-start, this helps to remove trace amounts of DNA (known as bioburden) that come from the manufacturing of the DNA polymerase. In addition there is no bioburden that comes with antibody hot-start, making it ideal for low-copy number targets and also microbial DNA and fungal DNA detection assays.
Low DNA qPCR master mix can also be used for fast, precise and highly reproducible genotyping of sequence variants, including loci, provides higher stringency and more specific binding of the allele-specific probes, with wider and clearer separation of allele cluster.
## Specifications
DescriptionA combination of the latest advances in buffer chemistry and PCR enhancers polymerase, dNTPs and MgCl2. The low DNA background and stringent hot-start properties are ideal for qPCR of low-copy bacterial targets, avoiding false-positive amplification of bacterial or fungal targets.Concentration2xAppearanceClear, colorless solutionApplicationProbe-based, real-time PCR, two-step RT-qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
[Bacterial and Fungal DNA Amplification](https://collateral.meridianlifescience.com/view/33644836/)**Bacterial and Fungal DNA Amplification**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
## FAQs: Low DNA qPCR mix
What are the advantages and considerations of a chemical hot-start DNA polymerase?
With a chemical hot-start DNA polymerase, the polymerase is covalently linked with chemical groups to block enzyme activity at room temperature.
Advantages
• More stringent than antibody hot-start methods, so there is no activity even for long periods at room temperature, minimizes non-specific amplification
• Low bioburden, as it is free of animal and bacterial-origin components
Considerations
• Longer activation time required for the polymerase to become fully active
What probes can be used in quantitative PCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most commonly used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Low DNA qPCR Mix be used with crude samples?
The Low DNA qPCR Mix has some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we have the universal Inhibitor-Tolerant qPCR mix and for even greater sensitivity, we have the sample specific (blood, saliva, urine, stool, and plant) mixes.
How can Low DNA qPCR Mix be used for genotyping?
Genotyping refers to the process of determining genetic variations among individuals in a population. Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation and are single-base differences at a specific locus. These genotype changes can confer positive or negative phenotypic outcomes, such as more robust stress tolerance in plants or enhance the susceptibility for disease in humans. Hence, SNPs are often useful markers for understanding the biology of organisms. Genotyping is done with two allele-specific probes that have a single base mismatch and a pair of primers at each end of the SNP of interest. Depending on which base is present at the SNP position, the probe will either not hybridize correctly during the qPCR and be left intact or hybridize correctly and be cleaved to give a signal. Since the dual-labeled probe assay is based on PCR, it is relatively simple to implement, and the scale can be drastically increased by performing many simultaneous reactions together.
Genotyping also refers copy number variation (CNV), which results from having different numbers of copies of a DNA segment in various genomes. Where the copy number variation is for an encoded gene, this can lead to susceptibility or resistance to disease. This uses two sets of primers and probes, one for a calibrator gene that does not change and the other for the gene thought to have the changed copy number. A comparison to the Ct values of each allows you to determine if the copy number has changed and by how much.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
**Published:** April 29, 2025
**Author:** hamza
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » [qPCR and RT-qPCR Master Mixes ](/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/)» Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes
# Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes
A variety of PCR inhibitors inherent to clinical and environmental samples can negatively impact the sensitivity and accuracy of a molecular assay. Conventionally, to overcome this, specimens undergo processing before testing. However, extraction technologies are not 100% efficient and can impact the amount of target nucleic acid available for testing. Some PCR inhibitors can also co-elute following purification, reducing the efficiency, particularly in quantitative PCR multiplex assays, and may even induce false-negative assay results.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes
- Ready-to-use qPCR master mixes engineered for amplification from crude samples without the need for complex or time-consuming extraction
- 4x concentration master mix allows for greater sample volume; simply add primers, probes and clinical samples
- Ideal for developing quantitative PCR assays where sample is limited
## Inhibitor-Tolerant qPCR Mix Reaction Efficiencies
Reaction efficiencies were determined from reactions containing a variety of known PCR inhibitors ranging from whole blood to biofluids (20% in reaction). The results demonstrate that the reaction efficiency of the Inhibitor-Tolerant qPCR Buffer (used in MDX013) remained within 90-110% in the presence of a wide range of common PCR inhibitors.
### Inhibitor-Tolerant qPCR Mix, MDX013
**Application:** qPCR**Specimen Type:** Blood,saliva,urine,stool,tissue,DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Universal inhibitor tolerant qPCR master mix, for direct amplification from crude lysates or inhibitor-rich samples such as urine, cerebral spinal fluid (CSF), blood, sputum, saliva and stool.
Available in 5 mL (500 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX013-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX013-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX013.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX013)
### Inhibitor-Tolerant RT-qPCR Mix, 4x, MDX016
**Application:** RT-qPCR**Specimen Type:** Blood,saliva,urine,stool,tissue,RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Universal, high concentration, inhibitor tolerant RT-qPCR master mix, for direct amplification from crude lysates or inhibitor-rich samples such as urine, cerebral spinal fluid (CSF), blood, sputum, saliva and stool.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX016-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX016-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX016.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX016)
### Inhibitor-Tolerant qPCR Mix, 5x, MDX073
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 5x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, together with high quality enzymes, dNTPs and MgCl2, for use in the presence of inhibitors.
Available in 2 mL (500 Rxns) or 40 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX073-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX073-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX073.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX073)
### Inhibitor-Tolerant RT-qPCR Lo-ROX Mix, 4x, MDX105
**Application:** RT-qPCR**Specimen Type:** Blood,saliva,urine,stool,tissue,RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, together with high quality enzymes, dNTPs and MgCl2, for use in the presence of inhibitors.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX105-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX105.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX105)
## Description
Meridian’s universal Inhibitor-Tolerant qPCR/RT-qPCR formulations are ready-to-use quantitative PCR supermixes, containing all components except primers, probes, and templates for direct qPCR and RT-qPCR. They are designed for developing qPCR multiplex assays that require minimal sample processing and fast turn-around times (TAT). Because the mixes are highly resistant to various qPCR inhibitors, they can be used with crude lysates or inhibitor-rich samples to directly detect pathogens, including viruses and bacteria, in various biological specimens and to analyze gene expression in cells.
Inhibitor-Tolerant qPCR Mix is available as a standard 2x or 5x quantitative PCR master mix; this flexibility allows assay developers more room for sample, increasing the sensitivity for low copy number samples. All steps, from pre-treatment (if required) to qPCR, to be performed in a single tube, greatly reducing hands-on time and the risk of contamination.
Inhibitor-Tolerant RT-qPCR Mix is a 4x quantitative PCR master mix, with and without low concentrations of ROX (passive reference dye), again allowing assay developers more room for sample, increasing the sensitivity for low copy number samples. Inhibitor-Tolerant RT-qPCR Mix has been designed for highly reproducible, accurate RNA and DNA target amplification under fast thermal cycling conditions, delivering excellent results in qPCR multiplex assays, even in the presence of difficult qPCR inhibitors found in blood, urine, and stool.
## Specifications
DescriptionA combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, together with high quality enzymes, dNTPs and MgCl2. Designed to be used in PCR reactions for highly reproducible, accurate assay results in the presence of inhibitors, such as human and animal blood.Concentration2x, 4x and 5 xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typecDNA, crude or purified RNA and/or DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency±0.5/1 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on E. coli and mouse genomic DNA specific targets.DNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR & RT-qPCR Mixes**
## Related Products
[Fast qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable Direct DNA qPCR Plant, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-plant-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: Inhibitor-Tolerant Mixes
What sample types can be used with the Inhibitor-Tolerant qPCR Mixes?
We have tested whole human and bovine blood, saliva, sputum, urine, cerebrospinal fluid (CSF), cow milk, stool sample, and plant lysate; other types of samples can be used but we would recommend testing different concentrations to determine the concentrations that can be tolerated. We also recommend you try out our specimen-specific qPCR/RT-qPCR master mixes specially designed for each specimen type, such as blood, saliva/sputum, urine, stool, or plant.
Do I need to add additional magnesium to the reaction?
The Inhibitor-Tolerant RT-qPCR mixes have been optimized for magnesium, dNTPs, stabilizers, and enhancers, resulting in highly reproducible, accurate RNA and DNA target amplification under fast thermal cycling conditions, delivering excellent results in qPCR multiplex assays, even in the presence of difficult PCR inhibitors. So we do not recommend adding any additional material, only the primers, probe(s), and sample.
What are the recommended reaction conditions for qPCR multiplex assays?
When multiplexing, standard conditions can be used, however, if necessary, the reverse transcription reaction time can be extended up to 20 minutes and/or the temperature can be increased up to 55° C and the annealing/extension time can be extended up to 60 seconds and/or the temperature can be increased up to 65° C, but this will need to be tested during optimization.
Do you use a mutant polymerase to overcome inhibitors?
We use our own proprietary Taq polymerase and a highly optimized buffer system to overcome inhibition.
Can these mixes be dried down for room temperature storage?
These mixes contain glycerol and so cannot be dried down; see our specimen-specific range of inhibitor-tolerant quantitative PCR mixes for lyophilized or air-dried.
Where do I begin with optimization of crude samples or crude extracts?
We would recommend using a range of crude sample concentrations or extract volumes to ascertain at what point unacceptable PCR inhibition starts to take place. This will vary as some sample types, such as blood and stool specimens typically contain more inhibitors for qPCR/RT-qPCR reactions.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Air-Dryable & Lyo-Ready Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-lyo-ready-enzymes/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Air-Dryable & Lyo-Ready Enzymes
# Air-Dryable & Lyo-Ready Enzymes
Meridian offers a selection of high-quality glycerol-free enzymes to help you develop highly sensitive assays. Removing the glycerol allows give assay developers the option for compatibility with lyophilization or air-drying, to dry down for stable ambient temperature shipment and storage. We also have high concentration enzymes that save on volume to allow more sample material to be added and gives greater flexibility in assay development strategies and allowing increase sensitivity, specificity, speed, stability, and enable a simplified workflow.
[ Contact a Specialist ](#requestasample)
## High-Sensitivity Air Dryable and Lyo Ready Enzymes for Assays
- Glycerol-free solution, for preparation of dried-down assays.
- High concentration, allowing smaller reaction volumes and greater flexibility in assay optimization.
- Ideal for POC microfluidic devices.
Meridian high-concentration, glycerol-free enzymes help you develop highly sensitive assays. They have been developed for speed and are designed for superior sensitivity and yield. The high concentration Being glycerol-free allows for the option of lyophilization or air-drying, allowing ambient temperature shipping and storage, and increased flexibility in sample volume.
- [Glycerol-Free Taq HS 50U/µL](/lifescience/products/molecular/glycerol-free-taq-hs-50-u-µl/)
- [Glycerol-Free Taq HS High Conc.](/lifescience/products/molecular/glycerol-free-taq-hs-high-conc-dna-polymerase/)
- [Aptamer Taq HS (Glycerol-Free)](/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
- [Glycerol-Free High-Fidelity Pfu (HC)](/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
- [Glycerol-Free HS Tth DNA Polymerase (HC)](/lifescience/products/molecular/glycerol-free-hs-tth-dna-polymerase-hc/)
- [High Conc. Glycerol-Free Bst](/lifescience/products/molecular/high-conc-glycerol-free-bst/)
- [Glycerol-Free T7 RNA Polymerase (HC)](/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
- [55C MMLV-RT](/lifescience/products/molecular/55c-mmlv-rt/)
- [Lyo-Compatible MMLV-RT](/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
- [RNase Inhibitor (Glycerol Free)](/lifescience/products/molecular/rnase-tolerant-mmlv-rt/)
- [Glycerol-Free RNase H (HC)](/lifescience/products/molecular/glycerol-free-rnase-h-hc/)
- [Glycerol-free T4 DNA Ligase (HC)](/lifescience/products/molecular/glycerol-free-t4-dna-ligase-hc/)
## Catalogs & Brochures
[Glycerol-Free Taq HS](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HS**
[Aptamer Taq HS (Glycerol-Free)](https://collateral.meridianlifescience.com/view/33669388/)**Aptamer Taq HS (Glycerol-Free)**
[High-Specificity Pfu HS](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HS**
[Glycerol-Free Tth DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/751572112/)**Glycerol-Free Tth DNA Polymerase (HC)**
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080/)**Glycerol-Free T7 RNA Polymerase**
[55C MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RT**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)**
## Related Products
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[dNTP Set, 100mM, Lithium Salt](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-set-100mm-lithium-salt/)
[Lyo-Ready qPCR Buffer w/o Excipients, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-w-o-excipients-4x/)
## FAQs
What is the difference between lyophilization and air drying?
Lyophilization is done by freezing and sublimation in a vacuum, forming a cake or bead, it has very low viscosity and up to 99% of the moisture is removed. Drying normally take 18-24 hours and requires cryo-excipients that protect the enzymes during the freezing. The reagents can be lyophilized to a bead or a cake format.
Air-drying is done by heating in a convection oven, forming a highly viscous pellet, with about 95% of the moisture removed. Drying normally take less than 2 hours and requires heat protecting excipients that protect the enzymes at higher temperatures. The reagents can be air-dried to a soft viscous format.
Lyophilization and air-drying helps to extend the product’s shelf life, enhance the stability of the reagents at higher temperatures, and allows for convenient and accurate dispensing of the reagents. After drying, the reagents are easily reconstituted with sample material.
Are reaction conditions the same for dried and liquid mixes?
Yes, reaction conditions are the same and they will produce the same results, this means that the liquid mixes can be used to create SOPs if you do not want to dry down and then later if drying is is required (for example to increase sensitivity), the SOP can be updated for drying, it does not require completely new SOPs to be written, but excipients will need to be added.
After drying for how long will the enzyme or mix stay stable to use?
Following drying in the presence or absence of a buffer containing excipients, primers/probes, the mix should be stable for a minimum of 24 months at ambient temperature. Following rehydration, the assay reproducibility, sensitivity, and robustness should be the same as for a freshly made liquid mix.
Do you supply lyo-excipients separately?
No, our lyo-excipients are proprietary, if you require a buffer that contains lyo-excipients, we have the Lyo-Ready qPCR Buffer, 2.5x (MDX022).
What are the advantages of a high-concentration enzyme?
High-concentration enzymes help reduce volumes when drying down, making the process faster, they also reduce volumes in microfluidic, cartridges and point of care (POC) devices, allowing for more sample to be added. They facilitate optimization and can speed up the reaction (as long as there is substrate available to bind to), increasing sensitivity and yield, as a result, they can be employed in a wide range of assay formats, allowing more flexibility for development and cost saving during commercialization.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Air-Dryable Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-master-mixes/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Air-Dryable Master Mixes
# Air-Dryable Master Mixes
Air-Dryable master mixes are glycerol-free mixes that contain optimized excipients compatible with air and oven drying. The mixes are easy to use and ideal for developing ambient temperature, multiplex molecular assays. Advantages to ambient-temperature assays include room temperature shipping and storage, extended shelf-life and increased flexibility in sample volume.
[ Contact a Specialist ](#requestasample)
## Advanced Air-Dryable Master Mixes for High-Sensitivity Assays
Meridian’s air-dryable master mixes are the market-leading solution for molecular diagnostic assays requiring fast cycling, superior sensitivity, high inhibitor tolerance and ambient temperature stability.
- High efficiency and sensitivity in multiplex reactions, just add primers, probes and sample.
- Available in universal or specimen-specific formulations for blood, saliva, urine or stool and suitable for direct detection assays using crude samples.
- Can be used in a liquid or dry format, reducing the cost and complexity of creating ambient-temperature stable assays.
Meridian master mixes combining the lasts advances in buffer chemistry and PCR enhancers, together with an optimized concentration of enzymes, dNTPs and MgCl2. and air-dry compatible excipients. They come as standard as well as specimen-specific qPCR and RT-qPCR master mixes, developed for highly reproducible, accurate RNA and DNA target amplification, delivering excellent results in multiplex assays, with sensitivity down to a single copy.
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Blood Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
- [Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine Master Mixes](/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
- [Air-Dryable™ Direct DNA qPCR Plant Master Mix](/lifescience/products/molecular/air-dryable-direct-dna-qpcr-plant-4x/)
- [Air-Dryable™ qPCR and RT-qPCR Mixes Master Mixes](/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## Catalogs & Brochures
[Air-Dryable Master Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Master Mixes**
[Air-Dryable Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood Master Mixes**
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct Saliva**
[Air-Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable Direct Stool**
[Air-Dryable Direct Urine](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct Urine**
[Air-Dryable Direct Plant Master Mixes](https://collateral.meridianlifescience.com/view/397948458/)**Air-Dryable Direct Plant Master Mixes**
[Air-Drying Molecular Assays](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
## Related Products
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA LAMP Urine Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)
## FAQs
What is the difference between lyophilization and air drying?
Lyophilization is done by freezing and sublimation in a vacuum, forming a cake or bead, it has very low viscosity and up to 99% of the moisture is removed. Drying normally take 18-24 hours and requires cryo-excipients that protect the enzymes during the freezing. The cost is high as a freeze vacuum drier and low moisture environment are required.
Air-drying is done by heating in a convection oven, forming a highly viscous pellet, with about 95% of the moisture removed. Drying normally take less than 2 hours and requires heat protecting excipients that protect the enzymes at higher temperatures. The cost is low as no additional equipment is required.
Can the standard Air-Dryable qPCR and RT-qPCR master mixes be used with crude samples?
The Air-Dryable™ qPCR and RT-qPCR master mixes have some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we have the air-dryable sample specific (blood, saliva, urine, stool, and plant) mixes.
Are reaction conditions the same for air-dried and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to dry down and then later if drying is required (for example to increase sensitivity), the SOP can be updated for oven drying, it does not require completely new SOPs to be written.
After drying for how long will the master mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Lyo-Ready Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-master-mixes/)
**Published:** August 12, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » Lyo-Ready Master Mixes
# Lyo-Ready Master Mixes
Lyo-ready master mixes are glycerol-free mixes that contain optimized excipients compatible with lyophilization. The mixes are easy to use and ideal for developing ambient temperature, multiplex molecular assays. Advantages to ambient-temperature assays include room temperature shipping and storage, extended shelf-life and increased flexibility in sample volume.
[ Contact a Specialist ](#requestasample)
## Optimized Lyo-Ready Master Mixes for Superior Diagnostic Assays
Meridian’s lyo-ready master mixes are the market-leading solution for molecular diagnostic assays requiring fast cycling, superior sensitivity, high inhibitor tolerance and ambient temperature stability.
- High efficiency and sensitivity in multiplex reactions, just add primers, probes and sample.
- Available in universal or specimen-specific formulations for blood, saliva, urine or stool and suitable for direct detection assays using crude samples.
- Can be used in liquid format or it can be lyophilized, for developing an ambient-temperate stable assay.
Meridian master mixes combining the lasts advances in buffer chemistry and PCR enhancers, together with an optimized concentration of enzymes, dNTPs and MgCl2. and lyophilization compatible excipients. They come as standard as well as specimen-specific qPCR and RT-qPCR master mixes, developed for highly reproducible, accurate RNA and DNA target amplification, delivering excellent results in multiplex assays, with sensitivity down to a single copy.
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Blood Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Blood Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-blood-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Blood](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-blood/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Saliva Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Stool Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Stool Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-stool-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Stool](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-stool/)
- [Lyo-Ready™ Direct DNA and RNA/DNA qPCR Urine Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-urine-master-mixes/)
- [Lyo-Ready™ Direct DNA and RNA/DNA LAMP Urine Master Mixes](/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-urine-master-mixes/)
- [Lyo-Ready™ Genotyping Direct qPCR Urine](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-urine/)
- [Lyo-Ready™ Genotyping Direct qPCR FFPE](/lifescience/products/molecular/lyo-ready-genotyping-direct-qpcr-ffpe/)
- [Lyo-Ready™ qPCR Mix](/lifescience/products/molecular/lyo-ready-qpcr-mix/)
- [Lyo-Ready™ qPCR Mix, 2.6x](/lifescience/products/molecular/lyo-ready-qpcr-mix-2-6x/)
- [Lyo-Ready™ 1-Step RT-qPCR Mix](/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
- [Lyo-Ready™ 1-Step RT-qPCR Virus Master Mix](/lifescience/products/molecular/lyo-ready-master-mixes/)
- [Lyo-Ready™ LAMP/RT-LAMP Mixes](/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## Catalogs & Brochures
[Lyo-Ready Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/222789736/)**Lyo-Ready Direct Blood Master Mixes**
[Lyo-Ready Direct LAMP Blood](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct LAMP Blood**
[Lyo-Ready Genotyping Direct qPCR Blood](https://collateral.meridianlifescience.com/view/330386481/)**Lyo-Ready Genotyping Direct qPCR Blood**
[Lyo-Ready Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct Saliva Master Mixes**
[Lyo-Ready Direct LAMP Saliva](https://collateral.meridianlifescience.com/view/180412872/)**Lyo-Ready Direct LAMP Saliva**
[Lyo-Ready Direct Stool Master Mixes](https://collateral.meridianlifescience.com/view/322486879/)**Lyo-Ready Direct Stool Master Mixes**
[Lyo-Ready Direct LAMP Stool](https://collateral.meridianlifescience.com/view/111612146/)**Lyo-Ready Direct LAMP Stool**
[Lyo-Ready Direct Urine](https://collateral.meridianlifescience.com/view/727810954/)**Lyo-Ready Direct Urine**
[Lyo-Ready Direct LAMP Urine](https://collateral.meridianlifescience.com/view/940080326/)**Lyo-Ready Direct LAMP Urine**
[Lyo-Ready Genotyping Direct qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/)**Lyo-Ready Genotyping Direct qPCR Urine**
[Lyo-Ready Genotyping Direct qPCR FFPE](https://collateral.meridianlifescience.com/view/487986445/)**Lyo-Ready Genotyping Direct qPCR FFPE**
[Specimen-specific and Universal qPCR & LAMP Master Mixes](https://collateral.meridianlifescience.com/view/205757818/)**Specimen-specific and Universal qPCR & LAMP Master Mixes**
## Related Products
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable™ Direct DNA LAMP Blood Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-lamp-blood-master-mix/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Urine](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-urine/)
[Air-Dryable Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-master-mixes/)
## FAQs
What is lyophilization?
Lyophilization (freeze-drying), is a process of removing the water content from a substance by sublimation after it has been frozen, while preserving its structure and properties. The reagents can be lyophilized to a bead or a cake format.
Lyophilization helps to extend the product’s shelf life, enhance the stability of the reagents at higher temperatures, and allows for convenient and accurate dispensing of the reagents. After lyophilization, the reagents are easily reconstituted with sample material.
What is the performance difference for DNA when using the DNA-specific product versus the DNA/RNA product?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-qPCR master mixes – Lyo-Ready™ Direct RNA/DNA qPCR master mixes, as it can be used for both.
Can the standard Lyo-Ready qPCR and RT-qPCR master mixes be used with crude samples?
The Lyo-Ready™ qPCR and RT-qPCR master mixes have some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we have the Lyo-Ready sample specific (blood, saliva, urine and stool) mixes.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
After drying for how long will the master mix stay stable to use?
Following lyophilization in the presence or absence of primers and probes, the mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
Do you supply lyo-excipients separately?
No, our lyo-excipients are proprietary, if you require a buffer that does not contain lyo-excipients, we have the Lyo-Ready™ qPCR Buffer w/o Excipients, 4x (MDX061), but you will need to supply your own excipients.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [dU Containing](https://www.meridianbioscience.com/lifescience/products/molecular/du-containing/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
# dU Containing
qPCR is an extremely sensitive technique; however, this comes with a down-side, any DNA fragments from the environment, such as from previous qPCR experiments, if they enter the qPCR reaction or reagents, even in small quantities, they can be amplified during the reaction. This contamination can cause false positive results. To prevent contamination, uracil instead of thymine is added in the deoxynucleotide (dNTP) mix, Uracil DNA Glycosylase (UDGase) can then be used to remove carryover amplification contamination, by cleaving DNA containing uracil. Once thermocycling is initiated, the high temperatures inactivate the UDGase, preventing the enzyme from affecting the newly generated amplification products, even if they contain uracil.
[ Contact a Specialist ](#contact-a-specialist)
[ View Products ](#rel-products)
## Ideal for High-Throughput Assays
- Optimized dTTP to dUTP ratio for high sensitivity and specificity.
- High efficiency, giving excellent performance in multiplex qPCR assays.
- Prevents carry-over qPCR contamination.
A combination of the latest advances in buffer chemistry and PCR enhancers and stabilizers, in conjunction with an antibody-mediated hot start polymerase and dNTP/dUTP mix. designed for highly reproducible, accurate target amplification. Assay specific primers and probes are added, and UDGase is used to remove background PCR product contamination, ideal for high-throughput assays where there is a greater risk of false positives from cross-over contamination.
- [Hi-throughput dUTP qPCR Mix Master Mix](/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
- [Hi-throughput dUTP qPCR Lo-ROX](/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
- [Lyo-Ready dUTP 1-Step RT-qPCR Master Mix](/lifescience/products/molecular/lyo-ready-dutp-1-step-rt-qpcr-mix/)
- [Low LOD 1-Step RT-qPCR Master Mix](/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
## Catalogs & Brochures
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/) **Low LOD 1-Step RT-qPCR Mix**
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics**
## Related Products
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Uracil DNA Glycosylase](https://www.meridianbioscience.com/lifescience/products/molecular/uracil-dna-glycosylase/)
## FAQs
What is carryover qPCR contamination?
As qPCR can amplify tiny amounts of DNA, preventing contamination is essential, as even small amounts of qPCR contamination can produce false positives. Cross-over qPCR contamination can include cross-contamination from other samples, contamination from elsewhere in the laboratory, and carryover qPCR contamination from amplification products and primers used in prior qPCR experiments. The latter causes most of the false positive results seen in qPCR. Preventing contamination can be difficult and so laboratory procedures must be in place to ensure DNA from one assay is not re-amplified in subsequent assay.
How is Uracil DNA Glycosylase used in qPCR?
Uracil DNA Glycosylase (UDGase) can specifically degrade products that have already been through the qPCR process and have incorporated dUTP, leaving native nucleic acid templates intended for amplification intact. UDGase activation occurs as the first step of qPCR at a 50°C incubation for 2 minutes and then the UDGase is denatured when the temperature increases to 95°C during hot-start activation.
What is the difference between UDG and UNG?
Uracil-DNA glycosylase (UDG or UDGase) is a family of enzymes comprising six sub-families. Family I UDGase enzymes are called UNG (uracil-N-glycosylase gene), so there is no difference, the terms UDG, UDGase and UNG are commonly used interchangeably because they perform the same function in qPCR—namely to prevent carryover qPCR contamination.
Why is dUTP not used for all qPCR assays?
Total elimination of contaminants is not always accomplished using this technique, particularly where PCR product length is short, which is a common situation in qPCR assays. In addition, there is the possibility, particularly when the initial sample contains only one or a few target molecules, that inclusion of UDGase may reduce amplification efficiency and thereby delay detection and so reduce sensitivity.
Do the master mixes already contain UDGase?
No, the qPCR master mixes contain dUTP, but UDGase needs to be added prior to running the qPCR reaction.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [RT-PCR/RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/rt-pcr-rt-qpcr-master-mixes/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
[Home](/ "Home") » [Life Science](/lifescience/ "Life Science") » [Products](/lifescience/products/ "Products") » [Molecular Reagents](/lifescience/products/molecular-reagents/ "Molecular Reagents") » RT-PCR/RT-qPCR Master Mixes
# RT-PCR/RT-qPCR Master Mixes
Meridian offers a selection of high-quality glycerol-free enzymes to help you develop highly sensitive assays. Removing the glycerol allows give assay developers the option for compatibility with lyophilization or air-drying, to dry down for stable ambient temperature shipment and storage. We also have high concentration enzymes that save on volume to allow more sample material to be added and gives greater flexibility in assay development strategies and allowing increase sensitivity, specificity, speed, stability, and enable a simplified workflow.
[ Contact a Specialist ](#requestasample)
[ View Products ](#products)
## RT-PCR/RT-qPCR
[Fast 1-Step RT-qPCR Mix ](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
[Inhibitor-Tolerant qPCR/RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable™ qPCR and RT-qPCR Mixes Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
[Lyo-Ready 1-Step RT-qPCR Virus Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)[Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)[Lyo-Ready Direct DNA and RNA/DNA qPCR Saliva Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-saliva/)[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)[Lyo-Ready qPCR and RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
Not seeing what you’re looking for? [Inquire about a new product](#requestasample)
## Robust qPCR, Real Time, and RT-qPCR Master Mixes for Fast Assays
- Developed to give robust, reproducible amplification under fast conditions.
- Novel buffer systems give reliable amplification in the presence of inhibitors.
- Engineered to increase affinity for DNA and RNA, so resulting in significant improvements in yield, sensitivity and speed.
A combination of the latest advances in buffer chemistry and PCR enhancers, in conjunction with an antibody, chemical-mediated or aptamer DNA polymerase promote rapid, consistently accurate detection of the intended targets, even with multiplex PCR and qPCR assays. Lyophilization and air-dryable ready options allow room temperature shipping and storage, extended shelf-life, and increased flexibility in sample volume and so sensitivity.
## Catalogs & Brochures
[Low LOD 1-Step RT-qPCR Master Mix](https://collateral.meridianlifescience.com/view/33946627/) **Low LOD 1-Step RT-qPCR Master Mix**
[Lyo-Ready 1-Step RT-qPCR Master Mixes](https://collateral.meridianlifescience.com/view/33956084/) **Lyo-Ready 1-Step RT-qPCR Master Mixes**
[Air-Dryable Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/33571180/) **Air-Dryable Direct Blood Master Mixes**
[Lyo-Ready Direct Blood Master Mixes](https://collateral.meridianlifescience.com/view/222789736/) **Lyo-Ready Direct Blood Master Mixes**
[Lyo-Ready Genotyping Direct qPCR Blood](https://collateral.meridianlifescience.com/view/330386481/) **Lyo-Ready Genotyping Direct qPCR Blood**
[Air-Dryable Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/856384693/) **Air-Dryable Direct Saliva Master Mixes**
[Lyo-Ready Direct Saliva Master Mixes](https://collateral.meridianlifescience.com/view/931223153/) **Lyo-Ready Direct Saliva Master Mixes**
[Air-Dryable Direct Stool Master Mixes](https://collateral.meridianlifescience.com/view/140230454/) **Air-Dryable Direct Stool Master Mixes**
[Lyo-Ready Direct Stool Master Mixes](https://collateral.meridianlifescience.com/view/322486879/) **Lyo-Ready Direct Stool Master Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Stool](https://collateral.meridianlifescience.com/view/967751022/) **Lyo-Ready Genotyping Direct DNA qPCR Stool**
[Air-Dryable Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/1027741197/) **Air-Dryable Direct Urine Master Mixes**
[Lyo-Ready Direct Urine Master Mixes](https://collateral.meridianlifescience.com/view/727810954/) **Lyo-Ready Direct Urine Master Mixes**
[Lyo-Ready Direct LAMP Urine Mixes](https://collateral.meridianlifescience.com/view/940080326/) **Lyo-Ready Direct LAMP Urine Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/) **Lyo-Ready Genotyping Direct DNA qPCR Urine**
[Lyo-Ready Genotyping Direct qPCR FFPE](https://collateral.meridianlifescience.com/view/487986445/) **Lyo-Ready Genotyping Direct qPCR FFPE**
## Related Products
[RT-qPCR Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/rt-qpcr-extraction-control-red/)
[RT-qPCR Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/rt-qpcr-extraction-control-orange/)
[VLP-RNA Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-red/)
[VLP-RNA Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-orange/)
[55C MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/55c-mmlv-rt/)
## FAQs
What are the advantages of using a one-step or a two-step?
One-step reaction 1/ Accurate representation of target copy number 2/ Simple and rapid 3/ Fewer pipetting steps (reducing possible errors and contamination) 4/ Best option for high-throughput screening 5/ Best method when only a few assays are run repeatedly 6/ Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample. Two-step reaction 1/ Two buffers optimized for independent RT and qPCR 2/ Highly sensitive 3/ Potentially more efficient because random primers and oligo d(T) can be used 4/ Possibility to stock cDNA to quantify several targets 5/ Recommended when the reaction is performed with a limiting amount of starting material.
So, one-step workflows are commonly favoured in molecular diagnostic tests. Two-step RT-qPCR is preferred when multiple interrogations will be made of the same starting material or where archiving of cDNA may be required.
What are the advantages and considerations of a chemical hot-start DNA polymerase?
With a chemical hot-start DNA polymerase, the polymerase is covalently linked with chemical groups to block enzyme activity at room temperature. Advantages 1/ More stringent than antibody hot-start methods, so there is no activity even for long periods at room temperature, minimizes non-specific amplification 2/ Low bioburden, as it is free of animal and bacterial-origin components Considerations 3/ Longer activation time required for the polymerase to become fully active.
What are the advantages of an aptamer-mediated hot-start polymerase?
Aptamers are engineered oligonucleotides that bind to the active site of the high-fidelity DNA polymerase but are denatured and released as the temperature is increased during the PCR amplification cycle. This aptamer-mediated inhibition/activation process is however fully reversible, and so at the end of thermal cycling, when the temperature of the reaction is decreased, the aptamer refolds and rebinds to high-fidelity DNA polymerase, inhibiting any further activity in the sample. This has proven to be important in workflows where undesired polymerase activity after reaction completion can disturb baseline readings, such as NGS following amplification of a library.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex RT-qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
How long are the lyophilized/air-dried mixes stable for at ambient temperature?
Following drying in the presence or absence of primers and probes, they are stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
**Published:** May 1, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ qPCR and RT-qPCR Mixes Master Mixes
Meridians Air-Dryable™ mixes are glycerol-free mixes, ideal for developing ambient temperature, air-dried, multiplex qPCR and RT-qPCR molecular diagnostic tests and are suited for high-throughput, automated platforms or microfluidic qPCR platforms. **Can also be used wet**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Air-Dryable qPCR and RT-qPCR Master Mixes
- Create ultra-sensitive multiplex qPCR tests for low-copy number targets.
- Glycerol-free mixes are pre-formulated with a specialized blend of excipients, compatible with air-drying.
- High-tolerance to PCR inhibitors carried over during purification, improving reproducibility.
- Can be used wet or it can be dried, for developing an ambient-temperate stable assay.
## Full enzyme activity following air-drying
Activity of Air-Dryable™ 1-Step RT-qPCR Mix in both wet (red) and air-dried (blue) formats were compared on 10-fold dilution mouse RNA template. The air-dried mix showed no loss of activity and sensitivity when compared to freshly prepared wet mix up to the assay limit of detection.
### Air-Dryable qPCR Mix, 4x, MDX082
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Glycerol-free qPCR mix containing Taq polymerase, reaction buffer, dNTPs, MgCl2 and air-dry compatible excipients, ideal for developing ambient temperature, multiplex molecular assays.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX082-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX082-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX082.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX082-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX082)
### Air-Dryable 1-Step RT-qPCR Mix, 4x, MDX095
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Glycerol-free RT-qPCR mix containing Taq polymerase, reverse transcriptase, reaction buffer, dNTPs, MgCl2 and air-dry compatible excipients, ideal for developing ambient temperature, multiplex molecular assays.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX095-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX095-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX095.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX095-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX095)
## Description
Molecular diagnostic tests are progressively moving towards dried formats. There are several advantages for this, including ambient temperature shipping and storage, extended shelf-life, reduced operating steps and potential errors and increased flexibility in sample volume. In order to be compatible with air or oven drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to higher temperatures.
Air-Dryable™ qPCR Mix (4x) is used for the development of multiplex molecular diagnostic tests, enabling highly sensitive detection of target DNA, whereas the Air-Dryable ™ 1-Step RT-qPCR Mix (4x) can be used for the development of multiplex molecular diagnostic tests both RNA and DNA targets. The air drying does not affect the specificity or reproducibility of the assay but increases the flexibility of the volume of sample that can be added, increasing sensitivity and also makes them ideal for microfluidic qPCR and point of care platforms.
## Specifications
DescriptionGlycerol-free qPCR and RT-qPCR mix containing Taq polymerase, reverse transcriptase, reaction buffer, dNTPs, MgCl2 and air-dry compatible excipients, ideal for developing ambient temperature, multiplex molecular assays.Concentration4xAppearanceClear, colorless solutionHot StartAntibody mediatedApplicationProbe-based, real-time PCR, two-step RT-qPCR, one-step RT-qPCRSample typecDNA, crude or purified RNA and/or DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelAssay stabilityUp to 24 months at ambient temperature following air-dryingConsistency± 0.5 Ct variance between test and reference sampleDNase/RNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable™ qPCR/RT-qPCR Mixes Catalog**
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood**
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct Saliva**
[Meridian Air Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable Direct Stool**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable Direct DNA qPCR Plant, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-plant-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: Air-Dryable qPCR and RT-qPCR Master Mixes
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
What are the advantages of using a one-step or a two-step?
One-step reaction
• Accurate representation of target copy number
• Simple and rapid
• Fewer pipetting steps (reducing possible errors and contamination)
• Best option for high-throughput screening
• Best method when only a few assays are run repeatedly
• Multiplex qPCR of gene of interest and control can be done in single well, from same RNA sample
Two-step reaction
• Two buffers optimized for independent RT and qPCR
• Highly sensitive
• Potentially more efficient because random primers and oligo d(T) can be used
• Possibility to stock cDNA to quantify several targets
• Recommended when the reaction is performed with a limiting amount of starting material
So one-step workflows are commonly favoured in molecular diagnostic tests. Two-step RT-qPCR is preferred when multiple interrogations will be made of the same starting material or where archiving of cDNA may be required.
Are reaction conditions the same for air-dried and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to dry down and then later if drying is required (for example to increase sensitivity), the SOP can be updated for oven drying, it does not require completely new SOPs to be written.
What probes can be used in quantitative PCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most commonly used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Air-Dryable™ qPCR and RT-qPCR master mixes be used with crude samples?
The Air-Dryable™ qPCR and RT-qPCR master mixes have some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we have the universal Inhibitor-Tolerant qPCR/RT-qPCR mixes and for even greater sensitivity, we have the air-dryable sample specific (blood, saliva, urine, stool, and plant) mixes.
Should I include a No-RT control reaction with my RT-qPCR?
No-RT control reactions are useful for determining issues that may arise from the amplification of genomic DNA that may be present in a sample. However, many RNA transcripts are present at low abundance and for these transcripts, it is recommended to perform a No-RT control reaction if primer sets do not span exon-exon junctions. If the primers do span exon-exon junctions, or genomic DNA is not likely to interfere (when looking at RNA viruses in a sample for example) a No-RT control is not required.
How long are the air-dried mixes stable for at ambient temperature?
Following air drying in the presence or absence of primers and probes, the Air-Dryable™ qPCR and RT-qPCR master mixes are stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
[ For Additional Support Please Contact Technical Support ](/contact-us-life-science/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [VLP-RNA Extraction Control Orange](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-orange/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# VLP-RNA Extraction Control Orange
Molecular IVD companies continue to experience tighter and tighter regulations in regard to incorporating appropriate positive and negative controls into their assays. Meridian’s VLP-RNA Extraction Controls offer a simple and effective way to reduce false-negative results in RT-qPCR assays. The biomimetic controls are composed of virus-like particle (VLP) shells packaged with a defined number of copies of target RNA molecules. Their composition closely resembles a test sample and serves as a full-process quantitative PCR positive control, monitoring the success of an RT-qPCR assay from lysis/extraction to reverse transcription and amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's VLP-RNA Extraction Control Orange
- Contains a defined number of copies of target RNA molecules, encapsidated within a virus-like particle (VLP).
- Closely mimics the test sample, undergoing the same processing from lysis and extraction to RT-qPCR detection.
- Non-infectious material for ease of handling and shipping.
- Compatible with commonly used RNA extraction methods and lyophilization for creating freeze-dried mixes.
## Why use VLP-RNA Extraction Controls in an RT-qPCR assay?
Possible causes of negative detection in an RT-qPCR
Spike-In internal controls are RNA molecules added between the nucleic acid isolation and the detection, they do not monitor the extraction and lysis steps. Mimics internal controls are RNA molecules provided in a format resembling a biological sample (i.e. micelles) and are added just before lysis, but do not allow long incubation with the sample. VLP-RNA Extraction Control have better nuclease resistance, for long incubation with the sample, better quantification for consistent input in MDx processes and are easier to ship and store, ensuring that the MDx process provides reliable results by questioning each step of the process from lysis, through extraction to detection.
### VLP-RNA Extraction Control Orange, MDX069
**Application:** RT-qPCR**Specimen Type:** RNA**Concentration:** 10^4 copies/µL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
An Internal Control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle and a VLP Detection Mix containing primers and probe to the internal control RNA sequence.
Available in 1 mL (~1×10^4 copies/µL) and 20 mL (~1×10^4 copies/µL) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX069-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX069-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX069.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX069)
## Description
VLP-RNA Extraction Control Orange contains an internal control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle. The VLP-RNA Extraction Control is spiked in the sample prior to RNA extraction. Following RNA extraction, VLP-RNA Extraction Control can be detected in RT-qPCR by adding the VLP Detection Mix (containing specific primers and probe (emission wavelength = 560nm)) to the reaction mix. The detection of VLP-RNA Extraction Control acts as a PCR positive control and confirms the success of the extraction, reverse transcription, and amplification steps, avoiding the misinterpretation of a false negative result.
## Specifications
DescriptionAn Internal Control RNA sequence, with no known homology to any organism, encapsidated in a virus-like particle and a VLP Detection Mix containing primers and probe to the internal control RNA sequence, used to confirms the success of the extraction, reverse transcription, and amplification stepsConcentration104 copies/µLDetection MixPrimers and HEX labeled probe (absorption λmax = 535 nm and emission λmax = 555 nm)Applicationone-step RT-qPCRSample typeTissue, cellsPresentation2 vialsStorage-20 °CMix stabilitySee outer labelFunctionality testVLP Detection Mix tested in an RT-qPCR of a serial dilution of Internal Control RNA.
## Catalogs & Brochures
[VLP-RNA Extraction Control](https://collateral.meridianlifescience.com/view/33936393/)**VLP-RNA Extraction Control Catalog**
[VLP RNA Extraction Control Custom Project](https://collateral.meridianlifescience.com/view/564722040/)**VLP RNA Extraction Control Custom Project**
## Related Products
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Fast 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/fast-1-step-rt-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[VLP-RNA Extraction Control Red](https://www.meridianbioscience.com/lifescience/products/molecular/vlp-rna-extraction-control-red/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
## FAQs: VLP-RNA Extraction Control
What is internal RNA control in RNA extraction?
When performing RNA extraction, it is often advantageous to have an exogenous source of RNA template that is spiked into the sample prior to lysis. This control RNA is then co-purified with the sample RNA and can be detected as a PCR positive control for the whole extraction process.
Do I have to have an internal PCR control?
Although it is not mandatory yet, regulators across the world are tightening up recommendations for the addition of internal controls, EU: IVDD to IVDR 2017/746 “Control materials with quantitative or qualitative assigned values intended for one specific analyte or multiple analytes shall be classified in the same class as the device.” MDSAP with FDA (“general controls ensuring effectiveness of the device”), TGA (“provisions for the user, at time of use, of device performance”), MHLW and ANVISA
Can the VLP interfere with screening for other RNA viruses?
The VLP-RNA Extraction Controls are in plant based VLPs, so there is no animal/human viruses used within the process, so there is no possibility of the VLP-RNA Extraction Control giving false positive results.
How careful do I need to be with the VLP-RNA Extraction Control?
The VLP-RNA Extraction Controls are extremely robust and stable quantitative PCR positive control, we have tested then for 20 cycles of freeze thawing, storage at ambient temperature for one month, heating to 50 ᵒC for 10 minutes, lyophilization and nuclease treatment without seeing any change in Ct values.
Can the VLP interfere with RNA extraction from other viruses?
The VLP-RNA Extraction Controls are in plant based VLPs, so there is no animal/human viruses used within the process, so there is no possibility of the VLP-RNA Extraction Control giving false positive results.
Do I need to supply the primers and probe for the VLP-RNA Extraction Control?
The primers and probe for the VLP-RNA Extraction Control are in the VLP Detection Mix for VLP-RNA Extraction Control Red, MDX068 and VLP-RNA Extraction Control Orange, MDX069. However we do not supply the primers and probe for the custom VLP-RNA Extraction Control, MDX071.
#####
Why are there two colors for the VLP-RNA Extraction Controls?
The two colors are for the fluorescent dyes on the VLP-RNA Extraction Control probe. VLP Detection Mix Red (Cy5 – emission wavelength = 670nm) and VLP Detection Mix Orange (HEX – emission wavelength = 555nm). This allows you to chose one that will fit with your existing protocol in a multiplex RT-qPCR assay.
Do I need a specific extraction method for the VLP-RNA Extraction Control?
No, the VLP-RNA Extraction Control will work with commercially available silica-membrane extraction kits and CHELEX matrices and has been tested on a wide range of qPCR platforms.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA-RNA Extraction Controls
---
### [NASBA](https://www.meridianbioscience.com/lifescience/products/molecular/nasba/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
# NASBA
Nucleic acid sequence-based amplification (NASBA) is a method of isothermal amplification which is used to produce multiple copies of RNA/DNA. NASBA is a two-step process that takes RNA and anneals specially designed primers, then utilizes an enzyme cocktail to amplify it at a constant reaction temperature of 41 °C.
[ Contact a Specialist ](#requestasample)
## Fast Time to Results, Ideal for Point of Care Testing
- Glycerol-free options, to eliminate the need for cold-chain shipping and storage.
- High-concentrated, to maximize sample input and increase sensitivity.
- Fast reaction kinetics for quicker time to results.
An enzyme cocktail containing, Avian Myeloblastosis Reverse Transcriptase (AMV-RT), RNase H, and RNA polymerase is used to synthesizes a complementary DNA strand (cDNA) from the RNA template, using a buffer and primers, RNase H then degrades the RNA template and additional primers binds to the cDNA to form double stranded DNA. The RNA polymerase is then uses to synthesize copies of RNA and the process is repeated. The isothermal conditions makes NASBA ideal for point of care testing (POCT) as an alternative to PCR, as it can be quicker and more sensitive in some circumstances. - [Glycerol-Free T7 RNA Polymerase (HC)](/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
- [Glycerol-Free RNase H (HC)](/lifescience/products/molecular/glycerol-free-rnase-h-hc/)
- [Glycerol-Free SP6 RNA Polymerase (HC)](/lifescience/products/molecular/glycerol-free-sp6-rna-polymerase-hc/)
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics**
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080/) **Glycerol-Free T7 RNA Polymerase**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs
What is the difference between SP6 and T7 RNA Polymerase?
SP6 RNA Polymerase is encoded by bacteriophage SP6, this is remarkably similar in structure and activity to T7 RNA polymerase, which is encoded by bacteriophage T7, both can be used to synthesize RNA sequences from short DNA templates which contain the 18 base pair promoter region, however the promoter sequences are highly specific.
The SP6 RNA polymerase start site can be advantageous in large-scale syntheses where high concentrations of RNA can lead to aggregation, however it does require a complete duplex DNA substrate for efficient synthesis, unlike the T7 RNA polymerase which works efficiently when only the 18 base promoter region is double stranded.
SP6 RNA polymerase consistently produces higher yields of RNA than does T7 RNA polymerase, and the reactions can be easily scaled up to produce milligram quantities of RNA and so it is the preferred enzyme for mRNA vaccine production.
What is the promoter sequence of SP6 RNA Polymerase?
*SP6 Promoter* 5′ ATTTAGGT/GGACACTATAG 3′
*SP6* RNA polymerase is very selective and efficient, resulting both in a high frequency of transcription initiation and effective elongation. *SP6* RNA polymerase starts transcription at the underlined G in the promoter sequence. The polymerase then transcribes using the opposite strand as a template from 5’->3’. The first base in the transcript will be a G.
The DNA contacts made by *SP6* RNA polymerase have been mapped during binding and during the subsequent initiation of transcription. The RNA polymerase alone protects 19 bases in a region from -21 to -3. The reason for some literature suggesting additional bases after this G is because synthesis of the hexanucleotide mRNA (ATTTAGGTGACACTATA**GAAGA**), expands the length of the sequence protected by the RNA polymerase1.
1. Pavco P. A. and Steege D, A. Characterization of elongating T7 and SP6 RNA polymerases and their response to a roadblock generated by a site-specific DNA binding protein. *NAR* 19 (17): 4639–4646 (1991).
What is the promoter sequence of T7 RNA Polymerase?
T7 Promoter 5′ TAATACGACTCACTATAG 3′
T7 RNA polymerase is very selective and efficient, resulting both in a high frequency of transcription initiation and effective elongation. T7 RNA polymerase starts transcription at the underlined G in the promoter sequence. The polymerase then transcribes using the opposite strand as a template from 5’->3’. The first base in the transcript will be a G. The DNA contacts made by T7 RNA polymerase have been mapped during binding and during the subsequent initiation of transcription. The RNA polymerase alone protects 19 bases in a region from -21 to -3. The reason for some literature suggesting additional bases after this G is because synthesis of the hexanucleotide mRNA (TAATACGACTCACTATAGGGAGA), expands the length of the sequence protected by the RNA polymerase to 32 bases and stabilizes the complex1.
1. Ikeda R. A. and Richardson C. C. Interactions of the RNA polymerase of bacteriophage T7 with its promoter during binding and initiation of transcription PNAS USA 83 (11): 3614-8 (1986).
Do the SP6 RNA Polymerase and T7 RNA Polymerase require a primer?
No, the SP6 RNA Polymerase and T7 RNA Polymerase recognize their promoter sequences and then transcribes using the final G of the promoter as the first base to transcribe the opposite strand as a template from 5’->3’.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Bst Enzymes & Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/bst-enzymes-buffers/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
# Bst Enzymes & Buffers
Bst DNA Polymerase is an enzyme derived from the large fragment of Bacillus stearothermophilus DNA Polymerase I. It contains 5´- 3´ DNA polymerase activity and strong strand displacement activity but lacks 5´- 3´ exonuclease activity. The strong strand displacement activity enables Bst DNA Polymerase to synthesize DNA at a constant temperature making it an ideal enzyme for isothermal amplification, including HDA, MCA, and for Loop-Mediated Isothermal DNA Amplification (LAMP).
[ Contact a Specialist ](#requestasample)
## Faster Polymerization, and Enhanced Tolerance in Point of Care Testing
- Glycerol-free options, to eliminate the need for cold-chain shipping and storage.
- High-concentrated, to maximize sample input and increase sensitivity.
- Fast reaction kinetics for quicker time to results.
Bst DNA Polymerase enzyme is supplied at standard concentration (8 U/µL), or as a high-concentration, glycerol-free enzyme (100 U/µL) and is used with an Enzyme Dilution Buffer and a Bst Reaction Buffer, formulated to deliver the fastest amplification speed (time-to-results), yield, salt tolerance, and sensitivity, speeding up your product development time and allowing you to commercialize your new products faster. The high-concentration, glycerol-free enzyme is also lyophilization-compatible, making it ideal for the development of point of care test (POCT) assays that require ambient temperature shipping and storage.
- [Bst DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/bst-dna-polymerase/)
- [High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
- [Buffers](https://www.meridianbioscience.com/lifescience/products/molecular/buffers/)
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular Diagnostics**
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080/) **Glycerol-Free T7 RNA Polymerase**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
[Lyo-Ready Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-master-mixes/)
## FAQs
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
Is Meridian’s Bst DNA polymerase enzyme warm/hot start?
No Meridian’s Bst DNA polymerase does not come with warm or hot start; instead, the reaction buffer does not contain magnesium and so the enzyme is completely inactive until magnesium is added. If you are concerned about setting your reaction up at room temperature, we recommend adding the magnesium last, just before running the experiment and it will prevent non-specific amplification.
Can LAMP be used for a multiplex assay?
Yes, it is possible to design a multiplex LAMP test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Can Bst DNA Polymerase be used in place of other DNA polymerases for thermal cycling? No, the reaction temperatures are too high for enzyme stability.
Does Bst DNA polymerase have reverse transcriptase activity?
Yes, Bst DNA polymerase does have some reverse transcriptase activity, however for robust and consistent reactions we recommend the addition of a reverse transcriptase.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Reverse Transcriptase](https://www.meridianbioscience.com/lifescience/products/molecular/reverse-transcriptase/)
**Published:** August 13, 2025
**Author:** Moaaz Ahmad
**Content:**
# Reverse Transcriptase
We offer a selection of high-quality reverse transcriptase enzymes help you develop highly sensitive assays.
[ Contact a Specialist ](#requestasample)
## Ideal for High-Throughput
- Reverse transcription is the process of transcribing RNA molecules into complementary DNA (cDNA). Moloney Murine Leukemia Virus reverse transcriptase (MMLV-RT) is the most commonly used reverse transcriptase in molecular biology workflows. It is highly sensitive; however, novel engineering has enhanced efficiency, improved thermostability, and increase cDNA yields.
- Highly sensitive, even low concentrations of template RNA
- Thermostability of up to 60°C, from RNA with high secondary structure
- Sensitive detection of low copy number RNA targets
- High-concentration, glycerol-free options for lyophilization
There are several key important features when determining the best reverse transcriptase for your application. The first is RNase H activity, if the RNase H activity of the reverse transcriptase is too high, it can lead to excessive degradation of the RNA template, resulting in incomplete or inefficient cDNA synthesis. Reverse transcriptase with low RNase H activity minimize the nonspecific degradation of RNA molecules in the reaction, improving the specificity and fidelity of cDNA synthesis. The second is processivity, the number of nucleotides incorporated in a single binding event, most engineered reverse transcriptases have improved processivity, (up to 65x greater than wild-type MMLV reverse transcriptase). The third is thermostability, high temperatures help denature RNA that has strong secondary structures and/or high GC content enabling full-length cDNA synthesis and high yields. Normally MMLV-RT performs optimally at 37°C whereas engineered thermostable MMLV-RTs can withstand temperatures up to 55°C without negatively impacting reverse transcription efficiency. Meridian offers several reverse transcriptases, each containing unique product features such as high thermostability or lyophilization compatibility for creating room-temperature stable mixes.
- 55C MMLV-RT
- Lyo-Compatible MMLV-RT
- RNase-Tolerant MMLV-RT
- MMLV-RT
- Glycerol-Free HS Tth DNA Polymerase (HC)
## Catalogs & Brochures
- Reagent Solutions for Molecular Diagnostics
- 55C MMLV-RT
- Accelerating Efficiency: A Comprehensive Guide to Essential Reagents for High-Throughput Molecular Diagnostic Assays (MDx)
## FAQs
I want to generate cDNA from viral RNA with very high secondary structure, can I use MMLV-RT?
For RNA with very high secondary structure, we recommend using 55C MMLV-RT (MDX117), this reverse transcriptase can be used at temperatures up to 60°C which improves the cDNA yield from difficult RNA targets that require higher temperature to denature strong secondary structures.
Can I improve the yield when using MMLV-RT?
Avoiding ribonuclease contamination is of primary concern since high quality template RNA is required. You can add RNase Inhibitor (MDX056), alternatively we also have RNase-Tolerant MMLV-RT (MDX043) which includes an RNase inhibitor.
What buffer do you recommend using with MMLV-RT?
If you are going to make cDNA, you will require a buffer that contains 0.2 mM each dATP, dCTP, dGTP & dTTP, 10 mM DTT (dithiothreitol), 25 mM KCl, 3.5 mM MgCl2 and 50 mM Tris–HCl (7.5). However, if you want to do RT-qPCR, we recommend 1-Step qPCR Buffer, 4x (MDX034) or Lyo-Ready 1-Step RT-qPCR Buffer (MDX052).
How is MMLV-RT inactivated?
The reverse transcriptase can be inactivated by adding a chelating agent such as EDTA or heating to 70°C or higher for 10 min.
Does MMLV-RT need a primer?
Yes, to initiate reverse transcription, the MMVL-RT reverse transcriptase require a primer to bind to its complementary sequences on the RNA template and serve as a starting point for synthesis of a new strand. For general cDNA synthesis, random hexamer primers and oligo(dT) primers can be used either separately or mixed. For RT-PCR and RT-qPCR gene-specific primers should be used.
What is the error rate of MMLV-RT?
Unlike eukaryotic replicative polymerases, reverse transcriptase lack exonuclease activity and so is error prone. MMLV-based reverse transcriptase has been reported to have an error rate in the range of 1.1 × 10−4 to 4.8 × 10−4.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
### [Custom Antibody & Protein Manufacturing Services](https://www.meridianbioscience.com/lifescience/products/molecular/custom-antibody-protein-manufacturing-services/)
**Published:** September 3, 2025
**Author:** Moaaz Ahmad
**Content:**
## Custom Antibody & Protein Manufacturing Services
##### Conversion to Animal-Free and Large-Scale Manufacturing
[ Request Information ](#contactform)
### Meridian’s Approach to Custom Manufacturing Services
At Meridian, we specialize in custom antibody and protein manufacturing services, delivering high-performance reagents tailored to meet the diverse needs of our IVD customers. Our services include hybridoma conversion to animal-free formats, animal IgG conversion to a recombinant Animal-Origin-Free (AOF) alternative, and large-scale production of antibodies, antigens, and enzymes. Transitioning to animal-free manufacturing is a vital step toward more efficient, lower-risk, and better sustainable bioproduction methods.
## What is Animal-Origin-Free (AOF)?
Animal origins free (AOF) means that the product does not contain materials derived from eukaryotic animals. Animal cell lines adapted to animal-free, chemically defined media are included.
## Why Choose Meridian?
- Increased Flexibility : Customize your protein design without the constraints typically linked to animal-derived products.
- Boost Performance: Improve your assays' reliability, safety, and sustainability through animal-free formulations.
- Large-Scale Production: Capacity up to 2,000L ensures consistent quality (ISO 13485), efficiency, and seamless scalability every step of the way.
- Faster Time to Market: Leverage our expertise, cutting-edge technologies and proven processes to accelerate your development and production timeline, bringing your products to the market faster.
## Request Information About Meridian's Custom Antibody & Protein Manufacturing Services
[
Contact an Expert ](#contactform)
### Conversion to Animal-Free
Recombinant antibodies offer numerous advantages over traditional hybridoma antibodies and can be produced using non-animal-derived materials. Our services include the conversion of your hybridoma-derived antibodies, or animal-derived blocker (e.g., goat IgG), into a recombinant, animal-free format. We provide a comprehensive solution encompassing sequencing, cloning, verification, expression, purification, and production, ensuring a seamless transition to a more ethical, stable, and efficient antibody source.
#### Advantages to Recombinant, Animal-Free Formats
- Supply chain security
- Improved quality control in production
- Reduced lot-to-lot variability
- Meets growing ethical and regulatory standards
#### Large-Scale Manufacturing from Sequence or Clone (ISO 13485)
Discover Meridian’s tailored protein manufacturing solutions, which offer customizable packages to suit your project’s unique needs. We provide large-scale production of recombinant antigens, antibodies, and enzymes in quantities up to gram-scale for commercial applications.
Scaling up production involves utilizing adaptable methodologies to enhance expression capacity and meet increasing demands. Our commitment to quality is underscored by stringent quality control measures and compliance with industry standards, ensuring that every product meets the highest specifications for reliability and performance.
## Our Cell Culture and Fermentation Equipment
Our facility is equipped with state-of-the-art cell culture and fermentation equipment, including single-use bioreactors and traditional stirred tank reactors with capacities up to 2,000L. Complimentary downstream processing equipment for protein purification and fill-and-finish operations is also available.
#### Protein Manufacturing Services (Up to 2,000L) Versatile Expression Systems: E. coli, Yeast, Insect, CHO, HEK
#### Cell Culture
Fermenter
Single-use Bioreactor
Glass Bioreactor
Biostat® C-PLUS
Biostat® RM
CELBIC 25
Multi-shaker
CO2 incubator
#### Purification
ÄKTA Prime
ÄKTA Pilot
ÄKTA Avant
Sartoflow® Advanced
ÄKTA Flux
Chromatography Columns & Resins
#### QC & Fill and Finish
SDS-PAGE
CE-PAGE
HPLC (SEC, RP)
IEF
Western Blot
Bioburden
Concentration
Others – Functional or binding assays
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
---
### [Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing](https://www.meridianbioscience.com/lifescience/products/molecular/shaping-the-future-of-precision-oncology-a-comparative-analysis-of-qpcr-targeted-ngs-and-whole-genome-sequencing-2/)
**Published:** September 17, 2025
**Author:** Moaaz Ahmad
---
### [Hi-throughput dUTP qPCR Lo-ROX](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-lo-rox/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Hi-throughput dUTP qPCR Lo-ROX
Hi-throughput dUTP qPCR Lo-ROX is fast, highly reproducible real-time PCR master mix containing a passive reference dye that has been designed with a highly optimized buffer chemistry and hot-start DNA polymerase, to deliver excellent results and very low background, allowing greater sensitivity.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Hi-throughput dUTP qPCR Lo-ROX, MDX060
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 2x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** No**Dryable:** No**Sustainability:**
Contains Taq polymerase, reaction buffer, dNTP, MgCl2, stabilizers, PCR enhancers, and ROX dye. The dTTP has been substituted for dUTP, so that UDGase can be added to remove background PCR carryover product contamination.
Available in 10 mL (1,000 Rxns) or 100 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX060-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX060-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX060.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX060)
## Description
Hi-throughput dUTP qPCR Lo-ROX master mix contains Taq polymerase, reaction buffer, dNTP, MgCl2, stabilizers, PCR enhancers, and ROX dye. However, the dTTP has been substituted for dUTP, so that Uracil DNA Glycosylase (UDGase) can be added to remove background PCR carryover product contamination. The Hi-throughput dUTP qPCR Lo-ROX is compatible with qPCR instruments having the capacity to analyze the qPCR data with the passive reference signal either on or off, as well as instruments that do not require the use of ROX, making it ideal for multiplex assays where there is a greater risk of false positives from cross-over contamination.
## Catalogs & Brochures
[ Reagent Solutions for Molecular Diagnostics ](https://collateral.meridianlifescience.com/view/864813412/)
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
[Hi-throughput dUTP qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/hi-throughput-dutp-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** qPCR and RT-qPCR Master Mixes
---
### [Lyo-Ready qPCR Buffer w/o Excipients, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-w-o-excipients-4x/)
**Published:** April 30, 2025
**Author:** hamza
**Content:**
# Lyo-Ready qPCR Buffer w/o Excipients, 4x
Molecular diagnostic tests are progressively moving towards lyophilized. There are several advantages for this, including room temperature shipping and storage, extended shelf-life, and increased flexibility in the sample volume. In order to be compatible with drying, however, enzyme preparations must be glycerol-free and include specialized excipients that preserve the mixture as it is exposed to freeze-dry, vacuum and dehydration.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready qPCR Buffer w/o Excipients, 4x
- Used to create ultra-sensitive qPCR assays
- Minimizes non-specific amplification for improved assay sensitivity and reliability
- High efficiency, giving excellent performance in multiplex qPCR assays
## Powerful multiplexing capacity
Three viral sequences, Cytomegalovirus (CMV) Adenovirus, Epstein-Barr Virus (EBV) and a DNA Extraction Control were amplified with equal efficiency from synthetic DNA templates with -Ready™ qPCR Mix in a quadruplex qPCR probe assay. The result illustrates that all three viruses were amplified with high efficiency and sensitivity, demonstrating the ability of Lyo-Ready qPCR Mix to detect low-copy number DNA targets simultaneously from a single sample.
### Lyo-Ready qPCR Buffer w/o Excipients, 4x, MDX061
**Application:** qPCR**Specimen Type:** DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Air-Dryable,Lyo-Ready**Sustainability:** Glycerol-Free
Glycerol-free qPCR reaction buffer that is designed to allow formulation optimization to freeze-drying methods by excipients selection.
Available in 2.5 mL (500 Rxns) or 100 mL (20,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX061-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX061-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX061.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX061-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX061)
## Description
Lyo-Ready qPCR Buffer w/o Excipients is a glycerol-free qPCR reaction buffer that allows formulation optimization to freeze-drying methods by excipients selection. In order to produce room temperature lyophilized qPCR reagents, lyo-excipients, a lyo-compatible Taq DNA polymerase (such as MDX011 or MDX015), assay-specific primers, and probes are added to Lyo-Ready Buffer for subsequent freeze-dry.
## Specifications
DescriptionA glycerol-free qPCR reaction buffer that is designed to allow formulation optimization to freeze-drying methods by excipients selection. In order to produce room temperature lyophilized qPCR reagents, lyo-excpients, a lyo-compatible Taq DNA polymerase, assay specific primers and probes are added for subsequent lyophilization.Concentration4xAppearanceClear, colorless solutionApplicationFast qPCRSample typecDNA, DNAPresentation1 vialStorage-20 °CMix stabilitySee outer labelConsistency± 0.5 Ct variance between test and reference sampleDNA ContaminationNone detected in PCR amplification with traces overlay with the negative control on *E. coli* and mouse genomic DNA specific targets.DNase ContaminationNo detectable degradation
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular Diagnostics**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable Assays**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Lyo-Ready qPCR Buffer, 2.5x](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-buffer-2-5x/)
[Lyo-Compatible MMLV-RT](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-compatible-mmlv-rt/)
[dNTP Mix, 100mM (Lithium)](https://www.meridianbioscience.com/lifescience/products/molecular/dntp-mix-100mm-lithium/)
## FAQs: Lyo-Ready qPCR Buffer
w/o Excipients, 4x
What causes low efficiency in qPCR?
Slope of standard 10-fold dilution curve indicates qPCR efficiency. The efficiency of the qPCR should be between 90–110% (−3.58 ≥ slope ≥ −3.1). If the efficiency is greater than 100%, this indicated inaccurate sample and reagent pipetting, if it is less than 100%, this indicates your samples may contain PCR inhibitors or your qPCR primer and/or probe design may not be optimal.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, reaction conditions are the same and they will produce the same Ct values, even with multiplex qPCR assays. This means that the liquid mixes can be used to create SOPs if you do not want to lyophilize and then later if lyophilization is required (for example to increase sensitivity), the SOP can be updated for lyophilization, it does not require completely new SOPs to be written.
What probes can be used in qPCR?
Many fluorescent qPCR primer- and probe-based chemistries have been devised and are available from different commercial vendors for molecular diagnostic tests, the two most used are:
• Hydrolysis (TaqMan) probes. The main advantages of using hydrolysis probes are high specificity, a high signal-to-noise ratio, and the ability to perform multiplex qPCR reactions. The disadvantages are that the initial cost of the probe.
• Molecular beacons. Molecular beacons are highly specific, can be used for multiplexing, and if the target sequence does not match the beacon sequence exactly, hybridization and fluorescence will not occur. Unlike hydrolysis probes, molecular beacons are displaced but not destroyed during amplification and can be used for melt curve analysis if necessary. The main disadvantage is that they are difficult to design, requiring a stable hairpin stem that is strong enough that the molecule will not spontaneously fold into non-hairpin conformations but not be too strong, or it may not properly hybridize to the target.
Can the Lyo-Ready qPCR Buffer w/o Excipients, 4x be used with crude samples?
The Lyo-Ready qPCR Buffer w/o Excipients, 4x has some inhibitor tolerance, but for amplification from crude lysates or inhibitor-rich samples we recommend using are optimized Lyo-Ready Specimen-specific™ (blood, saliva, urine, stool, and plant) qPCR and LAMP mixes.
How long are the lyophilized mixes stable for at ambient temperature?
Following lyophilization in the presence or absence of primers and probes, the Lyo-Ready qPCR Mix is stable for a minimum of 24 months at ambient temperature (17 – 23 °C). Following rehydration, the assay reproducibility, sensitivity, and robustness will be the same as for a freshly made liquid mix, making the mixes ideal for point-of-care molecular diagnostic tests and microfluidic qPCR devices.
Do you supply lyo-excipients separately?
No, our lyo-excipients are proprietary, if you require a buffer containing lyo-excipients, we have the Lyo-Ready qPCR Buffer, 2.5x (MDX022).
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Reaction Buffers
---
### [Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-stool/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA qPCR Stool
Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Stool mixes are glycerol-free mixes that contain optimized excipients compatible with freezing and lyophilization and they are designed for the direct molecular quantitation of DNA and RNA from crudely processed stool specimens. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Lyo-Ready Direct DNA and RNA/DNA qPCR Stool Mixes
- Create ultra-sensitive multiplex direct qPCR tests from stool specimens.
- Simplify the development of quantitative PCR stool tests, by removing the nucleic acid extraction step and shortening the sample-to-result workflow.
- Validated for detection of stool pathogens and liquid biopsy applications.
- Can be used in liquid format or it can be lyophilized, for developing an ambient-temperate stable assay.
## Sensitive Detection in up to 20% Stool
### Lyo-Ready Direct DNA qPCR Stool, 4x, MDX142
**Application:** qPCR**Specimen Type:** Stool, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 20% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX142-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX142-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX142.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX142-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX142)
### Lyo-Ready Direct RNA/DNA qPCR Stool, 4x, MDX143
**Application:** RT-qPCR**Specimen Type:** Stool, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 5% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX143-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX143-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX143.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX143-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX143)
## Description
PCR inhibitors found in stool specimens, such as bile salts, polysaccharides, hematin and catabolic substances, have posed a big challenge to developing assays that can directly amplify DNA or RNA. In addition, due to the high complexity and heterogeneity of fecal matter, sample preparation has traditionally been cumbersome, requiring the removal of possible interfering substances such as food debris, desquamated epithelial cells and mucus from the specimen. Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Stool mixes are designed for the direct qPCR/RT-qPCR analysis, requiring minimal stool sample processing. The mix contains an optimized blend of additives to negate inhibitors while maintaining the quality and integrity of the patient sample. As the need for fast, non-invasive testing for gastrointestinal conditions increases, short turn-around times, higher sensitivity and a long shelf-life become important distinguishing features.
If you are developing an infectious disease assay for parasites, viruses, bacteria, or a screening assay for inflammatory bowel disease or gastric or colon cancer, Lyo-Ready Direct DNA qPCR and RNA/DNA qPCR Stool mixes will speed up your assay development time. The mix only requires the addition of primers and probes to create a liquid or ambient-temperature stable assay that can be dried in a laboratory oven, avoiding the need for expensive lyophilization.
## Catalogs & Brochures
[Lyo-Ready Direct DNA and RNA/DNA qPCR Stool](https://collateral.meridianlifescience.com/view/322486879/)**Lyo-Ready Direct DNA and RNA/DNA qPCR Stool**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable Direct Blood**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
## FAQs: qPCR Stool Test
What are the advantages of using qPCR stool test?
A quantitative PCR stool test can allow identification of enteric pathogens such as harmful bacteria, fungi, viruses, or parasites down to the genus or species level, fast and accurately in a few hours, rather than the culture-based stool testing that can take several days. It can also be used as a non-invasive method for screening autoimmune conditions and cancer.
What is the advantage over a fecal occult blood test?
The fecal occult blood test (FOBT) has been the most widely used gastrointestinal immunoassay to screen colorectal cancer (CRC) for over three decades, however, recent large-scale studies have shown that the FOBT lacks the sensitivity to detect early stages of CRC. A qPCR cancer stool test is a better diagnostic tool as it offers significant improvement in sensitivity and accuracy and can be used to screen for multiple targets and so speed up diagnosis, therefore improving prognosis.
What is the maximum volume of fecal material you can use in a PCR stool test?
We have used up to 25% human stool with our mix, this is homogenized, and clarified by centrifugation and some pre-treatment may be required.
What carrier buffer do you recommend?
There are several buffers on the market that can be used for stool testing, they include phosphate-buffered saline (PBS), Cary-Blair Medium, Stool Transport and Recovery (STAR) buffer and DNA/RNA Shield.
After lyophilization for how long will the mix stay stable to use?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is stool DNA always present?
Yes, most of it comes from cells that are sloughed into the lumen after cells die and are replaced, these cells go through apoptosis, releasing the DNA. Tumor cells may be present, but they will normally be less than 1% of the total human DNA fragments present in the overall stool sample.
Is a pre-treatment needed if you want to detect human stool DNA?
Pre-treatment will depend on what you are looking at, cfDNA may not need pre-treatment, but you may need to heat to 95°C for 5 min and for some bacteria, a Proteinase K step (Proteinase K 55°C for 15 min and then at 98°C for 5 min) or using a non-ionic detergent (such as Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min) may be necessary.
What is the performance difference for DNA when using the DNA-specific stool mix versus the DNA/RNA stool mix?
We do not see a performance difference between the two mixes, which is why we call the Lyo-Ready Direct RT-qPCR Stool mix – Lyo-Ready Direct RNA/DNA qPCR Stool mix, as it can be used for both.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA qPCR Stool and Lyo-Ready Direct RNA/DNA qPCR Stool can be used as a liquid mix or lyophilization and stored for up to 24 months without needing to change the reaction conditions and lyophilization/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo-Ready & Air-Dryable Master Mixes & Reagents
---
### [Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-stool/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA and RNA/DNA qPCR Stool
Air-Dryable™ Direct DNA qPCR and RNA/DNA qPCR Stool mixes are glycerol-free and contain optimized excipients compatible with air and oven drying. The mixes have been designed for the direct detection of DNA and RNA from stool specimens without extraction. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
### Air-Dryable Direct DNA qPCR Stool, 4x, MDX140
**Application:** qPCR**Specimen Type:** Stool, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 20% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX140-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX140-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX140.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX140)
### Air-Dryable Direct RNA/DNA qPCR Stool, 4x, MDX141
**Application:** RT-qPCR**Specimen Type:** Stool, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 5% stool, 2 mg/mL bile salt and 40% Cary Blair media. Perfect for multiplexing and fast cycling conditions. Used in the detection of IBD, cancer, fecal microbiota and bacterial and viruses.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX141-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX141-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX141.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX141-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX141)
## Description
PCR inhibitors found in stool specimens, such as bile salts, polysaccharides, hematin, and catabolic substances, have posed challenges to developing assays that can directly amplify DNA or RNA. In addition, due to the high complexity and heterogeneity of fecal matter, sample preparation has traditionally been required to remove possible interfering substances such as food debris, microorganisms, desquamated epithelial cells, and mucus from the specimen. Air-Dryable Direct DNA qPCR and RNA/DNA qPCR Stool mixes are designed for the direct qPCR/RT-qPCR analysis from stool samples, requiring minimal sample processing. The mix contains an optimized blend of additives to negate inhibitor effects while maintaining the quality and integrity of the patient sample. As the need for fast, non-invasive testing for gastrointestinal conditions increases, short turn-around times, higher sensitivity and a long shelf-life become important distinguishing features.
If you are developing an infectious disease assay for parasites, viruses, bacteria, or a screening assay for inflammatory bowel disease or gastric or colon cancer, Air-Dryable Direct DNA qPCR and RNA/DNA qPCR Stool mixes will speed up your assay development time. The mix only requires the addition of primers and probes to create a liquid or ambient-temperature stable assay that can be dried in a laboratory oven, avoiding the need for expensive lyophilization.
## Catalogs & Brochures
[Meridian Air Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable Direct Stool**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
## Related Products
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
[Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
## FAQs: Important Principles for Air-Drying Molecular Assays
Can I use the Lyo-Ready mix for air-drying?
No, air-drying requires specific stabilizers, excipients, and preservatives which are different from those required for lyophilization.
Is it possible to adjust the oven temperature and do high temperatures damage the polymerase or reverse-transcriptase?
Yes, we recommend optimizing the oven temperature and drying time for each new assay formulation (mix including primers and probes), vessel used and lot size. High drying temperatures may affect the integrity of the mix and its components, including enzymes.
How do you know once drying is complete?
Ideally, 70% moisture should be removed from Air-Dryable™ 1-step RT-qPCR Mix (MDX095) and 95% from the Air-Dryable™ Mix (MDX082). However, the optimal moisture loss requires optimization for each assay. Retaining too much moisture may impact the shelf-life of the assay and over-drying may make the mixture difficult to rehydrate and cause a loss of performance. Moisture loss can be calculated by comparing the weight of the initial wet mix in the vessel to the dry mix (refer to the basic workflow for further information). Please note that the air-dried material must be packaged immediately after the drying cycle.
Is it easy to rehydrate an air-dried mix? Do you need to vortex?
The air-dried mix rehydrates in seconds after the addition of the sample. We do recommend, if possible, to gently shake/mix the vessels in order to resuspend the reaction mix before running the reaction, or alternatively mix the solution when adding the patient sample.
Why do I sometimes see a lower Ct value when I compare the performance of the re-hydrated dry mix against the wet mix?
If a mix becomes over-dried, the integrity of the enzymes will be compromised. Conceptually, the ideal “dryness” of a mix will be the highest percentage of moisture loss achieved without losing assay performance. If the Ct value of your dry mix is lower to the comparable wet mix, then the mix has been over-dried and further optimization is required.
Do different probes affect the performance of the assay after the mix is air-dried?
We did not observe any effect of the fluorophore type (Cy5, FAM, JOE or ROX) on the performance of the mix after air-drying.
Will the air circulation from the fan in the oven cause contamination?
We did not observe any contamination during air-drying however we do recommend good laboratory cleaning practices to minimize possible environmental contamination. Examples include surface cleaning or allocating separate locations for the oven drying, qPCR reaction setup, and analysis. In addition, we recommend maintaining the oven following the cleaning instructions provided by the manufacturer.
Could the fan air bring traces of primers/probes from one tube during the drying to another tube?
We did not observe any cross-contamination from fan-forced oven drying. Given the mix resides at the bottom of the vessel, it is very unlikely that cross-contamination can occur between the wells. In addition, in accordance with good manufacturing practices, we would discourage oven drying two different types of assay in the same drying cycle.
Do I have to use 8-well PCR tube strips?
Other vessels can be used such as plates, vials or various microchips, but the drying conditions for each vessel/assay would need to be optimized. Once the ideal conditions and parameters are established, they would need to be verified during validation and scale up.
Do you have a list of ovens that you recommend?
We recommend using a precision drying oven (temperature uniformity of +/- 1.5°C) with convection, fan-forced or vacuum capabilities. In our testing, we used a Memmert UF260Plus oven with fan and air flap settings at 100% and 20% respectively. Please note that different ovens will have different specifications and adjustable parameters that will need to be optimized based your assay, reaction volume, vessel type, batch size, relative humidity, and altitude.
Can I simply put the tubes back in the oven for longer incubation if the moisture loss is not enough, or add water if it is too much?
If the first attempt is not successful and does not provide the correct moisture loss value, we do not recommend putting the tubes back in the oven for additional drying or adding water. We recommend re-starting the experiment in order to control all of the variables so that they are reproducible. In addition, opening the door during the drying process is also not recommended unless it is done in a controllable manner and will be part of the process moving forward.
Would fluctuations in ambient humidity and temperature where the drying oven is located affect the drying protocol, such that the moisture lost is outside the 70% range?
Unlike the effects with lyophilization, there is no impact of the environment to the moisture loss with air-drying.
Can I test using different vessel types and/or different reaction volumes per well in the same drying cycle?
We recommend that different drying cycles are performed to test the effect of altering any assay variable such as vessel type, reaction volume, primer/probes, and lot size. This will ensure that the conditions and outcomes are reproducible.
Does the balance need to be next to the oven for quick weighing?
No, the balance does not have to be next to the oven, just close the vessel once it is out of the oven and go to the balance (even if in a different room) for measurement.
[ For Additional Support Please Contact Technical Support ](/contact-us-diagnostics/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-and-rna-dna-qpcr-saliva/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes
Air-Dryable™ Direct DNA qPCR and RNA/DNA qPCR Saliva master mixes are glycerol-free and contain optimized excipients compatible with oven drying and are designed for the direct qPCR assays. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Benefits of Meridian's Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva Master Mixes
- Create ultra-sensitive multiplex saliva/sputum qPCR tests on a broad range of formats.
- Simplify the development of qPCR saliva tests, by removing the nucleic acid extraction step.
- Save development time with an optimized ready-to-use mix.
- Can be used wet or oven-dried, for ambient-temperate stable assay.
## Highly efficient, ultra-sensitive amplification, using wet (blue) or dried down (red) format
Air-Dryable™ Direct DNA/RNA qPCR Saliva was used in a 10-fold serial dilution of VLP-RNA Extraction Control MDX068 (10,000, 1,000, 100, and 10 copies respectively), in the presence of 5% artificial sputum in both liquid (blue) and air-dried (red) formats. The results illustrate that the dried mix retains the ability to efficiently amplify to the same level as the wet mix with the same level of sensitivity and reproducibility.
### Air-Dryable Direct DNA qPCR Saliva, 4x, MDX130
**Application:** qPCR**Specimen Type:** Saliva, Sputum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX130-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX130-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX130.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX130)
### Air-Dryable Direct RNA/DNA qPCR Saliva, 4x, MDX131
**Application:** RT-qPCR**Specimen Type:** Saliva, Sputum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX131-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX131-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX131.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX131-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX131)
## Description
Over the last decade, saliva has been extensively studied as a diagnostic specimen due to its non-invasive and simple sample collection, and like serum, saliva contains hormones, antibodies, growth factors, enzymes, microbes that can be used as biomarkers for disease detection. However, there have been challenges in adopting saliva for molecular diagnostics due to the low concentration of analytes and high concentration of PCR inhibitors in saliva. Up until now cumbersome sample preparation steps have been required to homogenize the specimen and adequately purify the DNA/RNA.
Air-Dryable™ DNA qPCR Saliva is a 4x qPCR master mix for the development of DNA saliva tests, enabling highly sensitive detection of target DNA from crudely processed saliva or sputum samples. Air-Dryable™ RNA/DNA qPCR Saliva is 4x RT-qPCR master mix designed for the development of both RNA and DNA saliva tests from crudely processed saliva or sputum samples. These mixes have been formulated specifically to overcome the inhibitors found in saliva samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or dried down by oven to create ambient-temperature stable tests.
## Catalogs & Brochures
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable Direct Saliva**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable Mixes**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular Assays**
[Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples](https://collateral.meridianlifescience.com/view/1070676719/)**Saliva Specimen-specific Master Mixes for Multiplex Assays Using Crude Samples**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Air-Dryable qPCR Mix, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-qpcr-mix-4x/)
[Air-Dryable Direct DNA qPCR Blood, 4x](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-qpcr-blood-4x/)
## FAQs: qPCR Saliva Tests
What are the advantages of using saliva over other sample types?
Saliva samples are non-invasive, making it ideal for use with children or patients that will not comply with blood collections or even intrusive nasal swabs. Saliva/sputum tests also increase the efficiency of collection while minimizing sample handling and errors.
What can you test with saliva?
Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antimicrobial constituents, hormones, cytokines, and antibodies. Its composition virtually reflects the entire state of health and disease in a body, and it has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (avian influenza viruses and coronaviruses) and bacterial infections.
What are the advantages of using a saliva mix over a universal inhibitor tolerant mix?
Universal inhibitor tolerant mixes and universal inhibitor resistant mixes are designed to tolerate inhibitors from a wide range of sample types from blood to plants. In adjusting the composition of these mixes to fit all these sample types, some compromise is required, and this leads to a reduction in the sensitivity (Ct values). In designing the saliva specific mixes, we have not had to make these compromises and so the sensitivity is the same as if the nucleic acid had been purified, enabling assay sensitivity down to as low as 1 copy of DNA.
What are the advantages of using saliva or sputum directly in a qPCR test?
You will have faster time to results, no extraction is necessary.
You will get better sensitivity, for low copy number samples.
Less cross contamination, everything is done in a single tube, so there is less chance of mixing labels or adding materials into the wrong tubes.
More convenient, the dried assay can be stored at room temperature and the sample added directly and run.
Reduced cost, there are no extraction costs or cold storage and cold transport costs.
How sensitive is a direct qPCR saliva test?
With the Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva, you can see down to 1 copy in a 20 µL reaction.
What concentration of saliva or sputum can be used directly in a DNA or RNA test?
For a DNA test up to 60% saliva or sputum can be used and for an RNA test up to 50% saliva or sputum can be used.
How can I increase the sensitivity of my DNA or RNA test?
The Air-Dryable™ Direct DNA and RNA/DNA qPCR Saliva can both be used directly as a liquid mix, or air-dried, without changing the sensitivity of the assay. The master mixes are 4x concentration, this means that in a 20 µL reaction, 5 µL the master mix and 1 L of primers and probes are used allowing for up to 14 µL of saliva or sputum to be added, however if the master mix, primers, and probes are air-dried, then up to 20 µL of saliva or sputum can be added.
Do I need to pre-treat my saliva or sputum to use it in a direct DNA or RNA test?
This will depend on what you are testing for and the amount, for example with SARS-CoV-2 heating to 95°C for 10 minutes has been shown to be beneficial, particularly with low viral loads, however Zika virus does not need pre-treatment, whereas some bacteria may require strong pre-treatment (such as proteinase K and heat inactivation).
Does universal transport media (UTM) affect the qPCR test sensitivity?
Up to 35% UTM can be used in the qPCR saliva test without affecting the sensitivity of the assay.
Can crude saliva samples or sputum samples be used in multiplex assays?
Yes, the Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva can both be used in multiplex qPCR and RT-qPCR saliva test or sputum test.
Are reaction conditions the same for air-dried and liquid mixes?
Yes, the Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva can be used as a liquid mix or air-dried and stored for up to 24 months without needing to change the reaction conditions and this drying/ambient temperature storage will not affect the sensitivity of the PCR test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Lyo Ready Air Dryer Master Mixes Reagents
---
### [Glycerol-Free Thermostable DNA Helicase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-thermostable-dna-helicase-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Glycerol-Free Thermostable DNA Helicase (HC)
Glycerol-Free Thermostable DNA Helicase (HC) is a high concentration, glycerol-free mix multi-domain DNA Helicase enzyme, that uses ATP hydrolysis to unwind DNA duplexes with 3’ to 5’ polarity without a requirement for an overhang structure.
[ Product Support Material ](#requestasample)
## Key Product Features
- Unwinds double-stranded DNA
- Operates at up to 65°C, ideal for demanding diagnostic workflows
## Description
Glycerol-Free Thermostable DNA Helicase (MDX242) is a highly stable, multi-domain enzyme derived from the *Thermoanaerobacter tengcongensis* uvrD gene (Tte UvrD helicase). It unwinds double-stranded DNA with 3’ to 5’ polarity using ATP hydrolysis without requiring an overhang structure. Capable of generating single-stranded templates without thermocycling, it remains functional at temperatures up to 65°C.
### Key points:
- Glycerol-Free Thermostable DNA Helicase generates single-stranded templates without thermocycling (resistant up to 60-65°C)
- Ideal for robust, efficient, and precise DNA amplification
- Broader applications include NGS library preparation, SNP detection, mutation analysis, and coupling with CRISPR-based systems to enhance DNA accessibility for Cas enzyme binding
*Glycerol-Free Thermostable DNA Helicase (HC) was used in a DNA unwinding assay. Glycerol-Free Thermostable DNA Helicase (HC) was used at 1 ng/μL with 50 nM of double-stranded DNA substrate in Lyo-Ready Thermostable Helicase Reaction Buffer, compared to another supplier under the same conditions. The results demonstrate that Meridian’s Glycerol-Free Thermostable DNA Helicase (HC) has a higher reaction rate than other suppliers.*
### Glycerol-Free Thermostable DNA Helicase (HC), MDX242
**Application:** LAMP,RPA,RCA,SDA**Specimen Type:** DNA**Concentration:** 50 µg/mL**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration enzyme used to unwind double-stranded DNA. It operates at up to 65°C, ideal for demanding diagnostic workflows such as NGS library preparation, SNP detection and mutation analysis
Available in 20 µL (1 µg) or 200 µL (10 µg) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX242-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX242-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX242.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX242)
## Catalogs & Brochures
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase & Optimized Reaction Buffers for Isothermal AssaysCatalog**
[Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes](https://collateral.meridianlifescience.com/view/206034024/)**Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes**
## Related Products
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Glycerol-Free Taq HS High Conc. DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-high-conc-dna-polymerase/)
[Glycerol-Free High-Fidelity Pfu (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-high-fidelity-pfu-hc/)
## FAQs: Glycerol-Free Thermostable DNA Helicase (HC)
Do I need to add ATP for Glycerol-Free Thermostable DNA Helicase (HC) activity?
The Lyo-Ready Thermostable DNA Helicase Reaction Buffer, 5x contains ATP.
Does Glycerol-Free Thermostable DNA Helicase (HC) require a particular DNA structure to unwind the strands?
No, Glycerol-Free Thermostable DNA Helicase (HC) can unwind any dsDNA structure.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Glycerol-Free Phi29 DNA polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-phi29-dna-polymerase-hc/)
**Published:** May 5, 2025
**Author:** hamza
**Content:**
# Glycerol-Free Phi29 DNA polymerase (HC)
Glycerol-Free Phi29 DNA Polymerase (HC) is a highly processive, high-fidelity enzyme with strong strand displacement activity, enabling robust isothermal DNA amplification. Designed for applications requiring accurate and efficient DNA synthesis, it is ideal for whole genome amplification, single-cell genomics, and molecular diagnostics—whether in liquid or lyophilized assay formats.
[ Product Support Material ](#requestasample)
## Key Product Features
- Strong strand displacement activity enables efficient isothermal amplification at 30°C
- High processivity, synthesizing products up to 70 kb in length
- Exonuclease Activity (3' → 5') providing proofreading capability for high-fidelity replication
- High yields, ideal for amplification from small amounts of template
- Improved freeze-thaw stability, optimized for liquid and lyophilized assay development
## Description
**Meridian’s Glycerol-Free Phi29 DNA Polymerase (HC), (MDX240) is a highly processive enzyme with strong strand displacement activity, enabling efficient isothermal DNA amplification from low-copy samples. Its 3′→5′ exonuclease (proofreading) activity ensures high-fidelity amplification, while its exceptional processivity allows for the synthesis of ultra-long, high molecular weight DNA products.**
This high-concentration, glycerol-free formulation is optimized for multiple displacement amplification (MDA) and rolling circle amplification (RCA), facilitating whole genome amplification, single-cell genomics, and molecular diagnostics. The enzyme’s strong strand displacement activity ensures robust performance, even from low-copy templates.
Glycerol-Free Phi29 DNA Polymerase (HC) does not contain glycerol and has been optimized to deliver robust performance, making it ideal for the development of diagnostic assays in both liquid and lyophilized formats.
### Key points:
- Enables robust isothermal DNA amplification with high accuracy
- Produces ultra-long, high molecular weight DNA with minimal template
- Suitable for whole genome amplification (WGA), single-cell genomics, and molecular diagnostics
- Glycerol-free formulation improves stability for diagnostic applications
**Figure 1. Schematic for rolling circle amplification (RCA).**
Rolling circle amplification (RCA) is an efficient isothermal amplification method for synthesizing ultralong ssDNA by using a circular DNA template and a primer to generate long, concatemeric DNA strands. A strand-displacing DNA polymerase (Phi29 DNA polymerase) continuously synthesizes DNA, moving around the circular template and producing multiple tandem repeats of the original sequence. This process yields high-molecular-weight DNA, making RCA ideal for applications such as genomic studies, molecular diagnostics, pathogen detection, and single-cell analysis.
### Example Protocol
Reagent NameVolumeFinal concentrationLyo-Ready Phi29 DNA Pol Reaction Buffer, 5x10 µL1 xExo-resistant Primers (100 μM)0.5 µL1 μM100 mM dNTP mix0.5 µL1 mMdNTP Mix, 100 mM0.2 μL1 mMCircular DNA templateX μLvariableGlycerol-Free Phi29 DNA Polymerase (HC), 100 U/μL0.1 μL10 U/rxns100 mM MgCl2 mix2.5 μL5 mMWaterUp to 50 μL
### Glycerol-Free Phi29 DNA Polymerase (HC), MDX240
**Application:** RCA,WGA**Specimen Type:** DNA**Concentration:** 100 U/?L**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Requires excipients**Sustainability:** Glycerol-Free
Glycerol-free, high concentration enzyme with exceptional strand displacement and processive synthesis properties, ideal for rolling-circle amplification (RCA).
Available in 20 µL (2,000 Unit) or 100 µL (10,000 Unit) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX240-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX240-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX240.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX240)
## Catalogs & Brochures
[Glycerol-Free Phi29 DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/735768908/)**Glycerol-Free Phi29 DNA Polymerase (HC)**
[ Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/) **Reagent Solutions for Molecular DiagnosticsCatalog**
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase & Optimized Reaction Buffers for Isothermal AssaysCatalog**
[Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes](https://collateral.meridianlifescience.com/view/206034024/)**Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Glycerol-Free Taq HS High Conc. DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-high-conc-dna-polymerase/)
## FAQs: Glycerol-free Phi29 DNA polymerase (HC)
What is the recommended temperature for Phi29 Polymerase?
The recommended temperature for Phi29 Polymerase is 30°C.
Does the reaction need to contain DTT?
DTT can improve the activity of Phi29 Polymerase, so it is recommended that for reaction buffers that have undergone multiple freeze/thaw cycles, DTT should be replenished by adding additional DTT.
How can Phi29 DNA Polymerase be inactivated?
Phi29 DNA Polymerase can be heat inactivated at 65°C for 10 minutes.
What type of primers are used?
Phi29 DNA Polymerase has a strong 3′-5′ exonuclease activity that can degrade unprotected primers. Therefore, it is strongly recommended to use primers with at least two phosphorothioate internucleotide bonds at the 3′ end.
Why glycerol-free?
Enzymes supplied in glycerol-free formulations are compatible with ambient temperature stabilization processes such as lyophilization or air-drying
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-lamp-saliva-master-mixes/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva Master Mixes
Lyo-Ready Direct DNA and RNA/DNA LAMP Saliva mixes are glycerol-free mixes that contain optimized excipients compatible with lyophilization and they are designed for direct loop mediated isothermal amplification for saliva testing of DNA and RNA. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Direct DNA and RNA/DNA LAMP Saliva Master Mixes
- Inhibitor-tolerant isothermal mix designed for direct isothermal amplification from crude saliva or sputum samples.
- Very fast reaction kinetics – ideal for point of care saliva testing
- Fully optimized, concentrated 4x mix– just add custom primers and probes.
- Suitable for detecting RNA or DNA pathogens at very low titers, such as viral pathogens.
### Lyo-Ready Direct DNA LAMP Saliva, 4x, MDX134
**Application:** LAMP**Specimen Type:** Saliva, Sputum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX134-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX134-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX134.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX134-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX134)
### Lyo-Ready Direct RNA/DNA LAMP Saliva, 4x, MDX135
**Application:** RT-LAMP**Specimen Type:** Saliva, Sputum, RNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** Yes**Air-Dryable:** Yes**Dryable:** Lyo-Ready**Sustainability:** Lyophilizable
Inhibitor tolerance to 60% crude saliva, sputum or mucin samples and 50% UTM. Perfect for multiplexing and fast cycling conditions. Used in the detection of a broad range of diseases, including cancer, respiratory viruses and bacterial infections.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX135-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX135-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX135.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX135-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX135)
## Description
Saliva is ideal for use as a diagnostic specimen as it contains hormones, antibodies, growth factors, enzymes and microbes that can be used as biomarkers for disease detection. Saliva is easy-to-collect, making it perfect for point-of-care saliva testing. However, due to the low concentration of analytes and high concentration of inhibitors, the use of molecular diagnostic saliva testing has been limited. Isothermal amplification such as LAMP is more tolerant to inhibitors and the simple workflow allows fast, sensitive, reliable results in clinical diagnosis.
Lyo-Ready DNA Direct LAMP Saliva is a 4x RT-qPCR master mix for the development of DNA saliva and sputum tests, enabling highly sensitive detection of target DNA from crudely processed samples. Lyo-Ready RNA/DNA Direct LAMP Saliva is a 4x RT-qPCR master mix and can be used for the development of both RNA and DNA saliva and sputum tests from crudely processed samples. These mixes have been formulated specifically to overcome the inhibitors found in saliva samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used in a wet format or dried down by lyophilization to create ambient-temperature stable saliva tests or sputum tests.
## Catalogs & Brochures
[Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Saliva Master Mixes](https://collateral.meridianlifescience.com/view/180412872/)**Lyo-Ready Direct LAMP Saliva Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-qpcr-mix/)
[Lyo-Ready 1-Step RT-qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-mix/)
[Lyo-Ready LAMP/RT-LAMP Mixes](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-lamp-rt-lamp-mixes/)
## FAQs: LAMP Saliva Testing
What are the advantages of using saliva over other sample types?
Saliva testing allows painless, non-invasive sample collection from the patient, making it ideal for use with children or patients that will not comply with blood collections or even intrusive nasal swabs. Saliva and sputum tests also increase the efficiency of collection while minimizing sample handling and reducing handling errors.
What can saliva be used to test?
Saliva is a complex fluid containing various hormones, antibodies, growth factors, enzymes and microbes. Its composition virtually reflects the entire state of health and disease in a body, and it has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (avian influenza viruses and coronaviruses) and bacterial infections.
What are the advantages of using a saliva mix over a standard isothermal amplification mix?
Isothermal amplification mixes, particularly LAMP mixes generally tend to be reasonably inhibitor tolerant from a wide range of sample types from blood to plants, however the level of resistance is normally quite low. In designing the saliva specific mixes, we have been able to increase the inhibitor tolerance which results in faster time-to-results and reduced non-template amplification (NTC), both of which increase the assay sensitivity.
What are the advantages of using saliva or sputum directly in a LAMP test?
You will have faster time to results, no extraction is necessary.
You will get better sensitivity, for low copy number samples.
Less cross contamination, everything is done in a single tube, so there is less chance of mixing labels or adding materials into the wrong tubes.
More convenient, the lyophilized assay can be stored at room temperature and the sample added directly and run.
Reduced cost, there are no extraction costs or cold storage and cold transport costs. With a simple heater, it can be used as a point-of-care assay.
How is isothermal amplification different from qPCR?
The main difference between isothermal amplification and qPCR is that in isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
How can I increase the sensitivity of my DNA or RNA test?
Lyo-Ready DNA LAMP and RNA/DNA LAMP Saliva can both be used directly as a liquid mix, or lyophilized, without changing the sensitivity of the assay. The master mixes are 4x concentration, this means that in a 20 µL reaction, 5 µL the master mix and 1 µL of primers and probes are used allowing for up to 14 µL of saliva or sputum to be added, however if the master mix, primers, and probes are lyophilized, then up to 20 µL of saliva or sputum can be added.
Do I need to pre-treat my saliva or sputum to use it in a direct DNA or RNA test?
This will depend on what you are testing for and the amount, for example with SARS-CoV-2 heating to 95°C for 10 minutes has been shown to be beneficial, particularly with low viral loads, however Zika virus does not need pre-treatment, whereas some bacteria may require strong pre-treatment (such as proteinase K and heat inactivation).
Can LAMP be used for a multiplex assay?
Yes, it is possible to design multiplex LAMP assays using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Are reaction conditions the same for lyophilized and liquid mixes?
Yes, the Lyo-Ready Direct DNA LAMP Saliva and Lyo-Ready Direct RNA/DNA LAMP Saliva can be used as a liquid mix or lyophilized and stored for up to 24 months without needing to change the reaction conditions and this drying/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Air-Dryable™ Direct DNA LAMP Blood Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/air-dryable-direct-dna-lamp-blood-master-mix/)
**Published:** May 2, 2025
**Author:** hamza
**Content:**
# Air-Dryable™ Direct DNA LAMP Blood Master Mix
Air-Dryable™ Direct DNA LAMP Blood mix is a ready-to-use, 4x concentrated, fully optimized mix for isothermal amplification methods such as loop-mediated isothermal amplification (LAMP) on blood. It is designed to dramatically speed up assay development time and reduce time to results. The glycerol-free mix contain optimized excipients compatible with air drying, making it ideal for POC blood testing. **Can also be used wet and/or with purified nucleic acid**
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Air-Dryable™ Direct DNA LAMP Blood Master Mix
- Develop ultra-sensitive LAMP blood tests from whole blood, plasma, and serum samples.
- Shorten the time to results by removing the nucleic acid extraction.
- Simplify the development of POC blood testing by just adding primers and probes.
- Can be used wet or air dried, ideal for developing blood pathogen and liquid biopsy assay.
## Higher Specificity and Quicker Time to Detect Viral Targets
(A) Air-Dryable™ Direct DNA LAMP Blood (MDX126, red) was air-dried with primers for Epstein-Barr virus (EBV), Hepatitis B Virus (HBV), Herpes Simplex Virus 2 (HSV2), Trichomonas vaginalis and Mycoplasma pneumoniae. The performance of the mix was compared against NEB WarmStart® LAMP kit (orange) and Thermo SuperScript™ IV RT-LAMP Master Mix (black) using the same primers and DNA. Reactions were incubated at 65°C for 60 minutes. Error bars represent the standard deviation across three technical replicates. The Air-Dryable™ Direct LAMP Blood mix delivered faster target amplification (TTR) with higher specificity, as demonstrated by the longest delay in no-template control (NTC) amplification across range of pathogenic DNA targets.
### Air-Dryable Direct DNA LAMP Blood, 4x, MDX126
**Application:** LAMP**Specimen Type:** Blood, Plasma, Serum, DNA**Concentration:** 4x**High Concentration:** Yes**Wet:** Yes
**Glycerol-Free:** Yes**Lyo-Ready:** No**Air-Dryable:** Yes**Dryable:** Air-Dryable**Sustainability:** Air-Dryable
Inhibitor tolerance to 10% whole blood, 10% plasma, compatible with all anticoagulants. Perfect for multiplexing and fast cycling conditions. Used in the detection of blood pathogens and liquid biopsy applications.
Available in 5 mL (1,000 Rxns) or 50 mL (10,000 Rxns) aliquots
##### Documents & Resources
- [Safety Data Sheet](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-sds/MDX126-MSDS.pdf)
- [Product Handling Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-phg/MDX126-phg.pdf)
- [COA/Test Release](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-coa/MDX126.pdf)
- [User Guide](https://www.meridianbioscience.com/uploads/ls-uploads/mdx-ug/MDX126-ug.pdf)
[Order a Sample](/lifescience/molecular-reagent-sample/?sample_catalog_number=MDX126)
## Description
Blood is one of the most common specimens used for laboratory diagnostic testing and it is useful for diagnosing diseases such as bacterial and viral infections, cancer, cardiovascular disease, and metabolic disorders such as diabetes. However, whole blood specimens, serum, and plasma contain a number of inherent PCR inhibitors including immunoglobulin G, hemoglobin, lactoferrin, and leukocyte DNA. In addition, PCR inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin). Isothermal amplification such as LAMP is very tolerant to inhibitors and so is ideal for point of care (POC) testing, the simple workflow allows fast, sensitive and reliable results in clinical diagnosis.
The Air-Dryable Direct DNA LAMP Blood mix combines even greater tolerance with fast, robust isothermal amplification to enable highly sensitive direct detection using crudely processed whole blood, plasma, or serum samples. The mix are uniquely designed to overcome much higher concentrations of inhibitors, and so do not require a DNA purification step to concentrate and purify a patient sample. Very fast reaction kinetics result in faster time to results and superior amplification sensitivity and specificity. In addition, the 4x concentrated master mixes are formulated with excipients which are optimized for air drying to create ambient-temperature stable assays, making them ideal for POC blood testing.
## Catalogs & Brochures
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood Mixes**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMP Mix, 4x**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMP 1-Step Mix, 4x**
[Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP & Air-Dryable RNA/DNA LAMP Mix, 4x**
## Related Products
[Inhibitor-Tolerant qPCR Mix](https://www.meridianbioscience.com/lifescience/products/molecular/inhibitor-tolerant-qpcr-mix/)
[Lyo-Ready Direct DNA and RNA/DNA qPCR Blood](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-direct-dna-and-rna-dna-qpcr-blood/)
## FAQs: LAMP Saliva Testing
How is isothermal amplification different from qPCR?
The main difference between loop mediated isothermal amplification and qPCR is that in loop mediated isothermal amplification, the amplification is achieved using a single constant temperature, while in the qPCR, amplification requires cycling between multiple temperatures on a thermocycler. Instead of melting DNA strands apart at high temperatures, loop mediated isothermal amplification uses polymerases with high strand displacement activity, like Bst DNA polymerases. As these polymerases do not need multiple temperatures, they can amplify a target in less than an hour, and in some cases in as little time as 10 minutes.
What are the advantages of using blood over other sample types?
Blood contains abundant information about the health status of the organism, it can be used to evaluate organ function, detect proteins, nucleic acids, metabolites, infectious diseases and can be used for diagnosis of cancer (liquid biopsy), heart disease, diabetes. For POC Blood testing it is a simple and easily accessible (low-invasive) method to for monitor health.
What LAMP inhibitors are found in whole blood?
Immunoglobulin G is the major inhibitor of LAMP in blood, as it can bind to single-stranded genomic DNA, reducing the sensitivity of the whole blood test. The other two main inhibitors in blood are hemoglobin and lactoferrin that affected the Bst DNA polymerase activity and thus lowered the amplification efficiency. Hemoglobin and hematin can also cause some fluorescence quenching, particularly for FAM, although this should not affect the time to results (TTR). In addition, inhibitors can be found in the anticoagulants used to stabilize blood samples (e.g. EDTA, citrate, or heparin).
What is the maximum volume of whole blood you can use in a LAMP test.
We have used up to 20% whole blood with our mix, higher concentrations cause the solution to become viscous and difficult to work with.
After drying for how long will the mix stay stable to use? Or do we need to use it immediately after drying?
It is stable for up to 2 years at ambient temperature if correctly stored in sealed pouches.
Is a pre-treatment needed if you want to detect the DNA of gram-positive bacteria?
Yes, it is possible to create a multiplex LAMP whole blood test using different primers and probes, however they can be difficult to design and optimize as each sequence requires three sets of primers.
Can LAMP mixes be used for a multiplex assay?
Yes, it is possible that you may need to pre-treat the blood in order to release the DNA from the gram-positive bacteria. In some cases, a heat shock is sufficient, this will depend on the bacteria being examined.
Do the master mixes need any changes in LAMP protocol or are they compatible with my current setup?
They are compatible with standard isothermal amplification protocols; however, some optimization may be required for the amount of blood plasma or serum samples that is needed for the blood tests.
Do I need to elute dried blood spots, or can they be used directly?
You should elute in water, or TE buffer.
Are reaction conditions the same for dried and liquid mixes?
Yes, the Air-Dryable Direct DNA LAMP Blood can be used as a liquid mix or dried and stored for up to 24 months without needing to change the reaction conditions and drying/ambient temperature storage will not affect the sensitivity of the test.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Isothermal Amplification
---
### [Catalogs & Literature](https://www.meridianbioscience.com/lifescience/products/molecular/catalogs-literature/)
**Published:** September 3, 2025
**Author:** Moaaz Ahmad
**Content:**
## Catalogs & Literature
#### Learn more about us and our products by clicking on the catalogs below.
## About Meridian Life Science
[Meridian Life Science Company Overview](https://collateral.meridianlifescience.com/view/1015735341/)**Meridian OverviewBrochure**
[Immunoassay Full Product Catalog](https://collateral.meridianlifescience.com/view/1015303046/)**Antigen/AntibodyProduct Catalog**
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Molecular Overview](https://collateral.meridianlifescience.com/view/736341769/)**Molecular Overview**
[Immuno Overview](https://collateral.meridianlifescience.com/view/972086005/)**Immuno Overview**
## COVID-19
[COVID-19](https://collateral.meridianlifescience.com/view/33597782/)**COVID-19**
[Tripledemic Viruses – RSV, FLU & COVID](https://collateral.meridianlifescience.com/view/795558266/)**Tripledemic Viruses – RSV, FLU & COVID**
[MAb Pair to SARS-CoV-2 NP](https://collateral.meridianlifescience.com/view/475150359/)**High-Sensitivity SARS-CoV-2 Nucleoprotein Antibody PairCatalog**
[SARS-CoV-2 Recombinant Antigens](https://collateral.meridianlifescience.com/view/875184270/)**SARS-CoV-2 Recombinant AntigensCatalog**
[Novel RT-qPCR Reagents](https://collateral.meridianlifescience.com/view/475510132/)**Novel RT-qPCR ReagentsCatalog**
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR/RT-qPCRCatalog**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCR Catalog**
[AIR-DRYING MOLECULAR ASSAYS](https://collateral.meridianlifescience.com/view/398316371/)**Air-Drying Molecular AssaysQuick Reference Guide**
## Infectious Disease
[Infectious Diseases & Toxins](https://collateral.meridianlifescience.com/view/159860758/)**Infectious Diseases & ToxinsCatalog**
[ToRCH & Childhood Diseases](https://collateral.meridianlifescience.com/view/923314182/)**ToRCH & Childhood DiseasesCatalog**
[ToRCH IgG/IgM Assay Development Guide](https://collateral.meridianlifescience.com/view/922874448/)**ToRCH Reagents GuideCatalog**
[Rubella IgM MAX Antigen](https://collateral.meridianlifescience.com/view/159717506/)**Rubella IgM MAX™ AntigenCatalog**
[Sexually Transmitted Diseases (STDs)](https://collateral.meridianlifescience.com/view/159653059/)**Sexually Transmitted Diseases (STD)Catalog**
[Viral Hepatitis](https://collateral.meridianlifescience.com/view/159945696/)**Viral HepatitisCatalog**
[Tropical & Vector-Borne Diseases](https://collateral.meridianlifescience.com/view/923135831/)**Tropical & Vector- Borne DiseasesCatalog**
[Zika Virus](https://collateral.meridianlifescience.com/view/923687354/)**ZikaCatalog**
[Nipah Virus G Proteins](https://collateral.meridianlifescience.com/view/923766223/)**Nipah Catalog**
[Respiratory Diseases](https://collateral.meridianlifescience.com/view/455424416/)**Respiratory Catalog**
[Leading Respiratory Products/Pairs](https://collateral.meridianlifescience.com/view/455625468/)**Leading Respiratory Products/PairsCatalog**
[Gastrointestinal Pathogens for Stool Testing](https://collateral.meridianlifescience.com/view/455381450/)**Gastrointestinal Pathogens for Stool TestingCatalog**
[Blood Donor Screening](https://collateral.meridianlifescience.com/view/160293564/)**Blood Donor ScreeningCatalog**
## Cancer & Tumor Markers
[Cancer & Tumor Markers Catalog](https://collateral.meridianlifescience.com/view/592341234/)**Cancer and Tumor Markers Catalog**
[Cancer Products Pairs flyer](https://collateral.meridianlifescience.com/view/592174495/)**Cancer Products Pairs Brochure**
## Cardiac
[Cardiac & Metabolic Markers](https://collateral.meridianlifescience.com/view/591795949/)**Cardiac & Metabolic MarkersCatalog**
[Cardiac Pairs](https://collateral.meridianlifescience.com/view/592204925/)**Cardiac PairsCatalog**
## Bone Health
[Vitamin D Flyer](https://collateral.meridianlifescience.com/view/592376020/)**Vitamin DBrochure**
## Hormones & Steroids
[Hormones & Steroids](https://collateral.meridianlifescience.com/view/189848031/)**Hormones and Steroids Brochure**
[Anti-Müllerian Hormone (AMH)](https://collateral.meridianlifescience.com/view/190454639/)**Anti-Müllerian Hormone (AMH)Brochure**
## Drug of Abuse
[Drug Testing Reagents for Commercial Assay Development](https://collateral.meridianlifescience.com/view/591826635/)**Drug Testing Reagents for Commercial Assay DevelopmentCatalog**
## Autoimmune
[Autoimmune Flyer](https://collateral.meridianlifescience.com/view/591745596/)**AutoimmuneCatalog**
## Immunoassay Blocking Reagents
[TRU Block](https://collateral.meridianlifescience.com/view/190586606/)**TRU Block™Catalog**
[Blockers Practical Guide](https://collateral.meridianlifescience.com/view/190168198/)**Immunoassay Blocking Reagents Practical Guide**
[TRU Block Ultra](https://collateral.meridianlifescience.com/view/190593767/)**TRU Block™ UltraCatalog**
[Meridian Immunoassay Blockers for Heterophilic Interference](https://collateral.meridianlifescience.com/view/462794126/)**Meridian Immunoassay Blockers for Heterophilic Interference**
[Meridian K-Block Catalog](https://collateral.meridianlifescience.com/view/118170593/)**Meridian K-Block Catalog**
[Mouse-FREE IgG](https://collateral.meridianlifescience.com/view/790577272/)**Mouse-FREE IgG**
[Immunoassay Blocking Agents: Reducing False Results from Antibody Interference](https://collateral.meridianlifescience.com/view/537560556/)**Immunoassay Blocking Agents: Reducing False Results from Antibody Interference**
## Contract Manufacturing
[Meridian Contract Manufacturing](https://collateral.meridianlifescience.com/view/592363736/)**Contract ManufacturingBrochure**
## Veterinary and Animal Health
[Veterinary & Animal Health](https://collateral.meridianlifescience.com/view/591812349/)**Veterinary & Animal HealthCatalog**
[African Swine Fever Virus (ASFV)](https://collateral.meridianlifescience.com/view/591560695/)**African Swine Fever Virus (ASFV)Catalog**
[Veterinary Health](https://collateral.meridianlifescience.com/view/999379633/)**Veterinary HealthCatalog**
## Molecular Dx Reagents Polymerases
[Glycerol‑Free Taq HS](https://collateral.meridianlifescience.com/view/34333572/)**Glycerol-Free Taq HSCatalog**
[Aptamer Taq HS](https://collateral.meridianlifescience.com/view/33669388/)**Aptamer Taq HS (Glycerol-Free)Catalog**
[Bacterial and Fungal DNA Amplification](https://collateral.meridianlifescience.com/view/33644836/)**Bacterial & Fungal DNA AmplificationCatalog**
[Bst DNA Polymerase](https://collateral.meridianlifescience.com/view/33751484/)**Bst DNA Polymerase & Optimized Reaction Buffers for Isothermal AssaysCatalog**
[High-performing DNA polymerases](https://collateral.meridianlifescience.com/view/664490484/)**High-performing DNA polymerasesCatalog**
[Glycerol-Free Tth DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/751572112/)**Glycerol-Free Tth DNA Polymerase (HC)Catalog**
[Glycerol-Free Phi29 DNA Polymerase (HC)](https://collateral.meridianlifescience.com/view/735768908/)**Glycerol-Free Phi29 DNA Polymerase (HC)**
## Mixes
[Inhibitor-Tolerant qPCR & RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33799571/)**Inhibitor-Tolerant qPCR/RT-qPCRCatalog**
[Air-Dryable Direct Saliva](https://collateral.meridianlifescience.com/view/856384693/)**Air-Dryable™ Direct SalivaCatalog**
[Meridian Air Dryable Direct Stool](https://collateral.meridianlifescience.com/view/140230454/)**Air-Dryable™ Direct StoolCatalog**
[Air-Dryable Direct Blood](https://collateral.meridianlifescience.com/view/33571180/)**Air-Dryable™ Direct BloodCatalog**
[All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays](https://collateral.meridianlifescience.com/view/539655632/)**All-in-One dUTP qPCR Master Mix Optimized for High-Throughput & Multiplex Assays**
[Unlocking Precision in Liquid Biopsy with High-Sensitivity qPCR](https://collateral.meridianlifescience.com/view/648087398/)**Unlocking Precision in Liquid Biopsy with High-Sensitivity qPCR**
[Air-Dryable Mixes](https://collateral.meridianlifescience.com/view/742712993/)**Air-Dryable qPCR/RT-qPCRCatalog**
[Air-Dryable Direct Urine](https://collateral.meridianlifescience.com/view/1027741197/)**Air-Dryable Direct UrineCatalog**
[Air-Dryable Direct Plant](https://collateral.meridianlifescience.com/view/397948458/)**Air-Dryable Direct PlantCatalog**
[Master Mixes for Molecular Ambient-Temperature Stable Assays](https://collateral.meridianlifescience.com/view/34181912/)**Master Mixes for Molecular Ambient-Temperature Stable AssaysCatalog**
[High-Specificity Pfu HS Mix](https://collateral.meridianlifescience.com/view/34570908/)**High-Specificity Pfu HSCatalog**
[Lyo-Ready LAMP Mix, 4x](https://collateral.meridianlifescience.com/view/33803663/)**Lyo-Ready LAMPCatalog**
[Lyo-Ready RT-LAMP 1-Step Mix, 4x](https://collateral.meridianlifescience.com/view/159769789/)**Lyo-Ready RT-LAMPCatalog**
[Lyo-Ready Direct Saliva](https://collateral.meridianlifescience.com/view/931223153/)**Lyo-Ready Direct SalivaCatalog**
[Lyo-Ready 1-Step RT-qPCR Mixes](https://collateral.meridianlifescience.com/view/33956084/)**Lyo-Ready 1-Step RT-qPCRCatalog**
[Low LOD 1-Step RT-qPCR Mix](https://collateral.meridianlifescience.com/view/33946627/)**Low LOD 1-Step RT-qPCRCatalog**
[Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix 4x](https://collateral.meridianlifescience.com/view/438031880/)**Air-Dryable DNA LAMP and Air-Dryable RNA/DNA LAMP Mix, 4xCatalog**
[Lyo-Ready Direct DNA LAMP and RNA/DNA LAMP Saliva Master Mixes](https://collateral.meridianlifescience.com/view/180412872/)**Lyo-Ready Direct LAMP Saliva MixesCatalog**
[Lyo-Ready Direct DNA LAMP Blood Mixes](https://collateral.meridianlifescience.com/view/683928362/)**Lyo-Ready Direct DNA LAMP Blood MixesCatalog**
[Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes](https://collateral.meridianlifescience.com/view/111612146/)**Lyo-Ready Direct DNA and RNA/DNA LAMP Stool Master Mixes**
[Specimen-specific™ and Universal qPCR & LAMP Master Mixes for Ultra-Sensitive Detection](https://collateral.meridianlifescience.com/view/205757818/)**Specimen-specific™ and Universal qPCR & LAMP Master Mixes for Ultra-Sensitive Detection**
[Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes](https://collateral.meridianlifescience.com/view/206034024/)**Lyo-Ready & Air-Dryable LAMP & RT-LAMP Master Mixes**
[Lyo-Ready Genotyping Direct DNA qPCR Urine](https://collateral.meridianlifescience.com/view/658635603/)**Lyo-Ready Genotyping Direct DNA qPCR Urine**
[Lyo-Ready Genotyping Direct qPCR Stool](https://collateral.meridianlifescience.com/view/967751022/)**Lyo-Ready Genotyping Direct qPCR Stool**
## General Reagents
[Reagent Solutions for Molecular Diagnostics](https://collateral.meridianlifescience.com/view/864813412/)**Reagent Solutions for Molecular DiagnosticsCatalog**
[Next-Generation Sequencing (NGS)](https://collateral.meridianlifescience.com/view/34525896/)**Next-Generation Sequencing (NGS)Catalog**
[qPCR Extraction Controls](https://collateral.meridianlifescience.com/view/34470402/)**qPCR Extraction ControlsCatalog**
[VLP-RNA Extraction Control](https://collateral.meridianlifescience.com/view/33936393/)**VLP-RNA Extraction ControlCatalog**
[dNTPs](https://collateral.meridianlifescience.com/view/864093733/)**dNTPs (Deoxynucleotide triphosphates)Catalog**
[Food Safety Testing](https://collateral.meridianlifescience.com/view/34018489/)**Food Safety TestingCatalog**
[Thermostable MMLV-RT](https://collateral.meridianlifescience.com/view/877379816/)**55C MMLV-RTCatalog**
[Glycerol-Free T4 DNA Ligase (HC)](https://collateral.meridianlifescience.com/view/554843078/)**Glycerol-Free T4 DNA Ligase (HC)Catalog**
[Reverse transcriptases](https://collateral.meridianlifescience.com/view/1040476064/)**Reverse transcriptases Catalog**
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080)**Glycerol-Free T7 RNA Polymerase Catalog**
## Custom Services
[Immuno Contract Manufacturing Services](https://collateral.meridianlifescience.com/view/592363736/)**Immuno Contract Manufacturing ServicesCatalog**
[Custom Oligonucleotide Manufacturing](https://collateral.meridianlifescience.com/view/1069600406/)**Custom Oligonucleotide ManufacturingCatalog**
[Improve Your Assay Stability](https://collateral.meridianlifescience.com/view/341387842/)**Improve Your Assay Stability**
[Lateral Flow Services](https://collateral.meridianlifescience.com/view/1069892597/)**Lateral Flow ServicesCatalog**
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
---
### [Secure Your Mouse IgG Supply](https://www.meridianbioscience.com/lifescience/products/molecular/secure-your-mouse-igg-supply/)
**Published:** September 3, 2025
**Author:** Moaaz Ahmad
**Content:**
Meridian Bioscience has developed an animal-free recombinant mouse IgG, offering a reliable and sustainable alternative for supply chains. This innovation enhances supply chain security, minimizes inter-batch variability, improves assay specificity by reducing interference, and supports sustainability efforts.If you are still using traditional mouse IgG in your diagnostic assays, you could be dealing with rising costs, unpredictable lead times, shaky supply chains, and inventory headaches. It’s time to rethink your source!
---
### [Highly sensitive qPCR detection of biomarkers from liquid biopsies](https://www.meridianbioscience.com/lifescience/products/molecular/highly-sensitive-qpcr-detection-of-biomarkers-from-liquid-biopsies/)
**Published:** August 26, 2025
**Author:** Moaaz Ahmad
**Content:**
---
### [Custom Services Video](https://www.meridianbioscience.com/lifescience/products/molecular/custom-services-video/)
**Published:** August 26, 2025
**Author:** Moaaz Ahmad
**Content:**
## Contact Us To Learn More About Custom Services
[ Contact Us ](/contact-us-life-science)
---
### [Glycerol-Free SP6 RNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-sp6-rna-polymerase-hc/)
**Published:** August 19, 2025
**Author:** Moaaz Ahmad
**Content:**
# Glycerol-Free SP6 RNA Polymerase (HC)
SP6 RNA Polymerase is a DNA-dependant RNA Polymerase originating from the SP6 bacteriophage and is used for *in vitro* transcription (IVT). SP6 RNA Polymerase can be used for mRNA vaccine production, as well as other RNA-based therapeutic and research applications, including miRNA and siRNA synthesis, synthesis of sgRNA for the CRIPR/Cas9 system and in isothermal diagnostic methods, such as nucleic acid sequence-based amplification (NASBA).
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Meridian's Glycerol-Free SP6 RNA Polymerase (HC)
- Synthesis of guide RNA for gene targeting
- Synthesis of RNA probes for hybridization or RNA templates for in vitro RNA translation
- Radiolabelled/fluorescently labelled RNA probe preparation
- Nucleic acid sequence-based amplification (NASBA)
## ### Glycerol-Free SP6 RNA Polymerase (HC), MRNA106
Available in 10,000 Unit or 50,000 Unit aliquots
- [**Product Manual**](https://meridian-bioscience-web.s3.us-east-2.amazonaws.com/wp-content/uploads/2025/08/19144419/MRNA106_Glycerol-free_SP6_RNA_Polymerase_HC_Product_Manual.pdf)
- **[Safety Data Sheet](https://meridianbiostg.wpengine.com/uploads/MRNA106-MSDS.pdf?country=US)**
- [**COA/Test Release**](https://meridianbiostg.wpengine.com/uploads/MRNA106.pdf?country=US)Glycerol-Free SP6 RNA Polymerase (HC) is a high concentration (500 U/µL) DNA-dependent RNA Polymerase with very high specificity for the SP6 phage double-stranded promoter sequence. The enzyme catalyzes the 5’→3’ synthesis of RNA on either single-stranded DNA or double-stranded DNA downstream from the promoter. Glycerol-Free SP6 RNA Polymerase (HC) has been optimized to deliver excellent, stable performance without glycerol, allowing you to develop *in vitro* transcription workflows with a high-quality enzyme that delivers reliable results with the added capability for lyophilization. This gives you the flexibility to confidently store reaction mixtures at ambient temperature or produce diagnostic assays that rely on miniaturized reaction components.
## Catalogs & Brochures
[Glycerol-Free T7 RNA Polymerase](https://collateral.meridianlifescience.com/view/976072080)**Glycerol-Free T7 RNA Polymerase**
## Related Products
[High Conc. Glycerol-Free Bst](https://www.meridianbioscience.com/lifescience/products/molecular/high-conc-glycerol-free-bst/)
[Lyo-Ready 1-Step RT-qPCR Virus Mix](https://www.meridianbioscience.com/lifescience/products/molecular/lyo-ready-1-step-rt-qpcr-virus-mix/)
[Glycerol-Free T7 RNA Polymerase (HC)](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-t7-rna-polymerase-hc/)
## FAQs: Glycerol-Free SP6 RNA Polymerase (HC)
Why use an RNA Polymerase from a T7 bacteriophage?
RNA polymerase from a T7 bacteriophage is very selective and efficient, resulting in a high frequency of transcription initiation and effective elongation. These features result in an RNA elongation that is approximately five-fold faster than for *E. coli* RNA polymerase; hence, the T7 promoter is a much stronger promoter than the *E. coli* promoter.
What is the promoter sequence of SP6 RNA Polymerase?
RNA polymerase from a SP6 bacteriophage is very selective and efficient, resulting a high frequency of transcription initiation and effective elongation. These features result in an RNA elongation that is approximately five-fold faster than for *E. coli* RNA polymerase; hence, the SP6 promoter is a much stronger promoter than the *E. coli* promoter.
Does the SP6 RNA Polymerase require a primer?
No, the SP6 RNA Polymerase recognizes the SP6 Promoter sequence and then transcribes using the final G of the promoter as the first base to transcribe the opposite strand as a template from 5’->3’.
What can I do to optimize RNA yield using SP6 RNA Polymerase?
Higher yields of RNA may be obtained by raising rNTP concentrations and Mg2+ concentration (to 4 mM above the total NTP concentration). Inorganic pyrophosphatase can also be added to a final concentration of 4 units/mL to try to lower feedback inhibition caused by the build-up of pyrophosphates that bind and precipitate Mg2+ ions.
RNases are ubiquitous in the environment and a significant risk factor during RNA production. The activity of RNases is blocked using RNase inhibitor. We recommend using RNase inhibitor (MDX056) in the reaction.
What are the main causes of reaction failure with SP6 RNA Polymerase?
Degraded the RNA product caused by RNase contamination is often the main cause. We recommend using RNase inhibitor (MDX056) in the reaction. The DNA should also be prepared free of NaCl, as SP6 RNA Polymerase is sensitive to NaCl inhibition.
What is the difference between SP6 and T7 RNA Polymerase?
SP6 RNA Polymerase is encoded by bacteriophage SP6, this is remarkably similar in structure and activity to T7 RNA polymerase, which is encoded by bacteriophage T7, both can be used to synthesize RNA sequences from short DNA templates which contain the 18 base pair promoter region, however the promoter sequences are highly specific.
The SP6 RNA polymerase start site can be advantageous in large-scale syntheses where high concentrations of RNA can lead to aggregation, however it does require a complete duplex DNA substrate for efficient synthesis, unlike the T7 RNA polymerase which works efficiently when only the 18 base promoter region is double stranded.
SP6 RNA polymerase consistently produces higher yields of RNA than does T7 RNA polymerase, and the reactions can be easily scaled up to produce milligram quantities of RNA and so it is the preferred enzyme for mRNA vaccine production.
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** Enzymes
---
### [Low DNA Taq HS 10 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-10-u-µl/)
**Published:** May 7, 2025
**Author:** hamza
**Content:**
# Low DNA Taq HS 10 U/µL
Low DNA Taq HS, 10 U/µL is a highly purified chemically modified hot-start Taq DNA polymerase and buffer system, with separate magnesium. It has been developed for low bioburden and very high sensitivity over a wide range of PCR templates.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Description
The low DNA background and stringent hot-start properties of Low DNA Taq HS, 10 U/µL are ideal for PCR of low-copy bacterial targets and avoiding false-positive amplification, such as in water testing. The higher concentration is also ideal for POC microfluidic devices where lower volumes are needed.
## Related Products
[Taq HS DNA Polymerase](https://www.meridianbioscience.com/lifescience/products/molecular/taq-hs-dna-polymerase/)
[Low DNA Taq HS 5 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/low-dna-taq-hs-5-u-%c2%b5l/)
[Glycerol-Free Taq HS, 50 U/µL](https://www.meridianbioscience.com/lifescience/products/molecular/glycerol-free-taq-hs-50-u-%c2%b5l/)
[Aptamer Taq HS (Glycerol-Free)](https://www.meridianbioscience.com/lifescience/products/molecular/aptamer-taq-hs-glycerol-free/)
[Low LOD 1-Step RT-qPCR Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular/low-lod-1-step-rt-qpcr-master-mix/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
**Molecular Reagents:** DNA Polymerases
---
### [NGS High-Fidelity Pfu Buffer, 10x](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-high-fidelity-pfu-buffer-10x/)
**Published:** May 7, 2025
**Author:** hamza
**Content:**
# NGS High-Fidelity Pfu Buffer, 10x
NGS High-Fidelity Pfu Buffer, 10x is an optimized buffer containing dNTPs and Mg and requires only the addition of a high fidelity polymerase (such as High-Fidelity Pfu (MDX003)), primers and DNA template for robust amplification.
[ Request a Sample ](#requestasample)
#### Have questions about a product?
Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
[ Contact A Specialist ](/contact-us-life-science/)
## Description
The amplification of a next-generation sequencing (NGS) library is performed by PCR. In addition to increasing the amount of DNA, the PCR amplification step also enriches for fragments that have an adaptor-ligated to each end, as these will be the fragments that attach to the flow cell and will be sequenced. It is important that this PCR step does not introduce mutations or bias to the library, as a lower error rate and more even sequence representation means that less sequence coverage is required, saving expense and time.
## Related Products
[High-Fidelity Pfu](https://www.meridianbioscience.com/lifescience/products/molecular/high-fidelity-pfu/)
[High-Specificity Pfu HS Mix](https://www.meridianbioscience.com/lifescience/products/molecular/high-specificity-pfu-hs-mix/)
[NGS Clean and Select Beads](https://www.meridianbioscience.com/lifescience/products/molecular/ngs-clean-and-select-beads/)
## Get In Touch With A Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our [Privacy Statement](/privacy/).
## Learn More About Us
[ About ](/lifescience/about-life-science)
---
## Stool Specimen Collection
### [Ethyl Acetate / Reagent B](https://www.meridianbioscience.com/para-pak/ethyl-acetate-reagent-b/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
Reagent used during the stool concentration procedure for parasite detection.
**Para Pak Categories:** Stool Concentration System
---
### [C&S Stool Transport in Biobags](https://www.meridianbioscience.com/para-pak/cs-in-biobags/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials prefilled with C&S medium, packaged in biobags with patient instructions.
**Para Pak Categories:** One-Vial Stool Transport
---
### [Three-Vial Stool Transports](https://www.meridianbioscience.com/para-pak/three-vial-stool-transport/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
[Home](https://www.meridianbioscience.com "Home")» [Stool Specimen Collection](https://www.meridianbioscience.com/para-pak/ "Stool Specimen Collection")»Three-Vial Stool Transports Three-Vial Stool Transports
# Three-Vial Stool Sample Collection
Meridian’s Para‑Pak® Three‑Vial Stool Transport kits offer a comprehensive solution for stool specimen collection, preservation, and bacterial culture in parasitology testing. Each kit includes three vials—typically EcoFix®, C&S, and a Clean vial or combinations like SAF/Clean/C&S, Zn‑PVA/10% Formalin/C&S, or Zn‑PVA/10% Formalin/Clean—designed to support diverse lab protocols including direct examination, concentration, permanent staining, and bacterial recovery. Convenient and reliable, these triple-vial formats help ensure sample integrity across multiple diagnostic methods in one streamlined workflow
[ Contact Sales ](#paraform)
## Three-Vial Stool Transport for Comprehensive GI Testing
Meridian’s Para-Pak® Three Vial kits include a combination of Zn-PVA, 10% Formalin, and C&S preservatives, enabling multiple testing methods—O&P exams, cultures, and antigen detection—from one stool sample. Designed for high-throughput labs, these all-in-one kits streamline workflows and support a wide range of gastrointestinal diagnostic protocols.
[](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin-and-cs-stool-transport/)##### LV-PVA, 10% Formalin, and C&S Stool Transport
Intestinal Parasites Examination and Bacteria Recovery
Three-vial stool transport system with 15 mL vials of LV-PVA and 10% formalin fixative along with C&S medium.
[ View Product ](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin-and-cs-stool-transport/)
[](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-cs/)##### Zn-PVA, 10% Formalin, and C&S Stool transport
Intestinal Parasites Examination and Bacteria Recovery
Three-vial stool transport system with 15 mL vials of Zn-PVA and 10% formalin fixative along with C&S medium.
[ View Product ](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-cs/)
[](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-clean/)##### Zn-PVA, 10% Formalin, and Clean Stool Transport
Intestinal Parasites Examination and Non-Preserved/Clean Collection
Three-vial stool transport system with 15 mL vials of Zn-PVA fixative and 10% formalin, plus a 30 mL clean vial.
[ View Product ](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-clean/)
[](https://www.meridianbioscience.com/para-pak/saf-clean-cs/)##### SAF, Clean, and C&S Stool Transport
Intestinal Parasites Examination, Non-Preserved/Clean Collection, and Bacteria Recovery
Three-vial stool transport system with 15 mL vials of SAF fixative, C&S medium, and a 30 mL clean vial.
[ View Product ](https://www.meridianbioscience.com/para-pak/saf-clean-cs/)
[](https://www.meridianbioscience.com/para-pak/ecofix-cs-clean/)##### EcoFix®, C&S, and Clean Stool Transport
Intestinal Parasites Examination, Non-Preserved/Clean Collection, and Bacteria Recovery
Three-vial stool transport system with 15 mL vials of EcoFix fixative and C&S medium, plus a 30 mL clean vial.
[ View Product ](https://www.meridianbioscience.com/para-pak/ecofix-cs-clean/)
### Stool Specimen Collection
[](/para-pak/one-vial-stool-transports/) 
###### One-Vial Stool Transport
[](/para-pak/two-vial-stool-sample-collection-kit/) 
###### Two-Vial Stool Transport
[](/para-pak/three-vial-stool-transport/) 
###### Three-Vial Stool Transport
[](/para-pak/stool-concentration-kit-system/) 
###### Stool Concentration System
[](/para-pak/stool-specimens-parasitology-stains/) 
###### Parasitology Stains
### Ready to get more info on this? Lets talk!
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Two-Vial Stool Transports](https://www.meridianbioscience.com/para-pak/two-vial-stool-transport/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
[Home](https://www.meridianbioscience.com "Home")» [Stool Specimen Collection](https://www.meridianbioscience.com/para-pak/ "Stool Specimen Collection")»Two-Vial Stool Transports Two-Vial Stool Transports
# Two-Vial Stool Sample Collection
Meridian’s Para-Pak® Two-Vial Stool Transport systems provide dual-preservative options in a single kit to meet comprehensive diagnostic needs. Each system combines fixatives like 10% Formalin, EcoFix®, SAF, or PVA with a clean vial, supporting multiple testing methods such as direct examination, concentration, and permanent staining. Ideal for thorough parasitology workflows, these dual-vial formats help laboratories preserve sample integrity, streamline collection, and ensure accurate results across a wide range of gastrointestinal diagnostics.
[ Contact Sales ](#paraform)
## Two-Vial Stool Transport for Comprehensive GI Testing
Meridian’s Para-Pak® two-vial systems combine two preservatives in one convenient solution—such as Formalin with PVA or SAF with Clean—to support multiple diagnostic methods from a single stool specimen. Ideal for parasitology testing, these kits enhance flexibility, streamline workflows, and ensure sample integrity in clinical laboratories.
[](https://www.meridianbioscience.com/para-pak/saf-clean/)##### SAF and Clean Stool Transport
Intestinal Parasites Examination and Non-Preserved/Clean Collection
Two-vial system with SAF for direct examination, concentration, and permanent staining and a clean vial.
[ View Product ](https://www.meridianbioscience.com/para-pak/saf-clean/)
[](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin/)##### LV-PVA & 10% Formalin Stool Transport
Intestinal Parasites Examination
Two-vial system with low-viscosity PVA for permanent staining and 10% formalin.
[ View Product ](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin/)
[](https://www.meridianbioscience.com/para-pak/zn-pva-formalin-2/)##### Zn-PVA & 10% Formalin Stool Transport
Intestinal Parasites Examination
Two-vial system with Zn-PVA for permanent staining and 10% formalin.
[ View Product ](https://www.meridianbioscience.com/para-pak/zn-pva-formalin-2/)
[](https://www.meridianbioscience.com/para-pak/modified-cu-pva-formalin/)##### Modified (Cu) PVA & 10% Formalin Stool Transport
Intestinal Parasites Examination and Non-Preserved/Clean Collection
Two-vial system with modified (Cu) PVA for stool preservation and 10% formalin.
[ View Product ](https://www.meridianbioscience.com/para-pak/modified-cu-pva-formalin/)
[](https://www.meridianbioscience.com/para-pak/ecofix-clean/)##### EcoFix® & Clean Stool Transport
Intestinal Parasites Examination and Non-Preserved/Clean Collection
Two-vial system with EcoFix for direct examination, concentration, and permanent staining and a clean vial.
[ View Product ](https://www.meridianbioscience.com/para-pak/ecofix-clean/)
### Stool Specimen Collection
[](/para-pak/one-vial-stool-transports/) 
###### One-Vial Stool Transport
[](/para-pak/two-vial-stool-sample-collection-kit/) 
###### Two-Vial Stool Transport
[](/para-pak/three-vial-stool-transport/) 
###### Three-Vial Stool Transport
[](/para-pak/stool-concentration-kit-system/) 
###### Stool Concentration System
[](/para-pak/stool-specimens-parasitology-stains/) 
###### Parasitology Stains
### Ready to get more info on this? Lets talk!
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Macro-CON® Stool Concentration System](https://www.meridianbioscience.com/para-pak/macro-con-stool-concentration-system/)
**Published:** August 21, 2025
**Author:** Moaaz Ahmad
**Content:**
Para-Pak Macro-CON is a system for the concentration of eggs, larvae, and protozoa from preserved fecal specimens.
**Para Pak Categories:** Stool Concentration System
---
### [Mayer’s Albumin](https://www.meridianbioscience.com/para-pak/mayers-albumin/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
A premium adhesive for securely mounting specimens on glass slides for microscopic parasite detection.
**Para Pak Categories:** Parasitology Stains
---
### [Trichrome Enhancer A](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-a/)
**Published:** December 10, 2025
**Author:** hamza
**Content:**
Trichrome Enhancer A
**Para Pak Categories:** Parasitology Stains
---
### [Trichrome Enhancer B](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-b/)
**Published:** December 10, 2025
**Author:** hamza
**Para Pak Categories:** Parasitology Stains
---
### [CON-Trate® Stool Concentration System (500 sets/case)](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-system-500-sets-case/)
**Published:** October 23, 2025
**Author:** hamza
**Content:**
Stool concentration system with 15 mL tubes, caps, funnels, surfactant, packaged in 500 sets.
**Para Pak Categories:** Stool Concentration System
---
### [SAF and Clean Stool Transport](https://www.meridianbioscience.com/para-pak/saf-clean/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Two-vial system with SAF for direct examination, concentration, and permanent staining and a clean vial.
**Para Pak Categories:** Two-Vial Stool Transport
---
### [EcoFix® Stool Transport in Biobags](https://www.meridianbioscience.com/para-pak/ecofix-in-biobags/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Formalin and mercury-free stool transport vials containing EcoFix preservative, packaged in biobags.
**Para Pak Categories:** One-Vial Stool Transport
---
### [CON-Trate® Stool Concentration Filter and Reagent A](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-filter-and-reagent-a/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
Filtration devices with Reagent A.
**Para Pak Categories:** Stool Concentration System
---
### [CON-Trate® Stool Concentration System (200 sets/case)](https://www.meridianbioscience.com/para-pak/con-trate-concentration-system-200-sets-case/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
Stool concentration system containing 15 mL tubes, caps, funnels, surfactant, and ethyl acetate.
**Para Pak Categories:** Stool Concentration System
---
### [EcoFix® Stool Transport](https://www.meridianbioscience.com/para-pak/ecofix/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing EcoFix, a unique fixative, formaldehyde-free, and mercury-free.
**Para Pak Categories:** One-Vial Stool Transport
---
### [Zn-PVA Stool Transport](https://www.meridianbioscience.com/para-pak/zn-pva/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing polyvinyl alcohol and zinc sulphate as preservative (mercury-free).
**Para Pak Categories:** One-Vial Stool Transport
---
### [C&S Stool Transport](https://www.meridianbioscience.com/para-pak/cs/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing C&S medium. Recommended fixative for the recovery of bacteria.
**Para Pak Categories:** One-Vial Stool Transport
---
### [10% Formalin Stool Transport](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing 10% formalin. Recommended fixative for preserving fecal specimens.
**Para Pak Categories:** One-Vial Stool Transport
---
### [Clean Stool Transport](https://www.meridianbioscience.com/para-pak/clean-vial/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Clean stool transport vials for specimens not requiring a transport medium.
**Para Pak Categories:** One-Vial Stool Transport
---
### [SAF Stool Transport](https://www.meridianbioscience.com/para-pak/saf/)
**Published:** December 10, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing sodium acetate formalin as preservative.
**Para Pak Categories:** One-Vial Stool Transport
---
### [LV-PVA Stool Transport](https://www.meridianbioscience.com/para-pak/para-pak-lv-pva/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing low-viscosity polyvinyl alcohol (PVA) as preservative.
**Para Pak Categories:** One-Vial Stool Transport
---
### [CON-Trate® Stool Concentration Tubes and Caps](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-tubes-and-caps/)
**Published:** October 23, 2025
**Author:** hamza
**Content:**
Stool concentration system containing 15 mL tubes and caps.
**Para Pak Categories:** Stool Concentration System
---
### [Trichrome Stain 12 x 500 mL Bottles/Case](https://www.meridianbioscience.com/para-pak/trichrome-stain/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
12 bottles – 500 mL each of Trichrome Stain for rapid differentiation of intestinal parasites in stool specimens.
**Para Pak Categories:** Parasitology Stains
---
### [Trichrome Stain 1 x 500 mL Bottle](https://www.meridianbioscience.com/para-pak/wheatleys-trichrome-stain/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
1 bottle – 500 mL of Trichrome Stain for rapid differentiation of intestinal parasites in stool specimens.
**Para Pak Categories:** Parasitology Stains
---
### [Direct Detect® Stool Transport](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
**Published:** August 21, 2025
**Author:** Moaaz Ahmad
**Content:**
Stool collection kit with clean vial, sampling device, toilet collection hat, and transport bag.
**Para Pak Categories:** One-Vial Stool Transport
---
### [SVT Stool Transport](https://www.meridianbioscience.com/para-pak/svt/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials containing SVT, a unique fixative, formaldehyde-free, and mercury-free.
**Para Pak Categories:** One-Vial Stool Transport
---
### [Enteric Plus Stool Transport](https://www.meridianbioscience.com/para-pak/enteric-plus/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Stool transport vials similar to C&S media, with increased agar percentage.
**Para Pak Categories:** One-Vial Stool Transport
---
### [Trichrome Blue Stain](https://www.meridianbioscience.com/para-pak/trichrome-blue-stain/)
**Published:** July 11, 2025
**Author:** Salman Haider
**Content:**
1 bottle – 500 mL of Trichrome Blue Stain for differential identification of microsporidia.
**Para Pak Categories:** Parasitology Stains
---
### [Zn-PVA & 10% Formalin Stool Transport](https://www.meridianbioscience.com/para-pak/zn-pva-formalin-2/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Two-vial system with Zn-PVA for permanent staining and 10% formalin.
**Para Pak Categories:** Two-Vial Stool Transport
---
### [Zn-PVA, 10% Formalin, and Clean Stool Transport](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-clean/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Three-vial stool transport system with 15 mL vials of Zn-PVA fixative and 10% formalin, plus a 30 mL clean vial.
**Para Pak Categories:** Three-Vial Stool Transport
---
### [Zn-PVA, 10% Formalin, and C&S Stool transport](https://www.meridianbioscience.com/para-pak/zn-pva-10-formalin-cs/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Three-vial stool transport system with 15 mL vials of Zn-PVA and 10% formalin fixative along with C&S medium.
**Para Pak Categories:** Three-Vial Stool Transport
---
### [SAF, Clean, and C&S Stool Transport](https://www.meridianbioscience.com/para-pak/saf-clean-cs/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Three-vial stool transport system with 15 mL vials of SAF fixative, C&S medium, and a 30 mL clean vial.
**Para Pak Categories:** Three-Vial Stool Transport
---
### [LV-PVA, 10% Formalin, and C&S Stool Transport](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin-and-cs-stool-transport/)
**Published:** August 21, 2025
**Author:** Moaaz Ahmad
**Content:**
Three-vial stool transport system with 15 mL vials of LV-PVA and 10% formalin fixative along with C&S medium.
**Para Pak Categories:** Three-Vial Stool Transport
---
### [Modified (Cu) PVA & 10% Formalin Stool Transport](https://www.meridianbioscience.com/para-pak/modified-cu-pva-formalin/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Two-vial system with modified (Cu) PVA for stool preservation and 10% formalin.
**Para Pak Categories:** Two-Vial Stool Transport
---
### [LV-PVA & 10% Formalin Stool Transport](https://www.meridianbioscience.com/para-pak/lv-pva-10-formalin/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Two-vial system with low-viscosity PVA for permanent staining and 10% formalin.
**Para Pak Categories:** Two-Vial Stool Transport
---
### [EcoFix® & Clean Stool Transport](https://www.meridianbioscience.com/para-pak/ecofix-clean/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Two-vial system with EcoFix for direct examination, concentration, and permanent staining and a clean vial.
**Para Pak Categories:** Two-Vial Stool Transport
---
### [EcoFix®, C&S, and Clean Stool Transport](https://www.meridianbioscience.com/para-pak/ecofix-cs-clean/)
**Published:** July 9, 2025
**Author:** Salman Haider
**Content:**
Three-vial stool transport system with 15 mL vials of EcoFix fixative and C&S medium, plus a 30 mL clean vial.
**Para Pak Categories:** Three-Vial Stool Transport
---
### [Para-Pak® SAF Vials (Genova Diagnostics)](https://www.meridianbioscience.com/para-pak/para-pak-saf-vials-genova-diagnostics/)
**Published:** July 9, 2025
**Author:** hamza
**Content:**
**Manufactured for Genova Diagnostics**
Stool transport vials containing sodium acetate formalin as preservative.
**Para Pak Categories:** One-Vial Stool Transport
---
### [One-Vial Stool Transports](https://www.meridianbioscience.com/para-pak/one-vial-stool-transport/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
[Home](https://www.meridianbioscience.com "Home")» [Stool Specimen Collection](https://www.meridianbioscience.com/para-pak/ "Stool Specimen Collection")»One-Vial Stool Transports One-Vial Stool Transports
# One-Vial Stool Sample Collection
Meridian’s Para-Pak® One-Vial Stool Transport systems provide a comprehensive selection of ready-to-use solutions for stool specimen collection, preservation, and transport. Designed to support accurate detection of intestinal parasites and enteric pathogens, each vial is prefilled with a specific preservative or transport medium—such as 10% Formalin, C&S medium, EcoFix®, SAF, and mercury-free PVA options like LV-PVA and Zn-PVA—tailored to meet diverse laboratory protocols. With options including clean vials and individually bagged kits, these systems help ensure specimen integrity, user safety, and efficient laboratory workflows.
[ Contact Sales ](#paraform)
## Stool Collection for Accurate GI Diagnostics
Meridian’s Para-Pak® One-Vial systems offer convenient, prefilled solutions for stool specimen collection and preservation. With a variety of preservatives tailored for different testing needs, these vials support accurate detection of GI pathogens while maintaining specimen integrity and lab efficiency.
[](https://www.meridianbioscience.com/para-pak/saf/)##### SAF Stool Transport
Intestinal Parasites Examination
Stool transport vials containing sodium acetate formalin as preservative.
[ View Product ](https://www.meridianbioscience.com/para-pak/saf/)
[](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)##### Direct Detect® Stool Transport
Non-Preserved/Clean Collection
Stool collection kit with clean vial, sampling device, toilet collection hat, and transport bag.
[ View Product ](https://www.meridianbioscience.com/para-pak/direct-detect-stool-transport/)
[](https://www.meridianbioscience.com/para-pak/ecofix-in-biobags/)##### EcoFix® Stool Transport in Biobags
Intestinal Parasites Examination
Formalin and mercury-free stool transport vials containing EcoFix preservative, packaged in biobags.
[ View Product ](https://www.meridianbioscience.com/para-pak/ecofix-in-biobags/)
[](https://www.meridianbioscience.com/para-pak/para-pak-lv-pva/)##### LV-PVA Stool Transport
Intestinal Parasites Examination
Stool transport vials containing low-viscosity polyvinyl alcohol (PVA) as preservative.
[ View Product ](https://www.meridianbioscience.com/para-pak/para-pak-lv-pva/)
[](https://www.meridianbioscience.com/para-pak/ecofix/)##### EcoFix® Stool Transport
Intestinal Parasites Examination
Stool transport vials containing EcoFix, a unique fixative, formaldehyde-free, and mercury-free.
[ View Product ](https://www.meridianbioscience.com/para-pak/ecofix/)
[](https://www.meridianbioscience.com/para-pak/clean-vial/)##### Clean Stool Transport
Non-Preserved/Clean Collection
Clean stool transport vials for specimens not requiring a transport medium.
[ View Product ](https://www.meridianbioscience.com/para-pak/clean-vial/)
[](https://www.meridianbioscience.com/para-pak/zn-pva/)##### Zn-PVA Stool Transport
Intestinal Parasites Examination
Stool transport vials containing polyvinyl alcohol and zinc sulphate as preservative (mercury-free).
[ View Product ](https://www.meridianbioscience.com/para-pak/zn-pva/)
[](https://www.meridianbioscience.com/para-pak/svt/)##### SVT Stool Transport
Intestinal Parasites Examination
Stool transport vials containing SVT, a unique fixative, formaldehyde-free, and mercury-free.
[ View Product ](https://www.meridianbioscience.com/para-pak/svt/)
[](https://www.meridianbioscience.com/para-pak/para-pak-saf-vials-genova-diagnostics/)##### Para-Pak® SAF Vials (Genova Diagnostics)
Intestinal Parasites Examination
**Manufactured for Genova Diagnostics**
Stool transport vials containing sodium acetate formalin as preservative.
[ View Product ](https://www.meridianbioscience.com/para-pak/para-pak-saf-vials-genova-diagnostics/)
[](https://www.meridianbioscience.com/para-pak/enteric-plus/)##### Enteric Plus Stool Transport
Bacteria Recovery
Stool transport vials similar to C&S media, with increased agar percentage.
[ View Product ](https://www.meridianbioscience.com/para-pak/enteric-plus/)
[](https://www.meridianbioscience.com/para-pak/cs-in-biobags/)##### C&S Stool Transport in Biobags
Bacteria Recovery
Stool transport vials prefilled with C&S medium, packaged in biobags with patient instructions.
[ View Product ](https://www.meridianbioscience.com/para-pak/cs-in-biobags/)
[](https://www.meridianbioscience.com/para-pak/cs/)##### C&S Stool Transport
Bacteria Recovery
Stool transport vials containing C&S medium. Recommended fixative for the recovery of bacteria.
[ View Product ](https://www.meridianbioscience.com/para-pak/cs/)
[](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)##### 10% Formalin Stool Transport
Intestinal Parasites Examination
Stool transport vials containing 10% formalin. Recommended fixative for preserving fecal specimens.
[ View Product ](https://www.meridianbioscience.com/para-pak/10-formalin-fixative/)
### Stool Specimen Collection
[](/para-pak/one-vial-stool-transports/) 
###### One-Vial Stool Transport
[](/para-pak/two-vial-stool-sample-collection-kit/) 
###### Two-Vial Stool Transport
[](/para-pak/three-vial-stool-transport/) 
###### Three-Vial Stool Transport
[](/para-pak/stool-concentration-kit-system/) 
###### Stool Concentration System
[](/para-pak/stool-specimens-parasitology-stains/) 
###### Parasitology Stains
### Ready to get more info on this? Lets talk!
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Parasitology Stains](https://www.meridianbioscience.com/para-pak/stool-specimens-parasitology-stains/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
[Home](https://www.meridianbioscience.com "Home")» [Stool Specimen Collection](https://www.meridianbioscience.com/para-pak/ "Stool Specimen Collection")»Parasitology Stains Parasitology Stains
# Parasitology Stains
Meridian’s parasitology stains for stool specimens are designed to support accurate identification of intestinal parasites in clinical diagnostics. With trusted formulations like Trichrome, Trichrome Blue, and Mayer’s Albumin, these stains enhance visualization of protozoan cysts and trophozoites under the microscope. Ideal for routine ova and parasite (O&P) testing, these high-quality stains ensure consistent results and meet the needs of parasitology labs seeking efficiency and diagnostic precision.
[ Contact Sales ](#paraform)
## Trusted Parasitology Stains for Stool Specimen Diagnostics
Meridian’s staining solutions—including Mayer’s Albumin, Trichrome Stain, Wheatley’s Trichrome, and Trichrome Blue—support accurate identification of intestinal parasites. These stains enhance contrast and clarity for improved microscopic examination, making them ideal for routine O&P testing and reliable parasite detection in stool specimens.
[](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-b/)##### Trichrome Enhancer B
Staining Reagents
[ View Product ](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-b/)
[](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-a/)##### Trichrome Enhancer A
Staining Reagents
Trichrome Enhancer A
[ View Product ](https://www.meridianbioscience.com/para-pak/trichrome-enhancer-a/)
[](https://www.meridianbioscience.com/para-pak/trichrome-blue-stain/)##### Trichrome Blue Stain
Fecal Staining Reagents
1 bottle – 500 mL of Trichrome Blue Stain for differential identification of microsporidia.
[ View Product ](https://www.meridianbioscience.com/para-pak/trichrome-blue-stain/)
[](https://www.meridianbioscience.com/para-pak/wheatleys-trichrome-stain/)##### Trichrome Stain 1 x 500 mL Bottle
Fecal Staining Reagents
1 bottle – 500 mL of Trichrome Stain for rapid differentiation of intestinal parasites in stool specimens.
[ View Product ](https://www.meridianbioscience.com/para-pak/wheatleys-trichrome-stain/)
[](https://www.meridianbioscience.com/para-pak/trichrome-stain/)##### Trichrome Stain 12 x 500 mL Bottles/Case
Fecal Staining Reagents
12 bottles – 500 mL each of Trichrome Stain for rapid differentiation of intestinal parasites in stool specimens.
[ View Product ](https://www.meridianbioscience.com/para-pak/trichrome-stain/)
[](https://www.meridianbioscience.com/para-pak/mayers-albumin/)##### Mayer’s Albumin
Slide Preparation Reagents
A premium adhesive for securely mounting specimens on glass slides for microscopic parasite detection.
[ View Product ](https://www.meridianbioscience.com/para-pak/mayers-albumin/)
### Stool Specimen Collection
[](/para-pak/one-vial-stool-transports/) 
###### One-Vial Stool Transport
[](/para-pak/two-vial-stool-sample-collection-kit/) 
###### Two-Vial Stool Transport
[](/para-pak/three-vial-stool-transport/) 
###### Three-Vial Stool Transport
[](/para-pak/stool-concentration-kit-system/) 
###### Stool Concentration System
[](/para-pak/stool-specimens-parasitology-stains/) 
###### Parasitology Stains
### Ready to get more info on this? Lets talk!
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
### [Stool Concentration System](https://www.meridianbioscience.com/para-pak/stool-concentration-system/)
**Published:** July 8, 2025
**Author:** Salman Haider
**Content:**
[Home](https://www.meridianbioscience.com "Home")» [Stool Specimen Collection](https://www.meridianbioscience.com/para-pak/ "Stool Specimen Collection")»Stool Concentration System Stool Concentration System
# Stool Concentration System
Meridian’s CON-Trate® system streamlines fecal sample processing for accurate parasite detection. Standardized concentration system for the recovery of helminth eggs, larvae, and protozoan cysts from feces to ensure consistent recovery, minimal handling, and optimized lab efficiency.
[ Contact Sales ](#paraform)
## Efficient Stool Concentration Systems for Parasite Recovery
The Meridian Para-Pak® CON-Trate® System uses efficient, cost-effective methods for recovering protozoan cysts, helminth eggs (including operculated eggs), and larvae from preserved fecal specimens. The addition of CON-Trate Reagent A and thorough mixing of the preserved specimen enhances the breakdown of fecal aggregates and mucus, thus freeing parasites. Filtering the stool-Reagent A suspension through the unique CON-Trate filtering device removes macroscopic fecal aggregates and debris.
[](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-system-500-sets-case/)##### CON-Trate® Stool Concentration System (500 sets/case)
Parasite Recovery
Stool concentration system with 15 mL tubes, caps, funnels, surfactant, packaged in 500 sets.
[ View Product ](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-system-500-sets-case/)
[](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-tubes-and-caps/)##### CON-Trate® Stool Concentration Tubes and Caps
Parasite Recovery
Stool concentration system containing 15 mL tubes and caps.
[ View Product ](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-tubes-and-caps/)
[](https://www.meridianbioscience.com/para-pak/macro-con-stool-concentration-system/)##### Macro-CON® Stool Concentration System
Parasite Recovery
Para-Pak Macro-CON is a system for the concentration of eggs, larvae, and protozoa from preserved fecal specimens.
[ View Product ](https://www.meridianbioscience.com/para-pak/macro-con-stool-concentration-system/)
[](https://www.meridianbioscience.com/para-pak/con-trate-concentration-system-200-sets-case/)##### CON-Trate® Stool Concentration System (200 sets/case)
Parasite Recovery
Stool concentration system containing 15 mL tubes, caps, funnels, surfactant, and ethyl acetate.
[ View Product ](https://www.meridianbioscience.com/para-pak/con-trate-concentration-system-200-sets-case/)
[](https://www.meridianbioscience.com/para-pak/ethyl-acetate-reagent-b/)##### Ethyl Acetate / Reagent B
Parasitology Reagents
Reagent used during the stool concentration procedure for parasite detection.
[ View Product ](https://www.meridianbioscience.com/para-pak/ethyl-acetate-reagent-b/)
[](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-filter-and-reagent-a/)##### CON-Trate® Stool Concentration Filter and Reagent A
Parasite Recovery
Filtration devices with Reagent A.
[ View Product ](https://www.meridianbioscience.com/para-pak/con-trate-stool-concentration-filter-and-reagent-a/)
### Stool Specimen Collection
[](/para-pak/one-vial-stool-transports/) 
###### One-Vial Stool Transport
[](/para-pak/two-vial-stool-sample-collection-kit/) 
###### Two-Vial Stool Transport
[](/para-pak/three-vial-stool-transport/) 
###### Three-Vial Stool Transport
[](/para-pak/stool-concentration-kit-system/) 
###### Stool Concentration System
[](/para-pak/stool-specimens-parasitology-stains/) 
###### Parasitology Stains
### Ready to get more info on this? Lets talk!
## Get in Touch With Us
[ Contact Us ](/contact-us/)
---
## Categories
### [Life Science Blog](https://www.meridianbioscience.com/category/lifescience-blog/)
---
### [Diagnostics Blog](https://www.meridianbioscience.com/category/diagnostics-blog/)
---
### [Press Release](https://www.meridianbioscience.com/category/press-release/)
---
### [Immunology](https://www.meridianbioscience.com/category/lifescience-blog/immunology/)
---
### [Molecular](https://www.meridianbioscience.com/category/lifescience-blog/molecular/)
---
### [NGS](https://www.meridianbioscience.com/category/lifescience-blog/molecular/ngs/)
---
### [Sustainability](https://www.meridianbioscience.com/category/lifescience-blog/molecular/sustainability/)
---
### [Gastrointestinal](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/)
---
### [H. pylori](https://www.meridianbioscience.com/category/diagnostics-blog/gastrointestinal/h-pylori/)
---
### [CMV](https://www.meridianbioscience.com/category/diagnostics-blog/cmv/)
---
### [Pediatric & Neonatal](https://www.meridianbioscience.com/category/diagnostics-blog/pediatric-neonatal/)
---
### [LeadCare](https://www.meridianbioscience.com/category/diagnostics-blog/leadcare/)
---
### [POCT](https://www.meridianbioscience.com/category/poct/)
---
### [Liquid Biopsy](https://www.meridianbioscience.com/category/lifescience-blog/liquid-biopsy/)
---
### [Precision Oncology](https://www.meridianbioscience.com/category/lifescience-blog/precision-oncology/)
---
### [Blockers](https://www.meridianbioscience.com/category/lifescience-blog/blockers/)
---
### [campylobacter](https://www.meridianbioscience.com/category/diagnostics-blog/campylobacter/)
---
### [E. coli](https://www.meridianbioscience.com/category/diagnostics-blog/e-coli/)
---
## Antibodies & Antigens
### [Cancer Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/)
**Description:** High-quality cancer marker antigens and antibodies for ELISA, CLIA, and lateral flow diagnostics. Detect AFP, CEA, CA 125, PSA, and more with confidence.
---
### [PSA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/psa/)
**Description:** Prostate-specific antigen (PSA) is a protease that digests the high molecular weight protein of the seminal coagulum into smaller polypeptides. It exists in serum in multiple forms: complexed to alpha-1-anti-chymotrypsin (PSA-ACT complex), unbound (free PSA), and enveloped by alpha-2-macroglobulin. In the early 1990s, the FDA approved the measurement of PSA to diagnose prostate cancer. During the screening, higher total PSA levels observed with a lower percentage of free PSA correlate with higher risks of prostate cancer. Diagnostic assays for NSE are based on the antibody sandwich principle using ELISA or CLIA.
---
### [Cardiac, Cholesterol, & Metabolic Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/)
**Description:** Antibodies and antigens for cardiac, cholesterol, and metabolic biomarkers to support immunoassay development and research applications.
---
### [CRP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/crp/)
**Description:** C-reactive protein (CRP) is an acute-phase inflammation protein released by the liver leading to activation of the complement cascade and production of cytokines such as interleukin 6 (IL-6). It is elevated in autoimmune disorders, organ rejection, infection, and thrombosis. CRP is used as a marker of inflammation and high sensitivity CRP (hS-CRP) assays are able to detect low levels of CRP which can be seen in persistent levels of inflammation that can increase an individual’s risk of cardiovascular disease. Quantitative hs-CRP assays are based on the two-site sandwich ELISA or CLIA assay principles.
---
### [Autoimmune](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/)
**Description:** High-quality antigens and antibodies suited for the development of diagnostic assays detecting localized and systemic autoimmune disorders.
---
### [SS-B](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ss-b/)
**Description:** La (SS-B) is one of four autoantigens commonly referred to as extractable nuclear antigens (ENA). The other ENAs are SS-A/Ro, RNP, and Sm.
---
### [Cystatin C](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/cystatin-c/)
**Description:** Cystatin C is a cysteine protease inhibitor produced by all nucleated cells, serving as a crucial biomarker for assessing kidney function. Meridian Bioscience offers high-quality monoclonal antibodies targeting animal Cystatin C, facilitating the development of precise diagnostic assays. These antibodies are suitable for applications such as enzyme immunoassays (EIA) and protein purification processes. For instance, their monoclonal antibody is an IgG2a isotype derived from mouse hosts, purified for optimal performance in various immunoassays.
---
### [Adiponectin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/adiponectin/)
**Description:** Adiponectin is a hormone produced by fat cells that regulates glucose and fat metabolism. It has anti-inflammatory and insulin-sensitizing effects, promoting metabolic health. Lower adiponectin levels are linked to obesity and diabetes, while higher levels reduce these risks. Testing options like the Adiponectin blood test can measure Adiponectin levels and insulin sensitivity, and many opt for the best adiponectin supplements to support metabolic health.
---
### [CA50](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca50/)
**Description:** CA50 Cancer antigen 50 (CA50) is a glycolipid that is similar to the tumor marker CA19-9; however, CA50 antibodies recognize both the fucosyl form of sialylated Lewis(a) carbohydrate moiety and sialylated Lewis(a) moiety.
---
### [CA242](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca242/)
**Description:** description" content="CA242 is related to the sialylated Lewis (a) blood group antigen (CA19-9) and is found on the same mucin complex as CA50 and sialylated Lewis A (CA19-9), but it is chemically and immunologically distinct.
---
### [Intrinsic Factor](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/intrinsic-factor/)
**Description:** Intrinsic Factor Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Hemoglobin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/hemoglobin/)
**Description:** Hemoglobin is a crucial protein in red blood cells responsible for carrying oxygen throughout the body. Monitoring its levels is essential for assessing overall health. A Hemoglobin test or Hemoglobin blood test measures the concentration of hemoglobin in the blood, helping to diagnose conditions such as anemia or other blood disorders. For individuals managing diabetes, the Hemoglobin A1c test is important, as it reflects average blood sugar levels over the past few months. Regular Hemoglobin level tests, including the Hemoglobin A1c blood test, are critical for both diagnosing blood-related issues and managing long-term glucose control
---
### [Hormones & Steroids](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/)
**Description:** Hormones are a class of regulatory biochemicals that are produced by specific glands and tissues and travel to various sites in the body to affect bodily
---
### [hCG](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/hcg/)
**Description:** Human chorionic gonadotropin (hCG) is a placental hormone initially secreted by cells that surround an implanted embryo in pregnancy. Its primary role is to maintain the function of the corpus luteum during the first 3 to 4 months of pregnancy. The protein has many other roles including stimulating the onset of fetal gonadal steroidogenesis.
---
### [Allergens](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/allergens/)
**Description:** Learn about Meridian's comprehensive solutions for Allergen testing.
---
### [Seminal Plasma](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/allergens/seminal-plasma/)
**Description:** Meridian Bioscience provides Human Seminal Plasma Antigens, purified liquid reagents derived from human seminal plasma, intended for use in developing diagnostic assays. They also offer Prostate-Specific Antigen (PSA) products, including highly purified PSA antigens and monoclonal antibodies, supporting research and diagnostic applications related to prostate health.
---
### [hGH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/hgh/)
**Description:** Human growth hormone (hGH), also known as somatotropin, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration and is essential for normal growth and development in children. In adults, growth hormone plays a role in regulating bone density, muscle mass, and glucose and lipid metabolism. It can also affect heart and kidney function.
---
### [TPO](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/tpo/)
**Description:** TPO Thyroid peroxidase (TPO) is an enzyme normally found in the thyroid gland which plays an important role in the production of thyroid hormones, converting the thyroid hormone T4 to T3.
---
### [Testosterone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/testosterone/)
**Description:** Testosterone is the primary male sex hormone and an anabolic steroid. In male humans, it is secreted by the testes and it plays a key role in the development of male reproductive tissues, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair.
---
### [NSE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/neuron-specific-enolase-nse/)
**Description:** Neuron-specific enolase (NSE) is a glycolytic enzyme that catalyzes the conversion of phosphoglycerate to phosphoenolpyruvate and is the dominant enolase-isoenzyme found in neuronal and neuroendocrine tissues. NSE expression occurs in small cell lung cancer, neuroblastoma, neuroendocrine tumors, and events resulting in brain damage. NSE is currently used to monitor disease progression and management in small cell lung cancer, neuroblastoma, and select events of brain damage resulting from ischemic stroke. Assays for NSE are based on the antibody sandwich principle using ELISA or CLIA. They can be affected by false low results in the presence of extremely high NSE concentrations or autoantibodies to NSE and false results in the presence of heterophile antibodies.
---
### [tTG](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ttg/)
**Description:** tTG Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Blockers & Immunoglobulins](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/)
**Description:** Explore blockers and species-specific immunoglobulins to reduce background and enhance assay performance. Ideal for ELISA, lateral flow, and diagnostic development.
---
### [IgM](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/igm/)
**Description:** Learn more about our IgM antigens & antibodies. Human IgM can be used in flow cytometry, IHC, sandwich or competitive ELISAs, or lateral flow assays
---
### [Procalcitonin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/pct/)
**Description:** Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin and is a marker of inflammation in bacterial infections and heart failure. Severe or worsening heart failure is associated with systematic inflammation, and patients with heart failure have significantly higher plasma PCT concentrations than healthy subjects. High PCT levels are associated with worse outcomes, and quantitative measurements of PCT offer a prognostic value that correlates with clinical outcomes and can potentially guide drug therapy.
---
### [Mitochondrial Ag](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/mitochondrial-ag/)
**Description:** Mitochondrial Ag Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [BSA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/bsa/)
**Description:** Improve the specificity and sensitivity of your immunoassays with our high-quality Bovine Serum Albumin (BSA) blocking buffers. Our wide selection of BSA
---
### [CENP-B](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/cenp-b/)
**Description:** CENP-B Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Osteopontin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/osteopontin/)
**Description:** Osteopontin is a glycoprotein involved in bone remodeling and tumor progression. Meridian Bioscience offers a range of products to support research and diagnostic assay development related to osteopontin, including purified human osteopontin antigen and monoclonal antibodies targeting specific regions of the protein, such as the N-terminal and C-terminal regions
---
### [Ferritin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/ferritin/)
**Description:** Ferritin is a protein that stores iron in the body, and its levels are crucial for diagnosing various health conditions, especially those related to iron deficiency or overload. A Ferritin test or Ferritin blood test is commonly used to measure the amount of ferritin in your blood, providing valuable insights into your iron levels. If you’re experiencing symptoms of low iron, such as fatigue or weakness, a Ferritin blood test can help determine whether you have low Ferritin levels. For convenience, a Ferritin test kit is also available for home use, allowing you to monitor your iron levels easily.
---
### [LD](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ld/)
**Description:** Lactate dehydrogenase (LD) is an enzyme involved in energy production and serves as a biomarker for various diseases, including cancer. Meridian Bioscience offers human lactate dehydrogenase 3 (LD3) antigen to support research and diagnostic assay development related to LD.
---
### [AFP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/afp/)
**Description:** Learn about Meridian's antibodies and antigens for alpha-fetoprotein (AFP) AFP-L3 form used in prognostic and diagnostic testing.
---
### [Vitamin D](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/vitamin-d/)
**Description:** Vitamin D is a fat-soluble precursor of the steroid hormone calcitriol, which is required to maintain normal blood calcium and phosphate levels. It plays a critical role in several metabolic functions, including bone mineralization, muscle contraction, nerve conduction, and overall cellular functioning. Total Vitamin D assays measure the level of both 25 OH Vitamin D3 (calcidiol) and 1,25-Dihydroxy Vitamin D3 (calcitriol). Serum 25 OH Vitamin D3 is the most stable circulating form of vitamin D, and a low blood level suggests that a person is not getting enough exposure to sunlight or enough dietary vitamin D. 1,25-Dihydroxy Vitamin D3 regulates the expression of hundreds of genes and a low level is indicative of kidney failure.
---
### [Lp-PLA2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/lp-pla2/)
**Description:** Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory enzyme primarily produced by lymphocytes and macrophages. In plasma, Lp-PLA2 is predominantly bound to LDL and preferentially cleaves oxidized phospholipids, resulting in the generation of lysophosphatidylcholine and oxidized FFAs, both of which are proatherogenic and contribute to the cytotoxic effects of oxidized LDL on macrophages. Elevated levels of Lp-PLA2 indicate a greater risk of plaque formation and rupture and can indicate an increased risk of cardiac events. Approximately two-thirds of heart attacks and strokes are caused by the rupture of an unstable, rupture-prone atherosclerotic plaque.
---
### [Pepsinogen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/pepsinogen/)
**Description:** Pepsinogen is a precursor to pepsin, an enzyme critical for protein digestion in the stomach. There are two primary isoforms: Pepsinogen I and Pepsinogen II, both serving as biomarkers for various gastric conditions.
---
### [Myoglobin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/myoglobin/)
**Description:** Myoglobin is a protein found in muscle tissues that plays a vital role in oxygen storage and transport within muscles. When muscle damage occurs, Myoglobin can be released into the bloodstream, making it an important marker for detecting muscle injury or conditions like heart attacks. A Myoglobin test, often a Myoglobin blood test or Myoglobin urine test, helps measure the levels of this protein to assess muscle damage. Myoglobin level tests are commonly used in medical diagnostics, while Myoglobin test kits, including Myoglobin rapid test kits, offer convenient options for timely detection and monitoring in clinical or home settings.
---
### [CEA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/cea/)
**Description:** Carcinoembryonic Antigen (CEA) a protein produced by cancer cells and its role as a tumor marker in detecting and monitoring certain cancers. Elevated CEA
---
### [Beta 2 Microglobulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/beta-2-microglobulin/)
**Description:** Have questions about a Beta 2 Microglobulin? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Renal Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/renal-diseases/)
**Description:** Diagnostic assays targeting specific antigens and antibodies improve early detection and treatment decision-making, enhancing patient outcomes for renal diseases.
---
### [Microglobulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/renal-diseases/microglobulin/)
**Description:** Meridian Bioscience provides antigens and antibodies for alpha-1 microglobulin and beta-2 microglobulin, supporting research and diagnostic assay development. Their offerings include purified alpha-1 microglobulin antigen and beta-2 microglobulin antigen, valuable for studies related to renal diseases and cancer markers.
---
### [CA19-9](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca19-9/)
**Description:** Cancer antigen 19-9 (CA19-9), also known as the carbohydrate antigen Sialyl-Lewis(a) (sLe(a)), is widely expressed on epithelial tumors of gastrointestinal
---
### [D-Dimer](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/d-dimer/)
**Description:** D-Dimer is a fibrin degradation product – during fibrinolysis, plasmin breaks down fibrin and fibrinogen and a variety of cross-linked fibrin degradation products are produced. D-dimer is the smallest of these fibrin degradation products and it is a sensitive, but non-specific marker of fibrin formation and fibrinolysis that occurs with the formation of blood clots. Elevated serum D-Dimer levels indicate recent or ongoing fibrinolysis and is used to monitor patients for disseminated intravascular coagulation or other life-threatening thrombotic conditions like a pulmonary embolism. Levels of D-dimer can be measured quantitively using a two-site sandwich ELISA or CLIA assay.
---
### [Prolactin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/prolactin/)
**Description:** Prolactin (PRL) is a hormone that is best known for its role in initiating and maintaining lactation in mammals. It is secreted by the anterior pituitary gland and controlled by the hypothalamus.
---
### [Gastrointestinal Pathogens](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/)
**Description:** Gastrointestinal Pathogens A gastrointestinal infection (gastroenteritis) is an infection caused by a virus, bacteria, or parasite that causes inflammation of the gastrointestinal tract (GI) and has the characteristic symptoms of excessive, watery diarrhea and stomach pain.
---
### [Calprotectin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/calprotectin/)
**Description:** Calprotectin is a calcium and zinc-binding protein that belongs to the S100 family and is very abundant in the cytosol of neutrophils. It is involved in many physiological functions, including cell differentiation, immune regulation, tumorigenesis, apoptosis, and it plays a major role during inflammation. Fecal calprotectin serves as a sensitive marker for inflammation in the gastrointestinal tract and is useful for differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS). Its levels can be quantitively measured using a two-site sandwich ELISA or CLIA assay.
---
### [GBM](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/gbm/)
**Description:** The glomerular basement membrane (GBM) is a specialized structure with a significant role in maintaining the glomerular filtration barrier. Anti–GBM antibody disease (also known as Goodpasture’s Syndrome) is a rare autoimmune disorder in which autoantibodies target and cause damage to the GMB of the kidney. The primary target of these autoantibodies is collagen type IV which is present in the lung and the glomerulus of the nephron. Rapid diagnostic testing using native or recombinant GBM to detect the presence of GBM autoantibodies is critical in the management of this rare, life-threatening disease.
---
### [Histone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/histone/)
**Description:** Histones are proteins that are a part of chromatin and aid in the coiling of DNA. Certain autoimmune conditions cause the development of histone autoantibodies, which are a type of antinuclear antibodies (ANA). Antibodies to histones are usually found in people with drug-induced lupus, but they can also be found in people with systemic lupus. Detection of anti-histone antibodies is essential for diagnosing and caring for patients at risk of drug-induced lupus or in managing ongoing autoimmune conditions.
---
### [BPI Protein](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/bpi-protein/)
**Description:** Have questions about a BPI Protein?Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Cathepsin G](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/cathepsin-g/)
**Description:** Cathepsin G is a serine protease that plays an important role in inflammation and the immune reaction and works by modifying chemokines, cytokines, and cell surface receptors, controlling blood pressure and inducing thrombogenesis.
---
### [Elastase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/elastase/)
**Description:** Have questions about a Elastase? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [LH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/lh/)
**Description:** Luteinizing hormone (LH) is a gonadotropic hormone that is produced by the pituitary gland and operates in conjunction with FSH to drive puberty, menstruation and fertility. A surge in LH levels triggers ovulation and the development of the corpus luteum in females, and in males it causes the Leydig cells to release testosterone.
---
### [CA125](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca125/)
**Description:** CA125 Cancer antigen 125 (CA125) is a protein in humans encoded by the MUC16 gene and found on the cell membrane of ovarian cancer cells. CA125 is the only tumor marker recommended for clinical use in the diagnosis and management of ovarian cancer.
---
### [Entamoeba Dispar](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/entamoeba-dispar/)
**Description:** Entamoeba dispar is a non-pathogenic amoeba commonly found in the human intestine. Unlike its pathogenic relative, Entamoeba histolytica, which can cause severe illness, E. dispar typically does not cause symptoms or harm. Entamoeba dispar testing is used to differentiate it from E. histolytica and involves entamoeba dispar immunoassay reagents and enzyme immunoassay tests for accurate detection. While E. dispar generally does not require treatment, understanding its presence is important for accurate diagnosis. Entamoeba hartmanni, another similar amoeba, may also be tested and treated if needed, although it is typically asymptomatic as well.
---
### [Enterovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/enterovirus/)
**Description:** Enterovirus infections are caused by many different viruses including coxsackievirus, echovirus, enterovirus, and poliovirus. They are responsible for causing illnesses in 10 to 30 million people each year in the United States, primarily in the summer and fall and they are most common among children. Infections are highly contagious and typically affect many people in a community, sometimes reaching epidemic proportions.
---
### [Hemoglobin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/hemoglobin-cancer-markers/)
**Description:** Hemoglobin is a vital protein in red blood cells responsible for oxygen transport. Meridian Bioscience offers high-quality hemoglobin antigens and antibodies to support diagnostic assay development. These products are designed for applications in cardiac and cholesterol marker research.
---
### [Shigella](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/shigella/)
**Description:** Shigellosis is a very contagious diarrheal disease caused by infection with one of four species of Shigella bacteria (S. dysenteriae, S. flexneri, S. boydii or S. sonnei). Symptoms include an acute onset of diarrhea, fever, nausea, vomiting, and abdominal cramps. The infectious dose is very low (as few as 10 organisms) and the bacteria are spread by the fecal-oral route. Diagnosis relies on detection of the bacteria by ELISA, culture, or PCR in stool samples.
---
### [Yersinia Enterocolitica](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/yersinia-enterocolitica/)
**Description:** Yersinia enterocolitica is a bacterium that causes gastrointestinal infections, leading to symptoms like diarrhea, abdominal pain, and fever. It’s typically transmitted through contaminated food, especially pork, or untreated water. In some cases, it can mimic appendicitis, making diagnosis tricky.
---
### [Cryptosporidium](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/cryptosporidium/)
**Description:** Cryptosporidium is a microscopic parasite that can be found in soil, food, and water, or on surfaces that have been contaminated with feces from infected humans or animals. Transmission occurs by the fecal-oral route and infection causes the diarrheal disease cryptosporidiosis. The disease is usually mild and self-limiting (1–2 weeks) but in people with impaired immunity, the illness can be serious, prolonged, and life-threatening. Diagnosis relies on the detection of oocytes in fecal or environmental samples either by microscopy or monoclonal antibody ELISA.
---
### [Food & Water Testing](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/)
**Description:** Learn more about food and water testing and food testing antigens and how they play a vital part in the development of assays
---
### [Listeria](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/listeria/)
**Description:** Listeriosis is a rare but serious disease caused by the bacteria Listeria monocytogenes which is found in soil, water, and on certain high-risk foods. It is a foodborne illness that can be fatal for unborn babies in pregnant women, people older than 65, and people with weakened immune systems. It is most commonly caused by eating improperly processed deli meats and unpasteurized milk products. ELISA PCR and bacteria culture are commonly used for detecting Listeria in food and water samples.
---
### [Lactoferrin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/lactoferrin/)
**Description:** Meridian Bioscience offers high-quality lactoferrin antibodies and antigens for diagnostic and research applications. Lactoferrin, an iron-binding glycoprotein found in various body fluids, plays a key role in immune response and antimicrobial activity. These reagents are ideal for detecting lactoferrin in biological samples, useful in diagnosing infections and inflammatory conditions. Validated for use in immunoassays and laboratory tests, the products provide reliable, high-specificity results for accurate detection and analysis.
---
### [Campylobacter](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/campylobacter/)
**Description:** Campylobacteriosis is a foodborne gastrointestinal disease caused by bacteria called Campylobacter which is commonly found in food animals. Ingestion of undercooked meat is one of the main routes of transmission and bacteria is one of four key global causes of diarrheal diseases. Infections are generally mild, but they can be fatal among very young children and the elderly. Diagnosis is generally by culture or rapid antigen detection using stool or other body fluids.
---
### [C. jejuni](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/c-jejuni/)
**Description:** Campylobacter jejuni (C. jejuni) is a bacterium frequently linked to foodborne illnesses, particularly gastroenteritis, and is a leading cause of bacterial diarrhea globally. Infections typically occur after consuming undercooked poultry or contaminated water. Campylobacter jejuni treatment often involves supportive care, though in severe cases, antibiotics for Campylobacter jejuni, such as azithromycin or ciprofloxacin, may be required. Early diagnosis can be facilitated by using a Campylobacter antigen assay to detect the presence of C. jejuni bacteria in stool samples, enabling timely intervention.
---
### [Respiratory Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/)
**Description:** Meridian provides reagent solutions for immunological respiratory diseases and organisms which can cause respiratory infections including viruses, bacteria, fungi, and parasites diagnostic assays.
---
### [Legionella pneumophila](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/legionella-pneumophila/)
**Description:** Legionella species are consistently recognized as one of the most common causes of pneumonia. Legionella pneumophila serogroup 1 is responsible for most human infections and is the causative agent of Legionnaires’ disease, also known as legionellosis. The bacteria occur naturally in freshwater however, artificial water systems, such as large building air-conditioning systems, provide environments conducive to growth and can cause a disease outbreak.
---
### [Strep A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/streptococcus-group-a/)
**Description:** Group A Streptococcus (GAS) is part of the streptococcus group of bacteria, which includes over 200 strains, with Streptococcus pyogenes being the most common. Infection with GAS can cause a range of symptoms, including sore throats (pharyngitis), scarlet fever, or impetigo, and some strains can also cause serious conditions such as toxic shock syndrome. Diagnosis is typically by culture or rapid antigen detection assays; however, molecular detection is becoming more widely available.
---
### [E. coli](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/e-coli/)
**Description:** Escherichia coli (E. coli) are bacteria normally found in the environment, food, and intestines of people and animals. Most strains are harmless however some strains can produce toxins that cause diarrhea, urinary tract infections, respiratory disease, and other illnesses. Transmission is generally foodborne and the strain E. coli O157:H7 which produces Shiga toxin is responsible for the majority of foodborne outbreaks. Diagnosis is usually by serotype-specific enzyme immunoassays that detect E. coli O157 directly from stool samples. Other diagnostic tests include PCR and cytotoxicity testing.
---
### [Streptococcus pneumoniae](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/streptococcus-pneumoniae/)
**Description:** Streptococcus pneumonia are gram-positive bacteria responsible for most community-acquired pneumonia cases and 1-2 million infant deaths worldwide each year. There are over 100 serotypes of the bacteria, and they are found to naturally colonize in the nasopharynx without symptoms. However, in susceptible individuals such as babies and older adults, the bacteria can migrate to sterile tissues and organs and cause pneumonia over time. Diagnosis is by culture, antigen detection, or PCR. Rapid antigen testing using urine specimens is the most widely used test and relies on the detection of the group C polysaccharide cell wall antigen common to all pneumococcal strains.
---
### [H. Pylori](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/h-pylori/)
**Description:** Helicobacter pylori (H. pylori) is a gram-negative bacterium that causes chronic inflammation in the stomach and duodenum, which can develop into gastric ulcer disease and gastric cancer. Infection with H. pylori is the strongest known risk factor for gastric cancer, which is the second leading cause of cancer-related deaths worldwide. It is estimated that up to 50% of the world’s population is infected with H. pylori but are asymptomatic. Diagnosis is by a urea breath test, molecular detection, or rapid antigen stool assays.
---
### [CA72-4](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca72-4/)
**Description:** CA72-4 Cancer antigen 72-4 (CA72-4) is a tumor-associated-glycoprotein (TAG-72) used as a tumor marker for gastrointestinal and ovarian cancers.
---
### [Vet Health](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/)
**Description:** Meridian has a range of antigens & antibodies ideal for veterinary diagnostics. Many of the mixes have been designed for the direct detection of DNA or RNA from crude samples such as blood, saliva, and urine.
---
### [Thyroglobulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/tryroglobulin/)
**Description:** Thyroglobulin (Tg) is a dimeric protein produced by the follicular cells of the thyroid and accounts for approximately half of the protein content of the thyroid gland. It is the precursor for the thyroid hormones T3 and T4 and each Tg molecule forms approximately 10 thyroid hormone molecules.
---
### [Distemper](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/canine-distemper-virus/)
**Description:** Canine distemper is caused by the canine distemper virus (CDV), an RNA paramyxovirus that is highly contagious and spreads through direct contact or airborne exposure. CDV attacks the respiratory, gastrointestinal, and nervous systems and it is often fatal with a mortality rate of 50% in adult dogs and 80% in puppies. The virus can also be found in wildlife such as foxes, wolves, coyotes, raccoons, skunks, mink, and ferrets and has been reported in lions, tigers, leopards, and other wild cats as well as seals. Diagnosis is by serology testing for disease-specific IgM or IgG antibodies, RT-PCR analysis, or histopathology.
---
### [Parvovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/parvovirus/)
---
### [Canine Coronavirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/canine-coronavirus/)
---
### [FIV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/feline-immunodeficiency-fiv/)
**Description:** Feline immunodeficiency virus (FIV) is a retrovirus infection that is often referred to as cat HIV or cat AIDS because it has a similar effect on felines. The virus attacks the immune system and advances through 3 phases: the acute phase, the asymptomatic (or latent) phase, and the progressive phase, leaving the cat vulnerable to secondary infections. The primary mode of transmission for FIV is through bite wounds from an infected cat. Diagnosis is by ELISA which detects disease-specific IgG antibodies that take 2-6 months to develop post-infection, and confirmation is by PCR.
---
### [ENA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ena/)
**Description:** Have questions about a ENA? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [IgE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/ige/)
**Description:** IgE Human IgE can be used in flow cytometry, IHC, sandwich or competitive ELISAs, or lateral flow assays to block non-specific binding. Animal anti-IgE can be used as secondary antibodies for indirect detection in immunoassays.
---
### [Bovine Spleen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/bovine-spleen/)
**Description:** Bovine Spleen Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Epithelial Cells](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/epithelial-cells/)
**Description:** Epithelial Cells Epithelial Cell Extract, Human Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [SS-A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ss-a/)
**Description:** Have questions about a SS-A? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Jo-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/jo-1/)
**Description:** Jo-1 Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Sm Antigen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/sm-antigen/)
**Description:** Sm Antigen Smith antigen (Sm Ag) is one of four autoantigens commonly referred to as extractable nuclear antigens (ENA).
---
### [Sm/RNP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/sm-rnp/)
**Description:** Have questions about a Sm/RNP? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Scl-70](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/scl-70/)
**Description:** Scl-70 Scl-70 antigen is an abundant nuclear protein that is an extractable fragment (70 kD) of a larger protein (100-105kD), Topoisomerase I
---
### [Laminin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/laminin/)
**Description:** Laminin 5 is an essential extracellular matrix protein involved in cell adhesion and tissue organization. Meridian Bioscience offers a purified human Laminin 5 antigen suitable for Western Blot applications, supporting research and diagnostic assay development related to this protein.
---
### [Apolipoprotein](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/apolipoprotein/)
**Description:** Apolipoproteins are lipid transport proteins, helping to move lipids (and fat-soluble vitamins) in the body. They are produced in the small intestine and the liver and each apolipoprotein have a specific function in lipid transport and metabolism. Apolipoprotein A (Apo A) is the primary portion of the high-density lipoprotein (HDL) which plays an important role in transporting cholesterol from the peripheral tissues to the liver, where it can be excreted. Apo B, specifically the form ApoB-100, is the main lipoprotein of low-density lipoprotein (LDL) and which are the primary driver of plaques that cause vascular disease. Apo E is a major component of HDL-like particles in the brain and high levels are associated with increased all-cause, cardiovascular, and cancer mortality. The ε4 allele of Apo E is also the major genetic risk factor for Alzheimer’s disease. Diagnostic assays that measure the levels of Apo B-100 help determine the risk of developing cardiovascular disease and sometimes help monitor treatment for high cholesterol. Apo A testing is typically done in combination with Apo B as apo B/apo A1 ratio has been shown to be predictive of ischemic stroke in patients. Apo E levels are measured for diagnosing hyperlipoproteinemia in patients with increase plasma triglycerides and cholesterol.
---
### [MPO](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/myeloperoxidase/)
**Description:** Myeloperoxidase (MPO) is a peroxidase enzyme and a marker of inflammation and neutrophil activation during strenuous exercise. In addition, it has been implicated in the oxidation of lipids contained in low-density lipoproteins, infiltration of macrophages and neutrophils, formation of unstable coronary plaques, and plaque rupture. MPO is elevated in patients with coronary artery disease and can be a prognostic marker for identifying patients with unstable plaques before complete microvascular obstruction. MPO serves as a risk marker for atherosclerosis and coronary artery disease, predicting the early risk of myocardial infarction. Quantitative assays for MPO are based on the antibody sandwich principle using ELISA or CLIA.
---
### [CANCA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/canca/)
**Description:** CANCA Anti-neutrophil cytoplasmic antibodies (ANCA) are autoantibodies that cause systemic vascular inflammation by binding to target antigens of neutrophils.
---
### [CA15-3](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ca15-3/)
**Description:** CA15-3 Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Cyfra-21-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/cyfra-21-1/)
**Description:** Cyfra-21-1 Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Collagen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/collagen/)
**Description:** Collagen Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [HDL](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/hdl/)
**Description:** High-Density Lipoprotein (HDL) is often referred to as “good cholesterol” due to its role in transporting cholesterol from peripheral tissues to the liver for excretion, thereby reducing the risk of cardiovascular diseases. Apolipoprotein A-I (Apo A-I) is the major protein component of HDL and plays a crucial role in lipid metabolism.
---
### [LDH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ldh/)
**Description:** Lactate dehydrogenase (LDH) is an enzyme involved in energy production and serves as a biomarker for various diseases, including cancer. Meridian Bioscience offers a total LDH antigen sourced from human erythrocytes, provided in an ammonium sulfate suspension format. This antigen is designed to support research and diagnostic assay development related to LDH.
---
### [CK-MB](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ck-mb/)
**Description:** Meridian Bioscience offers a comprehensive range of recombinant Creatine Kinase (CK) isoenzymes, including CK-MM, CK-MB, and CK-BB, to support the development of precise diagnostic assays for cardiac and muscular health. These high-purity antigens are suitable for use in enzyme-linked immunosorbent assays (ELISA) and Western blot applications, ensuring reliable performance in clinical diagnostics.
---
### [IgG](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/igg/)
**Description:** IgG is the major immunoglobulin in blood, lymph fluid, cerebrospinal fluid, and peritoneal fluid and a key player in the humoral immune response.
---
### [SDF-1a](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/sdf-1a/)
**Description:** Stromal cell-derived factor 1 alpha (SDF-1α), also known as CXCL12, is a chemokine involved in various physiological processes, including embryonic development, hematopoiesis, and cardiac ventricular septal formation. Elevated levels of SDF-1α have been observed in several cardiac diseases and it has been suggested as a prognostic marker in atrial fibrillation.
---
### [Interleukin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/interleukin/)
**Description:** Interleukins are a group of cytokines that play crucial roles in the immune system by mediating communication between cells, regulating cell growth, differentiation, and motility, and orchestrating immune responses. They are involved in various physiological processes and have been implicated in numerous diseases, making them important targets for research and diagnostic applications.
---
### [Interleukin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/interleukin-cancer-markers/)
**Description:** Interleukins are cytokines that play pivotal roles in immune system regulation and inflammatory responses. Meridian Bioscience offers recombinant Interleukin 18 (IL-18) antigens to support research and diagnostic assay development related to autoimmune diseases. These high-quality reagents are designed to assist in the detection and study of IL-18’s involvement in various inflammatory conditions.
---
### [Antithrombin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/antithrombin/)
**Description:** Antithrombin is a critical serine protease inhibitor that regulates blood coagulation by neutralizing thrombin and other clotting factors, thereby preventing excessive clot formation. Deficiencies or dysfunctions in antithrombin can lead to an increased risk of thrombotic disorders, making it a vital marker in coagulation studies.
---
### [Macroglobulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/macroglobulin/)
**Description:** Alpha-2-macroglobulin is a plasma protein that functions as a broad-spectrum protease inhibitor, playing a significant role in inhibiting various proteases. Meridian Bioscience offers a purified human alpha-2-macroglobulin antigen to support research and diagnostic assay development related to this protein
---
### [HNE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/hne/)
**Description:** Have questions about a HNE? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Myeloma](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/myeloma/)
**Description:** Multiple myeloma is a cancer of plasma cells characterized by the overproduction of abnormal immunoglobulins. Meridian Bioscience provides purified human myeloma Immunoglobulin E (IgE) antigens to support research and diagnostic assay development related to this disease. These antigens are suitable for use in Enzyme Immunoassay (EIA) applications.
---
### [IgA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/iga/)
**Description:** Improve the specificity and sensitivity of your immunoassays with our high-quality Immunoglobulin A (IgA) reagents. Learn more about use of IgA
---
### [Plasminogen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/plasminogen/)
**Description:** Plasminogen is a glycoprotein synthesized primarily in the liver, circulating in the blood as an inactive precursor of plasmin, a serine protease essential for fibrinolysis—the process of breaking down blood clots. Beyond its central role in clot dissolution, plasminogen is involved in various physiological processes, including tissue remodeling, wound healing, and inflammation.
---
### [Prealbumin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/prealbumin/)
**Description:** Prealbumin, also known as transthyretin, is a hepatic protein that transports thyroxine (T4) and retinol-binding protein-bound vitamin A in the bloodstream. It serves as a sensitive marker for nutritional status and liver function. Accurate measurement of prealbumin levels is crucial for diagnosing and monitoring conditions such as malnutrition, inflammation, and hepatic diseases. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting prealbumin
---
### [Trypsin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/trypsin/)
**Description:** Trypsin is a serine protease essential for protein digestion and is utilized in various diagnostic assays. Meridian Bioscience provides purified human pancreatic trypsin antigen to support research and diagnostic assay development.
---
### [Serum](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/serum/)
**Description:** Serum Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [PAI-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/pai-1/)
**Description:** Plasminogen Activator Inhibitor 1 (PAI-1) is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), both of which are key activators of fibrinolysis. Elevated levels of PAI-1 have been associated with an increased risk of atherosclerosis and myocardial infarction due to their role in inhibiting fibrinolysis and promoting thrombosis.
---
### [Vitronectin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/vitronectin/)
**Description:** Vitronectin is a glycoprotein involved in cell adhesion and tissue remodeling. Meridian Bioscience offers purified human vitronectin antigen and a rabbit polyclonal antibody targeting vitronectin to support related research and diagnostic assay development.
---
### [Fibronectin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/fibronectin/)
**Description:** Fibronectin is a high-molecular-weight glycoprotein present in the extracellular matrix and plasma, playing a pivotal role in cell adhesion, growth, migration, and differentiation. It is essential for various physiological processes, including wound healing and embryogenesis, and has been implicated in pathological conditions such as cancer metastasis and fibrosis.
---
### [Blockers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/blockers/)
**Description:** Immunoassay blocking reagents and solutions, including recombinant and animal-free blockers, to reduce HAMA, RF, and heterophilic antibody interference.
---
### [FBP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/fbp/)
**Description:** FBP Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Miscellaneous Reagents](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/)
**Description:** Explore buffers, substrates, stabilizers, and other essential reagents for immunoassay development. Optimize ELISA, lateral flow, and diagnostic test performance.
---
### [Galactosidase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/galactosidase/)
**Description:** Galactosidase is an essential enzyme involved in the degradation of glycoproteins and glycolipids. Deficiencies in this enzyme are linked to genetic conditions such as GM1 gangliosidosis. Meridian Bioscience provides high-quality antibodies specific to β-galactosidase, supporting reliable immunoassay development and enhancing diagnostic accuracy for metabolic disorders.
---
### [Disialoganglioside GD1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/disialoganglioside-gd1/)
**Description:** Disialoganglioside GD1 Get In Touch With A Specialist Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [S-100](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/s100/)
**Description:** There are over 21 different S-100 proteins, and they have intracellular and extracellular functions, including regulation of protein phosphorylation, enzyme activities, cell growth and differentiation, and the inflammatory response. Dysregulated expression of several S100 proteins is a common feature of human cancers, with each type of cancer showing a unique S-100 protein profile and/or isoform. S-100B is a diagnostic marker for melanoma in human and veterinary medicine, and it may also aid the detection of micrometastatic disease in the lymph nodes. Circulating S-100B is measured by two-site sandwich ELISA assays.
---
### [Neurological Diseases & Trauma](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/)
**Description:** Meridian provides specialized reagents for diagnostic assays in neurological diseases, crucial for brain, spinal cord, and nerve function.
---
### [GFAP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/gfap/)
**Description:** Meridian Bioscience offers a range of products related to Glial Fibrillary Acidic Protein (GFAP), including recombinant GFAP antigens and monoclonal antibodies. These products are designed to support research and diagnostic applications in neurology.
---
### [FABP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/fabp/)
**Description:** Fatty Acid Binding Proteins (FABPs) are small cytoplasmic proteins that play a crucial role in the intracellular transport of long-chain fatty acids and other lipophilic substances. Among them, Heart-type FABP (H-FABP) is predominantly expressed in cardiac muscle tissue and is rapidly released into the bloodstream following myocardial injury, making it a valuable early biomarker for acute coronary syndromes.
---
### [Myelin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/myelin/)
**Description:** Meridian Bioscience offers products related to myelin, including Myelin Basic Protein Antigens and Monoclonal Antibodies to Myelin Basic Protein, supporting neurological disease research and diagnostics.
---
### [Viral Hepatitis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/)
**Description:** Meridian offers Viral Hepatitis Reagents for Assay Development. Commercial scale manufacturing of immuno raw material.
---
### [Hepatitis C](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-c/)
**Description:** Hepatitis C virus (HCV) is an infectious disease that primarily affects the liver. It is the most serious type of hepatitis virus and can lead to cirrhosis and liver failure or cancer. It is estimated that 150–200 million people, or about 3% of the world’s population, are living with chronic HCV.
---
### [ToRCH & Childhood](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/)
**Description:** Antibodies and antigens for TORCH infections, including rubella, CMV, toxoplasmosis, and herpes, to support immunoassay development and research applications
---
### [Toxoplasma gondii](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/toxoplasma-gondii/)
**Description:** Toxoplasmosis is a disease caused by the protozoan parasite Toxoplasma gondii, one of the world’s most common parasites. Infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy. The disease can cause flu-like symptoms but in general, infected people are asymptomatic. Infants born to infected mothers and for people with weakened immune systems, toxoplasmosis can cause serious complications.
---
### [Toxins & Biowarfare](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/toxins-biowarfare/)
**Description:** Learn more about Toxins & Biowarfare antibodies and antigens for diagnostic test development from Meridian Bioscience
---
### [Vaccinia](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/toxins-biowarfare/vaccinia/)
**Description:** Meridian Bioscience offers a range of monoclonal and polyclonal antibodies targeting the Vaccinia virus, suitable for applications such as ELISA, immunofluorescence assays, and immunohistochemistry.
---
### [EBV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/epstein-barr-virus-ebv/)
**Description:** Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a virus of the herpes family and infects more than 95% of the world’s population. The most common disease from primary infection is acute infectious mononucleosis, a self-limiting illness that frequently affects adolescents and young adults.
---
### [Rubella](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/rubella/)
**Description:** Rubella, also known as German Measles, is a viral illness caused by a togavirus of the genus Rubivirus and is an infection that primarily affects the skin and lymph nodes. It is generally a mild disease in adults and children, but it can have devastating effects on infants.
---
### [Sexually Transmitted Infections (STIs)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/)
**Description:** Antibodies and antigens for sexually transmitted infections, including HIV, HPV, syphilis, chlamydia, herpes, and HTLV, to support immunoassay development and diagnostic manufacturing.
---
### [Herpes](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/herpes/)
**Description:** Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are highly contagious infections that are lifelong and cause recurrent symptoms of painful blisters or open sores. HSV-1 is mainly transmitted by oral-to-oral contact and HSV-2 is a sexually transmitted infection that causes genital herpes. Neonatal herpes is rare but dangerous condition that can occur when an infant is exposed to HSV (HSV-1 or HSV-2) in the genital tract during delivery. Herpes are common infections worldwide. However, the majority of infected individuals remain undiagnosed because they are asymptomatic.
---
### [Rotavirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/rotavirus/)
**Description:** Discover the leading selection of rotavirus antigens and antibodies for assay development. Our products are designed to provide the highest level of specificity and sensitivity in rotavirus diagnostic testing. Our selection includes a variety of rotavirus antigens and antibodies to suit different assay formats, including ELISA, PCR and more. Our team of experts is also available to provide support and guidance in assay development and optimization. Improve your lab’s diagnostic capabilities with our specialized solutions.
---
### [Neisseria gonorrhoeae](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/neisseria-gonorrhoeae/)
**Description:** Neisseria gonorrhoeae is gram-negative bacteria that causes infections in the urethra, cervix, vagina, or anus. It is one of the two most common STDs in the United States along with chlamydia. If left untreated, gonorrhea infections can spread in the reproductive tract, causing prostatitis and epididymitis in men, or pelvic inflammatory disease (PID) in women.
---
### [Parainfluenza](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/parainfluenza/)
**Description:** Human parainfluenza viruses (HPIVs) commonly cause upper and lower respiratory illnesses. The symptoms of HPIVs are not severe enough to cause concern in healthy adults. However, they can be life-threatening in an infant, the elderly, or anyone with a compromised or weakened immune system.
---
### [Adenovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/adenovirus/)
**Description:** Adenoviruses are a family of DNA viruses that are an important cause of febrile illnesses in young children. They are most frequently associated with upper respiratory tract syndromes such as pharyngitis but can also cause pneumonia and less commonly, gastrointestinal, ophthalmologic, genitourinary, neurologic, and disseminated disease. Most adenoviral diseases are self-limiting, although fatal infections can occur in immunocompromised patients and occasionally in healthy children and adults.
---
### [Influenza A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/influenza-a/)
**Description:** Influenza is a highly infectious respiratory illness caused by the influenza virus. Common symptoms include fatigue, fever, chills, a hacking cough, and body aches which can self-resolve in 1-2 weeks. However, complications can arise including life-threatening secondary infections. Influenza is a serious disease, and approximately 1 in 1,000 cases result in death.
---
### [Tetanus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/tetanus/)
**Description:** Tetanus is a serious infection caused by Clostridium tetani, leading to painful muscle contractions, especially “lockjaw.” It can be life-threatening and usually enters the body through contaminated wounds. Vaccination is the best prevention.
---
### [Hepatitis B](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-b/)
**Description:** Hepatitis B (HBV) is virus that infects the liver and most adults (95%) who are infected are able to quickly recover however some have long-lasting illness that can lead to liver disease, liver cancer and death. In babies and young children, HBV can also develop into a chronic infection leading to liver cirrhosis or liver cancer later in life. 350 million people worldwide are infected with HBV and it is the cause of 620,000 deaths each year.
---
### [Treponema pallidum](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/treponema-pallidum/)
**Description:** Syphilis is a sexually transmitted bacterial infection caused by the spirochete bacterium Treponema pallidum. It is passed from person to person through direct contact with a syphilis sore and causes a systemic infection with symptoms that vary depending on the stage of the disease.
---
### [FeLV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/feline-leukemia-virus-felv/)
**Description:** Feline leukemia virus (FeLV) is second only to trauma as the leading cause of death in cats, killing 85% of persistently infected felines within three years of diagnosis. However, not all cats infected with FeLV progress to persistent infection, 70% of infected felines are able to eliminate the virus on their own. Transmission only occurs between cats, typically through saliva, blood, and to some extent, urine and feces. The virus causes immunosuppression and is a common cause of cancer, several blood disorders, and leaves a cat vulnerable to secondary infections. Diagnosis is by ELISA to detect the presence of FeLV p27, antigen and positive results are usually confirmed by IFA which can also detect the presence of virus particles within white blood cells, usually an indication of more advanced infection.
---
### [Chlamydia trachomatis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/chlamydia-trachomatis/)
**Description:** Chlamydia is the most common sexually transmitted disease and it is caused by the bacterium Chlamydia trachomatis. It affects 5% to 10% of the world’s population and it is particularly common in young adults under 25 years. It is a major public health concern due to its prevalence and potential long-term consequences.
---
### [Tropical & Vector-Borne Diseases](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/)
**Description:** Meridian offers a range of antigens and antibodies suitable for the development of sensitive and specific immunoassays that detect tropical and vector-borne diseases.
---
### [Borrelia](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/borrelia-lyme-disease/)
**Description:** Borrelia is a genus of bacteria primarily responsible for tick-borne illnesses, including Lyme disease. These bacteria are transmitted through tick bites and can lead to a range of symptoms, from mild to severe. Detection of Borrelia antibodies is crucial for early diagnosis, often achieved through Borrelia testing using Borrelia antibody immunoassay reagents. Antibiotics for Borrelia, such as doxycycline or amoxicillin, are commonly used as part of Borrelia treatment to eliminate the infection. Testing for anti-Borrelia antibodies helps monitor disease progression and guide appropriate treatment.
---
### [Influenza B](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/influenza-b/)
**Description:** Influenza is a highly infectious respiratory illness caused by the influenza virus. Common symptoms include fatigue, fever, chills, a hacking cough, and body aches which can self-resolve in 1-2 weeks. However, complications can arise including life-threatening secondary infections. Influenza is a serious disease, and approximately 1 in 1,000 cases result in death.
---
### [Leptospira](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/leptospira/)
**Description:** Meridian Bioscience offers a selection of antibodies and antigens for detecting Leptospira species, supporting diagnostic assay development. Their offerings include the Rabbit Anti-Leptospira biflexa polyclonal antibody and the Leptospira interrogans Recombinant Antigen. Additionally, they provide matched antibody pairs for immunoassay applications. These reagents are designed to enhance the sensitivity and specificity of diagnostic tests for Leptospira infections.
---
### [Candida albicans](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/candida-albicans/)
**Description:** Candida albicans is a type of fungus that naturally exists in the human body, typically without causing harm. However, when the body’s balance is disrupted, it can overgrow and lead to infections, commonly known as candidiasis. These infections can range from mild, like oral thrush or yeast infections, to more severe, especially in immunocompromised individuals.
---
### [Mycoplasma pneumoniae](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/mycoplasma-pneumoniae/)
**Description:** Mycoplasma Pneumoniae is a respiratory pathogen known to cause both upper and lower respiratory tract infections and is also referred to as “walking pneumonia.” According to the CDC, the prevalence of this infection is unknown, but it is estimated at roughly two million cases per year in the US. The spread of this pathogen is prevalent in crowded settings, young children, adolescents, immunocompromised individuals, and in patients recovering from other respiratory illnesses. Testing and surveillance are essential for identification and treatment with antibiotics in cases of mild or severe disease.
---
### [Strep B](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/streptococcus-group-b/)
**Description:** Streptococcus agalactiae or Group B strep is a gram-positive bacterium that expresses the Lancefield group B specific carbohydrate antigen on the cell wall. The prevalence of this bacterium in pregnant women as asymptomatic carriers is estimated to be 1 in 4, and its transmission during birth (early onset transmission) or after birth (late-onset transmission) to a newborn can have a fatality rate as high as 50%. Testing pregnant women in the third trimester is the recommended timeframe, and enzyme-linked immune assays and lateral flow may provide rapid diagnostic benefits in managing transmission to neonates and infants.
---
### [Mycobacterium tuberculosis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/mycobacterium-tuberculosis/)
**Description:** Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), which usually infects the lungs and infects any part of the body, such as the kidney, spine, and brain. As a respiratory disease, it is transmitted through infected respiratory droplets when someone coughs or sneezes. Not everyone infected with M. tuberculosis will develop TB, and only 10% of those who become infected will progress to TB disease. TB latent infection develops into TB disease when the bacteria overcome the body’s immune system defenses, which can happen with aging, serious illness, stressful events, HIV infection, or other conditions. If not treated properly, TB can be fatal. Diagnosis is by chest X-ray, a skin test, or a serologic assay that detects the presence of TB-specific IgG or IgM antibodies.
---
### [Giardia](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/giardia/)
**Description:** Giardia lamblia is a microscopic parasite that causes Giardiasis which is one of the most common causes of waterborne gastrointestinal disease. It is found naturally in streams and lakes but it can also contaminate public water supplies, swimming pools, whirlpool spas, and wells. In children under the age of five giardiasis can lead to complications such as malnutrition however it generally only causes mild symptoms in adults. The best single diagnostic test for giardiasis is the antigen detection test using stool samples. Molecular testing is also available and is commonly used in vet diagnostics.
---
### [Diphtheria](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/diphtheria/)
**Description:** Diphtheria is an infectious disease caused by the bacterium Corynebacterium diphtheriae. It mainly affects the respiratory system, causing a thick coating to form in the back of the throat, which can make it difficult to breathe. The disease can also cause damage to other organs, such as the heart and nervous system. Diphtheria is spread through close contact with an infected person and can be prevented through vaccination
---
### [Hepatitis A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-a/)
**Description:** Hepatitis A (HAV) is a contagious disease, spread by contact with infected people, their fluids and waste. It causes an acute infection of the liver that generally does not require treatment and can self-resolve. Young children infected with HAV typically have a milder form of the disease compared to adults who can be at risk of acute liver failure, especially if there is underlying chronic liver disease. HAV can affect people of all ages but can be prevented with vaccination.
---
### [C. difficile](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/clostridium-difficile/)
**Description:** Clostridium difficile infection is a gastrointestinal disease caused by toxins (Toxin A and Toxin B) produced by the spore-forming bacterium Clostridium difficile (C. difficile) and it is spread via the fecal-oral route by ingestion of the spores which are resistant to drying, heat, and many disinfectants. Disease severity varies with different C. difficile istrains, however, it is the most commonly recognized cause of infectious diarrhea in hospitalized patients. Diagnostic tests for C. difficile include PCR and immunoassays that detect the toxins A and/or B and glutamate dehydrogenase (GDH) – a C. difficile “common antigen”.
---
### [RSV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/respiratory-syncytial-virus-rsv/)
**Description:** Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms but can cause more serious problems such as bronchiolitis and pneumonia in babies and young children. In the United States, 60% of infants are infected during their first RSV season, and nearly all children will have been infected with the virus by 2–3 years of age.
---
### [Aspergillus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/aspergillus/)
**Description:** Aspergillus is a genus name that represents over 185 fungal species, 20 of which cause aspergillosis, or fungal infection, in humans. Aspergillosis symptoms vary with the type of aspergillus infection but all include airway problems that range from mild allergies to severe lung infections. The most serious form of aspergillosis is invasive aspergillosis when the infection spreads from the lungs to the brain, heart, kidneys, or skin and typically this only occurs in individuals with weakened immune systems. The contamination of food and feed by Aspergillus has become a global issue with a significant worldwide economic impact. Diagnosis is by ELISA, and possible chest x-ray to determine if there is fluid or abnormalities in the lungs.
---
### [HIV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/hiv/)
**Description:** Human immunodeficiency virus (HIV) is a sexually transmitted lentivirus that causes acquired immunodeficiency syndrome (AIDS), a condition that leads to progressive failure of the immune system. It is spread through contact with blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, or breast milk of a person with HIV. If left untreated, it is almost always fatal.
---
### [Microbial Detection](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/)
**Description:** High-performance microbial detection reagents for ELISA, PCR, and lateral flow assays. Detect bacterial and viral pathogens with sensitivity and accuracy.
---
### [Staphylococcus aureus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/staphylococcus-2/)
**Description:** Staphylococcus aureus (S. aureus) is a gram-positive bacteria that can cause a wide variety of clinical diseases. Some strains of S. aureus can produce enterotoxins (SEs) that can lead to staphylococcal food poisoning outbreaks. To date, 23 enterotoxins have been identified as distinct serological entities including SEA, SEB, SEC, SED, and SEE with SEA is most frequently involved in food poisoning caused by staphylococcus. Diagnosis is based on the detection of the SEs using sandwich immunoassays or by molecular analysis.
---
### [Klebsiella](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/klebsiella/)
**Description:** Klebsiella pneumoniae is a Gram-negative bacterium responsible for various healthcare-associated infections, including pneumonia, bloodstream infections, and surgical site infections. The emergence of carbapenem-resistant strains, particularly those producing Klebsiella pneumoniae carbapenemase (KPC), poses significant treatment challenges. Accurate detection of these resistant strains is crucial for effective patient management and infection control.
---
### [Cholera](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/cholera/)
**Description:** Cholera is a severe diarrheal disease caused by Vibrio cholerae, typically transmitted through contaminated water or food. The bacteria produce a toxin that leads to intense fluid loss and dehydration. Cholera toxin antibody plays a crucial role in neutralizing this toxin and is essential for developing vaccines and therapies. Cholera medication often includes antibiotics to treat cholera such as doxycycline or azithromycin, alongside rehydration therapies to manage symptoms and prevent complications. Cholera antibody testing can aid in diagnosis and monitoring. Effective cholera disease treatment involves addressing both symptoms and underlying causes, emphasizing the importance of timely medical intervention.
---
### [Clostridium botulinum](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/clostridium-botulinum/)
**Description:** Clostridium botulinum is an anaerobic, spore-forming bacterium that produces dangerous toxins (botulinum toxins) that can grow in food and cause a severe form of food poisoning. In addition, botulism can also be caused by intestinal infection with C. botulinum in infants, wound infections, and inhalation. There are 7 distinct forms of botulinum toxin (types A–G) and four of these (types A, B, E, and rarely F) cause human botulism. Types C, D, and E cause illness in other mammals, birds, and fish. C. botulinum neurotoxins can be detected in food using sandwich ELISA, lateral flow, or molecular tests.
---
### [SARS](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/sars/)
**Description:** Severe acute respiratory syndrome coronavirus (SARS-CoV) is a respiratory zoonotic virus first identified in February 2003 during an outbreak that emerged in China and spread to 4 other countries. The novel SARS-CoV-2 is a genetically closely related coronavirus responsible for the 2020 COVID-19 pandemic. The virus was first identified in the respiratory tract of patients with pneumonia in Wuhan, Hubei China, in December 2019 and declared a pandemic by the World Health Organization (WHO) on March 11, 2020.
---
### [Protein A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/protein-a/)
**Description:** Learn more about Protein A antibodies and antigens from Meridian Bioscience
---
### [CMV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/cmv/)
**Description:** Human cytomegalovirus (CMV, also called Human herpesvirus is a member of the herpes virus family and shares the characteristic ability to remain latent within the body for life within an infected individual. Although a CMV infection is typically asymptomatic in healthy persons, immunocompromised individuals such as AIDS patients, organ transplant recipients, and newborn infants, are at high risk of developing life-threatening complications from primary infections and reactivations. Most people (85%) have been infected by CMV by 40 years of age.
---
### [Norovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/norovirus/)
**Description:** Norovirus is a member of the Caliciviridae family of viruses which are responsible for about 90% of viral gastroenteritis outbreaks and close to 50% of cases across the world. Transmission is by the fecal-oral route and individuals can be infected several times in their lifetime as immunity is not long-lasting. There are 10 genotype groups (GI – GX) of norovirus and 48 genotypes. Diagnostic methods for detecting norovirus include molecular testing and immunoassay using stool samples.
---
### [Marek Disease](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/marek-disease/)
**Description:** Marek disease is a highly contagious viral disease of poultry caused by a herpes virus and characterized by T-cell lymphomas and peripheral nerve enlargement. Young birds are susceptible to infection and most deaths from Marek’s disease occur between 8 and 20 weeks of age. The virus can survive in the environment for as long as several months at room temperature and is transmitted by a chicken breathing in infected dust and dander particles that are shed from the feather follicles of infected birds. Diagnosis is by ELISA antigen-antibody detection to MDV in non-vaccinated chickens from about 4 weeks of age or PCR analysis. It is also critical to diagnose the tumors and not just the infection because Marek disease is considered ubiquitous within commercial poultry flocks.
---
### [SEI](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/sei/)
**Description:** Staphylococcal Enterotoxin I (SEI) is a toxin produced by Staphylococcus aureus that can cause food poisoning. It leads to symptoms like nausea, vomiting, and diarrhea, and can be detected using immunodetection assays. Symptoms typically appear quickly after ingestion of contaminated food.
---
### [SEG](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/seg/)
**Description:** Staphylococcal Enterotoxin G (SEG) is a toxin from Staphylococcus aureus that causes food poisoning, leading to nausea, vomiting, and diarrhea. It can be rapidly detected using specialized immunodetection assays. Symptoms usually appear quickly after exposure.
---
### [Astrovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/astrovirus/)
**Description:** Astrovirus is an RNA virus transmitted by the fecal-oral route either directly or by ingestion of contaminated food. It causes gastroenteritis and diarrhea, mostly in children under the age of 2, and accounts for 2 to 9% of all cases of acute, nonbacterial diarrhea in children requiring hospitalization. There are eight serotypes of astrovirus with serotype 1 being the most frequently detected and the majority of individuals (90%) develop antibodies towards astrovirus by 9 years old. Detection is by RT-PCR or antigen detection by ELISA using stool samples.
---
### [Newcastle](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/newcastle-disease/)
**Description:** Newcastle disease virus (NDV) is a paramyxovirus that infects domestic poultry and other bird species. It is a global problem that presents primarily as an acute respiratory disease, but depression, nervous manifestations, or diarrhea are also symptoms. The virus is excreted in manure and is breathed out into the air, and it usually spreads by direct physical contact with infected or diseased birds. Severity depends on the virulence of the infecting virus and host susceptibility. Diagnosis is mainly by PCR for acute disease detection and serology in NDV surveillance to differentiate vaccinated from infected animals.
---
### [Chlamydia pneumoniae](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/chlamydia-pneumoniae/)
**Description:** Chlamydia pneumoniae (C. pneumoniae) is a common species of bacteria and a major cause of pneumonia around the world. Approximately 50% of adults have evidence of past infection by age 20, and reinfection later in life is common. Many studies have suggested a direct association between C. pneumoniae infection and other inflammatory diseases such as atherosclerosis, acute exacerbations of COPD, and asthma.
---
### [Marburg](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/marburg/)
**Description:** Meridian provides monoclonal antibodies specific to Marburg virus antigens, produced in mouse hosts. These antibodies are purified and suitable for applications such as Enzyme Immunoassays (EIA) and Lateral Flow assays.
---
### [Rabies](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/rabies-virus/)
**Description:** Rabies virus (Rabies lyssavirus) is a neurotropic virus that causes inflammation of the brain (rabies) and is one of the deadliest diseases affecting both wild and domestic animals. It is spread when an infected animal bites or scratches a human or other animals. The disease progresses in stages and once clinical symptoms appear, it is nearly 100% fatal with the final stage resulting in death from progressive paralysis. Rabies is vaccine-preventable and in animals, rabies is diagnosed using the direct fluorescent antibody (DFA) test, which looks for the presence of rabies virus antigens in the brain tissue of a deceased animal. At present, there are no tests available that are able to diagnose infection with rabies immediately after suspected exposure to the virus.
---
### [Foot and Mouth](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/foot-and-mouth-disease-fmd/)
**Description:** Foot and mouth disease (FMD) is a severe, highly contagious viral disease of livestock that has a significant economic impact. It affects cattle, swine, sheep, goats, and other cloven-hoofed ruminants and is estimated to circulate in 77% of the global livestock population, in Africa, the Middle East, and Asia, as well as in a limited area of South America. FMD is caused by an Aphthovirus and seven strains (A, O, C, SAT1, SAT2, SAT3, and Asia1) are endemic in different countries worldwide. Each strain requires a specific vaccine to provide immunity to a vaccinated animal. Its prevention is based on the presence of early detection and warning systems and the implementation of effective surveillance among other measures. Diagnosis is ELISA, cell culture isolation, and PCR.
---
### [MRSA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/methicillin-resistant-staphylococcus-aureus-mrsa/)
**Description:** Meridian Bioscience offers a monoclonal antibody designed for diagnostic assay development to detect methicillin-resistant Staphylococcus aureus (MRSA). This antibody supports applications such as ELISA and lateral flow assays, contributing to sensitive and specific MRSA detection.
---
### [Mycoplasma hominis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/mycoplasma-hominis/)
**Description:** Mycoplasma hominis is a clinically significant pathogen often associated with urogenital and reproductive tract infections. Due to its fastidious nature and resistance to standard antibiotics, accurate and timely detection is critical. Meridian Bioscience offers molecular diagnostic solutions, including advanced real-time PCR assays, to support the precise identification of M. hominis. Our reliable, easy-to-use platforms help clinicians deliver fast, actionable results—enhancing patient outcomes and supporting effective infection management in diverse healthcare environments.
---
### [IBV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/infectious-bronchitis-virus-ibv/)
**Description:** Meridian Bioscience offers a monoclonal antibody designed for diagnostic assay development to detect Infectious Bronchitis Virus (IBV) infections in poultry. This mouse-derived IgG2a antibody specifically targets the IBV nucleoprotein and is suitable for applications such as ELISA and Western blotting, supporting the development of sensitive and specific diagnostic tests for IBV.
---
### [West Nile](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/west-nile/)
**Description:** West Nile virus is a flavivirus that is commonly found in Africa, Europe, the Middle East, North America, and West Asia and birds are the reservoir hosts (the virus is maintained in a mosquito-bird-mosquito transmission cycle). Transmission is mainly through mosquitos although people can also become infected through organ transplants, blood transfusions, and breast milk. Infection is asymptomatic in 80% of cases, however, 20% of those infected will develop West Nile fever which can lead to severe neurological disease and death. Diagnosis is by RT-PCR or by detection of IgG and IgM antibodies to the virus in serum or cerebral spinal fluid.
---
### [Trichomonas vaginalis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/trichomonas-vaginalis/)
**Description:** Trichomonas vaginalis is an anaerobic, flagellated protozoan parasite and the most common curable STD. The World Health Organization (WHO) estimates that 170-190 million cases of infection are acquired annually worldwide and are increasing each year. As a result, T. vaginalis is receiving more attention, prompting an increased demand for both diagnosis of trichomoniasis and screening for asymptomatic infections.
---
### [T.Foetus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/trichomonas-foetus/)
**Description:** Bovine trichomoniasis is a disease of the reproductive tract caused by Tritrichomonas foetus, a flagellate protozoan that is transmitted through coital contact between a bull and a heifer. In cows, infection leads to embryonic and early fetal death, abortion, fetal maceration, pyometra, and transient or permanent infertility. The disease is found in all cattle-producing countries in the world and in some, it still causes major economic loss due to abortion, infertility, and the culling of carrier bulls. Infection of T. foetus in bovines does not develop prominent immune responses and can be diagnosed by ELISA, direct smears or culture, or by PCR of preputial washings, vaginal material, or aborted tissues.
---
### [Malaria](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/malaria/)
**Description:** Malaria is a mosquito-borne life-threatening disease caused by Plasmodium parasites. There are five parasite species that cause malaria in humans, and two of these species, P. falciparum, and P. vivax, are the most common and can cause acute febrile illness. Most infections (94%) occur in the African region and cause nearly a half million deaths per year, predominately children under the age of five. Early diagnosis and treatment are critical to managing malaria and preventing death. Diagnosis relies on microscopy or rapid diagnostic tests that directly detect the parasite.
---
### [Chikungunya](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/chikungunya/)
**Description:** Chikungunya is a mosquito-borne viral disease that occurs mostly in countries such as Africa, Asia, Europe, and the Indian and Pacific Oceans where Ae. aegypti and Ae. albopictus mosquito species are common. The disease is characterized by severe joint pain and shares some clinical signs with dengue and Zika. The virus can cause acute, subacute, or chronic disease and there is currently no vaccine or specific drug against the virus. Detection mostly relies on serological tests that confirm the presence of IgM or IgG antibodies to the virus, or, during the early stage, direct detection is possibly by RT-qPCR.
---
### [Dengue](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/dengue/)
**Description:** Dengue is a mosquito-borne viral infection, found in tropical and sub-tropical climates worldwide, and mostly in urban and semi-urban areas. There are four Dengue serotypes and it is possible to be infected four times, each time by a different serotype. Most infectious cause only mild flu-like symptoms but they can also develop into a lethal complication called severe dengue which is a leading cause of serious illness and death in some Asian and Latin American countries. Several methods can be used for diagnosis including RT-qPCR, rapid antigen tests for the NS1 protein, and serological assays that detect both IgG and IgM antibodies to the four dengue serotypes.
---
### [Aflatoxin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/aflatoxin/)
**Description:** Meridian Bioscience offers a range of antibodies and antigens for detecting aflatoxins, toxic compounds produced by certain molds in food and water sources. Their product line includes monoclonal antibodies, such as those targeting aflatoxin, designed for use in diagnostic assays. These reagents support the development of sensitive assays for laboratories, contributing significantly to public health monitoring.
---
### [Mycoplasma genitalium](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/mycoplasma-genitalium/)
**Description:** Mycoplasma genitalium is a sexually transmitted disease caused by a small bacterium that colonizes the male and female reproductive tract and was only discovered in the 1980s. The bacteria can evade the adaptive immune system by establishing intracellular infection and can persist for months or years in asymptotic individuals. Infection is associated with acute and chronic urethritis in men and urethritis, cervicitis, pelvic inflammatory disease, and possibly infertility in women. Diagnosis is primarily by molecular testing; however, serology testing is used for epidemiological studies. M. genitalium shares several structural properties with M. pneumoniae, and cross-reactivity between these species can impact serology tests. Consequently, diagnosis is primarily by molecular testing; however, serology testing is used for epidemiological studies.
---
### [Ureaplasma Parvum](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/ureaplasma-parvum/)
---
### [Verotoxin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/verotoxin/)
**Description:** Verotoxins (also called Shiga toxins) are produced by certain strains of Escherichia coli and can cause a broad range of symptoms from mild intestinal discomfort, to bloody diarrhea, hemolytic uremic syndrome, end-stage renal disease, and death. Verotoxin-producing E. coli (VTEC) includes enterohaemorrhagic E. coli (EHEC) and shiga toxin-producing E. coli (STEC), specifically E. coli O157:H7, E. coli O111:H8 and E. coli O26:H11. Vertoxins are a significant contributor to foodborne disease and cause very large outbreaks every few years. Ingestion of contaminated food and water, and person-to-person and animal-to-person transmission by the fecal-oral route are responsible for VTEC infection. Detection of verotoxin in food is typically by culture or rapid antigen detection assays. Stool samples are required for diagnosis in infected individuals and testing can be by culture, ELISA, or PCR.
---
### [Rhinovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/rhinovirus/)
**Description:** Rhinovirus is a type of virus that is one of the most common causes of the common cold. It is highly contagious and spreads easily from person to person through respiratory droplets. Symptoms of a rhinovirus infection typically include a runny or stuffy nose, sneezing, cough, and sore throat. The illness is usually mild and resolves on its own within a few days to a week, although some people may experience more severe symptoms.
---
### [Parvovirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/parvovirus-b19/)
**Description:** The Parvoviridae family includes a large number of small, genetically-compact DNA viruses known collectively as parvoviruses. Parvovirus B19 was the first pathogenic human parvovirus to be discovered and it is best known for causing the childhood illness called fifth disease.
---
### [Mumps](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/mumps/)
**Description:** Mumps is an enveloped single-strand RNA virus of the Rubulavirus genus that causes painful swelling of the salivary glands. It is highly contagious and predominantly affects children.
---
### [Measles](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/measles/)
**Description:** Rubeola (also known as measles) is a highly contagious viral infection of the respiratory system, immune system, and skin. It is caused by a paramyxovirus of the genus Morbillivirus. The disease kills more than 100,000 people a year, most under the age of 5.
---
### [Ebola](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/ebola/)
**Description:** Ebola is a rare and deadly disease in people and nonhuman primates with an average fatality rate of 50%. It is transmitted to people from wild animals (such as fruit bats, porcupines, and non-human primates) and spreads in the human population through direct contact with the blood, secretions, organs, or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids. Symptoms include pain and fever, and as the disease progresses, can cause hemorrhagic fevers marked are marked by severe bleeding. Diagnosis includes both RT-PCR and rapid antigen detection assays.
---
### [Shiga Toxin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/shiga-toxin/)
**Description:** Shiga toxin is a potent toxin produced by Shigella dysenteriae and some strains of Escherichia coli (particularly E. coli O157). It can cause severe gastrointestinal illness, including dysentery, severe diarrhea, and abdominal pain. Shiga toxin works by inhibiting protein synthesis in cells, leading to cell death and tissue damage.
---
### [SEE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/see/)
**Description:** Staphylococcal Enterotoxin E (SEE) is a toxin from Staphylococcus aureus that causes food poisoning. It can be detected using a Staphylococcal Enterotoxin Immunodetection Assay, which identifies the toxin in contaminated food or samples. Symptoms include fever, vomiting, and diarrhea, usually appearing within hours of exposure.
---
### [Enterobacteriaciae](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/enterobacteriaciae/)
**Description:** Meridian Bioscience provides a range of antibodies and antigens for the detection and study of Enterobacteriaceae, a large family of Gram-negative bacteria that includes common pathogens such as Escherichia coli and Klebsiella. These reagents are essential for diagnostic applications, including the identification of infections caused by Enterobacteriaceae in clinical samples.
---
### [Zika](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/zika-virus/)
**Description:** Zika virus is a mosquito-borne flavivirus transmitted primarily by Aedes mosquitoes and generally only causes mild symptoms in infected people. However, infection during pregnancy can cause microcephaly and other congenital abnormalities and can also pregnancy complications such as fetal loss, stillbirth, and preterm birth. Diagnosis is by molecular testing for acute infections or serologic assays detecting an IgM response for recent infections.
---
### [ASFV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/african-swine-fever-virus-asfv/)
**Description:** African Swine Fever Virus (ASFV) is a DNA virus that is transmitted through direct contact with an infected pig, contaminated feed, or through the bite of an infected tick. There are over 22 different genotypes of ASFV, and they can vary in virulence from highly pathogenic strains that cause acute disease and high mortality (90-100%) to low–virulence isolates that present similar but less intense symptoms making the disease chronic and difficult to diagnose. Several immunogenic viral antigens have been identified, including p30 which is one of the most antigenic structural proteins involved in ASFV entry and is expressed very early on in infection (2-4 hours post-infection). ASFV can be diagnosed by virus isolation, ELISA, immunofluorescence, or PCR using clinical samples such as lymph nodes, kidneys, spleen, lung, blood, and serum. The simultaneous detection of both antigens and antibodies is recommended in order to identify the presence of potentially chronic infections that continue to spread the disease.
---
### [Yellow Fever](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/yellow-fever/)
**Description:** Most people infected with Yellow fever do not experience any symptoms but when they do occur, there is a risk of advancing to a toxic phase in which people develop jaundice, dark urine, and abdominal pain and have a 50% chance of dying. Yellow fever is difficult to diagnose and typically requires PCR detection during the early stages. In later stages, ELISA detecting IgM or IgG antibodies to the virus is required.
---
### [Entamoeba histolytica](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/entamoeba-histolytica/)
**Description:** Entamoeba histolytica is a parasitic amoeba that causes amebiasis, a serious intestinal infection. It is primarily transmitted through contaminated food or water and can lead to symptoms ranging from mild diarrhea to severe dysentery and liver abscesses.
---
### [Nipah](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/nipah-virus/)
**Description:** Nipah is an RNA zoonotic virus that emerged in Malaysia in 1999 that infects both pigs and humans. Fruit bats are the natural reservoir, and they can transmit the virus when pigs come in contact with their urine, feces, or saliva from infected animals. It can also spread between pigs by direct contact and through aerosol droplets. Infected pigs may show signs of respiratory distress, nasal discharge, non-productive cough, lethargy, and sudden death. Current diagnostics for Nipah include ELISA (IgG and IgM), RT-PCR, and virus isolation. However, the Nipah virus is classified as a biosecurity level (BSL) 4 agent so virus handling needs to be done in high containment laboratories.
---
### [JEV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/japanese-encephalitis-jev/)
**Description:** JEV is a flavivirus related to dengue, yellow fever, and West Nile viruses, and is spread by mosquitoes (mainly the Culex species). It is the main cause of viral encephalitis in many countries of Asia and there is no cure for the disease however vaccines are available. Most infections are mild, however, 1 in 250 infections results in severe disease which can lead to death (30% fatality rate) or permanent disability such as paralysis, recurrent seizure or the inability to speak. The WHO recommends testing for JEV-specific IgM antibodies in a single sample of cerebrospinal fluid (CSF) or serum, using an IgM-capture ELISA. Testing of CSF samples is preferred to reduce false-positivity rates from previous infection or vaccination.
---
### [Heartworm](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/canine-heartworm/)
**Description:** Heartworm is a parasitic worm called Dirofilaria immitis that infects mainly dogs through a mosquito bite. An infected mosquito injects a larval stage worm under the dog’s skin and travels through the body to the heart and blood vessels of the lungs where it matures over 6 months, and breeds releasing microfilariae that are ingested by mosquitos when they bite an infected dog. It usually takes several years before dogs show clinical signs of infection and at that point, the dog has advanced heartworm disease and substantial damage to the heart, lungs, blood vessels, kidneys, and liver, however, there are treatments available. The most common diagnostic assay used for heartworm is the ELISA antigen test which uses serum, plasma, or whole blood specimens for testing.
---
### [PEDV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/porcine-epidemic-diarrhea-virus-pedv/)
**Description:** Meridian Bioscience offers monoclonal antibodies for detecting Porcine Epidemic Diarrhea Virus (PEDV). These purified mouse IgG1 antibodies are suitable for applications such as ELISA, lateral flow assays, and Western blotting, supporting the development of sensitive diagnostic tests for PEDV infections in swine.
---
### [Cryptosporidium](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/cryptosporidium-2/)
**Description:** Meridian Bioscience provides high-quality raw materials to support the development of Cryptosporidium diagnostic tests for veterinary health. Cryptosporidium is a protozoan parasite that spreads via the fecal-oral route and causes cryptosporidiosis—a diarrheal disease affecting livestock, companion animals, and wildlife. Meridian offers monoclonal antibodies, antigens, and essential reagents used in ELISA-based and microscopy-based assays, helping diagnostic manufacturers deliver accurate, reliable detection for veterinary applications.
---
### [Salmonella](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/salmonella/)
**Description:** Salmonella infection (salmonellosis) is a bacterial disease that affects the intestinal tract and it is the most common foodborne infection in the United States. Salmonella colonizes the small and large intestine and can invade the lymphoid tissues of the gastrointestinal tract and spread to the bloodstream (bacteremia) and infect organs. Diagnosis is by immunoassay using stool sample or molecular detection and for cases or bacteremia, subtyping and antimicrobial susceptibility testing are important additional tools for treatment.
---
### [VZV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/varicella-zoster-virus-vzv/)
**Description:** VZV is one of eight herpes viruses and commonly causes chickenpox in children, teens and herpes zoster (shingles) in adults. It is usually a mild disease that lasts a short time in healthy children. However, it can be severe in adults and may cause serious and even fatal complications in people of any age.
---
### [Mycoplasma Bovis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/mycoplasma-bovis/)
**Description:** Meridian Bioscience offers a monoclonal antibody, a purified mouse IgG1, specifically designed for diagnostic assay development to detect Mycoplasma bovis infections in cattle. This antibody exhibits high specificity, showing no cross-reactivity with Streptococcus agalactiae, Staphylococcus aureus, or Escherichia coli. It is suitable for applications such as ELISA and Western blotting, supporting the development of sensitive and specific diagnostic tests for Mycoplasma bovis.
---
### [Hepatitis D](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-d/)
**Description:** Hepatitis D is a viral infection caused by the hepatitis D virus (HDV), which only occurs in individuals already infected with hepatitis B. It can lead to more severe liver disease, including cirrhosis and liver failure. Hepatitis D testing is essential for accurate diagnosis and involves detecting the hepatitis D antibody in the blood. Diagnostic tools, such as hepatitis D immunoassay reagents, are used to identify the virus and its antibodies. Hepatitis D treatment focuses on antiviral therapies to manage both hepatitis B and D infections. However, specific hepatitis D virus treatment options remain limited, making prevention and early detection crucial.
---
### [Gram Positive](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/gram-positive-bacteria/)
**Description:** Meridian Bioscience offers monoclonal antibodies targeting Gram-positive bacteria, suitable for applications such as ELISA, IFA, and lateral flow assays. They also provide specific reagents for pathogens like Streptococcus pneumoniae and Streptococcus agalactiae (Group B Strep), supporting the development of sensitive diagnostic tests.
---
### [Cryptococcus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/cryptococcus/)
**Description:** Cryptococcus is a type of fungus that can cause infections in humans and animals. The most common species that cause disease in humans are Cryptococcus neoformans and Cryptococcus gattii. These fungi can infect the lungs and cause pneumonia and can also spread to other parts of the body, such as the brain, where they can cause meningitis. Cryptococcal infections are most commonly seen in people with weakened immune systems, such as those with HIV/AIDS.
---
### [SLT](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/gastrointestinal-pathogens/slt/)
**Description:** Shiga-like Toxins 1 (Stx1) and 2 (Stx2) are harmful toxins produced by certain E. coli strains, notably E. coli O157.These toxins cause severe gastrointestinal symptoms, including bloody diarrhea, by inhibiting protein synthesis in host cells. In severe cases, they can lead to life-threatening conditions like hemolytic uremic syndrome (HUS), which can cause acute kidney failure.”
---
### [HPV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/hpv/)
**Description:** Human papilloma virus (HPV) refers to a group of more than 150 related viruses that cause warts (papillomas) on different parts of the body including the hands, feet, genitals, or anus. It is one of the most common STDs and although most HPV infections self-resolve, some types can cause cervical cancer in women and anal cancers in both men and women.
---
### [Brucella Abortus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/brucella-abortus/)
**Description:** Meridian Bioscience offers monoclonal antibodies targeting Brucella abortus. These purified mouse IgG1 antibodies are suitable for applications such as ELISA and Western blotting, supporting the development of diagnostic assays for detecting Brucella abortus infections.
---
### [Yersinia](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/toxins-biowarfare/yersinia-pestis/)
**Description:** Meridian Bioscience offers monoclonal antibodies targeting Yersinia pestis antigens, including the F1 and V antigens, designed for diagnostic assay development to detect Y. pestis infections. They also provide antibody pairs for immunoassays, such as capture and detection antibodies for the V antigen. Additionally, for Yersinia enterocolitica, Meridian offers specific antigens to support diagnostic research.
---
### [Bovine Coronavirus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/bovine-coronavirus/)
---
### [Ricin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/toxins-biowarfare/ricin/)
**Description:** Meridian Bioscience provides monoclonal antibodies targeting ricin, a potent toxin derived from Ricinus communis. These antibodies are designed for use in developing diagnostic assays to detect ricin exposure, supporting research and public health initiatives.
---
### [Uroguanylin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/uroguanylin/)
**Description:** Uroguanylin is a 16-amino-acid peptide hormone predominantly secreted by enterochromaffin cells in the duodenum and proximal small intestine. It serves as an agonist for the guanylyl cyclase-C (GC-C) receptor, regulating electrolyte and water transport in intestinal and renal epithelia.
---
### [TSH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/tsh/)
**Description:** Thyroid-stimulating hormone (TSH) is a pituitary hormone that regulates thyroid function in conjunction with thyrotropin-releasing hormone (TRH). Specifically, TSH induces production of Thyroxine (T4) which is converted triiodothyronine (T3) and is responsible for stimulating the metabolism. TSH is secreted throughout life but reaches high levels during the periods of rapid growth and development, as well as in response to stress.
---
### [DHEA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/dhea/)
**Description:** Dehydroepiandrosterone (DHEA) is one of the most abundant circulating steroids and is produced in the adrenal glands, the gonads, and the brain, where it functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids. Its production is controlled by ACTH and the majority of DHEA is secreted as 3-sulfoconjugate dehydroepiandrosterone sulfate (DHEAS). In the circulation, DHEA and DHEAS are mainly bound to albumin, with a small amount bound to sex hormone-binding globulin (SHBG).
---
### [Calcitonin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/calcitonin/)
**Description:** Calcitonin is a polypeptide hormone that is produced by the C-cells of the thyroid gland and it acts to reduce blood calcium and phosphate levels, opposing the effects of Parathyroid Hormone (PTH).
---
### [PAPP-A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/papp-a/)
**Description:** There are 2 forms of Pregnancy-associated plasma protein A (PAPP-A), one is heterotetrameric and produced by placental syncytiotrophoblast cells during pregnancy, and another is a homodimer secreted by vascular cells. PAPP-A secreted by vascular cells is a high molecular weight, zinc-binding metalloproteinase that is associated with vulnerable plaques and is a marker of adverse outcomes in both acute coronary syndrome and stable coronary disease. Serum PAPP-A level can be measured using a quantitative two-site sandwich immunoassay.
---
### [Retinol Binding Protein](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/retinol-binding-protein/)
**Description:** Retinol Binding Protein 4 (RBP4) is a transporter protein responsible for delivering retinol (vitamin A) from the liver to peripheral tissues. It plays a crucial role in vitamin A metabolism and has been implicated in insulin resistance and metabolic disorders.
---
### [Angiostatin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/angiostatin/)
**Description:** Learn about Meridians' highly specific monocolonal antibodies for Angiostatin testing.
---
### [Thyroglobulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/thyroglobulin/)
**Description:** Thyroglobulin (Tg) is a dimeric protein produced by the follicular cells of the thyroid and accounts for approximately half of the protein content of the thyroid gland. It is the precursor for the thyroid hormones T3 and T4 and each Tg molecule forms approximately 10 thyroid hormone molecules.
---
### [Calcitonin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/calcitonin-hormones-steroids/)
**Description:** Calcitonin is a polypeptide hormone that is produced by the C-cells of the thyroid gland and it acts to reduce blood calcium and phosphate levels, opposing the effects of Parathyroid Hormone (PTH).
---
### [Cortisol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/cortisol/)
**Description:** Cortisol is the primary glucocorticoid secreted by the adrenal gland in response to ACTH stimulation, stress, or low blood-glucose concentration. It functions to increase blood sugar through gluconeogenesis, to suppress the immune system, and to aid in the metabolism of fat, protein, and carbohydrates. It also decreases bone formation. It is secreted in a diurnal pattern with levels rising in the early morning, peaking around 8 am, and flattening in the evening.
---
### [C-Peptide](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/c-peptide/)
**Description:** Insulin is a peptide hormone secreted by the β cells of the pancreatic islets of Langerhans and maintains normal blood glucose levels by facilitating cellular glucose uptake, regulating carbohydrate, lipid and protein metabolism and promoting cell division and growth through its mitogenic effects. C-peptide is a byproduct created when insulin is produced. Both insulin and C-peptide are created from a larger molecule called proinsulin which undergoes enzymatic cleavage to become des-31,32-proinsulin and des-64,65-proinsulin and eventually, insulin and C-peptide (an inactive peptide chain).
---
### [Proinsulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/proinsulin/)
**Description:** Proinsulin is the precursor molecule to insulin, synthesized in the pancreatic β-cells. During insulin production, proinsulin undergoes enzymatic cleavage to form insulin and C-peptide. Accurate measurement of proinsulin levels is essential for diagnosing and monitoring conditions such as type 2 diabetes and insulinomas. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting proinsulin
---
### [Insulin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/insulin/)
**Description:** Insulin is a peptide hormone secreted by the β cells of the pancreatic islets of Langerhans and maintains normal blood glucose levels by facilitating cellular glucose uptake, regulating carbohydrate, lipid and protein metabolism and promoting cell division and growth through its mitogenic effects. C-peptide is a byproduct created when insulin is produced. Both insulin and C-peptide are created from a larger molecule called proinsulin which undergoes enzymatic cleavage to become des-31,32-proinsulin and des-64,65-proinsulin and eventually, insulin and C-peptide (an inactive peptide chain).
---
### [AMH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/amh/)
**Description:** Anti-Müllerian Hormone (AMH) is a glycoprotein hormone structurally related to inhibin and activin and is part of the transforming growth factor beta superfamily. AMH is considered an extremely sensitive marker of ovarian function and ovarian aging.
---
### [Estradiol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/estradiol/)
**Description:** Estradiol, also known as E2 or 17β-estradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of female reproductive cycles and it is responsible for the development of female secondary sexual characteristics.
---
### [Estriol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/estriol/)
**Description:** Estriol is one of the three primary estrogen hormones, predominantly produced during pregnancy. Accurate measurement of estriol levels is essential for monitoring fetal health and assessing placental function. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting estriol
---
### [Osteocalcin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/osteocalcin/)
**Description:** Osteocalcin is a non-collagenous protein hormone produced by osteoblasts, playing a crucial role in bone mineralization and calcium ion homeostasis. Accurate measurement of osteocalcin levels is essential for diagnosing and monitoring metabolic bone diseases such as osteoporosis. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting osteocalcin
---
### [Renin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/renin/)
**Description:** Renin is an enzyme secreted by the kidneys that plays a pivotal role in the renin-angiotensin system, which regulates blood pressure and fluid balance. Accurate measurement of renin levels is essential for diagnosing and managing conditions such as hypertension and certain kidney disorders. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting renin
---
### [TSH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/tsh-2/)
---
### [PTH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/parathyroid-hormone-pth/)
**Description:** Parathyroid Hormone (PTH) is secreted by the parathyroid gland and regulates calcium levels in the blood. It plays an important role in bone remodeling and works together with Vitamin D to maintain healthy bones.
---
### [Vasopressin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/vasopressin/)
**Description:** Vasopressin, also known as antidiuretic hormone (ADH), is a peptide hormone synthesized in the hypothalamus and released by the posterior pituitary gland. It plays a crucial role in regulating water balance and blood pressure by promoting water reabsorption in the kidneys and constricting blood vessels. Accurate measurement of vasopressin levels is essential for diagnosing and managing conditions such as diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
---
### [Relaxin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/relaxin/)
**Description:** Relaxin is a peptide hormone known for its role in reproductive physiology, including the relaxation of uterine muscles and facilitation of childbirth. Recent research has also identified its involvement in cardiovascular functions, with elevated relaxin levels observed in heart failure patients, correlating with disease severity. Additionally, relaxin has been evaluated as a potential therapeutic agent for acute heart failure.
---
### [Aldosterone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/aldosterone/)
**Description:** Adiponectin is a hormone produced by fat cells that regulates glucose and fat metabolism. It has anti-inflammatory and insulin-sensitizing effects, promoting metabolic health. Lower adiponectin levels are linked to obesity and diabetes, while higher levels reduce these risks. Testing options like the Adiponectin blood test can measure Adiponectin levels and insulin sensitivity, and many opt for the best adiponectin supplements to support metabolic health.
---
### [Thyroxine (T4)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/thyroxine-t4/)
**Description:** Triiodothyronine (T3) and Thyroxine (T4) are hormones produced by the thyroid and are responsible for regulating metabolism. Their expression is carefully controlled by thyroid-stimulating hormone (TSH) and they circulate in a biologically inactive form in the bloodstream to further restrict their activity. Thyroid dysfunction can lead to the production of too much to too little T3 or T4 causing hyper or hypothyroidism.
---
### [FSH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/follicle-stimulating-hormone-fsh/)
**Description:** Follicle-stimulating hormone (FSH) is a gonadotropin secreted by the anterior pituitary glands and regulates the activity of the gonads (e.g. ovaries and testes). Specifically, it operates in conjunction with luteinizing hormone (LH) to stimulate the development of graafian follicle in females and promote the development of the tubules in the testes and the differentiation of sperm.
---
### [ACTH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/acth/)
**Description:** Adrenocorticotropic hormone (ACTH) is produced by the pituitary gland and its key function is to stimulate the production and release of cortisol from the cortex. ACTH also plays a role in circadian rhythm in many organisms.
---
### [Somatomedin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/somatomedin/)
**Description:** Somatomedins are a group of proteins, primarily produced by the liver, that mediate the effects of growth hormone (GH) on various tissues, promoting cell growth and division. They are also known as insulin-like growth factors (IGFs) due to their structural similarity to insulin.
---
### [Progesterone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/progesterone/)
**Description:** Progesterone (P4) belongs to a group of steroid hormones called the progestogens and it is the major progestogen in the body. Its main role is to maintain pregnancy and to regulate the female’s menstrual cycle. Its levels increase sharply during the luteal phase of the menstrual cycle as it works to thicken the lining of the uterus to prepare it for a fertilized egg each month.
---
### [Ghrelin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/ghrelin/)
**Description:** Ghrelin is a peptide hormone predominantly produced in the stomach, playing a crucial role in stimulating appetite and regulating energy balance. Accurate measurement of ghrelin levels is essential for understanding and managing various metabolic disorders, including obesity and cachexia. To support the development of precise diagnostic assays, Meridian Bioscience offers high-quality reagents targeting ghrelin
---
### [Triiodothyronine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/triiodothyronine/)
**Description:** Triiodothyronine (T3) and Thyroxine (T4) are hormones produced by the thyroid and are responsible for regulating metabolism. Their expression is carefully controlled by thyroid-stimulating hormone (TSH) and they circulate in a biologically inactive form in the bloodstream to further restrict their activity. Thyroid dysfunction can lead to the production of too much to too little T3 or T4 causing hyper or hypothyroidism.
---
### [EPSPS](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/food-water-testing/epsps/)
**Description:** Meridian Bioscience offers monoclonal antibodies targeting 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), including those specific to CP4 EPSPS and G2 EPSPS. These purified mouse IgG1 antibodies are suitable for applications such as ELISA, Western blotting, and lateral flow assays, aiding in the development of diagnostic tests for food and water safety.
---
### [DOA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/)
**Description:** Drugs of Abuse
---
### [Cotinine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/cotinine/)
**Description:** Cotinine is an alkaloid found in tobacco and it is the predominant metabolite of nicotine. Its main use is as a biomarker for exposure to tobacco smoke. The half-life of cotinine is much longer than nicotine and it can be detected in urine, blood and saliva 7 – 40 hours after exposure to tobacco smoke. Detection is usually by competitive-based ELISAs using urine or saliva samples.
---
### [Oxycodone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/oxycodone/)
**Description:** Oxycodone is a semi-synthetic opioid with structural similarity to codeine and is made by modifying Thebaine, an organic chemical found in Opium. It produces potent euphoria, analgesic, and sedative effects, and has a dependence liability similar to morphine. It is used clinically to relieve moderate to severe pain however, it is also used illegally, especially the long-acting form of the drug which is marketed as OxyContin. The half-life of oxycodone is between 3.5 and 5.5 hours however its main metabolites noroxycodone and oxymorphone can be detectable 2-4 days in urine.
---
### [Dinitrophenol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/dinitrophenol/)
**Description:** 2,4-Dinitrophenol (DNP) is a chemical compound historically used in various industrial applications. Despite its industrial uses, DNP has been misused as a weight loss agent, leading to severe health risks and fatalities. Accurate detection and monitoring of DNP are essential in clinical diagnostics and forensic investigations.
---
### [THC](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/thc/)
**Description:** Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis and one of at least 113 total cannabinoids identified in the plant. Cannabis is a controlled substance although medicinal use for treating pain, nausea, and other symptoms of chronic diseases such as multiple sclerosis has been legalized recently by several countries. Detection of THC and its metabolites such as delta-9-THC is typically done by urine or saliva analysis and confirmed by mass spectrometry.
---
### [Buprenorphine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/buprenorphine/)
**Description:** Buprenorphine is a semi-synthetic opioid that is FDA-approved for acute pain, chronic pain, and opioid dependence and exerts its effects by acting as a partial opioid receptor antagonist. The drug is also in veterinary medicine for the treatment of pain in dogs and cats and recreationally by injection or in the nose for the high it produces. It has been reported to be the third most prevalent misused opioid, next to heroin and methadone. Buprenorphine is rapidly metabolized in the liver into major metabolites norbuprenorphine, buprenorphine-3-β-glucuronide, and norbuprenorphine-3-β-glucuronide. Very little free drug is detectable in the urine and ELISA-based drug screening assays for buprenorphine should be confirmed by mass spectrometry.
---
### [Chloramphenicol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/chloramphenicol/)
**Description:** Chloramphenicol is a broad-spectrum antibiotic effective against various bacterial infections. Monitoring its levels is crucial in both clinical and research settings to ensure therapeutic efficacy and avoid potential toxicity. To support the development of accurate assays for chloramphenicol detection, Meridian Bioscience offers specialized monoclonal antibodies
---
### [Tramadol](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/tramadol/)
**Description:** Tramadol is a synthetic opioid analgesic used to manage moderate to moderately severe pain. Monitoring its levels is important to ensure therapeutic efficacy and minimize potential adverse effects. To support accurate detection and research involving tramadol, Meridian Bioscience offers a specialized monoclonal antibody
---
### [Ketamine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/ketamine/)
**Description:** Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist which was developed in the 1960s for medical use and is now used widely throughout the world for anesthesia and pain relief in both humans and animals, particularly horses. Ketamine is a potent pain killer and is particularly useful for children undergoing agonizing procedures such as treatment of burns. As a dissociative drug, it is used recreationally and as a “date rape” drug. Ketamine can be detected in urine up to 14 days after the last use and up to 24 hours in blood.
---
### [MDMA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/mdma-ecstacy/)
**Description:** 3,4-methylenedioxy-methamphetamine (MDMA), also known as Ecstasy, is a synthetic drug and derivative of amphetamine that alters mood and perception. It is chemically similar to both stimulants and hallucinogens and acts by increasing the activity of three brain chemicals: dopamine, norepinephrine, and serotonin. MDMA is illegal in most countries and, as of 2018, has no approved medical uses. Screening assays are generally qualitative and based on competitive ELISAs using urine, saliva, or blood samples.
---
### [Barbital](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/barbital/)
**Description:** Barbital is a long-acting barbiturate that depresses most metabolic processes at high doses. It was widely used in the 1980s as a sleep-aid (sedative), however, it induces dependence and has largely been replaced by safer benzodiazepines. It is still used in veterinary practice for central nervous system depression. Barbital is detectable in blood and saliva for up to 3 days, 3 weeks in urine, and up to three months in hair.
---
### [Propoxyphene](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/propoxyphene/)
**Description:** Propoxyphene is an opioid pain reliever used to treat mild to moderate pain and it acts as a cough suppressant. It is structurally similar to methadone and its metabolite with a half-life of 8 – 24 hours. Since 2010, the FDA recommends avoiding the use of propoxyphene due to its toxic effect on the heart, even when used at therapeutic doses. Propoxyphene is typically measured in urine as part of a drug of abuse test.
---
### [Methadone](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/methadone/)
**Description:** Methadone is a long-acting synthetic opioid used to treat opioid dependence and chronic pain. It prevents symptoms of opioid withdrawal, reduces opioid cravings, and blocks the euphoric effects of short-acting opioids such as heroin and morphine. Patients who are taking methadone for therapeutic purposes should be monitored for compliance by testing both methadone and its major metabolite EDDP. Urine testing is considered to be more useful than blood testing for methadone as it has a window of detection of 1 to 3 days, compared to blood which has a window of detection for only a few hours.
---
### [Amphetamine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/amphetamine/)
**Description:** Amphetamines are central nervous system (CNS) stimulants that are used to treat ADHD and narcolepsy. They are also used illegally as recreational aphrodisiacs and euphoriants. Amphetamine is detectable in blood for up to 48 hours, 5 days in urine and saliva, and up to three months in hair. Certain drugs can cause false-positive results in urine drug screening for amphetamines including anti-depressants, anti-histamines, nasal inhalers and cold medicines that contain pseudoephedrine and/or promethazine.
---
### [Benzodiazepine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/benzodiazepine/)
**Description:** Benzodiazepines are a class of psychoactive drugs and nervous system depressants commonly prescribed to treat conditions such as anxiety, stress, insomnia, epilepsy and to sedate people before certain medical procedures. In the 1970s benzodiazepines were the most prescribed medications globally however, the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, have decreased their rates of prescription. They are considered a major addictive substance and are only recommended for short-term (2-4 week) use. Non-medical benzodiazepine use is mostly limited to individuals who use other substances, i.e., people who engage in polysubstance use. Urine tests for benzodiazepines are the most common as they are able to detect the drug for several weeks after use, whereas benzodiazepines are only detectable in saliva and blood for a few hours to a few days.
---
### [Cocaine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/cocaine/)
**Description:** Cocaine is a tropane alkaloid and stimulant drug which is most commonly used as a recreational drug and euphoriant. It acts as an indirect sympathomimetic by blocking the dopamine transporter and it is highly addictive due to its effect on the reward pathway in the brain. Cocaine has a short half-life of 6-hours and is only detectable in urine for up to one day after last use. Its major metabolite benzoylecgonine has a half-life of 12 hours and can be detected in urine up to 4 days after last use. Screening assays for cocaine usually detect both cocaine and benzoylecgonine using competitive-based ELISA assays on urine samples.
---
### [Benzoylecgonine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/benzoylecgonine/)
**Description:** Monoclonal Antibodies: Meridian provides several monoclonal antibodies targeting benzoylecgonine, produced in mouse hosts with an IgG1 isotype. These antibodies are purified and suitable for applications such as Enzyme Immunoassays (EIA), Radioimmunoassays (RIA), and Lateral Flow assays. For instance, the MAb to Benzoylecgonine has been validated for use in EIA and RIA applications.
---
### [Methamphetamine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/methamphetamine/)
**Description:** Methamphetamine is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. It is highly addictive, neurotoxic (it can damage dopamine and serotonin neurons in the brain) and it is the second-highest illicit drug used worldwide. As a stereoisomer it is available in two forms, d- and l-form, with the d- form being the most frequently used. Drug screening assays typically detect the presence of d-methamphetamine in whole blood, oral fluids, serum, plasma, and urine samples.
---
### [Morphine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/morphine/)
**Description:** Morphine is an opioid and part of a group of analgesic agents commonly used in clinical practice. It is used to help relieve severe ongoing pain (such as due to cancer) and it produces most of its analgesic effects by binding to the mu-opioid receptor within the central nervous system (CNS) and the peripheral nervous system (PNS). Opioid analgesic misuse has risen significantly over the past two decades and standard illegal drug screens typically test for the presence of morphine which can be detected for up to 36 hours in saliva and 3 days in urine samples.
---
### [K2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/k2/)
**Description:** K2, commonly known as “Spice,” refers to synthetic cannabinoids designed to mimic the effects of Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. These substances are typically sprayed onto plant material and marketed as legal alternatives to cannabis. However, their use has been associated with severe health risks, including psychosis, seizures, and even death.
---
### [EDDP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/eddp/)
**Description:** EDDP (2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine) is the metabolite of methadone, and testing for EDDP is used to determine the effective intake of Methadone when it is used as patient substitution treatment during use cessation. Methadone metabolizes in the liver into EDDP and EMDP. However, the rates of metabolism vary between individuals. The detection of EDDP in place of Methadone avoids the problems related to the metabolic differences of each person.
---
### [Erythromycin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/erythromycin/)
**Description:** Erythromycin is a macrolide antibiotic widely used to treat various bacterial infections. Accurate detection and monitoring of erythromycin levels are essential in both clinical diagnostics and research settings.
---
### [Carbamazepine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/carbamazepine/)
**Description:** Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly prescribed for epilepsy and bipolar disorder. Monitoring its levels is crucial to ensure therapeutic efficacy and avoid toxicity. To support the development of accurate assays for carbamazepine detection, Meridian Bioscience offers a specialized reagent
---
### [Digoxin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/digoxin/)
**Description:** Digoxin is a cardiac glycoside commonly used to treat various heart conditions, including atrial fibrillation and heart failure. Accurate monitoring of digoxin levels is essential to ensure therapeutic efficacy and prevent toxicity.
---
### [Theophylline](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/theophylline/)
**Description:** “Theophylline is a bronchodilator used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Monitoring its levels is crucial to ensure therapeutic efficacy and avoid potential toxicity. To facilitate accurate detection and research involving theophylline, Meridian Bioscience offers specialized monoclonal antibodies:”
---
### [Gentamicin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/gentamicin/)
**Description:** Gentamicin is an aminoglycoside antibiotic widely used to treat various bacterial infections. Accurate detection and monitoring of gentamicin levels are essential in both clinical diagnostics and research settings to ensure therapeutic efficacy and minimize potential toxicity.
---
### [Valproic](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/valproic/)
**Description:** Valproic acid is a medication primarily used to treat epilepsy and bipolar disorder, and to prevent migraine headaches. Monitoring its levels is crucial to ensure therapeutic efficacy and avoid potential toxicity. To support accurate detection and research involving valproic acid, Meridian Bioscience offers specialized monoclonal antibodies
---
### [Procainamide](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/procainamide/)
**Description:** Procainamide is an antiarrhythmic medication used to treat various cardiac arrhythmias by stabilizing the heart’s rhythm. Monitoring its levels is crucial to ensure therapeutic efficacy and avoid potential toxicity. To facilitate accurate detection and research involving procainamide, Meridian Bioscience offers specialized monoclonal antibodies
---
### [Cyclosporin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/cyclosporin/)
**Description:** Cyclosporin A is an immunosuppressive agent widely used to prevent organ transplant rejection and to treat certain autoimmune disorders. Monitoring its levels is crucial to ensure therapeutic efficacy and minimize potential toxicity.
---
### [CK-MM](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ck-mm/)
**Description:** CK-MM (Creatine Kinase Muscle Type) is a key enzyme found in muscle tissue, playing a crucial role in cellular energy metabolism. Elevated levels of CK-MM in the blood can indicate muscle damage or injury, including conditions like myocardial infarction and muscular dystrophy. Meridian Bioscience provides high-quality CK-MM antibodies that are vital for the accurate detection and diagnosis of muscle-related disorders, supporting clinicians in making informed decisions.
---
### [Mast Cell Tryptase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/mast-cell-tryptase/)
**Description:** Mast cell tryptase is a serine protease predominantly found in mast cells, serving as a biomarker for mast cell activation and associated disorders. Meridian Bioscience offers a monoclonal antibody that recognizes human mast cell tryptase, including both alpha and beta isoforms. This antibody is suitable for applications such as Enzyme Immunoassay (EIA) and Western Blot (WB), supporting research and diagnostic assay development related to mast cell activity.
---
### [NT-proBNP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/nt-probnp/)
**Description:** NT-proBNP is a 76–amino acid N-terminal fragment that is generated when proBNP is proteolytically cleaved into BNP (biologically active) and NT-proBNP (not biologically active). Both BNP and NT-proBNP are released in response to changes in pressure inside the heart, which can be related to heart failure and other cardiac problems. Like BNP, NT-proBNP is useful in the diagnosis and prognosis of heart failure and is considered a gold standard biomarker in heart failure. Levels of NT-proBNP can be measure quantitively using a two-site sandwich ELISA or CLIA assay.
---
### [CD Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/cd-markers/)
**Description:** Have questions about a CD Markers?Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [SAA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/saa/)
**Description:** Serum amyloid A protein (SAA) has been identified as a major acute-phase protein and marker for inflammation in several animal species including horses and cats. It is useful for diagnosing the presence of inflammation and for real-time monitoring of inflammatory changes in disease states and response to therapy. SAA is highly conserved across species and can be measured using a quantitative double antibody sandwich ELISA.
---
### [Interferon](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/interferon/)
**Description:** Interferons are crucial cytokines involved in antiviral defense and immune regulation. Meridian Bioscience offers monoclonal antibodies targeting various interferon types, including Interferon Alpha and Interferon Gamma. These antibodies are available in purified formats and are suitable for applications such as Enzyme Immunoassay (EIA), Western Blot (WB), and other immunoassays, supporting research and diagnostic assay development
---
### [SAA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/saa-2/)
---
### [Cystatin C](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/cystatin-c-vet-health/)
**Description:** Cystatin C is a cysteine protease inhibitor produced by all nucleated cells, serving as a crucial biomarker for assessing kidney function. Meridian Bioscience offers high-quality monoclonal antibodies targeting animal Cystatin C, facilitating the development of precise diagnostic assays. These antibodies are suitable for applications such as enzyme immunoassays (EIA) and protein purification processes. For instance, their monoclonal antibody is an IgG2a isotype derived from mouse hosts, purified for optimal performance in various immunoassays.
---
### [AAT](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/aat/)
**Description:** AAT testing, when used alongside a set of tumor markers, proves valuable in the context of diagnosing, treating, and monitoring SCCE
---
### [Low Density LRP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/low-density-lrp/)
**Description:** Low-density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor involved in the clearance of various ligands, including lipoproteins and protease inhibitor complexes. It plays roles in lipid metabolism, cell growth, migration, and tissue invasion.
---
### [GAPDH](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/gapdh/)
**Description:** GAPDH Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Transferrin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/transferrin/)
**Description:** Transferrin is an iron-binding glycoprotein essential for iron transport and serves as a significant biomarker in various clinical diagnostics. Meridian Bioscience provides monoclonal antibodies targeting transferrin and its receptor to support research and diagnostic assay development. These antibodies are valuable tools for studying iron metabolism and related disorders.
---
### [SOD](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/sod/)
**Description:** Superoxide dismutase (SOD) is an enzyme that plays a crucial role in protecting cells from oxidative damage by catalyzing the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Meridian Bioscience offers a range of monoclonal and polyclonal antibodies, antigens, and blockers to support research and diagnostic assay development.
---
### [HSA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/hsa/)
**Description:** Human Serum Albumin (HSA) is the most abundant protein in human blood plasma, playing a critical role in maintaining oncotic pressure and serving as a carrier protein for various endogenous and exogenous substances. To support research and diagnostic assay development targeting HSA, Meridian Bioscience offers high-quality monoclonal antibodies
---
### [HSP-20](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/hsp-20/)
**Description:** HSP-20 Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [TNF](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/tnf/)
**Description:** Tumor Necrosis Factor (TNF) is a proinflammatory cytokine primarily secreted by macrophages. It plays a pivotal role in regulating immune responses, including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.
---
### [Leptin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/leptin/)
**Description:** Leptin, a hormone produced by adipose tissue, regulates energy balance and appetite. Meridian Bioscience provides antibodies targeting human leptin, including the monoclonal antibody and the rabbit anti-leptin amino terminal polyclonal antibody, supporting research and diagnostic assay development
---
### [sGC](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/sgc/)
**Description:** Soluble Guanylate Cyclase (sGC) is an enzyme that plays a crucial role in the nitric oxide signaling pathway, converting GTP to cyclic GMP, which mediates various physiological processes. Meridian Bioscience offers a monoclonal antibody targeting the beta subunit of human sGC, supporting research and diagnostic assay development related to this enzyme
---
### [Glyceraldehyde](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/glyceraldehyde/)
**Description:** Glyceraldehyde Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [sLOX](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/slox/)
**Description:** Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) is the circulating form of the membrane-bound LOX-1 receptor, which binds oxidized low-density lipoprotein (oxLDL). Elevated levels of sLOX-1 are associated with acute coronary syndromes, making it a potential early diagnostic marker for these conditions.
---
### [HRP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/hrp/)
**Description:** Meridian Bioscience offers a range of Horseradish Peroxidase (HRP)-related products for diagnostic assay development. Their offerings include HRP-conjugated antibodies, such as the Monoclonal Antibody to Plasmodium falciparum HRP-2, and HRP-conjugated antigens like the Cotinine-3-HRP Conjugate. Additionally, they provide the HRP Conjugate Stabilizer Diluent to enhance the stability and performance of HRP conjugates in immunoassays.
---
### [PAI-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/pai-1-autoimmune/)
**Description:** PAI-1 Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [tPA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/tpa/)
**Description:** tPA Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Antiplasmin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/antiplasmin/)
**Description:** Alpha-2-antiplasmin (α2AP) is a serine protease inhibitor primarily responsible for inhibiting plasmin, the key enzyme involved in fibrinolysis. By regulating plasmin activity, α2AP plays a crucial role in maintaining hemostatic balance and preventing excessive fibrin degradation. Abnormal levels or dysfunction of α2AP can lead to bleeding disorders or thrombotic conditions, making it a significant marker in coagulation studies.
---
### [Fibrinogen](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/fibrinogen/)
**Description:** Fibrinogen is a coagulation factor that is essential for blood clot formation. It is produced in the liver and has a half-life of three to five days, and decreased levels indicate an increased risk of blood clots leading to conditions like disseminated intravascular coagulation.
---
### [Proteinase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/proteinase/)
**Description:** Proteinase Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [NGAL](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/ngal/)
**Description:** Neutrophil Gelatinase-Associated Lipocalin (NGAL), also known as Lipocalin-2, is a biomarker linked to various pathological conditions. Meridian Bioscience provides chicken-derived polyclonal antibodies against NGAL/Lipocalin-2 to support related research and diagnostic assay development.
---
### [C-1 Inhibitor](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/c-1-inhibitor/)
**Description:** Have questions about a C-1 Inhibitor? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Lambda Light Chain](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/lambda-light-chain/)
**Description:** Have questions about a Lambda Light Chain? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [RNP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/rnp/)
**Description:** RNP Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Ro (SS-A)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ro-ssa/)
**Description:** Have questions about a Ro (SS-A)? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [St Autoimmune](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/st-autoimmune/)
**Description:** St Autoimmune Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [dsDNA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/dsdna/)
**Description:** Anti-double stranded DNA (dsDNA) is a specific type of antinuclear antibody (ANA) that is found in about 30% of people with systemic lupus, and it is produced when a person’s immune system fails to distinguish between “self” and “non-self” cellular components. Less than 1% of healthy individuals have this antibody. Anti-dsDNA tests are carried out after a patient tests positive for antinuclear antibody (ANA) and has clinical signs and symptoms that suggest lupus. Immunoassays using recombinant double-stranded DNA (dsDNA) are used for the combined quantitative detection of IgG, IgA, and IgM antibodies against dsDNA in human serum.
---
### [Biotin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/biotin/)
**Description:** Meridian Bioscience offers biotin-related reagents, including a Vitamin D – Biotin Conjugate Antigen, designed for diagnostic assay development. They also provide biotin-conjugated antibodies, such as a chicken antibody to Staphylococcal Protein A, suitable for various immunoassay applications. These products support the development of sensitive and specific diagnostic tests.
---
### [FITC](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/fitc/)
**Description:** Meridian Bioscience offers monoclonal and polyclonal antibodies targeting FITC, including MAb to FITC and Rabbit anti-fluorescein. Suitable for ELISA and immunofluorescence in diagnostic assay development.
---
### [IGF](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/igf/)
---
### [Renin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/renin-cancer-markers/)
**Description:** Renin is an enzyme secreted by the kidneys that plays a critical role in blood pressure regulation and electrolyte balance. Meridian Bioscience offers a monoclonal antibody targeting renin, supporting research and diagnostic assay development related to hypertension and related disorders.
---
### [EGFR](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/egfr/)
**Description:** Epidermal growth factor receptor (EGFR) is a tyrosine kinase that stimulates proliferation and differentiation by binding its ligand, epidermal growth factor (EGF). Dysregulation and mutations of EGFR have been documented in many solid tumor disease states such as head and neck, breast, renal, colon, glioblastoma multiforme, and non-small-cell lung cancer. Clinical diagnosis of EGFR upregulation or mutations is important in determining which tumors will respond to cancer therapy using tyrosine kinase inhibitors. EGFR upregulation is usually diagnosed by serologic testing and EFGR mutations by real-time PCR or next-generation sequencing.
---
### [Streptavidin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/streptavidin/)
**Description:** Meridian Bioscience offers Streptavidin, a purified, lyophilized protein used in various immunoassay applications. Additionally, they provide a Monoclonal Antibody to Streptavidin, suitable for enhancing signal detection in assays like ELISA, immunoblotting, and flow cytometry.
---
### [CX3CR1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/cx3cr1/)
**Description:** CX3CR1, also known as the fractalkine receptor, is a chemokine receptor that mediates leukocyte migration and adhesion. It is expressed in various human tissues and cell lines, playing a significant role in immune surveillance and inflammatory responses.
---
### [C3](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/c3/)
**Description:** Have questions about a C3? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [C4](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/c4/)
**Description:** Have questions about a C4? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Kappa Light Chains](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/kappa-light-chains/)
**Description:** Kappa Light Chains Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Tobramycin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/tobramycin/)
**Description:** Tobramycin is an aminoglycoside antibiotic used to treat various bacterial infections, particularly those caused by Gram-negative organisms. Monitoring its levels is crucial to ensure therapeutic efficacy and minimize potential toxicity.
---
### [Sialyl Lewis](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/sialyl-lewis/)
**Description:** Sialyl Lewis antigens, including Sialyl Lewis A (sLe^a^) and Sialyl Lewis X (sLe^x^), are carbohydrate structures implicated in cell adhesion and cancer metastasis. Meridian Bioscience offers monoclonal antibodies targeting these antigens to support research and diagnostic assay development. These antibodies are valuable tools for studying the role of Sialyl Lewis antigens in cancer progression and other pathological conditions
---
### [PCNA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/pcna/)
**Description:** PCNA Proliferating cell nuclear antigen (PCNA) is an intranuclear protein that plays a role in DNA repair and replication.
---
### [Epithelial MuCIn](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/epithelial-mucin/)
**Description:** Epithelial MuCIn Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Desmin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/desmin/)
**Description:** Have questions about a Desmin? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [p53](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/p53/)
**Description:** p53 is a tumor suppressor protein that plays a critical role in regulating cell division and preventing cancer formation. Meridian Bioscience offers a monoclonal antibody targeting p53, specifically recognizing amino acids 32-79. This antibody is suitable for various research and diagnostic applications related to cancer studies.
---
### [TBG](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/thyroxine-binding-globulin-tbg/)
**Description:** Thyroxine-Binding Globulin (TBG) is a high-affinity serum protein responsible for transporting thyroid hormones—thyroxine (T4) and triiodothyronine (T3)—in the bloodstream. It accounts for approximately 76% of plasma protein thyroxine-binding activity. Variations in TBG levels can influence total concentrations of T4 and T3, potentially leading to misinterpretation as thyroid dysfunction. Therefore, accurate measurement of TBG is essential for distinguishing between true thyroid disorders and alterations due to binding protein levels.
---
### [HER2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/her2/)
**Description:** HER2 Receptor tyrosine-protein kinase erbB-2, also known as HER2/Neu (human epidermal growth factor receptor 2), is a member of the human epidermal growth factor receptor family.
---
### [EpCAM](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/epcam/)
**Description:** EpCAM Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [HE4](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/he4/)
**Description:** HE4 Human epididymis protein 4 (HE4) belongs to the whey acidic four-disulfide core protein family, and its biological function is currently unknown.
---
### [CRP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/crp-vet-health/)
**Description:** C-Reactive Protein (CRP) is a key acute-phase protein used in veterinary diagnostics to detect inflammation, monitor disease progression, and evaluate treatment response in companion animals, particularly dogs. Elevated CRP levels can indicate infections, autoimmune disorders, or post-surgical inflammation, making it a valuable biomarker in veterinary internal medicine. Meridian Bioscience offers high-quality CRP reagents for use in immunoassays, supporting fast and accurate results in veterinary clinics and diagnostic labs.
---
### [SCLC](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/sclc/)
**Description:** Small Cell Lung Cancer (SCLC) is an aggressive form of lung cancer characterized by rapid growth and early metastasis. To support research and diagnostic assay development related to SCLC, Meridian Bioscience offers a monoclonal antibody specifically targeting small cell lung carcinoma. This antibody aids in the detection and study of SCLC, providing a valuable tool for understanding this malignancy.
---
### [NPR](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/npr/)
**Description:** Natriuretic peptides are a family of hormones that play crucial roles in cardiovascular homeostasis by regulating blood pressure, electrolyte balance, and fluid volume. Among them, B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are widely recognized as biomarkers for heart failure and other cardiac conditions.
---
### [Factor XII](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/factor-xi/)
**Description:** Factor XII Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Prekallikrein](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/prekallikrein/)
**Description:** Prekallikrein Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Fibrinopeptide](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/fibrinopeptide/)
**Description:** Fibrinopeptide A is a segment of the fibrinogen alpha chain released during blood clot formation, serving as a marker for coagulation activity. Meridian Bioscience provides monoclonal antibodies specific to Fibrinopeptide A to aid in research and diagnostic assay development related to fibrinogen function and clotting disorders
---
### [Interferon](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/interferon-cardiac-cholesterol-metabolic-markers/)
**Description:** Interferons (IFNs) are critical cytokines in the immune system, known for their antiviral, antiproliferative, and immunomodulatory properties. They play a pivotal role in the body’s defense against pathogens and in regulating immune responses.
---
### [Defensin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/defensin/)
**Description:** Defensins are small cationic peptides produced by neutrophils and epithelial cells, playing a crucial role in the innate immune response due to their antimicrobial properties. Recent studies have linked single nucleotide polymorphisms (SNPs) in beta-defensins to an increased susceptibility to cancer. Specifically, downregulation of beta-defensins has been observed in oral cancer, indicating a potential tumor-suppressive role.
---
### [Erythropoietin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/epo/)
**Description:** Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys, playing a crucial role in regulating red blood cell production (erythropoiesis) in response to hypoxia. Beyond its hematopoietic function, EPO has been implicated in neuroprotection and tissue regeneration.
---
### [CD Markers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/cd-markers-cardiac-cholesterol-metabolic-markers/)
**Description:** Cluster of Differentiation (CD) markers are cell surface molecules expressed on leukocytes and other cells, serving as vital identifiers in immunophenotyping and aiding in the classification of immune cells. These markers are essential in diagnosing various hematological disorders, monitoring immune responses, and facilitating targeted therapies.
---
### [Map-2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/map-2/)
**Description:** Microtubule-associated protein 2 (MAP-2) is a neuronal protein involved in microtubule assembly, crucial for neurogenesis and neuronal differentiation. Meridian Bioscience offers a monoclonal antibody targeting MAP-2 subunits 2a and 2b, supporting research and diagnostic assay development related to neurological diseases.
---
### [SNAP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/snap/)
**Description:** Meridian Bioscience offers a Monoclonal Antibody to SNAP-25, targeting Synaptosomal-Associated Protein 25, essential for synaptic vesicle fusion. Suitable for ELISA and Western blotting.
---
### [Synuclein](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/synuclein/)
**Description:** Synucleins are a family of proteins implicated in neurodegenerative diseases and certain cancers. Meridian Bioscience offers monoclonal antibodies targeting alpha-synuclein to support research and diagnostic assay development related to these conditions.
---
### [Presenilin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/presenilin/)
**Description:** Meridian Bioscience offers the Goat Anti-Presenilin-1 (N-Terminal) polyclonal antibody, targeting amino acids 14-33 of human presenilin-1. Suitable for ELISA and Western blotting.
---
### [Amyloid](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/amyloid/)
**Description:** Meridian Bioscience offers monoclonal antibodies targeting amyloid beta peptides, such as MAb to Amyloid Beta (1-40) and MAb to Amyloid Beta, N-term for Alzheimer’s disease diagnostics. They also provide antigens and antibodies for Serum Amyloid A (SAA), an acute-phase protein and inflammation marker in various species
---
### [Dopamine](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/dopamine/)
**Description:** Meridian Bioscience offers high-quality dopamine antibodies and antigens for research and diagnostics. Their portfolio includes specific monoclonal antibodies targeting dopamine and its receptors (D2 and D4), validated for applications like immunocytochemistry and Western blotting. These reagents are ideal for studying neurological functions and developing assays related to dopamine signaling and drug testing.
---
### [T. cruzi (Chagas)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/chagas/)
**Description:** Chagas is a potentially life-threatening illness that is caused by the protozoan parasite Trypanosoma cruzi. The disease is predominately found in Latin America and mostly spreads by insects called triatomine bugs. However, there are other routes of transmission such as food-borne, congenital, and blood transfusions, which have enabled the disease to spread to other continents. The disease is curable if treatment is initiated soon after infection, however, chronic disease can cause long-term cardiac, digestive, or neurological complications. Universal screening of blood banks for Chagas is carried out in most Western and European countries and the screening of women of child-bearing age is essential in Latin America. Detection during the acute phase is by microscopy or PCR, however, as Chagas does not typically present any symptoms until the later stages of the disease, the most common tests are serological assays which detect the presence of IgM or IgG antibodies to the parasite.
---
### [HTLV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/sexually-transmitted-infections-stis/htlv/)
**Description:** Human T-cell lymphotropic virus-1 (HTLV-1) is part of a group of viruses, including HTLV-1, -II, and -III (also known as HIV-1 and HIV-2). It is endemic in many countries, principally Japan, the Caribbean, and central Africa, and it is estimated that 10-20 million people worldwide are infected. Most people do not develop any symptoms; however, about 1 in 20 people will develop adult T-cell leukemia/lymphoma or HTLV-1 associated myelopathy (a chronic nervous system disease). HTLV-1 infection is usually diagnosed by serology assays detection of HTLV-1 specific IgG or IgM antibodies.
---
### [Leishmania](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/leishmania/)
**Description:** Leishmaniasis is caused by a protozoa parasite called Leishmania that is spread by over 90 sandfly species which are mostly found in parts of the tropics, subtropics, and southern Europe. There are three main forms of the disease, visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis all of which are treatable and curable. Symptoms depend on the form of leishmaniasis and only visceral leishmaniasis can be fatal if left untreated. Diagnosis is made by combining clinical signs with parasitological, and serological rapid diagnostic tests are also available for visceral leishmaniasis.
---
### [Coxsackie](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/torch-childhood/coxsackievirus-cox/)
**Description:** Coxsackievirus is a member of the Picornaviridae family of viruses which is a subtype of Enterovirus. In cooler climates, outbreaks of coxsackievirus often occur in the summer and fall, though they can cause infections year-round in tropical parts of the world. The most well-known coxsackie disease is hand-foot and-mouth disease (HFMD), a common childhood illness which affects mostly children aged 5 or under and it is often from infection by coxsackie A16 or A6.
---
### [Interleukin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/interleukin-autoimmune/)
**Description:** Interleukin Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [LC-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/lc-1/)
**Description:** Have questions about a LC-1? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Ro52](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/ro52/)
**Description:** Have questions about a Ro52?Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Protein A](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/protein-a-miscellaneous-reagents/)
**Description:** Protein A is a bacterial protein with high affinity for the Fc region of immunoglobulins, particularly IgG, making it valuable in immunological research and diagnostics. Meridian Bioscience offers products such as Mouse IgG-Protein A complexes and Mouse IgG Protein A (Proclin) to support assay development.
---
### [SCCA](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/scca/)
**Description:** Squamous Cell Carcinoma Antigen 1 (SCCA-1) is a biomarker associated with certain types of cancer. Meridian Bioscience offers a recombinant SCCA-1 antigen to support research and diagnostic assay development related to squamous cell carcinoma.
---
### [CCL](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ccl/)
**Description:** CCL chemokines are a subgroup of chemokines characterized by two adjacent cysteine residues near their N-terminus, playing pivotal roles in immune responses by directing the migration of various immune cells to sites of inflammation or injury. To support research and diagnostic assay development targeting specific CCL chemokines, Meridian Bioscience offers high-quality recombinant antigens
---
### [snRNPC](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/snrnpc/)
**Description:** snRNPC Have questions about a product? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [P1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/p1/)
**Description:** Have questions about a P1? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [SmD2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/smd2/)
**Description:** Have questions about a SmD2? Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!
---
### [Leukemia](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/leukemia/)
---
### [BVDV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/veterinarian-health/bovine-viral-diarrhea-virus-bvdv/)
**Description:** Meridian Bioscience offers a recombinant form of the Bovine Viral Diarrhea Virus envelope glycoprotein Erns, known as the BVDV-Erns EP Glycoprotein. This antigen is designed to support the development of diagnostic assays for detecting BVDV infections in cattle.
---
### [THBD](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/thbd/)
**Description:** Thrombomodulin (TM), also known as CD141 or BDCA-3, is an integral membrane glycoprotein predominantly expressed on the surface of endothelial cells. It functions as a cofactor for thrombin, playing a critical role in the anticoagulant pathway by converting thrombin from a procoagulant to an anticoagulant enzyme.
---
### [Monkeypox](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/monkeypox/)
**Description:** Monkeypox virus (MPXV) is a zoonotic double-stranded DNA enveloped virus that belongs to the orthopoxvirus genus of the Poxviridae family, which also includes variola (VARV), cowpox (CPX), and vaccinia (VACV) viruses. The monkeypox virus is endemic to Africa with two distinct genetic groups (clades): the west African clade and the central African (Congo Basin) clade. For the second time in two years, the WHO has declared a global health emergency for mpox (monkeypox) virus, due to a newly emerging, highly contagious strain spreading across Africa. PCR is the only available FDA-approved test known to detect mpox virus, but it has limitations including complex sample collection and the requirement for sophisticated equipment and trained personnel. A rapid test, needing only a small sample of lesion swab and delivering results in 15 minutes, could dramatically slow the rate of transmission of the virus. Several immunodominant proteins for mpox have been identified and antibodies to the MPXV A29L protein have shown promise in lateral flow assays for the specific detection of mpox without cross-reactivity to other Orthopoxviruses. (doi.org/10.3389/fcimb.2024.1414224). Meridian has paired MAbs to Mpox A29L that are ideal for ELISA or lateral flow applications, alongside recombinant antigens to mpox proteins P4a, A5L, A11L, H3L, and A29L for IgM testing.
---
### [TBE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/tick-borne-encephalitis-tbe/)
**Description:** Tick-borne Encephalitis (TBE) is a viral disease transmitted by infected woodland ticks that is common in Central and Eastern Europe, and Northern Asia. It can cause severe central nervous system complications such as meningitis, encephalitis or meningoencephalitis. Over the past three decades, reported cases have increased by 400% and there is no specific treatment for the disease. Diagnosis is by detection of IgG and IgM antibodies to the virus in serum or cerebral spinal fluid.
---
### [Hepatitis E](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/viral-hepatitis/hepatitis-e/)
**Description:** Hepatitis E virus (HEV) is a waterborne disease mainly found in areas with poor sanitation and it is typically transmitted by ingesting fecal matter in contaminated water supplies. The disease is usually acute but can be particularly dangerous in pregnant women.
---
### [CK-BB](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ck-bb/)
**Description:** Creatine Kinase-BB (CK-BB) is one of the isoenzymes of creatine kinase, predominantly found in the brain and smooth muscle tissues. Elevated levels of CK-BB in the bloodstream can be indicative of brain injury, certain cancers, severe shock, stroke, hypothermia, or restricted blood flow to the bowel.
---
### [EGF](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/egf/)
**Description:** Epidermal Growth Factor Protein (EGF) is a growth factor with potential use as a cardiac biomarker due to its role in the proliferation of cardiac stem cells. Research suggests that the heart has an endogenous reserve of cardiac stem cells (CSCs) which can be activated by various growth factors to reconstitute the injured myocardium. EGF has been shown to significantly promote the proliferation, migration, and wound healing activities of this CSCs in comparison to the other growth factors.
---
### [Barbiturate](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/doa/barbiturate/)
**Description:** Barbiturates are central nervous system depressants historically prescribed for anxiety, insomnia, and seizure disorders. Due to their potential for dependence and overdose, monitoring barbiturate levels is essential in clinical and forensic settings.
---
### [UCHL1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/uchl1/)
**Description:** Meridian Bioscience offers the UCHL1 Recombinant Antigen, a purified, full-length recombinant human Ubiquitin C-terminal Hydrolase L1 (UCHL1) protein expressed in HEK cells. This antigen includes a DYKDDDDK tag at the C-terminus, has a molecular weight of approximately 27.9 kDa, and is affinity purified to a purity of ≥90% as determined by SDS-PAGE. It is suitable for use in ELISA, Western Blot, and CLIA applications.
---
### [MAPT](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/mapt/)
**Description:** Meridian Bioscience offers the MAPT Recombinant Antigen, a purified, full-length human tau protein expressed in HEK cells. This 80.7 kDa antigen, tagged with DYKDDDDK, is suitable for EIA, WB, and CLI applications.
---
### [NGAL](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ngal-cardiac-cholesterol-metabolic-markers/)
**Description:** Neutrophil Gelatinase-Associated Lipocalin (NGAL), also known as Lipocalin-2, is a glycoprotein involved in various physiological processes, including the innate immune response and iron transport. Traditionally recognized as a biomarker for kidney injury, recent studies have highlighted its significance in cardiovascular diseases. Elevated NGAL levels have been detected in patients with atherosclerotic plaques and myocardial infarction, suggesting its potential role in the development and progression of atherosclerosis.
---
### [ACE2](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/ace2/)
**Description:** Angiotensin-Converting Enzyme 2 (ACE2) is a membrane-bound enzyme that plays a pivotal role in the renin-angiotensin system, regulating blood pressure and fluid balance. Beyond its physiological functions, ACE2 serves as the entry receptor for the SARS-CoV-2 virus, facilitating viral attachment and entry into host cells. This dual role underscores the importance of ACE2 in both cardiovascular health and infectious disease contexts.
---
### [KIM](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/renal-diseases/kim/)
**Description:** Meridian Bioscience provides high-quality KIM (Kidney Injury Molecule) antibodies and antigens for diagnostic and research purposes. KIM is a biomarker for detecting acute kidney injury (AKI) and is involved in kidney cell injury and inflammation. These reagents are essential for detecting KIM levels in biological samples, aiding in early diagnosis and monitoring of kidney-related diseases. Validated for use in immunoassays and other laboratory techniques, they offer high specificity and reliability for accurate biomarker detection and clinical applications.
---
### [Antimicrobial Resistance](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/)
**Description:** Learn more about Antimicrobial Resistance antibodies and antigens used for diagnostic test manufacturing from Meridian Bioscience.
---
### [OXA-48](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/oxa-48/)
**Description:** OXA-48 is a common cause of Carbapenem Resistance in E. coli and Klebsiella pneumoniae Bacteria. Learn more about how Meridian can help you develop OXA-48
---
### [Klebsiella pneumoniae Carbapenemase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/klebsiella-pneumoniae-carbapenemase/)
**Description:** Accurately diagnosing KPC antimicrobial resistance is crucial for effective treatment. Testing involves laboratory techniques such as bacterial culture
---
### [New Delhi metallo-beta-lactamase-1](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/new-delhi-metallo-beta-lactamase/)
**Description:** NDM is a bacterium that resists carbapenem antibiotics, causing infections in various parts of the body. Testing for NDM involves lab techniques
---
### [Verona Integron Metallo-beta-lactamase](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/verona-integron-metallo-beta-lactamase/)
**Description:** Verona Integron-encoded Metallo-Beta-Lactamase (VIM) is a type of enzyme produced by some bacteria that makes them resistant to antibiotics
---
### [Imipenem](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/imipenem/)
**Description:** Imipenemases are a group of enzymes produced by some bacteria that make them resistant to imipenem antibiotics. Bacteria that produce IMP
---
### [Tsutsugamushi](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/tsutsugamushi/)
**Description:** Meridian provides purified O. tsutsugamushi antigens suitable for use in various immunoassays, including enzyme-linked immunosorbent assays (ELISA) and lateral flow assays. These antigens facilitate the detection of specific antibodies in patient samples, aiding in the diagnosis of scrub typhus.
---
### [Lassa](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/lassa/)
**Description:** Lassa virus, a significant cause of viral hemorrhagic fever in West Africa, requires swift and accurate diagnosis to prevent severe complications and limit transmission. Meridian Bioscience provides advanced molecular diagnostic solutions for the detection of Lassa virus, utilizing sensitive PCR-based assays for high specificity and rapid turnaround. Designed for clinical reliability, our testing platforms support healthcare professionals in identifying infections early, enhancing patient outcomes and strengthening public health response efforts.
---
### [Hantaan](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/tropical-vector-borne-diseases/hantaan/)
**Description:** Hantaan virus, a primary cause of hemorrhagic fever with renal syndrome (HFRS), poses a serious public health concern in endemic regions. Early and precise detection is essential for effective clinical management and outbreak control. Meridian Bioscience offers molecular diagnostic tools designed to accurately identify Hantaan virus using sensitive PCR-based technology. Our streamlined, high-performance testing solutions enable rapid, reliable results—empowering healthcare providers to make timely, informed decisions and support improved patient care.
---
### [MERS](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/respiratory-diseases/mers/)
**Description:** Middle East Respiratory Syndrome (MERS) is a serious viral infection caused by MERS-CoV, affecting the respiratory system with symptoms like fever, cough, and shortness of breath. Diagnosis relies on detecting the MERS antibody using immunoassay reagents and anti-MERS antibody tests. While there is no cure for MERS, treatment focuses on symptom management. Early detection through MERS antibody immunodiagnostic products is key to controlling the disease.
---
### [Neomycin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/antimicrobial-resistance/neomycin/)
**Description:** Discover Neomycin conjugates optimized for immunoassay development. Ideal for ELISA and lateral flow tests to detect neomycin residues in food, veterinary, and environmental samples.Meridian Bioscience provides high-purity Neomycin conjugates designed for use in the development of diagnostic assays and residue detection tests. Our Neomycin–protein conjugates are optimized for ELISA, lateral flow, and other immunoassay formats used in food safety, veterinary diagnostics, and environmental monitoring. These reagents enable the sensitive and specific detection of neomycin residues in complex sample matrices. Backed by consistent performance and lot-to-lot reproducibility, Meridian’s Neomycin reagents are ideal for laboratories developing reliable screening tools for antibiotic monitoring.
---
### [Chicken IgY](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/chicken-igy/)
**Description:** Shop high-quality Chicken IgY antibodies for ELISA, Western blot, and immunoassay development. Low cross-reactivity, high specificity, and consistent performance.
---
### [Fungus](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/fungus/)
**Description:** Meridian Bioscience provides high-quality fungal antigens and reagents to support the development of sensitive and specific diagnostic tests for fungal infections. Our portfolio includes purified fungal antigens and fungal-specific antibodies suitable for ELISA, lateral flow, and other immunoassay formats. These reagents enable accurate detection of clinically relevant fungi such as Aspergillus, Candida, and Cryptococcus. Designed for use in infectious disease diagnostics, Meridian’s fungal reagents offer reliable performance, consistency, and ease of integration into assay workflows.
---
### [LCMV](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/neurological-diseases-trauma/lcmv/)
**Description:** Meridian Bioscience offers high-quality LCMV (Lymphocytic choriomeningitis virus) antigens and reagents to support diagnostic assay development and infectious disease research. Our LCMV reagents include purified viral antigens ideal for use in ELISA and immunoassay platforms aimed at detecting LCMV-specific antibodies. These products enable the sensitive and specific detection of LCMV exposure, aiding in the study of viral pathogenesis and immune response. Meridian’s LCMV solutions are trusted by researchers and assay developers working in virology, zoonotic disease surveillance, and public health diagnostics.
---
### [Bacteriophage](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/bacteriophage/)
**Description:** Meridian Bioscience offers specialized bacteriophage reagents designed to support the development of rapid and accurate diagnostic assays. Our products include purified bacteriophage preparations and bacteriophage-derived proteins suitable for use in pathogen detection, bacterial identification, and phage-based assay development. These reagents provide a targeted, biologically active approach to diagnostics, enabling high specificity and sensitivity. Ideal for food safety, clinical microbiology, and environmental testing, Meridian’s bacteriophage solutions help accelerate innovation in next-generation diagnostics.
---
### [His tag](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/his-tag/)
**Description:** Meridian Bioscience provides high-quality His-tag reagents designed to support diagnostic assay development. Our product line includes a His Tag – Biotin Conjugate Antigen and His-tag–conjugated antibodies, ideal for use in ELISA, lateral flow, and other immunoassay platforms. These reagents enable efficient capture, detection, and purification of recombinant proteins, helping researchers develop sensitive, specific, and reproducible diagnostic tests. Trusted by assay developers worldwide, Meridian’s His-tag reagents deliver consistent performance and lot-to-lot reliability.
---
### [Alkaline Phosphatase (ALP)](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/alkaline-phosphatase-alp/)
**Description:** Explore Alkaline Phosphatase (ALP) enzyme conjugates optimized for ELISA and lateral flow assay development. High-performance, reliable reagents for sensitive detection.
---
### [Hemocyanin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/hemocyanin/)
**Description:** Shop Hemocyanin (KLH) proteins for hapten conjugation and immunoassay development. High-quality carrier proteins for antibody production and ELISA applications.
---
### [Saccharomyces](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/microbial-detection/saccharomyces/)
**Description:** Meridian Bioscience offers high-quality Saccharomyces antigens and related reagents to support the development of diagnostic assays for fungal infections and research applications. Our reagents are ideal for detecting immune responses to Saccharomyces cerevisiae, a key marker in Crohn’s disease, autoimmune studies, and fungal serology. Suitable for ELISA and other immunoassay formats, these products deliver high specificity, lot-to-lot consistency, and excellent sensitivity. Meridian’s Saccharomyces reagents enable researchers and assay developers to produce reliable and reproducible diagnostic tests for clinical and research use.
---
### [BrdU](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/miscellaneous-reagents/brdu/)
**Description:** Meridian Bioscience offers high-quality BrdU (Bromodeoxyuridine) reagents for use in DNA synthesis and cell proliferation assays. BrdU is a thymidine analog that incorporates into newly synthesized DNA during the S-phase of the cell cycle, enabling sensitive detection of dividing cells. Our BrdU products are optimized for use in ELISA, immunohistochemistry (IHC), flow cytometry, and fluorescence microscopy. With proven performance in both in vitro and in vivo applications, Meridian’s BrdU reagents are ideal for researchers studying cancer, immunology, toxicology, and cell biology.
---
### [Animal-Free, Recombinant Immunoassay Blockers](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/blockers-immunoglobulins/animal-free-blockers/)
**Description:** iscover the latest advancements in animal-free Immunoassay blocking reagents and interference inhibitors. Find out how Meridian's animal-free products can improve the accuracy and specificity of your Immunoassays.
---
### [IGFBP-3](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cancer-markers/igfbp-3-cancer-markers/)
**Description:** Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) is the most abundant IGFBP in human serum, playing a critical role in modulating the activity of insulin-like growth factors (IGFs). It serves as a biomarker in various cancers and metabolic disorders. Meridian Bioscience offers a monoclonal antibody specific to IGFBP-3, suitable for applications such as Enzyme Immunoassay (EIA), Chemiluminescent Immunoassay (CLIA), and Radioimmunoassay (RIA). This purified IgG1 antibody, derived from mouse, is designed to support research and diagnostic assay development related to IGFBP-3.
---
### [NT-proBNP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/nt-probnp-cardiac-cholesterol-markers/)
---
### [BNP & proBNP](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/bnp-probnp/)
**Description:** BNP belongs to a family of protein hormones called natriuretic peptides. It is formed when its precursor, proBNP is proteolytically cleaved into BNP (biologically active) and NT-proBNP (not biologically active). Both BNP and NT-proBNP are released in response to changes in pressure inside the heart which can be related to heart failure and other cardiac problems. BNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Levels of BNP can be measured quantitively using a two-site sandwich ELISA or CLIA assay.
---
### [Troponin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/cardiac-cholesterol-markers/troponin/)
---
### [Vitronectin](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/autoimmune/vitronectin-autoimmune/)
**Description:** Meridian Bioscience provides human vitronectin antigen and anti-vitronectin polyclonal antibody for research and diagnostic assay development in cancer and autoimmune diseases.
---
### [Enzymes](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/enzymes/)
---
### [Pfu Enzyme](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/enzymes/pfu-enzyme-enzymes/)
---
### [IgE](https://www.meridianbioscience.com/lifescience/products/antibodies-antigens/hormones/ige-hormones/)
---
## Categories
### [Immuno](https://www.meridianbioscience.com/lifescience/events/category/immuno/)
---
### [Molecular](https://www.meridianbioscience.com/lifescience/events/category/molecular/)
---
## Conditions
### [Gastrointestinal](https://www.meridianbioscience.com/condition/gastrointestinal/)
---
### [Healthcare Acquired Infections](https://www.meridianbioscience.com/condition/healthcare-acquired-infections/)
---
### [Other](https://www.meridianbioscience.com/condition/other/)
---
### [Parasitology](https://www.meridianbioscience.com/condition/parasitology/)
---
### [Pediatric & Neonatal](https://www.meridianbioscience.com/condition/pediatric-neonatal/)
---
### [Respiratory](https://www.meridianbioscience.com/condition/respiratory/)
---
### [Sexual Health](https://www.meridianbioscience.com/condition/sexual-health/)
---
### [Tropical Diseases](https://www.meridianbioscience.com/condition/tropical-diseases/)
---
## Country
### [Argentina](https://www.meridianbioscience.com/country/argentina/)
---
### [Australia](https://www.meridianbioscience.com/country/australia/)
---
### [Austria](https://www.meridianbioscience.com/country/austria/)
---
### [Bahrain](https://www.meridianbioscience.com/country/bahrain/)
---
### [Bolivia](https://www.meridianbioscience.com/country/bolivia/)
---
### [Brazil](https://www.meridianbioscience.com/country/brazil/)
---
### [Bulgaria](https://www.meridianbioscience.com/country/bulgaria/)
---
### [Canada](https://www.meridianbioscience.com/country/canada/)
---
### [Cayman Islands](https://www.meridianbioscience.com/country/cayman-islands/)
---
### [Chile](https://www.meridianbioscience.com/country/chile/)
---
### [Colombia](https://www.meridianbioscience.com/country/colombia/)
---
### [Croatia](https://www.meridianbioscience.com/country/croatia/)
---
### [Curacao](https://www.meridianbioscience.com/country/curacao/)
---
### [Cyprus](https://www.meridianbioscience.com/country/cyprus/)
---
### [Denmark](https://www.meridianbioscience.com/country/denmark/)
---
### [Dominican Republic](https://www.meridianbioscience.com/country/dominican-republic/)
---
### [Ecuador](https://www.meridianbioscience.com/country/ecuador/)
---
### [El Salvador](https://www.meridianbioscience.com/country/el-salvador/)
---
### [France](https://www.meridianbioscience.com/country/france/)
---
### [Germany](https://www.meridianbioscience.com/country/germany/)
---
### [Greece](https://www.meridianbioscience.com/country/greece/)
---
### [Guatemala](https://www.meridianbioscience.com/country/guatemala/)
---
### [Honduras](https://www.meridianbioscience.com/country/honduras/)
---
### [Hong Kong](https://www.meridianbioscience.com/country/hong-kong/)
---
### [Iceland](https://www.meridianbioscience.com/country/iceland/)
---
### [India](https://www.meridianbioscience.com/country/india/)
---
### [Indonesia](https://www.meridianbioscience.com/country/indonesia/)
---
### [Ireland](https://www.meridianbioscience.com/country/ireland/)
---
### [Italy](https://www.meridianbioscience.com/country/italy/)
---
### [Jordan](https://www.meridianbioscience.com/country/jordan/)
---
### [Kuwait](https://www.meridianbioscience.com/country/kuwait/)
---
### [Lebanon](https://www.meridianbioscience.com/country/lebanon/)
---
### [Luxembourg](https://www.meridianbioscience.com/country/luxembourg/)
---
### [Malaysia](https://www.meridianbioscience.com/country/malaysia/)
---
### [Mexico](https://www.meridianbioscience.com/country/mexico/)
---
### [Netherlands](https://www.meridianbioscience.com/country/netherlands/)
---
### [New Zealand](https://www.meridianbioscience.com/country/new-zealand/)
---
### [Nicaragua](https://www.meridianbioscience.com/country/nicaragua/)
---
### [Norway](https://www.meridianbioscience.com/country/norway/)
---
### [Pakistan](https://www.meridianbioscience.com/country/pakistan/)
---
### [Panama](https://www.meridianbioscience.com/country/panama/)
---
### [Paraguay](https://www.meridianbioscience.com/country/paraguay/)
---
### [Peru](https://www.meridianbioscience.com/country/peru/)
---
### [Philippines](https://www.meridianbioscience.com/country/philippines/)
---
### [Poland](https://www.meridianbioscience.com/country/poland/)
---
### [Portugal](https://www.meridianbioscience.com/country/portugal/)
---
### [Puerto Rico](https://www.meridianbioscience.com/country/puerto-rico/)
---
### [Qatar](https://www.meridianbioscience.com/country/qatar/)
---
### [Romania](https://www.meridianbioscience.com/country/romania/)
---
### [Saudi Arabia](https://www.meridianbioscience.com/country/saudi-arabia/)
---
### [Singapore](https://www.meridianbioscience.com/country/singapore/)
---
### [Slovak Republic](https://www.meridianbioscience.com/country/slovak-republic/)
---
### [Slovenia](https://www.meridianbioscience.com/country/slovenia/)
---
### [South Africa](https://www.meridianbioscience.com/country/south-africa/)
---
### [South Korea](https://www.meridianbioscience.com/country/south-korea/)
---
### [Spain](https://www.meridianbioscience.com/country/spain/)
---
### [Sweden](https://www.meridianbioscience.com/country/sweden/)
---
### [Switzerland](https://www.meridianbioscience.com/country/switzerland/)
---
### [Thailand](https://www.meridianbioscience.com/country/thailand/)
---
### [United Arab Emirates](https://www.meridianbioscience.com/country/united-arab-emirates/)
---
### [United States of America](https://www.meridianbioscience.com/country/united-states-of-america/)
---
### [United Kingdom](https://www.meridianbioscience.com/country/united-kingdom/)
---
### [Uruguay](https://www.meridianbioscience.com/country/uruguay/)
---
### [Venezuela](https://www.meridianbioscience.com/country/venezuela/)
---
### [Vietnam](https://www.meridianbioscience.com/country/vietnam/)
---
## LS Categories
### [Molecular](https://www.meridianbioscience.com/ls-category/molecular/)
---
## Molecular Reagents
### [Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzyme/)
**Description:** RT, PCR and qPCR enzymes including DNA polymerase for PCR, high-fidelity and hot-start polymerase, plus LAMP enzymes for molecular biology labs. including enzymes for isothermal amplification and NGS library preparation, available as glycerol-free and in high-concentration formats.
---
### [Reaction Buffers](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/reaction-buffers/)
**Description:** Meridian Bioscience offers a comprehensive selection of reaction buffers to optimize your scientific experiments. Find the perfect buffer for your needs today
---
### [qPCR and RT-qPCR Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/qpcr-and-rt-qpcr-master-mixes/)
**Description:** Meridian's ready-to-use qPCR and RT-qPCR master mixes have been developed for fast cycling and are designed for superior sensitivity and specificity with probe-detection technology.
---
### [Lyo-Ready & Air-Dryable Master Mixes & Reagents](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/)
**Description:** Lyophilized master mix solutions and lyo-ready enzymes for robust molecular testing. Ambient-stable reagents designed for consistent PCR/qPCR results.
---
### [Isothermal Amplification](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-amplification/)
**Description:** Isothermal amplification solutions, including LAMP and NASBA, for rapid DNA and RNA amplification. Reliable isothermal DNA and RNA amplification methods for molecular labs and point-of-care applications.
---
### [DNA-RNA Extraction Controls](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/dna-rna-extraction-controls/)
**Description:** DNA-RNA extraction controls, enables users of diagnostic assays to validate their entire workflow, from extraction, through purification to the qPCR.
---
### [General Reagent](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/general-reagent/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Nucleotides](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/nucleotides/)
**Description:** Enhance your results with our enzymatically synthesised, ultra-pure nucleotides, ideal for the most sensitive molecular assays.
---
### [RNase Inhibitor](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/rnase-inhibitor/)
**Description:** Discover high-quality RNase inhibitors at Meridian Bioscience - your trusted source for reliable solutions in molecular biology research
---
### [Specimen Specific Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/specimen-specific-inhibitor-tolerant-master-mixes/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Isothermal Master Mix](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/isothermal-master-mix/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [NGS Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ngs-enzymes/)
**Description:** Discover Meridian Bioscience's comprehensive range of glycerol-free NGS enzymes, designed to enhance all steps of your next-generation sequencing workflow. Achieve higher sensitivity and extend shelf-life with our innovative solutions, ideal for ambient temperature shipping and storage. Explore our products and elevate your NGS applications.
---
### [Reaction Buffer](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/reaction-buffer/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [DNA Polymerases](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/dna-polymerases/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Lyo Ready Air Dryer Master Mixes Reagents](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/lyo-ready-air-dryer-master-mixes-reagents/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Enzymes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Reverse Transcriptases](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/reverse-transcriptases/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
### [Liquid Ambient-Stable Master Mixes](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/liquid-ambient-stable-master-mixes/)
**Description:** Liquid Ambient-stable PCR and qPCR master mixes for room temperature storage. Cold-chain free DNA mix solutions for molecular diagnostics.
---
### [fragmentation](https://www.meridianbioscience.com/lifescience/products/molecular-reagents/enzymes/fragmentation/)
**Description:** Meridian is a trusted molecular reagent manufacturer providing high-quality PCR, qPCR, and isothermal reagents for diagnostics, research, and IVD development.
---
## Para Pak Categories
### [One-Vial Stool Transport](https://www.meridianbioscience.com/para-pak-cat/one-vial-stool-transport/)
---
### [Two-Vial Stool Transport](https://www.meridianbioscience.com/para-pak-cat/two-vial-stool-transport/)
---
### [Three-Vial Stool Transport](https://www.meridianbioscience.com/para-pak-cat/three-vial-stool-transport/)
---
### [Stool Concentration System](https://www.meridianbioscience.com/para-pak-cat/stool-concentration-system/)
---
### [Parasitology Stains](https://www.meridianbioscience.com/para-pak-cat/stool-specimens-parasitology-stains/)
---
## Regions
### [North America](https://www.meridianbioscience.com/lifescience/events/region/north-america/)
---
### [Europe](https://www.meridianbioscience.com/lifescience/events/region/europe/)
---
### [EMEA](https://www.meridianbioscience.com/lifescience/events/region/emea/)
---
### [Asia Pacific](https://www.meridianbioscience.com/lifescience/events/region/asia-pacific/)
---
## Regions
### [North America](https://www.meridianbioscience.com/diagnostics/event/region/north-america/)
---
### [EMEA](https://www.meridianbioscience.com/diagnostics/event/region/emea/)
---
## Solutions
### [Urea Breath](https://www.meridianbioscience.com/diagnostics/platforms/solutions/urea-breath/)
**Description:** Discover Meridian's FDA-approved Urea Breath Test for fast, accurate, non-invasive H. pylori detection. Trusted diagnostic solutions for clinical laboratories and healthcare providers.
---
### [Molecular](https://www.meridianbioscience.com/diagnostics/platforms/solutions/molecular/)
**Description:** Explore Meridian Bioscience's cutting-edge molecular instruments that deliver precise diagnostics
---
### [Immunoassay](https://www.meridianbioscience.com/diagnostics/platforms/solutions/immunoassay/)
**Description:** Discover the latest immunoassay platforms and diagnostic tests for accurate and efficient medical analysis.
---
### [Blood Chemistry](https://www.meridianbioscience.com/diagnostics/platforms/solutions/blood-chemistry/)
**Description:** LeadCare® by Meridian Bioscience offers cutting-edge solutions for rapid, accurate lead poisoning detection, enhancing patient care and community safety.
---
## Tags
### [Molecular](https://www.meridianbioscience.com/lifescience/events/tag/molecular/)
---
## Topics
### [Molecular](https://www.meridianbioscience.com/lifescience/webinars/topics/molecular/)
---
### [Inhibitor Tolerance](https://www.meridianbioscience.com/lifescience/webinars/topics/inhibitor-tolerance/)
---
### [Cancer Research](https://www.meridianbioscience.com/lifescience/webinars/topics/cancer-research/)
---
### [Immunology](https://www.meridianbioscience.com/lifescience/webinars/topics/immunology/)
---
### [Blockers](https://www.meridianbioscience.com/lifescience/webinars/topics/blockers/)
---
### [Infectious Disease](https://www.meridianbioscience.com/lifescience/webinars/topics/infectious-disease/)
---
### [Point-of-Care](https://www.meridianbioscience.com/lifescience/webinars/topics/point-of-care/)
---
### [Ambient Temperature Shipping and Storage](https://www.meridianbioscience.com/lifescience/webinars/topics/ambient-temperature-shipping-and-storage/)
---
### [Molecular Dx Controls](https://www.meridianbioscience.com/lifescience/webinars/topics/molecular-dx-controls/)
---
### [Cancer Research|Molecular](https://www.meridianbioscience.com/lifescience/webinars/topics/cancer-researchmolecular/)
---
### [Point-of-Care](https://www.meridianbioscience.com/lifescience/webinars/topics/point-of-care-cancer-researchmolecular/)
---
### [Immunology|Molecular](https://www.meridianbioscience.com/lifescience/webinars/topics/immunologymolecular/)
---
### [Infectious Disease](https://www.meridianbioscience.com/lifescience/webinars/topics/infectious-disease-immunologymolecular/)
---
### [STDs](https://www.meridianbioscience.com/lifescience/webinars/topics/stds/)
---
## Topics
### [分子](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/分子/)
---
### [癌症研究](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/癌症研究/)
---
### [常温稳定](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/常温稳定/)
---
### [免疫](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/免疫/)
---
### [免疫阻断剂](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/免疫阻断剂/)
---
### [传染病](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/传染病/)
---
### [抗抑性直扩](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/抗抑性直扩/)
---
### [优生优育](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/优生优育/)
---
### [Point-of-Care](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/point-of-care/)
---
### [常温稳定|分子](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/常温稳定分子/)
---
### [癌症研究](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/癌症研究-常温稳定分子-分子/)
---
### [分子检测质控](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/分子检测质控/)
---
### [分子核心酶](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/分子核心酶/)
---
### [天然抗原](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/天然抗原/)
---
### [Point-of-Care|分子](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/point-of-care分子/)
---
### [分子核心酶](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/分子核心酶-point-of-care分子-分子/)
---
### [NGS](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/ngs/)
---
### [癌症研究](https://www.meridianbioscience.com/lifescience/webinar-cn/topics/癌症研究-point-of-care分子-分子/)
---
## Types
### [Webinar](https://www.meridianbioscience.com/lifescience/events/type/webinar/)
---
### [Trade Show](https://www.meridianbioscience.com/lifescience/events/type/trade-show/)
---
## Types
### [Webinar](https://www.meridianbioscience.com/diagnostics/event/type/webinar/)
---
### [Trade Show](https://www.meridianbioscience.com/diagnostics/event/type/trade-show/)
---